<?xml version="1.0" encoding="UTF-8" standalone="no" ?><xml><records><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>338</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Abedi,S.A.</style></author><author><style face="normal" font="default"> Tarzamni,M.K.</style></author><author><style face="normal" font="default"> Nakhjavani,M.R.</style></author><author><style face="normal" font="default"> Bohlooli,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Effect of renal transplantation on coronary artery calcification in hemodialysis patients</style></title><secondary-title><style face="normal" font="default">Transplantation Proceedings</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Transplantation Proceedings</style></full-title></periodical><pages end="2831" start="2829">2829-2831</pages><volume><style face="normal" font="default">41</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Kidney Transplantation/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> 0 (Lipoproteins,HDL)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipoproteins,LDL)</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 0 (Triglycerides)</style></keyword><keyword><style face="normal" font="default"> 454-28-4 (Homocysteine)</style></keyword><keyword><style face="normal" font="default"> 57-88-5 (Cholesterol)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Calcinosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cholesterol/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Dialysis</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Homocysteine/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Lipoproteins,HDL/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Lipoproteins,LDL/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Renal Dialysis</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Triglycerides/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="9" Year="2009">2009/9</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Vascular calcification is a strong predictor of cardiovascular and all-cause mortality. Coronary artery calcification is more frequent, more extensive, and progresses more rapidly among subjects with chronic kidney disease (CKD) than in the general population. It is also considered to be a marker of coronary heart disease, the main cause of increased morbidity and mortality among patients either on maintenance hemodialysis or after transplantation. The aim of this study was to evaluate the effect of renal transplantation on the calcium scores of coronary arteries among hemodialysis patients. PATIENTS AND METHODS: The study included 31 patients (17 males and 14 females) of age range 19 to 56 years (mean, 38.08 +/- 13.49 years) who had been hemodialyzed 3 times a week for 6 to 49 months (mean, 20 +/- 15.72 months) prior to renal transplantation. Homocysteine, intact parathyroid hormone (iPTH), calcium, phosphate, and indices of lipid metabolism such as total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides were measured before and at 6 months after transplantation. To evaluate coronary artery calcification, all patients underwent multidetector coronary computed tomography (MDCT) using the Agatston technique for calcium scoring (CS) and color Doppler ultrasound for IMT before and at 6 months after the procedure. RESULTS: The prevalence of coronary artery calcifications among dialysis patients was 96% with a total CS ranging from 0 to 198. It affected more than 2 vessels in >50% of subjects with higher calcium scores in the left anterior descending artery (LAD). Mean total CS decreased significantly from pre- (39.82 +/- 63.05) to postoperation (24.34 +/- 39.55; P &lt; .001). CS decreased from pre- to postprocedure in the left main artery (7.4 +/- 13.03 to 4.3 +/- 8.54; P &lt; .01) and in LAD (15.76 +/- 23.53 to 10.23 +/- 15.81; P &lt; .01 and in the circumflex (7.8 +/- 14.98 to 5.1 +/- 9.57; P &lt; .001) and in the right coronary artery (9.2 +/- 17.18 to 4.7 +/- 8.18; P &lt; .01). The CS before the procedure correlated significantly with age (r = .39; P &lt; .005), P (r = .33; P &lt; .05), Ca x P product (r = .39; P &lt; .05), iPTH (r = .43; P &lt; .001), and IMT (r = .56; P &lt; .0001). There was a linear, meaningful correlation between CS and iPTH and Ca x P product reduction after renal transplantation. CONCLUSIONS: Renal transplantation significantly reduced coronary artery calcification among dialysis patients. It linearly correlated with a decrease in iPTH and Ca x P product at an early period after renal transplantation</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Transplantation Ward, Emam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran. sima-abedi@yahoo.comJC - we9, 0243532CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19765448</style></custom1><custom3><style face="normal" font="default">AS - Transplant Proc. 41(7):2829-31, 2009 Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>307</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Aboufakher,R.</style></author><author><style face="normal" font="default"> Torey,J.</style></author><author><style face="normal" font="default"> Szpunar,S.</style></author><author><style face="normal" font="default"> Davis,T.</style></author></authors></contributors><titles><title><style face="normal" font="default">Peripheral plaque volume changes pre- and post-rotational atherectomy followed by directional plaque excision: assessment by intravascular ultrasound and virtual histology</style></title><secondary-title><style face="normal" font="default">Journal of Invasive Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Invasive Cardiology</style></full-title></periodical><pages end="505" start="501">501-505</pages><volume><style face="normal" font="default">21</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherectomy,Coronary/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Atherectomy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Femoral Artery/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Femoral Artery/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Peripheral Vascular Diseases/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Peripheral Vascular Diseases/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Histological Techniques</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Outcome Assessment (Health Care)</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Ultrasonography,Interventional</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><abstract><style face="normal" font="default">Atherectomy in the infra-inguinal peripheral vascular bed may be an effective alternative to the balloon and stent-based approach. The change in plaque volume and composition with rotational atherectomy and directional plaque excision has not been studied. We performed rotational atherectomy (RA) followed by adjunctive plaque excision (PE) in 8 patients with infra-inguinal lesions. Lesions were assessed by quantitative angiography and intravascular ultrasound (IVUS) with virtual histology (VH) pretreatment, post-RA, and post-PE. Paired t-tests were used to assess the change in plaque volume, luminal area and dimensions and overall vessel size. Total plaque volume decreased by 24% (347 +/- 118 to 264 +/- 85 mm(3); p = 0.03), which resulted in a lumen increase of 66% (7.08 +/- 3 to 11.7 +/- 2.8 mm(2); p = 0.006). This was mainly due to PE compared to RA. This was achieved without any significant increase in the overall vessel area (27.4 +/- 6.3 to 28 +/- 6.7 mm(2); p = 0.42). The effect on minimal and maximal luminal diameters was synergistic between RA and PE. Fibrotic and fibrofatty plaque were amenable to PE, whereas necrotic core and dense calcium were less responsive to either atherectomy technique. In conclusion, RA followed by PE result in significant improvements in plaque volume and luminal area and diameter primarily by removing plaque rather than vessel expansion. This is mainly attributable to the removal of fibrotic and fibrofatty plaque</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiovascular Diseases, Department of Internal Medicine, St. John Hospital and Medical Center, Detroit, Michigan 48236, USAJC - bcz, 8917477CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19805835</style></custom1><custom3><style face="normal" font="default">AS - J Invasive Cardiol. 21(10):501-5, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>23</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Aboyans,V.</style></author><author><style face="normal" font="default"> Kamineni,A.</style></author><author><style face="normal" font="default"> Allison,M.A.</style></author><author><style face="normal" font="default"> McDermott,M.M.</style></author><author><style face="normal" font="default"> Crouse,J.R.</style></author><author><style face="normal" font="default"> Ni,H.</style></author><author><style face="normal" font="default"> Szklo,M.</style></author><author><style face="normal" font="default"> Criqui,M.H.</style></author></authors></contributors><titles><title><style face="normal" font="default">The epidemiology of subclavian stenosis and its association with markers of subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA)</style></title><secondary-title><style face="normal" font="default">Atherosclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Atherosclerosis</style></full-title></periodical><pages end="270" start="266">266-270</pages><volume><style face="normal" font="default">211</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Peripheral Vascular Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Subclavian Steal Syndrome/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Ankle Brachial Index</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Carotid Artery,Common/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Subclavian Steal Syndrome/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Tunica Intima/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Tunica Media/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> United States/ep [Epidemiology]</style></keyword></keywords><dates><year Day="0" Month="7" Year="2010">2010/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Recent studies indicate that subclavian stenosis (SS), diagnosed by a large systolic blood pressure difference (SBPD) between the right and left brachial arteries, is associated with cardiovascular disease (CVD) risk factors and outcomes. We sought to describe the epidemiology of SS and determine its association with markers of subclinical CVD in the baseline cohort of the Multi-Ethnic Study of Atherosclerosis. METHODS: We defined SS by an absolute SBPD>or=15 mmHg. Peripheral artery disease (PAD) was defined by an ankle-brachial index&lt;or=0.90. The coronary artery calcium score (CAC) and the common carotid artery intima-media thickness (CCA-IMT) were measured by computed tomography and B-mode ultrasound, respectively. Odds ratios for the associations of SS with risk factors and subclinical disease were estimated using logistic regression. RESULTS: Of 6743 subjects studied, 307 participants (4.6%) had SS, with a higher prevalence in women (5.1%) than men (3.9%), and in African Americans (7.4%) and non-Hispanic whites (5.1%) than Hispanic (1.9%) or Chinese (1.0%) participants (p&lt;0.01). In a model including age, gender, ethnicity, traditional and novel CVD risk factors, significant associations with SS were observed for C-reactive protein (highest vs. three lower quartiles: OR=1.41; 95%CI: 1.06-1.87) and brachial artery pulse pressure (OR=1.12/10 mmHg; 95%CI: 1.03-1.21). Adjusted for age, gender, ethnicity, traditional and novel CVD risk factors, SS was significantly associated with PAD (OR=2.35; 1.55-3.56), with CCA-IMT (highest vs. the lower three quartiles: OR=1.32; 1.00-1.75), and high CAC (score>100 vs. score=0; OR=1.43; 1.03-2.01). CONCLUSIONS: The subclavian stenosis is positively associated with other markers of subclinical atherosclerosis. Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Family and Preventive Medicine, University of California, San Diego, La Jolla, CA, USA. vaboyans@ucsd.eduJC - 95x, 0242543CP - IrelandPT - Journal ArticlePT - Multicenter StudyPT - Research Support, N.I.H., ExtramuralNO - N01-HC-95159 (United States NHLBI NIH HHS)NO - N01-HC-95165 (United States NHLBI NIH HHS)NO - N01-HC-95169 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20138280</style></custom1><custom3><style face="normal" font="default">AS - Atherosclerosis. 211(1):266-70, 2010 Jul.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>100</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Achouh,P.</style></author><author><style face="normal" font="default"> Boutekadjirt,R.</style></author><author><style face="normal" font="default"> Toledano,D.</style></author><author><style face="normal" font="default"> Hammoudi,N.</style></author><author><style face="normal" font="default"> Pagny,J.Y.</style></author><author><style face="normal" font="default"> Goube,P.</style></author><author><style face="normal" font="default"> Isselmou,K.O.</style></author><author><style face="normal" font="default"> Lancelin,B.</style></author><author><style face="normal" font="default"> Fouquet,R.</style></author><author><style face="normal" font="default"> Acar,C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Long-term (5- to 20-year) patency of the radial artery for coronary bypass grafting</style></title><secondary-title><style face="normal" font="default">Journal of Thoracic &amp; Cardiovascular Surgery</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Thoracic &amp; Cardiovascular Surgery</style></full-title></periodical><pages end="79" start="73">73-79</pages><volume><style face="normal" font="default">140</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Artery Bypass/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Graft Occlusion,Vascular/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Radial Artery/tr [Transplantation]</style></keyword><keyword><style face="normal" font="default"> *Vascular Patency</style></keyword><keyword><style face="normal" font="default"> 0 (Cardiovascular Agents)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angioplasty,Transluminal,Percutaneous Coronary</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Chi-Square Distribution</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Graft Occlusion,Vascular/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Graft Occlusion,Vascular/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Graft Occlusion,Vascular/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Internal Mammary-Coronary Artery Anastomosis/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Radial Artery/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Radial Artery/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Reoperation</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Stroke Volume</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="0" Year="1979">1979</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The aim of this study was to assess the angiographic results of the radial artery as a coronary bypass conduit at long term (>5 years). METHODS: Radial artery grafts were controlled in 202 patients at 10.1 years by conventional angiography (n = 79) and computed tomography (n = 123). Clinical or paraclinical evidence of ischemia was noted in 81 patients, whereas 121 patients were asymptomatic. Some 520 conduits were controlled: radial artery (n = 230), left internal thoracic artery (n = 190), right internal thoracic artery (n = 30), and veins (n = 70). Radial arteries were anastomosed to the right coronary (24%), marginal (58%), diagonal (16%), and left anterior descending (&lt;1%) arteries, whereas left internal thoracic arteries were primarily anastomosed to the left anterior descending artery (95%). The mean number of antithrombotic and anti-anginal medications was 1.2 and 1.9 per patient, respectively. RESULTS: The ejection fraction was slightly decreased compared with its preoperative value (54% +/- 11% vs 57% +/- 9%; P = .009). Nine reoperations were required at 10.5 years for valve replacement (n = 8) and isolated bypass (n = 1). Percutaneous intervention was performed in 48 patients (24%) at 7.6 years on a graft (28%) or a native coronary artery (72%). The 10-year patency of radial artery grafts was 83%, which was lower than the patency of left internal thoracic arteries (95%, P &lt; .001) and similar to the patency of right internal thoracic arteries (87%, P = .66) and veins (81%, P = .50). No medication seemed to influence radial artery graft patency (aspirin: P = .26; calcium blockers: P = .36). All graft patency was lower when clinical or paraclinical evidence of ischemia was present than in asymptomatic cases (83% vs 90% P = .02). The patency of left anterior descending grafts was higher than that of non-left anterior descending grafts (96% vs 82% P &lt; .001). CONCLUSION: The radial artery-to-coronary bypass conduit provided a low coronary reoperation rate with an excellent patency (83%) up to 20 years postoperatively. 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiovascular Surgery, H&amp;#x00F4;pital Georges Pompidou, Paris, FranceJC - k9j, 0376343CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19944433</style></custom1><custom3><style face="normal" font="default">AS - J Thorac Cardiovasc Surg. 140(1):73-9, 79.e1-2, 2010 Jul.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>30</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Adegboye,A.R.</style></author><author><style face="normal" font="default"> Fiehn,N.E.</style></author><author><style face="normal" font="default"> Twetman,S.</style></author><author><style face="normal" font="default"> Christensen,L.B.</style></author><author><style face="normal" font="default"> Heitmann,B.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Low calcium intake is related to increased risk of tooth loss in men</style></title><secondary-title><style face="normal" font="default">Journal of Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Nutrition</style></full-title></periodical><pages end="1868" start="1864">1864-1868</pages><volume><style face="normal" font="default">140</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium,Dietary/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Tooth Loss/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Tooth Loss/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> 0 (Calcium,Dietary)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Alcohol Drinking/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Denmark/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Energy Intake</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Nutrition Policy</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> Smoking/ae [Adverse Effects]</style></keyword></keywords><dates><year Day="0" Month="10" Year="2010">2010/10</year></dates><abstract><style face="normal" font="default">Our aim was to investigate the association between calcium (Ca) intake and number of teeth and tooth loss. The Danish Monica (Monitoring Trends and Determinants in Cardiovascular Disease) study is a prospective observational study from 1982-83 to 1993-94. The study population included 1602 adults (30-60 y) with information on dietary Ca intake and number of teeth and a subset of 511 participants with information on tooth loss from 1987-88 to 1993-94. Ca intake less than the recommendations, estimated by a 7-d food record or a diet history interview in 1982-83, was more frequent among females (55%) than males (45%; P &lt; 0.001). Low Ca intake was associated with low number of teeth (1-25 vs. 26-32 teeth) in males [odds ratio (OR) = 1.57 (95% CI = 1.10-2.29)] and females [OR = 1.44 (95% CI = 1.10-2.05)] after adjustment for age, education, smoking, alcohol and sucrose consumption, subjective oral dryness, and time since last dental care visit. The reference group (26-32 teeth) and edentulous participants did not significantly differ. A Ca intake below recommendations was significantly associated with increased risk of subsequent tooth loss in males [incidence-rate ratio = 1.70 (95% CI = 1.15-2.48)]. There was no association in women. Ca intake below recommendations was significantly associated with fewer teeth in both sexes. However, there was a significant, negative association between Ca intake below recommendations and tooth loss in males only. Given the high percentage of individuals with Ca intake below recommendations, consumption of foods rich in Ca should be promoted to preserve oral health</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Research Unit for Dietary Studies, Institute of Preventive Medicine, Copenhagen University Hospital, Copenhagen 1357, Denmark. AAR@ipm.regionh.dkJC - jev, 0404243CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20739448</style></custom1><custom3><style face="normal" font="default">AS - J Nutr. 140(10):1864-8, 2010 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>353</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Ahlstr&amp;#x00F6</style></author><author><style face="normal" font="default">m T</style></author><author><style face="normal" font="default"> Hagstr&amp;#x00F6</style></author><author><style face="normal" font="default">m E</style></author><author><style face="normal" font="default"> Larsson,A.</style></author><author><style face="normal" font="default"> Rudberg,C.</style></author><author><style face="normal" font="default"> Lind,L.</style></author><author><style face="normal" font="default"> Hellman,P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Correlation between plasma calcium, parathyroid hormone (PTH) and the metabolic syndrome (MetS) in a community-based cohort of men and women</style></title><secondary-title><style face="normal" font="default">Clinical Endocrinology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinical Endocrinology</style></full-title></periodical><pages end="678" start="673">673-678</pages><volume><style face="normal" font="default">71</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Metabolic Syndrome X/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Insulin Resistance</style></keyword><keyword><style face="normal" font="default"> Linear Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Waist Circumference</style></keyword></keywords><dates><year Day="0" Month="11" Year="2009">2009/11</year></dates><abstract><style face="normal" font="default">CONTEXT: In recent years, an association has been noted between several abnormalities that characterize the metabolic syndrome (MetS) and primary hyperparathyroidism (pHPT). These abnormalities include dyslipidaemia, obesity, insulin resistance and hypertension. The correlations between plasma calcium, parathyroid hormone (PTH) and the variables in the MetS in a normal population are still unclear. OBJECTIVE: To describe correlations between plasma calcium and PTH and the various abnormalities present in the MetS in a healthy population. DESIGN: We studied 1016 healthy individuals from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) population of 70 years old, by means of plasma analyses of calcium, PTH, creatinine, lipids, insulin and glucose, as well as by standardized blood pressure measurements. Further, body mass index (BMI) and waist circumference were determined. RESULTS: The more National Cholesterol Education Program (NCEP) criteria for the MetS that were met, the higher the s-PTH and albumin-corrected s-calcium. Further, positive correlations between plasma calcium and BMI (P = 0.0003), waist circumference (P = 0.0009) and insulin resistance (P = 0.079) were found. PTH and BMI (P &lt; 0.0001), waist circumference (P &lt; 0.0001), systolic blood pressure (P = 0.0034), diastolic blood pressure (P = 0.0008), serum triglycerides (P = 0.0003) and insulin resistance (P = 0.0003) were positively correlated, whereas serum high density lipoproteins (HDL) (P = 0.036) and PTH were negatively correlated. CONCLUSIONS: We conclude that PTH correlates with several of the metabolic factors included in the MetS within a normocalcaemic population. In addition, individuals with mild pHPT present significantly more NCEP criteria for MetS. We postulate that increased levels of PTH in pHPT may be associated with the increased cardiovascular morbidity and mortality seen in pHPT</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Surgical Sciences, University Hospital, Uppsala, SwedenJC - dci, 0346653CP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19250270</style></custom1><custom3><style face="normal" font="default">AS - Clin Endocrinol (Oxf). 71(5):673-8, 2009 Nov.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>304</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Ahmadi,N.</style></author><author><style face="normal" font="default"> Hajsadeghi,F.</style></author><author><style face="normal" font="default"> Gul,K.</style></author><author><style face="normal" font="default"> Leibfried,M.</style></author><author><style face="normal" font="default"> DeMoss,D.</style></author><author><style face="normal" font="default"> Lee,R.</style></author><author><style face="normal" font="default"> Flores,F.</style></author><author><style face="normal" font="default"> Nasir,K.</style></author><author><style face="normal" font="default"> Hecht,H.</style></author><author><style face="normal" font="default"> Naghavi,M.</style></author><author><style face="normal" font="default"> Budoff,M.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Vascular function measured by fingertip thermal reactivity is impaired in patients with metabolic syndrome and diabetes mellitus</style></title><secondary-title><style face="normal" font="default">Journal of Clinical Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Clinical Hypertension</style></full-title></periodical><pages end="684" start="678">678-684</pages><volume><style face="normal" font="default">11</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Body Temperature/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Fingers/bs [Blood Supply]</style></keyword><keyword><style face="normal" font="default"> *Metabolic Syndrome X/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Regional Blood Flow/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Signal Processing,Computer-Assisted/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Diabetes Complications/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Metabolic Syndrome X/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="11" Year="2009">2009/11</year></dates><abstract><style face="normal" font="default">Digital thermal monitoring (DTM) of vascular function has already been shown to correlate well with coronary artery calcium (CAC) score and coronary artery disease. To determine its utility in the metabolic syndrome (MS) and diabetes mellitus (DM), 233 asymptomatic patients with DM/MS but without coronary artery disease underwent DTM during and after 5 minutes of supra-systolic arm cuff inflation, as well as CAC. Post-cuff deflation adjusted temperature rebound (aTR) was lower in MS and DM compared with the normal group. The odds ratio of lowest vs upper 2 tertiles of aTR was 2.3 for MS and 3.5 for DM compared with the normal group, independent of age, sex, and risk factors. The area under the receiver operating characteristic curve to predict CAC > or =100 was 0.69 for metabolic status (DM/MS), 0.79 for aTR, and 0.87 for both. This study demonstrates that vascular dysfunction measured by DTM is associated with DM/MS and could potentially be used to detect asymptomatic individuals with increased subclinical atherosclerosis. 2009 Wiley Periodical, Inc</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USAJC - 100888554, d2qCP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19878383</style></custom1><custom3><style face="normal" font="default">AS - J Clin Hypertens (Greenwich). 11(11):678-84, 2009 Nov.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>120</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Ahmadi,N.</style></author><author><style face="normal" font="default"> Shavelle,D.</style></author><author><style face="normal" font="default"> Nabavi,V.</style></author><author><style face="normal" font="default"> Hajsadeghi,F.</style></author><author><style face="normal" font="default"> Moshrefi,S.</style></author><author><style face="normal" font="default"> Flores,F.</style></author><author><style face="normal" font="default"> Azmoon,S.</style></author><author><style face="normal" font="default"> Mao,S.S.</style></author><author><style face="normal" font="default"> Ebrahimi,R.</style></author><author><style face="normal" font="default"> Budoff,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Coronary distensibility index measured by computed tomography is associated with the severity of coronary artery disease</style></title><secondary-title><style face="normal" font="default">Journal of cardiovascular computed tomography</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of cardiovascular computed tomography</style></full-title></periodical><pages end="126" start="119">119-126</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography/st [Standards]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Diastole</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> ROC Curve</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed/st [Standards]</style></keyword></keywords><dates><year Day="0" Month="3" Year="2010">2010/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atherosclerotic changes within the coronary artery wall can affect vessel distensibility. OBJECTIVE: This study evaluated the relationship between the coronary distensibility index (CDI) and the severity of coronary artery disease (CAD) measured by computed tomographic angiography (CTA). METHODS: One hundred thirteen subjects, age 63 +/- 10 years, 32% women, who underwent coronary artery calcium (CAC) scanning and CTA, were studied. Early diastolic and mid diastolic (MD) cross-section area (CSA) of the left anterior descending (LAD) artery were measured 5 mm distal to the left main bifurcation. CDI was defined as Deltalumen CSA/[lumen CSA in MD x estimated central pulse pressure (eCPP)] x 10(3) {eCPP = 0.77 x peripheral pulse pressure}. LAD diameter measured by CTA and quantitative coronary angiography (QCA) was compared in 19 subjects without CAD. CAD was defined as normal (no stenosis and CAC 0), mild (stenosis &lt;or= 30%), moderate (stenosis 31%-69%), and severe (stenosis >or= 70%) on CTA. RESULTS: Excellent correlation was observed between CTA and QCA measured by CDI (r(2) = 0.96, P = 0.0001). CDI decreased from normal coronaries (6.75 +/- 1.43) to arteries with mild (5.78 +/- 1.45), moderate (3.96 +/- 1.06), and severe (3.31 +/- 1.06) disease (P = 0.004). The risk factor adjusted odds ratio of lowest versus 2 upper tertiles of CDI was 1.28 for mild, 8.47 for moderate, and 10.59 for severe CAD compared with the normal cohort. The area under the ROC curve to predict obstructive CAD (stenosis >or= 50%) increased significantly from 0.71 to 0.84 by addition of CDI to CAC (P &lt; 0.05). CONCLUSION: CTA-measured CDI is inversely related to the severity of CAD independent of age, sex, cardiovascular risk factors, and CAC. Copyright 2010 Society of Cardiovascular Computed Tomography. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Los Angeles Biomedical Research Institute at Harbor University of California Los Angeles (UCLA) Medical Center, Torrance, CA 90502, USA. nahmadi@labiomed.orgJC - 101308347CP - United StatesPT - Clinical TrialPT - Journal ArticlePT - Validation StudiesLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20430343</style></custom1><custom3><style face="normal" font="default">AS - J Cardiovasc Comput Tomogr. 4(2):119-26, 2010 Mar-Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>250</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Ahmadi,N.</style></author><author><style face="normal" font="default"> Tsimikas,S.</style></author><author><style face="normal" font="default"> Hajsadeghi,F.</style></author><author><style face="normal" font="default"> Saeed,A.</style></author><author><style face="normal" font="default"> Nabavi,V.</style></author><author><style face="normal" font="default"> Bevinal,M.A.</style></author><author><style face="normal" font="default"> Kadakia,J.</style></author><author><style face="normal" font="default"> Flores,F.</style></author><author><style face="normal" font="default"> Ebrahimi,R.</style></author><author><style face="normal" font="default"> Budoff,M.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Relation of oxidative biomarkers, vascular dysfunction, and progression of coronary artery calcium</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="466" start="459">459-466</pages><volume><style face="normal" font="default">105</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Fingers/bs [Blood Supply]</style></keyword><keyword><style face="normal" font="default"> *Garlic</style></keyword><keyword><style face="normal" font="default"> *Skin Temperature</style></keyword><keyword><style face="normal" font="default"> 0 (Apolipoprotein B-100)</style></keyword><keyword><style face="normal" font="default"> 0 (Autoantibodies)</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Immunoglobulin G)</style></keyword><keyword><style face="normal" font="default"> 0 (Immunoglobulin M)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipoprotein(a))</style></keyword><keyword><style face="normal" font="default"> 0 (Phospholipids)</style></keyword><keyword><style face="normal" font="default"> 0 (Plant Extracts)</style></keyword><keyword><style face="normal" font="default"> 12001-76-2 (Vitamin B Complex)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Apolipoprotein B-100/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Autoantibodies/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Dietary Supplements</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Double-Blind Method</style></keyword><keyword><style face="normal" font="default"> Equipment Design</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin G/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin M/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Lipoprotein(a)/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Oxidative Stress/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Phospholipids/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Phytotherapy</style></keyword><keyword><style face="normal" font="default"> Plant Extracts/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Thermography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Vitamin B Complex/tu [Therapeutic Use]</style></keyword></keywords><dates><year Day="15" Month="2" Year="2010">2010/2/15</year></dates><abstract><style face="normal" font="default">The relation between oxidative stress and coronary artery calcium (CAC) progression is currently not well described. The present study evaluated the relation among the biomarkers of oxidative stress, vascular dysfunction, and CAC. Sixty asymptomatic subjects participated in a randomized trial evaluating the effect of aged garlic extract plus supplement versus placebo and underwent measurement of CAC. The postcuff deflation temperature-rebound index of vascular function was assessed using a reactive hyperemia procedure. The content of oxidized phospholipids (OxPL) on apolipoprotein B-100 (apoB) particles detected by antibody E06 (OxPL/apoB), lipoprotein(a), IgG and IgM autoantibodies to malondialdehyde-low-density lipoprotein and apoB-immune complexes were measured at baseline and after 12 months of treatment. CAC progression was defined as an annual increase in CAC >15%. Vascular dysfunction was defined according to the tertiles of temperature-rebound at 1 year of follow-up. From baseline to 12 months, a strong inverse correlation was noted between an increase in CAC scores and increases in temperature-rebound (r(2) = -0.90), OxPL/apoB (r(2) = -0.85), and lipoprotein(a) (r(2) = -0.81) levels (p &lt;0.0001 for all). The improvement in temperature-rebound correlated positively with the increases in OxPL/apoB (r(2) = 0.81, p = 0.0008) and lipoprotein(a) (r(2) = 0.79, p = 0.0001) but inversely with autoantibodies to malondialdehyde-low-density lipoprotein and apoB-immune complexes. The greatest CAC progression was noted with the lowest tertiles of increases in temperature-rebound, OxPL/apoB and lipoprotein(a) and the highest tertiles of increases in IgG and IgM malondialdehyde-low-density lipoprotein. In conclusion, the present results have documented a strong relation among markers of oxidative stress, vascular dysfunction, and progression of coronary atherosclerosis. Increases in OxPL/apoB and lipoprotein(a) correlated strongly with increases in vascular function and predicted a lack of progression of CAC. Copyright 2010 Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Los Angeles Biomedical Research Institute, Harbor UCLA Medical Center, Torrance, California, USAJC - 3dq, 0207277CP - United StatesPT - Journal ArticlePT - Randomized Controlled TrialLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20152239</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 105(4):459-66, 2010 Feb 15.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>243</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Akat,K.</style></author><author><style face="normal" font="default"> Kaden,J.J.</style></author><author><style face="normal" font="default"> Schmitz,F.</style></author><author><style face="normal" font="default"> Ewering,S.</style></author><author><style face="normal" font="default"> Anton,A.</style></author><author><style face="normal" font="default"> Klomfass,S.</style></author><author><style face="normal" font="default"> Hoffmann,R.</style></author><author><style face="normal" font="default"> Ortlepp,J.R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Calcium metabolism in adults with severe aortic valve stenosis and preserved renal function</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="864" start="862">862-864</pages><volume><style face="normal" font="default">105</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aortic Valve Stenosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Kidney Function Tests</style></keyword><keyword><style face="normal" font="default"> 0 (Osteoprotegerin)</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 0 (Phosphates)</style></keyword><keyword><style face="normal" font="default"> 60-27-5 (Creatinine)</style></keyword><keyword><style face="normal" font="default"> 67-97-0 (Cholecalciferol)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aortic Valve Stenosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Cholecalciferol/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Creatinine/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Intensive Care</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Osteoprotegerin/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Phosphates/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="15" Month="3" Year="2010">2010/3/15</year></dates><abstract><style face="normal" font="default">Data suggest a link of aortic stenosis (AS) with calcium and bone metabolism. To further investigate this, the following parameters were analyzed in 38 patients with severe AS and in 38 age- and gender-matched controls, without obstructive coronary artery disease and with preserved renal function: calcium, phosphate, 1,25(OH(2))-vitamin D(3), intact parathyroid hormone (iPTH), and osteoprotegerin. Patients with AS had significantly higher serum levels of calcium (2.63 +/- 0.28 vs 2.48 +/- 0.23 mmol/L, p &lt;0.01) and phosphate (1.56 +/- 0.33 vs 1.38 +/- 0.26 mmol/L, p &lt;0.01) and increased calcium-phosphorus products (4.16 +/- 1.13 vs 3.44 +/- 0.89 mmol/L(2), p = 0.003). Notably, the iPTH concentration in the AS group was lower, and significantly more patients in the AS group had levels less than the study median of 60 ng/L. Osteoprotegerin was elevated in patients with AS, confirming reports in other populations (9.94 +/- 5.96 vs 6.73 +/- 4.28 pmol/L, p = 0.009). The relations of several parameters to iPTH were also altered (AS vs controls): calcium and iPTH, 0.071 +/- 0.034 versus 0.046 +/- 0.023, p &lt;0.0001; phosphate and iPTH, 0.042 +/- 0.020 versus 0.025 +/- 0.013, p &lt;0.0001; vitamin D and iPTH, 0.99 +/- 0.61 versus 0.63 +/- 0.46, p = 0.006; and osteoprotegerin and iPTH, 0.24 +/- 0.15 versus 0.12 +/- 0.09, p &lt;0.0001. In conclusion, these data support a hypothesis connecting (severe) AS to altered calcium and bone homeostasis. Copyright 2010. Published by Elsevier Inc</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - First Department of Medicine (Cardiology, Angiology, Pneumology, Intensive Care Medicine, Hemostaseology), Universit&amp;#x00E4;tsmedizin Mannheim, Heidelberg University, Mannheim, Germany. kemal.akat@umm.deJC - 3dq, 0207277CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20211333</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 105(6):862-4, 2010 Mar 15.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>463</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Aksun,M.</style></author><author><style face="normal" font="default"> Karahan,N.</style></author><author><style face="normal" font="default"> Adanir,T.</style></author><author><style face="normal" font="default"> Aran,G.</style></author><author><style face="normal" font="default"> Yetkin,U.</style></author><author><style face="normal" font="default"> rk,T.</style></author><author><style face="normal" font="default"> Sencan,A.</style></author><author><style face="normal" font="default"> Ozg&amp;#x00FC</style></author><author><style face="normal" font="default">rb&amp;#x00FC</style></author><author><style face="normal" font="default">z U</style></author><author><style face="normal" font="default"> G&amp;#x00FC</style></author><author><style face="normal" font="default">rb&amp;#x00FC</style></author><author><style face="normal" font="default">z A</style></author></authors></contributors><titles><title><style face="normal" font="default">Timing of levosimendan in cardiac surgery</style></title><secondary-title><style face="normal" font="default">Anadolu Kardiyoloji Dergisi</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Anadolu Kardiyoloji Dergisi</style></full-title></periodical><pages end="230" start="223">223-230</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiac Output,Low/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Cardiotonic Agents/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Hydrazones/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Pyridazines/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Ventricular Dysfunction,Left/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> 0 (Cardiotonic Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Hydrazones)</style></keyword><keyword><style face="normal" font="default"> 0 (Pyridazines)</style></keyword><keyword><style face="normal" font="default"> 131741-08-7 (simendan)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hemodynamics/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Intraoperative Care</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardial Contraction/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Patient Selection</style></keyword><keyword><style face="normal" font="default"> Postoperative Care</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Urine</style></keyword></keywords><dates><year Day="0" Month="6" Year="2009">2009/6</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Levosimendan (LS) is a new inodilator agent that improves cardiac contractility by increasing the sensitivity of troponin C to calcium, which usage in cardiac surgery has been growing in the recent years. We aimed to determine the best timing of the administration of LS in high-risk patients who underwent cardiovascular surgery. METHODS: Fifteen patients were evaluated retrospectively who have left ventricular dysfunction, underwent open-heart surgery and were applied LS in different phases of operation. Patients were divided into 3 groups according to timing of LS. Levosimendan infusion (0. 1 microg-1kg-1min) was applied after the induction of anaesthesia (n=5) (Group 1), during the pump removal period (n=5) (Group 2) and in postoperative period (n=5) (Group 3). Demographic data, operative characteristics, mean arterial pressure (MAP), mean pulmonary arterial pressure (MPAP), pulmonary wedge capillary pressure (PWCP), cardiac index (CI), inotropic agent consumption, postoperative urine output, lactate levels of groups were compared between before and after LS treatment. Data were evaluated by Fisher exact, Kruskal-Wallis, Mann-Whitney U and Wilcoxon rank tests. RESULTS: In all patients, urine output was satisfactory 24 hours after LS application. There was a significant increase in CI of all 3 groups (p=0.04). Also, there was a significant decrease in PCWP of all 3 groups before and after LS (p=0.04). There was a significant decrease in MPAP in Group 2 and 3 (p=0.04). Twenty- four hours after LS application, whereas all inotropic agents could be stopped in Group 1 and 2, in Group 3 inotropic infusion (dopamine [10 microg-1kg-1min (5-17.5)], dobutamine [15 microg-1kg-1min (5-20)] and adrenaline [0.4 microg-1kg-1min (0.15-0.65)]) couldn't be stopped (p=0.007). During postoperative period, in Groups 1 and 2 one case from each required intraaortic balloon pump, while in Group 3 four patients were applied intraaortic balloon pump (p=0.08). CONCLUSION: According to our experience, LS is effective in high-risk cases during cardiac surgery, especially during the intra-operative and pump removal periods;however, no successful outcomes were observed during the post-operative period. As a result, case selection and timing should be performed well when using LS</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - From II. Clinic of Anesthesiology and Reanimation, Izmir Atat&amp;#x00FC;rk Training and Research Hospital, Izmir, Turkey. murataksun@yahoo.comJC - 101095069CP - TurkeyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19520657</style></custom1><custom3><style face="normal" font="default">AS - Anadolu Kardiyol Derg. 9(3):223-30, 2009 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>202</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Akutsu,H.</style></author><author><style face="normal" font="default"> Kreutzer,J.</style></author><author><style face="normal" font="default"> Wasmeier,G.</style></author><author><style face="normal" font="default"> Ropers,D.</style></author><author><style face="normal" font="default"> Rost,C.</style></author><author><style face="normal" font="default"> hlig,M.</style></author><author><style face="normal" font="default"> Wallaschofski,H.</style></author><author><style face="normal" font="default"> Buchfelder,M.</style></author><author><style face="normal" font="default"> fl,C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Acromegaly per se does not increase the risk for coronary artery disease</style></title><secondary-title><style face="normal" font="default">European Journal of Endocrinology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">European Journal of Endocrinology</style></full-title></periodical><pages end="886" start="879">879-886</pages><volume><style face="normal" font="default">162</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Acromegaly/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword></keywords><dates><year Day="0" Month="5" Year="2010">2010/5</year></dates><abstract><style face="normal" font="default">CONTEXT: Information about the risk and course of coronary artery disease (CAD) in acromegaly is limited. OBJECTIVE: To evaluate CAD risk in acromegalic patients at diagnosis and after successful treatment during follow-up. SUBJECTS AND METHODS: Twenty-five consecutive patients (age 45.1+/-10.6 years, 15 women) were studied at the time of diagnosis, and 19 patients were re-evaluated after 4.6+/-1.1 years. The European Society of Cardiology (ESC) risk score was calculated, and a cardiac computed tomography was performed for detection and quantification (Agatston score (AS)) of coronary artery calcium (CACs). Fifty age-, sex-, and CAD risk-matched subjects and CAC data from the population-based Heinz Nixdorf Recall (HNR) study served as controls. RESULTS: In 21 of the 25 patients, the 10-year risk of developing CAD according to the ESC risk score was low (&lt;10%) and high (>20%) in four patients. The AS was lower than in controls (2.6+/-7.9 vs 66+/-182; P=0.014) and less patients had a positive CAC (AS>0) (20 vs 48%, P=0.024), which in the acromegalic patients was less than expected from the HNR study. The AS did not correlate with GH excess or disease duration. In 19 acromegalic patients, who were in remission and re-evaluated after 4.6+/-1.1 years, the ESC risk (P=0.102) and the AS (P=0.173) did not change significantly and no symptomatic CAD event occurred. CONCLUSION: CAD risk in newly diagnosed acromegalic patients was low and remained stable after successful treatment. CAC was lower than in controls suggesting that GH excess per se does not carry an additional CAD risk</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Neurosurgery, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, GermanyJC - bxu, 9423848CP - EnglandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20145047</style></custom1><custom3><style face="normal" font="default">AS - EUR. J. ENDOCRINOL.. 162(5):879-86, 2010 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>56</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Al-Mallah,M.H.</style></author><author><style face="normal" font="default"> Nasir,K.</style></author><author><style face="normal" font="default"> Katz,R.</style></author><author><style face="normal" font="default"> Takasu,J.</style></author><author><style face="normal" font="default"> Lima,J.A.</style></author><author><style face="normal" font="default"> Bluemke,D.A.</style></author><author><style face="normal" font="default"> Hundley,G.</style></author><author><style face="normal" font="default"> Blumenthal,R.S.</style></author><author><style face="normal" font="default"> Budoff,M.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Thoracic aortic distensibility and thoracic aortic calcium (from the Multi-Ethnic Study of Atherosclerosis [MESA])</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="580" start="575">575-580</pages><volume><style face="normal" font="default">106</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aorta,Thoracic/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Aortic Diseases/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Atherosclerosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aortic Diseases/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword></keywords><dates><year Day="15" Month="8" Year="2010">2010/8/15</year></dates><abstract><style face="normal" font="default">Decreased arterial distensibility is an early manifestation of adverse structural and functional changes within the vessel wall. Its correlation with thoracic aortic calcium (TAC), a marker of atherosclerosis, has not been well demonstrated. We tested the hypothesis that decreasing aortic compliance and increasing arterial stiffness would be independently associated with increased TAC. We included 3,540 subjects (61 +/- 10 years, 46% men) from the Multi-ethnic Study of Atherosclerosis who had undergone an aortic distensibility (AD) assessment using magnetic resonance imaging. TAC was calculated using a modified Agatston algorithm on noncontrast cardiac computed tomographic scans. Multivariate regression models were calculated for the presence of TAC. Overall, 861 subjects (24%) had detectable TAC. Lower AD was observed among those with versus without TAC (2.02 +/- 1.34 vs 1.28 +/- 0.74, p &lt;0.0001). The prevalence of TAC increased significantly across decreasing quartiles of AD (7%, 17%, 31%, and 42%, p &lt;0.0001). Using multivariate analysis, TAC was independently associated with AD after adjusting for age, gender, ethnicity, and other covariates. In conclusion, our analysis has demonstrated that increased arterial stiffness is associated with increased TAC, independent of ethnicity and other atherosclerotic risk factors</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiology, Henry Ford Hospital, Wayne State University, Detroit, MI, USA. mouaz74@gmail.comJC - 3dq, 0207277CP - United StatesPT - Clinical TrialPT - Journal ArticlePT - Research Support, U.S. Gov't, P.H.SNO - N01-HC-95159 (United States NHLBI NIH HHS)NO - N01-HC-95165 (United States NHLBI NIH HHS)NO - N01-HC-95169 (United States NHLBI NIH HHS)NO - R01 HL071739 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20691319</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 106(4):575-80, 2010 Aug 15.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>154</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Al-Solaiman,Y.</style></author><author><style face="normal" font="default"> Jesri,A.</style></author><author><style face="normal" font="default"> Mountford,W.K.</style></author><author><style face="normal" font="default"> Lackland,D.T.</style></author><author><style face="normal" font="default"> Zhao,Y.</style></author><author><style face="normal" font="default"> Egan,B.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">DASH lowers blood pressure in obese hypertensives beyond potassium, magnesium and fibre</style></title><secondary-title><style face="normal" font="default">Journal of Human Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Human Hypertension</style></full-title></periodical><pages end="246" start="237">237-246</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Blood Pressure</style></keyword><keyword><style face="normal" font="default"> *Hypertension/dh [Diet Therapy]</style></keyword><keyword><style face="normal" font="default"> *Metabolic Syndrome X/dh [Diet Therapy]</style></keyword><keyword><style face="normal" font="default"> *Obesity/dh [Diet Therapy]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Calcium,Dietary)</style></keyword><keyword><style face="normal" font="default"> 0 (Potassium,Dietary)</style></keyword><keyword><style face="normal" font="default"> 0 (Sodium,Dietary)</style></keyword><keyword><style face="normal" font="default"> 7439-95-4 (Magnesium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aorta/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Biological Markers</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcium,Dietary/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Dietary Fiber/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Elasticity</style></keyword><keyword><style face="normal" font="default"> Endothelium,Vascular/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fruit</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Magnesium/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Potassium,Dietary/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sodium,Dietary/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Vegetables</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">The mechanism underlying blood pressure (BP) reduction in the high fruits and vegetables arm of the Dietary Approaches to Stop Hypertension (DASH) study is unknown but may include potassium, magnesium and fibre. This study was designed to separate minerals and fibre from other components of DASH on BP in abdominally obese individuals with metabolic syndrome with pre-hypertension to stage 1 hypertension (obese hypertensives). A total of 15 obese hypertensives and 15 lean normotensives were studied on a standardized usual diet, randomized to DASH or usual diet supplemented with potassium, magnesium and fibre to match DASH, then crossed over to the complementary diet. All diets were 3 weeks long, isocaloric and matched for sodium and calcium. In obese hypertensives, BP was lower after 3 weeks on DASH than usual diet (-7.6+/-1.4/-5.3+/-1.4 mm Hg, P&lt;0.001/0.02) and usual diet supplemented (-6.2+/-1.4/-3.7+/-1.4 P&lt;0.005/0.06), whereas BP was not significantly different on usual and supplemented diets. BP values were not different among the three diets in lean normotensives. Small artery elasticity was lower in obese hypertensives than in lean normotensives on the usual and supplemented diets (P&lt;0.02). This index of endothelial function improved in obese hypertensives (P&lt;0.02) but not lean normotensives on DASH, and was no longer different from values in lean normotensives (P>0.50). DASH is more effective than potassium, magnesium and fibre supplements for lowering BP in obese hypertensives, which suggest that high fruits and vegetables DASH lowers BP and improves endothelial function in this group by nutritional factors in addition to potassium, magnesium and fibre</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, Medical University of South Carolina, Charleston, SC, USAJC - 8811625CP - EnglandPT - Journal ArticlePT - Randomized Controlled TrialPT - Research Support, N.I.H., ExtramuralPT - Research Support, U.S. Gov't, Non-P.H.SNO - HL04290 (United States NHLBI NIH HHS)NO - HL58794 (United States NHLBI NIH HHS)NO - MD00267 (United States NCMHD NIH HHS)NO - RR-01070 (United States NCRR NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19626043</style></custom1><custom3><style face="normal" font="default">AS - J Hum Hypertens. 24(4):237-46, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>211</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Albert,N.M.</style></author><author><style face="normal" font="default"> Rathman,L.</style></author><author><style face="normal" font="default"> Ross,D.</style></author><author><style face="normal" font="default"> Walker,D.</style></author><author><style face="normal" font="default"> Bena,J.</style></author><author><style face="normal" font="default"> McIntyre,S.</style></author><author><style face="normal" font="default"> Philip,D.</style></author><author><style face="normal" font="default"> Siedlecki,S.</style></author><author><style face="normal" font="default"> Lovelace,R.</style></author><author><style face="normal" font="default"> Fogarty,A.M.</style></author><author><style face="normal" font="default"> Maikut,B.</style></author><author><style face="normal" font="default"> Zielinski,P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Predictors of over-the-counter drug and herbal therapies use in elderly patients with heart failure</style></title><secondary-title><style face="normal" font="default">Journal of Cardiac Failure</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Cardiac Failure</style></full-title></periodical><pages end="606" start="600">600-606</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Heart Failure/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Nonprescription Drugs/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Phytotherapy/ut [Utilization]</style></keyword><keyword><style face="normal" font="default"> 0 (Nonprescription Drugs)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> Data Collection/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Dietary Supplements/ut [Utilization]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Forecasting</style></keyword><keyword><style face="normal" font="default"> Heart Failure/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Heart Failure/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Nonprescription Drugs/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Self Medication/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="9" Year="2009">2009/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Over-the-counter (OTC) drug and herbal therapies (HT) may worsen heart failure or interact with prescription medications. Frequency of and predictors for routine OTC drug and HT use are not well studied. METHODS AND RESULTS: We examined routine use of OTC drug and HT in patients at 8 medical centers. Medical conditions independently associated with use of OTC drugs, HT, or both were assessed using multivariable logistic regression models. Of 374 subjects, OTC drug and HT were routinely used by 349 and 43 patients, respectively. Mean age was 69.6 +/- 13.1 years, 63% were male, and 81% were Caucasian. Common OTC drugs were antiplatelets (baby-dose aspirin), vitamins, acetaminophen, antacids, laxatives, and calcium. The most common HT used was echinacea. History of hypercholesterolemia was associated with higher OTC drug use (OR 4.36; 95% CI 1.60-11.87; P = .004); renal failure predicted less use (OR 0.09; 95% CI 0.01-0.59; P = .013). History of hypertension was associated with less HT use (OR 0.47, 95% CI 0.24-0.92; P = .028). CONCLUSIONS: In HF patients, routine use of OTC drugs was common, but HT use was not. OTC drugs were used more often in patients with hypercholesterolemia and were used for a variety of reasons; thus, routine assessment and individualized education are advocated</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, OH 44195, USA. albertn@ccf.orgJC - cl6, 9442138CP - United StatesPT - Comparative StudyPT - Journal ArticlePT - Multicenter StudyLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19700137</style></custom1><custom3><style face="normal" font="default">AS - J Card Fail. 15(7):600-6, 2009 Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>93</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Alexopoulos,N.</style></author><author><style face="normal" font="default"> McLean,D.S.</style></author><author><style face="normal" font="default"> Janik,M.</style></author><author><style face="normal" font="default"> Arepalli,C.D.</style></author><author><style face="normal" font="default"> Stillman,A.E.</style></author><author><style face="normal" font="default"> Raggi,P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Epicardial adipose tissue and coronary artery plaque characteristics</style></title><secondary-title><style face="normal" font="default">Atherosclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Atherosclerosis</style></full-title></periodical><pages end="154" start="150">150-154</pages><volume><style face="normal" font="default">210</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Adipose Tissue/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Pericardium/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword></keywords><dates><year Day="0" Month="5" Year="2010">2010/5</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Epicardial adipose tissue (EAT) has been implicated in the pathogenesis of coronary atherosclerosis. The association of EAT volume with type of coronary artery plaque on computed tomography angiography (CTA) is not known. METHODS: Coronary artery calcium (CAC) scoring and EAT volume measurement were performed on 214 consecutive patients (mean age 54+/-14 years) referred for coronary CTA. CAC was performed on non-contrast images, while EAT volume, the severity of luminal stenoses, and plaque characterization were assessed using contrast-enhanced CTA images. EAT volume was also indexed to body surface area (EAT-i). RESULTS: EAT volume correlated with age, height, body mass index (BMI), and CAC score. EAT volume increased significantly with the severity of luminal stenosis (p&lt;0.001), and in patients with no plaques, calcified, mixed, and non-calcified plaques (62+/-33mL, 63+/-22mL, 98+/-47mL, and 99+/-36mL, respectively, p&lt;0.001). The EAT volume was significantly larger in patients with mixed or non-calcified plaques compared to patients with calcified plaques or no plaques (all p&lt;0.01 or smaller). The trend remained significant after adjustment for traditional risk factors for coronary artery disease. In adjusted models EAT was an independent predictor of CAC [exp(B)=3.916, p&lt;0.05], atherosclerotic plaques of any type [exp(B)=4.532, p&lt;0.01], non-calcified plaques [exp(B)=3.849, p&lt;0.01], and obstructive CAD [exp(B)=3.824, p&lt;0.05]. The above results were unchanged after replacing EAT with EAT-i. CONCLUSION: EAT volume was larger in the presence of obstructive CAD and non-calcified plaques. These data suggest that EAT is associated with the development of coronary atherosclerosis and potentially the most dangerous types of plaques. Copyright 2009 Elsevier Ireland Ltd. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiology, Department of Medicine, Emory University, Atlanta, GA, United StatesJC - 95x, 0242543CP - IrelandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20031133</style></custom1><custom3><style face="normal" font="default">AS - Atherosclerosis. 210(1):150-4, 2010 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>416</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Allison,M.A.</style></author><author><style face="normal" font="default"> Budoff,M.J.</style></author><author><style face="normal" font="default"> Nasir,K.</style></author><author><style face="normal" font="default"> Wong,N.D.</style></author><author><style face="normal" font="default"> Detrano,R.</style></author><author><style face="normal" font="default"> Kronmal,R.</style></author><author><style face="normal" font="default"> Takasu,J.</style></author><author><style face="normal" font="default"> Criqui,M.H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Ethnic-specific risks for atherosclerotic calcification of the thoracic and abdominal aorta (from the Multi-Ethnic Study of Atherosclerosis)</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="817" start="812">812-817</pages><volume><style face="normal" font="default">104</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aorta,Thoracic/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Aorta,Abdominal/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Atherosclerosis/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> *European Continental Ancestry Group/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> *Hispanic Americans/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Abdomen</style></keyword><keyword><style face="normal" font="default"> African Americans</style></keyword><keyword><style face="normal" font="default"> African Americans/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Asian Americans/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Diabetic Angiopathies/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Smoking/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="15" Month="9" Year="2009">2009/9/15</year></dates><abstract><style face="normal" font="default">The aims of this study were to (1) determine the association between ethnicity and thoracic aortic calcium (TAC) and abdominal aortic calcium (AAC) and (2) investigate associations between cardiovascular disease (CVD) risk factors and TAC and AAC. Participants were 1,957 men and women enrolled in the Multi-Ethnic Study of Atherosclerosis who had computed tomographic scans of the chest and abdomen. These scans were obtained at the same clinic visit and calcium scores were computed using the Agatston method. Regression analyses were conducted using relative risk regression. Mean age was 65 years and 50% were women. Forty percent were white, 26% Hispanic, 21% African-American, and 13% Chinese. Whites had the highest prevalence of AAC (80%), which was significantly higher than Hispanics (68%, p &lt;0.001), African-Americans (63%, p &lt;0.001), and Chinese (74%, p = 0.029). Similarly, whites had the highest prevalence of TAC (42%), which was significantly higher than in Hispanics (30%, p &lt;0.01) and African-Americans (27%, p &lt;0.001) but was not significantly different from that in Chinese (38%). Compared to whites and after adjustment for age, gender, body mass index, hypertension, diabetes, dyslipidemia, smoking, and family history of CVD, Hispanics and African-Americans, but not Chinese-Americans, had a significantly lower risk for the presence of any AAC or any TAC. In these models, diabetes, smoking, and dyslipidemia had stronger associations with AAC, whereas hypertension was stronger for TAC. In conclusion, compared to whites, African-Americans and Hispanics, but not Chinese, have evidence of less atherosclerosis in the thoracic and abdominal aortas, which does not appear to be accounted for by traditional CVD risk factors</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - University of California, San Diego, La Jolla, California, USA. mallison@ucsd.eduJC - 3dq, 0207277CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - N01-HC-95159 (United States NHLBI NIH HHS)NO - N01-HC-95165 (United States NHLBI NIH HHS)NO - N01-HC-95169 (United States NHLBI NIH HHS)NO - R01 HL071739 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19733716</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 104(6):812-7, 2009 Sep 15.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>507</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Almafragi,A.</style></author><author><style face="normal" font="default"> Vandorpe,J.</style></author><author><style face="normal" font="default"> Dujardin,K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Calciphylaxis in a cardiac patient without renal disease</style></title><secondary-title><style face="normal" font="default">Acta Cardiologica</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Acta Cardiologica</style></full-title></periodical><pages end="93" start="91">91-93</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Anticoagulants/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Calciphylaxis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Heart Diseases/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Warfarin/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> 0 (Anti-Bacterial Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Anticoagulants)</style></keyword><keyword><style face="normal" font="default"> 0 (Diphosphonates)</style></keyword><keyword><style face="normal" font="default"> 0 (Thienamycins)</style></keyword><keyword><style face="normal" font="default"> 1404-90-6 (Vancomycin)</style></keyword><keyword><style face="normal" font="default"> 18323-44-9 (Clindamycin)</style></keyword><keyword><style face="normal" font="default"> 81-81-2 (Warfarin)</style></keyword><keyword><style face="normal" font="default"> 96036-03-2 (meropenem)</style></keyword><keyword><style face="normal" font="default"> Alcoholism/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Anti-Bacterial Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Calciphylaxis/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> Calciphylaxis/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Calciphylaxis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies</style></keyword><keyword><style face="normal" font="default"> Clindamycin/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Diphosphonates/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Heart Diseases/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Thienamycins/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Vancomycin/tu [Therapeutic Use]</style></keyword></keywords><dates><year Day="0" Month="2" Year="2009">2009/2</year></dates><isbn><style face="normal" font="default">0001-5385</style></isbn><abstract><style face="normal" font="default">Calciphylaxis is a rare complication that occurs in 1% of patients with end-stage renal disease (ESRD) each year. Extensive microvascular calcification and occlusion/thrombosis lead to violaceous skin lesions, which progress to nonhealing ulcers with secondary infection, often leading to sepsis and death. The lower extremities are predominantly involved (roughly 90% of patients). Although most calciphylaxis patients have abnormalities of the calcium-phosphate axis or elevated levels of parathyroid hormone, these abnormalities do not appear to be fundamental to the pathophysiology of the disorder. We report on a case of histologically proven calciphylaxis in a 54-year-old woman with normal renal function and normal calcium-parathyroid homeostasis. She had a history of alcoholic cardiomyopathy, and was treated with warfarin anticoagulation. She has been successfully treated with antibiotics, i.v. biophosphonates and intensive local wound care. We recorded a complete wound healing in contrast to what is reported in other series</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Heilig-Hart Hospital Roeselare, Belgium. aser33@yahoo.comJC - 0370570CP - BelgiumPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19317304</style></custom1><custom3><style face="normal" font="default">AS - Acta Cardiol. 64(1):91-3, 2009 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>187</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Almirall,J.</style></author><author><style face="normal" font="default"> Vaqueiro,M.</style></author><author><style face="normal" font="default"> Bar&amp;#x00E9</style></author><author><style face="normal" font="default"> ML</style></author><author><style face="normal" font="default"> Anton,E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Association of low serum 25-hydroxyvitamin D levels and high arterial blood pressure in the elderly</style></title><secondary-title><style face="normal" font="default">Nephrology Dialysis Transplantation</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Nephrology Dialysis Transplantation</style></full-title></periodical><pages end="509" start="503">503-509</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Hypertension/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Vitamin D Deficiency/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Vitamin D Deficiency/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Vitamin D/aa [Analogs &amp; Derivatives]</style></keyword><keyword><style face="normal" font="default"> 1406-16-2 (Vitamin D)</style></keyword><keyword><style face="normal" font="default"> 64719-49-9 (25-hydroxyvitamin D)</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Vitamin D Deficiency/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Vitamin D/bl [Blood]</style></keyword></keywords><dates><year Day="0" Month="2" Year="2010">2010/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: Vitamin D and calcium metabolism are involved in vascular smooth muscle cell proliferation, endothelial function and blood pressure (BP) regulation. Their physiopathology has been a matter of intensive clinical investigation with variable and sometimes contradictory results. Vitamin D insufficiency is highly prevalent in the general population, particularly among the elderly. We evaluated the association between serum 25(OH)-D levels and arterial BP in this population. METHODS: An epidemiological cross-sectional study was designed to analyse the prevalence of hypovitaminosis D ('D'AVIS' study) in our reference area. The study was performed on a representative random sample of the population over 64 years of age obtained from five primary health care areas. A medical record, arterial BP and biological analysis: serum 25(OH)-D, iPTH, creatinine, urea, calcium, albumin were obtained. RESULTS: A total of 237 subjects (53% women), aged between 64 and 93 (mean 71.7 +/- 5.3), were evaluated. The mean serum 25(OH)-D levels were 17.21 +/- 7.57 ng/ml (interval 5-54; 86% had &lt;25 ng/ml). The mean BP was 138.8 +/- 14/80 +/- 7.4 mmHg, and 46% were on antihypertensive treatment. A significant negative association was observed between serum 25(OH)-D levels and systolic (r = -0.153, P = 0.018) and diastolic BP (r = -0.152, P = 0.019). This association persisted after controlling for possible confounders in the multivariate analyses. CONCLUSIONS: Low serum 25(OH)-D levels were inversely and independently associated with BP. Supplemental measures to prevent hypovitaminosis D in this population would be important, not only to protect the skeletal system but also for the possible beneficial effects on the cardiovascular system and the BP regulation</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Nephrology Service, UDIAT-CD, Departament de Medicina, Corporaci&amp;#x00F3; Sanit&amp;#x00E0;ria Parc Taul&amp;#x00ED;-Institut Universitari, Universitat Autonoma de Barcelona, Sabadell, Barcelona, Spain. jalmirall@tauli.catJC - n7j, 8706402CP - EnglandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19749143</style></custom1><custom3><style face="normal" font="default">AS - Nephrol Dial Transplant. 25(2):503-9, 2010 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>115</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Ambrus,C.</style></author><author><style face="normal" font="default"> Molnar,M.Z.</style></author><author><style face="normal" font="default"> Czira,M.E.</style></author><author><style face="normal" font="default"> Rosivall,L.</style></author><author><style face="normal" font="default"> Kiss,I.</style></author><author><style face="normal" font="default"> Remport,A.</style></author><author><style face="normal" font="default"> Szathmari,M.</style></author><author><style face="normal" font="default"> Mucsi,I.</style></author></authors></contributors><titles><title><style face="normal" font="default">Calcium, phosphate and parathyroid metabolism in kidney transplanted patients</style></title><secondary-title><style face="normal" font="default">International Urology &amp; Nephrology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">International Urology &amp; Nephrology</style></full-title></periodical><pages end="1038" start="1029">1029-1038</pages><volume><style face="normal" font="default">41</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Kidney Transplantation/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Parathyroid Hormone/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Phosphates/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Renal Insufficiency,Chronic/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 0 (Phosphates)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Biological Markers/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Biological Markers/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Blood Chemical Analysis</style></keyword><keyword><style face="normal" font="default"> Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Chi-Square Distribution</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default"> Graft Rejection</style></keyword><keyword><style face="normal" font="default"> Graft Survival</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Kidney Function Tests</style></keyword><keyword><style face="normal" font="default"> Kidney Transplantation</style></keyword><keyword><style face="normal" font="default"> Kidney Transplantation/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Phosphates/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Postoperative Complications/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Postoperative Complications/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Renal Insufficiency,Chronic/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Renal Insufficiency,Chronic/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Impaired kidney function is common in kidney-transplanted patients and complications of chronic kidney disease (CKD), such as mineral and bone disorders (MBD) are also prevalent in this population. Similarly to other stages of CKD, increasing evidence supports the association between MBD and cardiovascular risk after kidney transplantation as well. Still, little is known about the prevalence, clinical correlates of MBD and its management in transplanted patients. In this study, we aimed to examine the characteristics of MBD and its associations with clinical parameters in a large prevalent cohort of patients after kidney transplantation. METHODS: Nine hundred and ninety stable patients followed at a single kidney transplant outpatient clinic were included in the study. Detailed medical history, demographic data and routine laboratory results, including Ca, P and intact PTH were collected. Estimated GFR was calculated using the abbreviated MDRD formula, patients were stratified into three groups based on eGFR. Target levels for Ca, P and iPTH were based on CKD stages according to the NKF-K/DOQI guidelines. Standard statistical procedures, binomial and multinomial regressions were used in the analysis. RESULTS: The mean age was 51 years, 57% were males and 21% were diabetic, with 72 months (median) post-transplantation. Most of the patients were in CKD stage 3. Serum phosphorus showed strong negative correlation with graft function in CKD stages 4-5 (r = -0.633, P &lt; 0.001). Hyperphosphatemia was independently associated with the time spent on dialysis before transplantation, serum iPTH and CKD stages 4-5. iPTH showed negative correlation with eGFR in CKD stages 3-5 (rho = -0.289, P &lt; 0.001) and weak positive correlation with time spent on dialysis prior to transplant (rho = 0.114, P &lt; 0.001). Both hyperparathyroidism (42%) and relative hypoparathyroidism (15%) were frequent. The prescription of P-binders (6%) and vitamin D analogs (33%) was sporadic. CONCLUSION: Disturbances of bone and mineral metabolism after transplantation are prevalent and are strongly correlated with the kidney function, similarly to non-transplanted CKD patients. MBD in this population is not adequately managed</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Nephrology, University Health Network, University of Toronto, Toronto, CanadaJC - guq, 0262521CP - NetherlandsPT - Comparative StudyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19701690</style></custom1><custom3><style face="normal" font="default">AS - Int Urol Nephrol. 41(4):1029-38, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>140</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Amerling,R.</style></author><author><style face="normal" font="default"> Harbord,N.B.</style></author><author><style face="normal" font="default"> Pullman,J.</style></author><author><style face="normal" font="default"> Feinfeld,D.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series</style></title><secondary-title><style face="normal" font="default">Blood Purification</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Blood Purification</style></full-title></periodical><pages end="299" start="293">293-299</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Bone and Bones/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Diphosphonates/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure,Chronic/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> 0 (Diphosphonates)</style></keyword><keyword><style face="normal" font="default"> Absorptiometry,Photon</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Bone and Bones/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Bone Density</style></keyword><keyword><style face="normal" font="default"> Bone Diseases,Metabolic/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Bone Diseases/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> Bone Diseases/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Data Collection</style></keyword><keyword><style face="normal" font="default"> Diphosphonates/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Diphosphonates/ct [Contraindications]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Osteoporosis/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Renal Insufficiency,Chronic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Renal Insufficiency,Chronic/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Renal Osteodystrophy/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="0" Year="2010">2010</year></dates><abstract><style face="normal" font="default">Dual X-ray absorptiometry is the standard diagnostic modality for identification of low bone mineral density, a finding which is in the general population usually indicative of osteopenia or osteoporosis. However, chronic kidney disease (CKD) patients diagnosed with osteopenia or osteoporosis may in actual fact have renal osteodystrophy with high or low bone turnover. While bisphosphonates are currently prescribed for the prevention of fractures in osteoporosis and high-risk osteopenic patients, the clinical utility of bisphosphonate therapy in CKD has not been established. Furthermore, bisphosphonates accumulate in bone, inhibit osteoclasts, and may cause or exacerbate low-turnover (adynamic) bone disease - particularly in patients presenting with low parathyroid hormone (PTH) levels or receiving treatment for secondary hyperparathyroidism. Bone biopsy with non-decalcified histopathology remains the gold standard for the identification and evaluation of bone disorders, including osteoporosis and renal osteodystrophy. Thirteen CKD patients (stage II-IV), referred to our clinic over a 12-month period, were identified as having taken bisphosphonates from 4 to >60 months after a diagnosis of osteopenia or osteoporosis. All patients underwent biopsies of trabecular bone from the iliac crest following oral administration of time-separated doses of doxycycline and tetracycline. Bone pathology was assessed after processing for mineralized histology. For all patients, clinical data collection included assessment of likely causes of kidney disease, MDRD glomerular filtration rate, calcium-phosphate product, intact PTH level, alkaline phosphatase, and bisphosphonate exposure. All 13 patients were diagnosed with adynamic bone on biopsy evaluation. Eleven biopsies revealed decreased cancellous bone mass; 8 showed decreased osteoid surface; 8 disclosed decreased osteoid thickness, and all 13 demonstrated low or low-normal osteoclast/osteoblast interface. Assessment of dynamic bone formation demonstrated decreased or absent single- or double-labeled osteoid in all 13 bone specimens. Based on these observations, the use of bisphosphonates in CKD cannot be recommended. Copyright 2010 S. Karger AG, Basel</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Nephrology and Hypertension, Department of Medicine, Beth Israel Medical Center, New York, NY 10003, USAJC - aj6, 8402040CP - SwitzerlandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20090316</style></custom1><custom3><style face="normal" font="default">AS - Blood Purif. 29(3):293-9, 2010.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>514</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Anders,K.</style></author><author><style face="normal" font="default"> Baum,U.</style></author><author><style face="normal" font="default"> Gauss,S.</style></author><author><style face="normal" font="default"> Kuefner,M.A.</style></author><author><style face="normal" font="default"> Achenbach,S.</style></author><author><style face="normal" font="default"> Kuettner,A.</style></author><author><style face="normal" font="default"> Daniel,W.G.</style></author><author><style face="normal" font="default"> Uder,M.</style></author><author><style face="normal" font="default"> Ropers,D.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Initial experience with prospectively triggered, sequential CT coronary angiography on a 128-slice scanner]. [German]</style></title><secondary-title><style face="normal" font="default">Rofo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rofo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin</style></full-title></periodical><pages end="338" start="332">332-338</pages><volume><style face="normal" font="default">181</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Body Burden</style></keyword><keyword><style face="normal" font="default"> *Cardiac-Gated Imaging Techniques/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Radiographic Image Enhancement/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Tomography,Spiral Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Artifacts</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Rate</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Motion</style></keyword><keyword><style face="normal" font="default"> Pilot Projects</style></keyword><keyword><style face="normal" font="default"> Radiometry</style></keyword><keyword><style face="normal" font="default"> Relative Biological Effectiveness</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword></keywords><dates><year Day="0" Month="4" Year="2009">2009/4</year></dates><abstract><style face="normal" font="default">PURPOSE: Spiral CT angiography (CTA) of the coronaries using low-pitch scanning and ECG-gated image reconstruction is a robust method for detecting or excluding relevant coronary plaque. However, the resulting dose exposure is considerable. The aim of the present study was to evaluate image quality and artifacts as well as to record dose values for sequential coronary CTA using a 128-slice scanner with a temporal resolution of 150 ms. MATERIALS UND METHODS: 20 patients with a regular heart rate and without contraindications for oral/I.V. beta blockers, who were referred for CTA of the coronaries for exclusion or detection of relevant plaques, were examined by sequential CTA with the following parameters: 120 kV, 200 ref mAs, collimation 2 x 64 x 0.6, table feed of 34.5 mm at a detector width of 38.4 mm. A total acquisition time of 380 ms per table position allowed for mild shifting of the reconstruction window within the cardiac cycle of +/- 5 %. 50 ml of contrast agent were injected at 5 ml/s followed by a 50 ml split bolus (20 % contrast). The individual start delay was determined by a test bolus scan (10 ml contrast + 50 ml saline flush at 5 ml/s). The image quality for each segment, coronary artery, and patient was determined on a 4-point scale. Dose values were estimated based on the individual dose length product as provided by the scanner's patient protocol. Artifacts were evaluated to determine the cause (calcium vs. motion). RESULTS: All patients received beta blocker pretreatment. The mean heart rate was 62 +/- 5 beats/min. 5 % (13 / 286) of all segments in 5 / 20 patients were rated as non-diagnostic. The mean dose length product was 213 mGy x cm, and the mean effective dose was 3.6 mSv. Calcifications were the major cause of non-diagnostic images. However breathing or other motion artifacts occurred as well. CONCLUSION: In select patients with effective heart rate control and thorough instruction for breath hold compliance, sequential CTA of the coronaries using a 128-slice scanner with a temporal resolution of 150 ms is technically feasible. The resulting effective dose values are clearly below those of spiral coronary CT scans</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Radiologisches Institut, Friedrich-Alexander-Universit&amp;#x00E4;t Erlangen-N&amp;#x00FC;rnberg. katharina.anders@uk-erlangen.deOT - Erste Erfahrungen mit der sequenziellen, prospektiv getriggerten CT-Koronarangiografie an einem 128-Schicht-ComputertomografenJC - rof, 7507497CP - GermanyPT - Comparative StudyPT - English AbstractPT - Evaluation StudiesPT - Journal ArticleLG - German</style></notes><urls/><custom1><style face="normal" font="default">UI - 19291602</style></custom1><custom3><style face="normal" font="default">AS - ROFO Fortschr Geb Rontgenstr Nuklearmed. 181(4):332-8, 2009 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>287</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Andersen,R.</style></author><author><style face="normal" font="default"> Wethal,T.</style></author><author><style face="normal" font="default"> nther,A.</style></author><author><style face="normal" font="default"> Foss&amp;#x00E5</style></author><author><style face="normal" font="default"> A</style></author><author><style face="normal" font="default"> Edvardsen,T.</style></author><author><style face="normal" font="default"> Foss&amp;#x00E5</style></author><author><style face="normal" font="default"> SD</style></author><author><style face="normal" font="default"> Kjekshus,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Relation of coronary artery calcium score to premature coronary artery disease in survivors >15 years of Hodgkin's lymphoma</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="152" start="149">149-152</pages><volume><style face="normal" font="default">105</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Hodgkin Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Hodgkin Disease/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> 0 (Anthracyclines)</style></keyword><keyword><style face="normal" font="default"> 0 (Antineoplastic Agents)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Anthracyclines/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Antineoplastic Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Hodgkin Disease/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Norway</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Survivors</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="15" Month="1" Year="2010">2010/1/15</year></dates><abstract><style face="normal" font="default">Long-term survival in Hodgkin lymphoma (HL) survivors is complicated by an increased risk for coronary artery disease (CAD) due to radiation-induced endothelial damage. Our objective was to quantify total coronary artery calcium (CAC) in long-term HL survivors who had survived >or=15 years after treatment and relate it to the presence of verified CAD. Forty-seven HL survivors 50 +/- 7 years of age who had survived 22 +/- 3 years after mediastinal radiotherapy underwent CAC scoring (Agatston and volume scores) in a multidetector computed tomographic scanner. Total volume score was higher in 7 patients (15%) with verified CAD (median 439, range 8 to 2,057) compared to those without (median 68, 0 to 767, p = 0.022). Ten patients had CAC scores >200. Of these 10, 5 had undergone revascularization of coronary arteries. None of the 8 patients with a CAC score 0 had symptomatic CAD. In conclusion, postirradiation CAC can be quantified by CAC score and this may be a simple and suitable method to screen for CAD in long-term HL survivors. Patients with a CAC score >200 often have clinically significant CAD, and further investigation including angiography may be justified. Lower CAC scores, however, do not exclude CAD and further studies should be undertaken to define the best algorithm for follow-up of this patient group. Copyright 2010 Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Deprtment of Radiology, Oslo University Hospital, University of Oslo, Oslo, Norway. rune.andersen@rikshospitalet.noJC - 3dq, 0207277CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20102909</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 105(2):149-52, 2010 Jan 15.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>330</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Annweiler,C.</style></author><author><style face="normal" font="default"> Schott,A.M.</style></author><author><style face="normal" font="default"> Allali,G.</style></author><author><style face="normal" font="default"> Bridenbaugh,S.A.</style></author><author><style face="normal" font="default"> Kressig,R.W.</style></author><author><style face="normal" font="default"> Allain,P.</style></author><author><style face="normal" font="default"> Herrmann,F.R.</style></author><author><style face="normal" font="default"> Beauchet,O.</style></author></authors></contributors><titles><title><style face="normal" font="default">Association of vitamin D deficiency with cognitive impairment in older women: cross-sectional study</style></title><secondary-title><style face="normal" font="default">Neurology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Neurology</style></full-title></periodical><pages end="32" start="27">27-32</pages><volume><style face="normal" font="default">74</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cognition Disorders/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Geriatric Assessment</style></keyword><keyword><style face="normal" font="default"> *Vitamin D Deficiency/co [Complications]</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 1406-16-2 (Vitamin D)</style></keyword><keyword><style face="normal" font="default"> 64719-49-9 (25-hydroxyvitamin D)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Mental Status Schedule</style></keyword><keyword><style face="normal" font="default"> Neuropsychological Tests</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Vitamin D/aa [Analogs &amp; Derivatives]</style></keyword><keyword><style face="normal" font="default"> Vitamin D/bl [Blood]</style></keyword></keywords><dates><year Day="5" Month="1" Year="2010">2010/1/5</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The association between low serum 25-hydroxyvitamin D [25(OH)D] concentration and cognitive decline has been investigated by only a few studies, with mixed results. The objective of this cross-sectional population-based study was to examine the association between serum 25(OH)D deficiency and cognitive impairment while taking confounders into account. METHODS: The subjects, 752 women aged > or =75 years from the Epid&amp;#x00E9;miologie de l'Ost&amp;#x00E9;oporose (EPIDOS) cohort, were divided into 2 groups according to serum 25(OH)D concentrations (either deficient, &lt;10 ng/mL, or nondeficient, > or =10 ng/mL). Cognitive impairment was defined as a Pfeiffer Short Portable Mental State Questionnaire (SPMSQ) score &lt;8. Age, body mass index, number of chronic diseases, hypertension, depression, use of psychoactive drugs, education level, regular physical activity, and serum intact parathyroid hormone and calcium were used as potential confounders. RESULTS: Compared with women with serum 25(OH)D concentrations > or =10 ng/mL (n = 623), the women with 25(OH)D deficiency (n = 129) had a lower mean SPMSQ score (p &lt; 0.001) and more often had an SPMSQ score &lt;8 (p = 0.006). There was no significant linear association between serum 25(OH)D concentration and SPMSQ score (beta = -0.003, 95% confidence interval -0.012 to 0.006, p = 0.512). However, serum 25(OH)D deficiency was associated with cognitive impairment (crude odds ratio [OR] = 2.08 with p = 0.007; adjusted OR = 1.99 with p = 0.017 for full model; and adjusted OR = 2.03 with p = 0.012 for stepwise backward model). CONCLUSIONS: 25-Hydroxyvitamin D deficiency was associated with cognitive impairment in this cohort of community-dwelling older women</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Internal Medicine and Geriatrics, Angers University Hospital, 49933 Angers Cedex 9, France. ceannweiler@chu-angers.frJC - 0401060, nz0CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19794127</style></custom1><custom3><style face="normal" font="default">AS - Neurology. 74(1):27-32, 2010 Jan 5.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>288</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Arcand,J.</style></author><author><style face="normal" font="default"> Floras,V.</style></author><author><style face="normal" font="default"> Ahmed,M.</style></author><author><style face="normal" font="default"> Al-Hesayen,A.</style></author><author><style face="normal" font="default"> Ivanov,J.</style></author><author><style face="normal" font="default"> Allard,J.P.</style></author><author><style face="normal" font="default"> Newton,G.E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Nutritional inadequacies in patients with stable heart failure</style></title><secondary-title><style face="normal" font="default">Journal of the American Dietetic Association</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of the American Dietetic Association</style></full-title></periodical><pages end="1913" start="1909">1909-1913</pages><volume><style face="normal" font="default">109</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Diet,Sodium-Restricted</style></keyword><keyword><style face="normal" font="default"> *Heart Failure/dh [Diet Therapy]</style></keyword><keyword><style face="normal" font="default"> *Micronutrients/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Nutrition Assessment</style></keyword><keyword><style face="normal" font="default"> *Nutritional Status</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Micronutrients)</style></keyword><keyword><style face="normal" font="default"> Biological Markers/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Coronary Disease/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Coronary Disease/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Diet,Sodium-Restricted/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Failure/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Hypertension/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Micronutrients/df [Deficiency]</style></keyword><keyword><style face="normal" font="default"> Micronutrients/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Nutrition Policy</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Urinalysis</style></keyword><keyword><style face="normal" font="default"> Urine</style></keyword></keywords><dates><year Day="0" Month="11" Year="2009">2009/11</year></dates><abstract><style face="normal" font="default">Sodium restriction is the primary nutritional strategy in heart failure; however, other diet-related concerns may also occur. We characterized dietary intake among stable patients with heart failure and a non-heart-failure cardiac control group to quantify and determine prevalence of inadequate micronutrient intake. Two 3-day food records were completed by 123 patients with heart failure and 58 controls. A subset of each group provided two 24-hour urine collections. Mean intake of sodium (2,540+/-1,122 vs 2,596+/-1,184 mg/day) and potassium (3,190+/-980 vs 3,114+/-828 mg/day) was similar between the heart failure and control groups. Prevalence of inadequate potassium intake was 94% among patients with heart failure and 91% among controls. More than 50% in each group had inadequate intakes of calcium, magnesium, folate, and vitamins D and E. In stable patients with heart failure, sodium intake was not excessive. However, we demonstrated widespread dietary inadequacies of other vitamins and minerals. These findings highlight the importance of diet beyond that of sodium restriction</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Nutritional Sciences, University of Toronto and Mount Sinai Hospital, Toronto, Ontario, CanadaJC - h6f, 7503061CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19857633</style></custom1><custom3><style face="normal" font="default">AS - J Am Diet Assoc. 109(11):1909-13, 2009 Nov.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>215</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Ari,H.</style></author><author><style face="normal" font="default"> Ari,S.</style></author><author><style face="normal" font="default"> Koca,V.</style></author><author><style face="normal" font="default"> Bozat,T.</style></author></authors></contributors><titles><title><style face="normal" font="default">[A rare cause of reversible dilated cardiomyopathy: hypocalcemia]. [Turkish]</style></title><secondary-title><style face="normal" font="default">Turk Kardiyoloji Dernegi Arsivi</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Turk Kardiyoloji Dernegi Arsivi</style></full-title></periodical><pages end="268" start="266">266-268</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiomyopathy,Dilated/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Hypocalcemia/co [Complications]</style></keyword><keyword><style face="normal" font="default"> 1406-16-2 (Vitamin D)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathy,Dilated/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypocalcemia/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Vitamin D/tu [Therapeutic Use]</style></keyword></keywords><dates><year Day="0" Month="6" Year="2009">2009/6</year></dates><isbn><style face="normal" font="default">1016-5169</style></isbn><abstract><style face="normal" font="default">Hypocalcaemia is a rare cause of reversible heart failure. We present a 27-year-old man who had severe heart failure unresponsive to medical therapy. He had vitamin D-resistant rickets for which he had received replacement therapy with vitamin D and calcium until age 20, but he discontinued treatment for the past seven years. Severe hypocalcemia was detected. Echocardiography showed left ventricular dilatation, global hypokinesia (ejection fraction 25%), and mitral and tricuspid regurgitation of grades 3 and 2, respectively. After calcium and vitamin D supplementation, his symptoms showed rapid improvement. At nine months, myocardial dysfunction improved fully. Hypocalcemia should be considered among the causes of heart failure unresponsive to medical treatment</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Bursa Postgraduate Hospital, Bursa, Turkey. hasanari03@yahoo.comOT - Geri d&amp;#x00F6;n&amp;#x00FC;&amp;#x015F;&amp;#x00FC;ml&amp;#x00FC; dilate kardiyomiyopatinin nadir bir nedeni: HipokalsemiJC - 9426239CP - TurkeyPT - Case ReportsPT - English AbstractPT - Journal ArticleLG - Turkish</style></notes><urls/><custom1><style face="normal" font="default">UI - 19717962</style></custom1><custom3><style face="normal" font="default">AS - TURK KARDIYOLOJI DERNEGI ARS.. 37(4):266-8, 2009 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>66</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Arinzon,Z.</style></author><author><style face="normal" font="default"> Peisakh,A.</style></author><author><style face="normal" font="default"> Schrire,S.</style></author><author><style face="normal" font="default"> Berner,Y.N.</style></author></authors></contributors><titles><title><style face="normal" font="default">Prevalence of hypomagnesemia (HM) in a geriatric long-term care (LTC) setting</style></title><secondary-title><style face="normal" font="default">Archives of Gerontology &amp; Geriatrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Archives of Gerontology &amp; Geriatrics</style></full-title></periodical><pages end="40" start="36">36-40</pages><volume><style face="normal" font="default">51</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Health Services for the Aged/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> *Long-Term Care/ut [Utilization]</style></keyword><keyword><style face="normal" font="default"> *Magnesium Deficiency/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Magnesium Deficiency/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> 0 (Electrolytes)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Electrolytes/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="7" Year="2010">2010/7</year></dates><abstract><style face="normal" font="default">Electrolyte abnormalities are frequently observed in elderly long-term care (LTC) patients. Magnesium is a trace mineral, but is the second most abundant intracellular cation and the fourth most abundant cation in the body. This was a cross-sectional study to assess the prevalence of hypomagnesemia (HM) in non-selected elderly LTC patients. A total of 159 patients aged 65 years and older were included in the study. The attributes and variables related to the patients' hospital course were used to compare the two groups. We used univariate and multivariate analyses to correlate magnesium levels with demographic, clinical factors and laboratory data. HM was found in 36% of the patients, of whom 35% presented with moderate HM (0.8-0.9 microequiv./l) and 18% with severe HM (&lt;or=0.7 microequiv./l). Patients with HM had a higher number of comorbid diseases per patient (p=0.038), low body mass index (BMI) (p=0.044) and more of them presented with laboratory markers of malnutrition, such as low total cholesterol (TC) and serum albumin (SA) levels. Coexistence with other electrolyte abnormalities was higher among patients with HM than without (p=0.006), predominantly hypocalcemia and hypokalemia (p=0.023 and 0.032, respectively). Using regression analysis, independent variables significantly associated with serum magnesium levels were serum albumin, calcium, potassium, urea levels, chronic renal failure (CRF), chronic heart failure (CHF), diabetes mellitus (DM) and diuretic drugs (R(2)=0.877). Both early (up to 30 days) and late rate of death were higher in patients with HM. The incidence of HM in LTC elderly patients is high and multifactorial. Understanding the causes of HM, correction of magnesium level, and definitive and effective treatment of the cause leading to HM is important to improve patient prognosis. Copyright 2009 Elsevier Ireland Ltd. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - The Department of Geriatric Medicine, Sapir Medical Center, Kfar Saba, Israel. arinzon@walla.co.ilJC - 8214379, 7axCP - NetherlandsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19665241</style></custom1><custom3><style face="normal" font="default">AS - Arch Gerontol Geriatr. 51(1):36-40, 2010 Jul-Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>291</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Ariyarajah,V.</style></author><author><style face="normal" font="default"> Apiyasawat,S.</style></author><author><style face="normal" font="default"> Barac,I.</style></author><author><style face="normal" font="default"> Spodick,D.H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Is the presence of mitral annular calcification associated with poor left atrial function?</style></title><secondary-title><style face="normal" font="default">Echocardiography</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Echocardiography</style></full-title></periodical><pages end="884" start="877">877-884</pages><volume><style face="normal" font="default">26</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Echocardiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Heart Atria/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Heart Valve Diseases/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Mitral Valve/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Stroke Volume</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="9" Year="2009">2009/9</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Mitral annular calcification (MAC) is characterized by calcium and lipid deposition in the annular fibrosa of the mitral valve. MAC is associated with cardiovascular events but little is known of its association with left atrial (LA) function. METHODS: We prospectively obtained 12-lead electrocardiograms (ECGs) and transthoracic echocardiograms (TTE) on patients scheduled for nonemergent echocardiographic assessment at a tertiary care hospital. MAC was graded as 0 = none, 1 = mild, 2 = moderate, 3 = severe. LA linear and volume measurements (stroke volume, LA passive emptying fraction, LA active emptying fraction and LA kinetic energy) were done specifically in addition to commonly measured TTE parameters. RESULTS: From the 124 considered for the study, 72 patients remained (aged 68+/-18 years; 44% male) after excluding those with poor ECG tracings and/or poor TTE images. Eighteen patients had MAC; mild MAC = 14, moderate MAC = 3, severe MAC = 1. When patients with MAC were compared to those without MAC, no significant difference was noted, except for LA linear dimension index (2.1+/-0.4 vs. 1.9+/-0.3 cm/m(2); P = 0.03). For those with mild and moderate MAC, a trend was noted toward lower LA function with increasing MAC severity. In addition, significant differences were noted between those with and without interatrial conduction delay, where those with such delay had significantly impaired LA stroke volume (9.8+/-3 vs. 19.93+/-4 ml; P &lt; 0.0001), LA active emptying fraction (18.83+/-8 vs. 65.71+/-9%; P &lt; 0.0001) and LA total/reservoir fraction (39.54+/-6 vs. 75.1+/-6%; P &lt; 0.0001). CONCLUSIONS: MAC is associated with increase in LA linear dimension on TTE and may be equally represented with lower overall LA function. Further study in a much larger cohort is warranted to delineate these and other potential associations of MAC</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Interventional Cardiology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania 19107, USA. vignendra@hotmail.comJC - bcn, 8511187CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19486115</style></custom1><custom3><style face="normal" font="default">AS - Echocardiography. 26(8):877-84, 2009 Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>423</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Artmann,A.</style></author><author><style face="normal" font="default"> Enayati,S.</style></author><author><style face="normal" font="default"> ck,M.</style></author><author><style face="normal" font="default"> Schwarz,M.</style></author><author><style face="normal" font="default"> Weber,T.</style></author><author><style face="normal" font="default"> Eber,B.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Image quality of CT angiography of coronary arteries depending on the degree of coronary calcification using a dual source CT scanner]. [German]</style></title><secondary-title><style face="normal" font="default">Rofo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rofo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin</style></full-title></periodical><pages end="869" start="863">863-869</pages><volume><style face="normal" font="default">181</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Angiography,Digital Subtraction/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Angiography,Digital Subtraction/st [Standards]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/st [Standards]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Radiography,Dual-Energy Scanned Projection/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Radiography,Dual-Energy Scanned Projection/st [Standards]</style></keyword><keyword><style face="normal" font="default"> *Tomography,Spiral Computed/st [Standards]</style></keyword><keyword><style face="normal" font="default"> *Tomography,Spiral Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> 0 (Contrast Media)</style></keyword><keyword><style face="normal" font="default"> 62883-00-5 (Iopamidol)</style></keyword><keyword><style face="normal" font="default"> 78649-41-9 (iomeprol)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Artifacts</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Contrast Media/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Catheterization</style></keyword><keyword><style face="normal" font="default"> Heart Rate</style></keyword><keyword><style face="normal" font="default"> Heart Rate/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Iopamidol/aa [Analogs &amp; Derivatives]</style></keyword><keyword><style face="normal" font="default"> Iopamidol/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Observer Variation</style></keyword><keyword><style face="normal" font="default"> Radiography,Dual-Energy Scanned Projection/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> Reference Standards</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Statistics as Topic</style></keyword><keyword><style face="normal" font="default"> Tomography,Spiral Computed/is [Instrumentation]</style></keyword></keywords><dates><year Day="0" Month="9" Year="2009">2009/9</year></dates><abstract><style face="normal" font="default">PURPOSE: To evaluate the influence of severe calcification on image quality of CT angiography (CTA) of coronary arteries acquired with dual source CT. METHOD: 171 dual source CTAs in spiral mode were evaluated. Depending on the Agatston score (CS), patients where divided into four subgroups (I: CS 0 - 200, II: CS 201 - 600, III: CS 601 - 1000, IV: CS > 1000). Image quality was evaluated by two independent, blinded readers using a three-stage scale and the image quality of each subgroup was also shown with the help of an image quality index (BQI). In addition, a comparison with coronary catheter angiography was undertaken in a subgroup. RESULTS: Dual source CTA in spiral mode showed good image quality even in patients with Agatston scores of 601 - 1000 and > 1000. The four classes showed no significant difference in image quality. (BQI = 1,164 [I], BQI = 1,212 [II], BQI = 1,281 [III], BQI = 1,111 [IV]; p = 0,3145). The detailed analysis showed particularly good quality in patients with a heart rate &lt; 75 bpm. The smaller subgroup of patients with CS > 200 and heart rates > 75 bpm showed a statistically significant reduction in image quality (BQI = 1,625; p = 0.0016). There were no gender differences in the image quality (p = 0.9881) although the calcium scores differed significantly in men (CS = 313 [+/- 449]) and women (CS = 145 [+/- 304]). The comparison with coronary catheter angiography showed a good correlation (92%). CONCLUSION: CTA of coronary arteries performed with dual source CT in spiral mode provides good image quality even in patients with higher calcification scores. The reduction of heart rates > 75 bpm improves the image quality significantly in patients with higher calcification scores. Georg Thieme Verlag KG Stuttgart, New York</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Radiologie II, Klinikum Wels Grieskirchen, Osterreich. andreas.artmann@klinikumwegr.atOT - Bildqualit&amp;#x00E4;t von CT-Angiografien der Koronararterien in Abh&amp;#x00E4;ngigkeit vom Ausmass der Koronarverkalkungen bei Einsatz eines Dual-Source-CTsJC - rof, 7507497CP - GermanyPT - English AbstractPT - Journal ArticleLG - German</style></notes><urls/><custom1><style face="normal" font="default">UI - 19676015</style></custom1><custom3><style face="normal" font="default">AS - ROFO Fortschr Geb Rontgenstr Nuklearmed. 181(9):863-9, 2009 Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>351</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Aryan,M.</style></author><author><style face="normal" font="default"> Kepez,A.</style></author><author><style face="normal" font="default"> Atalar,E.</style></author><author><style face="normal" font="default"> Hazirolan,T.</style></author><author><style face="normal" font="default"> Haznedaroglu,I.</style></author><author><style face="normal" font="default"> Akata,D.</style></author><author><style face="normal" font="default"> Ozer,N.</style></author><author><style face="normal" font="default"> Aksoyek,S.</style></author><author><style face="normal" font="default"> Ovunc,K.</style></author><author><style face="normal" font="default"> Ozmen,F.</style></author></authors></contributors><titles><title><style face="normal" font="default">Association of plasma osteopontin levels with coronary calcification evaluated by tomographic coronary calcium scoring</style></title><secondary-title><style face="normal" font="default">Journal of Bone &amp; Mineral Metabolism</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Bone &amp; Mineral Metabolism</style></full-title></periodical><pages end="597" start="591">591-597</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Cardiomyopathies/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Cardiomyopathies/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Osteopontin/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> 0 (Anticholesteremic Agents)</style></keyword><keyword><style face="normal" font="default"> 106441-73-0 (Osteopontin)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Anticholesteremic Agents/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Renin-Angiotensin System/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><abstract><style face="normal" font="default">Evidence indicates that proteins controlling bone mineralization are also involved in the regulation of coronary calcification. The aim of the present study is to evaluate the association between plasma osteopontin (OPN) levels and coronary calcification quantified by using tomographic coronary calcium scoring. Plasma OPN levels were measured from samples of 80 intermediate-risk asymptomatic patients (56 +/- 10 years) who underwent tomographic coronary calcium scoring via multislice computed tomography for incremental risk stratification. There was no significant difference regarding OPN levels between patients with and without coronary calcification in the whole study population. Of 49 patients not receiving renin-angiotensin system inhibitors and/or statins, plasma OPN levels of patients with coronary calcification (38.7%) were significantly higher than those without coronary calcification (61.3%) (8.88 +/- 2.85 vs. 6.79 +/- 2.41, P = 0.008, respectively). On a binary logistic regression model, only age and plasma OPN level were found to be significant independent associated variables for the presence of coronary calcification in patients not receiving these medications (odds ratio for age, 1.15, P = 0.017; for plasma OPN levels, 1.63, P = 0.014). Our results indicate that plasma OPN levels may be predictive of coronary calcification, suggesting an important role of OPN in the atherosclerotic calcification pathogenesis</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Cardiology Department, Faculty of Medicine, Hacettepe University, Ankara, TurkeyJC - da5, 9436705CP - JapanPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19365701</style></custom1><custom3><style face="normal" font="default">AS - J Bone Miner Metab. 27(5):591-7, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>35</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Awan,Z.</style></author><author><style face="normal" font="default"> Alwaili,K.</style></author><author><style face="normal" font="default"> Alshahrani,A.</style></author><author><style face="normal" font="default"> Langsetmo,L.</style></author><author><style face="normal" font="default"> Goltzman,D.</style></author><author><style face="normal" font="default"> Genest,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Calcium homeostasis and skeletal integrity in individuals with familial hypercholesterolemia and aortic calcification</style></title><secondary-title><style face="normal" font="default">Clinical Chemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinical Chemistry</style></full-title></periodical><pages end="1607" start="1599">1599-1607</pages><volume><style face="normal" font="default">56</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aortic Diseases/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Bone and Bones/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Hyperlipoproteinemia Type II/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> 0 (Antilipemic Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipoproteins,LDL)</style></keyword><keyword><style face="normal" font="default"> 0 (Receptors,LDL)</style></keyword><keyword><style face="normal" font="default"> 104982-03-8 (Osteocalcin)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Antilipemic Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Aortic Diseases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Aortic Diseases/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Aortography</style></keyword><keyword><style face="normal" font="default"> Bone Density</style></keyword><keyword><style face="normal" font="default"> Calcinosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperlipoproteinemia Type II/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Hyperlipoproteinemia Type II/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Lipoproteins,LDL/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Osteocalcin/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Receptors,LDL/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword></keywords><dates><year Day="0" Month="10" Year="2010">2010/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Familial hypercholesterolemia (FH) due to mutations in the low-density lipoprotein receptor (LDLR) gene exhibit severe, premature aortic calcification in a gene-dosage, age-dependent fashion. We sought to determine potential associations with mineral and skeletal indices. METHODS: We obtained computed tomography (CT) scan aortic calcium scores (AoCSs) in 19 (age 49 [SD 14] years) FH patients heterozygous for the 15-kb deletion at the LDLR gene and examined associations with various indices of mineral and skeletal homeostasis. RESULTS: We found that mean bone mineral density (BMD) at the femoral neck in these patients did not differ from age-, sex-, and province-matched mean BMD, and we observed no association of AoCS with any marker of bone resorption. However, there were negative correlations between AoCS and serum concentrations of osteocalcin, a marker of bone formation (r = -0.64, P = 0.0034), urinary calcium (r = -0.59, P = 0.0085), and estimated glomerular filtration rate (r = -0.67, P = 0.0019). CONCLUSIONS: We found that LDLR-deficient FH was not associated with obvious bone loss or a major disturbance in calcium homeostasis. The lack of LDLR, however, may modify osteoblast function or extracellular calcium distribution, manifesting as lower bone formation, and reduced calcium excretion, resulting in increased deposition in calcifying vascular tissue</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Cardiovascular Research Laboratories, McGill University Health Centre and McGill University, Montreal, Quebec, CanadaJC - dbz, 9421549CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20702785</style></custom1><custom3><style face="normal" font="default">AS - Clin Chem. 56(10):1599-607, 2010 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>548</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Babaliaros,V.C.</style></author><author><style face="normal" font="default"> Liff,D.</style></author><author><style face="normal" font="default"> Chen,E.P.</style></author><author><style face="normal" font="default"> Rogers,J.H.</style></author><author><style face="normal" font="default"> Brown,R.A.</style></author><author><style face="normal" font="default"> Thourani,V.H.</style></author><author><style face="normal" font="default"> Guyton,R.A.</style></author><author><style face="normal" font="default"> Lerakis,S.</style></author><author><style face="normal" font="default"> Stillman,A.E.</style></author><author><style face="normal" font="default"> Raggi,P.</style></author><author><style face="normal" font="default"> Cheesborough,J.E.</style></author><author><style face="normal" font="default"> Veladar,E.</style></author><author><style face="normal" font="default"> Green,J.T.</style></author><author><style face="normal" font="default"> Block,P.C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Can balloon aortic valvuloplasty help determine appropriate transcatheter aortic valve size?</style></title><secondary-title><style face="normal" font="default">Jacc: Cardiovascular Interventions</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Jacc: Cardiovascular Interventions</style></full-title></periodical><pages end="586" start="580">580-586</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aortic Valve Stenosis/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> *Balloon Dilatation</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> *Heart Catheterization/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> *Heart Valve Prosthesis</style></keyword><keyword><style face="normal" font="default"> *Heart Valve Prosthesis Implantation/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Aortic Valve Stenosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Aortic Valve Stenosis/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Echocardiography,Transesophageal</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Georgia</style></keyword><keyword><style face="normal" font="default"> Heart Valve Prosthesis Implantation/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Pilot Projects</style></keyword><keyword><style face="normal" font="default"> Prosthesis Design</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="10" Year="2008">2008/10</year></dates><abstract><style face="normal" font="default">OBJECTIVES: We sought to study the potential role of balloon aortic valvuloplasty (BAV) in sizing the aortic annulus in patients before transcatheter heart valve (THV) implantation. BACKGROUND: Despite clinicians' growing experience with THV procedures, the best method of annulus sizing remains unclear. METHODS: Twenty-three patients with aortic stenosis (&lt;1.0 cm(2)) who were undergoing surgical valve replacement were enrolled. Pre-operative echocardiographic measurements of the annulus and computed tomography measurements of valve calcium were made. Intraoperatively, a valvuloplasty balloon of known size and inflatable pressure was inserted into the aortic valve and inflated. The development of intraballoon pressure in addition to the nominal inflation pressure (AIBP) reflected the apposition of balloon and valve. Surgical annulus was measured by cylindrical sizers. RESULTS: In patients with tricuspid valves, AIBP was generated in 11 of 12 patients when the balloon diameter was greater than the surgically measured annulus, regardless of leaflet calcification (2 of 10 patients when balloon &lt; or = surgical annulus). In bicuspid valves, high AIBP ( approximately 1 atm) was encountered with balloons that were within 1 mm of annulus size, and leaflet dehiscence occurred with larger balloons (n = 2 patients). Annulus size was underestimated by transthoracic echocardiogram and transesophageal echocardiogram compared with surgery (p &lt; 0.001): transthoracic echocardiogram = 21.5 +/- 1.8 mm, transesophageal echocardiogram = 22.0 +/- 1.6 mm and surgical = 23.2 +/- 1.9 mm (range 20 to 27 mm, mode 22 mm). CONCLUSIONS: These data suggest that measuring AIBP during balloon aortic valvuloplasty in tricuspid valves is an important adjunctive measurement of the aortic annulus and may help in determining the appropriate THV size</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Andreas Gruentzig Cardiovascular Center, Emory University Hospital, Atlanta, Georgia 30322, USA. Vasilis.babaliaros@emoryhealthcare.orgJC - 101467004CP - United StatesPT - Journal ArticlePT - Multicenter StudyLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19463362</style></custom1><custom3><style face="normal" font="default">AS - JACC Cardiovasc Interv. 1(5):580-6, 2008 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>22</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Bagheri,R.</style></author><author><style face="normal" font="default"> Qasim,A.N.</style></author><author><style face="normal" font="default"> Mehta,N.N.</style></author><author><style face="normal" font="default"> Terembula,K.</style></author><author><style face="normal" font="default"> Kapoor,S.</style></author><author><style face="normal" font="default"> Braunstein,S.</style></author><author><style face="normal" font="default"> Schutta,M.</style></author><author><style face="normal" font="default"> Iqbal,N.</style></author><author><style face="normal" font="default"> Lehrke,M.</style></author><author><style face="normal" font="default"> Reilly,M.P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Relation of plasma fatty acid binding proteins 4 and 5 with the metabolic syndrome, inflammation and coronary calcium in patients with type-2 diabetes mellitus</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="1123" start="1118">1118-1123</pages><volume><style face="normal" font="default">106</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 2/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Fatty Acid-Binding Proteins/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Metabolic Syndrome X/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (FABP4 protein,human)</style></keyword><keyword><style face="normal" font="default"> 0 (FABP5 protein,human)</style></keyword><keyword><style face="normal" font="default"> 0 (Fatty Acid-Binding Proteins)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Biological Markers/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus,Type 2/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Inflammation/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Inflammation/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Metabolic Syndrome X/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword></keywords><dates><year Day="15" Month="10" Year="2010">2010/10/15</year></dates><abstract><style face="normal" font="default">Fatty acid-binding proteins (FABPs) 4 and 5 play coordinated roles in rodent models of inflammation, insulin resistance, and atherosclerosis, but little is known of their role in human disease. The aim of this study was to examine the hypothesis that plasma adipocyte and macrophage FABP4 and FABP5 levels would provide additive value in the association with metabolic and inflammatory risk factors for cardiovascular disease as well as subclinical atherosclerosis. Using the Penn Diabetes Heart Study (PDHS; n = 806), cross-sectional analysis of FABP4 and FABP5 levels with metabolic and inflammatory parameters and with coronary artery calcium, a measure of subclinical coronary atherosclerosis, was performed. FABP4 and FABP5 levels had strong independent associations with the metabolic syndrome (for a 1-SD change in FABP levels, odds ratio [OR] 1.85, 95% confidence interval [CI] 1.43 to 2.23, and OR 1.66, 95% CI 1.41 to 1.95, respectively) but had differential associations with metabolic syndrome components. FABP4 and FABP5 were also independently associated with C-reactive protein and interleukin-6 levels. FABP4 (OR 1.26, 95% CI 1.05 to 1.52) but not FABP5 (OR 1.13, 95% CI 0.97 to 1.32) was associated with the presence of coronary artery calcium. An integrated score combining FABP4 and FABP5 quartile data had even stronger associations with the metabolic syndrome, C-reactive protein, interleukin-6, and coronary artery calcium compared to either FABP alone. In conclusion, this study provides evidence for an additive relation of FABP4 and FABP5 with the metabolic syndrome, inflammatory cardiovascular disease risk factors, and coronary atherosclerosis in type 2 diabetes mellitus. These findings suggest that FABP4 and FABP5 may represent mediators of and biomarkers for metabolic and cardiovascular disease in type 2 diabetes mellitus. Copyright [copyright sign] 2010. Published by Elsevier Inc</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Cardiovascular Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USAJC - 3dq, 0207277CP - United StatesPT - Comparative StudyPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - P50 HL-083799-SCCOR (United States NHLBI NIH HHS)NO - R0 1 HL-073278 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20920650</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 106(8):1118-23, 2010 Oct 15.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>487</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Bajkin,B.V.</style></author><author><style face="normal" font="default"> Popovic,S.L.</style></author><author><style face="normal" font="default"> Selakovic,S.D.</style></author></authors></contributors><titles><title><style face="normal" font="default">Randomized, prospective trial comparing bridging therapy using low-molecular-weight heparin with maintenance of oral anticoagulation during extraction of teeth</style></title><secondary-title><style face="normal" font="default">Journal of Oral &amp; Maxillofacial Surgery</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Oral &amp; Maxillofacial Surgery</style></full-title></periodical><pages end="995" start="990">990-995</pages><volume><style face="normal" font="default">67</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Anticoagulants/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Heparin,Low-Molecular-Weight/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Nadroparin/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Tooth Extraction</style></keyword><keyword><style face="normal" font="default"> 0 (Anticoagulants)</style></keyword><keyword><style face="normal" font="default"> 0 (Heparin,Low-Molecular-Weight)</style></keyword><keyword><style face="normal" font="default"> 0 (Nadroparin)</style></keyword><keyword><style face="normal" font="default"> 152-72-7 (Acenocoumarol)</style></keyword><keyword><style face="normal" font="default"> 81-81-2 (Warfarin)</style></keyword><keyword><style face="normal" font="default"> Acenocoumarol/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Administration,Oral</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hemostatic Techniques</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> International Normalized Ratio</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Postoperative Hemorrhage/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Postoperative Hemorrhage/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> SB - AIM,D,IM</style></keyword><keyword><style face="normal" font="default"> Serbia</style></keyword><keyword><style face="normal" font="default"> Thromboembolism/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Warfarin/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="5" Year="2009">2009/5</year></dates><abstract><style face="normal" font="default">PURPOSE: To evaluate postoperative bleeding and thromboembolic complications during dental extractions in anticoagulated patients, using 2 different protocols. PATIENTS AND METHODS: In total, 214 anticoagulated patients in need of simple dental extractions were randomized into 2 groups. Group A consisted of 109 patients on continuous oral anticoagulation therapy (OAT), with a mean international normalized ratio (INR) of 2.45 +/- 0.54. Local hemostasis in these patients was achieved with resorbable collagen sponges, without wound suturing. Group B consisted of 105 patients on bridging therapy with low-molecular-weight heparin (nadroparin-calcium), with a mean INR of 1.26 +/- 0.11 on the day of the procedure. Neither local hemostatic agents nor suturing of the wound was used in these patients. RESULTS: Eight (7.34%) patients in group A and 5 (4.76%) patients in group B manifested postextractional bleeding, without statistical significance (chi(2), Yates' = 0.253, P > .05). All cases of hemorrhage were mild and easily controlled using local hemostatic measures. None of the participants in either group experienced thromboembolic complications. CONCLUSIONS: In patients receiving OAT with an INR &lt;or=4.0, simple dental extractions can be performed safely without interruption or modification of OAT, using local hemostatic measures. Suturing of the wound should be reserved for cases with a greater extent of surgical trauma, and when primary hemostasis is insufficient. There is no need for bridging therapy with low-molecular-weight heparin in patients undergoing minor dentoalveolar procedures, although this approach can be used in patients with major oral surgical interventions</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Oral Surgery, Dental Clinic of Vojvodina, Medical Faculty, University of Novi Sad, Novi Sad, Serbia. bajkinb@eunet.yuJC - jic, 8206428CP - United StatesPT - Comparative StudyPT - Journal ArticlePT - Randomized Controlled TrialLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19375008</style></custom1><custom3><style face="normal" font="default">AS - J Oral Maxillofac Surg. 67(5):990-5, 2009 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>569</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Balbinot,A.L.</style></author><author><style face="normal" font="default"> Kalil,R.A.</style></author><author><style face="normal" font="default"> Prates,P.R.</style></author><author><style face="normal" font="default"> Sant'Anna,J.R.</style></author><author><style face="normal" font="default"> Wender,O.C.</style></author><author><style face="normal" font="default"> Teixeira Filho,G.F.</style></author><author><style face="normal" font="default"> Abrah&amp;#x00E3</style></author><author><style face="normal" font="default">o RS</style></author><author><style face="normal" font="default"> Nesralla,I.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Unsupported valvuloplasty for degenerative mitral regurgitation: long-term results</style></title><secondary-title><style face="normal" font="default">Arquivos Brasileiros de Cardiologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Arquivos Brasileiros de Cardiologia</style></full-title></periodical><pages end="369" start="363">363-369</pages><volume><style face="normal" font="default">90</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Mitral Valve Insufficiency/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Mitral Valve/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Endocarditis,Bacterial/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Postoperative Complications</style></keyword><keyword><style face="normal" font="default"> Postoperative Period</style></keyword><keyword><style face="normal" font="default"> Reoperation</style></keyword><keyword><style face="normal" font="default"> Reoperation/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Thromboembolism/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="6" Year="2008">2008/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: The advantages of valve repair for treatment of degenerative mitral regurgitation are well established. The procedure is associated with low mortality and morbidity rates, and low indices of reoperation, thromboembolic events and endocarditis have been reported. In most series, annuloplasty rings are implanted, but some institutions give preference to unsupported valvuloplasty. OBJECTIVE: To assess the clinical outcome of patients submitted to unsupported valvuloplasty for degenerative mitral regurgitation. METHODS: Between January 1980 and January 2003, 116 patients were submitted to the procedure. A total of 62 (53.4%) were men, and mean age was 47.2 +/- 16.5 years. The procedures included: Wooler annuloplasty (65.5%), unilateral annuloplasty (15.5%), quadrangular resection of the posterior leaflet (35.3%), anterior chordal shortening (20.7%), posterior chordal shortening (6.9%), and calcium debridement (0.9%). Mean follow-up was 6.5 +/- 5.1 years, and the longest follow-up was 24 years. RESULTS: Mortality was 0.86% (1 pt) early and 6.03% (7 pt) late. Actuarial survival was 85.3% in 20 years. Most patients (55.2%) presented preoperative NYHA functional class III, whereas class I was more frequent in the postoperative period (66.4%). Thromboembolic complications were observed in 4 patients (3.4%), and no correlation was seen with atrial fibrillation. Freedom from thromboembolic events was 94.8%, and similar results were observed for bacterial endocarditis. Survival free from reoperation was 79%, and 53% at 5 and 10 years, respectively. CONCLUSION: Unsupported valvuloplasty is effective and safe for treatment of degenerative mitral regurgitation, representing an adequate therapeutic alternative for selected cases</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Instituto de Cardiologia do Rio Grande do Sul, Funda&amp;#x00E7;&amp;#x00E3;o Universit&amp;#x00E1;ria de Cardiologia, Porto Alegre, RS - BrasilJC - 8pm, 0421031CP - BrazilPT - Journal ArticleLG - English, Portuguese</style></notes><urls/><custom1><style face="normal" font="default">UI - 18592088</style></custom1><custom3><style face="normal" font="default">AS - Arq Bras Cardiol. 90(6):363-9, 2008 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>109</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Bampi,A.B.</style></author><author><style face="normal" font="default"> Rochitte,C.E.</style></author><author><style face="normal" font="default"> Favarato,D.</style></author><author><style face="normal" font="default"> Lemos,P.A.</style></author><author><style face="normal" font="default"> da Luz,P.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Comparison of non-invasive methods for the detection of coronary atherosclerosis</style></title><secondary-title><style face="normal" font="default">Clinics (Sao Paulo, Brazil)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinics (Sao Paulo, Brazil)</style></full-title></periodical><pages end="682" start="675">675-682</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol,HDL)</style></keyword><keyword><style face="normal" font="default"> 0 (Triglycerides)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 9007-41-4 (C-Reactive Protein)</style></keyword><keyword><style face="normal" font="default"> Ankle Brachial Index</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> C-Reactive Protein/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Cholesterol,HDL/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Triglycerides/bl [Blood]</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><abstract><style face="normal" font="default">BACKGROUND: Non-invasive detection of atherosclerosis is critical for its prevention. OBJECTIVE: To correlate non-invasively detectable indicators of coronary atherosclerosis, or Coronary Artery Disease (i.e., classical risk factors, hs-CRP test results, carotid intima-media thickness, endothelial function, ankle-brachial index and calcium score by computed tomography) with the extent of coronary disease assessed by the Friesinger index from conventional coronary angiography. METHODS: We conducted a prospective study of 100 consecutive patients, mean age 55.1 +/- 10.7 years, 55% men and 45% women. Patients with acute coronary syndrome, renal dialytic insufficiency, collagen disease and cancer were not included. All patients were subjected to clinical evaluation and laboratory tests. Endothelial function of the brachial artery and carotid artery were evaluated by high-resolution ultrasound; ankle-brachial index and computed tomography for coronary determination of calcium score were also performed, and non-HDL cholesterol and TG/HDL-c ratio were calculated. All patients were subjected to coronary angiography at the request of the assistant physician. We considered patients without an obstructive lesion (&lt; 29% stenosis) demonstrated by coronary angiography to be normal. RESULTS: Univariate analysis showed that calcium score, HDL-c, TG/HDL ratio and IMT were significantly correlated with the Friesinger index. However, multivariate analysis indicated that only calcium score and low HDL-c levels correlated significantly with the extension of CAD. On the other hand, hs-CRP, LDL-c, flow-mediated dilation, and Framingham score did not correlate with the Friesinger index. ROC analysis showed that calcium score, HDL-c and TG-HDL ratio accurately predicted extensive CAD in a statistically significant manner. CONCLUSION: It is possible to approximately determine the presence and extent of CAD by non-invasive methods, especially by calcium score, HDL-c and TG/HDL-c ratio assays</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Clinical Atherosclerosis Unit, Heart Institute (InCor), Hospital das Clinicas, Faculdade de Medicina, Universidade de S&amp;#x00E3;o Paulo, S&amp;#x00E3;o Paulo/SP, BrazilJC - 101244734CP - BrazilPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19606245</style></custom1><custom3><style face="normal" font="default">AS - Clinics. 64(7):675-82, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>83</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Barbour,K.E.</style></author><author><style face="normal" font="default"> Zmuda,J.M.</style></author><author><style face="normal" font="default"> Strotmeyer,E.S.</style></author><author><style face="normal" font="default"> Horwitz,M.J.</style></author><author><style face="normal" font="default"> Boudreau,R.</style></author><author><style face="normal" font="default"> Evans,R.W.</style></author><author><style face="normal" font="default"> Ensrud,K.E.</style></author><author><style face="normal" font="default"> Petit,M.A.</style></author><author><style face="normal" font="default"> Gordon,C.L.</style></author><author><style face="normal" font="default"> Cauley,J.A.</style></author><author><style face="normal" font="default"> Osteoporotic Fractures in Men (MrOS) Research Group</style></author></authors></contributors><titles><title><style face="normal" font="default">Correlates of trabecular and cortical volumetric bone mineral density of the radius and tibia in older men: the Osteoporotic Fractures in Men Study</style></title><secondary-title><style face="normal" font="default">Journal of Bone &amp; Mineral Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Bone &amp; Mineral Research</style></full-title></periodical><pages end="1028" start="1017">1017-1028</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Bone and Bones/ah [Anatomy &amp; Histology]</style></keyword><keyword><style face="normal" font="default"> *Osteoporosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Radius/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tibia/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> 0 (Androgens)</style></keyword><keyword><style face="normal" font="default"> 58-08-2 (Caffeine)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Androgens/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Bone and Bones/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Bone Density</style></keyword><keyword><style face="normal" font="default"> Caffeine/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Diabetes Complications/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Diabetes Complications/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Life Style</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Osteoporosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Radius Fractures/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Radius/ah [Anatomy &amp; Histology]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tibia/ah [Anatomy &amp; Histology]</style></keyword><keyword><style face="normal" font="default"> Tibial Fractures/ra [Radiography]</style></keyword></keywords><dates><year Day="0" Month="5" Year="2010">2010/5</year></dates><abstract><style face="normal" font="default">Quantitative computed tomography (QCT) can estimate volumetric bone mineral density (vBMD) and distinguish trabecular from cortical bone. Few comprehensive studies have examined correlates of vBMD in older men. This study evaluated the impact of demographic, anthropometric, lifestyle, and medical factors on vBMD in 1172 men aged 69 to 97 years and enrolled in the Osteoporotic Fractures in Men Study (MrOS). Peripheral quantitative computed tomography (pQCT) was used to measure vBMD of the radius and tibia. The multivariable linear regression models explained up to 10% of the variance in trabecular vBMD and up to 9% of the variance in cortical vBMD. Age was not correlated with radial trabecular vBMD. Correlates associated with both cortical and trabecular vBMD were age (-), caffeine intake (-), total calcium intake (+), nontrauma fracture (-), and hypertension (+). Higher body weight was related to greater trabecular vBMD and lower cortical vBMD. Height (-), education (+), diabetes with thiazolidinedione (TZD) use (+), rheumatoid arthritis (+), using arms to stand from a chair (-), and antiandrogen use (-) were associated only with trabecular vBMD. Factors associated only with cortical vBMD included clinic site (-), androgen use (+), grip strength (+), past smoker (-), and time to complete five chair stands (-). Certain correlates of trabecular and cortical vBMD differed among older men. An ascertainment of potential risk factors associated with trabecular and cortical vBMD may lead to better understanding and preventive efforts for osteoporosis in men. (c) 2010 American Society for Bone and Mineral Research</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15213, USA. barbourk@edc.pitt.eduJC - 8610640CP - United StatesPT - Journal ArticlePT - Multicenter StudyPT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - U01 AG027810 (United States NIA NIH HHS)NO - U01 AG18197 (United States NIA NIH HHS)NO - U01 AR45580 (United States NIAMS NIH HHS)NO - U01 AR45583 (United States NIAMS NIH HHS)NO - U01 AR45614 (United States NIAMS NIH HHS)NO - U01 AR45632 (United States NIAMS NIH HHS)NO - U01 AR45647 (United States NIAMS NIH HHS)NO - U01 AR45654 (United States NIAMS NIH HHS)NO - UL1 RR024140 (United States NCRR NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20200975</style></custom1><custom3><style face="normal" font="default">AS - J Bone Miner Res. 25(5):1017-28, 2010 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>464</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Barrett-Connor,E.</style></author><author><style face="normal" font="default"> Bergstrom,J.</style></author><author><style face="normal" font="default"> Wright,M.</style></author><author><style face="normal" font="default"> Kramer,C.K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Heart disease risk factors in midlife predict subclinical coronary atherosclerosis more than 25 years later in survivors without clinical heart disease: the Rancho Bernardo Study</style></title><secondary-title><style face="normal" font="default">Journal of the American Geriatrics Society</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of the American Geriatrics Society</style></full-title></periodical><pages end="1044" start="1041">1041-1044</pages><volume><style face="normal" font="default">57</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Artery Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> 0 (Triglycerides)</style></keyword><keyword><style face="normal" font="default"> 57-88-5 (Cholesterol)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Cholesterol/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Pulse</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Survivors</style></keyword><keyword><style face="normal" font="default"> Triglycerides/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="6" Year="2009">2009/6</year></dates><abstract><style face="normal" font="default">OBJECTIVES: To determine which of the classic modifiable coronary heart disease (CHD) risk factors, measured in midlife, are associated with subclinical coronary atherosclerosis in older age. DESIGN: Prospective study. SETTING: Community based. PARTICIPANTS: Participants were 400 community-dwelling middle-aged adults who had no history of CHD at baseline (1972-1974), when CHD risk factors were measured, and who were still free of known CHD in 2000 to 2002. MEASUREMENTS: Coronary artery plaque burden was assessed according to coronary artery calcium (CAC) score using computed tomography in 2000 to 2002. RESULTS: Ordinal logistic regression analysis was used to compare baseline risk factors with severity of CAC. Mean age was 42 at baseline and 69 at the time of CAC assessment; 46.5% were male. In analyses adjusted for age, sex, and all other risk factors, one standard deviation increase in body mass index (odds ratio (OR)=1.24, 95%confidence interval (CI)=1.02-1.51; P=.03), cholesterol (OR=1.28, 95% CI=1.03-1.58; P=.020, pulse pressure (OR=1.24, 95% CI=1.03-1.50; P=.03), and log triglycerides (OR=1.22, 95% CI=0.99-1.50; P=.06) each independently predicted the presence and severity of coronary artery atherosclerosis. CONCLUSION: Modifiable risk factors measured more than 25 years earlier influence plaque burden in elderly survivors without clinical heart disease</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Epidemiology, Department of Family &amp; Preventive Medicine, School of Medicine, University of California, San Diego, 9500 Gilman Drive, MC 0607, La Jolla, CA 92093, USA. ebarrettconnor@ucsd.eduJC - 7503062, h6vCP - United StatesPT - Comparative StudyPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - AG07181 (United States NIA NIH HHS)NO - DK31801 (United States NIDDK NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19507296</style></custom1><custom3><style face="normal" font="default">AS - J Am Geriatr Soc. 57(6):1041-4, 2009 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>230</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Basiratnia,M.</style></author><author><style face="normal" font="default"> Fazel,M.</style></author><author><style face="normal" font="default"> Lotfi,M.</style></author><author><style face="normal" font="default"> Hosseini Al-Hashemi,G.</style></author><author><style face="normal" font="default"> Fallahzadeh,M.H.</style></author><author><style face="normal" font="default"> Derakhshan,A.</style></author><author><style face="normal" font="default"> Salehipour,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Subclinical atherosclerosis and related risk factors in renal transplant recipients</style></title><secondary-title><style face="normal" font="default">Pediatric Nephrology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatric Nephrology</style></full-title></periodical><pages end="348" start="343">343-348</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Carotid Arteries/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Kidney Transplantation/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Postoperative Complications/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Carotid Arteries/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Dialysis</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Iran/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Kidney Transplantation/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Kidney Transplantation/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Postoperative Complications/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Postoperative Complications/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tunica Intima/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Tunica Intima/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Tunica Media/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Tunica Media/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Ultrasonography</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="2" Year="2010">2010/2</year></dates><abstract><style face="normal" font="default">Long-term survival after successful renal transplantation is shortened by cardiovascular disease. Cardiovascular disease is a main cause of morbidity and death among children and young adults after renal transplantation. The aim of our study was to measure the carotid intima media thickness (cIMT) and determine its relationship to the risk factors for early arteriopathy in renal transplant recipients. Sixty-six stable renal transplant patients (36 female and 30 male), 7-25 years of age (mean 18.3 +/- 4.5 years) were enrolled in this study. The cIMT was measured by high-resolution B mode ultrasonography in multiple projections. The results were correlated with clinical and paraclinical parameters, including age, gender, body mass index (BMI), blood pressure, glomerular filtration rate (GFR), duration of dialysis, duration of chronic kidney disease (CKD), post-transplantation interval, calcium-phosphate (CaxP) product, cumulative dose of Ca-based P binder and calcitriol, lipid profile, uric acid, and cyclosporine level. The mean post-transplantation follow-up period was 64 +/- 40 months. The mean cIMT standard deviation score (SDS) of the patients and the control group was 0.60 +/- 0.81 mm (range -1.10 mm to 2.75 mm) and -1.25 +/- 0.95 mm (range -3.23 mm to 0.26 mm), respectively. Renal transplant recipients had a significantly greater cIMT than that of the controls (P &lt; 0.001). Among several risk factors, there were positive correlations between cIMT SDS and gender, and cumulative dose of calcitriol (P = 0.02 and P = 0.02, respectively). In conclusion, subclinical atherosclerosis is present in young transplant recipients. Non-invasive monitoring of cIMT in renal transplant patients for the detection of early vascular lesions might be of value in preventing cardiovascular disease. Further studies are needed to see if proper monitoring of vitamin D therapy before and after transplantation could be helpful in the prevention of arteriopathy in renal transplant recipients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Shiraz Nephrology Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. m_basiratnia@yahoo.comJC - avr, 8708728CP - GermanyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19911201</style></custom1><custom3><style face="normal" font="default">AS - Pediatr Nephrol. 25(2):343-8, 2010 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>88</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Bastarrika,G.</style></author><author><style face="normal" font="default"> Broncano,J.</style></author><author><style face="normal" font="default"> Schoepf,U.J.</style></author><author><style face="normal" font="default"> Schwarz,F.</style></author><author><style face="normal" font="default"> Lee,Y.S.</style></author><author><style face="normal" font="default"> Abro,J.A.</style></author><author><style face="normal" font="default"> Costello,P.</style></author><author><style face="normal" font="default"> Zwerner,P.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Relationship between coronary artery disease and epicardial adipose tissue quantification at cardiac CT: comparison between automatic volumetric measurement and manual bidimensional estimation</style></title><secondary-title><style face="normal" font="default">Academic Radiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Academic Radiology</style></full-title></periodical><pages end="734" start="727">727-734</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Adipose Tissue/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Imaging,Three-Dimensional/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Pattern Recognition,Automated/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Radiographic Image Interpretation,Computer-Assisted/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Algorithms</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Radiographic Image Enhancement/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Statistics as Topic</style></keyword></keywords><dates><year Day="0" Month="6" Year="2010">2010/6</year></dates><abstract><style face="normal" font="default">RATIONALE AND OBJECTIVES: The aim of this study was to compare the reproducibility of bidimensional and volumetric quantification of epicardial adipose tissue (EAT) on cardiac computed tomography (CT) and evaluate their relationship with the extent of coronary artery disease (CAD). MATERIALS AND METHODS: Forty-five individuals underwent cardiac dual-source CT and conventional coronary angiography for suspicion of CAD. Nonenhanced images acquired to assess calcium score were used to quantify EAT. Coronary stenosis grading was performed on conventional coronary angiograms using Gensini scores. Two independent observers manually measured right ventricular EAT thickness at three different levels and in two different planes (four chamber and short axis) to obtain mean values. Additionally, EAT volume was automatically determined using a commercially available software tool. RESULTS: Conventional coronary angiography demonstrated nonstenotic coronary arteries in 22 subjects and significant coronary artery stenosis in 23. Significant correlations were observed between volumetric estimation of EAT and body mass index, coronary artery calcification, and Gensini score. On automatic volumetry, patients with significant coronary artery stenosis had significantly greater EAT volumes (154.58 +/- 58.91 mL) than those without significant CAD (120.94 +/- 81.85 mL) (P = .016). The manual bidimensional approach based on thickness measurements failed to show a significant difference between the two groups. Reproducibility and interobserver agreement for EAT quantification were higher when the automatic volumetric method was used (concordance-correlation coefficient, 0.96) compared to manual measurements (concordance-correlation coefficients, 0.37 for four-chamber EAT, 0.53 for short-axis EAT, and 0.58 for average EAT). CONCLUSIONS: For the quantification of EAT on cardiac CT, automated volumetry is more reproducible and correlates better with the extent of CAD than manual bidimensional measurements. Copyright (c) 2010 AUR. Published by Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Radiology and Radiological Science, Ashley River Tower, 25 Courtenay Drive, Medical University of South Carolina, Charleston, SC 29401, USAJC - clv, 9440159CP - United StatesPT - Comparative StudyPT - Evaluation StudiesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20363161</style></custom1><custom3><style face="normal" font="default">AS - Acad Radiol. 17(6):727-34, 2010 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>119</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Bastarrika,G.</style></author><author><style face="normal" font="default"> Ramos-Duran,L.</style></author><author><style face="normal" font="default"> Schoepf,U.J.</style></author><author><style face="normal" font="default"> Rosenblum,M.A.</style></author><author><style face="normal" font="default"> Abro,J.A.</style></author><author><style face="normal" font="default"> Brothers,R.L.</style></author><author><style face="normal" font="default"> Zubieta,J.L.</style></author><author><style face="normal" font="default"> Chiaramida,S.A.</style></author><author><style face="normal" font="default"> Kang,D.K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Adenosine-stress dynamic myocardial volume perfusion imaging with second generation dual-source computed tomography: Concepts and first experiences</style></title><secondary-title><style face="normal" font="default">Journal of cardiovascular computed tomography</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of cardiovascular computed tomography</style></full-title></periodical><pages end="135" start="127">127-135</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Adenosine/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> *Cardiac Volume</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Exercise Test/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Heart Diseases/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> 58-61-7 (Adenosine)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Algorithms</style></keyword><keyword><style face="normal" font="default"> Contrast Media</style></keyword><keyword><style face="normal" font="default"> Coronary Aneurysm</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels</style></keyword><keyword><style face="normal" font="default"> Feasibility Studies</style></keyword><keyword><style face="normal" font="default"> Heart Diseases/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Heart Diseases/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> Heart Function Tests/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardial Perfusion Imaging</style></keyword><keyword><style face="normal" font="default"> Perfusion</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,Emission-Computed,Single-Photon</style></keyword></keywords><dates><year Day="0" Month="3" Year="2010">2010/3</year></dates><abstract><style face="normal" font="default">Recent research suggests that multidetector-row CT may have potential as a standalone modality for integrative imaging of coronary heart disease, including the assessment of the myocardial blood supply. However, the technical prerequisites for volumetric, time-resolved imaging of the passage of a contrast medium bolus through the myocardium have only been met with latest generation wide-detector CT scanners. Second-generation dual-source CT enables performing electrocardiographic (ECG)-synchronized dynamic myocardial perfusion imaging by a dedicated "shuttle" mode. With this acquisition mode, image data can be acquired during contrast medium infusion at 2 alternating table positions with the table shuttling back and forth between the 2 positions covering a 73-mm anatomic volume. We applied this acquisition technique for detecting differences in perfusion patterns between healthy and diseased myocardium and for quantifying myocardial blood flow under adenosine stress in 3 patients with coronary heart disease. According to our initial experience, the addition of adenosine stress volumetric dynamic CT perfusion to a cardiac CT protocol comprising coronary artery calcium quantification, prospectively ECG-triggered coronary CT angiography, and delayed acquisition appears promising for the comprehensive assessment of coronary artery luminal integrity, cardiac function, perfusion, and viability with a single modality. Copyright 2010 Society of Cardiovascular Computed Tomography. Published by Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Radiology and Radiological Science, Medical University of South Carolina, Charleston, SC 29401, USAJC - 101308347CP - United StatesPT - Case ReportsPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tPT - Technical ReportLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20430344</style></custom1><custom3><style face="normal" font="default">AS - J Cardiovasc Comput Tomogr. 4(2):127-35, 2010 Mar-Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>123</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Bastarrika,G.</style></author><author><style face="normal" font="default"> Alonso,A.</style></author><author><style face="normal" font="default"> Saiz-Mendiguren,R.</style></author><author><style face="normal" font="default"> Arias,J.</style></author><author><style face="normal" font="default"> Cos&amp;#x00ED</style></author><author><style face="normal" font="default">n O</style></author></authors></contributors><titles><title><style face="normal" font="default">[Coronary artery calcium quantification with non-ECG-gated low-radiation dose CT of the chest]. [Spanish]</style></title><secondary-title><style face="normal" font="default">Radiologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Radiologia</style></full-title></periodical><pages end="36" start="30">30-36</pages><volume><style face="normal" font="default">52</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Electrocardiography</style></keyword><keyword><style face="normal" font="default"> Feasibility Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Radiation Dosage</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="1" Year="2010">2010/1</year></dates><isbn><style face="normal" font="default">0033-8338</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: To evaluate the feasibility of quantifying coronary artery calcification in low-radiation dose chest CT (LDCT) studies performed in an early lung cancer detection program by comparing the results of this technique with those of dedicated retrospectively ECG-gated cardiac CT. MATERIAL AND METHODS: After obtaining informed consent, we evaluated the CT studies of 48 consecutive asymptomatic smokers (44 male, 4 female; mean age 59.7 years) included in an early lung cancer detection trial who underwent multislice LDCT (Volume Zoom, Siemens) of the chest and a retrospectively ECG-gated cardiac CT specifically dedicated to quantifying coronary artery calcification. LDCT examinations were reconstructed to reproduce cardiac CT parameters. Coronary calcium values were compared using the Wilcoxon signed-rank test. The concordance correlation coefficient (CCC) was calculated to determine the agreement between the two methods. RESULTS: Coronary calcium values ranged from 0 to 1,908.4 (median: 89.6; IQR: 3.2; 227.4) in LDCT exams and from 0 to 1,486.6 (median: 81.3; IQR: 2.5; 316.4) in cardiac CT studies. No statistically significant difference was observed in the estimation of total coronary calcium score (p=0.28). The concordance between the two techniques was excellent (CCC > or = 0.81). CONCLUSION: The LDCT study performed in lung cancer early detection trials enables coronary artery calcification to be quantified with the same accuracy as the dedicated retrospectively ECG-gated cardiac CT examination. Copyright 2009 SERAM. Published by Elsevier Espana. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Servicio de Radiolog&amp;#x00ED;a, Cl&amp;#x00ED;nica Universidad de Navarra, Pamplona, Espa&amp;#x00F1;a. bastarrika@unav.esOT - Cuantificaci&amp;#x00F3;n de la calcificaci&amp;#x00F3;n coronaria en tomograf&amp;#x00ED;a computarizada tor&amp;#x00E1;cica de baja dosis de radiaci&amp;#x00F3;n sin sincronizaci&amp;#x00F3;n cardiacaJC - 0120775CP - SpainPT - Comparative StudyPT - English AbstractPT - Journal ArticleLG - Spanish</style></notes><urls/><custom1><style face="normal" font="default">UI - 20035960</style></custom1><custom3><style face="normal" font="default">AS - RADIOLOGIA. 52(1):30-6, 2010 Jan-Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>391</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Bauer,M.</style></author><author><style face="normal" font="default"> hlenkamp,S.</style></author><author><style face="normal" font="default"> Lehmann,N.</style></author><author><style face="normal" font="default"> Schmermund,A.</style></author><author><style face="normal" font="default"> Roggenbuck,U.</style></author><author><style face="normal" font="default"> Moebus,S.</style></author><author><style face="normal" font="default"> Stang,A.</style></author><author><style face="normal" font="default"> Mann,K.</style></author><author><style face="normal" font="default"> ckel,K.H.</style></author><author><style face="normal" font="default"> Erbel,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">The effect of age and risk factors on coronary and carotid artery atherosclerotic burden in males-Results of the Heinz Nixdorf Recall Study</style></title><secondary-title><style face="normal" font="default">Atherosclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Atherosclerosis</style></full-title></periodical><pages end="602" start="595">595-602</pages><volume><style face="normal" font="default">205</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Carotid Arteries/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Carotid Arteries/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Tunica Intima/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Tunica Media/pa [Pathology]</style></keyword></keywords><dates><year Day="0" Month="8" Year="2009">2009/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Increased arterial intima-media thickness (IMT) and coronary artery calcification (CAC) are measures of subclinical arteriosclerosis burden. Little is known, however, whether risk factors have an impact differently on atherosclerosis in these distinct vascular territories in the same individuals. METHODS AND DESIGN: For 1620 men without coronary artery disease (CAD) and stroke, aged 45-75 years (59+/-8), IMT was measured 1cm proximal to the bulb in the common carotid artery (CCA). Both sides were measured and the average of the right and left artery were applied. Electron-beam CT was used to quantify coronary artery calcium (CAC). Cardiovascular risk factors were measured with standard techniques. RESULTS: IMT increased with age from 0.64+/-0.12mm in the lowest decade (45-54 years) up to 0.76+/-0.14mm in the highest decade (65-74 years) (p&lt;0.0001). CAC and IMT showed a significant correlation across the cohort. Individual variation in the extent of IMT and CAC was, however, high (r=0.26, p&lt;0.0001). Standard risk factors had a similar impact on IMT and CAC relative to 5 years of ageing, except for diabetes and HDL, which had a higher impact on IMT than on CAC. The effect of diabetes mellitus on IMT exceeded the effect of 5 years of ageing. CONCLUSIONS: IMT may be more sensitive to the atherosclerotic impact of diabetes than CAC, while blood pressure showed a higher effect on CAC. Thus, cardiovascular risk factors seem to have a different atherosclerotic impact on carotid arteries compared with coronary arteries</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Clinic of Cardiology, West-German Heart Center, University Duisburg-Essen, Germany. marcus.bauer@uk-essen.deJC - 95x, 0242543CP - IrelandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19200545</style></custom1><custom3><style face="normal" font="default">AS - Atherosclerosis. 205(2):595-602, 2009 Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>444</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Bauer,R.W.</style></author><author><style face="normal" font="default"> Thilo,C.</style></author><author><style face="normal" font="default"> Chiaramida,S.A.</style></author><author><style face="normal" font="default"> Vogl,T.J.</style></author><author><style face="normal" font="default"> Costello,P.</style></author><author><style face="normal" font="default"> Schoepf,U.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Noncalcified atherosclerotic plaque burden at coronary CT angiography: a better predictor of ischemia at stress myocardial perfusion imaging than calcium score and stenosis severity</style></title><secondary-title><style face="normal" font="default">AJR</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">AJR</style></full-title></periodical><pages end="418" start="410">410-418</pages><volume><style face="normal" font="default">American</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> *Coronary Stenosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography</style></keyword><keyword><style face="normal" font="default"> Exercise Test</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Image Interpretation,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Image Processing,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardial Perfusion Imaging</style></keyword><keyword><style face="normal" font="default"> Perfusion</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="8" Year="2009">2009/8</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The purpose of this study was to examine the relation between the coronary CT angiographic findings of calcified and noncalcified plaque burden and stenosis severity and the myocardial perfusion imaging finding of ischemia. MATERIALS AND METHODS: Seventy-two patients (41 men, 31 women; mean age, 56 years) underwent coronary CT angiography and stress-rest SPECT myocardial perfusion imaging. Calcium scoring was performed. Coronary CT angiograms were analyzed for stenosis and noncalcified or mixed plaque. A plaque analysis tool was used to calculate the volume of noncalcified plaque components. SPECT images were analyzed for perfusion defects. Data were analyzed per patient and per vessel. RESULTS: A total of 53 purely noncalcified, 50 mixed, and 201 purely calcified plaques were detected. Forty-five stenoses were rated > or = 50%, 19 of those being > or = 70%. Myocardial perfusion imaging depicted perfusion defects in 37 vessels (13%) in 24 patients (18 reversible, 19 fixed defects). Vessels with > or = 50% stenosis had significantly (p = 0.0009) more perfusion defects in their supplied territories (11 with, 22 without perfusion defects) than did vessels without significant lesions (26 with, 229 without perfusion defects). In vessel-based analysis, the sensitivity of coronary CT angiography in prediction of any perfusion defect on myocardial perfusion images was 30% with 91% specificity, 33% positive predictive value, and 90% negative predictive value. Between vessels with and those without perfusion defects, there was no significant difference in Agatston or calcium volume score (p = 0.25), but there was a significant difference in noncalcified plaque volume (44 +/- 77 vs 19 +/- 58 mm(3); p = 0.03). Multiple stepwise regression analysis showed noncalcified plaque volume was the only significant predictor of ischemia (p = 0.01). CONCLUSION: At coronary CT angiography, noncalcified plaque burden is a better predictor of the finding of myocardial ischemia at stress myocardial perfusion imaging than are calcium score and degree of stenosis</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Radiology and Radiological Science, Medical University of South Carolina, Ashley River Tower, 25 Courtenay Dr., MSC 226, Charleston, SC 29401, USAJC - 3ae, 7708173CP - United StatesPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19620437</style></custom1><custom3><style face="normal" font="default">AS - AJR Am J Roentgenol. 193(2):410-8, 2009 Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>441</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Bayturan,O.</style></author><author><style face="normal" font="default"> Tuzcu,E.M.</style></author><author><style face="normal" font="default"> Nicholls,S.J.</style></author><author><style face="normal" font="default"> Balog,C.</style></author><author><style face="normal" font="default"> Lavoie,A.</style></author><author><style face="normal" font="default"> Uno,K.</style></author><author><style face="normal" font="default"> Crowe,T.D.</style></author><author><style face="normal" font="default"> Magyar,W.A.</style></author><author><style face="normal" font="default"> Wolski,K.</style></author><author><style face="normal" font="default"> Kapadia,S.</style></author><author><style face="normal" font="default"> Nissen,S.E.</style></author><author><style face="normal" font="default"> Schoenhagen,P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Attenuated plaque at nonculprit lesions in patients enrolled in intravascular ultrasound atherosclerosis progression trials</style></title><secondary-title><style face="normal" font="default">Jacc: Cardiovascular Interventions</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Jacc: Cardiovascular Interventions</style></full-title></periodical><pages end="678" start="672">672-678</pages><volume><style face="normal" font="default">2</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Ultrasonography,Interventional</style></keyword><keyword><style face="normal" font="default"> 0 (Fluorobenzenes)</style></keyword><keyword><style face="normal" font="default"> 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)</style></keyword><keyword><style face="normal" font="default"> 0 (Pyrimidines)</style></keyword><keyword><style face="normal" font="default"> 0 (Sulfonamides)</style></keyword><keyword><style face="normal" font="default"> 287714-41-4 (rosuvastatin)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fluorobenzenes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Pyrimidines/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sulfonamides/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="7" Year="2009">2009/7</year></dates><abstract><style face="normal" font="default">OBJECTIVES: We investigated attenuated plaque (hypoechoic plaque with deep ultrasonic attenuation despite absence of bright calcium) in nonculprit lesions. BACKGROUND: Recent intravascular ultrasound (IVUS) studies describe acoustic shadowing behind large, echolucent, acute culprit lesion sites in the absence of bright calcium. Such "attenuated plaque" is considered a characteristic of high-risk lesions, but its prevalence in stable nonculprit lesions is incompletely known. METHODS: We reviewed IVUS pullback data from nonculprit vessels in 159 patients from the ASTEROID (A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden) trial. We identified attenuated plaque and compared volumetric IVUS data in the segments with and without attenuation. In addition, we described plaque morphology in segments with attenuation at baseline and follow-up. RESULTS: Attenuated plaque was found in 17 of 159 patients (10.7%, 95% confidence interval: 6% to 17%). At baseline, there were no significant differences in clinical presentation and cardiovascular risk factors between patients with and without attenuation. Other than a greater plaque eccentricity index (p = 0.008), there were no significant differences between segments with and without attenuation. In segments with attenuated plaque, expansive remodeling was observed in 53%, and calcified plaque adjacent to the attenuation site in 70% of patients. During follow-up, attenuation remained stable, and no events occurred in the patients with attenuation. CONCLUSIONS: Attenuated plaque is present in a significant number of nonculprit segments in patients enrolled in IVUS progression trials and remains stable during follow-up. There is a relationship with mixed calcified lesions. These findings challenge the prior assumption that attenuated plaque is a finding limited to culprit lesions associated with acute clinical presentation</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USAJC - 101467004CP - United StatesPT - Clinical TrialPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19628192</style></custom1><custom3><style face="normal" font="default">AS - JACC Cardiovasc Interv. 2(7):672-8, 2009 Jul.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>397</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Becker,J.T.</style></author><author><style face="normal" font="default"> Kingsley,L.</style></author><author><style face="normal" font="default"> Mullen,J.</style></author><author><style face="normal" font="default"> Cohen,B.</style></author><author><style face="normal" font="default"> Martin,E.</style></author><author><style face="normal" font="default"> Miller,E.N.</style></author><author><style face="normal" font="default"> Ragin,A.</style></author><author><style face="normal" font="default"> Sacktor,N.</style></author><author><style face="normal" font="default"> Selnes,O.A.</style></author><author><style face="normal" font="default"> Visscher,B.R.</style></author><author><style face="normal" font="default"> Multicenter AIDS,Cohort Study</style></author></authors></contributors><titles><title><style face="normal" font="default">Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men</style></title><secondary-title><style face="normal" font="default">Neurology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Neurology</style></full-title></periodical><pages end="1299" start="1292">1292-1299</pages><volume><style face="normal" font="default">73</style></volume><number><style face="normal" font="default">16</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Bisexuality</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Cerebrovascular Disorders/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Cognition Disorders/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *HIV Infections/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Homosexuality,Male</style></keyword><keyword><style face="normal" font="default"> 0 (RNA,Viral)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aging</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default"> Heart Rate</style></keyword><keyword><style face="normal" font="default"> HIV Infections/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> HIV Infections/vi [Virology]</style></keyword><keyword><style face="normal" font="default"> HIV/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Memory</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neuropsychological Tests</style></keyword><keyword><style face="normal" font="default"> Psychomotor Performance</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> RNA,Viral/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="20" Month="10" Year="2009">2009/10/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: The purpose of this study was to evaluate the relationship between cognitive performance, risk factors for cardiovascular and cerebrovascular disease (CVD), and HIV infection in the era of highly active antiretroviral therapy. METHODS: We evaluated the cognitive functions of men enrolled in the cardiovascular disease substudy of the Multicenter AIDS Cohort Study who were aged > or =40 years, with no self-reported history of heart disease or cerebrovascular disease. Results from comprehensive neuropsychological evaluations were used to construct composite scores of psychomotor speed and memory performance. Subclinical CVD was assessed by measuring coronary artery calcium and carotid artery intima-media thickness (IMT), as well as laboratory measures, including total cholesterol, fasting glucose, glycosylated hemoglobin, glomerular filtration rate (estimated), and standardized blood pressure and heart rate measures. RESULTS: After accounting for education, depression, and race, carotid IMT and glomerular filtration rate were significantly associated with psychomotor speed, whereas IMT was associated with memory test performance. HIV serostatus was not significantly associated with poorer cognitive test performance. However, among the HIV-infected individuals, the presence of detectable HIV RNA in plasma was linked to lower memory performance. CONCLUSIONS: These findings suggest that HIV infection may not be the most important predictor of cognitive performance among older gay and bisexual men in the post-highly active antiretroviral therapy era, at least among those with access to medical care and to appropriate medications. Medical factors associated with normal aging are significantly associated with performance on neuropsychological tests, and good clinical management of these factors both in HIV-infected individuals and those at risk for infection may have beneficial effects in the short term and could reduce the risk of subsequent cognitive decline</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. beckerjt@upmc.eduJC - 0401060, nz0CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - 5-M01-RR-00052 (United States NCRR NIH HHS)NO - U01-AI-35039 (United States NIAID NIH HHS)NO - U01-AI-35040 (United States NIAID NIH HHS)NO - U01-AI-35041 (United States NIAID NIH HHS)NO - U01-AI-35042 (United States NIAID NIH HHS)NO - U01-AI-35043 (United States NIAID NIH HHS)NO - U01-AI-37613 (United States NIAID NIH HHS)NO - U01-AI-37984 (United States NIAID NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19841381</style></custom1><custom3><style face="normal" font="default">AS - Neurology. 73(16):1292-9, 2009 Oct 20.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>309</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Berezhnova,I.A.</style></author><author><style face="normal" font="default"> Korshunov,G.V.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Biochemical markers of bone resorption and formation in geriatric patients with ischemic heart disease and osteoporosis]. [Russian]</style></title><secondary-title><style face="normal" font="default">Klinicheskaia Laboratornaia Diagnostika</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Klinicheskaia Laboratornaia Diagnostika</style></full-title></periodical><pages end="7" start="3">3-7</pages><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Bone and Bones/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Bone Resorption/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Myocardial Ischemia/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Osteogenesis/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Osteoporosis/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Bone Resorption/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Bone Resorption/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Bone Resorption/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardial Ischemia/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Myocardial Ischemia/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Myocardial Ischemia/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Osteoporosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Osteoporosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Osteoporosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Russia</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Urine</style></keyword></keywords><dates><year Day="0" Month="7" Year="2009">2009/7</year></dates><isbn><style face="normal" font="default">0869-2084</style></isbn><abstract><style face="normal" font="default">One hundred and seventy-eight patients aged 60-95 years who had ischemic heart disease (IHD) and osteoporosis (OP) were examined. The serum levels of total cholesterol, triglycerides, high-density lipoproteins, low-density lipoproteins, apoA- and apoB-lipoproteins, calcium, phosphorus, alkaline phosphatase, etc. were measured on a Vitalab Flexor E. biochemical analyzer. Bone metabolic markers, such as parathyroid hormone (PTH), osteocalcin (OC), calcitonin (CT), as well as C-terminal telopeptides (CTTP) resulting from collagen type I (in serum and urine) were determined on a Stat Fax photometer. There was a high direct correlation between the serum levels of OC, CTTP and those of calcium and an inverse correlation between the serum concentrations of alkaline phosphatase and PTH and those of calcium in the groups of geriatric patients with IHD and OP. The plots of the function approximating the relationship of the levels of total protein, total and ionized calcium, creatinine, and alkaline phosphatase to age could predict a adaptation potential reduction in these patient groups</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)JC - 9432021, 9432021CP - Russia (Federation)PT - English AbstractPT - Journal ArticleLG - Russian</style></notes><urls/><custom1><style face="normal" font="default">UI - 19718820</style></custom1><custom3><style face="normal" font="default">AS - Klin Lab Diagn. (7):3-7, 2009 Jul.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>398</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Berezhnova,I.A.</style></author><author><style face="normal" font="default"> Korshunov,G.V.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Plasma lipids and interleukins in geriatric patients with ischemic heart disease]. [Russian]</style></title><secondary-title><style face="normal" font="default">Klinicheskaia Laboratornaia Diagnostika</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Klinicheskaia Laboratornaia Diagnostika</style></full-title></periodical><pages end="6" start="3">3-6</pages><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Interleukins/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Lipids/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Myocardial Ischemia/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Interleukins)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipids)</style></keyword><keyword><style face="normal" font="default"> 0 (Tumor Necrosis Factor-alpha)</style></keyword><keyword><style face="normal" font="default"> 9008-11-1 (Interferons)</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immunoassay</style></keyword><keyword><style face="normal" font="default"> Interferons/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Russia</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> Tumor Necrosis Factor-alpha/bl [Blood]</style></keyword></keywords><dates><year Day="0" Month="8" Year="2009">2009/8</year></dates><isbn><style face="normal" font="default">0869-2084</style></isbn><abstract><style face="normal" font="default">One hundred and eighty-four patients aged 60-95 years who had ischemic heart disease (IHD) were examined. The serum levels of total cholesterol, triglycerides, high-density lipoproteins, low-density lipoproteins, apoA- and apoB-lipoproteins, calcium, phosphorus, alkaline phosphatase, etc. were measured on a Vitalab Flexor E. biochemical analyzer. The content of cytokines was determined by solid-phase immunoassay using the Protein contour test systems (State Research Institute of Particularly Pure Biologicals, Saint-Petersburg) on a Stat Fax photometer. There were pronounced changes in the cytokine spectrum in elderly and senile persons despite the fact that they had an adequate lipid spectrum. The increased levels of interleukin (IL)-1 beta and IL-6 suggest that there is an inflammatory reaction whereas those of tumor necrosis factor-alpha may be indicative of the body's autoimmune readiness. There was a high direct correlation of the content of apolipoproteins Apo-B1 and IL-6, as well as LP alpha and IL-6; ApoB1/Apo-A1 and IL-6. A high inverse correlation was found in the content of Apo-B1 and IL-6, which is a poor predictor in old age group patients. There was a mean correlation in the levels of apolipoproteins (B1 and B alpha) and the cytokines IL-1 beta, IL-4, IFN-gamma, TNF-alpha, and IFN-alpha; and there was a mean inverse correlation between the concentrations of apolipoproteins A1 and these cytokines</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)JC - 9432021, 9432021CP - Russia (Federation)PT - English AbstractPT - Journal ArticleLG - Russian</style></notes><urls/><custom1><style face="normal" font="default">UI - 19827189</style></custom1><custom3><style face="normal" font="default">AS - Klin Lab Diagn. (8):3-6, 2009 Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>372</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Beto,J.A.</style></author><author><style face="normal" font="default"> Nicholas,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">So just what can I eat? Nutritional care in patients with diabetes mellitus and chronic kidney disease</style></title><secondary-title><style face="normal" font="default">Nephrology Nursing Journal: Journal of the American Nephrology Nurses' Association</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Nephrology Nursing Journal: Journal of the American Nephrology Nurses' Association</style></full-title></periodical><pages end="504" start="497">497-504</pages><volume><style face="normal" font="default">36</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Diabetes Mellitus/dh [Diet Therapy]</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure,Chronic/dh [Diet Therapy]</style></keyword><keyword><style face="normal" font="default"> 0 (Dietary Carbohydrates)</style></keyword><keyword><style face="normal" font="default"> 0 (Dietary Fats)</style></keyword><keyword><style face="normal" font="default"> 0 (Dietary Proteins)</style></keyword><keyword><style face="normal" font="default"> 0 (Minerals)</style></keyword><keyword><style face="normal" font="default"> 0 (Vitamins)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Body Weight</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Diabetes Complications</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Dialysis</style></keyword><keyword><style face="normal" font="default"> Dietary Carbohydrates/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Dietary Fats/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Dietary Proteins/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Education,Nursing,Continuing</style></keyword><keyword><style face="normal" font="default"> Energy Intake</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Minerals/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Nutritional Status</style></keyword><keyword><style face="normal" font="default"> SB - N</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Vitamins/ad [Administration &amp; Dosage]</style></keyword></keywords><dates><year Day="20" Month="0" Year="505">505/20</year></dates><isbn><style face="normal" font="default">1526-744X</style></isbn><abstract><style face="normal" font="default">The balance of nutrition in patients with diabetes mellitus and chronic kidney disease is essential to optimum health outcomes. Multiple nutritional parameters need to be monitored, including energy balance, protein intake (type and amount), mineral control (sodium, potassium, calcium, phosphorus), fluid requirements, and coordination of carbohydrates, to achieve glycemic control in diabetes mellitus. The nephrology nurse benefits by understanding the multiple nutrition parameters required in diabetes mellitus and chronic kidney disease to participate and reinforce the complexities of the daily nutritional challenges in coordination with a registered dietitian. A comprehensive overview of the nutrition parameters in chronic kidney disease and diabetes mellitus is discussed so the question "So just what can I eat?" can be answered with greater confidence</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Loyola University Medical Center, Division of Nephrology and Hypertension, Dialysis Unit, Maywood, IL, USAJC - dn8, 100909377CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19856811</style></custom1><custom3><style face="normal" font="default">AS - Nephrol Nurs J. 36(5):497-504; quiz 505, 2009 Sep-Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>324</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Bhakta,M.</style></author><author><style face="normal" font="default"> Bruce,C.</style></author><author><style face="normal" font="default"> Messika-Zeitoun,D.</style></author><author><style face="normal" font="default"> Bielak,L.</style></author><author><style face="normal" font="default"> Sheedy,P.F.</style></author><author><style face="normal" font="default"> Peyser,P.</style></author><author><style face="normal" font="default"> Sarano,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Oral calcium supplements do not affect the progression of aortic valve calcification or coronary artery calcification</style></title><secondary-title><style face="normal" font="default">Journal of the American Board of Family Medicine: JABFM</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of the American Board of Family Medicine: JABFM</style></full-title></periodical><pages end="616" start="610">610-616</pages><volume><style face="normal" font="default">22</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Calcium/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Dietary Supplements/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Heart Valve Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="11" Year="2009">2009/11</year></dates><isbn><style face="normal" font="default">1557-2625</style></isbn><abstract><style face="normal" font="default">BACKGROUND: The use of oral calcium supplementation among the elderly for prevention and treatment of osteoporosis and osteopenia is increasing. The incidence of aortic valve disease and coronary artery disease also is increasing. No study thus far has been done to demonstrate whether this affects the progression of calcification in both the valves and vasculature. We sought to determine whether ingestion of oral calcium supplementation has an effect on aortic valve calcification (AVC) and coronary artery calcification (CAC). METHODS: We performed an independent assessment of AVC, CAC, and calcium supplementation among patients enrolled in the Epidemiology of Coronary Artery Calcification study who were >60 years of age and had baseline and 4-year follow-up AVC data. In this population-based study of Olmsted County (Minnesota) residents, AVC and CAC scores were determined prospectively by electron beam computed tomography. We evaluated baseline demographic data and analyzed whether those patients using calcium supplementation had a higher rate of progression of both AVC and CAC. RESULTS: We identified 257 patients (mean age, 67.8+/-5.2 years), 144 of whom were women. Twenty-five patients (all women) reported using calcium supplements. Analysis of the 144 women (25 taking calcium supplementation) showed there was no difference in the progression of AVC (mean difference in baseline and follow-up AVC score; no supplement versus supplement, 30+/-9 vs 39+/-28; P=.73) or CAC (mean difference in baseline and follow-up CAC score; no supplement vs supplement, 47+/-15 vs 112+/-22; P=.154). There were no significant differences between the 2 groups with regard to baseline AVC, serum calcium, renal function, diabetes, hypertension, cholesterol, or body mass index. CONCLUSION: In this community-based observational study with a 4-year follow-up, no significant increased progression of AVC or CAC was found in women taking oral calcium supplementation. Larger prospective, randomized studies are needed to confirm these findings</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Mayo Clinic, Scottsdale, AZ 85259, USA. bhakta.mayurkumar@mayo.eduJC - 101256526CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19897688</style></custom1><custom3><style face="normal" font="default">AS - J Am Board Fam Med. 22(6):610-6, 2009 Nov-Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>516</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Bhuriya,R.</style></author><author><style face="normal" font="default"> Li,S.</style></author><author><style face="normal" font="default"> Chen,S.C.</style></author><author><style face="normal" font="default"> McCullough,P.A.</style></author><author><style face="normal" font="default"> Bakris,G.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP)</style></title><secondary-title><style face="normal" font="default">American Journal of Kidney Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Kidney Diseases</style></full-title></periodical><pages end="10" start="Suppl">Suppl-10</pages><volume><style face="normal" font="default">53</style></volume><number><style face="normal" font="default">4:Suppl 4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiovascular Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure,Chronic/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Mass Screening/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> *Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 7723-14-0 (Phosphorus)</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Blood Pressure/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cause of Death</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default"> Glomerular Filtration Rate/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Health Surveys</style></keyword><keyword><style face="normal" font="default"> Hemoglobinometry</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Secondary/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Secondary/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Phosphorus/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="4" Year="2009">2009/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Cardiovascular disease (CVD) is the most common cause of death in patients with chronic kidney disease (CKD). Secondary hyperparathyroidism is common in patients with CKD, and its relationship to CVD is not well defined. This analysis aims to assess whether serum intact parathyroid hormone (PTH) level is an independent risk factor for CVD in patients with CKD stages 3 and 4. METHODS: In this cross-sectional study, medical history surveys, including CVD events, were collected from 4,472 patients with stages 3 and 4 CKD identified by the National Kidney Foundation Kidney Early Evaluation Program (KEEP), which included blood pressure measurement and laboratory testing. Age, hemoglobin level, estimated glomerular filtration rate, serum phosphorus level, and serum calcium level were evaluated as continuous variables, and plasma PTH levels, by tertile: less than 35, 35 to 70, and greater than 70 pg/mL. Multivariate logistic regression was used to estimate odds ratios (ORs) of CVD predictor variables. RESULTS: Mean age was 68.3 +/- 11.8 years. Of the study population, 68% were women, 69% were white, 6% were current smokers, 45% were obese, 46% had diabetes, and 83% had hypertension. A history of CVD was present for 1,972 (44.1%), and plasma PTH level greater than 70 pg/mL, for 2,239 (50.1%). Multivariate logistic regression showed ORs for CVD events increasing with age (OR, 1.03; P &lt; 0.001), male sex (OR, 1.51; P &lt; 0.001), diabetes (OR, 1.73; P &lt; 0.001), hypertension (OR, 1.43; P &lt; 0.001), and intact PTH level greater than 70 pg/mL (OR, 1.51; P &lt; 0.001; reference, &lt;35 pg/mL). CONCLUSIONS: PTH level greater than 70 pg/mL is independently associated with CVD events in patients with CKD stages 3 and 4. No association was observed between serum phosphorus or calcium level and CVD events. These findings provide support for intact PTH testing, along with testing for other indicators of CKD mineral and bone disorders, at earlier CKD stages</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, Chicago Medical School, North Chicago, IL, USAJC - 3h5, 8110075CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19285609</style></custom1><custom3><style face="normal" font="default">AS - Am J Kidney Dis. 53(4 Suppl 4):S3-10, 2009 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>559</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Bilancini,S.</style></author><author><style face="normal" font="default"> Lucchi,M.</style></author><author><style face="normal" font="default"> Mangiafico,R.A.</style></author><author><style face="normal" font="default"> Medolla,A.</style></author><author><style face="normal" font="default"> Ferazzoli,F.</style></author><author><style face="normal" font="default"> Bianchi,C.</style></author><author><style face="normal" font="default"> Salvatori,E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Peripheral obstructive arterial disease and carotid artery stenosis in end stage renal disease: a case-control study</style></title><secondary-title><style face="normal" font="default">Minerva Cardioangiologica</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Minerva Cardioangiologica</style></full-title></periodical><pages end="603" start="599">599-603</pages><volume><style face="normal" font="default">56</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Arterial Occlusive Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Carotid Stenosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure,Chronic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Peripheral Vascular Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Ambulatory Care</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Dialysis</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword></keywords><dates><year Day="0" Month="12" Year="2008">2008/12</year></dates><isbn><style face="normal" font="default">0026-4725</style></isbn><abstract><style face="normal" font="default">AIM: Cardiovascular diseases are an important cause of morbidity and mortality in end stage renal disease (ESRD) patients. The purpose of this study was to evaluate the predominance of carotid stenosis and peripheral obstructive arterial disease (POAD) in a group of patients subject to dialysis compared with a control group. METHODS: It is a control-case study performed on patients at different hemodialysis facilities; the exams were carried out in ambulatory care. Two groups of patients were examined, the first group was made up of 40 dialysis patients (46.6% men, average age 58.8), the second was the control group made up of 58 subjects matched by age, sex, arterial pressure, presence of diabetes and smoking habits. All patients underwent an Eco-Color Doppler exam on the over aortal trunks and lower extremities and had their Ankle-Brakial-Index (ABI) measured. Carotid stenosis was considered only if equal or over 50%. RESULTS: Twenty percent of dialysis patients showed carotid stenosis (CS) versus 12% in the control group, with an OR of 7.9 (CI 95% 1.3-47.7) adjusted to sex, age and hypertension. The ultrasound picture of the lesions showed large amounts of calcium deposits. Predominance of POAD in dialysis patients was 20% versus 9% in the control group. In dialysis patients the OR adjusted to age, sex and arterial pressure was 6.3 (CI 95%, 1.2-32.6). CONCLUSION: The ultrasound picture of the lesions showed mainly underpopliteal lesions with ''rosary bead'' calcifications. In diabetic dialysis patients the OR was 7.6 (CI 95% 1.4-46.3)</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - J. F. Merlen Vascular Diseases Research Center, Frosinone, Italy. silviasilvietta@ libero.itJC - n2m, 0400725CP - ItalyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19092735</style></custom1><custom3><style face="normal" font="default">AS - Minerva Cardioangiol. 56(6):599-603, 2008 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>462</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Blaha,M.</style></author><author><style face="normal" font="default"> Budoff,M.J.</style></author><author><style face="normal" font="default"> Shaw,L.J.</style></author><author><style face="normal" font="default"> Khosa,F.</style></author><author><style face="normal" font="default"> Rumberger,J.A.</style></author><author><style face="normal" font="default"> Berman,D.</style></author><author><style face="normal" font="default"> Callister,T.</style></author><author><style face="normal" font="default"> Raggi,P.</style></author><author><style face="normal" font="default"> Blumenthal,R.S.</style></author><author><style face="normal" font="default"> Nasir,K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Absence of coronary artery calcification and all-cause mortality</style></title><secondary-title><style face="normal" font="default">Jacc: Cardiovascular Imaging</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Jacc: Cardiovascular Imaging</style></full-title></periodical><pages end="700" start="692">692-700</pages><volume><style face="normal" font="default">2</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> 8067-82-1 (Alfaxalone Alfadolone Mixture)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Alfaxalone Alfadolone Mixture</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cause of Death</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="6" Year="2009">2009/6</year></dates><abstract><style face="normal" font="default">OBJECTIVES: We sought to quantify the mortality rates associated with absent and low positive (CAC 1 to 10) coronary artery calcium (CAC). BACKGROUND: There is increasing interest in the absence of CAC as a "negative" cardiovascular risk factor. However, published event rates for individuals with no CAC vary, likely owing to differences in baseline risk, follow-up period, and outcome ascertainment. The prognostic significance of low CAC (CAC 1 to 10) is not well described. METHODS: Annualized all-cause mortality rates were assessed in 44,052 consecutive asymptomatic patients referred for CAC testing. Mean follow-up of the cohort was 5.6 +/- 2.6 years (range 1 to 13 years). RESULTS: A total of 19,898 patients (45%) had no CAC on screening electron beam tomography, whereas 5,388 (12%) had low levels of CAC (CAC 1 to 10), and 18,766 (43%) had CAC >10. There were 104 deaths in those with no CAC (0.52%), 58 deaths in those with CAC 1 to 10 (1.06%), and 739 deaths in those with CAC >10 (3.96%). Annualized all-cause mortality rates for CAC = 0, CAC 1 to 10, and CAC >10 were 0.87, 1.92, and 7.48 deaths/1,000 person-years, respectively. The hazard ratio (HR) for all-cause mortality among CAC 1 to 10 versus CAC = 0 after adjustment for traditional risk factors was 1.99 (95% confidence interval [CI]: 1.44 to 2.75). Smoking (HR: 3.97, 95% CI: 2.75 to 5.41) and diabetes mellitus (HR: 3.36, 95% CI: 2.09 to 5.41) were associated with few events observed in CAC = 0 group. CONCLUSIONS: In appropriately selected asymptomatic patients, the absence of CAC predicts excellent survival with 10-year event rates of approximately 1%. A finding of 0 CAC might be used as a rationale to emphasize lifestyle therapies rather than pharmacotherapy and to forgo repeated imaging studies. Individuals with low CAC score (CAC 1 to 10) are at increased risk above individuals with a 0 score and could be considered a distinct risk group by physicians and investigators</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD 21287, USAJC - 101467978CP - United StatesPT - Journal ArticlePT - Multicenter StudyLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19520338</style></custom1><custom3><style face="normal" font="default">AS - JACC Cardiovasc Imaging. 2(6):692-700, 2009 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>314</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Blaha,M.J.</style></author><author><style face="normal" font="default"> Nasir,K.</style></author><author><style face="normal" font="default"> Rivera,J.J.</style></author><author><style face="normal" font="default"> Choi,E.K.</style></author><author><style face="normal" font="default"> Chang,S.A.</style></author><author><style face="normal" font="default"> Yoon,Y.E.</style></author><author><style face="normal" font="default"> Chun,E.J.</style></author><author><style face="normal" font="default"> Choi,S.I.</style></author><author><style face="normal" font="default"> Agatston,A.</style></author><author><style face="normal" font="default"> Blumenthal,R.S.</style></author><author><style face="normal" font="default"> Chang,H.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Gender differences in coronary plaque composition by coronary computed tomography angiography</style></title><secondary-title><style face="normal" font="default">Coronary Artery Disease</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Coronary Artery Disease</style></full-title></periodical><pages end="512" start="506">506-512</pages><volume><style face="normal" font="default">20</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Asian Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcinosis/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Chi-Square Distribution</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Republic of Korea/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Coronary computed tomography angiography allows the differentiation of non-calcified (NCAP), calcified (CAP), and mixed coronary artery plaques (MCAP). Although males are thought to have a higher prevalence of atherosclerosis for a given age, there are currently few data regarding age-adjusted sex differences in plaque morphology and composition. METHODS: We studied 1015 consecutive asymptomatic South Korean patients (49+/-10 years, 64% men) who underwent 64-slice coronary computed tomography angiography during a routine health evaluation. Coronary plaque characteristics were analyzed on a per-segment basis according to the modified AHA classification. Plaques with more than 50% calcified tissue were classified as CAP, plaques with less than 50% calcified tissue were classified as MCAP, and plaques without calcium were classified as NCAP. Multiple regression analysis was used to describe the cross-sectional association between sex and plaque-type burden (>or=2 affected segments) after adjustment for age and other cardiovascular risk factors. RESULTS: There was a greater prevalence of coronary plaque among men (13 vs. 4%, P&lt;0.001). Males were more likely to have an increased burden of CAP (4 vs. 1%, P = 0.01) and MCAP (5 vs. 1%, P&lt;0.001), whereas the burden of NCAP was similar across sex (2 vs. 1%, P = 0.28). After multivariable adjustment, men have six to seven times greater odds of having an increased burden of CAP and MCAP, whereas no sex difference was observed in the burden of NCAP. CONCLUSION: In this population of asymptomatic middle-aged Korean individuals, males had a significantly greater burden of MCAP and CAP. Future studies will determine whether these differences contribute to the accelerated cardiovascular risk observed in men</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Johns Hopkins Ciccarone Preventive Cardiology Center, Baltimore, Maryland, USAJC - 9011445, BYWCP - EnglandPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19858713</style></custom1><custom3><style face="normal" font="default">AS - Coron Artery Dis. 20(8):506-12, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>20</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Bolland,M.J.</style></author><author><style face="normal" font="default"> Wang,T.K.</style></author><author><style face="normal" font="default"> van Pelt,N.C.</style></author><author><style face="normal" font="default"> Horne,A.M.</style></author><author><style face="normal" font="default"> Mason,B.H.</style></author><author><style face="normal" font="default"> Ames,R.W.</style></author><author><style face="normal" font="default"> Grey,A.B.</style></author><author><style face="normal" font="default"> Ruygrok,P.N.</style></author><author><style face="normal" font="default"> Gamble,G.D.</style></author><author><style face="normal" font="default"> Reid,I.R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Abdominal aortic calcification on vertebral morphometry images predicts incident myocardial infarction</style></title><secondary-title><style face="normal" font="default">Journal of Bone &amp; Mineral Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Bone &amp; Mineral Research</style></full-title></periodical><pages end="512" start="505">505-512</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aorta,Abdominal/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Aortic Diseases/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Myocardial Infarction/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Spine/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Absorptiometry,Photon</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aorta,Abdominal/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Aortic Diseases/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Dietary Supplements</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Spine/pa [Pathology]</style></keyword></keywords><dates><year Day="0" Month="3" Year="2010">2010/3</year></dates><abstract><style face="normal" font="default">Abdominal aortic calcification (AAC) measured on spine X-rays is an established risk factor for cardiovascular disease. We investigated whether AAC assessed using vertebral morphometry and a recently developed scoring system (AAC-8) is reliable and associated with cardiovascular risk factors or events. A total of 1471 healthy postmenopausal women and 323 healthy middle-aged and older men participated in 5 and 2 year trials of calcium supplements, respectively. AAC-8 was assessed on vertebral morphometry images at baseline and follow-up. In addition, 163 men also had coronary artery calcification measured using computed tomography. Cardiovascular events during the trials were independently adjudicated. We found strong inter- and intrameasurer agreement for AAC-8 (kappa > 0.87). The prevalence of AAC increased with age (p &lt; .01) in women and in men. AAC was associated with many established cardiovascular risk factors, with serum calcium in women (p = .002) and with higher coronary calcium scores in men (p = .03). Estimated 5 year cardiovascular risk increased with increasing AAC-8 score (p &lt; .001) in women and in men. The presence of AAC independently predicted myocardial infarction (MI) in women [hazards ratio (HR) = 2.30, p = .007] and men (HR = 5.32, p = .04), even after adjustment for estimated cardiovascular risk in women. In women, AAC independently predicted cardiovascular events (MI, stroke, or sudden death) (HR = 1.74, p = .007), and changes in AAC-8 score over time were associated with MI and cardiovascular events, even after adjustment for estimated cardiovascular risk. In summary, scoring AAC on vertebral morphometric scans is a reproducible method of assessing cardiovascular risk that independently predicts incident MI and cardiovascular events, even after taking into account traditional cardiovascular risk factors. Copyright 2010 American Society for Bone and Mineral Research</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, University of Auckland, Auckland, New Zealand. m.bolland@auckland.ac.nzJC - 8610640CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19821777</style></custom1><custom3><style face="normal" font="default">AS - J Bone Miner Res. 25(3):505-12, 2010 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>333</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Bolland,M.J.</style></author><author><style face="normal" font="default"> Bacon,C.J.</style></author><author><style face="normal" font="default"> Horne,A.M.</style></author><author><style face="normal" font="default"> Mason,B.H.</style></author><author><style face="normal" font="default"> Ames,R.W.</style></author><author><style face="normal" font="default"> Wang,T.K.</style></author><author><style face="normal" font="default"> Grey,A.B.</style></author><author><style face="normal" font="default"> Gamble,G.D.</style></author><author><style face="normal" font="default"> Reid,I.R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Vitamin D insufficiency and health outcomes over 5 y in older women</style></title><secondary-title><style face="normal" font="default">American Journal of Clinical Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Clinical Nutrition</style></full-title></periodical><pages end="89" start="82">82-89</pages><volume><style face="normal" font="default">91</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> *Health Status</style></keyword><keyword><style face="normal" font="default"> *Vitamin D Deficiency/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> 0 (Hydroxycholecalciferols)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipids)</style></keyword><keyword><style face="normal" font="default"> 0 (Phosphates)</style></keyword><keyword><style face="normal" font="default"> 67-97-0 (Cholecalciferol)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Bone Density</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cholecalciferol/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Cholecalciferol/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Dietary Supplements</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fractures,Bone/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Fractures,Bone/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Hand Strength</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hydroxycholecalciferols/df [Deficiency]</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Lipids/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Phosphates/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Postmenopause</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="1" Year="2010">2010/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Vitamin D insufficiency was shown to be associated with adverse musculoskeletal and nonskeletal outcomes in numerous observational studies. However, some studies did not control for confounding factors such as age or seasonal variation of 25-hydroxyvitamin D [25(OH)D]. OBJECTIVE: We sought to determine the effect of vitamin D status on health outcomes. DESIGN: Healthy community-dwelling women (n = 1471) with a mean age of 74 y were followed in a 5-y trial of calcium supplementation. 25(OH)D was measured at baseline in all women. Skeletal and nonskeletal outcomes were evaluated according to seasonally adjusted vitamin D status at baseline. RESULTS: Fifty percent of women had a seasonally adjusted 25(OH)D concentration &lt;50 nmol/L. These women were significantly older, heavier, and less physically active and had more comorbidities than women with a seasonally adjusted 25(OH)D concentration > or =50 nmol/L. Women with a seasonally adjusted 25(OH)D concentration &lt;50 nmol/L had an increased incidence of stroke and cardiovascular events that did not persist after adjustment for between-group differences in age or comorbidities. Women with a seasonally adjusted 25(OH)D concentration &lt;50 nmol/L were not at increased risk of adverse consequences for any musculoskeletal outcome, including fracture, falls, bone density, or grip strength or any nonskeletal outcomes, including death, myocardial infarction, cancer, heart failure, diabetes, or adverse changes in blood pressure, weight, body composition, cholesterol, or glucose. CONCLUSIONS: Vitamin D insufficiency is more common in older, frailer women. Community-dwelling older women with a seasonally adjusted 25(OH)D concentration &lt;50 nmol/L were not at risk of adverse outcomes over 5 y after control for comorbidities. Randomized placebo-controlled trials are needed to determine whether vitamin D supplementation in individuals with vitamin D insufficiency influences health outcomes. This trial was registered at www.anzctr.org.au as ACTRN 012605000242628</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, University of Auckland, Auckland, New Zealand. m.bolland@auckland.ac.nzJC - 3ey, 0376027CP - United StatesPT - Journal ArticlePT - Randomized Controlled TrialPT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19906799</style></custom1><custom3><style face="normal" font="default">AS - Am J Clin Nutr. 91(1):82-9, 2010 Jan.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>252</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Bomback,A.S.</style></author><author><style face="normal" font="default"> Kshirsagar,A.V.</style></author><author><style face="normal" font="default"> Whaley-Connell,A.T.</style></author><author><style face="normal" font="default"> Chen,S.C.</style></author><author><style face="normal" font="default"> Li,S.</style></author><author><style face="normal" font="default"> Klemmer,P.J.</style></author><author><style face="normal" font="default"> McCullough,P.A.</style></author><author><style face="normal" font="default"> Bakris,G.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Racial differences in kidney function among individuals with obesity and metabolic syndrome: results from the Kidney Early Evaluation Program (KEEP)</style></title><secondary-title><style face="normal" font="default">American Journal of Kidney Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Kidney Diseases</style></full-title></periodical><pages end="S14" start="Suppl">Suppl-S14</pages><volume><style face="normal" font="default">55</style></volume><number><style face="normal" font="default">3:Suppl 2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*African Americans/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> *European Continental Ancestry Group/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> *Foundations</style></keyword><keyword><style face="normal" font="default"> *Kidney/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Metabolic Syndrome X/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> *Obesity/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> African Americans</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Community Health Services/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Continental Population Groups/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Kidney Diseases/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Kidney Diseases/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Kidney Diseases/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Kidney Function Tests</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Metabolic Syndrome X/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Metabolic Syndrome X/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Obesity/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Obesity/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> United States/eh [Ethnology]</style></keyword></keywords><dates><year Day="0" Month="3" Year="2010">2010/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: Obesity and metabolic syndrome may differ by race. For participants in the National Kidney Foundation's Kidney Early Evaluation Program (KEEP), we examined whether African American and white participants with obesity and metabolic syndrome differ regarding albuminuria, estimated glomerular filtration rate (eGFR), anemia, and bone/mineral metabolism derangements in chronic kidney disease (CKD). METHODS: 3 study cohorts were assembled: (1) eligible African American and white KEEP participants with body mass index > or = 30 kg/m(2), (2) a subgroup meeting criteria for metabolic syndrome, and (3) a subgroup with eGFR &lt; 60 mL/min/1.73 m(2) and laboratory measurements for hemoglobin, parathyroid hormone, calcium, and phosphorus. Patient characteristics and kidney function assessments were compared and tested using chi(2) (categorical variables) and t test (continuous variables). Univariate and multivariate logistic regression analyses were performed to evaluate associations of race with kidney disease measures. RESULTS: Of 37,107 obese participants, 48% were African American and 52% were white. Whites were more likely to have metabolic syndrome components (hypertension, 87.1% vs 84.8%; dyslipidemia, 81.6% vs 66.7%; diabetes, 42.7% vs 34.9%) and more profoundly decreased eGFR than African Americans (CKD stages 3-5 prevalence, 23.6% vs 13.0%; P &lt; 0.001). African Americans were more likely to have abnormal urinary albumin excretion (microalbuminuria, 12.5% vs 10.2%; OR, 1.60 [95% CI, 1.45-1.76]; macroalbuminuria, 1.3% vs 1.2%; OR, 1.61 [95% CI, 1.23-2.12]) and CKD stages 1-2 (10.3% vs 7.1%; OR, 1.54 [95% CI, 1.38-1.72]). For participants with CKD stages 3-5, anemia prevalence was 32.4% in African Americans and 14.1% in whites; corresponding values for secondary hyperparathyroidism were 66.2% and 46.6%, respectively. CONCLUSIONS: Obesity and metabolic syndrome may be heterogeneous disease states in African Americans and whites, possibly explaining differences in long-term kidney and cardiovascular outcomes. Copyright (c) 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, Division of Nephrology, Columbia University College of Physicians and Surgeons, 622 W 168th Street, New York, NY 10032, USA. asb68@columbia.eduJC - 3h5, 8110075CP - United StatesPT - Comparative StudyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20172446</style></custom1><custom3><style face="normal" font="default">AS - Am J Kidney Dis. 55(3 Suppl 2):S4-S14, 2010 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>449</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">bou-Raya,S.</style></author><author><style face="normal" font="default"> bou-Raya,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Osteoporosis and congestive heart failure (CHF) in the elderly patient: double disease burden</style></title><secondary-title><style face="normal" font="default">Archives of Gerontology &amp; Geriatrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Archives of Gerontology &amp; Geriatrics</style></full-title></periodical><pages end="254" start="250">250-254</pages><volume><style face="normal" font="default">49</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Heart Failure/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Osteoporosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> 0 (Tumor Necrosis Factor-alpha)</style></keyword><keyword><style face="normal" font="default"> 67-97-0 (Cholecalciferol)</style></keyword><keyword><style face="normal" font="default"> Absorptiometry,Photon</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Cholecalciferol/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Geriatric Assessment</style></keyword><keyword><style face="normal" font="default"> Heart Failure/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Osteoporosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Tumor Necrosis Factor-alpha/bl [Blood]</style></keyword></keywords><dates><year Day="0" Month="9" Year="2009">2009/9</year></dates><abstract><style face="normal" font="default">The present study aimed to evaluate the association between osteoporosis and CHF in elderly patients and to assess the effect of physical performance, vitamin D levels, inflammatory markers on this association. One hundred and twenty-six consecutive patients aged 65 years and above, with moderate to severe CHF who presented to our institution for CHF management and 54 age- and sex-matched controls were screened for osteoporosis. All patients were thoroughly interrogated for cause of CHF, medications, smoking, alcohol use, additional comorbidities and previous falls/fractures. A physical examination was performed to assess CHF severity and New York Heart Association (NYHA) class. Bone mineral density (BMD) measurements using dual-energy X-ray absorptiometry (DXA) were performed at the lumbar spine (LS) and femoral neck (FN). Physical performance assessment included grip strength, 6-min walk, "Get up and Go Test", activities of daily living (ADL) and frailty assessment. Biochemical assessment included measurement of levels of serum calcium, phosphorus, 1,25-dihyroxycholecalciferol=1,25(OH)(2)D (vitamin D(3)) and tumor necrosis factor-alpha (TNF-alpha). The BMD-Z-scores were significantly lower in HF patients compared to the non-HF controls. Furthermore, there was an association between the ejection fraction (EF) and the BMD-Z-scores. HF patients were significantly more likely to have poor physical performance, a higher frailty composite score, higher TNF-alpha and lower 1,25(OH)(2)D levels. A significant association was found between EF and frailty score, p&lt;0.001. The results suggest that there is an association between HF and lower BMD. The increased bone loss in conjunction with CHF is likely to increase fracture risk. Thus, strategies for optimal treatment of CHF and for optimizing vitamin D(3), calcium and physical activity to improve quality of life (QoL) in these patients who have double disease burden are critical in these individuals</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Geriatric Unit, Internal Medicine Department, Faculty of Medicine, University of Alexandria, 12 Heliopolis Street, Camp Cesar, 00203 Alexandria, Egypt. suzanraya@yahoo.comJC - 8214379, 7axCP - NetherlandsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18977041</style></custom1><custom3><style face="normal" font="default">AS - Arch Gerontol Geriatr. 49(2):250-4, 2009 Sep-Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>42</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Boxer,R.S.</style></author><author><style face="normal" font="default"> Kleppinger,A.</style></author><author><style face="normal" font="default"> Brindisi,J.</style></author><author><style face="normal" font="default"> Feinn,R.</style></author><author><style face="normal" font="default"> Burleson,J.A.</style></author><author><style face="normal" font="default"> Kenny,A.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Effects of dehydroepiandrosterone (DHEA) on cardiovascular risk factors in older women with frailty characteristics</style></title><secondary-title><style face="normal" font="default">Age &amp; Ageing</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Age &amp; Ageing</style></full-title></periodical><pages end="458" start="451">451-458</pages><volume><style face="normal" font="default">39</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Abdominal Fat/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Dehydroepiandrosterone Sulfate/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Dehydroepiandrosterone/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Frail Elderly</style></keyword><keyword><style face="normal" font="default"> 0 (Blood Glucose)</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol,LDL)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipids)</style></keyword><keyword><style face="normal" font="default"> 0 (Sex Hormone-Binding Globulin)</style></keyword><keyword><style face="normal" font="default"> 50-28-2 (Estradiol)</style></keyword><keyword><style face="normal" font="default"> 53-43-0 (Dehydroepiandrosterone)</style></keyword><keyword><style face="normal" font="default"> 58-22-0 (Testosterone)</style></keyword><keyword><style face="normal" font="default"> 651-48-9 (Dehydroepiandrosterone Sulfate)</style></keyword><keyword><style face="normal" font="default"> 67-97-0 (Cholecalciferol)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Blood Glucose/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Blood Pressure/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Body Composition/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Calcium/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Cholecalciferol/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Cholesterol,LDL/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Estradiol/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lipids/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sex Hormone-Binding Globulin/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Testosterone/bl [Blood]</style></keyword></keywords><dates><year Day="0" Month="7" Year="2010">2010/7</year></dates><abstract><style face="normal" font="default">OBJECTIVE: this analysis was to investigate the effects of dehydroepiandrosterone (DHEA) on cardiovascular risk factors in older women with frailty characteristics. DESIGN, SETTING AND PARTICIPANTS: the study was a double-blind, randomised, placebo-controlled trial of 99 women (mean 76.6 +/- 6.0 year) with the low DHEA-S level and frailty. INTERVENTION: participants received 50 mg/day DHEA or placebo for 6 months; all received calcium (1,000-1,200 mg/day diet) and supplement (combined) and cholecalciferol (1,000 IU/day). Women participated in 90-min twice weekly exercise regimens, either chair aerobics or yoga. MAIN OUTCOME MEASURES: assessment of outcome variables included hormone levels (DHEA-S, oestradiol, oestrone, testosterone and sex hormone-binding globulin (SHBG)), lipid profiles (total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol and triglycerides), body composition measured by dual energy absorptiometry, glucose levels and blood pressure (BP). RESULTS: eighty-seven women (88%) completed 6 months of study; 88% were pre-frail demonstrating 1-2 frailty characteristics and 12% were frail with > or =3 characteristics. There were significant changes in all hormone levels including DHEA-S, oestradiol, oestrone and testosterone and a decline in SHBG levels in those taking DHEA supplements. In spite of changes in hormone levels, there were no significant changes in cardiovascular risk factors including lipid profiles, body or abdominal fat, fasting glucose or BP. CONCLUSION: research to date has not shown consistent effects of DHEA on cardiovascular risk, and this study adds to the literature that short-term therapy with DHEA is safe for older women in relation to cardiovascular risk factors. This study is novel in that we recruited women with evidence of physical frailty</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Center on Aging, University of Connecticut Health Center, Farmington, 06030, USAJC - 0375655, 2xrCP - EnglandPT - Journal ArticlePT - Randomized Controlled TrialPT - Research Support, N.I.H., ExtramuralPT - Research Support, U.S. Gov't, Non-P.H.SNO - MO1-RR06192 (United States NCRR NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20484057</style></custom1><custom3><style face="normal" font="default">AS - Age Ageing. 39(4):451-8, 2010 Jul.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>270</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Boylan,S.</style></author><author><style face="normal" font="default"> Welch,A.</style></author><author><style face="normal" font="default"> Pikhart,H.</style></author><author><style face="normal" font="default"> Malyutina,S.</style></author><author><style face="normal" font="default"> Pajak,A.</style></author><author><style face="normal" font="default"> Kubinova,R.</style></author><author><style face="normal" font="default"> Bragina,O.</style></author><author><style face="normal" font="default"> Simonova,G.</style></author><author><style face="normal" font="default"> Stepaniak,U.</style></author><author><style face="normal" font="default"> Gilis-Januszewska,A.</style></author><author><style face="normal" font="default"> Milla,L.</style></author><author><style face="normal" font="default"> Peasey,A.</style></author><author><style face="normal" font="default"> Marmot,M.</style></author><author><style face="normal" font="default"> Bobak,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Dietary habits in three Central and Eastern European countries: the HAPIEE study</style></title><secondary-title><style face="normal" font="default">BMC Public Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">BMC Public Health</style></full-title></periodical><pages end="" start="439">439-</pages><volume><style face="normal" font="default">9</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Diet/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> *Energy Intake</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Czech Republic</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Diet Surveys</style></keyword><keyword><style face="normal" font="default"> Diet/st [Standards]</style></keyword><keyword><style face="normal" font="default"> Energy Intake</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fruit</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Pulse</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Russia</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Socioeconomic Factors</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Vegetables</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><abstract><style face="normal" font="default">BACKGROUND: The high cardiovascular mortality in Eastern Europe has often been attributed to poor diet, but individual-level data on nutrition in the region are generally not available. This paper describes the methods of dietary assessment and presents preliminary findings on food and nutrient intakes in large general population samples in Russia, Poland and the Czech Republic. METHODS: The HAPIEE (Health, Alcohol and Psychosocial factors In Eastern Europe) study examined random samples of men and women aged 45-69 years at baseline in Novosibirsk (Russia), Krakow (Poland) and six Czech urban centres in 2002-2005. Diet was assessed using a food frequency questionnaire (at least 136 items); complete dietary information was available for 26,870 persons. RESULTS: Total energy intakes among men ranged between 8.7 MJ in the Czech sample and 11.7 MJ in the Russian sample, while among women, energy intakes ranged between 8.2 MJ in the Czech sample and 9.8 MJ in the Russian sample. A Healthy Diet Indicator (HDI), ranging from a score of 0 (lowest) to 7 (highest), was developed using the World Health Organisation's (WHO) guidelines for the prevention of chronic diseases. The mean HDI scores were low, ranging from 1.0 (SD = 0.7) among the Polish subjects to 1.7 (SD = 0.8) among the Czech females. Very few subjects met the WHO recommended intakes for complex carbohydrates, pulses or nuts; intakes of saturated fatty acids, sugar and protein were too high. Only 16% of Polish subjects met the WHO recommendation for polyunsaturated fat intake. Consumption of fruits and vegetables was lower than recommended, especially among those Russian subjects who were assessed during the low intake season. Fewer than 65% of subjects consumed adequate amounts of calcium, magnesium and potassium, when compared with the United Kingdom's Reference Nutrient Intake. CONCLUSION: This first large scale study of individual-based dietary intakes in the general population in Eastern Europe implies that intakes of saturated fat, sugar and complex carbohydrates are a cause for concern. The development of country-specific nutritional tools must be encouraged and nutritional campaigns must undergo continuing development</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Epidemiology and Public Health, University College London, London, UK. s.boylan@public-health.ucl.ac.ukJC - 100968562CP - EnglandPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - 064947/Z/01/Z (United Kingdom Wellcome Trust)NO - 1R01 AG23522-01 (United States NIA NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19951409</style></custom1><custom3><style face="normal" font="default">AS - BMC Public Health. 9:439, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>238</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Brouns,R.</style></author><author><style face="normal" font="default"> De,Vil B.</style></author><author><style face="normal" font="default"> Cras,P.</style></author><author><style face="normal" font="default"> De,Surgeloose D.</style></author><author><style face="normal" font="default"> Mari&amp;#x00EB</style></author><author><style face="normal" font="default">n P</style></author><author><style face="normal" font="default"> De Deyn,P.P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Neurobiochemical markers of brain damage in cerebrospinal fluid of acute ischemic stroke patients</style></title><secondary-title><style face="normal" font="default">Clinical Chemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinical Chemistry</style></full-title></periodical><pages end="458" start="451">451-458</pages><volume><style face="normal" font="default">56</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Brain Ischemia/cf [Cerebrospinal Fluid]</style></keyword><keyword><style face="normal" font="default"> *Glial Fibrillary Acidic Protein/cf [Cerebrospinal Fluid]</style></keyword><keyword><style face="normal" font="default"> *Myelin Basic Proteins/cf [Cerebrospinal Fluid]</style></keyword><keyword><style face="normal" font="default"> *Nerve Growth Factors/cf [Cerebrospinal Fluid]</style></keyword><keyword><style face="normal" font="default"> *Phosphopyruvate Hydratase/cf [Cerebrospinal Fluid]</style></keyword><keyword><style face="normal" font="default"> *S100 Proteins/cf [Cerebrospinal Fluid]</style></keyword><keyword><style face="normal" font="default"> *Stroke/cf [Cerebrospinal Fluid]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Glial Fibrillary Acidic Protein)</style></keyword><keyword><style face="normal" font="default"> 0 (Myelin Basic Proteins)</style></keyword><keyword><style face="normal" font="default"> 0 (Nerve Growth Factors)</style></keyword><keyword><style face="normal" font="default"> 0 (S-100 calcium-binding protein beta subunit)</style></keyword><keyword><style face="normal" font="default"> 0 (S100 Proteins)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Biological Markers/cf [Cerebrospinal Fluid]</style></keyword><keyword><style face="normal" font="default"> EC 4-2-1-11 (Phosphopyruvate Hydratase)</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="3" Year="2010">2010/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: Ischemic injury to the central nervous system causes cellular activation and disintegration, leading to release of cell-type-specific proteins into the cerebrospinal fluid (CSF). We investigated CSF concentrations of myelin basic protein (MBP), glial fibrillary astrocytic protein (GFAP), the calcium-binding protein S100B, and neuron-specific enolase (NSE) in acute ischemic stroke patients and their relation to initial stroke severity, stroke location, and long-term stroke outcome. METHODS: CSF concentrations of MBP, GFAP, S100B, and NSE were assessed in 89 stroke patients on admission (mean 8.7 h after stroke onset) and in 35 controls. We evaluated the relation between CSF concentrations and (a) stroke severity (NIH Stroke Scale [NIHSS] score on admission, infarct volume), (b) stroke location, and (c) stroke outcome (modified Rankin Scale [mRS] score at month 3). RESULTS: MBP concentration was significantly higher in subcortical than in cortical infarcts (median MBP, 1.18 vs 0.66 microg/L, P &lt; 0.001). GFAP and S100B concentrations correlated with the NIHSS score on admission (GFAP, R = 0.35, P = 0.001; S100B, R = 0.29, P = 0.006), infarct volume (GFAP, R = 0.34, P = 0.001; S100B, R = 0.28, P = 0.008), and mRS score at month 3 (R = 0.42, P &lt; 0.001 and R = 0.28, P = 0.007). Concentrations of NSE did not correlate with stroke characteristics. CONCLUSIONS: MBP, GFAP, S100B, and NSE display relevant differences in cellular and subcellular origins, which are reflected in their relation to stroke characteristics. MBP is a marker for infarct location. GFAP and S100B correlate with stroke severity and outcome</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Neurology and Memory Clinic, ZNA Middelheim Hospital, Antwerp, BelgiumJC - dbz, 9421549CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19959621</style></custom1><custom3><style face="normal" font="default">AS - Clin Chem. 56(3):451-8, 2010 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>538</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Brown,I.J.</style></author><author><style face="normal" font="default"> Elliott,P.</style></author><author><style face="normal" font="default"> Robertson,C.E.</style></author><author><style face="normal" font="default"> Chan,Q.</style></author><author><style face="normal" font="default"> Daviglus,M.L.</style></author><author><style face="normal" font="default"> Dyer,A.R.</style></author><author><style face="normal" font="default"> Huang,C.C.</style></author><author><style face="normal" font="default"> Rodriguez,B.L.</style></author><author><style face="normal" font="default"> Sakata,K.</style></author><author><style face="normal" font="default"> Ueshima,H.</style></author><author><style face="normal" font="default"> Van,Horn L.</style></author><author><style face="normal" font="default"> Zhao,L.</style></author><author><style face="normal" font="default"> Stamler,J.</style></author><author><style face="normal" font="default"> INTERMAP Research Group</style></author></authors></contributors><titles><title><style face="normal" font="default">Dietary starch intake of individuals and their blood pressure: the International Study of Macronutrients and Micronutrients and Blood Pressure</style></title><secondary-title><style face="normal" font="default">Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Hypertension</style></full-title></periodical><pages end="236" start="231">231-236</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Blood Pressure</style></keyword><keyword><style face="normal" font="default"> *Dietary Carbohydrates</style></keyword><keyword><style face="normal" font="default"> *Starch</style></keyword><keyword><style face="normal" font="default"> 0 (Dietary Carbohydrates)</style></keyword><keyword><style face="normal" font="default"> 9005-25-8 (Starch)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Dietary Carbohydrates/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Linear Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Starch/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Urine</style></keyword></keywords><dates><year Day="0" Month="2" Year="2009">2009/2</year></dates><isbn><style face="normal" font="default">0263-6352</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: Data from the Multiple Risk Factor Intervention Trial show an independent direct association between starch intake and blood pressure in American men at higher risk of coronary heart disease. Cross-sectional data from the International Study of Macronutrients and Micronutrients and Blood Pressure (INTERMAP) were used to assess relations of dietary starch intake to blood pressure in men and women from four countries. METHODS: Data include 83 nutrients from four multipass 24-h dietary recalls and two timed 24-h urine collections; eight blood pressure readings; and questionnaire data, for 4680 participants aged 40-59 years from 17 population samples in Japan, People's Republic of China, United Kingdom, and United States of America. RESULTS: In multiple linear regression analyses--adjusted for urinary sodium, urinary potassium, consumption of alcohol, cholesterol, saturated fatty acids, polyunsaturated fatty acids, calcium, and other variables--starch intake higher by two standard deviations (14.1% kJ) was associated with systolic/diastolic blood pressure differences of -1.0/-0.9 mmHg (P = 0.09, P &lt; 0.05). Results were similar with additional control for fiber, magnesium, or phosphorus; reduced to -0.5/-0.7 mmHg (P = 0.47, P = 0.13) with separate adjustment for vegetable protein. Findings were similar for men analyzed separately, for American men, and for American men at higher coronary heart disease risk. CONCLUSION: Our findings indicate that--if any--relations of starch intake to blood pressure are modestly inverse. Current dietary guidelines for hypertension prevention and control remain relevant</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Epidemiology and Public Health, Imperial College London, St Mary's Campus, London, UKCM - Comment in: J Hypertens. 2009 Feb;27(2):212-3; PMID: 19155774]JC - iew, 8306882CP - EnglandPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - R01HL50490 (United States NHLBI NIH HHS)NO - (United Kingdom Medical Research Council)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19155780</style></custom1><custom3><style face="normal" font="default">AS - J Hypertens. 27(2):231-6, 2009 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>426</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Bruining,N.</style></author><author><style face="normal" font="default"> de,Winter S.</style></author><author><style face="normal" font="default"> Roelandt,J.R.</style></author><author><style face="normal" font="default"> Rodriguez-Granillo,G.A.</style></author><author><style face="normal" font="default"> Heller,I.</style></author><author><style face="normal" font="default"> van Domburg,R.T.</style></author><author><style face="normal" font="default"> Hamers,R.</style></author><author><style face="normal" font="default"> de Feijter,P.J.</style></author><author><style face="normal" font="default"> PERSPECTIVE,Investigators</style></author></authors></contributors><titles><title><style face="normal" font="default">Coronary calcium significantly affects quantitative analysis of coronary ultrasound: importance for atherosclerosis progression/regression studies</style></title><secondary-title><style face="normal" font="default">Coronary Artery Disease</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Coronary Artery Disease</style></full-title></periodical><pages end="414" start="409">409-414</pages><volume><style face="normal" font="default">20</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Angiotensin-Converting Enzyme Inhibitors/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Perindopril/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Ultrasonography,Interventional</style></keyword><keyword><style face="normal" font="default"> 0 (Angiotensin-Converting Enzyme Inhibitors)</style></keyword><keyword><style face="normal" font="default"> 82834-16-0 (Perindopril)</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Double-Blind Method</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Image Interpretation,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="9" Year="2009">2009/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Coronary atherosclerosis is a dynamic process, which progresses differently in coronary segments containing noncalcified or calcified plaques. This may have implications for the study of the effects of therapy on progression/regression. OBJECTIVE: To test this hypothesis, we performed a post-hoc analysis on data of a randomized trial in which perindopril treatment was compared with placebo on progression/regression of atherosclerosis with regard to the degree of calcification. METHODS AND RESULTS: The intracoronary ultrasound data of 118 patients, who were enrolled in the multicentre, double-blinded randomized trial (PERSPECTIVE), were analysed. Vessel, lumen and plaque areas were measured in 711 5-mm-long matched coronary segments (perindopril 360, placebo 351). Each individual intracoronary ultrasound cross-section was binary labelled for the presence of calcium (yes/no), and the degree of calcium was assessed as a percentage of length. The segments were classified into three groups: 0-25, 25-50 and 50-100% (percentage of length) calcification. Coronary plaques with no or little calcium (0-25%) regressed on perindopril and did not change on placebo (-0.33+/-1.74 vs. -0.03+/-1.66, respectively; P = 0.04). Plaques containing moderate calcium (group 25-50%) did not change and plaques with severe amounts of calcification (group 50-100%) equally progressed. CONCLUSION: Noncalcified plaques may be amenable to regression with ACE inhibitor treatment. The method, which considers the amount of calcium content in a plaque, may lead to new insights for quantitative analysis of the effects of therapy in progression/regression studies of atherosclerosis</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Thoraxcenter, Department of Cardiology, Erasmus MC, Rotterdam, The Netherlands. n.Bruining@erasmusmc.nlJC - 9011445, BYWCP - EnglandPT - Journal ArticlePT - Multicenter StudyPT - Randomized Controlled TrialLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19641457</style></custom1><custom3><style face="normal" font="default">AS - Coron Artery Dis. 20(6):409-14, 2009 Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>356</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Brunaud,L.</style></author><author><style face="normal" font="default"> Germain,A.</style></author><author><style face="normal" font="default"> Zarnegar,R.</style></author><author><style face="normal" font="default"> Rancier,M.</style></author><author><style face="normal" font="default"> Alrasheedi,S.</style></author><author><style face="normal" font="default"> Caillard,C.</style></author><author><style face="normal" font="default"> Ayav,A.</style></author><author><style face="normal" font="default"> Weryha,G.</style></author><author><style face="normal" font="default"> Mirallie,E.</style></author><author><style face="normal" font="default"> Bresler,L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism</style></title><secondary-title><style face="normal" font="default">Surgery</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Surgery</style></full-title></periodical><pages end="1041" start="1035">1035-1041</pages><volume><style face="normal" font="default">146</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aldosterone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Hyperparathyroidism,Primary/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Antihypertensive Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 52-39-1 (Aldosterone)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Antihypertensive Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Primary/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Primary/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Parathyroidectomy</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Primary hyperparathyroidism is associated with an increased cardiovascular morbidity and mortality. However, mechanisms underlying this association are currently unclear. As there is clear evidence of the independent role of aldosterone on the cardiovascular system, the aim of this study was to evaluate aldosterone levels in patients with primary hyperparathyroidism. METHODS: A prospective study of 134 consecutive patients with primary hyperparathyroidism before and 3 months after parathyroidectomy. RESULTS: Pre-operative serum aldosterone and parathyroid hormone (PTH) levels were correlated positively in all patients (.238; P = .005). In the 62 patients (46%) that were not on antihypertensive medications, this correlation was stronger (.441; P = .0003). In the 72 patients (54%) treated with at least 1 antihypertensive medication, no correlation between preoperative aldosterone and PTH serum levels was observed. By multivariate analysis, pre-operative PTH level (.409; P = .005) was an independent predictor of aldosterone. Pre-operative PTH level >100 ng/L was an independent predictor of abnormally elevated plasma aldosterone level (odds ratio 3.5; P = .01). At 3 months after parathyroidectomy, no correlation was observed between postoperative PTH and aldosterone levels. CONCLUSION: Aldosterone is correlated positively to preoperative PTH levels in patients with primary hyperparathyroidism. Aldosterone might be a key mediator of cardiovascular symptoms in patients with primary hyperparathyroidism</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of General, Digestive and Endocrine Surgery, University of Nancy, Vandoeuvre-les-Nancy, France. l.brunaud@chu-nancy.frJC - vc3, 0417347CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19958930</style></custom1><custom3><style face="normal" font="default">AS - Surgery. 146(6):1035-41, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>290</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Budoff,M.J.</style></author><author><style face="normal" font="default"> Ahmadi,N.</style></author><author><style face="normal" font="default"> Gul,K.M.</style></author><author><style face="normal" font="default"> Liu,S.T.</style></author><author><style face="normal" font="default"> Flores,F.R.</style></author><author><style face="normal" font="default"> Tiano,J.</style></author><author><style face="normal" font="default"> Takasu,J.</style></author><author><style face="normal" font="default"> Miller,E.</style></author><author><style face="normal" font="default"> Tsimikas,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Aged garlic extract supplemented with B vitamins, folic acid and L-arginine retards the progression of subclinical atherosclerosis: a randomized clinical trial</style></title><secondary-title><style face="normal" font="default">Preventive Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Preventive Medicine</style></full-title></periodical><pages end="107" start="101">101-107</pages><volume><style face="normal" font="default">49</style></volume><number><style face="normal" font="default">2-3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Arginine/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Folic Acid/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Garlic</style></keyword><keyword><style face="normal" font="default"> *Phytotherapy</style></keyword><keyword><style face="normal" font="default"> *Vitamin B Complex/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipids)</style></keyword><keyword><style face="normal" font="default"> 0 (Plant Extracts)</style></keyword><keyword><style face="normal" font="default"> 12001-76-2 (Vitamin B Complex)</style></keyword><keyword><style face="normal" font="default"> 59-30-3 (Folic Acid)</style></keyword><keyword><style face="normal" font="default"> 68-19-9 (Vitamin B 12)</style></keyword><keyword><style face="normal" font="default"> 74-79-3 (Arginine)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Dietary Supplements</style></keyword><keyword><style face="normal" font="default"> Double-Blind Method</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lipids/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Plant Extracts/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Vitamin B 12/tu [Therapeutic Use]</style></keyword></keywords><dates><year Day="0" Month="8" Year="2009">2009/8</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Previous studies demonstrated that aged garlic extract reduces multiple cardiovascular risk factors. This study was designed to assess whether aged garlic extract therapy with supplements (AGE+S) favorably affects inflammatory and oxidation biomarkers, vascular function and progression of atherosclerosis as compared to placebo. METHODS: In this placebo-controlled, double-blind, randomized trial (conducted 2005-2007), 65 intermediate risk patients (age 60+/-9 years, 79% male) were treated with a placebo capsule or a capsule containing aged garlic extract (250 mg) plus Vitamin B12 (100 microg), folic acid (300 microg), Vitamin B6 (12.5 mg) and l-arginine (100 mg) given daily for a 1 year. All patients underwent coronary artery calcium scanning (CAC), temperature rebound (TR) as an index of vascular reactivity using Digital Thermal Monitoring (DTM), and measurement of lipid profile, autoantibodies to malondialdehyde (MDA)-LDL, apoB-immune complexes, oxidized phospholipids (OxPL) on apolipoprotein B-100 (OxPL/apoB), lipoprotein (a) [Lp (a)], C-reactive protein (CRP), homocysteine were measured at baseline and 12 months. CAC progression was defined as an increase in CAC>15% per year and an increase in TR above baseline was considered a favorable response. RESULTS: At 1 year, CAC progression was significantly lower and TR significantly higher in the AGE+S compared to the placebo group after adjustment of cardiovascular risk factors (p&lt;0.05). Total cholesterol, LDL-C, homocysteine, IgG and IgM autoantibodies to MDA-LDL and apoB-immune complexes were decreased, whereas HDL, OxPL/apoB, and Lp (a) were significantly increased in AGE+S to placebo. CONCLUSION: AGE+S is associated with a favorable improvement in oxidative biomarkers, vascular function, and reduced progression of atherosclerosis</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiology, Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, CA, USA. MBudoff@labiomed.orgJC - pm4, 0322116CP - United StatesPT - Journal ArticlePT - Randomized Controlled TrialLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19573556</style></custom1><custom3><style face="normal" font="default">AS - Prev Med. 49(2-3):101-7, 2009 Aug-Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>344</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Budoff,M.J.</style></author><author><style face="normal" font="default"> Karwasky,R.</style></author><author><style face="normal" font="default"> Ahmadi,N.</style></author><author><style face="normal" font="default"> Nasserian,C.</style></author><author><style face="normal" font="default"> Pratt,F.</style></author><author><style face="normal" font="default"> Stephens,J.</style></author><author><style face="normal" font="default"> Chang,W.W.</style></author><author><style face="normal" font="default"> Flores,F.R.</style></author><author><style face="normal" font="default"> Rizzo,J.A.</style></author><author><style face="normal" font="default"> Gunnarsson,C.L.</style></author><author><style face="normal" font="default"> McKay,C.R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Cost-effectiveness of multidetector computed tomography compared with myocardial perfusion imaging as gatekeeper to invasive coronary angiography in asymptomatic firefighters with positive treadmill tests</style></title><secondary-title><style face="normal" font="default">Journal of cardiovascular computed tomography</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of cardiovascular computed tomography</style></full-title></periodical><pages end="330" start="323">323-330</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Angiography/ec [Economics]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ec [Economics]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Health Care Costs/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> *Myocardial Perfusion Imaging/ec [Economics]</style></keyword><keyword><style face="normal" font="default"> *Rescue Work</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/ec [Economics]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Exercise Test/ec [Economics]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fires</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardial Perfusion Imaging</style></keyword><keyword><style face="normal" font="default"> Myocardial Perfusion Imaging/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Occupational Diseases/ec [Economics]</style></keyword><keyword><style face="normal" font="default"> Occupational Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Occupational Diseases/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Perfusion</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="9" Year="2009">2009/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: In a prospective evaluation of 3950 Los Angeles County firefighters who underwent wellness/fitness examinations, 495 firefighters had abnormal treadmill tests and were referred for cardiology evaluation. Cost of the traditional myocardial perfusion imaging (MPI) followed by invasive coronary angiography (ICA) was compared with a method incorporating 64-slice multidetector computed tomography (MDCT) with coronary calcium score (CCS) followed by computed tomographic angiography (CTA) and ICA as indicated. OBJECTIVE: We compared the costs of 2 methods of predicting coronary artery disease (CAD) by ICA among asymptomatic patients with positive treadmill tests. METHODS: A decision-analytic framework was used to compare the net direct costs of CAD diagnosis associated with MDCT versus MPI. In the MDCT arm, all received CCS followed by CTA for those with calcium scores>10 and ICA for those with > or =50% stenosis on CTA. For the MPI arm, results were estimated from prior years' experience, in which firefighters with abnormal treadmill results were referred to ICA. RESULTS: Of 495 firefighters, 131 (26.9%) had abnormal CCS and went to CTA; 40 (8.1%) had > or =50% stenosis on CTA and went to ICA. According to prior years' experience with MPI, 146 (29.5%) would have shown abnormalities requiring ICA. Average cost was $1376/person for MPI versus $503/person for CCS with or without CTA as gatekeeper. All sensitivity analyses showed lower costs for the MDCT pathway compared with MPI. CONCLUSION: In this firefighter population, the cost of ICA-confirmed diagnosis of CAD is substantially lower with MDCT as gatekeeper than with MPI</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 W. Carson Street, Torrance, CA 90502, USA. mbudoff@labiomed.orgCM - Comment in: J Cardiovasc Comput Tomogr. 2009 Sep-Oct;3(5):331-3; PMID: 19818322JC - 101308347CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19818321</style></custom1><custom3><style face="normal" font="default">AS - J Cardiovasc Comput Tomogr. 3(5):323-30, 2009 Sep-Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>405</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Budoff,M.J.</style></author><author><style face="normal" font="default"> McClelland,R.L.</style></author><author><style face="normal" font="default"> Nasir,K.</style></author><author><style face="normal" font="default"> Greenland,P.</style></author><author><style face="normal" font="default"> Kronmal,R.A.</style></author><author><style face="normal" font="default"> Kondos,G.T.</style></author><author><style face="normal" font="default"> Shea,S.</style></author><author><style face="normal" font="default"> Lima,J.A.</style></author><author><style face="normal" font="default"> Blumenthal,R.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Cardiovascular events with absent or minimal coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA)</style></title><secondary-title><style face="normal" font="default">American Heart Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Heart Journal</style></full-title></periodical><pages end="561" start="554">554-561</pages><volume><style face="normal" font="default">158</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> *Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> *Ethnic Groups</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Age Distribution</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Carotid Arteries/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Sex Distribution</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> United States/ep [Epidemiology]</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Elevated coronary artery calcium (CAC) is a marker for increase risk of coronary heart disease (CHD). Although most CHD events occur among individuals with advanced CAC, CHD can also occur in individuals with little or no calcified plaque. In this study, we sought to evaluate the characteristics associated with incident CHD events in the setting of minimal (score &lt;or=10) or absent CAC (score of zero). METHODS: Asymptomatic participants in the MESA (N = 6,809) were followed for occurrence of all CHD events (including myocardial infarction, angina, resuscitated cardiac arrest, or CHD death) and hard CHD events (myocardial infarction or CHD death). Time to incident CHD was modeled using age-and gender-adjusted Cox regression. RESULTS: The final study population consisted of 3,923 MESA asymptomatic participants (mean age 58 +/- 9 years, 39% males) who had CAC scores of 0 to 10. Overall, no detectable CAC was seen in 3415 individuals, whereas 508 had CAC scores of 1 to 10. During follow-up (median 4.1 years), there were 16 incident hard events and 28 all CHD events in individuals with absent or minimal CAC. In age-, gender-, race-, and CHD risk factor-adjusted analysis, minimal CAC (1-10) was associated with an estimated 3-fold greater risk of a hard CHD event (HR 3.23, 95% CI 1.17-8.95) or of all CHD event (HR 3.66, 95% CI 1.71-7.85) compared to those with CAC = 0. Former smoking (HR 3.57, 95% CI 1.08-11.77), current smoking (HR 4.93, 95% CI 1.20-20.30), and diabetes (HR 3.09, 95% CI 1.07-8.93) were significant risk factors for events in those with CAC = 0. CONCLUSION: Asymptomatic persons with absent or minimal CAC are at very low risk of future cardiovascular events. Individuals with minimal CAC (1-10) were significantly increased to 3-fold increased risk for incident CHD events relative to those with CAC scores of zero</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiology, Los Angeles Biomedical Research Center, Torrance, CA 90502, USA. mbudoff@labiomed.orgJC - 0370465CP - United StatesPT - Comparative StudyPT - Journal ArticlePT - Multicenter StudyPT - Research Support, N.I.H., ExtramuralNO - N01-HC-95159 (United States NHLBI NIH HHS)NO - N01-HC-95165 (United States NHLBI NIH HHS)NO - N01-HC-95169 (United States NHLBI NIH HHS)NO - R01 HL071739 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19781414</style></custom1><custom3><style face="normal" font="default">AS - Am Heart J. 158(4):554-61, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>4</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Bula,G.</style></author><author><style face="normal" font="default"> Koziolek,H.</style></author><author><style face="normal" font="default"> Niemiec,A.</style></author><author><style face="normal" font="default"> Gawrychowski,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Management of patients with secondary and tertiary hyperparathyroidism referred to surgical treatment</style></title><secondary-title><style face="normal" font="default">Endokrynologia Polska</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Endokrynologia Polska</style></full-title></periodical><pages end="268" start="264">264-268</pages><volume><style face="normal" font="default">61</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Hyperparathyroidism,Primary/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Hyperparathyroidism,Secondary/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Referral and Consultation/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Primary/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Secondary/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Parathyroid Glands/tr [Transplantation]</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Parathyroidectomy</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Reoperation</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="5" Year="2010">2010/5</year></dates><isbn><style face="normal" font="default">0423-104X</style></isbn><abstract><style face="normal" font="default">INTRODUCTION: Aim of the study was present personal observations connected with the management of patients referred to surgical treatment for secondary hyperparathyroidism (SHT) or tertiary hyperparathyroidism (THT), and to assess immediate results of such management. MATERIAL AND METHODS: A total of 175 patients aged 21-80 years were treated surgically for SHT, and 16 patients aged 36-64 years were treated surgically for THT, between 1 January 1996 and 31 December 2008. The patients were classified for surgical treatment in cooperation with a nephrologist, internist, and anaesthesiologist. Each patient underwent bilateral exploration of the neck and assessment of all identified parathyroid glands. Subtotal parathyroidectomy or resection of parathyroid glands combined with autotransplantation (the latter in two patients with recurrent SHT) were performed. Ionized calcium concentration in blood serum, water-electrolyte equilibrium, and cardiovascular system were monitored postoperatively. RESULTS: A fall in ionized calcium levels was obtained postoperatively in all patients. Successful surgical treatment was confirmed by intraoperative macroscopic and immunochemical examinations. Intensive bleeding from the wound was noted in 2 (1%) patients, and intensified stenocardial symptoms in 15 (7.9%) patients with SHT. No deaths were noted during the perioperative period. Five (2.8%) patients with SHT required emergency dialyses. CONCLUSIONS: 1. Surgical treatment of secondary or tertiary hyperparathyroidism requires close cooperation between the surgeon, nephrologist, internist, and anaesthesiologist. 2. Successful results of the treatment, including minimum cardiovascular complications, can only be obtained in integrated cooperation with a dialysis centre</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of General Surgery in Bytom, Silesian Medical University, Katowice. gregor6007@onet.euJC - ehn, 0370674CP - PolandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20602300</style></custom1><custom3><style face="normal" font="default">AS - Endokrynol Pol. 61(3):264-8, 2010 May-Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>428</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Bural,G.G.</style></author><author><style face="normal" font="default"> Torigian,D.A.</style></author><author><style face="normal" font="default"> Botvinick,E.</style></author><author><style face="normal" font="default"> Houseni,M.</style></author><author><style face="normal" font="default"> Basu,S.</style></author><author><style face="normal" font="default"> Chen,W.</style></author><author><style face="normal" font="default"> Alavi,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">A pilot study of changes in (18)F-FDG uptake, calcification and global metabolic activity of the aorta with aging</style></title><secondary-title><style face="normal" font="default">Hellenic Journal of Nuclear Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Hellenic Journal of Nuclear Medicine</style></full-title></periodical><pages end="128" start="123">123-128</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aging/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Aorta/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Aortitis/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Fluorodeoxyglucose F18/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> *Fluorodeoxyglucose F18/pk [Pharmacokinetics]</style></keyword><keyword><style face="normal" font="default"> 0 (Radiopharmaceuticals)</style></keyword><keyword><style face="normal" font="default"> 63503-12-8 (Fluorodeoxyglucose F18)</style></keyword><keyword><style face="normal" font="default"> Abdomen</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Aging</style></keyword><keyword><style face="normal" font="default"> Aorta/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> Aortitis/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Pilot Projects</style></keyword><keyword><style face="normal" font="default"> Radiopharmaceuticals/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> Radiopharmaceuticals/pk [Pharmacokinetics]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="5" Year="2009">2009/5</year></dates><isbn><style face="normal" font="default">1790-5427</style></isbn><abstract><style face="normal" font="default">Our aim was to quantify changes in the inflammatory and calcific components of atherosclerosis in the aortic wall using fluoro-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (18)F-FDGPET and contrast enhanced computerized tomography (CECT) with increasing age. Twelve subjects, 8 men and 4 women aged from 21-80 years who had both (18)F-FDG-PET and CECT of the chest and abdomen were included in this study. Subjects were grouped into three according to age. (18)F-FDG uptake in four segments of the aorta was measured. Using CECT images, aortic segmental wall volumes were measured. Wall calcification volume in each aortic segment was also measured via adaptation of a coronary artery calcium-scoring program to the aorta. Calcification volumes were then subtracted from aortic wall volumes. Each net segmental aortic wall volume was then multiplied by the accompanying mean SUV of the segment to calculate global metabolic activity (GMA) for each aortic segment. Our results showed that in each aortic wall segment, mean SUV, wall volumes, wall calcification volumes, and GMA statistically significantly increased with age. In conclusion, (18)F-FDG uptake, wall volume, wall calcification volume, and GMA in the aorta increase with aging. The (18)F-FDG uptake represents the early inflammatory component of the atherosclerotic process, whereas calcification generally represents a later and irreversible stage of the disease. Measurement and combination of PET and CECT parameters to calculate GMA may allow for optimal morphologic and functional noninvasive quantitative assessment of global aortic atherosclerotic disease</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Nuclear Medicine, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USAJC - 101257471CP - GreecePT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19675864</style></custom1><custom3><style face="normal" font="default">AS - Hellenic J Nucl Med. 12(2):123-8, 2009 May-Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>205</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Burkhard,N.</style></author><author><style face="normal" font="default"> Herzog,B.A.</style></author><author><style face="normal" font="default"> Husmann,L.</style></author><author><style face="normal" font="default"> Pazhenkottil,A.P.</style></author><author><style face="normal" font="default"> Burger,I.A.</style></author><author><style face="normal" font="default"> Buechel,R.R.</style></author><author><style face="normal" font="default"> Valenta,I.</style></author><author><style face="normal" font="default"> Wyss,C.A.</style></author><author><style face="normal" font="default"> Kaufmann,P.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Coronary calcium score scans for attenuation correction of quantitative PET/CT 13N-ammonia myocardial perfusion imaging</style></title><secondary-title><style face="normal" font="default">European Journal of Nuclear Medicine &amp; Molecular Imaging</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">European Journal of Nuclear Medicine &amp; Molecular Imaging</style></full-title></periodical><pages end="521" start="517">517-521</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Ammonia/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> *Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Image Processing,Computer-Assisted/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Myocardial Perfusion Imaging</style></keyword><keyword><style face="normal" font="default"> *Positron-Emission Tomography</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> 0 (Nitrogen Radioisotopes)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 7664-41-7 (Ammonia)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Ammonia/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> Coronary Circulation</style></keyword><keyword><style face="normal" font="default"> Electrocardiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardial Perfusion Imaging</style></keyword><keyword><style face="normal" font="default"> Nitrogen Radioisotopes/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> Perfusion</style></keyword><keyword><style face="normal" font="default"> Rest</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="3" Year="2010">2010/3</year></dates><abstract><style face="normal" font="default">PURPOSE: The aim of this study was to evaluate whether ECG-triggered coronary calcium scoring (CCS) scans can be used for attenuation correction (AC) to quantify myocardial blood flow (MBF) and coronary flow reserve (CFR) assessed by PET/CT with (13)N-ammonia. METHODS: Thirty-five consecutive patients underwent a (13)N-ammonia PET/CT scan at rest and during standard adenosine stress. MBF values were calculated using AC maps obtained from the ECG-triggered CCS scan during inspiration and validated against MBF values calculated using standard non-gated transmission scans for AC. CFR was calculated as the ratio of hyperaemic over resting MBF. In all 35 consecutive patients intraobserver variability was assessed by blinded repeat analysis for both AC methods. RESULTS: There was an excellent correlation between CT AC and CCS for global MBF values at rest (n = 35, r = 0.94, p &lt; 0.001) and during stress (n = 35, r = 0.97, p &lt; 0.001) with narrow Bland-Altman (BA) limits of agreement (-0.21 to 0.10 ml/min per g and -0.41 to 0.30 ml/min per g) as well as for global CFR (n = 35, r = 0.96, p &lt; 0.001, BA -0.27 to 0.34). The excellent correlation was preserved on the segmental MBF analysis for both rest and stress (n = 1190, r = 0.93, p &lt; 0.001, BA -0.60 to 0.50) and for CFR (n = 595, r = 0.87, p &lt; 0.001, BA -0.71 to 0.74). In addition, reproducibility proved excellent for global CFR by CT AC (n = 35, r = 0.91, p &lt; 0.001, BA -0.42-0.58) and CCS scans (n = 35, r = 0.94, p &lt; 0.001, BA -0.34-0.45). CONCLUSION: Use of attenuation maps from CCS scans allows accurate quantitative MBF and CFR assessment with (13)N-ammonia PET/CT</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Cardiac Imaging, University Hospital Zurich, NUK C42, Ramistrasse 100, 8091, Zurich, SwitzerlandJC - 101140988CP - GermanyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19774376</style></custom1><custom3><style face="normal" font="default">AS - Eur J Nucl Med Mol Imaging. 37(3):517-21, 2010 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>16</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Bybee,K.A.</style></author><author><style face="normal" font="default"> Lee,J.</style></author><author><style face="normal" font="default"> Markiewicz,R.</style></author><author><style face="normal" font="default"> Longmore,R.</style></author><author><style face="normal" font="default"> McGhie,A.I.</style></author><author><style face="normal" font="default"> O'Keefe,J.H.</style></author><author><style face="normal" font="default"> Hsu,B.L.</style></author><author><style face="normal" font="default"> Kennedy,K.</style></author><author><style face="normal" font="default"> Thompson,R.C.</style></author><author><style face="normal" font="default"> Bateman,T.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Diagnostic and clinical benefit of combined coronary calcium and perfusion assessment in patients undergoing PET/CT myocardial perfusion stress imaging</style></title><secondary-title><style face="normal" font="default">Journal of Nuclear Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Nuclear Cardiology</style></full-title></periodical><pages end="196" start="188">188-196</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Heart/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> *Myocardium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Positron-Emission Tomography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Computer Simulation</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardium/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Perfusion</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: A limitation of stress myocardial perfusion imaging (MPI) is the inability to detect non-obstructive coronary artery disease (CAD). One advantage of MPI with a hybrid CT device is the ability to obtain same-setting measurement of the coronary artery calcium score (CACS). METHODS AND RESULTS: Utilizing our single-center nuclear database, we identified 760 consecutive patients with: (1) no CAD history; (2) a normal clinically indicated Rb-82 PET/CT stress perfusion study; and (3) a same-setting CAC scan. 487 of 760 patients (64.1%) had subclinical CAD based on an abnormal CACS. Of those with CAC, the CACS was > or =100, > or =400, and > or =1000 in 47.0%, 22.4%, and 8.4% of patients, respectively. Less than half of the patients with CAC were receiving aspirin or statin medications prior to PET/CT imaging. Patients with CAC were more likely to be initiated or optimized on proven medical therapy for CAD immediately following PET/CT MPI compared to those without CAC. CONCLUSIONS: Subclinical CAD is common in patients without known CAD and normal myocardial perfusion assessed by hybrid PET/CT imaging. Identification of CAC influences subsequent physician prescribing patterns such that those with CAC are more likely to be treated with proven medical therapy for the treatment of CAD</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA. Kbybee@cc-pc.comCM - Comment in: J Nucl Cardiol. 2010 Apr;17(2):168-71; PMID: 20039150JC - cmd, 9423534CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20012515</style></custom1><custom3><style face="normal" font="default">AS - J Nucl Cardiol. 17(2):188-96, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>142</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Cademartiri,F.</style></author><author><style face="normal" font="default"> Maffei,E.</style></author><author><style face="normal" font="default"> Palumbo,A.</style></author><author><style face="normal" font="default"> Seitun,S.</style></author><author><style face="normal" font="default"> Martini,C.</style></author><author><style face="normal" font="default"> Tedeschi,C.</style></author><author><style face="normal" font="default"> La,Grutta L.</style></author><author><style face="normal" font="default"> Midiri,M.</style></author><author><style face="normal" font="default"> Weustink,A.C.</style></author><author><style face="normal" font="default"> Mollet,N.R.</style></author><author><style face="normal" font="default"> Krestin,G.P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Coronary calcium score and computed tomography coronary angiography in high-risk asymptomatic subjects: assessment of diagnostic accuracy and prevalence of non-obstructive coronary artery disease</style></title><secondary-title><style face="normal" font="default">European Radiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">European Radiology</style></full-title></periodical><pages end="854" start="846">846-854</pages><volume><style face="normal" font="default">20</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Italy/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The aim of the study was to compare the coronary artery calcium score (CACS) and computed tomography coronary angiography (CTCA) for the assessment of non-obstructive/obstructive coronary artery disease (CAD) in high-risk asymptomatic subjects. METHODS: Two hundred and thirteen consecutive asymptomatic subjects (113 male; mean age 53.6 +/- 12.4 years) with more than one risk factor and an inconclusive or unfeasible non-invasive stress test result underwent CACS and CTCA in an outpatient setting. All patients underwent conventional coronary angiography (CAG). Data from CACS (threshold for positive image: Agatston score 1/100/1,000) and CTCA were compared with CAG regarding the degree of CAD (non-obstructive/obstructive; &lt;/>or=50% lumen reduction). RESULTS: The mean calcium score was 151 +/- 403 and the prevalence of obstructive CAD was 17% (8% one-vessel and 10% two-vessel disease). Per-patient sensitivity, specificity, positive and negative predictive values of CACS were: 97%, 75%, 45%, and 100%, respectively (Agatston >or=1); 73%, 90%, 60%, and 94%, respectively (Agatston >or=100); 30%, 98%, 79%, and 87%, respectively (Agatston >or=1,000). Per-patient values for CTCA were 100%, 98%, 97%, and 100%, respectively (p &lt; 0.05). CTCA detected 65% prevalence of all CAD (48% non-obstructive), while CACS detected 37% prevalence of all CAD (21% non-obstructive) (p &lt; 0.05). CONCLUSION: CACS proved inadequate for the detection of obstructive and non-obstructive CAD compared with CTCA. CTCA has a high diagnostic accuracy for the detection of non-obstructive and obstructive CAD in high-risk asymptomatic patients with inconclusive or unfeasible stress test results</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Radiology and Cardiology, Azienda Ospedaliero-Universitaria, Parma, Italy. filippocademartiri@hotmail.comJC - cl3, 9114774CP - GermanyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19760230</style></custom1><custom3><style face="normal" font="default">AS - Eur Radiol. 20(4):846-54, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>144</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Cademartiri,F.</style></author><author><style face="normal" font="default"> Runza,G.</style></author><author><style face="normal" font="default"> Palumbo,A.</style></author><author><style face="normal" font="default"> Maffei,E.</style></author><author><style face="normal" font="default"> Martini,C.</style></author><author><style face="normal" font="default"> McFadden,E.</style></author><author><style face="normal" font="default"> Somers,P.</style></author><author><style face="normal" font="default"> Knaapen,M.</style></author><author><style face="normal" font="default"> Verheye,S.</style></author><author><style face="normal" font="default"> Weustink,A.C.</style></author><author><style face="normal" font="default"> Mollet,N.R.</style></author><author><style face="normal" font="default"> de Feyter,P.J.</style></author><author><style face="normal" font="default"> Hamers,R.</style></author><author><style face="normal" font="default"> Bruining,N.</style></author></authors></contributors><titles><title><style face="normal" font="default">Lumen enhancement influences absolute noncalcific plaque density on multislice computed tomography coronary angiography: ex-vivo validation and in-vivo demonstration</style></title><secondary-title><style face="normal" font="default">Journal of Cardiovascular Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Cardiovascular Medicine</style></full-title></periodical><pages end="344" start="337">337-344</pages><volume><style face="normal" font="default">11</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Contrast Media/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Iopamidol/aa [Analogs &amp; Derivatives]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> 0 (Contrast Media)</style></keyword><keyword><style face="normal" font="default"> 62883-00-5 (Iopamidol)</style></keyword><keyword><style face="normal" font="default"> 78649-41-9 (iomeprol)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Iopamidol/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="5" Year="2010">2010/5</year></dates><abstract><style face="normal" font="default">AIM: The purpose of this study was to define the in-vitro and in-vivo effects of intracoronary enhancement on the absolute density values of coronary plaques during multislice computed tomography. METHODS: We studied seven ex-vivo left coronary artery specimens surrounded by olive oil and filled with isotonic saline and four solutions with decreasing dilutions of contrast material: control (isotonic saline), 1/200, 1/80, 1/50, and 1/20. The multislice computed tomography protocol was: slice/collimation 32 x 2 x 0.6 mm and rotation time 330 ms. The attenuation (Hounsfield units) value of atherosclerotic plaques was measured for each dilution in lumen, plaque (noncalcified coronary wall thickening), calcium, and surrounding oil. In-vivo assessment was performed in 12 patients (nine men; mean age 58.7 +/- 9.9 years) who underwent two subsequent multislice computed tomography scans (arterial and delayed) after intravenous administration of a single bolus of contrast material. The attenuation values of lumen and plaques during arterial and delayed computed tomography were compared. The results were compared with one-way analysis of variance and correlated with Pearson's test. RESULTS: Mean lumen (45 +/- 38-669 +/- 151 HU) and plaque (11 +/- 35-101 +/- 72 HU) attenuation differed significantly (P &lt; 0.001) among the different dilutions. The attenuation of lumen and plaque of coronary plaques showed moderate correlation (r = 0.54, P &lt; 0.001). The mean attenuation value in vivo for the arterial and delayed phase scans differed significantly (P &lt; 0.001) for lumen (325 +/- 70 and 174 +/- 46 HU, respectively) and plaque (138 +/- 71 and 100 +/- 52 HU, respectively). CONCLUSION: Coronary plaque attenuation values are significantly modified by differences in lumen contrast densities both ex vivo and in vivo. This should be taken into account when considering the distinction between lipid and fibrous plaques</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Radiology and Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands. filippocademartiri@hotmail.comJC - 101259752CP - United StatesPT - Journal ArticlePT - Validation StudiesLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20090551</style></custom1><custom3><style face="normal" font="default">AS - J Cardiovasc Med (Hagerstown). 11(5):337-44, 2010 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>241</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Cademartiri,F.</style></author><author><style face="normal" font="default"> Maffei,E.</style></author><author><style face="normal" font="default"> Palumbo,A.</style></author><author><style face="normal" font="default"> Martini,C.</style></author><author><style face="normal" font="default"> Seitun,S.</style></author><author><style face="normal" font="default"> Tedeschi,C.</style></author><author><style face="normal" font="default"> De,Rosa R.</style></author><author><style face="normal" font="default"> Arcadi,T.</style></author><author><style face="normal" font="default"> Salamone,I.</style></author><author><style face="normal" font="default"> Blandino,A.</style></author><author><style face="normal" font="default"> Weustink,A.C.</style></author><author><style face="normal" font="default"> Mollet,N.R.</style></author><author><style face="normal" font="default"> de Feyter,P.J.</style></author><author><style face="normal" font="default"> Krestin,G.P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Diagnostic accuracy of computed tomography coronary angiography in patients with a zero calcium score</style></title><secondary-title><style face="normal" font="default">European Radiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">European Radiology</style></full-title></periodical><pages end="87" start="81">81-87</pages><volume><style face="normal" font="default">20</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Stenosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Stenosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="1" Year="2010">2010/1</year></dates><abstract><style face="normal" font="default">To evaluate the diagnostic accuracy of 64-slice CT coronary angiography (CT-CA) for the detection of significant coronary artery stenosis in patients with zero on the Agatston Calcium Score (CACS). We enrolled 279 consecutive patients (96 male, mean age 48 +/- 12 years) with suspected coronary artery disease. Patients were symptomatic (n = 208) or asymptomatic (n = 71), and underwent conventional coronary angiography (CAG). For CT-CA we administered an IV bolus of 100 ml of iodinated contrast material. CT-CA was compared to CAG using a threshold for significant stenosis of >or=50%. The prevalence of disease demonstrated at CAG was 15% (1.4% in asymptomatic). The population at CAG showed no or non-significant disease in 85% (238/279), single vessel disease in 9% (25/279), and multi-vessel disease in 6% (16/279). Sensitivity, specificity, and positive and negative predictive values of CT-CA vs. CAG on the patient level were 100%, 95%, 76%, and 100% in the overall population and 100%, 100%, 100%, and 100% in asymptomatic patients, respectively. CT-CA proves high diagnostic performance in patients with or without symptoms and with zero CACS. The prevalence of significant disease detected by CT-CA was not negligible in asymptomatic patients. The role of CT-CA in asymptomatic patients remains uncertain</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Radiology and Cardiology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy. filippocademartiri@hotmail.comJC - cl3, 9114774CP - GermanyPT - Evaluation StudiesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19657651</style></custom1><custom3><style face="normal" font="default">AS - Eur Radiol. 20(1):81-7, 2010 Jan.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>437</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Carlin,A.M.</style></author><author><style face="normal" font="default"> Rao,D.S.</style></author><author><style face="normal" font="default"> Yager,K.M.</style></author><author><style face="normal" font="default"> Parikh,N.J.</style></author><author><style face="normal" font="default"> Kapke,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Treatment of vitamin D depletion after Roux-en-Y gastric bypass: a randomized prospective clinical trial</style></title><secondary-title><style face="normal" font="default">Surgery for Obesity &amp; Related Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Surgery for Obesity &amp; Related Diseases</style></full-title></periodical><pages end="449" start="444">444-449</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Dietary Supplements</style></keyword><keyword><style face="normal" font="default"> *Gastric Bypass</style></keyword><keyword><style face="normal" font="default"> *Obesity,Morbid/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Vitamin D Deficiency/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Vitamin D/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Vitamins/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 0 (Vitamins)</style></keyword><keyword><style face="normal" font="default"> 1406-16-2 (Vitamin D)</style></keyword><keyword><style face="normal" font="default"> 64719-49-9 (25-hydroxyvitamin D)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Bone Density</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Obesity,Morbid/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Obesity,Morbid/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sunlight</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Vitamin D Deficiency/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Vitamin D Deficiency/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Vitamin D/aa [Analogs &amp; Derivatives]</style></keyword><keyword><style face="normal" font="default"> Vitamin D/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Weight Loss</style></keyword></keywords><dates><year Day="0" Month="7" Year="2009">2009/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: A high prevalence (60%) of vitamin D (VitD) depletion, defined as a serum 25-hydroxyvitamin D level of &lt; or =20 ng/mL, is present in preoperative morbidly obese patients. Despite daily supplementation with 800 IU VitD and 1500 mg calcium after Roux-en-Y gastric bypass (RYGB), VitD depletion persists in almost one half (44%) of patients. However, the optimal management of VitD depletion after RYGB and the potential benefits of such treatment are currently unknown. METHODS: A total of 60 VitD-depleted morbidly obese women were randomly assigned to receive 50,000 IU of VitD weekly after RYGB (group 1; n = 30) or no additional VitD after RYGB (group 2; n = 30). All patients received a daily supplement of 800 IU VitD and 1500 mg calcium. The serum calcium, parathyroid hormone, 25-hydroxyvitamin D, bone-specific alkaline phosphatase, urinary N-telopeptide, and bone mineral density were measured preoperatively and 1 year after RYGB. Questionnaires were used to assess other potential sources of VitD, including sunlight exposure and ingestion of VitD-containing foods/liquids. RESULTS: At 1 year after RYGB, VitD depletion and mean 25-hydroxyvitamin D level had improved significantly in group 1 (14% and 37.8 ng/mL, respectively) compared with the values in group 2 (85% and 15.2 ng/mL, respectively; P &lt;.001 for both). A significant 33% retardation in hip bone mineral density decline (P = .043) and a significantly greater resolution of hypertension was seen in group 1 (75% versus 32%; P = .029). No significant adverse effects were encountered from pharmacologic VitD therapy. CONCLUSION: The results of our study have shown that 50,000 IU of VitD weekly after RYGB safely corrects VitD depletion in most women, attenuates cortical bone loss, and improves resolution of hypertension</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of General Surgery, Henry Ford Hospital, Detroit, Michigan, USAJC - 101233161CP - United StatesPT - Journal ArticlePT - Randomized Controlled TrialLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18996761</style></custom1><custom3><style face="normal" font="default">AS - Surg. obes. relat. dis.. 5(4):444-9, 2009 Jul-Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>103</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Carlsson,L.</style></author><author><style face="normal" font="default"> Lind,L.</style></author><author><style face="normal" font="default"> Larsson,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Reference values for 27 clinical chemistry tests in 70-year-old males and females</style></title><secondary-title><style face="normal" font="default">Gerontology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Gerontology</style></full-title></periodical><pages end="265" start="259">259-265</pages><volume><style face="normal" font="default">56</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Biological Markers/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Clinical Chemistry Tests</style></keyword><keyword><style face="normal" font="default"> *Geriatric Assessment</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Reference Values</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword></keywords><dates><year Day="0" Month="0" Year="2010">2010</year></dates><abstract><style face="normal" font="default">BACKGROUND: Reference values are usually defined based on blood samples from healthy men or nonpregnant women in the age range of 20-50 years. These values are not optimal for elderly patients, as many biological markers change over time and adequate reference values are important for correct clinical decisions. OBJECTIVE: To validate NORIP (Nordic Reference Interval Project) reference values in a 70-year-old population. METHODS: We studied 27 frequently used laboratory tests. The 2.5th and 97.5th percentiles for these markers were calculated according to the recommendations of the International Federation of Clinical Chemistry on the statistical treatment of reference values. RESULTS: Reference values are reported for plasma alanine aminotransferase, albumin, alkaline phosphatase, pancreas amylase, apolipoprotein A1, apolipoprotein B, aspartate aminotransferase, bilirubin, calcium, chloride, cholesterol, creatinine, creatine kinase, C-reactive protein, glucose, gamma-glutamyltransferase, HDL-cholesterol, iron, lactate dehydrogenase, LDL-cholesterol, magnesium, phosphate, potassium, sodium, transferrin, triglycerides, urate and urea. CONCLUSION: Reference values calculated from the whole population and a subpopulation without cardiovascular disease showed strong concordance. Several of the reference interval limits were outside the 90% CI of a Scandinavian population (NORIP). 2009 S. Karger AG, Basel</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medical Sciences, Uppsala University, SwedenJC - fpb, 7601655CP - SwitzerlandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tPT - Validation StudiesLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19844080</style></custom1><custom3><style face="normal" font="default">AS - Gerontology. 56(3):259-65, 2010.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>132</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Carlton,S.</style></author><author><style face="normal" font="default"> Clopton,D.</style></author><author><style face="normal" font="default"> Cappuzzo,K.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Vitamin D deficiency: appropriate replenishment therapies and the effects of vitamin D toxicity</style></title><secondary-title><style face="normal" font="default">Consultant Pharmacist</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Consultant Pharmacist</style></full-title></periodical><pages end="177" start="171">171-177</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Ergocalciferols/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Vitamin D Deficiency/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Vitamins/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> 0 (Ergocalciferols)</style></keyword><keyword><style face="normal" font="default"> 0 (Vitamins)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Appetite</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Drug</style></keyword><keyword><style face="normal" font="default"> Ergocalciferols/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Ergocalciferols/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> International Normalized Ratio</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Vitamins/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Vitamins/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Weight Loss/de [Drug Effects]</style></keyword></keywords><dates><year Day="0" Month="3" Year="2010">2010/3</year></dates><isbn><style face="normal" font="default">0888-5109</style></isbn><abstract><style face="normal" font="default">An 84-year-old patient diagnosed with a vitamin D deficiency was given a prescription for ergocalciferol (vitamin D2) 50,000 units weekly. The prescription was incorrectly filled for ergocalciferol 50,000 units daily. Incorrect therapy continued for two months. The patient's vitamin D level increased from &lt; 7.0 ng/mL to 100 ng/mL over a six-month span. The patient complained of decreased appetite and significant weight loss and presented with an elevated International Normalized Ratio at a pharmacist-run anticoagulation clinic. In conjunction with the physician, the pharmacist discontinued vitamin D therapy and monitored levels.Vitamin D plays an integral role in the body's ability to absorb calcium and regulate calcium homeostasis. Further benefits have been reported regarding the role of vitamin D in muscle strength, cardiovascular health, and in preventing osteoporosis and falls. Vitamin D deficiency is widespread in the older adult population as a result of low dietary intake, decreased sun exposure, decreased intrinsic vitamin D production, and decreased vitamin D receptor activity. Replenishment using high-dose ergocalciferol is one common replenishment therapy. Patients also are able to supplement with nonprescription vitamin D products of varying strengths. While many older patients can be expected to have vitamin D deficiencies, pharmacists should be aware of appropriate replenishment therapies and correct dosing of different vitamin D products. Pharmacists also should be familiar with possible toxic effects of vitamin D, particularly as public awareness of benefits continues to increase</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Stanford Hospital and Clinics, Stanford, California, USAJC - 9013983CP - United StatesPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20363711</style></custom1><custom3><style face="normal" font="default">AS - Consult Pharm. 25(3):171-7, 2010 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>340</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Carrasco,F.R.</style></author><author><style face="normal" font="default"> rez-Flores,I.</style></author><author><style face="normal" font="default"> Calvo,N.</style></author><author><style face="normal" font="default"> Ridao,N.</style></author><author><style face="normal" font="default"> nchez,A.</style></author><author><style face="normal" font="default"> Barrientos</style></author></authors></contributors><titles><title><style face="normal" font="default">Treatment of persistent hyperparathyroidism in renal transplant patients with cinacalcet improves control of blood pressure</style></title><secondary-title><style face="normal" font="default">Transplantation Proceedings</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Transplantation Proceedings</style></full-title></periodical><pages end="2387" start="2385">2385-2387</pages><volume><style face="normal" font="default">41</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Blood Pressure/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> *Hyperparathyroidism,Secondary/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Kidney Transplantation/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Naphthalenes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> 0 (Immunosuppressive Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Naphthalenes)</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 364782-34-3 (cinacalcet)</style></keyword><keyword><style face="normal" font="default"> 60-27-5 (Creatinine)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcinosis</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Creatinine/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Secondary/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Secondary/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Immunosuppressive Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Kidney Transplantation/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Kidney Transplantation/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Postoperative Complications/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Proteinuria</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="7" Year="2009">2009/7</year></dates><abstract><style face="normal" font="default">Persistent hyperparathyroidism is observed in 17% to 50% of patients at 1 year after renal transplantation. In 10% of these patients, hypercalcemia is also present. This condition increases the risk of vascular calcification, correlating with inferior graft function among patients with interstitial calcification in the renal allograft. Hypertension is appears in 60% to 90% of patients after transplantation, favoring progressive graft dysfunction. Hypercalcemia per se causes hypertension. Parathyroid hormone can potentiate the pressor effects of hypercalcemia. Fourteen renal transplant recipients were included based upon: total serum calcium > 10.0 mg/dL, intact parathyroid hormone levels > 70 pg/mL, graft function > 6 months, creatinine clearance > 50 mL/min, and stable immunosuppressive therapy. We also examined blood pressure and antihypertensive treatment. Initially patients received 30 mg of cinacalcet once a day. The follow-up was up to 6 months. The mean cinacalcet dose was 40 mg/24 h. Five patients received 60 mg/24 h. Both serum calcium and iPTH decreased significantly from 10.6 (DE 0.4) to 9.8 (DE Both serum calcium and iPTH decreased significantly from 10.6 (DE 0.4)to 9.8 (DE 0.6) mg/dL (P &lt; .001) and from 195.0 (DE 140.0) to 118.62 (DE 102.2; P &lt; .0001). There were no significant changes in renal function, proteinuria, or tacrolimus levels. Mean blood pressure diminished from 94.1 (DE 12.0) to 88.0 (DE 7.5) mm Hg (P &lt; .019) with no changes in antihypertensive treatment. Cinacalcet was suspended in one patient because of gastrointestinal discomfort and in another one because the iPTH was reduced to 51 pg/mL. Cinacalcet is an effective treatment for persistent hyperparathyroidism associated with hypercalcemia among renal transplant patients and may be helpful for hypertension control</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Hospital Cl&amp;#x00ED;nico San Carlos, Madrid, Spain. framos80@mail.comJC - we9, 0243532CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19715927</style></custom1><custom3><style face="normal" font="default">AS - Transplant Proc. 41(6):2385-7, 2009 Jul-Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>325</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Cassidy-Bushrow,A.E.</style></author><author><style face="normal" font="default"> Bielak,L.F.</style></author><author><style face="normal" font="default"> Rule,A.D.</style></author><author><style face="normal" font="default"> Sheedy,P.F.</style></author><author><style face="normal" font="default"> Turner,S.T.</style></author><author><style face="normal" font="default"> Garovic,V.D.</style></author><author><style face="normal" font="default"> Peyser,P.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Hypertension during pregnancy is associated with coronary artery calcium independent of renal function</style></title><secondary-title><style face="normal" font="default">Journal of Women's Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Women's Health</style></full-title></periodical><pages end="1716" start="1709">1709-1716</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Hypertension,Pregnancy-Induced/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Women's Health</style></keyword><keyword><style face="normal" font="default"> 60-27-5 (Creatinine)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Causality</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Creatinine/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Kidney Function Tests</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Hypertension during pregnancy (HDP) increases the risk of future coronary heart disease (CHD), but it is unknown whether this association is mediated by renal injury. Reduced renal function is both a complication of HDP and a risk factor for CHD. METHODS: Logistic regression models were fit to examine the association between a history of HDP and the presence and extent of coronary artery calcification (CAC), a measure of subclinical coronary artery atherosclerosis, in 498 women from the Epidemiology of Coronary Artery Calcification Study (mean age 63.3 +/- 9.3 years). RESULTS: Fifty-two (10.4%) women reported a history of HDP. After adjusting for age at time of study participation, HDP was associated with increased serum creatinine later in life (p = 0.014). HDP was positively associated with the presence of CAC after adjusting for age at time of study participation (OR = 2.7, 95% CI 1.4-5.4). This association was slightly attenuated with adjustment for body size and blood pressure (OR = 2.4, 95% CI 1.2-4.9) but was not further attenuated with adjustment for serum creatinine and urinary albumin/creatinine ratio (OR = 2.6, 95% CI 1.3-5.3). Results were similar for CAC extent. CONCLUSIONS: HDP may increase a woman's risk of future CHD beyond traditional risk factors and renal function. Women with a history of HDP should be monitored for potential increased risk of CHD as they age</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Biostatistics, Henry Ford Hospital, Detroit, Michigan, USAJC - 101159262, 9208978CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - K23 DK078229 (United States NIDDK NIH HHS)NO - M01RR00585 (United States NCRR NIH HHS)NO - R01 HL46292 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19785565</style></custom1><custom3><style face="normal" font="default">AS - J Womens Health (Larchmt). 18(10):1709-16, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>55</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Castillo,L.</style></author><author><style face="normal" font="default"> Rohatgi,A.</style></author><author><style face="normal" font="default"> Ayers,C.R.</style></author><author><style face="normal" font="default"> Owens,A.W.</style></author><author><style face="normal" font="default"> Das,S.R.</style></author><author><style face="normal" font="default"> Khera,A.</style></author><author><style face="normal" font="default"> McGuire,D.K.</style></author><author><style face="normal" font="default"> de Lemos,J.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Associations of four circulating chemokines with multiple atherosclerosis phenotypes in a large population-based sample: results from the dallas heart study</style></title><secondary-title><style face="normal" font="default">Journal of Interferon &amp; Cytokine Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Interferon &amp; Cytokine Research</style></full-title></periodical><pages end="347" start="339">339-347</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> *Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Chemokines/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Chemokines)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Population Groups</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="5" Year="2010">2010/5</year></dates><abstract><style face="normal" font="default">Specific chemokines contribute to vascular inflammation and may be useful biomarkers to detect atherosclerosis. The chemokines CXCL1 and CCL11 have previously been studied in animal or human models of atherosclerosis, while CXCL2 and CCL23 have not. Among 2,454 subjects enrolled in the Dallas Heart Study, a multi-ethnic population-based sample, we measured plasma CCL11, CCL23, CXCL1, and CXCL2, and associated levels with coronary artery calcium (CAC) by computed tomography, and aortic wall thickness, plaque burden, and compliance by magnetic resonance imaging. Elevated chemokine levels were defined as greater than or equal to the median for CCL11 and CCL23 and greater than or equal to the upper detection limit for CXCL1 and CXCL2. Elevated CCL23 (P &lt; 0.01) and CXCL1 (P = 0.01), but not CCL11 and CXCL2, associated with CAC in univariable analyses. After adjustment for traditional risk factors, elevated CCL23 remained associated with CAC (OR 1.3, 95% CI 1.0-1.7; P = 0.02), while the association with CXCL1 was modestly attenuated (OR 1.4, 95% CI 1.0-2.1; P = 0.06). CCL23 also associated with aortic wall thickness, plaque, and compliance in univariable analyses (P &lt; 0.05 for each), but these associations were attenuated after multivariable adjustment. The novel chemotactic protein, CCL23, which has not been previously studied in atherosclerosis, is independently associated with coronary atherosclerosis, suggesting that this chemokine merits further study in animal and human models</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Donald W. Reynolds Cardiovascular Research Center and Division of Cardiology, University of Texas Southwestern Medical Center , Dallas, Texas, USAJC - cd4, 9507088CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20187767</style></custom1><custom3><style face="normal" font="default">AS - J Interferon Cytokine Res. 30(5):339-47, 2010 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>465</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Cavusoglu,Y.</style></author><author><style face="normal" font="default"> Beyaztas,A.</style></author><author><style face="normal" font="default"> Birdane,A.</style></author><author><style face="normal" font="default"> Ata,N.</style></author></authors></contributors><titles><title><style face="normal" font="default">Levosimendan is not effective in reducing pulmonary pressures in patients with idiopathic pulmonary arterial hypertension: report of two cases</style></title><secondary-title><style face="normal" font="default">Journal of Cardiovascular Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Cardiovascular Medicine</style></full-title></periodical><pages end="507" start="503">503-507</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Antihypertensive Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Blood Pressure/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> *Hydrazones/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Hypertension,Pulmonary/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Pulmonary Artery/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> *Pyridazines/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Vasodilator Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> 0 (Antihypertensive Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Hydrazones)</style></keyword><keyword><style face="normal" font="default"> 0 (Pyridazines)</style></keyword><keyword><style face="normal" font="default"> 0 (Vasodilator Agents)</style></keyword><keyword><style face="normal" font="default"> 131741-08-7 (simendan)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Antihypertensive Agents/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Drug Therapy,Combination</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hydrazones/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension,Pulmonary/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Pulmonary Artery/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Pyridazines/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Treatment Failure</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Vasodilator Agents/ae [Adverse Effects]</style></keyword></keywords><dates><year Day="0" Month="6" Year="2009">2009/6</year></dates><isbn><style face="normal" font="default">1558-2027</style></isbn><abstract><style face="normal" font="default">Currently, prostacyclin, endothelin receptor antagonists and phosphodiesterase inhibitors are recommended therapy in idiopathic pulmonary arterial hypertension. However, each of these drugs has limited efficacy in the improvement of clinical symptoms, pulmonary hemodynamics and long-term survival. Levosimendan, a novel calcium-sensitizing inodilator agent, has been shown to have pulmonary vasodilatory action. However, the potential pulmonary vasodilating effect of levosimendan in patients with idiopathic pulmonary arterial hypertension remains unclear. Levosimendan administered in two patients with nonvasoreactive idiopathic pulmonary arterial hypertension exhibited deterioration in clinical status, and, contrary to what was expected, levosimendan was found to increase pulmonary pressures and did not lead to a substantial improvement of the patient's condition</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Eskisehir Osmangazi University, Eskisehir, Turkey. yukselc@ogu.edu.trJC - 101259752CP - United StatesPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19346968</style></custom1><custom3><style face="normal" font="default">AS - J Cardiovasc Med (Hagerstown). 10(6):503-7, 2009 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>411</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Cazalas,G.</style></author><author><style face="normal" font="default"> Sarran,A.</style></author><author><style face="normal" font="default"> Amabile,N.</style></author><author><style face="normal" font="default"> Chaumoitre,K.</style></author><author><style face="normal" font="default"> Marciano-Chagnaud,S.</style></author><author><style face="normal" font="default"> Jacquier,A.</style></author><author><style face="normal" font="default"> Paganelli,F.</style></author><author><style face="normal" font="default"> Panuel,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Comparison of 64 MDCT coronary CTA and coronary angiography in the detection of coronary artery stenosis in low risk patients with stable angina and acute coronary syndrome]. [French]</style></title><secondary-title><style face="normal" font="default">Journal de Radiologie</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal de Radiologie</style></full-title></periodical><pages end="66" start="t">t-66</pages><volume><style face="normal" font="default">90</style></volume><number><style face="normal" font="default">9:Pt 1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Acute Coronary Syndrome/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Angina Pectoris/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> *Coronary Stenosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Coronary Stenosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Artifacts</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Bypass</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed/mt [Methods]</style></keyword></keywords><dates><year Day="0" Month="9" Year="2009">2009/9</year></dates><isbn><style face="normal" font="default">0221-0363</style></isbn><abstract><style face="normal" font="default">PURPOSE: To determine the accuracy of 64 MDCT coronary CTA (CCTA) compared to coronary angiography in low risk patients with stable angina and acute coronary syndrome and determine the number of significant coronary artery stenoses ( 50%) in these patients. Materials and methods. Fifty-five patients underwent CCTA using a 32 MDCT unit with z flying focus allowing the acquisition of 64 slices of 0.6 mm thickness as well as coronary angiography (gold standard). Nine patients were excluded due to prior coronary artery bypass surgery (n=4), insufficient breath hold (n=3), calcium scoring>1000 (n=1) and delay between both examinations over 4 months (n=1). Forty-six patients: 27 males and 19 females were included. CCTA results were compared to coronary angiography per segment and artery with threshold detection of stenoses 50%. The degree of correlation between both examinations was performed using a regression analysis with a Pearson correlation coefficient&lt;0.05 considered significant. RESULTS: The overall accuracy of CCTA was 90%; limitations related to the presence of calcifications, motion artifacts or insufficient vessel opacification. The correlation for all analyzed segments was 96.4%. Thirty-eight of 50 significant stenoses seen on coronary angiography were correctly detected on CCTA. Sensitivity, specificity, PPVC and NPV for detection of stenoses 50% were 76%, 98.3%, 80.3% and 97.7% respectively. Evaluation per segment had a NPV of 96.8% (interventricular and diagonal segments) to 100% (main trunk). CONCLUSION: Our results for specificity and NPV are similar to reports from the literature. This suggests that CCTA in this clinical setting may replace coronary angiography</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Service d'Imagerie M&amp;#x00E9;dicale, CHU de Marseille, H&amp;#x00F4;pital Nord, 13915 Marseille Cedex 20. guillaume.cazalas@ap-hm.frOT - Comparaison du scanner 64-d&amp;#x00E9;tecteurs et de la coronarographie dans la d&amp;#x00E9;tection des st&amp;#x00E9;noses coronariennes chez des patients porteurs d'angor stable et de syndrome coronaire aigu &amp;#x00E0; bas risquesJC - 7906266CP - FrancePT - Comparative StudyPT - English AbstractPT - Journal ArticleLG - French</style></notes><urls/><custom1><style face="normal" font="default">UI - 19752809</style></custom1><custom3><style face="normal" font="default">AS - J Radiol. 90(9 Pt 1):1055-66, 2009 Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>91</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Celik,C.</style></author><author><style face="normal" font="default"> Altunkan,S.</style></author><author><style face="normal" font="default"> Yildirim,M.O.</style></author><author><style face="normal" font="default"> Akyuz,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Relationship between decreased bone mineral density and subclinical atherosclerosis in postmenopausal women</style></title><secondary-title><style face="normal" font="default">Climacteric</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Climacteric</style></full-title></periodical><pages end="258" start="254">254-258</pages><volume><style face="normal" font="default">13</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Bone Density</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Postmenopause</style></keyword><keyword><style face="normal" font="default"> Absorptiometry,Photon</style></keyword><keyword><style face="normal" font="default"> Bone Diseases,Metabolic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Bone Diseases,Metabolic/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Osteoporosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Osteoporosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword></keywords><dates><year Day="0" Month="6" Year="2010">2010/6</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The study aimed to compare measurements of coronary artery calcification (CAC) and bone mineral density (BMD) in postmenopausal women. METHODS: The CAC of the women was measured with electron beam tomography using a GE Imatron C150 XP EBT scanner. Subjects with calcium scores above 0 were classified as CAC(+); those without detectable coronary calcium were classified as CAC(-). BMD was measured by dual-energy X-ray absorptiometry (DEXA). Patients were divided into two groups, depending on the T scores of their lumbar spine, into those with normal bone and those with osteopenia-osteoporosis. RESULTS: The proportions of patients classified as CAC(+) were 20% in the normal group and 60% in the osteopenia-osteoporosis group (p = 0.037). BMD values in L1-4 were 1.13 +/- 2.29 and 0.98 +/- 2.79 g/cm(2) in the normal group and osteopenia-osteoporosis group, respectively and the mean total CAC scores were 1.34 +/- 1.2 and 69.0 +/- 20.5, respectively. The CAC scores of patients with osteopenia-osteoporosis were significantly higher compared with those of the normal group (p = 0.014). CONCLUSION: The study shows that postmenopausal women with decreased bone mineral density may have higher risk of subclinical coronary atherosclerosis</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Physical Medicine and Rehabilitation, Ankara Physical Medicine and Rehabilitation Education and Research Hospital, Ankara, TurkeyJC - d0i, 9810959CP - EnglandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20082602</style></custom1><custom3><style face="normal" font="default">AS - Climacteric. 13(3):254-8, 2010 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>345</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">CERRAHOGLU,M.</style></author><author><style face="normal" font="default"> TANER,KURDAL A.</style></author><author><style face="normal" font="default"> ISKESEN,I.</style></author><author><style face="normal" font="default"> ONUR,E.</style></author><author><style face="normal" font="default"> SIRIN,H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Calcium dobesilate reduces oxidative stress in cardiac surgery</style></title><secondary-title><style face="normal" font="default">Journal of Cardiovascular Surgery</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Cardiovascular Surgery</style></full-title></periodical><pages end="701" start="695">695-701</pages><volume><style face="normal" font="default">50</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium Dobesilate/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Cardiopulmonary Bypass/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Bypass/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Free Radical Scavengers/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Myocardial Reperfusion Injury/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Oxidative Stress/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Free Radical Scavengers)</style></keyword><keyword><style face="normal" font="default"> 0 (Myoglobin)</style></keyword><keyword><style face="normal" font="default"> 0 (Troponin T)</style></keyword><keyword><style face="normal" font="default"> 20123-80-2 (Calcium Dobesilate)</style></keyword><keyword><style face="normal" font="default"> 542-78-9 (Malondialdehyde)</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Bypass</style></keyword><keyword><style face="normal" font="default"> Double-Blind Method</style></keyword><keyword><style face="normal" font="default"> EC 1-11-1-9 (Glutathione Peroxidase)</style></keyword><keyword><style face="normal" font="default"> EC 1-15-1-1 (Superoxide Dismutase)</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glutathione Peroxidase/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Hemodynamics/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Malondialdehyde/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardial Reperfusion Injury/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Myocardial Reperfusion Injury/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Myocardial Reperfusion Injury/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Myoglobin/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Superoxide Dismutase/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Troponin T/bl [Blood]</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><isbn><style face="normal" font="default">0021-9509</style></isbn><abstract><style face="normal" font="default">AIM: Calcium dobesilate (CD) is a synthetic benzene sulfonate derivative and an angioprotective agent used orally. It can be used in patients who have diabetic retinopathy or chronic venous insufficiency. The aim of this study was to investigate the effect of CD on the reduction of oxidative stress during coronary artery bypass graft operations on cardiopulmonary bypass. METHODS: A double-blind prospective randomized study was carried out on 30 patients who underwent coronary artery bypass operations. The control and study groups were composed of 15 patients each. Pretreatment with CD started two weeks before the operation. Serial blood samples for superoxide dismutase, glutathione peroxidase were collected for the serum concentration measurements of the major endogenous antioxidant enzyme systems and malondialdehyde for scavenging capacity. RESULTS: After the release of cross clamp levels of superoxide dismutase and glutathione peroxidase. they were significantly higher in the study group than in the control group (P&lt;0.05). Malondialdehyde levels in the study group were significantly lower than those of the control group (P&lt;0.05). The cardiac function after aortic declamping was affected by CD, indicating contribution of CD to myocardial injury from ischemia/reperfusion. CONCLUSIONS: The study suggests that pretreatment with CD alleviates malondialdehyde production and preserves endogenous antioxidant capacity during cardiopulmonary bypass and cardioplegic arrest</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiovascular Surgery, Celal Bayar University School of Medicine Manisa, TurkeyJC - hmf, 0066127CP - ItalyPT - Journal ArticlePT - Randomized Controlled TrialLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19339957</style></custom1><custom3><style face="normal" font="default">AS - J Cardiovasc Surg (Torino). 50(5):695-701, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>174</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Chadha,M.K.</style></author><author><style face="normal" font="default"> Tian,L.</style></author><author><style face="normal" font="default"> Mashtare,T.</style></author><author><style face="normal" font="default"> Payne,V.</style></author><author><style face="normal" font="default"> Silliman,C.</style></author><author><style face="normal" font="default"> Levine,E.</style></author><author><style face="normal" font="default"> Wong,M.</style></author><author><style face="normal" font="default"> Johnson,C.</style></author><author><style face="normal" font="default"> Trump,D.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer</style></title><secondary-title><style face="normal" font="default">Cancer</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Cancer</style></full-title></periodical><pages end="2139" start="2132">2132-2139</pages><volume><style face="normal" font="default">116</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Antineoplastic Combined Chemotherapy Protocols/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Calcitriol/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Dexamethasone/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Prostatic Neoplasms/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> 32222-06-3 (Calcitriol)</style></keyword><keyword><style face="normal" font="default"> 50-02-2 (Dexamethasone)</style></keyword><keyword><style face="normal" font="default"> 60-27-5 (Creatinine)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Administration,Oral</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Antineoplastic Combined Chemotherapy Protocols/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Creatinine/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default"> EC 3-4-21-77 (Prostate-Specific Antigen)</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Injections,Intravenous</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prostate-Specific Antigen/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Retreatment</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="1" Month="5" Year="2010">2010/5/1</year></dates><isbn><style face="normal" font="default">0008-543X</style></isbn><abstract><style face="normal" font="default">BACKGROUND: Preclinical data indicate that there is substantial antitumor activity and synergy between calcitriol and dexamethasone. On the basis of these data, the authors conducted a phase 2 trial of intravenous (iv) calcitriol at a dose of 74 microg weekly (based on a recent phase 1 trial) and dexamethasone in patients with castration-resistant prostate cancer (CRPC). METHODS: A 2-stage Kepner-Chang design was used. Oral dexamethasone at a dose of 4 mg was given weekly on Days 1 and 2, and iv calcitriol (74 microg over 1 hour) was administered weekly on Day 2 from 4 to 8 hours after the dexamethasone dose in patients with CRPC. Laboratory data were monitored weekly, and renal sonograms, computed tomography scans, and bone scans were obtained every 3 months. Disease response was assessed by using the Response Evaluation Criteria in Solid Tumors (RECIST) and standard criteria for prostate-specific antigen (PSA) response. The calcitriol dose was delineated by from the authors' recent phase 1 trial. RESULTS: Of 18 evaluable patients, 15 patients were Caucasian (83%). No patients had a complete or partial response by either RECIST or PSA response criteria. Fourteen patients had progressive disease, 2 patients refused to continue treatment (after 64 days and 266 days), and 2 patients remain on the trial (for 306 days and 412 days).The median time to disease progression was 106 days (95% confidence interval, 80-182 days). Fourteen episodes of grade 3 or 4 toxicity were noted in 7 patients (hyperglycemia, hypocalemia, chest pain, dyspnea, hypercalcemia, hypophosphatemia, cardiac arrhythmia, and pain). Only 1 episode of grade 3/ 4 toxicity was related definitely to calcitriol (hypercalcemia). No treatment-related deaths were noted. CONCLUSIONS: High-dose, iv calcitriol at a dose of 74 microg weekly in combination with dexamethasone was well tolerated but failed to produce a clinical or PSA response in men with CRPC. (c) 2010 American Cancer Society</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USAJC - 0374236, clzCP - United StatesPT - Clinical Trial, Phase IIPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20166215</style></custom1><custom3><style face="normal" font="default">AS - Cancer. 116(9):2132-9, 2010 May 1.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>417</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Chang,A.Y.</style></author><author><style face="normal" font="default"> FitzGerald,S.J.</style></author><author><style face="normal" font="default"> Cannaday,J.</style></author><author><style face="normal" font="default"> Zhang,S.</style></author><author><style face="normal" font="default"> Patel,A.</style></author><author><style face="normal" font="default"> Palmer,M.D.</style></author><author><style face="normal" font="default"> Reddy,G.P.</style></author><author><style face="normal" font="default"> Ordovas,K.G.</style></author><author><style face="normal" font="default"> Stillman,A.E.</style></author><author><style face="normal" font="default"> Janowitz,W.</style></author><author><style face="normal" font="default"> Radford,N.B.</style></author><author><style face="normal" font="default"> Roberts,A.J.</style></author><author><style face="normal" font="default"> Levine,B.D.</style></author></authors></contributors><titles><title><style face="normal" font="default">Cardiovascular risk factors and coronary atherosclerosis in retired National Football League players</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="811" start="805">805-811</pages><volume><style face="normal" font="default">104</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Body Size</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Football/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> African Americans/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> European Continental Ancestry Group/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Football/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Retirement</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> United States/ep [Epidemiology]</style></keyword></keywords><dates><year Day="15" Month="9" Year="2009">2009/9/15</year></dates><abstract><style face="normal" font="default">A high prevalence of obesity exists in National Football League (NFL) players as determined by body mass index (BMI). It is not established whether increased BMI is associated with a greater prevalence of cardiovascular (CV) risk factors or coronary atherosclerosis in former NFL players than in nonathletes. This study compared CV risk factors and coronary atherosclerosis in retired NFL players to 2 groups of community controls, the population-based Dallas Heart Study and the preventive medicine cohort, the Aerobics Center Longitudinal Study. Retired NFL players (n = 201) were matched for ethnicity, age, and BMI (Aerobics Center Longitudinal Study, age only). CV risk factors were assessed by survey and screening visit. Coronary atherosclerosis was measured by computed tomography as coronary artery calcium (CAC). Compared to population-based controls, retired NFL players had a significantly lower prevalence of diabetes, hypertension, sedentary lifestyle, and metabolic syndrome, yet a higher prevalence of impaired fasting glucose and hyperlipidemia. However, there was no significant difference in the prevalence of detectable CAC (46% vs 48.3%, p = 0.69) or distribution of CAC (0 to 10, 10 to 100, 100 to 400, > or =400, p = 0.11). Comparing retired NFL players to the physically active preventive medicine controls, there was no difference in the amount of CAC. In retired NFL players, age and hyperlipidemia, not body size, were the most significant predictors of CAC. In conclusion, despite their large body size, retired NFL players do not have a greater prevalence of CV risk factors or amount of CAC than community controls</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USAJC - 3dq, 0207277CP - United StatesPT - Comparative StudyPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - AG06945 (United States NIA NIH HHS)NO - HL62508 (United States NHLBI NIH HHS)NO - UL1RR024982 (United States NCRR NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19733715</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 104(6):805-11, 2009 Sep 15.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>371</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Chang,S.M.</style></author><author><style face="normal" font="default"> Nabi,F.</style></author><author><style face="normal" font="default"> Xu,J.</style></author><author><style face="normal" font="default"> Peterson,L.E.</style></author><author><style face="normal" font="default"> Achari,A.</style></author><author><style face="normal" font="default"> Pratt,C.M.</style></author><author><style face="normal" font="default"> Mahmarian,J.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">The coronary artery calcium score and stress myocardial perfusion imaging provide independent and complementary prediction of cardiac risk</style></title><secondary-title><style face="normal" font="default">Journal of the American College of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of the American College of Cardiology</style></full-title></periodical><pages end="1882" start="1872">1872-1882</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">20</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Myocardial Perfusion Imaging</style></keyword><keyword><style face="normal" font="default"> *Tomography,Emission-Computed,Single-Photon</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Exercise Test</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardial Perfusion Imaging</style></keyword><keyword><style face="normal" font="default"> Perfusion</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="10" Month="11" Year="2009">2009/11/10</year></dates><abstract><style face="normal" font="default">OBJECTIVES: This study sought to examine the relationship between coronary artery calcium score (CACS) and single-photon emission computed tomography (SPECT) results for predicting the short- and long-term risk of cardiac events. BACKGROUND: The CACS and SPECT results both provide important prognostic information. It is unclear whether integrating these tests will better predict patient outcome. METHODS: We followed-up 1,126 generally asymptomatic subjects without previous cardiovascular disease who had a CACS and stress SPECT scan performed within a close time period (median 56 days). The median follow-up was 6.9 years. End points analyzed were total cardiac events and all-cause death/myocardial infarction (MI). RESULTS: An abnormal SPECT result increased with increasing CACS from &lt;1% (CACS &lt; or =10) to 29% (CACS >400) (p &lt; 0.001). Total cardiac events and death/MI also increased with increasing CACS and abnormal SPECT results (p &lt; 0.001). In subjects with a normal SPECT result, CACS added incremental prognostic information, with a 3.55-fold relative increase for any cardiac event (2.75-fold for death/MI) when the CACS was severe (>400) versus minimal (&lt; or =10). Separation of the survival curves occurred at 3 years after initial testing for all cardiac events and at 5 years for death/MI. CONCLUSIONS: The CACS and SPECT findings are independent and complementary predictors of short- and long-term cardiac events. Despite a normal SPECT result, a severe CACS identifies subjects at high long-term cardiac risk. After a normal SPECT result, our findings support performing a CACS in patients who are at intermediate or high clinical risk for coronary artery disease to better define those who will have a high long-term risk for adverse cardiac events. 2009 by the American College of Cardiology Foundation</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Methodist DeBakey Heart and Vascular Center and The Methodist Hospital Research Institute, The Methodist Hospital, Houston, Texas, USAJC - h50, 8301365CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19892239</style></custom1><custom3><style face="normal" font="default">AS - J Am Coll Cardiol. 54(20):1872-82, 2009 Nov 10.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>134</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Chen,C.H.</style></author><author><style face="normal" font="default"> Nien,C.K.</style></author><author><style face="normal" font="default"> Yang,C.C.</style></author><author><style face="normal" font="default"> Yeh,Y.H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Association between nonalcoholic fatty liver disease and coronary artery calcification</style></title><secondary-title><style face="normal" font="default">Digestive Diseases &amp; Sciences</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Digestive Diseases &amp; Sciences</style></full-title></periodical><pages end="1760" start="1752">1752-1760</pages><volume><style face="normal" font="default">55</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Fatty Liver/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Chi-Square Distribution</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Fatty Liver/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Fatty Liver/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Fatty Liver/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword></keywords><dates><year Day="0" Month="6" Year="2010">2010/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: Both nonalcoholic fatty liver disease (NAFLD) and coronary artery disease (CAD) are closely related to many metabolic disorders. Multislice computed tomography (MSCT) is a reliable noninvasive method in demonstrating coronary plaque. However, the association between coronary artery calcium (CAC) score and NAFLD remains controversial. AIMS: The aim of this study is to evaluate the association between CAC score and NAFLD. METHODS: This retrospective study enrolled 295 consecutive asymptomatic subjects who had both coronary angiography by MSCT and hepatobiliary imaging during self-paid physical check-ups. RESULTS: NAFLD was found in 41% of the enrolled 295 subjects; gall bladder stones were found in 10.8%, and CAC > 100 with moderate-high risk of CAD was found in 12.9% of subjects. Male gender (odds ratios (OR), 3.087; 95% confidence intervals (CI), 1.092-8.729), increased age (OR, 1.108; 95% CI, 1.067-1.151), diabetes mellitus (DM) (OR, 2.968; 95% CI, 1.129-7.803), and NAFLD (OR, 2.462; 95% CI, 1.065-5.691) were the independent factors that increased the risk of CAC > 100 in binary logistic regression. The prevalence of NAFLD also increased with the severity of CAC score (&lt;or=100, 38.1%; 101-400, 58.3%; >400, 64.3%; P = 0.03). CONCLUSIONS: Besides the traditional risk factors, such as male gender, increased age, and DM, NAFLD was also associated with moderate to high risk of CAD (CAC > 100)</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Digestive Disease Center, Changhua Show-Chwan Memorial Hospital, Section 1, Changhua, Taiwan. peach@show.org.twJC - ead, 7902782CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19688595</style></custom1><custom3><style face="normal" font="default">AS - Dig Dis Sci. 55(6):1752-60, 2010 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>208</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Chen,Z.Q.</style></author><author><style face="normal" font="default"> Xie,J.T.</style></author><author><style face="normal" font="default"> Gu,X.M.</style></author><author><style face="normal" font="default"> Xie,G.S.</style></author><author><style face="normal" font="default"> Hu,D.P.</style></author><author><style face="normal" font="default"> Wang,R.</style></author><author><style face="normal" font="default"> Lu,J.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Posterior short-segment pedicle screw fixation combined with vertebroplasty for the treatment of thoracolumbar burst fractures]. [Chinese]</style></title><secondary-title><style face="normal" font="default">Zhongguo Gushang</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Zhongguo Gushang</style></full-title></periodical><pages end="106" start="102">102-106</pages><volume><style face="normal" font="default">23</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Bone Screws</style></keyword><keyword><style face="normal" font="default"> *Fracture Fixation,Internal/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Lumbar Vertebrae/in [Injuries]</style></keyword><keyword><style face="normal" font="default"> *Spinal Fractures/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Thoracic Vertebrae/in [Injuries]</style></keyword><keyword><style face="normal" font="default"> *Vertebroplasty/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> 0 (Bone Cements)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Bone Cements</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword></keywords><dates><year Day="0" Month="2" Year="2010">2010/2</year></dates><isbn><style face="normal" font="default">1003-0034</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: To evaluate the clinical efficacy of posterior short-segment pedicle screw fixation combined reduction of central end-plate by end-plate expand clamp and vertebroplasty with calcium phosphate cement for the treatment of thoracolumbar burst fractures. METHODS: Thirty patients with thoracolumbar burst fractures were treated with posterior pedicle screw fixation combined reduction of central end-plate by end-plate expand clamp and vertebroplasty with calcium phosphate cement. There were 22 males and 8 females with an average of 47 years (range from 25 to 71 years). Segment of fracture had 1 case in T11, 5 in T12, 14 in L1, 8 in L2, 2 in L3, 1 in L4, 1 in L5. According to Denis typing, 4 cases were type A, 25 type B, 1 type C, 1 type D, 1 type E. The relative anterior height of vertebral body and the vertebral angle were measured before and after operation and during the follow-up period (8 months after operation) through X-ray, the failure of internal fixation and recurrent kyphosis were evaluated during the follow-up period. Vertebral intracorporeal gap was measured by CT images after operation and the central end-plate fracture and reduction were observed by the reconstructed CT images (sagittal and coronary) before and after operation. RESULTS: All patients were followed up from 8 to 15 months with an average of 12 months. Relative anterior height of vertebral body and vertebral angle were well restored after operation, and there was no significant change between after operation and 8 months after operation. Preoperative,postoperative and 8 months after operation, relative anterior height of vertebral body respectively was 40.1%, 98.2%, 97.8%, vertebral angle respectively was 18.30, 2.70, 3.20. No failure of internal fixation and recurrent kyphosis were found during the follow-up period. The vertebral intracorporeal gap was about 3.1% and reduction of central endplate fracture was satisfactory. CONCLUSION: Posterior short-segment pedicle screw fixation combined with vertebroplasty with calcium phosphate cement can provide excellent reduction of post-traumatic segmental kyphosis and restore vertebral body height in the fracture level, prevent the failure of internal fixation which is an ideal method for the treatment of thoracolumbar burst fractures</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Orthopaedics, the Second People's Hospital of Hangzhou, the Affiliated Hospital of Hangzhou Normal University, Hangzhou 310015, Zhejiang, China. czqchen2008@sina.comJC - 9815790CP - ChinaPT - English AbstractPT - Journal ArticleLG - Chinese</style></notes><urls/><custom1><style face="normal" font="default">UI - 20345031</style></custom1><custom3><style face="normal" font="default">AS - Zhongguo Gu Shang. 23(2):102-6, 2010 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>130</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Cheng,V.Y.</style></author><author><style face="normal" font="default"> Dey,D.</style></author><author><style face="normal" font="default"> Tamarappoo,B.</style></author><author><style face="normal" font="default"> Nakazato,R.</style></author><author><style face="normal" font="default"> Gransar,H.</style></author><author><style face="normal" font="default"> Miranda-Peats,R.</style></author><author><style face="normal" font="default"> Ramesh,A.</style></author><author><style face="normal" font="default"> Wong,N.D.</style></author><author><style face="normal" font="default"> Shaw,L.J.</style></author><author><style face="normal" font="default"> Slomka,P.J.</style></author><author><style face="normal" font="default"> Berman,D.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Pericardial fat burden on ECG-gated noncontrast CT in asymptomatic patients who subsequently experience adverse cardiovascular events</style></title><secondary-title><style face="normal" font="default">Jacc: Cardiovascular Imaging</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Jacc: Cardiovascular Imaging</style></full-title></periodical><pages end="360" start="352">352-360</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Adipose Tissue/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Electrocardiography</style></keyword><keyword><style face="normal" font="default"> *Pericardium/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Propensity Score</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">OBJECTIVES: We aimed to evaluate whether pericardial fat has value in predicting the risk of future adverse cardiovascular outcomes. BACKGROUND: Pericardial fat volume (PFV) and thoracic fat volume (TFV) can be routinely measured from noncontrast computed tomography (NCT) performed for calculating coronary calcium score (CCS) and may predict major adverse cardiac event (MACE) risk. METHODS: From a registry of 2,751 asymptomatic patients without known cardiac artery disease and 4-year follow-up for MACE (cardiac death, myocardial infarction, stroke, late revascularization) after NCT, we compared 58 patients with MACE with 174 same-sex, event-free control subjects matched by a propensity score to account for age, risk factors, and CCS. The TFV was automatically calculated, and PFV was calculated with manual assistance in defining the pericardial contour, within which fat voxels were automatically identified. Independent relationships of PFV and TFV to MACE were evaluated using conditional multivariable logistic regression. RESULTS: Patients experiencing MACE had higher mean PFV (101.8 +/- 49.2 cm(3) vs. 84.9 +/- 37.7 cm(3), p = 0.007) and TFV (204.7 +/- 90.3 cm(3) vs. 177 +/- 80.3 cm(3), p = 0.029) and higher frequencies of PFV >125 cm(3) (33% vs. 14%, p = 0.002) and TFV >250 cm(3) (31% vs. 17%, p = 0.025). After adjustment for Framingham risk score (FRS), CCS, and body mass index, PFV and TFV were significantly associated with MACE (odds ratio [OR]: 1.74, 95% confidence interval [CI]: 1.03 to 2.95 for each doubling of PFV; OR: 1.78, 95% CI: 1.01 to 3.14 for TFV). The area under the curve from receiver-operator characteristic analyses showed a trend of improved MACE prediction when PFV was added to FRS and CCS (0.73 vs. 0.68, p = 0.058). Addition of PFV, but not TFV, to FRS and CCS improved estimated specificity (0.72 vs. 0.66, p = 0.008) and overall accuracy (0.70 vs. 0.65, p = 0.009) in predicting MACE. CONCLUSIONS: Asymptomatic patients who experience MACE exhibit greater PFV on pre-MACE NCT when they are compared with event-free control subjects with similar cardiovascular risk profiles. Our preliminary findings suggest that PFV may help improve prediction of MACE. Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Imaging, Cedars-Sinai Medical Center, Los Angeles, California, USAJC - 101467978CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - R21EB006829 (United States NIBIB NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20394896</style></custom1><custom3><style face="normal" font="default">AS - JACC Cardiovasc Imaging. 3(4):352-60, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>458</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Chin,J.H.</style></author><author><style face="normal" font="default"> Kim,Y.K.</style></author><author><style face="normal" font="default"> Choi,D.K.</style></author><author><style face="normal" font="default"> Shin,W.J.</style></author><author><style face="normal" font="default"> Hwang,G.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Aggravation of mitral regurgitation by calcium administration in a patient with hypertrophic cardiomyopathy during liver transplantation: a case report</style></title><secondary-title><style face="normal" font="default">Transplantation Proceedings</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Transplantation Proceedings</style></full-title></periodical><pages end="1981" start="1979">1979-1981</pages><volume><style face="normal" font="default">41</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium Chloride/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Cardiomyopathy,Hypertrophic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Intraoperative Complications/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> *Liver Transplantation/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Mitral Valve Insufficiency/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> *Ventricular Outflow Obstruction/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> 10043-52-4 (Calcium Chloride)</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies</style></keyword><keyword><style face="normal" font="default"> Echocardiography,Transesophageal</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hemodynamics/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Hemodynamics/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypocalcemia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Hypocalcemia/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="6" Year="2009">2009/6</year></dates><abstract><style face="normal" font="default">Aggravation of mitral regurgitation (MR) due to left ventricular outflow tract obstruction (LVOTO) is likely to occur during liver transplantation in cirrhotic patients with hypertrophic cardiomyopathy (HCMP). Moreover, calcium administration following severe hypocalcemia due to inadequate citrate metabolism and massive transfusion may induce MR aggravation with LVOTO in such patients. Herein we have described a cirrhotic patient with HCMP in whom MR was aggravated due to LVOTO resulting from inadvertent rapid administration of calcium during liver transplantation</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KoreaJC - we9, 0243532CP - United StatesPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19545773</style></custom1><custom3><style face="normal" font="default">AS - Transplant Proc. 41(5):1979-81, 2009 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>15</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Chin,J.H.</style></author><author><style face="normal" font="default"> Park,J.Y.</style></author><author><style face="normal" font="default"> Kim,Y.K.</style></author><author><style face="normal" font="default"> Kim,S.H.</style></author><author><style face="normal" font="default"> Kong,Y.G.</style></author><author><style face="normal" font="default"> Park,P.H.</style></author><author><style face="normal" font="default"> Hwang,G.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Torsades de pointes triggered by severe diastolic hypotension with low hematocrit in the neohepatic stage of liver transplantation: a case report</style></title><secondary-title><style face="normal" font="default">Transplantation Proceedings</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Transplantation Proceedings</style></full-title></periodical><pages end="1962" start="1959">1959-1962</pages><volume><style face="normal" font="default">42</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Hypotension/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Intraoperative Complications/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Liver Transplantation/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Torsades de Pointes/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Diastole</style></keyword><keyword><style face="normal" font="default"> Hematocrit</style></keyword><keyword><style face="normal" font="default"> Hepatectomy</style></keyword><keyword><style face="normal" font="default"> Hepatitis B/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypotension/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Liver Cirrhosis/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Liver Cirrhosis/vi [Virology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Torsades de Pointes/pc [Prevention &amp; Control]</style></keyword></keywords><dates><year Day="0" Month="6" Year="2010">2010/6</year></dates><abstract><style face="normal" font="default">We have described herein a 39-year-old male patient with hepatitis B virus-related cirrhosis (Child class C), showing a prolonged corrected QT interval, who developed torsades de pointes (TdP) in the neohepatic stage of liver transplantation (LT). There was no arrhythmia in the pre-anhepatic and anhepatic stages. Multiple premature ventricular complexes, ventricular tachycardia, and TdP suddenly developed at 16 minutes after graft reperfusion without any prodromal arrhythmia; they persisted for 118 seconds. Laboratory tests showed that serum potassium, calcium, and magnesium concentrations of 4.7 mmol/L, 1.05 mmol/L, and 1.85 mg/dL, respectively were within normal ranges. Likely causative factors for TdP in this patient included a prolonged corrected QT interval (553 msec), a low hematocrit (21%), and a low arterial blood pressure (systolic blood pressure, 80-90 mm Hg; diastolic blood pressure; 20-26 mm Hg) in the neohepatic stage. This case demonstrated the importance of optimal maintenance of coronary perfusion, with an adequate hematocrit level and electrolyte concentrations, to prevent the development of TdP in cirrhotic patients with a prolonged corrected QT interval during LT</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KoreaJC - we9, 0243532CP - United StatesPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20620555</style></custom1><custom3><style face="normal" font="default">AS - Transplant Proc. 42(5):1959-62, 2010 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>52</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Chiu,Y.W.</style></author><author><style face="normal" font="default"> Adler,S.G.</style></author><author><style face="normal" font="default"> Budoff,M.J.</style></author><author><style face="normal" font="default"> Takasu,J.</style></author><author><style face="normal" font="default"> Ashai,J.</style></author><author><style face="normal" font="default"> Mehrotra,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Coronary artery calcification and mortality in diabetic patients with proteinuria</style></title><secondary-title><style face="normal" font="default">Kidney International</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Kidney International</style></full-title></periodical><pages end="1114" start="1107">1107-1114</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 2/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Diabetic Nephropathies/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Proteinuria/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Calcinosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus,Type 2/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus,Type 2/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus,Type 2/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Diabetic Nephropathies/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Ethnic Groups</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword></keywords><dates><year Day="0" Month="6" Year="2010">2010/6</year></dates><abstract><style face="normal" font="default">Vascular calcification is one of the mechanisms mediating the higher mortality risk associated with the hyperphosphatemia of chronic kidney disease. Though common, and often severe in non-dialyzed proteinuric diabetics, there are no studies on the prognostic significance of coronary artery calcification in early stage type 2 diabetic nephropathy. Here we determine this significance in 225 proteinuric diabetic patients (mean age 57 years, mean estimated glomerular filtration rate (eGFR) 52 ml/min per 1.73 m(2) and a median urine protein-creatinine ratio of 2.7). Coronary artery calcification, measured by electron beam computed tomography, was diagnosed in 86% of the patients, the severity of which correlated with older age, male gender, and white ethnicity. However, no association was found between eGFR, serum calcium, phosphorus, parathyroid hormone, or 25-hydroxy vitamin D. Over an average follow-up of 39 months, 54 patients died. A graded relationship between the severity of calcification and all-cause mortality was consistently demonstrated on both univariate and multivariate analyses. Patients in the highest quartile of calcification score had a 2.5-fold higher risk for death. Our results show the severity of coronary artery calcification early in the course of chronic kidney disease is an independent predictor of all-cause mortality. Additional studies need to determine whether altering the natural history of coronary artery calcification in early chronic kidney disease prolongs survival</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, Los Angeles Biomedical Research Institute, Torrance, California, USACM - Comment in: Kidney Int. 2010 Jun;77(12):1057-9; PMID: 20508663JC - kvb, 0323470CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - M01-RR00425 (United States NCRR NIH HHS)NO - RR18298 (United States NCRR NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20237457</style></custom1><custom3><style face="normal" font="default">AS - Kidney Int. 77(12):1107-14, 2010 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>223</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Cho,I.</style></author><author><style face="normal" font="default"> Min,H.S.</style></author><author><style face="normal" font="default"> Chun,E.J.</style></author><author><style face="normal" font="default"> Park,S.K.</style></author><author><style face="normal" font="default"> Choi,Y.</style></author><author><style face="normal" font="default"> Blumenthal,R.S.</style></author><author><style face="normal" font="default"> Rivera,J.J.</style></author><author><style face="normal" font="default"> Nasir,K.</style></author><author><style face="normal" font="default"> Kim,Y.J.</style></author><author><style face="normal" font="default"> Sohn,D.W.</style></author><author><style face="normal" font="default"> Oh,B.H.</style></author><author><style face="normal" font="default"> Park,Y.B.</style></author><author><style face="normal" font="default"> Chang,H.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Coronary atherosclerosis detected by coronary CT angiography in asymptomatic subjects with early chronic kidney disease</style></title><secondary-title><style face="normal" font="default">Atherosclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Atherosclerosis</style></full-title></periodical><pages end="411" start="406">406-411</pages><volume><style face="normal" font="default">208</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure,Chronic/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure,Chronic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Proteinuria/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="2" Year="2010">2010/2</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The purpose of this study is to assess the independent association between early CKD (stages 1-3a) with coronary atherosclerosis and the feasibility of risk stratification of coronary atherosclerosis according to The Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines using non-invasive coronary angiography. METHODS: We consecutively enrolled 4297 asymptomatic subjects who underwent coronary CT angiography as part of a general health evaluation and had estimated glomerular filtration rates (eGFR) over 45 ml/min/1.73 m(2). Subjects were categorized from no CKD to stage 3a CKD, and multiple regression analyses for coronary atherosclerosis were performed. RESULTS: Early CKD was an independent risk factor for coronary artery disease (CAD) and obstructive CAD. However, neither the risk of CAD nor CACS >100 increased as stage of CKD advanced. The reason for unsuccessful stratification of coronary atherosclerosis risk was that the presence of proteinuria, which was used to define stages 1 and 2 CKD, was an independent risk factor for coronary atherosclerosis, but eGFR of 45-89 ml/min/1.73 m(2) was not associated with coronary atherosclerosis. CONCLUSIONS: Early CKD was an independent risk factor for coronary atherosclerosis, and the risk stratification for coronary atherosclerosis should be based on the presence of proteinuria rather than decreased eGFR within early CKD. Copyright 2009 Elsevier Ireland Ltd. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Cardiovascular Center, Seoul National University Hospital, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South KoreaJC - 95x, 0242543CP - IrelandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19781704</style></custom1><custom3><style face="normal" font="default">AS - Atherosclerosis. 208(2):406-11, 2010 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>408</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Choi,E.K.</style></author><author><style face="normal" font="default"> Chun,E.J.</style></author><author><style face="normal" font="default"> Choi,S.I.</style></author><author><style face="normal" font="default"> Chang,S.A.</style></author><author><style face="normal" font="default"> Choi,S.H.</style></author><author><style face="normal" font="default"> Lim,S.</style></author><author><style face="normal" font="default"> Rivera,J.J.</style></author><author><style face="normal" font="default"> Nasir,K.</style></author><author><style face="normal" font="default"> Blumenthal,R.S.</style></author><author><style face="normal" font="default"> Jang,H.C.</style></author><author><style face="normal" font="default"> Chang,H.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Assessment of subclinical coronary atherosclerosis in asymptomatic patients with type 2 diabetes mellitus with single photon emission computed tomography and coronary computed tomography angiography</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="896" start="890">890-896</pages><volume><style face="normal" font="default">104</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 2/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Tomography,Emission-Computed,Single-Photon/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Age Distribution</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus,Type 2/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Perfusion</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Reference Values</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Sex Distribution</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="1" Month="10" Year="2009">2009/10/1</year></dates><abstract><style face="normal" font="default">We evaluated the characteristics of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus (DM) using single photon emission computed tomography (SPECT) and coronary computed tomographic angiography (CCTA). A total of 116 patients with DM without abnormal electrocardiographic findings or evidence of peripheral arterial disease (number of risk factors > or =2; 62 +/- 7 years, 59% men) underwent CCTA and SPECT. Of the 116 patients with DM, 88 (76%) had a normal single photon emission computed tomographic findings, and 28 (24%) had abnormal perfusion defects. Of the 116 patients, 92 (79%) had atherosclerotic plaques (2 +/- 2 segments per subject), and 20 (17%) had significant stenosis seen on CCTA. Patients with DM and normal findings on SPECT had a similar prevalence of atherosclerotic plaque (78% vs 82%), significant stenosis (15% vs 25%), severe stenosis (7% vs 7%), and calcified (40% vs 43%), mixed (49% vs 57%), and noncalcified plaques (26% vs 29%) and a high (>100) coronary artery calcium score (32% vs 29%; all p >0.05) compared to those with abnormal findings on SPECT. During the mid-term follow-up (24 +/- 4 months), 5 cardiac events occurred in patients with DM and normal findings on SPECT, only in those with occult CAD on CCTA: 1 sudden cardiac death and 4 revascularization procedures. In conclusion, a significant percentage of patients with DM and normal eletrocardiographic findings, no peripheral arterial disease, and normal findings on SPECT have evidence of occult CAD on CCTA. Furthermore, a small percentage had had a cardiac event by mid-term follow-up. SPECT showed limited capability to differentiate the coronary risks between patients with DM and no coronary plaque and from those with a certain degree of disease; 2 circumstances that represent different coronary risks</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam-Si, Gyeonggi-Do, Republic of KoreaJC - 3dq, 0207277CP - United StatesPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19766752</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 104(7):890-6, 2009 Oct 1.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>352</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Choi,S.H.</style></author><author><style face="normal" font="default"> An,J.H.</style></author><author><style face="normal" font="default"> Lim,S.</style></author><author><style face="normal" font="default"> Koo,B.K.</style></author><author><style face="normal" font="default"> Park,S.E.</style></author><author><style face="normal" font="default"> Chang,H.J.</style></author><author><style face="normal" font="default"> Choi,S.I.</style></author><author><style face="normal" font="default"> Park,Y.J.</style></author><author><style face="normal" font="default"> Park,K.S.</style></author><author><style face="normal" font="default"> Jang,H.C.</style></author><author><style face="normal" font="default"> Shin,C.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Lower bone mineral density is associated with higher coronary calcification and coronary plaque burdens by multidetector row coronary computed tomography in pre- and postmenopausal women</style></title><secondary-title><style face="normal" font="default">Clinical Endocrinology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinical Endocrinology</style></full-title></periodical><pages end="651" start="644">644-651</pages><volume><style face="normal" font="default">71</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Bone Density/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Postmenopause/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Premenopause/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword></keywords><dates><year Day="0" Month="11" Year="2009">2009/11</year></dates><abstract><style face="normal" font="default">OBJECTIVES: There is growing evidence for the association between bone mineral density (BMD) and vascular calcification, which is related to cardiovascular disease. Coronary multidetector row computed tomography (MDCT) is a noninvasive tool developed to evaluate coronary status precisely. We used MDCT to evaluate this association. DESIGN AND PATIENTS: Eight hundred and fifteen subjects received routine checkups. After excluding subjects with factors affecting bone metabolism and cardiovascular disease, 467 subjects were analysed. MEASUREMENTS: Coronary calcification was measured with MDCT and BMD was measured with dual X-ray absorptiometry (DXA). RESULTS: The BMD of the femur and the lumbar spine (L-spine) were negatively associated with the coronary calcium score (CCS) after adjusting for age in women but not in men. This inverse correlation was stronger in women with a longer time since menopause (r = -0.35 at femur, postmenopausal women vs. r = -0.10 at femur, premenopausal women, P &lt; 0.05), and it was stronger at the femur than in the L-spine (r = -0.35 at femur vs. r = -0.16 at L-spine, P &lt; 0.01). The relationship was also stronger in postmenopausal women with osteoporosis and osteopaenia than in women with normal BMD. The lower BMD was associated with higher coronary plaque burdens and multidiseased coronary vessels in both men and women (P &lt; 0.01). CONCLUSIONS: Increased CCS and subclinical atherosclerosis of plaque burdens as revealed by MDCT was associated with a low BMD in all women, independent of cardiovascular risk factors and age</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Seoul National University College of Medicine, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul, KoreaJC - dci, 0346653CP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19226260</style></custom1><custom3><style face="normal" font="default">AS - Clin Endocrinol (Oxf). 71(5):644-51, 2009 Nov.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>229</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Choudhary,G.</style></author><author><style face="normal" font="default"> Shin,V.</style></author><author><style face="normal" font="default"> Punjani,S.</style></author><author><style face="normal" font="default"> Ritter,N.</style></author><author><style face="normal" font="default"> Sharma,S.C.</style></author><author><style face="normal" font="default"> Wu,W.C.</style></author></authors></contributors><titles><title><style face="normal" font="default">The role of calcium score and CT angiography in the medical management of patients with normal myocardial perfusion imaging</style></title><secondary-title><style face="normal" font="default">Journal of Nuclear Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Nuclear Cardiology</style></full-title></periodical><pages end="51" start="45">45-51</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Myocardial Perfusion Imaging/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Tomography,Emission-Computed,Single-Photon/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> False Negative Reactions</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardial Perfusion Imaging</style></keyword><keyword><style face="normal" font="default"> Perfusion</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="1" Year="2010">2010/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Individuals with normal myocardial perfusion imaging (MPI) may still have substantial coronary artery disease (CAD), which would benefit from aggressive medical therapy. The role of coronary artery calcium-score (CAC) and/or coronary CT Angiography (CTA) to identify additional treatment candidates in this population is unknown. METHODS: Ninety-four patients completed the study protocol and underwent CAC and CTA after MPI. RESULTS: In 81 patients who had a normal MPI, an algorithm using the clinical predictors, CAC, and then CTA was created to identify candidates for aggressive medical management; 24/81 patients had a high Framingham Risk Score (FRS) or diabetes, and need aggressive medical management, while 6/81 patients had a low FRS and low post-MPI probability of CAD. The use of CAC in 51/81 patients with intermediate clinical predictors would identify 23/51 patients with low risk (CAC &lt; 100) and 11/51 patients (CAC > 400) for aggressive medical management. The remaining 17/51 patients with intermediate CAC scores (100-399) would require CTA, of which, would identify 8/17 additional patients with >50% stenosis for aggressive medical therapy. CONCLUSION: A stepwise approach including history, CAC and CTA can identify about 50% of the patients with normal MPI who have a higher risk and may benefit from aggressive medical management</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Vascular Research Laboratory, Providence VA Medical Center, 830 Chalkstone Ave., Providence, RI 02908, USA. Gaurav_choudhary@brown.eduCM - Comment in: J Nucl Cardiol. 2010 Jan-Feb;17(1):13-5; PMID: 19950009JC - cmd, 9423534CP - United StatesPT - Journal ArticlePT - Research Support, U.S. Gov't, Non-P.H.SLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19936862</style></custom1><custom3><style face="normal" font="default">AS - J Nucl Cardiol. 17(1):45-51, 2010 Jan-Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>418</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Chu,H.</style></author><author><style face="normal" font="default"> Chen,J.</style></author><author><style face="normal" font="default"> Guo,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">The association between cardiac calcification and coronary artery disease</style></title><secondary-title><style face="normal" font="default">Acta Cardiologica</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Acta Cardiologica</style></full-title></periodical><pages end="535" start="531">531-535</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Heart Valves/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aortic Valve/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypercholesterolemia/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mitral Valve/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword></keywords><dates><year Day="0" Month="8" Year="2009">2009/8</year></dates><isbn><style face="normal" font="default">0001-5385</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: The objective of this study was to determine whether there is an association between mitral annular calcification (MAC), aortic valve annulus calcification (AVAC) and aortic valve calcification (AVC) with coronary artery disease (CAD) in subjects &lt; or =65 years. METHODS: 386 patients under 65 years of age underwent transthoracic echocardiography and coronary arteriography at the same time. RESULTS: The following results were obtained: (I) The patients with calcium deposits were older than the patients without calcium deposits (P &lt; 0.01). Hypertension (P &lt; 0.05) and diabetes mellitus (P &lt; 0.001) were significantly associated with MAC. Hypertension (P &lt; 0.01), diabetes mellitus (P &lt; 0.05) and a smoking history (P &lt; 0.05) were significantly more prevalent in patients with AVC than in those without AVC. Hypertension was significantly more frequent in patients with AVAC (P &lt; 0.05). (II) There was a positive correlation between age (P &lt; 0.001), hypertension (P &lt; 0.001), diabetes (P &lt; 0.05) and the number of sites with calcium deposits. (III) Coronary arteriography was more frequently positive in patients with calcium deposits than in those without (P &lt; 0.01). (IV) Multivariable logistic regression analysis identified multiple calcium deposits (P &lt; 0.01), age (P &lt; 0.05), male gender (P &lt; 0.001), diabetes mellitus (P &lt; 0.001), and hypercholesterolaemia (P &lt; 0.05) as significant predictors for a positive coronary arteriography. Multiple calcium deposits (P &lt; 0.001) and diabetes mellitus (P &lt; 0.001) were also significant predictors in female patients. In patients aged &lt; or =55 years, multiple calcium deposits (P &lt; 0.05), diabetes mellitus (P &lt;0.05), smoking history (P &lt; 0.05) and male gender (P &lt; 0.05) were statistically significant predictors of a positive coronary arteriography. CONCLUSION: There is a significant association between the presence of calcium deposits and coronary artery disease. The presence of multiple calcium deposits is an independent predictor of coronary artery disease</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Ultrasound, Renmin Hospital, Wuhan University, Wuhan 430060, China. chg121@163.comJC - 0370570CP - BelgiumPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19725447</style></custom1><custom3><style face="normal" font="default">AS - Acta Cardiol. 64(4):531-5, 2009 Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>263</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Cianciolo,G.</style></author><author><style face="normal" font="default"> La,Manna G.</style></author><author><style face="normal" font="default"> Donati,G.</style></author><author><style face="normal" font="default"> Persici,E.</style></author><author><style face="normal" font="default"> Dormi,A.</style></author><author><style face="normal" font="default"> Cappuccilli,M.L.</style></author><author><style face="normal" font="default"> Corsini,S.</style></author><author><style face="normal" font="default"> Fattori,R.</style></author><author><style face="normal" font="default"> Russo,V.</style></author><author><style face="normal" font="default"> Nastasi,V.</style></author><author><style face="normal" font="default"> Col&amp;#x00EC</style></author><author><style face="normal" font="default"> L</style></author><author><style face="normal" font="default"> Wratten,M.</style></author><author><style face="normal" font="default"> Stefoni,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Coronary calcifications in end-stage renal disease patients: a new link between osteoprotegerin, diabetes and body mass index?</style></title><secondary-title><style face="normal" font="default">Blood Purification</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Blood Purification</style></full-title></periodical><pages end="22" start="13">13-22</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Body Mass Index</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Cardiomyopathies/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure,Chronic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Osteoprotegerin/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> 0 (Osteoprotegerin)</style></keyword><keyword><style face="normal" font="default"> 0 (Transforming Growth Factor beta1)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Dialysis</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Transforming Growth Factor beta1/ph [Physiology]</style></keyword></keywords><dates><year Day="0" Month="0" Year="2010">2010</year></dates><abstract><style face="normal" font="default">The aim of the study was to assess the factors potentially involved in coronary artery calcifications (CAC) in end-stage renal disease patients. 253 hemodialysis (HD) patients (92 females, 161 males), aged 62.5 +/- 13.5, who had been on HD treatment for at least 6 months, were enrolled in a cross-sectional study. Calcium-phosphate product (Ca x P), body mass index (BMI), fetuin-A, osteoprotegerin (OPG), osteopontin, transforming growth factor-beta1 (TGF-beta1), fibroblast growth factor-23 (FGF-23) and matrix Gla protein (MGP) were considered. CAC was assessed using multislice spiral computed tomography and calcium score was quantified by means of the Agatston score. The median calcium score was 364 Agatston (range 0-7,336). CAC was detected in 228/253 patients (90.1%). Multivariate regression analysis, adjusted for age and for dialysis vintage, showed that TGF-beta1, OPG and days with Ca x P >55 mg/dl are independent predictors of CAC, while MGP was shown to be a protective factor. Surprisingly, results showed that BMI was a protective factor too: the interpolation with cubic spline function revealed a significant reduction in calcium score in patients with a high BMI (>28). However, when diabetes was considered in the regression analysis, only OPG emerged as a predictor of a high CAC score. The interpolation with spline function continued to show a significant reduction in CAC score in nondiabetic and in diabetic patients with the highest BMI quartile. The protective effect of a high BMI on CAC might represent another example of inverse biology in dialysis patients but it needs to be further addressed in larger longitudinal studies. Copyright 2009 S. Karger AG, Basel</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Nephrology Dialysis and Renal Transplantation Unit, S. Orsola University Hospital, University of Bologna, Bologna, ItalyJC - aj6, 8402040CP - SwitzerlandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19816015</style></custom1><custom3><style face="normal" font="default">AS - Blood Purif. 29(1):13-22, 2010.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>392</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Cirillo,M.</style></author><author><style face="normal" font="default"> Del,Giudice L.</style></author><author><style face="normal" font="default"> Bilancio,G.</style></author><author><style face="normal" font="default"> Franzese,M.D.</style></author><author><style face="normal" font="default"> Chiricone,D.</style></author><author><style face="normal" font="default"> De Santo,N.G.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Early detection of chronic kidney disease: epidemiological data on renal dysfunction]. [Italian]</style></title><secondary-title><style face="normal" font="default">Giornale Italiano di Nefrologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Giornale Italiano di Nefrologia</style></full-title></periodical><pages end="693" start="690">690-693</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Renal Insufficiency,Chronic/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Renal Insufficiency,Chronic/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Early Diagnosis</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Kidney/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Renal Insufficiency,Chronic/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="11" Year="2008">2008/11</year></dates><isbn><style face="normal" font="default">0393-5590</style></isbn><abstract><style face="normal" font="default">Estimated glomerular filtration rate (eGFR) and urinary albumin (U-Alb) have been suggested as indicators for the early identification of persons with kidney dysfunction. The Gubbio Study collected data on serum creatinine, UAlb, other laboratory indices, blood pressure, and medical history in a population sample of 4574 adults (2083 men and 2491 women, age range 18- 95 years). The study included analyses on six disorders which are commonly associated with kidney disease (hypertension, cardiovascular disease, anemia, high serum uric acid, high serum phosphorus/low serum calcium, and high serum potassium). Low eGFR (&lt;60 mL/min per 1.73 m2) was found in 6.6% of men and 6.2% of women. Low eGFR prevalence varied largely with age (from &lt;1% at 18-24 years up to > 30% at > or =75 years in both sexes, p&lt;0.001). On the basis of these data, it was estimated that the prevalence of low eGFR in the whole Italian population could be 1.3 million among men (95%CI 1.1/1.5) and 1.5 million among women (95%CI 1.3/1.8). Data available only for age 45-64 indicate that 6.4% of men and 3.0% of women have high U-Alb (> or =20 microg/min) in the presence of non-low eGFR. Low eGFR was associated with at least two disorders potentially due to kidney disease in the majority of persons but was rarely associated with a previous diagnosis of kidney disease (&lt;5% of cases). These data support the use of eGFR for the screening of people with or at risk of developing kidney disease. Awareness of kidney disease is very low in the Italian population</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Policlinico-Nefrologia, Seconda Universit&amp;#x00E0; di Napoli, Via Sergio Pansini 5, Naples, Italy. massimo.cirillo@unina2.itOT - L'identificazione precoce della nefropatia cronica: dati epidemiologici sulla disfunzione renaleJC - 9426434CP - ItalyPT - English AbstractPT - Journal ArticleLG - Italian</style></notes><urls/><custom1><style face="normal" font="default">UI - 19048569</style></custom1><custom3><style face="normal" font="default">AS - G. ITAL. NEFROL.. 25(6):690-3, 2008 Nov-Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>532</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Civilibal,M.</style></author><author><style face="normal" font="default"> Caliskan,S.</style></author><author><style face="normal" font="default"> Kurugoglu,S.</style></author><author><style face="normal" font="default"> Candan,C.</style></author><author><style face="normal" font="default"> Canpolat,N.</style></author><author><style face="normal" font="default"> Sever,L.</style></author><author><style face="normal" font="default"> Kasapcopur,O.</style></author><author><style face="normal" font="default"> Arisoy,N.</style></author></authors></contributors><titles><title><style face="normal" font="default">Progression of coronary calcification in pediatric chronic kidney disease stage 5</style></title><secondary-title><style face="normal" font="default">Pediatric Nephrology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatric Nephrology</style></full-title></periodical><pages end="563" start="555">555-563</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Kidney Diseases/co [Complications]</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol,LDL)</style></keyword><keyword><style face="normal" font="default"> 0 (Serum Albumin)</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Cholesterol,LDL/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Dialysis</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Kidney Diseases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Peritoneal Dialysis</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Serum Albumin/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="3" Year="2009">2009/3</year></dates><isbn><style face="normal" font="default">0931-041X</style></isbn><abstract><style face="normal" font="default">Coronary artery calcification (CAC) is common in adults with chronic kidney disease (CKD) and progresses with time. However, data are limited for younger patients. We have previously reported CAC in eight of 53 children with CKD. After 2 years, CAC evaluation was repeated in 48 patients. The median CAC score (CACS) increased from 101.3 (1473.6 +/- 1978.6, range 8.5-4332) to 1759.2 (2236.4 +/- 2463.3, range 0-5858) Agatston units (AU). When the individual changes in CACS were evaluated one by one, we showed a mild decrease in two patients on hemodialysis (HD) and in one transplant (Tx) recipient, a moderate increase in one patient on HD, one on peritoneal dialysis (PD) and one Tx recipient, and a large increase in one HD patient. Also, CAC disappeared in one HD patient. All patients with no calcification at baseline remained calcification-free at follow-up. To obtain the individual cumulative exposure, we calculated time-averaged mean values, using the laboratory values from the beginning of dialysis to the first and second multidetector spiral computed tomography (MDCT) scans (baseline and final values, respectively). Final CACS was positively related to final calcium-phosphorus (CaxP) product, while CAC progression was inversely associated with final serum albumin level. This report is the first study with the largest number and the youngest cohort to document the natural history of coronary calcification</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Pediatric Nephrology, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey. drcivilibal@hotmail.comJC - avr, 8708728CP - GermanyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18982357</style></custom1><custom3><style face="normal" font="default">AS - Pediatr Nephrol. 24(3):555-63, 2009 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>526</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">ckel,K.H.</style></author><author><style face="normal" font="default"> Lehmann,N.</style></author><author><style face="normal" font="default"> Jaeger,B.R.</style></author><author><style face="normal" font="default"> Moebus,S.</style></author><author><style face="normal" font="default"> hlenkamp,S.</style></author><author><style face="normal" font="default"> Schmermund,A.</style></author><author><style face="normal" font="default"> Dragano,N.</style></author><author><style face="normal" font="default"> Stang,A.</style></author><author><style face="normal" font="default"> nemeyer,D.</style></author><author><style face="normal" font="default"> Seibel,R.</style></author><author><style face="normal" font="default"> Mann,K.</style></author><author><style face="normal" font="default"> Volbracht,L.</style></author><author><style face="normal" font="default"> Siegrist,J.</style></author><author><style face="normal" font="default"> Erbel,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Smoking cessation and subclinical atherosclerosis--results from the Heinz Nixdorf Recall Study</style></title><secondary-title><style face="normal" font="default">Atherosclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Atherosclerosis</style></full-title></periodical><pages end="227" start="221">221-227</pages><volume><style face="normal" font="default">203</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Atherosclerosis/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Coronary Disease/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Coronary Disease/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> *Smoking Cessation</style></keyword><keyword><style face="normal" font="default"> *Smoking/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aging</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Preventive Medicine/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword></keywords><dates><year Day="0" Month="3" Year="2009">2009/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: Smoking accounts for more than 5 million years of potential life lost per year in the US alone. Leading causes of smoking attributable mortality are acute atherothrombotic complications of coronary heart disease (CHD). Smoking cessation is a key issue in preventive medicine, but quantitative data on its benefit for the coronary arteries are sparse. METHODS: The Heinz Nixdorf Recall Study is an ongoing population-based, prospective cohort study, with 4814 participants aged 45-74 years (49.8% men). Baseline data of 4078 participants without history of established coronary heart disease or stroke are included in this report. Electron beam-computed tomography allows for non-invasive quantification of coronary artery calcium (CAC). We estimate the risk-related ageing of coronary arteries from multivariable regression of CAC on smoking behavior, sex, age and risk factors. RESULTS: Smoking 20 cigarettes per day since the age of 16 is associated with a CAC burden which is found in a person 10 years older who has never smoked (both sexes). Smoking cessation at 45, 55 or 65 leads to CAC at the age of 75 that would have been reached 9, 6 or 3 years earlier, respectively, had smoking been continued. CONCLUSIONS: In individuals without overt CHD, present smokers are about 10 years older in 'coronary artery age' than never smokers. The accumulation of CAC is accelerated by smoking and slows down after smoking cessation, but advanced CAC is persistent for a long period. These quantitative findings strongly support smoking cessation measures as early as possible, to prevent accelerated arterial ageing</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Institute for Medical Informatics, Biometry and Epidemiology, University Duisburg-Essen, Germany. k-h.joeckel@uk-essen.deJC - 95x, 0242543CP - IrelandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18602109</style></custom1><custom3><style face="normal" font="default">AS - Atherosclerosis. 203(1):221-7, 2009 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>546</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Cojocaru,I.M.</style></author><author><style face="normal" font="default"> Cojocaru,M.</style></author><author><style face="normal" font="default"> Tanasescu,R.</style></author><author><style face="normal" font="default"> Burcin,C.</style></author><author><style face="normal" font="default"> Mitu,A.C.</style></author><author><style face="normal" font="default"> Iliescu,I.</style></author><author><style face="normal" font="default"> Dumitrescu,L.</style></author><author><style face="normal" font="default"> Pavel,I.</style></author><author><style face="normal" font="default"> Silosi,I.</style></author></authors></contributors><titles><title><style face="normal" font="default">Detecting anti-prothrombin antibodies in young women with acute ischemic stroke</style></title><secondary-title><style face="normal" font="default">Romanian Journal of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Romanian Journal of Internal Medicine</style></full-title></periodical><pages end="341" start="337">337-341</pages><volume><style face="normal" font="default">46</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Brain Ischemia/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Prothrombin/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> *Stroke/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> 0 (Antibodies,Anticardiolipin)</style></keyword><keyword><style face="normal" font="default"> 0 (Autoantibodies)</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Immunologic Factors)</style></keyword><keyword><style face="normal" font="default"> 0 (Lupus Coagulation Inhibitor)</style></keyword><keyword><style face="normal" font="default"> 9001-26-7 (Prothrombin)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Algorithms</style></keyword><keyword><style face="normal" font="default"> Antibodies,Anticardiolipin/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Autoantibodies/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Biological Markers</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immunologic Factors/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Lupus Coagulation Inhibitor/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Stroke/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword></keywords><dates><year Day="0" Month="0" Year="2008">2008</year></dates><isbn><style face="normal" font="default">1220-4749</style></isbn><abstract><style face="normal" font="default">Prothrombin (PT) is a target for antibodies with lupus anticoagulant (LA) activity. Anti-prothrombin antibodies (aPT) were recently identified as antibodies directed toward a phospholipid-binding protein. aPT are a new serologic marker of antiphospholipid syndrome. The objective was to detect aPT in a group of 46 patients with acute ischemic stroke in order to correlate their presence with clinical diagnosis, laboratory and neuroradiological findings. We tested aPT, lupus anticoagulant (LA), anticardiolipin (aCL), and anti-beta2-glycoprotein I antibodies (anti-bbeta2-GPI) in 46 young women with acute ischemic stroke aged 34-45 years and 43 patients with nonischemic neurologic diseases and 141 normal controls. Anti-prothrombin antibodies were detected by calcium-containing aPT ELISA, aCL and anti-beta2-GPI by ELISA. All samples were screened using the activated partial thromboplastin time (aPTT); the dilute Russell viper venous time (dRVV) coagulation test was performed. The results were statistically analyzed. Anti-prothrombin antibodies were found in 26 (57%) of 46 stroke patients. Out of 43 patients with nonischemic neurological disorders, 2 (4.18%) were positive for aPT. aPT were detected in one (0.70%) of the normal controls. Ten stroke patients (21%) were positive for IgG aPT only, 9 stroke patients (18.2%) for IgM aPT only, and 8 stroke patients (16.9%) for both IgG and IgM isotypes of aPT. Two nonischemic neurological disorders patients (4.18%) presented IgM isotype of aPT. Patients with ischemic stroke presented aPT much more frequently than the healthy controls (OR 182.00 [95% CI 23.382-1416.6]. p &lt; 0.0001). Patients with ischemic stroke presented aPT much frequently than the nonischemic neurological disorders patients (OR 26.650 [95% CI 5.743-123.66], p &lt; 0.0001). When IgG or IgM aPT were considered separately, they were more frequently found in patients with ischemic stroke than in healthy control group (OR 38.889 [95% CI 4.817-313.95], p &lt; 0.0001) and (OR 34.054 [95% CI 4.178-277.5], p &lt; 0.0001), respectively. Simultaneous positive titers for both isotypes of aPT (IgG and IgM) were more frequently found in patients with ischemic stroke than in healthy control group (OR 29.474 [95% CI 3.573-243.12], p &lt; 0.0001). Eleven stroke patients (43%) were negative for aCL, LA and anti-beta2-GPI, but positive for aPT (OR 0.03287 [95% CI 0.001794-0.6022], p &lt; 0.001). aCL, LA and anti-beta2-GPI were not found both in nonischemic neurological disorders patients and in healthy controls</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Carol Davila University of Medicine and Pharmacy, Clinic of Neurology, Colentina Clinical Hospital, Bucharest. inimioaramihaela_cojocaru@yahoo.comJC - bos, 9304507CP - RomaniaPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19480300</style></custom1><custom3><style face="normal" font="default">AS - Rom J Intern Med. 46(4):337-41, 2008.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>14</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Colletti,P.M.</style></author><author><style face="normal" font="default"> Dustin,L.D.</style></author><author><style face="normal" font="default"> Wong,N.D.</style></author><author><style face="normal" font="default"> Shriki,J.E.</style></author><author><style face="normal" font="default"> Kawakubo,M.</style></author><author><style face="normal" font="default"> Azen,S.P.</style></author><author><style face="normal" font="default"> Detrano,R.C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Does coronary calcium score predict future cardiac function? Association of subclinical atherosclerosis with left ventricular systolic and diastolic dysfunction at MR imaging in an elderly cohort</style></title><secondary-title><style face="normal" font="default">Radiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Radiology</style></full-title></periodical><pages end="70" start="64">64-70</pages><volume><style face="normal" font="default">257</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Magnetic Resonance Imaging/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Ventricular Dysfunction,Left/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Chi-Square Distribution</style></keyword><keyword><style face="normal" font="default"> Diastole</style></keyword><keyword><style face="normal" font="default"> Electrocardiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Image Interpretation,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Systole</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword></keywords><dates><year Day="0" Month="10" Year="2010">2010/10</year></dates><abstract><style face="normal" font="default">PURPOSE: To evaluate subclinical atherosclerosis measured by using coronary artery calcium (CAC) as a predictor of future left ventricular (LV) systolic and diastolic function in asymptomatic elderly participants. MATERIALS AND METHODS: The institutional review boards of the University of Southern California and the Harbor University of California Los Angeles Research and Education Institute (where the South Bay Heart Watch study was initially conducted) approved this HIPAA-compliant study of 386 participants (mean age, 75.2 years) from among the original 1461 participants in the longitudinal South Bay Heart Watch prospective investigation of subclinical atherosclerosis. CAC at computed tomography was correlated with LV ejection fraction (LVEF), regional wall motion abnormalities (RWMAs), and peak filling rate (PFR) assessed a mean of 11.4 years +/- 0.6 (standard deviation) later with cardiac magnetic resonance imaging. Analysis of variance and covariance testing was performed with the Wald test, testing for trends across the CAC groups. Covariates included age, level of total cholesterol, level of high-density lipoprotein cholesterol, systolic blood pressure, use of lipid-lowering medication, and smoking status. RESULTS: Mean LVEF was 60.3% +/- 9.9, with 11 (2.8%) of 386 participants having an LVEF of less than 40%. Forty-six (11.9%) of 386 participants had RWMAs. Higher CAC scores were associated with slightly lower LVEF (P for trend = .04) and a greater percentage of participants with decreased PFR (P for trend = .47) and RWMAs (P for trend = .01). After age- and risk factor-adjustment, only RWMA (P = .05) was associated with higher CAC. RWMAs were associated with significantly (P &lt; .001) lower mean LVEF and PFR. Nineteen (41%) of 46 participants with RWMAs had documented Q-wave myocardial infarction, and three (7%) underwent coronary revascularization. CAC scores of 100 or greater were associated with a 2.2-fold (95% confidence interval: 1.30, 3.75) increase in RWMA (P &lt; .001). CONCLUSION: Subclinical atherosclerosis assessed by using CAC is associated with an increased future likelihood of RWMA, as a marker of previous and possible subclinical coronary artery disease</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Radiology, Keck School of Medicine, University of Southern California, LAC+USC Medical Center GH 3566, Los Angeles, CA 90033, USA. colletti@usc.eduJC - qsh, 0401260CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20713611</style></custom1><custom3><style face="normal" font="default">AS - Radiology. 257(1):64-70, 2010 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>494</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Connolly,G.M.</style></author><author><style face="normal" font="default"> Cunningham,R.</style></author><author><style face="normal" font="default"> McNamee,P.T.</style></author><author><style face="normal" font="default"> Young,I.S.</style></author><author><style face="normal" font="default"> Maxwell,A.P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Elevated serum phosphate predicts mortality in renal transplant recipients</style></title><secondary-title><style face="normal" font="default">Transplantation</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Transplantation</style></full-title></periodical><pages end="1044" start="1040">1040-1044</pages><volume><style face="normal" font="default">87</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Kidney Transplantation/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Phosphates/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 0 (Phosphates)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 9007-41-4 (C-Reactive Protein)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> C-Reactive Protein/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperphosphatemia/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Kidney Transplantation/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> Survivors</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="15" Month="4" Year="2009">2009/4/15</year></dates><abstract><style face="normal" font="default">BACKGROUND: High serum phosphate has been identified as an important contributor to the vascular calcification seen in patients with chronic kidney disease (Block et al., Am J Kidney Dis 1998; 31: 607). In patients on hemodialysis, elevated serum phosphate levels are an independent predictor of mortality (Block et al., Am J Kidney Dis 1998; 31: 607; Block, Curr Opin Nephrol Hypertens 2001; 10: 741). The aim of this study was to investigate whether an elevated serum phosphate level was an independent predictor of mortality in patients with a renal transplant. METHODS: Three hundred seventy-nine asymptomatic renal transplant recipients were recruited between June 2000 and December 2002. Serum phosphate was measured at baseline and prospective follow-up data were collected at a median of 2441 days after enrolment. RESULTS: Serum phosphate was significantly higher in those renal transplant recipients who died at follow-up when compared with those who were still alive at follow-up (P&lt;0.001). In Kaplan-Meier analysis, serum phosphate concentration was a significant predictor of mortality (P=0.0001). In multivariate Cox regression analysis, serum phosphate concentration remained a statistically significant predictor of all-cause mortality after adjustment for traditional cardiovascular risk factors, estimated glomerular filtration rate, and high sensitivity C reactive protein (P=0.036) and after adjustment for renal graft failure (P=0.001). CONCLUSIONS: The results of this prospective study are the first to show that a higher serum phosphate is a predictor of mortality in patients with a renal transplant and suggest that serum phosphate provides additional, independent, prognostic information to that provided by traditional risk factors in the risk assessment of patients with a renal transplant</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Clinical Biochemistry, Royal Victoria Hospital, Belfast, Northern Ireland. grainnemconnolly@aol.co.ukJC - wej, 0132144CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19352125</style></custom1><custom3><style face="normal" font="default">AS - Transplantation. 87(7):1040-4, 2009 Apr 15.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>369</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Cook,N.R.</style></author><author><style face="normal" font="default"> Rosner,B.A.</style></author><author><style face="normal" font="default"> Hankinson,S.E.</style></author><author><style face="normal" font="default"> Colditz,G.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Mammographic screening and risk factors for breast cancer</style></title><secondary-title><style face="normal" font="default">American Journal of Epidemiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Epidemiology</style></full-title></periodical><pages end="1432" start="1422">1422-1432</pages><volume><style face="normal" font="default">170</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Breast Neoplasms/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Mammography</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Bias (Epidemiology)</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Breast Neoplasms/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Breast Neoplasms/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hormone Replacement Therapy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Mass Screening</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Parity</style></keyword><keyword><style face="normal" font="default"> Postmenopause</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Smoking/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="1" Month="12" Year="2009">2009/12/1</year></dates><abstract><style face="normal" font="default">Screening mammography can distort estimated effects in breast cancer risk models due to associations with other risk factors. Mammography information was available in the Nurses' Health Study from 1988, and 1,815 incident breast cancers were accrued through 2000 among 55,625 women with risk factor data. Logistic models were fit for screening mammography, and inverse probability weighting was used to adjust parameters in an established breast cancer risk model. Approximately 80% of women in each 2-year follow-up period had screening mammograms, which were positively associated with history of benign breast disease, family history of breast cancer, hormone therapy, alcohol use, physical activity, multivitamins, and calcium supplements, and negatively associated with postmenopause, current smoking, and body mass index. Markers of medical attention, including hypertension, high cholesterol, and osteoarthritis, were positively associated, while cardiovascular disease was negative. Inverse probability weighting led to small changes in effects of benign breast disease, family history, and hormone therapy. An apparent reduced risk associated with current smoking in unadjusted models was eliminated after weighting. Thus, several risk factors for breast cancer and cancer diagnosis are associated with mammographic screening. Adjustment for screening had some impact on breast cancer prediction in this cohort, especially for hormone therapy and smoking</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Preventive Medicine, Brigham and Women's Hospital, 900 Commonwealth Avenue East, Boston, MA 02215, USA. ncook@rics.bwh.harvard.eduJC - 3h3, 7910653CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - CA087969 (United States NCI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19875646</style></custom1><custom3><style face="normal" font="default">AS - Am J Epidemiol. 170(11):1422-32, 2009 Dec 1.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>27</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Corciu,A.I.</style></author><author><style face="normal" font="default"> Siciliano,V.</style></author><author><style face="normal" font="default"> Poggianti,E.</style></author><author><style face="normal" font="default"> Petersen,C.</style></author><author><style face="normal" font="default"> Venneri,L.</style></author><author><style face="normal" font="default"> Picano,E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Cardiac calcification by transthoracic echocardiography in patients with known or suspected coronary artery disease</style></title><secondary-title><style face="normal" font="default">International Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">International Journal of Cardiology</style></full-title></periodical><pages end="295" start="288">288-295</pages><volume><style face="normal" font="default">142</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Echocardiography/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aorta/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Aortic Valve/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mitral Valve/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Observer Variation</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> ROC Curve</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="23" Month="7" Year="2010">2010/7/23</year></dates><abstract><style face="normal" font="default">OBJECTIVES: To estimate the correlation between the total heart calcification score index (CSI), assessed by echocardiography, left ventricle mass index (LVMI), Framingham risk score (FRS), and angiographically assessed coronary artery disease (CAD). BACKGROUND: Aortic valve and root sclerosis (AVS, ARS) and mitral annular calcium (MAC) detected by echocardiography have been associated with atherosclerosis. FRS is recommended for estimation of total coronary heart disease risk over the course of 10 years. The anatomic extent of CAD can be assessed with coronary angiography. Total and cardiovascular mortality risk increases with increasing LVMI. METHODS: 167 consecutive in-hospital patients (mean age 66.6+/-9.7 yrs, 119 men) underwent: 1) complete transthoracic echocardiography (TTE), with CSI assessment (from 0=normal to 10=diffuse calcification of aortic valve, mitral annulus and aortic root), 2) the FRS evaluation (FRS&lt;or=10=low, FRS>or=11 and &lt;or=20=average risk, and a FRS>or=21=high risk), and 3) coronary angiography (with Duke score evaluation, from 0=normal to 100=severe left main disease). RESULTS: The mean CSI of the entire population was 3.94+/-2.1, with a mean of 2.75+/-2 in patients at low risk, with a progressive increase in patients at average risk (4.11+/-2.2), at high risk (4.7+/-1.7), respectively. CSI was associated with the presence of CAD (p=0.003) and the presence of abnormal LVMI (p=0.002). CONCLUSIONS: Echocardiographically assessed CSI is correlated to FRS, Duke score and LVMI and can provide a simple, radiation-free index of cardiovascular risk. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Scuola Superiore Sant'Anna, Pisa, Italy. ancabistrita@yahoo.comJC - gqw, 8200291CP - NetherlandsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19195722</style></custom1><custom3><style face="normal" font="default">AS - Int J Cardiol. 142(3):288-95, 2010 Jul 23.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>106</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Cornily,J.C.</style></author><author><style face="normal" font="default"> Gilard,M.</style></author><author><style face="normal" font="default"> Bezon,E.</style></author><author><style face="normal" font="default"> Jan,V.</style></author><author><style face="normal" font="default"> Pennec,P.Y.</style></author><author><style face="normal" font="default"> Etienne,Y.</style></author><author><style face="normal" font="default"> Vinsonneau,U.</style></author><author><style face="normal" font="default"> Le,Gal G.</style></author><author><style face="normal" font="default"> Mansourati,J.</style></author><author><style face="normal" font="default"> Blanc,J.J.</style></author><author><style face="normal" font="default"> Boschat,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Cardiac multislice spiral computed tomography as an alternative to coronary angiography in the preoperative assessment of coronary artery disease before aortic valve surgery: a management outcome study</style></title><secondary-title><style face="normal" font="default">Archives of cardiovascular diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Archives of cardiovascular diseases</style></full-title></periodical><pages end="175" start="170">170-175</pages><volume><style face="normal" font="default">103</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aortic Valve Insufficiency/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Aortic Valve Stenosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aortic Valve Insufficiency/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Aortic Valve Stenosis/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Image Processing,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Preoperative Care</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,Spiral Computed</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="3" Year="2010">2010/3</year></dates><isbn><style face="normal" font="default">1875-2136</style></isbn><abstract><style face="normal" font="default">BACKGROUND: Conventional coronary angiography (CA) is still recommended before valvular surgery. Preliminary studies suggest that multislice spiral computed tomography coronary angiography (MSCT-CA) can be used to rule out coronary artery disease (CAD). AIM: To assess prospectively the safety of ruling out CAD before surgery solely on the basis of normal MSCT-CA in patients with severe aortic valve disease. METHODS: We included all consecutive patients scheduled for aortic valve surgery. We first estimated the calcium score (Agatston score equivalent [ASE]). Patients underwent injected MSCT if the ASE was&lt;1000. CA was cancelled when MSCT-CA quality was sufficient and showed no significant CAD. Our primary endpoint was the occurrence of perioperative myocardial infarction in patients who underwent surgery with no prior CA. RESULTS: Between 1st July 2005 and 30th June 2008, we included 199 patients with severe aortic valve disease: 118 men (59%); mean age 69+/-12 years; 63 patients (32%) underwent CA directly because the ASE was > or =1000. Of 136 patients who underwent MSCT-CA, 106 (78%) had a normal MSCT-CA and underwent aortic valve surgery without prior CA; CA was performed in 30 patients because of abnormal (n=18) or bad quality (n=12) MSCT-CA. One patient of the 106 (0.94%, 95% confidence interval 0.17-5.15) had a perioperative myocardial infarction. CONCLUSIONS: When the ASE is &lt;1000, MSCT is safe and may be recommended instead of CA as a first-line means of ruling out CAD in patients with severe aortic valve disease</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, La Cavale-Blanche Hospital, Brest University Hospital, Brest cedex, France. jean-christophe.cornily@chu-brest.frJC - 101465655CP - NetherlandsPT - Comparative StudyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20417448</style></custom1><custom3><style face="normal" font="default">AS - Arch Cardiovasc Dis. 103(3):170-5, 2010 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>549</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Costa,J.R.,Jr.</style></author><author><style face="normal" font="default"> Abizaid,A.</style></author><author><style face="normal" font="default"> Costa,R.</style></author><author><style face="normal" font="default"> Feres,F.</style></author><author><style face="normal" font="default"> Tanajura,L.F.</style></author><author><style face="normal" font="default"> Abizaid,A.</style></author><author><style face="normal" font="default"> Mattos,L.A.</style></author><author><style face="normal" font="default"> Staico,R.</style></author><author><style face="normal" font="default"> Siqueira,D.</style></author><author><style face="normal" font="default"> Sousa,A.G.</style></author><author><style face="normal" font="default"> Bonan,R.</style></author><author><style face="normal" font="default"> Sousa,J.E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system</style></title><secondary-title><style face="normal" font="default">Jacc: Cardiovascular Interventions</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Jacc: Cardiovascular Interventions</style></full-title></periodical><pages end="551" start="545">545-551</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Angioplasty,Transluminal,Percutaneous Coronary/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Agents/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> *Drug-Eluting Stents</style></keyword><keyword><style face="normal" font="default"> *Durapatite</style></keyword><keyword><style face="normal" font="default"> *Sirolimus/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> 0 (Cardiovascular Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Platelet Aggregation Inhibitors)</style></keyword><keyword><style face="normal" font="default"> 12597-68-1 (Stainless Steel)</style></keyword><keyword><style face="normal" font="default"> 1306-06-5 (Durapatite)</style></keyword><keyword><style face="normal" font="default"> 50-78-2 (Aspirin)</style></keyword><keyword><style face="normal" font="default"> 53123-88-9 (Sirolimus)</style></keyword><keyword><style face="normal" font="default"> 55142-85-3 (Ticlopidine)</style></keyword><keyword><style face="normal" font="default"> 90055-48-4 (clopidogrel)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Angioplasty,Transluminal,Percutaneous Coronary/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> Aspirin/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Coronary Restenosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Restenosis/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Coronary Thrombosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Thrombosis/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Pilot Projects</style></keyword><keyword><style face="normal" font="default"> Platelet Aggregation Inhibitors/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Polymers</style></keyword><keyword><style face="normal" font="default"> Prosthesis Design</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Stainless Steel</style></keyword><keyword><style face="normal" font="default"> Stents</style></keyword><keyword><style face="normal" font="default"> Ticlopidine/aa [Analogs &amp; Derivatives]</style></keyword><keyword><style face="normal" font="default"> Ticlopidine/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Ultrasonography,Interventional</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="10" Year="2008">2008/10</year></dates><abstract><style face="normal" font="default">OBJECTIVES: We sought to investigate the performance and efficacy of the third-generation polymer-free Vestasync-eluting stent (VES). BACKGROUND: Recent concerns regarding the long-term safety of drug-eluting stents have been raised. Synthetic polymers have been associated with intensive inflammatory response and late stent thrombosis. Newly developed, the VES combines a stainless steel platform with a nanothin-microporous hydroxyapatite surface coating impregnated with a polymer-free sirolimus formulation (55 mum). METHODS: In May 2007, 15 patients with single de novo lesion located in native coronary arteries 3.0 to 3.5 mm in diameter and &lt; or =14 mm in length were consecutively enrolled. Primary end points included in-stent late lumen loss and in-stent percent of obstruction at 4 months. Serial angiography and intravascular ultrasound were obtained at the index procedure and repeated at 4-month follow-up. RESULTS: Mean population age was 63.8 years; 33% of patients were diabetic. The left anterior descending artery was the prevalent target vessel (47%). Reference vessel diameter and lesion length were 2.67 +/- 0.32 mm and 9.98 +/- 1.98 mm, respectively. The VES was successfully implanted in all cases, and there were no procedure and in-hospital complications. Life-long aspirin and 6-month clopidogrel therapy were prescribed for all patients. At 4 months, in-stent late lumen loss was 0.30 +/- 0.25 mm and percent of stent obstruction was 2.8 +/- 2.2%. After up to 6 months of clinical follow-up, no major adverse cardiac event was registered. CONCLUSIONS: The third-generation VES demonstrated excellent acute results in the treatment of de novo coronary lesions. Longer follow-up with a more complex subset of patients and lesions is required to confirm these preliminary results</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Instituto Dante Pazzanese de Cardiologia, S&amp;#x00E3;o Paulo, BrazilJC - 101467004CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19463357</style></custom1><custom3><style face="normal" font="default">AS - JACC Cardiovasc Interv. 1(5):545-51, 2008 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>46</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Costa,J.R.,Jr.</style></author><author><style face="normal" font="default"> Abizaid,A.</style></author><author><style face="normal" font="default"> Costa,R.</style></author><author><style face="normal" font="default"> Feres,F.</style></author><author><style face="normal" font="default"> Tanajura,L.F.</style></author><author><style face="normal" font="default"> Abizaid,A.</style></author><author><style face="normal" font="default"> Maldonado,G.</style></author><author><style face="normal" font="default"> Staico,R.</style></author><author><style face="normal" font="default"> Siqueira,D.</style></author><author><style face="normal" font="default"> Sousa,A.G.</style></author><author><style face="normal" font="default"> Bonan,R.</style></author><author><style face="normal" font="default"> Sousa,J.E.</style></author></authors></contributors><titles><title><style face="normal" font="default">1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial</style></title><secondary-title><style face="normal" font="default">Jacc: Cardiovascular Interventions</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Jacc: Cardiovascular Interventions</style></full-title></periodical><pages end="427" start="422">422-427</pages><volume><style face="normal" font="default">2</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Angioplasty,Transluminal,Percutaneous Coronary</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Drug-Eluting Stents</style></keyword><keyword><style face="normal" font="default"> *Sirolimus/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> 0 (Platelet Aggregation Inhibitors)</style></keyword><keyword><style face="normal" font="default"> 0 (Polymers)</style></keyword><keyword><style face="normal" font="default"> 1306-06-5 (Durapatite)</style></keyword><keyword><style face="normal" font="default"> 50-78-2 (Aspirin)</style></keyword><keyword><style face="normal" font="default"> 53123-88-9 (Sirolimus)</style></keyword><keyword><style face="normal" font="default"> 55142-85-3 (Ticlopidine)</style></keyword><keyword><style face="normal" font="default"> 90055-48-4 (clopidogrel)</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Bypass</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Coronary Restenosis</style></keyword><keyword><style face="normal" font="default"> Durapatite</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Intensive Care Units</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Platelet Aggregation Inhibitors/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Polymers</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sirolimus/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Stents</style></keyword><keyword><style face="normal" font="default"> Ticlopidine/aa [Analogs &amp; Derivatives]</style></keyword><keyword><style face="normal" font="default"> Ticlopidine/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword></keywords><dates><year Day="0" Month="5" Year="2009">2009/5</year></dates><abstract><style face="normal" font="default">OBJECTIVES: We sought to assess the safety and efficacy of the novel VESTAsync-eluting stent (MIV Therapeutics, Atlanta, Georgia) combining a stainless steel platform with a nanothin-microporous hydroxyapatite surface coating impregnated with a polymer-free low-dose of sirolimus (55 microg). BACKGROUND: Durable polymers in first-generation drug-eluting stents (DES) have been linked to local inflammatory reaction leading to a positive vessel remodeling, late incomplete stent apposition, and in some cases, stent thrombosis. The removal of the polymer from the DES system could increase the safety profile of this novel technology. METHODS: A total of 15 patients with single de novo lesions in native coronary arteries with 3.0- to 3.5-mm diameter and &lt;or=14-mm length were enrolled in this first-in-man study. Primary end point was in-stent late lumen loss (LL) at 4 and 9 months. RESULTS: Baseline characteristics included mean age of 63 years and 33% of diabetics. Reference vessel diameter and lesion length were 2.7 +/- 0.3 mm and 10 +/- 2.0 mm, respectively. Procedure success was obtained in all cases. Lifelong aspirin and 5-month clopidogrel treatment were prescribed to all patients. At 4 months, in-stent LL and percentage of neointimal hyperplasia were 0.3 +/- 0.25 mm and 2.6 +/- 2.2%, respectively, with a nonsignificant increase at 9 months (0.36 +/- 0.23 mm and 4.0 +/- 2.2%, respectively). Serial intravascular ultrasound did not show late incomplete stent apposition. There were no major adverse cardiac events within 1 year of follow-up. CONCLUSIONS: The novel VESTAsync-eluting stent was effective in reducing LL and neointimal hyperplasia at 4 and 9 months, with no evidence of late catch-up by quantitative coronary angiography or intravascular ultrasound</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Instituto Dante Pazzanese de Cardiologia, Sao Paulo, BrazilJC - 101467004CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19463465</style></custom1><custom3><style face="normal" font="default">AS - JACC Cardiovasc Interv. 2(5):422-7, 2009 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>204</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Cottone,S.</style></author><author><style face="normal" font="default"> Palermo,A.</style></author><author><style face="normal" font="default"> Arsena,R.</style></author><author><style face="normal" font="default"> Riccobene,R.</style></author><author><style face="normal" font="default"> Guarneri,M.</style></author><author><style face="normal" font="default"> Mul&amp;#x00E8</style></author><author><style face="normal" font="default"> G</style></author><author><style face="normal" font="default"> Tornese,F.</style></author><author><style face="normal" font="default"> Altieri,C.</style></author><author><style face="normal" font="default"> Vaccaro,F.</style></author><author><style face="normal" font="default"> Previti,A.</style></author><author><style face="normal" font="default"> Cerasola,G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Relationship of fetuin-A with glomerular filtration rate and endothelial dysfunction in moderate-severe chronic kidney disease</style></title><secondary-title><style face="normal" font="default">Journal of Nephrology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Nephrology</style></full-title></periodical><pages end="69" start="62">62-69</pages><volume><style face="normal" font="default">23</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Blood Proteins/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Endothelium,Vascular/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Glomerular Filtration Rate/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Kidney Diseases/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> 0 (alpha2HS glycoprotein)</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Blood Proteins)</style></keyword><keyword><style face="normal" font="default"> 0 (Endothelin-1)</style></keyword><keyword><style face="normal" font="default"> 0 (Interleukin-6)</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Endothelin-1/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Interleukin-6/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Kidney Diseases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="1" Year="2010">2010/1</year></dates><isbn><style face="normal" font="default">1121-8428</style></isbn><abstract><style face="normal" font="default">BACKGROUND: In end-stage renal disease, fetuin-A has been demonstrated to be reduced and inversely related to cardiovascular mortality. This study had 2 distinct aims. The first was to verify if circulating concentration of fetuin-A may depend on renal function in patients with chronic kidney disease (CKD). Furthermore, we analyzed the correlation of fetuin-A with the biomarker of endothelial dysfunction endothelin-1 (ET-1), and with the inflammatory cytokine interleukin-6 (IL-6). METHODS: In 108 subjects with stage 3-5 CKD, plasma levels of fetuin-A, ET-1 and IL-6 were assayed. Patients were studied first as a whole group and then were divided according to stages of CKD and fetuin-A tertiles. RESULTS: Fetuin-A concentration decreased in parallel with the increase in ET-1 and IL-6 levels as renal function declined. Multiple regression analysis showed that fetuin-A was independently associated with estimated glomerular filtration rate (beta=0.386; p&lt;0.001), IL-6 (beta=-0.393; p=0.001) and ET-1 (beta=-0.219; p=0.02), in a multivariate model including also sex, parathyroid hormone and the calcium x phosphorus product. CONCLUSIONS: These results seem to indicate that in CKD, even when not severe, inflammatory processes are increased and linked to endothelial dysfunction, worsening progressively with the decline of renal function</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Internal Medicine, University of Palermo, Palermo, Italy. sancott@tin.itJC - 9012268CP - ItalyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20091488</style></custom1><custom3><style face="normal" font="default">AS - JN, J. nephrol.. 23(1):62-9, 2010 Jan-Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>10</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Criqui,M.H.</style></author><author><style face="normal" font="default"> McClelland,R.L.</style></author><author><style face="normal" font="default"> McDermott,M.M.</style></author><author><style face="normal" font="default"> Allison,M.A.</style></author><author><style face="normal" font="default"> Blumenthal,R.S.</style></author><author><style face="normal" font="default"> Aboyans,V.</style></author><author><style face="normal" font="default"> Ix,J.H.</style></author><author><style face="normal" font="default"> Burke,G.L.</style></author><author><style face="normal" font="default"> Liu,K.</style></author><author><style face="normal" font="default"> Shea,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">The ankle-brachial index and incident cardiovascular events in the MESA (Multi-Ethnic Study of Atherosclerosis)</style></title><secondary-title><style face="normal" font="default">Journal of the American College of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of the American College of Cardiology</style></full-title></periodical><pages end="1512" start="1506">1506-1512</pages><volume><style face="normal" font="default">56</style></volume><number><style face="normal" font="default">18</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*African Americans/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> *Ankle Brachial Index</style></keyword><keyword><style face="normal" font="default"> *Asian Americans/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> *Atherosclerosis/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> *European Continental Ancestry Group/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> *Hispanic Americans/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Ankle Brachial Index/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Cross-Cultural Comparison</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Population Surveillance/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Stroke/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Stroke/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Stroke/pp [Physiopathology]</style></keyword></keywords><dates><year Day="26" Month="10" Year="2010">2010/10/26</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The purpose of this study was to examine the association of both a low and a high ankle-brachial index (ABI) with incident cardiovascular events in a multiethnic cohort. BACKGROUND: Abnormal ABIs, both low and high, are associated with elevated cardiovascular disease (CVD) risk. However, it is unknown whether this association is consistent across different ethnic groups, and whether it is independent of both newer biomarkers and other measures of subclinical atherosclerotic CVD. METHODS: A total of 6,647 non-Hispanic white, African-American, Hispanic, and Chinese men and women age 45 to 84 years from free-living populations in 6 U.S. field centers and free of clinical CVD at baseline had extensive measures of traditional and newer biomarker risk factors, and measures of subclinical CVD, including the ABI. Incident CVD, defined as coronary disease, stroke, or other atherosclerotic CVD death, was determined over a mean follow-up of 5.3 years. RESULTS: Both a low (&lt;1.00) and a high (>=1.40) ABI were associated with incident CVD events. Sex- and ethnic-specific analyses showed consistent results. Hazard ratios were 1.77 (p&lt;0.001) for a low and 1.85 (p=0.050) for a high ABI after adjustment for both traditional and newer biomarker CVD risk factors, and the ABI significantly improved risk discrimination. Further adjustment for coronary artery calcium score, common and internal carotid intimal medial thickness, and major electrocardiographic abnormalities only modestly attenuated these hazard ratios. CONCLUSIONS: In this study, both a low and a high ABI were associated with elevated CVD risk in persons free of known CVD, independent of standard and novel risk factors, and independent of other measures of subclinical CVD. Further research should address the cost effectiveness of measuring the ABI in targeted population groups. Copyright [copyright sign] 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Family &amp; Preventive Medicine, University of California, San Diego, La Jolla, California 92093-0607, USA. mcriqui@ucsd.eduJC - h50, 8301365CP - United StatesPT - Comparative StudyPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - N01-HC-95159 (United States NHLBI NIH HHS)NO - N01-HC-95169 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20951328</style></custom1><custom3><style face="normal" font="default">AS - J Am Coll Cardiol. 56(18):1506-12, 2010 Oct 26.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>358</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Curillova,Z.</style></author><author><style face="normal" font="default"> Yaman,B.F.</style></author><author><style face="normal" font="default"> Dorbala,S.</style></author><author><style face="normal" font="default"> Kwong,R.Y.</style></author><author><style face="normal" font="default"> Sitek,A.</style></author><author><style face="normal" font="default"> El,Fakhri G.</style></author><author><style face="normal" font="default"> Anagnostopoulos,C.</style></author><author><style face="normal" font="default"> Di Carli,M.F.</style></author></authors></contributors><titles><title><style face="normal" font="default">Quantitative relationship between coronary calcium content and coronary flow reserve as assessed by integrated PET/CT imaging</style></title><secondary-title><style face="normal" font="default">European Journal of Nuclear Medicine &amp; Molecular Imaging</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">European Journal of Nuclear Medicine &amp; Molecular Imaging</style></full-title></periodical><pages end="1610" start="1603">1603-1610</pages><volume><style face="normal" font="default">36</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> *Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> *Positron-Emission Tomography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> 0 (Rubidium Radioisotopes)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Calcinosis/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Coronary Circulation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardial Perfusion Imaging/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Perfusion</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Rubidium Radioisotopes/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Vascular Resistance</style></keyword><keyword><style face="normal" font="default"> Vasodilation</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><abstract><style face="normal" font="default">PURPOSE: To evaluate the relationship between coronary artery calcium (CAC) and coronary vasodilator function. METHODS: We evaluated 136 patients without known coronary artery disease (CAD) undergoing vasodilator stress (82)Rb PET/CT and CAC scoring who showed normal myocardial perfusion. The CAC score, resting and hyperemic myocardial blood flow (MBF), coronary flow reserve (CFR) and coronary vascular resistance were analyzed. RESULTS: Global and regional CAC scores showed significant but weak inverse correlations with hyperemic MBF (r=-0.31 and r=-0.26, p&lt; or =0.0002 respectively) and CFR (r=-0.28 and r=-0.2, p&lt; or =0.001 respectively). With increasing CAC score, there was a modest stepwise decline in CFR on a per-patient basis (1.8+/-0.5 vs 1.7+/-0.5 vs 1.5+/-0.4, p=0.048, with total CAC=0, 1-400 and >400, respectively) and on a per-vessel basis. In multivariable modeling only body mass index and CAC score were predictive of CFR. CONCLUSION: In patients with an intermediate likelihood of, but without overt, CAD, there is a statistically significant but weak inverse correlation between CAC content and coronary vasodilator function. The strength of this association weakens after adjusting CAC scores for age, gender and coronary risk factors. This suggests that CAC and coronary vasodilator function provide biologically different information regarding atherosclerosis</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham &amp; Women's Hospital, Boston, MA, USAJC - 101140988CP - GermanyPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - R01 EB005876 (United States NIBIB NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19387640</style></custom1><custom3><style face="normal" font="default">AS - Eur J Nucl Med Mol Imaging. 36(10):1603-10, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>302</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Dabek,J.</style></author><author><style face="normal" font="default"> Swiderski,R.</style></author><author><style face="normal" font="default"> Glogowska-Ligus,J.</style></author><author><style face="normal" font="default"> Kulach,A.</style></author><author><style face="normal" font="default"> Gasior,Z.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Expression of genes connected with nuclear factor kappa B (NFkappaB) estimated by oligonucleotide microarray analysis HG-U133A in patients with acute myocardial infarction]. [Polish]</style></title><secondary-title><style face="normal" font="default">Polski Merkuriusz Lekarski</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Polski Merkuriusz Lekarski</style></full-title></periodical><pages end="272" start="265">265-272</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">160</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*CCAAT-Enhancer-Binding Protein-delta/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Myocardial Infarction/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> 0 (Carrier Proteins)</style></keyword><keyword><style face="normal" font="default"> 0 (CEBPD protein,human)</style></keyword><keyword><style face="normal" font="default"> 0 (IKBKAP protein,human)</style></keyword><keyword><style face="normal" font="default"> 0 (Oligonucleotide Probes)</style></keyword><keyword><style face="normal" font="default"> 0 (Receptors,Tumor Necrosis Factor,Type I)</style></keyword><keyword><style face="normal" font="default"> 0 (TLR2 protein,human)</style></keyword><keyword><style face="normal" font="default"> 0 (TNFRSF1A protein,human)</style></keyword><keyword><style face="normal" font="default"> 0 (Toll-Like Receptor 2)</style></keyword><keyword><style face="normal" font="default"> 142662-43-9 (CCAAT-Enhancer-Binding Protein-delta)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Carrier Proteins/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Oligonucleotide Probes</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Protein Array Analysis</style></keyword><keyword><style face="normal" font="default"> Receptors,Tumor Necrosis Factor,Type I/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Toll-Like Receptor 2/ge [Genetics]</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><isbn><style face="normal" font="default">1426-9686</style></isbn><abstract><style face="normal" font="default">Atherosclerosis is a permanently progressive chronic inflammatory disorder which nuclear factor kappaKB (NFkappaB) is involved. Therefore NFkappaB has become integral aspect of atherogenesis and its complications. THE AIM OF THE STUDY: Estimation of genes expression involved in NFkappaB signaling pathway and separation genes differentiate patients with acute myocardial infarction from healthy subjects. MATERIAL AND METHODS: The examination was assess using the Affymetrix HG-U133A oligonucleotide microarray. Differentiating genes were determined using Bland-Altman graph analysis. Patients wasn't treated due to cardiac diseases before. All patients were subjected to 12-lead ECG, 2-D echocardiography, coronarography and laboratory studies including cardiac troponin, CK and CK-MB. The healthy individuals were subjected to coronarography and computed tomography (calcium score)--coronary artery disease was out of the question. RESULTS: Hierarchical clusterization has demonstrated that the genes expression of patients with acute myocardial infarction was different from healthy individuals. It also demonstrated that the individual groups are homogeneous, especially the group of patients with acute myocardial infarction, regardless of diagnosis, number of risk factors and progression of coronary artery disease. Further Bland-Altman graph analysis showed three important differentiating genes: TLR2, TNFRSF1A i IKBKAP. CONCLUSIONS: Our results confirmed the share of genes involved in NFkappaB signaling pathway in acute complications of atherosclerosis. Noticed differences in genes expression of patients with acute myocardial infarction and healthy subjects can show important role isolated differentiating genes in destabilization of atherogenic plaque and acute myocardial infarction occurrence</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Slaski Uniwersytet Medyczny w Katowicach, Katedra i Klinika Kardiologii. jdabek@sum.edu.plOT - Ekspresja gen&amp;#x00F3;w zwiazanych z czynnikiem jadrowym kappa B (NFkappaB) oceniana technika mikromacierzy oligonukleotydowych HG-U133A u chorych z ostrym zawaltem sercaJC - 9705469CP - PolandPT - English AbstractPT - Journal ArticleLG - Polish</style></notes><urls/><custom1><style face="normal" font="default">UI - 19928652</style></custom1><custom3><style face="normal" font="default">AS - Pol Merkuriusz Lek. 27(160):265-72, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>37</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Dalton,B.R.</style></author><author><style face="normal" font="default"> Zuege,D.J.</style></author><author><style face="normal" font="default"> Shahpori,R.</style></author><author><style face="normal" font="default"> Laupland,K.B.</style></author></authors></contributors><titles><title><style face="normal" font="default">Concomitant ceftriaxone and high-concentration intravenous calcium therapy in adult critical care patients: a matched cohort study</style></title><secondary-title><style face="normal" font="default">Annals of Pharmacotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Annals of Pharmacotherapy</style></full-title></periodical><pages end="1163" start="1158">1158-1163</pages><volume><style face="normal" font="default">44</style></volume><number><style face="normal" font="default">7-8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Anti-Bacterial Agents/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Calcium Chloride/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Ceftriaxone/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Respiratory Insufficiency/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> 0 (Anti-Bacterial Agents)</style></keyword><keyword><style face="normal" font="default"> 10043-52-4 (Calcium Chloride)</style></keyword><keyword><style face="normal" font="default"> 73384-59-5 (Ceftriaxone)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Alberta</style></keyword><keyword><style face="normal" font="default"> Anti-Bacterial Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Calcium Chloride/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Calcium Chloride/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Ceftriaxone/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Critical Illness</style></keyword><keyword><style face="normal" font="default"> Drug Interactions</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hospital Mortality</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> Infusions,Intravenous</style></keyword><keyword><style face="normal" font="default"> Intensive Care</style></keyword><keyword><style face="normal" font="default"> Length of Stay</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword></keywords><dates><year Day="0" Month="7" Year="2010">2010/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Based on case reports in infants, the safety of concomitant use of ceftriaxone and intravenous calcium in all ages has recently come under challenge. Systematic population-based data to guide clinicians with respect to this risk are, however, lacking. OBJECTIVE: To determine whether concomitant administration of ceftriaxone and intravenous calcium was associated with the occurrence of severe cardiorespiratory events or death in critically ill adults. METHODS: We performed a matched-cohort study from retrospective data of adults admitted to intensive care units (ICUs) in Calgary, Canada, who were provided continuous high-dose intravenous calcium. Those who received ceftriaxone while on continuous renal replacement therapy were considered exposed. Up to 3 unexposed patients were selected by matching on a number of prognostic factors from the remaining subjects not concurrently exposed to ceftriaxone and calcium. Univariate methods and multivariate conditional logistic regression were used for statistical analysis. RESULTS: We identified 142 patients exposed to the implicated combination who could be matched to at least one unexposed patient. Hospital mortality was 66% in the exposed versus 63% in unexposed patients (p = 0.442). ICU length of stay, ICU mortality, hospital length of stay, and the frequency of acute oxygenation events were all similar by univariate analysis. Multivariate conditional logistic regression modeling failed to find a significant association between exposure and hospital mortality (adjusted OR 1.15, 95% CI 0.65 to 2.04) or other relevant outcomes. CONCLUSIONS: In this high-risk group, administration of high concentrations of calcium and concurrent ceftriaxone was not significantly associated with greater mortality or adverse outcomes compared to matched unexposed patients. Although this was an underpowered study and rare adverse effects from the interaction of these 2 compounds cannot be completely excluded, these data provide overall reassurance of the safety of this combination in the majority of critically ill adults</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Pharmacy Services, Foothills Medical Centre, Alberta Health Services, Calgary, Alberta, Canada. bruce.dalton@albertahealthservices.caJC - bbx, 9203131CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20530706</style></custom1><custom3><style face="normal" font="default">AS - Ann Pharmacother. 44(7-8):1158-63, 2010 Jul-Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>59</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Davidson,M.H.</style></author><author><style face="normal" font="default"> Beam,C.A.</style></author><author><style face="normal" font="default"> Haffner,S.</style></author><author><style face="normal" font="default"> Perez,A.</style></author><author><style face="normal" font="default"> D'Agostino,R.,Sr.</style></author><author><style face="normal" font="default"> Mazzone,T.</style></author></authors></contributors><titles><title><style face="normal" font="default">Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study</style></title><secondary-title><style face="normal" font="default">Arteriosclerosis, Thrombosis &amp; Vascular Biology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Arteriosclerosis, Thrombosis &amp; Vascular Biology</style></full-title></periodical><pages end="1876" start="1873">1873-1876</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 2/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Hypoglycemic Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Sulfonylurea Compounds/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Thiazolidinediones/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> 0 (Hypoglycemic Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Sulfonylurea Compounds)</style></keyword><keyword><style face="normal" font="default"> 0 (Thiazolidinediones)</style></keyword><keyword><style face="normal" font="default"> 111025-46-8 (pioglitazone)</style></keyword><keyword><style face="normal" font="default"> 93479-97-1 (glimepiride)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcinosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Carotid Artery Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Carotid Artery Diseases/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Carotid Artery Diseases/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Chi-Square Distribution</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus,Type 2/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="9" Year="2010">2010/9</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To compare coronary artery calcium (CAC) progression between 2 treatment groups, pioglitazone versus glimepiride. METHODS AND RESULTS: The CHICAGO (Carotid Intima-Media Thickness in Atherosclerosis Using Pioglitazone) study demonstrated that pioglitazone significantly decreased carotid intima-media thickness progression compared with glimepiride in patients with type 2 diabetes mellitus. The CAC level was determined at baseline and at the end of 72 weeks of treatment in the pioglitazone (n=146) and glimepiride (n=153) treatment groups using electron beam computed tomography. There was no difference in CAC progression between the treatment groups. By using backward and forward selection models, age, race/ethnicity, and baseline apolipoprotein B level predicted CAC progression. There was no relationship between carotid intima-media thickness and CAC progression during the study. CONCLUSIONS: There was no difference in CAC progression in patients with type 2 diabetes mellitus treated with pioglitazone or glimepiride. Age, race/ethnicity, and baseline apolipoprotein B level predicted CAC progression in patients with type 2 diabetes mellitus</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, Division of Cardiology, Pritzker School of Medicine, The University of Chicago, 515 N State St, Ste 2700, Chicago, IL 60654, USA. mdavidson@radiantresearch.comJC - 9505803, B89CP - United StatesPT - Comparative StudyPT - Journal ArticlePT - Randomized Controlled TrialPT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - UL1RR029879 (United States NCRR NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20576945</style></custom1><custom3><style face="normal" font="default">AS - Arterioscler Thromb Vasc Biol. 30(9):1873-6, 2010 Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>445</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Davis,W.</style></author><author><style face="normal" font="default"> Rockway,S.</style></author><author><style face="normal" font="default"> Kwasny,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Effect of a combined therapeutic approach of intensive lipid management, omega-3 fatty acid supplementation, and increased serum 25 (OH) vitamin D on coronary calcium scores in asymptomatic adults</style></title><secondary-title><style face="normal" font="default">American Journal of Therapeutics</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Therapeutics</style></full-title></periodical><pages end="332" start="326">326-332</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Cholecalciferol/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Fatty Acids,Omega-3/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Lipids/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Vitamin D/aa [Analogs &amp; Derivatives]</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol,HDL)</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol,LDL)</style></keyword><keyword><style face="normal" font="default"> 0 (Fatty Acids,Omega-3)</style></keyword><keyword><style face="normal" font="default"> 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipids)</style></keyword><keyword><style face="normal" font="default"> 0 (Triglycerides)</style></keyword><keyword><style face="normal" font="default"> 1406-16-2 (Vitamin D)</style></keyword><keyword><style face="normal" font="default"> 59-67-6 (Niacin)</style></keyword><keyword><style face="normal" font="default"> 64719-49-9 (25-hydroxyvitamin D)</style></keyword><keyword><style face="normal" font="default"> 67-97-0 (Cholecalciferol)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cholecalciferol/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Cholesterol,HDL/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cholesterol,LDL/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Drug Therapy,Combination</style></keyword><keyword><style face="normal" font="default"> Fatty Acids,Omega-3/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hydroxymethylglutaryl-CoA Reductase Inhibitors/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Niacin/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Niacin/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Triglycerides/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Vitamin D/bl [Blood]</style></keyword></keywords><dates><year Day="0" Month="7" Year="2009">2009/7</year></dates><abstract><style face="normal" font="default">The impact of intensive lipid management, omega-3 fatty acid, and vitamin D3 supplementation on atherosclerotic plaque was assessed through serial computed tomography coronary calcium scoring (CCS). Low-density lipoprotein cholesterol reduction with statin therapy has not been shown to reduce or slow progression of serial CCS in several recent studies, casting doubt on the usefulness of this approach for tracking atherosclerotic progression. In an open-label study, 45 male and female subjects with CCS of > or = 50 without symptoms of heart disease were treated with statin therapy, niacin, and omega-3 fatty acid supplementation to achieve low-density lipoprotein cholesterol and triglycerides &lt; or = 60 mg/dL; high-density lipoprotein > or = 60 mg/dL; and vitamin D3 supplementation to achieve serum levels of > or = 50 ng/mL 25(OH) vitamin D, in addition to diet advice. Lipid profiles of subjects were significantly changed as follows: total cholesterol -24%, low-density lipoprotein -41%; triglycerides -42%, high-density lipoprotein +19%, and mean serum 25(OH) vitamin D levels +83%. After a mean of 18 months, 20 subjects experienced decrease in CCS with mean change of -14.5% (range 0% to -64%); 22 subjects experienced no change or slow annual rate of CCS increase of +12% (range 1%-29%). Only 3 subjects experienced annual CCS progression exceeding 29% (44%-71%). Despite wide variation in response, substantial reduction of CCS was achieved in 44% of subjects and slowed plaque growth in 49% of the subjects applying a broad treatment program</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Milwaukee Heart Scan, Milwaukee, WI, USA. heartprotection@aol.comJC - db7, 9441347CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19092644</style></custom1><custom3><style face="normal" font="default">AS - Am J Ther. 16(4):326-32, 2009 Jul-Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>264</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Davy,J.M.</style></author><author><style face="normal" font="default"> Cransac,F.</style></author><author><style face="normal" font="default"> Roubille,F.</style></author><author><style face="normal" font="default"> Cung,T.T.</style></author><author><style face="normal" font="default"> Raczka,F.</style></author><author><style face="normal" font="default"> Pasquie,J.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Cardiac conduction disorders in the elderly]. [French]</style></title><secondary-title><style face="normal" font="default">Revue du Praticien</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Revue du Praticien</style></full-title></periodical><pages end="1403" start="1396">1396-1403</pages><volume><style face="normal" font="default">59</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Heart Block/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Heart Conduction System/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Bradycardia/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Bradycardia/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Electrocardiogram Pattern</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Heart Block/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Heart Block/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Pacemaker,Artificial</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword></keywords><dates><year Day="20" Month="12" Year="2009">2009/12/20</year></dates><isbn><style face="normal" font="default">0035-2640</style></isbn><abstract><style face="normal" font="default">While the left bundle branch block frequently reflects underlying cardiac disease, conductive disorders occurring at three levels (sinus node, atrioventricular node, and branches of the bundle of His), are usually part of the aging heart. In addition, AV nodal block and sinus node dysfunction are readily compounded with drugs, often indispensable (beta-blockers, calcium-blockers, digoxin, antiarrhythmic), and very common among the elderly. Indications for permanent pacing are accurately described and come in four classes: I, recommended (mandatory) - IIa, raisonable - IIb, possible - III, contraindicated. In 2009, 24H ECG Holter and electrophysiological study are generally disappointing in the positive diagnosis of syncope, so the clinical characteristics of syncope are essential in the decision of device implantation. Indeed, in the absence of ECG recorded at the time of the syncope, the diagnosis of BAV or BSA cannot be certain, and on the contrary, vague symptoms should not be attributed to a patent bradycardia of sinus or AV block origin without any precaution. Finally, the relationship between sinus dysfunction and carotid sinus syndrome remain poorly understood, dysautonomia is common among the elderly, and the existence of conduction disorders associated with syndrome of sleep apnea should not be ignored</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - D&amp;#x00E9;partement de cardiologie, CHU de Montpellier, h&amp;#x00F4;pital Arnaud-de-Villeneuve, Montpellier, France. jm-davy@chu-montpellier.frOT - Troubles conductifs cardiaques chez le sujet &amp;#x00E2;g&amp;#x00E9;JC - t1d, 0404334CP - FrancePT - English AbstractPT - Journal ArticleLG - French</style></notes><urls/><custom1><style face="normal" font="default">UI - 20058760</style></custom1><custom3><style face="normal" font="default">AS - Rev Prat. 59(10):1396-403, 2009 Dec 20.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>503</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">de Lemos,J.A.</style></author><author><style face="normal" font="default"> McGuire,D.K.</style></author><author><style face="normal" font="default"> Khera,A.</style></author><author><style face="normal" font="default"> Das,S.R.</style></author><author><style face="normal" font="default"> Murphy,S.A.</style></author><author><style face="normal" font="default"> Omland,T.</style></author><author><style face="normal" font="default"> Drazner,M.H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study</style></title><secondary-title><style face="normal" font="default">American Heart Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Heart Journal</style></full-title></periodical><pages end="753" start="746">746-753</pages><volume><style face="normal" font="default">157</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Hypertrophy,Left Ventricular/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Mass Screening/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Myocardial Contraction/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Natriuretic Peptides/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Ventricular Dysfunction,Left/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> 0 (Natriuretic Peptides)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertrophy,Left Ventricular/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Hypertrophy,Left Ventricular/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Systole</style></keyword><keyword><style face="normal" font="default"> Texas</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Ventricular Dysfunction,Left/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Ventricular Dysfunction,Left/bl [Blood]</style></keyword></keywords><dates><year Day="0" Month="4" Year="2009">2009/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Identification of individuals in the community with left ventricular systolic dysfunction (LVSD) or left ventricular hypertrophy (LVH) may allow earlier initiation of disease-modifying treatment. We performed a comprehensive evaluation of the screening performance of B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) for LVSD or LVH. METHODS: In 2,429 subjects without a history of heart failure, myocardial infarction, valvular abnormalities, or a serum creatinine >2.0 mg/dL enrolled in the Dallas Heart Study, measurement of BNP and NT-proBNP and cardiovascular magnetic resonance imaging were performed. RESULTS: B-type natriuretic peptide and NT-proBNP were robustly associated with magnetic resonance imaging-defined LVH and LVSD (ejection fraction &lt;55%) among men and women (P &lt; .0001 for each). In the overall population, neither test discriminated well for LVH or LVSD (area under the receiver operating characteristic curve [AUROC] &lt;0.7). Among women, no differences in AUROC were observed between BNP and NT-proBNP. Among men, AUROCs were similar between BNP and NT-proBNP in the overall population, but among subgroups age 50 or older, or with hypertension, the AUROCs for NT-proBNP (0.73-0.79) were higher than for BNP (0.63-0.69, P &lt; .05 for each comparison). Compared with subjects with isolated BNP elevation (>97.5th percentile), those with isolated NT-proBNP elevation had worse renal function and more LVH and coronary calcium (P &lt; .05 for each). CONCLUSIONS: Overall, neither BNP nor NT-proBNP accurately discriminated subjects with LVH or LVSD in this predominately young and healthy population-based cohort. However, among high-risk men, NT-proBNP performed slightly better than BNP and comparably with other routinely used screening tests such as prostate-specific antigen measurement for prostate cancer</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Donald W. Reynolds Cardiovascular Research Center, UT Southwestern Medical Center, Dallas, TX 75390-9047, USA. james.delemos@utsouthwestern.eduJC - 0370465CP - United StatesPT - Comparative StudyPT - Journal ArticlePT - Multicenter StudyPT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19332205</style></custom1><custom3><style face="normal" font="default">AS - Am Heart J. 157(4):746-53.e2, 2009 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>530</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Delisle,H.F.</style></author><author><style face="normal" font="default"> Vioque,J.</style></author><author><style face="normal" font="default"> Gil,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Dietary patterns and quality in West-African immigrants in Madrid</style></title><secondary-title><style face="normal" font="default">Nutrition Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Nutrition Journal</style></full-title></periodical><pages end="" start="3">3-</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Emigrants and Immigrants</style></keyword><keyword><style face="normal" font="default"> *Food Habits</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Body Weight</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Dairy Products</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Eating</style></keyword><keyword><style face="normal" font="default"> Energy Intake</style></keyword><keyword><style face="normal" font="default"> Equatorial Guinea/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Equatorial Guinea/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fruit</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Meat</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Obesity/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Vegetables</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><abstract><style face="normal" font="default">BACKGROUND: Eating patterns of immigrants deserve to be better documented because they may reflect the extent of acculturation and associated health risks. The study assessed dietary patterns and quality in Bubi immigrants (from Equatorial Guinea) using cluster analysis and comparing different diet quality indexes. METHODS: A random sample of 83 Bubi men and 130 women living in Madrid were studied. A 99-item food frequency questionnaire was administered, body weights and heights were self-reported and socio-demographic and health information was collected during interviews. Usual intakes were collapsed into 19 food groups. Cluster analysis of standardized food intakes per 1000 kcalories was performed. Dietary quality was appraised using the Alternative Mediterranean Diet Score, the Alternative Healthy Eating Index and scores of micronutrient adequacy and prevention based on WHO/FAO recommendations. RESULTS: Two dietary patterns were identified. The 'Healthier' pattern, so confirmed by two dietary quality indexes, featured a higher consumption of fish, fruits, vegetables, legumes, dairy products and bread while the 'Western' pattern included more processed meat, animal fat, and sweetened foods and drinks. One third of the subjects were in the 'Healthier' food cluster, with the same proportion of men and women. Age >or= 30 and residence in Madrid >or= 11 years were independently associated with the healthier diet. Consumption of traditional foods was unrelated to dietary pattern, however. Overall, Bubi diets were somewhat protective because of high intakes of fruits and vegetables and monounsaturated fat (olive oil), but not with respect to sugar, cholesterol, omega-3 fatty acids and fibre. Less than two thirds of subjects had adequate intakes of iron, calcium and folate in both dietary phenotypes. Body mass index, physical exercise, and self-reported health and cardiovascular disease condition showed no significant association with the dietary pattern. CONCLUSION: Cluster analysis combined with dietary quality assessment facilitates the interpretation of dietary patterns, but choosing the appropriate quality indexes is a problem. A small number of such indexes should be standardized and validated for international use. In the group studied, younger subjects and more recent immigrants were more likely to have a 'Western' pattern and should be a priority target for nutrition communication</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - WHO Collaborating Centre on Nutrition Changes and Development, Department of Nutrition, Faculty of Medicine, Universit&amp;#x00E9; de Montr&amp;#x00E9;al, PO Box 6128, Downtown Station, Montreal, Que, H3C 3J7, Canada. helene.delisle@umontreal.caJC - 101152213CP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19166606</style></custom1><custom3><style face="normal" font="default">AS - Nutr J. 8:3, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>24</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Delles,C.</style></author><author><style face="normal" font="default"> Dymott,J.A.</style></author><author><style face="normal" font="default"> Neisius,U.</style></author><author><style face="normal" font="default"> Rocchiccioli,J.P.</style></author><author><style face="normal" font="default"> Bryce,G.J.</style></author><author><style face="normal" font="default"> Moreno,M.U.</style></author><author><style face="normal" font="default"> Carty,D.M.</style></author><author><style face="normal" font="default"> Berg,G.A.</style></author><author><style face="normal" font="default"> Hamilton,C.A.</style></author><author><style face="normal" font="default"> Dominiczak,A.F.</style></author></authors></contributors><titles><title><style face="normal" font="default">Reduced LDL-cholesterol levels in patients with coronary artery disease are paralleled by improved endothelial function: An observational study in patients from 2003 and 2007</style></title><secondary-title><style face="normal" font="default">Atherosclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Atherosclerosis</style></full-title></periodical><pages end="277" start="271">271-277</pages><volume><style face="normal" font="default">211</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cholesterol,LDL/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Endothelium/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Nitric Oxide Synthase Type III/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol,LDL)</style></keyword><keyword><style face="normal" font="default"> 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)</style></keyword><keyword><style face="normal" font="default"> 11062-77-4 (Superoxides)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> EC 1-14-13-39 (Nitric Oxide Synthase Type III)</style></keyword><keyword><style face="normal" font="default"> EC 1-14-13-39 (NOS3 protein,human)</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Superoxides/bl [Blood]</style></keyword></keywords><dates><year Day="0" Month="7" Year="2010">2010/7</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Recent guidelines recommend more aggressive lipid-lowering in secondary prevention protocols. We examined whether this resulted in improved endothelial function. METHODS: We studied saphenous vein specimens of patients undergoing surgical coronary revascularisation in 2007 and compared results with those of patients examined in 2003. Endothelium-dependent vasodilation was assessed by relaxation to calcium ionophore A23187, and vascular superoxide production by lucigenin enhanced chemiluminescence. RESULTS: Statin dose increased from 26+/-16 mg/d in 2003 to 37+/-17 mg/d in 2007 (P&lt;0.001), and total (4.0+/-0.9 mmol/L vs 4.8+/-1.0 mmol/L) and LDL-cholesterol levels (2.0+/-0.7 mmol/L vs 3.0+/-0.9 mmol/L) were lower in 2007 compared to 2003 (P&lt;0.001; n=90 each). Endothelium-dependent vasodilation was greater in 2007 (44+/-15%) compared to 2003 (28+/-12%; n=36 each; P&lt;0.001). Vascular superoxide derived from endothelial NO synthase (eNOS) was lower in 2007 than in 2003 (reduction by NG-nitro-L-arginine-methyl ester, 0.29+/-0.21 nmol/(mg min) vs 0.09+/-0.20 nmol/(mg min); P=0.002). In linear regression analysis, LDL-cholesterol levels have been shown to be the major determinant of endothelial function in the combined 2003 and 2007 cohort. CONCLUSION: Intensive lipid-lowering is associated with improved endothelial function and reduced superoxide production from eNOS. Further improvement in vascular function could be achieved by targeting other sources of superoxide including xanthine oxidase. Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - BHF Glasgow Cardiovascular Research Centre, Faculty of Medicine, University of Glasgow, and Department of Vascular Surgery, Gartnavel General Hospital, 126 University Place, Glasgow G12 8TA, Scotland, UK. c.delles@clinmed.gla.ac.ukJC - 95x, 0242543CP - IrelandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tNO - BHF RG/07/005/23633 (United Kingdom British Heart Foundation)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20138279</style></custom1><custom3><style face="normal" font="default">AS - Atherosclerosis. 211(1):271-7, 2010 Jul.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>156</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Despas,F.</style></author><author><style face="normal" font="default"> Trouillet,C.</style></author><author><style face="normal" font="default"> Franchitto,N.</style></author><author><style face="normal" font="default"> Labrunee,M.</style></author><author><style face="normal" font="default"> Galinier,M.</style></author><author><style face="normal" font="default"> Senard,J.M.</style></author><author><style face="normal" font="default"> Pathak,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Levosimedan improves hemodynamics functions without sympathetic activation in severe heart failure patients: direct evidence from sympathetic neural recording</style></title><secondary-title><style face="normal" font="default">Acute Cardiac Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Acute Cardiac Care</style></full-title></periodical><pages end="30" start="25">25-30</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiotonic Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Electromyography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Heart Failure/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Hemodynamics/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> *Hydrazones/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Pyridazines/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Sympathetic Nervous System/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> 0 (Cardiotonic Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Hydrazones)</style></keyword><keyword><style face="normal" font="default"> 0 (Pyridazines)</style></keyword><keyword><style face="normal" font="default"> 131741-08-7 (simendan)</style></keyword><keyword><style face="normal" font="default"> Acute Disease</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Cardiotonic Agents/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> Drug Monitoring/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Electromyography/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Failure/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Heart Failure/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hydrazones/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> Infusions,Intravenous</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Microelectrodes</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Perfusion</style></keyword><keyword><style face="normal" font="default"> Plethysmography</style></keyword><keyword><style face="normal" font="default"> Pyridazines/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Single-Blind Method</style></keyword><keyword><style face="normal" font="default"> Statistics,Nonparametric</style></keyword><keyword><style face="normal" font="default"> Stroke Volume</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="3" Year="2010">2010/3</year></dates><abstract><style face="normal" font="default">Levosimendan is a new inodilatory agent with calcium sensitizing activity. A major concern regarding the use of inotropic agent in heart failure is their effect on the sympathetic tone. This effect could explain increase in short term mortality with other inotropes. We aimed to assess the effect of levosimendan on sympathetic tone measured directly by microneurogra-phy. In a group of acute decompensated heart failure patients, we assessed cardiac performance by digital plethysmography measurement. Sympathetic tone was assessed through recording of muscle sympathetic nerve activity (MSNA) by micro-neurography. Recording were done blindly, for each patient after dobutamine perfusion was stopped (baseline) and 48 h after levosimendan infusion. Clinical, biological and morphological data were collected. We compared cardiac parameters and MSNA before and after administration of levosimendan. 13 patients were recruited (48 +/- 3.6 years). Systolic blood pressure and rate pressure product (mmHg x Beat/min) decreased significantly after levosimendan infusion (P&lt; 0.05). Cardiac output and stroke volume were significantly increased after levosimendan infusion (P&lt; 0.05). A significant decrease of MSNA activity is observed after levosimendan infusion (P&lt; 0.01). Levosimendan induced improvement of cardiac performance, associated with a decreased in MSNA. This study show for the first time that levosimendan has no direct detrimental effect on the sympathetic nervous system</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - INSERM U858 &amp;#x00E9;quipe 8, F-31432 Toulouse, France. fabien.despas@yahoo.frJC - 101276603CP - EnglandPT - Clinical TrialPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19929264</style></custom1><custom3><style face="normal" font="default">AS - Acute Card Care. 12(1):25-30, 2010 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>161</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Dey,D.</style></author><author><style face="normal" font="default"> Wong,N.D.</style></author><author><style face="normal" font="default"> Tamarappoo,B.</style></author><author><style face="normal" font="default"> Nakazato,R.</style></author><author><style face="normal" font="default"> Gransar,H.</style></author><author><style face="normal" font="default"> Cheng,V.Y.</style></author><author><style face="normal" font="default"> Ramesh,A.</style></author><author><style face="normal" font="default"> Kakadiaris,I.</style></author><author><style face="normal" font="default"> Germano,G.</style></author><author><style face="normal" font="default"> Slomka,P.J.</style></author><author><style face="normal" font="default"> Berman,D.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Computer-aided non-contrast CT-based quantification of pericardial and thoracic fat and their associations with coronary calcium and Metabolic Syndrome</style></title><secondary-title><style face="normal" font="default">Atherosclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Atherosclerosis</style></full-title></periodical><pages end="141" start="136">136-141</pages><volume><style face="normal" font="default">209</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Adipose Tissue/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Metabolic Syndrome X/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Metabolic Syndrome X/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Pericardium/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Radiography,Thoracic/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Waist Circumference</style></keyword></keywords><dates><year Day="0" Month="3" Year="2010">2010/3</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Pericardial fat is emerging as an important parameter for cardiovascular risk stratification. We extended previously developed quantitation of thoracic fat volume (TFV) from non-contrast coronary calcium (CC) CT scans to also quantify pericardial fat volume (PFV) and investigated the associations of PFV and TFV with CC and the Metabolic Syndrome (METS). METHODS: TFV is quantified automatically from user-defined range of CT slices covering the heart. Pericardial fat contours are generated by spline interpolation between 5-7 control points, placed manually on the pericardium within this cardiac range. Contiguous fat voxels within the pericardium are identified as pericardial fat. PFV and TFV were measured from non-contrast CT for 201 patients. In 105 patients, abdominal visceral fat area (VFA) was measured from an additional single-slice CT. In 26 patients, images were quantified by two readers to establish inter-observer variability. TFV and PFV were examined in relation to Body Mass Index (BMI), waist circumference and VFA, standard coronary risk factors (RF), CC (Agatston score >0) and METS. RESULTS: PFV and TFV showed excellent correlation with VFA (R=0.79, R=0.89, p&lt;0.0001), and moderate correlation with BMI (R=0.49, R=0.48, p&lt;0.0001). In 26 scans, the inter-observer variability was greater for PFV (8.0+/-5.3%) than for TFV (4.4+/-3.9%, p=0.001). PFV and TFV, but not RF, were associated with CC [PFV: p=0.04, Odds Ratio 3.1; TFV: p&lt;0.001, OR 7.9]. PFV and TFV were also associated with METS [PFV: p&lt;0.001, OR 6.1; TFV p&lt;0.001, OR 5.7], unlike CC [OR=1.0 p=NS] or RF. PFV correlated with low-HDL and high-glucose; TFV correlated with low-HDL, low-adiponectin, and high glucose and triglyceride levels. CONCLUSIONS: PFV and TFV can be obtained easily and reproducibly from routine CC scoring scans, and may be important for risk stratification and monitoring</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Departments of Imaging and Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. deyd@cshs.orgJC - 95x, 0242543CP - IrelandPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - R21EB006829-01A2 (United States NIBIB NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19748623</style></custom1><custom3><style face="normal" font="default">AS - Atherosclerosis. 209(1):136-41, 2010 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>47</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Diaz,V.A.</style></author><author><style face="normal" font="default"> Mainous,A.G.,III</style></author><author><style face="normal" font="default"> Everett,C.J.</style></author><author><style face="normal" font="default"> Schoepf,U.J.</style></author><author><style face="normal" font="default"> Codd,V.</style></author><author><style face="normal" font="default"> Samanii,N.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Effect of healthy lifestyle behaviors on the association between leukocyte telomere length and coronary artery calcium</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="663" start="659">659-663</pages><volume><style face="normal" font="default">106</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Health Behavior</style></keyword><keyword><style face="normal" font="default"> *Leukocytes/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Life Style</style></keyword><keyword><style face="normal" font="default"> *Telomere/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/px [Psychology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/px [Psychology]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Social Support</style></keyword></keywords><dates><year Day="1" Month="9" Year="2010">2010/9/1</year></dates><abstract><style face="normal" font="default">The telomere length is an indicator of biologic aging, and shorter telomeres have been associated with coronary artery calcium (CAC), a validated indicator of coronary atherosclerosis. It is unclear, however, whether healthy lifestyle behaviors affect the relation between telomere length and CAC. In a sample of subjects aged 40 to 64 years with no previous diagnosis of coronary heart disease, stroke, diabetes mellitus, or cancer (n = 318), healthy lifestyle behaviors of greater fruit and vegetable consumption, lower meat consumption, exercise, being at a healthy weight, and the presence of social support were examined to determine whether they attenuated the association between a shorter telomere length and the presence of CAC. Logistic regression analyses controlling for age, gender, race/ethnicity, and Framingham risk score revealed that the relation between having shorter telomeres and the presence of CAC was attenuated in the presence of high social support, low meat consumption, and high fruit and vegetable consumption. Those with shorter telomeres and these characteristics were not significantly different from those with longer telomeres. Conversely, the subjects with shorter telomeres and less healthy lifestyles had a significantly increased risk of the presence of CAC: low fruit and vegetable consumption (odds ratio 3.30, 95% confidence interval 1.61 to 6.75), high meat consumption (odds ratio 3.33, 95% confidence interval 1.54 to 7.20), and low social support (odds ratio 2.58, 95% confidence interval 1.24 to 5.37). Stratification by gender yielded similar results for men; however, among women, only fruit and vegetable consumption attenuated the shorter telomere length and CAC relation. In conclusion, the results of the present study suggest that being involved in healthy lifestyle behaviors might attenuate the association between shorter telomere length and coronary atherosclerosis, as identified using CAC. 2010 Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Family Medicine, Medical University of South Carolina, Charleston, USA. diazva@musc.eduJC - 3dq, 0207277CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - 5M01RR001070-31 (United States NCRR NIH HHS)NO - (United Kingdom British Heart Foundation)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20723641</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 106(5):659-63, 2010 Sep 1.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>36</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Diederichsen,A.C.</style></author><author><style face="normal" font="default"> Petersen,H.</style></author><author><style face="normal" font="default"> Jensen,L.O.</style></author><author><style face="normal" font="default"> Thayssen,P.</style></author><author><style face="normal" font="default"> Gerke,O.</style></author><author><style face="normal" font="default"> Sandgaard,N.C.</style></author><author><style face="normal" font="default"> Hoilund-Carlsen,P.F.</style></author><author><style face="normal" font="default"> Mickley,H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Diagnostic value of cardiac 64-slice computed tomography: importance of coronary calcium</style></title><secondary-title><style face="normal" font="default">Scandinavian Cardiovascular Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Scandinavian Cardiovascular Journal</style></full-title></periodical><pages end="344" start="337">337-344</pages><volume><style face="normal" font="default">43</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Stenosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angioplasty,Transluminal,Percutaneous Coronary/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Stenosis/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Stents</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Coronary computed tomography angiography (CTA) has proven clinically useful for non-invasive assessment of coronary pathology. However, coronary calcium can reduce its diagnostic value. The objective of this study was to define a calcium score above which CTA appears less reliable. DESIGN: We prospectively investigated 109 patients referred for elective coronary angiography (CA). With a 64-slice CT-scanner, coronary calcium was determined and expressed in Agatston unit (AU). A significant coronary stenosis was defined as > or =50% luminal diameter reduction. Following blinded interpretation, diagnostic values of CTA at different levels of AU were calculated using quantitative CA as reference. RESULTS: A strong association with stent and the severity of coronary calcium was observed. In patients without stents (n = 91) sensitivity, specificity and positive and negative predictive value for presence of significant stenosis were: 100%, 91%, 74%, and 100% in patients with a calcium score &lt; or =400 AU versus 100%, 17%, 75%, and 100% in patients with a score >400 AU. CONCLUSIONS: The diagnostic accuracy of CTA in patients with no or little coronary calcium is excellent. However, in patients with an Agatston score >400 specificity declines and therefore, these patients should not go on to CTA, but be referred to CA instead</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Odense University Hospital, Denmark. a.diederichsen@dadlnet.dkJC - cta, 9708377CP - EnglandPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19266395</style></custom1><custom3><style face="normal" font="default">AS - Scand Cardiovasc J. 43(5):337-44, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>224</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Ditomasso,D.</style></author><author><style face="normal" font="default"> Carnethon,M.R.</style></author><author><style face="normal" font="default"> Wright,C.M.</style></author><author><style face="normal" font="default"> Allison,M.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">The associations between visceral fat and calcified atherosclerosis are stronger in women than men</style></title><secondary-title><style face="normal" font="default">Atherosclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Atherosclerosis</style></full-title></periodical><pages end="536" start="531">531-536</pages><volume><style face="normal" font="default">208</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aorta,Abdominal/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Atherosclerosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Atherosclerosis/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Intra-Abdominal Fat/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adipose Tissue</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="2" Year="2010">2010/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: Previous studies have found a significant association between body mass index (BMI) and coronary artery calcium (CAC). Little is known about whether body fatness is linked with atherosclerotic calcium (AC) in the non-coronary vasculature. Accordingly, this study tested the hypothesis that there would be significant associations between CAC and AC in the non-coronary vasculature and BMI, visceral fat (VF), and percent body fat (BF%). METHODS: Subjects (n=1160; mean age 57 years; 55% men) underwent electron beam computed tomography (EBCT) screening for AC in the carotid, coronary, thoracic and abdominal aorta, and iliac arteries. Visceral fat and BF% were measured using EBCT and electrical bioimpedance analysis, respectively. RESULTS: In sex-stratified models adjusted for CVD risk factors, there were significant associations among both sexes between 1-SD increments of BMI, BF% and VF and the presence of CAC (p&lt;0.01) as well as for quartiles of BMI and VF and prevalent CAC. Higher levels (tertiles) of BF% and VF were significantly associated with higher amounts of both abdominal aortic calcium (OR=1.90, 1.57 with p=0.02, 0.05 in females and males, respectively) and CAC. CONCLUSIONS: Measures of body morphology are significantly associated with AC in the coronary arteries and abdominal aorta. Of the measures studied, VF appears to be the most relevant by having the most consistent and stronger magnitudes of association, especially in women. These results suggest that VF may be more relevant in women than men with respect to the presence and extent of atherosclerosis in multiple vascular beds. Copyright 2009 Elsevier Ireland Ltd. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Family and Preventive Medicine, University of California, San Diego 92093-0965, United StatesJC - 95x, 0242543CP - IrelandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19765708</style></custom1><custom3><style face="normal" font="default">AS - Atherosclerosis. 208(2):531-6, 2010 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>360</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Djaberi,R.</style></author><author><style face="normal" font="default"> Roodt,J.</style></author><author><style face="normal" font="default"> Schuijf,J.D.</style></author><author><style face="normal" font="default"> Rabelink,T.J.</style></author><author><style face="normal" font="default"> de Koning,E.J.</style></author><author><style face="normal" font="default"> Pereira,A.M.</style></author><author><style face="normal" font="default"> Stokkel,M.P.</style></author><author><style face="normal" font="default"> Smit,J.W.</style></author><author><style face="normal" font="default"> Bax,J.J.</style></author><author><style face="normal" font="default"> Jukema,J.W.</style></author></authors></contributors><titles><title><style face="normal" font="default">Endothelial dysfunction in diabetic patients with abnormal myocardial perfusion in the absence of epicardial obstructive coronary artery disease</style></title><secondary-title><style face="normal" font="default">Journal of Nuclear Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Nuclear Medicine</style></full-title></periodical><pages end="1986" start="1980">1980-1986</pages><volume><style face="normal" font="default">50</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Vessels/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Complications/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Endothelium,Vascular/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> Diabetes Complications/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Diabetes Complications/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Endothelium,Vascular/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Endothelium,Vascular/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardial Perfusion Imaging</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Perfusion</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,Emission-Computed,Single-Photon</style></keyword><keyword><style face="normal" font="default"> Ultrasonography</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><abstract><style face="normal" font="default">In patients with diabetes mellitus, myocardial perfusion defects are often observed in the absence of obstructive epicardial coronary artery disease (CAD), thereby presenting a diagnostic problem. We hypothesized that these perfusion abnormalities may be explained by endothelial dysfunction or occult coronary atherosclerosis. METHODS: Prospectively, 130 asymptomatic patients with diabetes mellitus underwent cardiovascular screening by coronary artery calcium (CAC) scoring, multislice CT coronary angiography, and myocardial perfusion imaging by SPECT. Multislice CT images were evaluated for the presence of obstructive epicardial CAD (>or=50% luminal narrowing). To quantify abnormal myocardial perfusion on SPECT images, we determined the summed stress score for each patient. The presence of abnormal myocardial perfusion was defined as a summed stress score of 3 or more. In addition, flow-mediated dilatation of the brachial artery, a marker of endothelial function, was determined using ultrasonography. RESULTS: In 35 patients (27%), obstructive epicardial CAD was observed on multislice CT, and these patients were excluded from further analysis. In the remaining 95 patients, abnormal myocardial perfusion was observed in 30 (32%) of patients. Flow-mediated dilatation was significantly lower in patients with abnormal myocardial perfusion (3.6% +/- 2.4%) than in those with normal myocardial perfusion (6.4% +/- 2.6%) (P &lt; 0.001). Importantly, flow-mediated dilatation remained a significant predictor of the extent of abnormal myocardial perfusion after correction for cardiovascular risk factors and CAC score (P &lt; 0.001). In contrast, no association was observed between nonobstructive plaque burden as reflected by CAC scores and extent of abnormal myocardial perfusion. CONCLUSION: In patients with diabetes mellitus, myocardial perfusion abnormalities in the absence of obstructive epicardial CAD are associated with endothelial dysfunction</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Leiden University Medical Center, Leiden, The NetherlandsJC - jec, 0217410CP - United StatesPT - Clinical TrialPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19910438</style></custom1><custom3><style face="normal" font="default">AS - J Nucl Med. 50(12):1980-6, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>435</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Djaberi,R.</style></author><author><style face="normal" font="default"> Schuijf,J.D.</style></author><author><style face="normal" font="default"> Boersma,E.</style></author><author><style face="normal" font="default"> Kroft,L.J.</style></author><author><style face="normal" font="default"> Pereira,A.M.</style></author><author><style face="normal" font="default"> Romijn,J.A.</style></author><author><style face="normal" font="default"> Scholte,A.J.</style></author><author><style face="normal" font="default"> Jukema,J.W.</style></author><author><style face="normal" font="default"> Bax,J.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Differences in atherosclerotic plaque burden and morphology between type 1 and 2 diabetes as assessed by multislice computed tomography</style></title><secondary-title><style face="normal" font="default">Diabetes Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Diabetes Care</style></full-title></periodical><pages end="1512" start="1507">1507-1512</pages><volume><style face="normal" font="default">32</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Atherosclerosis/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 1/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 1/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 2/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 2/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Diabetic Angiopathies/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Diabetic Angiopathies/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus,Type 1/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus,Type 2/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Research Design</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="8" Year="2009">2009/8</year></dates><abstract><style face="normal" font="default">OBJECTIVE It is unclear whether the coronary atherosclerotic plaque burden is similar in patients with type 1 and type 2 diabetes. By using multislice computed tomography (MSCT), the presence, degree, and morphology of coronary artery disease (CAD) in patients with type 1 and type 2 diabetes were compared. RESEARCH DESIGN AND METHODS Prospectively, coronary artery calcium (CAC) scoring and MSCT coronary angiography were performed in 135 asymptomatic patients (65 patients with type 1 diabetes and 70 patients with type 2 diabetes). The presence and extent of coronary atherosclerosis as well as plaque phenotype were assessed and compared between groups. RESULTS No difference was observed in average CAC score (217 +/- 530 vs. 174 +/- 361) or in the prevalence of coronary atherosclerosis (65% vs. 71%) in patients with type 1 and type 2 diabetes. However, the prevalence of obstructive atherosclerosis was higher in patients with type 2 diabetes (n = 24; 34%) compared with that in patients with type 1 diabetes (n = 11; 17%) (P = 0.02). In addition, a higher mean number of atherosclerotic and obstructive plaques was observed in patients with type 2 diabetes. In addition, the percentage of noncalcified plaques was higher in patients with type 2 (66%) versus type 1 diabetes (27%) (P &lt; 0.001), resulting in a higher plaque burden for each CAC score compared with that in type 1 diabetic patients. CONCLUSIONS Although CAC scores and the prevalence of coronary atherosclerosis were similar between patients with type 1 and type 2 diabetes, CAD was more extensive in the latter. Also, a relatively higher proportion of noncalcified plaques was observed in patients with type 2 diabetes. These observations may be valuable in the development of targeted management strategies adapted to diabetes type</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Leiden University Medical Center, Leiden, the NetherlandsJC - eag, 7805975CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19487642</style></custom1><custom3><style face="normal" font="default">AS - Diabetes Care. 32(8):1507-12, 2009 Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>511</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Donnino,R.</style></author><author><style face="normal" font="default"> Jacobs,J.E.</style></author><author><style face="normal" font="default"> Doshi,J.V.</style></author><author><style face="normal" font="default"> Hecht,E.M.</style></author><author><style face="normal" font="default"> Kim,D.C.</style></author><author><style face="normal" font="default"> Babb,J.S.</style></author><author><style face="normal" font="default"> Srichai,M.B.</style></author></authors></contributors><titles><title><style face="normal" font="default">Dual-source versus single-source cardiac CT angiography: comparison of diagnostic image quality</style></title><secondary-title><style face="normal" font="default">AJR</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">AJR</style></full-title></periodical><pages end="1056" start="1051">1051-1056</pages><volume><style face="normal" font="default">American</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> 0 (Contrast Media)</style></keyword><keyword><style face="normal" font="default"> 66108-95-0 (Iohexol)</style></keyword><keyword><style face="normal" font="default"> 73334-07-3 (iopromide)</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Artifacts</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Contrast Media</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography/st [Standards]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Rate</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Image Interpretation,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Imaging,Three-Dimensional</style></keyword><keyword><style face="normal" font="default"> Iohexol/aa [Analogs &amp; Derivatives]</style></keyword><keyword><style face="normal" font="default"> Iohexol/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Motion</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed/st [Standards]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="4" Year="2009">2009/4</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Dual-source CT improves temporal resolution, and theoretically improves the diagnostic image quality of coronary artery examinations without requiring preexamination beta-blockade. The purpose of our study was to show the improved diagnostic image quality of dual-source CT compared with single-source CT despite the absence of preexamination beta-blockade in the dual-source CT group. MATERIALS AND METHODS: We performed a retrospective analysis of consecutive patients who underwent coronary artery evaluation with either single-source CT or dual-source CT at our institution between February 2005 and October 2006. Examination reports were analyzed for the presence of image artifacts, and image quality was graded on a 3-point scale (no, mild, or severe artifact). Type of artifact (motion, calcium, quantum mottle) was also noted. RESULTS: Examinations (339 single-source CT and 126 dual-source CT) of 465 patients were analyzed. Artifact was reported in 39.8% of examinations using single-source CT and in 29.4% of examinations using dual-source CT (p &lt; 0.05). The number of examinations with motion artifact was significantly higher with single-source CT than with dual-source CT (15.9% vs 4.8%; p &lt; 0.001) despite significantly higher heart rates in the dual-source CT group (59.4 +/- 8.4 vs 68.6 +/- 14.6 beats per minute; p &lt; 0.001). No patients in the dual-source CT group received preexamination beta-blockade compared with 81% of patients in the single-source CT group. The presence of severe (nondiagnostic) calcium artifact was also significantly reduced in the dual-source CT group (13.0% vs 3.2%; p &lt; 0.001). CONCLUSION: Dual-source CT provides significantly better diagnostic image quality than single-source CT despite higher heart rates in the dual-source CT group. These findings support the use of dual-source CT for coronary artery imaging without the need for preexamination beta-blockade</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, New York University School of Medicine, NYHHA VA Manhattan, 423 First Ave., 12 West Cardiology, New York, NY 10010, USAJC - 3ae, 7708173CP - United StatesPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19304713</style></custom1><custom3><style face="normal" font="default">AS - AJR Am J Roentgenol. 192(4):1051-6, 2009 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>557</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Dora,J.M.</style></author><author><style face="normal" font="default"> Siqueira,D.R.</style></author><author><style face="normal" font="default"> Meyer,E.L.</style></author><author><style face="normal" font="default"> ales,M.K.</style></author><author><style face="normal" font="default"> Maia,A.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Pancreatitis as the first manifestation of multiple endocrine neoplasia type 2A</style></title><secondary-title><style face="normal" font="default">Arquivos Brasileiros de Endocrinologia e Metabologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Arquivos Brasileiros de Endocrinologia e Metabologia</style></full-title></periodical><pages end="1336" start="1332">1332-1336</pages><volume><style face="normal" font="default">52</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Hyperparathyroidism,Primary/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Multiple Endocrine Neoplasia Type 2a/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Pancreatitis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Proto-Oncogene Proteins c-ret/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Acute Disease</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> EC 2-7-10-1 (Proto-Oncogene Proteins c-ret)</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Germ-Line Mutation/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Pancreatitis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="11" Year="2008">2008/11</year></dates><abstract><style face="normal" font="default">Multiple endocrine neoplasia type 2A (MEN2A) is an autosomal dominant inherited condition that predisposes to the triad of medullary thyroid cancer (MTC), pheochromocytoma (Pheo), and primary hyperparathyroidism (PHT). Nearly 100% of MEN2A are associated with germ line mutation of the RET proto-oncogene (RET), and DNA-based RET genotype analysis is now considered essential for earlier diagnosis. The first manifestation of MEN2A is most often due to MTC, and less frequently to Pheo. Rarely, MEN2A is recognized during the search for PHT associated conditions. Most patients with primary hyperparathyroidism are asymptomatic, and the focus of the presentation may be the side effects of chronic hypercalcemia, osteoporosis, renal lithiasis, peptic ulcer disease, and hypertension. Hypercalcemic pancreatitis is rare, being an uncommon first manifestation of PHT. Here, we report on a patient who presented recurrent pancreatitis as the first manifestation of MEN2A. In the present case, prompt sequential dosage of calcium, diagnosis of PHT, and genetic analysis would have resulted in pancreatitis prevention and early MEN2A management</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Hospital de Cl&amp;#x00ED;nicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, RS, BrazilJC - 8q8, 0403437CP - BrazilPT - Case ReportsPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19169490</style></custom1><custom3><style face="normal" font="default">AS - Arq Bras Endocrinol Metabol. 52(8):1332-6, 2008 Nov.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>48</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Duque,G.</style></author><author><style face="normal" font="default"> Close,J.J.</style></author><author><style face="normal" font="default"> de Jager,J.P.</style></author><author><style face="normal" font="default"> Ebeling,P.R.</style></author><author><style face="normal" font="default"> Inderjeeth,C.</style></author><author><style face="normal" font="default"> Lord,S.</style></author><author><style face="normal" font="default"> McLachlan,A.J.</style></author><author><style face="normal" font="default"> Reid,I.R.</style></author><author><style face="normal" font="default"> Troen,B.R.</style></author><author><style face="normal" font="default"> Sambrook,P.N.</style></author></authors></contributors><titles><title><style face="normal" font="default">Treatment for osteoporosis in Australian residential aged care facilities: consensus recommendations for fracture prevention</style></title><secondary-title><style face="normal" font="default">Medical Journal of Australia</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Medical Journal of Australia</style></full-title></periodical><pages end="179" start="173">173-179</pages><volume><style face="normal" font="default">193</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Fractures,Bone/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Osteoporosis/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> 0 (Calcium,Dietary)</style></keyword><keyword><style face="normal" font="default"> 0 (Diphosphonates)</style></keyword><keyword><style face="normal" font="default"> 1406-16-2 (Vitamin D)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Accidental Falls/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Calcium,Dietary/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Calcium/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Consensus</style></keyword><keyword><style face="normal" font="default"> Diphosphonates/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Fractures,Bone/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Homes for the Aged</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Nursing Homes</style></keyword><keyword><style face="normal" font="default"> Protective Devices</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Vitamin D/tu [Therapeutic Use]</style></keyword></keywords><dates><year Day="2" Month="8" Year="2010">2010/8/2</year></dates><isbn><style face="normal" font="default">0025-729X</style></isbn><abstract><style face="normal" font="default">Older people living in residential aged care facilities (RACFs) are at considerably higher risk of suffering fractures than older people living in the community. When admitted to RACFs, patients should be assessed for fracture risk to ensure early implementation of effective fracture prevention measures. Routine or regular determination of calcium and phosphate serum levels in institutionalised older people is not indicated. Opinion is divided about the value of routine measurements of serum concentrations of 25-hydroxyvitamin D, parathyroid hormone and bone turnover markers. The non-pharmacological approach to fracture prevention includes multifactorial programs of falls prevention and the use of hip protectors. Vitamin D supplementation is recommended for all patients in RACFs. Dietary calcium intake should be optimised (1200-1500 mg per day is recommended) and supplementation offered to those with inadequate intake. The decision to prescribe calcium supplements should be guided by patients' tolerance, whether or not they have a history of kidney stones, and emerging data about its cardiovascular safety. Bisphosphonates are the first-choice pharmacological agents for fracture prevention in older persons at high risk. Intravenous administration is as efficient as oral and has the significant advantage of better adherence. Use of strontium ranelate has not been tested on people in RACFs, but evidence in the "old-old" (those aged 75 years and older) suggests it could be a therapeutic option for fracture prevention in this setting. In general, teriparatide should not be considered as a first-line treatment for fracture prevention, particularly for people in RACFs</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Ageing Bone Research Program, Sydney Medical School-Nepean Campus, University of Sydney, Sydney, NSW, Australia. gduque@med.usyd.edu.auJC - 0400714, m26CP - AustraliaPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20678047</style></custom1><custom3><style face="normal" font="default">AS - Med J Aust. 193(3):173-9, 2010 Aug 2.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>34</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Dzemidzic,J.</style></author><author><style face="normal" font="default"> Rasic,S.</style></author><author><style face="normal" font="default"> Saracevic,A.</style></author><author><style face="normal" font="default"> Rebic,D.</style></author><author><style face="normal" font="default"> Uncanin,S.</style></author><author><style face="normal" font="default"> Srna,A.</style></author><author><style face="normal" font="default"> Muslimovic,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Predictors of left ventricular remodelling in kidney transplant recipents in the first posttransplant year</style></title><secondary-title><style face="normal" font="default">Bosnian Journal of Basic Medical Sciences</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Bosnian Journal of Basic Medical Sciences</style></full-title></periodical><pages end="5" start="Suppl">Suppl-5</pages><volume><style face="normal" font="default">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Kidney Transplantation/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Ventricular Remodeling</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Anemia/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Echocardiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Kidney Transplantation</style></keyword><keyword><style face="normal" font="default"> Kidney/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">Cardiovascular diseases (CVD) are a major cause of morbidity and leading cause of mortality in almost 50% of patients (pts) with chronic kidney disease (CKD), including kidney transplant recipients. Left ventricular hypertrophy (LVH) is the most common structural alteration and powerful risk factor for cardiovascular complications in the uremic patients. The aim of this study is to analyze predictors of the left ventricular remodelling in the first year after kidney transplantation based on comparison of echocardiographic findings, which had been done before and twelve months after transplantation. In five years retrospective study, we followed up 30 kidney transplant patients in the first post-transplant year. All patients data - blood pressure, BMI, ECG, blood haemoglobin, serum protein, calcium, phosphorus, product of calcium and phosphorus, the values of parathyroid hormone, serum creatinine and creatinine clearance were recorded just before kidney transplantation and in one month interval after transplantation in the first post-transplant year. Echocardiographic examination was done before transplantation and one year after kidney transplantation. Before transplantation, 33% of patients had normal echocardiographic finding and 67% of patients had echocardiographic signs of left ventricular hypertrophy. After first post-transplant year, 63% of patients showed normal echocardiographic finding of LV, while 37% of patients remained with LV hypertrophy. Diastolic dysfunction of LV until the end of study had been reduced in 40% of pts compared to 70% pts at the beginning of the study. The positive echocardiographic remodelling of LV significantly correlated with rising values of haemoglobin (p&lt;0.05), creatinine clearance (p=0.039) and with the reduction of the serum creatinine values (p=0.047), as well as values of parathyroid hormone (p=0.022). These results confirmed positive relationship between echocardiographic remodelling of left ventricular hypertrophy and elimination uraemia-related risk factors after successful renal transplantation</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Clinic of Nephrology, University of Sarajevo Clinics Centre, Bolnicka 25, Sarajevo, Bosnia and HerzegovinaJC - 101200947CP - Bosnia and HercegovinaPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20433432</style></custom1><custom3><style face="normal" font="default">AS - Bosn. j. basic med. sci.. 10 Suppl 1:S51-5, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>571</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Eby,G.</style></author><author><style face="normal" font="default"> Halcomb,W.W.</style></author></authors></contributors><titles><title><style face="normal" font="default">Elimination of cardiac arrhythmias using oral taurine with l-arginine with case histories: Hypothesis for nitric oxide stabilization of the sinus node</style></title><secondary-title><style face="normal" font="default">Medical Hypotheses</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Medical Hypotheses</style></full-title></periodical><pages end="1204" start="1200">1200-1204</pages><volume><style face="normal" font="default">67</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Arginine/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Arrhythmias,Cardiac/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Atrial Premature Complexes/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Nitric Oxide/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Sinoatrial Node/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Taurine/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> 10102-43-9 (Nitric Oxide)</style></keyword><keyword><style face="normal" font="default"> 107-35-7 (Taurine)</style></keyword><keyword><style face="normal" font="default"> 74-79-3 (Arginine)</style></keyword><keyword><style face="normal" font="default"> Administration,Oral</style></keyword><keyword><style face="normal" font="default"> Aging</style></keyword><keyword><style face="normal" font="default"> Arginine/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Atrial Premature Complexes/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Heart Atria/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Heart Ventricles/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Models,Biological</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Myocardial Contraction/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Reference Values</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sinoatrial Node/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Taurine/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Ventricular Premature Complexes/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Ventricular Premature Complexes/pp [Physiopathology]</style></keyword></keywords><dates><year Day="0" Month="0" Year="2006">2006</year></dates><abstract><style face="normal" font="default">We searched for nutrient deficiencies that could cause cardiac arrhythmias [premature atrial contractions (PACs), premature ventricular contractions (PVCs), atrial fibrillation, and related sinus pauses], and found literature support for deficiencies of taurine and l-arginine. Case histories of people with very frequent arrhythmias are presented showing 10-20g taurine per day reduced PACs by 50% and prevented all PVCs but did not prevent pauses. Adding 4-6g of l-arginine immediately terminated essentially all remaining pauses and PACs, maintaining normal cardiac rhythm with continued treatment. Effects of taurine useful in preventing arrhythmias include regulating potassium, calcium and sodium levels in the blood and tissues, regulating excitability of the myocardium, and protecting against free radicals damage. Taurine restored energy and endurance in one of the cases from a debilitated status to normal. Arrhythmias may also respond to taurine because it dampens activity of the sympathetic nervous system and dampens epinephrine release. l-arginine may have anti-arrhythmic properties resulting from its role as a nitric oxide (NO) precursor and from its ability to restore sinus rhythm spontaneously. Endogenous production of taurine and l-arginine may decline in aging perturbing cardiac rhythm, and these "conditional" essential nutrients therefore become "essential" and require supplementation to prevent morbidity and mortality. l-arginine is hypothesized to prevent cardiac arrhythmias by NO stabilization of the sinus node. Cardiac arrhythmias having no known cause in otherwise healthy people are hypothesized to be symptoms of deficiencies of taurine and arginine</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - George Eby Research, 14909-C Fitzhugh Road, Austin, TX 78736, USAJC - m0m, 7505668CP - ScotlandPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 16797868</style></custom1><custom3><style face="normal" font="default">AS - Med Hypotheses. 67(5):1200-4, 2006.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>456</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Eddington,H.</style></author><author><style face="normal" font="default"> Sinha,S.</style></author><author><style face="normal" font="default"> Li,E.</style></author><author><style face="normal" font="default"> Hegarty,J.</style></author><author><style face="normal" font="default"> Ting,J.</style></author><author><style face="normal" font="default"> Lane,B.</style></author><author><style face="normal" font="default"> Chrysochou,C.</style></author><author><style face="normal" font="default"> Foley,R.</style></author><author><style face="normal" font="default"> O'Donoghue,D.</style></author><author><style face="normal" font="default"> Kalra,P.A.</style></author><author><style face="normal" font="default"> Middleton,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Factors associated with vascular stiffness: cross-sectional analysis from the Chronic Renal Insufficiency Standards Implementation Study</style></title><secondary-title><style face="normal" font="default">Nephron</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Nephron</style></full-title></periodical><pages end="c198" start="c190">c190-c198</pages><volume><style face="normal" font="default">112</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure,Chronic/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure,Chronic/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Vascular Resistance</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Dialysis</style></keyword><keyword><style face="normal" font="default"> Elastic Modulus</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default"> Great Britain/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><abstract><style face="normal" font="default">BACKGROUND: Vascular stiffness is associated with increased cardiovascular risk. This study aimed to identify factors associated with vascular stiffness in a cohort of chronic kidney disease (CKD) patients. METHODS: The Chronic Renal Insufficiency Standards Implementation Study is a prospective epidemiological study of CKD patients not on dialysis, who are managed in a clinic setting. Phenotypic parameters were collected annually, and vascular stiffness was assessed using augmentation index (AI). Cross-sectional analysis was performed across quintiles of AI to evaluate factors associated with vascular stiffness. RESULTS: Mean patient age was 66.1 +/- 14.1 years and estimated glomerular filtration rate (eGFR) was 31.2 +/- 5.7 ml/min. Corrected calcium was 2.26 +/- 0.2 SD mmol/l, phosphate 1.2 +/- 0.4 SD mmol/l and intact parathyroid hormone 94 +/- 96 SD pg/ml; 18.3% of patients had cardiovascular disease. Increased age and systolic blood pressure were associated with increased AI (all p &lt; 0.001). No statistical association was present between AI and eGFR, intact parathyroid hormone, phosphate or protein excretion. CONCLUSION: This study identified blood pressure as a potentially modifiable risk factor associated with AI, whereas eGFR was not associated with increased AI in a population of CKD stage 3-5 patients. Further knowledge of factors which influence progression of vascular stiffness will be important in risk quantification and management. Copyright 2009 S. Karger AG, Basel</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Renal Medicine, Salford Royal NHS Foundation Trust, Salford, UKJC - nw8, 0331777, 101159763CP - SwitzerlandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19439990</style></custom1><custom3><style face="normal" font="default">AS - Nephron. 112(3):c190-8, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>209</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Eisner,B.H.</style></author><author><style face="normal" font="default"> Porten,S.P.</style></author><author><style face="normal" font="default"> Bechis,S.K.</style></author><author><style face="normal" font="default"> Stoller,M.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">The role of race in determining 24-hour urine composition in white and Asian/Pacific Islander stone formers</style></title><secondary-title><style face="normal" font="default">Journal of Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Urology</style></full-title></periodical><pages end="1411" start="1407">1407-1411</pages><volume><style face="normal" font="default">183</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Asian Americans</style></keyword><keyword><style face="normal" font="default"> *European Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default"> *Oceanic Ancestry Group</style></keyword><keyword><style face="normal" font="default"> *Urinary Calculi/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Urine</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">PURPOSE: We examined differences in 24-hour urine composition between white and Asian/Pacific Islander stone formers. MATERIALS AND METHODS: We retrospectively reviewed the 24-hour urinalysis database at a metabolic stone clinic. We identified and included in the study patients 18 years old or older who presented for the initial metabolic stone evaluation when race was marked as white or Asian/Pacific Islander in the electronic medical record. Univariate analysis was done to compare 24-hour urine composition between white and Asian/Pacific Islander stone formers. We performed multivariate linear regression adjusted for possible confounders, including age, gender, body mass index, hypertension, diabetes mellitus, thiazide use, potassium citrate use and 24-hour urine chemistry (volume, pH, calcium, citrate, creatinine, oxalate, magnesium, phosphate, potassium, sodium, sulfate and uric acid). RESULTS: Included in analysis were 371 white and 91 Asian/Pacific Islander patients. On univariate analysis Asian/Pacific Islander patients excreted significantly greater uric acid, and significantly less citrate, magnesium, phosphate and creatinine than white patients. On multivariate analysis Asian/Pacific Islander patients excreted significantly greater uric acid, and significantly less urine citrate, phosphate, creatinine and volume than white patients. CONCLUSIONS: Significant differences exist in 24-hour urine chemistry between white and Asian/PI stone formers. Knowledge of these differences would be useful to evaluate and treat these patients, and prevent stone recurrence. Copyright (c) 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Urology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. beisner@partners.orgJC - kc7, 0376374CP - United StatesPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20171692</style></custom1><custom3><style face="normal" font="default">AS - J Urol. 183(4):1407-11, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>293</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Eisner,B.H.</style></author><author><style face="normal" font="default"> Porten,S.P.</style></author><author><style face="normal" font="default"> Bechis,S.K.</style></author><author><style face="normal" font="default"> Stoller,M.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Hypertension is associated with increased urinary calcium excretion in patients with nephrolithiasis</style></title><secondary-title><style face="normal" font="default">Journal of Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Urology</style></full-title></periodical><pages end="579" start="576">576-579</pages><volume><style face="normal" font="default">183</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> *Hypertension/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Nephrolithiasis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Nephrolithiasis/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Urine</style></keyword></keywords><dates><year Day="0" Month="2" Year="2010">2010/2</year></dates><abstract><style face="normal" font="default">PURPOSE: The epidemiological relationship between nephrolithiasis and hypertension is well-known. Patients with hypertension are at increased risk for nephrolithiasis and those with nephrolithiasis are at risk for hypertension. Urine calcium or urine citrate may be related to hypertension status. We examined the relationship between hypertension and 24-hour urine composition in patients with nephrolithiasis. MATERIALS AND METHODS: We retrospectively reviewed the database on 462 stone forming patients to examine the relationship between hypertension and 24-hour urine composition. Multivariate linear regression models were adjusted for age, race, gender, body mass index, diabetes mellitus and 24-hour urine constituents. Nominal logistic regression was also done to examine the hypertension prevalence by quintile of calcium and citrate excretion. RESULTS: On adjusted multivariate analysis compared with normotensive stone formers those with hypertension excreted 25.6 mg per day more urine calcium, corresponding to a 12% increase in urinary calcium excretion. The relative risk of hypertension was significantly associated with quintile of calcium excretion but not with quintile of citrate excretion (1.29, 95% CI 1.02 to 1.61 vs 0.94, 95% CI 0.78 to 1.14). CONCLUSIONS: In stone formers hypertension was associated only with significantly increased urine calcium. This association is important when treating patients with nephrolithiasis since those with hypertension may require unique dietary and medical therapy. Copyright 2010 American Urological Association. Published by Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA. beisner@partners.orgJC - kc7, 0376374CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20018328</style></custom1><custom3><style face="normal" font="default">AS - J Urol. 183(2):576-9, 2010 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>336</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Ekmekci,A.</style></author><author><style face="normal" font="default"> Abaci,N.</style></author><author><style face="normal" font="default"> Colak,Ozbey N.</style></author><author><style face="normal" font="default"> Agayev,A.</style></author><author><style face="normal" font="default"> Aksakal,N.</style></author><author><style face="normal" font="default"> Oflaz,H.</style></author><author><style face="normal" font="default"> Erginel-Unaltuna,N.</style></author><author><style face="normal" font="default"> Erbil,Y.</style></author></authors></contributors><titles><title><style face="normal" font="default">Endothelial function and endothelial nitric oxide synthase intron 4a/b polymorphism in primary hyperparathyroidism</style></title><secondary-title><style face="normal" font="default">Journal of Endocrinological Investigation</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Endocrinological Investigation</style></full-title></periodical><pages end="616" start="611">611-616</pages><volume><style face="normal" font="default">32</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> *Endothelium,Vascular</style></keyword><keyword><style face="normal" font="default"> *Hyperparathyroidism,Primary/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Hyperparathyroidism,Primary/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Introns</style></keyword><keyword><style face="normal" font="default"> *Nitric Oxide Synthase Type III/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Polymorphism,Genetic</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Brachial Artery/ah [Anatomy &amp; Histology]</style></keyword><keyword><style face="normal" font="default"> Brachial Artery/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> EC 1-14-13-39 (Nitric Oxide Synthase Type III)</style></keyword><keyword><style face="normal" font="default"> EC 1-14-13-39 (NOS3 protein,human)</style></keyword><keyword><style face="normal" font="default"> Endothelium,Vascular/en [Enzymology]</style></keyword><keyword><style face="normal" font="default"> Endothelium,Vascular/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Primary/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide Synthase Type III/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Parathyroidectomy</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Vasodilation/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Vasodilation/ph [Physiology]</style></keyword></keywords><dates><year Day="0" Month="7" Year="2009">2009/7</year></dates><abstract><style face="normal" font="default">BACKGROUND AND AIM: Patients with symptomatic primary hyperparathyroidism (pHT) have increased cardiovascular morbidity and mortality. Endothelial nitric oxide synthase (eNOS) intron 4a/b polymorphism is associated with coronary artery disease and hypertension in various populations. Our aim is to evaluate endothelial function in patients with pHT during pre-operative hypercalcemic and post-operative normocalcemic periods and to determine whether intron 4a/b polymorphism of eNOS gene influences endothelial function. SUBJECTS AND METHODS: Forty patients with pHT (age 48.48+/-11.64 yr) were examined pre-operatively and reexamined 5.8+/-1.9 months after parathyroidectomy. Forty-three healthy subjects (age 47.13+/-8.14 yr) were served as control group. Endothelial function was determined by flow-mediated dilation of brachial artery (FMD). eNOS4a/b polymorphism was detected by polymerase chain reaction. RESULTS: FMD was significantly lower in patients pre-operatively compared with controls (8.48+/-1.78% vs 19.49+/-2.34%, p&lt;0.001). FMD improved significantly after parathyroidectomy (16.19+/-2.16%, p&lt;0.001 compared with pre-operative measurements), but was still significantly lower than controls (p&lt;0.001). The distribution of eNOS4a/b genotype frequencies was not significantly different between patients and controls. Logistic regression analysis showed that increased serum calcium (>2.47 mmol/l) and PTH concentrations (>7.75 pmol/l) were significant independent predictors of lower FMD (&lt;16.7%). ENOS4a/b polymorphism did not enter in this model. CONCLUSION: Impaired endothelial function in patients with pHT improves after successful parathyroid surgery. No compelling data are evident to suggest that eNOS4a/b polymorphism modifies the endothelial function in patients with pHT</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, TurkeyJC - iam, 7806594CP - ItalyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19574729</style></custom1><custom3><style face="normal" font="default">AS - J Endocrinol Invest. 32(7):611-6, 2009 Jul.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>413</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">El-Hamamsy,I.</style></author><author><style face="normal" font="default"> Zaki,M.</style></author><author><style face="normal" font="default"> Stevens,L.M.</style></author><author><style face="normal" font="default"> Clark,L.A.</style></author><author><style face="normal" font="default"> Rubens,M.</style></author><author><style face="normal" font="default"> Melina,G.</style></author><author><style face="normal" font="default"> Yacoub,M.H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Rate of progression and functional significance of aortic root calcification after homograft versus freestyle aortic root replacement</style></title><secondary-title><style face="normal" font="default">Circulation</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Circulation</style></full-title></periodical><pages end="75" start="Suppl">Suppl-75</pages><volume><style face="normal" font="default">120</style></volume><number><style face="normal" font="default">11:Suppl</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aortic Valve/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Bioprosthesis/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Heart Valve Prosthesis Implantation/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aortic Valve/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Reoperation</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Transplantation,Homologous</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Ventricular Function</style></keyword></keywords><dates><year Day="15" Month="9" Year="2009">2009/9/15</year></dates><abstract><style face="normal" font="default">BACKGROUND: Calcification is an important limitation after aortic root replacement. The aims were to compare the long-term degree and rate of calcification of homografts versus Medtronic freestyle aortic roots to determine the functional consequences and predictive factors. METHODS AND RESULTS: One hundred sixty-six patients were prospectively randomized to undergo homograft versus freestyle total aortic root replacement. Of those, 98 patients underwent a total of 248 electron beam computed tomography studies at 0.5, 1, 1.5, 2, 3, and 8 years. All patients underwent yearly clinical and echocardiographic follow-up. Calcium scores were measured using Agatston scoring. Mixed effects models demonstrate significantly higher calcium scores in homograft roots than freestyle at 1.5 years (P=0.02), 2 years (P=0.02), and 3 years (P=0.01), with a trend at 1 year (P=0.06) and 8 years (P=0.1). Homograft calcification occurs significantly faster than in freestyle prostheses between 6 months and 3 years after surgery (P=0.02). Calcification occurs at a similar rate thereafter up to 8 years (P=0.3). At 8 years, freedom from aortic valve dysfunction was lower in homografts than freestyle roots (P=0.06). Freedom from reoperation was 93+/-4% in the homograft group versus 100+/-0% in the freestyle group at 8 years (P=0.01). On multivariate analysis, redo surgery (P&lt;0.001), smoking (P&lt;0.01), atrial fibrillation (P=0.001), family history of coronary artery disease (P&lt;0.01), and a degenerative etiology (P=0.02) were predictive of higher calcium scores. CONCLUSIONS: Homograft roots exhibit significantly higher calcium scores than freestyle roots because of faster early calcification</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiac Surgery, Harefield and Royal Brompton NHS Trust, National Heart and Lung Institute, Imperial College London, UKJC - daw, 0147763CP - United StatesPT - Comparative StudyPT - Journal ArticlePT - Randomized Controlled TrialPT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19752378</style></custom1><custom3><style face="normal" font="default">AS - Circulation. 120(11 Suppl):S269-75, 2009 Sep 15.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>102</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Elder,D.H.</style></author><author><style face="normal" font="default"> Pauriah,M.</style></author><author><style face="normal" font="default"> Lang,C.C.</style></author><author><style face="normal" font="default"> Shand,J.</style></author><author><style face="normal" font="default"> Menown,I.B.</style></author><author><style face="normal" font="default"> Sin,B.D.</style></author><author><style face="normal" font="default"> Gupta,S.</style></author><author><style face="normal" font="default"> Duckett,S.G.</style></author><author><style face="normal" font="default"> Foster,W.</style></author><author><style face="normal" font="default"> Zachariah,D.</style></author><author><style face="normal" font="default"> Kalra,P.R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Is there a Failure to Optimize theRapy in anGina pEcToris (FORGET) study?</style></title><secondary-title><style face="normal" font="default">Qjm</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Qjm</style></full-title></periodical><pages end="310" start="305">305-310</pages><volume><style face="normal" font="default">103</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Angina Pectoris/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> *Guideline Adherence/st [Standards]</style></keyword><keyword><style face="normal" font="default"> 0 (Cardiovascular Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipids)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angina Pectoris/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Angina Pectoris/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Angioplasty,Transluminal,Percutaneous Coronary</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Great Britain</style></keyword><keyword><style face="normal" font="default"> Heart Rate</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lipids/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Practice Guidelines as Topic</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="5" Year="2010">2010/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: In the management of chronic stable angina, percutaneous coronary intervention (PCI) provides symptomatic relief of angina rather than improvement of prognosis. Current guidelines recommend optimization of medical therapy prior to elective PCI. It is not clear if these guidelines are adhered to in clinical practice. AIM: The aim of this multi-centre study was to determine the extent to which these treatment guidelines are being implemented in the UK. DESIGN: This was a multi-centre study involving six hospitals in the UK. METHODS: The medical treatment and extent of risk factor modification was recorded for consecutive patients undergoing elective PCI for chronic stable angina at each site. Data collected included anti-anginal drug therapy, lipid levels and blood pressure (BP). Data on heart rate (HR) control were also collected, since this represents a fundamental part of medical anti-anginal therapy. Target HR is &lt;60 b.p.m. for symptomatic angina. RESULTS: A total of 500 patients [74% male; mean age +/- SD (64.4 +/- 10.1 years)] were included. When considering secondary prevention, 85% were receiving a statin and 76% were on an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. In terms of medical anti-ischaemic therapy, 78% were receiving beta-blockers [mean equivalent dose of bisoprolol 3.1 mg (range 1.25-20 mg)], 11% a rate limiting calcium antagonist, 35% a nitrate or nicorandil and one patient was receiving ivabradine. The mean total cholesterol (95% confidence interval) was 4.3 mmol/l (4.2-4.4), mean systolic BP of 130 +/- 24 mmHg and mean diastolic BP of 69 +/- 13 mmHg. Serum cholesterol was &lt;5 mmol/l in 77% and &lt;4 mmol/l in 42% of the patients, 62% of the patients had systolic BP &lt; 140 mmHg and 92% had diastolic BP &lt; 90 mmHg. Considering European Society of Cardiology targets, 50% had systolic BP &lt; 130 mmHg and 76% had diastolic BP &lt; 80 mmHg. A large proportion of patients did not achieve target resting HR; 27% of patients had a resting HR of >or=70 b.p.m., 40% had a resting HR between 60 and 69 b.p.m. and 26% had a resting HR between 50 and 59 b.p.m. The resting HR was not related to the dose of beta-blocker. CONCLUSION: A significant proportion of the patients with chronic stable angina undergoing elective PCI did not achieve therapeutic targets for lipid, BP and HR control. Over 50% of patients did not receive adequate HR lowering anti-anginal therapy to achieve recommended target resting HR</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Portsmouth Hospitals NHS Trust, St Mary's Hospital, Milton Road, Portsmouth PO3 6AD, UKJC - 9438285, B4VCP - EnglandPT - Journal ArticlePT - Multicenter StudyPT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20181676</style></custom1><custom3><style face="normal" font="default">AS - QJM. 103(5):305-10, 2010 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>170</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Elezi,S.</style></author><author><style face="normal" font="default"> Qerkini,G.</style></author><author><style face="normal" font="default"> Bujupi,L.</style></author><author><style face="normal" font="default"> Shabani,D.</style></author><author><style face="normal" font="default"> Bajraktari,G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Management and comorbidities of atrial fibrillation in patients admitted in cardiology service in Kosovo-a single-center study</style></title><secondary-title><style face="normal" font="default">Anadolu Kardiyoloji Dergisi</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Anadolu Kardiyoloji Dergisi</style></full-title></periodical><pages end="40" start="36">36-40</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Anticoagulants/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Atrial Fibrillation/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Stroke/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> 0 (Anticoagulants)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> Atrial Fibrillation/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Atrial Fibrillation/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Atrial Fibrillation/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Electrocardiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Serbia</style></keyword><keyword><style face="normal" font="default"> Stroke/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Stroke/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Stroke/pp [Physiopathology]</style></keyword></keywords><dates><year Day="0" Month="2" Year="2010">2010/2</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Atrial fibrillation (AF) is the most important risk factor for ischemic stroke. Anticoagulation therapy can substantially decrease the risk of stroke in patients with AF. The aim of our study was to investigate the patient's comorbidities and management of patients with AF on the discharge. METHODS: From 5382 consecutive patients admitted in our institution between January 2005 and March 2008, 525 (mean age 66.4+/- 11.4 years, 53.3% male) had AF upon discharge, who were included in this retrospective study. Patients were divided in two groups according to prescription of anticoagulation therapy at discharge. Continuous data were compared between groups using a two-tailed unpaired Student t test. Discrete variables were compared using Chi-square test or Fisher's exact probability test as appropriate. Logistic regression analysis was used to identify the independent clinical and echocardiographic predictors of prescribing oral anticoagulation therapy. RESULTS: Associated comorbidities of AF in our patients were: ischemic heart disease (21.4%), hypertensive heart disease (27.44%), valvular heart disease (17.4%), congestive heart failure (47%), chronic obstructive pulmonary disease (6.7%), and diabetes 14.3%). Of 525 patients 76% were discharged on beta-blockers, 67% on angiotensin converting enzyme inhibitors, 23% on digoxin, 16% on calcium antagonists, 67% on diuretics, 72% on aspirin, and 27% on oral anticoagulant (OAC) therapy, 11% were with both antithrombotics. Multivariate analysis showed that the under-prescription of OAC therapy in patients with AF was independently associated with elder age (OR=0.916, 95%CI 0.891-0.942, p&lt;0.001), non-enlarged left atrium (OR=1.148, 95%CI 1.100-1.198, p&lt;0.001) and good left ventricular ejection fraction (OR=0.970, 95%CI 0.948-0.993, p=0.011). CONCLUSIONS: Patients with atrial fibrillation were mainly with ischemic, hypertensive heart disease and congestive heart failure. Our study, suggests underuse of anticoagulation therapy. The independent predictors of under prescription of anticoagulants in patients with atrial fibrillation were elder age, non-enlarged left atrium, and good left ventricular ejection fraction. Medical treatment with other groups of drugs for atrial fibrillation and comorbidities seems to be according to current guidelines</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Internal Medicine, Faculty of Medicine, University of Prishtina, Prishtina, KosovoCM - Comment in: Anadolu Kardiyol Derg. 2010 Feb;10(1):41-2; PMID: 20150003JC - 101095069CP - TurkeyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20150002</style></custom1><custom3><style face="normal" font="default">AS - Anadolu Kardiyol Derg. 10(1):36-40, 2010 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>12</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Elias-Smale,S.E.</style></author><author><style face="normal" font="default"> Proenca,R.V.</style></author><author><style face="normal" font="default"> Koller,M.T.</style></author><author><style face="normal" font="default"> Kavousi,M.</style></author><author><style face="normal" font="default"> van Rooij,F.J.</style></author><author><style face="normal" font="default"> Hunink,M.G.</style></author><author><style face="normal" font="default"> Steyerberg,E.W.</style></author><author><style face="normal" font="default"> Hofman,A.</style></author><author><style face="normal" font="default"> Oudkerk,M.</style></author><author><style face="normal" font="default"> Witteman,J.C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Coronary calcium score improves classification of coronary heart disease risk in the elderly: the Rotterdam study</style></title><secondary-title><style face="normal" font="default">Journal of the American College of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of the American College of Cardiology</style></full-title></periodical><pages end="1414" start="1407">1407-1414</pages><volume><style face="normal" font="default">56</style></volume><number><style face="normal" font="default">17</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Disease/cl [Classification]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcinosis/cl [Classification]</style></keyword><keyword><style face="normal" font="default"> Coronary Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword></keywords><dates><year Day="19" Month="10" Year="2010">2010/10/19</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The purpose of this study was to examine the effect of coronary artery calcium (CAC) on the classification of 10-year hard coronary heart disease (CHD) risk and to empirically derive cut-off values of the calcium score for a general population of elderly patients. BACKGROUND: Although CAC scoring has been found to improve CHD risk prediction, there are limited data on its impact in clinical practice. METHODS: The study comprised 2,028 asymptomatic participants (age 69.6 +/- 6.2 years) from the Rotterdam Study. During a median follow-up of 9.2 years, 135 hard coronary events occurred. Persons were classified into low (&lt;10%), intermediate (10% to 20%), and high (>20%) 10-year coronary risk categories based on a Framingham refitted risk model. In a second step, the model was extended by CAC, and reclassification percentages were calculated. Cutoff values of CAC for persons in the intermediate-risk category were empirically derived based on 10-year hard CHD risk. RESULTS: Reclassification by means of CAC scoring was most substantial in persons initially classified as intermediate risk. In this group, 52% of men and women were reclassified, all into more accurate risk categories. CAC values above 615 or below 50 Agatston units were found appropriate to reclassify persons into high or low risk, respectively. CONCLUSIONS: In a general population of elderly patients at intermediate CHD risk, CAC scoring is a powerful method to reclassify persons into more appropriate risk categories. Empirically derived CAC cutoff values at which persons at intermediate risk reclassified to either high or low risk were 615 and 50 Agatston units, respectively. Copyright [copyright sign] 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Epidemiology, Erasmus Medical Center, Rotterdam, the NetherlandsCM - Comment in: J Am Coll Cardiol. 2010 Oct 19;56(17):1415-7; PMID: 20946999JC - h50, 8301365CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20946998</style></custom1><custom3><style face="normal" font="default">AS - J Am Coll Cardiol. 56(17):1407-14, 2010 Oct 19.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>131</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Emeric,C.S.</style></author><author><style face="normal" font="default"> Mesenbrink,P.</style></author><author><style face="normal" font="default"> Lyles,K.W.</style></author><author><style face="normal" font="default"> Pieper,C.F.</style></author><author><style face="normal" font="default"> Boonen,S.</style></author><author><style face="normal" font="default"> Delmas,P.</style></author><author><style face="normal" font="default"> Eriksen,E.F.</style></author><author><style face="normal" font="default"> Magaziner,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Potential mediators of the mortality reduction with zoledronic acid after hip fracture</style></title><secondary-title><style face="normal" font="default">Journal of Bone &amp; Mineral Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Bone &amp; Mineral Research</style></full-title></periodical><pages end="97" start="91">91-97</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Bone Density Conservation Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Diphosphonates/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Hip Fractures/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Hip Fractures/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> *Imidazoles/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> 0 (Bone Density Conservation Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Diphosphonates)</style></keyword><keyword><style face="normal" font="default"> 0 (Imidazoles)</style></keyword><keyword><style face="normal" font="default"> 0 (Placebos)</style></keyword><keyword><style face="normal" font="default"> 118072-93-8 (zoledronic acid)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Bone Density</style></keyword><keyword><style face="normal" font="default"> Cause of Death</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Placebos</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States/ep [Epidemiology]</style></keyword></keywords><dates><year Day="0" Month="1" Year="2010">2010/1</year></dates><abstract><style face="normal" font="default">Zoledronic acid reduces the risk of death by 28% after hip fracture, but the mechanisms are not known. This exploratory analysis sought to identify potential pathways for the reduction in mortality with zoledronic acid after hip fracture. This was a retrospective analysis of a randomized, controlled trial. Patients with recent hip fracture (n = 2111) were treated with zoledronic acid or placebo infusion yearly, as well as calcium and vitamin D supplementation. Causes of death were adjudicated by a blinded central review committee. Baseline comorbidities, events occurring during the study period, including subsequent fracture, change in bone density, infections, cardiovascular events, arrhythmias, and falls, were included in multivariable analyses. In a model adjusted for baseline risk factors, zoledronic acid reduced the risk of death by 25% [95% confidence interval (CI) 0.58-0.97). The effect was consistent across most subgroups. Subsequent fractures were significantly associated with death (hazard ratio 1.72, 95% CI 1.17-2.51) but explained only 8% of the zoledronic acid effect. Adjusting for acute events occurring during follow-up eliminated the death benefit, and zoledronic acid-treated subjects were less likely to die from pneumonia (interaction p = .04) and arrhythmias (interaction p = .02) than placebo-treated subjects. Only 8% of zoledronic acid's death benefit is due to a reduction in secondary fractures. Zoledronic acid may have an effect on cardiovascular events and pneumonia. Further studies of zoledronic acid in other acute illnesses may be warranted. 2010 American Society for Bone and Mineral Research</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Duke University Medical Center, Durham, NC 27710, USA. colon001@mc.duke.eduJC - 8610640CP - United StatesPT - Journal ArticlePT - Randomized Controlled TrialPT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19580467</style></custom1><custom3><style face="normal" font="default">AS - J Bone Miner Res. 25(1):91-7, 2010 Jan.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>481</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Erem,C.</style></author><author><style face="normal" font="default"> Kocak,M.</style></author><author><style face="normal" font="default"> Nuhoglu,I.</style></author><author><style face="normal" font="default"> Yilmaz,M.</style></author><author><style face="normal" font="default"> Ucuncu,O.</style></author></authors></contributors><titles><title><style face="normal" font="default">Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism</style></title><secondary-title><style face="normal" font="default">European Journal of Endocrinology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">European Journal of Endocrinology</style></full-title></periodical><pages end="868" start="863">863-868</pages><volume><style face="normal" font="default">160</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Carboxypeptidase U/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Hyperparathyroidism,Primary/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Lipoproteins/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Plasminogen Activator Inhibitor 1/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Chlorides)</style></keyword><keyword><style face="normal" font="default"> 0 (lipoprotein-associated coagulation inhibitor)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipoproteins)</style></keyword><keyword><style face="normal" font="default"> 0 (Plasminogen Activator Inhibitor 1)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 7723-14-0 (Phosphorus)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Chlorides/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> EC 3-4-17-20 (Carboxypeptidase U)</style></keyword><keyword><style face="normal" font="default"> Endocrinology</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Phosphorus/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="5" Year="2009">2009/5</year></dates><abstract><style face="normal" font="default">BACKGROUND AND OBJECTIVES: Primary hyperparathyroidism (PHPT) is associated with increased cardiovascular mortality and morbidity. Little is known about hemostatic features of patients with PHPT. To our knowledge, plasma tissue factor pathway inhibitor (TFPI) and thrombin-activatable fibrinolysis inhibitor (TAFI) levels in these patints have not been investigated. Therefore, the main purpose of this study was to evaluate the markers of endogenous coagulation/fibrinolysis, including TFPI and TAFI, and to investigate the relationships between serum calcium and PTH and these hemostatic parameters in patients with PHPT. DESIGN AND METHODS: Twenty-four patients with PHPT and 20 age-, sex-, and-weight-matched healthy controls were included in the study. Tissue plasminogen activator (t-PA), tissue plasminogen activator inhibitor-1 (PAI-1), TFPI, and TAFI were measured. The relationships between serum calcium, phosphorus, and PTH and these hemostatic parameters were examinated. RESULTS: Compared with the control subjects, t-PA, PAI-1, and PAI-1/t-PA ratios were significantly increased in patients with PHPT (P&lt;0.0001), whereas TFPI levels were significantly decreased (P&lt;0.0001). Plasma TAFI Ag levels did not significantly change in patients with PHPT compared with the controls. In patients with PHPT, serum phosphorus was negatively correlated with plasma PAI-1 Ag levels and PAI-1/t-PA ratio (r: -0.453, P&lt;0.05; r: -0.580, P&lt;0.01 respectively). There was a positive correlation between Cl/P ratio and plasma PAI-1 levels and PAI-1/t-PA ratio (r: 0.434, P&lt;0.05; r: 0.528, P&lt;0.05 respectively). iPTH was positively correlated with plasma PAI-1/t-PA ratio (r: 0.429, P&lt;0.05). INTERPRETATION AND CONCLUSIONS: In conclusion, we found some important differences in the hemostatic parameters between the patients with PHPT and healthy controls. Increased PAI-1, PAI-1/t-PA ratios and decreased TFPI levels in these patients represent a potential hypercoagulable and hypofibrinolytic state, which might augment the risk for atherosclerotic and atherothrombotic complications. This condition may contribute to the excess mortality due to cardiovascular disease seen in patients with PHPT</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Karadeniz Technical University, 61080 Trabzon, Turkey. cihangirerem@meds.ktu.edu.trJC - bxu, 9423848CP - EnglandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19233920</style></custom1><custom3><style face="normal" font="default">AS - EUR. J. ENDOCRINOL.. 160(5):863-8, 2009 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>125</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Eremenko,A.A.</style></author><author><style face="normal" font="default"> Kolpakov,P.E.</style></author><author><style face="normal" font="default"> Babaev,M.A.</style></author><author><style face="normal" font="default"> Revunenkov,G.V.</style></author><author><style face="normal" font="default"> Fominykh,M.V.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Use of levosimendan in cardiosurgical patients with chronic heart insufficiency]. [Russian]</style></title><secondary-title><style face="normal" font="default">Anesteziologiia i Reanimatologiia</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Anesteziologiia i Reanimatologiia</style></full-title></periodical><pages end="26" start="24">24-26</pages><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiotonic Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Heart Failure/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Heart Failure/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Hydrazones/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Pyridazines/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> 0 (Cardiotonic Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Hydrazones)</style></keyword><keyword><style face="normal" font="default"> 0 (Pyridazines)</style></keyword><keyword><style face="normal" font="default"> 131741-08-7 (simendan)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies</style></keyword><keyword><style face="normal" font="default"> Cardiotonic Agents/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Failure/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Heart Valve Prosthesis Implantation/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Hemodynamics/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Hospital Mortality</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hydrazones/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Intensive Care</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Postoperative Complications/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Postoperative Complications/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Postoperative Complications/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Pyridazines/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="3" Year="2010">2010/3</year></dates><isbn><style face="normal" font="default">0201-7563</style></isbn><abstract><style face="normal" font="default">The impact of administration of the calcium sensitizer levosimendan on hemodynamic parameters, dose of intraoperative and postoperative cardiotonic maintenance, length of intensive care unit stay, and hospital mortality was studied in cardiosurgical patients with dilated cardiomyopathy, second-fourth degree mitral valve insufficiency, or NYHA Class IV circulatory insufficiency. Levosimendan was administered to 25 patients 3-5 days prior to surgery. A control group of 22 patients did not receive levosimendan. The use of the agent caused statistically significant reductions in pulmonary artery pressure and pulmonary wedge pressure and increases in cardiac index and left ventricular ejection fraction. The levosimedan-treated patients needed smaller doses of sjmpathomimetics, less length of intensive care unit stay and showed lower mortality rates (p &lt; O.05 for all indices)</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)JC - 4st, 7705399CP - Russia (Federation)PT - Clinical TrialPT - English AbstractPT - Journal ArticleLG - Russian</style></notes><urls/><custom1><style face="normal" font="default">UI - 20524326</style></custom1><custom3><style face="normal" font="default">AS - Anesteziol Reanimatol. (2):24-6, 2010 Mar-Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>455</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Evans,M.D.</style></author><author><style face="normal" font="default"> Barton,K.</style></author><author><style face="normal" font="default"> Pritchard,G.A.</style></author><author><style face="normal" font="default"> Williams,E.J.</style></author><author><style face="normal" font="default"> Karandikar,S.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Plasma magnesium should be monitored perioperatively in patients undergoing colorectal resection</style></title><secondary-title><style face="normal" font="default">Colorectal Disease</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Colorectal Disease</style></full-title></periodical><pages end="618" start="613">613-618</pages><volume><style face="normal" font="default">11</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atrial Fibrillation/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Cathartics/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Colon/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Magnesium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Picolines/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Preoperative Care/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> 0 (Cathartics)</style></keyword><keyword><style face="normal" font="default"> 0 (Picolines)</style></keyword><keyword><style face="normal" font="default"> 10040-45-6 (picosulfate sodium)</style></keyword><keyword><style face="normal" font="default"> 7439-95-4 (Magnesium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Colonoscopy</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Postoperative Care</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Water-Electrolyte Imbalance/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Water-Electrolyte Imbalance/ci [Chemically Induced]</style></keyword></keywords><dates><year Day="0" Month="7" Year="2009">2009/7</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Hypomagnesemia has been shown to have several clinically important sequelae. The aims of this study were: to assess the impact of bowel preparation, with sodium picosulphate (Picolax), on plasma electrolytes, with particular regard to plasma magnesium, in patients undergoing bowel preparation for colonoscopy and colorectal resection and to evaluate the influence of perioperative magnesium levels on postoperative cardiac dysrhythmias. METHOD: Sixty-one patients receiving sodium picosulphate (Picolax) bowel preparation were studied in two groups: Colonoscopy (31 patients) and Colorectal resection (30 patients). Plasma sodium, potassium, magnesium, calcium, urea, creatinine and blood haematocrit were measured in all patients prior to commencement of bowel preparation, at the time of colonoscopy or colorectal resection and 24 h postoperatively (surgery group only). Mean electrolyte and haematocrit levels were then compared. Postoperative cardiac dysrhythmias were recorded and analysed. RESULTS: No significant changes following bowel preparation were observed in plasma sodium, potassium, calcium or creatinine. Plasma urea fell following bowel preparation (colonoscopy P &lt; 0.001, resection P = 0.004) and rose following resection (P = 0.002). Magnesium levels increased following bowel preparation in both groups (colonoscopy P &lt; 0.001, resection P = 0.007) and fell following resection (P &lt; 0.001). Thirty-four per cent (21/60 patients) were hypermagnesemic following bowel preparation and 20% (6/30 patients) became hypomagnesemic following surgery. Postoperative cardiac dysrhythmias were associated with lower magnesium levels at induction and postoperatively (P = 0.022 and P = 0.033). CONCLUSION: Bowel preparation with Picolax does not appear to cause significant electrolyte disturbance, except in elevating plasma magnesium. Postcolorectal resection plasma magnesium dropped significantly suggesting perioperative monitoring and replacement should be routine following colorectal surgery</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Surgery, Princess of Wales Hospital, Bridgend, UKJC - 100883611CP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18624818</style></custom1><custom3><style face="normal" font="default">AS - Colorectal Dis. 11(6):613-8, 2009 Jul.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>457</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Fahrleitner-Pammer,A.</style></author><author><style face="normal" font="default"> Piswanger-Soelkner,J.C.</style></author><author><style face="normal" font="default"> Pieber,T.R.</style></author><author><style face="normal" font="default"> Obermayer-Pietsch,B.M.</style></author><author><style face="normal" font="default"> Pilz,S.</style></author><author><style face="normal" font="default"> Dimai,H.P.</style></author><author><style face="normal" font="default"> Prenner,G.</style></author><author><style face="normal" font="default"> Tscheliessnigg,K.H.</style></author><author><style face="normal" font="default"> Hauge,E.</style></author><author><style face="normal" font="default"> Portugaller,R.H.</style></author><author><style face="normal" font="default"> Dobnig,H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial</style></title><secondary-title><style face="normal" font="default">Journal of Bone &amp; Mineral Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Bone &amp; Mineral Research</style></full-title></periodical><pages end="1344" start="1335">1335-1344</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Bone Density Conservation Agents/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Bone Resorption/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Diphosphonates/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Heart Transplantation</style></keyword><keyword><style face="normal" font="default"> *Lumbar Vertebrae/in [Injuries]</style></keyword><keyword><style face="normal" font="default"> *Spinal Fractures/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> 0 (Antacids)</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Bone Density Conservation Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Collagen Type I)</style></keyword><keyword><style face="normal" font="default"> 0 (Diphosphonates)</style></keyword><keyword><style face="normal" font="default"> 0 (Isoenzymes)</style></keyword><keyword><style face="normal" font="default"> 114084-78-5 (ibandronic acid)</style></keyword><keyword><style face="normal" font="default"> 471-34-1 (Calcium Carbonate)</style></keyword><keyword><style face="normal" font="default"> 67-97-0 (Cholecalciferol)</style></keyword><keyword><style face="normal" font="default"> Acid Phosphatase/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Antacids/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Bone Resorption/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Bone Resorption/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Bone Resorption/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium Carbonate/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Cholecalciferol/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Collagen Type I/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Double-Blind Method</style></keyword><keyword><style face="normal" font="default"> EC 3-1-3 (tartrate-resistant acid phosphatase)</style></keyword><keyword><style face="normal" font="default"> EC 3-1-3-2 (Acid Phosphatase)</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Isoenzymes/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Spinal Fractures/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Spinal Fractures/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Transplantation,Homologous</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> X-Rays</style></keyword></keywords><dates><year Day="0" Month="7" Year="2009">2009/7</year></dates><abstract><style face="normal" font="default">Bone loss and fractures are common complications after cardiac transplantation (CTP). The aim of this study was to investigate whether intravenous ibandronate is an effective preventive option. Thirty-five male cardiac transplant recipients received either ibandronate (IBN) 2 mg intravenously every 3 mo or matching placebo (CTR) in addition to 500 mg calcium carbonate and 400 IE vitamin D(3). Sera were collected at CTP and every 3 mo thereafter. At baseline and 6 and 12 mo, standardized spinal X-rays and BMD measurements were taken. Bone biopsies were taken at CTP and after 6 mo from six patients. In the IBN group, 13% of the patients sustained a new morphometric vertebral fracture compared with 53% in the CTR group (absolute risk reduction [ARR], 40%; relative risk reduction [RRR], 75%; p = 0.04). BMD remained unchanged with IBN treatment but in the CTR group decreased at the lumbar spine by 25% and at the femoral neck by 23% (both p &lt; 0.0001) over the 1-yr period. Serum bone resorption markers carboxy-terminal telopeptide region of type I collagen (sCTX) and TRACP 5b were significantly increased in the CTR group and decreased in the IBN group at all time points compared with baseline. In contrast, both osteocalcin and bone-specific alkaline phosphatase levels showed, after a similar decrease over the first 3 mo in both groups, a marked rise in the CTR subjects and steadily declining levels in the IBN patients throughout the remainder of the study period. Three paired biopsies were available from each group. Despite the small sample size, a difference in the relative change of eroded surface (68% in the CTR versus -23% in the IBN group, p &lt; 0.05) could be shown. Intravenous IBN reduced fractures, preserved bone mass, and prevented uncoupling of bone formation and resorption after CTP. The favorable effects on bone turnover were also supported by histomorphometric findings</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Internal Medicine, Division of Endocrinology and Nuclear Medicine, Medical University of Graz, Graz, Austria. astrid.fahrleitner@meduni-graz.atJC - 8610640CP - United StatesPT - Comparative StudyPT - Journal ArticlePT - Randomized Controlled TrialLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19257824</style></custom1><custom3><style face="normal" font="default">AS - J Bone Miner Res. 24(7):1335-44, 2009 Jul.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>168</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Falcone,E.L.</style></author><author><style face="normal" font="default"> Mangili,A.</style></author><author><style face="normal" font="default"> Tang,A.M.</style></author><author><style face="normal" font="default"> Jones,C.Y.</style></author><author><style face="normal" font="default"> Woods,M.N.</style></author><author><style face="normal" font="default"> Polak,J.F.</style></author><author><style face="normal" font="default"> Wanke,C.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Micronutrient concentrations and subclinical atherosclerosis in adults with HIV</style></title><secondary-title><style face="normal" font="default">American Journal of Clinical Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Clinical Nutrition</style></full-title></periodical><pages end="1219" start="1213">1213-1219</pages><volume><style face="normal" font="default">91</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *HIV Infections/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Vitamin A/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Vitamin E/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Lipoproteins)</style></keyword><keyword><style face="normal" font="default"> 0 (Micronutrients)</style></keyword><keyword><style face="normal" font="default"> 11103-57-4 (Vitamin A)</style></keyword><keyword><style face="normal" font="default"> 1406-18-4 (Vitamin E)</style></keyword><keyword><style face="normal" font="default"> 7440-66-6 (Zinc)</style></keyword><keyword><style face="normal" font="default"> 7782-49-2 (Selenium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Antiretroviral Therapy,Highly Active</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Carotid Arteries/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Carotid Arteries/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> HIV Infections/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> HIV Infections/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lipoproteins/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Micronutrients/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Selenium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Tunica Intima/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Tunica Media/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Viral Load</style></keyword><keyword><style face="normal" font="default"> Zinc/bl [Blood]</style></keyword></keywords><dates><year Day="0" Month="5" Year="2010">2010/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: Extremes in micronutrient intakes are common in HIV-infected patients in developed countries and may affect the progression of atherosclerosis in this population. OBJECTIVE: We completed a cross-sectional study examining the association between serum micronutrient concentrations and surrogate markers of atherosclerosis in a cohort of HIV-infected adults. DESIGN: We measured serum selenium, zinc, vitamin A, and vitamin E concentrations as well as carotid intima-media thickness (c-IMT) and coronary artery calcium (CAC) in 298 Nutrition for Healthy Living participants. We assessed cardiovascular disease risk factors, c-IMT, and CAC for each micronutrient tertile by using a chi-square test for binary variables and analysis of variance for continuous variables. We performed multivariate regression of c-IMT and CAC with each micronutrient with adjustment for HIV-related and cardiovascular disease risk factors. RESULTS: In the multivariate analysis, the highest tertile of serum vitamin E concentration was associated with higher common and internal c-IMT and CAC scores (P &lt; 0.05 for c-IMT and CAC). Participants with higher vitamin E concentrations were more likely to have detectable CAC (50% compared with 44% compared with 67% for tertiles 1, 2, and 3, respectively; P = 0.004) and common c-IMT >0.8 mm (5% compared with 4% compared with 17% for tertiles 1, 2, and 3, respectively; P = 0.002). Other than vitamin E, micronutrients had no association with markers of atherosclerosis. CONCLUSIONS: Our study showed that elevated serum vitamin E concentrations are associated with abnormal markers of atherosclerosis and may increase the risk of cardiovascular complications in HIV-infected adults</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA. efalcone@tuftsmedicalcenter.orgJC - 3ey, 0376027CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - 1K24 AI055293-05 (United States NIAID NIH HHS)NO - 1P30AI42853-106637 (United States NIAID NIH HHS)NO - 1P30DA13868 (United States NIDA NIH HHS)NO - 1R01HL065947-06A1 (United States NHLBI NIH HHS)NO - 5T32AI007329-16 (United States NIAID NIH HHS)NO - P01DK045734 (United States NIDDK NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20219956</style></custom1><custom3><style face="normal" font="default">AS - Am J Clin Nutr. 91(5):1213-9, 2010 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>283</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Falkiewicz,K.</style></author><author><style face="normal" font="default"> Boratynska,M.</style></author><author><style face="normal" font="default"> Speichert-Bidzinska,B.</style></author><author><style face="normal" font="default"> Magott-Procelewska,M.</style></author><author><style face="normal" font="default"> Biecek,P.</style></author><author><style face="normal" font="default"> Patrzalek,D.</style></author><author><style face="normal" font="default"> Klinger,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">1,25-dihydroxyvitamin D deficiency predicts poorer outcome after renal transplantation</style></title><secondary-title><style face="normal" font="default">Transplantation Proceedings</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Transplantation Proceedings</style></full-title></periodical><pages end="3005" start="3002">3002-3005</pages><volume><style face="normal" font="default">41</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcitriol/df [Deficiency]</style></keyword><keyword><style face="normal" font="default"> *Kidney Transplantation/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Vitamin D Deficiency/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 0 (Phosphates)</style></keyword><keyword><style face="normal" font="default"> 32222-06-3 (Calcitriol)</style></keyword><keyword><style face="normal" font="default"> 60-27-5 (Creatinine)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Creatinine/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Kidney Transplantation/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Patient Selection</style></keyword><keyword><style face="normal" font="default"> Phosphates/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Treatment Failure</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Vitamin D Deficiency/bl [Blood]</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To assess 1,25-dihydroxyvitamin D status and the effect of vitamin concentration on transplantation outcome in renal allograft recipients. PATIENTS AND METHODS: Ninety patients underwent renal transplantation between 2002 and 2005. All received alfacalcidol supplementation before surgery. 1,25-Dihydroxyvitamin D concentration was determined on day 3 posttransplantation and at 1-, 6-, 12-, 18-, and 24-month follow-up. RESULTS: Severe 1,25-dihydroxyvitamin D deficiency was noted in 83% of patients immediately posttransplantation. From 1 to 12 months thereafter, concentrations increased almost 3-fold, and remained constant to 24 months. In 50% of patients, the 1,25-dihydroxyvitamin D concentration reached a concentration of more than 30 pg/mL, similar to that in healthy volunteers; in the other 50%, the concentration reached 17.2 pg/mL. A high incidence of delayed graft function was observed in patients with 1,25-dihydroxyvitamin D deficiency (44% vs 6%). There was a negative correlation between the initial 1,25-dihydroxyvitamin D and serum creatinine concentrations at day 3 and month 6 (P &lt; .03). Similarly, the 1,25-dihydroxyvitamin D concentration at 1 month was negatively correlated with creatinine concentration at months 1 through 24 (P &lt; .01). Poor outcome was observed primarily in patients with 1,25-dihydroxyvitamin D deficiency; 2 patients developed cancer, 5 grafts were lost, and 4 patients died of cardiovascular events. CONCLUSIONS: 1,25-Dihydroxyvitamin D deficiency is highly prevalent in renal allograft recipients. Patients with 1,25-dihydroxyvitamin D deficiency are at greater risk of delayed graft function, and the graft is more likely to be lost. These findings suggest the necessity of adequate vitamin D supplementation both before and after transplantation</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, 50-417 Wroclaw, PolandJC - we9, 0243532CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19857661</style></custom1><custom3><style face="normal" font="default">AS - Transplant Proc. 41(8):3002-5, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>236</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Fallahi,B.</style></author><author><style face="normal" font="default"> Beiki,D.</style></author><author><style face="normal" font="default"> Mousavi,S.A.</style></author><author><style face="normal" font="default"> Gholamrezanezhad,A.</style></author><author><style face="normal" font="default"> Eftekhari,M.</style></author><author><style face="normal" font="default"> Fard-Esfahani,A.</style></author><author><style face="normal" font="default"> Alimoghaddam,K.</style></author><author><style face="normal" font="default"> Mirpour,S.</style></author><author><style face="normal" font="default"> Eskandarian,A.</style></author><author><style face="normal" font="default"> Saghari,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">99mTc-MIBI whole body scintigraphy and P-glycoprotein for the prediction of multiple drug resistance in multiple myeloma patients</style></title><secondary-title><style face="normal" font="default">Hellenic Journal of Nuclear Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Hellenic Journal of Nuclear Medicine</style></full-title></periodical><pages end="259" start="255">255-259</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Antineoplastic Combined Chemotherapy Protocols/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Multiple Myeloma/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Multiple Myeloma/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *P-Glycoprotein/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Radiopharmaceuticals/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> *Technetium Tc 99m Sestamibi/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> *Whole Body Imaging/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> 0 (P-Glycoprotein)</style></keyword><keyword><style face="normal" font="default"> 0 (Radiopharmaceuticals)</style></keyword><keyword><style face="normal" font="default"> 109581-73-9 (Technetium Tc 99m Sestamibi)</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Drug Resistance,Multiple</style></keyword><keyword><style face="normal" font="default"> Drug Resistance,Neoplasm</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multiple Myeloma/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="9" Year="2009">2009/9</year></dates><isbn><style face="normal" font="default">1790-5427</style></isbn><abstract><style face="normal" font="default">Multi-drug resistance (MDR) is a major challenge in the treatment of multiple myeloma (MM). There is low sensitivity of technetium-99m methoxy isobutyl isonitrile ((99m)Tc-MIBI) whole body scan (WBS) in the detection of active MM lesions, because (99m)Tc-MIBI is washed out from malignant cells in the presence of P-glycoprotein (PGP). The objective of the present cohort study was to evaluate of (99m)Tc-MIBI WBS in the prediction of MDR in MM patients during a course of one year follow up. Thirty four patients with MM (25 male, 9 female of mean age 54.12+/-11.46 years) entered the study. Thirteen patients had no previous history of treatment and 21 had a history of previous chemo-radiotherapy. The diagnosis and staging of the disease were based upon routine laboratory and clinical criteria like bone marrow plasma cell count, serum M component, calcium, albumin, beta(2)-microglobulin. Measurements of PGP and WBS using (99m)Tc-MIBI were performed before initialization of treatment and the response to treatment was assessed one year later. The baseline (99m)Tc-MIBI WBS were considered positive for the detection of active lesions when at least one area of non-physiologic increased activity was noted. The follow up (99m)Tc-MIBI WBS was positive for MDR when the patient had active disease but normal WBS. Our results showed that for WBS, the sensitivity, specificity, positive predictive value, negative predictive value and accuracy in active state for the diagnosis of MDR were 38.9%, 62.5%, 70%, 31.2% and 46.1%, respectively. Also the above values for the detection of MDR, using PGP values were 50%, 50%, 69.2%, 30.8% and 50%, respectively. The relative risk of resistant to multiple regimens of chemotherapy after one year follow up in patients with negative to patients with positive (99m)Tc-MIBI WBS was 1.02 (0.60-1.72). In conclusion, we found a low sensitivity of WBS and of PGP in the detection of MDR in patients with active MM. However, both WBS and PGP have 70% and 69% positive predictive value for MDR</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Research Institute for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, IranJC - 101257471CP - GreecePT - Clinical TrialPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19936339</style></custom1><custom3><style face="normal" font="default">AS - Hellenic J Nucl Med. 12(3):255-9, 2009 Sep-Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>76</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Feldstein,C.A.</style></author><author><style face="normal" font="default"> Akopian,M.</style></author><author><style face="normal" font="default"> Pietrobelli,D.</style></author><author><style face="normal" font="default"> Olivieri,A.</style></author><author><style face="normal" font="default"> Garrido,D.</style></author></authors></contributors><titles><title><style face="normal" font="default">Long-term effects of parathyroidectomy on hypertension prevalence and circadian blood pressure profile in primary hyperparathyroidism</style></title><secondary-title><style face="normal" font="default">Clinical &amp; Experimental Hypertension (New York)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinical &amp; Experimental Hypertension (New York)</style></full-title></periodical><pages end="158" start="154">154-158</pages><volume><style face="normal" font="default">32</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Blood Pressure/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Hyperparathyroidism,Primary/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Hypertension/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Parathyroidectomy</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 60-27-5 (Creatinine)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Argentina</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Blood Pressure Monitoring,Ambulatory</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Circadian Rhythm</style></keyword><keyword><style face="normal" font="default"> Creatinine/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Primary/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Primary/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Parathyroidectomy</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="5" Year="2010">2010/5</year></dates><abstract><style face="normal" font="default">Our aims were to evaluate the prevalence and outcome of hypertension in patients with primary hyperparathyroidism (PHPT), previously and after follow-up of parathyroidectomy. A group of 46 consecutive patients with sporadic PHPT due to adenoma undergoing surgery were followed an average of 3.5 years (range 36 to 53 months). In 16 nonselected, consecutive parathyroidectomized patients, with normalized biochemical measurements, circadian rhythm of blood pressure was evaluated with ambulatory blood pressure monitoring (ABPM). Prevalence of hypertension in PHPT was 54.35%, and there was no significant association of PTH, total and ionic calcium levels with SBP and DBP. During follow-up, none of the patients with presurgical hypertension became normotensive and five of the normotensive patients developed clinical hypertension. In ABPM, 6/11 hypertensive and 3/5 normotensive subjects showed nondipper behavior. Serum total calcium was significantly related to night-time systolic blood pressure (SBP) (r = 0.620, P &lt; 0.02), and night-time diastolic blood pressure (DBP) (r = 0.758, P &lt; 0.002). In dippers, creatinine clearance was significantly higher (91.3 +/- 18.5 vs. 64.3 +/- 11.5 ml/min, P &lt; 0.01), while serum total calcium was lower (2.42 +/- 0.13 vs. 2.23 +/- 0.17 mmol/L, P &lt; 0.04) than in nondippers. In conclusion, our results suggest that parathyroidectomy has little effect on hypertension prevalence. Renal impairment, a condition that did not improve after parathyroidectomy, may be a causal factor of hypertension in PHPT. Also, the high prevalence of nondipper behavior in hypertensive and normotensive subjects after parathyroidectomy, suggests that target organ risk persists. We hypothesized that slight elevations of serum total calcium even in the normal range could be involved in the alteration of the circadian rhythm of blood pressure</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Hypertension Program, Hospital de Cl&amp;#x00ED;nicas Jos&amp;#x00E9; de San Mart&amp;#x00ED;n, School of Medicine, Universidad de Buenos Aires, Buenos Aires 1120, Argentina. carlfel@yahoo.comJC - bp0, 9305929CP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20504122</style></custom1><custom3><style face="normal" font="default">AS - Clin Exp Hypertens. 32(3):154-8, 2010 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>199</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">fer,R.</style></author><author><style face="normal" font="default"> Mittag,F.</style></author><author><style face="normal" font="default"> nschel,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Arterial occlusion caused by a non-adsorbable bone graft after open wedge tibial osteotomy</style></title><secondary-title><style face="normal" font="default">Knee</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Knee</style></full-title></periodical><pages end="175" start="174">174-175</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Arterial Occlusive Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Biomimetic Materials/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Bone Plates</style></keyword><keyword><style face="normal" font="default"> *Knee Prosthesis/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Osteotomy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> 1306-06-5 (Durapatite)</style></keyword><keyword><style face="normal" font="default"> Amputation</style></keyword><keyword><style face="normal" font="default"> Arterial Occlusive Diseases/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Durapatite</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Postoperative Complications</style></keyword><keyword><style face="normal" font="default"> Prosthesis Failure</style></keyword><keyword><style face="normal" font="default"> Reoperation</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Toes/su [Surgery]</style></keyword></keywords><dates><year Day="0" Month="3" Year="2010">2010/3</year></dates><abstract><style face="normal" font="default">We report a case of a near fatal complication of an open wedge high tibial osteotomy held by a Puddu plate. CT-scan and lysis therapy revealed a compression of the popliteal artery by the implanted hydroxyapatite wedge resulting in ischaemia of the lower limb. Revision surgery was performed and the prominent part of the wedge was removed, however two toes had to be amputated due to the initial tissue damage. Copyright 2009 Elsevier B.V. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Orthop&amp;#x00E4;dische Universit&amp;#x00E4;tsklinik T&amp;#x00FC;bingen, Hoppe-Seyler-Str. 3, 72076 T&amp;#x00FC;bingen, Germany. Ralf.Schaefer@med.uni-tuebingen.deJC - 9430798CP - NetherlandsPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19782571</style></custom1><custom3><style face="normal" font="default">AS - Knee. 17(2):174-5, 2010 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>43</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Ferda,J.</style></author><author><style face="normal" font="default"> Linhartova,K.</style></author><author><style face="normal" font="default"> Kreuzberg,B.</style></author></authors></contributors><titles><title><style face="normal" font="default">Comparison of the aortic valve calcium content in the bicuspid and tricuspid stenotic aortic valve using non-enhanced 64-detector-row-computed tomography with prospective ECG-triggering</style></title><secondary-title><style face="normal" font="default">European Journal of Radiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">European Journal of Radiology</style></full-title></periodical><pages end="475" start="471">471-475</pages><volume><style face="normal" font="default">68</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aortic Valve Stenosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Aortography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Cardiac-Gated Imaging Techniques/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Mitral Valve/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Tricuspid Valve/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> 0 (Contrast Media)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Contrast Media</style></keyword><keyword><style face="normal" font="default"> Electrocardiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword></keywords><dates><year Day="0" Month="12" Year="2008">2008/12</year></dates><abstract><style face="normal" font="default">PURPOSE: The aim of our study was to compare the calcium content measured by non-enhanced multidetector-row-computed tomography (MDCT) between patients with significant stenosis of bicuspid (BAV) and tricuspid aortic valve (TAV). Another aim of our study was to assess the accuracy of the non-enhanced MDCT to distinguish BAV and TAV based on the calcified plaque morphology, and to compare the results with the transesophageal echocardiography. SUBJECTS AND METHODS: A retrospective analysis of prospectively collected data was performed. Consecutive patients with symptomatic aortic stenosis (AS) admitted to hospital for evaluation before valve surgery underwent clinical evaluation, transthoracic and transesophageal echocardiography, and non-enhanced examination with the 64-detector-row CT using prospective ECG triggering with data acquisition in diastolic phase. The data acquisition started at 55% of the R-R interval. The patients were examined in the supine position in mild inspiration. Data were evaluated using dedicated software for calcium scoring, the volume of calcifications and calcium content were obtained. RESULTS: Thirty-seven patients (20 males, age 48-83 years) were enrolled. BAV was present in 13 patients, TAV in 24 patients. The calcium score in patients with severe AS (mean gradient >50 mmHg) was higher than in those with moderate AS (1123+/-616 mg versus 634+/-475, P=0.011). Significant correlation between the calcium scores and transaortic gradients was found (r=0.53, P=0.002). The patients with BAV did not differ significantly from those with TAV in the AS severity (58+/-13 versus 53+/-20 mmHg), nor in the valve calcium score (1168+/-717 versus 795+/-530 mg, P=0.093). The overall sensitivity to detect BAV in patients with calcified severe AS was 0.923 (12/13) and specificity 0.958 (23/24). The overall accuracy was 0.945 (35/37). CONCLUSION: We observed higher calcium score in patients with severe AS than with moderate AS. However, no difference in aortic valve calcium score between BAV and TAV was found. Thus, in our sample, the aortic valve calcium score correlated with AS severity, not with aortic valve morphology. Based on the calcified plaque space relationship, the aortic BAV and TAV could be distinguished in most cases</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Radiology, Charles University Hospital Plzen, Alej Svobody 80, CZ-306 40 Plzen, Czech Republic. ferda@fnplzen.czJC - em6, 8106411CP - IrelandPT - Comparative StudyPT - Evaluation StudiesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 17961946</style></custom1><custom3><style face="normal" font="default">AS - Eur J Radiol. 68(3):471-5, 2008 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>3</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Feuchtner,G.M.</style></author><author><style face="normal" font="default"> Jodocy,D.</style></author><author><style face="normal" font="default"> Klauser,A.</style></author><author><style face="normal" font="default"> Haberfellner,B.</style></author><author><style face="normal" font="default"> Aglan,I.</style></author><author><style face="normal" font="default"> Spoeck,A.</style></author><author><style face="normal" font="default"> Hiehs,S.</style></author><author><style face="normal" font="default"> Soegner,P.</style></author><author><style face="normal" font="default"> Jaschke,W.</style></author></authors></contributors><titles><title><style face="normal" font="default">Radiation dose reduction by using 100-kV tube voltage in cardiac 64-slice computed tomography: a comparative study</style></title><secondary-title><style face="normal" font="default">European Journal of Radiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">European Journal of Radiology</style></full-title></periodical><pages end="e56" start="e51">e51-e56</pages><volume><style face="normal" font="default">75</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Body Burden</style></keyword><keyword><style face="normal" font="default"> *Cardiac-Gated Imaging Techniques/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Radiation Dosage</style></keyword><keyword><style face="normal" font="default"> *Radiation Protection/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Radiometry</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed/is [Instrumentation]</style></keyword></keywords><dates><year Day="0" Month="7" Year="2010">2010/7</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To evaluate a 100-kilovoltage (kV) tube voltage protocol regarding radiation dose and image quality, in comparison with the standard 120 kV setting in cardiac computed tomography angiography (CCTA). METHODS: 103 patients undergoing retrospective ECG-gated helical 64-slice CCTA were enrolled (100 kV group: 51 patients; 120 kV group: 52 patients). Inclusion criteria were: (1) BMI &lt;28 kg/m(2); (2) weight &lt;85 kg; (3) coronary calcium score &lt;300 Agatston Units (AU). Quantitative image quality parameters were calculated [image noise, contrast-to-noise ratio (CNR), intracoronary CT-attenuation (HU)]. Each coronary artery segment (AHA/ACC-16-segments-classification) was evaluated for image quality on a 4-point scale. RESULTS: There was no statistical difference in age, gender, BMI and eff. tube current (mAs), and the use of ECG-tube current modulation (50.9% vs. 50% of patients) between both groups. 84.2% of patients in the 100 kV group had zero calcium score or less than 100 AU, the remaining had between 100 and 300 AU. The effective radiation dose was significantly lower in the 100 kV group with mean 7.1 mSv+/-2.4 (range, 3.4-11.1) compared to the 120 kV group with 13.4 mSv+/-5.2 (range, 6.3-22.7) (p&lt;0.001) (dose reduction, 47%). In the 100 kV group, the use of ECG-dependent tube current modulation reduced the radiation exposure (by 44.8%) to 5.3 mSv+/-1.1 (range, 3.4-8.5 mSv) (p&lt;0.001), the dose without was 9.6 mSv+/-1.1 (range, 6.3-11.1). Image noise in the coronary arteries was not different between both groups with 29.8 and 30.5 SD [HU], respectively. CNR in the 100 kV group was with 20.9+/-6.8 for the coronary arteries and with 19.9+/-5.9 for the aorta similar to the 120 kV group. Intraluminal CT-attenuation (HU) of the coronary arteries were higher in the 100 kV group (p&lt;0.001). Image quality on 100 kV scans was excellent in 86.3%, good in 9.2%, acceptable in 3.1% of coronary segments; 1.4% were non-interpretable (in 1/4 due to increased image noise because of BMI >25 kg/m(2)). CONCLUSIONS: The 100 kV protocol significantly reduces the radiation dose in CCTA in patients with a low BMI &lt;25 kg/m(2) and a low calcium load while maintaining high image quality and the advantages of helical scan algorithm. Copyright 2009 Elsevier Ireland Ltd. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Radiology II, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria. Gudrun.Feuchtner@i-med.ac.atJC - em6, 8106411CP - IrelandPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19671491</style></custom1><custom3><style face="normal" font="default">AS - Eur J Radiol. 75(1):e51-6, 2010 Jul.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>334</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Fischer,D.C.</style></author><author><style face="normal" font="default"> Nissel,R.</style></author><author><style face="normal" font="default"> Puhlmann,A.</style></author><author><style face="normal" font="default"> Mitzner,A.</style></author><author><style face="normal" font="default"> Tiess,M.</style></author><author><style face="normal" font="default"> Schmidt,R.</style></author><author><style face="normal" font="default"> Haffner,D.</style></author></authors></contributors><titles><title><style face="normal" font="default">Differential effects of short-term growth hormone therapy on the cardiovascular risk profile in patients with chronic kidney disease: a pilot study</style></title><secondary-title><style face="normal" font="default">Clinical Nephrology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinical Nephrology</style></full-title></periodical><pages end="352" start="344">344-352</pages><volume><style face="normal" font="default">72</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Human Growth Hormone/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure,Chronic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Malnutrition/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Blood Glucose)</style></keyword><keyword><style face="normal" font="default"> 0 (fibroblast growth factor 23)</style></keyword><keyword><style face="normal" font="default"> 0 (Insulin-Like Growth Factor Binding Protein 3)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipids)</style></keyword><keyword><style face="normal" font="default"> 12629-01-5 (Human Growth Hormone)</style></keyword><keyword><style face="normal" font="default"> 62031-54-3 (Fibroblast Growth Factors)</style></keyword><keyword><style face="normal" font="default"> 67763-96-6 (Insulin-Like Growth Factor I)</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Blood Glucose/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fibroblast Growth Factors/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Insulin-Like Growth Factor Binding Protein 3/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Insulin-Like Growth Factor I/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Lipids/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Malnutrition/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Malnutrition/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="11" Year="2009">2009/11</year></dates><isbn><style face="normal" font="default">0301-0430</style></isbn><abstract><style face="normal" font="default">Chronic kidney disease (CKD) is highly associated with an increased cardiovascular morbidity and mortality and is also a state of growth hormone (GH) resistance. We examined the impact of a short-term treatment with rhGH on circulating markers of cardiovascular risk in nonmalnourished CKD patients in a single-center, nonrandomized pilot study. Patients with stable CKD Stage 3 - 5 and age- and sex-matched healthy controls (n = 15 each) received a 7-day treatment with rhGH (1.33 mg/m2 body surface area per day, approximately 30 microg/kg). Prior to onset of rhGH therapy, at the end of the treatment period and at the end of a 7-day wash-out period blood was drawn to assess changes in circulating markers of cardiovascular risk. At time of enrollment CKD patients showed elevated serum concentrations of phosphate, calcium x phosphate product, PTH, fibroblast growth factor-23 (FGF-23), triglycerides, leptin and homocysteine compared to controls. In patients and controls rhGH treatment induced an increase in circulating insulin-like growth factor I (IGF-I), and the molar ratio of IGF-I/IGF binding protein 3 as well as an elevation of glucose, insulin, and triglycerides, whereas serum urea was decreased. In CKD patients, rhGH treatment raised concentrations of leptin, whereas LDL-cholesterol, homocysteine, phosphate, and 25-hydroxyvitamin D were significantly reduced. In controls, but not in CKD patients, rhGH raised 1,25-dihydroxy-vitamin D3 serum levels, which were even more elevated at the end of the wash-out period. In conclusion, short-term treatment with rhGH in CKD patients affects not only insulin and glucose metabolism but also affects serum lipid profile, i.e., LDL-cholesterol, leptin and homocysteine. Long-term trials are required to evaluate the impact of rhGH on cardiovascular morbidity and mortality</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Pediatrics, University Children's Hospital Rostock, Rostock, Germany. dagmar-christiane.fischer@med.uni-rostock.deJC - dey, 0364441CP - GermanyPT - Clinical TrialPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19863876</style></custom1><custom3><style face="normal" font="default">AS - Clin Nephrol. 72(5):344-52, 2009 Nov.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>39</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Fisher,A.</style></author><author><style face="normal" font="default"> Srikusalanukul,W.</style></author><author><style face="normal" font="default"> Davis,M.</style></author><author><style face="normal" font="default"> Smith,P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Hip fracture type: important role of parathyroid hormone (PTH) response to hypovitaminosis D</style></title><secondary-title><style face="normal" font="default">Bone</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Bone</style></full-title></periodical><pages end="407" start="400">400-407</pages><volume><style face="normal" font="default">47</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Hip Fractures/cl [Classification]</style></keyword><keyword><style face="normal" font="default"> *Hip Fractures/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Parathyroid Hormone/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Vitamin D Deficiency/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Vitamin D Deficiency/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Bone and Bones/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Bone and Bones/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Bone and Bones/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Bone Remodeling/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hip Fractures/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="8" Year="2010">2010/8</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To investigate whether clinical and laboratory characteristics, including serum 25-hydroxyvitamin D (25(OH) D), PTH and parameters of mineral and bone metabolism, differ by hip fracture (HF) type. PATIENTS AND METHODS: We studied prospectively 761 consecutively admitted older patients (mean age 82.3+8.8(SD) years; 74.9% women) with low trauma non-pathological HF. A detailed clinical examination was performed, haematologic, renal, liver and thyroid function tests, serum 25(OH)D, PTH, calcium, phosphate, magnesium, C-reactive protein (CRP) and cardiac troponin I (cTnI) measured. In a subset of 294 patients' markers of bone formation (serum osteocalcin, OC; bone specific alkaline phosphatase, BAP) and bone resorption (urinary deoxypyridinoline, DPD/Cr; N-terminal cross-linked telopeptide of type 1 collagen, NTx/Cr; both corrected to urinary creatinine, Cr) were also measured. RESULTS: In the trochanteric compared to the cervical group, females were older than males and the prevalence of Parkinson's disease, mean haemoglobin and albumin levels were lower. Incidence and degree of myocardial injury (cTnl rise) and inflammatory reaction (CRP elevation) as well as length of hospital stay, need of institutionalisation or in-hospital mortality were similar in both groups. Hypovitaminosis D (25(OH)D &lt;50 mmol/L) was present in 77.8% of patients with cervical and in 82.1% with trochanteric HF, elevated PTH (>6.8 pmol/L) in 30.2% and 41.3%, respectively. The associations between 25(OH)D, PTH, and parameters of mineral metabolism and bone turnover were site-specific. In multivariate analyses, PTH (both as a continuous or categorical variable) response to hypovitaminosis D was a strong independent predictor of HF type. Coexistence of vitamin D deficiency (25(OH) D&lt; 25 nmol/L) and elevated PTH predicts trochanteric HF while blunted PTH response predicts cervical HF (OR=3.5; 95% CI 1.5-80; p=0.005). PTH response and phosphate status (above or below median level) correctly discriminated HF type in 73.8% of patients with vitamin D deficiency. CONCLUSIONS: HF type is significantly associated with PTH response to hypovitaminosis D and impaired phosphate homeostasis. We detected only minor differences between two main HF types with regard to a wide range of clinical and routine laboratory variables as well as short-term outcomes. Copyright 2010 Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Geriatric Medicine, The Canberra Hospital, ACT, Australia. alex.fisher@act.gov.auJC - asr, 8504048CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20451678</style></custom1><custom3><style face="normal" font="default">AS - Bone. 47(2):400-7, 2010 Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>470</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Folsom,A.R.</style></author><author><style face="normal" font="default"> Delaney,J.A.</style></author><author><style face="normal" font="default"> Lutsey,P.L.</style></author><author><style face="normal" font="default"> Zakai,N.A.</style></author><author><style face="normal" font="default"> Jenny,N.S.</style></author><author><style face="normal" font="default"> Polak,J.F.</style></author><author><style face="normal" font="default"> Cushman,M.</style></author><author><style face="normal" font="default"> Multiethnic Study of Atherosclerosis Investigators</style></author></authors></contributors><titles><title><style face="normal" font="default">Associations of factor VIIIc, D-dimer, and plasmin-antiplasmin with incident cardiovascular disease and all-cause mortality</style></title><secondary-title><style face="normal" font="default">American Journal of Hematology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Hematology</style></full-title></periodical><pages end="353" start="349">349-353</pages><volume><style face="normal" font="default">84</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*alpha-2-Antiplasmin/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Factor VIII/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Fibrin Fibrinogen Degradation Products/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> 0 (alpha-2-Antiplasmin)</style></keyword><keyword><style face="normal" font="default"> 0 (Fibrin Fibrinogen Degradation Products)</style></keyword><keyword><style face="normal" font="default"> 0 (fibrin fragment D)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 9001-27-8 (Factor VIII)</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Carotid Arteries/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Carotid Arteries/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tunica Media/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="6" Year="2009">2009/6</year></dates><abstract><style face="normal" font="default">To examine the associations of three understudied hemostatic factors--D-dimer, factor VIII(c), and plasmin-antiplasmin (PAP) complex--with incident cardiovascular disease (CVD) and all cause mortality in the Multiethnic Study of Atherosclerosis cohort. Hemostatic factors were measured at baseline in 45-84-year-old patients (n = 6,391) who were free of clinically recognized CVD. Over 4.6 years of follow-up, we identified 307 CVD events, 207 hard coronary heart disease events, and 210 deaths. D-dimer, factor VIII(c), and PAP were not associated with CVD incidence after adjustment for other risk factors. In contrast, each factor was associated positively with total mortality, and D-dimer and factor VIII(c) were associated positively with cancer mortality. When modeled as ordinal variables and adjusted for risk factors, total mortality was greater by 33% (95% CI 15-54) for each quartile increment of D-dimer, 26% (11-44) for factor VIIIc, and 20% (4-38) for PAP. This prospective cohort study did not find D-dimer, factor VIII(c), or PAP to be risk factors for CVD. Instead, elevated levels of these three hemostatic factors were associated independently with increased risk of death. Elevated D-dimer and factor VIII(c) were associated with increased cancer death</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USAJC - 3h4, 7610369CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - N01-HC-95159 (United States NHLBI NIH HHS)NO - N01-HC-95165 (United States NHLBI NIH HHS)NO - N01-HC-95169 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19472201</style></custom1><custom3><style face="normal" font="default">AS - Am J Hematol. 84(6):349-53, 2009 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>469</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Fredrikson,G.N.</style></author><author><style face="normal" font="default"> Anand,D.V.</style></author><author><style face="normal" font="default"> Hopkins,D.</style></author><author><style face="normal" font="default"> Corder,R.</style></author><author><style face="normal" font="default"> Alm,R.</style></author><author><style face="normal" font="default"> Bengtsson,E.</style></author><author><style face="normal" font="default"> Shah,P.K.</style></author><author><style face="normal" font="default"> Lahiri,A.</style></author><author><style face="normal" font="default"> Nilsson,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes</style></title><secondary-title><style face="normal" font="default">Diabetologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Diabetologia</style></full-title></periodical><pages end="1433" start="1426">1426-1433</pages><volume><style face="normal" font="default">52</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Apolipoprotein B-100/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> *Autoantibodies/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Complications/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Complications/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 2/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 2/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> 0 (Apolipoprotein B-100)</style></keyword><keyword><style face="normal" font="default"> 0 (Autoantibodies)</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Immunoglobulin G)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipoproteins,LDL)</style></keyword><keyword><style face="normal" font="default"> 0 (oxidized low density lipoprotein)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Albuminuria/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Albuminuria/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Disease/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> Diabetic Angiopathies/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Diabetic Angiopathies/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> Diabetic Nephropathies/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Diabetic Nephropathies/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> Diabetic Retinopathy/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Diabetic Retinopathy/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin G/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Lipoproteins,LDL/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Microcirculation/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Oxidative Stress</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword></keywords><dates><year Day="0" Month="7" Year="2009">2009/7</year></dates><abstract><style face="normal" font="default">AIMS/HYPOTHESIS: Oxidation of LDL in the arterial extracellular matrix is a key event in the development of atherosclerosis and autoantibodies against oxidised LDL antigens reflect disease severity and the risk of developing acute cardiovascular events. Since type 2 diabetes is associated with increased oxidative stress, we tested the hypothesis that autoantibodies against oxidised LDL antigens are biomarkers for vascular complications in diabetes. METHODS: We studied 497 patients with type 2 diabetes without clinical signs of coronary heart disease. Oxidised LDL autoantibodies were determined by ELISA detecting IgG and IgM specific for native and malondialdehyde (MDA)-modified apolipoprotein B-100 peptides p45 and p210. The severity of coronary disease was assessed as the coronary artery calcium score. RESULTS: Patients affected by retinopathy had significantly higher levels of IgG against MDA-p45 and MDA-p210. In contrast, high levels of autoantibodies against the corresponding native peptides were associated with less coronary calcification and a lower risk of progression of coronary disease. CONCLUSIONS/INTERPRETATION: Our observations suggest that LDL oxidation is involved in the pathogenesis of diabetic retinopathy and that autoantibodies against apolipoprotein B peptides may act as biomarkers for both micro- and macrovascular complications in diabetes</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Clinical Sciences, Malm&amp;#x00F6; University Hospital, Lund University, Malm&amp;#x00F6;, SwedenJC - e93, 0006777CP - GermanyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19448981</style></custom1><custom3><style face="normal" font="default">AS - Diabetologia. 52(7):1426-33, 2009 Jul.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>410</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Gallo,L.C.</style></author><author><style face="normal" font="default"> de Los Monteros,K.E.</style></author><author><style face="normal" font="default"> Allison,M.</style></author><author><style face="normal" font="default"> Roux,A.D.</style></author><author><style face="normal" font="default"> Polak,J.F.</style></author><author><style face="normal" font="default"> Watson,K.E.</style></author><author><style face="normal" font="default"> Morales,L.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Do socioeconomic gradients in subclinical atherosclerosis vary according to acculturation level? Analyses of Mexican-Americans in the multi-ethnic study of atherosclerosis</style></title><secondary-title><style face="normal" font="default">Psychosomatic Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Psychosomatic Medicine</style></full-title></periodical><pages end="762" start="756">756-762</pages><volume><style face="normal" font="default">71</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Acculturation</style></keyword><keyword><style face="normal" font="default"> *Atherosclerosis/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> *Mexican Americans/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aorta,Thoracic/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Aorta,Thoracic/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Emigrants and Immigrants/px [Psychology]</style></keyword><keyword><style face="normal" font="default"> Emigrants and Immigrants/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Health Status Disparities</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Mexican Americans/px [Psychology]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> Socioeconomic Factors</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> United States/ep [Epidemiology]</style></keyword></keywords><dates><year Day="0" Month="9" Year="2009">2009/9</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To examine whether the association between socioeconomic position (SEP) and subclinical atherosclerosis in Mexican-Americans would be moderated by acculturation. Although SEP shows a consistent, inverse relationship with cardiovascular disease (CVD) risk in westernized non-Hispanic white populations, the relationship in ethnic minorities, including Hispanics, is often weak or even reversed (i.e., worse health with higher SEP). METHODS: Participants were 801 Hispanics of Mexican origin (49.6% = female; average age = 60.47 years) from the Multi-Ethnic Study of Atherosclerosis cohort who underwent computed tomography of the chest for coronary artery calcium (CAC) and thoracic aortic calcium (TAC). SEP was represented by a composite of self-reported education and income. Acculturation was a composite score, including language spoken at home, generation, and years of "exposure" to U.S. culture. RESULTS: Small but statistically significant SEP by acculturation interaction effects were identified in relation to prevalent CAC, prevalent TAC, and extent of TAC (all p &lt; .05). Follow-up analyses revealed that the direction of the SEP gradient on detectable CAC changed as individuals progressed from low to high acculturation. Specifically, the association between SEP and calcification was positive at low levels of acculturation (i.e., a "reversed" gradient), and negative in circumstances of high acculturation (i.e., the expected, protective effect of higher SEP). CONCLUSIONS: The findings support the utility of examining SEP and acculturation simultaneously, and of disaggregating large ethnic groupings (e.g., "Hispanic") into meaningful subgroups to better understand health risks</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - San Diego State University/University of California San Diego Joint Doctoral Program in Clinical Psychology, San Diego, California 92120, USA. lcgallo@sciences.sdsu.eduJC - qgr, 0376505CP - United StatesPT - Comparative StudyPT - Journal ArticlePT - Multicenter StudyPT - Research Support, N.I.H., ExtramuralPT - Research Support, U.S. Gov't, P.H.SNO - 1P20MD002293-01 (United States NCMHD NIH HHS)NO - 1R01HL081604-01 (United States NHLBI NIH HHS)NO - N01-HC-95159 (United States NHLBI NIH HHS)NO - N01-HC-95160 (United States NHLBI NIH HHS)NO - N01-HC-95161 (United States NHLBI NIH HHS)NO - N01-HC-95162 (United States NHLBI NIH HHS)NO - N01-HC-95163 (United States NHLBI NIH HHS)NO - N01-HC-95164 (United States NHLBI NIH HHS)NO - N01-HC-95165 (United States NHLBI NIH HHS)NO - N01-HC-95166 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19661194</style></custom1><custom3><style face="normal" font="default">AS - Psychosom Med. 71(7):756-62, 2009 Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>490</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Gao,S.K.</style></author><author><style face="normal" font="default"> Fitzpatrick,A.L.</style></author><author><style face="normal" font="default"> Psaty,B.</style></author><author><style face="normal" font="default"> Jiang,R.</style></author><author><style face="normal" font="default"> Post,W.</style></author><author><style face="normal" font="default"> Cutler,J.</style></author><author><style face="normal" font="default"> Maciejewski,M.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Suboptimal nutritional intake for hypertension control in 4 ethnic groups</style></title><secondary-title><style face="normal" font="default">Archives of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Archives of Internal Medicine</style></full-title></periodical><pages end="707" start="702">702-707</pages><volume><style face="normal" font="default">169</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Health Behavior</style></keyword><keyword><style face="normal" font="default"> *Health Knowledge,Attitudes,Practice</style></keyword><keyword><style face="normal" font="default"> *Hypertension/dh [Diet Therapy]</style></keyword><keyword><style face="normal" font="default"> *Hypertension/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> *Patient Compliance/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> African Americans</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Dietary Supplements</style></keyword><keyword><style face="normal" font="default"> Ethnic Groups</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Guidelines as Topic</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Nutrition Policy</style></keyword><keyword><style face="normal" font="default"> Nutritional Requirements</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="13" Month="4" Year="2009">2009/4/13</year></dates><abstract><style face="normal" font="default">BACKGROUND: This study compared intake of specific nutrients based on the Dietary Approaches to Stop Hypertension (DASH) guidelines for hypertension management among multiethnic middle-aged and older adults. METHODS: We conducted quantitative analysis using baseline data of a prospective cohort study of 5972 adults aged 45 to 84 years recruited between July 2000 and August 2002 who participated in the Multi-Ethnic Study of Atherosclerosis (MESA). Diet information was collected using a 120-item food frequency questionnaire. Bivariate and multivariate methods were used to evaluate associations between DASH-accordant intake of each nutrient (fat, saturated fat, cholesterol, protein, fiber, calcium, magnesium, and potassium) with ethnicity and hypertension status. RESULTS: Less than 30% of MESA participants met any DASH nutrient target. DASH accordance was lowest in saturated fat intake and highest in cholesterol intake (5.3% and 29.5% of the participants, respectively). Multivariate analyses showed significant ethnic differences in DASH accordance in all nutrients but saturated fat. Compared with white participants, Chinese American participants had greater DASH accordance in cholesterol (odds ratio [OR], 1.37; 95% confidence interval [CI], 1.13-1.67) and protein intake (2.32; 1.55-3.49) but less in total fat (0.47; 0.30-0.74), magnesium (0.58; 0.51-0.67), and potassium intake (0.40; 0.20-0.81); African Americans and Hispanics had greater DASH accordance in fiber intake (1.36; 1.13-1.62; and 2.23; 1.53-3.23, respectively) but less in calcium intake (0.44; 0.37-0.52; and 0.79; 0.68-0.91, respectively). Diagnosed and uncontrolled hypertension was associated with less DASH accordance in saturated fat (OR, 0.80; 95% CI, 0.70-0.91) and magnesium (0.80; 0.71-0.91). DASH accordance differed significantly with and without inclusion of dietary supplements in the analysis. CONCLUSIONS: There is significant variation in DASH goal attainment among different ethnic groups. Assessments of nutrient intake that exclude dietary supplements may be underestimating DASH accordance</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Amgen Inc, 1 Amgen Center Dr, MS28-3A, Thousand Oaks, CA 91320-1799, USA. sgao@amgen.comJC - 0372440, 7fsCP - United StatesPT - Comparative StudyPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - 1 R21 AT002152-01 (United States NCCAM NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19365000</style></custom1><custom3><style face="normal" font="default">AS - Arch Intern Med. 169(7):702-7, 2009 Apr 13.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>108</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Garakyaraghi,M.</style></author><author><style face="normal" font="default"> Kerdegari,M.</style></author><author><style face="normal" font="default"> Siavash,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Calcium and vitamin D status in heart failure patients in Isfahan, Iran</style></title><secondary-title><style face="normal" font="default">Biological Trace Element Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Biological Trace Element Research</style></full-title></periodical><pages end="73" start="67">67-73</pages><volume><style face="normal" font="default">135</style></volume><number><style face="normal" font="default">1-3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Heart Failure/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Vitamin D/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 1406-16-2 (Vitamin D)</style></keyword><keyword><style face="normal" font="default"> 19356-17-3 (Calcifediol)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcifediol/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Iran/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Ventricular Dysfunction,Left/bl [Blood]</style></keyword></keywords><dates><year Day="0" Month="6" Year="2010">2010/6</year></dates><abstract><style face="normal" font="default">Both calcium and vitamin D play important roles in cardiac muscle contraction and performance. In this cross-sectional study, we evaluated the status of serum calcium, PTH and 25(OH)D(3) and their correlation with left ventricular Function and NYHA Functional class in 95 heart failure patients referred to Shahid Chamran Hospital, Isfahan, Iran, by colorimetric, immunoradiometric, and Immunochemiluminescent assays, echocardiography and interview respectively. The study was performed between Oct 2007 and Feb 2008. Twenty eight women and 67 men of functional classes 1, 2, or 3 participated in the study. Mean (SD) of age of the participants was 62(11) years. Mean (SD) serum calcium and 25(OH)D(3) were 2.41(0.16) mmol/L and 56.78(51.33) nmol/L, respectively. The overall prevalence of low vitamin D status was 84.2%. There was no correlation between serum calcium and 25(OH)D(3) with LVEF. Interestingly, patients with hyperparathyroidism (serum PTH>65 ng/L) had lower LVEF (27% versus 32.5% p = 0.03). NYHA functional class was worse in patients with hyperparathyroidism (p = 0.08). Hypovitaminosis D is very prevalent in heart failure patients. Hyperparathyroidism in these patients may adversely affect cardiac function. Vitamin D3 might serve as an adjunctive treatment for heart failure patients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Isfahan University of Medical Sciences, Isfahan Cardiovascular Research Center, Isfahan, IranJC - au1, 7911509CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19690819</style></custom1><custom3><style face="normal" font="default">AS - Biol Trace Elem Res. 135(1-3):67-73, 2010 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>567</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Garc&amp;#x00ED</style></author><author><style face="normal" font="default">a-Garc&amp;#x00ED</style></author><author><style face="normal" font="default">a HM</style></author><author><style face="normal" font="default"> Gonzalo,N.</style></author><author><style face="normal" font="default"> Tanimoto,S.</style></author><author><style face="normal" font="default"> Meliga,E.</style></author><author><style face="normal" font="default"> de,Jaegere P.</style></author><author><style face="normal" font="default"> Serruys,P.W.</style></author></authors></contributors><titles><title><style face="normal" font="default">Characterization of edge effects with paclitaxel-eluting stents using serial intravascular ultrasound radiofrequency data analysis: the BETAX (BEside TAXus) Study.[Erratum appears in Rev Esp Cardiol. 2009 Apr;62(4):463]</style></title><secondary-title><style face="normal" font="default">Revista Espanola de Cardiologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Revista Espanola de Cardiologia</style></full-title></periodical><pages end="1019" start="1013">1013-1019</pages><volume><style face="normal" font="default">61</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Vessels/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Drug-Eluting Stents</style></keyword><keyword><style face="normal" font="default"> *Paclitaxel/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> *Ultrasonography,Interventional</style></keyword><keyword><style face="normal" font="default"> 33069-62-4 (Paclitaxel)</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/ah [Anatomy &amp; Histology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Paclitaxel/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Stents</style></keyword></keywords><dates><year Day="0" Month="10" Year="2008">2008/10</year></dates><abstract><style face="normal" font="default">INTRODUCTION AND OBJECTIVES: At present, the effect of paclitaxel on tissue structure at the edges of Taxus(R) stents is unknown. The objective of this study was to investigate in vivo the temporal changes occurring at the edges of paclitaxel-eluting stents using intravascular ultrasound radiofrequency (IVUS-RF) data analysis. METHODS: The study included 24 patients who had a total of 26 paclitaxel-eluting stented segments. In all patients, IVUS-RF imaging was performed 5 mm proximally and 5 mm distally to the stent edges 6 months after stent implantation. For subsequent analysis, proximal and distal segments were divided into five 1-mm subsegments. RESULTS: In the first two subsegments adjacent to the proximal edge of the stent, the vessel wall had grown to compensate for plaque growth without affecting the vessel lumen, while in the remaining three subsegments there was overcompensation (i.e., the vessel wall increased to greater than the plaque size). Consequently, the lumen had increased in size. At the distal edge of the stent, overcompensation was observed in all five subsegments and the lumen had increased in size. In general, proximal and distal growth was due to an increase in fibrolipid plaque (P&lt; .001 and P&lt; .001, respectively) along with a decrease in the necrotic core (P=.014 and P&lt; .001, respectively) and the presence of dense calcium (P&lt; .001 and P&lt; .001, respectively). CONCLUSIONS: Serial expansive vascular remodeling was observed at proximal and distal stent edges. Remodeling occurred in response to tissue growth, which was mainly due to increased fibrofatty tissue</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Thoraxcenter, Erasmus MC, Rotterdam, The NetherlandsCM - Comment in: Rev Esp Cardiol. 2008 Oct;61(10):1001-6; PMID: 18817674]JC - rtd, 0404277CP - SpainPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18817677</style></custom1><custom3><style face="normal" font="default">AS - Rev Esp Cardiol. 61(10):1013-9, 2008 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>485</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Garc&amp;#x00ED</style></author><author><style face="normal" font="default">a-Garc&amp;#x00ED</style></author><author><style face="normal" font="default">a HM</style></author><author><style face="normal" font="default"> van Mieghem,C.A.</style></author><author><style face="normal" font="default"> Gonzalo,N.</style></author><author><style face="normal" font="default"> Meijboom,W.B.</style></author><author><style face="normal" font="default"> Weustink,A.C.</style></author><author><style face="normal" font="default"> Onuma,Y.</style></author><author><style face="normal" font="default"> Mollet,N.R.</style></author><author><style face="normal" font="default"> Schultz,C.J.</style></author><author><style face="normal" font="default"> Meliga,E.</style></author><author><style face="normal" font="default"> van der,Ent M.</style></author><author><style face="normal" font="default"> Sianos,G.</style></author><author><style face="normal" font="default"> Goedhart,D.</style></author><author><style face="normal" font="default"> den,Boer A.</style></author><author><style face="normal" font="default"> de,Feyter P.</style></author><author><style face="normal" font="default"> Serruys,P.W.</style></author></authors></contributors><titles><title><style face="normal" font="default">Computed tomography in total coronary occlusions (CTTO registry): radiation exposure and predictors of successful percutaneous intervention</style></title><secondary-title><style face="normal" font="default">Eurointervention</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eurointervention</style></full-title></periodical><pages end="616" start="607">607-616</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Angioplasty,Transluminal,Percutaneous Coronary</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Occlusion/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> 0 (Contrast Media)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcinosis/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Contrast Media/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Contrast Media/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Coronary Occlusion/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Practice Guidelines as Topic</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Radiation Dosage</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Treatment Failure</style></keyword></keywords><dates><year Day="0" Month="3" Year="2009">2009/3</year></dates><isbn><style face="normal" font="default">1774-024X</style></isbn><abstract><style face="normal" font="default">AIMS: There is no mention in the current "appropriateness criteria for CTCA" of the need of CTCA investigation prior to an attempt at recanalisation of a CTO. To define better the role of CTCA in the treatment of patients with CTOs, we performed CTCA in a consecutive cohort of eligible patients who were scheduled for percutaneous recanalisation of a CTO. METHODS AND RESULTS: Symptomatic patients due to a CTO suitable for percutaneous treatment were included. One hundred and thirty-nine (142 CTOs) patients were studied. Overall success rate was 62.7%. By CTCA, the occlusion length was 24.9 +/- 18.3 vs. 30.7 +/- 20.7 mm in successful and failed cases (p = 0.1), but the frequency of patients with an occlusion length >15 mm was different, i.e., 63.2% vs. 82.7%, respectively (p = 0.02). Severe calcification, (> 50% CSA) was more prevalent in failed cases (54.7% vs. 35.9%, p = 0.03). Calcification at the entry of the occlusion was present in 58.5% of the failures vs. 41.6% of the successful cases (p = 0.04), while calcium at the exit was not different. The length of calcification was 8.5 +/- 8.4 vs. 5.5 +/- 6.6 mm in the failed and successful cases respectively (p = 0.027). By multivariable analysis, the only independent predictor of procedural success was the absence of severe calcification as defined by CTCA. The mean effective radiation dose of the PCI was 39.3 +/- 30.1 mSv. The mean effective radiation dose of CT scan was 22.4 mSv: 19.2 +/- 6.5 mSv for contrast-enhanced scan, 3.2 +/- 1.7 mSv for calcium scoring scan. CONCLUSIONS: More severe calcified patterns, as assessed by CTCA, are seen in failed cases. The radiation exposure during a CT scan prior to a CTO PCI is considerable, and further studies are required to determine whether this extra diagnostic study is warranted</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Thoraxcenter, Erasmus Medical Center, Rotterdam, The NetherlandsCM - Comment in: EuroIntervention. 2009 Mar;4(5):551, 553; PMID: 19378672]JC - 101251040CP - FrancePT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19378681</style></custom1><custom3><style face="normal" font="default">AS - EuroIntervention. 4(5):607-16, 2009 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>286</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Gardin,J.M.</style></author><author><style face="normal" font="default"> Allebban,Z.</style></author><author><style face="normal" font="default"> Wong,N.D.</style></author><author><style face="normal" font="default"> Sklar,S.K.</style></author><author><style face="normal" font="default"> Bess,R.L.</style></author><author><style face="normal" font="default"> Spence,M.A.</style></author><author><style face="normal" font="default"> Pershadsingh,H.A.</style></author><author><style face="normal" font="default"> Detrano,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Do differences in subclinical cardiovascular disease in mexican americans versus European americans help explain the Hispanic paradox?</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="209" start="205">205-209</pages><volume><style face="normal" font="default">105</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiovascular Diseases/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> *European Continental Ancestry Group/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> *Health Status Disparities</style></keyword><keyword><style face="normal" font="default"> *Mexican Americans/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Ventricles/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="15" Month="1" Year="2010">2010/1/15</year></dates><abstract><style face="normal" font="default">Mexican Americans have exhibited increases in various coronary heart disease risk factors compared to European Americans but have also had reportedly lower coronary heart disease mortality from vital statistics studies. We hypothesized this apparent paradox might relate to lower levels of subclinical disease in Mexican Americans. A total of 105 adult Mexican Americans (42 men and 63 women, age 46 +/- 14 years) and 100 European Americans (59 men and 41 women, age 50 +/- 11 years) were studied using blood tests, transthoracic echocardiography, and computed tomography coronary artery calcium (CAC) scans. Despite a greater body mass index and triglycerides in Mexican Americans (p &lt;0.001), the Mexican Americans demonstrated less subclinical disease than did the European Americans (14.4% vs 25.7% with CAC scores >0, p &lt;0.05 and mean left ventricular mass [LV] of 146 vs 160 g, p &lt;0.05). Also, the LV mass was significantly greater in Mexican Americans with than in those without CAC (mean 172 vs 140 g, p &lt;0.05). On logistic regression analysis, age and diastolic blood pressure were associated with an increased likelihood of CAC (p &lt;0.001 and p &lt;0.01, respectively), and Mexican-American ethnicity was associated with a decreased likelihood of CAC (odds ratio 0.33, 95% confidence interval 0.12 to 0.87, p &lt;0.05). On multiple regression analysis, male gender, body surface area, and systolic blood pressure were independently associated with an increased LV mass (all p &lt;0.001). The body mass index was less strongly related to the LV mass than was the body surface area and was not related to CAC. In conclusion, Mexican-American ethnicity is associated with both a lower LV mass and a lower prevalence of CAC, although the differences in LV mass did not remain after adjustment for other factors. Although systolic blood pressure, body surface area, and male gender were most strongly associated with the LV mass, age and diastolic blood pressure, in addition to Mexican-American ethnicity, were the most important indicators of CAC. Copyright 2010 Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiology, Department of Medicine, St. John Hospital and Medical Center and Wayne State University, Detroit, Michigan, USA. JGardin@humed.comJC - 3dq, 0207277CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20102919</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 105(2):205-9, 2010 Jan 15.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>210</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Garelnabi,M.</style></author><author><style face="normal" font="default"> Gupta,V.</style></author><author><style face="normal" font="default"> Mallika,V.</style></author><author><style face="normal" font="default"> Bhattacharjee,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Platelets oxidative stress in Indian patients with ischemic heart disease</style></title><secondary-title><style face="normal" font="default">Journal of Clinical Laboratory Analysis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Clinical Laboratory Analysis</style></full-title></periodical><pages end="54" start="49">49-54</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Blood Platelets/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Myocardial Ischemia/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Oxidative Stress/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> 0 (Antioxidants)</style></keyword><keyword><style face="normal" font="default"> 542-78-9 (Malondialdehyde)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Antioxidants/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Blood Platelets/en [Enzymology]</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> EC 1-11-1-9 (Glutathione Peroxidase)</style></keyword><keyword><style face="normal" font="default"> EC 1-15-1-1 (Superoxide Dismutase)</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glutathione Peroxidase/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Linear Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Malondialdehyde/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardial Ischemia/en [Enzymology]</style></keyword><keyword><style face="normal" font="default"> Platelet Aggregation</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Superoxide Dismutase/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2010">2010</year></dates><abstract><style face="normal" font="default">BACKGROUND: Oxidative stress has been implicated in the development of atherosclerosis and vascular tissue injury. Both platelet activation and lipid peroxidation are known to play major role in ischemic heart disease. The purpose of this study was to investigate the status of platelets oxidative stress in Indian patients with ischemic heart disease. METHODS: We measured platelets aggregation, malonyldialdehyde (MDA), plasma-ionized Ca2+, and antioxidant enzymes, i.e., glutathione peroxidase and superoxide dismutase in healthy volunteers and patients with myocardial infarction, unstable and stable angina 40 subjects each. RESULTS: Platelets aggregation, MDA, and plasma-ionized Ca(2+) have increased significantly across the patients groups compared with controls, this increase was accompanied by an overall decrease in the antioxidant enzymes activity; except for the slight increases in the glutathione peroxidase levels among the myocardial infarction patients. CONCLUSIONS: The current results suggest that platelet lipid peroxidation as marked by increased MDA level is augmented in ischemic heart diseases. The increased oxidative stress seen in these patients was accompanied by platelet activation and impaired antioxidant enzymes activity</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Clinical Laboratory and Nutritional Sciences, University of Massachusetts Lowell, Massacchusetts 01854, USA. Mahdi_Garelnabi@uml.eduJC - jla, 8801384CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20088006</style></custom1><custom3><style face="normal" font="default">AS - J Clin Lab Anal. 24(1):49-54, 2010.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>257</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Gatto,N.M.</style></author><author><style face="normal" font="default"> Henderson,V.W.</style></author><author><style face="normal" font="default"> St John,J.A.</style></author><author><style face="normal" font="default"> McCleary,C.</style></author><author><style face="normal" font="default"> Detrano,R.</style></author><author><style face="normal" font="default"> Hodis,H.N.</style></author><author><style face="normal" font="default"> Mack,W.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Subclinical atherosclerosis is weakly associated with lower cognitive function in healthy hyperhomocysteinemic adults without clinical cardiovascular disease</style></title><secondary-title><style face="normal" font="default">International Journal of Geriatric Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">International Journal of Geriatric Psychiatry</style></full-title></periodical><pages end="399" start="390">390-399</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Cognition Disorders/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Hyperhomocysteinemia/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Carotid Arteries/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Carotid Arteries/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Carotid Artery Diseases/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Carotid Artery Diseases/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Cognition Disorders/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperhomocysteinemia/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Hyperhomocysteinemia/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neuropsychological Tests</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="4" Year="2009">2009/4</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Atherosclerosis is the most common pathologic process underlying cardiovascular disease (CVD). It is not well known whether subclinical atherosclerosis is an independent risk factor for lower cognitive function among individuals without clinically evident CVD. METHODS: We examined cross-sectional associations between subclinical atherosclerosis and cognitive function in a community-based sample of otherwise healthy adults with plasma homocysteine >or=8.5 micromol/L enrolled in the BVAIT study (n = 504, mean age 61 years). Carotid artery intima-media thickness (CIMT), coronary artery calcium (CAC) and abdominal aortic calcium (AAC) were used to measure subclinical atherosclerosis. Cognitive function was assessed with a battery of neuropsychological tests. A principal components analysis was used to extract five uncorrelated cognitive factors from scores on individual tests, and a measure of global cognition was derived. Multivariable linear regression was used to examine the association between subclinical atherosclerosis and cognitive function, adjusting for other correlates of cognition. RESULTS: Increasing thickness of CIMT was associated with significantly lower scores on the verbal learning factor (beta = -0.07 per 0.1 mm increase CIMT [SE(beta) = 0.03], p = 0.01). CAC and AAC were not individually associated with any of the cognitive factors. CONCLUSIONS: This study provides evidence that increasing CIMT is weakly associated with lower verbal learning abilities but not global cognition in a population of otherwise healthy middle-to-older aged adults with elevated plasma homocysteine levels but without clinically evident CVD. The association between CIMT and poor verbal learning may pertain particularly to men. (c) 2008 John Wiley &amp; Sons, Ltd</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Preventive Medicine, USC Keck School of Medicine, Los Angeles, CA 90089-9010, USAJC - co0, 8710629CP - EnglandPT - Journal ArticlePT - Randomized Controlled TrialPT - Research Support, N.I.H., ExtramuralNO - 5-T32-AG00037 (United States NIA NIH HHS)NO - R01 AG-17160 (United States NIA NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18836986</style></custom1><custom3><style face="normal" font="default">AS - Int J Geriatr Psychiatry. 24(4):390-9, 2009 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>206</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Gaubatz,J.W.</style></author><author><style face="normal" font="default"> Ballantyne,C.M.</style></author><author><style face="normal" font="default"> Wasserman,B.A.</style></author><author><style face="normal" font="default"> He,M.</style></author><author><style face="normal" font="default"> Chambless,L.E.</style></author><author><style face="normal" font="default"> Boerwinkle,E.</style></author><author><style face="normal" font="default"> Hoogeveen,R.C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Association of circulating matrix metalloproteinases with carotid artery characteristics: the Atherosclerosis Risk in Communities Carotid MRI Study</style></title><secondary-title><style face="normal" font="default">Arteriosclerosis, Thrombosis &amp; Vascular Biology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Arteriosclerosis, Thrombosis &amp; Vascular Biology</style></full-title></periodical><pages end="1042" start="1034">1034-1042</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiovascular Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Carotid Arteries/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Carotid Artery Diseases/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Magnetic Resonance Angiography</style></keyword><keyword><style face="normal" font="default"> *Matrix Metalloproteinases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipids)</style></keyword><keyword><style face="normal" font="default"> 0 (Tissue Inhibitor of Metalloproteinase-1)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/en [Enzymology]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Carotid Arteries/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> Carotid Artery Diseases/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Carotid Artery Diseases/en [Enzymology]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> EC 3-4-24 (Matrix Metalloproteinases)</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lipids/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Tissue Inhibitor of Metalloproteinase-1/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="5" Year="2010">2010/5</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To examine the relationship of plasma levels of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase 1 (TIMP-1) with carotid artery characteristics measured by MRI in a cross-sectional investigation among Atherosclerosis Risk in Communities Carotid MRI Study participants. METHODS AND RESULTS: A stratified random sample was recruited based on intima-media thickness from a previous ultrasonographic examination. A high-resolution gadolinium-enhanced MRI examination of the carotid artery was performed from 2004 to 2005 on 1901 Atherosclerosis Risk in Communities cohort participants. Multiple carotid wall characteristics, including wall thickness, lumen area, calcium area, lipid core, and fibrous cap measures, were evaluated for associations with plasma MMPs 1, 2, 3, 7, 8, and 9 and TIMP-1. Plasma MMPs 1, 3, and 7 were significantly higher among participants in the high intima-media thickness group compared with those in the low intima-media thickness group. The normalized wall index was independently associated with MMPs 3 and 7 and TIMP-1. MMP-7 was positively associated with carotid calcification. The mean fibrous cap thickness was significantly higher in individuals with elevated TIMP-1 levels. In addition, TIMP-1 was positively associated with measures of lipid core. CONCLUSION: Circulating levels of specific MMPs and TIMP-1 were associated with carotid wall remodeling and structural changes related to plaque burden in elderly participants</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, Baylor College of Medicine, 6565 Fannin St, Houston, TX 77030, USAJC - 9505803, B89CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - N01-HC-55015 (United States NHLBI NIH HHS)NO - N01-HC-55016 (United States NHLBI NIH HHS)NO - N01-HC-55018 (United States NHLBI NIH HHS)NO - N01-HC-55019 (United States NHLBI NIH HHS)NO - N01-HC-55020 (United States NHLBI NIH HHS)NO - N01-HC-55021 (United States NHLBI NIH HHS)NO - N01-HC-55022 (United States NHLBI NIH HHS)NO - U01HL075572-01 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20167662</style></custom1><custom3><style face="normal" font="default">AS - Arterioscler Thromb Vasc Biol. 30(5):1034-42, 2010 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>260</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Gaudio,C.</style></author><author><style face="normal" font="default"> Mirabelli,F.</style></author><author><style face="normal" font="default"> Pelliccia,F.</style></author><author><style face="normal" font="default"> Francone,M.</style></author><author><style face="normal" font="default"> Tanzilli,G.</style></author><author><style face="normal" font="default"> Di,Michele S.</style></author><author><style face="normal" font="default"> Leonetti,S.</style></author><author><style face="normal" font="default"> De,Vincentis G.</style></author><author><style face="normal" font="default"> Carbone,I.</style></author><author><style face="normal" font="default"> Mangieri,E.</style></author><author><style face="normal" font="default"> Catalano,C.</style></author><author><style face="normal" font="default"> Passariello,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Early detection of coronary artery disease by 64-slice multidetector computed tomography in asymptomatic hypertensive high-risk patients</style></title><secondary-title><style face="normal" font="default">International Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">International Journal of Cardiology</style></full-title></periodical><pages end="286" start="280">280-286</pages><volume><style face="normal" font="default">135</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Hypertension/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,Spiral Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Early Diagnosis</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Hypertension/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="10" Month="7" Year="2009">2009/7/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: The 64-slice multidetector-row computed tomography (MDCT) is an accurate noninvasive technique for assessing the degree of luminal narrowing in coronary arteries of patients with chronic ischemic disease. Aim of this study was to determine the value of MDCT in comparison to invasive coronary angiography (ICA) for detecting the presence and extent of coronary atherosclerotic plaques in a population of asymptomatic, hypertensive patients considered to be at high risk for cardiovascular events. METHODS: We studied 67 asymptomatic, hypertensive patients at high-risk (Euro Score >5%). All patients had negative or nondiagnostic findings at exercise stress testing and therefore underwent both MDCT and ICA. RESULTS: In the per-patient analysis, MDCT correctly identified 16/17 (94%) patients with significant coronary artery disease involving at least 1 vessel and 48/50 (96%) normal subjects. In the per-segment analysis, MDCT correctly detected 21/22 (95%) coronary segments with a stenosis >or=50% and 856/868 (98%) normal segments, with a high negative predictivity of normal scans (100%). There was a good concordance between MDCT and ICA, with a high Pearson correlation coefficient between the coronary narrowings with the two techniques (r=0.84, p&lt;0.01). Mean coronary calcium score was higher for the 17 patients with significant coronary artery disease on ICA than in the 50 patients without (422+/-223 HU vs 72+/-21 HU p&lt;0.001). The ROC curves identified 160 as the best calcium volumetric score cut-off value able to identify >or=1 significant coronary stenosis with sensitivity 88% and specificity 85%. CONCLUSIONS: MDCT is an excellent noninvasive technique for early identification of significant coronary stenoses in high risk asymptomatic hypertensive patients and might provide unique information for the screening of this broad population</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Heart and Great Vessels A. Reale, University La Sapienza of Rome, Rome, Italy. carlo.gaudio@uniroma1.itJC - gqw, 8200291CP - NetherlandsPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18614251</style></custom1><custom3><style face="normal" font="default">AS - Int J Cardiol. 135(3):280-6, 2009 Jul 10.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>95</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Gayed,I.W.</style></author><author><style face="normal" font="default"> Raslan,O.A.</style></author><author><style face="normal" font="default"> Bhosale,P.R.</style></author><author><style face="normal" font="default"> Perrier,N.D.</style></author><author><style face="normal" font="default"> Wei,W.</style></author><author><style face="normal" font="default"> Gladish,G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Significant coronary calcification detected using contrast-enhanced computed tomography: is it an indication for further investigation?</style></title><secondary-title><style face="normal" font="default">Clinical Nuclear Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinical Nuclear Medicine</style></full-title></periodical><pages end="408" start="404">404-408</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Contrast Media/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> 0 (Contrast Media)</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardial Perfusion Imaging</style></keyword><keyword><style face="normal" font="default"> Perfusion</style></keyword><keyword><style face="normal" font="default"> Pilot Projects</style></keyword><keyword><style face="normal" font="default"> Radiography,Thoracic</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Stress,Physiological</style></keyword></keywords><dates><year Day="0" Month="6" Year="2010">2010/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: Evaluate the significance of coronary arteries calcifications detected using contrast-enhanced chest computed tomography (CECCT) scans. METHODS: A total of 145 patients who underwent both CECCT and gated stress myocardial perfusion imaging (MPI) within 2 weeks were included. The chest CT scans were reviewed for the presence of coronary artery calcium (CAC) by 2 experienced blinded readers. The degree of calcifications seen in any visualized area of the major coronary arteries was graded on a scale of 1 to 3 (1 when 0 to 4 small scattered plaques were seen, 2 when 5 or more scattered plaques were seen, and 3 when diffuse contiguous calcification were seen). The grade of CAC was correlated with the presence of MPI abnormalities. Additionally, the locations of the MPI abnormality was correlated with the CAC grade in the culprit coronary artery. RESULTS: Of 580 major coronary arteries evaluated, 79% had grade 1 CAC, 10% had grade 2, 11% had grade 3, and 1% were inevaluable. Of the 145 patients, 33 (23%) had abnormal MPI results. Twenty-three of the patients with abnormal MPI results (70%) had more than 4 calcified plaques (CAC grade of 2 or 3) in one or more of their coronary arteries, whereas 41 of 122 patients with normal MPI results (37%) had similar CAC grades (P=0.001). Seventeen of the 33 patients (52%) who had MPI defects also had significant CAC in the culprit coronary artery, 7 patients (21%) had significant CAC in a different coronary artery from the MPI defect territory, 8 patients (24%) had no significant CAC visualized, and in 1 patient a pacemaker wire interfered with CAC grading in the culprit coronary artery (RCA). The sensitivity, specificity, the positive, and negative predictive values of grade 2 or 3 CAC for an abnormal MPI results were 70%, 63%, 36%, and 88%, respectively. When a subgroup of patients above 60 years old with grade 3 CAC was reanalyzed, the sensitivity, specificity, the positive, and negative predictive values for an abnormal MPI results were 69%, 73%, 41%, and 90%, respectively. CONCLUSION: Multiple diffuse CAC as detected during the interpretation of CECCT scans in combination with advanced age is a significant finding that warrants further investigation for functionally significant CAD</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Nuclear Medicine, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. isis.w.gayed@uth.tmc.eduJC - df6, 7611109CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20479585</style></custom1><custom3><style face="normal" font="default">AS - Clin Nucl Med. 35(6):404-8, 2010 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>337</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Gebska,E.</style></author><author><style face="normal" font="default"> Vanaga-Besser,S.</style></author><author><style face="normal" font="default"> Zajeck,W.</style></author><author><style face="normal" font="default"> Matuszewska,G.</style></author><author><style face="normal" font="default"> Jarzab,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Calcyphylaxis in a patient with end-stage renal disease in the course of systemic lupus erythematosus, diagnostic problems--case report]. [Polish]</style></title><secondary-title><style face="normal" font="default">Polski Merkuriusz Lekarski</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Polski Merkuriusz Lekarski</style></full-title></periodical><pages end="128" start="123">123-128</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">158</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure,Chronic/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Lupus Erythematosus,Systemic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Vasculitis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Vasculitis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Dialysis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Peritoneal Dialysis</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Renal Dialysis</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Skin Diseases,Vascular/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Skin Diseases,Vascular/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Skin/pa [Pathology]</style></keyword></keywords><dates><year Day="0" Month="8" Year="2009">2009/8</year></dates><isbn><style face="normal" font="default">1426-9686</style></isbn><abstract><style face="normal" font="default">Calcyphylaxis consists in vascular calcium deposition and skin necrosis, which appears in the final stage of renal failure. Advanced forms of systemic connective tissue disease such as lupus erythematosus, especially with concomitant vasculitis, leading to renal failure and uremia may be conducive to calcyphylaxis. We are presenting a case of a 50-year-old male requiring chronic peritoneal dialysis since the age of 43, due to end-stage renal disease resulting from chronic glomeluronephritis. The patient presented to our Dermatology Department with large and painful coalescent cutaneous lesions on both lower extremities, fingertips and lips. Both clinical picture and disease history indicated systemic vasculitis that was previously unrecognized. Additional examinations revealed the following markers of inflammation: leukocytosis (11 G/I) with normal level of eosinophils, CRP > 0.6 mg/I, ESR 120 mm/h, and IgG 20 g/l, without any source of infection. Indirect immunofluorescence showed the absence of antineutrophil cytoplasmic antibodies (ANCA) on polynuclear leucocytes. A distinct fluorescence pattern observed in liver sinusoids was suggestive of the presence of some form of anti-granulocyte antibodies. Anti-nuclear antibodies (ANA) were detected in serum (1:1000) with homogenous and microgranular fluorescence pattern. Anti-extractable nuclear antigen panel (ENA), C3/C4 levels, anti-smooth muscle, anti-dsDNA and anti-glomerular basement membrane (GBM) antibodies were within normal limits. Lupus band test revealed IgA and IgG deposits at the dermis-epidermis junction. Histopathological examination of the skin showed calcification complicated by small vessel thrombosis, however, it was non-specific for vasculitis. Our case represents an example of calcyphylaxis associated with a widespread medial vascular calcification in a patient with end stage renal disease secondary to systemic lupus erythematosus. Although renal dialysis itself is known to trigger calcyphylaxis, there have been few reports in literature suggesting that collagen vascular disease may also contribute to this process</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Silesian Medical University in Katowice, Department of Internal Medicine, Dermatology and Allergology, Zabrze, Poland. egebska@gmail.comOT - Kalcyfilaksja u chorego z terminalna niewydolno&amp;#x015B;cia nerek w przebiegu tocznia rumieniowatego ukladowego, trudno&amp;#x015B;ci diagnostyczne--opis przypadkuJC - 9705469CP - PolandPT - Case ReportsPT - English AbstractPT - Journal ArticleLG - Polish</style></notes><urls/><custom1><style face="normal" font="default">UI - 19856878</style></custom1><custom3><style face="normal" font="default">AS - Pol Merkuriusz Lek. 27(158):123-8, 2009 Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>347</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Ghaffari,S.</style></author><author><style face="normal" font="default"> Pourafkari,L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Heart in a calcium case: a case of constrictive pericarditis</style></title><secondary-title><style face="normal" font="default">American Journal of the Medical Sciences</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of the Medical Sciences</style></full-title></periodical><pages end="" start="505">505-</pages><volume><style face="normal" font="default">338</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Pericarditis,Constrictive/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Electrocardiography</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Pericarditis,Constrictive/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Pericarditis,Constrictive/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Cardiovascular Research Center of Tabriz University of Medical Sciences, Tabriz, IranJC - 3l2, 0370506CP - United StatesPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19834320</style></custom1><custom3><style face="normal" font="default">AS - Am J Med Sci. 338(6):505, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>232</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Gianni,D.</style></author><author><style face="normal" font="default"> Li,A.</style></author><author><style face="normal" font="default"> Tesco,G.</style></author><author><style face="normal" font="default"> McKay,K.M.</style></author><author><style face="normal" font="default"> Moore,J.</style></author><author><style face="normal" font="default"> Raygor,K.</style></author><author><style face="normal" font="default"> Rota,M.</style></author><author><style face="normal" font="default"> Gwathmey,J.K.</style></author><author><style face="normal" font="default"> Dec,G.W.</style></author><author><style face="normal" font="default"> Aretz,T.</style></author><author><style face="normal" font="default"> Leri,A.</style></author><author><style face="normal" font="default"> Semigran,M.J.</style></author><author><style face="normal" font="default"> Anversa,P.</style></author><author><style face="normal" font="default"> Macgillivray,T.E.</style></author><author><style face="normal" font="default"> Tanzi,R.E.</style></author><author><style face="normal" font="default"> del,Monte F.</style></author></authors></contributors><titles><title><style face="normal" font="default">Protein aggregates and novel presenilin gene variants in idiopathic dilated cardiomyopathy</style></title><secondary-title><style face="normal" font="default">Circulation</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Circulation</style></full-title></periodical><pages end="1226" start="1216">1216-1226</pages><volume><style face="normal" font="default">121</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiomyopathy,Dilated/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Cardiomyopathy,Dilated/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Presenilin-1/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Proteins/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> 0 (Amyloid beta-Protein)</style></keyword><keyword><style face="normal" font="default"> 0 (Amyloid)</style></keyword><keyword><style face="normal" font="default"> 0 (Presenilin-1)</style></keyword><keyword><style face="normal" font="default"> 0 (Presenilin-2)</style></keyword><keyword><style face="normal" font="default"> 0 (Proteins)</style></keyword><keyword><style face="normal" font="default"> 0 (PSEN1 protein,human)</style></keyword><keyword><style face="normal" font="default"> 0 (PSEN2 protein,human)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Amyloid beta-Protein/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Amyloid/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Polymorphism,Single Nucleotide</style></keyword><keyword><style face="normal" font="default"> Presenilin-2/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="16" Month="3" Year="2010">2010/3/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: Heart failure is a debilitating condition resulting in severe disability and death. In a subset of cases, clustered as idiopathic dilated cardiomyopathy (iDCM), the origin of heart failure is unknown. In the brain of patients with dementia, proteinaceous aggregates and abnormal oligomeric assemblies of beta-amyloid impair cell function and lead to cell death. METHODS AND RESULTS: We have similarly characterized fibrillar and oligomeric assemblies in the hearts of iDCM patients, pointing to abnormal protein aggregation as a determinant of iDCM. We also showed that oligomers alter myocyte Ca(2+) homeostasis. Additionally, we have identified 2 new sequence variants in the presenilin-1 (PSEN1) gene promoter leading to reduced gene and protein expression. We also show that presenilin-1 coimmunoprecipitates with SERCA2a. CONCLUSIONS: On the basis of these findings, we propose that 2 mechanisms may link protein aggregation and cardiac function: oligomer-induced changes on Ca(2+) handling and a direct effect of PSEN1 sequence variants on excitation-contraction coupling protein function</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, MA 02125, USAJC - daw, 0147763CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - K08-HL69842 (United States NHLBI NIH HHS)NO - R01AG014713 (United States NIA NIH HHS)NO - R01MH60009 (United States NIMH NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20194882</style></custom1><custom3><style face="normal" font="default">AS - Circulation. 121(10):1216-26, 2010 Mar 16.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>173</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Gil-Dones,F.</style></author><author><style face="normal" font="default"> Rojas,T.</style></author><author><style face="normal" font="default"> pez-Almodovar,L.F.</style></author><author><style face="normal" font="default"> rez-Tosina,R.</style></author><author><style face="normal" font="default"> de la,Cuesta F.</style></author><author><style face="normal" font="default"> varez-Llamas,G.</style></author><author><style face="normal" font="default"> Alonso-Org</style></author><author><style face="normal" font="default"> Vivanco,F.</style></author><author><style face="normal" font="default"> guez-Padial,L.</style></author><author><style face="normal" font="default"> Barderas,M.G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Development of an optimal protocol for the proteomic analysis of stenotic and healthy aortic valves</style></title><secondary-title><style face="normal" font="default">Revista Espanola de Cardiologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Revista Espanola de Cardiologia</style></full-title></periodical><pages end="53" start="46">46-53</pages><volume><style face="normal" font="default">63</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aortic Valve Stenosis/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Clinical Protocols</style></keyword><keyword><style face="normal" font="default"> *Proteomics</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="1" Year="2010">2010/1</year></dates><abstract><style face="normal" font="default">INTRODUCTION AND OBJECTIVES: For many years, degenerative aortic stenosis was thought to be a passive process secondary to calcium deposition in aortic valves. Although its etiology remains unknown, several authors have pointed out that degenerative aortic stenosis is associated with the same risk factors as coronary artery disease. Furthermore, histological similarities have been found between aortic valve stenosis and atherosclerotic plaque, giving rise to the hypothesis that degenerative aortic stenosis is an inflammatory process similar to atherosclerosis. Nevertheless, some data do not fit with this hypothesis and, consequently, greater understanding of the condition is needed. The main aim of this study was to develop a practical protocol for extracting protein for use in proteomic analysis from both stenotic and healthy aortic valves. METHODS: The study was carried out using a number of different proteomic methods: two-dimensional electrophoresis, mass spectrometry and additional techniques. RESULTS: We developed a simple and reproducible methodology in the laboratory for carrying out the proteomic analysis of human aortic valves and for identifying their component proteins. CONCLUSIONS: We developed a simple and reproducible method for extracting protein that can be used with mass spectrometry and that makes it possible to carry out large-scale proteomic analysis of stenotic aortic valves. Furthermore, the methodology will significantly increase our understanding of the valve proteome</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Laboratorio de Fisiopatolog&amp;#x00ED;a Vascular, Hospital Nacional de Parapl&amp;#x00E9;jicos, SESCAM, Toledo, SpainJC - rtd, 0404277CP - SpainPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English, Spanish</style></notes><urls/><custom1><style face="normal" font="default">UI - 20089225</style></custom1><custom3><style face="normal" font="default">AS - Rev Esp Cardiol. 63(1):46-53, 2010 Jan.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>143</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Goh,V.K.</style></author><author><style face="normal" font="default"> Lau,C.P.</style></author><author><style face="normal" font="default"> Mohlenkamp,S.</style></author><author><style face="normal" font="default"> Rumberger,J.A.</style></author><author><style face="normal" font="default"> Achenbach,S.</style></author><author><style face="normal" font="default"> Budoff,M.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Outcome of coronary plaque burden: a 10-year follow-up of aggressive medical management</style></title><secondary-title><style face="normal" font="default">Cardiovascular Ultrasound</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Cardiovascular Ultrasound</style></full-title></periodical><pages end="" start="5">5-</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> 0 (Antihypertensive Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)</style></keyword><keyword><style face="normal" font="default"> 0 (Hypoglycemic Agents)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Antihypertensive Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypoglycemic Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Life Style</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Outcome Assessment (Health Care)</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword></keywords><dates><year Day="0" Month="0" Year="2010">2010</year></dates><abstract><style face="normal" font="default">BACKGROUND: The effect of aggressive medical therapy on quantitative coronary plaque burden is not generally known, especially in ethnic Chinese. AIMS: We reasoned that Cardiac CT could conveniently quantify early coronary atherosclerosis in our patient population, and hypothesized that serial observation could differentiate the efficacy of aggressive medical therapy regarding progression and regression of the atherosclerotic process, as well as evaluating the additional impact of life-style modification and the relative effects of the application of statin therapy. METHODS: We employed a standardized Cardiac CT protocol to serially scan 113 westernized Hong Kong Chinese individuals (64 men and 49 women) with Chest Pain and positive coronary risk factors. In all cases included for this serial investigation, subsequent evaluation showed no significantly-obstructive coronary disease by functional studies and angiography. After stringent risk factor modification, including aggressive statin therapy to achieve LDL-cholesterol lowering conforming to N.C.E.P. ATP III guidelines, serial CT scans were performed 1-12 years apart for changes in coronary artery calcification (CAC), using the Agatston Score (AS) for quantification. RESULTS: At baseline, the mean AS was 1413.6 for males (mean age 54.4 years) and 2293.3 for females (mean age 62.4 years). The average increase of AS in the entire study population was 24% per year, contrasting with 16.4% per year on strict risk factor modification plus statin therapy, as opposed to 33.2% per year for historical control patients (p &lt; 0.001). Additionally, 20.4% of the 113 patients demonstrated decreasing calcium scores. Medical therapy also yielded a remarkably low adverse event rate during the follow-up period --- 2 deaths, 2 strokes and only 1 case requiring PCI. CONCLUSIONS: This study revealed that aggressive medical therapy can positively influence coronary plaque aiding in serial regression of calcium scores</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Imaging Centre, Matilda International Hospital, 41 Mount Kellett Road, The Peak, Hong Kong, SAR China. victorgoh@netvigator.comJC - 101159952CP - EnglandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20226020</style></custom1><custom3><style face="normal" font="default">AS - Cardiovasc. ultrasound. 8:5, 2010.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>75</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Gong,C.</style></author><author><style face="normal" font="default"> Huang,S.L.</style></author><author><style face="normal" font="default"> Huang,J.F.</style></author><author><style face="normal" font="default"> Zhang,Z.F.</style></author><author><style face="normal" font="default"> Luo,M.</style></author><author><style face="normal" font="default"> Zhao,Y.</style></author><author><style face="normal" font="default"> Jiang,X.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Effects of combined therapy of Xuezhikang Capsule and Valsartan on hypertensive left ventricular hypertrophy and heart rate turbulence</style></title><secondary-title><style face="normal" font="default">Chinese Journal of Integrative Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Chinese Journal of Integrative Medicine</style></full-title></periodical><pages end="118" start="114">114-118</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Arrhythmias,Cardiac/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Drugs,Chinese Herbal/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Hypertension/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Hypertrophy,Left Ventricular/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Tetrazoles/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Valine/aa [Analogs &amp; Derivatives]</style></keyword><keyword><style face="normal" font="default"> 0 (Antihypertensive Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Antilipemic Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Capsules)</style></keyword><keyword><style face="normal" font="default"> 0 (Drug Combinations)</style></keyword><keyword><style face="normal" font="default"> 0 (Drugs,Chinese Herbal)</style></keyword><keyword><style face="normal" font="default"> 0 (Tetrazoles)</style></keyword><keyword><style face="normal" font="default"> 0 (xuezhikang)</style></keyword><keyword><style face="normal" font="default"> 137862-53-4 (valsartan)</style></keyword><keyword><style face="normal" font="default"> 7004-03-7 (Valine)</style></keyword><keyword><style face="normal" font="default"> Administration,Oral</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Antihypertensive Agents/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Antihypertensive Agents/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Antilipemic Agents/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Antilipemic Agents/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Arrhythmias,Cardiac/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Capsules</style></keyword><keyword><style face="normal" font="default"> Combined Modality Therapy</style></keyword><keyword><style face="normal" font="default"> Drug Combinations</style></keyword><keyword><style face="normal" font="default"> Drugs,Chinese Herbal/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Rate/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Hypertrophy,Left Ventricular/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Integrative Medicine/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medicine,Chinese Traditional/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tetrazoles/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Valine/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Valine/ae [Adverse Effects]</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><isbn><style face="normal" font="default">1672-0415</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: To observe the effect of combined therapy with Xuezhikang Capsule (XZK) and Valsartan on left ventricular hypertrophy (LVH) and heart rate turbulence (HRT) in hypertensive patients. METHODS: Ninety primary hypertensive patients with LVH were randomly assigned to three groups. Basic treatment, including aspirin, beta-blockers, calcium antagonists, etc. were administered to all patients. Additionally, Valsartan (VS, 80 mg once a day) was given to the 30 patients in the VS group. Valsartan (in the same dosage) and XZK (600 mg, twice a day) were given to the 32 patients in the Chinese medicine (CM) group, while none was given to the 28 patients in the control group. The therapeutic course lasted for 24 months. Changes in left ventricular mass index (LVMI) measured by cardiac ultrasonic indices, HRT parameters, including the original heart rate (TO) and slope coeffificient (TS), systolic and diastolic blood pressures (SBP and DBP), as well as blood cholesterol level (TC) were measured before and after treatment. RESULTS: After treatment, TO and LVMI were lowered, while TS increased in both the VS group and the CM group (P&lt;0.01), but changed insignificantly in the control group. Significant differences between the CM group and the control group were shown in terms of TO, LVMI, SBP, DBP and TS (P&lt;0.01); and between the CM group and the VS group in terms of TO, LVMI and TS (P&lt;0.01). Moreover, HRT parameters showed an evident correlation with LVMI (r=0.519-0.635, P&lt;0.01). CONCLUSION: Combined therapy with XZK and Valsartan can improve hypertensive LVH and HRT parameters, and lessen the damage on the autonomous nervous system</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - The Cardiovascular Department, the First Affiliated Hospital of Nanchang University, Nanchang (330006), ChinaJC - 101181180CP - ChinaPT - Journal ArticlePT - Randomized Controlled TrialLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20473735</style></custom1><custom3><style face="normal" font="default">AS - Chin J Integr Med. 16(2):114-8, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>501</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Gopal,A.</style></author><author><style face="normal" font="default"> Nasir,K.</style></author><author><style face="normal" font="default"> Ahmadi,N.</style></author><author><style face="normal" font="default"> Gul,K.</style></author><author><style face="normal" font="default"> Tiano,J.</style></author><author><style face="normal" font="default"> Flores,M.</style></author><author><style face="normal" font="default"> Young,E.</style></author><author><style face="normal" font="default"> Witteman,A.M.</style></author><author><style face="normal" font="default"> Holland,T.C.</style></author><author><style face="normal" font="default"> Flores,F.</style></author><author><style face="normal" font="default"> Mao,S.S.</style></author><author><style face="normal" font="default"> Budoff,M.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Cardiac computed tomographic angiography in an outpatient setting: an analysis of clinical outcomes over a 40-month period</style></title><secondary-title><style face="normal" font="default">Journal of cardiovascular computed tomography</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of cardiovascular computed tomography</style></full-title></periodical><pages end="95" start="90">90-95</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Ambulatory Care</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Myocardial Infarction/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Kaplan-Meiers Estimate</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="3" Year="2009">2009/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: Cardiac computed tomographic angiography (CTA) provides for accurate noninvasive diagnosis of coronary artery disease (CAD). OBJECTIVES: We analyzed the clinical outcomes over 40 months in patients with and without CAD as determined by CTA in an outpatient setting. METHODS: Consecutive symptomatic patients (n = 493; mean age, 58 +/- 15 years; 70% men) with an intermediate likelihood of CAD referred for outpatient CTA evaluation were prospectively followed for a mean of 40 +/- 9 months. RESULTS: Results of CTA included as normal (defined as normal coronary lumen), found in 32% (157), nonobstructive disease (&lt;50% luminal stenosis) in 41% (204), obstructive disease (>or=50% luminal stenosis) in 19% (93). Eight percent (n = 39) had >or=1 major nondiagnostic coronary artery segment. Follow-up identified 21 patients with myocardial infarction (MI) in the significant obstructive CAD and nondiagnostic group. No patients with either normal coronary arteries or nonobstructive disease experienced an MI during follow-up. The 40-month event-free survival was 100% for both the normal and nonobstructive disease groups, 97.5% for the nondiagnostic study group, and 79% for the group with obstructive CAD. After adjustment for age, sex, diabetes mellitus, hypertension, hypercholesterolemia, and baseline coronary artery calcium (CAC), a stepwise multivariable model (Cox regression) showed that obstructive CAD was an independent predictor of cardiac events and had significant incremental value over clinical risk factors and CAC (HR = 16.6; 95% CI, 4.9-55.2; P = 0.0001). CONCLUSION: In symptomatic patients with an intermediate likelihood of CAD referred for CTA, normal coronary arteries or nonobstructive CAD portends an excellent prognosis. The finding of obstructive CAD identifies patients at higher risk of subsequent MI, independent of cardiovascular risk factors and coronary artery calcium</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Los Angeles Biomedical Research Institute at Harbor-UCLA, 1124 W. Carson Street, RB2, Torrance, CA 90502, USACM - Comment in: J Cardiovasc Comput Tomogr. 2009 Mar-Apr;3(2):96-9; PMID: 19278913]JC - 101308347CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19269915</style></custom1><custom3><style face="normal" font="default">AS - J Cardiovasc Comput Tomogr. 3(2):90-5, 2009 Mar-Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>303</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Gopinath,B.</style></author><author><style face="normal" font="default"> Wescombe,L.</style></author><author><style face="normal" font="default"> Nguyen,B.</style></author><author><style face="normal" font="default"> Wall,J.R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Can autoimmunity against calsequestrin explain the eye and eyelid muscle inflammation of thyroid eye disease?</style></title><secondary-title><style face="normal" font="default">Orbit</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Orbit</style></full-title></periodical><pages end="261" start="256">256-261</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Autoantibodies/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> *Autoimmunity/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> *Calsequestrin/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> *Graves Ophthalmopathy/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> *Oculomotor Muscles/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> 0 (Autoantibodies)</style></keyword><keyword><style face="normal" font="default"> 0 (Calsequestrin)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Autoantibodies/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Autoimmunity/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cell Proliferation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Graves Ophthalmopathy/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Hashimoto Disease/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Hashimoto Disease/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Inflammation/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Inflammation/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><abstract><style face="normal" font="default">Extra-ocular and upper eyelid (levator) muscle damage in thyroid orbitopathy may be due to autoimmunity against eye muscle auto antigens. The main antigen appears to be the calcium binding protein calsequestrin. In this study we have tested for T lymphocyte sensitization to calsequestrin in patients with Graves' disease, with and without orbitopathy, in standard proliferation assay. We have also tested total RNA prepared from thyroid tissue of patients with Graves' disease with and without orbitopathy for expression across 20,589 genes using micro array analysis technology. We were looking for differences in gene expression between the two groups which might provide information about the early thyroid events that lead to the development of eye muscle autoimmunity. Positive lymphocyte reactivity to calsequestrin was demonstrated in 59% of Graves' patients with orbitopathy, 33% without evident ophthalmopathy and in 43% of patients with Hashimoto's thyroiditis and upper eyelid retraction (UER). Two hundred and ninety six genes were identified to be differentially expressed between in patients with Graves' disease with and without orbitopathy. Of these, the cardiac calsequestrin gene CASQ2 was the most highly up regulated, 2.2-fold. The closely related skeletal muscle calsequestrin gene CASQ1 was also up-regulated, 4.1 fold, but this was not significant, while genes encoding the thyroid antigens thyroglobulin, thyroid peroxidase and the TSH-receptor were not differentially expressed. These findings provide further evidence for a prominent role of autoimmunity against calsequestrin in the pathogenesis of the eye muscle components of thyroid orbitopathy</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, the University of Sydney, Nepean Clinical School, Penrith, NSW, AustraliaJC - 8301221CP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19839885</style></custom1><custom3><style face="normal" font="default">AS - Orbit. 28(4):256-61, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>524</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Gorbunov,V.M.</style></author><author><style face="normal" font="default"> Smirnova,G.F.</style></author><author><style face="normal" font="default"> Andreeva,G.F.</style></author><author><style face="normal" font="default"> Deev,A.D.</style></author><author><style face="normal" font="default"> Shal'nova,S.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Prevalence and predictors of masked inefficacy of treatment of arterial hypertension during use of various groups of antihypertensive drugs]. [Russian]</style></title><secondary-title><style face="normal" font="default">Kardiologiia</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Kardiologiia</style></full-title></periodical><pages end="37" start="32">32-37</pages><volume><style face="normal" font="default">49</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Antihypertensive Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Blood Pressure/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Hypertension/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> 0 (Antihypertensive Agents)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Blood Pressure Monitoring,Ambulatory</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Hypertension/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Russia</style></keyword><keyword><style face="normal" font="default"> Russia/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><isbn><style face="normal" font="default">0022-9040</style></isbn><abstract><style face="normal" font="default">Prevalence and predictors of masked arterial hypertension (AH) in patients receiving antihypertensive therapy (concealed treatment inefficacy--CTI) was studied on material of data base comprising 219 observations. Drugs from 5 groups were used. Prevalence of CTI AH with the use of various definitions was 8.1-17.4%. With the help of procedure of logistic regression analysis the following predictors of CTI were selected: (1) sociopsychological--high working capacity, high psychological abilities and social self feeling; (2) parameters of 24-hour BP profile--24-hour variability, variability during working period, minimal daytime BP level, time of maximal BP. According to our data CTI is most probable during treatment with calcium antagonists and beta-adrenoblockers</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)JC - 0376351, ku9CP - Russia (Federation)PT - Comparative StudyPT - English AbstractPT - Journal ArticleLG - Russian</style></notes><urls/><custom1><style face="normal" font="default">UI - 19254214</style></custom1><custom3><style face="normal" font="default">AS - Kardiologiia. 49(2):32-7, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>505</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Gorelik,O.</style></author><author><style face="normal" font="default"> moznino-Sarafian,D.</style></author><author><style face="normal" font="default"> Shteinshnaider,M.</style></author><author><style face="normal" font="default"> Alon,I.</style></author><author><style face="normal" font="default"> Tzur,I.</style></author><author><style face="normal" font="default"> Sokolsky,I.</style></author><author><style face="normal" font="default"> Efrati,S.</style></author><author><style face="normal" font="default"> Babakin,Z.</style></author><author><style face="normal" font="default"> Modai,D.</style></author><author><style face="normal" font="default"> Cohen,N.</style></author></authors></contributors><titles><title><style face="normal" font="default">Clinical variables affecting survival in patients with decompensated diastolic versus systolic heart failure</style></title><secondary-title><style face="normal" font="default">Clinical Research in Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinical Research in Cardiology</style></full-title></periodical><pages end="232" start="224">224-232</pages><volume><style face="normal" font="default">98</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Diuretics/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Furosemide/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Heart Failure,Diastolic/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> *Heart Failure,Systolic/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> 0 (Antilipemic Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Diuretics)</style></keyword><keyword><style face="normal" font="default"> 54-31-9 (Furosemide)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Antilipemic Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Electrocardiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Heart Failure,Diastolic/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Heart Failure,Diastolic/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Heart Failure,Systolic/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Heart Failure,Systolic/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Obesity/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword></keywords><dates><year Day="0" Month="4" Year="2009">2009/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: The impact of various clinical variables on long-term survival of patients with acutely decompensated diastolic heart failure (DHF) compared to systolic heart failure (SHF) has not been sufficiently investigated. METHODS: Clinical, laboratory, electrocardiographic and echocardiographic data were collected and analyzed for all-cause mortality in 473 furosemide-treated patients aged >or=60 years, hospitalized for acutely decompensated HF. RESULTS: Diastolic heart failure patients (n = 183) were more likely to be older, female, hypertensive, obese, with shorter preexisting HF duration, atrial fibrillation, lower New York Heart Association (NYHA) class, lower maintenance furosemide dosages, and to receive calcium antagonists. The SHF group (290 patients) demonstrated prevailing coronary artery disease, nitrate or digoxin treatment, and electrocardiographic conduction disturbances (P &lt;or= 0.01 in all comparisons). On median 35-month follow-up, the respective one-, three- and five-year survival rates were 82%, 48% and 33% in DHF versus 74%, 46% and 30% in SHF (P = 0.3). Higher furosemide daily dosage at discharge (OR = 1.24, 95% CI = 1.11-1.37, P &lt; 0.001), increasing age (OR = 1.29, 95% CI = 1.09-1.54, P = 0.003), peripheral arterial disease (OR = 1.47, 95% CI = 1.02-2.13, P = 0.043), and a history of stroke (OR = 1.44, 95% CI = 0.98-2.1, P = 0.066) were most significantly associated with shorter survival in SHF. DHF, in turn, demonstrated higher NYHA class (OR = 2.52, 95% CI = 1.48-4.29, P &lt; 0.001), history of non-advanced malignancy (OR = 2.51, 95% CI = 1.3-4.85, P = 0.012), and atrial fibrillation (OR = 1.6, 95% CI = 0.97-2.64, P = 0.066). Antilipid treatment (OR = 0.56, 95% CI = 0.3-1.02, P = 0.049) predicted better survival. CONCLUSION: In-patients with acutely decompensated DHF differ from similar SHF subjects with respect to prognostic significance of a number of clinical variables. This observation might carry practical implications</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Internal Medicine F, Assaf Harofeh Medical Center (affiliated to Sackler School of Medicine, Tel Aviv University), Zerifin, Israel. internal6@asaf.health.gov.ilJC - 101264123CP - GermanyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19219395</style></custom1><custom3><style face="normal" font="default">AS - Clin. res. cardiol.. 98(4):224-32, 2009 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>292</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Gorgulu,N.</style></author><author><style face="normal" font="default"> Yelken,B.</style></author><author><style face="normal" font="default"> Caliskan,Y.</style></author><author><style face="normal" font="default"> Elitok,A.</style></author><author><style face="normal" font="default"> Cimen,O.</style></author><author><style face="normal" font="default"> Yazici,H.</style></author><author><style face="normal" font="default"> Oflaz,H.</style></author><author><style face="normal" font="default"> Turkmen,A.</style></author><author><style face="normal" font="default"> Bozfakioglu,S.</style></author><author><style face="normal" font="default"> Sever,M.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Endothelial dysfunction in peritoneal dialysis patients with and without failed renal transplants</style></title><secondary-title><style face="normal" font="default">Transplantation Proceedings</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Transplantation Proceedings</style></full-title></periodical><pages end="3650" start="3647">3647-3650</pages><volume><style face="normal" font="default">41</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Endothelium,Vascular/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Kidney Transplantation/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 57-88-5 (Cholesterol)</style></keyword><keyword><style face="normal" font="default"> 60-27-5 (Creatinine)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 9007-41-4 (C-Reactive Protein)</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> C-Reactive Protein/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Cholesterol/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Circulation</style></keyword><keyword><style face="normal" font="default"> Creatinine/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Dialysis</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Patient Selection</style></keyword><keyword><style face="normal" font="default"> Peritoneal Dialysis</style></keyword><keyword><style face="normal" font="default"> Postoperative Complications/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Postoperative Complications/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="11" Year="2009">2009/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Endothelial dysfunction (ED) is a common, early abnormality that predisposes patients to develop atherosclerosis and cardiovascular events; inflammation is associated with atherosclerosis and malnutrition. Patients with failed transplants are usually complicated by inflammation; however, ED in this group of patients has not been well defined. In this cross-sectional study, we sought to investigate ED among na&amp;#x00EF;ve peritoneal dialysis (nPD) patients who were never transplanted as well as patients with failed renal transplants who were re-starting peritoneal dialysis (fTxPD). METHODS: Twenty-five nPD patients (15 female/10 males; mean age, 44 +/- 11 years), and 12 fTxPD patients (4 males; mean age, 37 +/- 10 years) were included in the study. Coronary flow reserve (CFR) measurements were used to evaluate ED. Serum creatinine, calcium, phosphorus, total cholesterol, albumin, hemoglobin, and intact parathyroid hormone (iPTH) were measured. Also, highly sensitive C-reactive protein (hs-CRP) levels and weekly Kt/V were determined as possible confounding factors. Results were compared between the 2 groups. RESULTS: There were no significant differences regarding age, gender, mean systolic and diastolic blood pressures, or smoking status. Mean duration on PD, peritoneal transport characteristics, PD modality and doses, frequency of peritonitis episodes, as well as serum creatinine, calcium, phosphorus, total cholesterol, albumin, hemoglobin and iPTH levels were similar between the 2 groups. Weekly Kt/V of both groups were similar as well. However, hs-CRP levels were significantly higher (34 +/- 52 vs 6.7 +/- 7.5 mg/L; P = .017) and CFR significantly lower among patients with fTxPD compared with nPD patients (1.52 +/- 0.20 vs 1.91 +/- 0.53; P = .022). CONCLUSION: ED was more prominent among patients with failed transplants than nPD cases, suggesting that the failed allograft may be responsible for this abnormality</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Istanbul University, Istanbul School of Medicine, Department of Internal Medicine, Istanbul, Turkey. numangorgulu@gmail.comJC - we9, 0243532CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19917360</style></custom1><custom3><style face="normal" font="default">AS - Transplant Proc. 41(9):3647-50, 2009 Nov.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>246</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Gottlieb,I.</style></author><author><style face="normal" font="default"> Miller,J.M.</style></author><author><style face="normal" font="default"> rbab-Zadeh,A.</style></author><author><style face="normal" font="default"> Dewey,M.</style></author><author><style face="normal" font="default"> Clouse,M.E.</style></author><author><style face="normal" font="default"> Sara,L.</style></author><author><style face="normal" font="default"> Niinuma,H.</style></author><author><style face="normal" font="default"> Bush,D.E.</style></author><author><style face="normal" font="default"> Paul,N.</style></author><author><style face="normal" font="default"> Vavere,A.L.</style></author><author><style face="normal" font="default"> Texter,J.</style></author><author><style face="normal" font="default"> Brinker,J.</style></author><author><style face="normal" font="default"> Lima,J.A.</style></author><author><style face="normal" font="default"> Rochitte,C.E.</style></author></authors></contributors><titles><title><style face="normal" font="default">The absence of coronary calcification does not exclude obstructive coronary artery disease or the need for revascularization in patients referred for conventional coronary angiography</style></title><secondary-title><style face="normal" font="default">Journal of the American College of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of the American College of Cardiology</style></full-title></periodical><pages end="634" start="627">627-634</pages><volume><style face="normal" font="default">55</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Occlusion/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Stenosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Myocardial Revascularization</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Occlusion/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Coronary Stenosis/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Linear Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Referral and Consultation</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="16" Month="2" Year="2010">2010/2/16</year></dates><abstract><style face="normal" font="default">OBJECTIVES: This study was designed to evaluate whether the absence of coronary calcium could rule out >or=50% coronary stenosis or the need for revascularization. BACKGROUND: The latest American Heart Association guidelines suggest that a calcium score (CS) of zero might exclude the need for coronary angiography among symptomatic patients. METHODS: A substudy was made of the CORE64 (Coronary Evaluation Using Multi-Detector Spiral Computed Tomography Angiography Using 64 Detectors) multicenter trial comparing the diagnostic performance of 64-detector computed tomography to conventional angiography. Patients clinically referred for conventional angiography were asked to undergo a CS scan up to 30 days before. RESULTS: In all, 291 patients were included, of whom 214 (73%) were male, and the mean age was 59.3 +/- 10.0 years. A total of 14 (5%) patients had low, 218 (75%) had intermediate, and 59 (20%) had high pre-test probability of obstructive coronary artery disease. The overall prevalence of >or=50% stenosis was 56%. A total of 72 patients had CS = 0, among whom 14 (19%) had at least 1 >or=50% stenosis. The overall sensitivity for CS = 0 to predict the absence of >or=50% stenosis was 45%, specificity was 91%, negative predictive value was 68%, and positive predictive value was 81%. Additionally, revascularization was performed in 9 (12.5%) CS = 0 patients within 30 days of the CS. From a total of 383 vessels without any coronary calcification, 47 (12%) presented with >or=50% stenosis; and from a total of 64 totally occluded vessels, 13 (20%) had no calcium. CONCLUSIONS: The absence of coronary calcification does not exclude obstructive stenosis or the need for revascularization among patients with high enough suspicion of coronary artery disease to be referred for coronary angiography, in contrast with the published recommendations. Total coronary occlusion frequently occurs in the absence of any detectable calcification. (Coronary Evaluation Using Multi-Detector Spiral Computed Tomography Angiography Using 64 Detectors [CORE-64]; NCT00738218)</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Johns Hopkins University School of Medicine, Baltimore, Maryland, USAJC - h50, 8301365CP - United StatesPT - Clinical TrialPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tSI - ClinicalTrials.govSA - ClinicalTrials.gov/NCT00738218NO - HO1-HC95162-01 (United States NHLBI NIH HHS)NO - R01-AG021570-01 (United States NIA NIH HHS)NO - R01-HL66075-01 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20170786</style></custom1><custom3><style face="normal" font="default">AS - J Am Coll Cardiol. 55(7):627-34, 2010 Feb 16.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>163</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Grau,M.</style></author><author><style face="normal" font="default"> Bongard,V.</style></author><author><style face="normal" font="default"> Fito,M.</style></author><author><style face="normal" font="default"> Ruidavets,J.B.</style></author><author><style face="normal" font="default"> Sala,J.</style></author><author><style face="normal" font="default"> Taraszkiewicz,D.</style></author><author><style face="normal" font="default"> Masia,R.</style></author><author><style face="normal" font="default"> Galinier,M.</style></author><author><style face="normal" font="default"> Subirana,I.</style></author><author><style face="normal" font="default"> Carri&amp;#x00E9</style></author><author><style face="normal" font="default"> D</style></author><author><style face="normal" font="default"> Vila,J.</style></author><author><style face="normal" font="default"> Marrugat,J.</style></author><author><style face="normal" font="default"> res,J.</style></author><author><style face="normal" font="default"> REGICOR,GENES Investigators</style></author></authors></contributors><titles><title><style face="normal" font="default">Prevalence of cardiovascular risk factors in men with stable coronary heart disease in France and Spain</style></title><secondary-title><style face="normal" font="default">Archives of cardiovascular diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Archives of cardiovascular diseases</style></full-title></periodical><pages end="89" start="80">80-89</pages><volume><style face="normal" font="default">103</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiovascular Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Coronary Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> 0 (Cardiovascular Agents)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Chi-Square Distribution</style></keyword><keyword><style face="normal" font="default"> Coronary Disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Dyslipidemias/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Dyslipidemias/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> France/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Health Status Disparities</style></keyword><keyword><style face="normal" font="default"> Healthcare Disparities</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Hypertension/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Obesity/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Obesity/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Smoking/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Smoking/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Spain/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword></keywords><dates><year Day="0" Month="2" Year="2010">2010/2</year></dates><isbn><style face="normal" font="default">1875-2136</style></isbn><abstract><style face="normal" font="default">BACKGROUND: Cigarette smoking, raised blood pressure, unfavourable lipid concentrations, diabetes and - more indirectly - obesity, are responsible for most coronary heart disease events in developed and developing countries. AIMS: The objective of our study was to compare prevalence, treatment and control of cardiovascular risk factors in two samples of men with stable coronary heart disease, recruited in France and Spain. METHODS: Standardized measurements of body mass index, systolic and diastolic blood pressures, plasma lipids, glycaemia, and smoking were collected and drug use was registered. Cross-sectional comparisons were made between French and Spanish samples. RESULTS: Data from 982 individuals were analysed (420 French and 562 Spanish men). Current smoking was more frequent in Spain (p&lt;0.001), whereas hypertension and uncontrolled blood pressure were more frequent in France (p&lt;0.001). Mean concentrations of low-density lipoprotein cholesterol and triglycerides were significantly higher in France (p&lt;0.001). No significant differences were observed regarding obesity, high-density lipoprotein cholesterol and diabetes. More than 97% of participants presented with at least one of the following conditions: hypertension, dyslipidaemia, diabetes, obesity or smoking. Antiplatelet agents, calcium inhibitors, diuretics and hypoglycaemic drugs were used more frequently in France, whereas angiotensin-converting enzyme inhibitors and lipid-lowering treatments were used more frequently in Spain. CONCLUSION: Prevalence of cardiovascular risk factors is high among French and Spanish patients with stable coronary heart disease, with differences between countries regarding the distribution of the various risk factors. A great proportion of patients do not reach the recommended levels for risk factor control</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Lipids and Cardiovascular Epidemiology Unit, Cardiovascular Epidemiology and Genetics Group, Municipal Institute for Medical Research (IMIM-Hospital del Mar), Barcelona, SpainJC - 101465655CP - NetherlandsPT - Comparative StudyPT - Journal ArticlePT - Multicenter StudyPT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20226427</style></custom1><custom3><style face="normal" font="default">AS - Arch Cardiovasc Dis. 103(2):80-9, 2010 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>114</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Greenlund,K.J.</style></author><author><style face="normal" font="default"> Kiefe,C.I.</style></author><author><style face="normal" font="default"> Giles,W.H.</style></author><author><style face="normal" font="default"> Liu,K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Associations of job strain and occupation with subclinical atherosclerosis: The CARDIA Study</style></title><secondary-title><style face="normal" font="default">Annals of Epidemiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Annals of Epidemiology</style></full-title></periodical><pages end="331" start="323">323-331</pages><volume><style face="normal" font="default">20</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Occupational Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Occupational Health</style></keyword><keyword><style face="normal" font="default"> *Stress,Psychological/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Adaptation,Psychological</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> African Americans</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Decision Making</style></keyword><keyword><style face="normal" font="default"> European Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Health Status Indicators</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Occupational Diseases/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Occupational Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Occupational Diseases/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Socioeconomic Factors</style></keyword><keyword><style face="normal" font="default"> United States/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="5" Year="2010">2010/5</year></dates><abstract><style face="normal" font="default">PURPOSE: Although occupational factors have been associated with symptomatic ischemic heart disease, associations between job strain (low decision latitude and high psychological demands) and risk for subclinical atherosclerosis measured by coronary artery calcium (CAC) have not been assessed. METHODS: CAC was measured in 3695 participants in the Coronary Artery Risk Development in Young Adults study in 2000 to 2001 and 2005 to 2006. Job characteristics measured by the demand-control model (psychological demands and decision latitude) were assessed in 1987 to 1988 and in 1995 to 1996. Associations between non-zero CAC and previous job characteristics and occupation were assessed, adjusting for potential covariates. RESULTS: Low decision latitude, high psychological demands, and job strain at either earlier examination were not associated with a positive CAC, nor were changes in the status of these job characteristics between 1987/1988 and 1995/1996. However, participants whose jobs were classified as managerial or professional in 1995/1996 were less likely to have a positive CAC than those in laborer occupations. CONCLUSIONS: Job strain measured at two earlier time points was not related to the presence of CAC at follow-up 5 to 18 years later. The association between earlier occupation and CAC may reflect socioeconomic differences or other occupational, industrial, or labor market characteristics. Published by Elsevier Inc</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Centers for Disease Control and Prevention, Atlanta, GA 30341, USA. keg9@cdc.govJC - 9100013, bx8CP - United StatesPT - Journal ArticlePT - Multicenter StudyPT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - N01-HC-05187 (United States NHLBI NIH HHS)NO - N01-HC-45134 (United States NHLBI NIH HHS)NO - N01-HC-45205 (United States NHLBI NIH HHS)NO - N01-HC-48047 (United States NHLBI NIH HHS)NO - N01-HC-48048 (United States NHLBI NIH HHS)NO - N01-HC-48049 (United States NHLBI NIH HHS)NO - N01-HC-48050 (United States NHLBI NIH HHS)NO - N01-HC-95095 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20382332</style></custom1><custom3><style face="normal" font="default">AS - Ann Epidemiol. 20(5):323-31, 2010 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>227</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Greenwood,A.</style></author><author><style face="normal" font="default"> Altarescu,G.</style></author><author><style face="normal" font="default"> Zimran,A.</style></author><author><style face="normal" font="default"> Elstein,D.</style></author></authors></contributors><titles><title><style face="normal" font="default">Vitamin D receptor (VDR) polymorphisms in the cardiac variant of Gaucher disease</style></title><secondary-title><style face="normal" font="default">Pediatric Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatric Cardiology</style></full-title></periodical><pages end="32" start="30">30-32</pages><volume><style face="normal" font="default">31</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Gaucher Disease/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Heart Valve Diseases/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Polymorphism,Genetic</style></keyword><keyword><style face="normal" font="default"> *Receptors,Calcitriol/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> 0 (Receptors,Calcitriol)</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Arabs/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Pilot Projects</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="1" Year="2010">2010/1</year></dates><abstract><style face="normal" font="default">Type 3c Gaucher disease, an ultra-rare cardiac variant with progressive calcification of aortic and/or mitral heart valves, is generally fatal in teenage-hood. Vitamin D Receptors (VDR) are involved in calcium transport. The purpose of this pilot was to ascertain if VDR polymorphisms (BsmI, TaqI, ApaI, and FokI) are associated with type 3c Gaucher disease. There was a higher incidence of wild type alleles of all polymorphisms. Although a very small series, results seem to confirm preponderance of the BsmI B allele in type 3c as in other aortic calcifications, but also implicate linkage between ApaI and BsmI genotypes</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Gaucher Clinic, Shaare Zedek Medical Center, Jerusalem 91031, IsraelJC - pa3, 8003849CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19784695</style></custom1><custom3><style face="normal" font="default">AS - Pediatr Cardiol. 31(1):30-2, 2010 Jan.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>186</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Grunfeld,C.</style></author><author><style face="normal" font="default"> Scherzer,R.</style></author><author><style face="normal" font="default"> Varosy,P.D.</style></author><author><style face="normal" font="default"> Ambarish,G.</style></author><author><style face="normal" font="default"> Nasir,K.</style></author><author><style face="normal" font="default"> Budoff,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Relation of coronary artery plaque location to extent of coronary artery disease studied by computed tomographic angiography</style></title><secondary-title><style face="normal" font="default">Journal of cardiovascular computed tomography</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of cardiovascular computed tomography</style></full-title></periodical><pages end="26" start="19">19-26</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Angiography/ut [Utilization]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Stenosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Stenosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/ut [Utilization]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Statistics as Topic</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> United States/ep [Epidemiology]</style></keyword></keywords><dates><year Day="0" Month="1" Year="2010">2010/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Distal coronary artery disease (CAD) is less amenable to surgery or stenting compared with proximal disease. However, little is known about the epidemiology of distal versus proximal CAD. METHODS: We determined the prevalence and factors associated with proximal, mid, and distally located plaque in the left anterior descending, left circumflex, and right coronary arteries in 418 subjects without prior CAD history who underwent coronary computed tomographic angiography for symptoms or stress test results. Clinical characteristics and coronary artery calcium (CAC) scores were also determined. RESULTS: Most subjects (88%) had plaque, but only 18% of plaques were associated with stenosis >50%. In subjects with single-vessel plaque, only 7% had distal plaque, whereas 75% had proximal plaque. With 3-vessel plaque, 70% had distal and 100% had proximal plaques. Of subjects with a single location of plaque along a vessel, most had proximal plaque (69%); isolated distal-vessel plaque was rare (2%). Distal plaque was dominantly found in association with both proximal and mid plaque (88%). After multivariable adjustment for demographics, traditional, and nontraditional risk factors, both increasing number of vessels with plaque and clinically significant CAC scores were independently associated with higher odds of distal plaque, whereas associations of traditional risk factors were weaker. Distal plaque was independently associated with stenosis > 50%. CONCLUSION: These data support the concept that early lesions are most often proximal and that CAC scoring may be a poor screening tool for detecting proximal disease. Furthermore, distal lesions are more associated with advanced disease than with traditional cardiovascular risk factors. 2010 Society of Cardiovascular Computed Tomography. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, University of California, San Francisco, CA, USA. carl.grunfeld@ucsf.eduCM - Comment in: J Cardiovasc Comput Tomogr. 2010 Jan-Feb;4(1):27-8; PMID: 20159624JC - 101308347CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tPT - Research Support, U.S. Gov't, Non-P.H.SLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20159623</style></custom1><custom3><style face="normal" font="default">AS - J Cardiovasc Comput Tomogr. 4(1):19-26, 2010 Jan-Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>318</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Guaraldi,G.</style></author><author><style face="normal" font="default"> Zona,S.</style></author><author><style face="normal" font="default"> Alexopoulos,N.</style></author><author><style face="normal" font="default"> Orlando,G.</style></author><author><style face="normal" font="default"> Carli,F.</style></author><author><style face="normal" font="default"> Ligabue,G.</style></author><author><style face="normal" font="default"> Fiocchi,F.</style></author><author><style face="normal" font="default"> Lattanzi,A.</style></author><author><style face="normal" font="default"> Rossi,R.</style></author><author><style face="normal" font="default"> Modena,M.G.</style></author><author><style face="normal" font="default"> Esposito,R.</style></author><author><style face="normal" font="default"> Palella,F.</style></author><author><style face="normal" font="default"> Raggi,P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Coronary aging in HIV-infected patients</style></title><secondary-title><style face="normal" font="default">Clinical Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinical Infectious Diseases</style></full-title></periodical><pages end="1762" start="1756">1756-1762</pages><volume><style face="normal" font="default">49</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *HIV Infections/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> 0 (Anti-HIV Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol,HDL)</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol,LDL)</style></keyword><keyword><style face="normal" font="default"> 0 (Triglycerides)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Anti-HIV Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> CD4 Lymphocyte Count</style></keyword><keyword><style face="normal" font="default"> Cholesterol,HDL/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cholesterol,LDL/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> HIV Infections/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> HIV Infections/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Triglycerides/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="1" Month="12" Year="2009">2009/12/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Human immunodeficiency virus (HIV)-infected patients often demonstrate accelerated aging processes. We investigated whether the vascular age of a cohort of stable HIV-infected patients receiving antiretroviral therapy (ART) was increased and sought out predictors of increased vascular age. METHODS: In this cross-sectional study, 400 HIV-infected patients (mean age, 48 years) attending a cardiometabolic clinic underwent cardiac computed tomography imaging to identify coronary artery calcium (CAC). Vascular age was estimated on the basis of the extent of CAC by means of previously published equations. RESULTS: Increased vascular age was observed in 162 patients (40.5%), with an average increase of 15 years (range, 1-43 years) over the chronological age. In univariable analyses, chronological age, male sex, systolic blood pressure, duration of ART, fasting glucose level, fasting serum triglyceride level, total cholesterol level, low-density and high-density lipoprotein cholesterol levels, hypertension, and the presence of the metabolic syndrome were associated with increased vascular age. In multivariable linear regression analyses, current CD4+ cell count was the only predictor of increased vascular age (beta = 0.51; P = .005). CONCLUSIONS: Increased vascular age is frequent among HIV-infected patients and appears to be associated with CD4+ cell count. If these findings were to be confirmed in prospective trials, a positive response to ART with an increase in CD4+ cell count may become a marker of increased risk of atherosclerosis development</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Metabolic Clinic, Infectious and Tropical Disease Unit, Department of Medicine, University of Modena and Reggio Emilia, Modena, ItalyJC - a4j, 9203213CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19886793</style></custom1><custom3><style face="normal" font="default">AS - Clin Infect Dis. 49(11):1756-62, 2009 Dec 1.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>267</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Guaraldi,G.</style></author><author><style face="normal" font="default"> Stentarelli,C.</style></author><author><style face="normal" font="default"> Zona,S.</style></author><author><style face="normal" font="default"> Orlando,G.</style></author><author><style face="normal" font="default"> Carli,F.</style></author><author><style face="normal" font="default"> Ligabue,G.</style></author><author><style face="normal" font="default"> Lattanzi,A.</style></author><author><style face="normal" font="default"> Zaccherini,G.</style></author><author><style face="normal" font="default"> Rossi,R.</style></author><author><style face="normal" font="default"> Modena,M.G.</style></author><author><style face="normal" font="default"> Alexopoulos,N.</style></author><author><style face="normal" font="default"> Palella,F.</style></author><author><style face="normal" font="default"> Raggi,P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects</style></title><secondary-title><style face="normal" font="default">Atherosclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Atherosclerosis</style></full-title></periodical><pages end="227" start="222">222-227</pages><volume><style face="normal" font="default">208</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Anti-Retroviral Agents/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Atherosclerosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *HIV Infections/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *HIV Infections/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Lipodystrophy/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> 0 (Anti-Retroviral Agents)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Anti-Retroviral Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="1" Year="2010">2010/1</year></dates><abstract><style face="normal" font="default">BACKGROUND AND OBJECTIVE: Although anti-retroviral therapy (ART) prolonged survival in HIV-infected persons, an increase in cardiovascular disease has also been observed. A frequent complication of ART is the development of lipodystrophy (LD) with its multiple phenotypes that may be associated with cardiovascular disease. We assessed the contribution of chronic HIV infection, ART use and LD to the presence of sub-clinical atherosclerosis as evaluated by coronary artery calcium (CAC) imaging. METHODS: Observational cross-sectional study of 372 HIV-infected patients receiving ART who attended a cardiometabolic clinic (48.2+/-8-year old; 74% men). All patients underwent CAC surveillance with computed tomography and the Agatston score was used to quantitate CAC. Presence of CAC was defined as a score >10. Multivariable logistic regression was used to evaluate associations between HIV clinical factors, ART and LD with the presence of CAC. FINDINGS: CAC was found in 134 patients (36%) with a median CAC score of 50 (range 10; 1243). Lipoatrophy alone (OR 3.82, 95% CI: 1.11; 13.1), fat accumulation alone (OR 7.65, 95% CI: 1.71; 37.17) and mixed lipodystrophy phenotypes (OR 4.36, 95% CI: 1.26; 15.01) were strongly associated with presence of CAC after adjusting for age, sex, hypertension and cumulative exposure to ART. CONCLUSION: CAC is common among long-term ART users. The association between CAC and LD underscores the potential atherosclerosis risk inherent with ART and the need to undertake routine cardiovascular surveillance in patients treated with these drugs. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Metabolic Clinic, Infectious and Tropical Disease Unit, Department of Medicine, University of Modena and Reggio Emilia, Modena, ItalyJC - 95x, 0242543CP - IrelandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19595354</style></custom1><custom3><style face="normal" font="default">AS - Atherosclerosis. 208(1):222-7, 2010 Jan.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>121</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">guez-Granillo,G.A.</style></author><author><style face="normal" font="default"> Rosales,M.A.</style></author><author><style face="normal" font="default"> Renes,P.</style></author><author><style face="normal" font="default"> Diez,E.</style></author><author><style face="normal" font="default"> Pereyra,J.</style></author><author><style face="normal" font="default"> Gomez,E.</style></author><author><style face="normal" font="default"> De,Lillo G.</style></author><author><style face="normal" font="default"> Degrossi,E.</style></author><author><style face="normal" font="default"> Rodriguez,A.E.</style></author><author><style face="normal" font="default"> McFadden,E.P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Chronic myocardial infarction detection and characterization during coronary artery calcium scoring acquisitions</style></title><secondary-title><style face="normal" font="default">Journal of cardiovascular computed tomography</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of cardiovascular computed tomography</style></full-title></periodical><pages end="107" start="99">99-107</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Myocardial Infarction/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Myocardial Revascularization</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> 0 (Contrast Media)</style></keyword><keyword><style face="normal" font="default"> Adipose Tissue/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Adipose Tissue/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Argentina</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Contrast Media/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Circulation</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Myocardium/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Ventricular Function,Left</style></keyword></keywords><dates><year Day="0" Month="3" Year="2010">2010/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: Hypoenhanced regions on multidetector CT (MDCT) coronary angiography correlate with myocardial hyperperfusion. In addition to a limited capillary density, chronic myocardial infarction (MI) commonly contains a considerable amount of adipose tissue. OBJECTIVE: We explored whether regional myocardial hypoenhancement on contrast-enhanced MDCT could be identified with standard coronary artery calcium (CAC) scoring acquisitions with noncontrast CT. METHODS: Consecutive patients with a history of MI who were referred for contrast-enhanced MDCT from November 2006 until March 2009 were studied. Noncontrast CT for CAC scoring was also performed. The correlation between regional myocardial hypoenhancement on contrast-enhanced CT and regional myocardial hypoattenuated areas on noncontrast CT was defined. RESULTS: Eighty-three patients (mean age, 61.5+/-12.5 years; n=67; 81% male) with previous MI were studied. A total of 1411 myocardial segments were evaluated. Two hundred thirty-nine segments (17%) showed myocardial hypoenhancement by MDCT and 140 segments (9.6%) by CAC. On a patient level, noncontrast CT showed a sensitivity, specificity, positive predictive value, (PPV) and negative predictive value (NPV) of 66% (95% CI, 0.53-0.77), 100% (95% CI, 0.76-1.00), 100% (95% CI, 0.90-1.00), and 41% (95% CI, 0.26-0.58), respectively, to detect myocardial hypoenhancement. On a per segment level, noncontrast CT showed a sensitivity, specificity, PPV, and NPV of 58% (95% CI, 0.51-0.64), 100% (95% CI, 0.99-1.00), 99% (95% CI, 0.94-1.00), and 92% (95% CI, 0.90-0.93), respectively, to detect myocardial hypoenhancement. CONCLUSIONS: Our findings suggest that chronic MI can be detected with standard CAC scoring acquisitions. Copyright 2010 Society of Cardiovascular Computed Tomography. Published by Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiovascular Imaging, Otamendi Hospital, Azcuenaga 870 (C1115AAB), Buenos Aires, Argentina. grodriguezgranillo@gmail.comJC - 101308347CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20060800</style></custom1><custom3><style face="normal" font="default">AS - J Cardiovasc Comput Tomogr. 4(2):99-107, 2010 Mar-Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>49</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Gupta,S.</style></author><author><style face="normal" font="default"> Berry,J.D.</style></author><author><style face="normal" font="default"> Ayers,C.R.</style></author><author><style face="normal" font="default"> Peshock,R.M.</style></author><author><style face="normal" font="default"> Khera,A.</style></author><author><style face="normal" font="default"> de Lemos,J.A.</style></author><author><style face="normal" font="default"> Patel,P.C.</style></author><author><style face="normal" font="default"> Markham,D.W.</style></author><author><style face="normal" font="default"> Drazner,M.H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Left ventricular hypertrophy, aortic wall thickness, and lifetime predicted risk of cardiovascular disease:the Dallas Heart Study.[Erratum appears in JACC Cardiovasc Imaging. 2010 Jul;3(7):795]</style></title><secondary-title><style face="normal" font="default">Jacc: Cardiovascular Imaging</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Jacc: Cardiovascular Imaging</style></full-title></periodical><pages end="613" start="605">605-613</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aorta,Abdominal/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Aortic Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Hypertrophy,Left Ventricular/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aortic Diseases/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Chi-Square Distribution</style></keyword><keyword><style face="normal" font="default"> Coronary Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertrophy,Left Ventricular/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Linear Models</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Texas/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword></keywords><dates><year Day="0" Month="6" Year="2010">2010/6</year></dates><abstract><style face="normal" font="default">OBJECTIVES: To examine whether individuals with low short-term risk of coronary heart disease but high lifetime predicted risk of cardiovascular disease (CVD) have greater prevalence of left ventricular (LV) hypertrophy and increased aortic wall thickness (AWT) than those with low short-term and low lifetime risk. BACKGROUND: Lifetime risk prediction can be used for stratifying individuals younger than 50 years of age into 2 groups: low short-term/high lifetime and low short-term/low lifetime predicted risk of CVD. Individuals with low short-term/high lifetime risk have a greater burden of subclinical atherosclerosis as measured by coronary artery calcium and carotid intima-media thickness. However, >75% of individuals with low short-term/high lifetime risk do not have detectable coronary artery calcium, suggesting the presence of alternative subclinical abnormalities. METHODS: We stratified 1,804 Dallas Heart Study subjects between the ages of 30 and 50 years who had cardiac magnetic resonance into 3 groups: low short-term (&lt;10% 10-year risk of coronary heart disease)/low lifetime predicted risk (&lt;39% lifetime risk of CVD), low short-term (&lt;10%)/high lifetime risk (> or =39%), and high short-term risk (> or =10%, prevalent diabetes, or previous stroke, or myocardial infarction). In those with low short-term risk, we compared measures of LV hypertrophy and AWT between those with low versus high lifetime risk. RESULTS: Subjects with low short-term/high lifetime risk compared with those with low short-term/low lifetime risk had increased LV mass (men: 95 +/- 17 g/m(2) vs. 90 +/- 12 g/m(2) and women: 75 +/- 14 g/m(2) vs. 71 +/- 10 g/m(2), respectively; p &lt; 0.001 for both). LV concentricity (mass/volume), wall thickness, and AWT were also significantly greater in those with high lifetime risk in this comparison (p &lt; 0.001 for all), but LV end-diastolic volume was not (p > 0.3). These associations persisted among participants without detectable coronary artery calcium. CONCLUSIONS: Among individuals 30 to 50 years of age with low short-term risk, a high lifetime predicted risk of CVD is associated with concentric LV hypertrophy and increased AWT. Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USAJC - 101467978CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - K23 HL092229 (United States NHLBI NIH HHS)NO - UL1 RR024982 (United States NCRR NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20541716</style></custom1><custom3><style face="normal" font="default">AS - JACC Cardiovasc Imaging. 3(6):605-13, 2010 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>81</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Hadamitzky,M.</style></author><author><style face="normal" font="default"> Hein,F.</style></author><author><style face="normal" font="default"> Meyer,T.</style></author><author><style face="normal" font="default"> Bischoff,B.</style></author><author><style face="normal" font="default"> Martinoff,S.</style></author><author><style face="normal" font="default"> mig,A.</style></author><author><style face="normal" font="default"> Hausleiter,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Prognostic value of coronary computed tomographic angiography in diabetic patients without known coronary artery disease</style></title><secondary-title><style face="normal" font="default">Diabetes Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Diabetes Care</style></full-title></periodical><pages end="1363" start="1358">1358-1363</pages><volume><style face="normal" font="default">33</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Diabetes Complications/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Research Design</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="6" Year="2010">2010/6</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Diabetic patients have a high prevalence of coronary artery disease (CAD), but timely diagnosis of CAD remains challenging. We assessed the ability of coronary computed tomography angiography (CCTA) to detect CAD in diabetic patients and to predict subsequent cardiac events. RESEARCH DESIGN AND METHODS: We analyzed 140 diabetic patients without known CAD undergoing CCTA; 1,782 patients without diabetes were used as a control group. Besides calcium scoring and the degree of the most severe stenosis, the atherosclerotic burden score counting the number of segments having either a nonstenotic plaque or a stenosis was recorded. The primary end point was a composite of hard cardiac events defined as all-cause death, nonfatal myocardial infarction, or unstable angina requiring hospitalization. RESULTS: During a mean follow-up of 33 months, there were seven events in the diabetic group and 24 events in the control group. The best predictor in diabetic patients was the atherosclerotic burden score: the annual event rate ranged from 0.5% for patients with &lt;5 lesions to 9.6% for patients with >9 lesions, resulting in a hazard ratio (HR) of 1.3 (95% CI 1.1-1.7) for each additional lesion (P = 0.005). For comparison, in nondiabetic patients the annual event rate ranged from 0.3 to 2.2%, respectively, resulting in an HR of 1.2 (95% CI 1.1-1.3, P &lt; 0.001). The atherosclerotic burden score improved the prognostic value of conventional risk factors significantly (P &lt; 0.001). CONCLUSIONS: In diabetic patients without known CAD, CCTA can identify a patient group at particularly high risk for subsequent hard cardiac events</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Klinik f&amp;#x00FC;r Herz- und Kreislauferkrankungen, Deutsches Herzzentrum M&amp;#x00FC;nchen, Hospital at the Technische Universit&amp;#x00E4;t M&amp;#x00FC;nchen, Munich, Germany. mhy@dhm.mhn.deJC - eag, 7805975CP - United StatesPT - Clinical TrialPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20200300</style></custom1><custom3><style face="normal" font="default">AS - Diabetes Care. 33(6):1358-63, 2010 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>535</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Haddaway,M.J.</style></author><author><style face="normal" font="default"> Bainbridge,N.J.</style></author><author><style face="normal" font="default"> Powell,D.E.</style></author><author><style face="normal" font="default"> Davie,M.W.</style></author></authors></contributors><titles><title><style face="normal" font="default">Bone resorption in stroke and institutionalized subjects</style></title><secondary-title><style face="normal" font="default">Calcified Tissue International</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Calcified Tissue International</style></full-title></periodical><pages end="125" start="118">118-125</pages><volume><style face="normal" font="default">84</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Bone Resorption/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Stroke/co [Complications]</style></keyword><keyword><style face="normal" font="default"> 0 (collagen type I trimeric cross-linked peptide)</style></keyword><keyword><style face="normal" font="default"> 0 (Collagen Type I)</style></keyword><keyword><style face="normal" font="default"> 0 (Peptides)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Bone Density</style></keyword><keyword><style face="normal" font="default"> Bone Resorption/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Collagen Type I/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Peptides/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Stroke/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="2" Year="2009">2009/2</year></dates><abstract><style face="normal" font="default">Stroke increases the risk of hip fracture on the affected side. Although bone is lost by 1 year, rapidity of onset and relationship with immobility are uncertain. Using the bone resorption marker urinary cross-linked N telopeptide of type I collagen (uNTx), we examined bone resorption in the first 4 weeks after stroke, relating uNTx with bone density and mobility in subjects over 60 years. Two separate control groups acted as comparators, healthy (HC) and institutionalized (IC) controls, the latter to control for the effects of institutionalization. uNTx, urinary calcium (both related to creatinine and log-transformed), heel bone mineral density (BMD), Tinetti scores, and Barthel scores for prestroke function were measured. Log uNTx/Cr was lower in males compared with females, but this difference was not evident in stroke or IC subjects. Log uNTx/Cr was inversely related with BMD in females from both control groups and in male stroke subjects. Tinetti scores were divided into tertiles and were lower in stroke than IC subjects (P &lt; 0.01). Log uNTx/Cr was similar in stroke and IC subjects in the lowest Tinetti tertile. Log uNTx/Cr was higher in stroke subjects of both sexes in the lowest tertile compared with the higher two tertiles combined (P &lt; 0.05) and higher in all tertiles compared with HC subjects (P &lt; 0.05). Subjects with a prestroke Barthel index of &lt; or = 17 had higher log uNTx/Cr compared with HCs. Log uCa/Cr was higher only in male stroke patients. Bone resorption in stroke starts early, and measures to reduce this are merited</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Charles Salt Centre for Human Metabolism, Robert Jones &amp; Agnes Hunt Orthopaedic NHS Trust, Oswestry, Shropshire SY107AG, UK. mike.haddaway@rjah.nhs.ukJC - cgh, 7905481CP - United StatesPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19142679</style></custom1><custom3><style face="normal" font="default">AS - Calcif Tissue Int. 84(2):118-25, 2009 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>466</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Hagstr&amp;#x00F6</style></author><author><style face="normal" font="default">m E</style></author><author><style face="normal" font="default"> Hellman,P.</style></author><author><style face="normal" font="default"> Larsson,T.E.</style></author><author><style face="normal" font="default"> Ingelsson,E.</style></author><author><style face="normal" font="default"> Berglund,L.</style></author><author><style face="normal" font="default"> Sundstr&amp;#x00F6</style></author><author><style face="normal" font="default">m J</style></author><author><style face="normal" font="default"> Melhus,H.</style></author><author><style face="normal" font="default"> Held,C.</style></author><author><style face="normal" font="default"> Lind,L.</style></author><author><style face="normal" font="default"> lsson,K.</style></author><author><style face="normal" font="default"> Arnl&amp;#x00F6</style></author><author><style face="normal" font="default">v J</style></author></authors></contributors><titles><title><style face="normal" font="default">Plasma parathyroid hormone and the risk of cardiovascular mortality in the community</style></title><secondary-title><style face="normal" font="default">Circulation</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Circulation</style></full-title></periodical><pages end="2771" start="2765">2765-2771</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">21</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiovascular Diseases/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> *Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Blood Glucose)</style></keyword><keyword><style face="normal" font="default"> 0 (Calcium,Dietary)</style></keyword><keyword><style face="normal" font="default"> 0 (CST3 protein,human)</style></keyword><keyword><style face="normal" font="default"> 0 (Cystatin C)</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 0 (Peptide Fragments)</style></keyword><keyword><style face="normal" font="default"> 0 (Phosphates)</style></keyword><keyword><style face="normal" font="default"> 0 (pro-brain natriuretic peptide (1-76))</style></keyword><keyword><style face="normal" font="default"> 0 (Troponin I)</style></keyword><keyword><style face="normal" font="default"> 114471-18-0 (Natriuretic Peptide,Brain)</style></keyword><keyword><style face="normal" font="default"> 1406-16-2 (Vitamin D)</style></keyword><keyword><style face="normal" font="default"> 64719-49-9 (25-hydroxyvitamin D)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 9007-41-4 (C-Reactive Protein)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Blood Glucose/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> C-Reactive Protein/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium,Dietary</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Cystatin C/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Natriuretic Peptide,Brain/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Peptide Fragments/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Phosphates/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Sweden/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Troponin I/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Vitamin D/aa [Analogs &amp; Derivatives]</style></keyword><keyword><style face="normal" font="default"> Vitamin D/bl [Blood]</style></keyword></keywords><dates><year Day="2" Month="6" Year="2009">2009/6/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: Diseases with elevated levels of parathyroid hormone (PTH) such as primary and secondary hyperparathyroidism are associated with increased incidence of cardiovascular disease and death. However, data on the prospective association between circulating PTH levels and cardiovascular mortality in the community are lacking. METHODS AND RESULTS: The Uppsala Longitudinal Study of Adult Men (ULSAM), a community-based cohort of elderly men (mean age, 71 years; n=958), was used to investigate the association between plasma PTH and cardiovascular mortality. During follow-up (median, 9.7 years), 117 participants died of cardiovascular causes. In Cox proportional-hazards models adjusted for established cardiovascular risk factors (age, systolic blood pressure, diabetes, smoking, body mass index, total cholesterol, high-density lipoprotein cholesterol, antihypertensive treatment, lipid-lowering treatment, and history of cardiovascular disease), higher plasma PTH was associated with higher risk for cardiovascular mortality (hazard ratio for 1-SD increase in PTH, 1.38; 95% confidence interval, 1.18 to 1.60; P&lt;0.001). This association remained essentially unaltered in participants without previous cardiovascular disease and in participants with normal PTH (&lt;6.8 pmol/L) with no other signs of a disturbed mineral metabolism (normal serum calcium, 2.2 to 2.6 mmol/L; normal glomerular filtration rate, >50 mL . min(-1) . 1.73 m(-2) and without vitamin D deficiency, plasma 25-OH vitamin D >37.5 nmol/L). Interestingly, elevated plasma PTH (>5.27 pmol/L) accounted for 20% (95% confidence interval, 10 to 26) of the population-attributable risk proportion for cardiovascular mortality. CONCLUSIONS: Plasma PTH levels predict cardiovascular mortality in the community, even in individuals with PTH within the normal range. Further studies are warranted to evaluate the clinical implications of measuring PTH in cardiovascular risk prediction and to elucidate whether PTH is a modifiable risk factor</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Uppsala Clinical Research Center, Uppsala University, Sweden. emil.hagstrom@ucr.uu.seJC - daw, 0147763CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19451355</style></custom1><custom3><style face="normal" font="default">AS - Circulation. 119(21):2765-71, 2009 Jun 2.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>26</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Halon,D.A.</style></author><author><style face="normal" font="default"> Dobrecky-Mery,I.</style></author><author><style face="normal" font="default"> Gaspar,T.</style></author><author><style face="normal" font="default"> Azencot,M.</style></author><author><style face="normal" font="default"> Yaniv,N.</style></author><author><style face="normal" font="default"> Peled,N.</style></author><author><style face="normal" font="default"> Lewis,B.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Pulse pressure and coronary atherosclerosis in asymptomatic type 2 diabetes mellitus: a 64 channel cardiac computed tomography analysis</style></title><secondary-title><style face="normal" font="default">International Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">International Journal of Cardiology</style></full-title></periodical><pages end="71" start="63">63-71</pages><volume><style face="normal" font="default">143</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Blood Pressure/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 2/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> 0 (Antihypertensive Agents)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Antihypertensive Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Compliance/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus,Type 2/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Diabetic Retinopathy/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Rate/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Hypertension/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed/sn [Statistics &amp; Numerical Data]</style></keyword></keywords><dates><year Day="6" Month="8" Year="2010">2010/8/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: Identification of high risk sub-groups for early initiation of preventive medical therapy requires widespread population screening using simple, inexpensive tests. High pulse pressure has been shown to predict adverse coronary events. We examined if this correlation was related to a greater coronary plaque burden in patients with high pulse pressure using 64 channel coronary computed tomographic angiography (CCTA) in patients with type 2 diabetes mellitus. METHODS: The study included 427 consecutive asymptomatic diabetic patients with no history of coronary disease, (age 55-74 years, 58% women), undergoing CCTA as part of a prospective outcomes study. RESULTS: Coronary atheroma was present in 76.6% of patients, multivessel coronary atheroma in 55.1% and luminal stenosis (>or=50% of diameter) in 22.9%. Pulse pressure (adjusted for age, gender, mean blood pressure and heart rate) correlated with number of coronary arteries with atheroma (p=0.005) and with multivessel coronary atheroma (odds ratio 1.24 95%CI 1.06-1.43 for each 10 mm Hg pulse pressure, p=0.009). The correlation was independent of Framingham and United Kingdom Prospective Diabetic Study risk scores (p=0.027 and p=0.036 respectively). Adjusted pulse pressure also correlated with quartiles of coronary artery calcium score (p=0.009). CONCLUSION: Elevated pulse pressure was a useful independent marker of presence and extent of pre-clinical coronary artery disease in an asymptomatic diabetic population. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiovascular Medicine, Lady Davis Carmel Medical Center, Haifa, IsraelJC - gqw, 8200291CP - NetherlandsPT - Clinical TrialPT - Journal ArticleSI - ClinicalTrials.govSA - ClinicalTrials.gov/NCT00321542LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19246107</style></custom1><custom3><style face="normal" font="default">AS - Int J Cardiol. 143(1):63-71, 2010 Aug 6.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>380</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Hamaji,M.</style></author><author><style face="normal" font="default"> Sakaguchi,Y.</style></author><author><style face="normal" font="default"> Matsuda,M.</style></author><author><style face="normal" font="default"> Kono,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Reinforced closure of the sternum with absorbable pins for high-risk patients</style></title><secondary-title><style face="normal" font="default">Interactive Cardiovascular &amp; Thoracic Surgery</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Interactive Cardiovascular &amp; Thoracic Surgery</style></full-title></periodical><pages end="561" start="559">559-561</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Absorbable Implants</style></keyword><keyword><style face="normal" font="default"> *Bone Nails</style></keyword><keyword><style face="normal" font="default"> *Mediastinitis/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Sternotomy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Surgical Wound Dehiscence/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Surgical Wound Infection/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Suture Techniques/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> 0 (Polyesters)</style></keyword><keyword><style face="normal" font="default"> 12597-68-1 (Stainless Steel)</style></keyword><keyword><style face="normal" font="default"> 1306-06-5 (Durapatite)</style></keyword><keyword><style face="normal" font="default"> 26969-66-4 (poly(lactide))</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Bone Wires</style></keyword><keyword><style face="normal" font="default"> Durapatite</style></keyword><keyword><style face="normal" font="default"> Equipment Design</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Mediastinitis/mi [Microbiology]</style></keyword><keyword><style face="normal" font="default"> Methicillin-Resistant Staphylococcus aureus/ip [Isolation &amp; Purification]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Polyesters</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Stainless Steel</style></keyword><keyword><style face="normal" font="default"> Surgical Wound Dehiscence/mi [Microbiology]</style></keyword><keyword><style face="normal" font="default"> Surgical Wound Infection/mi [Microbiology]</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><abstract><style face="normal" font="default">We report our result of the reinforced sternal closure in 51 consecutive patients. We applied a new type of absorbable radiopaque pins (Super FIXSORB) composed of poly-lactide acid and hydroxyapatite, in addition to conventional stainless steel wires. The risk scores of our patients were calculated from the simplified risk scoring system for major infection based on the Society of Thoracic Surgeons National Cardiac Database. The expected probability of infection is significantly higher than the actual infection rate in our patients. Our procedure may contribute to minimizing the fatal sternal complication particularly in high-risk patients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Thoracic and Cardiovascular Surgery, Nagahama City Hospital, Nagahama, Japan. masamasatsugu@nifty.comJC - 101158399CP - EnglandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19574265</style></custom1><custom3><style face="normal" font="default">AS - Interact Cardiovasc Thorac Surg. 9(4):559-61, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>432</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Hamdani,N.</style></author><author><style face="normal" font="default"> Paulus,W.J.</style></author><author><style face="normal" font="default"> van,Heerebeek L.</style></author><author><style face="normal" font="default"> ly,A.</style></author><author><style face="normal" font="default"> Boontje,N.M.</style></author><author><style face="normal" font="default"> Zuidwijk,M.J.</style></author><author><style face="normal" font="default"> Bronzwaer,J.G.</style></author><author><style face="normal" font="default"> Simonides,W.S.</style></author><author><style face="normal" font="default"> Niessen,H.W.</style></author><author><style face="normal" font="default"> Stienen,G.J.</style></author><author><style face="normal" font="default"> van,der,V</style></author></authors></contributors><titles><title><style face="normal" font="default">Distinct myocardial effects of beta-blocker therapy in heart failure with normal and reduced left ventricular ejection fraction</style></title><secondary-title><style face="normal" font="default">European Heart Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">European Heart Journal</style></full-title></periodical><pages end="1872" start="1863">1863-1872</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">15</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Adrenergic beta-Antagonists/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Heart Failure/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Myocardium</style></keyword><keyword><style face="normal" font="default"> *Stroke Volume/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Ventricular Dysfunction,Left</style></keyword><keyword><style face="normal" font="default"> 0 (Adrenergic beta-Antagonists)</style></keyword><keyword><style face="normal" font="default"> 0 (Microfilament Proteins)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Failure/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Heart Failure/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Microfilament Proteins/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardium/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Myocardium/ul [Ultrastructure]</style></keyword><keyword><style face="normal" font="default"> Myocytes,Cardiac/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phosphorylation</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Stroke Volume/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Ventricular Dysfunction,Left/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Ventricular Dysfunction,Left/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Ventricular Dysfunction,Left/pp [Physiopathology]</style></keyword></keywords><dates><year Day="0" Month="8" Year="2009">2009/8</year></dates><abstract><style face="normal" font="default">AIMS: Left ventricular (LV) myocardial structure and function differ in heart failure (HF) with normal (N) and reduced (R) LV ejection fraction (EF). This difference could underlie an unequal outcome of trials with beta-blockers in heart failure with normal LVEF (HFNEF) and heart failure with reduced LVEF (HFREF) with mixed results observed in HFNEF and positive results in HFREF. To investigate whether beta-blockers have distinct myocardial effects in HFNEF and HFREF, myocardial structure, cardiomyocyte function, and myocardial protein composition were compared in HFNEF and HFREF patients without or with beta-blockers. METHODS AND RESULTS: Patients, free of coronary artery disease, were divided into beta-(HFNEF) (n = 16), beta+(HFNEF) (n = 16), beta-(HFREF) (n = 17), and beta+(HFREF) (n = 22) groups. Using LV endomyocardial biopsies, we assessed collagen volume fraction (CVF) and cardiomyocyte diameter (MyD) by histomorphometry, phosphorylation of myofilamentary proteins by ProQ-Diamond phosphostained 1D-gels, and expression of beta-adrenergic signalling and calcium handling proteins by western immunoblotting. Cardiomyocytes were also isolated from the biopsies to measure active force (F(active)), resting force (F(passive)), and calcium sensitivity (pCa(50)). Myocardial effects of beta-blocker therapy were either shared by HFNEF and HFREF, unique to HFNEF or unique to HFREF. Higher F(active), higher pCa(50), lower phosphorylation of troponin I and myosin-binding protein C, and lower beta(2) adrenergic receptor expression were shared. Higher F(passive), lower CVF, lower MyD, and lower expression of stimulatory G protein were unique to HFNEF and lower expression of inhibitory G protein was unique to HFREF. CONCLUSION: Myocardial effects unique to either HFNEF or HFREF could contribute to the dissimilar outcome of beta-blocker therapy in both HF phenotypes</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Laboratory for Physiology, Institute for Cardiovascular Research, VU University Medical Center, van der Boechorststraat 7, 1081 BT Amsterdam, the NetherlandsJC - em8, 8006263CP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19487234</style></custom1><custom3><style face="normal" font="default">AS - Eur Heart J. 30(15):1863-72, 2009 Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>92</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Hamer,M.</style></author><author><style face="normal" font="default"> Kivimaki,M.</style></author><author><style face="normal" font="default"> Lahiri,A.</style></author><author><style face="normal" font="default"> Marmot,M.G.</style></author><author><style face="normal" font="default"> Steptoe,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Persistent cognitive depressive symptoms are associated with coronary artery calcification</style></title><secondary-title><style face="normal" font="default">Atherosclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Atherosclerosis</style></full-title></periodical><pages end="213" start="209">209-213</pages><volume><style face="normal" font="default">210</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Depression/co [Complications]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Calcinosis</style></keyword><keyword><style face="normal" font="default"> Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword></keywords><dates><year Day="0" Month="5" Year="2010">2010/5</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The association between depression and sub-clinical atherosclerosis remains unclear. By assessing depressive symptoms only at one point in time, most previous studies have failed to ascertain long-term exposure. We examined the association of long-term depressive symptoms assessed at three time points (over 10 yrs) with a marker of sub-clinical atherosclerosis. METHODS: Participants included 454 healthy, non-medicated men and women from the Whitehall II epidemiological cohort without known cardiovascular disease (CVD). Depressive symptoms were assessed at three time points (over 10 yrs) and coronary atherosclerosis was assessed at follow-up in terms of coronary artery calcification (CAC). RESULTS: 18.9% of the sample reported depressive symptoms at least once during follow-up. Participants that were persistently depressed had over a two-fold increased risk of detectable CAC (Agatston score>0) (odds ratio [OR]=2.56, 95% CI, 1.14-5.78) and high CAC (Agatston score > or = 100) (OR=2.36, 1.04-5.35) compared with never depressed after adjustment for age, sex, and a range of conventional cardiac risk factors. These associations were more robust in men. Participants who were depressed on only one occasion were not at elevated risk of CAC. CONCLUSIONS: Persistent cognitive symptoms of depression assessed over several time points, but not on a single occasion, are related to sub-clinical coronary atherosclerosis in men free of known CVD and diabetes. Copyright 2010 Elsevier Ireland Ltd. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Epidemiology and Public Health, 1-19 Torrington Place, University College London, London, WC1E 6BT, UK. m.hamer@ucl.ac.ukCM - Comment in: Atherosclerosis. 2010 May;210(1):41-2; PMID: 20197190JC - 95x, 0242543CP - IrelandPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - R01AG034454-01 (United States NIA NIH HHS)NO - R01HL036310-20A2 (United States NHLBI NIH HHS)NO - RG 05/006 (United Kingdom British Heart Foundation)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20153471</style></custom1><custom3><style face="normal" font="default">AS - Atherosclerosis. 210(1):209-13, 2010 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>111</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Han,C.J.</style></author><author><style face="normal" font="default"> Taira,K.</style></author><author><style face="normal" font="default"> Yu,X.</style></author><author><style face="normal" font="default"> Shen,H.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Nutritional status survey in 200 of the Korean and Han nationality elderly in Yanji]. [Chinese]</style></title><secondary-title><style face="normal" font="default">Wei Sheng Yen Chiu/Journal of Hygiene Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Wei Sheng Yen Chiu/Journal of Hygiene Research</style></full-title></periodical><pages end="114" start="112">112-114</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Nutrition Surveys</style></keyword><keyword><style face="normal" font="default"> *Nutritional Status</style></keyword><keyword><style face="normal" font="default"> 11103-57-4 (Vitamin A)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 83-88-5 (Riboflavin)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Asian Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcium/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> China/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Energy Intake</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Riboflavin/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Vitamin A/ad [Administration &amp; Dosage]</style></keyword></keywords><dates><year Day="0" Month="1" Year="2005">2005/1</year></dates><isbn><style face="normal" font="default">1000-8020</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: To assess the nutritional status and dietary intake of the Korean and Han nationality elderly in Yanji. METHODS: We selected 200 of the Korean and Han nationality adults aged 60 and older and measured their blood pressure. Dietary survey was performed with 24-hour dietary recall method. RESULTS: (1) The daily average intake of energy surpassed recommended nutrient intake (RNI) value in male and amounted RNI in women. In the male, Breakfast energy intake ratio was significantly lower and supper energy intake ratio was significantly higher than female. Supper energy intake in male with hypertension was significantly higher than normal blood pressure. (2) The daily average intake of fat in the Korean was significantly lower than in Han nationality (P &lt; 0.01), and also was lower than RNI value. The daily average intake of carbohydrate in the Korean was significantly higher than in Han nationality (P &lt; 0.01). (3) The daily average intake of protein exceed RNI value in the Korean male and was slightly lower than RNI value in Han male and both nationality women. The daily average intake of protein in the Korean males was significantly higher than in Han males (P &lt; 0.01). The ratio of good protein was 35%-45% and bean protein exceed 15%. (4) The daily average intakes of calcium and vitamin A were only half RNI value and vitamin B2 lower than RNI values. CONCLUSION: The consumption of some nutrients among the Korean and Han nationality is inequality. The daily intake of calcium, vitamin A and vitamin B2 in elderly is seriously inadequate. Distribution of three meal energy is irrational and the high ratio of supper energy in male relates to hypertension</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Preventive Medicine, Yanbian University College of Medicine, Yanji 133000, China. hanchunhee@tom.comJC - 9426367, cpbCP - ChinaPT - English AbstractPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - Chinese</style></notes><urls/><custom1><style face="normal" font="default">UI - 15862041</style></custom1><custom3><style face="normal" font="default">AS - Wei Sheng Yen Chiu. 34(1):112-4, 2005 Jan.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>486</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Haritoglou,C.</style></author><author><style face="normal" font="default"> Gerss,J.</style></author><author><style face="normal" font="default"> Sauerland,C.</style></author><author><style face="normal" font="default"> Kampik,A.</style></author><author><style face="normal" font="default"> Ulbig,M.W.</style></author><author><style face="normal" font="default"> CALDIRET study group</style></author></authors></contributors><titles><title><style face="normal" font="default">Effect of calcium dobesilate on occurrence of diabetic macular oedema (CALDIRET study): randomised, double-blind, placebo-controlled, multicentre trial</style></title><secondary-title><style face="normal" font="default">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Lancet</style></full-title></periodical><pages end="1371" start="1364">1364-1371</pages><volume><style face="normal" font="default">373</style></volume><number><style face="normal" font="default">9672</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium Dobesilate/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Diabetic Retinopathy/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Hemostatics/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Macular Edema/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> 0 (Hemostatics)</style></keyword><keyword><style face="normal" font="default"> 20123-80-2 (Calcium Dobesilate)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium Dobesilate/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus,Type 2/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Diabetic Retinopathy/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Diabetic Retinopathy/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Double-Blind Method</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fluorescein Angiography</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Hemostatics/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Kaplan-Meiers Estimate</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Macular Edema/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Macular Edema/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Outpatients</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Reduction Behavior</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword></keywords><dates><year Day="18" Month="4" Year="2009">2009/4/18</year></dates><abstract><style face="normal" font="default">BACKGROUND: Medical treatment for diabetic retinopathy could have an important role in prevention of complications such as visual loss. We aimed to assess the effect of calcium dobesilate on occurrence of diabetic macular oedema. METHODS: We undertook a randomised, double-blind, placebo-controlled, multicentre study in 40 centres in 11 countries. We enrolled outpatients with adult-onset type 2 diabetes and mild-to-moderate non-proliferative diabetic retinopathy, and randomly allocated them via sealed envelopes either calcium dobesilate (1500 mg per day) or placebo. The primary endpoint was development of clinically significant macular oedema (CSME) within a follow-up period of 5 years. Patients who dropped out of the study early were censored. Analysis was by intention to treat. FINDINGS: We enrolled 635 patients. 324 were randomly allocated calcium dobesilate and 311 were assigned placebo. In the calcium dobesilate group, 86 patients developed CSME compared with 69 in the placebo group. Accounting for censored cases, estimated cumulative 5-year CSME probability was 35% and 28%, respectively (hazard ratio 1.32, 95% CI 0.96-1.81; p=0.0844). Adverse events did not differ between treatment groups (78 [24%] on calcium dobesilate and 90 [29%] with placebo). No relevant drug-related complications were noted. Nine patients (3%) died in the calcium dobesilate group and eight (3%) deaths were recorded on placebo. INTERPRETATION: Calcium dobesilate did not reduce the risk of development of CSME</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Ophthalmology, Ludwig-Maximilians-University, Munich, GermanyCM - Comment in: Lancet. 2009 Apr 18;373(9672):1316-8; PMID: 19376433]JC - 2985213r, l0s, 0053266CP - EnglandPT - Journal ArticlePT - Multicenter StudyPT - Randomized Controlled TrialPT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19376452</style></custom1><custom3><style face="normal" font="default">AS - Lancet. 373(9672):1364-71, 2009 Apr 18.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>184</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Harnden,K.E.</style></author><author><style face="normal" font="default"> Frayn,K.N.</style></author><author><style face="normal" font="default"> Hodson,L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Dietary Approaches to Stop Hypertension (DASH) diet: applicability and acceptability to a UK population</style></title><secondary-title><style face="normal" font="default">Journal of Human Nutrition &amp; Dietetics</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Human Nutrition &amp; Dietetics</style></full-title></periodical><pages end="10" start="3">3-10</pages><volume><style face="normal" font="default">23</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Diet</style></keyword><keyword><style face="normal" font="default"> *Health Promotion/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Hypertension/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Patient Compliance</style></keyword><keyword><style face="normal" font="default"> 0 (Calcium,Dietary)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcium,Dietary/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Diet Records</style></keyword><keyword><style face="normal" font="default"> Diet,Sodium-Restricted</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Food Preferences</style></keyword><keyword><style face="normal" font="default"> Fruit</style></keyword><keyword><style face="normal" font="default"> Great Britain</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Reference Values</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Vegetables</style></keyword></keywords><dates><year Day="0" Month="2" Year="2010">2010/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: The Dietary Approaches to Stop Hypertension (DASH) diet is widely promoted in the USA for the prevention and treatment of high blood pressure. It is high in fruit and vegetables, low-fat dairy and wholegrain foods and low in saturated fat and refined sugar. To our knowledge, the use of this dietary pattern has not been assessed in a free-living UK population. METHODS: The DASH diet was adapted to fit UK food preferences and portion sizes. Fourteen healthy subjects followed the adapted DASH diet for 30 days in which they self-selected all food and beverages. Dietary intake was assessed by 5-day food diaries completed before and towards the end of the study. Blood pressure was measured at the beginning and end of the study to assess compliance to the DASH style diet. RESULTS: The DASH diet was easily adapted to fit with UK food preferences. Furthermore, it was well tolerated and accepted by subjects. When on the DASH style diet, subjects reported consuming significantly (P &lt; 0.01) more carbohydrate and protein and less total fat (5%, 6% and 9% total energy, respectively). Sodium intakes decreased by 860 mg day(-1) (P &lt; 0.001). Systolic and diastolic blood pressure decreased significantly (P &lt; 0.05) by 4.6 and 3.9 mmHg, respectively when on the DASH style diet. CONCLUSIONS: The DASH style diet was well accepted and was associated with a decrease in blood pressure in normotensive individuals and should be considered when giving dietary advice to people with elevated blood pressure in the UK</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UKJC - d1s, 8904840CP - EnglandPT - Clinical TrialPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tNO - BB/D008123/1 (United Kingdom Biotechnology and Biological Sciences Research Council)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19843201</style></custom1><custom3><style face="normal" font="default">AS - J Hum Nutr Diet. 23(1):3-10, 2010 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>545</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Hartmann,M.</style></author><author><style face="normal" font="default"> Mattern,E.S.</style></author><author><style face="normal" font="default"> Huisman,J.</style></author><author><style face="normal" font="default"> van Houwelingen,G.K.</style></author><author><style face="normal" font="default"> de Man,F.H.</style></author><author><style face="normal" font="default"> Stoel,M.G.</style></author><author><style face="normal" font="default"> Danse,P.W.</style></author><author><style face="normal" font="default"> Louwerenburg,H.W.</style></author><author><style face="normal" font="default"> von,Birgelen C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Reproducibility of volumetric intravascular ultrasound radiofrequency-based analysis of coronary plaque composition in vivo</style></title><secondary-title><style face="normal" font="default">The International Journal of Cardiovascular Imaging</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">The International Journal of Cardiovascular Imaging</style></full-title></periodical><pages end="23" start="13">13-23</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Artery Disease/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Ultrasonography,Interventional/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Image Processing,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Linear Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="1" Year="2009">2009/1</year></dates><abstract><style face="normal" font="default">Intravascular ultrasound radiofrequency (RF-IVUS) data permit the analysis of coronary plaque composition in vivo and is used as an endpoint of ongoing pharmacological intervention trials. We assessed the reproducibility of volumetric RF-IVUS analyses in mild-to-moderately diseased atherosclerotic human coronary arteries in vivo. A total of 9,212 IVUS analyses on cross-sectional IVUS frames was performed to evaluate the reproducibility of volumetric RF-IVUS measurements in 33 coronary segments with a length of 27 +/- 7 mm. For vessel, lumen, and plaque + media volume the relative measurement differences (P = NS for all) were (A = intraobserver comparison, same pullback) -0.40 +/- 1.0%; -0.48 +/- 1.4%; -0.35 +/- 1.6%, (B = intraobserver comparison, repeated pullback) -0.42 +/- 1.2%; -0.52 +/- 1.8%; -0.43 +/- 4.5% (C = interobserver comparison, same pullback) 0.71 +/- 1.8%; 0.71 +/- 2.2%, and 0.89 +/- 5.0%, respectively. For fibrous, fibro-lipidic, calcium, and necrotic-core volumes the relative measurement differences (P = NS for all) were (A) 0.45 +/- 2.1%; -1.12 +/- 4.9%; -0.84 +/- 2.1%; -0.22 +/- 1.8%, (B) 1.40 +/- 4.1%; 1.26 +/- 6.7%; 2.66 +/- 7.4%; 0.85 +/- 4.4%, and (C) -1.60 +/- 4.9%; 3.85 +/- 8.2%; 1.66 +/- 7.5%, and -1.58 +/- 4.7%, respectively. Of note, necrotic-core volume showed on average the lowest measurement variability. Thus, in mild-to-moderate atherosclerotic coronary artery disease the reproducibility of volumetric compositional RF-IVUS measurements from the same pullback is relatively high, but lower than the reproducibility of geometrical IVUS measurements. Measurements from repeated pullbacks and by different observers show acceptable reproducibilities; the volumetric measurement of the necrotic-core shows on average the highest reproducibility of the compositional RF-IVUS measurements</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Haaksbergerstraat 55, Enschede, 7513ER, The NetherlandsJC - 100969716CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18704753</style></custom1><custom3><style face="normal" font="default">AS - Int J Cardiovasc Imaging. 25(1):13-23, 2009 Jan.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>19</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Hawkesworth,S.</style></author><author><style face="normal" font="default"> Sawo,Y.</style></author><author><style face="normal" font="default"> Fulford,A.J.</style></author><author><style face="normal" font="default"> Goldberg,G.R.</style></author><author><style face="normal" font="default"> Jarjou,L.M.</style></author><author><style face="normal" font="default"> Prentice,A.</style></author><author><style face="normal" font="default"> Moore,S.E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Effect of maternal calcium supplementation on offspring blood pressure in 5- to 10-y-old rural Gambian children</style></title><secondary-title><style face="normal" font="default">American Journal of Clinical Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Clinical Nutrition</style></full-title></periodical><pages end="747" start="741">741-747</pages><volume><style face="normal" font="default">92</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Blood Pressure/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Calcium,Dietary/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Dietary Supplements</style></keyword><keyword><style face="normal" font="default"> 0 (Calcium,Dietary)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipids)</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Child,Preschool</style></keyword><keyword><style face="normal" font="default"> Diet Records</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Gambia/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Heart Rate/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lipids/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patient Selection</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Rural Population</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Waist Circumference</style></keyword></keywords><dates><year Day="0" Month="10" Year="2010">2010/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Evidence suggests that increased maternal calcium intake during pregnancy may result in lower offspring blood pressure, prompting calls for more robust data in this field, particularly in settings of habitually low calcium intake. OBJECTIVE: The objective was to investigate the effect of maternal calcium supplementation on blood pressure in offspring by recruiting children born after a randomized, double-blind, placebo-controlled trial of calcium supplementation during pregnancy. DESIGN: Children (n = 389) from a rural area of The Gambia (mean age: 7.4 +/- 1.2 y; range: 5-10 y), whose mothers received a calcium supplement (1500 mg Ca/d from 20 wk of gestation until delivery) or placebo, were followed up in West Africa. Blood pressure was assessed under standardized conditions with use of the Omron 705IT automated oscillometric device (Morton Medical Ltd, London, United Kingdom), and anthropometric and body composition (bioelectrical impedance) measurements were also made. RESULTS: The analysis was restricted to 350 children born at term, which represented 64% of original trial births. There was no difference in systolic (adjusted mean difference: -0.04 mm Hg; 95% CI: -1.78, 1.69 mm Hg) or diastolic (adjusted mean difference: 0.25 mm Hg; 95% CI: -1.27, 1.77 mm Hg) blood pressure between children whose mothers had received calcium and those who received placebo. No interaction between childhood body mass index (in kg/m(2); mean: 14.0) and maternal calcium supplementation was observed in this study. CONCLUSION: Calcium supplementation in the second half of pregnancy in Gambian women with very low habitual calcium intakes may not result in lower offspring blood pressure at 5-10 y of age</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Medical Research Council International Nutrition Group, London School of Hygiene and Tropical Medicine, London, United Kingdom. sophie.hawkesworth@lshtm.ac.ukJC - 3ey, 0376027CP - United StatesPT - Controlled Clinical TrialPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tNO - (United Kingdom Medical Research Council)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20668051</style></custom1><custom3><style face="normal" font="default">AS - Am J Clin Nutr. 92(4):741-7, 2010 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>162</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Hay,C.S.</style></author><author><style face="normal" font="default"> Morse,R.J.</style></author><author><style face="normal" font="default"> Morgan-Hughes,G.J.</style></author><author><style face="normal" font="default"> Gosling,O.</style></author><author><style face="normal" font="default"> Shaw,S.R.</style></author><author><style face="normal" font="default"> Roobottom,C.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Prognostic value of coronary multidetector CT angiography in patients with an intermediate probability of significant coronary heart disease</style></title><secondary-title><style face="normal" font="default">British Journal of Radiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">British Journal of Radiology</style></full-title></periodical><pages end="330" start="327">327-330</pages><volume><style face="normal" font="default">83</style></volume><number><style face="normal" font="default">988</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Great Britain</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">The aim of this study was to determine the prognostic value of coronary multidetector CT angiography (MDCTA) in patients with an intermediate pre-test probability of significant coronary artery disease (CAD). Patients who underwent 64-slice coronary MDCTA and met the selection criteria were identified and assessed for intermediate pre-test probability. Coronary MDCTA scans were preceded by calcium scoring, whereas all MDCTA scans were interrogated for the presence of plaque composition and the distribution and degree of stenosis. Significant stenosis was classified as being >50% of the luminal diameter. All patients were followed up for the occurrence of (i) cardiac death, (ii) non-fatal myocardial infarction, (iii) unstable angina requiring hospital admission and (iv) revascularisation. 138 patients were included (follow-up of 19.9 months); of these, 8 had a cardiac event (all revascularisations) and all had a positive coronary MDCTA. Patients with normal coronary arteries or non-significant stenosis suffered no cardiac events during follow-up. There were significant differences between the two groups regarding the presence of significant stenosis (p&lt;0.001), the presence of plaque (p = 0.011) and a calcium score >10 (p = 0.003); 36.4% of patients with significant stenosis underwent revascularisation. In conclusion, this is the first UK study to investigate survival data in a population of intermediate-risk patients with no prior history of CAD who were investigated with coronary MDCTA. Coronary MDCTA can confidently rule out significant CAD in the intermediate-risk population and guide risk factor modification in patients with demonstrated coronary atheroma</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Departments of Clinical Radiology, Derriford Hospital, Plymouth PL6 8DH, UK. c.hay@nhs.netJC - b28, 0373125CP - EnglandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19723770</style></custom1><custom3><style face="normal" font="default">AS - Br J Radiol. 83(988):327-30, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>253</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">He,F.J.</style></author><author><style face="normal" font="default"> Marciniak,M.</style></author><author><style face="normal" font="default"> Carney,C.</style></author><author><style face="normal" font="default"> Markandu,N.D.</style></author><author><style face="normal" font="default"> Anand,V.</style></author><author><style face="normal" font="default"> Fraser,W.D.</style></author><author><style face="normal" font="default"> Dalton,R.N.</style></author><author><style face="normal" font="default"> Kaski,J.C.</style></author><author><style face="normal" font="default"> MacGregor,G.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Effects of potassium chloride and potassium bicarbonate on endothelial function, cardiovascular risk factors, and bone turnover in mild hypertensives</style></title><secondary-title><style face="normal" font="default">Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Hypertension</style></full-title></periodical><pages end="688" start="681">681-688</pages><volume><style face="normal" font="default">55</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Bicarbonates/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Bone Remodeling/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> *Endothelium,Vascular/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> *Hypertension/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Potassium Chloride/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Potassium Compounds/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> 0 (Bicarbonates)</style></keyword><keyword><style face="normal" font="default"> 0 (Potassium Compounds)</style></keyword><keyword><style face="normal" font="default"> 0 (Sodium Chloride,Dietary)</style></keyword><keyword><style face="normal" font="default"> 298-14-6 (potassium bicarbonate)</style></keyword><keyword><style face="normal" font="default"> 7440-09-7 (Potassium)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 7447-40-7 (Potassium Chloride)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Albuminuria/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Albuminuria/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Albuminuria/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Blood Pressure/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Bone Remodeling/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Brachial Artery/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Brachial Artery/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Calcium/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> Cross-Over Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Hypertension/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Hypertrophy,Left Ventricular/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Hypertrophy,Left Ventricular/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Hypertrophy,Left Ventricular/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Potassium/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Pulsatile Flow/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Pulse</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Sodium Chloride,Dietary/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="3" Year="2010">2010/3</year></dates><abstract><style face="normal" font="default">To determine the effects of potassium supplementation on endothelial function, cardiovascular risk factors, and bone turnover and to compare potassium chloride with potassium bicarbonate, we carried out a 12-week randomized, double-blind, placebo-controlled crossover trial in 42 individuals with untreated mildly raised blood pressure. Urinary potassium was 77+/-16, 122+/-25, and 125+/-27 mmol/24 hours after 4 weeks on placebo, potassium chloride, and potassium bicarbonate, respectively. There were no significant differences in office blood pressure among the 3 treatment periods, and only 24-hour and daytime systolic blood pressures were slightly lower with potassium chloride. Compared with placebo, both potassium chloride and potassium bicarbonate significantly improved endothelial function as measured by brachial artery flow-mediated dilatation, increased arterial compliance as assessed by carotid-femoral pulse wave velocity, decreased left ventricular mass, and improved left ventricular diastolic function. There was no significant difference between the 2 potassium salts in these measurements. The study also showed that potassium chloride reduced 24-hour urinary albumin and albumin:creatinine ratio, and potassium bicarbonate decreased 24-hour urinary calcium, calcium:creatinine ratio, and plasma C-terminal cross-linking telopeptide of type 1 collagen significantly. These results demonstrated that an increase in potassium intake had beneficial effects on the cardiovascular system, and potassium bicarbonate may improve bone health. Importantly, these effects were found in individuals who already had a relatively low-salt and high-potassium intake</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. f.he@qmul.ac.ukJC - gk7, 7906255CP - United StatesPT - Journal ArticlePT - Randomized Controlled TrialPT - Research Support, Non-U.S. Gov'tNO - FS/06/009 (United Kingdom British Heart Foundation)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20083724</style></custom1><custom3><style face="normal" font="default">AS - Hypertension. 55(3):681-8, 2010 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>262</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Heilbron,B.G.</style></author><author><style face="normal" font="default"> Leipsic,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Submillisievert coronary computed tomography angiography using adaptive statistical iterative reconstruction - a new reality</style></title><secondary-title><style face="normal" font="default">Canadian Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Canadian Journal of Cardiology</style></full-title></periodical><pages end="36" start="35">35-36</pages><volume><style face="normal" font="default">26</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> 0 (Contrast Media)</style></keyword><keyword><style face="normal" font="default"> 0 (Triiodobenzoic Acids)</style></keyword><keyword><style face="normal" font="default"> 92339-11-2 (iodixanol)</style></keyword><keyword><style face="normal" font="default"> Contrast Media</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Image Processing,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Radiation Dosage</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Triiodobenzoic Acids</style></keyword></keywords><dates><year Day="0" Month="1" Year="2010">2010/1</year></dates><abstract><style face="normal" font="default">Coronary computed tomography angiography (CCTA) is becoming an increasingly robust tool in the assessment and exclusion of coronary artery disease. Multiple recent studies have raised concerns regarding the radiation dose exposure of CCTA. A novel approach to dose reduction in CCTA using adaptive statistical iterative reconstruction, resulting in a submillisievert CCTA examination, is described. To the authors' knowledge, the present report describes the first submillisievert study performed in Canada. The ability to perform a diagnostic CCTA with such a low dose challenges the role of coronary calcium scoring and will likely have implications for the future use of this test</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - University of British Columbia, Providence Heart &amp; Lung Institute/St Paul's Hospital, Vancouver, Canada. bheilbron@gmail.comJC - chp, 8510280CP - CanadaPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20101355</style></custom1><custom3><style face="normal" font="default">AS - Can J Cardiol. 26(1):35-6, 2010 Jan.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>2</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Hernandez-Romero,D.</style></author><author><style face="normal" font="default"> Ruiz-Nodar,J.M.</style></author><author><style face="normal" font="default"> Marin,F.</style></author><author><style face="normal" font="default"> Tello-Montoliu,A.</style></author><author><style face="normal" font="default"> Roldan,V.</style></author><author><style face="normal" font="default"> Mainar,L.</style></author><author><style face="normal" font="default"> Perez-Andreu,V.</style></author><author><style face="normal" font="default"> Anton,A.I.</style></author><author><style face="normal" font="default"> Bonaque,J.C.</style></author><author><style face="normal" font="default"> Valdes,M.</style></author><author><style face="normal" font="default"> Vicente,V.</style></author><author><style face="normal" font="default"> Gonzalez-Conejero,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">CALU A29809G polymorphism in coronary atherothrombosis: Implications for coronary calcification and prognosis</style></title><secondary-title><style face="normal" font="default">Annals of Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Annals of Medicine</style></full-title></periodical><pages end="446" start="439">439-446</pages><volume><style face="normal" font="default">42</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Acute Coronary Syndrome/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Calcium-Binding Proteins/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Calcium-Binding Proteins)</style></keyword><keyword><style face="normal" font="default"> 0 (CALU protein,human)</style></keyword><keyword><style face="normal" font="default"> 0 (Peptide Fragments)</style></keyword><keyword><style face="normal" font="default"> 0 (pro-brain natriuretic peptide (1-76))</style></keyword><keyword><style face="normal" font="default"> 114471-18-0 (Natriuretic Peptide,Brain)</style></keyword><keyword><style face="normal" font="default"> Acute Coronary Syndrome/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Acute Coronary Syndrome/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Natriuretic Peptide,Brain/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Peptide Fragments/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Polymorphism,Single Nucleotide</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="9" Year="2010">2010/9</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Arterial calcification is a risk factor for atherosclerosis. Calumenin (CALU), a protein regulating proteins involved in coagulation and arterial calcification also has extracellular functions related to atherosclerosis. We recently described that CALU polymorphism A29809G was related to acenocoumarol requirements, and we wanted to evaluate its role in arterial calcification and prognosis. PATIENTS AND METHODS: A total of 374 consecutive patients with non-ST-elevation acute coronary syndrome (nSTACS). In 175 of them, who underwent percutaneous coronary intervention, we assessed calcification in each main coronary artery. Follow-up at 1 and 6 months was performed for adverse end-points. RESULTS: CALU 29809G carriers were more frequent in the low calcium group (P = 0.037). The presence of >or=3 cardiovascular risk factors and CALU polymorphism were associated with arterial calcification (OR 2.34, P = 0.049; and OR 0.34, P = 0.019, respectively). CALU 29809G allele was the only variable associated with events at 1 month (HR 0.42; P = 0.042). Multivariate analysis showed that, at 6 months, age and severe anginal symptoms were associated with worse prognosis (HR 2.13, P = 0.023; and HR 2.01, P = 0.011, respectively), whereas CALU 29809G allele associated with good prognosis (HR 0.59, P = 0.044). Our results suggest that CALU A29809G is associated with arterial calcification and short-term prognosis of the outcome of patients with nSTACS</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Hospital Universitario Virgen de la Arrixaca, Murcia, SpainJC - amd, 8906388CP - EnglandPT - Journal ArticlePT - Multicenter StudyPT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20673165</style></custom1><custom3><style face="normal" font="default">AS - Ann Med. 42(6):439-46, 2010 Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>382</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Herrmann,B.L.</style></author><author><style face="normal" font="default"> Severing,M.</style></author><author><style face="normal" font="default"> Schmermund,A.</style></author><author><style face="normal" font="default"> Berg,C.</style></author><author><style face="normal" font="default"> Budde,T.</style></author><author><style face="normal" font="default"> Erbel,R.</style></author><author><style face="normal" font="default"> Mann,K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Impact of disease duration on coronary calcification in patients with acromegaly</style></title><secondary-title><style face="normal" font="default">Experimental &amp; Clinical Endocrinology &amp; Diabetes</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Experimental &amp; Clinical Endocrinology &amp; Diabetes</style></full-title></periodical><pages end="422" start="417">417-422</pages><volume><style face="normal" font="default">117</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Acromegaly/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Cardiomyopathies/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Coronary Disease/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> 12629-01-5 (Human Growth Hormone)</style></keyword><keyword><style face="normal" font="default"> 67763-96-6 (Insulin-Like Growth Factor I)</style></keyword><keyword><style face="normal" font="default"> Acromegaly/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Adenoma/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Adenoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Chemiluminescent Measurements</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Human Growth Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Insulin-Like Growth Factor I/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Pituitary Neoplasms/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Pituitary Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Radiosurgery</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword></keywords><dates><year Day="0" Month="9" Year="2009">2009/9</year></dates><abstract><style face="normal" font="default">It is well established, that the increased mortality in patients with acromegaly is due to cardiac diseases. Cardiomyopathy is the predominant cardiac alteration in patients with acromegaly. There are less data about coronary heart disease or coronary calcifications. Electron beam computed tomography (EBCT) is the standard imaging modality for identification of coronary artery calcifications (CAC) and can determine the extent and severity of coronary atherosclerosis. Coronary risk was evaluated by the Framingham risk score (FRS). The prospective study included 30 patients with acromegaly (mean age 53+/-14 year; 16 females, 14 males; BMI 28.1+/-3.6 kg/m (2); mean+/-SD), 12 patients had active disease (IGF-1 751+/-338 microg/L; GH 25.6+/-36.4 microg/L), 9 were well-controlled (IGF-1 157+/-58 microg/L; GH 1.8+/-1.1 microg/L) under somatostatin analogue octreotide (n=5), dopamine agonists (n=2), and the GH receptor antagonist pegvisomant (n=2; GH levels were not determined in this subgroup) and 9 were cured IGF-1 (148+/-57 microg/L; GH 0.5+/-0.2 microg/L). Increased left ventricular muscle mass index (LVMI >132 g/m (2)) was focused in 53%, hypercholesterinemia in 63%, hypertension in 43%, diabetes mellitus/impaired glucose tolerance in 27%, and smokers in 53% (pack per year 9+/-15 yr). For quantification of CAC the EBCT was used and the Agatston calcium score was determined. Results were composed to established age and sex adjusted percentile distribution of CAC. CAC was present in 53%, high CAC score (75 (th) percentile) in 37% and were categorized as cardiovascular high risk patients. FRS was related to the CAC score (p=0.008, r (2)=0.22) and the disease duration (p=0.002, r (2)=0.29). The CAC score correlated with LVMI (p=0.02, r (2)=0.17), the disease duration of acromegaly (p=0.004, r (2)=0.36), and the FRS (p=0.008, r (2)=0.22). Patients with a high CAC score had a longer disease duration of 9.6+/-4.7 versus 5.4+/-2.8 years with CAC&lt;75 (th) percentile (p=0.02). In summary, the disease duration and consequently the accompanying metabolic disorders appear to influence the degree of CAC in patients with acromegaly. The observations underline the importance of early and sufficient treatment of acromegaly in high risk patients. J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart.New York</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Endocrinology and Division of Laboratory Research, University Duisburg-Essen, Germany. herrmann@endokrinologie-tzr.deJC - ccv, 9505926CP - GermanyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19373755</style></custom1><custom3><style face="normal" font="default">AS - Exp Clin Endocrinol Diabetes. 117(8):417-22, 2009 Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>274</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Hershberger,R.E.</style></author><author><style face="normal" font="default"> Pinto,J.R.</style></author><author><style face="normal" font="default"> Parks,S.B.</style></author><author><style face="normal" font="default"> Kushner,J.D.</style></author><author><style face="normal" font="default"> Li,D.</style></author><author><style face="normal" font="default"> Ludwigsen,S.</style></author><author><style face="normal" font="default"> Cowan,J.</style></author><author><style face="normal" font="default"> Morales,A.</style></author><author><style face="normal" font="default"> Parvatiyar,M.S.</style></author><author><style face="normal" font="default"> Potter,J.D.</style></author></authors></contributors><titles><title><style face="normal" font="default">Clinical and functional characterization of TNNT2 mutations identified in patients with dilated cardiomyopathy</style></title><secondary-title><style face="normal" font="default">Circulation</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Circulation</style></full-title></periodical><pages end="313" start="306">306-313</pages><volume><style face="normal" font="default">Cardiovascular</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiomyopathy,Dilated/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Troponin T/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> 0 (TNNT2 protein,human)</style></keyword><keyword><style face="normal" font="default"> 0 (Troponin T)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Amino Acid Substitution</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathy,Dilated/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathy,Hypertrophic/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Child,Preschool</style></keyword><keyword><style face="normal" font="default"> Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Mutation,Missense</style></keyword><keyword><style face="normal" font="default"> Pedigree</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="8" Year="2009">2009/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: A key issue for cardiovascular genetic medicine is ascertaining if a putative mutation indeed causes dilated cardiomyopathy (DCM). This is critically important as genetic DCM, usually presenting with advanced, life-threatening disease, may be preventable with early intervention in relatives known to carry the mutation. METHODS AND RESULTS: We recently undertook bidirectional resequencing of TNNT2, the cardiac troponin T gene, in 313 probands with DCM. We identified 6 TNNT2 protein-altering variants in 9 probands, all who had early onset, aggressive disease. Additional family members of mutation carriers were then studied when available. Four of the 9 probands had DCM without a family history, and 5 probands had familial DCM. Only 1 mutation (Lys210del) could be attributed as definitively causative from previous reports. Four of the 5 missense mutations were novel (Arg134Gly, Arg151Cys, Arg159Gln, and Arg205Trp), and one was previously reported with hypertrophic cardiomyopathy (Glu244Asp). Based on the clinical, pedigree, and molecular genetic data, these 5 mutations were considered possibly or likely disease causing. To further clarify their potential pathophysiologic impact, we undertook functional studies of these mutations in cardiac myocytes reconstituted with mutant troponin T proteins. We observed decreased Ca(2+) sensitivity of force development, a hallmark of DCM, in support of the conclusion that these mutations are disease causing. CONCLUSIONS: We conclude that the combination of clinical, pedigree, molecular genetic, and functional data strengthen the interpretation of TNNT2 mutations in DCM</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiovascular Medicine, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA. rhershberger@med.miami.eduJC - 101489144CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - 5 M01 RR000334 (United States NCRR NIH HHS)NO - N01-HV-48194 (United States NHLBI NIH HHS)NO - R01-HL42325 (United States NHLBI NIH HHS)NO - R01-HL58626 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20031601</style></custom1><custom3><style face="normal" font="default">AS - Circ Cardiovasc Genet. 2(4):306-13, 2009 Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>404</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Herzog,B.A.</style></author><author><style face="normal" font="default"> Wyss,C.A.</style></author><author><style face="normal" font="default"> Husmann,L.</style></author><author><style face="normal" font="default"> Gaemperli,O.</style></author><author><style face="normal" font="default"> Valenta,I.</style></author><author><style face="normal" font="default"> Treyer,V.</style></author><author><style face="normal" font="default"> Landmesser,U.</style></author><author><style face="normal" font="default"> Kaufmann,P.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">First head-to-head comparison of effective radiation dose from low-dose 64-slice CT with prospective ECG-triggering versus invasive coronary angiography</style></title><secondary-title><style face="normal" font="default">Heart</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Heart</style></full-title></periodical><pages end="1661" start="1656">1656-1661</pages><volume><style face="normal" font="default">95</style></volume><number><style face="normal" font="default">20</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> *Radiation Dosage</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Electrocardiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Reduction of radiation burden of multidetector computed tomography coronary angiography (CTCA) has remained an important task. OBJECTIVE: To compare effective radiation dose of low-dose 64-slice CTCA using prospective ECG-triggering versus diagnostic invasive coronary angiography (CA). METHODS: 42 patients referred for elective invasive CA owing to suspected coronary artery disease (CAD) were prospectively enrolled to undergo a low-dose CTCA without calcium scoring within the same day before CA. Dose-area product of diagnostic invasive CA and dose-length product of CTCA were measured, converted into effective radiation dose and compared using Mann-Whitney U tests. In addition, accuracy of CTCA to detect CAD (coronary artery narrowing > or =50%) was assessed using invasive CA as standard of reference. On an intention-to-diagnose basis all non-evaluative vessels were included in the analysis and censored as positive. RESULTS: The estimated mean effective radiation dose was 8.5 (4.4) mSv (range 1.4-20.5 mSv) for diagnostic invasive CA, and 2.1 (0.7) mSv (range 1.0-3.3 mSv) for CTCA (p&lt;0.001). 19 patients (42.9%) had no CAD by invasive CA. 40 (95.2%) patients have been correctly classified as having CAD (23/23) or no CAD (17/19). Over 97% (551/567) of segments were evaluable. Vessel-based analysis revealed sensitivity, specificity, positive and negative predictive value of 94.2% (CI 0.8% to 1.0%), 94.8% (CI 09% to 1.0%), 89.0% (CI 0.8% to 1.0%), 97.4% (CI 09% to 1.0%) and an accuracy of 94.6%. CONCLUSIONS: Low dose CTCA allows evaluation of CAD with high accuracy, but delivers a significantly less effective radiation dose to patients compared to diagnostic invasive CA</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Nuclear Cardiology, University Hospital Zurich, Ramistrasse 100, CH-8091 Zurich, SwitzerlandJC - 9602087CP - EnglandPT - Comparative StudyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19581273</style></custom1><custom3><style face="normal" font="default">AS - Heart. 95(20):1656-61, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>355</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Heyliger,A.</style></author><author><style face="normal" font="default"> Tangpricha,V.</style></author><author><style face="normal" font="default"> Weber,C.</style></author><author><style face="normal" font="default"> Sharma,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Parathyroidectomy decreases systolic and diastolic blood pressure in hypertensive patients with primary hyperparathyroidism</style></title><secondary-title><style face="normal" font="default">Surgery</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Surgery</style></full-title></periodical><pages end="1047" start="1042">1042-1047</pages><volume><style face="normal" font="default">146</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Blood Pressure</style></keyword><keyword><style face="normal" font="default"> *Hyperparathyroidism,Primary/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Hyperparathyroidism,Primary/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Hypertension/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Hypertension/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Parathyroidectomy</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Diastole</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Primary/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical Records</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Parathyroidectomy</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Systole</style></keyword><keyword><style face="normal" font="default"> Thyroidectomy</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Primary hyperparathyroidism (PHPT) is associated with an increased risk of cardiovascular disease, including hypertension. The purpose of this study was to determine the effect of parathyroidectomy on systolic and diastolic blood pressures (BP) in hypertensive patients with PHPT. METHODS: A retrospective review of medical records was performed in 368 patients undergoing parathyroidectomy and 96 patients undergoing thyroidectomy by a single surgeon. We evaluated changes in serum calcium, parathyroid hormone (PTH), and BP before and 6 months after surgery. RESULTS: In patients undergoing parathyroidectomy with hypertension (n = 147), a significant decrease in both systolic and diastolic BP was observed; systolic BP decreased from 152.5 +/- 10.5 to 140.3 +/- 16.2 mmHg (P &lt; .001) and diastolic BP decreased from 94.5 +/- 6.8 to 81.7 +/- 10.3 mmHg (P &lt; .001). In these patients, PTH decreased from 136 +/- 186 to 58.7 +/- 44.3 pg/mL (P &lt; .001) and serum calcium decreased from 11.1 +/- 0.6 to 9.5 +/- 0.7 mg/dL (P &lt; .001). In patients undergoing parathyroidectomy without hypertension (n = 145) and thyroidectomy alone (n = 96), no significant change in systolic or diastolic BP was observed. CONCLUSION: Parathyroidectomy in hypertensive patients seems to reduce both systolic and diastolic BP . The mechanisms responsible for this effect are unknown and deserve further study</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of General Internal Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USAJC - vc3, 0417347CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - K23AR054334 (United States NIAMS NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19958931</style></custom1><custom3><style face="normal" font="default">AS - Surgery. 146(6):1042-7, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>17</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Hirst,J.E.</style></author><author><style face="normal" font="default"> Arbuckle,S.M.</style></author><author><style face="normal" font="default"> Do,T.M.</style></author><author><style face="normal" font="default"> Ha,L.T.</style></author><author><style face="normal" font="default"> Jeffery,H.E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Epidemiology of stillbirth and strategies for its prevention in Vietnam</style></title><secondary-title><style face="normal" font="default">International Journal of Gynaecology &amp; Obstetrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">International Journal of Gynaecology &amp; Obstetrics</style></full-title></periodical><pages end="113" start="109">109-113</pages><volume><style face="normal" font="default">110</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Abortion,Induced/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> *Stillbirth/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Chorioamnionitis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Chorioamnionitis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Gestational Age</style></keyword><keyword><style face="normal" font="default"> Hospitals,Maternity/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Infant,Newborn</style></keyword><keyword><style face="normal" font="default"> Infant,Small for Gestational Age</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Rural Population/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Urban Population</style></keyword><keyword><style face="normal" font="default"> Vietnam/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="8" Year="2010">2010/8</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To describe major epidemiologic and placental findings regarding stillbirth in Vietnam. METHODS: A cross-sectional study of all stillbirths in a tertiary referral facility in Ho Chi Minh City, Vietnam, was performed. Detailed examination of each infant, placental pathology, and semi-structured maternal interviews were conducted according to the Perinatal Society of Australia and New Zealand Perinatal Death Classification guidelines. Maternal, fetal, and placental characteristics were examined. RESULTS: Between December 8, 2008, and January 9, 2009, there were 4694 live births and 122 stillbirths at the facility. In total, 107 (87.7%) cases were included in the study. Low education level was associated with a lack of prenatal care; induced abortion accounted for 34.6% of fetal deaths (gender selection was not the reason); 35.5% of infants were born at 22-28 weeks of gestation; 31.8% of stillbirths were small for gestational age; histologic evidence of chorioamnionitis was present in 40.2% of cases. Calcium supplements were less likely to have been taken in cases in which death from hypertension occurred. alpha-Thalassemia was the main cause of fetal hydrops (6.2%). CONCLUSION: Improving access to prenatal care and prenatal calcium and iron supplementation, and screening for congenital abnormalities and alpha-thalassemia may help to reduce rates of perinatal death in Vietnam. Crown Copyright 2010. Published by Elsevier Ireland Ltd. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Obstetrics and Gynaecology, University of Sydney, Sydney, Australia. jhirst@med.usyd.edu.auJC - e4t, 0210174CP - IrelandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20553788</style></custom1><custom3><style face="normal" font="default">AS - Int J Gynaecol Obstet. 110(2):109-13, 2010 Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>379</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">hlenkamp,S.</style></author><author><style face="normal" font="default"> Lehmann,N.</style></author><author><style face="normal" font="default"> Schmermund,A.</style></author><author><style face="normal" font="default"> Roggenbuck,U.</style></author><author><style face="normal" font="default"> Moebus,S.</style></author><author><style face="normal" font="default"> Dragano,N.</style></author><author><style face="normal" font="default"> Bauer,M.</style></author><author><style face="normal" font="default"> lsch,H.</style></author><author><style face="normal" font="default"> Hoffmann,B.</style></author><author><style face="normal" font="default"> Stang,A.</style></author><author><style face="normal" font="default"> cker-Preuss,M.</style></author><author><style face="normal" font="default"> hm,M.</style></author><author><style face="normal" font="default"> Mann,K.</style></author><author><style face="normal" font="default"> ckel,K.H.</style></author><author><style face="normal" font="default"> Erbel,R.</style></author><author><style face="normal" font="default"> Heinz Nixdorf Recall Study Investigators</style></author></authors></contributors><titles><title><style face="normal" font="default">Association of exercise capacity and the heart rate profile during exercise stress testing with subclinical coronary atherosclerosis: data from the Heinz Nixdorf Recall study</style></title><secondary-title><style face="normal" font="default">Clinical Research in Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinical Research in Cardiology</style></full-title></periodical><pages end="676" start="665">665-676</pages><volume><style face="normal" font="default">98</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Exercise Test</style></keyword><keyword><style face="normal" font="default"> *Exercise Tolerance</style></keyword><keyword><style face="normal" font="default"> *Heart Rate</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Rate</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Linear Models</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Recovery of Function</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Exercise capacity and heart rate profile parameters obtained from exercise stress testing as well as the subclinical coronary atherosclerosis burden from cardiac CT have been suggested to improve cardiovascular (CV) risk stratification beyond traditional risk factors (RF) in persons at risk of CV events. AIM: To study the association of exercise stress-test variables with the coronary artery calcium (CAC) burden in relation to age, sex and traditional RF in subjects without known coronary artery disease from the general population. METHODS: In 3,163 subjects, CV and RF were measured, a bicycle stress test was performed and the electron beam CT-based CAC-Agatston score was quantified. RESULTS: Exercise capacity, chronotropic response and an abnormal HR recovery were significantly and inversely related to CAC scores in men and women in univariate unadjusted analysis. This association was diminished after adjustment for age and sex and further after adjustment for traditional risk factors. In multivariate analysis, chronotropic response in men [estimate (95% CI): 0.94 (0.91-0.97), P = 0.0005] and an abnormal HR recovery (&lt;15 bpm after 1 min) in women [estimate: 1.34 (1.07-1.70), P = 0.013] but not exercise capacity remained associated with CAC independent of traditional RF. In subjects not taking lipid-lowering, antiarrhythmic or antihypertensive drugs, estimates for the observed associations were essentially unchanged. The clinical ability of these variables to predict a high CAC score was limited. CONCLUSION: The strong inverse association of exercise capacity, chronotropic response and abnormal HR recovery during exercise stress testing with the CAC burden in unadjusted univariate analysis is largely influenced by age, sex and cardiovascular RFs. The degree, to which exercise stress-test variables and the CAC burden independently contribute to the prediction of cardiovascular events, remains to be shown</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, West-German Heart Center Essen, University Clinic Duisburg-Essen, Hufelandstrasse 55, Essen, Germany. stefan.moehlenkamp@uk-essen.deJC - 101264123CP - GermanyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19693626</style></custom1><custom3><style face="normal" font="default">AS - Clin. res. cardiol.. 98(10):665-76, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>407</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Ho,J.S.</style></author><author><style face="normal" font="default"> Cannaday,J.J.</style></author><author><style face="normal" font="default"> Barlow,C.E.</style></author><author><style face="normal" font="default"> Willis,B.</style></author><author><style face="normal" font="default"> Haskell,W.L.</style></author><author><style face="normal" font="default"> FitzGerald,S.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Comparative relation of general, central, and visceral adiposity measures for coronary artery calcium in subjects without previous coronary events</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="946" start="943">943-946</pages><volume><style face="normal" font="default">104</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Coronary Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Intra-Abdominal Fat/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Subcutaneous Fat,Abdominal/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Waist Circumference</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Disease/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Reference Values</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Waist Circumference</style></keyword><keyword><style face="normal" font="default"> Waist-Hip Ratio</style></keyword></keywords><dates><year Day="1" Month="10" Year="2009">2009/10/1</year></dates><abstract><style face="normal" font="default">It is unclear whether visceral obesity is largely responsible for an increased risk of coronary artery disease. In the present study, 1,054 men underwent coronary artery calcium (CAC) scoring and abdominal computed tomography. Risk factor information, body mass index, waist circumference, and waist-to-hip ratio were collected for all participants. The total fat, visceral fat, and subcutaneous fat areas were also quantified at the level of the umbilicus using computed tomography. We then investigated the association of these obesity parameters with the CAC score. Participants with a CAC score >10 had a larger waist circumference (97 +/- 12 vs 95 +/- 12 cm, p &lt;0.001), a larger total fat area (434 cm(2), interquartile range 339 to 565, vs 415 cm(2), interquartile range 315 to 521; p = 0.005), a larger visceral fat area (200 cm(2), interquartile range 143 to 256, vs 175 cm(2), interquartile range 124 to 225; p &lt;0.001), and a greater waist-to-hip ratio (0.93 +/- 0.07 vs 0.91 +/- 0.07, p &lt;0.001) than those with a CAC score of &lt; or =10. Those with a CAC score >10 also tended to have a greater body mass index and larger subcutaneous fat area. After adjusting for traditional cardiovascular risk factors, however, only a large waist circumference (odds ratio 1.5, 95% confidence interval 1.04 to 2.0), a high total fat area (odds ratio 1.5, 95% confidence interval 1.1 to 2.1), and a high waist-to-hip ratio (odds ratio 1.6, 95% confidence interval 1.2 to 2.3) remained significantly associated with a CAC score >10. In conclusion, the measures of central obesity were more strongly associated with the CAC score than either the parameters assessing overall obesity or other more direct measures of visceral adiposity. These findings suggest that the total amount of central obesity is more important than the relative distribution of visceral versus subcutaneous fat</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Cooper Clinic, Dallas, TX, USA. jsho@cooper-clinic.comJC - 3dq, 0207277CP - United StatesPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19766761</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 104(7):943-6, 2009 Oct 1.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>133</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Holecki,M.</style></author><author><style face="normal" font="default"> Zahorska-Markiewicz,B.</style></author><author><style face="normal" font="default"> Wiecek,A.</style></author><author><style face="normal" font="default"> Mizia-Stec,K.</style></author><author><style face="normal" font="default"> Nieszporek,T.</style></author><author><style face="normal" font="default"> Zak-Golab,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Influence of calcium and vitamin D supplementation on weight and fat loss in obese women</style></title><secondary-title><style face="normal" font="default">Obesity Facts</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Obesity Facts</style></full-title></periodical><pages end="279" start="274">274-279</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium Carbonate/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Diet,Reducing</style></keyword><keyword><style face="normal" font="default"> *Hydroxycholecalciferols/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Obesity</style></keyword><keyword><style face="normal" font="default"> *Weight Loss/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> 0 (Antacids)</style></keyword><keyword><style face="normal" font="default"> 0 (Hydroxycholecalciferols)</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 0 (Vitamins)</style></keyword><keyword><style face="normal" font="default"> 1406-16-2 (Vitamin D)</style></keyword><keyword><style face="normal" font="default"> 471-34-1 (Calcium Carbonate)</style></keyword><keyword><style face="normal" font="default"> 64719-49-9 (25-hydroxyvitamin D)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 7723-14-0 (Phosphorus)</style></keyword><keyword><style face="normal" font="default"> Adipose Tissue/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Antacids/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Dairy Products</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Life Style</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Obesity/dh [Diet Therapy]</style></keyword><keyword><style face="normal" font="default"> Obesity/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Obesity/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Phosphorus/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Vitamin D/aa [Analogs &amp; Derivatives]</style></keyword><keyword><style face="normal" font="default"> Vitamin D/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Vitamins/ad [Administration &amp; Dosage]</style></keyword></keywords><dates><year Day="0" Month="0" Year="2008">2008</year></dates><isbn><style face="normal" font="default">1662-4025</style></isbn><abstract><style face="normal" font="default">BACKGROUND: Dairy products not only reduce the risk of hypertension and cardiovascular diseases but may play a role in the treatment of obesity. As there is some evidence that calcium (Ca) and vitamin D may play a role in effective weight management, we decided to evaluate the influence of Ca and vitamin D supplementation on weight and fat loss in obese women. MATERIAL AND METHODS: Forty obese women were enrolled in this study. Subjects were divided into 2 groups comparable with body mass index (BMI) and age. Group 1 was provided with calcium carbonate and 1-(OH)-vitamin D supplementation. Group 2 was provided with only a diet. Subjects participated in a 3-month weight reduction therapy (balanced diet, modification of life style, and regular physical exercise). Blood samples (serum concentration of Ca, phosphorus (P), parathormone (PTH), 25-(OH)-D3) and clinical characteristics (weight, height, BMI, body composition) were taken at baseline and after the 3-month program. RESULTS: No significant differences of body weight, body fat content, serum parathormone, 25-(OH)-D3 concentration, and plasma total Ca and P concentration were observed between analyzed groups both before and after the treatment. Additionally, we did not observe any significant influence of Ca and vitamin D supplementation on weight and fat loss. CONCLUSION: Ca plus vitamin D supplementation during a 3-month low caloric diet has no additional effect on weight and fat loss in obese women</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Pathophysiology, Medical University of Silesia, Katowice, Poland. holomed@poczta.onet.plJC - 101469429CP - SwitzerlandPT - Controlled Clinical TrialPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20054189</style></custom1><custom3><style face="normal" font="default">AS - Obes Facts. 1(5):274-9, 2008.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>440</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Hong,M.K.</style></author><author><style face="normal" font="default"> Park,D.W.</style></author><author><style face="normal" font="default"> Lee,C.W.</style></author><author><style face="normal" font="default"> Lee,S.W.</style></author><author><style face="normal" font="default"> Kim,Y.H.</style></author><author><style face="normal" font="default"> Kang,D.H.</style></author><author><style face="normal" font="default"> Song,J.K.</style></author><author><style face="normal" font="default"> Kim,J.J.</style></author><author><style face="normal" font="default"> Park,S.W.</style></author><author><style face="normal" font="default"> Park,S.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Effects of statin treatments on coronary plaques assessed by volumetric virtual histology intravascular ultrasound analysis</style></title><secondary-title><style face="normal" font="default">Jacc: Cardiovascular Interventions</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Jacc: Cardiovascular Interventions</style></full-title></periodical><pages end="688" start="679">679-688</pages><volume><style face="normal" font="default">2</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Artery Disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Fluorobenzenes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Pyrimidines/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Simvastatin/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Sulfonamides/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Ultrasonography,Interventional</style></keyword><keyword><style face="normal" font="default"> *User-Computer Interface</style></keyword><keyword><style face="normal" font="default"> 0 (Fluorobenzenes)</style></keyword><keyword><style face="normal" font="default"> 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)</style></keyword><keyword><style face="normal" font="default"> 0 (Pyrimidines)</style></keyword><keyword><style face="normal" font="default"> 0 (Sulfonamides)</style></keyword><keyword><style face="normal" font="default"> 287714-41-4 (rosuvastatin)</style></keyword><keyword><style face="normal" font="default"> 79902-63-9 (Simvastatin)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcinosis/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="7" Year="2009">2009/7</year></dates><abstract><style face="normal" font="default">OBJECTIVES: We evaluated the effects of statin treatments for each component of coronary plaques. BACKGROUND: Effects of statin treatments on coronary plaques have not been sufficiently evaluated. METHODS: One hundred patients without significant lesion stenosis underwent baseline and 12-month follow-up virtual histology (VH) intravascular ultrasound (IVUS) studies and were treated with statin for 1 year. They were randomized to simvastatin (20 mg/day, n = 50) or rosuvastatin (10 mg/day, n = 50). With VH-IVUS, plaque was characterized as fibrotic, fibrofatty, dense calcium, and necrotic core. RESULTS: In overall patients, necrotic core volume significantly reduced (15.7 to 13.7 mm(3), p = 0.010) and fibrofatty plaque volume increased (4.3 to 5.5 mm(3), p = 0.006) after statin treatments for 1 year. There were no significant differences of changes in either plaque component volume between simvastatin- and rosuvastatin-treated subgroups. In serial comparisons during 1-year follow-up, simvastatin treatment did not achieve statistically significant changes in fibrofatty plaque (4.1 to 5.1 mm(3), p = 0.131) and necrotic core volume (15.8 to 14.4 mm(3), p = 0.216). However, there was a significant decrease in necrotic core volume (15.5 to 13.0 mm(3), p = 0.015) and an increase in fibrofatty plaque volume (4.5 to 5.9 mm(3), p = 0.017) in the rosuvastatin-treated subgroup. CONCLUSIONS: Serial volumetric VH-IVUS analysis showed that statin treatments might be associated with significant changes in necrotic core and fibrofatty plaque volume in overall patients. The changes in both plaques' component volume were not statistically different between simvastatin- and rosuvastatin-treated subgroup</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiology, Yonsei Cardiovascular Center, Yonsei University College of Medicine, Seoul, KoreaCM - Comment in: JACC Cardiovasc Interv. 2009 Jul;2(7):697-700; PMID: 19628195]JC - 101467004CP - United StatesPT - Comparative StudyPT - Journal ArticlePT - Randomized Controlled TrialPT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19628193</style></custom1><custom3><style face="normal" font="default">AS - JACC Cardiovasc Interv. 2(7):679-88, 2009 Jul.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>316</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Hong,Y.J.</style></author><author><style face="normal" font="default"> Ahn,Y.</style></author><author><style face="normal" font="default"> Sim,D.S.</style></author><author><style face="normal" font="default"> Yoon,N.S.</style></author><author><style face="normal" font="default"> Yoon,H.J.</style></author><author><style face="normal" font="default"> Kim,K.H.</style></author><author><style face="normal" font="default"> Park,H.W.</style></author><author><style face="normal" font="default"> Kim,J.H.</style></author><author><style face="normal" font="default"> Jeong,M.H.</style></author><author><style face="normal" font="default"> Cho,J.G.</style></author><author><style face="normal" font="default"> Park,J.C.</style></author><author><style face="normal" font="default"> Kang,J.C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Relation between N-terminal pro-B-type natriuretic peptide and coronary plaque components in patients with acute coronary syndrome: virtual histology-intravascular ultrasound analysis</style></title><secondary-title><style face="normal" font="default">Coronary Artery Disease</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Coronary Artery Disease</style></full-title></periodical><pages end="524" start="518">518-524</pages><volume><style face="normal" font="default">20</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Acute Coronary Syndrome/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Acute Coronary Syndrome/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Natriuretic Peptide,Brain/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Peptide Fragments/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Ultrasonography,Interventional</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Peptide Fragments)</style></keyword><keyword><style face="normal" font="default"> 0 (pro-brain natriuretic peptide (1-76))</style></keyword><keyword><style face="normal" font="default"> 114471-18-0 (Natriuretic Peptide,Brain)</style></keyword><keyword><style face="normal" font="default"> 60-27-5 (Creatinine)</style></keyword><keyword><style face="normal" font="default"> Acute Coronary Syndrome/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Acute Coronary Syndrome/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angioplasty,Transluminal,Percutaneous Coronary</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Creatinine/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Up-Regulation</style></keyword><keyword><style face="normal" font="default"> Ventricular Function,Left</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: The N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) is a sensitive indicator of hemodynamic stress and its increased level is associated with higher mortality in acute coronary syndrome (ACS) patients. Virtual histology-intravascular ultrasound (VH-IVUS) can provide quantitative information on plaque components. METHODS: We measured preprocedural serum NT-pro-BNP levels in 156 ACS patients with preserved left ventricular systolic function and normal serum creatinine. VH-IVUS classified the color-coded tissue into four major components: fibrotic, fibro-fatty, dense calcium, and necrotic core (NC). Thin-cap fibroatheroma (TCFA) was defined as focal, NC-rich (>or=10% of the cross-sectional area) plaques being in contact with the lumen in a plaque burden of at least 40%. We divided the patients into two groups according to the NT-pro-BNP levels [group I: >or=200 pg/ml (n = 58) vs. group II: &lt;200 pg/ml (n = 98)]. RESULTS: The percent areas of NC at the minimum lumen site (19.8+/-13.1% vs. 15.2+/-11.1%, P = 0.027) and at the largest NC site (24.7+/-10.3% vs. 19.2+/-11.4%, P = 0.015) were significantly greater in group I than in group II. Percent NC volume was significantly greater in group I than in group II (15.8+/-8.1% vs. 10.1+/-9.1%, P = 0.008). The total number of TCFAs was 38 in group I and 56 in group II. The presence of at least one TCFA (58 vs. 38%, P = 0.009) and multiple TCFAs (25 vs. 10%, P = 0.005) within culprit lesions were observed more frequently in group I than in group II. The TCFAs were located more in proximal in group I than in group II [the length from coronary ostium to TCFA: 10.8+/-7.6 mm in group I vs. 25.7+/-16.3 mm in group II (P&lt;0.001)]: 85% of TCFAs was located within 20 mm from coronary ostium in group I; conversely only 36% of TCFAs was located within 20 mm from coronary ostium in group II (P&lt;0.001). CONCLUSION: VH-IVUS analysis shows that ACS patients with high NT-pro-BNP levels had more vulnerable plaque component (more NC-containing lesions and higher frequency of culprit lesion TCFAs) and had more proximally located TCFAs</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - The Heart Center of Chonnam National University Hospital, Chonnam National University Research Institute of Medical Sciences, Dong-gu, Gwangju, KoreaJC - 9011445, BYWCP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19838110</style></custom1><custom3><style face="normal" font="default">AS - Coron Artery Dis. 20(8):518-24, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>41</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Hong,Y.J.</style></author><author><style face="normal" font="default"> Jeong,M.H.</style></author><author><style face="normal" font="default"> Choi,Y.H.</style></author><author><style face="normal" font="default"> Ma,E.H.</style></author><author><style face="normal" font="default"> Ko,J.S.</style></author><author><style face="normal" font="default"> Lee,M.G.</style></author><author><style face="normal" font="default"> Park,K.H.</style></author><author><style face="normal" font="default"> Sim,D.S.</style></author><author><style face="normal" font="default"> Yoon,N.S.</style></author><author><style face="normal" font="default"> Youn,H.J.</style></author><author><style face="normal" font="default"> Kim,K.H.</style></author><author><style face="normal" font="default"> Park,H.W.</style></author><author><style face="normal" font="default"> Kim,J.H.</style></author><author><style face="normal" font="default"> Ahn,Y.</style></author><author><style face="normal" font="default"> Cho,J.G.</style></author><author><style face="normal" font="default"> Park,J.C.</style></author><author><style face="normal" font="default"> Kang,J.C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Differences in intravascular ultrasound findings in culprit lesions in infarct-related arteries between ST segment elevation myocardial infarction and non-ST segment elevation myocardial infarction</style></title><secondary-title><style face="normal" font="default">Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Cardiology</style></full-title></periodical><pages end="22" start="15">15-22</pages><volume><style face="normal" font="default">56</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Vessels/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Endosonography</style></keyword><keyword><style face="normal" font="default"> *Myocardial Infarction/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Electrocardiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Stents</style></keyword></keywords><dates><year Day="0" Month="7" Year="2010">2010/7</year></dates><isbn><style face="normal" font="default">0914-5087</style></isbn><abstract><style face="normal" font="default">BACKGROUND: Previous studies have reported diffuse destabilization of atherosclerotic plaques in acute myocardial infarction (AMI). We used intravascular ultrasound (IVUS) to assess coronary culprit lesions in ST segment elevation MI (STEMI) vs. in non-ST segment elevation MI (NSTEMI). METHODS: Patient population comprised 125 STEMI and 185 NSTEMI patients. IVUS findings included ruptured plaque (a cavity that communicated with the lumen with an overlying residual fibrous cap fragment), lipid-pool like image (a pooling of hypoechoic or echolucent material covered with a hyperechoic layer), thrombus (discrete intraluminal filling defects), and plaque prolapse (tissue extrusion through the stent strut at post-stenting). RESULTS: Culprit lesions had larger external elastic membrane area (13.5+/-4.9mm(2) vs. 11.9+/-4.3mm(2), p=0.002), larger plaque plus media area (10.8+/-4.4mm(2) vs. 9.1+/-4.1mm(2), p=0.001), and greater plaque burden (78.7+/-10.1% vs. 74.8+/-12.0%, p=0.002), and smaller culprit lesion site calcium arc (96+/-90 degrees vs. 153+/-114 degrees , p=0.002) in patients with STEMI than in those with NSTEMI. Culprit lesion plaque ruptures, lipid-pool like images, and thrombus were observed more frequently in patients with STEMI than in those with NSTEMI (46% vs. 29%, p=0.002; 39% vs. 25%, p=0.010; and 34% vs. 21%, p=0.006, respectively). Culprit lesions were more predominantly hypoechoic in patients with STEMI than in those with NSTEMI (62% vs. 40%, p&lt;0.001). There was a trend that post-stenting plaque prolapse was observed more frequently in patients with STEMI than in those with NSTEMI (33% vs. 24%, p=0.081). CONCLUSIONS: Culprit lesions in STEMI have more markers of plaque instability (more plaque rupture and thrombus, and larger plaque mass) compared with lesions in NSTEMI. Copyright 2010 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Heart Center of Chonnam National University Hospital, Chonnam National University Research Institute of Medical Sciences, 671 Jaebongro, Dong-gu, Gwangju 501-757, Republic of KoreaJC - joa, 8804703CP - JapanPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20350520</style></custom1><custom3><style face="normal" font="default">AS - J Cardiol. 56(1):15-22, 2010 Jul.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>72</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Hong,Y.J.</style></author><author><style face="normal" font="default"> Jeong,M.H.</style></author><author><style face="normal" font="default"> Choi,Y.H.</style></author><author><style face="normal" font="default"> Ma,E.H.</style></author><author><style face="normal" font="default"> Ko,J.S.</style></author><author><style face="normal" font="default"> Lee,M.G.</style></author><author><style face="normal" font="default"> Park,K.H.</style></author><author><style face="normal" font="default"> Sim,D.S.</style></author><author><style face="normal" font="default"> Yoon,N.S.</style></author><author><style face="normal" font="default"> Youn,H.J.</style></author><author><style face="normal" font="default"> Kim,K.H.</style></author><author><style face="normal" font="default"> Park,H.W.</style></author><author><style face="normal" font="default"> Kim,J.H.</style></author><author><style face="normal" font="default"> Ahn,Y.</style></author><author><style face="normal" font="default"> Cho,J.G.</style></author><author><style face="normal" font="default"> Park,J.C.</style></author><author><style face="normal" font="default"> Kang,J.C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Relation between aortic knob calcium observed by simple chest x-ray or fluoroscopy and plaque components in patients with diabetes mellitus</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="43" start="38">38-43</pages><volume><style face="normal" font="default">106</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aortic Diseases</style></keyword><keyword><style face="normal" font="default"> *Calcinosis</style></keyword><keyword><style face="normal" font="default"> *Diabetic Angiopathies</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aortic Diseases/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Aortic Diseases/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Diabetic Angiopathies/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Diabetic Angiopathies/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fluoroscopy</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Ultrasonography,Interventional</style></keyword></keywords><dates><year Day="1" Month="7" Year="2010">2010/7/1</year></dates><abstract><style face="normal" font="default">We used virtual histology and intravascular ultrasound (VH-IVUS) to evaluate the relation between aortic knob calcium (AKC) and plaque components in diabetic patients. The presence of AKC was assessed by posteroanterior view of chest x-ray or fluoroscopy at the time of coronary angiography. A total of 137 de novo coronary culprit lesions in 137 consecutive diabetic patients were studied and coronary plaque components were analyzed using VH-IVUS according to the presence (n = 45) or absence (n = 92) of AKC. Patients with AKC were significantly older (68 +/- 8 vs 62 +/- 9 years, p &lt;0.001) and had significantly higher high-sensitivity C-reactive protein levels (1.97 +/- 1.33 vs 0.48 +/- 1.35 mg/dl, p = 0.005) compared to patients without AKC. Absolute and percent necrotic core (NC) volumes (30 +/- 26 vs 20 +/- 19 mm(3), p = 0.003; 23.4 +/- 10.3% vs 17.4 +/- 8.9%, p = 0.005, respectively) and absolute and percent dense calcium (DC) volumes (17 +/- 12 vs 11 +/- 12 mm(3), p = 0.010; 13.3 +/- 7.3% vs 9.6 +/- 7.9%, p = 0.011, respectively) were significantly greater in lesions with AKC compared to those without AKC. Multivariable analysis showed that age (odds ratio [OR] 1.233, 95% confidence interval [CI] 1.121 to 1.355, p &lt;0.001), high-sensitivity C-reactive protein (OR 1.871, 95% CI 1.090 to 2.943, p = 0.007), absolute DC volume (OR 1.020, 95% CI 1.050 to 1.178, p = 0.003), and absolute NC volume (OR 1.026, 95% CI 1.057 to 1.199, p &lt;0.001) were independent predictors of AKC. In conclusion, diabetic patients with AKC were older, had greater NC- and DC-containing plaques, and higher inflammatory status compared to diabetic patients without AKC. Copyright (c) 2010 Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - The Heart Center of Chonnam National University Hospital, Gwangju, KoreaJC - 3dq, 0207277CP - United StatesPT - Comparative StudyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20609644</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 106(1):38-43, 2010 Jul 1.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>84</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Hong,Y.J.</style></author><author><style face="normal" font="default"> Jeong,M.H.</style></author><author><style face="normal" font="default"> Choi,Y.H.</style></author><author><style face="normal" font="default"> Ma,E.H.</style></author><author><style face="normal" font="default"> Ko,J.S.</style></author><author><style face="normal" font="default"> Lee,M.G.</style></author><author><style face="normal" font="default"> Park,K.H.</style></author><author><style face="normal" font="default"> Sim,D.S.</style></author><author><style face="normal" font="default"> Yoon,N.S.</style></author><author><style face="normal" font="default"> Youn,H.J.</style></author><author><style face="normal" font="default"> Kim,K.H.</style></author><author><style face="normal" font="default"> Park,H.W.</style></author><author><style face="normal" font="default"> Kim,J.H.</style></author><author><style face="normal" font="default"> Ahn,Y.</style></author><author><style face="normal" font="default"> Cho,J.G.</style></author><author><style face="normal" font="default"> Park,J.C.</style></author><author><style face="normal" font="default"> Kang,J.C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Age-related differences in virtual histology-intravascular ultrasound findings in patients with coronary artery disease</style></title><secondary-title><style face="normal" font="default">Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Cardiology</style></full-title></periodical><pages end="231" start="224">224-231</pages><volume><style face="normal" font="default">55</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Disease/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> 9007-41-4 (C-Reactive Protein)</style></keyword><keyword><style face="normal" font="default"> Acute Coronary Syndrome/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Acute Coronary Syndrome/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angina Pectoris/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Angina Pectoris/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> C-Reactive Protein/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Diabetes Complications</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Ultrasonography,Interventional</style></keyword><keyword><style face="normal" font="default"> User-Computer Interface</style></keyword></keywords><dates><year Day="0" Month="3" Year="2010">2010/3</year></dates><isbn><style face="normal" font="default">0914-5087</style></isbn><abstract><style face="normal" font="default">BACKGROUND: We assessed the age-related differences in pre-intervention virtual histology-intravascular ultrasound (VH-IVUS) findings at target lesion sites in patients with coronary artery disease. METHODS: A total of 553 patients who underwent pre-intervention VH-IVUS imaging were grouped according to age: non-elderly (&lt; or = 70 years, n=429) and elderly (>70 years, n=124); 191 had stable angina and 362 acute coronary syndrome. VH-IVUS classified the tissue into: fibrotic, fibro-fatty, dense calcium (DC), and necrotic core (NC). RESULTS: Overall, the absolute and percent volumes of DC (11.0 + or - 11.0mm(3) vs. 9.7 + or - 11.9 mm(3), P=0.033; 11.7 + or - 8.1% vs. 9.8 + or - 7.2%, P=0.014, respectively) and NC (18.5 + or - 17.6mm(3) vs. 16.6 + or - 18.9 mm(3), P=0.020; 18.8 + or - 8.8% vs. 16.5 + or - 9.3%, P=0.026, respectively) were significantly greater in the elderly than in the non-elderly. In stable angina patients, the absolute and percent volumes of DC (10.4 + or - 9.9 mm(3) vs. 7.2 + or - 7.6 mm(3), P=0.022; 13.4 + or - 10.0% vs. 9.2 + or - 6.5%, P=0.011, respectively) and NC (14.8 + or - 11.2 mm(3) vs. 12.0 + or - 11.9 mm(3), P=0.035; 19.6 + or - 8.8% vs. 15.5 + or - 8.4%, P=0.006, respectively) were significantly greater in the elderly. However, in acute coronary syndrome patients, there were no significant differences in absolute and percent volumes of DC (11.4 + or - 11.6 mm(3) vs. 10.9 + or - 13.4 mm(3), P=0.8; 10.7 + or - 6.5% vs. 10.1 + or - 7.5%, P=0.5, respectively) and NC (24.1 + or - 20.3 mm(3) vs. 23.9 + or - 21.2 mm(3), P=0.9; 22.0 + or - 8.8% vs. 21.3 + or - 9.6%, P=0.6, respectively) between the elderly and non-elderly groups. Myocardial infarction (OR: 2.56, 95% CI: 1.45-4.12, P=0.003), diabetes mellitus (OR: 2.23, 95% CI: 1.30-3.53, P=0.009), and high-sensitivity C-reactive protein (OR: 1.44, 95% CI: 1.06-2.45, P=0.042), but not age, were independent predictors of percent NC volume >20% in lesion site. CONCLUSIONS: Myocardial infarction, diabetes mellitus, and high-sensitivity C-reactive protein, but not age, were associated with NC-rich lesions. Clinical presentation, risk factors, and inflammatory status, but not age, are important factors for plaque components. Copyright 2009 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Heart Center of Chonnam National University Hospital, Chonnam National University Research Institute of Medical Sciences, 671 Jaebongro, Dong-gu, Gwangju 501-757, Republic of KoreaJC - joa, 8804703CP - JapanPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20206076</style></custom1><custom3><style face="normal" font="default">AS - J Cardiol. 55(2):224-31, 2010 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>384</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Horiguchi,J.</style></author><author><style face="normal" font="default"> Matsuura,N.</style></author><author><style face="normal" font="default"> Yamamoto,H.</style></author><author><style face="normal" font="default"> Kitagawa,T.</style></author><author><style face="normal" font="default"> Sato,K.</style></author><author><style face="normal" font="default"> Kihara,Y.</style></author><author><style face="normal" font="default"> Ito,K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Evaluation of attenuation-based tube current control in coronary artery calcium scoring on prospective ECG-triggered 64-detector CT</style></title><secondary-title><style face="normal" font="default">Academic Radiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Academic Radiology</style></full-title></periodical><pages end="1240" start="1231">1231-1240</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Artifacts</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Cardiac-Gated Imaging Techniques/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Radiographic Image Enhancement/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Body Height</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Radiation Dosage</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><abstract><style face="normal" font="default">RATIONALE AND OBJECTIVES: The aims of this study were to investigate image noise (standard deviation of computed tomographic value) and to assess variability in repeated coronary artery calcium (CAC) scoring on prospective electrocardiographically triggered 64-detctor computed tomography. MATERIALS AND METHODS: Patients (n = 428) suspected of having coronary artery disease were scanned twice using three protocols: with tube current modified by body mass index (BMI; group A), by BMI and body height (group B), and by attenuation at the maximal heart diameter (group C). Image noise was plotted against BMI. Interscan variability of CAC scores was determined. The effective dose was estimated by computed tomographic dose index. RESULTS: The mean effective dose and image noise, respectively, were 0.9 +/- 0.2 mSv (range, 0.6-1.5 mSv) and 19 +/- 4 Hounsfield units (HU) (range, 10-32 HU) for group A; 0.8 +/- 0.2 mSv (range, 0.5-1.4 mSv) and 18 +/- 4 HU (range, 10-31 HU) for group B; and 0.8 +/- 0.4 mSv (range, 0.3-2.2 mSv) and 20 +/- 2 HU (range, 16-26 HU) for group C. Group C used a wide dose range and controlled noise within a small range. The positive slopes of image noise versus BMI, 0.81 HU/(kg/m(2)) in group A and 0.62 HU/(kg/m(2)) in group B, suggested insufficient control of the tube current. In contrast, the nearly flat slope in group C, 0.091 HU/(kg/m(2)), indicated optimal control. The interscan variability for Agatston score, volume, and mass in patients with CAC (n = 300) was 13% (median, 8%), 12% (median, 7%), and 11% (median, 6%), respectively. CONCLUSIONS: CAC scoring on prospective electrocardiographically triggered 64-detector computed tomography using attenuation-based tube current control has the potential to favorably control image noise with low dose and low interscan variability</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Clinical Radiology, Hiroshima University Hospital, 1-2-3, Kasumi-cho, Minami-ku, Hiroshima 734-8551, Japan. horiguch@hiroshima-u.ac.jpJC - clv, 9440159CP - United StatesPT - Case ReportsPT - Evaluation StudiesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19515586</style></custom1><custom3><style face="normal" font="default">AS - Acad Radiol. 16(10):1231-40, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>452</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Horiguchi,J.</style></author><author><style face="normal" font="default"> Matsuura,N.</style></author><author><style face="normal" font="default"> Yamamoto,H.</style></author><author><style face="normal" font="default"> Kiguchi,M.</style></author><author><style face="normal" font="default"> Fujioka,C.</style></author><author><style face="normal" font="default"> Kitagawa,T.</style></author><author><style face="normal" font="default"> Ito,K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Effect of heart rate and body mass index on the interscan and interobserver variability of coronary artery calcium scoring at prospective ECG-triggered 64-slice CT</style></title><secondary-title><style face="normal" font="default">Korean Journal of Radiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Korean Journal of Radiology</style></full-title></periodical><pages end="346" start="340">340-346</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Body Mass Index</style></keyword><keyword><style face="normal" font="default"> *Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> *Electrocardiography</style></keyword><keyword><style face="normal" font="default"> *Heart Rate</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Algorithms</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Rate</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Observer Variation</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="7" Year="2009">2009/7</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To test the effects of heart rate, body mass index (BMI) and noise level on interscan and interobserver variability of coronary artery calcium (CAC) scoring on a prospective electrocardiogram (ECG)-triggered 64-slice CT. MATERIALS AND METHODS: One hundred and ten patients (76 patients with CAC) were scanned twice on prospective ECG-triggered scans. The scan parameters included 120 kV, 82 mAs, a 2.5 mm thickness, and an acquisition center at 45% of the RR interval. The interscan and interobserver variability on the CAC scores (Agatston, volume, and mass) was calculated. The factors affecting the variability were determined by plotting it against heart rate, BMI, and noise level (defined as the standard deviation: SD). RESULTS: The estimated effective dose was 1.5 +/- 0.2 mSv. The mean heart rate was 63 +/- 12 bpm (range, 44-101 bpm). The patient BMIs were 24.5 +/- 4.5 kg/m(2) (range, 15.5-42.3 kg/m(2)). The mean and median interscan variabilities were 11% and 6%, respectively by volume, and 11% and 6%, respectively, by mass. Moreover, the mean and median of the algorithms were lower than the Agatston algorithm (16% and 9%, respectively). The mean and median interobserver variability was 10% and 4%, respectively (average of algorithms). The mean noise levels were 15 +/- 4 Hounsfield unit (HU) (range, 8-25 HU). The interscan and interobserver variability was not correlated with heart rate, BMI, or noise level. CONCLUSION: The interscan and interobserver variability of CAC on a prospective ECG-triggered 64-slice CT with high image quality and 45% of RR acquisition is not significantly affected by heart rate, BMI, or noise level. The volume or mass algorithms show reduced interscan variability compared to the Agatston scoring (p &lt; 0.05)</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Clinical Radiology, Hiroshima University Hospital, Minami-ku, Hiroshima, Japan. horiguch@hiroshima-u.ac.jpJC - 100956096CP - Korea (South)PT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19568461</style></custom1><custom3><style face="normal" font="default">AS - Korean J Radiol. 10(4):340-6, 2009 Jul-Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>396</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Horjus,C.</style></author><author><style face="normal" font="default"> Groot,I.</style></author><author><style face="normal" font="default"> Telting,D.</style></author><author><style face="normal" font="default"> van,Setten P.</style></author><author><style face="normal" font="default"> van,Sorge A.</style></author><author><style face="normal" font="default"> Kovacs,C.S.</style></author><author><style face="normal" font="default"> Hermus,A.</style></author><author><style face="normal" font="default"> de,Boer H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Cinacalcet for hyperparathyroidism in pregnancy and puerperium</style></title><secondary-title><style face="normal" font="default">Journal of Pediatric Endocrinology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Pediatric Endocrinology</style></full-title></periodical><pages end="749" start="741">741-749</pages><volume><style face="normal" font="default">22</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Hyperparathyroidism,Primary/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Naphthalenes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Pregnancy Complications/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> 0 (Naphthalenes)</style></keyword><keyword><style face="normal" font="default"> 364782-34-3 (cinacalcet)</style></keyword><keyword><style face="normal" font="default"> 9007-12-9 (Calcitonin)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Calcitonin/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Drug Therapy,Combination</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypercalcemia/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Hypercalcemia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Hypercalcemia/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Primary/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Primary/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Infant,Newborn/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Postpartum Period/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Pregnancy Complications/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Pregnancy/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="8" Year="2009">2009/8</year></dates><isbn><style face="normal" font="default">0334-018X</style></isbn><abstract><style face="normal" font="default">The efficacy and safety of various modes of medical treatment for primary hyperparathyroidism (PHPT) in pregnancy is largely unknown. This report describes two cases of PHPT in pregnancy that were temporarily treated with the calcimimetic cinacalcet. The first case was diagnosed in the 31st week of pregnancy. The patient was asymptomatic and had an albumin-corrected total calcium level (Ca(corr)) of 3.24 mmol/l. As serum calcium was only mildly elevated it was decided to postpone surgery to the postpartum period. Cinacalcet was started immediately after delivery to prevent a postpartum surge in serum calcium. The second patient presented with hypertension and symptomatic hypercalcemia (Ca(corr) 3.96 mmol/l) in the 32nd week of pregnancy. Surgery was postponed because of suspected pheochromocytoma. Treatment with a combination of cinacalcet and calcitonin reduced serum Ca(corr) to 3.0 mmol/l. This report describes the monitoring of mother and child, and explores the pros and cons of the use of calcimimetics during pregnancy and puerperium</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Internal Medicine, Rijnstate Hospital, Arnhem, The NetherlandsJC - bu0, 8510464, cef, 9508900CP - EnglandPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19845125</style></custom1><custom3><style face="normal" font="default">AS - J Pediatr Endocrinol. 22(8):741-9, 2009 Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>467</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Horne,B.D.</style></author><author><style face="normal" font="default"> May,H.T.</style></author><author><style face="normal" font="default"> Muhlestein,J.B.</style></author><author><style face="normal" font="default"> Ronnow,B.S.</style></author><author><style face="normal" font="default"> Lapp&amp;#x00E9</style></author><author><style face="normal" font="default"> DL</style></author><author><style face="normal" font="default"> Renlund,D.G.</style></author><author><style face="normal" font="default"> Kfoury,A.G.</style></author><author><style face="normal" font="default"> Carlquist,J.F.</style></author><author><style face="normal" font="default"> Fisher,P.W.</style></author><author><style face="normal" font="default"> Pearson,R.R.</style></author><author><style face="normal" font="default"> Bair,T.L.</style></author><author><style face="normal" font="default"> Anderson,J.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Exceptional mortality prediction by risk scores from common laboratory tests</style></title><secondary-title><style face="normal" font="default">American Journal of Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Medicine</style></full-title></periodical><pages end="558" start="550">550-558</pages><volume><style face="normal" font="default">122</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Blood Cell Count</style></keyword><keyword><style face="normal" font="default"> *Cause of Death</style></keyword><keyword><style face="normal" font="default"> *Diagnostic Tests,Routine</style></keyword><keyword><style face="normal" font="default"> *Metabolome</style></keyword><keyword><style face="normal" font="default"> 0 (Bicarbonates)</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Blood Glucose)</style></keyword><keyword><style face="normal" font="default"> 60-27-5 (Creatinine)</style></keyword><keyword><style face="normal" font="default"> 7440-09-7 (Potassium)</style></keyword><keyword><style face="normal" font="default"> 7440-23-5 (Sodium)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 7647-14-5 (Sodium Chloride)</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Bicarbonates/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Blood Glucose/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Blood Urea Nitrogen</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Creatinine/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Potassium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> Research Design</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Sodium Chloride/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Sodium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Utah</style></keyword></keywords><dates><year Day="0" Month="6" Year="2009">2009/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: Some components of the complete blood count and basic metabolic profile are commonly used risk predictors. Many of their components are not commonly used, but they might contain independent risk information. This study tested the ability of a risk score combining all components to predict all-cause mortality. METHODS: Patients with baseline complete blood count and basic metabolic profile measurements were randomly assigned (60%/40%) to independent training (N = 71,921) and test (N = 47,458) populations. A third population (N = 16,372) from the Third National Health and Nutrition Examination Survey and a fourth population of patients who underwent coronary angiography (N = 2558) were used as additional validation groups. Risk scores were computed in the training population for 30-day, 1-year, and 5-year mortality using age- and sex-adjusted weights from multivariable modeling of all complete blood count and basic metabolic profile components. RESULTS: Area under the curve c-statistics were exceptional in the training population for death at 30 days (c = 0.90 for women, 0.87 for men), 1 year (c = 0.87, 0.83), and 5-years (c = 0.90, 0.85) and in the test population for death at 30 days (c = 0.88 for women, 0.85 for men), 1 year (c = 0.86, 0.82), and 5 years (c = 0.89, 0.83). In the test, the Third National Health and Nutrition Examination Survey, and the angiography populations, risk scores were highly associated with death (P &lt;.001), and thresholds of risk significantly stratified all 3 populations. CONCLUSION: In large patient and general populations, risk scores combining complete blood count and basic metabolic profile components were highly predictive of death. Easily computed in a clinical laboratory at negligible incremental cost, these risk scores aggregate baseline risk information from both the popular and the underused components of ubiquitous laboratory tests</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Cardiovascular Department, Intermountain Medical Center, Murray, Utah 84157, USA. benjamin.horne@imail.orgJC - 0267200, 3juCP - United StatesPT - Comparative StudyPT - Evaluation StudiesPT - Journal ArticlePT - Multicenter StudySI - ClinicalTrials.govSA - ClinicalTrials.gov/NCT00406185LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19486718</style></custom1><custom3><style face="normal" font="default">AS - Am J Med. 122(6):550-8, 2009 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>477</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Hosseinsabet,A.</style></author><author><style face="normal" font="default"> Mohebbi,A.</style></author><author><style face="normal" font="default"> Almasi,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Association between C-reactive protein and coronary calcium score in coronary artery disease</style></title><secondary-title><style face="normal" font="default">Cardiovascular Journal of Africa</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Cardiovascular Journal of Africa</style></full-title></periodical><pages end="111" start="107">107-111</pages><volume><style face="normal" font="default">20</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Thyroid Hormone Receptors alpha/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> 0 (Thyroid Hormone Receptors alpha)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Bypass</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Nephelometry and Turbidimetry</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword></keywords><dates><year Day="0" Month="3" Year="2009">2009/3</year></dates><isbn><style face="normal" font="default">1995-1892</style></isbn><abstract><style face="normal" font="default">BACKGROUND: Both high-sensitivity C-reactive protein (hs- CRP) and spiral computed tomography coronary artery calcium score (CCS) are valid markers of cardiovascular risk. It is unknown whether hs-CRP is a marker of atherosclerotic burden or if it reflects a process leading to acute coronary events. METHODS AND RESULTS: We studied the association between hs- CRP and CCS in 143 patients who were candidates for coronary artery bypass grafting (CABG). In our cross-sectional study, we found no significant association between hs-CRP and the CCS in bivariant (p = 0.162) and multivariant (p = 0.062) analyses. However, in patients who did not use statins, this association was significant and positive in the bivariant analysis (p = 0.001), but in the multivariant analysis it was negative and significant (p = 0.008). CONCLUSION: High-sensitivity CRP was not correlated with CCS. The relationship between CRP and clinical events might not be related to atherosclerotic burden. Measures of inflammation, such as hs-CRP, and indices of atherosclerosis, such as CCS, are likely to provide distinct information regarding cardiovascular risk</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Shaheed Rajaei Cardiovascular Center, Iran University of Medical Sciences, Tehran, Iran. ali_hosseinsabet@yahoo.comJC - 101313864CP - South AfricaPT - Comparative StudyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19421644</style></custom1><custom3><style face="normal" font="default">AS - Cardiovasc. j. Afr.. 20(2):107-11, 2009 Mar-Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>350</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Hsu,T.H.</style></author><author><style face="normal" font="default"> Lin,S.Y.</style></author><author><style face="normal" font="default"> Lin,C.C.</style></author><author><style face="normal" font="default"> Cheng,W.T.</style></author><author><style face="normal" font="default"> Li,M.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Spectral diagnosis and analysis of a superior vesical artery calcification</style></title><secondary-title><style face="normal" font="default">Urological Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Urological Research</style></full-title></periodical><pages end="256" start="253">253-256</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Arteries/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Spectroscopy,Fourier Transform Infrared</style></keyword><keyword><style face="normal" font="default"> *Spectrum Analysis,Raman</style></keyword><keyword><style face="normal" font="default"> *Urinary Bladder/bs [Blood Supply]</style></keyword><keyword><style face="normal" font="default"> *Vascular Diseases/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> 1306-06-5 (Durapatite)</style></keyword><keyword><style face="normal" font="default"> 57-88-5 (Cholesterol)</style></keyword><keyword><style face="normal" font="default"> 7235-40-7 (beta Carotene)</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> beta Carotene/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Cholesterol/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Durapatite/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidental Findings</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><abstract><style face="normal" font="default">A case of urinary vessel calcification was detected incidentally in pelvic cavity of a 59-year-old man by computed tomography. The silver reticulin, actin, and hematoxylin and eosin stains were applied to diagnose the feature of vessel and confirmed that the vessel was the vesical artery. To our knowledge, this is the first report to find out the obliteration of superior vesical artery caused by calcified deposit. The calcified deposit in superior vesical artery was qualitatively identified to consist of hydroxyapatite, cholesterol and beta-carotene by Fourier transform infrared and Raman microspectroscopies, in which A-type carbonated apatite was a predominate component</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Urology, Department of Surgery, Lotung Pohai Hospital, Ilan, TaiwanJC - wrx, 0364311CP - GermanyPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19533114</style></custom1><custom3><style face="normal" font="default">AS - Urol Res. 37(5):253-6, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>225</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Huang,W.C.</style></author><author><style face="normal" font="default"> Liu,C.P.</style></author><author><style face="normal" font="default"> Wu,M.T.</style></author><author><style face="normal" font="default"> Mar,G.Y.</style></author><author><style face="normal" font="default"> Lin,S.K.</style></author><author><style face="normal" font="default"> Hsiao,S.H.</style></author><author><style face="normal" font="default"> Lin,S.L.</style></author><author><style face="normal" font="default"> Chiou,K.R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Comparing culprit lesions in ST-segment elevation and non-ST-segment elevation acute coronary syndrome with 64-slice multidetector computed tomography</style></title><secondary-title><style face="normal" font="default">European Journal of Radiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">European Journal of Radiology</style></full-title></periodical><pages end="81" start="74">74-81</pages><volume><style face="normal" font="default">73</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Acute Coronary Syndrome/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Decision Making</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword></keywords><dates><year Day="0" Month="1" Year="2010">2010/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Classifying acute coronary syndrome (ACS) as ST elevation ACS (STE-ACS) or non-ST elevation ACS (NSTE-ACS) is critical for clinical prognosis and therapeutic decision-making. Assessing the differences in composition and configuration of culprit lesions between STE-ACS and NSTE-ACS can clarify their pathophysiologic differences. OBJECTIVE: This study focused on evaluating the ability of 64-slice multidetector computed tomography (MDCT) to investigate these differences in culprit lesions in patients with STE-ACS and NSTE-ACS. METHODS: Of 161 ACS cases admitted, 120 who fit study criteria underwent MDCT and conventional coronary angiography. The following MDCT data were analyzed: calcium volume, Agatston calcium scores, plaque area, plaque burden, remodeling index, and plaque density. RESULTS: The MDCT angiography had a good correlation with conventional coronary angiography regarding the stenotic severity of culprit lesions (r=0.86, p&lt;0.001). The STE-ACS culprit lesions (n=54) had significantly higher luminal area stenosis (78.6+/-21.2% vs. 66.7+/-23.9%, p=0.006), larger plaque burden (0.91+/-0.10 vs. 0.84+/-0.12, p=0.007) and remodeling index (1.28+/-0.34 vs. 1.16+/-0.22, p=0.021) than those with NSTE-ACS (n=66). The percentage of expanding remodeling index (remodeling index >1.05) was significantly higher in the STE-ACS group (81.5% vs. 63.6%, p=0.031). The patients with STE-ACS had significantly lower MDCT density of culprit lesions than patients with NSTE-ACS (25.8+/-13.9HU vs. 43.5+/-19.1HU, p&lt;0.001). CONCLUSIONS: Sixty-four-slice MDCT can accurately evaluate the stenotic severity and composition of culprit lesions in selected patients with either STE-ACS or NSTE-ACS. Culprit lesions in NSTE-ACS patients had significantly lower luminal area stenosis, plaque burden, remodeling index and higher MDCT density, which possibly reflect differences in the composition of vulnerable culprit plaques and thrombi. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC. w.c.huang@yahoo.com.twJC - em6, 8106411CP - IrelandPT - Comparative StudyPT - Evaluation StudiesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19004589</style></custom1><custom3><style face="normal" font="default">AS - Eur J Radiol. 73(1):74-81, 2010 Jan.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>50</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Huisman,J.</style></author><author><style face="normal" font="default"> Egede,R.</style></author><author><style face="normal" font="default"> Rdzanek,A.</style></author><author><style face="normal" font="default"> Bose,D.</style></author><author><style face="normal" font="default"> Erbel,R.</style></author><author><style face="normal" font="default"> Kochman,J.</style></author><author><style face="normal" font="default"> Jensen,L.O.</style></author><author><style face="normal" font="default"> van de,Palen J.</style></author><author><style face="normal" font="default"> Hartmann,M.</style></author><author><style face="normal" font="default"> Mintz,G.S.</style></author><author><style face="normal" font="default"> von,Birgelen C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Between-centre reproducibility of volumetric intravascular ultrasound radiofrequency-based analyses in mild-to-moderate coronary atherosclerosis: an international multicentre study</style></title><secondary-title><style face="normal" font="default">Eurointervention</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eurointervention</style></full-title></periodical><pages end="931" start="925">925-931</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Artery Disease/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Ultrasonography,Interventional</style></keyword><keyword><style face="normal" font="default"> 0 (Lipids)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angina Pectoris/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Angina Pectoris/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Automation,Laboratory</style></keyword><keyword><style face="normal" font="default"> Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Image Interpretation,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Lipids/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Observer Variation</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">AIMS: To assess for the first time in a multicentre design the between-centre reproducibility of volumetric virtual histology intravascular ultrasound (VH-IVUS) measurements with a semi-automated, computerassisted contour detection system in mild-to-moderately diseased coronary segments. METHODS AND RESULTS: Analysts of four European IVUS centres performed independent IVUS analyses (in total 7,188 cross-sectional analyses) and obtained volumetric data to evaluate the reproducibility of volumetric VH-IVUS measurements in 36 coronary segments (length 20.0+/-0.4 mm) from patients with stable angina. Geometric and compositional VH-IVUS measurements were highly correlated for the different comparisons. Overall intraclass correlation for vessel, lumen, plaque volume and plaque burden were 0.98, 0.92 0.95, and 0.86, respectively; for fibrous, fibro-lipidic, necrotic core and calcified volumes overall intraclass correlations were 0.95, 0.93, 0.99, and 1.00, respectively. There were significant but small differences for vessel, lumen, fibrous and calcified volumes, and there was no significant difference for plaque volume. Of the plaque components necrotic core and calcified volume showed on average the highest reproducibility. CONCLUSIONS: These findings underline the necessity to centrally analyse IVUS data obtained in multicentre studies addressing mild-to-moderately diseased coronary arteries. In addition, pooling VH-IVUS data from different studies, analysed at different centres, may be problematical</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, The NetherlandsJC - 101251040CP - FrancePT - Comparative StudyPT - Journal ArticlePT - Multicenter StudyLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20542777</style></custom1><custom3><style face="normal" font="default">AS - EuroIntervention. 5(8):925-31, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>414</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Hultin,H.</style></author><author><style face="normal" font="default"> Hellman,P.</style></author><author><style face="normal" font="default"> Lundgren,E.</style></author><author><style face="normal" font="default"> Olovsson,M.</style></author><author><style face="normal" font="default"> Ekbom,A.</style></author><author><style face="normal" font="default"> Rastad,J.</style></author><author><style face="normal" font="default"> Montgomery,S.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Association of parathyroid adenoma and pregnancy with preeclampsia</style></title><secondary-title><style face="normal" font="default">Journal of Clinical Endocrinology &amp; Metabolism</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Clinical Endocrinology &amp; Metabolism</style></full-title></periodical><pages end="3399" start="3394">3394-3399</pages><volume><style face="normal" font="default">94</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Adenoma/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Parathyroid Neoplasms/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Pre-Eclampsia/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Pregnancy Complications,Neoplastic</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="9" Year="2009">2009/9</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Case reports have described associations between calcium metabolism disturbances and primary hyperparathyroidism with preeclampsia, suggesting parathyroid involvement in preeclampsia etiology. This study examines whether parathyroid adenoma, the main cause of hyperparathyroidism, diagnosed and treated before pregnancy is associated with preeclampsia. DESIGN: We conducted a register-based study to assess the association between parathyroid adenoma and subsequent preeclampsia. SETTING: Births among Sweden's general population were studied. POPULATION: The study population included 52 women with a diagnosis of parathyroid adenoma and 519 without, all of whom had a subsequent singleton pregnancy between 1973 and 1997. METHODS: We performed a conditional logistic regression investigating the association of parathyroid adenoma with subsequent preeclampsia in the first singleton pregnancy with adjustment for potential confounding factors. MAIN OUTCOME MEASURE: The main outcome was a diagnosis of preeclampsia that does not include women with prior chronic hypertension. To ensure that treatment of parathyroid adenoma was completed before pregnancy, those with a diagnosis of parathyroid adenoma made less than 2 yr before delivery (and the matched comparison women) were excluded. RESULTS: Statistically, parathyroid adenoma prior to delivery is significantly (P &lt; 0.001) associated with preeclampsia, producing an adjusted odds ratio of 6.89 (95% confidence interval, 2.30, 20.58). CONCLUSION: A history of parathyroid adenoma should be viewed as a risk for preeclampsia</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Surgical Sciences, University Hospital, SE-751 85 Uppsala, SwedenJC - hrb, 0375362CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19531594</style></custom1><custom3><style face="normal" font="default">AS - J Clin Endocrinol Metab. 94(9):3394-9, 2009 Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>221</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Husmann,L.</style></author><author><style face="normal" font="default"> Herzog,B.A.</style></author><author><style face="normal" font="default"> Burger,I.A.</style></author><author><style face="normal" font="default"> Buechel,R.R.</style></author><author><style face="normal" font="default"> Pazhenkottil,A.P.</style></author><author><style face="normal" font="default"> von,Schulthess P.</style></author><author><style face="normal" font="default"> Wyss,C.A.</style></author><author><style face="normal" font="default"> Gaemperli,O.</style></author><author><style face="normal" font="default"> Landmesser,U.</style></author><author><style face="normal" font="default"> Kaufmann,P.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Usefulness of additional coronary calcium scoring in low-dose CT coronary angiography with prospective ECG-triggering impact on total effective radiation dose and diagnostic accuracy</style></title><secondary-title><style face="normal" font="default">Academic Radiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Academic Radiology</style></full-title></periodical><pages end="206" start="201">201-206</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Body Burden</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Cardiac-Gated Imaging Techniques/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Electrocardiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Radiation Dosage</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="2" Year="2010">2010/2</year></dates><abstract><style face="normal" font="default">RATIONALE AND OBJECTIVES: To determine the impact of additional coronary calcium scoring on total effective radiation dose and diagnostic accuracy of low-dose computed tomography coronary angiography (CTCA) with prospective electrocardiogram (ECG) triggering. MATERIALS AND METHODS: Sixty-one consecutive patients underwent 64-slice CTCA using prospective ECG triggering, calcium scoring, and invasive quantitative coronary angiography, the latter served as standard of reference. Diagnostic accuracy was calculated for CTCA, calcium scoring, and for the combination of both. Receiver operator characteristic analyses were performed to determine cutoffs for prediction of significant coronary artery stenoses. RESULTS: Mean effective radiation dose was 2.1 + or - 0.7 mSv (range, 1.0-3.3 mSv) for CTCA and 1.1 + or - 0.1 mSv (range, 0.9-1.4 mSv) for calcium scoring. Per-patient sensitivity, specificity, positive predictive value, and negative predictive value were 100%, 85.7%, 89.2%, and 100% for CTCA, and 72.7%, 82.1%, 82.8%, and 71.9% for calcium scoring. Adding calcium-scoring with a cutoff at 133 in patients aged >50.7 years with nondiagnostic CTCA improved the respective values of diagnostic accuracy of the entire study population to 100%, 96.4%, 97.1%, and 100%; the added value of calcium scoring was confined to only three patients (5%), who were reclassified from false positive to true negative. CONCLUSION: Specificity and PPV of low-dose CTCA may be further improved by combining it with coronary calcium scoring. However, only a fraction of patient may benefit, whereas exposing the entire population to more than 50% increase in effective radiation dose. Copyright 2010 AUR. Published by Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, CH-8091 Zurich, SwitzerlandJC - clv, 9440159CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19944630</style></custom1><custom3><style face="normal" font="default">AS - Acad Radiol. 17(2):201-6, 2010 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>370</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Huybrechts,K.F.</style></author><author><style face="normal" font="default"> Caro,J.J.</style></author><author><style face="normal" font="default"> O'Brien,J.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Prevention and management of hyperphosphatemia with sevelamer in Canada: health and economic consequences</style></title><secondary-title><style face="normal" font="default">Value in Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Value in Health</style></full-title></periodical><pages end="19" start="16">16-19</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium Carbonate/ec [Economics]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/ec [Economics]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Chelating Agents/ec [Economics]</style></keyword><keyword><style face="normal" font="default"> *Hyperphosphatemia</style></keyword><keyword><style face="normal" font="default"> *Polyamines/ec [Economics]</style></keyword><keyword><style face="normal" font="default"> 0 (Chelating Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Polyamines)</style></keyword><keyword><style face="normal" font="default"> 182683-00-7 (sevelamer)</style></keyword><keyword><style face="normal" font="default"> 471-34-1 (Calcium Carbonate)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium Carbonate/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Chelating Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Cost-Benefit Analysis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperphosphatemia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Hyperphosphatemia/ec [Economics]</style></keyword><keyword><style face="normal" font="default"> Hyperphosphatemia/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Models,Economic</style></keyword><keyword><style face="normal" font="default"> Polyamines/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="1" Year="2009">2009/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Sevelamer hydrochloride (Renagel) binds phosphate in patients with end-stage renal disease without the use of exogenous calcium and may reduce the progression of coronary vascular calcification. This intervention was shown to be cost-effective in the United States. This paper presents the Canadian adaptation. METHODS: A discrete event simulation of the long-term cardiovascular implications of 1 year of phosphate binding in a prevalent hemodialysis population was used to estimate the cost-effectiveness of sevelamer use in Canada based on the demographics, comorbidities, physiological and renal characteristics. Initial calcification score and expected changes over 1 year were derived using regression equations developed from a clinical trial and translated to cardiovascular disease risk based on equations developed from a long-term cohort study. Direct medical costs from a Canadian Medicare perspective were taken from Ontario data. Ten replications of 10,000 patients over 13 years (discounting at 3%) were done for the base case and extensive sensitivity analyses were conducted. RESULTS: The cardioprotective effect of sevelamer over 1 year is estimated to prevent 10 cardiovascular events and gain 18 life-years compared with calcium carbonate in 100 patients over a lifetime. These benefits are obtained at a net cost of CAD$2,096; an incremental cost-effectiveness ratio of CAD$12,384 per discounted life-year gained. Sensitivity analyses showed that the time horizon and efficacy were the most important factors. CONCLUSION: The results of this study provide evidence that use of sevelamer in Canada would be economically sound</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Caro Research Institute, Concord, MA 01742, USA. krista.huybrechts@unitedbiosource.comJC - 100883818CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18647261</style></custom1><custom3><style face="normal" font="default">AS - Value Health. 12(1):16-9, 2009 Jan.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>6</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Hwang,Y.</style></author><author><style face="normal" font="default"> Kim,Y.</style></author><author><style face="normal" font="default"> Chung,I.M.</style></author><author><style face="normal" font="default"> Ryu,J.</style></author><author><style face="normal" font="default"> Park,H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Coronary heart disease risk assessment and characterization of coronary artery disease using coronary CT angiography: comparison of asymptomatic and symptomatic groups</style></title><secondary-title><style face="normal" font="default">Clinical Radiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinical Radiology</style></full-title></periodical><pages end="608" start="601">601-608</pages><volume><style face="normal" font="default">65</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Chest Pain/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Chest Pain/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Practice Guidelines as Topic</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> ROC Curve</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed/mt [Methods]</style></keyword></keywords><dates><year Day="0" Month="8" Year="2010">2010/8</year></dates><abstract><style face="normal" font="default">AIM: To evaluate the prevalence of coronary artery disease (CAD) in relation to risk of coronary heart disease (CHD) and assess plaque characteristics from coronary computed tomography (CT) angiography in asymptomatic and symptomatic patients. MATERIALS AND METHODS: Three hundred and ninety consecutive patients [asymptomatic group, n=138; symptomatic group (atypical or non-anginal chest pain), n=252] were retrospectively enrolled. They were subsequently classified into three CHD risk categories, based on the National Cholesterol Education Program guidelines, and 10 year risks of coronary events were calculated using Framingham risk score. CT was evaluated for stenosis, plaque composition, and coronary calcium scores. RESULTS: CAD was observed in 42% of the asymptomatic group and 62% of the symptomatic group. In the former, the prevalence of CAD in low-, moderate- and high-risk subgroups was 21.4, 47.4 and 65%, respectively, and was 33.3, 74.4, and 72.4% in the symptomatic group. Framingham 10-year risks of coronary events were significantly higher in patients with CAD than in normal participants, and receiver operating characteristics curves showed that discriminatory power was poor in the asymptomatic group and symptomatic men, and good in symptomatic women. Of the participants in the asymptomatic group, 12% exhibited only non-calcified plaques and of the symptomatic group, 7% exhibited only non-calcified plaques. The coronary calcium score was significantly higher for significant stenosis than for non-significant stenosis in both groups. CONCLUSIONS: The prevalence of CAD was not negligible even in subgroups with low-to-moderate CHD risk. Additionally, the Framingham risk score was effective for predicting CAD only in symptomatic women. Coronary calcium scores correlated with significant stenosis; however, a sizeable percentage of both groups had only non-calcified plaques</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Radiology, School of Medicine, Ewha Womans University, Seoul, Republic of KoreaJC - diu, 1306016CP - EnglandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20599061</style></custom1><custom3><style face="normal" font="default">AS - Clin Radiol. 65(8):601-8, 2010 Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>158</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Hyder,J.A.</style></author><author><style face="normal" font="default"> Allison,M.A.</style></author><author><style face="normal" font="default"> Barrett-Connor,E.</style></author><author><style face="normal" font="default"> Detrano,R.</style></author><author><style face="normal" font="default"> Wong,N.D.</style></author><author><style face="normal" font="default"> Sirlin,C.</style></author><author><style face="normal" font="default"> Gapstur,S.M.</style></author><author><style face="normal" font="default"> Ouyang,P.</style></author><author><style face="normal" font="default"> Carr,J.J.</style></author><author><style face="normal" font="default"> Criqui,M.H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Bone mineral density and atherosclerosis: the Multi-Ethnic Study of Atherosclerosis, Abdominal Aortic Calcium Study</style></title><secondary-title><style face="normal" font="default">Atherosclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Atherosclerosis</style></full-title></periodical><pages end="289" start="283">283-289</pages><volume><style face="normal" font="default">209</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aorta,Abdominal/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Atherosclerosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Bone Density</style></keyword><keyword><style face="normal" font="default"> *Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Ankle Brachial Index</style></keyword><keyword><style face="normal" font="default"> Aorta,Abdominal/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Carotid Arteries/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Carotid Arteries/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Lumbar Vertebrae/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Lumbar Vertebrae/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="3" Year="2010">2010/3</year></dates><abstract><style face="normal" font="default">CONTEXT: Molecular and cell biology studies have demonstrated an association between bone and arterial wall disease, but the significance of a population-level association is less clear and potentially confounded by inability to account for shared risk factors. OBJECTIVE: To test population-level associations between atherosclerosis types and bone integrity. MAIN OUTCOME MEASURES: Volumetric trabecular lumbar bone mineral density (vBMD), ankle-brachial index (ABI), intima-media thickness (IMT) of the common carotid (CCA-IMT) and internal carotid (ICA-IMT) arteries, and carotid plaque echogenicity. DESIGN, SETTING AND PARTICIPANTS: A random subset of participants from the Multi-Ethnic Study of Atherosclerosis (MESA) assessed between 2002 and 2005. RESULTS: 904 post-menopausal female (62.4 years; 62% non-white; 12% ABI &lt;1; 17% CCA-IMT >1mm; 33% ICA-IMT >1mm) and 929 male (61.4 years; 58% non-white; 6% ABI &lt;1; 25% CCA-IMT >1mm; 40% ICA-IMT >1mm) were included. In serial, sex-specific regression models adjusting for age, ethnicity, body mass index, dyslipidemia, hypertension, smoking, alcohol consumption, diabetes, homocysteine, interleukin-6, sex hormones, and renal function, lower vBMD was associated with lower ABI in men (p for trend &lt;0.01) and greater ICA-IMT in men (p for trend &lt;0.02). CCA-IMT was not associated with vBMD in men or women. Carotid plaque echogenicity was independently associated with lower vBMD in both men (trend p=0.01) and women (trend p&lt;0.04). In all models, adjustment did not materially affect results. CONCLUSIONS: Lower vBMD is independently associated with structural and functional measures of atherosclerosis in men and with more advanced and calcified carotid atherosclerotic plaques in both sexes</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Anesthesiology, Mayo Clinic, Rochester, MN 55905, USA. joseph.a.hyder@gmail.comJC - 95x, 0242543CP - IrelandPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - N01-HC-95159 (United States NHLBI NIH HHS)NO - N01-HC-95165 (United States NHLBI NIH HHS)NO - N01-HC-95169 (United States NHLBI NIH HHS)NO - R01 HL074338 (United States NHLBI NIH HHS)NO - R01 HL074406 (United States NHLBI NIH HHS)NO - R01 HL72403 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19819456</style></custom1><custom3><style face="normal" font="default">AS - Atherosclerosis. 209(1):283-9, 2010 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>427</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Ibebuogu,U.N.</style></author><author><style face="normal" font="default"> Nasir,K.</style></author><author><style face="normal" font="default"> Gopal,A.</style></author><author><style face="normal" font="default"> Ahmadi,N.</style></author><author><style face="normal" font="default"> Mao,S.S.</style></author><author><style face="normal" font="default"> Young,E.</style></author><author><style face="normal" font="default"> Honoris,L.</style></author><author><style face="normal" font="default"> Nuguri,V.K.</style></author><author><style face="normal" font="default"> Lee,R.S.</style></author><author><style face="normal" font="default"> Usman,N.</style></author><author><style face="normal" font="default"> Rostami,B.</style></author><author><style face="normal" font="default"> Pal,R.</style></author><author><style face="normal" font="default"> Flores,F.</style></author><author><style face="normal" font="default"> Budoff,M.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Comparison of atherosclerotic plaque burden and composition between diabetic and non diabetic patients by non invasive CT angiography</style></title><secondary-title><style face="normal" font="default">The International Journal of Cardiovascular Imaging</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">The International Journal of Cardiovascular Imaging</style></full-title></periodical><pages end="723" start="717">717-723</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Stenosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 2/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Diabetic Angiopathies/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> 0 (Contrast Media)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Calcinosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Contrast Media/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Stenosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus,Type 2/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Diabetic Angiopathies/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Linear Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Radiographic Image Enhancement</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><abstract><style face="normal" font="default">Type 2 diabetes mellitus (DM) is associated with a higher risk of cardiovascular disease and atherosclerotic burden. However little data exists in regards to plaque distribution and plaque composition in these patients. To assess for differences in the coronary plaques burden and composition among symptomatic patients with and without type 2 DM using multidetector computed tomography angiography (MDCTA). The 416 symptomatic patients (64% males, mean age: 61 +/- 13 years) with 61 (15%) reporting type 2 DM, who underwent contrast-enhanced MDCTA were studied. Enrolled patients had an intermediate to high pre-test probability of obstructive coronary artery disease. Multivariate analysis was used to correct for differences in age and gender. Patients with type 2 DM were more likely to have significant stenosis >or=70% in at least one coronary segments (33% in type 2 DM vs. 18% in non diabetic, P = 0.013), whereas 11% of both type 2 DM and non diabetics had stenosis of 50-70% (P = NS). Also type 2 DM patients had a higher number of coronary segments with mixed plaques compared to nondiabetic patients (1.67 +/- 2.01 vs. 1.23 +/- 1.61, P = 0.05), whereas no such differences were observed for non-calcified or calcified plaques. Nearly half (43%) of type 2 DM had coronary artery calcium scores (CACS) >or=400 vs. 29% in non diabetic patients (P = 0.03). Patients with type 2 DM tend to have atherosclerotic plaques which are more likely to be mixed in nature. Future studies need to elucidate the prognostic value of differences in plaque characteristics observed according to type 2 diabetic status</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Section of Cardiology, Medical College of Georgia, Augusta, GA 30912, USA. ibebuogu@yahoo.comJC - 100969716CP - United StatesPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19633998</style></custom1><custom3><style face="normal" font="default">AS - Int J Cardiovasc Imaging. 25(7):717-23, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>561</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Iqbal,N.</style></author><author><style face="normal" font="default"> Ducharme,J.</style></author><author><style face="normal" font="default"> Desai,S.</style></author><author><style face="normal" font="default"> Chambers,S.</style></author><author><style face="normal" font="default"> Terembula,K.</style></author><author><style face="normal" font="default"> Chan,G.W.</style></author><author><style face="normal" font="default"> Shults,J.</style></author><author><style face="normal" font="default"> Leonard,M.B.</style></author><author><style face="normal" font="default"> Kumanyika,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Status of bone mineral density in patients selected for cardiac transplantation</style></title><secondary-title><style face="normal" font="default">Endocrine Practice</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Endocrine Practice</style></full-title></periodical><pages end="712" start="704">704-712</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Bone Density/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Heart Transplantation</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 1406-16-2 (Vitamin D)</style></keyword><keyword><style face="normal" font="default"> 64719-49-9 (25-hydroxyvitamin D)</style></keyword><keyword><style face="normal" font="default"> Absorptiometry,Photon</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Endocrinology</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Femur Neck/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lumbar Vertebrae/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Osteoporosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Outpatients</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Veterans</style></keyword><keyword><style face="normal" font="default"> Vitamin D/aa [Analogs &amp; Derivatives]</style></keyword><keyword><style face="normal" font="default"> Vitamin D/bl [Blood]</style></keyword></keywords><dates><year Day="0" Month="9" Year="2008">2008/9</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To determine the prevalence and correlates of low bone mineral density (BMD) in ambulatory outpatients with end-stage heart failure who were awaiting cardiac transplantation. METHODS: Fifty-five cardiac transplant candidates with end-stage heart failure were enrolled in this study. Bone mineral density at the lumbar spine and proximal femur was determined by dual-energy x-ray absorptiometry. Laboratory studies included serum alkaline phosphatase, calcium, intact parathyroid hormone, and 25-hydroxyvitamin D. RESULTS: The mean proximal femur and lumbar spine Z scores were 0.3 +/- 1.1 and 0.3 +/- 1.5, respectively. The mean BMD was not lower than that of the age-and sex-matched reference population. Z scores were less than -1 in 23% at the lumbar spine and 15% at the proximal femoral neck. On the basis of T scores, osteopenia (T scores between -1 and -2.5) was present in 24% (confidence interval, 13% to 35%) of patients at the lumbar spine and in 20% (confidence interval, 10% to 30%) at the proximal femur; osteoporosis (T scores of less than -2.5) was present in 4% of the study population. Half of the patients in this study sample had elevated intact parathyroid hormone levels, and a third of the patients had low 25-hydroxyvitamin D levels. CONCLUSION: Lumbar spine and hip BMD measurements were not significantly low relative to age and sex in ambulatory patients with heart failure awaiting cardiac transplantation</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Endocrinology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania Section of Endocrinology, Department of Medicine, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA 19104, USAJC - 9607439, dy1CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18996789</style></custom1><custom3><style face="normal" font="default">AS - Endocr Pract. 14(6):704-12, 2008 Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>453</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Irzyniec,T.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Responsiveness of parathyroid hormone secretion to a phosphate load in hypertensive patients with non insulin dependent diabetes mellitus]. [Polish]</style></title><secondary-title><style face="normal" font="default">Endokrynologia Polska</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Endokrynologia Polska</style></full-title></periodical><pages end="188" start="180">180-188</pages><volume><style face="normal" font="default">60</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Diabetes Mellitus,Type 2/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Hypertension/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Parathyroid Hormone/se [Secretion]</style></keyword><keyword><style face="normal" font="default"> *Phosphates/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 0 (Phosphates)</style></keyword><keyword><style face="normal" font="default"> 67-97-0 (Cholecalciferol)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Administration,Oral</style></keyword><keyword><style face="normal" font="default"> Area Under Curve</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Cholecalciferol/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus,Type 2/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Phosphates/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Phosphates/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="5" Year="2009">2009/5</year></dates><isbn><style face="normal" font="default">0423-104X</style></isbn><abstract><style face="normal" font="default">INTRODUCTION: Abnormalities in calcium phosphate (Ca-P) metabolism and Ca-P related hormones are well documented in patients with essential hypertension (EH), but less in patients with non insulin dependent diabetes mellitus (NIDDM). The present study was designed to assess the responsiveness of parathormone (PTH) secretion to an oral phosphate (Pi) load (100 mmol) in patients with EH - NTS and hypertensive patients with NIDDM - CNT. MATERIAL AND METHODS: In 29 patients in NTS group (45.6 +/- 1.3 y), 32 in CNT group (48.4 +/- 0.9 y) and in 23 healthy subjects-GK (42.7 +/- 2.7 y) - 25-OH-D(3), intact PTH, ionized (Ca(2+)) and phosphate (P) were estimated in blood serum before and PTH in 4, 8, 12, 18 and 24 hours, Ca(2+) and P in 2, 4, 6, 8, 10, 12, 18 and 24 hours after an oral administration of Pi. Urinary excretion of calcium and phosphate were also estimated on day before and at the day of an oral Pi load. RESULTS: In NTS group lower basal 25-OH-D(3) serum levels (22.9 +/- 1.7 vs. 30.9 +/- 2 ng/ml; p = 0.02), while in CNT group higher PTH (22.7 +/- +/- 2.2 vs. 15.6 +/- 1.9 pg/ml; p &lt; 0.05) levels were found. Both NTS and CNT patients showed an exaggerated response of PTH secretion to the Pi load (as expressed as the AUC) as compared with GK [757 +/- 51.7 vs. 790 +/- 53.8 vs. 600 +/- 39 (pg/ml)*24 h]. In addition patients in groups NTS and CNT showed a higher calciuria than GK (2.48 +/- 0.2 and 2.42 +/- 0,2 vs. 1.77 +/- 0.2 mmol/d.) and a delayed normalization of plasma P at the day of the Pi load. CONCLUSIONS: 1. Both NTS and CNT groups are characterized by an abnormal calcium and phosphate metabolism and exaggerated response of PTH secretion to an oral phosphate load as compared with GK controls. 2. Probably hypertension and not NIDDM seems to be the leading cause of calcium-phosphate abnormalities in hypertensive diabetic patients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Zaklad Promocji Zdrowia i Pielegniarstwa Srodowiskowego Slaskiego Uniwersytetu Medycznego, Katowice. promzdrow@sum.edu.plOT - Wydzelanie parathormonu stymulowane doustnym obciazeniem fostoranem sodowym u chorych na cukrcyce 2 z nadci&amp;#x015B;nieniem tetniczymJC - ehn, 0370674CP - PolandPT - Controlled Clinical TrialPT - English AbstractPT - Journal ArticleLG - Polish</style></notes><urls/><custom1><style face="normal" font="default">UI - 19569018</style></custom1><custom3><style face="normal" font="default">AS - Endokrynol Pol. 60(3):180-8, 2009 May-Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>311</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Ishigami,K.</style></author><author><style face="normal" font="default"> Uemura,S.</style></author><author><style face="normal" font="default"> Morikawa,Y.</style></author><author><style face="normal" font="default"> Soeda,T.</style></author><author><style face="normal" font="default"> Okayama,S.</style></author><author><style face="normal" font="default"> Nishida,T.</style></author><author><style face="normal" font="default"> Takemoto,Y.</style></author><author><style face="normal" font="default"> Onoue,K.</style></author><author><style face="normal" font="default"> Somekawa,S.</style></author><author><style face="normal" font="default"> Takeda,Y.</style></author><author><style face="normal" font="default"> Kawata,H.</style></author><author><style face="normal" font="default"> Horii,M.</style></author><author><style face="normal" font="default"> Saito,Y.</style></author></authors></contributors><titles><title><style face="normal" font="default">Long-term follow-up of neointimal coverage of sirolimus-eluting stents--evaluation with optical coherence tomography</style></title><secondary-title><style face="normal" font="default">Circulation Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Circulation Journal</style></full-title></periodical><pages end="2307" start="2300">2300-2307</pages><volume><style face="normal" font="default">73</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Angioplasty,Transluminal,Percutaneous Coronary/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Agents/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Drug-Eluting Stents</style></keyword><keyword><style face="normal" font="default"> *Sirolimus/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Thrombosis/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Tomography,Optical Coherence</style></keyword><keyword><style face="normal" font="default"> *Tunica Intima/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> 0 (Cardiovascular Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Platelet Aggregation Inhibitors)</style></keyword><keyword><style face="normal" font="default"> 53123-88-9 (Sirolimus)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angioplasty,Transluminal,Percutaneous Coronary/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cell Proliferation</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Linear Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Platelet Aggregation Inhibitors/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Thrombosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Thrombosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Late stent thrombosis related to delayed neointimal growth is a major concern after drug-eluting stent (DES) implantation. The time course of neointimal growth and risk factors of uncovered stent struts after sirolimus-eluting stent (SES) was studied using optical coherence tomography (OCT). METHODS AND RESULTS: The 60 patients were enrolled and classified into G1 (follow-up period &lt;9 months, n=27), G2 (9-24 months, n=18), and G3 (>25 months, n=15). The time elapsed since SES implantation was associated with a significant increase in mean neointimal area and neointimal thickness, and also with a significant decrease in the number of uncovered stent struts (G1: 14.8%, G2: 11.7%, and G3: 4.1%, P&lt;0.001). However, only 17.6% of implanted SES was completely covered by neointima, even in the G3 period. Small-diameter SES, complex coronary lesions with lipid and calcium content adjacent to stent struts, and diabetes predicted delayed neointimal coverage of SES struts in G1. CONCLUSIONS: Neointima inside SES progressively increases after the routine follow-up period, but only a few SES were completely covered at 3 years after implantation. OCT is a useful modality for assessing neointimal formation after SES implantation, and may give important information about the strategy of antiplatelet therapy after DES implantation</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - First Department of Medicine, Nara Medical University, Kashihara, JapanCM - Comment in: Circ J. 2009 Dec;73(12):2210-1; PMID: 19940371JC - 101137683CP - JapanPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19789417</style></custom1><custom3><style face="normal" font="default">AS - Circ J. 73(12):2300-7, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>448</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Ishiyama,M.</style></author><author><style face="normal" font="default"> Suzuki,E.</style></author><author><style face="normal" font="default"> Katsuda,J.</style></author><author><style face="normal" font="default"> Murase,H.</style></author><author><style face="normal" font="default"> Tajima,Y.</style></author><author><style face="normal" font="default"> Horikawa,Y.</style></author><author><style face="normal" font="default"> Goto,S.</style></author><author><style face="normal" font="default"> Fujita,T.</style></author><author><style face="normal" font="default"> Takeda,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Associations of coronary artery calcification and carotid intima-media thickness with plasma concentrations of vascular calcification inhibitors in type 2 diabetic patients</style></title><secondary-title><style face="normal" font="default">Diabetes Research &amp; Clinical Practice</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Diabetes Research &amp; Clinical Practice</style></full-title></periodical><pages end="196" start="189">189-196</pages><volume><style face="normal" font="default">85</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 2/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Diabetic Angiopathies/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Osteopontin/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Osteoprotegerin/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Hemoglobin A,Glycosylated)</style></keyword><keyword><style face="normal" font="default"> 0 (Osteoprotegerin)</style></keyword><keyword><style face="normal" font="default"> 106441-73-0 (Osteopontin)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age of Onset</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus,Type 2/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Diabetic Angiopathies/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hemoglobin A,Glycosylated/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Ultrasonography</style></keyword></keywords><dates><year Day="0" Month="8" Year="2009">2009/8</year></dates><abstract><style face="normal" font="default">Vascular calcification is frequently accompanied by intima-media thickening, but the associations among these atherosclerotic features and bone-related peptides in diabetic patients are unclear. We enrolled 168 type 2 diabetic patients and 40 non-diabetic subjects consecutively admitted to our hospital. Mean intima-media thickness (mean-IMT) in common carotid arteries was measured by B-mode ultrasonography. Agatston coronary artery calcium score (CACS) was obtained using multidetector-row computed tomography (MDCT). Plasma bone-related peptides osteopontin and osteoprotegerin levels were measured. Diabetic patients had higher mean-IMT (p=0.0002) and log(CACS+1) (p&lt;0.0001) and similar bone-related peptides compared to non-diabetic subjects. In diabetic patients classified into tertiles according to their CACS levels, those with the highest scores showed the highest mean-IMT (p=0.0004) and bone-related peptides (p&lt;0.05) among the groups. log(CACS+1) and mean-IMT were associated (p&lt;0.0001) and were positively correlated with osteopontin (p&lt;0.01) and osteoprotegerin (p&lt;0.01) in diabetic patients. Multivariate analyses revealed that the significant independent determinants of log(CACS+1) were age, duration of diabetes and osteopontin (p&lt;0.0001) and those of mean-IMT were age, hypertension, osteopontin and osteoprotegerin (p&lt;0.0001), respectively. We have demonstrated that vascular calcification in type 2 diabetic patients is frequently accompanied by intima-media thickening, and osteopontin may act as a vascular calcification inhibitor by increasing intima-media thickness</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Diabetes and Endocrinology, Gifu University School of Medicine, Gifu, JapanJC - ebi, 8508335CP - IrelandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19497632</style></custom1><custom3><style face="normal" font="default">AS - Diabetes Res Clin Pract. 85(2):189-96, 2009 Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>33</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Iwasaki,K.</style></author><author><style face="normal" font="default"> Matsumoto,T.</style></author><author><style face="normal" font="default"> Aono,H.</style></author><author><style face="normal" font="default"> Furukawa,H.</style></author><author><style face="normal" font="default"> Samukawa,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Prevalence of non-calcified coronary plaque on 64-slice computed tomography in asymptomatic patients with zero and low coronary artery calcium</style></title><secondary-title><style face="normal" font="default">Canadian Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Canadian Journal of Cardiology</style></full-title></periodical><pages end="380" start="377">377-380</pages><volume><style face="normal" font="default">26</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword></keywords><dates><year Day="0" Month="7" Year="2010">2010/7</year></dates><abstract><style face="normal" font="default">OBJECTIVES: To study the prevalence of noncalcified plaque in asymptomatic low-risk patients with no or mild coronary artery calcium (CAC). METHODS: From 502 patients with coronary risk factors who underwent 64-slice computed tomography, 224 asymptomatic patients were identified with no CAC (n=117) or mild CAC (n=107; defined as patients with Agatston scores from 1 to 100). RESULTS: Patients with no CAC were younger and had diabetes less often. Medications and laboratory data were not significantly different between the two groups. The prevalence of noncalcified plaque was 11.1% in patients with no CAC and 23.4% in the mild CAC group (P=0.0142). Multiple plaques were detected in 2.6% of the group with no CAC and 3.7% of the group with mild CAC (P=0.5934). Significant coronary artery stenosis was found in one patient in the group with no CAC (0.9%) and three patients in the group with mild CAC (2.8%, P=0.3506). CONCLUSIONS: Significant percentages of noncalcified plaque were found in asymptomatic low-risk patients with no or mild coronary calcium</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Okayama Central Hospital, Okayama, Japan. kiwasaki@kyokuto.or.jpCM - Comment in: Can J Cardiol. 2010 Jul;26(7):381; PMID: 20847966JC - chp, 8510280CP - CanadaPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20847965</style></custom1><custom3><style face="normal" font="default">AS - Can J Cardiol. 26(7):377-80, 2010 Jul.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>245</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Iwasaki,K.</style></author><author><style face="normal" font="default"> Matsumoto,T.</style></author><author><style face="normal" font="default"> Aono,H.</style></author><author><style face="normal" font="default"> Furukawa,H.</style></author><author><style face="normal" font="default"> Nagamachi,K.</style></author><author><style face="normal" font="default"> Samukawa,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Distribution of coronary atherosclerosis in patients with coronary artery disease</style></title><secondary-title><style face="normal" font="default">Heart &amp; Vessels</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Heart &amp; Vessels</style></full-title></periodical><pages end="18" start="14">14-18</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword></keywords><dates><year Day="0" Month="1" Year="2010">2010/1</year></dates><abstract><style face="normal" font="default">The distribution of coronary atherosclerosis has not been fully clarified. We measured coronary artery calcium score (CACS) in 624 consecutive patients for the right coronary artery (RCA), left main trunk (LMT), left anterior descending coronary artery (LAD), and left circumflex coronary artery (LCx), then calculated total CACS. Coronary artery calcium score was measured using the Agatston method. We divided these patients into four groups: CACS 1-100 (Group A, n = 267), CACS 101-400 (Group B, n = 160), CACS 401-1000 (Group C, n = 110), and CACS >1000 (Group D, n = 87). In Group A, B, and C, the CACS in LAD was significantly higher than in the other three arteries (P &lt; 0.0001). In Group D, the CACS was not significantly different between LAD and RCA (P = 0.6930). In Groups A, B, and C, coronary artery calcium (CAC) was more frequently found in LAD compared with other arteries (P &lt; 0.0001). However, in Group D the prevalence of CAC was not significantly different among the three arteries (P = 0.4435). Coronary artery calcium was found more frequently in LAD than in the other coronary arteries in patients with mild to high CAC, but not in those with very high CAC</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Okayama Central Hospital, 6-3 Ishimakitamachi, Okayama 700-0017, Japan. iwasaki_k@kohjin.ne.jpJC - her, 8511258CP - JapanPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20091393</style></custom1><custom3><style face="normal" font="default">AS - Heart Vessels. 25(1):14-8, 2010 Jan.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>150</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Jacobs,P.C.</style></author><author><style face="normal" font="default"> Prokop,M.</style></author><author><style face="normal" font="default"> van der,Graaf Y.</style></author><author><style face="normal" font="default"> Gondrie,M.J.</style></author><author><style face="normal" font="default"> Janssen,K.J.</style></author><author><style face="normal" font="default"> de Koning,H.J.</style></author><author><style face="normal" font="default"> Isgum,I.</style></author><author><style face="normal" font="default"> van Klaveren,R.J.</style></author><author><style face="normal" font="default"> Oudkerk,M.</style></author><author><style face="normal" font="default"> van,Ginneken B.</style></author><author><style face="normal" font="default"> Mali,W.P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Comparing coronary artery calcium and thoracic aorta calcium for prediction of all-cause mortality and cardiovascular events on low-dose non-gated computed tomography in a high-risk population of heavy smokers</style></title><secondary-title><style face="normal" font="default">Atherosclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Atherosclerosis</style></full-title></periodical><pages end="462" start="455">455-462</pages><volume><style face="normal" font="default">209</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aorta,Thoracic/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aorta,Thoracic/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Aortic Diseases</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Netherlands/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Coronary artery calcium (CAC) and thoracic aorta calcium (TAC) can be detected simultaneously on low-dose, non-gated computed tomography (CT) scans. CAC has been shown to predict cardiovascular (CVD) and coronary (CHD) events. A comparable association between TAC and CVD events has yet to be established, but TAC could be a more reproducible alternative to CAC in low-dose, non-gated CT. This study compared CAC and TAC as independent predictors of all-cause mortality and cardiovascular events in a population of heavy smokers using low-dose, non-gated CT. METHODS: Within the NELSON study, a population-based lung cancer screening trial, the CT screen group consisted of 7557 heavy smokers aged 50-75 years. Using a case-cohort study design, CAC and TAC scores were calculated in a total of 958 asymptomatic subjects who were followed up for all-cause death, and CVD, CHD and non-cardiac events (stroke, aortic aneurysm, peripheral arterial occlusive disease). We used Cox proportional-hazard regression to compute hazard ratios (HRs) with adjustment for traditional cardiovascular risk factors. RESULTS: A close association between the prevalence of TAC and increasing levels of CAC was established (p&lt;0.001). Increasing CAC and TAC risk categories were associated with all-cause mortality (p for trend=0.01 and 0.001, respectively) and CVD events (p for trend &lt;0.001 and 0.03, respectively). Compared with the lowest quartile (reference category), multivariate-adjusted HRs across categories of CAC were higher (all-cause mortality, HR: 9.13 for highest quartile; CVD events, HR: 4.46 for highest quartile) than of TAC scores (HR: 5.45 and HR: 2.25, respectively). However, TAC is associated with non-coronary events (HR: 4.69 for highest quartile, p for trend=0.01) and CAC was not (HR: 3.06 for highest quartile, p for trend=0.40). CONCLUSIONS: CAC was found to be a stronger predictor than TAC of all-cause mortality and CVD events in a high-risk population of heavy smokers scored on low-dose, non-gated CT. TAC, however, is stronger associated with non-cardiac events than CAC and could prove to be a preferred marker for these events. Copyright 2009 Elsevier Ireland Ltd. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Julius Center for Health Sciences and Primary Care, Department of Radiology, University Medical Center Utrecht, Netherlands. p.c.a.jacobs@umcutrecht.nlJC - 95x, 0242543CP - IrelandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19875116</style></custom1><custom3><style face="normal" font="default">AS - Atherosclerosis. 209(2):455-62, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>176</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Jacobs,P.C.</style></author><author><style face="normal" font="default"> Isgum,I.</style></author><author><style face="normal" font="default"> Gondrie,M.J.</style></author><author><style face="normal" font="default"> Mali,W.P.</style></author><author><style face="normal" font="default"> van,Ginneken B.</style></author><author><style face="normal" font="default"> Prokop,M.</style></author><author><style face="normal" font="default"> van der,Graaf Y.</style></author></authors></contributors><titles><title><style face="normal" font="default">Coronary artery calcification scoring in low-dose ungated CT screening for lung cancer: interscan agreement</style></title><secondary-title><style face="normal" font="default">AJR</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">AJR</style></full-title></periodical><pages end="1249" start="1244">1244-1249</pages><volume><style face="normal" font="default">American</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Lung Neoplasms/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Lung Neoplasms/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/ut [Utilization]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Mass Screening/ut [Utilization]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Netherlands/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Radiation Dosage</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> Respiratory-Gated Imaging Techniques/ut [Utilization]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="5" Year="2010">2010/5</year></dates><abstract><style face="normal" font="default">OBJECTIVE: In previous studies detection of coronary artery calcification (CAC) with low-dose ungated MDCT performed for lung cancer screening has been compared with detection with cardiac CT. We evaluated the interscan agreement of CAC scores from two consecutive low-dose ungated MDCT examinations. SUBJECTS AND METHODS: The subjects were 584 participants in the screening segment of a lung cancer screening trial who underwent two low-dose ungated MDCT examinations within 4 months (mean, 3.1 +/- 0.6 months) of a baseline CT examination. Agatston score, volume score, and calcium mass score were measured by two observers. Interscan agreement of stratification of participants into four Agatston score risk categories (0, 1-100, 101-400, > 400) was assessed with kappa values. Interscan variability and 95% repeatability limits were calculated for all three calcium measures and compared by repeated measures analysis of variance. RESULTS: An Agatston score > 0 was detected in 443 baseline CT examinations (75.8%). Interscan agreement of the four risk categories was good (kappa = 0.67). The Agatston scores were in the same risk category in both examinations in 440 cases (75.3%); 578 participants (99.0%) had scores differing a maximum of one category. Furthermore, mean interscan variability ranged from 61% for calcium volume score to 71% for Agatston score (p &lt; 0.01). A limitation of this study was that no comparison of CAC scores between low-dose ungated CT and the reference standard ECG-gated CT was performed. CONCLUSION: Cardiovascular disease risk stratification with low-dose ungated MDCT is feasible and has good interscan agreement of stratification of participants into Agatston score risk categories. High mean interscan variability precludes the use of this technique for monitoring CAC scores for individual patients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Radiology, University Medical Center Utrecht, Utrecht, The NetherlandsJC - 3ae, 7708173CP - United StatesPT - Comparative StudyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20410410</style></custom1><custom3><style face="normal" font="default">AS - AJR Am J Roentgenol. 194(5):1244-9, 2010 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>438</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Jakubeniene,M.</style></author><author><style face="normal" font="default"> Irnius,A.</style></author><author><style face="normal" font="default"> Chaker,G.A.</style></author><author><style face="normal" font="default"> Paliulis,J.M.</style></author><author><style face="normal" font="default"> Bechelis,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Post-mortem investigation of calcium content in liver, heart, and skeletal muscle in accidental hypothermia cases</style></title><secondary-title><style face="normal" font="default">Forensic Science International</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Forensic Science International</style></full-title></periodical><pages end="90" start="87">87-90</pages><volume><style face="normal" font="default">190</style></volume><number><style face="normal" font="default">1-3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> *Heart Ventricles/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> *Hypothermia/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Liver/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> *Muscle,Skeletal/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> 0 (Central Nervous System Depressants)</style></keyword><keyword><style face="normal" font="default"> 64-17-5 (Ethanol)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Autopsy</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Cause of Death</style></keyword><keyword><style face="normal" font="default"> Central Nervous System Depressants/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Ethanol/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Fatty Liver/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Flame Ionization</style></keyword><keyword><style face="normal" font="default"> Forensic Pathology</style></keyword><keyword><style face="normal" font="default"> Gastric Mucosa/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Spectrophotometry,Atomic</style></keyword></keywords><dates><year Day="10" Month="9" Year="2009">2009/9/10</year></dates><abstract><style face="normal" font="default">The identification of hypothermia as cause of the death was always quite problematic in the field of forensic medicine. The aim of the present study was to verify the determination of calcium content in post-mortem liver, heart, and skeletal muscle samples as the biochemical marker defining hypothermia as the cause of death. The study involved 43 autopsy cases in which the circumstances of death indicated the effects of overcooling. The control group consisted of material collected from the corpses of 30 persons who were not exposed to low temperatures but died due to technical injuries (n=5), asphyxia (n=6), intoxication with ethanol and other substances (n=8), and acute myocardial infarction/ischemia (n=11). The concentration of calcium in autopsy samples was determined applying flame atomic absorption spectroscopy. Our study showed no significant differences of calcium content in tissues of persons who died due to hypothermia, over those who died in normothermic conditions</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Institute of Forensic Medicine of Mykolas Romeris University, Didlaukio str. 86E, Vilnius LT-08303, Lithuania. marija.jakubeniene@gmail.comJC - f49, 7902034CP - IrelandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19540681</style></custom1><custom3><style face="normal" font="default">AS - Forensic Sci Int. 190(1-3):87-90, 2009 Sep 10.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>126</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Javadrashid,R.</style></author><author><style face="normal" font="default"> Salehi,A.</style></author><author><style face="normal" font="default"> Tarzamni,M.K.</style></author><author><style face="normal" font="default"> Aslanabadi,N.</style></author><author><style face="normal" font="default"> Pak,N.</style></author></authors></contributors><titles><title><style face="normal" font="default">Diagnostic efficacy of coronary calcium score in the assessment of significant coronary artery stenosis</style></title><secondary-title><style face="normal" font="default">Kardiologia Polska</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Kardiologia Polska</style></full-title></periodical><pages end="291" start="285">285-291</pages><volume><style face="normal" font="default">68</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> *Coronary Stenosis/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Coronary Stenosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Area Under Curve</style></keyword><keyword><style face="normal" font="default"> Biological Markers/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> ROC Curve</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed/mt [Methods]</style></keyword></keywords><dates><year Day="0" Month="3" Year="2010">2010/3</year></dates><isbn><style face="normal" font="default">0022-9032</style></isbn><abstract><style face="normal" font="default">BACKGROUND: Coronary artery calcium score (CCS) is a quantitative assessment of calcifications detectable by multidetector computed tomography (MDCT). AIM: To evaluate diagnostic accuracy of CCS to detect significant stenosis in coronary arteries in symptomatic patients. METHODS: The study population included consecutive symptomatic patients with suspected coronary artery disease (CAD) who were referred for coronary angiography. The group included 158 patients (64.6% males) who were all evaluated by unenhanced 64-slice computed tomography where calcium was quantified according to the Agatston method. The ROC curves were constructed to evaluate the discriminating power of the total CCS and CCS for each individual coronary artery in predicting the presence of significant stenosis. RESULTS: The prevalence of significant CAD strongly increased with higher CCS. The area under the curve (AUC) for total CCS for diagnosing significant stenosis (> or = 50%) in at least one coronary artery was 0.83 (95% CI 0.74-0.92). Using the cut-off value of CCS > or = 7.7 at least one significant coronary stenosis was detected with the sensitivity and specificity of 86% and 71%, respectively. Significant coronary artery stenosis was better predicted by measuring CCS for individual coronary arteries than total CCS. The AUC of CCS for significant stenosis of each coronary artery was 0.80 for the right coronary artery (RCA), 0.72 for the left main (LM), 0.73 for the left anterior descending (LAD) and 0.76 for the left circumflex arteries (LCX). The optimal cut-off point was estimated for CCS of each coronary artery. It was set at > or = 3.1 for RCA, > or = 7.7 for LM, > or = 9.5 for LAD and > or = 4.5 for LCX. Positive and negative predictive values for an intact artery using a CCS of zero were 92.8% and 83.8%, respectively. Diagnostic performance of CCS for predicting stenosis of LM and LCX arteries was better in patients over age 65 than in younger patients. CONCLUSIONS: Coronary artery calcium score is useful in predicting coronary artery stenosis, especially in subjects in whom invasive diagnostic or therapeutic utilities seem to be used untimely. The current study suggests an optimal cut-off value of total CCS > or = 7.7 for detecting significant stenosis, and underlines the better predictive value for CCS of individual arteries</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Radiology, Tabriz University of Medical Sciences, Tabriz, IranCM - Comment in: Kardiol Pol. 2010 Mar;68(3):292-3; PMID: 20491180JC - ku4, 0376352CP - PolandPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20411452</style></custom1><custom3><style face="normal" font="default">AS - Kardiol Pol. 68(3):285-91, 2010 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>62</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Jenkins,D.J.</style></author><author><style face="normal" font="default"> Srichaikul,K.</style></author><author><style face="normal" font="default"> Wong,J.M.</style></author><author><style face="normal" font="default"> Kendall,C.W.</style></author><author><style face="normal" font="default"> Bashyam,B.</style></author><author><style face="normal" font="default"> Vidgen,E.</style></author><author><style face="normal" font="default"> Lamarche,B.</style></author><author><style face="normal" font="default"> Rao,A.V.</style></author><author><style face="normal" font="default"> Jones,P.J.</style></author><author><style face="normal" font="default"> Josse,R.G.</style></author><author><style face="normal" font="default"> Jackson,C.J.</style></author><author><style face="normal" font="default"> Ng,V.</style></author><author><style face="normal" font="default"> Leong,T.</style></author><author><style face="normal" font="default"> Leiter,L.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Supplemental barley protein and casein similarly affect serum lipids in hypercholesterolemic women and men</style></title><secondary-title><style face="normal" font="default">Journal of Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Nutrition</style></full-title></periodical><pages end="1637" start="1633">1633-1637</pages><volume><style face="normal" font="default">140</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Caseins/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> *Hordeum/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> *Hypercholesterolemia/dh [Diet Therapy]</style></keyword><keyword><style face="normal" font="default"> *Lipids/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Plant Proteins/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> 0 (Antilipemic Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Caseins)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipids)</style></keyword><keyword><style face="normal" font="default"> 0 (Plant Proteins)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Antilipemic Agents</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Bread/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Caseins/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> Cross-Over Studies</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Dietary Supplements</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Plant Proteins/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="9" Year="2010">2010/9</year></dates><abstract><style face="normal" font="default">High-protein diets have been advocated for weight loss and the treatment of diabetes. Yet animal protein sources are often high in saturated fat and cholesterol. Vegetable protein sources, by contrast, are low in saturated fat and without associated cholesterol. We have therefore assessed the effect on serum lipids of raising the protein intake by 5% using a cereal protein, barley protein, as part of a standard therapeutic diet. Twenty-three hypercholesterolemic men and postmenopausal women completed a randomized crossover study comparing a bread enriched with either barley protein or calcium caseinate [30 g protein, 8374 kJ (2000 kcal)] taken separately as two 1-mo treatment phases with a minimum 2-wk washout. Body weight and diet history were collected weekly during each treatment. Fasting blood samples were obtained at wk 0, 2, and 4. Palatability, satiety, and compliance were similar for both the barley protein- and casein-enriched breads, with no differences between the treatments in effects on serum LDL cholesterol or C-reactive protein, measures of oxidative stress, or blood pressure. Nevertheless, because no adverse effects were observed on cardiovascular risk factors, barley protein remains an additional option for raising the protein content of the diet</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Clinical Nutrition and Risk Factor Modification Center, St. Michael's Hospital, Toronto, CanadaJC - jev, 0404243CP - United StatesPT - Journal ArticlePT - Randomized Controlled TrialPT - Research Support, Non-U.S. Gov'tSI - ClinicalTrials.govSA - ClinicalTrials.gov/NCT00334308NO - (Canada Canadian Institutes of Health Research)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20668250</style></custom1><custom3><style face="normal" font="default">AS - J Nutr. 140(9):1633-7, 2010 Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>193</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Jennings,L.A.</style></author><author><style face="normal" font="default"> Auerbach,A.D.</style></author><author><style face="normal" font="default"> Maselli,J.</style></author><author><style face="normal" font="default"> Pekow,P.S.</style></author><author><style face="normal" font="default"> Lindenauer,P.K.</style></author><author><style face="normal" font="default"> Lee,S.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture</style></title><secondary-title><style face="normal" font="default">Journal of the American Geriatrics Society</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of the American Geriatrics Society</style></full-title></periodical><pages end="657" start="650">650-657</pages><volume><style face="normal" font="default">58</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Hip Fractures</style></keyword><keyword><style face="normal" font="default"> *Hospitalization</style></keyword><keyword><style face="normal" font="default"> *Osteoporosis/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Physician's Practice Patterns/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> 0 (Bone Density Conservation Agents)</style></keyword><keyword><style face="normal" font="default"> 1406-16-2 (Vitamin D)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Bone Density Conservation Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Calcium/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Drug Therapy,Combination</style></keyword><keyword><style face="normal" font="default"> Drug Utilization/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Guideline Adherence/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Hip Fractures/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Hip Fractures/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalization/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Osteoporosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Practice Guidelines as Topic</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> United States/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Vitamin D/tu [Therapeutic Use]</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Although osteoporosis treatment can dramatically reduce fracture risk, rates of treatment after hip fracture remain low. In-hospital initiation of recommended medications has improved outcomes in heart disease; hospitalization for hip fracture may represent a similar opportunity for improvement. The objective of this study was to examine rates of in-hospital treatment with a combination of calcium and vitamin D (Cal+D) and antiresorptive or bone-forming medications in patients hospitalized for hip fractures DESIGN: Observational cohort. SETTING: Three hundred eighteen hospitals in the United States. PARTICIPANTS: Fifty-one thousand three hundred forty-six patients aged 65 and older hospitalized for osteoporotic hip fracture. MEASUREMENTS: In-hospital administration of Cal+D and antiresorptive or bone-forming medications. RESULTS: Three thousand four hundred five patients (6.6%) received Cal+D anytime after a procedure to correct femoral fracture; 3,763 patients (7.3%) received antiresorptive or bone-forming medications. Only 1,023 patients (2.0%) were prescribed ideal therapy, receiving Cal+D and an antiresorptive or bone-forming medication. Treatment rates remained low across virtually all patient-, provider-, and hospital-level characteristics. The strongest predictor of treatment with Cal+D was the receipt of an antiresorptive or bone-forming medication (adjusted odds ratio=5.50, 95% confidence interval=4.84-6.25), but only 27.2% of patients who received these medications also received Cal+D. CONCLUSION: Rates of in-hospital initiation of osteoporosis treatment for patients with hip fracture are low and may represent an opportunity to improve care</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - San Francisco VA Medical Center, and Department of Medicine, University of California San Francisco, San Francisco, California, USA. lee.jennings@ucsf.eduCM - Comment in: J Am Geriatr Soc. 2010 Apr;58(4):762-4; PMID: 20398160JC - 7503062, h6vCP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - 5R01HL086473 (United States NHLBI NIH HHS)NO - 5R21AG026668 (United States NIA NIH HHS)NO - KL2RR024130 (United States NCRR NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20398147</style></custom1><custom3><style face="normal" font="default">AS - J Am Geriatr Soc. 58(4):650-7, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>160</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Jenny,N.S.</style></author><author><style face="normal" font="default"> Brown,E.R.</style></author><author><style face="normal" font="default"> Detrano,R.</style></author><author><style face="normal" font="default"> Folsom,A.R.</style></author><author><style face="normal" font="default"> Saad,M.F.</style></author><author><style face="normal" font="default"> Shea,S.</style></author><author><style face="normal" font="default"> Szklo,M.</style></author><author><style face="normal" font="default"> Herrington,D.M.</style></author><author><style face="normal" font="default"> Jacobs,D.R.,Jr.</style></author></authors></contributors><titles><title><style face="normal" font="default">Associations of inflammatory markers with coronary artery calcification: results from the Multi-Ethnic Study of Atherosclerosis</style></title><secondary-title><style face="normal" font="default">Atherosclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Atherosclerosis</style></full-title></periodical><pages end="229" start="226">226-229</pages><volume><style face="normal" font="default">209</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *C-Reactive Protein/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels</style></keyword><keyword><style face="normal" font="default"> *Fibrinogen/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> *Inflammation/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Interleukin-6/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Interleukin-6)</style></keyword><keyword><style face="normal" font="default"> 9001-32-5 (Fibrinogen)</style></keyword><keyword><style face="normal" font="default"> 9007-41-4 (C-Reactive Protein)</style></keyword><keyword><style face="normal" font="default"> African Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Asian Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcinosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Ethnic Groups</style></keyword><keyword><style face="normal" font="default"> European Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hispanic Americans</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="3" Year="2010">2010/3</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Inflammatory markers predict coronary heart disease (CHD). However, associations with coronary artery calcium (CAC), a marker of subclinical CHD, are not established. METHODS: We examined cross-sectional associations of C-reactive protein (CRP), interleukin-6 (IL-6) and fibrinogen with CAC presence (Agatston score>0 by computed tomography) in 6783 Multi-Ethnic Study of Atherosclerosis (MESA) participants. RESULTS: In all participants, those in the highest, compared to lowest, quartile of CRP had a relative risk (RR, 95% confidence interval) of 1.13 (1.06-1.19; p&lt;0.01) for CAC in age, sex and ethnicity adjusted models. For highest versus lowest quartiles, relative risks were 1.22 (1.15-1.30; p&lt;0.01) for IL-6 and 1.18 (1.11-1.24; p&lt;0.01) for fibrinogen. Adjusting for CHD risk factors (smoking, diabetes, blood pressure, obesity and dyslipidemia) attenuated RRs. RRs for CAC were 1.05 (0.99-1.12; p=0.63) for CRP, 1.12 (1.06-1.20; p&lt;0.01) for IL-6 and 1.09 (1.02-1.16; p=0.01) for fibrinogen in multivariable adjusted models. Results were similar for men and women and across ethnic groups. CONCLUSION: Inflammatory markers were weakly associated with CAC presence and burden in MESA. Our data support the hypothesis that inflammatory biomarkers and CAC reflect distinct pathophysiology</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Pathology, University of Vermont College of Medicine, Burlington, VT 05446, USA. Nancy.Jenny@uvm.eduJC - 95x, 0242543CP - IrelandPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - N01-HC-95159 (United States NHLBI NIH HHS)NO - N01-HC-95165 (United States NHLBI NIH HHS)NO - N01-HC-95169 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19766217</style></custom1><custom3><style face="normal" font="default">AS - Atherosclerosis. 209(1):226-9, 2010 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>335</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Jiang,H.J.</style></author><author><style face="normal" font="default"> Huang,X.J.</style></author><author><style face="normal" font="default"> Tan,Y.C.</style></author><author><style face="normal" font="default"> Liu,D.Z.</style></author><author><style face="normal" font="default"> Wang,L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Core decompression and implantation of calcium phosphate cement/Danshen drug delivery system for treating ischemic necrosis of femoral head at Stages I, II and III of antigen reactive cell opsonization</style></title><secondary-title><style face="normal" font="default">Chinese Journal of Traumatology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Chinese Journal of Traumatology</style></full-title></periodical><pages end="290" start="285">285-290</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Bone Cements</style></keyword><keyword><style face="normal" font="default"> *Calcium Phosphates/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Decompression,Surgical</style></keyword><keyword><style face="normal" font="default"> *Drug Delivery Systems</style></keyword><keyword><style face="normal" font="default"> *Femur Head Necrosis/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> *Salvia miltiorrhiza</style></keyword><keyword><style face="normal" font="default"> 0 (Bone Cements)</style></keyword><keyword><style face="normal" font="default"> 0 (Calcium Phosphates)</style></keyword><keyword><style face="normal" font="default"> 10103-46-5 (calcium phosphate)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Femur Head Necrosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Femur Head/bs [Blood Supply]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Ischemia/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medicine,Chinese Traditional</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><isbn><style face="normal" font="default">1008-1275</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: To introduce a new method using calcium phosphate cement/Danshen drug delivery system for treating ischemic necrosis of the femoral head and evaluate its curative effect. METHODS: From May 2000 to June 2005, 48 adult patients (54 hips) with ischemic necrosis of the femoral head at Stages I, II and III of antigen reactive cell opsonization (ARCO) were treated with implantation of calcium phosphate cement/Danshen drug delivery system in the involved femoral head. The operation consisted of removal of the necrotic bone under weight-loading cartilage and the implantation of phosphate cement/Danshen drug delivery system, and all manipulations were made percutaneously through a bone tunnel in the trochanter. The functions of the hip joint were evaluated and X-ray films were taken preoperatively and postoperatively. RESULTS: Postoperative follow-up was 45.5 months on average, ranging from 27 to 78 months. According to the evaluation criterion of "Dandong 1995" for therapeutic effect of adult ischemic necrosis of the femoral head, the therapeutic effects were excellent in 33 hips, good in 17, fair in 3 and poor in 1, with the excellent and good rate of 92.6%. CONCLUSIONS: This method is relatively simple with little invasion. It not only improves the microcirculation of the femoral head by local application of traditional Chinese medicine, but also provides mechanic buttress in the weight-loading area to prevent collapse during repairing, which is beneficial to repair and reconstruction of femoral head. It may be a choice of minimal invasion surgery for ischemic necrosis of the femoral head at Stages I, II and III of ARCO</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Institute of Composite Material, Tianjin University, Tianjin 300072, China. boneman@163.comJC - 100886162CP - ChinaPT - Case ReportsPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19788846</style></custom1><custom3><style face="normal" font="default">AS - Chin J Traumatol. 12(5):285-90, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>80</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Jim,M.H.</style></author><author><style face="normal" font="default"> Hau,W.K.</style></author><author><style face="normal" font="default"> Ko,R.L.</style></author><author><style face="normal" font="default"> Siu,C.W.</style></author><author><style face="normal" font="default"> Ho,H.H.</style></author><author><style face="normal" font="default"> Yiu,K.H.</style></author><author><style face="normal" font="default"> Lau,C.P.</style></author><author><style face="normal" font="default"> Chow,W.H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Virtual histology by intravascular ultrasound study on degenerative aortocoronary saphenous vein grafts</style></title><secondary-title><style face="normal" font="default">Heart &amp; Vessels</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Heart &amp; Vessels</style></full-title></periodical><pages end="181" start="175">175-181</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Bypass</style></keyword><keyword><style face="normal" font="default"> *Graft Occlusion,Vascular/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Saphenous Vein/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Ultrasonography,Interventional</style></keyword><keyword><style face="normal" font="default"> 0 (Lipids)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angioplasty,Transluminal,Percutaneous Coronary</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Chi-Square Distribution</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Bypass</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Bypass/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> Graft Occlusion,Vascular/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Graft Occlusion,Vascular/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Graft Occlusion,Vascular/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Linear Models</style></keyword><keyword><style face="normal" font="default"> Lipids/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Saphenous Vein/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> Saphenous Vein/tr [Transplantation]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="5" Year="2010">2010/5</year></dates><abstract><style face="normal" font="default">Data of virtual histology (VH) acquired by intravascular ultrasound (IVUS) on saphenous vein graft (SVG) lesions is lacking. This study sought to report the VH IVUS findings in degenerative aortocoronary SVG lesions and correlate various types of plaque compositions (fibrous, fibro-fatty, dense calcium, and necrotic core) with different clinical and lesion characteristics. Virtual histology IVUS was performed on SVG in 38 symptomatic patients with a history of coronary artery bypass grafting, who underwent percutaneous coronary intervention on either native vessels or SVG. Measurements were made at the image slice with the smallest lumen. A total of 54 SVG lesions were analyzed; the mean graft age was 13.7 +/- 4.0 years. The mean vessel size was 5.0 +/- 1.0 mm; plaque area was 13.4 +/- 7.3 mm(2), and plaque burden was 63.0% +/- 15.0%. Fibrous tissue represented the major plaque component (62.1% +/- 17.1%). Lesions with a plaque burden of >or=70% were associated with positive remodeling, larger vessel size, higher percentage of fibro-fatty tissue, but lower percentage of dense calcium. Plaque burden was found to be positively correlated with remodeling index (r = 0.37, P = 0.01) and % fibro-fatty tissue (r = 0.49, P &lt; 0.001) but negatively correlated with % dense calcium (r= -0.31, P = 0.03). The severity of SVG atherosclerosis paralleled with a proportional increase in fibro-fatty tissue. Unstable plaques in SVG were associated with positive remodeling, lipid-rich atheroma, and less calcium deposition, similar to the VH IVUS findings in native coronary arteries</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Cardiac Medical Unit, Grantham Hospital, 125 Wong Chuk Hang Road, Hong Kong, China. jimmanh2002@yahoo.comJC - her, 8511258CP - JapanPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20512443</style></custom1><custom3><style face="normal" font="default">AS - Heart Vessels. 25(3):175-81, 2010 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>213</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Johnson,G.J.</style></author><author><style face="normal" font="default"> Leis,L.A.</style></author><author><style face="normal" font="default"> Bach,R.R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Tissue factor activity of blood mononuclear cells is increased after total knee arthroplasty</style></title><secondary-title><style face="normal" font="default">Thrombosis &amp; Haemostasis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Thrombosis &amp; Haemostasis</style></full-title></periodical><pages end="734" start="728">728-734</pages><volume><style face="normal" font="default">102</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Arthroplasty,Replacement,Knee/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Leukocytes,Mononuclear/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Thromboplastin/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Venous Thromboembolism/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Venous Thromboembolism/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 9035-58-9 (Thromboplastin)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Blood Coagulation</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Leukocytes,Mononuclear/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> Leukocytes,Mononuclear/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Thromboplastin/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Thromboplastin/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> Venous Thromboembolism/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Venous Thromboembolism/pa [Pathology]</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><isbn><style face="normal" font="default">0340-6245</style></isbn><abstract><style face="normal" font="default">Tissue factor (TF) is present in small quantities in normal blood and is reported to be elevated in arterial and venous thrombosis. Patients undergoing total knee arthoplasty (TKA) are at high risk of post-operative venous thromboembolism (VTE). To evaluate the possible contribution of elevated blood TF to VTE risk, we performed serial studies of peripheral blood mononuclear cell (PBMC) functional TF procoagulant activity (PCA) in 19 patients after TKA. PBMC and platelet TF PCA were measured by a functional, clot-based assay following decryption with a calcium ionophore. Plasma TF antigen levels were measured by ELISA. All subjects received chemoprophylaxis and none had VTE. After TKA total TF PCA of PBMC was elevated in 19 of 19 subjects. The peak increase above preoperative levels was 1.1-13.6 fold (>two-fold in 58% and >three-fold in 42%). Median TF PCA of PBMC was not elevated following tourniquet removal, but it was significantly elevated on postoperative days 1 and 2. Thereafter, it decreased to near preoperative values at day 6. Neither platelet TF PCA nor plasma TF antigen levels increased significantly. Since the PBMC count did not rise, the increase in TF PCA was attributable to cell synthesis. The increase in blood TF PCA preceded the median time of diagnosis of venous thromboembolism after TKA established previously. These observations indicate a) TKA stimulates synthesis of encrypted PBMC TF PCA which is likely to contribute to the pathophysiology of VTE; b) TF antigen is not a reliable indicator of TF PCA</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Hematology-Oncology (111E), VA Medical Center, 1 Veterans Drive, Minneapolis, MN 55417, USA. johns337@umn.eduJC - vq7, 7608063CP - GermanyPT - Journal ArticlePT - Research Support, U.S. Gov't, Non-P.H.SLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19806259</style></custom1><custom3><style face="normal" font="default">AS - Thromb Haemost. 102(4):728-34, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>177</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Johnson,K.M.</style></author><author><style face="normal" font="default"> Dowe,D.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">The detection of any coronary calcium outperforms Framingham risk score as a first step in screening for coronary atherosclerosis</style></title><secondary-title><style face="normal" font="default">AJR</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">AJR</style></full-title></periodical><pages end="1243" start="1235">1235-1243</pages><volume><style face="normal" font="default">American</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/ut [Utilization]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Health Status Indicators</style></keyword><keyword><style face="normal" font="default"> *Pattern Recognition,Automated/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/ut [Utilization]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> United States/ep [Epidemiology]</style></keyword></keywords><dates><year Day="0" Month="5" Year="2010">2010/5</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The Framingham risk score is often recommended as the starting point for coronary disease screening. We compared the sensitivity of the Framingham risk score for moderate or greater degrees of atherosclerosis to the sensitivity achieved by simple observation of whether any coronary calcium is present. The reference standard was plaque burden as determined by coronary CT angiography. MATERIALS AND METHODS: Of 1,416 men (mean age, 51.4 +/- 9.9 [SD] years) and 707 women (56.9 +/- 10.6 years), most were asymptomatic. Plaque burden (segment plaque score) and stenoses burden (Duke prognostic score) were estimated. A segment plaque score >or= 4 or a Duke prognostic score >or= 3 indicated moderate or greater disease burden. RESULTS: For a segment plaque score >or= 4, the presence of any calcium was 98% sensitive in men and 97% sensitive in women, whereas a Framingham risk score >or= 10% was 74% sensitive in men and 36% sensitive in women. The negative likelihood ratio for the presence of calcium was 0.04 in subjects of either sex, whereas, for a Framingham risk score &lt;or= 10%, the negative likelihood ratio was 0.38 in men and 0.71 in women. For a Duke prognostic score >or= 3, calcium was 97% sensitive in men and 92% sensitive in women, whereas a Framingham risk score >or= 10% was 88% sensitive in men and 35% sensitive in women. The negative likelihood ratio of calcium presence was 0.05 in men and 0.13 in women, whereas the negative likelihood ratio for a Framingham risk score &lt;or= 10% was 0.20 in men and 0.75 in women. CONCLUSION: If subjects are excluded from further screening because they are in the Framingham low-risk category, almost two thirds of women and a quarter of men with substantial atherosclerosis will be missed. In contrast, the simple observation of any coronary calcium is highly sensitive and moderately specific</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Diagnostic Radiology, Yale University School of Medicine, 17 Hillhouse Ave, New Haven, CT 06510, USA. kevin.johnson@yale.eduJC - 3ae, 7708173CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20410409</style></custom1><custom3><style face="normal" font="default">AS - AJR Am J Roentgenol. 194(5):1235-43, 2010 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>313</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Joo,M.</style></author><author><style face="normal" font="default"> Bae,W.K.</style></author><author><style face="normal" font="default"> Kim,N.H.</style></author><author><style face="normal" font="default"> Han,S.R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Colonic mucosal necrosis following administration of calcium polystryrene sulfonate (Kalimate) in a uremic patient</style></title><secondary-title><style face="normal" font="default">Journal of Korean Medical Science</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Korean Medical Science</style></full-title></periodical><pages end="1211" start="1207">1207-1211</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Colon/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Intestinal Mucosa/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Necrosis/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> *Polystyrenes/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Uremia/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> 0 (Polystyrenes)</style></keyword><keyword><style face="normal" font="default"> 28210-41-5 (polystyrene sulfonic acid)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Gastrointestinal Hemorrhage/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperkalemia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Necrosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Necrosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Polystyrenes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><abstract><style face="normal" font="default">Colonic necrosis is known as a rare complication following the administration of Kayexalate (sodium polystryrene sulfonate) in sorbitol. We report a rare case of colonic mucosal necrosis following Kalimate (calcium polystryrene sulfonate), an analogue of Kayexalate without sorbitol in a 34-yr-old man. He had a history of hypertension and uremia. During the management of intracranial hemorrhage, hyperkalemia developed. Kalimate was administered orally and as an enema suspended in 20% dextrose water to treat hyperkalemia. Two days after administration of Kalimate enema, he had profuse hematochezia, and a sigmoidoscopy showed diffuse colonic mucosal necrosis in the rectum and sigmoid colon. Microscopic examination of random colonic biopsies by two consecutive sigmoidoscopies revealed angulated crystals with a characteristic crystalline mosaic pattern on the ulcerated mucosa, which were consistent with Kayexalate crystals. Hematochezia subsided with conservative treatment after a discontinuance of Kalimate administration</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Pathology, Inje University Ilsan Paik Hospital, Ilsan, Korea. mjoo@paik.ac.krJC - ah4, 8703518CP - Korea (South)PT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19949685</style></custom1><custom3><style face="normal" font="default">AS - J Korean Med Sci. 24(6):1207-11, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>112</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Jorde,R.</style></author><author><style face="normal" font="default"> Sneve,M.</style></author><author><style face="normal" font="default"> Torjesen,P.</style></author><author><style face="normal" font="default"> Figenschau,Y.</style></author><author><style face="normal" font="default"> Hansen,J.B.</style></author></authors></contributors><titles><title><style face="normal" font="default">Parameters of the thrombogram are associated with serum 25-hydroxyvitamin D levels at baseline, but not affected during supplementation with vitamin D</style></title><secondary-title><style face="normal" font="default">Thrombosis Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Thrombosis Research</style></full-title></periodical><pages end="e213" start="e210">e210-e213</pages><volume><style face="normal" font="default">125</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Dietary Supplements</style></keyword><keyword><style face="normal" font="default"> *Obesity/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Obesity/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> *Thrombosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Thrombosis/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Ultraviolet Therapy/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> *Vitamin D/aa [Analogs &amp; Derivatives]</style></keyword><keyword><style face="normal" font="default"> 1406-16-2 (Vitamin D)</style></keyword><keyword><style face="normal" font="default"> 64719-49-9 (25-hydroxyvitamin D)</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Norway/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Obesity/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Thrombosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Vitamin D/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Vitamin D/bl [Blood]</style></keyword></keywords><dates><year Day="0" Month="5" Year="2010">2010/5</year></dates><abstract><style face="normal" font="default">INTRODUCTION: In vitro studies indicate an anticoagulant effect of 1,25-dihydroxyvitamin D, and sun exposure may lower the risk of thrombotic events. Accordingly, an effect on haemostatic parameters could be expected after supplementation with vitamin D. MATERIALS AND METHODS: 158 obese or overweight subjects were included in a one year intervention study with supplementation with 40.000 IU vitamin D(3) per week or placebo. All subjects were given 500 mg calcium daily. Plasminogen activator inhibitor 1 (PAI-1), tissue plasminogen activator antigen (tPA Ag), and tissue factor-induced thrombin generation over time in plasma assessed by the calibrated automated thrombogram (CAT) method as a parameter of over all thrombotic activity, were measured before and at the end of the study. RESULTS: Mean baseline serum 25(OH)D level was 61.8 nmol/L and increased in the vitamin D group to 145.6 nmol/L at the end of the study. At baseline there was a significant decrease in the CAT variables lag time and time to peak of the thrombogram across increasing serum 25(OH)D quartiles, whereas no significant associations between serum 25(OH)D and PAI-1 or tPA Ag were found. After one year, no significant differences were found between the vitamin D and placebo groups regarding change in any of the haemostatic parameters. CONCLUSIONS: The association between lag time and time to peak in the CAT assay and serum 25(OH)D levels could indicate a pro-thrombotic state in subjects with high serum 25(OH)D levels, whereas the lack of effect of high dose vitamin D supplementation questions the causality of this relation. Copyright (c) 2009 Elsevier Ltd. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Institute of Clinical Medicine, University of Troms&amp;#x00F8;, Norway. rolf.jorde@unn.noJC - vrn, 0326377CP - United StatesPT - Clinical TrialPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20071011</style></custom1><custom3><style face="normal" font="default">AS - Thromb Res. 125(5):e210-3, 2010 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>149</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Jorde,R.</style></author><author><style face="normal" font="default"> Sneve,M.</style></author><author><style face="normal" font="default"> Torjesen,P.</style></author><author><style face="normal" font="default"> Figenschau,Y.</style></author></authors></contributors><titles><title><style face="normal" font="default">No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year</style></title><secondary-title><style face="normal" font="default">Journal of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Internal Medicine</style></full-title></periodical><pages end="472" start="462">462-472</pages><volume><style face="normal" font="default">267</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiovascular Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Cholecalciferol/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Obesity/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Vitamins/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> 0 (Blood Glucose)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipids)</style></keyword><keyword><style face="normal" font="default"> 0 (Vitamins)</style></keyword><keyword><style face="normal" font="default"> 67-97-0 (Cholecalciferol)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Blood Glucose/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Double-Blind Method</style></keyword><keyword><style face="normal" font="default"> Fasting/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Lipids/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Norway</style></keyword><keyword><style face="normal" font="default"> Obesity/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Obesity/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Overweight/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Overweight/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Overweight/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="5" Year="2010">2010/5</year></dates><abstract><style face="normal" font="default">BACKGROUND AND AIM: Cross-sectional studies indicate vitamin D to be of importance for glucose tolerance, blood pressure and serum lipids, but whether supplementation with vitamin D would improve cardio-vascular risk factors is not known. DESIGN AND SETTING: The study was a 1 year, double blind placebo-controlled intervention trial performed at the University Hospital of North Norway from November 2005 to October 2007. Subjects. A total of 438 overweight or obese subjects, 21-70 years old, were included and 330 completed the study. INTERVENTIONS: The subjects were randomized to vitamin D (cholecalciferol, vitamin D(3)) 40 000 IU per week (DD group), vitamin D 20 000 IU per week (DP group), or placebo (PP group). All subjects were given 500 mg calcium daily. MAIN OUTCOME MEASURES: Fasting serum lipids and blood pressure were measured and an oral glucose tolerance test performed at start and end of the study. RESULTS: At baseline the mean serum 25(OH)D levels were 58 nmol L(-1) (all subjects) and increased to 140 and 101 nmol L(-1) in the DD and DP groups, respectively. No significant differences were found between the three groups regarding change in measures of glucose metabolism or serum lipids. In the DP group, there was a slight but significant increase in systolic blood pressure compared with the placebo group. CONCLUSIONS: Our results do not support a positive effect of vitamin D on glucose tolerance, blood pressure or serum lipids. Further studies in subjects with low serum 25(OH)D levels combined with impaired glucose tolerance, hypertension or dyslipidaemia are needed</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Institute of Clinical Medicine, University of Troms&amp;#x00F8;, Troms&amp;#x00F8;, Norway. rolf.jorde@unn.noJC - i2g, 8904841CP - EnglandPT - Journal ArticlePT - Randomized Controlled TrialLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20141565</style></custom1><custom3><style face="normal" font="default">AS - J Intern Med. 267(5):462-72, 2010 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>521</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Jung,J.</style></author><author><style face="normal" font="default"> Foroud,T.M.</style></author><author><style face="normal" font="default"> Eckert,G.J.</style></author><author><style face="normal" font="default"> Flury-Wetherill,L.</style></author><author><style face="normal" font="default"> Edenberg,H.J.</style></author><author><style face="normal" font="default"> Xuei,X.</style></author><author><style face="normal" font="default"> Zaidi,S.A.</style></author><author><style face="normal" font="default"> Pratt,J.H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Association of the calcium-sensing receptor gene with blood pressure and urinary calcium in African-Americans</style></title><secondary-title><style face="normal" font="default">Journal of Clinical Endocrinology &amp; Metabolism</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Clinical Endocrinology &amp; Metabolism</style></full-title></periodical><pages end="1048" start="1042">1042-1048</pages><volume><style face="normal" font="default">94</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*African Americans/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Blood Pressure</style></keyword><keyword><style face="normal" font="default"> *Calcium/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> *Loop of Henle/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Polymorphism,Single Nucleotide</style></keyword><keyword><style face="normal" font="default"> *Receptors,Calcium-Sensing/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> 0 (Receptors,Calcium-Sensing)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> African Americans</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Child,Preschool</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="3" Year="2009">2009/3</year></dates><abstract><style face="normal" font="default">CONTEXT: Calcium binding to the Ca-sensing receptor (CASR) expressed in thick ascending limb inhibits the Na,K,2Cl cotransporter, which decreases sodium reabsorption and secondarily decreases Ca reabsorption. CASR gene variants could influence blood pressure (BP) by affecting Na retention. OBJECTIVE: The objective of the study was to determine whether variations in CASR associated with BP in African-Americans, an ethnic group at high risk for hypertension. DESIGN: Population- and family-based association studies of single-nucleotide polymorphisms (SNPs) in CASR with BP measured over the age range 5.6-25 yr (14 biannual visits per subject on average) were carried out. In a cross-sectional study where urinary Ca excretion had been measured, Ca excretion was used as an additional phenotype of CASR influence on Na,K,2Cl cotransporter activity. PARTICIPANTS: Subjects were normotensive. In the longitudinal study, there were 223 subjects (mean age 14 yr) and 123 families (one or both parents provided a DNA sample); in the cross-sectional study, there were 106 subjects (mean age 23 yr) and 88 families. RESULTS: Three SNPs in linkage disequilibrium associated with systolic BP at P &lt; 0.005 (the significance threshold corrected for multiple comparisons) in the population-based longitudinal study. In the cross-sectional study, SNPs contained in the same linkage disequilibrium block associated with urinary Ca excretion in both population- and family-based association studies. CONCLUSION: The findings suggest that in African-Americans, functional heterogeneity of the CASR in thick ascending limb may influence BP</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana 46202, USAJC - hrb, 0375362CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tPT - Research Support, U.S. Gov't, Non-P.H.SNO - MO1-RR00750 (United States NCRR NIH HHS)NO - R01-HL35795 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19066294</style></custom1><custom3><style face="normal" font="default">AS - J Clin Endocrinol Metab. 94(3):1042-8, 2009 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>517</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Jung,J.Y.</style></author><author><style face="normal" font="default"> Lee,C.</style></author><author><style face="normal" font="default"> Ro,H.</style></author><author><style face="normal" font="default"> Kim,H.S.</style></author><author><style face="normal" font="default"> Joo,K.W.</style></author><author><style face="normal" font="default"> Kim,Y.</style></author><author><style face="normal" font="default"> Ahn,C.</style></author><author><style face="normal" font="default"> Han,J.S.</style></author><author><style face="normal" font="default"> Kim,S.</style></author><author><style face="normal" font="default"> Oh,K.H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Sequential occurrence of life-threatening hypokalemia and rebound hyperkalemia associated with barbiturate coma therapy</style></title><secondary-title><style face="normal" font="default">Clinical Nephrology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinical Nephrology</style></full-title></periodical><pages end="337" start="333">333-337</pages><volume><style face="normal" font="default">71</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Barbiturates/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Coma</style></keyword><keyword><style face="normal" font="default"> *Hyperkalemia/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> *Hypokalemia/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> 0 (Barbiturates)</style></keyword><keyword><style face="normal" font="default"> Barbiturates/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> Hematoma,Subdural/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Subarachnoid Hemorrhage/th [Therapy]</style></keyword></keywords><dates><year Day="0" Month="3" Year="2009">2009/3</year></dates><isbn><style face="normal" font="default">0301-0430</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: To report a sequential occurrence of life-threatening hypokalemia and rebound hyperkalemia following barbiturate coma therapy. CASE HISTORY: A 53-year-old man was admitted to the division of nephrology due to sudden development of severe hypokalemia. The patient had been treated following a clinical diagnosis of traumatic subarachnoid hemorrhage and subdural hematoma. Barbiturate coma therapy had been performed on this patient. He developed fatal hypokalemia 10 hours after the start of thiopental administration which did not respond to potassium supplementation. The lowest potassium level following barbiturate coma therapy was 1.0 mmol/l. Severe bradycardia and cardiac arrest developed, which necessitated cardiac massage and treatment with epinephrine and atropine. He recovered from cardiac arrest. When thiopental infusion was suddenly stopped, the potassium level increased to 8.9 mmol/l, which required quick administration of calcium gluconate and infusion of glucose solution mixed with regular insulin. Despite such management, he developed asystole. After direct current cardioversion and emergency hemodialysis, he recovered from cardiac arrest and his serum potassium level was stabilized. CONCLUSION: We recommend that clinicians must be aware of the potential occurrence of severe hypokalemia, which is rare but fatal, following barbiturate coma therapy. Rebound hyperkalemia, which is fatal, may also occur following cessation of thiopental infusion. Clinicians should also be aware of this potential complication. Further studies are needed to elucidate the precise mechanism of this clinical event</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Nephrology, Department of Internal Medicine, Seoul National University Hospital, Seoul, KoreaJC - dey, 0364441CP - GermanyPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19281748</style></custom1><custom3><style face="normal" font="default">AS - Clin Nephrol. 71(3):333-7, 2009 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>543</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Kaid,K.A.</style></author><author><style face="normal" font="default"> Gopinathapillai,R.</style></author><author><style face="normal" font="default"> Qian,F.</style></author><author><style face="normal" font="default"> Salvaji,M.</style></author><author><style face="normal" font="default"> Wasty,N.</style></author><author><style face="normal" font="default"> Cohen,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Analysis of particulate debris after superficial femoral artery atherectomy</style></title><secondary-title><style face="normal" font="default">Journal of Invasive Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Invasive Cardiology</style></full-title></periodical><pages end="10" start="7">7-10</pages><volume><style face="normal" font="default">21</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherectomy/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> *Atherectomy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Debridement/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> *Debridement/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Embolism/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> *Femoral Artery</style></keyword><keyword><style face="normal" font="default"> 57-88-5 (Cholesterol)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 9001-31-4 (Fibrin)</style></keyword><keyword><style face="normal" font="default"> 9007-34-5 (Collagen)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Cholesterol/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Cholesterol/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Collagen/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Collagen/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Embolism/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Embolism/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Femoral Artery/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Femoral Artery/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Fibrin/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Fibrin/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Macrophages/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> Macrophages/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Macrophages/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Peripheral Vascular Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="1" Year="2009">2009/1</year></dates><abstract><style face="normal" font="default">PURPOSE: To evaluate the occurrence, size and composition of embolized debris captured during routine directional atherectomy using the SilverHawk device. METHODS: 15 consecutive eligible patients with a nonocclusive superficial femoral artery (SFA) were enrolled. Patients were included if they were > 18 years of age and had > or = 70% stenosis in the SFA. All lesions underwent plaque excision with the SilverHawk atherectomy device. A FilterWire EZ was used for distal protection and retrieval of embolized material. Specimens were collected separately from the filter basket and the SilverHawk atherectomy device's nosecone and were studied by a pathologist for number, size and composition. RESULTS: Visible debris captured in the filter was found in the majority of patients 14/15 (93%). Clinically-significant debris was found in 7/15 (47%) patients. The proportion of captured debris ranged from 0.1-0.4 cm. Microscopy revealed that the shaved particles consisted predominantly of collagen, fibrin, lipid-laden macrophages, cholesterol and calcium. Analysis of the embolized material revealed a different composition, mostly consisting of collagen with fibrosis, cholesterol and macrophages. CONCLUSION: In this single-center comparative study we have shown that during SilverHawk atherectomy of SFA lesions, distal embolization is universal. The debris captured in the filter is different in overall composition from the captured material in the nosecone of the SilverHawk device. Debris large enough to cause clinically-significant embolization, no-reflow and ischemia following SFA interventions occurred in nearly 50% of cases</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, NJ 07112, USA. drkaid@yahoo.comCM - Comment in: J Invasive Cardiol. 2009 Jan;21(1):11-2; PMID: 19126921]JC - bcz, 8917477CP - United StatesPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19126920</style></custom1><custom3><style face="normal" font="default">AS - J Invasive Cardiol. 21(1):7-10, 2009 Jan.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>484</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Kalender,W.A.</style></author><author><style face="normal" font="default"> Deak,P.</style></author><author><style face="normal" font="default"> Kellermeier,M.</style></author><author><style face="normal" font="default"> Van,Straten M.</style></author><author><style face="normal" font="default"> Vollmar,S.V.</style></author></authors></contributors><titles><title><style face="normal" font="default">Application- and patient size-dependent optimization of x-ray spectra for CT</style></title><secondary-title><style face="normal" font="default">Medical Physics</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Medical Physics</style></full-title></periodical><pages end="1007" start="993">993-1007</pages><volume><style face="normal" font="default">36</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> 1306-06-5 (Durapatite)</style></keyword><keyword><style face="normal" font="default"> 7732-18-5 (Water)</style></keyword><keyword><style face="normal" font="default"> Abdomen</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Biophysical Phenomena</style></keyword><keyword><style face="normal" font="default"> Body Size</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Computer Simulation</style></keyword><keyword><style face="normal" font="default"> Contrast Media</style></keyword><keyword><style face="normal" font="default"> Durapatite</style></keyword><keyword><style face="normal" font="default"> Heart/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Monte Carlo Method</style></keyword><keyword><style face="normal" font="default"> Phantoms,Imaging</style></keyword><keyword><style face="normal" font="default"> Radiography,Abdominal/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Radiography,Abdominal/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Radiography,Thoracic/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Radiography,Thoracic/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Water</style></keyword></keywords><dates><year Day="0" Month="3" Year="2009">2009/3</year></dates><isbn><style face="normal" font="default">0094-2405</style></isbn><abstract><style face="normal" font="default">Although x-ray computed tomography (CT) has been in clinical use for over 3 decades, spectral optimization has not been a topic of great concern; high voltages around 120 kV have been in use since the beginning of CT. It is the purpose of this study to analyze, in a rigorous manner, the energies at which the patient dose necessary to provide a given contrast-to-noise ratio (CNR) for various diagnostic tasks can be minimized. The authors used cylindrical water phantoms and quasianthropomorphic phantoms of the thorax and the abdomen with inserts of 13 mm diameter mimicking soft tissue, bone, and iodine for simulations and measurements. To provide clearly defined contrasts, these inserts were made of solid water with a 1% difference in density (DD) to represent an energy-independent soft-tissue contrast of 10 Hounsfield units (HU), calcium hydroxyapatite (Ca) representing bone, and iodine (I) representing the typical contrast medium. To evaluate CT of the thorax, an adult thorax phantom (300 x 200 mm2) plus extension rings up to a size of 460 x 300 mm2 to mimic different patient cross sections were used. For CT of the abdomen, we used a phantom of 360 x 200 mm2 and an extension ring of 460 x 300 mm2. The CT scanner that the authors used was a SOMATOM Definition (Siemens Healthcare, Forchheim, Germany) at 80, 100, 120, and 140 kV. Further voltage settings of 60, 75, 90, and 105 kV were available in an experimental mode. The authors determined contrast for the density difference, calcium, and iodine, and noise and 3D dose distributions for the available voltages by measurements. Additional voltage values and monoenergetic sources were evaluated by simulations. The dose-weighted contrast-to-noise ratio (CNRD) was used as the parameter for optimization. Simulations and measurements were in good agreement with respect to absolute values and trends regarding the dependence on energy for the parameters investigated. For soft-tissue imaging, the standard settings of 120-140 kV were found as adequate choices with optimal values increasing for larger cross sections, e.g., for large abdomens voltages higher than 140 kV may be indicated. For bone and iodine imaging the optimum values were generally found at significantly lower voltages of typically below 80 kV. This offers a potential for dose reduction of up to 50%, but demands significantly higher power values in most cases. The authors concluded that voltage settings in CT should be varied more often than is common in practice today and should be chosen not only according to patient size but also according to the substance imaged in order to minimize dose while not compromising image quality. A reduction from 120 to 80 kV, for example, would yield a reduction in patient dose by more than half for coronary CT angiography. The use of lower voltages has to be recommended for contrast medium studies in cardiac and pediatric CT</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Institute of Medical Physics, University Erlangen-N&amp;#x00FC;rnberg, Henkestr 91 91052 Erlangen, Germany. willi.kalender@imp.uni-erlangen.deJC - m82, 0425746CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19378760</style></custom1><custom3><style face="normal" font="default">AS - Med Phys. 36(3):993-1007, 2009 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>362</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Kaliebe,J.W.</style></author><author><style face="normal" font="default"> Murdock,D.K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Suppression of non-sustained ventricular tachycardia with ranolazine: a case report</style></title><secondary-title><style face="normal" font="default">WMJ</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">WMJ</style></full-title></periodical><pages end="375" start="373">373-375</pages><volume><style face="normal" font="default">108</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Acetanilides/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Enzyme Inhibitors/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Piperazines/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Tachycardia,Ventricular/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> 0 (Acetanilides)</style></keyword><keyword><style face="normal" font="default"> 0 (Enzyme Inhibitors)</style></keyword><keyword><style face="normal" font="default"> 0 (Piperazines)</style></keyword><keyword><style face="normal" font="default"> 110445-25-5 (ranolazine)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Electrocardiography,Ambulatory</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tachycardia,Ventricular/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Tachycardia,Ventricular/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><isbn><style face="normal" font="default">1098-1861</style></isbn><abstract><style face="normal" font="default">BACKGROUND: Ranolazine is a new anti-anginal agent that inhibits abnormal late sodium currents, indirectly causing a decrease in diastolic cardiomyocyte calcium levels. This produces an energy-sparing effect and stabilizes cardiac membranes. Ranolazine has been shown to be a potent inhibitor of triggered activity in the experimental setting. METHODS: This case report describes the dramatic antiarrhythmic effects of ranolazine in a patient with highly symptomatic complex ventricular ectopy, including non-sustained ventricular tachycardia (NSVT). Cardiac ischemia and left ventricular systolic dysfunction were ruled out by cardiac catheterization. After failing standard treatment, we initiated ranolazine therapy. RESULTS: Ranolazine was effective in suppressing ectopic ventricular activity and completely suppressed NSVT. CONCLUSIONS: Further research on the anti-arrhythmic properties of ranolazine in the clinical setting is needed</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - CaRE Foundation, Inc, Wausau, WI 54401, USAJC - 9716054, cybCP - United StatesPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19886587</style></custom1><custom3><style face="normal" font="default">AS - WMJ. 108(7):373-5, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>226</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Kaluza,J.</style></author><author><style face="normal" font="default"> Orsini,N.</style></author><author><style face="normal" font="default"> Levitan,E.B.</style></author><author><style face="normal" font="default"> Brzozowska,A.</style></author><author><style face="normal" font="default"> Roszkowski,W.</style></author><author><style face="normal" font="default"> Wolk,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Dietary calcium and magnesium intake and mortality: a prospective study of men</style></title><secondary-title><style face="normal" font="default">American Journal of Epidemiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Epidemiology</style></full-title></periodical><pages end="807" start="801">801-807</pages><volume><style face="normal" font="default">171</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium,Dietary</style></keyword><keyword><style face="normal" font="default"> *Food Habits</style></keyword><keyword><style face="normal" font="default"> *Magnesium</style></keyword><keyword><style face="normal" font="default"> *Mortality</style></keyword><keyword><style face="normal" font="default"> 0 (Calcium,Dietary)</style></keyword><keyword><style face="normal" font="default"> 7439-95-4 (Magnesium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcium,Dietary/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Cause of Death</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Dietary Supplements</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Magnesium/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Neoplasms/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Sweden/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="1" Month="4" Year="2010">2010/4/1</year></dates><abstract><style face="normal" font="default">The authors examined the association of dietary calcium and magnesium intake with all-cause, cardiovascular disease (CVD), and cancer mortality among 23,366 Swedish men, aged 45-79 years, who did not use dietary supplements. Cox proportional hazards regression models were used to estimate the multivariate hazard ratios and 95% confidence intervals of mortality. From baseline 1998 through December 2007, 2,358 deaths from all causes were recorded in the Swedish population registry; through December 2006, 819 CVD and 738 cancer deaths were recorded in the Swedish cause-of-death registry. Dietary calcium was associated with a statistically significant lower rate of all-cause mortality (hazard ratio (HR) = 0.75, 95% confidence interval (CI): 0.63, 0.88; P(trend) &lt; 0.001) and a nonsignificantly lower rate of CVD (HR = 0.77, 95% CI: 0.58, 1.01; P(trend) = 0.064) but not cancer mortality (HR = 0.87, 95% CI: 0.65, 1.17; P(trend) = 0.362) when the highest intake tertile (mean = 1,953 mg/day; standard deviation (SD), 334) was compared with the lowest (990 mg/day; SD, 187). Dietary magnesium intake (means of tertiles ranged from 387 mg/day (SD, 31) to 523 mg/day (SD, 38) was not associated with all-cause, CVD, or cancer mortality. This population-based, prospective study of men with relatively high intakes of dietary calcium and magnesium showed that intake of calcium above that recommended daily may reduce all-cause mortality</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Nutritional Epidemiology, Karolinska Institutet, Stockholm, SwedenJC - 3h3, 7910653CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20172919</style></custom1><custom3><style face="normal" font="default">AS - Am J Epidemiol. 171(7):801-7, 2010 Apr 1.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>539</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Kanei,Y.</style></author><author><style face="normal" font="default"> Huang,Y.</style></author><author><style face="normal" font="default"> Fox,J.T.</style></author><author><style face="normal" font="default"> Rachko,M.</style></author><author><style face="normal" font="default"> Bergmann,S.R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Correlation of antecedent stress myocardial perfusion imaging with the infarct related artery in ST-elevation myocardial infarction</style></title><secondary-title><style face="normal" font="default">The International Journal of Cardiovascular Imaging</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">The International Journal of Cardiovascular Imaging</style></full-title></periodical><pages end="149" start="145">145-149</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Myocardial Infarction/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> *Myocardial Perfusion Imaging/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> 0 (Radiopharmaceuticals)</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Electrocardiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Catheterization</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Myocardial Perfusion Imaging</style></keyword><keyword><style face="normal" font="default"> Perfusion</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Radiopharmaceuticals/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="2" Year="2009">2009/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: While stress myocardial perfusion imaging (MPI) has strong prognostic power, it predicts the site of a subsequent acute myocardial infarction (AMI) in only 47-77% of patients. Prior studies have included small number of subjects and the interval between the stress test and the AMI has varied. The objective of the present study was to further evaluate the relationship between antecedent stress MPI and subsequent AMI. METHODS: We screened 600 patients admitted to our institution with acute ST-elevation MI and identified 21 patients who had a stress MPI an average of 4.8 months prior to the event. The location of perfusion defects on MPI were compared to the angiographic findings at the time of the subsequent AMI. RESULTS: Sixteen patients (76%) with AMI had defects on antecedent stress MPI while 5 patients (24%) had normal scans. Reversible or fixed perfusion defects in the territory corresponding to the site of AMI were seen in 62% of patients. All 5 patients with normal scans had multiple risk factors for coronary artery disease. CONCLUSION: Although a normal stress MPI portends an excellent outcome, a small proportion of patients with normal scans, but with risk factors go on to develop AMI. Stress MPI has reasonable power in predicting future STEMI, but a lesser degree for the location of the future MI. Complementary imaging approaches such as coronary calcium scoring or CT angiography may be beneficial in the assessment of patients at high risk for MI</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiology, Department of Internal Medicine, Beth Israel Medical Center, 1st Avenue at 16th Street, New York, NY 10003, USA. yumikanei@hotmail.comJC - 100969716CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18787977</style></custom1><custom3><style face="normal" font="default">AS - Int J Cardiovasc Imaging. 25(2):145-9, 2009 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>504</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Kaple,R.K.</style></author><author><style face="normal" font="default"> Maehara,A.</style></author><author><style face="normal" font="default"> Sano,K.</style></author><author><style face="normal" font="default"> Missel,E.</style></author><author><style face="normal" font="default"> Castellanos,C.</style></author><author><style face="normal" font="default"> Tsujita,K.</style></author><author><style face="normal" font="default"> Fahy,M.</style></author><author><style face="normal" font="default"> Moses,J.W.</style></author><author><style face="normal" font="default"> Stone,G.W.</style></author><author><style face="normal" font="default"> Leon,M.B.</style></author><author><style face="normal" font="default"> Mintz,G.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">The axial distribution of lesion-site atherosclerotic plaque components: an in vivo volumetric intravascular ultrasound radio-frequency analysis of lumen stenosis, necrotic core and vessel remodeling</style></title><secondary-title><style face="normal" font="default">Ultrasound in Medicine &amp; Biology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ultrasound in Medicine &amp; Biology</style></full-title></periodical><pages end="557" start="550">550-557</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Disease/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Signal Processing,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> *Ultrasonography,Interventional/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="4" Year="2009">2009/4</year></dates><abstract><style face="normal" font="default">Radio-frequency intravascular ultrasound (IVUS) analysis characterizes atherosclerotic plaques into necrotic core (NC), dense calcium (DC), fibrofatty (FF) and fibrotic (FI) tissue. We studied axial plaque component distribution with respect to stenosis and remodeling. Preintervention virtual histology (VH) IVUS was performed in 81 pts (90 de novo lesions: 43 left anterior descending artery [LAD] and 47 right coronary artery [RCA]). VH-IVUS at the reference, minimum lumen area (MLA) and maximum NC (MaxNC) sites were analyzed. Pullback length of 31.1 +/- 12.0 mm spanned a lesion length of 13.8 +/- 9.5 mm. The MaxNC site was located at the MLA in 3.3% of lesions, proximal to the MLA in 61% of lesions (by 4.11 mm) and distal to the MLA in 35.6% of lesions (by 3.56 mm). The %DC was greater at the MaxNC and %FI and %FF plaque were less than at the MLA site. Lesion fiberoatheromas (FAs) were more often detected at the MaxNC than the MLA (96% versus 51%) and were more often classified as thin-caped or multilayered than the MLA sites. The remodeling index was larger at the MaxNC than MLA sites and correlated with the NC area both at the MLA (r(2) 0.068, p = 0.013) and at the MaxNC (r(2) 0.074, p = 0.009). In conclusion, grey-scale and VH-IVUS analysis showed that the MLA is rarely at the site of greatest instability (largest NC and remodeling) and necrotic core on VH is correlated with remodeling index. These in vivo findings are consistent with previously reported histopathologic data and have important implications for the detection and treatment of coronary artery disease</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Columbia University and The Cardiovascular Research Foundation, New York City, NY, USAJC - wne, 0410553CP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19110364</style></custom1><custom3><style face="normal" font="default">AS - Ultrasound Med Biol. 35(4):550-7, 2009 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>442</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Karaahmet,T.</style></author><author><style face="normal" font="default"> Tigen,K.</style></author><author><style face="normal" font="default"> Gurel,E.</style></author><author><style face="normal" font="default"> Tanalp,A.C.</style></author><author><style face="normal" font="default"> Basaran,Y.</style></author></authors></contributors><titles><title><style face="normal" font="default">Dystrophic calcification of the aneurysmatic left ventricular apex</style></title><secondary-title><style face="normal" font="default">Congestive Heart Failure</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Congestive Heart Failure</style></full-title></periodical><pages end="198" start="196">196-198</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Coronary Aneurysm/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Heart Ventricles/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcinosis/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Aneurysm/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Diagnosis,Differential</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Electrocardiography</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="7" Year="2009">2009/7</year></dates><abstract><style face="normal" font="default">Pathologic calcium deposition may be observed in the valve leaflets, valvular annulus, pericardial scar areas in chronic constructive pericarditis, and myocardial tissue. A direct x-ray may reveal the area of calcification in any of these tissues. The most common cause of myocardial calcification is myocardial infarction (MI) in which calcium accumulates in the infarcted tissue during myocardial healing process. The authors present a case of diffuse myocardial calcification located in the left ventricular apical aneurysm in a patient who had an MI 24 years ago, together with a diagnostic and therapeutic approach</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Kartal Kosuyolu Heart and Research Hospital, Istanbul, TurkeyJC - 9714174CP - United StatesPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19627295</style></custom1><custom3><style face="normal" font="default">AS - Congest Heart Fail. 15(4):196-8, 2009 Jul-Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>459</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Kassab,M.Y.</style></author><author><style face="normal" font="default"> Gupta,R.</style></author><author><style face="normal" font="default"> Majid,A.</style></author><author><style face="normal" font="default"> Farooq,M.U.</style></author><author><style face="normal" font="default"> Giles,B.P.</style></author><author><style face="normal" font="default"> Johnson,M.D.</style></author><author><style face="normal" font="default"> Graybeal,D.F.</style></author><author><style face="normal" font="default"> Rappard,G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Extent of intra-arterial calcification on head CT is predictive of the degree of intracranial atherosclerosis on digital subtraction angiography</style></title><secondary-title><style face="normal" font="default">Cerebrovascular Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Cerebrovascular Diseases</style></full-title></periodical><pages end="48" start="45">45-48</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Intracranial Arterial Diseases/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Intracranial Arteriosclerosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Angiography,Digital Subtraction</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Constriction,Pathologic/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><abstract><style face="normal" font="default">BACKGROUND: Intracranial intra-arterial calcifications (ICAC) are a common finding on head CT examinations, but their significance is not known. The aim of this study is to determine if a relationship exists between ICAC on head CT and the presence of a high-grade atherosclerotic stenosis on cerebral angiography. METHODS: This was a retrospective study of 108 consecutive patients admitted to the stroke service at Parkland Hospital in Dallas, Tex., USA. Each patient had undergone a head CT and catheter-based angiographic study to meet the inclusion criteria. Demographic information was recorded along with CT imaging data in regards to the amount of calcification. Angiographic images were reviewed independently, and a comparison was made to determine if calcification was predictive of finding a high-grade stenosis on angiography. RESULTS: A total of 108 consecutive patients with a mean age of 56 +/- 12 years were studied. Of the 540 vessels studied, 65 (12%) were found to have a stenosis of >or=50% on angiography, and 71 (13.1%) were found to have a calcium grade of 3 or 4 on head CT. ICAC appeared to be more common in the anterior circulation compared to the posterior circulation. Patients with grade 3 or 4 calcification of an intracranial vessel on head CT were more likely to have a stenosis of >or=50% on cerebral angiography. CONCLUSIONS: The presence of ICAC on head CT appears to correlate with the presence of an underlying intracranial stenosis on angiography. Further study is required to validate these preliminary findings. (c) 2009 S. Karger AG, Basel</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cerebrovascular Diseases, Michigan State University and Sparrow Health System, East Lansing, MI 48824, USA. mounzer.kassab@ht.msu.eduJC - c2g, 9100851CP - SwitzerlandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19468214</style></custom1><custom3><style face="normal" font="default">AS - Cerebrovasc Dis. 28(1):45-8, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>500</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Katz,R.</style></author><author><style face="normal" font="default"> Budoff,M.J.</style></author><author><style face="normal" font="default"> Takasu,J.</style></author><author><style face="normal" font="default"> Shavelle,D.M.</style></author><author><style face="normal" font="default"> Bertoni,A.</style></author><author><style face="normal" font="default"> Blumenthal,R.S.</style></author><author><style face="normal" font="default"> Ouyang,P.</style></author><author><style face="normal" font="default"> Wong,N.D.</style></author><author><style face="normal" font="default"> O'Brien,K.D.</style></author></authors></contributors><titles><title><style face="normal" font="default">Relationship of metabolic syndrome with incident aortic valve calcium and aortic valve calcium progression: the Multi-Ethnic Study of Atherosclerosis (MESA).[Erratum appears in Diabetes. 2009 Aug;58(8):1937]</style></title><secondary-title><style face="normal" font="default">Diabetes</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Diabetes</style></full-title></periodical><pages end="819" start="813">813-819</pages><volume><style face="normal" font="default">58</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aortic Valve/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Atherosclerosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Metabolic Syndrome X/co [Complications]</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol,LDL)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Aortic Valve Stenosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Aortic Valve Stenosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Aortic Valve/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Cholesterol,LDL/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Continental Population Groups</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Ethnic Groups</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Research Design</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Smoking/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Socioeconomic Factors</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> United States/ep [Epidemiology]</style></keyword></keywords><dates><year Day="0" Month="4" Year="2009">2009/4</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Metabolic syndrome (MetS) has been associated with increased prevalence of aortic valve calcium (AVC) and with increased progression of aortic stenosis. The purpose of this study was to determine whether MetS is associated with increased risks for the development of new ("incident") AVC or for progression of established AVC as assessed by CT. RESEARCH DESIGN AND METHODS: The relationships of MetS or its components as well as of diabetes to risks for incident AVC or AVC progression were studied among participants with CT scans performed at baseline and at either year 2 or year 3 examinations in the Multi-Ethnic Study of Atherosclerosis (MESA). RESULTS: Of 5,723 MESA participants meeting criteria for inclusion, 1,674 had MetS by Adult Treatment Panel III criteria, whereas 761 had diabetes. Among the 5,123 participants without baseline AVC, risks for incident AVC, adjusted for time between scans, age, sex, race/ethnicity, LDL cholesterol, lipid-lowering medications, and smoking, were increased significantly for MetS (odds ratio [OR] 1.67 [95% CI 1.21-2.31]) or diabetes (2.06 [1.39-3.06]). In addition, there was an increase in incident AVC risk with increasing number of MetS components. Similar results were found using the International Diabetes Federation MetS criteria. Among the 600 participants (10.5%) with baseline AVC, neither MetS nor diabetes was associated with AVC progression. CONCLUSIONS: In the MESA cohort, MetS was associated with a significant increase in incident ("new") AVC, raising the possibility that MetS may be a potential therapeutic target to prevent AVC development</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - University of Washington, Seattle, Washington, USA. rkatz@u.washington.eduJC - e8x, 0372763CP - United StatesPT - Journal ArticlePT - Multicenter StudyPT - Research Support, N.I.H., ExtramuralNO - N01-HC-95159 (United States NHLBI NIH HHS)NO - N01-HC-95160 (United States NHLBI NIH HHS)NO - N01-HC-95161 (United States NHLBI NIH HHS)NO - N01-HC-95162 (United States NHLBI NIH HHS)NO - N01-HC-95163 (United States NHLBI NIH HHS)NO - N01-HC-95164 (United States NHLBI NIH HHS)NO - N01-HC-95165 (United States NHLBI NIH HHS)NO - N01-HC-95169 (United States NHLBI NIH HHS)NO - R01-HL071739 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19136658</style></custom1><custom3><style face="normal" font="default">AS - Diabetes. 58(4):813-9, 2009 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>57</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Kendrick,J.</style></author><author><style face="normal" font="default"> Ix,J.H.</style></author><author><style face="normal" font="default"> Targher,G.</style></author><author><style face="normal" font="default"> Smits,G.</style></author><author><style face="normal" font="default"> Chonchol,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Relation of serum phosphorus levels to ankle brachial pressure index (from the Third National Health and Nutrition Examination Survey)</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="568" start="564">564-568</pages><volume><style face="normal" font="default">106</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Ankle Brachial Index</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Phosphorus/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 7723-14-0 (Phosphorus)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Nutrition Surveys</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword></keywords><dates><year Day="15" Month="8" Year="2010">2010/8/15</year></dates><abstract><style face="normal" font="default">Higher levels of serum phosphorus that remain within the reference range are associated with increased risk of cardiovascular disease (CVD). However, the mechanisms by which higher serum phosphorus concentrations may contribute to the development of CVD remain unclear. Cross-sectional association between serum phosphorus levels and arterial stiffness as estimated by an ankle brachial pressure index (ABPI) >1.3 was examined in 581 participants in the Third National Health and Nutrition Examination Survey. Logistic regression analysis was performed to evaluate whether higher serum phosphorus levels were associated with high ABPI, independently of several potential confounders. Of 581 participants, 38% and 10% had a serum phosphorus levels >3.5 and >4.0 mg/dl, respectively. An ABPI >1.3 was present in 7.3% of participants. Higher quartiles of serum phosphorus levels were associated with a greater prevalence of high ABPI: 5.4%, 3.7%, 7.8%, and 12.9% for quartiles 1 (&lt;3.1 mg/dl), 2 (3.1 to 3.4 mg/dl), 3 (3.4 to 3.7 mg/dl), and 4 (3.7 to 5.0 mg/dl), respectively. There was a strong, positive association between the highest quartile of serum phosphorus (3.7 to 5.0 mg/dl) and high ABPI compared to the reference group (3.1 to 3.4 mg/dl) after adjustment for demographics, traditional CVD risk factors, kidney function, C-reactive protein, serum calcium, and 25-hydroxyvitamin D levels (adjusted odds ratio 4.78, 95% confidence interval 1.73 to 13.2, p = 0.003). In conclusion, serum phosphorus levels, even within the reference range, are independently associated with high ABPI, a marker of arterial stiffness, in the US adult population</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Renal Diseases and Hypertension, University of Colorado Denver, Health Sciences Center, Aurora, CO, USAJC - 3dq, 0207277CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20691317</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 106(4):564-8, 2010 Aug 15.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>540</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Kepez,A.</style></author><author><style face="normal" font="default"> Harmanci,A.</style></author><author><style face="normal" font="default"> Hazirolan,T.</style></author><author><style face="normal" font="default"> Isildak,M.</style></author><author><style face="normal" font="default"> Kocabas,U.</style></author><author><style face="normal" font="default"> Ates,A.</style></author><author><style face="normal" font="default"> Ciftci,O.</style></author><author><style face="normal" font="default"> Tokgozoglu,L.</style></author><author><style face="normal" font="default"> rlek,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Evaluation of subclinical coronary atherosclerosis in mild asymptomatic primary hyperparathyroidism patients</style></title><secondary-title><style face="normal" font="default">The International Journal of Cardiovascular Imaging</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">The International Journal of Cardiovascular Imaging</style></full-title></periodical><pages end="193" start="187">187-193</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Hyperparathyroidism,Primary/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Chi-Square Distribution</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Electrocardiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Statistics,Nonparametric</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="2" Year="2009">2009/2</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Although there is sufficient data supporting the increased cardiovascular risk in patients with advanced stage of primary hyperparathyroidism (pHPT), it is not clear whether same is valid for patients with subclinical forms of this disease. In this study we aimed to evaluate coronary atherosclerosis burden of asymptomatic pHPT patients by using tomographic coronary calcification scoring. PATIENTS AND METHODS: Thirty-one mild asymptomatic pHPT patients (28 female, 3 male; mean age: 54.4 +/- 12.1 years) and 19 gender- and age-matched normotensive healthy controls (17 female, 2 male; mean age: 50.6 +/- 5.8) constituted our study population. Asymptomatic pHPT patients were subdivided according to presence of hypertension (19 hypertensive and 12 non-hypertensive patients). All subjects in study population underwent tomographic coronary calcification scoring by using 16-multidetector computed tomography (16-MDCT). RESULTS: Median tomographic coronary calcification score was comparable between the whole group of pHPT patients [0.0 (Interquartile Range, IQR:18.70] and the controls [0.0 (IQR: 0.90). Median tomographic coronary calcification scores of pHPT patients with hypertension was 0.90 (IQR: 75.0) HU, whereas no calcification was noted in coronary arteries of normotensive pHPT patients. Calcification scores of hypertensive pHPT patients were significantly higher than both normotensive pHPT patients (P = 0.014) and controls (P = 0.046). There was no significant difference regarding calcification scores of normotensive pHPT patients versus controls. In the binary logistic regression model, only the presence of hyperlipidemia was found to be independently associated with presence of calcification on coronary arteries (relative risk 6.56, 95% CI 1.18-36.56, P = 0.032). CONCLUSION: These results suggest that mild asymptomatic pHPT with serum calcium levels in the high-normal range does not constitute an independent risk factor for coronary atherosclerosis. The combined presence of classic cardiovascular risk factors determines the severity of coronary atherosclerosis in these patients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Cardiology Clinic, Yunus Emre Public Hospital, Eskisehir, Turkey. alperkepez@yahoo.comJC - 100969716CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18784985</style></custom1><custom3><style face="normal" font="default">AS - Int J Cardiovasc Imaging. 25(2):187-93, 2009 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>443</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Ker,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">The subaortic tendon as a mimic of hypertrophic cardiomyopathy</style></title><secondary-title><style face="normal" font="default">Cardiovascular Ultrasound</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Cardiovascular Ultrasound</style></full-title></periodical><pages end="" start="31">31-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiomyopathy,Hypertrophic/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Tendons</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies</style></keyword><keyword><style face="normal" font="default"> Diagnosis,Differential</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><abstract><style face="normal" font="default">Originally described by Brock and Teare, today hypertrophic cardiomyopathy is clinically defined as left (or right) ventricular hypertrophy without a known cardiac or systemic cause, such as systemic hypertension, Fabry's disease or aortic stenosis.Also appreciated today is the enormous genotypic and phenotypic heterogeneity of this disease with more than 300 mutations over more than 24 genes, encoding various sarcomeric, mitochondrial and calcium-handling proteins, all as genetic causes for hypertrophic cardiomyopathy.Phenotypically, the disease can vary from negligible to extreme hypertrophy, affecting either the left and/or right ventricle in an apical, midventricular or subaortic location.Left ventricular false tendons are thin, fibrous or fibromuscular structures that traverse the left ventricular cavity. Recently, a case report was presented where it was shown that such a false tendon, originating from a subaortic location, was responsible for striking ST-segment elevation on the surface electrocardiogram.In this case report, a case is presented where such a subaortic tendon led to the classic echocardiographic appearance of hypertrophic cardiomyopathy, thus in the assessment of hypertrophic cardiomyopathy, this entity needs to be excluded in order to prevent a false positive diagnosis of hypertrophic cardiomyopathy</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Physiology, University of Pretoria, Pretoria, South Africa, Gesina, Pretoria, South Africa 0031. jker@wol.co.zaJC - 101159952CP - EnglandPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19573250</style></custom1><custom3><style face="normal" font="default">AS - Cardiovasc. ultrasound. 7:31, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>117</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Kestenbaum,B.</style></author><author><style face="normal" font="default"> Glazer,N.L.</style></author><author><style face="normal" font="default"> ttgen,A.</style></author><author><style face="normal" font="default"> Felix,J.F.</style></author><author><style face="normal" font="default"> Hwang,S.J.</style></author><author><style face="normal" font="default"> Liu,Y.</style></author><author><style face="normal" font="default"> Lohman,K.</style></author><author><style face="normal" font="default"> Kritchevsky,S.B.</style></author><author><style face="normal" font="default"> Hausman,D.B.</style></author><author><style face="normal" font="default"> Petersen,A.K.</style></author><author><style face="normal" font="default"> Gieger,C.</style></author><author><style face="normal" font="default"> Ried,J.S.</style></author><author><style face="normal" font="default"> Meitinger,T.</style></author><author><style face="normal" font="default"> Strom,T.M.</style></author><author><style face="normal" font="default"> Wichmann,H.E.</style></author><author><style face="normal" font="default"> Campbell,H.</style></author><author><style face="normal" font="default"> Hayward,C.</style></author><author><style face="normal" font="default"> Rudan,I.</style></author><author><style face="normal" font="default"> de,Boer,I</style></author><author><style face="normal" font="default"> Psaty,B.M.</style></author><author><style face="normal" font="default"> Rice,K.M.</style></author><author><style face="normal" font="default"> Chen,Y.D.</style></author><author><style face="normal" font="default"> Li,M.</style></author><author><style face="normal" font="default"> Arking,D.E.</style></author><author><style face="normal" font="default"> Boerwinkle,E.</style></author><author><style face="normal" font="default"> Coresh,J.</style></author><author><style face="normal" font="default"> Yang,Q.</style></author><author><style face="normal" font="default"> Levy,D.</style></author><author><style face="normal" font="default"> van Rooij,F.J.</style></author><author><style face="normal" font="default"> Dehghan,A.</style></author><author><style face="normal" font="default"> Rivadeneira,F.</style></author><author><style face="normal" font="default"> Uitterlinden,A.G.</style></author><author><style face="normal" font="default"> Hofman,A.</style></author><author><style face="normal" font="default"> van Duijn,C.M.</style></author><author><style face="normal" font="default"> Shlipak,M.G.</style></author><author><style face="normal" font="default"> Kao,W.H.</style></author><author><style face="normal" font="default"> Witteman,J.C.</style></author><author><style face="normal" font="default"> Siscovick,D.S.</style></author><author><style face="normal" font="default"> Fox,C.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Common genetic variants associate with serum phosphorus concentration</style></title><secondary-title><style face="normal" font="default">Journal of the American Society of Nephrology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of the American Society of Nephrology</style></full-title></periodical><pages end="1232" start="1223">1223-1232</pages><volume><style face="normal" font="default">21</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Genetic Loci/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Genetic Variation/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Genome-Wide Association Study</style></keyword><keyword><style face="normal" font="default"> *Phosphorus/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Polymorphism,Single Nucleotide/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> 0 (CASR protein,human)</style></keyword><keyword><style face="normal" font="default"> 0 (fibroblast growth factor 23)</style></keyword><keyword><style face="normal" font="default"> 0 (Receptors,Calcium-Sensing)</style></keyword><keyword><style face="normal" font="default"> 0 (SLC34A1 protein,human)</style></keyword><keyword><style face="normal" font="default"> 0 (Sodium-Phosphate Cotransporter Proteins,Type IIa)</style></keyword><keyword><style face="normal" font="default"> 62031-54-3 (Fibroblast Growth Factors)</style></keyword><keyword><style face="normal" font="default"> 7723-14-0 (Phosphorus)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> European Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fibroblast Growth Factors/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Gene Frequency/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Kidney/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Receptors,Calcium-Sensing/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> Sodium-Phosphate Cotransporter Proteins,Type IIa/ge [Genetics]</style></keyword></keywords><dates><year Day="0" Month="7" Year="2010">2010/7</year></dates><abstract><style face="normal" font="default">Phosphorus is an essential mineral that maintains cellular energy and mineralizes the skeleton. Because complex actions of ion transporters and regulatory hormones regulate serum phosphorus concentrations, genetic variation may determine interindividual variation in phosphorus metabolism. Here, we report a comprehensive genome-wide association study of serum phosphorus concentration. We evaluated 16,264 participants of European ancestry from the Cardiovascular Heath Study, Atherosclerosis Risk in Communities Study, Framingham Offspring Study, and the Rotterdam Study. We excluded participants with an estimated GFR &lt;45 ml/min per 1.73 m(2) to focus on phosphorus metabolism under normal conditions. We imputed genotypes to approximately 2.5 million single-nucleotide polymorphisms in the HapMap and combined study-specific findings using meta-analysis. We tested top polymorphisms from discovery cohorts in a 5444-person replication sample. Polymorphisms in seven loci with minor allele frequencies 0.08 to 0.49 associate with serum phosphorus concentration (P = 3.5 x 10(-16) to 3.6 x 10(-7)). Three loci were near genes encoding the kidney-specific type IIa sodium phosphate co-transporter (SLC34A1), the calcium-sensing receptor (CASR), and fibroblast growth factor 23 (FGF23), proteins that contribute to phosphorus metabolism. We also identified genes encoding phosphatases, kinases, and phosphodiesterases that have yet-undetermined roles in phosphorus homeostasis. In the replication sample, five of seven top polymorphisms associate with serum phosphorous concentrations (P &lt; 0.05 for each). In conclusion, common genetic variants associate with serum phosphorus in the general population. Further study of the loci identified in this study may help elucidate mechanisms of phosphorus regulation</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Nephrology, Department of Medicine, University of Washington, Kidney Research Institute, Seattle, Washington 98104-2499, USA. brk@u.washington.eduJC - a6h, 9013836CP - United StatesPT - Journal ArticlePT - Meta-AnalysisPT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - DK063491 (United States NIDDK NIH HHS)NO - HHSN268200625226C (United States PHS HHS)NO - M01RR00069 (United States NCRR NIH HHS)NO - N01-HC-15103 (United States NHLBI NIH HHS)NO - N01-HC-35129 (United States NHLBI NIH HHS)NO - N01-HC-45133 (United States NHLBI NIH HHS)NO - N01-HC-55015 (United States NHLBI NIH HHS)NO - N01-HC-55016 (United States NHLBI NIH HHS)NO - N01-HC-55018 (United States NHLBI NIH HHS)NO - N01-HC-55019 (United States NHLBI NIH HHS)NO - N01-HC-55020 (United States NHLBI NIH HHS)NO - N01-HC-55021 (United States NHLBI NIH HHS)NO - N01-HC-55022 (United States NHLBI NIH HHS)NO - N01-HC-55222 (United States NHLBI NIH HHS)NO - N01-HC-75150 (United States NHLBI NIH HHS)NO - N01-HC-85079 (United States NHLBI NIH HHS)NO - N01-HC-85086 (United States NHLBI NIH HHS)NO - R01 AG027002 (United States NIA NIH HHS)NO - R01 HL084443 (United States NHLBI NIH HHS)NO - R01 HL087652 (United States NHLBI NIH HHS)NO - R01HL086694 (United States NHLBI NIH HHS)NO - R01HL087641 (United States NHLBI NIH HHS)NO - R01HL59367 (United States NHLBI NIH HHS)NO - U01-HL080295 (United States NHLBI NIH HHS)NO - U01HG004402 (United States NHGRI NIH HHS)NO - UL1RR025005 (United States NCRR NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20558539</style></custom1><custom3><style face="normal" font="default">AS - J Am Soc Nephrol. 21(7):1223-32, 2010 Jul.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>147</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Khan,J.N.</style></author><author><style face="normal" font="default"> Prasad,N.</style></author><author><style face="normal" font="default"> Glancy,J.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">QTc prolongation during therapeutic hypothermia: are we giving it the attention it deserves?</style></title><secondary-title><style face="normal" font="default">Europace</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Europace</style></full-title></periodical><pages end="270" start="266">266-270</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Electrocardiography</style></keyword><keyword><style face="normal" font="default"> *Hypothermia,Induced/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Tachycardia,Ventricular/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Ventricular Fibrillation/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> 7440-09-7 (Potassium)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Body Temperature/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Guidelines as Topic</style></keyword><keyword><style face="normal" font="default"> Heart Arrest/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Heart Arrest/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Monitoring,Physiologic</style></keyword><keyword><style face="normal" font="default"> Potassium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tachycardia,Ventricular/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Ventricular Fibrillation/co [Complications]</style></keyword></keywords><dates><year Day="0" Month="2" Year="2010">2010/2</year></dates><abstract><style face="normal" font="default">AIMS: Therapeutic hypothermia (TH) is used in neuroprotection following cardiac arrest due to ventricular tachycardia (VT) and ventricular fibrillation (VF). Accidental hypothermia is itself known to cause prolongation of the corrected QT interval (QTc). QTc prolongation can cause polymorphic VT and VF. If this also occurs in TH, it may induce refibrillation. We investigated the effect of TH on the QTc interval. METHODS AND RESULTS: Prospective case series of all patients undergoing TH following cardiac arrest following VT/VF at our hospital between July 2008 and January 2009. We studied the effect of temperature on QTc. All electrocardiograms (ECGs) undertaken during TH were studied and compared with the ECG prior to this. Four patients underwent TH. A total of 10 ECGs were undertaken during TH. The QTc was normal prior to TH. It became prolonged (>460 ms) in all cases during TH and normalized after cessation of TH, apart from Patient 4 who did not have an ECG post-TH since she died from cardiogenic shock. There was a negative correlation between temperature and QTc (Pearson's correlation coefficient, r= -0.71). CONCLUSION: Our series illustrates QTc prolongation during TH. This carries potential for refibrillation. Guidelines on ECG monitoring during TH are needed, especially since hypothermic myocardium is intrinsically prone to arrhythmias and commonly used antiarrythmic drugs such as amiodarone can prolong the QTc</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Sandwell and City Hospitals NHS Trust, Bham B18 7QH, UK. mally777@hotmail.comJC - dxd, 100883649CP - EnglandPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19948565</style></custom1><custom3><style face="normal" font="default">AS - Europace. 12(2):266-70, 2010 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>234</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Kharitonova,T.V.</style></author><author><style face="normal" font="default"> Kozina,L.S.</style></author><author><style face="normal" font="default"> Zakharchuk,A.G.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Some indices of lipids metabolism and antioxidant profile in geriatric patients with arterial hypertension]. [Russian]</style></title><secondary-title><style face="normal" font="default">Advances in Gerontology = Uspekhi Gerontologii/Rossiiskaia Akademiia Nauk, Gerontologicheskoe Obshchestvo</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Advances in Gerontology = Uspekhi Gerontologii/Rossiiskaia Akademiia Nauk, Gerontologicheskoe Obshchestvo</style></full-title></periodical><pages end="321" start="316">316-321</pages><volume><style face="normal" font="default">22</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aging/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Antioxidants/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Hypertension/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Lipid Metabolism</style></keyword><keyword><style face="normal" font="default"> *Lipid Peroxidation</style></keyword><keyword><style face="normal" font="default"> 0 (Antioxidants)</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Sulfhydryl Compounds)</style></keyword><keyword><style face="normal" font="default"> 542-78-9 (Malondialdehyde)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Biological Markers/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Homeostasis/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/en [Enzymology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Malondialdehyde/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Oxidation-Reduction</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Sulfhydryl Compounds/me [Metabolism]</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><isbn><style face="normal" font="default">1561-9125</style></isbn><abstract><style face="normal" font="default">Arterial hypertension contributes essentially into development of chronic heart failure and chronic ischemia of the brain, which results in social dependence of geriatric patients. One of the important factors in the development of arterial hypertension is the state of lipids peroxidation. Misbalance among the products of lipids peroxidation and components of antioxidation defense system revealed in cardiovascular diseases (mainly in arterial hypertension and heart failure) promotes progress of these diseases and premature aging of an organism. The therapy aimed at normalization of the oxidative profile of the patients with arterial hypertension should include prolonged beta-blockers, ACE inhibitors, calcium antagonists, statines and polyvitamin complexes with vitamins A and E</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)JC - 100971443CP - Russia (Federation)PT - English AbstractPT - Journal ArticleLG - Russian</style></notes><urls/><custom1><style face="normal" font="default">UI - 19947395</style></custom1><custom3><style face="normal" font="default">AS - Adv Gerontol. 22(2):316-21, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>258</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Khau Van,Kien P.</style></author><author><style face="normal" font="default"> Baux,D.</style></author><author><style face="normal" font="default"> Pallares-Ruiz,N.</style></author><author><style face="normal" font="default"> Baudoin,C.</style></author><author><style face="normal" font="default"> Plancke,A.</style></author><author><style face="normal" font="default"> Chassaing,N.</style></author><author><style face="normal" font="default"> Collignon,P.</style></author><author><style face="normal" font="default"> Drouin-Garraud,V.</style></author><author><style face="normal" font="default"> Hovnanian,A.</style></author><author><style face="normal" font="default"> Martin-Coignard,D.</style></author><author><style face="normal" font="default"> Collod,B.</style></author><author><style face="normal" font="default"> roud,C.</style></author><author><style face="normal" font="default"> Roux,A.F.</style></author><author><style face="normal" font="default"> Claustres,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Missense mutations of conserved glycine residues in fibrillin-1 highlight a potential subtype of cb-EGF-like domains</style></title><secondary-title><style face="normal" font="default">Human Mutation</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Human Mutation</style></full-title></periodical><pages end="E1042" start="E1021">E1021-E1042</pages><volume><style face="normal" font="default">31</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Epidermal Growth Factor</style></keyword><keyword><style face="normal" font="default"> *Marfan Syndrome/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Microfilament Proteins/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Mutation,Missense</style></keyword><keyword><style face="normal" font="default"> 0 (fibrillin)</style></keyword><keyword><style face="normal" font="default"> 0 (Microfilament Proteins)</style></keyword><keyword><style face="normal" font="default"> 56-40-6 (Glycine)</style></keyword><keyword><style face="normal" font="default"> 62229-50-9 (Epidermal Growth Factor)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Epidermal Growth Factor/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> Epidermal Growth Factor/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Epidermal Growth Factor/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Glycine/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> Glycine/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Marfan Syndrome/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Microfilament Proteins/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Models,Molecular</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Pedigree</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sequence Analysis,DNA</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="1" Year="2010">2010/1</year></dates><abstract><style face="normal" font="default">In six index cases/families referred for Marfan syndrome (MFS) molecular diagnosis, we identified six novel mutations in the FBN1 gene: c.1753G>C (p.Gly585Arg), c.2456G>A (p.Gly819Glu), c.4981G>A (p.Gly1661Arg), c.5339G>A (p.Gly1780Glu), c.6418G>A (p.Gly2140Arg) and c.6419G>A (p.Gly2140Glu). These variants, predicted to result in Glycine substitutions are located at the third position of a 4 amino acids loop-region of calcium-binding Epidermal Growth Factor-like (cb-EGF) fibrillin-1 domains 5, 9, 24, 25 and 32. Familial segregation studies showing cosegregation with MFS manifestations or de novo inheritance in addition to in silico analyses (conservation, 3D modeling) suggest evidence for a crucial role of the respective Glycine positions. Extending these analyses to all Glycine residue at position 3 of this 4 residues loop in fibrillin-1 cb-EGF with the UMD predictor tool and alignment of 2038 available related sequences strongly support a steric strain that only allows Glycine or even Alanine residues for domain structure maintenance and for the fibrillin functions. Our data compared with those of the literature strongly suggest the existence of a cb-EGF domain subtype with implications for related diseases</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - CHU Montpellier, H&amp;#x00F4;pital Arnaud de Villeneuve, Laboratoire de G&amp;#x00E9;n&amp;#x00E9;tique Mol&amp;#x00E9;culaire, Montpellier, F-34000 France. p-khau_van_kien@chu-montpellier.frJC - brd, 9215429CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19802897</style></custom1><custom3><style face="normal" font="default">AS - Hum Mutat. 31(1):E1021-42, 2010 Jan.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>182</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Kiani,A.N.</style></author><author><style face="normal" font="default"> Vogel-Claussen,J.</style></author><author><style face="normal" font="default"> Magder,L.S.</style></author><author><style face="normal" font="default"> Petri,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Noncalcified coronary plaque in systemic lupus erythematosus</style></title><secondary-title><style face="normal" font="default">Journal of Rheumatology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Rheumatology</style></full-title></periodical><pages end="584" start="579">579-584</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Lupus Erythematosus,Systemic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> 0 (Anti-Inflammatory Agents,Non-Steroidal)</style></keyword><keyword><style face="normal" font="default"> 0 (Complement C3)</style></keyword><keyword><style face="normal" font="default"> 0 (Complement C4)</style></keyword><keyword><style face="normal" font="default"> 0 (Immunosuppressive Agents)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Anti-Inflammatory Agents,Non-Steroidal/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Complement C3/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Complement C4/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hormone Replacement Therapy</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immunosuppressive Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Lupus Erythematosus,Systemic/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,Spiral Computed</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="3" Year="2010">2010/3</year></dates><isbn><style face="normal" font="default">0315-162X</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: To study noncalcified coronary plaque (NCP) in systemic lupus erythematosus (SLE). METHODS: Sixty-four-slice coronary multidetector computed tomography (MDCT) was performed in 39 consecutive patients with SLE. MDCT scans were evaluated semiquantitatively by a radiologist using dedicated software. The presence or absence of NCP in each coronary artery was assessed. Patients with mixed plaque (calcified and noncalcified portions) were included in the NCP group. RESULTS: The patient group was 90% women, 64% Caucasian, 31% African American, 5% other; mean age 50.5 +/- 9.6 years. Fifty-four percent (21/39) had NCP. Seventy-six percent (16/21) of those with NCP also had coronary calcium (range 0.7 to 1264.1 Agatston units). In univariate analysis, NCP was associated with age (p = 0.01), current nonsteroidal antiinflammatory drug (NSAID) use (p = 0.04), hormone replacement therapy (p = 0.02), current use of immunosuppressive drugs (p = 0.02), current low serum C3 level (p = 0.07), current physician's global assessment of activity (PGA; p = 0.05), and low-density lipoprotein cholesterol (p = 0.04). NCP was not associated with other risk factors for atherosclerosis, including total serum cholesterol, high sensitivity C-reactive protein, and lipoprotein(a). CONCLUSION: Unlike coronary calcium, which is not associated with SLE activity measures or with active serologies, NCP is more common in patients with SLE with current, 3-, and 6-month activity by PGA. NCP was also associated with the need for current NSAID or immunosuppressive therapy. NCP is an important part of the total atherosclerotic burden in SLE</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Rheumatology and Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USAJC - 7501984, jwxCP - CanadaPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - AR 43727 (United States NIAMS NIH HHS)NO - UL1 RR 025005 (United States NCRR NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20110529</style></custom1><custom3><style face="normal" font="default">AS - J Rheumatol. 37(3):579-84, 2010 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>294</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">kiewicz,A.</style></author><author><style face="normal" font="default"> Sygnowska,E.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Vitamins and minerals intake from diet and supplements among subjects with a history of cardiovascular events in Polish population]. [Polish]</style></title><secondary-title><style face="normal" font="default">Roczniki Panstwowego Zakladu Higieny</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Roczniki Panstwowego Zakladu Higieny</style></full-title></periodical><pages end="278" start="275">275-278</pages><volume><style face="normal" font="default">60</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiovascular Diseases/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Diet/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> *Dietary Supplements/ut [Utilization]</style></keyword><keyword><style face="normal" font="default"> *Food Habits</style></keyword><keyword><style face="normal" font="default"> *Minerals/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Vitamins/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> 0 (Minerals)</style></keyword><keyword><style face="normal" font="default"> 0 (Vitamins)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Food Preferences</style></keyword><keyword><style face="normal" font="default"> Health Behavior</style></keyword><keyword><style face="normal" font="default"> Health Knowledge,Attitudes,Practice</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Poland/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Population Surveillance</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><isbn><style face="normal" font="default">0035-7715</style></isbn><abstract><style face="normal" font="default">Some vitamins and minerals play an important role in the secondary prevention of cardiovascular diseases (CVD). The aim of this study was the assessment of dietary vitamins and minerals intake and patterns of supplement use among subjects with diagnosed CVD in Polish population. Within the frame of the WOBASZ study, a representative sample of whole Polish population aged 20-74 (7257 subjects) was screened in 2003-2005. A subsample of 803 persons with a clinical history of cardiovascular events was analyzed. It was found, that the average diet of adult Polish citizens with established CVD was not balanced concerning the intake of vitamins and minerals. Daily intake of antioxidant vitamins (A, C and E) and vitamin B12 was satisfactory the realization degree of recommended dietary allowances (RDA) was about 126-310%. The insufficient amounts of vitamins B1, B2, folates, as well as potassium, calcium, magnesium in diet of both genders and vitamin B6 in men and iron in women were noted. The highest deficiency has been noticed in vitamins B1, B2 and calcium and magnesium intake--the realization degree of RDA has stayed on 54-82% level. Around 1% of potassium, calcium and magnesium intake in both genders and more than 25% of vitamins E and B6 consumption in women derived from the supplementation</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Zaklad Epidemiologii, Prewencji Chor&amp;#x00F3;b Ukladu Krazenia i Promocji Zdrowia, Instytut Kardiologii, Warszawa. awaskiwicz@ikard.plOT - Spozycie witamin i skladnik&amp;#x00F3;w mineralnych z uwzglednieniem suplementacji u os&amp;#x00F3;b po przebytych incydentach sercowo-naczyniowych w populacji polskiejJC - txt, 0414756CP - PolandPT - English AbstractPT - Journal ArticleLG - Polish</style></notes><urls/><custom1><style face="normal" font="default">UI - 20063699</style></custom1><custom3><style face="normal" font="default">AS - Rocz Panstw Zakl Hig. 60(3):275-8, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>259</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Kim,J.E.</style></author><author><style face="normal" font="default"> Yoo,C.</style></author><author><style face="normal" font="default"> Lee,D.H.</style></author><author><style face="normal" font="default"> Kim,S.W.</style></author><author><style face="normal" font="default"> Lee,J.S.</style></author><author><style face="normal" font="default"> Suh,C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma</style></title><secondary-title><style face="normal" font="default">Annals of Hematology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Annals of Hematology</style></full-title></periodical><pages end="397" start="391">391-397</pages><volume><style face="normal" font="default">89</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Multiple Myeloma/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Multiple Myeloma/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Serum Albumin/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> 0 (Antineoplastic Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Serum Albumin)</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Antineoplastic Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multiple Myeloma/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Multiple Myeloma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Stem Cell Transplantation</style></keyword><keyword><style face="normal" font="default"> Transplantation,Autologous</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">Serum albumin level, in association with serum interleukin-6 level, is a significant prognostic factor in multiple myeloma patients. The aim of this study was to determine any clinical factors associated with decreased serum albumin level. We retrospectively reviewed the records of 373 patients diagnosed with multiple myeloma at the Asan Medical Center, Seoul, Korea, between January 1996 and March 2008. Patients were divided into two groups according to serum albumin level (above or below 3.5 g/dL, the prognostic cutoff value), and clinical parameters were compared between groups. We aimed to identify any clinical parameters associated with low serum albumin levels. The group with serum albumin &lt;3.5 g/dL showed older patient age, lower hemoglobin level, and poorer performance status. By contrast, levels of serum beta(2)-microglobulin, serum M protein, and bone marrow plasma cells were significantly higher in the group with low serum albumin levels. No significant between-group differences were found when serum calcium and creatinine levels were compared. Numbers of cytogenetic abnormalities and lytic bone lesions also showed no significant between-group differences. In both univariate and multivariate analyses, serum albumin level less than 3.5 g/dL was identified as a significant pretreatment prognostic factor. Lower serum albumin levels in multiple myeloma patients are associated with clinical factors reflecting disease severity</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 86 Asan Byeongwon gil, Songpa-gu, Seoul, 138-736, South KoreaJC - a2p, 9107334CP - GermanyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19844712</style></custom1><custom3><style face="normal" font="default">AS - Ann Hematol. 89(4):391-7, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>90</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Kinoshita,H.</style></author><author><style face="normal" font="default"> Kokudo,T.</style></author><author><style face="normal" font="default"> Ide,T.</style></author><author><style face="normal" font="default"> Kondo,Y.</style></author><author><style face="normal" font="default"> Mori,T.</style></author><author><style face="normal" font="default"> Homma,Y.</style></author><author><style face="normal" font="default"> Yasuda,M.</style></author><author><style face="normal" font="default"> Tomiyama,J.</style></author><author><style face="normal" font="default"> Yakushiji,F.</style></author></authors></contributors><titles><title><style face="normal" font="default">A patient with DiGeorge syndrome with spina bifida and sacral myelomeningocele, who developed both hypocalcemia-induced seizure and epilepsy</style></title><secondary-title><style face="normal" font="default">Seizure</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Seizure</style></full-title></periodical><pages end="305" start="303">303-305</pages><volume><style face="normal" font="default">19</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*DiGeorge Syndrome/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Epilepsy/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Hypocalcemia/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Hypocalcemia/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Meningomyelocele/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Seizures/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Spinal Dysraphism/co [Complications]</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Brain/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Brain/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Chromosome Aberrations</style></keyword><keyword><style face="normal" font="default"> Gene Deletion</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Mental Retardation/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Parathyroid Glands/ab [Abnormalities]</style></keyword><keyword><style face="normal" font="default"> Parathyroid Glands/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword></keywords><dates><year Day="0" Month="6" Year="2010">2010/6</year></dates><abstract><style face="normal" font="default">DiGeorge syndrome - a component of the 22q11 deletion syndrome - causes a disturbance in cervical neural crest migration that results in parathyroid hypoplasia. Patients can develop hypocalcemia-induced seizures. Spina bifida is caused by failure of neurulation, including a disturbance in the adhesion processes at the neurula stage. Spina bifida has been reported as a risk factor for epilepsy. We report, for the first time, the case of a patient with DiGeorge syndrome with spina bifida and sacral myelomeningocele, who developed both hypocalcemia-induced seizures and epilepsy. The patient had spina bifida and sacral myelomeningocele at birth. At the age of 13 years, he experienced a seizure for the first time. At this time, the calcium concentration was normal. An electroencephalogram (EEG) proved that the seizure was due to epilepsy. Antiepileptic medications controlled the seizure. At the age of 29, the patient's calcium concentration began to reduce. At the age of 40, hypocalcemia-induced seizure occurred. At this time, the calcium concentration was 5.5mg/dL (reference range, 8.7-10.1mg/dL). The level of intact parathyroid hormone (PTH) was 6 pg/mL (reference range, 10-65 pg/mL). Chromosomal and genetic examinations revealed a deletion of TUP-like enhancer of split gene 1 (tuple1)-the diagnostic marker of DiGeorge syndrome. Many patients with DiGeorge syndrome have cardiac anomalies; however, our patient had none. We propose that the association among DiGeorge syndrome, spina bifida, epilepsy, cardiac anomaly, 22q11, tuple1, and microdeletion inheritance should be clarified for appropriate diagnosis and treatment. Copyright 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Internal Medicine, Tokyo Metropolitan Bokutoh Hospital, 4-23-15, Koutoh-bashi, Sumida-ku, Tokyo, Japan. hkinoshita-tky@umin.ac.jpJC - b1j, 9306979CP - EnglandPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20430655</style></custom1><custom3><style face="normal" font="default">AS - Seizure. 19(5):303-5, 2010 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>97</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Kirsch,J.</style></author><author><style face="normal" font="default"> Johansen,C.K.</style></author><author><style face="normal" font="default"> Araoz,P.A.</style></author><author><style face="normal" font="default"> Brady,P.A.</style></author><author><style face="normal" font="default"> Williamson,E.E.</style></author><author><style face="normal" font="default"> Glockner,J.F.</style></author></authors></contributors><titles><title><style face="normal" font="default">Prevalence of fat deposition within the right ventricular myocardium in asymptomatic young patients without ventricular arrhythmias</style></title><secondary-title><style face="normal" font="default">Journal of Thoracic Imaging</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Thoracic Imaging</style></full-title></periodical><pages end="178" start="173">173-178</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Adipose Tissue/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Heart Ventricles/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Adipose Tissue/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Chi-Square Distribution</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Ventricles/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Mass Screening</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Radiographic Image Interpretation,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="5" Year="2010">2010/5</year></dates><abstract><style face="normal" font="default">PURPOSE: Variable amounts of intramyocardial fat can be found within the right ventricular muscle fibers. We aimed to determine the prevalence of intramyocardial fat deposition within the right ventricle (RV) in asymptomatic patients aged 40 years and younger who underwent imaging of the heart for coronary artery disease screening. MATERIALS AND METHODS: Retrospective review of 540 consecutive patients aged 40 years or younger referred for coronary calcium scoring. RESULTS: The images were reviewed by 2 dedicated cardiac radiologists, and the following specific observations were made: presence or absence of macroscopic fat in the RV by location, RV size as normal or enlarged, and presence of additional foci of fat deposition in the visualized thorax. The clinical data were reviewed from the patients' medical record, and the following information was recorded: age, sex, body mass index, and the presence of cardiac risk factors. The electrocardiographic examinations were reviewed as well. The study cohort included 398 males (73%) and 142 females (27%), with a mean age of 36.2+/-4.3 years and a range of 12 to 40 years. Sixty-two patients (11.5%) had macroscopic fatty deposition of the RV myocardium. CONCLUSIONS: Fatty replacement of the free wall of the RV is common, occurring in up to 11% of asymptomatic patients younger than 40 years of age undergoing cardiac screening examinations. No statistically significant association with cardiac risk factors or body mass index was found</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Radiology, Mayo Clinic, Rochester, MN, USA. kirschj@ccf.orgJC - kau, 8606160CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20463537</style></custom1><custom3><style face="normal" font="default">AS - J Thorac Imaging. 25(2):173-8, 2010 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>510</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Kobayashi,N.</style></author><author><style face="normal" font="default"> Hata,N.</style></author><author><style face="normal" font="default"> Yokoyama,S.</style></author><author><style face="normal" font="default"> Shinada,T.</style></author><author><style face="normal" font="default"> Shirakabe,A.</style></author><author><style face="normal" font="default"> Mizuno,K.</style></author></authors></contributors><titles><title><style face="normal" font="default">A case of Takotsubo cardiomyopathy during 5-fluorouracil treatment for rectal adenocarcinoma</style></title><secondary-title><style face="normal" font="default">Journal of Nippon Medical School = Nihon Ika Daigahu Zasshi</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Nippon Medical School = Nihon Ika Daigahu Zasshi</style></full-title></periodical><pages end="33" start="27">27-33</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Adenocarcinoma/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Antimetabolites,Antineoplastic/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Fluorouracil/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Rectal Neoplasms/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Takotsubo Cardiomyopathy/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> 0 (Antimetabolites,Antineoplastic)</style></keyword><keyword><style face="normal" font="default"> 51-21-8 (Fluorouracil)</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Electrocardiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Failure/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Takotsubo Cardiomyopathy/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Takotsubo Cardiomyopathy/di [Diagnosis]</style></keyword></keywords><dates><year Day="0" Month="2" Year="2009">2009/2</year></dates><isbn><style face="normal" font="default">1345-4676</style></isbn><abstract><style face="normal" font="default">A case of acute heart failure due to Takotsubo cardiomyopathy induced by 5-fluorouracil is described. Acute heart failure developed during the administration of 5-fluorouracil (5-FU) and levofolinate calcium in a 62-year-old woman who had underwent a Miles operation for rectal adenocarcinoma. Electrocardiography upon admission showed slight ST elevation in leads V1-3, and follow-up electrocardiography on the third hospital day evealed QT interval prolongation and giant negative T waves in leads II, III, aVF, and V1-6. Echocardiography and myocardial scintigraphy showed left ventricular apical ballooning in the acute phase of heart failure, but left ventricular contraction was normal during the recovery phase. Coronary angiography demonstrated normal coronary arteries, and multi-vessel coronary artery vasospasms including microcirculation disorders could be provoked by intracoronary acetylcholine infusion during, but not before, the intravenous administration of levofolinate calcium and 5-FU. The cause of heart failure in this patient, Takotsubo cardiomyopathy induced by multivessel coronary vasospasm including microcirculation disorders only during 5-FU administration, is notable</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Internal Medicine, Graduate School of Medicine, Nippon Medical School, Chiba Hokusoh Hospital, Chiba, Japan. s5047@nms.ac.jpJC - 100935589, dlaCP - JapanPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19305108</style></custom1><custom3><style face="normal" font="default">AS - J Nippon Med Sch. 76(1):27-33, 2009 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>64</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Koenig,W.</style></author></authors></contributors><titles><title><style face="normal" font="default">Integrating biomarkers: the new frontier?</style></title><secondary-title><style face="normal" font="default">Scandinavian Journal of Clinical and Laboratory Investigation Supplement</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Scandinavian Journal of Clinical and Laboratory Investigation Supplement</style></full-title></periodical><pages end="123" start="117">117-123</pages><volume><style face="normal" font="default">242</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Carotid Artery Diseases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Chemistry,Clinical/td [Trends]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcinosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Carotid Artery Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Carotid Artery Diseases/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Chemistry,Clinical/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Models,Statistical</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="7" Year="2010">2010/7</year></dates><isbn><style face="normal" font="default">0085-591X</style></isbn><abstract><style face="normal" font="default">Risk stratification for cardiovascular diseases (CVD) remains suboptimal even after the introduction of global risk assessment by various scores. This has prompted the search for additional biomarkers which might help to improve risk stratification. Basically, there are blood biomarkers representing various pathophysiological pathways of atherosclerosis, markers of subclinical disease, and potentially genetic markers. Since inflammatory processes accompany all stages of atherosclerosis, measurement of plasma/serum concentrations of circulating inflammatory biomarkers has received great attention. Such biomarkers can be measured systemically by sensitive assays and elevated concentrations in the circulation have been shown to be associated with future CVD events. Thus, they might add to the predictive value of the atherogenic lipoprotein phenotype to further improve CVD risk assessment. In addition, several non-invasive imaging techniques are available for which also a predictive value for CVD could be established, in particular measurement of the intima-media thickness of the carotid artery using high resolution ultrasound and measurements of coronary calcium by coronary computed tomography. However, for most of these biomarkers the clinical utility has not yet been firmly established. This applies even more to an integrated approach combining blood biomarkers and markers of subclinical disease. Thus, more data, preferably from serial measurements in large populations taking also into account new candidates from "omics" technology are needed to gain further insight in the potential clinical usefulness of an integrated approach</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, Ulm, Germany. wolfgang.koenig@uniklinik-ulm.deJC - ucr, 2984789rCP - EnglandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20515289</style></custom1><custom3><style face="normal" font="default">AS - Scand J Clin Lab Invest Suppl. 242:117-23, 2010 Jul.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>446</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Koleganova,N.</style></author><author><style face="normal" font="default"> Piecha,G.</style></author><author><style face="normal" font="default"> Ritz,E.</style></author><author><style face="normal" font="default"> Schirmacher,P.</style></author><author><style face="normal" font="default"> ller,A.</style></author><author><style face="normal" font="default"> Meyer,H.P.</style></author><author><style face="normal" font="default"> Gross,M.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Arterial calcification in patients with chronic kidney disease</style></title><secondary-title><style face="normal" font="default">Nephrology Dialysis Transplantation</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Nephrology Dialysis Transplantation</style></full-title></periodical><pages end="2496" start="2488">2488-2496</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aorta/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Biological Markers/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure,Chronic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Vascular Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Tumor Necrosis Factor-alpha)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 7723-14-0 (Phosphorus)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aorta/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Apoptosis</style></keyword><keyword><style face="normal" font="default"> Autopsy</style></keyword><keyword><style face="normal" font="default"> Calcinosis/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Cell Differentiation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Osteoblasts/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Osteoblasts/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Oxidative Stress</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phosphorus/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tumor Necrosis Factor-alpha/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Tunica Intima/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Vascular Diseases/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Vascular Diseases/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> X-Rays</style></keyword></keywords><dates><year Day="0" Month="8" Year="2009">2009/8</year></dates><abstract><style face="normal" font="default">OBJECTIVE: In patients with chronic kidney disease (CKD), aortic calcification is more frequent and severe and it is also predictive of adverse cardiovascular outcome. The aim of the present study was to characterize aortic calcification in renal compared with non-renal patients. METHODS: Aortas of 31 patients with advanced CKD and of 31 age-and gender-matched controls were obtained at autopsy. Calcium and phosphorus content in the aorta was quantitated using x-ray analysis. The expression of calcification-promoting and calcification-inhibiting proteins was assessed using immunohistochemistry. RESULTS: The calcium and phosphorus content of the aorta was higher in CKD patients than in controls. Even in non-calcified aortic specimens of CKD, staining for Msx-2, BMP-2, bone sialo-protein, TNF-alpha and nitrotyrosine was significantly more marked compared to controls. The same proteins were immunodetected in calcified aortic specimens of both CKD and controls. In contrast, staining for transglutaminase-2 and Fetuin A was significantly reduced in CKD. Higher expression of cbfa-1 and Pit-1 was observed in all calcified aortas with no difference between CKD and controls. The expression of TNF-alpha, phospho-p38 and Msx-2 was correlated to the intensity of upregulation of BMP-2 and osteoblastic transdifferentiation by VSMC even in non-calcified areas of the aortas of CKD. CONCLUSION: The expression of markers characteristic for calcification is not different in calcified aorta of CKD patients compared to controls, but in CKD patients, evidence of inflammation, transformation to an osteoblastic phenotype and reduced expression of transglutaminase are also found even in non-calcified aorta</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Internal Medicine, University of Heidelberg, Heidelberg, Germany. nad_ko@gmx.deJC - n7j, 8706402CP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19329792</style></custom1><custom3><style face="normal" font="default">AS - Nephrol Dial Transplant. 24(8):2488-96, 2009 Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>256</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Kolseth,S.M.</style></author><author><style face="normal" font="default"> Nordhaug,D.O.</style></author><author><style face="normal" font="default"> Stenseth,R.</style></author><author><style face="normal" font="default"> Sellevold,O.</style></author><author><style face="normal" font="default"> Kirkeby-Garstad,I.</style></author><author><style face="normal" font="default"> Wahba,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Prophylactic treatment with levosimendan: a retrospective matched-control study of patients with reduced left ventricular function</style></title><secondary-title><style face="normal" font="default">European Journal of Cardio-Thoracic Surgery</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">European Journal of Cardio-Thoracic Surgery</style></full-title></periodical><pages end="1030" start="1024">1024-1030</pages><volume><style face="normal" font="default">36</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiopulmonary Bypass/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Heart Failure/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Hydrazones/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Pyridazines/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Vasodilator Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Ventricular Dysfunction,Left/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> 0 (Cardiotonic Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Hydrazones)</style></keyword><keyword><style face="normal" font="default"> 0 (Phosphodiesterase Inhibitors)</style></keyword><keyword><style face="normal" font="default"> 0 (Pyridazines)</style></keyword><keyword><style face="normal" font="default"> 0 (Vasodilator Agents)</style></keyword><keyword><style face="normal" font="default"> 131741-08-7 (simendan)</style></keyword><keyword><style face="normal" font="default"> 51-41-2 (Norepinephrine)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Cardiotonic Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default"> Drug Evaluation/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Failure/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Heart Rate</style></keyword><keyword><style face="normal" font="default"> Hemodynamics/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hydrazones/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Intensive Care</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Norepinephrine/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Norway</style></keyword><keyword><style face="normal" font="default"> Phosphodiesterase Inhibitors/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Phosphodiesterase Inhibitors/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Preanesthetic Medication</style></keyword><keyword><style face="normal" font="default"> Pyridazines/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Stroke Volume</style></keyword><keyword><style face="normal" font="default"> Stroke Volume/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Vasodilator Agents/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Ventricular Dysfunction,Left/pp [Physiopathology]</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Levosimendan is a calcium-sensitising inotropic agent and a vasodilator used in the treatment of heart failure. Post-cardiotomy cardiac failure is more common in patients with a low preoperative left ventricular ejection fraction (LVEF). We aim at investigating how prophylactic treatment with levosimendan before weaning from cardiopulmonary bypass (CPB) affects postoperative haemodynamics and outcome in patients with low preoperative LVEF. METHODS: Patients with a preoperative LVEF &lt; or =30% treated with levosimendan before weaning from CPB were included in the study. Each patient was matched to a control patient with respect to the following criteria: surgical procedure, EuroSCORE, age, gender and the use of intra-aortic balloon pump. We investigated postoperative haemodynamics in the intensive care unit (ICU) at time points: 1, arrival; 2, approximately 7h after arrival; and 3, the first postoperative morning. In addition, mortality was evaluated. RESULTS: Thirty patients treated with levosimendan and 30 matched controls were enrolled in the study. No statistically significant differences in cardiac index (CI) (l min(-1)m(-2)), stroke volume index (SVI) (mlm(-2)), mixed venous O(2)-saturation (SvO(2)) (%) or heart rate (HR) (beats per minute) between the two groups measured at the three time points 1-3 were registered. Mean arterial blood pressure (MAP) (mmHg) was lower in the levosimendan group both at time points 2 (68, range: 65-71 vs 75, range: 72-78; p=0.009) and 3 (72, range: 69-74 vs 78, range: 74-82; p=0.01), despite a higher dose of norepinephrine in the treatment group (p=0.021). A significantly higher number of control patients were treated with classic adrenergic inotropes both in the operating room (p=0.013) and in the ICU (p&lt;0.001). Thirty days mortality was the same in both groups (7%). CONCLUSIONS: Prophylactic infusion of levosimendan initiated before weaning from CPB did not lead to superior haemodynamic parameters (CI, SVI, SvO(2)) compared to controls. Levosimendan reduced MAP and increased the need for norepinephrine postoperatively</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Circulation and Medical Imaging, The Norwegian University of Science and Technology, Trondheim, NorwayJC - aoj, 8804069CP - GermanyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19592266</style></custom1><custom3><style face="normal" font="default">AS - Eur J Cardiothorac Surg. 36(6):1024-30, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>87</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Kontaraki,J.E.</style></author><author><style face="normal" font="default"> Parthenakis,F.I.</style></author><author><style face="normal" font="default"> Nyktari,E.G.</style></author><author><style face="normal" font="default"> Patrianakos,A.P.</style></author><author><style face="normal" font="default"> Vardas,P.E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Myocardial gene expression alterations in peripheral blood mononuclear cells of patients with idiopathic dilated cardiomyopathy</style></title><secondary-title><style face="normal" font="default">European Journal of Heart Failure</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">European Journal of Heart Failure</style></full-title></periodical><pages end="548" start="541">541-548</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiomyopathy,Dilated/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Leukocytes,Mononuclear/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Ventricular Dysfunction,Left/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathy,Dilated/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathy,Dilated/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Ventricular Dysfunction,Left/us [Ultrasonography]</style></keyword></keywords><dates><year Day="0" Month="6" Year="2010">2010/6</year></dates><abstract><style face="normal" font="default">AIMS: To assess cardiac gene expression in peripheral blood cells of patients with idiopathic dilated cardiomyopathy (IDCM) and its relationship to echocardiographic left ventricular (LV) function. METHODS AND RESULTS: A complete echocardiographic study and blood sampling were performed in 65 consecutive stable IDCM patients with LV ejection fraction (LVEF) 31.76 +/- 10.07% and chronic mild to moderate heart failure (NYHA functional class II to III) for > or =9 months. Blood samples from 19 healthy individuals were included for comparison. Transcript levels of myocardin, GATA4, alpha- and beta-myosin heavy chain (MHC), sarcoplasmic reticulum calcium ATPase 2 (SERCA2), and phospholamban were determined by quantitative real-time reverse transcription-polymerase chain reaction. Myocardin (24.88 +/- 4.93 vs. 3.98 +/- 1.12, P = 0.0048) and GATA4 (17.85 +/- 4.85 vs. 0.45 +/- 0.15, P = 0.0069 x 10(-5)) were upregulated in IDCM patients compared with controls, whereas SERCA2 (5.11 +/- 0.42 vs. 8.93 +/- 1.07, P = 0.001) was downregulated. In IDCM patients, myocardin (r = 0.279, P = 0.025), GATA4 (r = 0.314, P = 0.011), beta-MHC (r = 0.444, P=0.0002), and alpha-MHC (r = 0.272, P = 0.034) showed positive correlations, whereas SERCA2 (r = -0.264, P = 0.034) exhibited a negative correlation with LVEF. Patients with elevated LV filling pressures had lower myocardin (15.06 +/- 3.10 vs. 43.12 +/- 12.03, P = 0.048), GATA4 (8.96 +/- 2.17 vs. 34.38 +/- 12.60, P = 0.026), beta-MHC (10.59 +/- 4.05 vs. 16.43 +/- 4.91, P = 0.013), and alpha-MHC (0.27 +/- 0.08 vs. 0.79 +/- 0.20, P = 0.033) and higher SERCA2 (5.65 +/- 0.54 vs. 3.90 +/- 0.61, P = 0.037) levels. Patients with atrial fibrillation (AF) had higher SERCA2 levels compared with sinus rhythm patients (6.75 +/- 0.84 vs. 4.54 +/- 0.45, P = 0.017). CONCLUSION: Our data indicate that cardiac gene expression alterations in peripheral blood cells of IDCM patients may reflect alterations in LV function, whereas the presence of AF may be associated with increased SERCA2 levels in these patients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Molecular Cardiology Laboratory, School of Medicine, University of Crete, Crete, Greece. kontarak@med.uoc.grJC - dr4, 100887595CP - NetherlandsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20388650</style></custom1><custom3><style face="normal" font="default">AS - Eur J Heart Fail. 12(6):541-8, 2010 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>239</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Kooij,V.</style></author><author><style face="normal" font="default"> Boontje,N.</style></author><author><style face="normal" font="default"> Zaremba,R.</style></author><author><style face="normal" font="default"> Jaquet,K.</style></author><author><style face="normal" font="default"> dos,Remedios C.</style></author><author><style face="normal" font="default"> Stienen,G.J.</style></author><author><style face="normal" font="default"> van,der,V</style></author></authors></contributors><titles><title><style face="normal" font="default">Protein kinase C alpha and epsilon phosphorylation of troponin and myosin binding protein C reduce Ca2+ sensitivity in human myocardium</style></title><secondary-title><style face="normal" font="default">Basic Research in Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Basic Research in Cardiology</style></full-title></periodical><pages end="300" start="289">289-300</pages><volume><style face="normal" font="default">105</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Heart Failure/en [Enzymology]</style></keyword><keyword><style face="normal" font="default"> *Myocardium/en [Enzymology]</style></keyword><keyword><style face="normal" font="default"> *Protein Kinase C-alpha/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Protein Kinase C-epsilon/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> 0 (Carrier Proteins)</style></keyword><keyword><style face="normal" font="default"> 0 (myosin-binding protein C)</style></keyword><keyword><style face="normal" font="default"> 0 (Troponin I)</style></keyword><keyword><style face="normal" font="default"> 0 (Troponin T)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Carrier Proteins/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Cells,Cultured</style></keyword><keyword><style face="normal" font="default"> EC 2-7-11-13 (Protein Kinase C-alpha)</style></keyword><keyword><style face="normal" font="default"> EC 2-7-11-13 (Protein Kinase C-epsilon)</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Phosphorylation</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Troponin I/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Troponin T/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="3" Year="2010">2010/3</year></dates><abstract><style face="normal" font="default">Previous studies indicated that the increase in protein kinase C (PKC)-mediated myofilament protein phosphorylation observed in failing myocardium might be detrimental for contractile function. This study was designed to reveal and compare the effects of PKCalpha- and PKCepsilon-mediated phosphorylation on myofilament function in human myocardium. Isometric force was measured at different [Ca2+] in single permeabilized cardiomyocytes from failing human left ventricular tissue. Activated PKCalpha and PKCepsilon equally reduced Ca2+ sensitivity in failing cardiomyocytes (DeltapCa50 = 0.08 +/- 0.01). Both PKC isoforms increased phosphorylation of troponin I- (cTnI) and myosin binding protein C (cMyBP-C) in failing cardiomyocytes. Subsequent incubation of failing cardiomyocytes with the catalytic subunit of protein kinase A (PKA) resulted in a further reduction in Ca2+ sensitivity, indicating that the effects of both PKC isoforms were not caused by cross-phosphorylation of PKA sites. Both isozymes showed no effects on maximal force and only PKCalpha resulted in a modest significant reduction in passive force. Effects of PKCalpha were only minor in donor cardiomyocytes, presumably because of already saturated cTnI and cMyBP-C phosphorylation levels. Donor tissue could therefore be used as a tool to reveal the functional effects of troponin T (cTnT) phosphorylation by PKCalpha. Massive dephosphorylation of cTnT with alkaline phosphatase increased Ca2+ sensitivity. Subsequently, PKCalpha treatment of donor cardiomyocytes reduced Ca2+ sensitivity (DeltapCa50 = 0.08 +/- 0.02) and solely increased phosphorylation of cTnT, but did not affect maximal and passive force. PKCalpha- and PKCepsilon-mediated phosphorylation of cMyBP-C and cTnI as well as cTnT decrease myofilament Ca2+ sensitivity and may thereby reduce contractility and enhance relaxation of human myocardium</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Laboratory for Physiology, Institute for Cardiovascular Research, VU University Medical Center, van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands. v.kooij@vumc.nlJC - 9k3, 0360342CP - GermanyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19655190</style></custom1><custom3><style face="normal" font="default">AS - Basic Res Cardiol. 105(2):289-300, 2010 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>181</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Koos,R.</style></author><author><style face="normal" font="default"> Brandenburg,V.</style></author><author><style face="normal" font="default"> Mahnken,A.H.</style></author><author><style face="normal" font="default"> hlenbruch,G.</style></author><author><style face="normal" font="default"> Stanzel,S.</style></author><author><style face="normal" font="default"> nther,R.W.</style></author><author><style face="normal" font="default"> Floege,J.</style></author><author><style face="normal" font="default"> Jahnen-Dechent,W.</style></author><author><style face="normal" font="default"> Kelm,M.</style></author><author><style face="normal" font="default"> hl,H.P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Association of fetuin-A levels with the progression of aortic valve calcification in non-dialyzed patients</style></title><secondary-title><style face="normal" font="default">European Heart Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">European Heart Journal</style></full-title></periodical><pages end="2061" start="2054">2054-2061</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">16</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aortic Diseases/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Aortic Valve</style></keyword><keyword><style face="normal" font="default"> *Blood Proteins/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> 0 (alpha2HS glycoprotein)</style></keyword><keyword><style face="normal" font="default"> 0 (Blood Proteins)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Blood Proteins/df [Deficiency]</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Tomography,Spiral Computed</style></keyword></keywords><dates><year Day="0" Month="8" Year="2009">2009/8</year></dates><abstract><style face="normal" font="default">AIMS: Fetuin-A has been identified as a potent circulating inhibitor of ectopic calcification. We investigated the relationship between baseline fetuin-A serum levels and the rate of progression of aortic valve calcification (AVC) in non-dialyzed patients with aortic valve disease (AVD). METHODS AND RESULTS: Seventy-seven patients (mean age 70 +/- 8 years) with echocardiographically proven AVD were collected. In all patients, serum fetuin-A levels, creatinine, calcium, lipid parameters, and C-reactive protein were measured at baseline. For quantification of AVC progression, all patients underwent multislice spiral computed tomography examinations at baseline and after a mean follow-up of 12.6 +/- 1.4 months (range 7-18 months). In a multifactorial analysis of covariance including fetuin-A levels, baseline AVC score, the covariables sex, age, body mass index, C-reactive protein, glomerular filtration rate, serum lipids, diabetes, smoking status, and hypertension, only serum fetuin-A levels significantly predict the progression of AVC (P &lt; 0.001). Post hoc analysis demonstrated that patients with baseline fetuin-A levels lower than the median of the cohort (0.72 g/L) showed a significantly higher increase of AVC scores (34.6 +/- 31.4%) than patients with fetuin-A levels larger than the median (10.0 +/- 11.2%, P &lt; 0.001) despite comparable baseline AVC scores. In addition, fetuin-A levels were associated with major adverse clinical events (MACE; P = 0.03). CONCLUSION: Serum levels of the calcification inhibitor fetuin-A are associated with the progression of AVC and MACE, independent of the renal function and inflammation</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department for Cardiology, Pulmonology, and Vascular Medicine, University Hospital RTWH Aachen, RWTH University Aachen, Pauwelsstrasse 30, Aachen 52057, Germany. rkoos@ukaachen.deJC - em8, 8006263CP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19429630</style></custom1><custom3><style face="normal" font="default">AS - Eur Heart J. 30(16):2054-61, 2009 Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>113</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Kopec,J.</style></author><author><style face="normal" font="default"> Januszek,R.</style></author><author><style face="normal" font="default"> Wieczorek-Surdacka,E.</style></author><author><style face="normal" font="default"> Sulowicz,W.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Chronic kidney disease in the source documentation of the outpatient clinic Department of Nephrology. Part I. Causes of renal failure and characteristics of the studied population]. [Polish]</style></title><secondary-title><style face="normal" font="default">Przeglad Lekarski</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Przeglad Lekarski</style></full-title></periodical><pages end="1010" start="1003">1003-1010</pages><volume><style face="normal" font="default">66</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Ambulatory Care Facilities/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure,Chronic/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Causality</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default"> Hospitals,University/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypercholesterolemia/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Poland/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><isbn><style face="normal" font="default">0033-2240</style></isbn><abstract><style face="normal" font="default">During the last years the incidence of chronic kidney disease (CKD) is permanently increasing and has become a global social and economical problem in the world as well as in Poland. The aim of the study was the retrospective analysis of medical records of patients with renal failure under supervision at the outpatient clinic, Department of Nephrology, University Hospital in Cracow. The study population enclosed 1183 patients (640 men and 543 women) aged between 17 and 98 years (mean 64.7) with creatinine concentration >120 micromol/l and/or creatinine clearance &lt;90 ml/min/1.73 m2. Hemoglobin, iron, creatinine, urea, sodium, potasium, calcium, phosphate, magnesium, PTH, uric acid, albumin, total protein, bilirubin, glucose, total cholesterol, LDL and HDL cholesterol, triglicerydes concentration and values of hematocrite, MCV, HbA1, as well as alkaline phosphatase, AspAT, AIAT activity were estimated based on standard laboratory methods. Creatinine clearances were evaluated based on 3 different methods: simplified MDRD formula, Cockcroft-Gault formula and 24-h urine collection. Mean creatinine concentration in the studied population was 172.8 micromol/l (1.95 mg/dl). Hypertension was diagnosed in 65% of patients. In spite of treatment, more than half of the patients (51.9%) have increased systolic blood pressure and above 1/3 (35%) increased diastolic blood pressure. Mean hemoglobin concentration was 13.02 g/dl; more than 12% of patients had decreased hemoglobin below 11 g/dl. Mean values of parameters discovering calcium-phosphate metabolism were: calcium--2.33 mmol/l, phosphate--1.23 mmol/l and parathormon--169.3 pg/ml. Increased value of total serum cholesterol level was noted more than half of the patients (56.5%). Significant positive correlations were found between GFR calculated based on Cockcroft-Gault formula and BMI, hemoglobin, hematocrite, serum iron, diastolic blood pressure, total and LDL serum cholesterol, triglicerydes level, as well as AIAT activity and % values of HbA1c and negative with age, serum potassium, phosphorus, PTH and uric acid</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Katedra i Klinika Nefrologii, Uniwersytet Jagiellonski, Collegium Medicum, Krak&amp;#x00F3;wOT - Przewlekla choroba nerek w materiale Poradni Nefrologicznej. Cze&amp;#x015B;c I. Przyczyny uszkodzenia nerek oraz charakterystyka badanej populacjiJC - q96, 19840720rCP - PolandPT - English AbstractPT - Journal ArticleLG - Polish</style></notes><urls/><custom1><style face="normal" font="default">UI - 20514896</style></custom1><custom3><style face="normal" font="default">AS - Przegl Lek. 66(12):1003-10, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>308</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Koppe,C.</style></author><author><style face="normal" font="default"> guez,M.</style></author><author><style face="normal" font="default"> Winkler,K.</style></author><author><style face="normal" font="default"> Pietzsch,J.</style></author><author><style face="normal" font="default"> Neumann,K.</style></author><author><style face="normal" font="default"> Hiemann,N.E.</style></author><author><style face="normal" font="default"> Hetzer,R.</style></author><author><style face="normal" font="default"> Malmsten,M.</style></author><author><style face="normal" font="default"> Siegel,G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Reduction of arteriosclerotic nanoplaque formation and size by n-3 fatty acids in patients after valvular defect operation</style></title><secondary-title><style face="normal" font="default">Forschende Komplementarmedizin (2006)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Forschende Komplementarmedizin (2006)</style></full-title></periodical><pages end="245" start="237">237-245</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Arteriosclerosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Arteriosclerosis/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Fatty Acids,Omega-3/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Heart Valve Diseases/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> 0 (Fatty Acids,Omega-3)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipids)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipoproteins)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Endothelium,Vascular/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Valve Diseases/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Heart Valves/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lipids/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Lipoproteins/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Models,Cardiovascular</style></keyword><keyword><style face="normal" font="default"> Nanotechnology</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="8" Year="2009">2009/8</year></dates><abstract><style face="normal" font="default">BACKGROUND/METHODS: Coating a silica surface with the isolated lipoprotein receptor heparan sulfate proteoglycan (HS-PG) from arterial endothelium and vascular matrices, we could observe the very earliest stages of arteriosclerotic plaque development by ellipsometric techniques in vitro (patent EP 0 946 876). This so-called nanoplaque formation is represented by the ternary aggregational complex of the HS-PG receptor, lipoprotein particles and calcium ions. The model was validated in several clinical studies on statins in cardiovascular high-risk patients applying their native blood lipoprotein fractions. RESULTS: In 7 patients who had undergone a valvular defect operation, the reduction of arteriosclerotic nanoplaque formation in normal Krebs solution amounted to 6.1 +/- 2.3% (p &lt; 0.0156) and of nanoplaque size to 37.5 +/- 13.2% (p &lt; 0.0312), respectively, after a 3-month therapy with n-3 fatty acids (3 ..3 g daily, Ameu 500 mg). Additionally, the quotient oxLDL/LDL was lowered by 6.8 +/- 2.1% (p &lt; 0.0166), the MDA concentration remained unchanged and the lipoprotein(a) concentration decreased by 15.8 +/- 5.6% (p &lt; 0.0469) in the patients' blood. The concentration of the nanoplaque promoting particles VLDL and total triglycerides was diminished by 34.1 +/- 11.6% (p &lt; 0.0469) and 26.7 +/- 10.8% (p &lt; 0.0156), respectively. Furthermore, the ratio of the strongly atherogenic small dense to the total LDL cholesterol (LDL5+LDL6)/LDLtot decreased by 9.9 +/- 3.0% (p &lt; 0.0174). CONCLUSIONS: A combinatorial regression analysis revealed a basis for a mechanistic explanation of nanoplaque reduction under n-3 fatty acid treatment. This effect was possibly due to the beneficial changes in lipid concentrations and an attenuation of the risk factors oxLDL/LDL and (LDL5+LDL6)/LDLtot. Copyright 2009 S. Karger AG, Basel</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Institute of Physiology, Charit&amp;#x00E9;, Campus Benjamin Franklin, Berlin, GermanyJC - 101269884CP - SwitzerlandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19729934</style></custom1><custom3><style face="normal" font="default">AS - Forsch Komplementarmed. 16(4):237-45, 2009 Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>348</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Kramer,C.K.</style></author><author><style face="normal" font="default"> von,M.</style></author><author><style face="normal" font="default"> Gross,J.L.</style></author><author><style face="normal" font="default"> Barrett-Connor,E.</style></author></authors></contributors><titles><title><style face="normal" font="default">A prospective study of abdominal obesity and coronary artery calcium progression in older adults</style></title><secondary-title><style face="normal" font="default">Journal of Clinical Endocrinology &amp; Metabolism</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Clinical Endocrinology &amp; Metabolism</style></full-title></periodical><pages end="5044" start="5039">5039-5044</pages><volume><style face="normal" font="default">94</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Abdominal Fat/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Obesity/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Obesity/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> 0 (Blood Glucose)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipoproteins,HDL)</style></keyword><keyword><style face="normal" font="default"> Adipose Tissue</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Blood Glucose/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Body Height</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Body Weight</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lipoproteins,HDL/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Waist Circumference</style></keyword><keyword><style face="normal" font="default"> Waist-Hip Ratio</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Little is known about obesity measurements and coronary artery calcium (CAC) progression in older adults. We examined the sex-specific association between measures of body size and fat distribution with CAC progression. SUBJECTS AND METHODS: Participants were 156 men and 182 women (mean age 67 yr) without known heart disease who had electron-beam computed tomography for CAC at baseline and again 4.5 yr later. Obesity assessments were weight, height, body mass index, waist and hip circumference, waist to hip ratio, waist to height ratio, sc and visceral adipose tissue (SAT, VAT), and SAT to VAT ratio based on abdominal electron-beam computed tomography. CAC progression was defined as categorical (square root increased on total CAC volume score > or = 2.5 mm(3)) and continuous variables. RESULTS: During the follow-up, 55% of men and 38.5% of women had CAC progression. Increased waist to hip ratio (> or = 0.9 for men, > or = 0.85 for women) and waist to height ratio (> or = 0.55 for men, > or = 0.54 for women) were positively and independently associated with CAC progression [median (interquartile range)] [60.8 (145) vs. 10.8 (56) mm(3), P = 0.002 and 50 (153) vs. 22(84) mm(3), P = 0.03, respectively]. In women but not men, an increased waist circumference (> 88 cm) independently predicted CAC progression (odds ratio 3.0 95% confidence interval 1.03-8.0, P = 0.04), whereas VAT to SAT ratio predicted CAC progression in men but not women (odds ratio 2.8 95% confidence interval 1.01-7.8, P = 0.04). CONCLUSION: In this study of older adults without known heart disease, abdominal obesity was an independent predictor of CAC progression. These results point to the importance of using clinical measurements of abdominal obesity to identify individuals at increased risk for atherosclerosis</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Family and Preventive Medicine, University of California, La Jolla, California 92093-0631, USAJC - hrb, 0375362CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - AG028507 (United States NIA NIH HHS)NO - AG07181 (United States NIA NIH HHS)NO - DK31801 (United States NIDDK NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19846732</style></custom1><custom3><style face="normal" font="default">AS - J Clin Endocrinol Metab. 94(12):5039-44, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>315</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Kubo,T.</style></author><author><style face="normal" font="default"> Matsuo,Y.</style></author><author><style face="normal" font="default"> Hayashi,Y.</style></author><author><style face="normal" font="default"> Yamano,T.</style></author><author><style face="normal" font="default"> Tanimoto,T.</style></author><author><style face="normal" font="default"> Ino,Y.</style></author><author><style face="normal" font="default"> Kitabata,H.</style></author><author><style face="normal" font="default"> Takarada,S.</style></author><author><style face="normal" font="default"> Hirata,K.</style></author><author><style face="normal" font="default"> Tanaka,A.</style></author><author><style face="normal" font="default"> Nakamura,N.</style></author><author><style face="normal" font="default"> Mizukoshi,M.</style></author><author><style face="normal" font="default"> Imanishi,T.</style></author><author><style face="normal" font="default"> Akasaka,T.</style></author></authors></contributors><titles><title><style face="normal" font="default">High-sensitivity C-reactive protein and plaque composition in patients with stable angina pectoris: a virtual histology intravascular ultrasound study</style></title><secondary-title><style face="normal" font="default">Coronary Artery Disease</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Coronary Artery Disease</style></full-title></periodical><pages end="535" start="531">531-535</pages><volume><style face="normal" font="default">20</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Angina Pectoris/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *C-Reactive Protein/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Ultrasonography,Interventional</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 9007-41-4 (C-Reactive Protein)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angina Pectoris/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> Angina Pectoris/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Up-Regulation</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Elevated high-sensitivity C-reactive protein (hs-CRP) is related to clinical outcome in coronary artery disease. We used virtual histology intravascular ultrasound to evaluate the relationship between serum hs-CRP level and coronary plaque composition in patients with stable angina pectoris. METHODS AND RESULTS: Overall 113 consecutive patients with stable angina pectoris who had a de-novo culprit lesion were examined in this study. Patients were divided into an elevated hs-CRP group (>3 mg/l; n=40) or a normal hs-CRP group (n=73). Grayscale and virtual histology intravascular ultrasound analysis was performed across the entire culprit lesion. Mean plaque area was similar in both groups. Lesion length (18+/-5 vs. 16+/-6 mm, P&lt;0.046) was significantly greater in the elevated hs-CRP group than that in the normal hs-CRP group. Although the percentage of dense calcium, fibrofatty tissue, and fibrous tissue was not different between the two groups, the percentage of necrotic core was significantly greater in the elevated hs-CRP group compared with the normal hs-CRP group (20+/-9 vs. 16+/-8%, P=0.014). The percentage of necrotic core was positively correlated with the serum hs-CRP level (r=0.20, P=0.037). A multivariate logistic regression model showed that the percentage of necrotic core was associated with elevated hs-CRP (P=0.019; odds ratio=1.1; 95% confidence interval=1.01-1.12). CONCLUSION: Elevated hs-CRP was related to the amount of necrotic core in the culprit lesion of stable angina pectoris. Our results suggest that elevated hs-CRP might reflect the inflammatory activity of the coronary atherosclerotic plaque even in the setting of stable angina pectoris</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiovascular Medicine, Wakayama Medical University, Wakayama, JapanJC - 9011445, BYWCP - EnglandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19855269</style></custom1><custom3><style face="normal" font="default">AS - Coron Artery Dis. 20(8):531-5, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>5</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Kubota,H.</style></author><author><style face="normal" font="default"> Fujioka,Y.</style></author><author><style face="normal" font="default"> Yoshino,H.</style></author><author><style face="normal" font="default"> Koji,H.</style></author><author><style face="normal" font="default"> Yoshihara,K.</style></author><author><style face="normal" font="default"> Tonari,K.</style></author><author><style face="normal" font="default"> Endo,H.</style></author><author><style face="normal" font="default"> Tsuchiya,H.</style></author><author><style face="normal" font="default"> Mera,H.</style></author><author><style face="normal" font="default"> Soga,Y.</style></author><author><style face="normal" font="default"> Taniai,S.</style></author><author><style face="normal" font="default"> Sakata,K.</style></author><author><style face="normal" font="default"> Sudo,K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Cardiac swinging calcified amorphous tumors in end-stage renal failure patients</style></title><secondary-title><style face="normal" font="default">Annals of Thoracic Surgery</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Annals of Thoracic Surgery</style></full-title></periodical><pages end="1694" start="1692">1692-1694</pages><volume><style face="normal" font="default">90</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Heart Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure,Chronic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mitral Valve/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword></keywords><dates><year Day="0" Month="11" Year="2010">2010/11</year></dates><abstract><style face="normal" font="default">We recently encountered 2 patients with mobile cardiac calcified amorphous tumors who were successfully treated by surgery. Both patients had mitral annular calcification and were on hemodialysis. These tumors showed swinging motion on echocardiography and they grew rapidly. Intraoperatively, the tumors were found to be fragile and they easily detached from their origin. The histologic findings were thrombus with angiogenesis, fibrin, and calcium deposition. This rapid-growing mobile tumor in end-stage renal failure patients is speculated to increase the risk of embolic events and should be included as a special entity of cardiac amorphous tumors. Copyright [copyright sign] 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiovascular Surgery, Kyorin University, Tokyo, Japan. kub@ks.kyorin-u.ac.jpJC - 15030100RCP - NetherlandsPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20971294</style></custom1><custom3><style face="normal" font="default">AS - Ann Thorac Surg. 90(5):1692-4, 2010 Nov.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>564</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Kuller,L.H.</style></author><author><style face="normal" font="default"> Matthews,K.A.</style></author><author><style face="normal" font="default"> Edmundowicz,D.</style></author><author><style face="normal" font="default"> Chang,Y.</style></author></authors></contributors><titles><title><style face="normal" font="default">Incident coronary artery calcium among postmenopausal women</style></title><secondary-title><style face="normal" font="default">Atherosclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Atherosclerosis</style></full-title></periodical><pages end="285" start="278">278-285</pages><volume><style face="normal" font="default">200</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> 0 (Apolipoproteins B)</style></keyword><keyword><style face="normal" font="default"> 0 (Triglycerides)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aorta/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Apolipoproteins B/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Postmenopause</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Triglycerides/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="10" Year="2008">2008/10</year></dates><abstract><style face="normal" font="default">Recent studies have shown that individuals with 0 coronary artery calcium (CAC) scores have very low risk of coronary heart disease. In the Healthy Women Study, we evaluated development of new CAC among postmenopausal women (n=272) over a 6-year period, age 62 at the 1st and 68 at the 3rd electron beam tomography (EBT) examination. At the 1st EBT, 155 of 272 (57%) women had 0 CAC. By the 3rd, 56 (36%) of these women had developed new CAC, including 38 with >or=5 Agatston units. There was practically no regression from having CAC at the 1st EBT to no CAC at the 3rd EBT. The risk of developing new CAC over 6 years among women with 0 CAC on their 1st EBT was strongly and significantly related to presence of both aortic calcium and carotid plaque at the time of 1st EBT. Baseline premenopausal risk factors, age 47, apolipoprotein B, body mass index (BMI) and triglycerides, were significant predictors of incident CAC as were the changes in BMI and low density lipoprotein cholesterol between premenopause and the 1st post exam, age 53. Risk factors measured premenopause and change in risk factors from premenopause to the 1st post exam and the extent of subclinical disease in other vascular beds are primary determinants of the risk of developing incident CAC in women over a 6-year period</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA 15213, United States. kullerl@edc.pitt.eduJC - 95x, 0242543CP - IrelandPT - Journal ArticleNO - R01 HL028266-24 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18289547</style></custom1><custom3><style face="normal" font="default">AS - Atherosclerosis. 200(2):278-85, 2008 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>537</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Kumar,N.</style></author><author><style face="normal" font="default"> Lindberg,J.</style></author><author><style face="normal" font="default"> David,K.</style></author><author><style face="normal" font="default"> Morris,J.</style></author><author><style face="normal" font="default"> Menoyo,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Real-world doxercalciferol treatment in SHPT CKD stage 3 and 4: an analysis of change in iPTH and accordance to KDOQI recommendations</style></title><secondary-title><style face="normal" font="default">American Journal of Nephrology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Nephrology</style></full-title></periodical><pages end="78" start="71">71-78</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Bone Density Conservation Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Ergocalciferols/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Hyperparathyroidism,Secondary/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure,Chronic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> 0 (Bone Density Conservation Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Ergocalciferols)</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 54573-75-0 (1 alpha-hydroxyergocalciferol)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 7723-14-0 (Phosphorus)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Dialysis</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Secondary/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Secondary/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical Records</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Phosphorus/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Practice Guidelines as Topic</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><abstract><style face="normal" font="default">BACKGROUND: National Kidney Foundation's Kidney Disease Outcome Quality Initiative (KDOQI) guidelines offer an outline for providing standardized care for best outcomes in chronic kidney disease (CKD). It is unknown whether real-world treatment practices follow these guidelines. METHODS: The Hectorol Registry Outcome in Chronic Kidney Disease (HeROICkd), an observational patient registry, captured information on adult patients with CKD Stage 3 or 4 throughout US clinics during a 9-month observation period. Data were collected quarterly from patients' medical records, throughout each patient's normal treatment course. The proportion of patients with intact parathyroid hormone (iPTH) levels within KDOQI guidelines, change in iPTH, Ca, P, and Ca x P product over the 9-month observation period, incidence of hypercalcemia and hyperphosphatemia, and predictors of change in iPTH were examined. RESULTS: 1,339 CKD Stage 3 and 4 patients from 78 nephrology and internal medicine clinics were included. 40% of CKD Stage 3 participants and 45% of Stage 4 had a 30% or greater reduction in iPTH levels from baseline to 9 months follow-up. While the proportion of CKD Stage 3 and 4 participants with iPTH levels within the KDOQI recommendations improved significantly over the 9 months, it was still modest, at 28% and 23%, respectively. Mean doxercalciferol dose was below that recommended in the package insert and a minority of patients had all mineral metabolism parameters (iPTH, Ca, P) regularly recorded in their medical records. CONCLUSIONS: The results of this registry, which examined iPTH treatment with doxercalciferol in CKD Stage 3 and 4, suggest that in the real-world treatment setting, the adherence to KDOQI guidelines is not optimal. Copyright (c) 2008 S. Karger AG, Basel</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Nephrology and Hypertension, Kidney and Hypertension Center P.C.-Davita Dialysis Unit, Roseburg, OR 97470, USA. kidneyhtn@hotmail.comJC - 3mb, 8109361CP - SwitzerlandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18689981</style></custom1><custom3><style face="normal" font="default">AS - Am J Nephrol. 29(2):71-8, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>376</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Kuo,H.W.</style></author><author><style face="normal" font="default"> Tsai,S.S.</style></author><author><style face="normal" font="default"> Tiao,M.M.</style></author><author><style face="normal" font="default"> Liu,Y.C.</style></author><author><style face="normal" font="default"> Yang,C.Y.</style></author></authors></contributors><titles><title><style face="normal" font="default">Management of chronic kidney disease in Taiwan: room for quality improvement</style></title><secondary-title><style face="normal" font="default">Journal of Nephrology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Nephrology</style></full-title></periodical><pages end="661" start="654">654-661</pages><volume><style face="normal" font="default">22</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Delivery of Health Care/td [Trends]</style></keyword><keyword><style face="normal" font="default"> *Kidney Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Kidney Diseases/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> *Quality Assurance,Health Care/td [Trends]</style></keyword><keyword><style face="normal" font="default"> 0 (Antihypertensive Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipids)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Antihypertensive Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Hypertension/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Kidney Diseases/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Lipids/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Renal Replacement Therapy</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Taiwan/ep [Epidemiology]</style></keyword></keywords><dates><year Day="0" Month="9" Year="2009">2009/9</year></dates><isbn><style face="normal" font="default">1121-8428</style></isbn><abstract><style face="normal" font="default">BACKGROUND: End-stage renal disease is epidemic in Taiwan. Although early intervention in chronic kidney disease (CKD) has proven to be effective in modifying its clinical course, little is known about the quality and trend of CKD care in Taiwan. METHODS: From a nationally representative database of 200,000 individuals, CKD patients were identified by diagnostic codes, and their medical interventions were extracted from service claims. The predictors for care delivery were analyzed in a logistic regression model. RESULTS: Of the 7,740 patients with CKD, only 54.8% had follow-up of renal function. Tests for anemia, calcium/ phosphorus and lipid profile were performed in 34.5%, 5.2% and 40.9% of patients, respectively. Most hypertensive CKD patients have used antihypertensive agents, but only 58.1% of them received angiotensinconverting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). Of CKD patients with diabetes, less than half had glycosylated hemoglobin measured, and only 49.7% received ACEIs/ARBs. We observed an encouraging trend in the use of ACEIs/ ARBs and in most aspects of laboratory monitoring. CONCLUSIONS: Management of CKD patients is suboptimal, and lack of awareness is common. Further work is needed to evaluate the impact of educational initiatives and multidisciplinary teams on outcomes in CKD patients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Nephrology, Department of Internal Medicine, Yuan's General Hospital, Kaohsiung, TaiwanJC - 9012268CP - ItalyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19809999</style></custom1><custom3><style face="normal" font="default">AS - JN, J. nephrol.. 22(5):654-61, 2009 Sep-Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>493</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">LaCroix,A.Z.</style></author><author><style face="normal" font="default"> Kotchen,J.</style></author><author><style face="normal" font="default"> Anderson,G.</style></author><author><style face="normal" font="default"> Brzyski,R.</style></author><author><style face="normal" font="default"> Cauley,J.A.</style></author><author><style face="normal" font="default"> Cummings,S.R.</style></author><author><style face="normal" font="default"> Gass,M.</style></author><author><style face="normal" font="default"> Johnson,K.C.</style></author><author><style face="normal" font="default"> Ko,M.</style></author><author><style face="normal" font="default"> Larson,J.</style></author><author><style face="normal" font="default"> Manson,J.E.</style></author><author><style face="normal" font="default"> Stefanick,M.L.</style></author><author><style face="normal" font="default"> Wactawski-Wende,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women's Health Initiative calcium-vitamin D randomized controlled trial</style></title><secondary-title><style face="normal" font="default">Journals of Gerontology Series A-Biological Sciences &amp; Medical Sciences</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journals of Gerontology Series A-Biological Sciences &amp; Medical Sciences</style></full-title></periodical><pages end="567" start="559">559-567</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Bone Density Conservation Agents/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Calcium/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Dietary Supplements</style></keyword><keyword><style face="normal" font="default"> *Postmenopause</style></keyword><keyword><style face="normal" font="default"> *Vitamin D/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> 0 (Bone Density Conservation Agents)</style></keyword><keyword><style face="normal" font="default"> 1406-16-2 (Vitamin D)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Drug Therapy,Combination</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Women's Health</style></keyword></keywords><dates><year Day="0" Month="5" Year="2009">2009/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: Calcium and vitamin D (CaD) supplementation trials including the Women's Health Initiative (WHI) trial of CaD have shown nonsignificant reductions in total mortality. This report examines intervention effects on total and cause-specific mortality by age and adherence. METHODS: The WHI CaD trial was a randomized, double-blind, placebo-controlled trial that enrolled 36,282 postmenopausal women aged 51-82 years from 40 U.S. clinical centers. Women were assigned to 1,000 mg of elemental calcium carbonate and 400 IU of vitamin D(3) daily or placebo with average follow-up of 7.0 years. RESULTS: The hazard ratio (HR) for total mortality was 0.91 (95% confidence interval [CI], 0.83-1.01) with 744 deaths in women randomized to CaD versus 807 deaths in the placebo group. HRs were in the direction of reduced risk but nonsignificant for stroke and cancer mortality, but near unity for coronary heart disease and other causes of death. HRs for total mortality were 0.89 in the 29,942 women younger than 70 years (95% CI, 0.79-1.01) and 0.95 in the 6,340 women aged 70 and older (95% CI, 0.80-1.12; p value for age interaction = .10). No statistically significant interactions were observed for any baseline characteristics. Treatment effects did not vary significantly by season. CONCLUSIONS: In the WHI CaD trial, supplementation did not have a statistically significant effect on mortality rates but the findings support the possibility that these supplements may reduce mortality rates in postmenopausal women. These data can neither support nor refute recommendations for higher dose vitamin D supplementation to reduce cancer or total mortality</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - WHI Clinical Coordinating Center, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M3-A410, PO Box 19024, Seattle, WA 98109-1024, USA. alacroix@whi.orgJC - cba, 9502837CP - United StatesPT - Journal ArticlePT - Randomized Controlled TrialPT - Research Support, N.I.H., ExtramuralSI - ClinicalTrials.govSA - ClinicalTrials.gov/NCT00000611LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19221190</style></custom1><custom3><style face="normal" font="default">AS - J Gerontol A Biol Sci Med Sci. 64(5):559-67, 2009 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>273</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Lakdawala,N.K.</style></author><author><style face="normal" font="default"> Dellefave,L.</style></author><author><style face="normal" font="default"> Redwood,C.S.</style></author><author><style face="normal" font="default"> Sparks,E.</style></author><author><style face="normal" font="default"> Cirino,A.L.</style></author><author><style face="normal" font="default"> Depalma,S.</style></author><author><style face="normal" font="default"> Colan,S.D.</style></author><author><style face="normal" font="default"> Funke,B.</style></author><author><style face="normal" font="default"> Zimmerman,R.S.</style></author><author><style face="normal" font="default"> Robinson,P.</style></author><author><style face="normal" font="default"> Watkins,H.</style></author><author><style face="normal" font="default"> Seidman,C.E.</style></author><author><style face="normal" font="default"> Seidman,J.G.</style></author><author><style face="normal" font="default"> McNally,E.M.</style></author><author><style face="normal" font="default"> Ho,C.Y.</style></author></authors></contributors><titles><title><style face="normal" font="default">Familial dilated cardiomyopathy caused by an alpha-tropomyosin mutation: the distinctive natural history of sarcomeric dilated cardiomyopathy</style></title><secondary-title><style face="normal" font="default">Journal of the American College of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of the American College of Cardiology</style></full-title></periodical><pages end="329" start="320">320-329</pages><volume><style face="normal" font="default">55</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiomyopathy,Dilated/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Sarcomeres/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> 0 (Tropomyosin)</style></keyword><keyword><style face="normal" font="default"> 0 (Troponin)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Child,Preschool</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> EC 3-6-4-1 (Myosins)</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Myosins/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Tropomyosin/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Troponin/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Ventricular Remodeling/ph [Physiology]</style></keyword></keywords><dates><year Day="26" Month="1" Year="2010">2010/1/26</year></dates><abstract><style face="normal" font="default">OBJECTIVES: We sought to further define the role of sarcomere mutations in dilated cardiomyopathy (DCM) and associated clinical phenotypes. BACKGROUND: Mutations in several contractile proteins contribute to DCM, but definitive evidence for the roles of most sarcomere genes remains limited by the lack of robust genetic support. METHODS: Direct sequencing of 6 sarcomere genes was performed on 334 probands with DCM. A novel D230N missense mutation in the gene encoding alpha-tropomyosin (TPM1) was identified. Functional assessment was performed by the use of an in vitro reconstituted sarcomere complex to evaluate ATPase regulation and Ca(2+) affinity as correlates of contractility. RESULTS: TPM1 D230N segregated with DCM in 2 large unrelated families. This mutation altered an evolutionarily conserved residue and was absent in >1,000 control chromosomes. In vitro studies demonstrated major inhibitory effects on sarcomere function with reduced Ca(2+) sensitivity, maximum activation, and Ca(2+) affinity compared with wild-type TPM1. Clinical manifestations ranged from decompensated heart failure or sudden death in those presenting early in life to asymptomatic left ventricular dysfunction in those diagnosed during adulthood. Notably, several affected infants had remarkable improvement. CONCLUSIONS: Genetic segregation in 2 unrelated families and functional analyses conclusively establish a pathogenic role for TPM1 mutations in DCM. In vitro results demonstrate contrasting effects of DCM and hypertrophic cardiomyopathy mutations in TPM1, suggesting that specific functional consequences shape cardiac remodeling. Along with previous reports, our data support a distinctive, age-dependent phenotype with sarcomere-associated DCM where presentation early in life is associated with severe, sometimes lethal, disease. These observations have implications for the management of familial DCM. Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts 02115, USACM - Comment in: J Am Coll Cardiol. 2010 Jan 26;55(4):330-2; PMID: 20117438JC - h50, 8301365CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tPT - Research Support, U.S. Gov't, Non-P.H.SNO - (United States Howard Hughes Medical Institute)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20117437</style></custom1><custom3><style face="normal" font="default">AS - J Am Coll Cardiol. 55(4):320-9, 2010 Jan 26.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>357</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Lal,G.</style></author><author><style face="normal" font="default"> Nowell,A.G.</style></author><author><style face="normal" font="default"> Liao,J.</style></author><author><style face="normal" font="default"> Sugg,S.L.</style></author><author><style face="normal" font="default"> Weigel,R.J.</style></author><author><style face="normal" font="default"> Howe,J.R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Determinants of survival in patients with calciphylaxis: a multivariate analysis</style></title><secondary-title><style face="normal" font="default">Surgery</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Surgery</style></full-title></periodical><pages end="1034" start="1028">1028-1034</pages><volume><style face="normal" font="default">146</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calciphylaxis/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 0 (Phosphates)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calciphylaxis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calciphylaxis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Calciphylaxis/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Diabetes Complications/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Early Diagnosis</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Kaplan-Meiers Estimate</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical Records</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Parathyroidectomy</style></keyword><keyword><style face="normal" font="default"> Peripheral Vascular Diseases/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Phosphates/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Our study aims to assess the factors affecting survival in patients with calciphylaxis. METHODS: We identified 26 patients with biopsy-proven calciphylaxis treated between 1995 and 2007. Clinical and follow-up data were obtained from medical records. Cox proportional hazards models were used to assess the factors affecting survival. RESULTS: The study group consisted of 23 women and 3 men with a mean age of 56.4 +/- 12.9 years. All patients had multiple comorbidities/risk factors including coronary artery disease (58%), diabetes mellitus (58%), and peripheral vascular disease (23%). Mean laboratory values were: calcium, 9.0 mg/dL (range, 6.8-11.6); albumin, 2.8 mg/dL; phosphate, 4.5 mg/dL (range, 2.5-7.5); Ca *phosphate, 35.9; and parathyroid hormone, 320.9 pg/mL (range, 4.6-2,419). Parathyroidectomy was performed in 9 of 26 patients (35%). Of our patients, 19% underwent revascularization procedures and 58% underwent debridement. In multivariate analyses, factors associated with poor survival were female gender ( P = .01), increased weight ( P = .01), and need for vascular procedures ( P = .06). Improved survival was associated with operative debridement ( P = .01). Parathyroidectomy alone did not emerge as a determinant of patient survival, although there was a trend to improved survival when debridement and parathyroidectomy were combined ( P = .09). CONCLUSION: Rather than a single intervention such as parathyroidectomy, a multidisciplinary approach involving early diagnosis, aggressive medical management, operative debridement, and parathyroidectomy may improve survival in calciphylaxis</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Surgery, University of Iowa Hospitals, Iowa City, IA 52242, USA. Geeta-lal@uiowa.eduJC - vc3, 0417347CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19958929</style></custom1><custom3><style face="normal" font="default">AS - Surgery. 146(6):1028-34, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>305</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Lambers Heerspink,H.J.</style></author><author><style face="normal" font="default"> Agarwal,R.</style></author><author><style face="normal" font="default"> Coyne,D.W.</style></author><author><style face="normal" font="default"> Parving,H.H.</style></author><author><style face="normal" font="default"> Ritz,E.</style></author><author><style face="normal" font="default"> Remuzzi,G.</style></author><author><style face="normal" font="default"> Audhya,P.</style></author><author><style face="normal" font="default"> Amdahl,M.J.</style></author><author><style face="normal" font="default"> Andress,D.L.</style></author><author><style face="normal" font="default"> de,Zeeuw D.</style></author></authors></contributors><titles><title><style face="normal" font="default">The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics</style></title><secondary-title><style face="normal" font="default">American Journal of Nephrology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Nephrology</style></full-title></periodical><pages end="286" start="280">280-286</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Albuminuria/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Ergocalciferols/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Receptors,Calcitriol/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> 0 (Ergocalciferols)</style></keyword><keyword><style face="normal" font="default"> 0 (Receptors,Calcitriol)</style></keyword><keyword><style face="normal" font="default"> 131918-61-1 (paricalcitol)</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Double-Blind Method</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><abstract><style face="normal" font="default">BACKGROUND: Patients with diabetic nephropathy are at high risk for further progressive renal function loss. Treatments that decrease albuminuria have been linked with renal and cardiovascular protection. However, even when taking optimal treatment, residual renal and cardiovascular risk remains high which correlates with the magnitude of residual albuminuria. Use of vitamin D receptor activators, such as calcitriol and paricalcitol, is associated with improved sur- vival. A small study with paricalcitol showed reductions in albuminuria. The VITAL study tests the hypothesis whether paricalcitol persistently reduces albuminuria in diabetic subjects already receiving angiotensin-converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker (ARB) therapy. METHODS: Randomization in this double-blind trial is equal allocation to paricalcitol 1 micro/day, 2 microg/day, or placebo. Inclusion criteria include: a diagnosis of type 2 diabetes, urinary albumin/creatinine ratio (UACR) between 100-3,000 mg/g, estimated glomerular filtration rate (eGFR) between 15-90 ml/min/1.73 m(2), serum calcium &lt;9.8 mg/dl, and parathyroid hormone (PTH) between 35-500 pg/ml. RESULTS: Baseline characteristics of the 281 subjects are: 69% men, mean age 64.9 +/- 10.4 years, eGFR 40.7 +/- 16.7 ml/min, median UACR (interquartile range) 612.3 mg/g (281-1,181 mg/g) and PTH 98.4 +/- 63.8 pg/ml. CONCLUSION: This trial will be the first clinical test of the hypothesis that paricalcitol possesses pleiotropic effects and can modulate albuminuria in the setting of ACEI and/or ARB therapy. Results will have important clinical implications and are expected in November 2009. Copyright 2009 S. Karger AG, Basel</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The NetherlandsJC - 3mb, 8109361CP - SwitzerlandPT - Journal ArticlePT - Randomized Controlled TrialPT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19521070</style></custom1><custom3><style face="normal" font="default">AS - Am J Nephrol. 30(3):280-6, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>489</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Langer,C.</style></author><author><style face="normal" font="default"> Wiemer,M.</style></author><author><style face="normal" font="default"> der,A.</style></author><author><style face="normal" font="default"> Franzke,K.</style></author><author><style face="normal" font="default"> Mellwig,K.P.</style></author><author><style face="normal" font="default"> van,Buuren F.</style></author><author><style face="normal" font="default"> Koester-Eiserfunke,W.</style></author><author><style face="normal" font="default"> Butz,T.</style></author><author><style face="normal" font="default"> Diekmann,J.</style></author><author><style face="normal" font="default"> Horstkotte,D.</style></author></authors></contributors><titles><title><style face="normal" font="default">Stratification for noninvasive coronary angiography: patient preselection considering atypical angina pectoris, conventional cardiovascular risk assessment, and calcium scoring</style></title><secondary-title><style face="normal" font="default">European Journal of Cardiovascular Prevention &amp; Rehabilitation</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">European Journal of Cardiovascular Prevention &amp; Rehabilitation</style></full-title></periodical><pages end="209" start="201">201-209</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Angina Pectoris/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Magnetic Resonance Angiography</style></keyword><keyword><style face="normal" font="default"> *Patient Selection</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angina Pectoris/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,Emission-Computed,Single-Photon</style></keyword></keywords><dates><year Day="0" Month="4" Year="2009">2009/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Noninvasive coronary angiography (NCA) is recommended to be applied as a filter before invasive coronary angiography in patients with intermediate cardiovascular risk. DESIGN: In this prospective single-center study, we validated multislice computed tomography (MSCT) and magnetic resonance imaging (MRI)-based NCA by primarily selecting patients with atypical angina pectoris (AAP). METHODS: In 68 patients (63.6+/-11.4 years) with AAP, the Prospective Cardiovascular Muenster Study score and the Agatston score equivalent (ASE; calcium score) were initially determined for cardiovascular risk assessment. Subsequently, MSCT and MRI-based NCA were performed followed by quantitative invasive coronary angiography for validation. All tests were finally analyzed. RESULTS: CAD (prevalence 38.2%) was diagnosed in 67.7% of patients at high, 61.5% at intermediate, and 37.8% at low cardiovascular risk according to the Prospective Cardiovascular Muenster Study. CAD was diagnosed in 88.2% of patients with an ASE >or=75th percentile and in 90.9% with an ASE >or=90th percentile. With regard to NCA, patient-based analysis resulted in a sensitivity of 96.2% for MSCT versus 69.2% for MRI, in a specificity of 95.2 versus 64.3%, in a positive predictive value of 97.6 versus 77.1%, in a negative predictive value of 92.6 versus 54.5%, and a diagnostic accuracy of 95.6 versus 66.2% (P&lt;0.05). CONCLUSION: In a patient group with a heterogeneous cardiovascular risk, primarily considering AAP allows for effective patient preselection for NCA. This may be optimized by precluding patients with an ASE >or=75th percentile. MSCT rather than MRI may then effectively be involved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Heart and Diabetes Centre North Rhine-Westphalia, Bad Oeynhausen, Germany. clanger@hdz-nrw.deJC - 101192000CP - EnglandPT - Comparative StudyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tPT - Validation StudiesLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19305353</style></custom1><custom3><style face="normal" font="default">AS - Eur J Cardiovasc Prev Rehabil. 16(2):201-9, 2009 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>495</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Langer,C.</style></author><author><style face="normal" font="default"> der,A.</style></author><author><style face="normal" font="default"> Franzke,K.</style></author><author><style face="normal" font="default"> Esdorn,H.</style></author><author><style face="normal" font="default"> rperich,H.</style></author><author><style face="normal" font="default"> Meyer,H.</style></author><author><style face="normal" font="default"> Horstkotte,D.</style></author><author><style face="normal" font="default"> Wiemer,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Noninvasive coronary angiography focusing on calcification: multislice computed tomography compared with magnetic resonance imaging</style></title><secondary-title><style face="normal" font="default">Journal of Computer Assisted Tomography</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Computer Assisted Tomography</style></full-title></periodical><pages end="185" start="179">179-185</pages><volume><style face="normal" font="default">33</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> *Coronary Stenosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Magnetic Resonance Imaging/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Artifacts</style></keyword><keyword><style face="normal" font="default"> Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Stenosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Image Interpretation,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Image Processing,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Observer Variation</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography Scanners,X-Ray Computed/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="3" Year="2009">2009/3</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Calcification is a principal problem in noninvasive coronary angiography (CA) performed with multislice computed tomography (MSCT). Magnetic resonance imaging (MRI) supposedly neglects calcium. We compared both modalities. METHODS: Sixty-eight patients admitted for CA underwent MSCT- and MRI-based noninvasive CA the day before. Stenosis detection (>or=50%) was visually performed and validated by quantitative CA. RESULTS: The patient-based overall sensitivity, specificity, positive predictive value, and negative predictive value were 96.2%, 95.2%, 92.6%, and 97.6% for MSCT versus 69.2%, 64.3, 54.5%, 64.3%, and 77.1% for MRI, respectively. The segment-based overall results were 74.7%, 97.8%, 75.7%, and 97.6% for MSCT versus 40%, 93.8%, 37.5%, and 94.4% for MRI, respectively. Investigating the impact of coronary calcifications in the patient group with a volume score of 300 microL or greater resulted in 100%, 80%, 92.3%, and 100% for MSCT versus 70.8%, 86.7%, 89.5%, and 65% for MRI, respectively. The segment group with considerable hardening artifacts resulted in 85.3%, 83.9%, 76.3%, and 90.4% for MSCT versus 52.9%, 92.9%, 81.8%, and 76.5% for MRI, respectively. CONCLUSIONS: There are no major advantages of MRI in cases of advanced coronary calcification</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Ruhr University Bochum, Bad Oeynhausen, GermanyJC - hvt, 7703942CP - United StatesPT - Comparative StudyPT - Evaluation StudiesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19346842</style></custom1><custom3><style face="normal" font="default">AS - J Comput Assist Tomogr. 33(2):179-85, 2009 Mar-Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>296</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Larsson,T.E.</style></author><author><style face="normal" font="default"> Olauson,H.</style></author><author><style face="normal" font="default"> Hagstr&amp;#x00F6</style></author><author><style face="normal" font="default">m E</style></author><author><style face="normal" font="default"> Ingelsson,E.</style></author><author><style face="normal" font="default"> Arnl&amp;#x00F6</style></author><author><style face="normal" font="default">v J</style></author><author><style face="normal" font="default"> Lind,L.</style></author><author><style face="normal" font="default"> Sundstr&amp;#x00F6</style></author><author><style face="normal" font="default">m J</style></author></authors></contributors><titles><title><style face="normal" font="default">Conjoint effects of serum calcium and phosphate on risk of total, cardiovascular, and noncardiovascular mortality in the community</style></title><secondary-title><style face="normal" font="default">Arteriosclerosis, Thrombosis &amp; Vascular Biology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Arteriosclerosis, Thrombosis &amp; Vascular Biology</style></full-title></periodical><pages end="339" start="333">333-339</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> *Hypercalcemia/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Hypercalcemia/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> *Hyperphosphatemia/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Hyperphosphatemia/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> *Phosphates/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Phosphates)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Cause of Death</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default"> Health Surveys</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypercalcemia/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Hypercalcemia/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Hyperphosphatemia/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Hyperphosphatemia/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Kidney Diseases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Kidney Diseases/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Kidney Diseases/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Sweden/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="2" Year="2010">2010/2</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Hyperphosphatemia is a cardiovascular risk factor in patients with chronic kidney disease. Relations of circulating calcium (Ca) and phosphorus (Pi) to long-term mortality risk in the community require further investigation. METHODS AND RESULTS: Associations of serum Ca and Pi to mortality were evaluated in a community-based cohort of 2176 men (mean age, 50.1 years). During follow-up (median, 29.8 years), 1009 men died, and 466 of these deaths resulted from cardiovascular causes. In Cox proportional hazards models, serum Pi and [CaxPi] were independent predictors of total mortality (hazard ratio per SD, 1.06; 95% CI, 1.01-1.12; P=0.03; 1.07; 95% CI, 1.01-1.12; P=0.01) and cardiovascular mortality (1.10; 95% CI, 1.02-1.18; P=0.01; 1.10; 95% CI, 1.03-1.19; P=0.008). Serum Ca was associated with risk of total mortality (1.08; 95% CI, 1.01-1.16; P=0.02) and noncardiovascular mortality (1.10; 95% CI, 1.01-1.21; P=0.04). Results were consistent after multivariate adjustments in subsamples of individuals with estimated glomerular filtration rate >90 mL/min and low-to-normal serum Ca and Pi. CONCLUSIONS: Circulating Ca and Pi levels are associated with risks of total, cardiovascular, and noncardiovascular mortality in the community, and their conjoint effects are additive. Additional studies are warranted to evaluate whether Ca and Pi are modifiable risk factors in the general population</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Nephrology, Karolinska University Hospital, Stockholm, Sweden. tobias.larsson@ki.seJC - 9505803, B89CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19948843</style></custom1><custom3><style face="normal" font="default">AS - Arterioscler Thromb Vasc Biol. 30(2):333-9, 2010 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>528</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Laudisio,A.</style></author><author><style face="normal" font="default"> Marzetti,E.</style></author><author><style face="normal" font="default"> Pagano,F.</style></author><author><style face="normal" font="default"> Cocchi,A.</style></author><author><style face="normal" font="default"> Bernabei,R.</style></author><author><style face="normal" font="default"> Zuccal&amp;#x00E0</style></author><author><style face="normal" font="default"> G</style></author></authors></contributors><titles><title><style face="normal" font="default">Digoxin and cognitive performance in patients with heart failure: a cohort, pharmacoepidemiological survey</style></title><secondary-title><style face="normal" font="default">Drugs &amp; Aging</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Drugs &amp; Aging</style></full-title></periodical><pages end="112" start="103">103-112</pages><volume><style face="normal" font="default">26</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Anti-Arrhythmia Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Cognition/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> *Digoxin/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Heart Failure/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> 0 (Anti-Arrhythmia Agents)</style></keyword><keyword><style face="normal" font="default"> 20830-75-5 (Digoxin)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Failure/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Italy/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Pharmacoepidemiology</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><isbn><style face="normal" font="default">1170-229X</style></isbn><abstract><style face="normal" font="default">BACKGROUND: Cognitive dysfunction is a prevalent condition among patients with heart failure (HF), and is independently associated with disability and mortality. A large study of patients with atrial fibrillation incidentally demonstrated superior cognitive performance among participants who received digoxin. Interestingly, endogenous cerebral digoxin influences neuronal Na(+)-dependent transport of calcium and amino acids, as well as the release and reuptake of several neurotransmitters involved in cognitive functioning. OBJECTIVE: To assess whether treatment with digoxin might improve cognition in patients with HF. METHODS: This pharmacoepidemiological cohort study included hospitalized elderly people (age > or = 65 years) from the GIFA (Gruppo Italiano di Farmacoepidemiologia nell'Anziano [Italian Group of Pharmacoepidemiology in the Elderly]) study. The GIFA study included 13,598 patients (1590 with a verified diagnosis of HF) without cerebrovascular or Alzheimer's disease. The main outcome measure was cognitive performance, which was assessed on admission and immediately before discharge using the Hodkinson Abbreviated Mental Test. The diagnosis of HF was verified by the study investigators. RESULTS: Among participants with HF, cognitive performance improved in 25% of 1172 participants who received digoxin compared with 16% of remaining patients (p &lt; 0.0001). Among participants without HF, cognition improved in 23% of 2431 patients receiving digoxin compared with 17% of untreated patients (p &lt; 0.0001). According to logistic regression analysis, the probability (odds ratio) of improving cognitive performance associated with administration of digoxin was 1.69 (95% CI 1.20, 2.38) among patients with HF, and 1.13 (95% CI 0.98, 1.31) among patients without HF, after adjusting for potential confounders. Analysis of the interaction term 'use of digoxin by diagnosis of HF' in fully adjusted logistic regression confirmed (p = 0.018) that the association between use of digoxin and improving cognitive performance varied according to diagnosis of HF. CONCLUSION: Treatment with digoxin might selectively improve cognitive performance among older patients with HF</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Gerontology, Geriatrics, and Physiatrics, Catholic University of Medicine, Rome, Italy. postalice@tiscali.itJC - bek, 9102074CP - New ZealandPT - Journal ArticlePT - Multicenter StudyPT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19220067</style></custom1><custom3><style face="normal" font="default">AS - Drugs Aging. 26(2):103-12, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>222</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Laudon,D.A.</style></author><author><style face="normal" font="default"> Behrenbeck,T.R.</style></author><author><style face="normal" font="default"> Wood,C.M.</style></author><author><style face="normal" font="default"> Bailey,K.R.</style></author><author><style face="normal" font="default"> Callahan,C.M.</style></author><author><style face="normal" font="default"> Breen,J.F.</style></author><author><style face="normal" font="default"> Vukov,L.F.</style></author></authors></contributors><titles><title><style face="normal" font="default">Computed tomographic coronary artery calcium assessment for evaluating chest pain in the emergency department: long-term outcome of a prospective blind study</style></title><secondary-title><style face="normal" font="default">Mayo Clinic Proceedings</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Mayo Clinic Proceedings</style></full-title></periodical><pages end="322" start="314">314-322</pages><volume><style face="normal" font="default">85</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Chest Pain/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Emergency Service,Hospital/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> *Triage/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Acute Disease</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Algorithms</style></keyword><keyword><style face="normal" font="default"> Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Chest Pain/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Chest Pain/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Clinical Competence</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Bypass</style></keyword><keyword><style face="normal" font="default"> Coronary Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Coronary Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Diagnosis,Differential</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Observer Variation</style></keyword><keyword><style face="normal" font="default"> Outcome Assessment (Health Care)</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> ROC Curve</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Single-Blind Method</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To determine the long-term outcome of computed tomographic (CT) quantification of coronary artery calcium (CAC) used as a triage tool for patients presenting with chest pain to an emergency department (ED). PATIENTS AND METHODS: Patients (men aged 30-62 years and women aged 30-65 years) with chest pain and low-to-moderate probability of coronary artery disease underwent both conventional ED chest pain evaluation and CT CAC assessment prospectively. Patients' physicians were blinded to the CAC results. The results of the conventional evaluation were compared with CAC findings on CT, and the long-term outcome in patients undergoing CT CAC assessment was established. Primary end points (acute coronary syndrome, death, fatal or nonfatal non-ST-segment elevation myocardial infarction, fatal or nonfatal ST-segment elevation myocardial infarction) and secondary outcomes (coronary artery bypass grafting, percutaneous transluminal coronary angioplasty, coronary stenting, or a combination thereof) were obtained when the patient was dismissed from the ED or hospital and then at 30 days, 1 year, and 5 years. RESULTS: Of the 263 study patients, 133 (51%) had a CAC score of zero. This absence of CAC correlated strongly with the likelihood of noncardiac chest pain. Among 133 patients with a CAC score of zero, only 1 (&lt;1%) had cardiac chest pain. Conversely, of the 31 patients shown to have cardiac chest pain, 30 (97%) had evidence of CAC on CT. When a CAC cutoff score of 36 was used, as suggested by receiver operating characteristic analysis, sensitivity was 90%; specificity, 85%; positive predictive value, 44%; and negative predictive value, 99%. During long-term follow-up, patients without CAC experienced no cardiac events at 30 days, 1 year, and 5 years. CONCLUSION: Findings suggest that CT CAC assessment is a powerful adjunct in chest pain evaluation for the population at low-to-intermediate risk. Absent or minimal CAC in this population makes cardiac chest pain extremely unlikely. The absence of CAC suggests an excellent long-term (5-year) prognosis, with no primary or secondary cardiac outcomes occurring in study patients at 5-year follow-up</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Emergency Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. laudon.dennis@mayo.eduCM - Comment in: Mayo Clin Proc. 2010 Apr;85(4):309-13; PMID: 20360290JC - 0405543, llyCP - United StatesPT - Journal ArticlePT - Randomized Controlled TrialPT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20360291</style></custom1><custom3><style face="normal" font="default">AS - Mayo Clin Proc. 85(4):314-22, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>420</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Lavi,S.</style></author><author><style face="normal" font="default"> Bae,J.H.</style></author><author><style face="normal" font="default"> Rihal,C.S.</style></author><author><style face="normal" font="default"> Prasad,A.</style></author><author><style face="normal" font="default"> Barsness,G.W.</style></author><author><style face="normal" font="default"> Lennon,R.J.</style></author><author><style face="normal" font="default"> Holmes,D.R.,Jr.</style></author><author><style face="normal" font="default"> Lerman,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Segmental coronary endothelial dysfunction in patients with minimal atherosclerosis is associated with necrotic core plaques</style></title><secondary-title><style face="normal" font="default">Heart</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Heart</style></full-title></periodical><pages end="1530" start="1525">1525-1530</pages><volume><style face="normal" font="default">95</style></volume><number><style face="normal" font="default">18</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Artery Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Endothelium,Vascular/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Endothelium,Vascular/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Endothelium,Vascular/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Necrosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Necrosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Ultrasonography,Doppler/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="9" Year="2009">2009/9</year></dates><abstract><style face="normal" font="default">BACKGROUND/OBJECTIVE: Endothelial dysfunction and atherosclerosis are systemic disorders, but are often characterised by segmental involvement and complications. A potential mechanism for local involvement early in the disease process may be related to plaque composition. This study was designed to test the hypothesis that in patients with minimal coronary atherosclerosis, coronary artery segments with abnormal endothelial function have specific plaque characteristics. METHODS: Intravascular ultrasound (IVUS) images were obtained from 30 patients who underwent coronary endothelial function assessment. Spectral analysis of the IVUS radiofrequency data was used for assessment of plaque composition. IVUS findings of the coronary sections were compared according to the corresponding endothelial response to acetylcholine. RESULTS: Sections with a decrease epicardial coronary arterial diameter in response to acetylcholine had smaller baseline lumen (7.5 (2.4) mm(2) vs 8.8 (3.3) mm(2), p = 0.006) but larger plaque burden (37.1% (9.4%) vs 31% (7%), p = 0.003) than sections with normal endothelial response. Sections with endothelial dysfunction had larger necrotic core plaques: 0.13 (0.03-0.33) mm(2) vs 0.0 (0.0-0.07), p&lt;0.001 and more dense calcium: 0.03 (IQR 0.0-0.13) mm(2) vs 0.0 (0.0-0.10) mm(2), p&lt;0.01), than those with normal endothelial response. Only necrotic core area was associated with endothelial dysfunction (p&lt;0.001) after adjusting for other measures. CONCLUSIONS: This study suggests that local coronary endothelial dysfunction in patients with minimal coronary atherosclerosis is associated with plaque characteristics that are typical of vulnerable plaques</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiovascular Diseases and the Center for Coronary Physiology and Imaging, Mayo Clinic, Rochester, MN 55905, USAJC - 9602087CP - EnglandPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - HL-77131 (United States NHLBI NIH HHS)NO - K24 HL-69840 (United States NHLBI NIH HHS)NO - R01 HL-63911 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19497916</style></custom1><custom3><style face="normal" font="default">AS - Heart. 95(18):1525-30, 2009 Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>525</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Lee,C.D.</style></author><author><style face="normal" font="default"> Jacobs,D.R.,Jr.</style></author><author><style face="normal" font="default"> Hankinson,A.</style></author><author><style face="normal" font="default"> Iribarren,C.</style></author><author><style face="normal" font="default"> Sidney,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Cardiorespiratory fitness and coronary artery calcification in young adults: The CARDIA Study</style></title><secondary-title><style face="normal" font="default">Atherosclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Atherosclerosis</style></full-title></periodical><pages end="268" start="263">263-268</pages><volume><style face="normal" font="default">203</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> African Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> European Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Exercise Test</style></keyword><keyword><style face="normal" font="default"> Fasting</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="3" Year="2009">2009/3</year></dates><abstract><style face="normal" font="default">Whether cardiorespiratory fitness relates to early subclinical atherosclerotic vascular disease remains unknown. We investigated the relation of cardiorespiratory fitness to coronary artery calcification (CAC) in 2373 African-American and White young adults from the Coronary Artery Risk Development in Young Adults (CARDIA) Study. We measured cardiorespiratory fitness in 1985-1986 (baseline) using a symptom-limited exercise test on a treadmill. Coronary calcium scores were measured in 2001-2002 (year 15) using electron-beam or multi-detector computed tomography. CAC was classified as present or absent, while cardiorespiratory fitness was classified as sex-specific low, moderate, and high fitness categories. After adjustment for age, sex, race, clinical center, education, cigarette smoking, waist girth, alcohol intake, physical activity, systolic blood pressure, antihypertensive medication use, diabetes mellitus, and fasting insulin, baseline cardiorespiratory fitness was inversely associated with prevalence of CAC in young adults (P for trend=0.03). The odds ratios of having CAC for persons in the moderately and highly fit individuals were 0.80 (95% confidence interval (CI), 0.55-1.15) and 0.59 (95% CI, 0.36-0.97), respectively, as compared with the low-fit individuals. High levels of cardiorespiratory fitness were associated with a lower risk of having coronary calcification 15 years later in African-American and White young adults</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Exercise and Wellness, Arizona State University, Mesa, AZ, United States. Chong.Lee@asu.eduJC - 95x, 0242543CP - IrelandPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - N01-HC-45134 (United States NHLBI NIH HHS)NO - N01-HC-48047 (United States NHLBI NIH HHS)NO - N01-HC-48048 (United States NHLBI NIH HHS)NO - N01-HC-48049 (United States NHLBI NIH HHS)NO - N01-HC-48050 (United States NHLBI NIH HHS)NO - N01-HC-95095 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18653190</style></custom1><custom3><style face="normal" font="default">AS - Atherosclerosis. 203(1):263-8, 2009 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>105</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Lee,D.H.</style></author><author><style face="normal" font="default"> Steffes,M.W.</style></author><author><style face="normal" font="default"> Gross,M.</style></author><author><style face="normal" font="default"> Park,K.</style></author><author><style face="normal" font="default"> Holvoet,P.</style></author><author><style face="normal" font="default"> Kiefe,C.I.</style></author><author><style face="normal" font="default"> Lewis,C.E.</style></author><author><style face="normal" font="default"> Jacobs,D.R.,Jr.</style></author></authors></contributors><titles><title><style face="normal" font="default">Differential associations of weight dynamics with coronary artery calcium versus common carotid artery intima-media thickness: The CARDIA Study</style></title><secondary-title><style face="normal" font="default">American Journal of Epidemiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Epidemiology</style></full-title></periodical><pages end="189" start="180">180-189</pages><volume><style face="normal" font="default">172</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Body Weight</style></keyword><keyword><style face="normal" font="default"> *Carotid Artery,Common/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Tunica Intima/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Tunica Media/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Health Behavior</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="15" Month="7" Year="2010">2010/7/15</year></dates><abstract><style face="normal" font="default">Change and fluctuation in body mass index (BMI; weight (kg)/height (m)(2)) may be associated differently with coronary artery calcification (CAC) than with carotid artery intima-media thickness (IMT). The authors analyzed data on 2,243 participants in the Coronary Artery Risk Development in Young Adults (CARDIA) Study, initially aged 18-30 years, who were examined every 2-5 years over a 20-year period (1985-2006). BMI at year 0 was associated positively and linearly with CAC at year 20; however, the association of BMI with year 20 CAC became progressively U-shaped in subsequent examinations (years 10, 15, and 20). To understand the deepening U shape, the authors modeled year 20 BMI and its history using 3 indices: year 0 BMI, linear slope of BMI during 20 years, and BMI fluctuation during 20 years. In models including these 3 terms, year 0 BMI was associated positively with CAC, as was BMI fluctuation. However, adjusted odds ratios across quintiles of BMI slope (vs. the lowest quintile) were 0.7, 0.4, 0.5, and 0.4 (P(trend) &lt; 0.01), suggesting higher risk of CAC with weight loss, plateauing after moderate weight gain. In contrast, IMT was associated positively with BMI at all examinations and with 20-year BMI slope and was unassociated with BMI fluctuation. Surprisingly, CAC risk was higher with BMI loss and lower with BMI gain, whereas associations with IMT were as expected</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Preventive Medicine, Kyungpook National University, Daegu, South KoreaJC - 3h3, 7910653CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - N01-HC-05187 (United States NHLBI NIH HHS)NO - N01-HC-48047 (United States NHLBI NIH HHS)NO - N01-HC-48048 (United States NHLBI NIH HHS)NO - N01-HC-48049 (United States NHLBI NIH HHS)NO - N01-HC-48050 (United States NHLBI NIH HHS)NO - N01-HC-95095 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20519263</style></custom1><custom3><style face="normal" font="default">AS - Am J Epidemiol. 172(2):180-9, 2010 Jul 15.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>178</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Lee,H.J.</style></author><author><style face="normal" font="default"> Kim,Y.J.</style></author><author><style face="normal" font="default"> Hur,J.</style></author><author><style face="normal" font="default"> Nam,J.E.</style></author><author><style face="normal" font="default"> Kim,T.H.</style></author><author><style face="normal" font="default"> Choe,K.O.</style></author><author><style face="normal" font="default"> Choi,B.W.</style></author></authors></contributors><titles><title><style face="normal" font="default">Coronary artery anomalies: detection on coronary artery calcium scoring scan</style></title><secondary-title><style face="normal" font="default">AJR</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">AJR</style></full-title></periodical><pages end="W387" start="W382">W382-W387</pages><volume><style face="normal" font="default">American</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/ut [Utilization]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessel Anomalies/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/ut [Utilization]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Korea/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="5" Year="2010">2010/5</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The objective of this study was to evaluate the accuracy of coronary artery calcium scanning in identifying coronary anomalies and potentially high-risk interarterial courses. MATERIALS AND METHODS: Ninety-five consecutive patients who were diagnosed with a coronary anomaly on CT coronary angiography were enrolled, and 95 age- and sex-matched individuals in whom any coronary anomalies were excluded on CT coronary angiography were used as control subjects (total, 190 patients; 106 men and 84 women; mean age, 58 +/- 12 years). The coronary artery calcium scan for each patient was retrospectively evaluated by three radiologists for the presence of coronary anomalies and the presence of an interarterial course in cases of suspected anomaly. Interobserver agreement was assessed. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of a coronary artery calcium scan for coronary anomalies and their interarterial courses were calculated, with CT coronary angiography as the reference standard. RESULTS: Almost perfect interobserver agreement was achieved in evaluating coronary anomalies and interarterial courses (kappa = 0.81 and 0.92, respectively). We achieved a high grade of diagnostic performance of coronary artery calcium scanning in detecting coronary anomalies (sensitivity, 79-80%; specificity, 95-98%; PPV, 94-97%; and NPV, 82-83%) and interarterial courses (sensitivity, 88-91%; specificity, 95-97%; PPV, 84-91%; and NPV, 97%). CONCLUSION: Coronary anomalies and interarterial courses were detected with great accuracy on coronary artery calcium scans</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Diagnostic Radiology, Severance Hospital, Yonsei University College of Medicine, Shinchon-dong, Seodaemun-gu, Seoul 120-752, KoreaJC - 3ae, 7708173CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20410382</style></custom1><custom3><style face="normal" font="default">AS - AJR Am J Roentgenol. 194(5):W382-7, 2010 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>563</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Lee,J.H.</style></author><author><style face="normal" font="default"> Ngengwe,R.</style></author><author><style face="normal" font="default"> Jones,P.</style></author><author><style face="normal" font="default"> Tang,F.</style></author><author><style face="normal" font="default"> O'Keefe,J.H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Erectile dysfunction as a coronary artery disease risk equivalent</style></title><secondary-title><style face="normal" font="default">Journal of Nuclear Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Nuclear Cardiology</style></full-title></periodical><pages end="803" start="800">800-803</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Erectile Dysfunction/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> 0 (Triglycerides)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Erectile Dysfunction/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Pilot Projects</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Triglycerides/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="11" Year="2008">2008/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: The conditions that predispose patients to erectile dysfunction are substantially similar to the coronary artery disease risk factors, including diabetes mellitus, hypertension, hyperlipidemia, obesity, sedentary lifestyle, depression, age, and smoking. Because of these shared risks and overlapping pathophysiologic mechanisms, we designed this pilot study to address the hypothesis that the presence of coronary artery calcium, a known indicator of increased cardiac risk, is associated with erectile dysfunction. METHODS AND RESULTS: A prospective registry enrolled 9150 men who underwent multidetector computed tomography. Subjects supplied baseline data regarding demographic variables, coronary risk factors, and erectile dysfunction symptoms or lack thereof. The 2 groups then underwent computed tomography to screen for the presence or absence of coronary artery calcium. Subjects with erectile dysfunction were older, had higher triglyceride levels, had higher blood pressures, and were more likely to have measurable coronary artery calcification than men without erectile dysfunction (79% vs 58%, P &lt; .001). CONCLUSION: Erectile dysfunction is significantly associated with abnormal coronary artery calcification and, like peripheral arterial disease, might warrant consideration as a coronary artery disease risk equivalent</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Mid America Heart Institute, Kansas City, MO, USAJC - cmd, 9423534CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18984455</style></custom1><custom3><style face="normal" font="default">AS - J Nucl Cardiol. 15(6):800-3, 2008 Nov-Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>488</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Lee,K.K.</style></author><author><style face="normal" font="default"> Fortmann,S.P.</style></author><author><style face="normal" font="default"> Fair,J.M.</style></author><author><style face="normal" font="default"> Iribarren,C.</style></author><author><style face="normal" font="default"> Rubin,G.D.</style></author><author><style face="normal" font="default"> Varady,A.</style></author><author><style face="normal" font="default"> Go,A.S.</style></author><author><style face="normal" font="default"> Quertermous,T.</style></author><author><style face="normal" font="default"> Hlatky,M.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Insulin resistance independently predicts the progression of coronary artery calcification</style></title><secondary-title><style face="normal" font="default">American Heart Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Heart Journal</style></full-title></periodical><pages end="945" start="939">939-945</pages><volume><style face="normal" font="default">157</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Coronary Disease/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Insulin Resistance/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Insulin/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Risk Assessment/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 11061-68-0 (Insulin)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> California/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Insulin Resistance</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Pulse</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="5" Year="2009">2009/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: Change in coronary artery calcification is a surrogate marker of subclinical coronary artery disease (CAD). In the only large prospective study, CAD risk factors predicted progression of coronary artery calcium (CAC). METHODS: We measured CAC at enrollment and after 24 months in a community-based sample of 869 healthy adults aged 60 to 72 years who were free of clinical CAD. We assessed predictors of the progression of CAC using univariate and multivariate models after square root transformation of the Agatston scores. Predictors tested included age, sex, race/ethnicity, smoking status, body mass index, family history of CAD, C-reactive protein and several measures of diabetes, insulin levels, blood pressure, and lipids. RESULTS: The mean age of the cohort was 66 years, and 62% were male. The median CAC at entry was 38.6 Agatston units and increased to 53.3 Agatston units over 24 months (P &lt; .01). The CAC progression was associated with white race, diabetes, dyslipidemia, hypertension, lower diastolic blood pressure, and higher pulse pressure. After controlling for these variables, higher fasting insulin levels independently predicted CAC progression. CONCLUSIONS: Insulin resistance, in addition to the traditional cardiac risk factors, independently predicts progression of CAC in a community-based population without clinical CAD</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Stanford University School of Medicine, Stanford, CA, USA. klee@cvmed.stanford.eduJC - 0370465CP - United StatesPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19376325</style></custom1><custom3><style face="normal" font="default">AS - Am Heart J. 157(5):939-45, 2009 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>431</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Lee,W.S.</style></author><author><style face="normal" font="default"> Kim,S.W.</style></author><author><style face="normal" font="default"> Hong,S.A.</style></author><author><style face="normal" font="default"> Lee,T.J.</style></author><author><style face="normal" font="default"> Park,E.S.</style></author><author><style face="normal" font="default"> Kim,H.J.</style></author><author><style face="normal" font="default"> Lee,K.J.</style></author><author><style face="normal" font="default"> Kim,T.H.</style></author><author><style face="normal" font="default"> Kim,C.J.</style></author><author><style face="normal" font="default"> Ryu,W.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Atherosclerotic progression attenuates the expression of Nogo-B in autopsied coronary artery: pathology and virtual histology intravascular ultrasound analysis</style></title><secondary-title><style face="normal" font="default">Journal of Korean Medical Science</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Korean Medical Science</style></full-title></periodical><pages end="604" start="596">596-604</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Myelin Proteins/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> 0 (Myelin Proteins)</style></keyword><keyword><style face="normal" font="default"> 0 (Nogo protein)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Ultrasonography,Interventional</style></keyword></keywords><dates><year Day="0" Month="8" Year="2009">2009/8</year></dates><abstract><style face="normal" font="default">The relation of Nogo-B to atherosclerotic plaque progression is not well understood. Thus, the purpose of this study was to assess the expression of Nogo-B in fibroatheromas (FA) of different stages, classified using virtual histology intravascular ultrasound (VH-IVUS) analysis in 19 autopsied cases of non-sudden cardiac death. VH-IVUS imaging analysis was performed 30 mm from the ostium of each coronary artery. VH-IVUS revealed 11 early FAs (34.5+/-8.3 yr), 12 late FAs (42.6+/-16.6 yr), 8 thick-cap FAs (TkCFAs) (46.4+/-11.1 yr), and 6 thin-cap FAs (TCFAs) (51.8+/-6.8 yr). TkCFAs and TCFAs were defined as advanced FA. FA progression advanced with age (P=0.04). VH-IVUS analysis of small, early FAs showed smaller necrotic cores and relatively less calcium compared to more advanced FAs with large necrotic cores (P&lt;0.001). Histopathology and immunohistochemical stains demonstrated that early or late FAs had smaller necrotic cores, less empty space of decalcification, and greater Nogo-B expression compared to advanced FAs (vs. early FA, P=0.013; vs. late FA, P=0.008, respectively). These findings suggest that FA progression is inversely associated with Nogo-B expression. Local reduction of Nogo-B may contribute to plaque formation and/or instability</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Internal Medicine, College of Medicine, Chung-Ang University, Seoul, Korea. wslee1227@dreamwiz.comJC - ah4, 8703518CP - Korea (South)PT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19654939</style></custom1><custom3><style face="normal" font="default">AS - J Korean Med Sci. 24(4):596-604, 2009 Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>499</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Lehti,M.</style></author><author><style face="normal" font="default"> Kivel&amp;#x00E4</style></author><author><style face="normal" font="default"> R</style></author><author><style face="normal" font="default"> Komi,P.</style></author><author><style face="normal" font="default"> Komulainen,J.</style></author><author><style face="normal" font="default"> Kainulainen,H.</style></author><author><style face="normal" font="default"> inen,H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Effects of fatiguing jumping exercise on mRNA expression of titin-complex proteins and calpains</style></title><secondary-title><style face="normal" font="default">Journal of Applied Physiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Applied Physiology</style></full-title></periodical><pages end="1424" start="1419">1419-1424</pages><volume><style face="normal" font="default">106</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calpain/bi [Biosynthesis]</style></keyword><keyword><style face="normal" font="default"> *Exercise/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Muscle Fatigue/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Muscle Proteins/bi [Biosynthesis]</style></keyword><keyword><style face="normal" font="default"> *Protein Kinases/bi [Biosynthesis]</style></keyword><keyword><style face="normal" font="default"> *RNA,Messenger/bi [Biosynthesis]</style></keyword><keyword><style face="normal" font="default"> 0 (connectin)</style></keyword><keyword><style face="normal" font="default"> 0 (Muscle Proteins)</style></keyword><keyword><style face="normal" font="default"> 0 (RNA,Messenger)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Ankyrin Repeat</style></keyword><keyword><style face="normal" font="default"> Biomechanics</style></keyword><keyword><style face="normal" font="default"> EC 2-7 (Protein Kinases)</style></keyword><keyword><style face="normal" font="default"> EC 3-4-22 (Calpain)</style></keyword><keyword><style face="normal" font="default"> Electrophoresis,Polyacrylamide Gel</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Muscle Contraction/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Muscle,Skeletal/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Muscle,Skeletal/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> RNA,Messenger/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Stress,Mechanical</style></keyword><keyword><style face="normal" font="default"> Thigh/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="4" Year="2009">2009/4</year></dates><isbn><style face="normal" font="default">8750-7587</style></isbn><abstract><style face="normal" font="default">Eccentric exercise induced by electrostimulation increases mRNA expression of titin-complex proteins in rodent skeletal muscle. In this study, mRNA expression of titin, muscle LIM protein (MLP), cardiac ankyrin repeat protein (CARP), ankyrin repeat domain protein 2 (Ankrd2), diabetes-related ankyrin repeat protein (DARP), and calcium-activated proteinases, calpains, were investigated in human skeletal muscle after fatiguing jumping exercise. Fatiguing jumping exercise did not change mRNA expression of titin, DARP, calpain 1, or calpain 3. MLP, Ankrd2 and calpain 2 mRNA levels were increased 2 days postexercise. CARP mRNA level was already elevated 30 min and remained elevated 2 days postexercise. Increased mRNA expression of MLP, CARP, and Ankrd2, observed for the first time in human skeletal muscle, may be part of the signaling activated by physical exercise. The rapid increase in the level of CARP mRNA nominates CARP as one of the first genes to respond to exercise. The increase in the mRNA level of calpain 2 suggests its involvement in myofiber remodeling after strenuous jumping exercise</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - LIKES Research Center, Rautpohjankatu 8, FIN-40700 Jyv&amp;#x00E4;skyl&amp;#x00E4;, Finland. maarit.lehti@likes.fiCM - Comment in: J Appl Physiol. 2009 Jun;106(6):2068; author reply 2069; PMID: 19470844]JC - heg, 8502536CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19150862</style></custom1><custom3><style face="normal" font="default">AS - J Appl Physiol. 106(4):1419-24, 2009 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>77</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Lemon,S.C.</style></author><author><style face="normal" font="default"> Olendzki,B.</style></author><author><style face="normal" font="default"> Magner,R.</style></author><author><style face="normal" font="default"> Li,W.</style></author><author><style face="normal" font="default"> Culver,A.L.</style></author><author><style face="normal" font="default"> Ockene,I.</style></author><author><style face="normal" font="default"> Goldberg,R.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">The dietary quality of persons with heart failure in NHANES 1999-2006</style></title><secondary-title><style face="normal" font="default">Journal of General Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of General Internal Medicine</style></full-title></periodical><pages end="140" start="135">135-140</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Food Habits</style></keyword><keyword><style face="normal" font="default"> *Heart Failure/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Nutrition Surveys</style></keyword><keyword><style face="normal" font="default"> 0 (Sodium,Dietary)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Failure/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Heart Failure/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sodium,Dietary/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> United States/ep [Epidemiology]</style></keyword></keywords><dates><year Day="0" Month="2" Year="2010">2010/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: Dietary quality may impact heart failure outcomes. However, the current status of the dietary quality of persons with heart failure has not been previously reported. OBJECTIVE: To describe sodium intake, patient factors associated with sodium intake and overall dietary quality in a national sample of persons with heart failure. DESIGN: Analysis of repeated cross-sectional probability sample surveys using data from National Health and Nutrition Examination Surveys (NHANES) of 1999-2000, 2001-2002, 2003-2004 and 2005-2006. PARTICIPANTS: The study sample consisted of 574 persons with self-reported heart failure (mean age = 70 years; 52% women). MEASUREMENTS: Diet of each survey participant was assessed using single 24 hour recall. Dietary nutrients of interest included sodium, the mainstay of heart failure dietary recommendations, and additionally potassium, calcium, magnesium, fish oils, saturated fat and fiber. Specific dietary goals were based on established guidelines. RESULTS: Mean sodium intake was 2,719 mg, with 34% consuming less than 2,000 mg per day. Patient factors associated with greater sodium intake included male gender, lower education, lower income and no reported diagnosis of hypertension. Mean potassium intake was 2,367 mg/day, with no differences by type of diuretic used or renal disease status. Adherence rates to established guidelines for other nutrients were 13% for calcium, 10% for magnesium, 2% for fish oils, 13% for saturated fat and 4% for fiber. CONCLUSIONS: Dietary quality of persons with self-reported heart failure was poor. Public health approaches and clinical dietary interventions are needed for persons with this increasingly prevalent clinical syndrome</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Preventive and Behavioral Medicine, S7-745, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA. Stephenie.Lemon@umassmed.eduJC - 8605834CP - United StatesPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19882192</style></custom1><custom3><style face="normal" font="default">AS - J Gen Intern Med. 25(2):135-40, 2010 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>275</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Lerner,R.G.</style></author><author><style face="normal" font="default"> Aronow,W.S.</style></author><author><style face="normal" font="default"> Sekhri,A.</style></author><author><style face="normal" font="default"> Palaniswamy,C.</style></author><author><style face="normal" font="default"> Ahn,C.</style></author><author><style face="normal" font="default"> Singh,T.</style></author><author><style face="normal" font="default"> Sandhu,R.</style></author><author><style face="normal" font="default"> McClung,J.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Warfarin use and the risk of valvular calcification</style></title><secondary-title><style face="normal" font="default">Journal of Thrombosis &amp; Haemostasis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Thrombosis &amp; Haemostasis</style></full-title></periodical><pages end="2027" start="2023">2023-2027</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aortic Valve/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> *Mitral Valve/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Warfarin/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> 0 (Calcium-Binding Proteins)</style></keyword><keyword><style face="normal" font="default"> 0 (Extracellular Matrix Proteins)</style></keyword><keyword><style face="normal" font="default"> 0 (matrix Gla protein)</style></keyword><keyword><style face="normal" font="default"> 81-81-2 (Warfarin)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Angiotensin-Converting Enzyme Inhibitors</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> Atrial Fibrillation/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Atrial Fibrillation/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium-Binding Proteins/bi [Biosynthesis]</style></keyword><keyword><style face="normal" font="default"> Calcium-Binding Proteins/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Extracellular Matrix Proteins/bi [Biosynthesis]</style></keyword><keyword><style face="normal" font="default"> Extracellular Matrix Proteins/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Warfarin/tu [Therapeutic Use]</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Warfarin affects the synthesis and function of the matrix Gla-protein, a vitamin K-dependent protein, which is a potent inhibitor of tissue calcification. OBJECTIVES: To investigate the incidence of mitral valve calcium (MVC), mitral annular calcium (MAC) and aortic valve calcium (AVC) in patients with non-valvular atrial fibrillation (AF) treated with warfarin vs. no warfarin. PATIENTS AND METHODS: Of 1155 patients, mean age 74 years, with AF, 725 (63%) were treated with warfarin and 430 (37%) without warfarin. The incidence of MVC, MAC and AVC was investigated in these 1155 patients with two-dimensional echocardiograms. Unadjusted logistic regression analysis was conducted to examine the association between the use of warfarin and the incidence of MVC, MAC or AVC. Logistic regression analyses were also conducted to investigate whether the relationship stands after adjustment for confounding risk factors such as age, sex, race, ejection fraction, smoking, hypertension, diabetes, dyslipidemia, coronary artery disease (CAD), glomerular filtration rate, calcium, phosphorus, calcium-phosphorus product, alkaline phosphatase, use of aspirin, beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins. RESULTS: There was a significant association between the use of warfarin and the risk of calcification [unadjusted odds ratio = 1.71, 95% CI = (1.34-2.18)]. The association still stands after adjustment for confounding risk factors. MVC, MAC or AVC was present in 473 of 725 patients (65%) on warfarin vs. 225 of 430 patients (52%) not on warfarin (P &lt; 0.0001). Whether this is a causal relationship remains unknown. CONCLUSIONS: Use of warfarin in patients with AF is associated with an increased prevalence of MVC, MAC or AVC</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiology, Department of Medicine, New York Medical College, Valhalla, NY 10595, USA. ROBERT_LERNER@nymc.eduJC - 101170508CP - EnglandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19793187</style></custom1><custom3><style face="normal" font="default">AS - J Thromb Haemost. 7(12):2023-7, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>247</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Leschka,S.</style></author><author><style face="normal" font="default"> Kim,C.H.</style></author><author><style face="normal" font="default"> Baumueller,S.</style></author><author><style face="normal" font="default"> Stolzmann,P.</style></author><author><style face="normal" font="default"> Scheffel,H.</style></author><author><style face="normal" font="default"> Marincek,B.</style></author><author><style face="normal" font="default"> Alkadhi,H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Scan length adjustment of CT coronary angiography using the calcium scoring scan: effect on radiation dose</style></title><secondary-title><style face="normal" font="default">AJR</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">AJR</style></full-title></periodical><pages end="W277" start="W272">W272-W277</pages><volume><style face="normal" font="default">American</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> 0 (Contrast Media)</style></keyword><keyword><style face="normal" font="default"> 66108-95-0 (Iohexol)</style></keyword><keyword><style face="normal" font="default"> 73334-07-3 (iopromide)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Contrast Media</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Iohexol/aa [Analogs &amp; Derivatives]</style></keyword><keyword><style face="normal" font="default"> Iohexol/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Radiation Dosage</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Statistics,Nonparametric</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="3" Year="2010">2010/3</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The objective of our study was to prospectively investigate the effect of adjusting the scan length of CT coronary angiography using the calcium scoring images instead of the scout view with regard to radiation dose. SUBJECTS AND METHODS: One hundred twenty-five consecutive patients (mean age +/- SD, 62 +/- 10 years) undergoing both calcium scoring and CT coronary angiography were included in our study. The scan length of calcium scoring was planned on the scout view; the scan length of CT coronary angiography was planned on the axial images of the calcium scoring by identifying the origin of the left main artery and cardiac apex and adding 1 cm cranially and caudally. Effective radiation doses were calculated for CT coronary angiography using both scout view-derived and calcium scoring-derived scan lengths. RESULTS: The scout view-derived scan length (mean +/- SD, 139 +/- 13 mm) was significantly greater than the calcium scoring-derived scan length (117 +/- 9 mm; p &lt; 0.01). The average radiation dose was 0.8 +/- 0.3 mSv (range, 0.6-1.5 mSv) for calcium scoring and 9.0 +/- 0.6 mSv (range, 6.5-10.2 mSv) for CT coronary angiography. Using the scout view-derived scan length would have been associated with an effective radiation dose of 10.7 +/- 1.2 mSv (mean +/- SD) for CT coronary angiography, which is significantly higher than that using the calcium scoring-derived scan length (p &lt; 0.05). The average difference between CT coronary angiography using a calcium scoring-derived scan length and that using a scout view-derived scan length was 1.7 +/- 0.9 mSv, corresponding to a radiation dose reduction of 16%. The average dose reduction when using a calcium scoring-derived instead of a scout view-derived scan length for CT coronary angiography-including the radiation dose of the calcium scoring scan-was 1.2 +/- 0.8 mSv (range, 0.1-2.7 mSv) (p &lt; 0.05). CONCLUSION: Adjustment of the scan length of CT coronary angiography using the images from calcium scoring instead of the scout view is feasible and is associated with a 16% reduction in radiation dose of dual-source CT coronary angiography</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Institute of Diagnostic Radiology, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland. sebastian.leschka@usz.chJC - 3ae, 7708173CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20173126</style></custom1><custom3><style face="normal" font="default">AS - AJR Am J Roentgenol. 194(3):W272-7, 2010 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>321</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Li,D.R.</style></author><author><style face="normal" font="default"> Quan,L.</style></author><author><style face="normal" font="default"> Zhu,B.L.</style></author><author><style face="normal" font="default"> Ishikawa,T.</style></author><author><style face="normal" font="default"> Michiue,T.</style></author><author><style face="normal" font="default"> Zhao,D.</style></author><author><style face="normal" font="default"> Yoshida,C.</style></author><author><style face="normal" font="default"> Chen,J.H.</style></author><author><style face="normal" font="default"> Wang,Q.</style></author><author><style face="normal" font="default"> Komatsu,A.</style></author><author><style face="normal" font="default"> Azuma,Y.</style></author><author><style face="normal" font="default"> Maeda,H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Evaluation of postmortem calcium and magnesium levels in the pericardial fluid with regard to the cause of death in medicolegal autopsy</style></title><secondary-title><style face="normal" font="default">Legal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Legal Medicine</style></full-title></periodical><pages end="8" start="Suppl">Suppl-8</pages><volume><style face="normal" font="default">11</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Magnesium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Pericardium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Postmortem Changes</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 7439-95-4 (Magnesium)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Autopsy</style></keyword><keyword><style face="normal" font="default"> Biological Markers/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cause of Death</style></keyword><keyword><style face="normal" font="default"> Cerebral Hemorrhage/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Child,Preschool</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fires</style></keyword><keyword><style face="normal" font="default"> Forensic Pathology</style></keyword><keyword><style face="normal" font="default"> Fresh Water</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypothermia/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> Infant,Newborn</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Pneumonia/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Seawater</style></keyword><keyword><style face="normal" font="default"> Wounds and Injuries/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="4" Year="2009">2009/4</year></dates><abstract><style face="normal" font="default">Previous studies have suggested the usefulness of postmortem serum calcium (Ca) and magnesium (Mg) for investigating cause of death. The present study investigated their levels in the pericardial fluid of serial autopsy cases of adults within 48 h postmortem (n=385), including fatalities from blunt injury (n=57), sharp instrument injury (n=9), mechanical asphyxiation (n=28), salt- and freshwater drowning (n=14 and n=61, respectively), fire fatality (n=35), intoxication (n=23), hypothermia (cold exposure, n=12), hyperthermia (heat stroke, n=7), acute cardiac death (ACD, n=86), pneumonia (n=9) and spontaneous cerebral hemorrhage (n=11). The pericardial Ca level was independent of the postmortem interval, showing a value similar to that of the clinical reference range in cases other than saltwater drowning, while the Mg level was higher than the clinical reference range and showed a mild postmortem time-dependent increase. Pericardial Ca was significantly higher for saltwater drowning than other groups, and a lower level was seen for hyperthermia, and some cases of blunt injury and intoxication. The Mg level was also significantly higher for saltwater drowning than the other groups, and showed a higher level for sharp instrument injury, but a lower level for hypothermia. The Mg/Ca ratio was higher for sharp instrument injury and saltwater drowning, but was lower for hypothermia. These findings suggest that postmortem pericardial Ca and Mg can be used to investigate the cause of death, especially for saltwater drowning, hypothermia and hyperthermia</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Legal Medicine, Osaka City University Medical School, Asahi-machi 1-4-3, Abeno, 545-8585 Osaka, JapanJC - 100889186CP - IrelandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19251451</style></custom1><custom3><style face="normal" font="default">AS - Leg Med (Tokyo). 11 Suppl 1:S276-8, 2009 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>430</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Li,Y.</style></author><author><style face="normal" font="default"> Ma,A.</style></author><author><style face="normal" font="default"> Sun,Y.</style></author><author><style face="normal" font="default"> Liang,H.</style></author><author><style face="normal" font="default"> Wang,Q.</style></author><author><style face="normal" font="default"> Yi,X.</style></author><author><style face="normal" font="default"> Han,X.</style></author></authors></contributors><titles><title><style face="normal" font="default">Magnesium status and dietary intake of mid-old people in a rural area of China</style></title><secondary-title><style face="normal" font="default">Magnesium Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Magnesium Research</style></full-title></periodical><pages end="71" start="66">66-71</pages><volume><style face="normal" font="default">22</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Diet</style></keyword><keyword><style face="normal" font="default"> *Erythrocytes/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Magnesium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> 0 (Blood Glucose)</style></keyword><keyword><style face="normal" font="default"> 7439-95-4 (Magnesium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Blood Glucose/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Body Weight</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Insulin Resistance</style></keyword><keyword><style face="normal" font="default"> Magnesium Deficiency/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Rural Population</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="6" Year="2009">2009/6</year></dates><isbn><style face="normal" font="default">0953-1424</style></isbn><abstract><style face="normal" font="default">To evaluate the status and dietary intake of magnesium in mid-old people in a rural area of China, a total of 324 mid-old people (111 males and 213 females) aged 55-70 were randomly selected. All the subjects were divided into four groups: a normal group (N), a hypertension group (H), an impaired fasting glucose group (IFG) and a diabetic group (D). Magnesium, sodium, potassium, calcium, iron, zinc, and copper concentrations in red blood cells (RBC) were measured by emission spectroscopy (ICP-OES), and dietary intakes were surveyed by 24-hr recall questionnaires. The data were analyzed between groups and also between genders. The average body weight and BMI were 59.4 kg and 22.1 in subjects with IFG, and 62.4 kg and 23.5 in the diabetics, which were higher than those of the normal group (p &lt; 0.05 and p &lt; 0.01). The average magnesium concentration in RBC was significantly lower in the hypertension group than in the normal group (2.0 mmol/L vs. 2.2 mmol/L, p &lt; 0.05). Groups H, IFG and D took less magnesium than group N (315.9 mg/d, 331.6 mg/d and 323.3 mg/d vs. 371.54 mg/d, p &lt; 0.05). Women took less magnesium than men (326.2 mg/d vs. 373.7 mg/d, p &lt; 0.05). There were no significant differences in other mineral concentrations in RBC and dietary intakes. Results of this study show that magnesium concentration in RBC is lower in mid-old people suffering hypertension as compared to healthy subjects. Dietary intakes of magnesium are lower in mid-old people suffering hypertension, IFG and diabetes as compared to healthy subjects. This indicates that an increase in the magnesium supply would be beneficial to mid-old people</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Institute of Human Nutrition, Medical College of Qingdao University, 38 Dengzhou Road, 266021, Qingdao, PR ChinaJC - avn, 8900948CP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19658275</style></custom1><custom3><style face="normal" font="default">AS - Magnes Res. 22(2):66-71, 2009 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>200</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Liang,Y.</style></author><author><style face="normal" font="default"> Zhu,J.</style></author><author><style face="normal" font="default"> Tan,H.Q.</style></author><author><style face="normal" font="default"> Zhang,Y.</style></author><author><style face="normal" font="default"> Liu,L.S.</style></author><author><style face="normal" font="default"> Chinese Coordinating Center of OASIS Registry</style></author></authors></contributors><titles><title><style face="normal" font="default">[Risk factors associated with increased end points of patients with non-ST elevation acute coronary syndromes in China: 2 years follow up results of China-OASIS Registry]. [Chinese]</style></title><secondary-title><style face="normal" font="default">Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology]</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology]</style></full-title></periodical><pages end="584" start="580">580-584</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Acute Coronary Syndrome/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Acute Coronary Syndrome/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> China/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Heart Rate</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword></keywords><dates><year Day="0" Month="7" Year="2009">2009/7</year></dates><isbn><style face="normal" font="default">0253-3758</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: To identify the risk factors associated with increased combined end points (including death, new myocardial infarction and stroke) of patients with non-ST elevation acute coronary syndrome in China. METHODS: Patients with non-ST elevation acute coronary syndrome hospitalized in 38 hospitals in China were included in this registry study as part of an international multicentre registry-OASIS. Data including clinical characteristics, previous medical history, therapeutic procedure and follow-up medicines, were collected and analyzed. The follow up period was two years. Cox regression model was used to analyze the association between multiple risk factors and combined end points. RESULTS: From April 1999 to December 2001, 2294 eligible patients were enrolled nationwide and 2294 patients finished the 2 years follow up (mean age: 62.8 +/- 8.3 years and 62.3% males). The mortality was 7.6% (174/2294), 168 new myocardial infarction and 93 stroke were recorded during follow up and the combined end point events was 365 (15.9%) at the end of the two year's follow-up. Forty-eight factors were analyzed by Cox regression model to determine the impact of these factors on the occurrence of end point event. Risk factors that promoting end points were: thrombolysis during hospitalization, heart rate more than 120 bpm at admission, current smoker, history of PTCA, length of the first hospitalization, intravenous nitrate use during hospitalization, history of heart failure, low molecular weight heparin or subcutaneous heparin use during hospitalization, former smoker, calcium antagonist use during hospitalization, history of hypertension or coronary artery disease, recurrent angina pectoris during hospitalization and age by the first hospitalization. Protective factors that reducing end point were: normal ECG at admission, use of oral nitrate, anti-platelet medicine, calcium antagonist, lipid lowering agents and angiotensin converting enzyme inhibitor during follow-up period. CONCLUSION: The two-years incidence of combined endpoints of death, new myocardial infarction and stroke in patients with non-ST elevation acute coronary syndromes is 15.9% in China. Fifteen factors are associated with increased and 8 factors (mostly related to regular medication use) are associated with reduced occurrence of endpoints during follow up in this cohort</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Chinese Academy of Medical Sciences, Beijing 100037, ChinaJC - ebn, 7910682CP - ChinaPT - English AbstractPT - Journal ArticleLG - Chinese</style></notes><urls/><custom1><style face="normal" font="default">UI - 19961723</style></custom1><custom3><style face="normal" font="default">AS - Chung Hua Hsin Hsueh Kuan Ping Tsa Chih. 37(7):580-4, 2009 Jul.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>566</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Lima,M.V.</style></author><author><style face="normal" font="default"> Ochiai,M.E.</style></author><author><style face="normal" font="default"> Cardoso,J.N.</style></author><author><style face="normal" font="default"> Morgado,P.C.</style></author><author><style face="normal" font="default"> Munhoz,R.T.</style></author><author><style face="normal" font="default"> Barretto,A.C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Hyperkalemia during spironolactone use in patients with decompensated heart failure</style></title><secondary-title><style face="normal" font="default">Arquivos Brasileiros de Cardiologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Arquivos Brasileiros de Cardiologia</style></full-title></periodical><pages end="182" start="177">177-182</pages><volume><style face="normal" font="default">91</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aldosterone Antagonists/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Heart Failure/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Hyperkalemia/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> *Spironolactone/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> 0 (Aldosterone Antagonists)</style></keyword><keyword><style face="normal" font="default"> 52-01-7 (Spironolactone)</style></keyword><keyword><style face="normal" font="default"> 57-13-6 (Urea)</style></keyword><keyword><style face="normal" font="default"> 7440-09-7 (Potassium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aldosterone Antagonists/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Brazil/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Epidemiologic Methods</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperkalemia/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Hyperkalemia/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Potassium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Spironolactone/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Urea/bl [Blood]</style></keyword></keywords><dates><year Day="0" Month="9" Year="194">194/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: The incidence of hyperkalemia related to spironolactone use is low in stable heart failure; however, it has not been studied during decompensation. OBJECTIVE: To evaluate the influence of spironolactone on serum potassium in decompensated heart failure (HF). METHODS: In a cohort study, patients that had been hospitalized due to decompensated HF, with left ventricular ejection fraction (LVEF) &lt; 0.45 and serum potassium between 3.5 and 5.5 mEq/l were selected. The patients were divided according to spironolactone use (Group S) or no use (Group C). The outcome was potassium increase (> 6.0 mEq/l) and the use of calcium polystyrene. A multivariate analysis through logistic regression was carried out and values of p &lt; 0.05 were considered significant. RESULTS: A total of 186 patients (group S: 56; group C: 130) were studied; LVEF of 0.25, aged 55.5 years and 65.2% of them males. The incidence of hyperkalemia was 10.7% in group S and 5.4% in group C (p = 0.862). The multivariate analysis showed that serum urea > 60.5 mg/dl during the hospitalization presents a relative risk of 9.6 (95%CI 8.03 - 11.20; p = 0.005) for the occurrence of hyperkalemia. CONCLUSION: The incidence of hyperkalemia was two-fold higher with spironolactone use, but it was not statistically significant. The increase in urea levels was associated to the hyperkalemia. Randomized studies are necessary to clarify this issue</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Hospital Auxiliar de Cotox&amp;#x00F3;, S&amp;#x00E3;o Paulo, Brasil. villacalima@cardiol.brJC - 8pm, 0421031CP - BrazilPT - Journal ArticleLG - English, Portuguese</style></notes><urls/><custom1><style face="normal" font="default">UI - 18853060</style></custom1><custom3><style face="normal" font="default">AS - Arq Bras Cardiol. 91(3):177-82, 194-9, 2008 Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>367</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Limpatanachote,P.</style></author><author><style face="normal" font="default"> Swaddiwudhipong,W.</style></author><author><style face="normal" font="default"> Mahasakpan,P.</style></author><author><style face="normal" font="default"> Krintratun,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Cadmium-exposed population in Mae Sot District, Tak Province: 2. Prevalence of renal dysfunction in the adults</style></title><secondary-title><style face="normal" font="default">Journal of the Medical Association of Thailand</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of the Medical Association of Thailand</style></full-title></periodical><pages end="1353" start="1345">1345-1353</pages><volume><style face="normal" font="default">92</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Kidney Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> 0 (beta 2-Microglobulin)</style></keyword><keyword><style face="normal" font="default"> 60-27-5 (Creatinine)</style></keyword><keyword><style face="normal" font="default"> 7440-43-9 (Cadmium)</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> beta 2-Microglobulin/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Cadmium/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Creatinine/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Environmental Exposure</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Kidney Diseases/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Thailand/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Urine</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><isbn><style face="normal" font="default">0125-2208</style></isbn><abstract><style face="normal" font="default">BACKGROUND: In 2004, 7,697 cadmium-exposed persons aged 15 years and older in Mae Sot District, Tak Province, Thailand, were screened for urinary cadmium levels and 554 cases (7.2%) had > or = 5 microg/g creatinine. OBJECTIVE: The present study reported the prevalence of renal dysfunction among those with high urinary cadmium (> or = 5 microg/g creatinine). MATERIAL AND METHOD: The study persons were interviewed and examined for detection of renal dysfunction. Venous blood and second morning urine were obtained from each subject for microscopic analysis and biochemistry measurements. RESULTS: Of the 527 examined persons, 14.2% had urinary beta2-microglobulin excretion between 300 and 999 microg/g creatinine, and 19.9% contained > or = 1,000 microg/g creatinine. About 21.1% had serum creatinine concentrations between 1.1 and 1.4 mg/dl and 4.2% contained > or = 1.5 mg/dl. Low glomerular filtration rate (GFR &lt; 60 ml/min/1.73 m2 body surface area) was present in 16.9% of the study persons. Of the persons surveyed, 75.3% had the fractional excretion of phosphate > 5% and 24.7% contained the fractional excretion of potassium > 10%. The overall prevalence rates of hypertension and urinary stones in the study population were 31.3% and 8.9%, respectively. Excretion of urinary beta2-microglobulin significantly increased with increasing urinary cadmium levels. Both increased serum creatinine and decreased GFR appeared to be associated with increasing urinary cadmium although the difference was not statistically significant. There were no significant associations between urinary cadmium levels and excretion of urinary protein, urinary calcium, hypertension, and urinary stones. CONCLUSION: Excessive exposure to cadmium might produce renal dysfunction among the present study population. Increased urinary excretion of beta2-microglobulin is a good indicator of renal tubular dysfunction among persons with excessive cadmium exposure</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Internal Medicine, Mae Sot General Hospital, Tak, ThailandJC - izr, 7507216CP - ThailandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19845243</style></custom1><custom3><style face="normal" font="default">AS - J Med Assoc Thai. 92(10):1345-53, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>242</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Lin,H.H.</style></author><author><style face="normal" font="default"> Yang,Y.F.</style></author><author><style face="normal" font="default"> Chang,J.K.</style></author><author><style face="normal" font="default"> Ting,I.W.</style></author><author><style face="normal" font="default"> Kuo,H.L.</style></author><author><style face="normal" font="default"> Wang,I.K.</style></author><author><style face="normal" font="default"> Huang,C.C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Renin-angiotensin system blockade is not associated with hyperkalemia in chronic hemodialysis patients</style></title><secondary-title><style face="normal" font="default">Renal Failure</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Renal Failure</style></full-title></periodical><pages end="945" start="942">942-945</pages><volume><style face="normal" font="default">31</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Angiotensin II Type 1 Receptor Blockers/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Angiotensin-Converting Enzyme Inhibitors/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Hyperkalemia/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure,Chronic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Renin-Angiotensin System</style></keyword><keyword><style face="normal" font="default"> 0 (Angiotensin II Type 1 Receptor Blockers)</style></keyword><keyword><style face="normal" font="default"> 0 (Angiotensin-Converting Enzyme Inhibitors)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angiotensin-Converting Enzyme Inhibitors</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><abstract><style face="normal" font="default">BACKGROUND: Serious hyperkalemia was reported in 10% of chronic hemodialysis (HD) patients that could lead to arrhythmia and death. Angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin II receptor blockers (ARB) are well accepted for cardio-protective benefits. The relationship between renin-angiotensin system blockade (RASB) and hyperkalemia in chronic HD patients remains controversial. The aim of this study was to find the relationship between RASB and hyperkalemia in these patients. METHODS: Pre-dialysis serum potassium, clinical factors, and drugs were evaluated in 200 chronic HD patients in one HD center. Hyperkalemia was defined as serum K >or= 5.3 meq/L. Finally, multivariate analysis with logistic regression was used to evaluate the risk of hyperkalemia by RASB and other factors. RESULTS: In 200 patients, the mean K was 4.93 +/- 0.79 meq/L, and 70 (35%) patients had hyperkalemia. Fifty-eight (29%) patients were prescribed with RASB. Seven variables--non-DM, longer HD duration, lower dialysate calcium, lower serum glucose, higher serum iPTH, not using RASB, and not using furosemide--were more frequent in hyperkalemia group. In logistic regression analysis, RASB was associated with decreased odds for hyperkalemia (OR 0.262, p = 0.001 in model A; OR 0.205, p = 0.001 in model B). In addition, furosemide was associated with decreased odds for hyperkalemia (OR 0.068, p = 0.022 in model B). CONCLUSIONS: RASB is not associated with hyperkalemia in chronic HD patients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Nephrology and Kidney Institute, China Medical University Hospital, Taichung, TaiwanJC - rcg, 8701128CP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20030530</style></custom1><custom3><style face="normal" font="default">AS - Ren Fail. 31(10):942-5, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>454</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Lindsey,J.B.</style></author><author><style face="normal" font="default"> de Lemos,J.A.</style></author><author><style face="normal" font="default"> Cipollone,F.</style></author><author><style face="normal" font="default"> Ayers,C.R.</style></author><author><style face="normal" font="default"> Rohatgi,A.</style></author><author><style face="normal" font="default"> Morrow,D.A.</style></author><author><style face="normal" font="default"> Khera,A.</style></author><author><style face="normal" font="default"> McGuire,D.K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study</style></title><secondary-title><style face="normal" font="default">Diabetes Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Diabetes Care</style></full-title></periodical><pages end="1220" start="1218">1218-1220</pages><volume><style face="normal" font="default">32</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Receptors,Immunologic/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (advanced glycosylation end-product receptor)</style></keyword><keyword><style face="normal" font="default"> 0 (Receptors,Immunologic)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Continental Population Groups</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Research Design</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Texas</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="7" Year="2009">2009/7</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To determine the association between circulating soluble receptor for advanced glycation end products (sRAGE) and coronary atherosclerosis. RESEARCH DESIGN AND METHODS: Using data from the Dallas Heart Study, a probability-based population sample, the association between plasma levels of sRAGE and coronary artery calcium (CAC) was assessed among 2,571 subjects with complete imaging and sRAGE data. RESULTS: An inverse graded association was observed between sRAGE quartiles and CAC, with CAC prevalence of 28.5% in quartile 1 compared with 15.7% in quartile 4 (P &lt; 0.0001). After multivariable adjustment, the associations between sRAGE levels in the first and second quartiles (versus fourth quartile) and CAC remained statistically significant (adjusted odds ratio 1.71 [95% CI 1.2-2.4] and 1.5 [1.0-2.1], respectively). CONCLUSIONS: sRAGE is a novel biomarker that is inversely associated with coronary atherosclerosis. The role of sRAGE in the pathobiology of atherosclerosis and its potential prognostic and therapeutic implications warrant further investigation</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Donald W. Reynolds Cardiovascular Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, Texas, USAJC - eag, 7805975CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19366975</style></custom1><custom3><style face="normal" font="default">AS - Diabetes Care. 32(7):1218-20, 2009 Jul.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>165</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Liu,W.M.</style></author><author><style face="normal" font="default"> Zhu,Z.G.</style></author><author><style face="normal" font="default"> Leng,H.X.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Analysis of the contents of K, Na, Ca, Mg, Zn, Cu, Fe and Mn in serum of middle and old-aged hypertension patients]. [Chinese]</style></title><secondary-title><style face="normal" font="default">Guang Pu Xue Yu Guang Pu Fen Xi/Spectroscopy &amp; Spectral Analysis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Guang Pu Xue Yu Guang Pu Fen Xi/Spectroscopy &amp; Spectral Analysis</style></full-title></periodical><pages end="362" start="360">360-362</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Hypertension/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 7439-89-6 (Iron)</style></keyword><keyword><style face="normal" font="default"> 7439-95-4 (Magnesium)</style></keyword><keyword><style face="normal" font="default"> 7439-96-5 (Manganese)</style></keyword><keyword><style face="normal" font="default"> 7440-09-7 (Potassium)</style></keyword><keyword><style face="normal" font="default"> 7440-23-5 (Sodium)</style></keyword><keyword><style face="normal" font="default"> 7440-66-6 (Zinc)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Iron/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Laboratory Techniques and Procedures</style></keyword><keyword><style face="normal" font="default"> Magnesium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Manganese/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Potassium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Reference Values</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sex Characteristics</style></keyword><keyword><style face="normal" font="default"> Sodium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Zinc/bl [Blood]</style></keyword></keywords><dates><year Day="0" Month="3" Year="2004">2004/3</year></dates><isbn><style face="normal" font="default">1000-0593</style></isbn><abstract><style face="normal" font="default">Atomic absorption method was used to detect the contents of K, Na, Ca, Mg, Zn, Cu, Fe and Mn in serum of 48 hypertension patients and 52 healthy people. The results show that the contents of Na, Mg, Zn, Fe and Mn in hypertension were higher than healthy control, while K, Ca and Cu were lower. Na/K were higher, but Ca/Mg and Cu/Zn were lower, than healthy control. These suggested that we should add K, Ca, Mg and Cu properly, reduce Na, scientifically control the increase of Zn, Fe and Mn, pay attention to the balance relation of Na/K, Ca/Mg and Cu/Zn, reduce Na/K, raise Cu/Zn, and add Ca with Mg properly. This can be useful for preventing and treating hypertension</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Jilin Military Medical College, Fourth Military Medical University, Jilin 132013, ChinaJC - 9424805CP - ChinaPT - English AbstractPT - Journal ArticleLG - Chinese</style></notes><urls/><custom1><style face="normal" font="default">UI - 15760000</style></custom1><custom3><style face="normal" font="default">AS - Guang Pu Xue Yu Guang Pu Fen Xi. 24(3):360-2, 2004 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>342</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Liu,X.</style></author><author><style face="normal" font="default"> Tsujita,K.</style></author><author><style face="normal" font="default"> Maehara,A.</style></author><author><style face="normal" font="default"> Mintz,G.S.</style></author><author><style face="normal" font="default"> Weisz,G.</style></author><author><style face="normal" font="default"> Dangas,G.D.</style></author><author><style face="normal" font="default"> Lansky,A.J.</style></author><author><style face="normal" font="default"> Kreps,E.M.</style></author><author><style face="normal" font="default"> Rabbani,L.E.</style></author><author><style face="normal" font="default"> Collins,M.</style></author><author><style face="normal" font="default"> Stone,G.W.</style></author><author><style face="normal" font="default"> Moses,J.W.</style></author><author><style face="normal" font="default"> Mehran,R.</style></author><author><style face="normal" font="default"> Leon,M.B.</style></author></authors></contributors><titles><title><style face="normal" font="default">Intravascular ultrasound assessment of the incidence and predictors of edge dissections after drug-eluting stent implantation</style></title><secondary-title><style face="normal" font="default">Jacc: Cardiovascular Interventions</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Jacc: Cardiovascular Interventions</style></full-title></periodical><pages end="1004" start="997">997-1004</pages><volume><style face="normal" font="default">2</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aneurysm,Dissecting/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Angioplasty,Transluminal,Percutaneous Coronary/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> *Coronary Aneurysm/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Stenosis/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> *Drug-Eluting Stents</style></keyword><keyword><style face="normal" font="default"> *Hematoma/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Ultrasonography,Interventional</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aneurysm,Dissecting/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Angioplasty,Transluminal,Percutaneous Coronary/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Aneurysm/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Stenosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hematoma/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><abstract><style face="normal" font="default">OBJECTIVES: We used intravascular ultrasound (IVUS) to assess incidence, predictors, morphology, and angiographic findings of edge dissections after drug-eluting stent (DES) implantation. BACKGROUND: DES implantation strategies differ compared with bare-metal stenting; coronary dissections after DES implantation have not been well studied. METHODS: We studied 887 patients with 1,045 non-in-stent restenosis lesions in 977 native arteries undergoing DES implantation with IVUS imaging. RESULTS: Eighty-two dissections were detected; 51.2% (42 of 82) involved the proximal and 48.8% (40 of 82) the distal stent edge. Residual plaque area (8.0 +/- 4.3 mm(2) vs. 5.2 +/- 3.0 mm(2), p &lt; 0.0001); plaque burden (52.2 +/- 11.7% vs. 36.2 +/- 15.3%, p &lt; 0.0001); plaque eccentricity (8.4 +/- 5.5 vs. 4.0 +/- 3.4, p &lt; 0.0001); and stent edge symmetry (1.2 +/- 0.1 vs. 1.1 +/- 0.1, p = 0.02) were larger; plaque burden > or =50% was more frequent (62.0% vs. 17.2%, p &lt; 0.0001); calcium deposits (52.1% vs. 35.2%, p = 0.03) more common; and lumen-to-stent-edge-area ratio (0.9 +/- 0.2 vs. 1.0 +/- 0.2, p &lt; 0.0001) was smaller in the edge dissection group compared with the nondissection group. Intramural hematomas occurred in 34.1% (28 of 82) of dissections. When compared with nonhematoma dissections, residual plaque and media area (6.4 +/- 2.5 mm(2) vs. 8.9 +/- 4.6 mm(2), p = 0.04) was smaller, and stent edges less asymmetric (1.1 +/- 0.1 vs. 1.2 +/- 0.1, p = 0.009) in the dissection with hematoma group. Independent predictors of any stent edge dissection were residual plaque eccentricity (odds ratio [OR]: 1.4, p = 0.02), lumen-to-stent-edge-area ratio (OR: 0.0, p = 0.007), and stent edge symmetry (OR: 1.2, p = 0.02 for each 0.01 increase). CONCLUSIONS: IVUS identified edge dissections after 9.2% of DES implantations. Residual plaque eccentricity, lumen-to-stent-edge-area ratio, and stent edge symmetry predicted coronary stent edge dissections. Dissections in less diseased reference segments more often evolved into an intramural hematoma</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York, USAJC - 101467004CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19850262</style></custom1><custom3><style face="normal" font="default">AS - JACC Cardiovasc Interv. 2(10):997-1004, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>197</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Liu,X.H.</style></author><author><style face="normal" font="default"> Li,Y.F.</style></author><author><style face="normal" font="default"> Lai,C.L.</style></author><author><style face="normal" font="default"> Ji,Y.R.</style></author><author><style face="normal" font="default"> Zhao,J.Q.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Plasma endothelin level in hypertensive patients receiving standard anti-hypertensive therapy with or without statins]. [Chinese]</style></title><secondary-title><style face="normal" font="default">Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology]</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology]</style></full-title></periodical><pages end="803" start="800">800-803</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Antihypertensive Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Endothelins/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Hypertension/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Simvastatin/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> 0 (Antihypertensive Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Endothelins)</style></keyword><keyword><style face="normal" font="default"> 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)</style></keyword><keyword><style face="normal" font="default"> 79902-63-9 (Simvastatin)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Hypertension/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="9" Year="2009">2009/9</year></dates><isbn><style face="normal" font="default">0253-3758</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: To observe the association between plasma endothelin (ET) concentration and blood pressure level in essential hypertensive (EH) patients with or without complications and possible impact of statins on ET concentration. METHODS: From Sep 2007 to Mar 2009, 149 patients with EH were analyzed [44 EH, 40 EH complicated by left ventricular hypertrophy (EH-LVH), 36 EH complicated by atrial fibrillation (EH-AF), and 29 EH complicated by lacunar infarction (EH-LI)], 30 healthy persons were selected as controls. EH patients were randomly divided into routine treatment group (calcium antagonists, ACEI, diuretics, beta-receptor blocker for 8 weeks) and simvastatin intervention group (routine treatment + simvastatin 40 mg/d for 8 weeks), plasma ET concentrations before and after drug intervention were measured. RESULTS: (1) ET concentration was higher in EH group than that in control group [(71.42 +/- 6.62) pg/ml vs. (45.52 +/- 8.28) pg/ml, P &lt; 0.01]. ET concentration was higher in EH-LVH group, EH-AF group and EH-LI group than that in EH group [(97.67 +/- 10.53) pg/ml, (102.15 +/- 12.96) pg/ml, (103.49 +/- 9.91) pg/ml vs. (71.42 +/- 6.62) pg/ml, P &lt;0.01]. The degrees of elevated blood pressure was positively correlated with ET concentrations(all P &lt; 0.001). (2) The left atrial diameters of EH-AF group were positively correlated with ET concentration (r = 0.684, P &lt; 0.001). The left ventricular mass index of EH-LVH group were positively correlated with ET concentration (r = 0.545, P &lt; 0.001). (3) The percentages of class 3 hypertension in EH-LVH group, EH-AF group and EH-LI group were higher than that in EH group (57.5%, 50.0%, 62.1% vs. 25.0%, all P &lt; 0.05). (4) Blood pressure in class 3 hypertension patient treated with simvastatin decreased more significantly than that in routine treatment group (P &lt; 0.05). (5) ET concentration of class 2 hypertension patient treated with simvastatin decreased significantly than that in routine treatment group (P &lt; 0.05). ET concentrations of class 3 hypertension patient treated with simvastatin and routine treatment patient decreased significantly after treatment (P &lt; 0.05), and the former was lower (P &lt; 0.05). CONCLUSION: The level of ET were positively correlated with the severity of EH. Simvastatin could decrease the ET levels of patients with EH and blood pressure levels of patients with class 3 hypertension. It suggested that therapeutic alliance of antihypertensive drugs and statins could be benefit to patients with EH</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Shanxi Province People's Hospital, Taiyuan 030012, China. docliuxh@126.comJC - ebn, 7910682CP - ChinaPT - English AbstractPT - Journal ArticlePT - Randomized Controlled TrialLG - Chinese</style></notes><urls/><custom1><style face="normal" font="default">UI - 20128377</style></custom1><custom3><style face="normal" font="default">AS - Chung Hua Hsin Hsueh Kuan Ping Tsa Chih. 37(9):800-3, 2009 Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>402</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Lloyd-Jones,D.M.</style></author><author><style face="normal" font="default"> Walsh,J.A.</style></author><author><style face="normal" font="default"> Prineas,R.J.</style></author><author><style face="normal" font="default"> Ning,H.</style></author><author><style face="normal" font="default"> Liu,K.</style></author><author><style face="normal" font="default"> Daviglus,M.L.</style></author><author><style face="normal" font="default"> Shea,S.</style></author><author><style face="normal" font="default"> Detrano,R.C.</style></author><author><style face="normal" font="default"> Tandri,H.</style></author><author><style face="normal" font="default"> Greenland,P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Association of electrocardiographic abnormalities with coronary artery calcium and carotid artery intima-media thickness in individuals without clinical coronary heart disease (from the Multi-Ethnic Study of Atherosclerosis [MESA])</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="1091" start="1086">1086-1091</pages><volume><style face="normal" font="default">104</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Carotid Artery,Common/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Electrocardiography</style></keyword><keyword><style face="normal" font="default"> *Ethnic Groups</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcinosis/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Rest</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> ROC Curve</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Tunica Intima/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> United States/ep [Epidemiology]</style></keyword></keywords><dates><year Day="15" Month="10" Year="2009">2009/10/15</year></dates><abstract><style face="normal" font="default">Isolated minor nonspecific ST-segment and T-wave abnormalities (NSSTAs), minor and major electrocardiographic (ECG) abnormalities are established, independent risk markers for incident cardiovascular events. Their association with subclinical atherosclerosis has been postulated but is not clearly defined. The aim of this study was to define the association between ECG abnormalities and measurements of subclinical atherosclerosis. We studied participants from MESA, a multiethnic sample of men and women 45 to 84 years of age and free of clinical cardiovascular disease at enrollment. Baseline examination included measurement of traditional risk factors, 12-lead electrocardiograms at rest, coronary artery calcium (CAC) measurement, and common carotid intima-media thickness (CC-IMT). Electrocardiograms were coded using Novacode criteria and were defined as having minor abnormalities (e.g., minor NSSTTAs, first-degree atrioventricular block, and QRS-axis deviations) or major abnormalities (e.g., pathologic Q waves, major STTAs, significant dysrhythmias, and conduction system delays). Multivariable logistic and linear regressions were used to determine cross-sectional associations of ECG abnormalities with CAC and CC-IMT. Of 6,710 participants, 52.7% were women, with a mean age of 62 years. After multivariable adjustment, isolated minor STTAs and minor and major ECG abnormalities were not associated with presence of CAC (>0) in men (odds ratio 1.04, 95% confidence interval 0.81 to 1.33; 1.10, 0.91 to 1.32; and 1.03, 0.81 to 1.31, respectively) or women (1.01, 0.82 to 1.24; 1.04, 0.87 to 1.23; and 0.94, 0.73 to 1.22, respectively). Lack of association remained consistent when using log CAC and CC-IMT as continuous variables. In conclusion, ECG abnormalities are not associated with markers of subclinical atherosclerosis in a large multiethnic cohort</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. dlj@northwestern.eduJC - 3dq, 0207277CP - United StatesPT - Comparative StudyPT - Journal ArticlePT - Multicenter StudyPT - Research Support, N.I.H., ExtramuralNO - N01-HC-95159 (United States NHLBI NIH HHS)NO - N01-HC-95165 (United States NHLBI NIH HHS)NO - N01-HC-95169 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19801030</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 104(8):1086-91, 2009 Oct 15.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>378</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Loffroy,R.</style></author><author><style face="normal" font="default"> Bernard,S.</style></author><author><style face="normal" font="default"> rusclat,A.</style></author><author><style face="normal" font="default"> Boussel,L.</style></author><author><style face="normal" font="default"> Bonnefoy,E.</style></author><author><style face="normal" font="default"> D'Athis,P.</style></author><author><style face="normal" font="default"> Moulin,P.</style></author><author><style face="normal" font="default"> Revel,D.</style></author><author><style face="normal" font="default"> Douek,P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Noninvasive assessment of the prevalence and characteristics of coronary atherosclerotic plaques by multidetector computed tomography in asymptomatic type 2 diabetic patients at high risk of significant coronary artery disease: a preliminary study</style></title><secondary-title><style face="normal" font="default">Archives of cardiovascular diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Archives of cardiovascular diseases</style></full-title></periodical><pages end="615" start="607">607-615</pages><volume><style face="normal" font="default">102</style></volume><number><style face="normal" font="default">8-9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 2/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Diabetic Angiopathies/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,Spiral Computed</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Calcinosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Carotid Artery Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Carotid Artery Diseases/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus,Type 2/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus,Type 2/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Diabetic Angiopathies/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Diabetic Angiopathies/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Pilot Projects</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Radiographic Image Interpretation,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword></keywords><dates><year Day="0" Month="8" Year="2009">2009/8</year></dates><isbn><style face="normal" font="default">1875-2136</style></isbn><abstract><style face="normal" font="default">BACKGROUND: There is a need to identify diabetic patients at risk of cardiovascular events before symptom onset. AIMS: To evaluate the prevalence and characteristics of coronary atherosclerotic plaques in asymptomatic type 2 diabetic patients with coronary risk factors but without known coronary artery disease, using multidetector computed tomography. METHODS: High-resolution 40-slice coronary computed tomography was performed prospectively in 42 consecutive type 2 diabetic patients (mean age 62 years; range 50-77 years; 28 men) with over one or more carotid atherosclerotic plaque and no coronary artery disease symptoms. Computed tomography data were evaluated for calcium score and the presence of coronary plaques. Plaque type, distribution, extensive character and obstructive nature were determined per patient for each segment. RESULTS: No plaques were detected in 11 (26.2%) patients. Atherosclerotic plaques were detected in 31 (73.8%) patients. A total of 147 coronary segments with plaque were identified, of which 11 (7.5%) contained hypodense plaques, 28 (19%) mixed plaques and 108 (73.5%) calcified plaques. Hypodense plaques were noted in 4/15 (26.7%) patients without coronary calcifications. Most calcified and hypodense plaques resulted in lumen narrowing of less than 50%; most mixed plaques resulted in lumen narrowing greater than 50%. Obstructive disease was detected in 9/11 patients with a high calcium score (>400). CONCLUSION: This preliminary study demonstrates that a high proportion of asymptomatic type 2 diabetic patients present without coronary plaques detectable by multidetector computed tomography, despite concomitant carotid atherosclerotic lesions. Computed tomography seems to detect a high proportion of plaques compared with conventional angiography in these specific patients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiovascular Imaging, Louis-Pradel Hospital, LRMN Creatis, UMR CNRS 5515, Inserm U630, Claude-Bernard University, Lyon 1, 28 Avenue du Doyen-Jean-L&amp;#x00E9;pine, 69500 Lyon, France. romaric.loffroy@chu-dijon.frJC - 101465655CP - NetherlandsPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19786264</style></custom1><custom3><style face="normal" font="default">AS - Arch Cardiovasc Dis. 102(8-9):607-15, 2009 Aug-Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>191</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Lofgren,I.</style></author><author><style face="normal" font="default"> Greene,G.</style></author><author><style face="normal" font="default"> Schembre,S.</style></author><author><style face="normal" font="default"> Delmonico,M.J.</style></author><author><style face="normal" font="default"> Riebe,D.</style></author><author><style face="normal" font="default"> Clark,P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Comparison of diet quality, physical activity and biochemical values of older adults either reporting or not reporting use of lipid-lowering medication</style></title><secondary-title><style face="normal" font="default">Journal of Nutrition, Health &amp; Aging</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Nutrition, Health &amp; Aging</style></full-title></periodical><pages end="172" start="168">168-172</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Antilipemic Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Diet/st [Standards]</style></keyword><keyword><style face="normal" font="default"> *Exercise/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Hyperlipidemias/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Lipids/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Nutritional Status</style></keyword><keyword><style face="normal" font="default"> 0 (Antilipemic Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipids)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Blood Chemical Analysis</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Energy Metabolism/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperlipidemias/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Life Style</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Nutrition Policy</style></keyword><keyword><style face="normal" font="default"> Nutritive Value</style></keyword><keyword><style face="normal" font="default"> Patient Education as Topic</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Self Disclosure</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Waist Circumference</style></keyword></keywords><dates><year Day="0" Month="0" Year="2010">2010</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The aim of this study was to compare standard lipid profile, reported dietary intake, and physical activity in older adults who reported taking or not taking a lipid-lowering medication, namely statins. DESIGN: Cross-sectional study utilizing baseline data collected from a subsample of a larger randomized clinical trial, The Study of Exercise and Nutrition in Older Rhode Islanders (SENIOR) Project. PARTICIPANTS AND SETTING: A total of 115 participants, 33 males and 82 females, over the age of 60, community-dwelling, primarily retired, and from East Providence, Rhode Island and surrounding communities in Rhode Island and Massachusetts. MEASUREMENTS: Height and weight were measured and used to calculate body mass index. Waist circumference was measured. Medical history and medication use surveys were completed. Dietary assessment was done via three 24 hour recalls using NDS-R. The Yale Physical Activity Survey was used to determine energy expenditure during exercise and a physical activity summary score. Fasting blood samples were obtained to determine lipid profile. RESULTS: 37 participants (32.2%) reported taking lipid-lowering medication, statins exclusively, and 78 (67.8%) reported not taking any lipid-lowering medication. Participants who reported taking statins had better lipid profiles than those participants who reported not taking statins but had significantly lower intakes of vitamin B12, vitamin K, calcium, and potassium. There were no differences between groups on reported physical activity. However, the mean intakes for both groups did not meet the Dietary Reference Intakes for multiple nutrients. CONCLUSION: Older adults need additional education on the importance of lifestyle changes in reducing CHD risk, whether taking lipid-lowering medications or not</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Nutrition and Food Sciences, University of Rhode Island, Ranger Hall, Kingston, Rhode Island 02881, USA. ingridlofgren@uri.eduJC - dlt, 100893366CP - FrancePT - Comparative StudyPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - 1R01AG16588 (United States NIA NIH HHS)NO - OD-93-002 (United States NIH HHS)NO - R0IAG16588 (United States PHS HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20126967</style></custom1><custom3><style face="normal" font="default">AS - J Nutr Health Aging. 14(2):168-72, 2010.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>89</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Louren&amp;#x00E7</style></author><author><style face="normal" font="default">o BH</style></author><author><style face="normal" font="default"> Vieira,L.P.</style></author><author><style face="normal" font="default"> Macedo,A.</style></author><author><style face="normal" font="default"> Nakasato,M.</style></author><author><style face="normal" font="default"> Marucci,Mde F.</style></author><author><style face="normal" font="default"> Bocchi,E.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Nutritional status and adequacy of energy and nutrient intakes among heart failure patients</style></title><secondary-title><style face="normal" font="default">Arquivos Brasileiros de Cardiologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Arquivos Brasileiros de Cardiologia</style></full-title></periodical><pages end="548" start="541">541-548</pages><volume><style face="normal" font="default">93</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Diet/st [Standards]</style></keyword><keyword><style face="normal" font="default"> *Energy Intake/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Heart Failure/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Micronutrients/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Nutritional Status/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> 0 (Micronutrients)</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Energy Intake</style></keyword><keyword><style face="normal" font="default"> Epidemiologic Methods</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Failure/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Muscle,Skeletal/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Nutrition Surveys</style></keyword><keyword><style face="normal" font="default"> Nutritional Requirements</style></keyword><keyword><style face="normal" font="default"> Outpatients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sex Distribution</style></keyword></keywords><dates><year Day="0" Month="11" Year="2009">2009/11</year></dates><abstract><style face="normal" font="default">SUMMARY: Increased knowledge about nutritional status and energy and nutrient intakes is required to improve the treatment of patients with heart failure (HF). OBJECTIVES: To verify the nutritional status and evaluate the adequacy of energy, macronutrient and micronutrient intakes in patients with HF in outpatient clinical settings. METHODS: We collected anthropometric and habitual dietary intake data of 125 patients (72% men, 52.1 +/- 9.8 years, BMI 26.9 +/- 4.4 kg/m2). Anthropometric variables were compared between genders, and the adequacy of energy and nutrient intakes was analyzed according to current recommendations. RESULTS: Muscle depletion or risk of depletion was present in 38.4% of patients (association with male gender, p &lt;0.0001). In 69.6% of cases the mean energy intake was lower than the one required (p &lt;0.0001). Among the micronutrients evaluated in this study, there was an important prevalence of inadequacy in magnesium, zinc, iron and thiamine intakes, and most patients had calcium and potassium intakes below the adequate levels, and sodium intake above the adequate levels. CONCLUSIONS: Outpatients with HF showed muscle depletion, and inadequate energy and nutrient intakes. There was no significant association between habitual dietary energy intake and nutritional status. Multidisciplinary care should be encouraged to better assess the general condition of these patients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Curso de Nutri&amp;#x00E7;&amp;#x00E3;o, Faculdade de Sa&amp;#x00FA;de P&amp;#x00FA;blica, Universidade de S&amp;#x00E3;o Paulo, S&amp;#x00E3;o Paulo, SP, Brasil. barbaralourenco@usp.brCM - Comment in: Arq Bras Cardiol. 2009 Nov;93(5):454-5; PMID: 20084305JC - 8pm, 0421031CP - BrazilPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20084317</style></custom1><custom3><style face="normal" font="default">AS - Arq Bras Cardiol. 93(5):541-8, 2009 Nov.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>179</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">lsch,H.</style></author><author><style face="normal" font="default"> Lehmann,N.</style></author><author><style face="normal" font="default"> hlenkamp,S.</style></author><author><style face="normal" font="default"> Neumann,T.</style></author><author><style face="normal" font="default"> Slomiany,U.</style></author><author><style face="normal" font="default"> Schmermund,A.</style></author><author><style face="normal" font="default"> Stang,A.</style></author><author><style face="normal" font="default"> Moebus,S.</style></author><author><style face="normal" font="default"> Bauer,M.</style></author><author><style face="normal" font="default"> Mann,K.</style></author><author><style face="normal" font="default"> ckel,K.H.</style></author><author><style face="normal" font="default"> Erbel,R.</style></author><author><style face="normal" font="default"> Heinz Nixdorf,Recall Study</style></author></authors></contributors><titles><title><style face="normal" font="default">Association of coronary artery calcium and congestive heart failure in the general population: Results of the Heinz Nixdorf Recall study</style></title><secondary-title><style face="normal" font="default">Clinical Research in Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinical Research in Cardiology</style></full-title></periodical><pages end="182" start="175">175-182</pages><volume><style face="normal" font="default">99</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Heart Failure/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Hypertension/co [Complications]</style></keyword><keyword><style face="normal" font="default"> 114471-18-0 (Natriuretic Peptide,Brain)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Exercise Test</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Natriuretic Peptide,Brain/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="3" Year="2010">2010/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: The main causes of congestive heart failure (CHF) are coronary artery disease (CAD) and arterial hypertension. Coronary artery calcification (CAC) evidencing coronary atherosclerosis may occur prior to clinical CAD. The aim of our study was to assess the association between CAC as a sign of subclinical CAD and CHF in a general unselected population. METHODS: Participants of the Heinz Nixdorf Recall Study without known CAD but with known CHF as defined by a physicians' diagnosis of CHF and dyspnea were identified. B-natriuretic peptide was measured and an exercise stress test was performed as possible. Cardiovascular risk factors and the EBCT-based CAC Agatston score were determined. RESULTS: Those 105/4,230 subjects (2.5%) with CHF (age 65 +/- 7 years, 44% males), had higher brain natriuretic peptide (BNP) levels (median BNP 36.8 [16.5-70.1] vs. 17.6 [9.5-31.7] pg/ml, p&lt;0.01) and lower exercise capacity (108.7 +/- 39.4 vs. 130.0 +/- 40.7 W, p&lt;0.01) than those without. CAC in subjects with CHF was significantly higher than in those without (median CAC 64.7 [8.5-312.3] vs. 11.6 [0-109.8], p&lt;0.01). In univariate analysis, CAC-burden after logarithmic transformation according to log(2)(CAC + 1) showed a significant association with the presence of CHF (odds ratio (OR) (95% CI): 1.16 (1.1-1.23), p&lt;0.0001). Adjustment for age and sex (OR 1.11 (1.04-1.18), p&lt;0.001), additional Framingham risk score (OR 1.09 (1.02-1.16), p = 0.015), and additional cardiovascular medication (OR 1.07 (0.998-1.14), p = 0.058) attenuated this association. Age, systolic blood pressure, antihypertensive medication and increased body mass index also remained significantly associated with presence of CHF in the full multivariate model. CONCLUSION: The observed association between CAC and CHF in persons without clinically overt CAD is partly determined by risk factors that are involved in the natural history of both CAC and CHF. Whether CAC has a role to identify subjects at risk of future CHF remains to be determined using follow-up analyses</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, West-German Heart Center Essen, University Clinic Duisburg-Essen, Essen, Germany. Hagen.Kaelsch@uk-essen.deJC - 101264123CP - GermanyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20054694</style></custom1><custom3><style face="normal" font="default">AS - Clin. res. cardiol.. 99(3):175-82, 2010 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>558</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">lu,E.</style></author><author><style face="normal" font="default"> Bayrak,F.</style></author><author><style face="normal" font="default"> Gemici,G.</style></author><author><style face="normal" font="default"> neysu,T.</style></author><author><style face="normal" font="default"> Mutlu,B.</style></author><author><style face="normal" font="default"> Kalkan,A.K.</style></author><author><style face="normal" font="default"> ertekin,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Prevalence of coronary artery disease in low to moderate-risk asymptomatic women: a multislice computed tomography study</style></title><secondary-title><style face="normal" font="default">Turk Kardiyoloji Dernegi Arsivi</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Turk Kardiyoloji Dernegi Arsivi</style></full-title></periodical><pages end="445" start="439">439-445</pages><volume><style face="normal" font="default">36</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperlipidemias/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Hyperlipidemias/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Hyperlipidemias/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Hypertension/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Hypertension/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword></keywords><dates><year Day="0" Month="10" Year="2008">2008/10</year></dates><isbn><style face="normal" font="default">1016-5169</style></isbn><abstract><style face="normal" font="default">OBJECTIVES: Traditional risk factors may underestimate the burden of subclinical atherosclerosis in women. Recently, multislice computed tomography (MSCT) has become widely available in detecting early coronary artery disease (CAD). We sought the prevalence of CAD in low to moderate-risk asymptomatic women by MSCT coronary artery calcium (CAC) scoring and coronary angiography. STUDY DESIGN: The study included 185 women (mean age 57+/-12 years) without known CAD and diabetes, with low or moderate risk for CAD based on traditional risk scoring. Coronary artery calcium scoring and coronary angiography were performed by MSCT, which included a segment-based plaque detection and characterization of calcification. The plaques were classified based on the luminal stenotic effect (>50%). Patients with = or >1 stenotic plaque were classified as having obstructive CAD. Angiographic findings were compared with calcium scores. RESULTS: Coronary artery calcium scoring and coronary angiography detected CAD in 63 (34.1%) and 100 (54.1%) women, respectively. In both groups, women were significantly older and had higher prevalences of hypertension and dyslipidemia. Coronary angiography showed CAD in 41 women (41%; 14.6% were obstructive) without CAC. These women were significantly younger than those with a positive CAC score (p&lt;0.01). Age (p&lt;0.02) and hypertension (p&lt;0.05) were found as independent predictors of CAD detected by coronary angiography. CONCLUSION: Multislice computed tomography identified a subset of low-risk women who might be at higher risk than that suggested by current risk stratification strategies. Women, especially having hypertension and dyslipidemia may be potential candidates for further risk stratification by MSCT coronary angiography</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Medicine Faculty of Yeditepe University, Istanbul, TurkeyJC - 9426239CP - TurkeyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19155656</style></custom1><custom3><style face="normal" font="default">AS - TURK KARDIYOLOJI DERNEGI ARS.. 36(7):439-45, 2008 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>301</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Lu,P.H.</style></author><author><style face="normal" font="default"> Tao,G.Q.</style></author><author><style face="normal" font="default"> Shen,W.</style></author><author><style face="normal" font="default"> Cai,B.</style></author><author><style face="normal" font="default"> Jiang,Z.Y.</style></author><author><style face="normal" font="default"> Sun,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Surgery for rare aneurysm associated with colorectal cancer</style></title><secondary-title><style face="normal" font="default">World Journal of Gastroenterology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">World Journal of Gastroenterology</style></full-title></periodical><pages end="5881" start="5879">5879-5881</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">46</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aortic Aneurysm,Abdominal</style></keyword><keyword><style face="normal" font="default"> *Rectal Neoplasms</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aortic Aneurysm,Abdominal/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Aortic Aneurysm,Abdominal/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Digestive System Surgical Procedures/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Postoperative Complications</style></keyword><keyword><style face="normal" font="default"> Pulse</style></keyword><keyword><style face="normal" font="default"> Rectal Neoplasms/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Rectal Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Rectal Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Rupture</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="14" Month="12" Year="2009">2009/12/14</year></dates><isbn><style face="normal" font="default">1007-9327</style></isbn><abstract><style face="normal" font="default">The occurrence of concomitant aortic aneurysm and colorectal cancer is a rare medical entity, and controversy surrounds its optimal treatment. We report a case of rectal cancer and concomitant aneurysm from the ascending aorta to the common iliac artery. As with DeBakey type I aortic dissecting aneurysm, our patient was treated by rectal cancer resection, with preservation of the anus (Dixon operation) under controlled hypotension. Blood pressure was maintained at 80-90/50-60 mmHg and the pulse at 70-90 beats/min. The pathological examination of the surgical specimen showed a poorly differentiated T3N0 tumor. The patient had an uneventful recovery without aneurysm rupture, and was discharged from hospital on postoperative day 15 after 3 d adjuvant chemotherapy with oxaliplatin combined with calcium folinate and fluorouracil. The patient was given six courses of adjuvant chemotherapy in 6 mo, without recurrence or metastasis, and the aneurysm was still stable after 2 years follow-up</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of General Surgery, Wuxi People's Hospital of Nanjing Medical University, No. 299, Qingyang Road, Wuxi 214023, Jiangsu Province, China. lphty1_1@yahoo.com.cnJC - 100883448CP - ChinaPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19998515</style></custom1><custom3><style face="normal" font="default">AS - World J Gastroenterol. 15(46):5879-81, 2009 Dec 14.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>436</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Luboshitzky,R.</style></author><author><style face="normal" font="default"> Chertok-Schaham,Y.</style></author><author><style face="normal" font="default"> Lavi,I.</style></author><author><style face="normal" font="default"> Ishay,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Cardiovascular risk factors in primary hyperparathyroidism</style></title><secondary-title><style face="normal" font="default">Journal of Endocrinological Investigation</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Endocrinological Investigation</style></full-title></periodical><pages end="321" start="317">317-321</pages><volume><style face="normal" font="default">32</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiovascular Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Hyperparathyroidism,Primary/co [Complications]</style></keyword><keyword><style face="normal" font="default"> 0 (Blood Glucose)</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol,HDL)</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol,LDL)</style></keyword><keyword><style face="normal" font="default"> 0 (Interleukin-6)</style></keyword><keyword><style face="normal" font="default"> 0 (Triglycerides)</style></keyword><keyword><style face="normal" font="default"> 11061-68-0 (Insulin)</style></keyword><keyword><style face="normal" font="default"> 9007-41-4 (C-Reactive Protein)</style></keyword><keyword><style face="normal" font="default"> Blood Glucose/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Body Weight</style></keyword><keyword><style face="normal" font="default"> C-Reactive Protein/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Cholesterol,HDL/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cholesterol,LDL/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Primary/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Insulin Resistance</style></keyword><keyword><style face="normal" font="default"> Insulin/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Interleukin-6/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Parathyroidectomy</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Triglycerides/bl [Blood]</style></keyword></keywords><dates><year Day="0" Month="4" Year="2009">2009/4</year></dates><abstract><style face="normal" font="default">BACKGROUND AND AIMS: Severe primary hyperparathyroidism (PHP) has been associated with increased cardiovascular morbidity. Such an association in mild PHP is not known. We conducted a cross-sectional study to assess the correlation between mild and traditional PHP and emergent cardiovascular risk factors. SUBJECTS AND METHODS: A total of 139 patients with PHP (72 with severe PHP and indications for parathyroidectomy, 67 with mild PHP and no indications for surgery) and 111 control subjects, of similar age and body weight, were enrolled in this study. Participants had measurement of fasting blood levels of calcium, PTH, insulin, glucose, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, interleukin-6, and C-reactive protein. Body mass index (BMI), waist and hip circumferences, blood pressure, homeostasis model assessment 2-insulin resistance index (IR) and the presence of metabolic syndrome (MS) were evaluated. RESULTS: Severe PHP patients had significantly higher rates of MS (37.5%), IR (38.9 %) vs mild PHP (34.3 and 23.9%, respectively) and controls (14.4 and 14.4%, respectively). Multivariate logistic-regression model, adjusted for age and BMI, and for age and waist size, revealed that severe PHP had significantly higher likelihood of cardiovascular risks [odds ratio (OR) 3.5, 95% confidence interval (CI) 1.5-8.125, p=0.004 for MS, and OR 3.7, 95% CI 1.64-8.29, p=0.002 for IR]. Serum calcium significantly predicted the presence of MS (OR 1.875, 95% CI 1.259-2.793, p=0.002) and IR (OR 2.043, 95% CI 1.365-3.057, p=0.002). CONCLUSIONS: Greater probability of MS and insulin resistance was observed in patients with severe PHP. Serum calcium is a predictor of these cardiovascular risk factors</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Endocrine Institute, Haemek Medical Center, 18101 Afula, Israel. Luboshitzky_r@clalit.org.ilJC - iam, 7806594CP - ItalyPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19636198</style></custom1><custom3><style face="normal" font="default">AS - J Endocrinol Invest. 32(4):317-21, 2009 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>447</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Lunkes,D.S.</style></author><author><style face="normal" font="default"> Lunkes,G.I.</style></author><author><style face="normal" font="default"> Ahmed,M.</style></author><author><style face="normal" font="default"> Morsch,A.L.</style></author><author><style face="normal" font="default"> Zanin,R.F.</style></author><author><style face="normal" font="default"> Maldonado,P.A.</style></author><author><style face="normal" font="default"> Corr&amp;#x00EA</style></author><author><style face="normal" font="default">a M</style></author><author><style face="normal" font="default"> Schetinger,M.R.</style></author><author><style face="normal" font="default"> Morsch,V.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Effect of different vasodilators on NTPDase activity in healthy and hypertensive patients</style></title><secondary-title><style face="normal" font="default">Thrombosis Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Thrombosis Research</style></full-title></periodical><pages end="274" start="268">268-274</pages><volume><style face="normal" font="default">124</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Adenosine Triphosphatases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Hypertension/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Hypertension/en [Enzymology]</style></keyword><keyword><style face="normal" font="default"> *Vasodilator Agents/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> 0 (Vasodilator Agents)</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Drug</style></keyword><keyword><style face="normal" font="default"> EC 3-6-1 (Adenosine Triphosphatases)</style></keyword><keyword><style face="normal" font="default"> Enzyme Activation/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="7" Year="2009">2009/7</year></dates><abstract><style face="normal" font="default">INTRODUCTION: The thrombogenic process that affects the hypertensive patient is associated with regulatory mechanisms present in the vascular endothelium. These mechanisms involve release of an endothelium-derived relaxing factor, ectonucleotidase activity and calcium ion concentration. METHODS: Interference with ENTPDase activity in platelets of hypertensive patients and healthy donors was evaluated for arginine, sodium nitroprusside, and hydralazine. In addition, the kinetic behavior of NTPDase was determined in the presence of the vasodilator that showed the greatest inhibitory influence. RESULTS: Vasodilators decreased NTPDase activity with ATP and ADP as substrates. In controls, hydrolysis was increased in the presence of arginine. Captopril did not affect enzyme activities. The dose response for increasing sodium nitroprusside was biphasic. Kinetic behavior studies were estimated in the presence of sodium nitroprusside, which caused a mixed inhibition. The K(m) values increased and V(max) decreased with increasing sodium nitroprusside concentrations. The IC(50) and K(i) values indicated that the vasodilator was a strong NTPDase inhibitor when tested for the control and hypertensive group, using ATP and ADP as substrate, respectively. CONCLUSION: It is postulated that there was an interaction between vasodilators, NO donors and inhibition of NTPDase</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Centro de Ci&amp;#x00EA;ncias Naturais e Exatas, Programa de P&amp;#x00F3;s-Gradua&amp;#x00E7;&amp;#x00E3;o em Bioqu&amp;#x00ED;mica Toxicol&amp;#x00F3;gica, Universidade Federal de Santa Maria, Santa Maria, RS, BrazilJC - vrn, 0326377CP - United StatesPT - Controlled Clinical TrialPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19174306</style></custom1><custom3><style face="normal" font="default">AS - Thromb Res. 124(3):268-74, 2009 Jul.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>8</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Ma,S.</style></author><author><style face="normal" font="default"> Liu,A.</style></author><author><style face="normal" font="default"> Carr,J.</style></author><author><style face="normal" font="default"> Post,W.</style></author><author><style face="normal" font="default"> Kronmal,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Statistical modeling of Agatston score in multi-ethnic study of atherosclerosis (MESA)</style></title><secondary-title><style face="normal" font="default">PLoS ONE [Electronic Resource]</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">PLoS ONE [Electronic Resource]</style></full-title></periodical><pages end="" start="e12036">e12036-</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Atherosclerosis/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Ethnic Groups</style></keyword><keyword><style face="normal" font="default"> *Models,Statistical</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Nonlinear Dynamics</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="0" Year="2010">2010</year></dates><abstract><style face="normal" font="default">The MESA (Multi-Ethnic Study of Atherosclerosis) is an ongoing study of the prevalence, risk factors, and progression of subclinical cardiovascular disease in a multi-ethnic cohort. It provides a valuable opportunity to examine the development and progression of CAC (coronary artery calcium), which is an important risk factor for the development of coronary heart disease. In MESA, about half of the CAC scores are zero and the rest are continuously distributed. Such data has been referred to as "zero-inflated data" and may be described using two-part models. Existing two-part model studies have limitations in that they usually consider parametric models only, make the assumption of known forms of the covariate effects, and focus only on the estimation property of the models. In this article, we investigate statistical modeling of CAC in MESA. Building on existing studies, we focus on two-part models. We investigate both parametric and semiparametric, and both proportional and nonproportional models. For various models, we study their estimation as well as prediction properties. We show that, to fully describe the relationship between covariates and CAC development, the semiparametric model with nonproportional covariate effects is needed. In contrast, for the purpose of prediction, the parametric model with proportional covariate effects is sufficient. This study provides a statistical basis for describing the behaviors of CAC and insights into its biological mechanisms</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - School of Public Health, Yale University, New Haven, Connecticut, United States of America. Shuangge.ma@yale.eduJC - 101285081CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, U.S. Gov't, Non-P.H.SNO - N01-HC-95159 (United States NHLBI NIH HHS)NO - N01-HC-95169 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20711503</style></custom1><custom3><style face="normal" font="default">AS - PLoS ONE. 5(8):e12036, 2010.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>216</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Maahs,D.M.</style></author><author><style face="normal" font="default"> Snell-Bergeon,J.K.</style></author><author><style face="normal" font="default"> Hokanson,J.E.</style></author><author><style face="normal" font="default"> Kinney,G.L.</style></author><author><style face="normal" font="default"> Berl,T.</style></author><author><style face="normal" font="default"> Rewers,M.</style></author><author><style face="normal" font="default"> Ogden,L.G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Relationship between cystatin C and coronary artery atherosclerosis progression differs by type 1 diabetes</style></title><secondary-title><style face="normal" font="default">Diabetes Technology &amp; Therapeutics</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Diabetes Technology &amp; Therapeutics</style></full-title></periodical><pages end="33" start="25">25-33</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Cystatin C/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 1/cl [Classification]</style></keyword><keyword><style face="normal" font="default"> *Diabetic Angiopathies/co [Complications]</style></keyword><keyword><style face="normal" font="default"> 0 (Cystatin C)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus,Type 1/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus,Type 1/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Reference Values</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="1" Year="2010">2010/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Cystatin C has been proposed to better estimate renal function and predict cardiovascular disease (CVD) than serum creatinine. To expand on our previous report, we investigated whether the relationship of cystatin C to progression of coronary artery atherosclerosis (CA) differed between individuals with type 1 diabetes (T1D) and persons without diabetes. METHODS: Coronary artery calcium was measured twice over 2.4 +/- 0.4 years (n = 1,123, age = 39 +/- 9 years, 47% male, 45% T1D). Significant CA progression was defined as a > or = 2.5 increase in square root calcium volume score or development of clinical coronary artery disease. Stepwise multiple logistic regression was performed to investigate whether the association of cystatin C to CA progression differed by T1D status. RESULTS: The main finding and novelty of this article is that while the univariate association of cystatin C to CA progression was similar in T1D patients and persons without diabetes mellitus and in the expected direction (increased cystatin C as a biomarker of worsening renal function associated with CA progression), the association of cystatin C to progression of CA differed by T1D status (P = 0.01) after adjustment for other CVD risk factors. Unexpectedly, in persons without diabetes mellitus having relatively normal renal function, increased cystatin C was associated with decreased CA progression (odd ratio [OR] = 0.65, 95% confidence interval 0.44-0.96, P = 0.029) after adjustment, primarily due to adjustment for body mass index (BMI). Removal of BMI from this model resulted in a 49% change in the OR. CONCLUSIONS: Our hypothesis-generating data suggest a complex relationship among cystatin C, BMI, and CA progression that requires further study</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado 80045, USA. David.Maahs@uchsc.eduJC - 100889084, d3xCP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - HL79611 (United States NHLBI NIH HHS)NO - K23 DK075360 (United States NIDDK NIH HHS)NO - M01-RR00051 (United States NCRR NIH HHS)NO - P30 DK57516 (United States NIDDK NIH HHS)NO - R01 HL61753 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20082582</style></custom1><custom3><style face="normal" font="default">AS - Diabetes Technol Ther. 12(1):25-33, 2010 Jan.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>137</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Maccubbin,D.</style></author><author><style face="normal" font="default"> Tipping,D.</style></author><author><style face="normal" font="default"> Kuznetsova,O.</style></author><author><style face="normal" font="default"> Hanlon,W.A.</style></author><author><style face="normal" font="default"> Bostom,A.G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial</style></title><secondary-title><style face="normal" font="default">Clinical Journal of The American Society of Nephrology: CJASN</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinical Journal of The American Society of Nephrology: CJASN</style></full-title></periodical><pages end="589" start="582">582-589</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Antilipemic Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Dyslipidemias/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Hyperphosphatemia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Hypophosphatemia/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> *Kidney Diseases/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Niacin/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Phosphorus/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Antilipemic Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Delayed-Action Preparations)</style></keyword><keyword><style face="normal" font="default"> 0 (Indoles)</style></keyword><keyword><style face="normal" font="default"> 0 (MK-0524)</style></keyword><keyword><style face="normal" font="default"> 0 (prostaglandin D2 receptor)</style></keyword><keyword><style face="normal" font="default"> 0 (Receptors,Immunologic)</style></keyword><keyword><style face="normal" font="default"> 0 (Receptors,Prostaglandin)</style></keyword><keyword><style face="normal" font="default"> 59-67-6 (Niacin)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 7723-14-0 (Phosphorus)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Antilipemic Agents/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Delayed-Action Preparations</style></keyword><keyword><style face="normal" font="default"> Double-Blind Method</style></keyword><keyword><style face="normal" font="default"> Drug Therapy,Combination</style></keyword><keyword><style face="normal" font="default"> Dyslipidemias/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Dyslipidemias/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Dyslipidemias/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glomerular Filtration Rate/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperphosphatemia/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Hyperphosphatemia/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Hyperphosphatemia/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypophosphatemia/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Hypophosphatemia/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Indoles/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Kidney Diseases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Kidney Diseases/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Niacin/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Receptors,Immunologic/ai [Antagonists &amp; Inhibitors]</style></keyword><keyword><style face="normal" font="default"> Receptors,Prostaglandin/ai [Antagonists &amp; Inhibitors]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">BACKGROUND AND OBJECTIVES: Niacin administration lowers the marked hyperphosphatemia that is characteristic of renal failure. We examined whether niacin administration also reduces serum phosphorus concentrations in patients who have dyslipidemia and are free of advanced renal disease. DESIGN, SETTING, PARTICIPANTS, &amp; MEASUREMENTS: We performed a post hoc data analysis of serum phosphorus concentrations that had been determined serially (at baseline and weeks 4, 8, 12, 18, and 24) among 1547 patients who had dyslipidemia and were randomly assigned in a 3:2:1 ratio to treatment with extended release niacin (ERN; 1 g/d for 4 weeks and dose advanced to 2 g/d for 20 weeks) combined with the selective prostaglandin D2 receptor subtype 1 inhibitor laropiprant (L; n = 761), ERN alone (n = 518), or placebo (n = 268). RESULTS: Repeated measures analysis revealed that ERN-L treatment resulted in a net mean (95% confidence interval) serum phosphorus change comparing ERN-L with placebo treatment of -0.13 mmol/L (-0.15 to -0.13 mmol/L; -0.41 mg/dl [-0.46 to -0.37 mg/dl]). These results were consistent across the subgroups defined by estimated GFR of &lt;60 or > or =60 ml/min per 1.73 m(2), a serum phosphorus of >1.13 mmol/L (3.5 mg/dl) versus &lt; or =1.13 mmol/L (3.5 mg/dl), the presence of clinical diabetes, or concomitant statin use. CONCLUSIONS: We have provided definitive evidence that once-daily ERN-L treatment causes a sustained 0.13-mmol/L (0.4-mg/dl) reduction in serum phosphorus concentrations, approximately 10% from baseline, which is unaffected by estimated GFR ranging from 30 to > or =90 ml/min per 1.73 m(2) (i.e., stages 1 through 3 chronic kidney disease)</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Rhode Island Hospital, Division of Kidney Diseases and Hypertension, 593 Eddy Street, Providence, RI, 02903, USAJC - 101271570CP - United StatesPT - Journal ArticlePT - Multicenter StudyPT - Randomized Controlled TrialLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20299362</style></custom1><custom3><style face="normal" font="default">AS - Clin J Am Soc Nephrol. 5(4):582-9, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>104</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Madaj,P.</style></author><author><style face="normal" font="default"> Gopal,A.</style></author><author><style face="normal" font="default"> Hamirani,Y.</style></author><author><style face="normal" font="default"> Zeb,I.</style></author><author><style face="normal" font="default"> Elamir,S.</style></author><author><style face="normal" font="default"> Budoff,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">The degree of stenosis on cardiac catheterization compared to calcified coronary segments on multi-detector row cardiac computed tomography MDCT</style></title><secondary-title><style face="normal" font="default">Academic Radiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Academic Radiology</style></full-title></periodical><pages end="1005" start="1001">1001-1005</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Stenosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Heart Catheterization</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Stenosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="8" Year="2010">2010/8</year></dates><abstract><style face="normal" font="default">RATIONALE AND OBJECTIVES: Cardiac computed tomography is increasingly being used to assess the degree of stenosis in coronary arteries. It has been shown in multiple studies to have high negative predictive value for obstructive disease compared to invasive cardiac catheterization (ICA). However, calcified segments are interpreted differently in each study. The aim of this study was to examine the association of calcified plaques on multi-detector row cardiac computed tomography (MDCT) with the degree of stenosis on ICA. MATERIALS AND METHODS: A total of 129 consecutive patients who underwent coronary evaluation on MDCT and also underwent ICA within 1 month of MDCT were included in the study. Each segment in the coronary artery was classified as mixed, calcified, or noncalcified. All segments with calcified plaque were evaluated, further classifying them as mild, moderate, or severe, and obstructive disease on ICA was used as the reference standard, in a blinded fashion. RESULTS: The average age of the patients was 60.8 9.5 years. A total of 379 calcified segments were included in the study. Among these segments, 363 (95.8%) were found to be nonobstructive (&lt;70% stenosis) on ICA. Calcifications were categorized as mild, moderate, and severe in 283 (74.7%), 58 (15.3%), and 38 (10.0%) segments, respectively. When calcium was incomplete in the cross-section of the lumen (mild or moderate calcification), 98.5% of these segments (336 of 341) were associated with nonobstructive disease, decreasing to 71% with severe calcification. CONCLUSION: Calcified plaques seen on MDCT were commonly associated with nonobstructive disease on invasive angiography. Increasing focal calcification increased the likelihood of obstructive disease, but only 29% of severe segments were associated with significant obstructive disease</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USAJC - clv, 9440159CP - United StatesPT - Comparative StudyPT - Evaluation StudiesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20605733</style></custom1><custom3><style face="normal" font="default">AS - Acad Radiol. 17(8):1001-5, 2010 Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>393</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Madi,H.A.</style></author><author><style face="normal" font="default"> Riches,K.</style></author><author><style face="normal" font="default"> Warburton,P.</style></author><author><style face="normal" font="default"> O'Regan,D.J.</style></author><author><style face="normal" font="default"> Turner,N.A.</style></author><author><style face="normal" font="default"> Porter,K.E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Inherent differences in morphology, proliferation, and migration in saphenous vein smooth muscle cells cultured from nondiabetic and Type 2 diabetic patients</style></title><secondary-title><style face="normal" font="default">American Journal of Physiology - Cell Physiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Physiology - Cell Physiology</style></full-title></periodical><pages end="C1317" start="C1307">C1307-C1317</pages><volume><style face="normal" font="default">297</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cell Movement</style></keyword><keyword><style face="normal" font="default"> *Cell Proliferation</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 2/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 2/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Myocytes,Smooth Muscle/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Myocytes,Smooth Muscle/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> 0 (S100 Proteins)</style></keyword><keyword><style face="normal" font="default"> 142662-27-9 (S100A4 protein,human)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Blotting,Western</style></keyword><keyword><style face="normal" font="default"> Cells,Cultured</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Bypass</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> EC 2-7-11-1 (Proto-Oncogene Proteins c-akt)</style></keyword><keyword><style face="normal" font="default"> EC 2-7-11-24 (Extracellular Signal-Regulated MAP Kinases)</style></keyword><keyword><style face="normal" font="default"> Extracellular Signal-Regulated MAP Kinases/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fluorescent Antibody Technique</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperplasia</style></keyword><keyword><style face="normal" font="default"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Muscle,Smooth,Vascular/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Muscle,Smooth,Vascular/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phosphorylation</style></keyword><keyword><style face="normal" font="default"> Proto-Oncogene Proteins c-akt/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Reverse Transcriptase Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> S100 Proteins/bi [Biosynthesis]</style></keyword><keyword><style face="normal" font="default"> Saphenous Vein/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Saphenous Vein/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Signal Transduction/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="11" Year="2009">2009/11</year></dates><abstract><style face="normal" font="default">Individuals with Type 2 diabetes mellitus (T2DM) are at increased risk of saphenous vein (SV) graft stenosis following coronary artery bypass. Graft stenosis is caused by intimal hyperplasia, a pathology characterized by smooth muscle cell (SMC) proliferation and migration. We hypothesized that SV-SMC from T2DM patients were intrinsically more proliferative and migratory than those from nondiabetic individuals. SV-SMC were cultured from nondiabetic and T2DM patients. Cell morphology (light microscopy, immunocytochemistry), S100A4 expression (real-time RT-PCR, immunoblotting), proliferation (cell counting), migration (Boyden chamber assay), and cell signaling (immunoblotting with phosphorylation state-specific antibodies) were studied. SV-SMC from T2DM patients were morphologically distinct from nondiabetic patients and exhibited a predominantly rhomboid phenotype, accompanied by disrupted F-actin cytoskeleton, disorganized alpha-smooth muscle actin network, and increased focal adhesion formation. However, no differences were observed in expression of the calcium-binding protein S100A4, a marker of rhomboid SMC phenotype, between the two cell populations. T2DM cells were less proliferative in response to fetal calf serum than nondiabetic cells, but both populations had similar proliferative responses to insulin plus PDGF. Under high glucose concentration conditions in the presence of insulin, migration of diabetic SV-SMC was greater than nondiabetic cells. Glucose concentration did not affect SV-SMC proliferation. No differences in insulin or PDGF-induced phosphorylation of ERK-1/2 or components of the Akt pathway (Akt-Ser473, Akt-Thr308, and GSK-3beta) were apparent between the two populations. In conclusion, SV-SMC from T2DM patients differ from nondiabetic SV-SMC in that they exhibit a rhomboid phenotype and are more migratory, but less proliferative, in response to serum</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiovascular and Neuronal Remodelling, Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, Leeds LS2 9JT, United KingdomJC - dkj, 100901225CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19741193</style></custom1><custom3><style face="normal" font="default">AS - Am J Physiol Cell Physiol. 297(5):C1307-17, 2009 Nov.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>320</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Maeda,H.</style></author><author><style face="normal" font="default"> Zhu,B.L.</style></author><author><style face="normal" font="default"> Ishikawa,T.</style></author><author><style face="normal" font="default"> Quan,L.</style></author><author><style face="normal" font="default"> Michiue,T.</style></author><author><style face="normal" font="default"> Bessho,Y.</style></author><author><style face="normal" font="default"> Okazaki,S.</style></author><author><style face="normal" font="default"> Kamikodai,Y.</style></author><author><style face="normal" font="default"> Tsuda,K.</style></author><author><style face="normal" font="default"> Komatsu,A.</style></author><author><style face="normal" font="default"> Azuma,Y.</style></author></authors></contributors><titles><title><style face="normal" font="default">Analysis of postmortem biochemical findings with regard to the lung weight in drowning</style></title><secondary-title><style face="normal" font="default">Legal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Legal Medicine</style></full-title></periodical><pages end="72" start="Suppl">Suppl-72</pages><volume><style face="normal" font="default">11</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Drowning/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Drowning/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Lung/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Chlorides)</style></keyword><keyword><style face="normal" font="default"> 7439-95-4 (Magnesium)</style></keyword><keyword><style face="normal" font="default"> 7440-23-5 (Sodium)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Biological Markers/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Blood Urea Nitrogen</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Chlorides/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Forensic Pathology</style></keyword><keyword><style face="normal" font="default"> Fresh Water</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Magnesium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Organ Size</style></keyword><keyword><style face="normal" font="default"> Pericardium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Pleural Effusion/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Pleural Effusion/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Seawater</style></keyword><keyword><style face="normal" font="default"> Sodium/me [Metabolism]</style></keyword></keywords><dates><year Day="0" Month="4" Year="2009">2009/4</year></dates><abstract><style face="normal" font="default">To clarify drowning death, positive evidence for aspiration of the immersion medium and the subsequent fatal mechanism is necessary. This study investigated biochemical findings with regard to lung weight in drowning cases of adults (n=56, >18 years of age, &lt;48 h postmortem: salt water, n=19; fresh water, n=21; brackish water, n=16), using acute cardiac death cases (n=240) as controls. The biochemical markers used in this study were urea nitrogen (UN), sodium (Na), chloride (Cl), calcium (Ca) and magnesium (Mg) in the blood and pericardial fluid (PCF). The left-to-right ratio of cardiac blood UN levels was lower for drowning, showing an inverse correlation to the total lung weight. There was a mild postmortem decrease in serum and PCF Na and Cl levels; however, left cardiac serum and PCF Na, Cl, Ca and Mg levels were higher for saltwater drowning, and left cardiac serum Na and Cl levels were lower for fresh water drowning. Correlation of the left cardiac serum level with lung weight was positive for Na, Cl and Mg in saltwater and brackish water drowning, and was also positive for Ca in saltwater drowning. There was an inverse correlation with lung weight for PCF Na and Cl levels in freshwater drowning. These findings suggest that analyses of serum and pericardial markers in relation to lung weight are useful for evaluating the composition and amount of aspirated medium when investigating drowning death</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Legal Medicine, Osaka City University Medical School, Asahi-machi 1-4-3, Abeno, Osaka 545-8585, JapanJC - 100889186CP - IrelandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19261521</style></custom1><custom3><style face="normal" font="default">AS - Leg Med (Tokyo). 11 Suppl 1:S269-72, 2009 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>237</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Mahajan,A.</style></author><author><style face="normal" font="default"> Narayanan,M.</style></author><author><style face="normal" font="default"> Jaffers,G.</style></author><author><style face="normal" font="default"> Concepcion,L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Hypoparathyroidism associated with severe mineral bone disease postrenal transplantation, treated successfully with recombinant PTH</style></title><secondary-title><style face="normal" font="default">Hemodialysis International</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Hemodialysis International</style></full-title></periodical><pages end="550" start="547">547-550</pages><volume><style face="normal" font="default">13</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Hyperparathyroidism,Secondary/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Hyperparathyroidism,Secondary/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> *Hypocalcemia/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Hypocalcemia/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> *Kidney Transplantation</style></keyword><keyword><style face="normal" font="default"> *Parathyroidectomy</style></keyword><keyword><style face="normal" font="default"> *Teriparatide/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> 0 (Phosphates)</style></keyword><keyword><style face="normal" font="default"> 0 (Recombinant Proteins)</style></keyword><keyword><style face="normal" font="default"> 52232-67-4 (Teriparatide)</style></keyword><keyword><style face="normal" font="default"> 60-27-5 (Creatinine)</style></keyword><keyword><style face="normal" font="default"> 7439-95-4 (Magnesium)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcium/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Creatinine/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Magnesium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Magnesium/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Parathyroidectomy</style></keyword><keyword><style face="normal" font="default"> Phosphates/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Phosphates/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Recombinant Proteins/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Recombinant Proteins/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Teriparatide/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><abstract><style face="normal" font="default">Chronic kidney disease (CKD) is commonly, if not universally, associated with derangements in bone and mineral metabolism, characterized by hyperphosphatemia, low calcitriol levels, and secondary hyperparathyroidism. The spectrum of these disorders is termed renal osteodystrophy or chronic kidney disease-mineral bone disease complex. Aggressive phosphorus control is the cornerstone of management to prevent debilitating complications. Dietary control, phosphate binders, and administration of active vitamin D analogues is the most common initial therapy. Frequently parathyroidectomy is required to reverse or slow the pathological changes when medical management fails. The most common adverse effect of parathyroidectomy is hypocalcemia. We describe a case report of severe hypocalcemia (secondary to surgical hypoparathyroidism) and "hungry bone syndrome," treated successfully with teriparatide (Forteo) in a patient who underwent renal transplantation following subtotal parathyroidectomy</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Nephrology and Hypertension, Scott and White Hospital, Temple, Texas 76508, USAJC - 101093910CP - CanadaPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19493022</style></custom1><custom3><style face="normal" font="default">AS - Hemodial. int.. 13(4):547-50, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>299</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Malag&amp;#x00F2</style></author><author><style face="normal" font="default"> R</style></author><author><style face="normal" font="default"> D'Onofrio,M.</style></author><author><style face="normal" font="default"> Baglio,I.</style></author><author><style face="normal" font="default"> Brunelli,S.</style></author><author><style face="normal" font="default"> Tavella,D.</style></author><author><style face="normal" font="default"> Beltrame,F.</style></author><author><style face="normal" font="default"> Benussi,P.</style></author><author><style face="normal" font="default"> Mucelli,R.P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Choice strategy of different dose-saving protocols in 64-slice MDCT coronary angiography</style></title><secondary-title><style face="normal" font="default">Radiologia Medica</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Radiologia Medica</style></full-title></periodical><pages end="1213" start="1196">1196-1213</pages><volume><style face="normal" font="default">114</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Radiation Dosage</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Practice Guidelines as Topic</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed/is [Instrumentation]</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><abstract><style face="normal" font="default">PURPOSE: Multidetector-row computed tomography coronary angiography (MDCT-CA) produces high-level radiation dose because of submillimetre slice thickness and short scan time. As a result, manufacturers have produced different dose-saving protocols that may, however, reduce image quality and thus diagnostic accuracy. The aim of our study was to assess the diagnostic quality of MDCT-CA using different dose-saving protocols. MATERIALS AND METHODS: Between April and August 2008, we examined 65 patients with 64-slice MDCT-CA: 6/65 using the step-and-shoot dose-saving protocol, 45/65 the cardiac dose right protocol and 14/65 using a standard protocol. Image quality was evaluated on a per-patient and per-segment basis, and the effective dose of each protocol was recorded. RESULTS: In the per-patient analysis, image quality was excellent in 100% of the step-and-shoot protocols, in 91.1% of the cardiac dose right protocols and in 85.8% of the standard protocols. Effective dose to the patient considering the whole study (i.e. scout, calcium score, triggering and MDCT-CA) was 20.49 mSv in the standard protocol, 14.8 mSv in the cardiac dose right protocol and 6.63 mSv in the step-and-shoot protocol. CONCLUSIONS: The radiologist should apply the appropriate protocol in relation to the clinical indications, type of patient and information required in order to spare as much dose as possible while maintaining high image quality</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Istituto di Radiologia, Policlinico G.B. Rossi Universit&amp;#x00E0; di Verona, P.le L.A.Scuro 10, 37134, Verona, Italy. rmalag@sirm.orgJC - rbz, 0177625CP - ItalyPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19669112</style></custom1><custom3><style face="normal" font="default">AS - Radiol Med (Torino). 114(8):1196-213, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>261</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Malik,R.K.</style></author><author><style face="normal" font="default"> Landis,G.S.</style></author><author><style face="normal" font="default"> Sundick,S.</style></author><author><style face="normal" font="default"> Cayne,N.</style></author><author><style face="normal" font="default"> Marin,M.</style></author><author><style face="normal" font="default"> Faries,P.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Predicting embolic potential during carotid angioplasty and stenting: analysis of captured particulate debris, ultrasound characteristics, and prior carotid endarterectomy</style></title><secondary-title><style face="normal" font="default">Journal of Vascular Surgery</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Vascular Surgery</style></full-title></periodical><pages end="322" start="317">317-322</pages><volume><style face="normal" font="default">51</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Angioplasty,Transluminal,Percutaneous Coronary</style></keyword><keyword><style face="normal" font="default"> *Carotid Stenosis/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> *Embolism/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Endarterectomy,Carotid</style></keyword><keyword><style face="normal" font="default"> *Filtration</style></keyword><keyword><style face="normal" font="default"> *Stents</style></keyword><keyword><style face="normal" font="default"> *Ultrasonography,Doppler,Duplex</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Angioplasty,Transluminal,Percutaneous Coronary/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Angioplasty,Transluminal,Percutaneous Coronary/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Carotid Stenosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Carotid Stenosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Carotid Stenosis/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Carotid Stenosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Embolism/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Embolism/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Endarterectomy,Carotid/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Filtration/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Particle Size</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Ulcer/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Ulcer/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Video Recording</style></keyword></keywords><dates><year Day="0" Month="2" Year="2010">2010/2</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Extracranial carotid stenoses exhibit significant variance in embolic potential, with restenotic lesions having a particularly low propensity for embolization. This study sought to identify characteristics associated with increased generation of embolic debris during carotid angioplasty and stenting (CAS). METHODS: Captured particulate was available for analysis in 56 consecutive patients. Demographics were mean age, 74 years (range, 60-94 years); mean stenosis, 88% (range, 70%-99%); symptomatic, 27%; prior carotid endarterectomy (CEA), 27%; prior radiotherapy, 7%. Plaque echogenicity, heterogenicity, ulceration, and irregularity were assessed with B-mode duplex ultrasound analysis. Gray scale median (GSM) was calculated from normalized B-mode VHS video recordings. Calcification and degree of stenosis were determined angiographically. Captured particulate debris was evaluated for total number; number >200 microm, >500 microm, >1000 microm; mean and median size. Hematoxylin and eosin, trichrome, and von Kossa stains were used for histologic analysis of captured material. RESULTS: Restenotic carotid stenoses after prior CEA generated minimal embolic debris compared with primary stenoses. Four of 15 patients (27%) with restenotic lesions demonstrated embolic particles; all debris was &lt;500 microm. All 41 patients with primary stenoses had some embolic debris; particulate size was >200 microm in 91%, >500 microm in 72%, and >1000 microm in 43%. In primary lesions, the number and size of captured particulate correlated with GSM and with the combined ultrasound findings of echogenicity, heterogenicity, and luminal irregularity/ulceration (P &lt; .02, 95% confidence interval, 4.5-27.6). None of these ultrasound factors correlated independently with embolic particulate (P = NS). Patients aged >70 years exhibited more total particles (8.1 vs 2.3, P = .008) and increased mean particle size (370 vs 157 mum, P = .02). No significant correlation was observed between the number and size of captured embolic particulate and any other variable (stenosis percentage, prior radiotherapy, preprocedural symptoms, periprocedural symptoms, and calcification). Histologically, the embolic debris consisted of extensive amorphous, acellular proteinaceous material. Calcium debris in the embolic particulate was associated with heavily and moderately calcified lesions. CONCLUSIONS: Considerable variation exists in the number and size of embolic particles generated during CAS. Embolic potential is positively correlated with lesion GSM and the combination of lesion echogenicity, heterogenicity, and irregularity. Restenosis after prior CEA is associated with minimal embolic particulate generation, suggesting that embolic protection may not be necessary for CAS of restenotic lesions. Copyright 2010 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Vascular Surgery, Mount Sinai School of Medicine, New York, NY 10029, USAJC - kd2, 8407742CP - United StatesPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20006918</style></custom1><custom3><style face="normal" font="default">AS - J Vasc Surg. 51(2):317-22, 2010 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>13</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Manson,J.E.</style></author><author><style face="normal" font="default"> Allison,M.A.</style></author><author><style face="normal" font="default"> Carr,J.J.</style></author><author><style face="normal" font="default"> Langer,R.D.</style></author><author><style face="normal" font="default"> Cochrane,B.B.</style></author><author><style face="normal" font="default"> Hendrix,S.L.</style></author><author><style face="normal" font="default"> Hsia,J.</style></author><author><style face="normal" font="default"> Hunt,J.R.</style></author><author><style face="normal" font="default"> Lewis,C.E.</style></author><author><style face="normal" font="default"> Margolis,K.L.</style></author><author><style face="normal" font="default"> Robinson,J.G.</style></author><author><style face="normal" font="default"> Rodabough,R.J.</style></author><author><style face="normal" font="default"> Thomas,A.M.</style></author><author><style face="normal" font="default"> Women's Health Initiative and Women's Health Initiative-Coronary Artery Calcium Study Investigators</style></author></authors></contributors><titles><title><style face="normal" font="default">Calcium/vitamin D supplementation and coronary artery calcification in the Women's Health Initiative</style></title><secondary-title><style face="normal" font="default">Menopause</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Menopause</style></full-title></periodical><pages end="691" start="683">683-691</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Bone Density Conservation Agents/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Calcium Carbonate/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Cholecalciferol/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> 0 (Bone Density Conservation Agents)</style></keyword><keyword><style face="normal" font="default"> 471-34-1 (Calcium Carbonate)</style></keyword><keyword><style face="normal" font="default"> 67-97-0 (Cholecalciferol)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Double-Blind Method</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Postmenopause</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword></keywords><dates><year Day="0" Month="7" Year="2010">2010/7</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Coronary artery calcified plaque is a marker for atheromatous plaque burden and predicts future risk of cardiovascular events. The relationship between calcium plus vitamin D (calcium/D) supplementation and coronary artery calcium (CAC) has not been previously assessed in a randomized trial setting. We compared CAC scores after trial completion between women randomized to calcium/vitamin D supplementation and women randomized to placebo. METHODS: In an ancillary substudy of women randomized to calcium carbonate (1,000 mg of elemental calcium daily) plus vitamin D3 (400 IU daily) or placebo, nested within the Women's Health Initiative trial of estrogen among women who underwent hysterectomy, we measured CAC with cardiac CT in 754 women aged 50 to 59 years at randomization. Imaging for CAC was performed at 28 of 40 centers after a mean of 7 years of treatment, and scans were read centrally. CAC scores were measured by a central reading center with masking to randomization assignments. RESULTS: Posttrial CAC measurements were similar in women randomized to calcium/D supplementation and those receiving placebo. The mean CAC score was 91.6 for women receiving calcium/D and 100.5 for women receiving placebo (rank test P value = 0.74). After adjustment for coronary risk factors, multivariate odds ratios for increasing CAC score cutpoints (CAC >0, > or =10, and > or =100) for calcium/D versus placebo were 0.92 (95% CI, 0.64-1.34), 1.29 (0.88-1.87), and 0.90 (0.56-1.44), respectively. Corresponding odds ratios among women with a 50% or higher adherence to study pills and for higher levels of CAC (>300) were similar. CONCLUSIONS: Treatment with moderate doses of calcium plus vitamin D3 did not seem to alter coronary artery calcified plaque burden among postmenopausal women. Whether higher or lower doses would affect this outcome remains uncertain</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. jmanson@rics.bwh.harvard.eduCM - Comment in: Menopause. 2010 Jul;17(4):667-8; PMID: 20551843JC - c5b, 9433353CP - United StatesPT - Journal ArticlePT - Multicenter StudyPT - Randomized Controlled TrialPT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - N01WH22110 (United States WHI NIH HHS)NO - N01WH24152 (United States WHI NIH HHS)NO - N01WH32100-2 (United States WHI NIH HHS)NO - N01WH32105-6 (United States WHI NIH HHS)NO - N01WH32108-9 (United States WHI NIH HHS)NO - N01WH32111-13 (United States WHI NIH HHS)NO - N01WH32115 (United States WHI NIH HHS)NO - N01WH32118-32119 (United States WHI NIH HHS)NO - N01WH32122 (United States WHI NIH HHS)NO - N01WH42107-26 (United States WHI NIH HHS)NO - N01WH42129-32 (United States WHI NIH HHS)NO - N01WH44221 (United States WHI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20551849</style></custom1><custom3><style face="normal" font="default">AS - Menopause. 17(4):683-91, 2010 Jul.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>70</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Mansoor,A.H.</style></author><author><style face="normal" font="default"> Aggarwal,P.</style></author><author><style face="normal" font="default"> Bhardwaj,S.</style></author><author><style face="normal" font="default"> Tandon,V.</style></author><author><style face="normal" font="default"> Kaul,U.</style></author></authors></contributors><titles><title><style face="normal" font="default">Coronary vasospasm presenting as Prinzmetals angina and life threatening Brady-arrhythmia independently at different times</style></title><secondary-title><style face="normal" font="default">Indian Heart Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Indian Heart Journal</style></full-title></periodical><pages end="391" start="389">389-391</pages><volume><style face="normal" font="default">61</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Angina Pectoris,Variant/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Bradycardia/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vasospasm/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vasospasm/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Vasospasm/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Dizziness/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Electrocardiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword></keywords><dates><year Day="0" Month="7" Year="2009">2009/7</year></dates><isbn><style face="normal" font="default">0019-4832</style></isbn><abstract><style face="normal" font="default">A 65-years-old female presented with features suggesting acute coronary syndrome, initially as non STEMI and later as classical Prinzmetal's angina. While being treated she also had recurrent episodes of dizziness and cardiac arrest due to complete heart block and asystole. These episodes occurred while on nitroglycerine infusion and were not accompanied by chest pain or ST-T segment changes. Coronary angiography revealed evidence of reversible multi-vessel coronary spasm. Electrophysiological studies were normal. She was treated with nitrates and calcium blockers and a permanent pacemaker implantation</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Escorts Heart Institute and Research Centre, New Delhi, IndiaJC - ghr, 0374675CP - IndiaPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20635748</style></custom1><custom3><style face="normal" font="default">AS - Indian Heart J. 61(4):389-91, 2009 Jul-Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>496</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Mao,S.S.</style></author><author><style face="normal" font="default"> Pal,R.S.</style></author><author><style face="normal" font="default"> McKay,C.R.</style></author><author><style face="normal" font="default"> Gao,Y.G.</style></author><author><style face="normal" font="default"> Gopal,A.</style></author><author><style face="normal" font="default"> Ahmadi,N.</style></author><author><style face="normal" font="default"> Child,J.</style></author><author><style face="normal" font="default"> Carson,S.</style></author><author><style face="normal" font="default"> Takasu,J.</style></author><author><style face="normal" font="default"> Sarlak,B.</style></author><author><style face="normal" font="default"> Bechmann,D.</style></author><author><style face="normal" font="default"> Budoff,M.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Comparison of coronary artery calcium scores between electron beam computed tomography and 64-multidetector computed tomographic scanner</style></title><secondary-title><style face="normal" font="default">Journal of Computer Assisted Tomography</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Computer Assisted Tomography</style></full-title></periodical><pages end="178" start="175">175-178</pages><volume><style face="normal" font="default">33</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> *Coronary Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Artifacts</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Rate</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Observer Variation</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography Scanners,X-Ray Computed/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="3" Year="2009">2009/3</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Because almost all data currently available with coronary calcium scanning are from electron beam tomography (EBT), we assessed whether scores obtained with 64-multidetector computed tomography (CT; MDCT) are similar. We evaluated the interscan variation in coronary artery calcium (CAC), Agatston score (AS), and volume score (VS) between EBT and 64-MDCT (VCT; GE, Milwaukee, Wis). MATERIALS AND METHODS: One hundred two patients (mean age, 61.1 years; 27 women) underwent dual CAC scanning with both EBT and 64-MDCT. The AS and VS were measured with the Aquarius workstation (TeraRecon, Inc, San Mateo, Calif). The correlation coefficient, Bland-Altman analysis, interscanner variation, and agreement in AS and VS scores between EBT and 64-MDCT were computed. RESULTS: Interscan agreement for presence of CAC was 99%. Median values were 286 and 268 mm for AS and 243 and 213 mm for VS with EBT and 64-MDCT, respectively (P > 0.05). There was significant linear relationship between scores from the 2 scanners (R = 0.98 in AS and R = 0.99 in VS; P &lt; 0.001). The interscanner variability between EBT and 64-MDCT was 20.9% and 17.6% in AS and VS, respectively (P = NS). Bland-Altman analysis demonstrated a mean difference in scores of 8.3% for AS and 7.8% by VS. When compared with EBT, there were larger and more prevalent motion artifacts (P &lt; 0.001) and larger mean Hounsfield units using 64-MDCT (P &lt; 0.001). CONCLUSIONS: At CAC scanning, 64-MDCT and EBT were comparable in AS and VS. The interscan variability between scanners is similar to interscan variability of 2 calcium scores done on the same equipment. However, heart rate control was achieved for this study for calcium scores. Whether these results are repeatable without heart rate control needs to be further assessed</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiology, Los Angeles Biomedical Research Institute and Saint John's Cardiovascular Research Center, Torrance, California, USAJC - hvt, 7703942CP - United StatesPT - Comparative StudyPT - Evaluation StudiesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19346841</style></custom1><custom3><style face="normal" font="default">AS - J Comput Assist Tomogr. 33(2):175-8, 2009 Mar-Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>60</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Marini,H.</style></author><author><style face="normal" font="default"> Bitto,A.</style></author><author><style face="normal" font="default"> Altavilla,D.</style></author><author><style face="normal" font="default"> Burnett,B.P.</style></author><author><style face="normal" font="default"> Polito,F.</style></author><author><style face="normal" font="default"> Di,Stefano,V</style></author><author><style face="normal" font="default"> Minutoli,L.</style></author><author><style face="normal" font="default"> Atteritano,M.</style></author><author><style face="normal" font="default"> Levy,R.M.</style></author><author><style face="normal" font="default"> Frisina,N.</style></author><author><style face="normal" font="default"> Mazzaferro,S.</style></author><author><style face="normal" font="default"> Frisina,A.</style></author><author><style face="normal" font="default"> D'Anna,R.</style></author><author><style face="normal" font="default"> Cancellieri,F.</style></author><author><style face="normal" font="default"> Cannata,M.L.</style></author><author><style face="normal" font="default"> Corrado,F.</style></author><author><style face="normal" font="default"> Lubrano,C.</style></author><author><style face="normal" font="default"> Marini,R.</style></author><author><style face="normal" font="default"> Adamo,E.B.</style></author><author><style face="normal" font="default"> Squadrito,F.</style></author></authors></contributors><titles><title><style face="normal" font="default">Efficacy of genistein aglycone on some cardiovascular risk factors and homocysteine levels: A follow-up study</style></title><secondary-title><style face="normal" font="default">Nutrition Metabolism &amp; Cardiovascular Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Nutrition Metabolism &amp; Cardiovascular Diseases</style></full-title></periodical><pages end="340" start="332">332-340</pages><volume><style face="normal" font="default">20</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiovascular Diseases/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Genistein/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> *Homocysteine/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Lipids)</style></keyword><keyword><style face="normal" font="default"> 0 (Osteoprotegerin)</style></keyword><keyword><style face="normal" font="default"> 446-72-0 (Genistein)</style></keyword><keyword><style face="normal" font="default"> 454-28-4 (Homocysteine)</style></keyword><keyword><style face="normal" font="default"> 471-34-1 (Calcium Carbonate)</style></keyword><keyword><style face="normal" font="default"> 67-97-0 (Cholecalciferol)</style></keyword><keyword><style face="normal" font="default"> Calcium Carbonate/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Cholecalciferol/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Genistein/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Insulin Resistance</style></keyword><keyword><style face="normal" font="default"> Lipids/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Osteoprotegerin/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Postmenopause</style></keyword><keyword><style face="normal" font="default"> Research Design</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="6" Year="2010">2010/6</year></dates><abstract><style face="normal" font="default">BACKGROUND AND AIM: Recent evidence suggests that genistein aglycone may act beneficially on surrogate cardiovascular risk markers in postmenopausal women. We assessed the effects of genistein aglycone on some cardiovascular risk factors and homocysteine levels after 3-years of continued therapy in a cohort of osteopenic, postmenopausal women. METHODS AND RESULTS: The parent study was a randomized, double-blind, placebo-controlled trial involving 389 postmenopausal women with low bone mass for 24 months. Subsequently, a subcohort (138 patients) continued therapy for an additional year. Participants received 54mg of genistein aglycone (n=71) or placebo (n=67), daily. Both arms received calcium and vitamin D(3) in therapeutic doses. Moreover, 4 weeks before randomization procedures and during our follow-up study, all patients received dietary instructions in an isocaloric fat-restricted diet. Blood lipid profiles, fasting glucose and insulin, insulin resistance (HOMA-IR), fibrinogen, osteoprotegerin (OPG) and homocysteine at baseline and after 24 and 36 months of treatment were measured. Compared to placebo, genistein significantly decreased fasting glucose and insulin, HOMA-IR, fibrinogen and homocysteine after 24 and 36 months of treatment. By contrast, isoflavone administration did not affect high-density lipoprotein cholesterol and triglycerides though serum OPG was higher in the genistein recipients. There were no differences in adverse events or discomfort between groups. Results on routine biochemical, liver function, and hematologic testing did not change over time in placebo or genistein group. CONCLUSIONS: After 3-years of treatment, genistein aglycone plus calcium, vitamin D(3) and a healthy diet showed positive effects on some cardiovascular risk factors and homocysteine levels in a cohort of postmenopausal women with low bone mass</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Biochemical, Physiological and Nutritional Sciences, Section of Physiology and Human Nutrition, University of Messina, ItalyJC - 9111474, DGWCP - GermanyPT - Journal ArticlePT - Randomized Controlled TrialPT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19631515</style></custom1><custom3><style face="normal" font="default">AS - Nutr Metab Cardiovasc Dis. 20(5):332-40, 2010 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>107</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Math,R.S.</style></author><author><style face="normal" font="default"> Parakh,N.</style></author><author><style face="normal" font="default"> Sarin,S.S.</style></author><author><style face="normal" font="default"> Tyagi,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Anomalous origin of the left coronary artery from the pulmonary artery (ALCAPA) presenting as a complete heart block</style></title><secondary-title><style face="normal" font="default">Pediatric Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatric Cardiology</style></full-title></periodical><pages end="529" start="526">526-529</pages><volume><style face="normal" font="default">31</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Cardiomyopathies/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessel Anomalies/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Heart Block/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Pulmonary Artery/ab [Abnormalities]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Endocardial Fibroelastosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Endocardial Fibroelastosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Endocardium</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> Fluoroscopy</style></keyword><keyword><style face="normal" font="default"> Heart Block/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Heart Block/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Heart Septum</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Pacemaker,Artificial</style></keyword><keyword><style face="normal" font="default"> Papillary Muscles</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Video Recording</style></keyword></keywords><dates><year Day="0" Month="5" Year="2010">2010/5</year></dates><abstract><style face="normal" font="default">A 51-year-old previously asymptomatic man presented with complete heart block (CHB). During pacemaker implantation, fluoroscopy showed a peculiar pattern of cardiac calcification. Coronary angiography, performed to determine the origin of calcification, demonstrated an anomalous origin of the left coronary artery from the pulmonary artery (ALCAPA). A left ventriculogram showed normal ventricular contraction. Echocardiography demonstrated normal systolic function without any regional wall motion abnormality. The endocardium of the mid and basal portions of the anteroseptal, anterior and anterolateral walls as well as both of the papillary muscles were calcified. Specifically noted was a calcific bar extending across the base of the interventricular septum (IVS) on both the echocardiogram and the left ventricle angiogram. The development of CHB in the absence of transmural myocardial infarction is intriguing. It is likely that endocardial fibroelastosis during infancy led to endocardial fibrosis and scarring subsequent calcium deposition. Extension of this calcification into the conduction system may have led to CHB. This is the first report of an adult patient with ALCAPA presenting with CHB</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, GB Pant Hospital and Maulana Azad Medical College, Suite 127, First Floor, Academic Building, New Delhi 110002, IndiaJC - pa3, 8003849CP - United StatesPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20165845</style></custom1><custom3><style face="normal" font="default">AS - Pediatr Cardiol. 31(4):526-9, 2010 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>506</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Matsuda,N.</style></author><author><style face="normal" font="default"> Takei,T.</style></author><author><style face="normal" font="default"> Fujiu,A.</style></author><author><style face="normal" font="default"> Ogawa,T.</style></author><author><style face="normal" font="default"> Nitta,K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Arterial stiffness in patients with non-diabetic chronic kidney disease (CKD)</style></title><secondary-title><style face="normal" font="default">Journal of Atherosclerosis &amp; Thrombosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Atherosclerosis &amp; Thrombosis</style></full-title></periodical><pages end="62" start="57">57-62</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Arteries/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure,Chronic/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 7723-14-0 (Phosphorus)</style></keyword><keyword><style face="normal" font="default"> 9007-41-4 (C-Reactive Protein)</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> C-Reactive Protein/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Manometry</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Nephrosclerosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Phosphorus/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Pulse</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="3" Year="2009">2009/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: Patients with chronic kidney disease (CKD) have a high prevalence of cardiovascular disease (CVD). Arterial stiffness plays an important role in the pathogenesis of CVD; however, to date, there have been no reports of the assessment of arterial stiffness in patients at different stages of non-diabetic CKD. METHODS: We studied 50 patients with non-diabetic CKD (stages 1-5, 5D) receiving medical treatment at Tokyo Women's Medical University. Pulse wave velocity (PWV) was assessed using an applanation tonometer to determine arterial compliance. All current medications were recorded and biochemical parameters were analyzed. RESULTS: Non-diabetic CKD stage 5D patients had a higher PWV, and higher serum levels of C-reactive protein (CRP), Ca, P and intact parathyroid hormone (iPTH) than non-diabetic CKD stage 1-5 patients (p=0.03, p=0.009, p=0.006, p=0.00005, and p=0.002, respectably). As compared to non-diabetic CKD stage 1-2 patients, patients with non-diabetic CKD stage 3-5 were older, and had higher serum levels of P and iPTH and a higher PWV (p=0.0002, p=0.009, p=0.03, and p=0.004). Nephrosclerosis was associated with a higher PWV, higher serum levels of CRP, and a higher prevalence of CVD than patients with CKD of other origins. CONCLUSION: We showed a stepwise increase of arterial stiffness with increasing disease severity stage in patients with CKD not associated with diabetes mellitus. CKD caused by nephrosclerosis was found to be associated with increased arterial stiffness and to be a risk factor for CVD</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, Kidney Center, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, JapanJC - 9506298, cwcCP - JapanPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19261997</style></custom1><custom3><style face="normal" font="default">AS - J Atheroscler Thromb. 16(1):57-62, 2009 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>58</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Maurovich-Horvat,P.</style></author><author><style face="normal" font="default"> ri,T.</style></author><author><style face="normal" font="default"> Kerecsen,G.</style></author><author><style face="normal" font="default"> nyi,J.</style></author><author><style face="normal" font="default"> Sallai,T.</style></author><author><style face="normal" font="default"> So&amp;#x00F3</style></author><author><style face="normal" font="default">s P</style></author><author><style face="normal" font="default"> da,I.</style></author><author><style face="normal" font="default"> Merkely,B.</style></author><author><style face="normal" font="default"> Jermendy,G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Assessment of coronary artery calcification using dual-source computed tomography in adult asymptomatic patients with type 1 diabetes mellitus</style></title><secondary-title><style face="normal" font="default">Medical Science Monitor</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Medical Science Monitor</style></full-title></periodical><pages end="MT64" start="MT59">MT59-MT64</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 1/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 1/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Waist Circumference</style></keyword></keywords><dates><year Day="0" Month="0" Year="2010">2010</year></dates><abstract><style face="normal" font="default">BACKGROUND: Experience with dual-source computed tomography (DSCT) for detecting coronary artery calcification (CAC) in patients with type 1 diabetes is limited. MATERIAL/METHODS: A non-contrast DSCT scan was acquired in 46 type 1 diabetic patients. All scans were suitable for evaluating CAC expressed in Agatston-scores (effective radiation dose 0.66 [0.59-0.81] mSv; median [interquartile range]). RESULTS: In 21 patients Agatston scores were > or =1 (range 1-2353), while 25 patients had no detectable calcium deposits in the coronary arteries. Patients with vs. without CAC had higher age (52 [44-59] vs. 41 [38-48] yrs; p=0.0045), longer duration of diabetes (25.3 [23.4-36.3] vs. 23.3 [15.7-30.4] yrs; p=0.0238), greater waist circumference (88 [77-98] vs. 79 [75-87] cm; p=0.0147) and BMI (26.7 [24.5-28.4] vs. 22.6 [21.7-25.6] kg/m(2); p=0.0109). Moreover, patients with vs. without detectable CAC had higher serum LDL-cholesterol (3.35 [3.15-3.53] vs. 2.92 [2.62-3.33] mmol/l; p=0.0069) and serum uric acid values (236 [191-266] vs. 200 [170-219] micromol/l; p=0.0437). Hypertension was more frequent (p=0.0144) in patients with than without CAC. The 2 subgroups did not differ in long-term average HbA1c values (7.97 [7.30-8.56] vs. 8.06 [7.24-9.05]%; p=0.7491); however, estimated insulin sensitivity (estimated glucose disposal rate) was lower in patients with vs. without detectable CAC (7.43 [5.73-8.58] vs. 9.24 [8.22-10.72] mg/kg/min; p=0.0017). CONCLUSIONS: Non-invasive detection of CAC is feasible with a low dose DSCT scan. CAC in type 1 diabetic patients is associated with cardiovascular risk factors rather than with long-term glycemic control</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Semmelweis University, Heart Center, Budapest, HungaryJC - dxw, 9609063CP - PolandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20581785</style></custom1><custom3><style face="normal" font="default">AS - Med Sci Monit. 16(7):MT59-64, 2010.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>116</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Mavroudis,K.</style></author><author><style face="normal" font="default"> Aloumanis,K.</style></author><author><style face="normal" font="default"> Stamatis,P.</style></author><author><style face="normal" font="default"> Antonakoudis,G.</style></author><author><style face="normal" font="default"> Kifnidis,K.</style></author><author><style face="normal" font="default"> Antonakoudis,C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Irreversible end-stage heart failure in a young patient due to severe chronic hypocalcemia associated with primary hypoparathyroidism and celiac disease</style></title><secondary-title><style face="normal" font="default">Clinical Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinical Cardiology</style></full-title></periodical><pages end="E75" start="E72">E72-E75</pages><volume><style face="normal" font="default">33</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Celiac Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Heart Failure/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Hypocalcemia/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Hypoparathyroidism/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies</style></keyword><keyword><style face="normal" font="default"> Celiac Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Celiac Disease/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Electrocardiogram Pattern</style></keyword><keyword><style face="normal" font="default"> Heart Failure/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Heart Failure/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypocalcemia/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Hypocalcemia/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Hypoparathyroidism/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Hypoparathyroidism/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="2" Year="2010">2010/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: Chronic hypocalcemia may cause electrocardiographic (ECG) changes and mimic acute myocardial infarction. It has also been associated with reversible cardiac dysfunction. On the other hand cardiomyopathy and heart failure have been reported in patients with idiopathic hypoparathyroidism or celiac disease. CLINICAL CASE: A 39-year-old male was admitted to the emergency room with acute retrosternal pain and dyspnea. He exhibited severe hypocalcemia and acute renal failure. High creatine kinase (CK) levels did not correlate with biomarkers of myocardial necrosis (negative troponin test, heart type creatine kinase isoenzyme (CK-MB) &lt; 1% of CK value). The ECG showed an extremely long QT interval (0.6 sec) and T-wave inversions on V(4) through V(6). The left ventricular ejection fraction (LVEF) was as low as 25%, while coronary angiography was normal. Investigation of the hypocalcemia revealed primary hypoparathyroidism (Parathyroid hormone (PTH) &lt; 3 pg/ml) and concomitant celiac disease with positive antigliadin and endomysial antibodies. The cardiovascular episodes and the dilated heart failure were attributed to the chronic hypocalcemia since no other cause was found. The correction of hypocalcemia has not been sufficient to reverse the end-stage heart failure after more than 6 months of treatment, even though ECG abnormalities have receded, implying permanent cardiac impairment. CONCLUSION: This case demonstrates an unusual clinical condition where 2 calcium homeostasis disorders led to severe hypocalcemia with clinical manifestations of end-stage heart failure. The severe cardiac failure appeared to be nonreversible after calcium repletion suggesting permanent cardiac muscle dysfunction due to associated cardiomyopathy. Copyright 2010 Wiley Periodicals, Inc</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Endocrinology, Diabetes &amp; Metabolism, General Hospital Asklipieion, Voula, Athens, GreeceJC - de9, 7903272CP - United StatesPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20043335</style></custom1><custom3><style face="normal" font="default">AS - Clin Cardiol. 33(2):E72-5, 2010 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>395</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Meijers,B.K.</style></author><author><style face="normal" font="default"> Van,Kerckhoven S.</style></author><author><style face="normal" font="default"> Verbeke,K.</style></author><author><style face="normal" font="default"> Dehaen,W.</style></author><author><style face="normal" font="default"> Vanrenterghem,Y.</style></author><author><style face="normal" font="default"> Hoylaerts,M.F.</style></author><author><style face="normal" font="default"> Evenepoel,P.</style></author></authors></contributors><titles><title><style face="normal" font="default">The uremic retention solute p-cresyl sulfate and markers of endothelial damage</style></title><secondary-title><style face="normal" font="default">American Journal of Kidney Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Kidney Diseases</style></full-title></periodical><pages end="901" start="891">891-901</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cresols/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Endothelium,Vascular/cy [Cytology]</style></keyword><keyword><style face="normal" font="default"> *Endothelium,Vascular/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Kidney Diseases/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Uremia/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Cresols)</style></keyword><keyword><style face="normal" font="default"> 106-44-5 (4-cresol)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cells,Cultured</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Cresols/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Uremia/bl [Blood]</style></keyword></keywords><dates><year Day="0" Month="11" Year="2009">2009/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Cardiovascular disease is highly prevalent in patients with chronic kidney disease. In hemodialysis patients, the protein-bound uremic retention solute p-cresol is independently associated with cardiovascular disease. The underlying mechanisms have not been elucidated. STUDY DESIGN: (1) Prospective observational study of humans and (2) in vitro study in human umbilical vein endothelial cells. SETTING: Hemodialysis patients. FACTOR: p-Cresol and its main derivative p-cresyl sulfate. OUTCOMES: Endothelial dysfunction. MEASUREMENTS: We studied: (1) the relation between p-cresol and blood markers of endothelial dysfunction, including soluble P-selectin and endothelial microparticles; and (2) direct effects of p-cresol and p-cresyl sulfate on endothelial cell cultures. RESULTS: (1) In a cohort of 100 maintenance hemodialysis patients, free serum p-cresol concentrations (median, 11.7 micromol/L; interquartile range, 15.2) were directly associated with circulating endothelial microparticles (P = 0.007), but not with soluble P-selectin (mean, 37.7 +/- 14.4 [SD] pg/mL). Other independent determinants of the degree of circulating microparticles were greater serum phosphorus (mean, 4.8 +/- 1.5 mg/dL; P = 0.008) and serum calcium concentrations (mean, 9.3 +/- 0.8 mg/dL; P = 0.03), whereas treatment with active vitamin D (P = 0.008) and vintage (median, 25 months; P = 0.04) were inversely associated. (2) In vitro, p-cresyl sulfate induced a dose-dependent increase in the shedding of endothelial microparticles (P &lt; 0.001) by human umbilical vein endothelial cells. Shedding was reduced, but not completely aborted, in the presence of albumin, whereas the selective Rho kinase inhibitor Y-27632 abrogated the p-cresyl sulfate-induced generation of endothelial microparticles. LIMITATIONS: The relationship between p-cresyl sulfate and shedding of endothelial microparticles in vivo was not mechanistically explored. CONCLUSION: p-Cresyl sulfate induces shedding of endothelial microparticles in the absence of overt endothelial damage in vitro and is independently associated with the number of endothelial microparticles in hemodialysis patients. These findings suggest that p-cresyl sulfate alters endothelial function in hemodialysis patients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, Division of Nephrology, University Hospitals Leuven, Leuven, BelgiumCM - Comment in: Am J Kidney Dis. 2009 Nov;54(5):792-4; PMID: 19853197]JC - 3h5, 8110075CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19615803</style></custom1><custom3><style face="normal" font="default">AS - Am J Kidney Dis. 54(5):891-901, 2009 Nov.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>244</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Meijs,M.F.</style></author><author><style face="normal" font="default"> Meijboom,W.B.</style></author><author><style face="normal" font="default"> Prokop,M.</style></author><author><style face="normal" font="default"> Mollet,N.R.</style></author><author><style face="normal" font="default"> van Mieghem,C.A.</style></author><author><style face="normal" font="default"> Doevendans,P.A.</style></author><author><style face="normal" font="default"> de Feyter,P.J.</style></author><author><style face="normal" font="default"> Cramer,M.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Is there a role for CT coronary angiography in patients with symptomatic angina? Effect of coronary calcium score on identification of stenosis</style></title><secondary-title><style face="normal" font="default">The International Journal of Cardiovascular Imaging</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">The International Journal of Cardiovascular Imaging</style></full-title></periodical><pages end="854" start="847">847-854</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Angina Pectoris/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Stenosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angina Pectoris/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Angina,Unstable/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Angina,Unstable/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Stenosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Patient Selection</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><abstract><style face="normal" font="default">Present guidelines discourage the use of CT coronary angiography (CTCA) in symptomatic angina patients. We examined the relation between coronary calcium score (CS) and the performance of CTCA in patients with stable and unstable angina in order to understand under which conditions CTCA might be a gate-keeper to conventional coronary angiography (CCA) in such patients. We included 360 patients between 50 and 70 years old with stable and unstable angina who were clinically referred for CCA irrespective of CS. Patients received CS and CCTA on 64-slice scanners in a multicenter cross-sectional trial. The institutional review board approved the study. Diagnostic performance of CTCA to detect or rule out significant coronary artery disease was calculated on a per patient level in pre-defined CS categories. The prevalence of significant coronary artery disease strongly increased with CS. Negative CTCA were associated with a negative likelihood ratio of &lt;0.1 independent of CS. Positive CTCA was associated with a high positive likelihood ratio of 9.4 if CS was &lt;10. However, for higher CS the positive likelihood ratio never exceeded 3.0 and for CS >400 it decreased to 1.3. In the 62 (17%) patients with CS &lt;10, CTCA reliably identified the 42 (68%) of these patients without significant CAD, at no false negative CTCA scans. In symptomatic angina patients, a negative CTCA reliably excludes significant CAD but the additional value of CTCA decreases sharply with CS >10 and especially with CS >400. In patients with CS &lt;10, CTCA provides excellent diagnostic performance</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Utrecht University Medical Center, Heidelberglaan 100, Utrecht, The Netherlands. m.meijs@umcutrecht.nlCM - Comment in: Int J Cardiovasc Imaging. 2009 Dec;25(8):855-7; PMID: 19937126JC - 100969716CP - United StatesPT - Journal ArticlePT - Multicenter StudyPT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19649721</style></custom1><custom3><style face="normal" font="default">AS - Int J Cardiovasc Imaging. 25(8):847-54, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>451</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Meng,L.</style></author><author><style face="normal" font="default"> Cui,L.</style></author><author><style face="normal" font="default"> Cheng,Y.</style></author><author><style face="normal" font="default"> Wu,X.</style></author><author><style face="normal" font="default"> Tang,Y.</style></author><author><style face="normal" font="default"> Wang,Y.</style></author><author><style face="normal" font="default"> Xu,F.</style></author></authors></contributors><titles><title><style face="normal" font="default">Effect of heart rate and coronary calcification on the diagnostic accuracy of the dual-source CT coronary angiography in patients with suspected coronary artery disease</style></title><secondary-title><style face="normal" font="default">Korean Journal of Radiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Korean Journal of Radiology</style></full-title></periodical><pages end="354" start="347">347-354</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/st [Standards]</style></keyword><keyword><style face="normal" font="default"> *Coronary Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Heart Rate</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/st [Standards]</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Rate</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed/mt [Methods]</style></keyword></keywords><dates><year Day="0" Month="7" Year="2009">2009/7</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To evaluate the diagnostic accuracy of a dual-source computed tomography (DSCT) coronary angiography, with a particular focus on the effect of heart rate and calcifications. MATERIALS AND METHODS: One hundred and nine patients with suspected coronary disease were divided into 2 groups according to a mean heart rate (&lt; 70 bpm and >or= 70 bpm) and into 3 groups according to the mean Agatston calcium scores (&lt;or= 100, 101-400, and > 400). Next, the effect of heart rate and calcification on the accuracy of coronary artery stenosis detection was analyzed by using an invasive coronary angiography as a reference standard. Coronary segments of less than 1.5 mm in diameter in an American Heart Association (AHA) 15-segment model were independently assessed. RESULTS: The mean heart rate during the scan was 71.8 bpm, whereas the mean Agatston score was 226.5. Of the 1,588 segments examined, 1,533 (97%) were assessable. A total of 17 patients had calcium scores above 400 Agatston U, whereas 50 had heart rates >or= 70 bpm. Overall the sensitivity, specificity, positive predictive values (PPV) and negative predictive values (NPV) for significant stenoses were: 95%, 91%, 65%, and 99% (by segment), respectively and 97%, 90%, 81%, and 91% (by artery), respectively (n = 475). Heart rate showed no significant impact on lesion detection; however, vessel calcification did show a significant impact on accuracy of assessment for coronary segments. The specificity, PPV and accuracy were 96%, 80%, and 96% (by segment), respectively for an Agatston score less than 100% and 99%, 96% and 98% (by artery). For an Agatston score of greater to or equal to 400 the specificity, PPV and accuracy were reduced to 79%, 55%, and 83% (by segment), respectively and to 79%, 69%, and 85% (by artery), respectively. CONCLUSION: The DSCT provides a high rate of accuracy for the detection of significant coronary artery disease, even in patients with high heart rates and evidence of coronary calcification. However, patients with severe coronary calcification (> 400 U) remain a challenge to diagnose</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Shandong Province Ji'nan 4th People's Hospital, Ji'nan, ChinaJC - 100956096CP - Korea (South)PT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19568462</style></custom1><custom3><style face="normal" font="default">AS - Korean J Radiol. 10(4):347-54, 2009 Jul-Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>101</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Mhatre,M.</style></author><author><style face="normal" font="default"> Hall,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Student forum: Does calcium and vitamin D intake affect incidence of type 2 diabetes mellitus and insulin resistance syndrome?</style></title><secondary-title><style face="normal" font="default">Consultant Pharmacist</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Consultant Pharmacist</style></full-title></periodical><pages end="381" start="379">379-381</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium,Dietary/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 2/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Insulin Resistance</style></keyword><keyword><style face="normal" font="default"> *Vitamin D/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> 0 (Calcium,Dietary)</style></keyword><keyword><style face="normal" font="default"> 0 (Vitamins)</style></keyword><keyword><style face="normal" font="default"> 1406-16-2 (Vitamin D)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Dairy Products</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus,Type 2/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus,Type 2/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Insulin Resistance</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Obesity/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Obesity/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Vitamins/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="6" Year="2010">2010/6</year></dates><isbn><style face="normal" font="default">0888-5109</style></isbn><abstract><style face="normal" font="default">The past few decades have seen an enormous increase in the incidence of type 2 diabetes mellitus (T2DM). Hyperinsulinemia, hypertension, abdominal obesity, dyslipidemia, and coagulation abnormalities-which contribute to insulin resistance syndrome-are major risk factors for T2DM and heart disease. Diet plays an important role in prevention of these risk factors. Recent evidence suggests an inverse relationship among calcium, vitamin D status, and dairy intake, specifically with the development of the insulin resistance syndrome and T2DM. It has been found that there is a decrease in dairy intake in the past three decades, which runs parallel with an increase in the incidence of obesity and T2DM. As our population ages, the risk of diabetes and insulin resistance will rise, so the question is whether calcium and vitamin D (D3, cholecalciferol) supplementation is necessary or is warranted at a greater or lesser degree than the current recommendations</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - University of Oklahoma, Oklahoma City, Oklahoma, USAJC - 9013983CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20534409</style></custom1><custom3><style face="normal" font="default">AS - Consult Pharm. 25(6):379-81, 2010 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>18</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Michaelsson,K.</style></author><author><style face="normal" font="default"> Baron,J.A.</style></author><author><style face="normal" font="default"> Snellman,G.</style></author><author><style face="normal" font="default"> Gedeborg,R.</style></author><author><style face="normal" font="default"> Byberg,L.</style></author><author><style face="normal" font="default"> Sundstrom,J.</style></author><author><style face="normal" font="default"> Berglund,L.</style></author><author><style face="normal" font="default"> Arnlov,J.</style></author><author><style face="normal" font="default"> Hellman,P.</style></author><author><style face="normal" font="default"> Blomhoff,R.</style></author><author><style face="normal" font="default"> Wolk,A.</style></author><author><style face="normal" font="default"> Garmo,H.</style></author><author><style face="normal" font="default"> Holmberg,L.</style></author><author><style face="normal" font="default"> Melhus,H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Plasma vitamin D and mortality in older men: a community-based prospective cohort study</style></title><secondary-title><style face="normal" font="default">American Journal of Clinical Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Clinical Nutrition</style></full-title></periodical><pages end="848" start="841">841-848</pages><volume><style face="normal" font="default">92</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Mortality</style></keyword><keyword><style face="normal" font="default"> *Vitamin D/aa [Analogs &amp; Derivatives]</style></keyword><keyword><style face="normal" font="default"> 1406-16-2 (Vitamin D)</style></keyword><keyword><style face="normal" font="default"> 57-88-5 (Cholesterol)</style></keyword><keyword><style face="normal" font="default"> 64719-49-9 (25-hydroxyvitamin D)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Cholesterol/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Energy Metabolism</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Leisure Activities</style></keyword><keyword><style face="normal" font="default"> Life Style</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Vitamin D/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Vitamin D/me [Metabolism]</style></keyword></keywords><dates><year Day="0" Month="10" Year="2010">2010/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Vitamin D status is known to be important for bone health but may also affect the development of several chronic diseases, including cancer and cardiovascular diseases, which are 2 major causes of death. OBJECTIVE: We aimed to examine how vitamin D status relates to overall and cause-specific mortality. DESIGN: The Uppsala Longitudinal Study of Adult Men, a community-based cohort of elderly men (mean age at baseline: 71 y; n = 1194), was used to investigate the association between plasma 25-hydroxyvitamin D [25(OH)D] and mortality. Total plasma 25(OH)D was determined with HPLC atmospheric pressure chemical ionization mass spectrometry. Proportional hazards regression was used to compute hazard ratios (HRs). RESULTS: During follow-up (median: 12.7 y), 584 (49%) participants died. There was a U-shaped association between vitamin D concentrations and total mortality. An approximately 50% higher total mortality rate was observed among men in the lowest 10% (&lt;46 nmol/L) and the highest 5% (>98 nmol/L) of plasma 25(OH)D concentrations compared with intermediate concentrations. Cancer mortality was also higher at low plasma concentrations (multivariable-adjusted HR: 2.20; 95% CI: 1.44, 3.38) and at high concentrations (HR: 2.64; 95% CI: 1.46, 4.78). For cardiovascular death, only low (HR: 1.89; 95% CI: 1.21, 2.96) but not high (HR: 1.33; 95% CI: 0.69, 2.54) concentrations indicated higher risk. CONCLUSIONS: Both high and low concentrations of plasma 25(OH)D are associated with elevated risks of overall and cancer mortality. Low concentrations are associated with cardiovascular mortality</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Surgical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. karl.michaelsson@surgsci.uu.seJC - 3ey, 0376027CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20720256</style></custom1><custom3><style face="normal" font="default">AS - Am J Clin Nutr. 92(4):841-8, 2010 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>547</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Michos,E.D.</style></author><author><style face="normal" font="default"> Santos,R.D.</style></author><author><style face="normal" font="default"> Narla,V.</style></author><author><style face="normal" font="default"> Pandey,S.</style></author><author><style face="normal" font="default"> Meneghelo,R.</style></author><author><style face="normal" font="default"> Carvalho,J.A.</style></author><author><style face="normal" font="default"> Budoff,M.J.</style></author><author><style face="normal" font="default"> Blumenthal,R.S.</style></author><author><style face="normal" font="default"> Nasir,K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Favorable cardiovascular risk factor profile is associated with reduced prevalence of coronary artery calcification and inflammation in asymptomatic nondiabetic white men</style></title><secondary-title><style face="normal" font="default">Preventive Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Preventive Cardiology</style></full-title></periodical><pages end="194" start="189">189-194</pages><volume><style face="normal" font="default">11</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Inflammation/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> 0 (Blood Glucose)</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol,LDL)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Blood Glucose/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Cholesterol,LDL/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> European Continental Ancestry Group/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Fasting</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Inflammation/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Leukocyte Count</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Waist Circumference</style></keyword></keywords><dates><year Day="0" Month="0" Year="2008">2008</year></dates><abstract><style face="normal" font="default">Middle-aged individuals with favorable levels of all major cardiovascular risk factors (CVRFs) have much lower age-specific risks for incident cardiovascular disease (CVD). However, the relationship of the absence of CVRFs with subclinical CVD and inflammation is not well described. We classified 440 asymptomatic Brazilian men (aged 46+/-7 years) based on the number of CVRFs (smoking, systolic blood pressure > or =130 mm Hg, low-density lipoprotein cholesterol > or =130 mg/dL, high-density lipoprotein cholesterol &lt;40 mg/dL, triglycerides > or =150 mg/dL, fasting glucose > or =100 mg/dL, and waist circumference >102 cm). Only 7% had no CVRFs, whereas 1, 2, 3, and > or =4 CVRFs were observed in 18%, 24%, 21%, and 29%, respectively. In age-adjusted analysis, each lower CVRF profile was associated with lower odds of prevalent coronary artery calcium (odds ratio, 0.75; P=.002) and elevated white blood cell count (odds ratio, 0.70; P&lt;.001). Our study supports the notion that a favorable CVD profile is associated with less underlying atherosclerosis and inflammation and further highlights the importance of primary prevention of CVRFs. 2008 Le Jacq</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Johns Hopkins School of Medicine, Baltimore, MD 21287, USA. edonnell@jhmi.eduJC - 9813731CP - United StatesPT - Comparative StudyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19476570</style></custom1><custom3><style face="normal" font="default">AS - Prev Cardiol. 11(4):189-94, 2008.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>248</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Miesbach,W.</style></author><author><style face="normal" font="default"> Scharrer,I.</style></author><author><style face="normal" font="default"> Henschen,A.</style></author><author><style face="normal" font="default"> Neerman-Arbez,M.</style></author><author><style face="normal" font="default"> Spitzer,S.</style></author><author><style face="normal" font="default"> Galanakis,D.</style></author></authors></contributors><titles><title><style face="normal" font="default">Inherited dysfibrinogenemia: clinical phenotypes associated with five different fibrinogen structure defects</style></title><secondary-title><style face="normal" font="default">Blood Coagulation &amp; Fibrinolysis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Blood Coagulation &amp; Fibrinolysis</style></full-title></periodical><pages end="40" start="35">35-40</pages><volume><style face="normal" font="default">21</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Afibrinogenemia/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Fibrinogen/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Hemorrhage/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Purpura/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Thrombosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> 0 (Protein Subunits)</style></keyword><keyword><style face="normal" font="default"> 9001-32-5 (Fibrinogen)</style></keyword><keyword><style face="normal" font="default"> Abortion,Spontaneous/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Abortion,Spontaneous/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Afibrinogenemia/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Afibrinogenemia/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Amino Acid Substitution</style></keyword><keyword><style face="normal" font="default"> Arterial Occlusive Diseases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Arterial Occlusive Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Blood Coagulation Tests</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> DNA Mutational Analysis</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fibrinogen/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Hemorrhage/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Mutation,Missense</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Point Mutation</style></keyword><keyword><style face="normal" font="default"> Postpartum Hemorrhage/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Pregnancy Complications,Hematologic/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Pregnancy Complications,Hematologic/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Protein Structure,Quaternary</style></keyword><keyword><style face="normal" font="default"> Protein Subunits</style></keyword><keyword><style face="normal" font="default"> Purpura/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sequence Deletion</style></keyword><keyword><style face="normal" font="default"> Structure-Activity Relationship</style></keyword><keyword><style face="normal" font="default"> Thrombosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="1" Year="2010">2010/1</year></dates><abstract><style face="normal" font="default">Hereditary dysfibrinogenemia is a rare clotting disorder, which results from mutations in at least one of the three fibrinogen genes. We examined the frequency of hemostatic clinical and laboratory anomalies at presentation of 37 probands from 12 unrelated families with five different defects (Aalpha R16C, gamma A357T, gamma318-319 del, gamma M310T, and Aalpha R16S), among. The median age was 51 years (11-86 years). Among 62% who were women three (13%) had experienced one or more spontaneous abortion. More than half of the probands had experienced one or more undue bleeding episode, easy bruising being by far the most common. In 19% of probands (9/37, all above age of 50 years), had experienced at least one episode of arterial or venous thrombosis. Among these, were two (7%) with deep venous thrombosis, seven with arterial thrombosis, and five (14%) had experienced both. We propose that the higher frequency of prolonged PT than aPTT, in ours and in other reported studies, reflects the polymerization delay, which in aPTT is attenuated owing to contact activation prior to calcium addition</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Medical Clinic III, Institute of Transfusion Medicine, Goethe University, Frankfurt, Germany. Wolfgang.Miesbach@kgu.deJC - a5j, 9102551CP - EnglandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19923982</style></custom1><custom3><style face="normal" font="default">AS - Blood Coagul Fibrinolysis. 21(1):35-40, 2010 Jan.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>228</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Min,J.K.</style></author><author><style face="normal" font="default"> Lin,F.Y.</style></author><author><style face="normal" font="default"> Gidseg,D.S.</style></author><author><style face="normal" font="default"> Weinsaft,J.W.</style></author><author><style face="normal" font="default"> Berman,D.S.</style></author><author><style face="normal" font="default"> Shaw,L.J.</style></author><author><style face="normal" font="default"> Rozanski,A.</style></author><author><style face="normal" font="default"> Callister,T.Q.</style></author></authors></contributors><titles><title><style face="normal" font="default">Determinants of coronary calcium conversion among patients with a normal coronary calcium scan: what is the "warranty period" for remaining normal?</style></title><secondary-title><style face="normal" font="default">Journal of the American College of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of the American College of Cardiology</style></full-title></periodical><pages end="1117" start="1110">1110-1117</pages><volume><style face="normal" font="default">55</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="16" Month="3" Year="2010">2010/3/16</year></dates><abstract><style face="normal" font="default">OBJECTIVES: This study identified the incidence and predictors of conversion of a normal to abnormal coronary artery calcium (CAC) scan during serial CAC scanning over 5 years. BACKGROUND: Although a normal CAC scan signifies absence of significant atherosclerosis and is used to identify individuals at low clinical risk, the "warranty period" of a normal CAC scan relative to its ability to predict sustained absence of coronary atherosclerosis remains unknown. METHODS: We assessed frequency of and time to progression, as well as proportional increase of CAC in 422 individuals with normal CAC scan (CAC = 0) undergoing annual CAC scanning for 5 years. Results were compared with those of a referent cohort of 621 individuals with baseline CAC scan (CAC >0). RESULTS: A total of 106 (25.1%) patients with CAC = 0 developed CAC during follow-up at a mean time to conversion of 4.1 +/- 0.9 years. Incidence of conversion to CAC >0 was nonlinear and was highest in the fifth year. In multivariable analysis, progression to CAC >0 was associated with age, diabetes, and smoking (p &lt; 0.01 for all). Among the 621 individuals with baseline CAC >0, only the presence of CAC itself, rather than CAD risk factors, was predictive of CAC progression. Among propensity score-matched individuals with CAC >0 versus CAC = 0, baseline CAC >0 emerged as the strongest predictor of CAC progression (hazard ratio [HR]: 12.50, 95% confidence interval [CI]: 9.31 to 16.77), followed by diabetes (HR: 2.07, 95% CI: 1.47 to 2.90) and smoking (HR: 1.29, 95% CI: 1.02 to 1.63, p &lt; 0.05 for all). CONCLUSIONS: Among individuals with CAC = 0, conversion to CAC >0 is nonlinear and occurs at low frequency before 4 years. No clinical factor seems to mandate earlier repeat CAC scanning. Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine and Radiology, Weill Medical College of Cornell University, The New York Presbyterian Hospital, New York, New York 10021, USA. jkm2001@med.cornell.eduCM - Comment in: J Am Coll Cardiol. 2010 Mar 16;55(11):1118-20; PMID: 20223366JC - h50, 8301365CP - United StatesPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20223365</style></custom1><custom3><style face="normal" font="default">AS - J Am Coll Cardiol. 55(11):1110-7, 2010 Mar 16.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>328</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Mitchell,C.T.</style></author><author><style face="normal" font="default"> Kamineni,A.</style></author><author><style face="normal" font="default"> Palmas,W.</style></author><author><style face="normal" font="default"> Cushman,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Tissue factor pathway inhibitor, vascular risk factors and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis</style></title><secondary-title><style face="normal" font="default">Atherosclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Atherosclerosis</style></full-title></periodical><pages end="283" start="277">277-283</pages><volume><style face="normal" font="default">207</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Carotid Artery Diseases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Lipoproteins/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (lipoprotein-associated coagulation inhibitor)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipoproteins)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Ankle Brachial Index</style></keyword><keyword><style face="normal" font="default"> Ankle/bs [Blood Supply]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Brachial Artery/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Carotid Arteries/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Carotid Artery Diseases/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Carotid Artery Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Carotid Artery Diseases/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Carotid Artery Diseases/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Ethnic Groups</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Linear Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Tunica Intima/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Tunica Media/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> United States/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Up-Regulation</style></keyword></keywords><dates><year Day="0" Month="11" Year="2009">2009/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Tissue factor pathway inhibitor (TFPI) is an endothelial membrane-associated anticoagulant protein. Higher circulating levels might reflect endothelial damage. OBJECTIVE: We hypothesized an association of higher total TFPI with subclinical atherosclerosis. PATIENTS/METHODS: Total TFPI was measured in 1000 participants of the Multi-Ethnic Study of Atherosclerosis, a cohort of 6814 men and women without clinical vascular disease, aged 45-84, from four ethnic groups. Subclinical atherosclerosis measures were coronary artery calcium (CAC), carotid intima-media thickness (IMT) and ankle-brachial index (ABI). RESULTS: TFPI was higher with age, male gender, higher LDL-cholesterol, smoking and diabetes, but not ethnicity. Adjusting for risk factors, TFPI in the 4th quartile versus 1st quartile was associated with a 1.2-fold increased risk of detectable CAC (95% CI 1.0-1.4), a 2.1-fold increased risk of CAC >400 Agatston units (95% CI 1.1-4.0) and a 1.6-fold (95% CI 1.1-2.5) increased risk of internal carotid IMT above the 80th percentile, but not with external carotid IMT or low ABI. Findings were consistent across ethnic groups. CONCLUSIONS: In this diverse population, higher total TFPI was associated with prevalent CAC (limited to levels >400 units), and elevated internal carotid IMT, independent of other factors. Higher TFPI may indicate endothelial dysfunction. Further study is needed of TFPI and progression of atherosclerosis</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, University of Vermont, Burlington, VT 05446, USAJC - 95x, 0242543CP - IrelandPT - Journal ArticlePT - Multicenter StudyPT - Research Support, N.I.H., ExtramuralNO - N01-HC-95159 (United States NHLBI NIH HHS)NO - N01-HC-95166 (United States NHLBI NIH HHS)NO - T32 HL076132-01 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19467658</style></custom1><custom3><style face="normal" font="default">AS - Atherosclerosis. 207(1):277-83, 2009 Nov.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>198</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Miura,K.</style></author><author><style face="normal" font="default"> Okuda,N.</style></author><author><style face="normal" font="default"> Turin,T.C.</style></author><author><style face="normal" font="default"> Takashima,N.</style></author><author><style face="normal" font="default"> Nakagawa,H.</style></author><author><style face="normal" font="default"> Nakamura,K.</style></author><author><style face="normal" font="default"> Yoshita,K.</style></author><author><style face="normal" font="default"> Okayama,A.</style></author><author><style face="normal" font="default"> Ueshima,H.</style></author><author><style face="normal" font="default"> NIPPON,D.A.T.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Dietary salt intake and blood pressure in a representative Japanese population: baseline analyses of NIPPON DATA80</style></title><secondary-title><style face="normal" font="default">Journal of Epidemiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Epidemiology</style></full-title></periodical><pages end="30" start="Suppl">Suppl-30</pages><volume><style face="normal" font="default">20</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Blood Pressure/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> *Diet/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> *Hypertension/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Sodium Chloride,Dietary/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> 0 (Sodium Chloride,Dietary)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fruit</style></keyword><keyword><style face="normal" font="default"> Health Surveys</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Japan/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Nutrition Surveys</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> Sodium Chloride,Dietary/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Vegetables</style></keyword></keywords><dates><year Day="0" Month="0" Year="2010">2010</year></dates><abstract><style face="normal" font="default">BACKGROUND: The relationship between dietary salt intake and blood pressure (BP) has been rarely investigated in a large population of Japanese. The characteristics of nutrients intake and foods intake in Japanese people with high salt intake have also not investigated well. METHODS: Data of 10,422 participants (4585 men and 5837 women) aged 30 or older who participated in both the National Survey on Circulatory Disorders and National Nutrition Survey in Japan conducted in 1980 were used. The nutrition surveys were performed with weighing record method for three consecutive days to each household. BP and intakes of nutrients and foods were compared by the quintiles of estimated individual salt intake per day. Analyses of covariance were used to calculate multivariate-adjusted mean BP values by the quintiles. RESULTS: Participants with higher salt intake showed higher intakes of soy beans/legume, fruit, other vegetables, and fish/shellfish. Intakes of protein, potassium, calcium, iron, magnesium, and fiber were higher in higher quintiles of salt intake. In men, adjusted systolic BPs were higher in the higher salt intake quintiles; there was 4.3 mm Hg difference in multivariate-adjusted systolic BP between the lowest quintile (mean salt intake 8.7 g/day) and the highest quintile (mean salt intake 23.5 g/day) (P &lt; 0.001). In women, adjusted mean systolic BPs were not statistically different among the quintile of salt intake. CONCLUSIONS: A positive relationship of dietary salt intake to BP was observed, especially in men, in this large-scale representative Japanese population</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Health Science, Shiga University of Medical Scienc, Ohtsu, Japan. miura@belle.shiga-med.ac.jpJC - cl8, 9607688CP - JapanPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20351473</style></custom1><custom3><style face="normal" font="default">AS - J Epidemiol. 20 Suppl 3:S524-30, 2010.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>568</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Mizia-Stec,K.</style></author><author><style face="normal" font="default"> Haberka,M.</style></author><author><style face="normal" font="default"> Mizia,M.</style></author><author><style face="normal" font="default"> Chmiel,A.</style></author><author><style face="normal" font="default"> Wierzbicka-Chmiel,J.</style></author><author><style face="normal" font="default"> Skowerski,M.</style></author><author><style face="normal" font="default"> Gasior,Z.</style></author></authors></contributors><titles><title><style face="normal" font="default">Coronary artery calcium score assessed by a 64 multislice computed tomography and early indexes of functional and structural vascular remodeling in cardiac syndrome X patients</style></title><secondary-title><style face="normal" font="default">Journal of Nuclear Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Nuclear Cardiology</style></full-title></periodical><pages end="662" start="655">655-662</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Microvascular Angina/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Microvascular Angina/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Arteries/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Brachial Artery/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> Echocardiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Pulse</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Tunica Intima/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Tunica Media/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Waist-Hip Ratio</style></keyword></keywords><dates><year Day="0" Month="9" Year="2008">2008/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Regardless of normal coronary angiograms, coronary artery calcium (CAC) can be found in cardiac syndrome X (CSX) patients. According to some data, a relationship between the CAC score and markers of early atherosclerosis in CSX has been observed. Our aim was to assess whether the extent of the CAC score assessed by multislice computed tomography (MSCT) with a 64-slice system in CSX patients is related to brachial artery reactivity, intima-media thickness (IMT), and arterial compliance indexes. METHODS AND RESULTS: High-resolution ultrasound was used to measure flow-mediated dilatation (FMD) and nitroglycerin-mediated vasodilatation, as well as the following parameters of arterial structural changes: IMT, pulse wave velocity, total arterial compliance, and stiffness index. MSCT was used to assess the presence and the quantity of CAC. The study group consisted of 46 CSX patients (mean age, 56.3 +/- 9 years), whereas the control group comprised 21 healthy subjects (mean age, 54.9 +/- 7 years). The assessment of the vascular parameters showed significantly decreased FMD and increased IMT in the CSX subjects (9.06% +/- 3.2% and 0.67 +/- 0.1 mm, respectively) in comparison to the control subjects (17.42% +/- 8.4% [P = .008] and 0.57 +/- 0.2 mm [P = .021], respectively). CAC was detectable in 19 CSX patients (41%) (CAC range according to Agatston score, 2-500; mean, 101.6; median, 26.5) and in 1 control subject (4.8%) (CAC value, 13). CSX patients with detectable CAC were characterized by a significantly higher age (P = .001), lower body mass index (P = .017), and increased stiffness index (P = .020); there were no differences in FMD and IMT values. In a multivariate logistic and linear regression analysis, age was the only risk factor independently associated with the presence of CAC (P = .001) and the log(CAC + 1) value (P = .01). In the subgroup of women, log(CAC + 1) significantly correlated with age (r = 0.587, P = .002) and stiffness index (r = 0.427, P = .024), and in a borderline significant manner, it correlated with weight (r = -0.329, P = .07) and waist-hip ratio (r = 0.315, P = .07). There were no significant correlations in the male subgroup. CONCLUSIONS: Low ranges of CAC are frequently detectable in CSX patients, and the results are age-related and independent of impaired early indexes of functional and structural vascular remodeling</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Medical University of Silesia, Katowice, Poland. kmizia@op.plCM - Comment in: J Nucl Cardiol. 2008 Sep-Oct;15(5):615-6; PMID: 18761263]JC - cmd, 9423534CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18761268</style></custom1><custom3><style face="normal" font="default">AS - J Nucl Cardiol. 15(5):655-62, 2008 Sep-Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>289</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Mizrachi,A.</style></author><author><style face="normal" font="default"> Gilat,H.</style></author><author><style face="normal" font="default"> Bachar,G.</style></author><author><style face="normal" font="default"> Feinmesser,R.</style></author><author><style face="normal" font="default"> Shpitzer,T.</style></author></authors></contributors><titles><title><style face="normal" font="default">Elevated parathyroid hormone levels after parathyroidectomy for primary hyperparathyroidism</style></title><secondary-title><style face="normal" font="default">Head &amp; Neck</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Head &amp; Neck</style></full-title></periodical><pages end="1460" start="1456">1456-1460</pages><volume><style face="normal" font="default">31</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Hyperparathyroidism,Primary/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Hyperparathyroidism,Primary/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Parathyroidectomy</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adenoma/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Adenoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Adenoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Bone Density</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Primary/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Parathyroid Neoplasms/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Parathyroid Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Parathyroid Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Parathyroidectomy</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Urine</style></keyword></keywords><dates><year Day="0" Month="11" Year="2009">2009/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Curative parathyroidectomy is associated with elevated levels of parathyroid hormone (PTH) with eucalcemia. This study sought to determine the frequency, clinical significance, and risk factors of this finding. METHODS: Seventy-six consecutive patients surgically treated for primary hyperparathyroidism due to a single parathyroid adenoma in 2006 to 2007 were monitored for 1 month postoperatively; those with elevated PTH levels (>70 pg/mL) were monitored for 18 months. RESULTS: Nineteen patients (25%) had high postoperative PTH levels with normal calcium levels. Compared with the remaining patients, this group had a significantly higher average preoperative PTH level (224.89 vs 156.86 pg/mL) and a lesser intraoperative decrease in PTH. CONCLUSIONS: About 25% of eucalcemic patients may have elevated PTH levels after parathyroidectomy. A high preoperative PTH level (>225 pg/mL) may predict a persistently high postoperative level. Evaluation of blood and urine calcium, bone density, and cardiac function should be considered in affected patients. (c) 2009 Wiley Periodicals, Inc. Head Neck, 2009</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Otorhinolaryngology-Head and Neck Surgery, Rabin Medical Center, Petach Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelJC - g1p, 8902541CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19405085</style></custom1><custom3><style face="normal" font="default">AS - Head Neck. 31(11):1456-60, 2009 Nov.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>68</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Mohamed,S.A.</style></author><author><style face="normal" font="default"> Misfeld,M.</style></author><author><style face="normal" font="default"> Hanke,T.</style></author><author><style face="normal" font="default"> Charitos,E.I.</style></author><author><style face="normal" font="default"> Bullerdiek,J.</style></author><author><style face="normal" font="default"> Belge,G.</style></author><author><style face="normal" font="default"> Kuehnel,W.</style></author><author><style face="normal" font="default"> Sievers,H.H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Inhibition of caspase-3 differentially affects vascular smooth muscle cell apoptosis in the concave versus convex aortic sites in ascending aneurysms with a bicuspid aortic valve</style></title><secondary-title><style face="normal" font="default">Annals of Anatomy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Annals of Anatomy</style></full-title></periodical><pages end="150" start="145">145-150</pages><volume><style face="normal" font="default">192</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aneurysm/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Aorta/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Caspase 3/ai [Antagonists &amp; Inhibitors]</style></keyword><keyword><style face="normal" font="default"> *Heart Valves/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Muscle,Smooth,Vascular/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Apoptosis</style></keyword><keyword><style face="normal" font="default"> Cell Culture Techniques</style></keyword><keyword><style face="normal" font="default"> EC 3-4-22 (Caspase 3)</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Protein Array Analysis</style></keyword><keyword><style face="normal" font="default"> Pulmonary Disease,Chronic Obstructive/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="20" Month="5" Year="2010">2010/5/20</year></dates><abstract><style face="normal" font="default">Apoptosis of vascular smooth muscle cells (VSMCs) is involved in bicuspid aortic valve (BAV) ascending aorta aneurysms characteristically affecting the convex site. Caspase-3 is a pivotal effector of the apoptosis machinery. The aim of this study was to investigate the impact of an inhibited caspase-3 pathway on apoptosis in convex and concave sites VSMCs of ascending aortic tissue in vitro. Specimens from the convex and concave sites of ascending aortic aneurysm were collected from nine patients with BAV (mean age 58.7+/-14.8). Cultured VSMCs were characterized morphologically and immunohistochemically. Apoptosis activity was measured in VSMCs using Annexin V-APC with propidium iodide nuclear staining in flow cytometry. To investigate apoptotic modulation, caspase-3 was inhibited by N-acetyl-Asp-Glu-Val-Asp-CHO (Ac-DEVD-CHO). Apoptosis was initiated by calcium chloride. Inhibition of caspase-3 with Ac-DEVD-CHO protected VSMCs against calcium chloride apoptosis significantly more in the concave site than in the convex site (25.8+/-9.8 versus 38.5+/-8.0% apoptotic cells, p=0.01). Morphological scanning using light microscopy revealed typical VSMCs. We provide evidence that VSMCs show a different behavior with respect to apoptosis in the concave versus the convex sites in BAV ascending aortic aneurysm. Inhibition of caspase-3 resulted in a significantly increased protection of VSMCs against apoptosis in the concave site compared with the convex site in ascending aortic aneurysm in BAV. These findings may have some implications on understanding aneurysmal formation and its potential modulation. Copyright 2010 Elsevier GmbH. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - University Clinic of Schleswig-Holstein, Department of Cardiac Surgery, D-23538 Luebeck, GermanyJC - dug, 100963897CP - GermanyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20427168</style></custom1><custom3><style face="normal" font="default">AS - Ann Anat. 192(3):145-50, 2010 May 20.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>271</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Mok,C.C.</style></author><author><style face="normal" font="default"> Poon,W.L.</style></author><author><style face="normal" font="default"> Lai,J.P.</style></author><author><style face="normal" font="default"> Wong,C.K.</style></author><author><style face="normal" font="default"> Chiu,S.M.</style></author><author><style face="normal" font="default"> Wong,C.K.</style></author><author><style face="normal" font="default"> Lun,S.W.</style></author><author><style face="normal" font="default"> Ko,G.T.</style></author><author><style face="normal" font="default"> Lam,C.W.</style></author><author><style face="normal" font="default"> Lam,C.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Metabolic syndrome, endothelial injury, and subclinical atherosclerosis in patients with systemic lupus erythematosus</style></title><secondary-title><style face="normal" font="default">Scandinavian Journal of Rheumatology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Scandinavian Journal of Rheumatology</style></full-title></periodical><pages end="49" start="42">42-49</pages><volume><style face="normal" font="default">39</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Endothelium,Vascular/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Lupus Erythematosus,Systemic/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Metabolic Syndrome X/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Metabolic Syndrome X/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Cytokines)</style></keyword><keyword><style face="normal" font="default"> 0 (Tumor Necrosis Factor-alpha)</style></keyword><keyword><style face="normal" font="default"> 9007-41-4 (C-Reactive Protein)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age Distribution</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Blood Chemical Analysis</style></keyword><keyword><style face="normal" font="default"> C-Reactive Protein/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Carotid Stenosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Carotid Stenosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Cytokines/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lupus Erythematosus,Systemic/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Sex Distribution</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Tumor Necrosis Factor-alpha/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Tunica Intima/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Tunica Intima/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Tunica Media/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Tunica Media/us [Ultrasonography]</style></keyword></keywords><dates><year Day="0" Month="0" Year="2010">2010</year></dates><abstract><style face="normal" font="default">OBJECTIVES: To study the link between metabolic syndrome (MetS), endothelial injury, and atherosclerosis in patients with systemic lupus erythematosus (SLE). METHODS: Consecutive SLE patients without a history of arterial thrombosis were screened for atherosclerosis at the carotid and coronary arteries by B-mode ultrasound [intima-media thickness (IMT)] and multidetector computed tomography (MDCT) scan (Agatston calcium scores), respectively. Plasma levels of homocysteine, high-sensitivity C-reactive protein (hsCRP), soluble vascular cell adhesion molecule (sVCAM)-1, P-selectin, and soluble thrombomodulin (sTM) were assayed. Patients were stratified according to the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) criteria for MetS, using the Asian criteria for abdominal obesity. Risk factors for atherosclerosis were studied. RESULTS: Of the 123 SLE patients (93% women; age 47.9+/-11 years; SLE duration 10.9+/-7.0 years) studied, 20 (16.3%) had MetS. The prevalence of MetS in the SLE patients was significantly higher than in 492 age- and sex-matched healthy controls (9.6%; p=0.03). Coronary calcification and abnormal carotid IMT were detected in 38 (31%) and 72 (59%) of SLE patients, respectively. Patients with MetS had a significantly higher Agatston score (69.5+/-95 vs. 16.4+/-57; p=0.03) and a numerically higher carotid IMT (p=0.43) than those without. In a logistic regression model, the MetS [odds ratio (OR) 3.11, 95% confidence interval (CI) 1.01-9.59, p=0.049] was associated with coronary atherosclerosis after adjustment for age and other risk factors. In addition, patients with MetS had significantly higher levels of hsCRP (p=0.002), homocysteine (p=0.03), and sTM (p=0.01). CONCLUSIONS: The MetS is more prevalent in SLE patients than the general population and is associated with endothelial injury and coronary atherosclerosis. More aggressive control of risk factors is justified in these patients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, Tuen Mun Hospital, Hong Kong, SAR China. ccmok2005@yahoo.comJC - ud1, 0321213CP - EnglandPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20132070</style></custom1><custom3><style face="normal" font="default">AS - Scand J Rheumatol. 39(1):42-9, 2010.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>272</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Mok,M.Y.</style></author><author><style face="normal" font="default"> Chiu,S.S.</style></author><author><style face="normal" font="default"> Lo,Y.</style></author><author><style face="normal" font="default"> Mak,H.K.</style></author><author><style face="normal" font="default"> Wong,W.S.</style></author><author><style face="normal" font="default"> Khong,P.L.</style></author><author><style face="normal" font="default"> Lau,C.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Coronary atherosclerosis using computed tomography coronary angiography in patients with systemic sclerosis</style></title><secondary-title><style face="normal" font="default">Scandinavian Journal of Rheumatology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Scandinavian Journal of Rheumatology</style></full-title></periodical><pages end="385" start="381">381-385</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Scleroderma,Systemic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Stenosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Stenosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Scleroderma,Systemic/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Statistics,Nonparametric</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><abstract><style face="normal" font="default">BACKGROUND: Impaired coronary artery reserve has previously been demonstrated in patients with systemic sclerosis (SSc). Both micro- and macrovascular factors are probably contributory to the underlying pathogenesis. OBJECTIVES: To examine the frequency of coronary atherosclerosis in a series of SSc patients by computed tomography coronary angiography (CTCA), a less invasive method than conventional coronary angiography, the current gold standard in the detection of coronary atherosclerosis, and to explore its clinical associations. METHODS: Nineteen consecutive SSc patients [six with diffuse (dSSc) and 13 with limited disease (lSSc)] with disease duration of >or= 3 years were recruited. Coronary calcium score and contrast angiography were examined by CT scan. Conventional cardiovascular factors and inflammatory markers were measured and correlated with CT findings. RESULTS: The mean+/-SD age of these patients was 52.5+/-12.5 years with median disease duration of 12.5 years. Six (31.6%) patients were found to have coronary artery calcification (calcium score 13-2008). Coronary calcium was detected in one dSSc patient but contrast angiography was not performed because of interference from an in situ implantable cardiac device. Some parts of the coronary arteries were not assessable in two patients who had ectopic cardiac rhythm. Five lSSc patients had calcified plaques causing variable coronary luminal stenosis. All patients were asymptomatic. Patients with abnormal CTCA findings were more likely to be older (p &lt; 0.001) and were less likely to have serum anti-Scl70 antibodies (p = 0.003) than those without, after Bonferroni correction. CONCLUSIONS: Coronary atherosclerosis is not uncommon in asymptomatic SSc patients. CTCA is a convenient and non-invasive method for studying coronary atherosclerosis</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, PR China. temy@hkucc.hku.hkJC - ud1, 0321213CP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19585378</style></custom1><custom3><style face="normal" font="default">AS - Scand J Rheumatol. 38(5):381-5, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>285</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Molino,C.</style></author><author><style face="normal" font="default"> Fabbian,F.</style></author><author><style face="normal" font="default"> Russo,G.</style></author><author><style face="normal" font="default"> Cantelli,S.</style></author><author><style face="normal" font="default"> Bortot,A.</style></author><author><style face="normal" font="default"> Galdi,A.</style></author><author><style face="normal" font="default"> Catizone,L.</style></author></authors></contributors><titles><title><style face="normal" font="default">[MEN type 1 and chronic renal failure: a rarely reported association]. [Italian]</style></title><secondary-title><style face="normal" font="default">Giornale Italiano di Nefrologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Giornale Italiano di Nefrologia</style></full-title></periodical><pages end="82" start="79">79-82</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Kidney Failure,Chronic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Multiple Endocrine Neoplasia Type 1/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword></keywords><dates><year Day="0" Month="1" Year="2007">2007/1</year></dates><isbn><style face="normal" font="default">0393-5590</style></isbn><abstract><style face="normal" font="default">BACKGROUND: Multiple endocrine neoplasia type 1 (MEN 1), or Wermer's syndrome, is a rare autosomal dominant genetic syndrome characterized by tumors or hyperplasia involving the pituitary, parathyroid, and pancreatic islet cells. Association between MEN 1 and nephrocalcinosis is well known, though data published in medical literature regarding Wermer's syndrome and chronic renal failure relation are still rare. CASE: A 70-year-old Caucasian female patient had a history of primitive hyperparathyroidism, prolactinoma, glucagonoma, adrenal adenoma and pulmonary neuroendocrine neoplasia. She presented at our clinic first when she was 62 years old because of hypertension, nephrolithiasis (calcium oxalate) and diabetes mellitus treated with oral agents. During the eight-year follow-up she developed chronic renal failure (serum creatinine 1.8 mg/dL, glomerular clearance 35 mL/min) and partial thrombosis of abdominal aortic wall. CONCLUSIONS: Although the association between renal failure and MEN 1 is rarely reported, patients affected by Wermer's syndrome have several risk factors of decreasing renal function such as hypertension, nephrolithiasis and diabetes mellitus. Moreover, hyperparathyroidism in MEN 1 is clinically similar to the kidney failure condition; indeed, diffuse hyper-plasia of more than one gland is common. Vitamin D should not be administered to these patients. Nephrologists should be involved in MEN 1 follow-up, with the aim to prevent kidney failure development by correcting risk factors</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - U.O. di Nefrologia e Dialisi, Arcispedale S. Anna, Ferrara - ItalyOT - MEN tipo 1 ed insufficienza renale: una associazione poco conosciutaJC - 9426434CP - ItalyPT - Case ReportsPT - English AbstractPT - Journal ArticleLG - Italian</style></notes><urls/><custom1><style face="normal" font="default">UI - 17342698</style></custom1><custom3><style face="normal" font="default">AS - G. ITAL. NEFROL.. 24(1):79-82, 2007 Jan-Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>531</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Molloi,S.</style></author><author><style face="normal" font="default"> Mehraien,T.</style></author><author><style face="normal" font="default"> Iribarren,C.</style></author><author><style face="normal" font="default"> Smith,C.</style></author><author><style face="normal" font="default"> Ducote,J.L.</style></author><author><style face="normal" font="default"> Feig,S.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Reproducibility of breast arterial calcium mass quantification using digital mammography</style></title><secondary-title><style face="normal" font="default">Academic Radiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Academic Radiology</style></full-title></periodical><pages end="282" start="275">275-282</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Breast Diseases/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Mammography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Radiographic Image Enhancement/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Radiographic Image Interpretation,Computer-Assisted/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Algorithms</style></keyword><keyword><style face="normal" font="default"> Breast Diseases/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Breast/bs [Blood Supply]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="3" Year="2009">2009/3</year></dates><abstract><style face="normal" font="default">RATIONALE AND OBJECTIVES: Breast arterial calcification (BAC) detected on mammography is frequently not included in final reports. However, previous studies have indicated that BAC may be evidence of general atherosclerotic vascular disease, and it can potentially be a useful marker of coronary artery disease. In addition, there are currently no available techniques for the quantification of calcium mass using mammography. The purpose of this study was to evaluate the reproducibility and inter-reader agreement of a technique for the quantification of BAC using standard digital mammography. MATERIALS AND METHODS: BAC mass was measured in a convenient, consecutive sample of 39 women aged 49 to 82 years attending routine mammographic examinations. BAC mass measurements were performed in standard mediolateral oblique (MLO) and craniocaudal (CC) views. To assess reproducibility, the BAC measurements obtained in MLO and CC views were compared. RESULTS: The measured BAC masses in CC (M(CC)) and MLO (M(MLO)) projections were related by M(CC) = 0.82(M(MLO)) + 0.27 mg (r = 0.97; standard error of estimation [SEE], 3.44 mg). The measured BAC masses in the left (M(L)) and right (M(R)) breasts were related by M(L) = 0.86(M(R)) - 0.06 mg (r = 0.95; SEE, 4.30 mg). The intraclass correlation coefficients for the measurement of calcium mass ranged from 0.94 in the left CC view to 0.99 in the right CC view. CONCLUSION: A densitometry technique for the quantification of BAC mass was evaluated in patients using standard full-field digital mammography. The results demonstrated that this densitometric technique for the quantification of BAC mass is highly reproducible and has excellent inter-reader agreement. This technique may provide a quantitative metric for future studies relating the severity of BAC and cardiovascular risk</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Radiological Sciences, University of California, Irvine, Medical Sciences I, B-140, Irvine, CA 92697, USA. symolloi@uci.eduJC - clv, 9440159CP - United StatesPT - Evaluation StudiesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - R01 HL083295 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19201356</style></custom1><custom3><style face="normal" font="default">AS - Acad Radiol. 16(3):275-82, 2009 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>513</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Montagnana,M.</style></author><author><style face="normal" font="default"> Lippi,G.</style></author><author><style face="normal" font="default"> Albiero,A.</style></author><author><style face="normal" font="default"> Scevarolli,S.</style></author><author><style face="normal" font="default"> Salvagno,G.L.</style></author><author><style face="normal" font="default"> Franchi,M.</style></author><author><style face="normal" font="default"> Guidi,G.C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy</style></title><secondary-title><style face="normal" font="default">Journal of Clinical Laboratory Analysis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Clinical Laboratory Analysis</style></full-title></periodical><pages end="92" start="88">88-92</pages><volume><style face="normal" font="default">23</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Matrix Metalloproteinase 2/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Matrix Metalloproteinase 9/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Pre-Eclampsia/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Pregnancy/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Tissue Inhibitor of Metalloproteinase-1/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Tissue Inhibitor of Metalloproteinase-2/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Tissue Inhibitor of Metalloproteinase-1)</style></keyword><keyword><style face="normal" font="default"> 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> EC 3-4-24-24 (Matrix Metalloproteinase 2)</style></keyword><keyword><style face="normal" font="default"> EC 3-4-24-35 (Matrix Metalloproteinase 9)</style></keyword><keyword><style face="normal" font="default"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Gestational Age</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Statistics,Nonparametric</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><abstract><style face="normal" font="default">Matrix metalloproteinases (MMPs) are a family of zinc and calcium-dependent endopeptidases involved in remodeling and physiological homeostasis of extracellular matrix (ECM). The metalloproteinases activity is predominantly modulated by specific tissue inhibitors of matrix metalloproteinases (TIMPs). The balance between MMPs and TIMPs is likely to play an important role in remodeling uterine arteries in pregnancy, and it may represent means by which vasodilatation is maintained in later pregnancy. Moreover, increased levels of MMPs and in particular MMP-2 play a role in the vascular alterations induced by hypertension. The aim of this study was the evaluation of MMP-2 and -9, along with their inhibitors TIMP-1 and -2, in pre-eclamptic women compared with normotensive pregnancy and non-pregnant women. Fourteen pre-eclamptic women were compared with 37 normotensive women in different gestational age and 21 non-pregnant women. Multiplexed sandwich enzyme-linked immunosorbent assay was used to measure MMPs and TIMPs simultaneously. MMP-2 levels were significantly higher in pre-eclamptic women vs. both non-pregnant and physiologic pregnant women. MMP-9 concentrations were significantly higher in physiologic pregnant vs. non-pregnant women. The serum levels of TIMP-1 were significantly higher in pre-eclamptic vs. both non-pregnant and physiologic pregnant women. TIMP-2 values were higher in physiologic pregnant women and pre-eclamptic women vs. non-pregnant women. A positive correlation between MMP-9 values and gestational age was observed in normal pregnant women. Results of the present investigation confirm that MMP-2 and TIMP-1 values are significantly higher in preeclampsia. We confirm that the modification of the fine balance between MMPs and their inhibitors plays a greater role in the structural and functional vascular changes of women with complicated pregnancies. (c) 2009 Wiley-Liss, Inc</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Sezione di Chimica Clinica, Dipartimento di Scienze Morfologico-Biomediche, Universit&amp;#x00E0; degli Studi di Verona, Ospedale Policlinico G.B. Rossi, Piazzale Scuro 10, Verona, Italy. martina.montagnana@med.lu.seJC - jla, 8801384CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19288452</style></custom1><custom3><style face="normal" font="default">AS - J Clin Lab Anal. 23(2):88-92, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>79</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Moon,S.S.</style></author><author><style face="normal" font="default"> Choi,Y.K.</style></author><author><style face="normal" font="default"> Seo,H.A.</style></author><author><style face="normal" font="default"> Jeon,J.H.</style></author><author><style face="normal" font="default"> Lee,J.E.</style></author><author><style face="normal" font="default"> Jeong,J.Y.</style></author><author><style face="normal" font="default"> Lee,J.Y.</style></author><author><style face="normal" font="default"> Lee,D.H.</style></author><author><style face="normal" font="default"> Park,W.J.</style></author><author><style face="normal" font="default"> Kim,J.G.</style></author><author><style face="normal" font="default"> Kim,B.W.</style></author><author><style face="normal" font="default"> Lee,I.K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Relationship between cardiovascular autonomic neuropathy and coronary artery calcification in patients with type 2 diabetes</style></title><secondary-title><style face="normal" font="default">Endocrine Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Endocrine Journal</style></full-title></periodical><pages end="454" start="445">445-454</pages><volume><style face="normal" font="default">57</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Cardiomyopathies/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 2/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Diabetic Neuropathies/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Heart/ir [Innervation]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus,Type 2/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus,Type 2/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Diabetic Neuropathies/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Diabetic Neuropathies/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed/mt [Methods]</style></keyword></keywords><dates><year Day="0" Month="0" Year="2010">2010</year></dates><abstract><style face="normal" font="default">To test the hypothesis that cardiovascular autonomic neuropathy (CAN) in Type 2 diabetes is a risk factor of coronary artery calcification (CAC), in this cross-sectional study, 118 patients (60 males, 58 females) with type 2 diabetes mellitus were randomly selected from the diabetes clinic of Kyungpook National University Hospital, Daegu, Korea, between January, 2008 and September, 2008. The subjects, whose mean age was 56.9+/-1.1 years, were tested for CAN by Ewing's method which employs five non-invasive tests of autonomic function. The coronary calcium score (CCS) was determined by Multi Detector-row Computed Tomography (MDCT). Statistical analysis was performed by using SPSS 13.0 (SPSS, Inc., Chicago,-Illinois). CAN was found in 31/118 (26.3%) patients. Compared to the patients without CAN, the patients with CAN were significantly older and had significantly higher triglyceride levels, blood pressure, pulse pressure, fasting c-peptide levels, CAN scores, and log-transformed coronary calcium scores [ln(CCS+1)]. The CAN scores correlated positively with ln(CCS+1) values (r = 0.214; P = 0.028). Multiple regression analysis using ln(CCS+1) as a dependent variable showed that CAN score (beta coefficient 0.623, 95% CI 0.059 approximately 1.188, P = 0.031) associated independently with ln(CCS+1). In conclusion, CAN was associated independently with CAC, which suggests that CAN is a risk factor of coronary atherosclerosis in patients with type 2 diabetes. This may help to explain the excess cardiovascular mortality seen in diabetic patients with CAN</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Endocrinology and Metabolism, Kyungpook National University Hospital, Jungu, Daegu, Korea. drmoonss@hanmail.netJC - bt5, 9313485CP - JapanPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20185862</style></custom1><custom3><style face="normal" font="default">AS - Endocr J. 57(5):445-54, 2010.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>343</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Morena,M.</style></author><author><style face="normal" font="default"> Dupuy,A.M.</style></author><author><style face="normal" font="default"> Jaussent,I.</style></author><author><style face="normal" font="default"> Vernhet,H.</style></author><author><style face="normal" font="default"> Gahide,G.</style></author><author><style face="normal" font="default"> Klouche,K.</style></author><author><style face="normal" font="default"> Bargnoux,A.S.</style></author><author><style face="normal" font="default"> Delcourt,C.</style></author><author><style face="normal" font="default"> Canaud,B.</style></author><author><style face="normal" font="default"> Cristol,J.P.</style></author></authors></contributors><titles><title><style face="normal" font="default">A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients</style></title><secondary-title><style face="normal" font="default">Nephrology Dialysis Transplantation</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Nephrology Dialysis Transplantation</style></full-title></periodical><pages end="3397" start="3389">3389-3397</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Kidney Diseases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Osteoprotegerin/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Osteoprotegerin)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Biological Markers</style></keyword><keyword><style face="normal" font="default"> Calcinosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Kidney Diseases/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> ROC Curve</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword></keywords><dates><year Day="0" Month="11" Year="2009">2009/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Expression of bone proteins resulting from transdifferentiation of vascular smooth muscle cells into osteoblasts suggests that vascular calcifications are a bioactive process. Osteoprotegerin (OPG) could play a key role in bone-vascular calcification imbalance and could be a marker of vascular calcification extent and progression. The purpose of this study was to evaluate relationships between vascular risk biomarkers (including classic risk factors and OPG) and coronary artery calcification (CAC) extent in chronic kidney disease (CKD) patients and to establish within the markers the appropriate cut-off value to predict CAC. METHODS: A total of 133 non-dialyzed CKD patients at various stages of kidney disease [75 males/58 females, median age: 69.9 (27.4-94.6)] were enrolled, excluding extrarenal replacement therapy patients. All underwent chest multidetector computed tomography for CAC scoring. Blood samples were collected for measurement of vascular risk markers (kidney disease, inflammation, nutrition, calcium phosphate and OPG). A potential relationship between CAC and these biological markers was investigated, and a receiver-operating characteristic (ROC) curve was designed thereafter to identify a cut-off value of involved markers that best predicted the presence of CAC. RESULTS: After adjustment for age, diabetes, smoking and gender, among biological markers, only low-estimated glomerular filtration rate using Modification of Diet in Renal Disease [OR = 3.63 (1.10-12.02)], high FEPO(4) [OR = 3.99 (1.17-13.6)] and high OPG levels [OR = 8.54 (2.14-34.11)] were associated with the presence of CAC. A protective effect of 1.25(OH)(2) vitamin D [OR = 0.20 (0.05-0.79)] and LDL cholesterol [OR = 0.27 (0.08-0.94)] on CAC was also observed. ROC curve analysis showed that the OPG best cut-off value predicting CAC was 757.7 pg/mL. CONCLUSION: These results suggest that a CAC increase is strongly associated with a plasma OPG increase in CKD patients. The values of OPG >757.7 pg/mL allow us to predict the presence of CAC in these patients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Laboratoire de Biochimie, CHRU Montpellier, F-34000 France; Univ Montpellier 1, Montpellier, F-34000 FranceJC - n7j, 8706402CP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19574342</style></custom1><custom3><style face="normal" font="default">AS - Nephrol Dial Transplant. 24(11):3389-97, 2009 Nov.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>203</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Morrow,D.A.</style></author><author><style face="normal" font="default"> Scirica,B.M.</style></author><author><style face="normal" font="default"> Sabatine,M.S.</style></author><author><style face="normal" font="default"> de Lemos,J.A.</style></author><author><style face="normal" font="default"> Murphy,S.A.</style></author><author><style face="normal" font="default"> Jarolim,P.</style></author><author><style face="normal" font="default"> Theroux,P.</style></author><author><style face="normal" font="default"> Bode,C.</style></author><author><style face="normal" font="default"> Braunwald,E.</style></author></authors></contributors><titles><title><style face="normal" font="default">B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial</style></title><secondary-title><style face="normal" font="default">Journal of the American College of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of the American College of Cardiology</style></full-title></periodical><pages end="1196" start="1189">1189-1196</pages><volume><style face="normal" font="default">55</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Acetanilides/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> *Acute Coronary Syndrome/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Acute Coronary Syndrome/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Enzyme Inhibitors/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> *Natriuretic Peptide,Brain/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Piperazines/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> 0 (Acetanilides)</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Enzyme Inhibitors)</style></keyword><keyword><style face="normal" font="default"> 0 (Piperazines)</style></keyword><keyword><style face="normal" font="default"> 110445-25-5 (ranolazine)</style></keyword><keyword><style face="normal" font="default"> 114471-18-0 (Natriuretic Peptide,Brain)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Double-Blind Method</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="23" Month="3" Year="2010">2010/3/23</year></dates><abstract><style face="normal" font="default">OBJECTIVES: We designed a prospective evaluation of the interaction between B-type natriuretic peptide (BNP) and the effect of ranolazine in patients with acute coronary syndromes (ACS) as part of a randomized, blinded, placebo-controlled trial. BACKGROUND: Ranolazine is believed to exert anti-ischemic effects by reducing myocardial sodium and calcium overload and consequently ventricular wall stress. BNP increases in response to increased wall stress and is a strong risk indicator in ACS. METHODS: We measured plasma BNP in all available baseline samples (n = 4,543) among patients with non-ST-segment elevation ACS randomized to ranolazine or placebo in the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial and followed them for a mean of 343 days. The primary end point was a composite of cardiovascular death, myocardial infarction, and recurrent ischemia. BNP elevation was defined as >80 pg/ml. RESULTS: Patients with elevated BNP (n = 1,935) were at significantly higher risk of the primary trial end point (26.4% vs. 20.4%, p &lt; 0.0001), cardiovascular death (8.0% vs. 2.1%, p &lt; 0.001), and myocardial infarction (10.6% vs. 5.8%, p &lt; 0.001) at 1 year. In patients with BNP >80 pg/ml, ranolazine reduced the primary end point (hazard ratio [HR]: 0.79; 95% confidence interval [CI]: 0.66 to 0.94, p = 0.009). The effect of ranolazine in patients with BNP >80 pg/ml was directionally similar for recurrent ischemia (HR: 0.78; 95% CI: 0.62 to 0.98; p = 0.04) and cardiovascular death or myocardial infarction (HR: 0.83; 95% CI: 0.66 to 1.05, p = 0.12). There was no detectable effect in those with low BNP (p interaction value = 0.05). CONCLUSIONS: Our findings indicate that ranolazine may have enhanced efficacy in high-risk patients with ACS identified by increased BNP. The interaction of biomarkers of hemodynamic stress and the effects of ranolazine warrants additional investigation. (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes; NCT00099788). Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA. dmorrow@partners.orgCM - Comment in: J Am Coll Cardiol. 2010 Mar 23;55(12):1197-9; PMID: 20298925JC - h50, 8301365CP - United StatesPT - Journal ArticlePT - Randomized Controlled TrialPT - Research Support, Non-U.S. Gov'tSI - ClinicalTrials.govSA - ClinicalTrials.gov/NCT00099788LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20298924</style></custom1><custom3><style face="normal" font="default">AS - J Am Coll Cardiol. 55(12):1189-96, 2010 Mar 23.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>394</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Muehrcke,D.D.</style></author><author><style face="normal" font="default"> Shimp,W.M.</style></author><author><style face="normal" font="default"> ponte-Lopez,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Calcium phosphate cements improve bone density when used in osteoporotic sternums</style></title><secondary-title><style face="normal" font="default">Annals of Thoracic Surgery</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Annals of Thoracic Surgery</style></full-title></periodical><pages end="1661" start="1658">1658-1661</pages><volume><style face="normal" font="default">88</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Bone Cements</style></keyword><keyword><style face="normal" font="default"> *Bone Density</style></keyword><keyword><style face="normal" font="default"> *Calcium Phosphates</style></keyword><keyword><style face="normal" font="default"> *Cardiac Surgical Procedures</style></keyword><keyword><style face="normal" font="default"> *Osteoporosis/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> *Sternum</style></keyword><keyword><style face="normal" font="default"> 0 (Bone Cements)</style></keyword><keyword><style face="normal" font="default"> 0 (Calcium Phosphates)</style></keyword><keyword><style face="normal" font="default"> 10103-46-5 (calcium phosphate)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Bone Density</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Osteoporosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword></keywords><dates><year Day="0" Month="11" Year="2009">2009/11</year></dates><abstract><style face="normal" font="default">PURPOSE: Calcium phosphate cements control bleeding and are safe to use in osteoporotic sternums during open heart surgery. We looked at the clinical and radiographic effects of this agent on bone healing. DESCRIPTION: Since March 2006, 18 patients had calcium phosphate cement inserted in their sternal tables at heart surgery. They were followed-up by office visits and chest computed tomographic (CT) scans. All preoperative and postoperative CT chest scans were evaluated for cement absorption, bone replacement, and bone density. EVALUATION: Five preoperative and 41 postoperative CT chest scans were available for evaluation. Median interval from surgery to CT scan was 531 days (range, 3 to 966 days). At follow-up there were neither clinical dehiscences nor nonunions of the sternums. Calcium phosphate cement appears to reabsorb quickly, but not completely. Five patients with pre-surgical CT chest scans demonstrated an average, improved bone density of 281.66 Hounsfield units at follow-up (p = 0.006). CONCLUSIONS: In each patient, cement was replaced by new bone, and there is evidence that more bone is present as a result of cement use</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiac Surgery, Flagler Hospital, St. Augustine, Florida, USA. dmuehrcke@aol.comJC - 15030100RCP - NetherlandsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19853129</style></custom1><custom3><style face="normal" font="default">AS - Ann Thorac Surg. 88(5):1658-61, 2009 Nov.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>32</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Muelas,N.</style></author><author><style face="normal" font="default"> Hackman,P.</style></author><author><style face="normal" font="default"> Luque,H.</style></author><author><style face="normal" font="default"> Garces-Sanchez,M.</style></author><author><style face="normal" font="default"> Azorin,I.</style></author><author><style face="normal" font="default"> Suominen,T.</style></author><author><style face="normal" font="default"> Sevilla,T.</style></author><author><style face="normal" font="default"> Mayordomo,F.</style></author><author><style face="normal" font="default"> Gomez,L.</style></author><author><style face="normal" font="default"> Marti,P.</style></author><author><style face="normal" font="default"> Maria,Millan J.</style></author><author><style face="normal" font="default"> Udd,B.</style></author><author><style face="normal" font="default"> Vilchez,J.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">MYH7 gene tail mutation causing myopathic profiles beyond Laing distal myopathy</style></title><secondary-title><style face="normal" font="default">Neurology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Neurology</style></full-title></periodical><pages end="741" start="732">732-741</pages><volume><style face="normal" font="default">75</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiac Myosins/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Distal Myopathies/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Gene Deletion</style></keyword><keyword><style face="normal" font="default"> *Myosin Heavy Chains/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> 0 (MYH7 protein,human)</style></keyword><keyword><style face="normal" font="default"> 0 (Myosin Heavy Chains)</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Cardiac Myosins/df [Deficiency]</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Child,Preschool</style></keyword><keyword><style face="normal" font="default"> Distal Myopathies/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Distal Myopathies/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> EC 3-6-1 (Cardiac Myosins)</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Genetic Predisposition to Disease/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> Infant,Newborn</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myosin Heavy Chains/df [Deficiency]</style></keyword><keyword><style face="normal" font="default"> Pedigree</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="24" Month="8" Year="2010">2010/8/24</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To describe a wide range of clinical and pathologic myopathic profiles associated with the p.K1729del mutation in the MYH7 gene, known to cause Laing distal myopathy. METHODS: A study conducted in the Safor region (Spain), setting of a large cluster of patients. Clinical, neurophysiologic, muscle imaging, and muscle biopsy studies and MYH7 gene sequencing were investigated in 32 patients from 4 kindreds. Data from 36 deceased or nonexamined patients were collected from hospital records or relatives. RESULTS: Onset ranged from congenital to the 6th decade. All patients presented weakness of great toe/ankle dorsiflexors and many had associated neck flexor, finger extensor, and mild facial weakness. In most cases, involvement of proximal and axial muscles was observed either clinically or by muscle imaging, sometimes giving rise to scapuloperoneal and limb-girdle syndromes. Disabling myalgias, skeletal deformities, and dilated cardiomyopathy in one patient were associated features. Life expectancy was not reduced but the spectrum of disability ranged from asymptomatic to wheelchair confined. Electromyographic neurogenic features were frequently recorded. Muscle fiber type disproportion, core/minicore lesions, and mitochondrial abnormalities were the most relevant pathologic alterations. All patients carried the p.K1729del mutation in MYH7. CONCLUSIONS: The p.K1729del mutation in the MYH7 gene expresses notable clinical variability and electromyographic and pathologic features that can lead to the misdiagnosis of neurogenic atrophies, congenital myopathies, or mitochondrial myopathies. Mutations in genes encoding other sarcomeric and reticulo-sarcoplasmic proteins involved in calcium regulation share pathologic characteristics with our patients, suggesting a possible pathogenetic connection</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Neurology, Hospital Universitario La Fe, Avda. Campanar 21, 46009 Valencia, SpainJC - 0401060, nz0CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20733148</style></custom1><custom3><style face="normal" font="default">AS - Neurology. 75(8):732-41, 2010 Aug 24.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>63</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Mulvagh,S.L.</style></author><author><style face="normal" font="default"> Behrenbeck,T.</style></author><author><style face="normal" font="default"> Lahr,B.A.</style></author><author><style face="normal" font="default"> Bailey,K.R.</style></author><author><style face="normal" font="default"> Zais,T.G.</style></author><author><style face="normal" font="default"> Araoz,P.A.</style></author><author><style face="normal" font="default"> Miller,V.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Endothelial function and cardiovascular risk stratification in menopausal women</style></title><secondary-title><style face="normal" font="default">Climacteric</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Climacteric</style></full-title></periodical><pages end="54" start="45">45-54</pages><volume><style face="normal" font="default">13</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiovascular Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Endothelium,Vascular/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Menopause/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol,LDL)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipids)</style></keyword><keyword><style face="normal" font="default"> 57-88-5 (Cholesterol)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Carotid Arteries/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Cholesterol,LDL/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cholesterol/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> Double-Blind Method</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperemia/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Hyperemia/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Lipids/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Assessment/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tunica Intima/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Tunica Media/us [Ultrasonography]</style></keyword></keywords><dates><year Day="0" Month="2" Year="2010">2010/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: Peripheral arterial, endothelium-dependent, flow-mediated reactive hyperemia is reduced in individuals with atherosclerosis. This study tested the hypothesis that digital tonometry, as a surrogate of endothelial function, is useful to stratify cardiovascular risk in recently menopausal women who are asymptomatic for cardiovascular disease. METHODS: Women undergoing screening for the Kronos Early Estrogen Prevention Study (KEEPS) were evaluated for conventional risk factors, flow-mediated reactive hyperemia by digital tonometry (RHI), carotid intima-media thickness (CIMT) by ultrasound, and coronary arterial calcium (CAC) by 64-slice CT scanner. RESULTS: One hundred and two non-diabetic Caucasian women (53.0 +/- 2.3 years old, 18.0 +/- 9.0 months past their last menses) participated; 72% were never-smokers. Fourteen women had positive CAC scores (range 0.5-133 Agatston units); CIMT ranged from 0.57 to 1.06 mm. RHI ranged from 1.26 to 5.44. RHI did not correlate with time past menopause, CAC, CIMT, total cholesterol or low density lipoprotein cholesterol. The significant negative correlation of RHI with body mass index (r = -0.21, p = 0.031) was lost in non-smokers (r = - 0.17, p = 0.14). There was also a negative correlation of high density lipoprotein cholesterol with CAC, both in the overall group and non-smokers (rho = -0.20, p = 0.05 and rho = -0.27, p = 0.02, respectively). CONCLUSIONS: RHI varies widely in healthy women within the first 3 years of menopause. RHI was not associated with standard risk assessment algorithms, CAC or CIMT. RHI may indicate an additional, independent component and non-invasive tool to further stratify cardiovascular risk in recently menopausal women. As KEEPS continues, data on RHI will provide information regarding hormonal therapy, endovascular biology and atherosclerotic risk</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Internal Medicine, Division of Cardiovascular Diseases, College of Medicine, Mayo Clinic, Rochester, MN 55905, USAJC - d0i, 9810959CP - EnglandPT - Journal ArticlePT - Randomized Controlled TrialPT - Research Support, Non-U.S. Gov'tSI - ClinicalTrials.govSA - ClinicalTrials.gov/NCT00154180LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19657788</style></custom1><custom3><style face="normal" font="default">AS - Climacteric. 13(1):45-54, 2010 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>541</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Muntner,P.</style></author><author><style face="normal" font="default"> Jones,T.M.</style></author><author><style face="normal" font="default"> Hyre,A.D.</style></author><author><style face="normal" font="default"> Melamed,M.L.</style></author><author><style face="normal" font="default"> Alper,A.</style></author><author><style face="normal" font="default"> Raggi,P.</style></author><author><style face="normal" font="default"> Leonard,M.B.</style></author></authors></contributors><titles><title><style face="normal" font="default">Association of serum intact parathyroid hormone with lower estimated glomerular filtration rate</style></title><secondary-title><style face="normal" font="default">Clinical Journal of The American Society of Nephrology: CJASN</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinical Journal of The American Society of Nephrology: CJASN</style></full-title></periodical><pages end="194" start="186">186-194</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default"> *Kidney Diseases/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Kidney/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Hydroxycholecalciferols)</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 7723-14-0 (Phosphorus)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default"> Health Surveys</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hydroxycholecalciferols/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Kidney Diseases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Kidney Diseases/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Kidney Diseases/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Models,Biological</style></keyword><keyword><style face="normal" font="default"> Nutrition Surveys</style></keyword><keyword><style face="normal" font="default"> Phosphorus/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> United States/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Up-Regulation</style></keyword></keywords><dates><year Day="0" Month="1" Year="2009">2009/1</year></dates><abstract><style face="normal" font="default">BACKGROUND AND OBJECTIVES: The prevalence of mineral metabolism abnormalities is almost universal in stage 5 chronic kidney disease (CKD), but the presence of abnormalities in milder CKD is not well characterized. DESIGN, SETTING, PARTICIPANTS, &amp; MEASUREMENTS: Data on adults > or =20 yr of age from the National Health and Nutrition Examination Survey 2003-2004 (N = 3949) were analyzed to determine the association between moderate declines in estimated GFR (eGFR), calculated using the Modfication of Diet in Renal Disease formula, and serum intact parathyroid hormone (iPTH) > or = 70 pg/ml. RESULTS: The geometric mean iPTH level was 39.3 pg/ml. The age-standardized prevalence of elevated iPTH was 8.2%, 19.3%, and 38.3% for participants with eGFR > or = 60, 45 to 59, and 30 to 44 ml/min/1.73 m(2), respectively (P-trend &lt; 0.001). After adjustment for age; race/ethnicity; sex; menopausal status; education; income; cigarette smoking; alcohol consumption; body mass index; hypertension; diabetes mellitus; vitamin D supplement use; total calorie and calcium intake; and serum calcium, phosphorus, and 25-hydroxyvitamin D levels-and compared with their counterparts with an eGFR > or = 60 ml/min/1.73 m(2)-the prevalence ratios of elevated iPTH were 2.30 and 4.69 for participants with an eGFR of 45 to 59 and 30 to 44 ml/min/1.73 m(2), respectively (P-trend &lt; 0.001). Serum phosphorus > or = 4.2 mg/dl and 25-hydroxyvitamin D &lt; 17.6 ng/ml were more common at lower eGFR levels. No association was present between lower eGFR and serum calcium &lt; 9.4 mg/dl. CONCLUSIONS: This study indicates that elevated iPTH levels are common among patients with moderate CKD</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Community and Preventive Medicine, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY 10016, USA. paul.muntner@mssm.eduJC - 101271570CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19019998</style></custom1><custom3><style face="normal" font="default">AS - Clin J Am Soc Nephrol. 4(1):186-94, 2009 Jan.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>44</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Nabi,F.</style></author><author><style face="normal" font="default"> Chang,S.M.</style></author><author><style face="normal" font="default"> Pratt,C.M.</style></author><author><style face="normal" font="default"> Paranilam,J.</style></author><author><style face="normal" font="default"> Peterson,L.E.</style></author><author><style face="normal" font="default"> Frias,M.E.</style></author><author><style face="normal" font="default"> Mahmarian,J.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Coronary artery calcium scoring in the emergency department: identifying which patients with chest pain can be safely discharged home</style></title><secondary-title><style face="normal" font="default">Annals of Emergency Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Annals of Emergency Medicine</style></full-title></periodical><pages end="229" start="220">220-229</pages><volume><style face="normal" font="default">56</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Chest Pain/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Coronary Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Emergency Service,Hospital</style></keyword><keyword><style face="normal" font="default"> 0 (Troponin)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography</style></keyword><keyword><style face="normal" font="default"> Chest Pain/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Patient Discharge</style></keyword><keyword><style face="normal" font="default"> Perfusion</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Troponin/bl [Blood]</style></keyword></keywords><dates><year Day="0" Month="9" Year="2010">2010/9</year></dates><abstract><style face="normal" font="default">STUDY OBJECTIVE: Coronary artery calcium scoring (CACS) is a simple and readily available test for identifying coronary artery disease. Our objective is to evaluate whether a CACS of zero will identify chest pain patients who can be safely discharged home, without need for further cardiac testing. METHODS: This was a prospective observational cohort study conducted at an urban tertiary care hospital of stable patients presenting to the emergency department (ED) with chest pain of uncertain cardiac cause. Patients with a normal initial troponin level, nonischemic ECG, and no history of coronary artery disease had stress myocardial perfusion imaging (SPECT) and CACS within 24 hours of ED admission. Cardiac events were defined as an acute coronary syndrome during the index hospitalization or in follow-up. CACS results were assessed in relation to SPECT findings and cardiac events. RESULTS: The 1,031 patients enrolled (mean [SD] age 54 [13] years) had a median CACS of 0 (61% with CACS of 0). The frequency of an abnormal SPECT ranged from 0.8% (CACS of 0) to17% (CACS>400). Cardiac events occurred in 32 patients (3.1%) during the index hospitalization (N=28) or after hospital discharge (N=4) (mean 7.4 [3.3] months). Only 2 events occurred in 625 patients with a CACS of 0 (0.3%; 95% confidence interval 0.04% to 1.1%). Thus, 2 of 32 patients with a cardiac event had a CACS of 0 (6%; 95% confidence interval 0.8% to 21%). Both of these patients developed increased troponin levels during their index visit but had normal serial ECG and SPECT study results and no cardiac events at 6-month follow-up. CONCLUSION: A majority of patients (61% in our sample) evaluated for chest pain of uncertain cardiac cause have a CACS of 0, which predicts both a normal SPECT result and an excellent short-term outcome. Our results suggest that patients with a CACS of 0 can be discharged home, without further cardiac testing. Copyright (c) 2010 American College of Emergency Physicians. Published by Mosby, Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Methodist DeBakey Heart and Vascular Center, The Methodist Hospital, Houston, TX, USACM - Comment in: Ann Emerg Med. 2010 Sep;56(3):230-2; PMID: 20363532JC - 8002646CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20138399</style></custom1><custom3><style face="normal" font="default">AS - Ann Emerg Med. 56(3):220-9, 2010 Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>282</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Nakamura,S.</style></author><author><style face="normal" font="default"> Ishibashi-Ueda,H.</style></author><author><style face="normal" font="default"> Niizuma,S.</style></author><author><style face="normal" font="default"> Yoshihara,F.</style></author><author><style face="normal" font="default"> Horio,T.</style></author><author><style face="normal" font="default"> Kawano,Y.</style></author></authors></contributors><titles><title><style face="normal" font="default">Coronary calcification in patients with chronic kidney disease and coronary artery disease</style></title><secondary-title><style face="normal" font="default">Clinical Journal of The American Society of Nephrology: CJASN</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinical Journal of The American Society of Nephrology: CJASN</style></full-title></periodical><pages end="1900" start="1892">1892-1900</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Renal Insufficiency,Chronic/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> *Renal Insufficiency,Chronic/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Autopsy</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Renal Insufficiency,Chronic/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><abstract><style face="normal" font="default">BACKGROUND AND OBJECTIVES: A close linkage between chronic kidney disease (CKD) and cardiovascular disease (CVD) has been demonstrated. Coronary artery calcification (CAC) is considered to be the causal link connecting them. The aim of the study is to determine the relationship between level of kidney function and the prevalence of CAC. DESIGN, SETTING, PARTICIPANTS, &amp; MEASUREMENTS: Autopsy subjects known to have coronary artery disease and a wide range of kidney function were studied. Patients without CKD were classified into five groups depending on estimated GFR (eGFR) and proteinuria: eGFR > or =60 ml/min/1.73 m(2) without proteinuria; CKD1/2: eGFR > or =60 ml/min/1.73 m(2) with proteinuria; CKD3: 60 ml/min/1.73 m(2) >eGFR > or =30 ml/min/1.73 m(2); CKD4/5: eGFR &lt;30 ml/min/1.73 m(2); and CKD5D: on hemodialysis. Intimal and medial calcification of the coronary arteries was evaluated. Risk factors for CVD and uremia were identified as relevant to CAC using logistic regression analysis. RESULTS: Intimal calcification of plaques was present in all groups, but was most frequent and severe in the CKD5D group and less so in the CKD4/5 and CKD3 groups. Risk factors included luminal stenosis, age, smoking, diabetes, calcium-phosphorus product, inflammation, and kidney function. Medial calcification was seen in a small number of CKD4/5 and CKD5D groups. Risk factors were use of calcium-containing phosphate binders, hemodialysis treatment, and duration. CONCLUSIONS: It was concluded that CAC was present in the intimal plaque of both nonrenal and renal patients. Renal function and traditional risks were linked to initimal calcification. Medial calcification occurred only in CKD patients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Hypertension and Nephrology, Department of Medicine, National Cardiovascular Center, Suita, Osaka, Japan. snakamur@hsp.ncvc.go.jpCM - Comment in: Clin J Am Soc Nephrol. 2009 Dec;4(12):1883-5; PMID: 19965543JC - 101271570CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19833908</style></custom1><custom3><style face="normal" font="default">AS - Clin J Am Soc Nephrol. 4(12):1892-900, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>425</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Nakamura,T.</style></author><author><style face="normal" font="default"> Kubo,N.</style></author><author><style face="normal" font="default"> Funayama,H.</style></author><author><style face="normal" font="default"> Sugawara,Y.</style></author><author><style face="normal" font="default"> Ako,J.</style></author><author><style face="normal" font="default"> Momomura,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Plaque characteristics of the coronary segment proximal to the culprit lesion in stable and unstable patients</style></title><secondary-title><style face="normal" font="default">Clinical Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinical Cardiology</style></full-title></periodical><pages end="12" start="E9">E9-12</pages><volume><style face="normal" font="default">32</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Acute Coronary Syndrome/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Angina Pectoris/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Stenosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Ultrasonography,Interventional</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 9007-41-4 (C-Reactive Protein)</style></keyword><keyword><style face="normal" font="default"> Acute Coronary Syndrome/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Acute Coronary Syndrome/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angina Pectoris/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Angina Pectoris/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> C-Reactive Protein/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Stenosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Coronary Stenosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Up-Regulation</style></keyword><keyword><style face="normal" font="default"> User-Computer Interface</style></keyword></keywords><dates><year Day="0" Month="8" Year="2009">2009/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Identifying vulnerable plaque is important for preventing an acute coronary event. The present study examined the relationship between the clinical presentation of coronary artery disease and the plaque characteristics of nonculprit segment assessed by virtual histology intravascular ultrasound (VH-IVUS). METHOD: We performed VH-IVUS analysis on nonculprit segments with &lt; 50% diameter stenosis in 91 patients (48 acute coronary syndrome [ACS] patients, 43 stable angina [SA] patients). RESULTS: ACS patients showed significantly higher ratio of dense calcium (7.9% +/- 1.0% versus 5.0% +/- 0.9%, p = 0.03) and necrotic core plaque (13.7% +/- 1.1% versus 8.6% +/- 1.1%, p = 0.001) compared with SA patients. VH-IVUS-derived thin-cap fibroatheroma (VH-TCFA) was more frequently observed in ACS patients compared with SA patients (64.6% versus 35.7%, p = 0.006). Among ACS patients, plasma high sensitivity C-reactive protein (hs-CRP) levels were significantly higher in patients with VH-TCFA than in patients without VH-TCFA (7.9 +/- 2.6 mg/l versus 1.6 +/- 0.3 mg/l, p = 0.004). CONCLUSION: ACS patients presented higher prevalence of VH-TCFA in nonculprit segment. Presence of VH-TCFA was associated with an increased level of plasma hs-CRP in ACS patients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Cardiovascular Division, Jichi Medical University, Saitama Medical Center, Saitama, Japan. tomonaka@omiya.jichi.ac.jpJC - de9, 7903272CP - United StatesPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19455670</style></custom1><custom3><style face="normal" font="default">AS - Clin Cardiol. 32(8):E9-12, 2009 Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>460</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Narumi,H.</style></author><author><style face="normal" font="default"> Yoshida,K.</style></author><author><style face="normal" font="default"> Hashimoto,N.</style></author><author><style face="normal" font="default"> Umehara,I.</style></author><author><style face="normal" font="default"> Funabashi,N.</style></author><author><style face="normal" font="default"> Yoshida,S.</style></author><author><style face="normal" font="default"> Komuro,I.</style></author></authors></contributors><titles><title><style face="normal" font="default">Increased subcutaneous fat accumulation has a protective role against subclinical atherosclerosis in asymptomatic subjects undergoing general health screening</style></title><secondary-title><style face="normal" font="default">International Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">International Journal of Cardiology</style></full-title></periodical><pages end="155" start="150">150-155</pages><volume><style face="normal" font="default">135</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Atherosclerosis/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Subcutaneous Fat/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> 0 (Adiponectin)</style></keyword><keyword><style face="normal" font="default"> 0 (adiponectin,human)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adiponectin/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Adipose Tissue/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Adipose Tissue/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Aortic Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Aortic Diseases/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Aortic Diseases/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Aortography</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Mass Screening</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Subcutaneous Fat/me [Metabolism]</style></keyword></keywords><dates><year Day="26" Month="6" Year="2009">2009/6/26</year></dates><abstract><style face="normal" font="default">PURPOSE: To evaluate the clinical role of subcutaneous fat accumulation in subclinical arteriosclerosis, using computed tomography (CT), we measured the subcutaneous fat area (SFA), the visceral fat area (VFA) and the VFA/SFA ratio and compared these with the calcium score of the whole aorta (CSWA) in asymptomatic subjects who were undergoing general health screening. METHODS: 122 consecutive asymptomatic subjects (40 female, mean age 56.2+/-8.4 years) were analyzed. Whole-body low-dose CT scan (mAs=50, slice thickness=5 mm) was performed. The SFA and VFA were measured at the umbilical level. Calcification of whole aorta was defined as an area with >90 HU and 1 mm(2), and CSWA was calculated using the modified Agatston method. RESULTS: Mean+/-SD of SFA, VFA and log CSWA were 158+/-67.1 cm(2), 94.0+/-44.8 cm(2), and 7.93+/-1.08, respectively. SFA was significantly and inversely correlated with log CSWA (r=-0.219, P=0.015) but VFA was not (r=0.105, P=0.250) and as a result, the VFA/SFA ratio was significantly and positively correlated with log CSWA (r=0.221, P=0.015). Subsequently, all predictor variables were used in a stepwise multiple regression model with log CSWA as dependent variable, and age, SFA and fasting plasma glucose significantly influenced log CSWA (P&lt;0.001) by the multiple regression formula Y=0.046X1***-0.005X2**+0.015X3*+4.426, (***P&lt;0.001, **P&lt;0.01, and *P&lt;0.05) where Y=log CSWA, X1=age, X2=SFA, and X3=fasting plasma glucose). CONCLUSIONS: SFA was significantly and inversely associated with log CSWA, in an independent fashion. These results suggest that subcutaneous fat accumulation might have a protective role against atherosclerosis in asymptomatic subjects</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, JapanJC - gqw, 8200291CP - NetherlandsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18593641</style></custom1><custom3><style face="normal" font="default">AS - Int J Cardiol. 135(2):150-5, 2009 Jun 26.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>54</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Nasir,K.</style></author><author><style face="normal" font="default"> McClelland,R.L.</style></author><author><style face="normal" font="default"> Blumenthal,R.S.</style></author><author><style face="normal" font="default"> Goff,D.C.,Jr.</style></author><author><style face="normal" font="default"> Hoffmann,U.</style></author><author><style face="normal" font="default"> Psaty,B.M.</style></author><author><style face="normal" font="default"> Greenland,P.</style></author><author><style face="normal" font="default"> Kronmal,R.A.</style></author><author><style face="normal" font="default"> Budoff,M.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Coronary artery calcium in relation to initiation and continuation of cardiovascular preventive medications: The Multi-Ethnic Study of Atherosclerosis (MESA)</style></title><secondary-title><style face="normal" font="default">Circulation</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Circulation</style></full-title></periodical><pages end="235" start="228">228-235</pages><volume><style face="normal" font="default">Cardiovascular</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Antihypertensive Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Aspirin/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Atherosclerosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Atherosclerosis/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Ethnic Groups</style></keyword><keyword><style face="normal" font="default"> *Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> 0 (Antihypertensive Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)</style></keyword><keyword><style face="normal" font="default"> 50-78-2 (Aspirin)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medication Therapy Management</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Risk Management</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States/ep [Epidemiology]</style></keyword></keywords><dates><year Day="0" Month="5" Year="2010">2010/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: Whether measuring and reporting of coronary artery calcium scores (CACS) might lead to changes in cardiovascular risk management is not established. In this observational study, we examined whether high baseline CACS were associated with the initiation as well continuation of new lipid-lowering medication (LLM), blood pressure-lowering medication (BPLM), and regular aspirin (ASA) use in a multi-ethnic population-based cohort. METHODS AND RESULTS: The Multi-Ethnic Study of Atherosclerosis (MESA) is a prospective cohort study of 6814 participants free of clinical cardiovascular disease at entry who underwent CAC testing at baseline examination (examination 1). Information on LLM, BPLM, and regular ASA usage was also obtained at baseline and at exams 2 and 3 (average of 1.6 and 3.2 years after baseline, respectively). In this study, we examined (1) initiation of these medications at examination 2 among participants not taking these medications at baseline; and (2) continuation of medication use to examination 3 among participants already on medication at baseline. Among MESA participants, initiation of LLM, BPLM, and ASA was greater in those with higher CACS. After taking into account age, sex, race, MESA site, LDL cholesterol, diabetes mellitus, body mass index, smoking status, hypertension, systolic blood pressure, and socioeconomic status (income, education, and health insurance), the risk ratios for medication initiation comparing those with CACS >400 versus CACS=0 were 1.53 (95% confidence interval [CI], 1.08, 2.15) for LLM, 1.55 (95% CI, 1.10 to 2.17) for BPLM, and 1.32 (95% CI, 1.03 to 1.69) for ASA initiation, respectively. The risk ratios for medication continuation among those with CAC >400 versus CACS=0 were 1.10 (95% CI, 1.01 to 1.20) for LLM, 1.05 (95% CI, 1.02 to 1.08) for BPLM, and 1.14 (95% CI, 1.04 to 1.25) for ASA initiation, respectively. CONCLUSIONS: CACS >400 was associated with a higher likelihood of initiation and continuation of LLM, BPLM, and ASA. The association was weaker for continuation than for initiation of these preventive therapies</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Ciccarone Preventive Cardiology Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. knasir1@jhmi.edu &lt;knasir1@jhmi.edu>CM - Comment in: Circ Cardiovasc Qual Outcomes. 2010 May;3(3):223-5; PMID: 20484200JC - 101489148CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - N01 HC 95169 (United States NHLBI NIH HHS)NO - N01-HC-95159 (United States NHLBI NIH HHS)NO - N01-HC-95160 (United States NHLBI NIH HHS)NO - N01-HC-95161 (United States NHLBI NIH HHS)NO - N01-HC-95162 (United States NHLBI NIH HHS)NO - N01-HC-95163 (United States NHLBI NIH HHS)NO - N01-HC-95164 (United States NHLBI NIH HHS)NO - N01-HC-95165 (United States NHLBI NIH HHS)NO - R01-HL-63963-01A1 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20371760</style></custom1><custom3><style face="normal" font="default">AS - Circ Cardiovasc Qual Outcomes. 3(3):228-35, 2010 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>185</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Nasir,K.</style></author><author><style face="normal" font="default"> Katz,R.</style></author><author><style face="normal" font="default"> Al-Mallah,M.</style></author><author><style face="normal" font="default"> Takasu,J.</style></author><author><style face="normal" font="default"> Shavelle,D.M.</style></author><author><style face="normal" font="default"> Carr,J.J.</style></author><author><style face="normal" font="default"> Kronmal,R.</style></author><author><style face="normal" font="default"> Blumenthal,R.S.</style></author><author><style face="normal" font="default"> O'Brien,K.</style></author><author><style face="normal" font="default"> Budoff,M.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Relationship of aortic valve calcification with coronary artery calcium severity: the Multi-Ethnic Study of Atherosclerosis (MESA)</style></title><secondary-title><style face="normal" font="default">Journal of cardiovascular computed tomography</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of cardiovascular computed tomography</style></full-title></periodical><pages end="46" start="41">41-46</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aortic Valve/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Heart Valve Diseases/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> *Heart Valve Diseases/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sex Distribution</style></keyword><keyword><style face="normal" font="default"> Statistics as Topic</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed/ut [Utilization]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> United States/eh [Ethnology]</style></keyword></keywords><dates><year Day="0" Month="1" Year="2010">2010/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Aortic valve calcification (AVC) and atherosclerosis share causative and pathologic features. OBJECTIVE: We evaluated the relationship between AVC and coronary artery calcium (CAC) severity in the Multi-Ethnic Study of Atherosclerosis (MESA). METHODS: Men and women aged 45-84 years (n=6809; mean age, 62 years) were studied. The presence and burden of AVC and CAC were determined by noncontrast cardiac computed tomography. Relative risk regression was used to model the probability of AVC as a function of CAC > 0 as well as CAC categories (0, 1-99, 100-399, and > or = 400) with the reference group being CAC=0. RESULTS: The prevalence of AVC and CAC was 13% and 50%, respectively. Among those without CAC, the prevalence of AVC was 5% and increased across levels of CAC severity such that 14%, 25%, and 38% had AVC with increasing CAC scores of 1-99, 100-399, and > or = 400, respectively (P for trend&lt;0.0001). After controlling for patient demographic factors and cardiovascular risk factors, the prevalence ratio of AVC among those with mild CAC (1-99) was 1.83 (95% CI, 1.45-2.31) and increased to 3.36 (95% CI, 2.56-4.42) for CAC > or = 400. Similar statistically significant increased risk of AVC was found when CAC was assessed as a continuous variable. CONCLUSION: Our study shows that AVC is independently associated with increasing severity of CAC. 2010 Society of Cardiovascular Computed Tomography. Published by Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiology, Blalock 524 C, Johns Hopkins University, 600N Wolfe Street, Baltimore, MD 21287, USA. knasir1@jhmi.eduCM - Comment in: J Cardiovasc Comput Tomogr. 2010 Jan-Feb;4(1):47-8; PMID: 20159628JC - 101308347CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - N01 HC 95169 (United States NHLBI NIH HHS)NO - N01-HC-95159 (United States NHLBI NIH HHS)NO - N01-HC-95160 (United States NHLBI NIH HHS)NO - N01-HC-95161 (United States NHLBI NIH HHS)NO - N01-HC-95162 (United States NHLBI NIH HHS)NO - N01-HC-95163 (United States NHLBI NIH HHS)NO - N01-HC-95164 (United States NHLBI NIH HHS)NO - N01-HC-95165 (United States NHLBI NIH HHS)NO - R01 HL071739 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20159627</style></custom1><custom3><style face="normal" font="default">AS - J Cardiovasc Comput Tomogr. 4(1):41-6, 2010 Jan-Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>389</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Nasser,T.</style></author><author><style face="normal" font="default"> Qari,F.</style></author></authors></contributors><titles><title><style face="normal" font="default">Pheochromocytoma, papillary thyroid carcinoma</style></title><secondary-title><style face="normal" font="default">Saudi Medical Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Saudi Medical Journal</style></full-title></periodical><pages end="1090" start="1087">1087-1090</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Adrenal Gland Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Neoplasms,Multiple Primary/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Pheochromocytoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Thyroid Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> 5001-33-2 (Metanephrine)</style></keyword><keyword><style face="normal" font="default"> Adrenal Gland Neoplasms/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Adrenalectomy</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> DNA Mutational Analysis</style></keyword><keyword><style face="normal" font="default"> EC 2-7-10-1 (Proto-Oncogene Proteins c-ret)</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Metanephrine/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Neoplasms,Multiple Primary/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Pheochromocytoma/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Proto-Oncogene Proteins c-ret/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Thyroid Neoplasms/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Thyroidectomy</style></keyword><keyword><style face="normal" font="default"> Ultrasonography</style></keyword><keyword><style face="normal" font="default"> Urine</style></keyword></keywords><dates><year Day="0" Month="8" Year="2009">2009/8</year></dates><isbn><style face="normal" font="default">0379-5284</style></isbn><abstract><style face="normal" font="default">A 53-year-old woman presented with labile and difficult to control hypertension on 3 different anti-hypertensive medications. Abdominal computed tomography and ultrasonography of the thyroid gland showed a 1.8 cm thyroid nodule. Fine needle aspiration biopsy of the thyroid nodule revealed papillary thyroid carcinoma. Serum thyroid stimulating hormone and free thyroxine, calcitonin, carcinoembryonic antigen, intact parathyroid hormone, and calcium levels were within normal limits. A 24-hour urine metanephrine showed significant elevation in urine metanephrine of approximately 3 times the upper limit of normal, and the result of 131I-metaiodobenzyleguanjdjne (131I-MIBG) scintigraphy confirmed that the adrenal mass was pheochromocytoma. Right adrenalectomy and total thyroidectomy were performed. The final pathology was pheochromocytoma and papillary thyroid carcinoma. An analysis of c-ret porto-oncogene mutation yielded a negative result. This unusual association of 2 tumors represents a new entity</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Endocrinology, King Khalid National Guard Hospital, Jeddah, Kingdom of Saudi ArabiaJC - dyw, 7909441CP - Saudi ArabiaPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19668893</style></custom1><custom3><style face="normal" font="default">AS - Saudi Med J. 30(8):1087-90, 2009 Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>439</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Nasu,K.</style></author><author><style face="normal" font="default"> Tsuchikane,E.</style></author><author><style face="normal" font="default"> Katoh,O.</style></author><author><style face="normal" font="default"> Tanaka,N.</style></author><author><style face="normal" font="default"> Kimura,M.</style></author><author><style face="normal" font="default"> Ehara,M.</style></author><author><style face="normal" font="default"> Kinoshita,Y.</style></author><author><style face="normal" font="default"> Matsubara,T.</style></author><author><style face="normal" font="default"> Matsuo,H.</style></author><author><style face="normal" font="default"> Asakura,K.</style></author><author><style face="normal" font="default"> Asakura,Y.</style></author><author><style face="normal" font="default"> Terashima,M.</style></author><author><style face="normal" font="default"> Takayama,T.</style></author><author><style face="normal" font="default"> Honye,J.</style></author><author><style face="normal" font="default"> Hirayama,A.</style></author><author><style face="normal" font="default"> Saito,S.</style></author><author><style face="normal" font="default"> Suzuki,T.</style></author></authors></contributors><titles><title><style face="normal" font="default">Effect of fluvastatin on progression of coronary atherosclerotic plaque evaluated by virtual histology intravascular ultrasound</style></title><secondary-title><style face="normal" font="default">Jacc: Cardiovascular Interventions</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Jacc: Cardiovascular Interventions</style></full-title></periodical><pages end="696" start="689">689-696</pages><volume><style face="normal" font="default">2</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Artery Disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Fatty Acids,Monounsaturated/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Indoles/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Ultrasonography,Interventional</style></keyword><keyword><style face="normal" font="default"> *User-Computer Interface</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol,LDL)</style></keyword><keyword><style face="normal" font="default"> 0 (Fatty Acids,Monounsaturated)</style></keyword><keyword><style face="normal" font="default"> 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)</style></keyword><keyword><style face="normal" font="default"> 0 (Indoles)</style></keyword><keyword><style face="normal" font="default"> 9007-41-4 (C-Reactive Protein)</style></keyword><keyword><style face="normal" font="default"> 93957-54-1 (fluvastatin)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> C-Reactive Protein/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cholesterol,LDL/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Fatty Acids,Monounsaturated/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hydroxymethylglutaryl-CoA Reductase Inhibitors/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Indoles/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="7" Year="2009">2009/7</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The aim of this study was to evaluate the effect of treatment with statins on the progression of coronary atherosclerotic plaques of a nonculprit vessel by serial volumetric virtual histology (VH) intravascular ultrasound (IVUS). BACKGROUND: Recent clinical trials have demonstrated a reduction of atherosclerotic plaque, yet whether statin therapy affects the change in components of plaque remains unknown. METHODS: This study was a nonrandomized and nonblinded design. Eighty patients with stable angina pectoris were divided into either the fluvastatin group (n = 40) or the control group (n = 40) according to their total or low-density lipoprotein (LDL) cholesterol level. The volume of each plaque component (dense calcium, fibrous tissue, fibro-fatty, or necrotic core) was evaluated at baseline and at 12-month follow-up. RESULTS: The LDL cholesterol and high-sensitivity C-reactive protein (hsCRP) levels in the fluvastatin group were significantly decreased at time of follow-up. In VH IVUS findings, fibro-fatty volume was significantly decreased (baseline 80.1 +/- 57.9 mm(3) vs. follow-up 32.5 +/- 27.7 mm(3), p &lt; 0.0001) and fibrous tissue volume was increased (baseline 146.5 +/- 85.6 mm(3) vs. follow-up 163.3 +/- 94.5 mm(3), p &lt; 0.0001) in the fluvastatin group. In the control group, the volumes of all plaque components without fibrous tissue were significantly increased. Change in fibro-fatty volume has a significant correlation with a change in LDL cholesterol level (R = 0.703, p &lt; 0.0001) and change in hsCRP level (R = 0.357, p = 0.006). CONCLUSIONS: One-year lipid-lowering therapy by fluvastatin showed significant regression of plaque volume and alterations in atherosclerotic plaque composition with a significant reduction of fibro-fatty volume</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan. nasu@heartcenter.or.jpCM - Comment in: JACC Cardiovasc Interv. 2009 Jul;2(7):697-700; PMID: 19628195]JC - 101467004CP - United StatesPT - Controlled Clinical TrialPT - Journal ArticlePT - Multicenter StudyLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19628194</style></custom1><custom3><style face="normal" font="default">AS - JACC Cardiovasc Interv. 2(7):689-96, 2009 Jul.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>339</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">nez,Alvaro S.</style></author><author><style face="normal" font="default"> Marc&amp;#x00E9</style></author><author><style face="normal" font="default">n R</style></author><author><style face="normal" font="default"> Teruel,J.L.</style></author><author><style face="normal" font="default"> ndez,Rodr</style></author><author><style face="normal" font="default"> Pascual,J.</style></author><author><style face="normal" font="default"> Galeano,C.</style></author><author><style face="normal" font="default"> Villacorta,J.</style></author><author><style face="normal" font="default"> Burgos,F.J.</style></author><author><style face="normal" font="default"> Ortu&amp;#x00F1</style></author><author><style face="normal" font="default">o J</style></author></authors></contributors><titles><title><style face="normal" font="default">Management of chronic kidney disease after renal transplantation: is it different from nontransplant patients?</style></title><secondary-title><style face="normal" font="default">Transplantation Proceedings</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Transplantation Proceedings</style></full-title></periodical><pages end="2411" start="2409">2409-2411</pages><volume><style face="normal" font="default">41</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Kidney Failure,Chronic/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> *Kidney Transplantation/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> 0 (Angiotensin-Converting Enzyme Inhibitors)</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol,LDL)</style></keyword><keyword><style face="normal" font="default"> 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)</style></keyword><keyword><style face="normal" font="default"> 9007-73-2 (Ferritins)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angiotensin-Converting Enzyme Inhibitors/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cholesterol,LDL/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Ferritins/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Hypertension/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Kidney Transplantation/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="7" Year="2009">2009/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: The Kidney Disease Quality Initiative (K/DOQI) of the National Kidney Foundation has published guidelines for the diagnosis and management of chronic kidney disease (CKD). Renal transplant recipients frequently have CKD and complications similar to native kidney disease patients. The purpose of the present study was to compare the management of CKD complications of transplant recipients and nontransplant patients. PATIENTS AND METHODS: Eighty three renal transplant recipients with CKD stages 4T and 5T were compared with 83 nontransplant CKD patients matched by CKD stage. RESULTS: There were no differences between the groups in serum hemoglobin, prevalence of anemia, and percentage of patients treated with erythropoiesis-stimulating agents, but serum ferritin levels were higher among recipients (186.3 +/- 161.3 vs 119.1 +/- 113.4 ng/mL; P = .003). Mean blood pressure (BP) was similar in both groups but a systolic BP > 130 mm Hg was more frequent among recipients (83.3% vs 72.6%). More recipients were treated with either angiotensin-converting enzyme (ACE)-inhibitors or angiotensin receptor antagonist (43.3% vs 8.4%; P &lt; .001). Low-density lipoprotein cholesterol was lower in recipients (108.9 +/- 30.3 vs 120.8 +/- 39.5 mg/dL; P = .033) and a higher percentage was on statin treatment (44.6% vs 28.9%; P = .053). Serum calcium was higher in transplant recipients (9.5 +/- 0.8 vs 8.9 +/- 0.7 mg/dL; P &lt; .005) and phosphate was lower (3.9 +/- 0.9 vs 4.2 +/- 1.1; P = .043); there were no differences in intact parathyroid hormone blood levels. CONCLUSIONS: The management of renal transplant recipients is no worse than that of nontransplant patients. However, in both populations, some parameters are far from the target recommended by the guidelines</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Nephrology, Hospital Ram&amp;#x00F3;n y Cajal, Madrid, Spain. guduld5@hotmail.comJC - we9, 0243532CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19715935</style></custom1><custom3><style face="normal" font="default">AS - Transplant Proc. 41(6):2409-11, 2009 Jul-Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>218</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Ngo,D.T.</style></author><author><style face="normal" font="default"> Sverdlov,A.L.</style></author><author><style face="normal" font="default"> McNeil,J.J.</style></author><author><style face="normal" font="default"> Horowitz,J.D.</style></author></authors></contributors><titles><title><style face="normal" font="default">Does vitamin D modulate asymmetric dimethylarginine and C-reactive protein concentrations?</style></title><secondary-title><style face="normal" font="default">American Journal of Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Medicine</style></full-title></periodical><pages end="341" start="335">335-341</pages><volume><style face="normal" font="default">123</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Arginine/aa [Analogs &amp; Derivatives]</style></keyword><keyword><style face="normal" font="default"> *C-Reactive Protein/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Vitamin D/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> 0 (Angiotensin-Converting Enzyme Inhibitors)</style></keyword><keyword><style face="normal" font="default"> 0 (dimethylarginine)</style></keyword><keyword><style face="normal" font="default"> 0 (Receptors,Angiotensin)</style></keyword><keyword><style face="normal" font="default"> 1406-16-2 (Vitamin D)</style></keyword><keyword><style face="normal" font="default"> 19356-17-3 (Calcifediol)</style></keyword><keyword><style face="normal" font="default"> 74-79-3 (Arginine)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 9007-41-4 (C-Reactive Protein)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angiotensin-Converting Enzyme Inhibitors</style></keyword><keyword><style face="normal" font="default"> Arginine/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcifediol/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Radioimmunoassay</style></keyword><keyword><style face="normal" font="default"> Receptors,Angiotensin/ai [Antagonists &amp; Inhibitors]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Seasons</style></keyword><keyword><style face="normal" font="default"> Sex Characteristics</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Vitamin D deficiency is associated with significant increases in the incidence of cardiovascular risk factors and mortality. However, the mechanisms underlying this association remain unclear. The current study evaluated the possible relationships among vitamin D status, endothelial dysfunction, and inflammation. METHODS: Plasma concentrations of 25-hydroxyvitamin D(3) were determined by radioimmunoassay in a normal population cohort (n=253) aged 51 to 77 years (mean 63.4+/-6 years). Asymmetric dimethylarginine, a marker/mediator of endothelial dysfunction, was assayed by high-performance liquid chromatography. High-sensitivity C-reactive protein levels were used as a marker of inflammatory activation. RESULTS: On univariate analyses, low 25-hydroxyvitamin D(3) levels were inversely correlated with asymmetric dimethylarginine concentrations, high-sensitivity C-reactive protein levels, and body mass index. Seasonal fluctuations in 25-hydroxyvitamin D(3) levels were associated with reciprocal asymmetric dimethylarginine concentration fluctuations. Hypertension and treatment with an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker also were associated with low 25-hydroxyvitamin D(3) levels. On multiple linear analysis, both asymmetric dimethylarginine (beta=-0.19, P=.003) and high-sensitivity C-reactive protein (beta=-0.14, P=.03) concentrations were inversely correlated with plasma 25-hydroxyvitamin D(3) concentrations; other significant correlates were male gender (beta=0.19, P=.003), calcium levels (beta=0.14, P=.03), and use of angiotensin-converting enzyme inhibitor (beta=-0.17, P=.007). CONCLUSION: Low 25-hydroxyvitamin D(3) levels are associated with markers of endothelial dysfunction and inflammatory activation, representing potential mechanisms for incremental coronary risk</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Pharmacy, University of South Australia, South Australia, AustraliaJC - 0267200, 3juCP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20362753</style></custom1><custom3><style face="normal" font="default">AS - Am J Med. 123(4):335-41, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>497</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Nicol,E.D.</style></author><author><style face="normal" font="default"> Stirrup,J.</style></author><author><style face="normal" font="default"> Roughton,M.</style></author><author><style face="normal" font="default"> Padley,S.P.</style></author><author><style face="normal" font="default"> Rubens,M.B.</style></author></authors></contributors><titles><title><style face="normal" font="default">64-Channel cardiac computed tomography: intraobserver and interobserver variability (part 1): coronary angiography</style></title><secondary-title><style face="normal" font="default">Journal of Computer Assisted Tomography</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Computer Assisted Tomography</style></full-title></periodical><pages end="168" start="161">161-168</pages><volume><style face="normal" font="default">33</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Angiography/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> *Coronary Stenosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> 0 (Contrast Media)</style></keyword><keyword><style face="normal" font="default"> 66108-95-0 (Iohexol)</style></keyword><keyword><style face="normal" font="default"> 73334-07-3 (iopromide)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Contrast Media/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Image Processing,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Iohexol/aa [Analogs &amp; Derivatives]</style></keyword><keyword><style face="normal" font="default"> Iohexol/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> Likelihood Functions</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Observer Variation</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="3" Year="2009">2009/3</year></dates><abstract><style face="normal" font="default">OBJECTIVES: To assess intraobserver and interobserver variation in computed tomography coronary angiography (CTA) in 3 patient cohorts at very low, low-to-intermediate, and intermediate-to-high likelihood of coronary artery disease (CAD). METHODS: One hundred thirty-three patients underwent 64-channel CTA. Coronary arteries were analyzed by 2 experienced blinded observers and reported as having 0%, 1% to 29%, 30% to 49%, 50% to 69%, 70% to 99%, or 100% stenosis. Intraobserver and interobserver agreement was calculated at cohort level and combined. RESULTS: Overall intraobserver and interobserver agreement was good (kappa = 0.74 and kappa = 0.78, respectively). Segmental agreement for stenoses 50% or greater and 70% or greater was greater than 96%. Disagreements were more likely in the presence of noneccentric calcification for both intraobserver (odds ratio = 0.45 and 0.22) and interobserver (odds ratio = 0.40 and 0.10) measurements. CONCLUSIONS: Interobserver and intraobserver variability for the detection of coronary stenoses on CTA is good and justifies routine clinical use. The presence of noneccentric calcium and mixed plaque morphology are important causes of disagreement</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Royal Brompton Hospital and Harefield NHS Trust, London, United Kingdom. cyprusdoc@doctors.org.ukJC - hvt, 7703942CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19346839</style></custom1><custom3><style face="normal" font="default">AS - J Comput Assist Tomogr. 33(2):161-8, 2009 Mar-Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>96</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Nicolae,I.</style></author><author><style face="normal" font="default"> Schipor,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">PTH-independent hypercalcaemia and non-melanoma skin cancer</style></title><secondary-title><style face="normal" font="default">Journal of the European Academy of Dermatology &amp; Venereology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of the European Academy of Dermatology &amp; Venereology</style></full-title></periodical><pages end="452" start="449">449-452</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Carcinoma,Basal Cell/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Hypercalcemia/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Keratoacanthoma/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Skin Neoplasms/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 0 (Serum Albumin)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcium/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Basal Cell/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Electrocardiography</style></keyword><keyword><style face="normal" font="default"> Extracellular Fluid/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypercalcemia/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Keratoacanthoma/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Models,Biological</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Romania/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Serum Albumin/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Skin Neoplasms/me [Metabolism]</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Recently, it became more evident that skin is a target for neuroendocrine signals. AIMS: (1) To evaluate the relationship between tumour aggressiveness and hypercalcaemia in patients with non-melanoma skin cancer; (2) to identify clinical, functional, biological alterations caused by this setting; (3) calcium redistribution from extracellular fluids to intracellular compartments; (4) to describe several molecular aspects of hypercalcaemia development. MATERIALS AND METHODS: This study was conducted between January 2000 and May 2009 in Dermatoveneorological Center, Bucharest. From the 1232 cases that were investigated, there were 32 patients with keratoachantoma, 468 patients with basal cell carcinoma, 412 patients with squamous cell carcinoma and 320 healthy volunteers. All the patients were screened by clinical and paraclinical examinations (haematology, biochemistry, immunology). After biochemical confirmation of hypercalcaemia, patients had endocrine tests, electrocardiography and imagistic approaches. Total serum calcium was measured in extracellular fluids (serum, urine) by spectrophotometric methods. Ionized calcium was calculated depending on total serum calcium and total proteins. Corrected serum total calcium (cTCa) levels were calculated using albumin and total serum calcium levels. In tumour tissues and intact skin, calcium was assayed by physical methods of analysis: Instrumental Neutron Activation Analysis (INAA), Proton-Induced X-ray Emission (PIXE). Intact PTH was measured by ELISA. RESULTS: PTH-independent hypercalcaemia prevalence is low in SCC patients (1.21%). Hypercalcaemia manifestations are multiple including: digestive, renal, neuromuscular, and cardiovascular abnormalities. In these patients, intact PTH (iPTH) is normal, urinary calcium is decreased, serum albumin is reduced, and calcium concentration in tumour tissue is significantly increased compared to healthy tissue. CONCLUSIONS: PTH-independent hypercalcaemia has a low prevalence in SCC patients. Hypercalcaemia is correlated with susceptibility to develop metastases in SCC. A possible mechanism is PTHrp hypersecretion by malignant keratinocytes</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Biochemistry Department, Dermatovenerological Center, Bucharest, Romania. koranik85@yahoo.comJC - c2r, 9216037CP - NetherlandsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19778357</style></custom1><custom3><style face="normal" font="default">AS - J Eur Acad Dermatol Venereol. 24(4):449-52, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>518</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Nicolaou,P.</style></author><author><style face="normal" font="default"> Kranias,E.G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Role of PP1 in the regulation of Ca cycling in cardiac physiology and pathophysiology</style></title><secondary-title><style face="normal" font="default">Frontiers in Bioscience</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Frontiers in Bioscience</style></full-title></periodical><pages end="3585" start="3571">3571-3585</pages><volume><style face="normal" font="default">14</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Heart/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Protein Phosphatase 1/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Catalytic Domain</style></keyword><keyword><style face="normal" font="default"> EC 3-1-3-16 (Protein Phosphatase 1)</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardial Contraction</style></keyword><keyword><style face="normal" font="default"> Protein Phosphatase 1/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><abstract><style face="normal" font="default">Type 1 protein phosphatase (PP1) is a critical regulator of several cellular processes. In the heart, it mediates restoration of contractility to basal levels by dephosphorylating key phospho-proteins, after beta-adrenergic stimulation. PP1 is a holoenzyme consisting of its catalytic and regulatory subunits, which anchor the catalytic subunit to desired subcellular locations, define substrate specificity and modulate catalytic activity. At the level of the cardiac sarcoplasmic reticulum (SR), PP1 is regulated by Inhibitor-1 (I-1) and Inhibitor-2 (I-2), which modulate its activity, and the striated muscle-specific glycogen-targeting subunit, GM/RGL, which targets it to the SR vicinity. PP1 regulation is highly important in maintaining cardiac function under physiological conditions. In fact, aberrant Ca handling and depressed contractility in heart failure have been, at least partly, attributed to increases in PP1 activity, mediated by impaired regulation via its inhibitors. Importantly, increases in the level and activity of I-1 and I-2 in animal models have been successful in ameliorating dysfunction and remodeling in heart failure, suggesting that PP1 inhibition may be a plausible therapeutic strategy in heart failure</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Pharmacology and Cell Biophysics, University of Cincinnati College of Medicine, Cincinnati, OH, 45267-0575, USAJC - 9709506, 9702166, cueCP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - HL-26507 (United States NHLBI NIH HHS)NO - HL-64018 (United States NHLBI NIH HHS)NO - HL-77101 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19273294</style></custom1><custom3><style face="normal" font="default">AS - Front Biosci. 14:3571-85, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>306</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Nieman,K.</style></author><author><style face="normal" font="default"> Galema,T.W.</style></author><author><style face="normal" font="default"> Neefjes,L.A.</style></author><author><style face="normal" font="default"> Weustink,A.C.</style></author><author><style face="normal" font="default"> Musters,P.</style></author><author><style face="normal" font="default"> Moelker,A.D.</style></author><author><style face="normal" font="default"> Mollet,N.R.</style></author><author><style face="normal" font="default"> de,Visser R.</style></author><author><style face="normal" font="default"> Boersma,E.</style></author><author><style face="normal" font="default"> de Feijter,P.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Comparison of the value of coronary calcium detection to computed tomographic angiography and exercise testing in patients with chest pain</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="1504" start="1499">1499-1504</pages><volume><style face="normal" font="default">104</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Chest Pain/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Exercise Test</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Chest Pain/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Chest Pain/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Electrocardiography</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Image Interpretation,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="1" Month="12" Year="2009">2009/12/1</year></dates><abstract><style face="normal" font="default">The aim of this study was to investigate the value of coronary calcium detection by computed tomography compared to computed tomographic angiography (CTA) and exercise testing to detect obstructive coronary artery disease (CAD) in patients with stable chest pain. A total of 471 consecutive patients with new stable chest complaints were scheduled to undergo dual-source multislice computed tomography (Siemens, Germany; coronary calcium score [CCS] and coronary CTA) and exercise electrocardiography (XECG). Clinically driven invasive quantitative angiography was performed in 98 patients. Only 3 of 175 patients (2%) with a negative CCS had significant CAD on CT angiogram, with only 1 confirmed by quantitative angiography. In patients with a high calcium score (Agatston score >400), CTA could exclude significant CAD in no more than 4 of 65 patients (6%). In patients with a low-intermediate CCS, CTA more often yielded diagnostic results compared to XECG and could rule out obstructive CAD in 56% of patients. For patients with CAD on CT angiogram, those with abnormal exercise electrocardiographic results more often showed severe CAD (p &lt;0.034). In patients with diagnostic results for all tests, the sensitivity and specificity to detect >50% quantitative angiographic diameter stenosis were 100% and 15% for CCS >0, 82% and 64% for CCS >100, 97% and 36% for CTA, and 70% and 76% for XECG, respectively. In conclusion, nonenhanced computed tomography for calcium detection is a reliable means to exclude obstructive CAD in stable, symptomatic patients. Contrast-enhanced CTA can exclude significant CAD in patients with a low-intermediate CCS but is of limited value in patients with a high CCS</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands. koennieman@hotmail.comJC - 3dq, 0207277CP - United StatesPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19932782</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 104(11):1499-504, 2009 Dec 1.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>207</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">nig,A.</style></author><author><style face="normal" font="default"> Bleie &amp;#x00D8</style></author></authors></contributors><titles><title><style face="normal" font="default">Intravascular ultrasound radiofrequency analysis of the lesion segment profile in ACS patients</style></title><secondary-title><style face="normal" font="default">Clinical Research in Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinical Research in Cardiology</style></full-title></periodical><pages end="91" start="83">83-91</pages><volume><style face="normal" font="default">99</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Acute Coronary Syndrome/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Ultrasonography,Interventional/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword></keywords><dates><year Day="0" Month="2" Year="2010">2010/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: Intravascular ultrasound radiofrequency analysis (IVUS-RF) characterizes plaque components as necrotic core (NC) and dense calcium (DC). The aim of this study was to perform an IVUS-RF derived analysis of the lesion segment profile in acute coronary syndrome (ACS) patients. Therefore, we compared the site of the minimum lumen area--cross sectional area (mla-CSA) with the worst lesion site--CSA (ws-CSA) defined by the maximum NC site. METHODS: We performed IVUS-RF derived plaque composition and plaque-type classification analysis in 48 ACS patients with 48 culprit (CL) and 69 non-culprit lesions (NCL). RESULTS: The plaque dimension of the mla- and ws-CSA was significantly different regarding the lumen area (5.18 +/- 2.09 mm2 vs. 6.72 +/- 2.73 mm2, p = 0.0013) and the vessel area (14.80 +/- 5.86 mm2 vs. 17.15 +/- 4.94 mm2, p = 0.0142). The absolute plaque composition was also significantly different regarding the DC tissue (0.71 +/- 0.57 mm2 vs. 0.98 +/- 0.54 mm2, p = 0.0102) and the NC tissue (1.41 +/- 1.28 mm2 vs. 1.85 +/- 1.37 mm2, p = 0.0469). The plaque-type classification revealed significantly more thin cap fibroatheroma (TCFA) lesions at the ws-CSA compared to the mla-CSA (n = 53/89.8% vs. n = 26/44.1%, p &lt; 0.0001). In the majority of the CL and NCL lesion segments the ws-CSA was located proximal to the mla-CSA compared to the distal location (n = 65/55.6% vs. n = 23/19.7%). CONCLUSIONS: In the majority of the lesion segments in ACS patients the ws-CSA is not identical with the mla-CSA. The ws-CSA compared to mla-CSA presented with significantly more NC and DC tissue resulting in a higher amount of TCFA lesions</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiology, Department of Medicine, Medizinische Klinik und Poliklinik, Ludwig-Maximilians-Universit&amp;#x00E4;t, Ziemssenstr. 1, Campus Innenstadt, 80336 Munich, Germany. Andreas.Koenig@med.uni-muenchen.deJC - 101264123CP - GermanyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19768480</style></custom1><custom3><style face="normal" font="default">AS - Clin. res. cardiol.. 99(2):83-91, 2010 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>11</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Nishino,M.</style></author><author><style face="normal" font="default"> Hoshida,S.</style></author><author><style face="normal" font="default"> Taniike,M.</style></author><author><style face="normal" font="default"> Kato,H.</style></author><author><style face="normal" font="default"> Egami,Y.</style></author><author><style face="normal" font="default"> Shutta,R.</style></author><author><style face="normal" font="default"> Yamaguchi,H.</style></author><author><style face="normal" font="default"> Tanaka,K.</style></author><author><style face="normal" font="default"> Tanouchi,J.</style></author><author><style face="normal" font="default"> Yamada,Y.</style></author></authors></contributors><titles><title><style face="normal" font="default">Vulnerable disease may induce neointimal coverage after sirolimus-eluting stent implantation</style></title><secondary-title><style face="normal" font="default">American Heart Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Heart Journal</style></full-title></periodical><pages end="569" start="564">564-569</pages><volume><style face="normal" font="default">160</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Stenosis/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Drug-Eluting Stents</style></keyword><keyword><style face="normal" font="default"> *Immunosuppressive Agents/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Sirolimus/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Tunica Intima/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> 0 (Immunosuppressive Agents)</style></keyword><keyword><style face="normal" font="default"> 53123-88-9 (Sirolimus)</style></keyword><keyword><style face="normal" font="default"> 9007-41-4 (C-Reactive Protein)</style></keyword><keyword><style face="normal" font="default"> Acute Coronary Syndrome/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angioscopy</style></keyword><keyword><style face="normal" font="default"> C-Reactive Protein/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Image Processing,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword></keywords><dates><year Day="0" Month="9" Year="2010">2010/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Neointimal formation can protect against thrombosis after sirolimus-eluting stent (SES) implantation; however, promoters of neointimal formation are unknown. METHODS: Six-month follow-up angioscopy was performed in 141 consecutive patients with SES implantation. All patients received aspirin (100 mg) and ticlopidine (200 mg) daily until angioscopy. We defined 2 grades of neointimal coverage as follows: insufficient coverage including no or partial neointimal coverage of stent struts, and sufficient coverage. The possible promoters of neointimal formation that were evaluated in this study were the condition of coronary artery disease (stable angina or acute coronary syndrome); angioscopic markers, including visible thrombus and plaque color (white or yellow); serum markers, including low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, fasting blood glucose, hemoglobin A(1c), high-sensitive C-reactive protein, and fibrinogen; blood pressure and smoking; intervention markers, including stent size and length and intravascular ultrasound measurements; and medication, including statins, anticoagulants, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, calcium antagonists, and -blockers. RESULTS: Univariate analysis revealed that high-sensitive C-reactive protein, plaque color, and the condition of coronary artery disease were significantly correlated with the grade of neointimal coverage. Multivariate analysis using these 3 parameters revealed that only acute coronary syndrome (vulnerable disease) significantly promoted neointimal coverage. CONCLUSION: Vulnerable disease may promote neointimal coverage after SES implantation. 2010 Mosby, Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Osaka Rosai Hospital, Japan. mnishino@orh.go.jpJC - 0370465CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20826267</style></custom1><custom3><style face="normal" font="default">AS - Am Heart J. 160(3):564-9, 2010 Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>276</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Nishioka,K.</style></author><author><style face="normal" font="default"> Imae,S.</style></author><author><style face="normal" font="default"> Kitayama,M.</style></author><author><style face="normal" font="default"> Miki,J.</style></author><author><style face="normal" font="default"> Okawa,T.</style></author><author><style face="normal" font="default"> Itakura,T.</style></author></authors></contributors><titles><title><style face="normal" font="default">Percutaneous vertebroplasty using hydroxyapatite blocks for the treatment of vertebral body fracture</style></title><secondary-title><style face="normal" font="default">Neurologia Medico-Chirurgica</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Neurologia Medico-Chirurgica</style></full-title></periodical><pages end="506" start="501">501-506</pages><volume><style face="normal" font="default">49</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Biocompatible Materials/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Durapatite/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Spinal Fractures/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Spine/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Surgical Procedures,Minimally Invasive/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Vertebroplasty/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> 0 (Biocompatible Materials)</style></keyword><keyword><style face="normal" font="default"> 1306-06-5 (Durapatite)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Back Pain/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Back Pain/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Back Pain/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Biocompatible Materials/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Durapatite/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Equipment Failure/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Foreign-Body Migration/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Pain,Postoperative/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Postoperative Complications/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Pulmonary Embolism/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Radiography</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Spinal Fractures/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Spinal Fractures/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Spine/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Spine/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Surgical Procedures,Minimally Invasive/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Surgical Procedures,Minimally Invasive/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Vertebroplasty/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Vertebroplasty/is [Instrumentation]</style></keyword></keywords><dates><year Day="0" Month="11" Year="2009">2009/11</year></dates><abstract><style face="normal" font="default">Vertebroplasty with hydroxyapatite blocks through a modified percutaneous approach was used to treat 30 patients with vertebral body fractures in 32 vertebral bodies between February 2003 and March 2007. The mean follow-up period was 16.6 months. The pain associated with this procedure, effects on adjacent vertebral bodies, and other complications were evaluated. The rate of recollapse after vertebroplasty was examined in 26 patients with 26 vertebral bodies treated and followed up for more than 3 months. Mean time of operation was 57 minutes and mean number of blocks used per vertebral body was 104. The mean visual analogue scale score was 7.0 preoperatively and 1.6 postoperatively. The mean decline in postoperative vertebral body height was 13%. New vertebral body fractures occurred postoperatively in 3 vertebral bodies in 2 patients. Leakage of blocks outside the vertebral body occurred in 2 patients during the operation, and after the operation in one patient, and the hydroxyapatite plug broke postoperatively in one patient. Hydroxyapatite blocks yielded good pain relief comparable to bone cement, with no serious complications such as a pulmonary embolism or leakage into the spinal canal, and are effective for percutaneous vertebroplasty</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Neurological Surgery, Wakayama Medical University, WakayamaJC - nyd, 0400775CP - JapanPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19940397</style></custom1><custom3><style face="normal" font="default">AS - Neurol Med Chir (Tokyo). 49(11):501-6, 2009 Nov.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>188</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Nouri-Majalan,N.</style></author><author><style face="normal" font="default"> Baghianimoghadam,B.</style></author><author><style face="normal" font="default"> Amiri,N.</style></author><author><style face="normal" font="default"> Moghaddasi-Moosavi,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Metabolic abnormalities in patients with recurrent stone formation in a hot territory</style></title><secondary-title><style face="normal" font="default">Bratislavske Lekarske Listy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Bratislavske Lekarske Listy</style></full-title></periodical><pages end="82" start="79">79-82</pages><volume><style face="normal" font="default">111</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Climate</style></keyword><keyword><style face="normal" font="default"> *Kidney Calculi/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> 0 (Phosphates)</style></keyword><keyword><style face="normal" font="default"> 69-93-2 (Uric Acid)</style></keyword><keyword><style face="normal" font="default"> 7440-23-5 (Sodium)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcium/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Kidney Calculi/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Phosphates/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Phosphates/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sodium/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Uric Acid/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Uric Acid/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Urine</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="0" Year="2010">2010</year></dates><isbn><style face="normal" font="default">0006-9248</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: This was a cross-sectional study of 150 consecutive patients (105 males and 44 females) with nephrolithiasis. Serum and urine metabolic evaluations were preformed. RESULTS: 70 percent (n=105) of patients were males. Sixty patients (40%) had hypertension. The urine volume of 114 subjects (76%) was less than 1 liter/day. There was an inverse correlation between urine pH and weight of patients (r=-0.48, p=0.001). The prevalence of hypophosphatemia, hypokalemia, hyperuricemia and hypercalcemia was 11% (n=17), 12.6% (n=19), 20% (n=30), and 5% (n=8), respectively. The prevalence of hypercalciuria and hyperuricosuria was 24% (n=36) and 14% (n=21), respectively. The urine calcium significantly correlated with urine sodium (r=0.3, p&lt;0.001) and uric acid (r=0.43, p&lt;0.001). Serum phosphate concentrations were inversely correlated with urine calcium concentrations (r=-0.37, p=0.016). CONCLUSION: Our findings suggest that lower urine volume has an important role in nephrolithiasis in hot areas. Higher urine sodium and uric acid and lower serum phosphor correlate with higher urine calcium in stone formers. However, further cohort studies should be performed to establish these findings (Tab. 2, Fig. 3, Ref. 26). Full Text (Free, PDF) www.bmj.sk</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Nephrology, Department of Internal Medicine, Shahid Sadoughi Medical University, Yazd, IranJC - b5n, 0065324CP - SlovakiaPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20429319</style></custom1><custom3><style face="normal" font="default">AS - Bratisl Lek Listy. 111(2):79-82, 2010.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>374</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Nowson,C.A.</style></author><author><style face="normal" font="default"> Patchett,A.</style></author><author><style face="normal" font="default"> Wattanapenpaiboon,N.</style></author></authors></contributors><titles><title><style face="normal" font="default">The effects of a low-sodium base-producing diet including red meat compared with a high-carbohydrate, low-fat diet on bone turnover markers in women aged 45-75 years</style></title><secondary-title><style face="normal" font="default">British Journal of Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">British Journal of Nutrition</style></full-title></periodical><pages end="1170" start="1161">1161-1170</pages><volume><style face="normal" font="default">102</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Bone Remodeling/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> *Diet,Fat-Restricted</style></keyword><keyword><style face="normal" font="default"> *Diet,Sodium-Restricted</style></keyword><keyword><style face="normal" font="default"> *Dietary Carbohydrates/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Hypertension/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Dietary Carbohydrates)</style></keyword><keyword><style face="normal" font="default"> 7440-09-7 (Potassium)</style></keyword><keyword><style face="normal" font="default"> 7440-23-5 (Sodium)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Acid-Base Equilibrium</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Body Weight/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Bone Remodeling/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Bone Resorption/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Calcium/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Meat</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Potassium/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sodium/ur [Urine]</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><abstract><style face="normal" font="default">A randomised, parallel-design dietary intervention study was conducted in women (aged 45-75 years) with prehypertension or stage 1 hypertension. The aim was to compare the effects on bone turnover of a low-Na base-producing (LNAB) Dietary Approaches to Stop Hypertension (DASH)-type diet (including six serves lean red meat/week) with a high-carbohydrate low-fat (HCLF) diet with a higher acid load (both >800 mg dietary Ca/d). Fasting serum bone markers (baseline and week 14) and 24 h urinary electrolyte excretion (baseline, weeks 4, 8, 12 and 14) were measured. After the intervention period, the LNAB group (n 46) had a fall of 26 (sem 6) % (P &lt; 0.0001) in urinary Na, an increase in K excretion (6.8 (sem 3.6) mmol/d; P = 0.07) and, compared with the HCLF group (n 49), a greater reduction in urinary Ca excretion by 0.7 (sem 0.3) mmol/d. Serum 25-hydroxyvitamin D, intact parathyroid hormone and osteocalcin did not change, and both groups had a similar increase of 23 (sem 5) % (P &lt; 0.0001) in C-terminal telopeptide of type I collagen. The HCLF group had an 11 (sem 4) % increase (P = 0.003) in N-terminal propeptide, type I procollagen, which could indicate an increased rate of bone turnover. The fall in urinary Ca with the lower-Na lower-acid load diet is likely to have long-term beneficial effects on bone. As bone resorption was not different between the two dietary patterns with relatively high Ca intake, the effect on bone health of a dietary pattern with a lower acid load warrants further study on a lower Ca intake</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - School of Exercise and Nutrition Sciences, Centre for Physical Activity and Nutrition Research, Deakin University, 221 Burwood Highway, Burwood 3125, Victoria, Australia. caryl.nowson@deakin.edu.auJC - az4, 0372547CP - EnglandPT - Comparative StudyPT - Journal ArticlePT - Randomized Controlled TrialPT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19445819</style></custom1><custom3><style face="normal" font="default">AS - Br J Nutr. 102(8):1161-70, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>429</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">nsson,T.</style></author><author><style face="normal" font="default"> Granfeldt,Y.</style></author><author><style face="normal" font="default"> Ahr&amp;#x00E9</style></author><author><style face="normal" font="default">n B</style></author><author><style face="normal" font="default"> Branell,U.C.</style></author><author><style face="normal" font="default"> lsson,G.</style></author><author><style face="normal" font="default"> Hansson,A.</style></author><author><style face="normal" font="default"> S&amp;#x00F6</style></author><author><style face="normal" font="default">derstr&amp;#x00F6</style></author><author><style face="normal" font="default">m M</style></author><author><style face="normal" font="default"> Lindeberg,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Beneficial effects of a Paleolithic diet on cardiovascular risk factors in type 2 diabetes: a randomized cross-over pilot study</style></title><secondary-title><style face="normal" font="default">Cardiovascular Diabetology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Cardiovascular Diabetology</style></full-title></periodical><pages end="" start="35">35-</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Diabetes Mellitus,Type 2/dh [Diet Therapy]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 2/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Diabetic Diet/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> 0 (Blood Glucose)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Blood Glucose/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cross-Over Studies</style></keyword><keyword><style face="normal" font="default"> Dairy Products</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Diet,Sodium-Restricted/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Diet/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Eating</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fruit</style></keyword><keyword><style face="normal" font="default"> Glycemic Index/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Meat</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Pilot Projects</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Vegetables</style></keyword><keyword><style face="normal" font="default"> Waist Circumference</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><abstract><style face="normal" font="default">BACKGROUND: Our aim was to compare the effects of a Paleolithic ('Old Stone Age') diet and a diabetes diet as generally recommended on risk factors for cardiovascular disease in patients with type 2 diabetes not treated with insulin. METHODS: In a randomized cross-over study, 13 patients with type 2 diabetes, 3 women and 10 men, were instructed to eat a Paleolithic diet based on lean meat, fish, fruits, vegetables, root vegetables, eggs and nuts; and a Diabetes diet designed in accordance with dietary guidelines during two consecutive 3-month periods. Outcome variables included changes in weight, waist circumference, serum lipids, C-reactive protein, blood pressure, glycated haemoglobin (HbA1c), and areas under the curve for plasma glucose and plasma insulin in the 75 g oral glucose tolerance test. Dietary intake was evaluated by use of 4-day weighed food records. RESULTS: Study participants had on average a diabetes duration of 9 years, a mean HbA1c of 6,6% units by Mono-S standard and were usually treated with metformin alone (3 subjects) or metformin in combination with a sulfonylurea (3 subjects) or a thiazolidinedione (3 subjects). Mean average dose of metformin was 1031 mg per day. Compared to the diabetes diet, the Paleolithic diet resulted in lower mean values of HbA1c (-0.4% units, p = 0.01), triacylglycerol (-0.4 mmol/L, p = 0.003), diastolic blood pressure (-4 mmHg, p = 0.03), weight (-3 kg, p = 0.01), BMI (-1 kg/m2, p = 0.04) and waist circumference (-4 cm, p = 0.02), and higher mean values of high density lipoprotein cholesterol (+0.08 mmol/L, p = 0.03). The Paleolithic diet was mainly lower in cereals and dairy products, and higher in fruits, vegetables, meat and eggs, as compared with the Diabetes diet. Further, the Paleolithic diet was lower in total energy, energy density, carbohydrate, dietary glycemic load, saturated fatty acids and calcium, and higher in unsaturated fatty acids, dietary cholesterol and several vitamins. Dietary GI was slightly lower in the Paleolithic diet (GI = 50) than in the Diabetic diet (GI = 55). CONCLUSION: Over a 3-month study period, a Paleolithic diet improved glycemic control and several cardiovascular risk factors compared to a Diabetes diet in patients with type 2 diabetes</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Clinical Sciences, Lund, Lund University, Box 117, 221 00 Lund, Sweden. Tommy.Jonsson@med.lu.seJC - 101147637CP - EnglandPT - Comparative StudyPT - Journal ArticlePT - Randomized Controlled TrialPT - Research Support, Non-U.S. Gov'tSI - ClinicalTrials.govSA - ClinicalTrials.gov/NCT00435240LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19604407</style></custom1><custom3><style face="normal" font="default">AS - Cardiovasc. diabetol.. 8:35, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>401</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Nucifora,G.</style></author><author><style face="normal" font="default"> Schuijf,J.D.</style></author><author><style face="normal" font="default"> Tops,L.F.</style></author><author><style face="normal" font="default"> Van Werkhoven,J.M.</style></author><author><style face="normal" font="default"> Kajander,S.</style></author><author><style face="normal" font="default"> Jukema,J.W.</style></author><author><style face="normal" font="default"> Schreur,J.H.</style></author><author><style face="normal" font="default"> Heijenbrok,M.W.</style></author><author><style face="normal" font="default"> Trines,S.A.</style></author><author><style face="normal" font="default"> Gaemperli,O.</style></author><author><style face="normal" font="default"> Turta,O.</style></author><author><style face="normal" font="default"> Kaufmann,P.A.</style></author><author><style face="normal" font="default"> Knuuti,J.</style></author><author><style face="normal" font="default"> Schalij,M.J.</style></author><author><style face="normal" font="default"> Bax,J.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Prevalence of coronary artery disease assessed by multislice computed tomography coronary angiography in patients with paroxysmal or persistent atrial fibrillation</style></title><secondary-title><style face="normal" font="default">Circulation</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Circulation</style></full-title></periodical><pages end="106" start="100">100-106</pages><volume><style face="normal" font="default">Cardiovascular</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atrial Fibrillation/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="3" Year="2009">2009/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: Although atrial fibrillation (AF) has been linked to underlying coronary artery disease (CAD), data supporting this association have been based on ECG and clinical history for the definition of CAD rather than direct visualization of atherosclerosis. METHODS AND RESULTS: The prevalence of CAD among patients with paroxysmal or persistent AF and without history of CAD was evaluated using multislice computed tomography. Multislice computed tomography was performed in 150 patients with AF (61+/-11 years, 67% males, 58% asymptomatic) with predominantly low (59%) or intermediate (25%) pretest likelihood of CAD. CAD was classified as obstructive (> or =50% luminal narrowing) or not. A population of 148 patients without history of AF, similar to the AF group as to age, gender, symptomatic status, and pretest likelihood, served as a control group. Logistic regression analysis was applied to evaluate the relationship between demographic and clinical data and the presence of obstructive CAD. On the basis of multislice computed tomography, 18% of patients with AF were classified as having no CAD, whereas 41% showed nonobstructive CAD and the remaining 41% had obstructive CAD. Among patients without AF, 32% were classified as having no CAD, whereas 41% showed nonobstructive CAD and 27% had obstructive CAD (P=0.010 compared with patients with AF). At logistic regression analysis, age, male gender, and the presence of AF were significantly related to obstructive CAD. CONCLUSIONS: A higher prevalence of obstructive CAD was observed among patients with AF, confirming the hypothesis that AF could be a marker of advanced coronary atherosclerosis</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Leiden University Medical Center, Leiden, The NetherlandsJC - 101479935CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19808575</style></custom1><custom3><style face="normal" font="default">AS - Circ Cardiovasc Imaging. 2(2):100-6, 2009 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>491</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Nucifora,G.</style></author><author><style face="normal" font="default"> Schuijf,J.D.</style></author><author><style face="normal" font="default"> Van Werkhoven,J.M.</style></author><author><style face="normal" font="default"> Jukema,J.W.</style></author><author><style face="normal" font="default"> Marsan,N.A.</style></author><author><style face="normal" font="default"> Holman,E.R.</style></author><author><style face="normal" font="default"> van der Wall,E.E.</style></author><author><style face="normal" font="default"> Bax,J.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Usefulness of echocardiographic assessment of cardiac and ascending aorta calcific deposits to predict coronary artery calcium and presence and severity of obstructive coronary artery disease</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="1050" start="1045">1045-1050</pages><volume><style face="normal" font="default">103</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aortic Diseases/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Heart Diseases/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Aorta</style></keyword><keyword><style face="normal" font="default"> Arterial Occlusive Diseases/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Outpatients</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="15" Month="4" Year="2009">2009/4/15</year></dates><abstract><style face="normal" font="default">The presence of cardiac and aortic calcific deposits has been related to coronary artery disease (CAD) and cardiovascular events. The present study aimed to evaluate whether comprehensive echocardiographic assessment of cardiac and ascending aorta calcific deposits could predict coronary calcium and obstructive CAD. A total of 140 outpatients (age 61 +/- 11 years; 90 men) without a history of CAD were studied. Aortic valve sclerosis and mitral annular, papillary muscle, and ascending aorta calcific deposits were assessed using echocardiography and semiquantified using an echocardiography-derived calcium score (ECS) ranging from 0 (no calcium visible) to 8 (severe calcific deposits). Coronary calcium scoring and noninvasive coronary angiography were performed using multislice computed tomography. Angiograms showing atherosclerosis were classified as having obstructive (> or =50% luminal narrowing) CAD or not. The relation between ECS and multislice computed tomographic findings was explored using multivariate and receiver-operator characteristic curve analyses. Only ECS was associated with coronary calcium score >400 (odds ratio [OR] 3.6, 95% confidence interval [CI] 2.4 to 5.5, p &lt;0.001). Similarly, only ECS (OR 1.8, 95% CI 1.4 to 2.4, p &lt;0.001) and pretest likelihood of CAD (OR 1.7, 95% CI 1.0 to 2.8, p = 0.04) were associated with obstructive CAD. ECS > or =3 had high sensitivity and specificity in identifying patients with coronary calcium score >400 (87% for both) and obstructive CAD (74% and 82%, respectively). In conclusion, echocardiographic assessment of cardiac and ascending aorta calcium may allow detection of patients with extensive calcified coronary arterial atherosclerotic plaques</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Leiden University Medical Center, The NetherlandsJC - 3dq, 0207277CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19361587</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 103(8):1045-50, 2009 Apr 15.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>415</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Okamura,T.</style></author><author><style face="normal" font="default"> Sekikawa,A.</style></author><author><style face="normal" font="default"> Kadowaki,T.</style></author><author><style face="normal" font="default"> El-Saed,A.</style></author><author><style face="normal" font="default"> Abbott,R.D.</style></author><author><style face="normal" font="default"> Curb,J.D.</style></author><author><style face="normal" font="default"> Edmundowicz,D.</style></author><author><style face="normal" font="default"> Nakamura,Y.</style></author><author><style face="normal" font="default"> Murata,K.</style></author><author><style face="normal" font="default"> Kashiwagi,A.</style></author><author><style face="normal" font="default"> Sutton-Tyrrell,K.</style></author><author><style face="normal" font="default"> Evans,R.W.</style></author><author><style face="normal" font="default"> Zmuda,J.M.</style></author><author><style face="normal" font="default"> Maegawa,H.</style></author><author><style face="normal" font="default"> Hozawa,A.</style></author><author><style face="normal" font="default"> Mitsunami,K.</style></author><author><style face="normal" font="default"> Nishio,Y.</style></author><author><style face="normal" font="default"> Miljkovic-Gacic,I.</style></author><author><style face="normal" font="default"> Horie,M.</style></author><author><style face="normal" font="default"> Miyamatsu,N.</style></author><author><style face="normal" font="default"> Murakami,Y.</style></author><author><style face="normal" font="default"> Kuller,L.H.</style></author><author><style face="normal" font="default"> Ueshima,H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Cholesteryl ester transfer protein, coronary calcium, and intima-media thickness of the carotid artery in middle-age Japanese men</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="822" start="818">818-822</pages><volume><style face="normal" font="default">104</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> *Carotid Arteries/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Cholesterol Ester Transfer Proteins/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> *Tunica Intima/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Tunica Media/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol Ester Transfer Proteins)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="15" Month="9" Year="2009">2009/9/15</year></dates><abstract><style face="normal" font="default">The relation between cholesteryl ester transfer protein (CETP) levels and atherosclerosis is controversial. We examined whether the serum CETP levels were associated with subclinical atherosclerosis, independent of its most common gene variant, in a sample of Japanese men. A population-based cross-sectional study of 250 Japanese men aged 40 to 49 years was conducted to assess the intima-media thickness of the carotid artery, coronary artery calcium, serum CETP levels, and the CETP D442G gene variant. Compared with the lowest CETP quartile, the multivariate adjusted odds ratio for coronary artery calcium was 0.77 (95% confidence interval 0.18 to 3.36), 0.96 (95% confidence interval 0.27 to 3.40), and 3.49 (95% confidence interval 1.05 to 11.6) with increasing CETP quartiles. The serum CETP quartiles were also positively associated with the intima-media thickness of the carotid artery (adjusted mean 602, 616, 615, and 646 mum for the lowest to top quartile, respectively). The findings remained unchanged after additional adjustment for the CETP D442G gene variant. No significant difference was found in the prevalence of coronary artery calcium or in the mean intima-media thickness of the carotid artery between participants with and without the CETP D442G gene variant</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Preventive Cardiology, National Cardiovascular Center, Suita, Osaka, Japan. okamurat@hsp.ncvc.go.jpJC - 3dq, 0207277CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - HL071561 (United States NHLBI NIH HHS)NO - R01 HL68200 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19733717</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 104(6):818-22, 2009 Sep 15.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>172</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Olmos,J.M.</style></author><author><style face="normal" font="default"> ndez,J.L.</style></author><author><style face="normal" font="default"> nez,J.</style></author><author><style face="normal" font="default"> Castillo,J.</style></author><author><style face="normal" font="default"> Valero,C.</style></author><author><style face="normal" font="default"> rez,Pajares,I</style></author><author><style face="normal" font="default"> Nan,D.</style></author><author><style face="normal" font="default"> lez,Mac</style></author></authors></contributors><titles><title><style face="normal" font="default">Bone turnover markers and bone mineral density in hypertensive postmenopausal women on treatment</style></title><secondary-title><style face="normal" font="default">Maturitas</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Maturitas</style></full-title></periodical><pages end="402" start="396">396-402</pages><volume><style face="normal" font="default">65</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Antihypertensive Agents/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> *Bone Density/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> *Bone Remodeling/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> *Hypertension/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Postmenopause/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> *Thiazides/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> 0 (Antihypertensive Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Thiazides)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Absorptiometry,Photon</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Antihypertensive Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Homeostasis/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Postmenopause/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Thiazides/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Ultrasonography</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To evaluate bone mineral density (BMD) and bone metabolism in hypertensive postmenopausal women, and to differentiate the effect of thiazides from that of other antihypertensive agents. SUBJECTS AND METHODS: A community-based population of 636 postmenopausal women, 293 with hypertension (160 receiving thiazides, and 133 receiving other antihypertensive treatments), and 343 control women, were evaluated. Serum levels of aminoterminal propeptide of type I collagen (P1NP), C-terminal telopeptide of type I collagen (beta-CTX), 25-hydroxivitamin D, and intact parathyroid hormone were measured by electrochemiluminiscence. BMD was determined by DXA, and heel quantitative ultrasound measurements (QUS) with a gel-coupled device. RESULTS: BMD expressed as Z-score was higher in both groups of hypertensive women at all locations. Expressed as g/cm(2), it was also higher in patients on thiazides at femoral neck and lumbar spine. Only in the latter site, differences remained significant after adjusting for potential confounding variables, including BMI. Bone turnover markers were lower in both groups of hypertensive women, although the difference was greater in those on thiazides. After adjusting for potential confounders, differences remained significant only in the thiazide group. CONCLUSIONS: Our results add evidence to the idea that thiazides are beneficial to prevent bone loss. Copyright 2010 Elsevier Ireland Ltd. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Internal Medicine, Hospital Universitario Marqu&amp;#x00E9;s de Valdecilla, University of Cantabria, RETICEF, Santander, Spain. miromj@humv.esJC - mwn, 7807333CP - IrelandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20129746</style></custom1><custom3><style face="normal" font="default">AS - Maturitas. 65(4):396-402, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>73</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Otsuka,R.</style></author><author><style face="normal" font="default"> Imai,T.</style></author><author><style face="normal" font="default"> Kato,Y.</style></author><author><style face="normal" font="default"> Ando,F.</style></author><author><style face="normal" font="default"> Shimokata,H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Relationship between number of metabolic syndrome components and dietary factors in middle-aged and elderly Japanese subjects</style></title><secondary-title><style face="normal" font="default">Hypertension Research - Clinical &amp; Experimental</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Hypertension Research - Clinical &amp; Experimental</style></full-title></periodical><pages end="554" start="548">548-554</pages><volume><style face="normal" font="default">33</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Diet</style></keyword><keyword><style face="normal" font="default"> *Metabolic Syndrome X/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Metabolic Syndrome X/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 8059-24-3 (Vitamin B 6)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Alcohol Drinking/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Asian Continental Ancestry Group/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Cereals/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Dairy Products</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Dietary Fiber/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Energy Intake</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Motor Activity</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Vitamin B 6/me [Metabolism]</style></keyword></keywords><dates><year Day="0" Month="6" Year="2010">2010/6</year></dates><abstract><style face="normal" font="default">Metabolic syndrome (MetS) represents a cluster of risk factors for atherosclerosis and is considered a risk factor for cardiovascular disease. The role of diet in the etiology of MetS is poorly understood, especially among Asian subjects. This cross-sectional study assessed the relationship between diet and the number of MetS components among Japanese men (n=609) and women (n=631). Mean (s.d.) age and body mass index were 57.1 (12.1) years and 22.8 (2.8) kg m(-2) for men and 55.5 (12.0) years and 22.0 (3.0) kg m(-2) for women, respectively. Diet was assessed by a 3-day dietary record that included photographs: 16 nutrients, 11 food groups, and energy % of protein and dietary fat were selected as a dietary index. The definition of MetS was based on modified National Cholesterol Education Program, Adult Treatment Panel III criteria, and the number of clustering MetS components was calculated by adding the presence of each five MetS components. A total of 61 men (10.0%) and 46 women (7.3%) were determined to have MetS. After adjusting for age, energy intake, alcohol intake, smoking status and physical activity, a lower intake of vitamin B6 and dietary fiber in men, and lower intake of calcium, milk and dairy products and higher intake of cereal in women were related to the number of MetS components. These results suggest that some dietary factors were related to the number of MetS components among community-dwelling Japanese men and women</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Epidemiology, National Institute for Longevity Sciences, National Center for Geriatrics and Gerontology, Aichi, Japan. otsuka@ncgg.go.jpJC - 9307690CP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20224573</style></custom1><custom3><style face="normal" font="default">AS - Hypertens Res. 33(6):548-54, 2010 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>233</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Owens,D.S.</style></author><author><style face="normal" font="default"> Katz,R.</style></author><author><style face="normal" font="default"> Takasu,J.</style></author><author><style face="normal" font="default"> Kronmal,R.</style></author><author><style face="normal" font="default"> Budoff,M.J.</style></author><author><style face="normal" font="default"> O'Brien,K.D.</style></author></authors></contributors><titles><title><style face="normal" font="default">Incidence and progression of aortic valve calcium in the Multi-ethnic Study of Atherosclerosis (MESA)</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="708" start="701">701-708</pages><volume><style face="normal" font="default">105</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aortic Valve</style></keyword><keyword><style face="normal" font="default"> *Atherosclerosis/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Ethnic Groups/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> *European Continental Ancestry Group/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> *Heart Valve Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Valve Diseases/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="1" Month="3" Year="2010">2010/3/1</year></dates><abstract><style face="normal" font="default">Aortic valve calcium (AVC) is common among older adults and shares epidemiologic and histopathologic similarities to atherosclerosis. However, prospective studies have failed to identify meaningful risk associations with incident ("new") AVC or its progression. In the present study, AVC was quantified from serial computed tomographic images from 5,880 participants (aged 45 to 84 years) in the Multi-Ethnic Study of Atherosclerosis, using the Agatston method. Multivariate backward selection modeling was used to identify the risk factors for incident AVC and AVC progression. During a mean follow-up of 2.4 +/- 0.9 years, 210 subjects (4.1%) developed incident AVC. The incidence rate (mean 1.7%/year) increased significantly with age (p &lt;0.001). The risk factors for incident AVC included age, male gender, body mass index, current smoking, and the use of lipid-lowering and antihypertensive medications. Among those with AVC at baseline, the median rate of AVC progression was 2 Agatston units/year (interquartile range -21 to 37). The baseline Agatston score was a strong, independent predictor of progression, especially among those with high calcium scores at baseline. In conclusion, in this ethnically diverse, preclinical cohort, the rate of incident AVC increased significantly with age. The incident AVC risk was associated with several traditional cardiovascular risk factors, specifically age, male gender, body mass index, current smoking, and the use of both antihypertensive and lipid-lowering medications. AVC progression risk was associated with male gender and the baseline Agatston score. Additional research is needed to determine whether age- and stage-specific mechanisms underlie the risk of AVC progression. Copyright 2010 Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - University of Washington, Seattle, Washington, USA. dsowens@u.washington.eduJC - 3dq, 0207277CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - N01-HC-95159 (United States NHLBI NIH HHS)NO - N01-HC-95160 (United States NHLBI NIH HHS)NO - N01-HC-95161 (United States NHLBI NIH HHS)NO - N01-HC-95162 (United States NHLBI NIH HHS)NO - N01-HC-95163 (United States NHLBI NIH HHS)NO - N01-HC-95164 (United States NHLBI NIH HHS)NO - N01-HC-95165 (United States NHLBI NIH HHS)NO - N01-HC-95169 (United States NHLBI NIH HHS)NO - R01-HL-63963-01A1 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20185020</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 105(5):701-8, 2010 Mar 1.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>122</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Oz,O.</style></author><author><style face="normal" font="default"> Bayram,N.A.</style></author><author><style face="normal" font="default"> Durmaz,T.</style></author><author><style face="normal" font="default"> Keles,T.</style></author><author><style face="normal" font="default"> Akcay,M.</style></author><author><style face="normal" font="default"> Bozkurt,E.</style></author></authors></contributors><titles><title><style face="normal" font="default">The relationship between coronary slow flow phenomenon and coronary calcium score</style></title><secondary-title><style face="normal" font="default">Perfusion</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Perfusion</style></full-title></periodical><pages end="102" start="97">97-102</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> *Coronary Circulation/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol,HDL)</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol,LDL)</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age Distribution</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Cholesterol,HDL/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cholesterol,LDL/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="3" Year="2010">2010/3</year></dates><abstract><style face="normal" font="default">AIM: Coronary slow flow phenomenon (CSFP) is an angiographic finding characterized by delayed distal vessel opacification without any significant epicardial coronary artery disease. Several studies have suggested that CSFP might be a form of atherosclerosis. The present study was aimed to investigate the relationship between CSFP and coronary artery calcification, which is one of the clear-cut indicators of coronary atherosclerotic plaque, by using computerized tomography. METHOD: Fifty-five patients were included in the study. The coronary arteries of all patients were shown by angiography to be normal. Coronary slow flow (CSF) patterns were evaluated by the thrombolysis in myocardial infarction frame count (TFC) method. Patients with normal coronary arteries and CSF were allocated into the CSF group, and patients with normal coronary arteries and normal coronary flow were allocated into the control group. Coronary artery calcium (CAC) score was measured in 28 patients with CSF and in 27 controls by 64-slice computerized tomography. RESULTS: The CSF and control groups were similar with respect to age, gender, smoking status, presence of hypertension and diabetes mellitus, cholesterol profiles, and Framingham risk scores (p>0.05). The CSF and control groups were not significantly different with respect to CAC score (p>0.05). Sub-group analysis of cardiac risk factors in patients with or without coronary artery calcification revealed that advanced age and low high density lipoprotein (HDL) levels were significantly associated with coronary artery calcification. There wasn't any relationship between coronary slow flow and cardiac risk factors or coronary calcium scores. CONCLUSION: In the present study, no association was found between the CSFP and calcified atherosclerosis. Additionally, it was demonstrated that, among the cardiac risk factors, advanced age and low HDL levels were associated with coronary artery calcification</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Cardiology Department, Ataturk Education and Research Hospital, Ankara, TurkeyJC - bdd, 8700166CP - EnglandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20427414</style></custom1><custom3><style face="normal" font="default">AS - Perfusion. 25(2):97-102, 2010 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>368</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Ozerkan,F.</style></author><author><style face="normal" font="default"> G&amp;#x00FC</style></author><author><style face="normal" font="default">ng&amp;#x00F6</style></author><author><style face="normal" font="default">r H</style></author><author><style face="normal" font="default"> Zoghi,M.</style></author><author><style face="normal" font="default"> Nalbantgil,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Cardiac failure secondary to idiopathic hypoparathyroidism: a case report]. [Turkish]</style></title><secondary-title><style face="normal" font="default">Turk Kardiyoloji Dernegi Arsivi</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Turk Kardiyoloji Dernegi Arsivi</style></full-title></periodical><pages end="56" start="53">53-56</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Heart Failure/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Hypocalcemia/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Hypoparathyroidism/co [Complications]</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 0 (Vitamins)</style></keyword><keyword><style face="normal" font="default"> 1406-16-2 (Vitamin D)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Heart Failure/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypocalcemia/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Hypocalcemia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Hypoparathyroidism/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Hypoparathyroidism/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Vitamin D/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Vitamins/ad [Administration &amp; Dosage]</style></keyword></keywords><dates><year Day="0" Month="1" Year="2009">2009/1</year></dates><isbn><style face="normal" font="default">1016-5169</style></isbn><abstract><style face="normal" font="default">Hypocalcemic cardiomyopathy due to hypoparathyroidism is a very rare condition. Ensuing heart failure due to hypocalcemia is refractory to conventional treatment. We reported a 41-year-old man who developed cardiac failure due to hypocalcemia secondary to idiopathic hypoparathyroidism. Echocardiography showed biventricular low ejection fraction, dilated heart chambers, pulmonary hypertension, and valvular regurgitations. Serum calcium and parathyroid hormone levels were low. After treatment of heart failure and calcium-vitamin D supplementation, signs and symptoms of heart failure improved rapidly. At 6 months, biventricular systolic and diastolic functions returned to normal. Serum calcium level should be monitored in every patient with cardiac failure and hypocalcemia should be considered in patients with refractory heart failure</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Ege Universitesi Tip Fak&amp;#x00FC;ltesi, Kardiyoloji Anabilim Dali, Izmir, Turkey. fozerkan@yahoo.comOT - Idiyopatik hipoparatiroidiye ba&amp;#x011F;li geli&amp;#x015F;en kalp yetersizli&amp;#x011F;i: olgu sunumuJC - 9426239CP - TurkeyPT - Case ReportsPT - English AbstractPT - Journal ArticleLG - Turkish</style></notes><urls/><custom1><style face="normal" font="default">UI - 19225256</style></custom1><custom3><style face="normal" font="default">AS - TURK KARDIYOLOJI DERNEGI ARS.. 37(1):53-6, 2009 Jan.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>312</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Pai,S.G.</style></author><author><style face="normal" font="default"> Shivashankara,K.N.</style></author><author><style face="normal" font="default"> Pandit,V.</style></author><author><style face="normal" font="default"> Sheshadri,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Symptomatic hypocalcemia in primary hyperaldosteronism: a case report</style></title><secondary-title><style face="normal" font="default">Journal of Korean Medical Science</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Korean Medical Science</style></full-title></periodical><pages end="1223" start="1220">1220-1223</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Adrenal Cortex Neoplasms/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Adrenocortical Adenoma/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Hyperaldosteronism</style></keyword><keyword><style face="normal" font="default"> *Hypocalcemia/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Adrenal Cortex Neoplasms/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Adrenal Cortex Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Adrenal Cortex Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Adrenocortical Adenoma/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Adrenocortical Adenoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Adrenocortical Adenoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperaldosteronism/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Hyperaldosteronism/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Hyperaldosteronism/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><abstract><style face="normal" font="default">The metabolic alterations caused by hyperaldosteronism are being increasingly recognized and have generated considerable interest among the medical fraternity. Hyperaldosteronism is suspected to have a pivotal role in the patho-physiology of congestive cardiac failure where it has been studied extensively. But its effects on calcium metabolism, parathyroid metabolism and renal handling of calcium are less well described. Recent experimental models have shed light into the roles played by previously unknown mechanisms in causing these metabolic alterations. We hereby report a case of primary hyperaldosteronism due to adrenal adenoma (Conn's syndrome) who presented with a myriad of clinical features including symptomatic hypocalcemia, significant weight loss along with uncontrolled hypertension for a prolonged period before eventually detected to have primary hyperaldosteronism. Surgical removal of the causative tumor resulted in prompt disappearance of all the symptoms and signs and regain of lost weight</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, Kasturba Medical College, Manipal, Karnataka, India. sachingpai@gmail.comJC - ah4, 8703518CP - Korea (South)PT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19949688</style></custom1><custom3><style face="normal" font="default">AS - J Korean Med Sci. 24(6):1220-3, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>433</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Palumbo,A.A.</style></author><author><style face="normal" font="default"> Maffei,E.</style></author><author><style face="normal" font="default"> Martini,C.</style></author><author><style face="normal" font="default"> Tarantini,G.</style></author><author><style face="normal" font="default"> Di Tanna,G.L.</style></author><author><style face="normal" font="default"> Berti,E.</style></author><author><style face="normal" font="default"> Grilli,R.</style></author><author><style face="normal" font="default"> Casolo,G.</style></author><author><style face="normal" font="default"> Brambilla,V.</style></author><author><style face="normal" font="default"> Cerrato,M.</style></author><author><style face="normal" font="default"> Rotondo,A.</style></author><author><style face="normal" font="default"> Weustink,A.C.</style></author><author><style face="normal" font="default"> Mollet,N.R.</style></author><author><style face="normal" font="default"> Cademartiri,F.</style></author></authors></contributors><titles><title><style face="normal" font="default">Coronary calcium score as gatekeeper for 64-slice computed tomography coronary angiography in patients with chest pain: per-segment and per-patient analysis</style></title><secondary-title><style face="normal" font="default">European Radiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">European Radiology</style></full-title></periodical><pages end="2135" start="2127">2127-2135</pages><volume><style face="normal" font="default">19</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Algorithms</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Chest Pain/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Radiographic Image Interpretation,Computer-Assisted/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Chest Pain/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Radiographic Image Enhancement/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword></keywords><dates><year Day="0" Month="9" Year="2009">2009/9</year></dates><abstract><style face="normal" font="default">We sought to investigate the performance of 64-slice CT in symptomatic patients with different coronary calcium scores. Two hundred patients undergoing 64-slice CT coronary angiography for suspected coronary artery disease were enrolled into five groups based on Agatston calcium score using the Mayo Clinic risk stratification: group 1: score 0, group 2: score 1-10, group 3: score 11-100, group 4: score 101-400, and group 5: score > 401. Diagnostic accuracy for the detection of significant (>/=50% lumen reduction) coronary artery stenosis was assessed on a per-segment and per-patient base using quantitative coronary angiography as the gold standard. For groups 1 through 5, sensitivity was 97, 96, 91, 90, 92%, and specificity was 99, 98, 96, 88, 90%, respectively, on a per-segment basis. On a per-patient basis, the best diagnostic performance was obtained in group 1 (sensitivity 100% and specificity 100%) and group 5 (sensitivity 95% and specificity 100%). Progressively higher coronary calcium levels affect diagnostic accuracy of CT coronary angiography, decreasing sensitivity and specificity on a per-segment base. On a per-patient base, the best results in terms of diagnostic accuracy were obtained in the populations with very low and very high cardiovascular risk</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Radiology and Cardiology, Azienda Ospedaliero-Universitaria di Parma, Non-Invasive Cardiovascular Imaging, Piastra Tecnica - Piano 0, Via Gramsci, 14, Parma 43100, ItalyJC - cl3, 9114774CP - GermanyPT - Comparative StudyPT - Evaluation StudiesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19387651</style></custom1><custom3><style face="normal" font="default">AS - Eur Radiol. 19(9):2127-35, 2009 Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>527</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Pan,N.H.</style></author><author><style face="normal" font="default"> Tsao,H.M.</style></author><author><style face="normal" font="default"> Chang,N.C.</style></author><author><style face="normal" font="default"> Lee,C.M.</style></author><author><style face="normal" font="default"> Chen,Y.J.</style></author><author><style face="normal" font="default"> Chen,S.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Dilated left atrium and pulmonary veins in patients with calcified coronary artery: a potential contributor to the genesis of atrial fibrillation</style></title><secondary-title><style face="normal" font="default">Journal of Cardiovascular Electrophysiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Cardiovascular Electrophysiology</style></full-title></periodical><pages end="158" start="153">153-158</pages><volume><style face="normal" font="default">20</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atrial Fibrillation/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Cardiomyopathy,Dilated/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Pulmonary Veins/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Atrial Fibrillation/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathy,Dilated/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Atria</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="2" Year="2009">2009/2</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Coronary artery disease (CAD) is an important etiology of atrial fibrillation (AF). Coronary artery calcification is a marker of coronary atherosclerosis and coronary events. The purpose of this study was to investigate whether larger left atrium (LA) and pulmonary veins (PVs) were seen by multidetector computed tomography (MDCT) scans in those patients with higher coronary calcium scores. METHODS AND RESULTS: A total of 166 patients undergoing MDCT for general check-up (n = 128, 77%) or suspected CAD (n = 38, 23%) were enrolled and divided into a control (calcium score = 0, n = 60), medium calcium score (calcium score = 100 approximately 400, n = 47), and high calcium score (calcium score >400, n = 59) groups. Diameters and areas of the LA, left atrial appendage (LAA), and PVs were measured by MDCT. The high calcium score group had significantly larger PVs diameters, LAA orifice area (1.9 +/- 1.4 cm(2), 0.9 +/- 0.5 cm(2), 0.8 +/- 0.4 cm(2), P &lt; 0.005), LA anterior-posterior distance (32.2 +/- 6.8 mm, 30.4 +/- 6.5 mm, 27.3 +/- 6.0 mm, P &lt; 0.05), and transverse distance (52.6 +/- 7.3 mm, 50.2 +/- 9 mm, 49.5 +/- 4.6 mm, P &lt; 0.05) than the medium calcium score and control groups. Six (3.6%) patients with paroxysmal AF had higher calcium scores and larger diameters of LA, LAA, and PVs than those (96.4%) without paroxysmal AF. Two patients in the high calcium score group had calcified PVs localized to the right upper and left upper PVs. The incidence of calcified PVs was 1.2% for the total patients and 3.3% for the high calcium score patients. CONCLUSION: In the presence of high calcium scores in this patient population, the LA, LAA, and PVs were enlarged</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiovascular Medicine, Taipei Medical University Hospital, Taipei, TaiwanJC - by4, 9010756CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18803575</style></custom1><custom3><style face="normal" font="default">AS - J Cardiovasc Electrophysiol. 20(2):153-8, 2009 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>38</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Paramsothy,P.</style></author><author><style face="normal" font="default"> Knopp,R.H.</style></author><author><style face="normal" font="default"> Bertoni,A.G.</style></author><author><style face="normal" font="default"> Blumenthal,R.S.</style></author><author><style face="normal" font="default"> Wasserman,B.A.</style></author><author><style face="normal" font="default"> Tsai,M.Y.</style></author><author><style face="normal" font="default"> Rue,T.</style></author><author><style face="normal" font="default"> Wong,N.D.</style></author><author><style face="normal" font="default"> Heckbert,S.R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Association of combinations of lipid parameters with carotid intima-media thickness and coronary artery calcium in the MESA (Multi-Ethnic Study of Atherosclerosis)</style></title><secondary-title><style face="normal" font="default">Journal of the American College of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of the American College of Cardiology</style></full-title></periodical><pages end="1041" start="1034">1034-1041</pages><volume><style face="normal" font="default">56</style></volume><number><style face="normal" font="default">13</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Carotid Artery Diseases/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Dyslipidemias/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Lipids/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol,HDL)</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol,LDL)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipids)</style></keyword><keyword><style face="normal" font="default"> 0 (Triglycerides)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Carotid Arteries/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Carotid Artery Diseases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Carotid Artery Diseases/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Carotid Artery Diseases/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Cholesterol,HDL/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cholesterol,LDL/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Dyslipidemias/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypercholesterolemia/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Hypercholesterolemia/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Hyperlipidemia,Familial Combined/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Hyperlipidemia,Familial Combined/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Triglycerides/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Tunica Intima/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Tunica Media/us [Ultrasonography]</style></keyword></keywords><dates><year Day="21" Month="9" Year="2010">2010/9/21</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The purpose of this study was to determine the association of combinations of lipid parameters with subclinical atherosclerosis. BACKGROUND: Carotid intima-media thickness (CIMT) and coronary artery calcium (CAC) are significantly associated with incident cardiovascular disease (CVD). The association between common dyslipidemias (combined hyperlipidemia, [simple] hypercholesterolemia, dyslipidemia of metabolic syndrome, isolated low high-density lipoprotein cholesterol, and isolated hypertriglyceridemia) compared with normolipemia, and CIMT and CAC has not been previously examined. METHODS: The MESA (Multi-Ethnic Study of Atherosclerosis) participants were White, Chinese, African-American, or Hispanic adults without clinical CVD. Subjects with diabetes mellitus or who were receiving lipid-lowering therapy were excluded. Every participant was classified into only 1 of 6 groups defined by specific low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, or triglyceride cut points. Multivariate linear and relative risk regressions evaluated the cross-sectional associations with CIMT and CAC after adjusting for CVD risk factors. Interactions with race, sex, and high-sensitivity C-reactive protein were evaluated for CIMT and CAC outcomes. RESULTS: Among 4,792 participants, only those with combined hyperlipidemia and hypercholesterolemia demonstrated both increased common CIMT (combined hyperlipidemia 0.048 mm thicker, 95% confidence interval [CI]: 0.016 to 0.080 mm; hypercholesterolemia 0.048 mm thicker, 95% CI: 0.029 to 0.067 mm) and internal CIMT (combined hyperlipidemia 0.120 mm thicker, 95% CI: 0.032 to 0.208 mm; and hypercholesterolemia 0.161 mm thicker, 95% CI: 0.098 to 0.223 mm) as well as increased risk for prevalent CAC (combined hyperlipidemia relative risk: 1.22, 95% CI: 1.08 to 1.38; hypercholesterolemia relative risk: 1.22, 95% CI: 1.11 to 1.34) compared with normolipemia. The interactions between lipid parameters and race, sex, or high-sensitivity C-reactive protein were not significant for any outcomes. CONCLUSIONS: Combined hyperlipidemia and simple hypercholesterolemia were associated with increased CIMT and prevalent CAC in a relatively healthy multiethnic population. Copyright [copyright sign] 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiology, Department of Internal Medicine, University of Washington, Seattle, Washington 98104, USA. nmbob@u.washington.eduCM - Comment in: J Am Coll Cardiol. 2010 Sep 21;56(13):1042-4; PMID: 20846603JC - h50, 8301365CP - United StatesPT - Clinical TrialPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - 1KL2RR025015-01 (United States NCRR NIH HHS)NO - N01-HC-95159 (United States NHLBI NIH HHS)NO - N01-HC-95165 (United States NHLBI NIH HHS)NO - N01-HC-95167 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20846602</style></custom1><custom3><style face="normal" font="default">AS - J Am Coll Cardiol. 56(13):1034-41, 2010 Sep 21.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>279</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Paramsothy,P.</style></author><author><style face="normal" font="default"> Katz,R.</style></author><author><style face="normal" font="default"> Owens,D.S.</style></author><author><style face="normal" font="default"> Burke,G.L.</style></author><author><style face="normal" font="default"> Probstfield,J.L.</style></author><author><style face="normal" font="default"> O'Brien,K.D.</style></author></authors></contributors><titles><title><style face="normal" font="default">Age-modification of lipoprotein, lipid, and lipoprotein ratio-associated risk for coronary artery calcium (from the Multi-Ethnic Study of Atherosclerosis [MESA])</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="358" start="352">352-358</pages><volume><style face="normal" font="default">105</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Atherosclerosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Lipids/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol,LDL)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipids)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipoproteins)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Biological Markers</style></keyword><keyword><style face="normal" font="default"> Calcinosis/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cholesterol,LDL/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lipoproteins/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Washington/ep [Epidemiology]</style></keyword></keywords><dates><year Day="1" Month="2" Year="2010">2010/2/1</year></dates><abstract><style face="normal" font="default">Although abnormal lipoproteins and lipoprotein ratios are powerful risk factors for clinical cardiovascular events, these associations are stronger in younger than in older subjects. Whether age modifies the relation of lipoproteins and lipoprotein ratios to the relative risk of subclinical cardiovascular disease (CVD), as assessed by coronary artery calcium (CAC) scores, has not been examined in a contemporary, multiethnic cohort. We performed multivariate relative risk regression analyses to determine the relative risks for associations of lipoproteins and lipoprotein ratios with prevalent CAC in participants in Multi-Ethnic Study of Atherosclerosis (MESA). The participants were community-dwelling adults aged 45 to 84 years without clinically apparent CVD at baseline. We excluded those taking lipid-lowering therapy (15%) and stratified the results by decades of age. A total of 5,092 participants met the inclusion criteria. In the fully adjusted models, per SD of low-density lipoprotein, the age-stratified, adjusted relative risk for CAC was 1.17 (95% confidence interval [CI] 1.07 to 1.28) for those aged 45 to 84 years but was 1.05 (95% CI 1.01 to 1.10) for those aged 75 to 84 years (p-interaction = 0.12). The relative risk per SD of total/high-density lipoprotein cholesterol ratio was 1.20 (95% CI 1.12 to 1.29) for those aged 45 to 54 years but only 1.04 (95% CI 1.00 to 1.09) for those aged 75 to 84 years (p-interaction &lt;0.001). The lipoproteins levels and lipoprotein ratios were associated with increased relative risks for CAC across all age categories. However, these associations were markedly attenuated by age. In conclusion, abnormal lipoprotein levels in middle age are a powerful risk factor for early atherosclerosis, as manifested by prevalent CAC. Copyright 2010 Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, Division of Cardiology, University of Washington, Seattle, Washington, USA. nmbob@u.washington.eduJC - 3dq, 0207277CP - United StatesPT - Journal ArticlePT - Multicenter StudyPT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - 1KL2RR025015-01 (United States NCRR NIH HHS)NO - N01-HC-95159 (United States NHLBI NIH HHS)NO - N01-HC-95165 (United States NHLBI NIH HHS)NO - N01-HC-95167 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20102947</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 105(3):352-8, 2010 Feb 1.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>281</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Park,S.K.</style></author><author><style face="normal" font="default"> Mukherjee,B.</style></author><author><style face="normal" font="default"> Xia,X.</style></author><author><style face="normal" font="default"> Sparrow,D.</style></author><author><style face="normal" font="default"> Weisskopf,M.G.</style></author><author><style face="normal" font="default"> Nie,H.</style></author><author><style face="normal" font="default"> Hu,H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Bone lead level prediction models and their application to examine the relationship of lead exposure and hypertension in the Third National Health and Nutrition Examination Survey</style></title><secondary-title><style face="normal" font="default">Journal of Occupational &amp; Environmental Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Occupational &amp; Environmental Medicine</style></full-title></periodical><pages end="1436" start="1422">1422-1436</pages><volume><style face="normal" font="default">51</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Environmental Exposure/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> *Lead/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> *Patella/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> *Tibia/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> 7439-92-1 (Lead)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Bone and Bones/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> Bone and Bones/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hematocrit</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> Lead/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Nutrition Surveys</style></keyword><keyword><style face="normal" font="default"> Patella/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Risk Assessment/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Spectrometry,X-Ray Emission</style></keyword><keyword><style face="normal" font="default"> Tibia/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> United States Department of Veterans Affairs</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><abstract><style face="normal" font="default">OBJECTIVE: We developed prediction models for bone lead using blood lead levels and other standard covariates in a community-based cohort of older men. METHODS: Participants having bone lead levels measured by K X-ray fluorescence were included in the model selection process (n = 825). Predictors of each tibia and patella lead were identified in three quarters of the population and then predicted the bone lead levels in the remaining one quarter and in the Community Lead Study. RESULTS: Eighteen predictors were selected for tibia (blood lead, age, education, occupation, smoking status, pack-years of cigarette, serum levels of phosphorus, uric acid, calcium, creatinine and total and high-density lipoprotein cholesterols, hematocrit, body mass index, systolic and diastolic blood pressure, and diagnoses of cancer and diabetes; R2 = 0.32) and 16 for patella lead (among the predictors included in the tibia model diagnosis of cancer, serum levels of calcium, and total cholesterol were not included in patella lead model, but diagnosis of hypertension was included; R2 = 0.34), respectively. The correlation coefficients between the observed and predicted values were 0.43 to 0.50 for tibia and 0.52 to 0.58 for patella lead in internal and external validation. We applied these predicted bone lead models to the Third National Health and Nutrition Examination Survey (NHANES-III) to examine associations with hypertension and found relatively more significant associations compared with blood lead. CONCLUSIONS: This study suggests that the prediction equations may be used to predict bone lead levels in other community-based cohorts with reasonable accuracy</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Environmental Health Sciences, University of Michigan School of Public Health, Ann Arbor, MI 48109, USAJC - b7h, 9504688CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, U.S. Gov't, Non-P.H.SPT - Validation StudiesNO - ES10798 (United States NIEHS NIH HHS)NO - K01-ES016587-01A1 (United States NIEHS NIH HHS)NO - P30-ES00002 (United States NIEHS NIH HHS)NO - R01-ES05257 (United States NIEHS NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19952788</style></custom1><custom3><style face="normal" font="default">AS - J Occup Environ Med. 51(12):1422-36, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>544</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Park,W.</style></author><author><style face="normal" font="default"> Kim,B.S.</style></author><author><style face="normal" font="default"> Lee,J.E.</style></author><author><style face="normal" font="default"> Huh,J.K.</style></author><author><style face="normal" font="default"> Kim,B.J.</style></author><author><style face="normal" font="default"> Sung,K.C.</style></author><author><style face="normal" font="default"> Kang,J.H.</style></author><author><style face="normal" font="default"> Lee,M.H.</style></author><author><style face="normal" font="default"> Park,J.R.</style></author><author><style face="normal" font="default"> Rhee,E.J.</style></author><author><style face="normal" font="default"> Oh,K.W.</style></author><author><style face="normal" font="default"> Lee,W.Y.</style></author><author><style face="normal" font="default"> Park,C.Y.</style></author><author><style face="normal" font="default"> Park,S.W.</style></author><author><style face="normal" font="default"> Kim,S.W.</style></author></authors></contributors><titles><title><style face="normal" font="default">Serum phosphate levels and the risk of cardiovascular disease and metabolic syndrome: a double-edged sword</style></title><secondary-title><style face="normal" font="default">Diabetes Research &amp; Clinical Practice</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Diabetes Research &amp; Clinical Practice</style></full-title></periodical><pages end="125" start="119">119-125</pages><volume><style face="normal" font="default">83</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiovascular Diseases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Metabolic Syndrome X/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Phosphates/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol,HDL)</style></keyword><keyword><style face="normal" font="default"> 0 (Phosphates)</style></keyword><keyword><style face="normal" font="default"> 0 (Serum Albumin)</style></keyword><keyword><style face="normal" font="default"> 11061-68-0 (Insulin)</style></keyword><keyword><style face="normal" font="default"> 57-88-5 (Cholesterol)</style></keyword><keyword><style face="normal" font="default"> 69-93-2 (Uric Acid)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Cholesterol,HDL</style></keyword><keyword><style face="normal" font="default"> Cholesterol/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Fasting</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Insulin/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Metabolic Syndrome X/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Serum Albumin/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Uric Acid/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Waist Circumference</style></keyword></keywords><dates><year Day="0" Month="1" Year="2009">2009/1</year></dates><abstract><style face="normal" font="default">This study was performed to evaluate the relationship between serum phosphate levels and cardiovascular risk factors and metabolic syndrome components in a cross-sectional survey. Plasma phosphate was measured by immunoturbidimetry in 46,798 subjects over 20 years of age with an estimated GFR>or=60 mL/(min 1.73 m(2)) who participated in a health-check survey at the Kangbuk Samsung Hospital in South Korea. The median plasma phosphate level was 3.49+/-0.44 mg/dL and the mean estimated GFR was 77.46+/-8.51 mL/(min 1.73 m(2)). We found that serum phosphate levels had a positive correlation with total cholesterol, HDL-C, lipoprotein a, apolipoprotein A1, calcium, and albumin. In addition, serum phosphate levels had a negative correlation with age, body mass index, uric acid, fasting glucose, insulin, HOMA-IR, HS-CRP, triglyceride levels, systolic blood pressure, diastolic blood pressure, and waist circumference (P&lt;0.001). In conclusion, we found that a high phosphate level is correlated with cardiovascular disease while a lower phosphate level is correlated with metabolic syndrome. Serum phosphate levels that were too high or too low correlated with cardiovascular risk factors and elements of metabolic syndrome, respectively, showing that it may be important to maintain an appropriate level of phosphate for the prevention of cardiovascular events and metabolic syndrome</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South KoreaJC - ebi, 8508335CP - IrelandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19101054</style></custom1><custom3><style face="normal" font="default">AS - Diabetes Res Clin Pract. 83(1):119-25, 2009 Jan.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>145</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Parker,B.D.</style></author><author><style face="normal" font="default"> Bauer,D.C.</style></author><author><style face="normal" font="default"> Ensrud,K.E.</style></author><author><style face="normal" font="default"> Ix,J.H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Association of osteocalcin and abdominal aortic calcification in older women: the study of osteoporotic fractures</style></title><secondary-title><style face="normal" font="default">Calcified Tissue International</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Calcified Tissue International</style></full-title></periodical><pages end="191" start="185">185-191</pages><volume><style face="normal" font="default">86</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aorta,Abdominal/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Aortic Diseases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Aortic Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Osteocalcin/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 104982-03-8 (Osteocalcin)</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aorta,Abdominal/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Aorta,Abdominal/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Aortic Diseases/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Biological Markers/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Bone Density/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Bone Development/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Bone Regeneration/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fractures,Bone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Fractures,Bone/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Hypertension/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Osteocalcin/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Osteoporosis,Postmenopausal/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Osteoporosis,Postmenopausal/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="3" Year="2010">2010/3</year></dates><abstract><style face="normal" font="default">Osteocalcin (OC) is produced by osteoblasts and vascular smooth muscle cells. In animal models, serum OC levels are strongly correlated with vascular calcium content, however, the association of OC with vascular calcification in humans is uncertain. The Study of Osteoporotic Fractures (SOF) enrolled community-living women, age > or =65 years. The present study included a subsample of 363 randomly selected SOF participants. Serum total OC was measured by ELISA, and abdominal aortic calcification (AAC) was evaluated on lateral lumbar radiographs. We examined the cross-sectional association between serum OC and AAC. The mean serum OC level was 24 +/- 11 ng/ml and AAC was present in 188 subjects (52%). We observed no association of OC and AAC in either unadjusted or adjusted analyses. For example, each standard deviation higher OC level was associated with an odds ratio (OR) for AAC prevalence (AAC score >0) near unity (OR = 1.06; 95% CI, 0.82-1.36) in models adjusted for CVD risk factors. Further adjustment for intact parathyroid hormone, bone-specific alkaline phosphatase, 25-hydroxyvitamin D, and hip and spine bone mineral density did not materially change the results (OR = 1.22; 95% CI, 0.86-1.75). Similarly, higher OC levels were not associated with severity of AAC (P = 0.87). In conclusion, among community-living older women, serum OC is not associated with AAC. These findings suggest that serum OC levels may more closely reflect bone formation than vascular calcification in humans</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Nephrology and Hypertension, Department of Medicine, University of California, San Diego, San Diego, CA 92093, USAJC - cgh, 7905481CP - United StatesPT - Journal ArticlePT - Multicenter StudyPT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - 2 R01 AG005394-22A1 (United States NIA NIH HHS)NO - 2 R01 AG027574-22A1 (United States NIA NIH HHS)NO - AG05394 (United States NIA NIH HHS)NO - AG05407 (United States NIA NIH HHS)NO - AR35582 (United States NIAMS NIH HHS)NO - AR35583 (United States NIAMS NIH HHS)NO - AR35584 (United States NIAMS NIH HHS)NO - R01 AG005407 (United States NIA NIH HHS)NO - R01 AG027576-22 (United States NIA NIH HHS)NO - R21 HL091217 (United States NHLBI NIH HHS)NO - R21 HL091217-01A2S1 (United States NHLBI NIH HHS)NO - T32 HL007261 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20094707</style></custom1><custom3><style face="normal" font="default">AS - Calcif Tissue Int. 86(3):185-91, 2010 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>474</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Patel,M.J.</style></author><author><style face="normal" font="default"> de Lemos,J.A.</style></author><author><style face="normal" font="default"> McGuire,D.K.</style></author><author><style face="normal" font="default"> See,R.</style></author><author><style face="normal" font="default"> Lindsey,J.B.</style></author><author><style face="normal" font="default"> Murphy,S.A.</style></author><author><style face="normal" font="default"> Grundy,S.M.</style></author><author><style face="normal" font="default"> Khera,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Evaluation of coronary artery calcium screening strategies focused on risk categories: the Dallas Heart Study</style></title><secondary-title><style face="normal" font="default">American Heart Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Heart Journal</style></full-title></periodical><pages end="1009" start="1001">1001-1009</pages><volume><style face="normal" font="default">157</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Mass Screening</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Texas</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="6" Year="2009">2009/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: A strategy using coronary artery calcium (CAC) screening to refine coronary heart disease risk assessment in moderately high risk (MHR) subjects (10-year risk 10%-20%) has been suggested. The potential impact of this strategy is unknown. METHODS: Coronary artery calcium screening strategies focused on MHR subjects were modeled in 2,610 subjects aged 30 to 65 years undergoing Framingham risk scoring and CAC assessment in the Dallas Heart Study. The proportions of subjects eligible for imaging and reclassified from MHR to high risk (HR) (10-year risk >20%) based upon CAC scores were determined. RESULTS: Only 1.0% of women and 15.4% of men were at MHR by Framingham risk scoring and thus eligible for imaging, and &lt;0.1% and 1.1% respectively, changed from MHR to HR using a CAC threshold > or = 400. Coronary artery calcium imaging targeting MHR subjects was also relatively inefficient (>100 women, 14.3 men scanned per subject reclassified). Restricting to an older age range (45-65 years) or expanding the MHR group to 6% to 20% risk had virtually no impact on risk assessment in women. In a secondary analysis, a proposed imaging strategy targeting promotion of subjects from lower risk to MHR was more efficient and had greater yield than current recommendations targeting promotion from MHR to HR. CONCLUSIONS: Coronary artery calcium screening strategies focused on MHR subjects will have a negligible impact on risk assessment in women and a modest impact in men. Further studies are needed to optimize the use of CAC screening as an adjunct to coronary heart disease risk assessment, especially for women and those at seemingly lower risk</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiology, The University of Texas-Southwestern Medical Center, Dallas, TX, USA. mahesh.patel@duke.eduJC - 0370465CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19464410</style></custom1><custom3><style face="normal" font="default">AS - Am Heart J. 157(6):1001-9, 2009 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>278</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Penugonda,N.</style></author><author><style face="normal" font="default"> Billecke,S.S.</style></author><author><style face="normal" font="default"> Yerkey,M.W.</style></author><author><style face="normal" font="default"> Rebner,M.</style></author><author><style face="normal" font="default"> Marcovitz,P.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Usefulness of breast arterial calcium detected on mammography for predicting coronary artery disease or cardiovascular events in women with angina pectoris and/or positive stress tests</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="361" start="359">359-361</pages><volume><style face="normal" font="default">105</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Angina Pectoris/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Exercise Test</style></keyword><keyword><style face="normal" font="default"> *Mammary Arteries/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Mammography</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angina Pectoris/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Medical Records</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="1" Month="2" Year="2010">2010/2/1</year></dates><abstract><style face="normal" font="default">Breast arterial calcium (BAC) has been suggested as a marker and predictor of cardiovascular risk and coronary artery disease (CAD). However, an association between BAC and these cardiovascular end points has not been fully elucidated in patients undergoing cardiac catheterization. Consecutive patients undergoing mammography and cardiac catheterization within a 36-month period were retrospectively evaluated through chart review. Cardiac catheterization films and mammograms from 94 patients were independently reviewed for the presence of CAD and BAC, respectively. Cardiovascular risk factors, history of revascularization, and history of myocardial infarction were compared between women with and without BAC. BAC was more prevalent in older women (mean age 69 + or - 10 vs 63 + or - 11 years, p = 0.02). Aside from an inverse correlation with smoking, there was no difference in the presence of CAD or cardiovascular risk factors between patients with and without BAC. Patients with BAC had a lesser history of acute myocardial infarction (21% vs 41%, p &lt;0.05) and were less likely to undergo revascularization (23% vs 43%, p &lt;0.05). In conclusion, BAC was not positively associated with cardiovascular risk factors, documented CAD, or acute cardiovascular events, suggesting that the presence of BAC as determined by mammography is not a useful predictor of CAD in intermediate- to high-risk patients. Copyright 2010. Published by Elsevier Inc</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - William Beaumont Hospital, Royal Oak, Michigan, USAJC - 3dq, 0207277CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20102948</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 105(3):359-61, 2010 Feb 1.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>310</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Peralta,C.A.</style></author><author><style face="normal" font="default"> Adeney,K.L.</style></author><author><style face="normal" font="default"> Shlipak,M.G.</style></author><author><style face="normal" font="default"> Jacobs,D.,Jr.</style></author><author><style face="normal" font="default"> Duprez,D.</style></author><author><style face="normal" font="default"> Bluemke,D.</style></author><author><style face="normal" font="default"> Polak,J.</style></author><author><style face="normal" font="default"> Psaty,B.</style></author><author><style face="normal" font="default"> Kestenbaum,B.R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Structural and functional vascular alterations and incident hypertension in normotensive adults: the Multi-Ethnic Study of Atherosclerosis</style></title><secondary-title><style face="normal" font="default">American Journal of Epidemiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Epidemiology</style></full-title></periodical><pages end="71" start="63">63-71</pages><volume><style face="normal" font="default">171</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aorta/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Carotid Arteries/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Hypertension/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Hypertension/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Elasticity</style></keyword><keyword><style face="normal" font="default"> Ethnic Groups</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Models,Statistical</style></keyword><keyword><style face="normal" font="default"> Poisson Distribution</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> United States/ep [Epidemiology]</style></keyword></keywords><dates><year Day="1" Month="1" Year="2010">2010/1/1</year></dates><abstract><style face="normal" font="default">Vascular abnormalities may exist before clinical hypertension. Using Poisson regression, the authors studied the association of coronary artery calcium (CAC), common carotid intima-media thickness (CIMT), aortic distensibility, and large and small arterial elasticity with incident hypertension among 2,512 normotensive US adults free of cardiovascular disease. Incidence rate ratios for incident hypertension (blood pressure > or =140/90 mm Hg or new antihypertensive medication) were calculated. Increased CAC was associated with incident hypertension in demographics-adjusted models (incidence rate ratio (IRR) = 1.35, 95% confidence interval (CI): 1.04, 1.75; IRR = 1.35, 95% CI: 1.02, 1.78; and IRR = 1.59, 95% CI: 1.12, 2.25 for CAC scores of 30-99, 100-399, and > or =400, respectively) but was attenuated after further adjustment. Increased common CIMT was associated with incident hypertension (IRR = 1.77, 95% CI: 1.28, 2.46 for quintile 4; IRR = 1.80, 95% CI: 1.28, 2.53 for quintile 5). Participants with the lowest, compared with the highest, aortic distensibility had an increased risk of hypertension (IRR = 1.75, 95% CI: 1.10, 2.79), as did those with the lowest large arterial elasticity (IRR = 1.49, 95% CI: 1.11, 1.99). Lower small arterial elasticity was incrementally associated with incident hypertension starting at quintile 2 (IRR = 2.01, 95% CI: 1.39, 2.91; IRR = 2.47, 95% CI: 1.71, 3.57; IRR = 2.73, 95% CI: 1.88, 3.95; and IRR = 2.85, 95% CI: 1.95, 4.16). Structural and functional vascular abnormalities are independent predictors of incident hypertension. These findings are important for understanding the pathogenesis of hypertension</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - General Internal Medicine Section 111A1, VA Medical Center, 4150 Clement Street, San Francisco, CA 94124, USA. carmenalicia.peralta@ucsf.eduJC - 3h3, 7910653CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - KL2 RR024130 (United States NCRR NIH HHS)NO - N01-HC-95159 (United States NHLBI NIH HHS)NO - N01-HC-95165 (United States NHLBI NIH HHS)NO - N01-HC-95169 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19951938</style></custom1><custom3><style face="normal" font="default">AS - Am J Epidemiol. 171(1):63-71, 2010 Jan 1.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>254</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Pessana,F.</style></author><author><style face="normal" font="default"> Armentano,R.</style></author><author><style face="normal" font="default"> Chironi,G.</style></author><author><style face="normal" font="default"> Megnien,J.L.</style></author><author><style face="normal" font="default"> Mousseaux,E.</style></author><author><style face="normal" font="default"> Simon,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Subclinical atherosclerosis modeling: Integration of coronary artery calcium score to Framingham equation</style></title><secondary-title><style face="normal" font="default">Conference Proceedings:</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Conference Proceedings:</style></full-title></periodical><pages end="51" start="International">International-51</pages><volume><style face="normal" font="default">Annual</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Models,Cardiovascular</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age Distribution</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Argentina</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Linear Models</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> ROC Curve</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><isbn><style face="normal" font="default">1557-170X</style></isbn><abstract><style face="normal" font="default">Medical prevention consists to identify as soon as possible apparently healthy individuals who develop a disease and to engage them for active preventive treatment. Several cross-sectional studies of general populations or high cardiovascular risk have shown that coronary calcium score (coronary artery calcium, CAC) was positively associated with traditional risk factors (hypertension, dyslipidemia, diabetes, and smoking) and some new risk factors (fibrinogen). In this work, we first calculated, among 618 men, the risk of 10-years cardiovascular heart disease (CHD) according to the Framingham risk model, and then we calculated the probability that the CAC score of an individual falls in all four CAC categories (0, 1-100, 101-400 and > 400). We obtained risk factors adjusted relative risk (RR) estimates from a meta-analysis comparing the risk of coronary heart disease in individuals with CAC scores of 1-100 (RR = 1.7), 101 - 400 (RR = 3.0) and > 400 (RR = 4.3) with the risk of a person with a CAC score zero. The new model for the risk of CHD for each CAC score category were then calculated assuming an average 1-year risk of CHD and risk assessment of the four CAC score categories, weighted by the probability that scores fall into each category. The combination of modeling the CCA with the modeling of conventional risk factors allows obtaining a remarkable predictive value that can improve the assessment of overall risk Framingham through the reclassification of the risk of CHD to an extent which may be clinically important</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Faculty of Engineering and Exact and Natural Sciences, Favaloro University, Buenos Aires, Argentina. fpessana@favaloro.edu.arJC - 101243413CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19964672</style></custom1><custom3><style face="normal" font="default">AS - Conf Proc IEEE Eng Med Biol Soc. 2009:5348-51, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>319</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">pez,de Guzm</style></author><author><style face="normal" font="default"> de,D.Garc</style></author><author><style face="normal" font="default"> ez,P.</style></author><author><style face="normal" font="default"> Cuende,Quintana E.</style></author><author><style face="normal" font="default"> nchez,Atrio A.</style></author><author><style face="normal" font="default"> Sivera,Monz</style></author></authors></contributors><titles><title><style face="normal" font="default">[Coronary calcification and subclinical myocardial dysfuncion in rheumatoid arthritis]. [Spanish]</style></title><secondary-title><style face="normal" font="default">Revista Clinica Espanola</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Revista Clinica Espanola</style></full-title></periodical><pages end="432" start="428">428-432</pages><volume><style face="normal" font="default">209</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Arthritis,Rheumatoid/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Cardiomyopathies/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><isbn><style face="normal" font="default">0014-2565</style></isbn><abstract><style face="normal" font="default">Rheumatoid arthritis (RA) is characterized by high cardiovascular (CV) mortality, which has been related to systemic inflammation. Our aim was to analyze coronary calcification by computed tomography and subclinical myocardial dysfunction evaluated by brain natriuretic peptide (BNP) levels and an electrocardiogram in RA patients and its relationship with disease characteristics. Seventy-three RA patients and same number of controls formed by osteoarthritis patients were studied, all without a background of cardiovascular clinical events. RA patients had a higher calcium score than the control group (19.2% vs. 11%; p=0.17)), this being associated with disease duration. BNP levels (90.0 vs. 45.4; p=0.003), corrected QT length, large QT frequency and silent myocardial infarct were higher in the RA group. In conclusion, RA patients showed more coronary calcification frequency than in general population and more biochemical and electrocardiogram myocardial subclinical dysfunction signs. Copyright (c) 2008 Elsevier Espa&amp;#x00F1;a, S.L. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Servicio de Medicina Interna, Hospital Universitario Pr&amp;#x00ED;ncipe de Asturias, Universidad de Alcal&amp;#x00E1;, Alcal&amp;#x00E1; de Henares, Madrid, Spain. aloguz2001@yahoo.esOT - Calcificaci&amp;#x00F3;n coronaria y disfunci&amp;#x00F3;n mioc&amp;#x00E1;rdica subcl&amp;#x00ED;nica en la artritis reumatoideJC - rnl, 8608576CP - SpainPT - English AbstractPT - Journal ArticleLG - Spanish</style></notes><urls/><custom1><style face="normal" font="default">UI - 19852912</style></custom1><custom3><style face="normal" font="default">AS - Rev Clin Esp. 209(9):428-32, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>476</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Piers,L.H.</style></author><author><style face="normal" font="default"> Touw,H.R.</style></author><author><style face="normal" font="default"> Gansevoort,R.</style></author><author><style face="normal" font="default"> Franssen,C.F.</style></author><author><style face="normal" font="default"> Oudkerk,M.</style></author><author><style face="normal" font="default"> Zijlstra,F.</style></author><author><style face="normal" font="default"> Tio,R.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Relation of aortic valve and coronary artery calcium in patients with chronic kidney disease to the stage and etiology of the renal disease</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="1477" start="1473">1473-1477</pages><volume><style face="normal" font="default">103</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aortic Valve/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Heart Valve Diseases/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure,Chronic/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Valve Diseases/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Statistics,Nonparametric</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="15" Month="5" Year="2009">2009/5/15</year></dates><abstract><style face="normal" font="default">Patients with chronic renal failure have increased cardiac calcium loads. Previous studies have investigated the prevalence and quantitative extent of aortic valve calcium (AVC) and coronary artery calcium (CAC) in patients with various stages of chronic kidney disease (CKD). However, the impact of preexisting atherosclerosis on the calcification burden has not been clarified. Therefore, this study was conducted to examine the effect of CKD stage as well as the primary cause of renal failure (atherosclerotic vs nonatherosclerotic) on AVC and CAC. Twenty-two, 13, and 28 patients with stage 3, 4, and 5 CKD, respectively, were included, of whom 24 had atherosclerotic CKD. Patients underwent electron-beam computed tomography to assess AVC and CAC. AVC was present in 27% of patients with stage 3 CKD, in 38% of patients with stage 4 CKD, and in 43% of patients with stage 5 CKD. CAC was present in 77% of patients with stage 3 CKD, in 54% of patients with stage 4 CKD, and in 64% of patients with stage 5 CKD. There was no correlation between CKD stage and the quantitative extent of AVC and CAC. AVC was more frequent (58% vs 23%, p &lt;0.01) and more extensive (median score 43 [range 0 to 494] vs 0 [range 0 to 8], p &lt;0.01) in patients with CKD caused by atherosclerotic renal disease than in patients with nonatherosclerotic causes of CKD. CAC was more frequent (83% vs 56%, p &lt;0.05) and more extensive (median score 437 [range 61 to 1,565] vs 31 [range 0 to 155], p &lt;0.001) in patients with atherosclerotic causes of CKD than in patients with CKD caused by nonatherosclerotic renal disease. In conclusion, the prevalence as well as the severity of AVC and CAC did not vary between patients with stage 3, 4, and 5 CKD. Cardiac calcification, both AVC and CAC, were more frequent and more severe in patients with atherosclerotic causes of renal failure. These results suggest that cardiac calcium is related to atherosclerotic burden rather than to the severity of CKD</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. l.h.piers@thorax.umcg.nlJC - 3dq, 0207277CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19427449</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 103(10):1473-7, 2009 May 15.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>322</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Pikilidou,M.I.</style></author><author><style face="normal" font="default"> Befani,C.D.</style></author><author><style face="normal" font="default"> Sarafidis,P.A.</style></author><author><style face="normal" font="default"> Nilsson,P.M.</style></author><author><style face="normal" font="default"> Koliakos,G.G.</style></author><author><style face="normal" font="default"> Tziolas,I.M.</style></author><author><style face="normal" font="default"> Kazakos,K.A.</style></author><author><style face="normal" font="default"> Yovos,J.G.</style></author><author><style face="normal" font="default"> Lasaridis,A.N.</style></author></authors></contributors><titles><title><style face="normal" font="default">Oral calcium supplementation ambulatory blood pressure and relation to changes in intracellular ions and sodium-hydrogen exchange</style></title><secondary-title><style face="normal" font="default">American Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Hypertension</style></full-title></periodical><pages end="1269" start="1263">1263-1269</pages><volume><style face="normal" font="default">22</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Blood Pressure/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> *Calcium,Dietary/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 2/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Hypertension/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Sodium-Hydrogen Antiporter/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Calcium,Dietary)</style></keyword><keyword><style face="normal" font="default"> 0 (growth factor-activatable Na-H exchanger NHE-1)</style></keyword><keyword><style face="normal" font="default"> 0 (Sodium-Hydrogen Antiporter)</style></keyword><keyword><style face="normal" font="default"> 7439-95-4 (Magnesium)</style></keyword><keyword><style face="normal" font="default"> 7440-09-7 (Potassium)</style></keyword><keyword><style face="normal" font="default"> 7440-23-5 (Sodium)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Dietary Supplements</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Magnesium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Potassium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Single-Blind Method</style></keyword><keyword><style face="normal" font="default"> Sodium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Calcium (Ca2+) supplementation has been shown paradoxically to reduce intracellular Ca2+ and induce vascular relaxation. The aim of the study was to assess 24-h blood pressure (BP) change after Ca2+ supplementation and to investigate its relation to changes in intracellular ions and the activity of the first isoform of sodium-hydrogen exchange (NHE-1) in subjects with hypertension and type 2 diabetes. METHODS: This parallel, randomized controlled, single-blinded trial, consisted of 31 patients with type 2 diabetes, and hypertension who were allocated to receive 1,500 mg of Ca2+ per day (n = 15) or no treatment (n = 16) for 8 weeks. RESULTS: In the Ca2+ group a decrease of 1.7 +/- 2.7 mm Hg (mean +/- SE) P = 0.52 for mean 24-h systolic BP (SBP) and 2.1 +/- 1.5 mm Hg, P = 0.19 for mean 24-h diastolic BP (DBP) was recorded. Whereas in the control group an increase of 1.4 +/- 2.7 mm Hg, P = 0.59 for mean 24-h SBP and 1.2 +/- 2.8 mm Hg, P = 0.83 for mean 24-h DBP was observed. Intraplatelet Ca2+ decreased whereas intraplatelet magnesium (Mg2+) and erythrocyte K+ increased in the intervention group. Change in mean 24-h SBP in the pooled group correlated with both change in intraplatelet Ca2+ (r = 0.49, P &lt; 0.05) and NHE-1 activity (r = 0.6, P &lt; 0.001). The contribution of intraplatelet Ca2+ was attenuated when both parameters were entered in a multivariate regression model. CONCLUSIONS: The present study shows a weak, statistically nonsignificant trend towards association of Ca2+ supplementation on 24-h BP in hypertensive subjects with type 2 diabetes. However, our results indicated an interrelation of [Ca2+]i levels and NHE-1 activity on BP in patients with hypertension and type 2 diabetes</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - 1st Department of Internal Medicine, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece. m_pikilidou@yahoo.comJC - aji, 8803676CP - United StatesPT - Journal ArticlePT - Randomized Controlled TrialPT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19779467</style></custom1><custom3><style face="normal" font="default">AS - Am J Hypertens. 22(12):1263-9, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>7</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Plaza,Santos R.</style></author><author><style face="normal" font="default"> Jaquotot,Herranz M.</style></author><author><style face="normal" font="default"> Froilan,Torres C.</style></author><author><style face="normal" font="default"> Poza,Cordon J.</style></author><author><style face="normal" font="default"> Casado,Verrier B.</style></author><author><style face="normal" font="default"> de Tena Diaz-Agero FL</style></author><author><style face="normal" font="default"> Vazquez,Lopez P.</style></author><author><style face="normal" font="default"> Suarez de Parga,J.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Leukocytoclastic vasculitis associated with Crohn's disease]. [Spanish]</style></title><secondary-title><style face="normal" font="default">Gastroenterologia y Hepatologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Gastroenterologia y Hepatologia</style></full-title></periodical><pages end="435" start="433">433-435</pages><volume><style face="normal" font="default">33</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Crohn Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Vasculitis,Leukocytoclastic,Cutaneous/co [Complications]</style></keyword><keyword><style face="normal" font="default"> 0 (Analgesics)</style></keyword><keyword><style face="normal" font="default"> 0 (Anti-Inflammatory Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Anti-Inflammatory Agents,Non-Steroidal)</style></keyword><keyword><style face="normal" font="default"> 0 (Heparin,Low-Molecular-Weight)</style></keyword><keyword><style face="normal" font="default"> 1406-16-2 (Vitamin D)</style></keyword><keyword><style face="normal" font="default"> 50-24-8 (Prednisolone)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 89-57-6 (Mesalamine)</style></keyword><keyword><style face="normal" font="default"> Analgesics/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Anti-Inflammatory Agents,Non-Steroidal/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Anti-Inflammatory Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Calcium/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Combined Modality Therapy</style></keyword><keyword><style face="normal" font="default"> Crohn Disease/dh [Diet Therapy]</style></keyword><keyword><style face="normal" font="default"> Crohn Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Crohn Disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Crohn Disease/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Diabetes Complications</style></keyword><keyword><style face="normal" font="default"> Diet,Protein-Restricted</style></keyword><keyword><style face="normal" font="default"> Drug Therapy,Combination</style></keyword><keyword><style face="normal" font="default"> Endoscopy,Digestive System</style></keyword><keyword><style face="normal" font="default"> Enteral Nutrition</style></keyword><keyword><style face="normal" font="default"> Heparin,Low-Molecular-Weight/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Mesalamine/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prednisolone/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Vasculitis,Leukocytoclastic,Cutaneous/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Vasculitis,Leukocytoclastic,Cutaneous/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Vitamin D/tu [Therapeutic Use]</style></keyword></keywords><dates><year Day="0" Month="6" Year="2010">2010/6</year></dates><isbn><style face="normal" font="default">0210-5705</style></isbn><abstract><style face="normal" font="default">In the course of inflammatory bowel disease (IBD) a number of extraintestinal manifestations are known to occur, being the dermatological ones often associated to both ulcerative colitis and Crohn's disease. Pyoderma gangrenosum and erythema nodosum are the most frequent, but there are other skin manifestations less frequently reported such as leukocytoclastic vasculitis. We present a case, in which Crohn's disease and leukocytoclastic vasculitis were simultaneously diagnosed, and corticoids treatment achieved complete remission of the both cutaneous and gastrointestinal manifestations. Copyright 2009. Published by Elsevier Espana</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Servicio de Aparato Digestivo, Hospital Universitario La Paz, Madrid, Espana. rocio_plaza@yahoo.esOT - Vasculitis leucocitoclastica asociada a enfermedad de CrohnJC - 8406671, ce5CP - SpainPT - Case ReportsPT - English AbstractPT - Journal ArticleLG - Spanish</style></notes><urls/><custom1><style face="normal" font="default">UI - 19818534</style></custom1><custom3><style face="normal" font="default">AS - Gastroenterol Hepatol. 33(6):433-5, 2010 Jun-Jul.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>94</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Pletcher,M.J.</style></author><author><style face="normal" font="default"> Bibbins-Domingo,K.</style></author><author><style face="normal" font="default"> Liu,K.</style></author><author><style face="normal" font="default"> Sidney,S.</style></author><author><style face="normal" font="default"> Lin,F.</style></author><author><style face="normal" font="default"> Vittinghoff,E.</style></author><author><style face="normal" font="default"> Hulley,S.B.</style></author></authors></contributors><titles><title><style face="normal" font="default">Nonoptimal lipids commonly present in young adults and coronary calcium later in life: the CARDIA (Coronary Artery Risk Development in Young Adults) study</style></title><secondary-title><style face="normal" font="default">Annals of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Annals of Internal Medicine</style></full-title></periodical><pages end="146" start="137">137-146</pages><volume><style face="normal" font="default">153</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Dyslipidemias/co [Complications]</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol,HDL)</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol,LDL)</style></keyword><keyword><style face="normal" font="default"> 0 (Triglycerides)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Calcinosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Cholesterol,HDL/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cholesterol,LDL/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Dyslipidemias/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Dyslipidemias/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Triglycerides/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> United States/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="3" Month="8" Year="2010">2010/8/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: Dyslipidemia causes coronary heart disease in middle-aged and elderly adults, but the consequences of lipid exposure during young adulthood are unclear. OBJECTIVE: To assess whether nonoptimal lipid levels during young adulthood cause atherosclerotic changes that persist into middle age. DESIGN: Prospective cohort study. SETTING: 4 cities in the United States. PARTICIPANTS: 3258 participants from the 5115 black and white men and women recruited at age 18 to 30 years in 1985 to 1986 for the CARDIA (Coronary Artery Risk Development in Young Adults) study. MEASUREMENTS: Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, triglycerides, and coronary calcium. Time-averaged cumulative exposures to lipids between age 20 and 35 years were estimated by using repeated serum lipid measurements over 20 years in the CARDIA study; these measurements were then related to coronary calcium scores assessed later in life (45 years [SD, 4]). RESULTS: 2824 participants (87%) had nonoptimal levels of LDL cholesterol (>or=2.59 mmol/L [>or=100 mg/dL]), HDL cholesterol (&lt;1.55 mmol/L [&lt;60 mg/dL]), or triglycerides (>or=1.70 mmol/L [>or=150 mg/dL]) during young adulthood. Coronary calcium prevalence 2 decades later was 8% in participants who maintained optimal LDL levels (&lt;1.81 mmol/L [&lt;70 mg/dL]), and 44% in participants with LDL cholesterol levels of 4.14 mmol/L (160 mg/dL) or greater (P &lt; 0.001). The association was similar across race and sex and strongly graded, with odds ratios for coronary calcium of 1.5 (95% CI, 0.7 to 3.3) for LDL cholesterol levels of 1.81 to 2.56 mmol/L (70 to 99 mg/dL), 2.4 (CI, 1.1 to 5.3) for levels of 2.59 to 3.34 mmol/L (100 to 129 mg/dL), 3.3 (CI, 1.3 to 7.8) for levels of 3.37 to 4.12 mmol/L (130 to 159 mg/dL), and 5.6 (CI, 2.0 to 16) for levels of 4.14 mmol/L (160 mg/dL) or greater, compared with levels less than 1.81 mmol/L (&lt;70 mg/dL), after adjustment for lipid exposure after age 35 years and other coronary risk factors. Both LDL and HDL cholesterol levels were independently associated with coronary calcium after participants who were receiving lipid-lowering medications or had clinically abnormal lipid levels were excluded. LIMITATION: Coronary calcium, although a strong predictor of future coronary heart disease, is not a clinical outcome. CONCLUSION: Nonoptimal levels of LDL and HDL cholesterol during young adulthood are independently associated with coronary atherosclerosis 2 decades later. PRIMARY FUNDING SOURCE: National Heart, Lung, and Blood Institute</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California 94107, USA. mpletcher@epi.ucsf.eduCM - Comment in: Ann Intern Med. 2010 Aug 3;153(3):I25; PMID: 20679554, Comment in: Ann Intern Med. 2010 Aug 3;153(3):202-3; PMID: 20679564JC - 0372351CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - N01-HC-05187 (United States NHLBI NIH HHS)NO - N01-HC-45134 (United States NHLBI NIH HHS)NO - N01-HC-45204 (United States NHLBI NIH HHS)NO - N01-HC-45205 (United States NHLBI NIH HHS)NO - N01-HC-48047 (United States NHLBI NIH HHS)NO - N01-HC-48048 (United States NHLBI NIH HHS)NO - N01-HC-48049 (United States NHLBI NIH HHS)NO - N01-HC-48050 (United States NHLBI NIH HHS)NO - N01-HC-95095 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20679558</style></custom1><custom3><style face="normal" font="default">AS - Ann Intern Med. 153(3):137-46, 2010 Aug 3.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>127</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Polishchuk,P.R.</style></author><author><style face="normal" font="default"> Petrenko,L.I.</style></author><author><style face="normal" font="default"> Kriuchkov,M.I.</style></author><author><style face="normal" font="default"> Morozov,S.P.</style></author><author><style face="normal" font="default"> Brodetski&amp;#x012D</style></author><author><style face="normal" font="default"> BM</style></author></authors></contributors><titles><title><style face="normal" font="default">[Multiple myeloma: evaluation of invasiveness by magnetic resonance imaging]. [Russian]</style></title><secondary-title><style face="normal" font="default">Terapevticheskii Arkhiv</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Terapevticheskii Arkhiv</style></full-title></periodical><pages end="67" start="64">64-67</pages><volume><style face="normal" font="default">82</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> *Multiple Myeloma/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Tomography,Spiral Computed</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Antineoplastic Combined Chemotherapy Protocols/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Antineoplastic Combined Chemotherapy Protocols/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Diagnosis,Differential</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Multiple Myeloma/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Multiple Myeloma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Multiple Myeloma/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Invasiveness</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="0" Year="2010">2010</year></dates><isbn><style face="normal" font="default">0040-3660</style></isbn><abstract><style face="normal" font="default">The paper presents a case history of multiple myeloma in a female patient. Its diagnosis was established only 10 years after the onset of the disease, which results in severe invalidity (she was treated with calcium preparations in accordance with the diagnosis of generalized osteoporosis. Persistent therapy with calcium preparations was ineffective; the number of pathological fractures increased. Further bone study and current instrumental imaging methods could make a precise diagnosis and use etiotropic treatment, which yielded a positive clinical effect. The data on high-technology studies, body magnetic resonance imaging used in the diagnosis of the diseases accompanied by bone destructive changes are given. The problems in the diagnosis of multiple myeloma are outlined</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)JC - vlu, 2984818rCP - Russia (Federation)PT - Case ReportsPT - English AbstractPT - Journal ArticleLG - Russian</style></notes><urls/><custom1><style face="normal" font="default">UI - 20481220</style></custom1><custom3><style face="normal" font="default">AS - Ter Arkh. 82(4):64-7, 2010.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>212</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Polonsky,T.S.</style></author><author><style face="normal" font="default"> McClelland,R.L.</style></author><author><style face="normal" font="default"> Jorgensen,N.W.</style></author><author><style face="normal" font="default"> Bild,D.E.</style></author><author><style face="normal" font="default"> Burke,G.L.</style></author><author><style face="normal" font="default"> Guerci,A.D.</style></author><author><style face="normal" font="default"> Greenland,P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Coronary artery calcium score and risk classification for coronary heart disease prediction</style></title><secondary-title><style face="normal" font="default">JAMA</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">JAMA</style></full-title></periodical><pages end="1616" start="1610">1610-1616</pages><volume><style face="normal" font="default">303</style></volume><number><style face="normal" font="default">16</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/cl [Classification]</style></keyword><keyword><style face="normal" font="default"> *Cardiomyopathies/cl [Classification]</style></keyword><keyword><style face="normal" font="default"> *Coronary Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Coronary Disease/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Coronary Disease/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Forecasting</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="28" Month="4" Year="2010">2010/4/28</year></dates><abstract><style face="normal" font="default">CONTEXT: The coronary artery calcium score (CACS) has been shown to predict future coronary heart disease (CHD) events. However, the extent to which adding CACS to traditional CHD risk factors improves classification of risk is unclear. OBJECTIVE: To determine whether adding CACS to a prediction model based on traditional risk factors improves classification of risk. DESIGN, SETTING, AND PARTICIPANTS: CACS was measured by computed tomography in 6814 participants from the Multi-Ethnic Study of Atherosclerosis (MESA), a population-based cohort without known cardiovascular disease. Recruitment spanned July 2000 to September 2002; follow-up extended through May 2008. Participants with diabetes were excluded from the primary analysis. Five-year risk estimates for incident CHD were categorized as 0% to less than 3%, 3% to less than 10%, and 10% or more using Cox proportional hazards models. Model 1 used age, sex, tobacco use, systolic blood pressure, antihypertensive medication use, total and high-density lipoprotein cholesterol, and race/ethnicity. Model 2 used these risk factors plus CACS. We calculated the net reclassification improvement and compared the distribution of risk using model 2 vs model 1. MAIN OUTCOME MEASURES: Incident CHD events. RESULTS: During a median of 5.8 years of follow-up among a final cohort of 5878, 209 CHD events occurred, of which 122 were myocardial infarction, death from CHD, or resuscitated cardiac arrest. Model 2 resulted in significant improvements in risk prediction compared with model 1 (net reclassification improvement = 0.25; 95% confidence interval, 0.16-0.34; P &lt; .001). In model 1, 69% of the cohort was classified in the highest or lowest risk categories compared with 77% in model 2. An additional 23% of those who experienced events were reclassified as high risk, and an additional 13% without events were reclassified as low risk using model 2. CONCLUSION: In this multi-ethnic cohort, addition of CACS to a prediction model based on traditional risk factors significantly improved the classification of risk and placed more individuals in the most extreme risk categories</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Preventive Medicine, Northwestern University, Chicago, Illinois, USACM - Comment in: JAMA. 2010 Apr 28;303(16):1646-7; PMID: 20424257JC - 7501160CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - 1UL1RR025741 (United States NCRR NIH HHS)NO - 5T32HL069771 (United States NHLBI NIH HHS)NO - N01-HC-95159 (United States NHLBI NIH HHS)NO - N01-HC-95160 (United States NHLBI NIH HHS)NO - N01-HC-95161 (United States NHLBI NIH HHS)NO - N01-HC-95162 (United States NHLBI NIH HHS)NO - N01-HC-95163 (United States NHLBI NIH HHS)NO - N01-HC-95164 (United States NHLBI NIH HHS)NO - N01-HC-95165 (United States NHLBI NIH HHS)NO - N01-HC-95166 (United States NHLBI NIH HHS)NO - N01-HC-95167 (United States NHLBI NIH HHS)NO - N01-HC-95168 (United States NHLBI NIH HHS)NO - N01-HC-95169 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20424251</style></custom1><custom3><style face="normal" font="default">AS - JAMA. 303(16):1610-6, 2010 Apr 28.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>520</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Prasad,N.</style></author><author><style face="normal" font="default"> Kumar,S.</style></author><author><style face="normal" font="default"> Singh,A.</style></author><author><style face="normal" font="default"> Sinha,A.</style></author><author><style face="normal" font="default"> Chawla,K.</style></author><author><style face="normal" font="default"> Gupta,A.</style></author><author><style face="normal" font="default"> Sharma,R.K.</style></author><author><style face="normal" font="default"> Sinha,N.</style></author><author><style face="normal" font="default"> Kapoor,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Carotid intimal thickness and flow-mediated dilatation in diabetic and nondiabetic continuous ambulatory peritoneal dialysis patients</style></title><secondary-title><style face="normal" font="default">Peritoneal Dialysis International</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Peritoneal Dialysis International</style></full-title></periodical><pages end="S101" start="Suppl">Suppl-S101</pages><volume><style face="normal" font="default">29</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Carotid Artery Diseases/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Carotid Artery,Common/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure,Chronic/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> *Peritoneal Dialysis,Continuous Ambulatory/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Tunica Intima/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Vasodilation/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Blood Flow Velocity/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Carotid Artery Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Carotid Artery Diseases/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Carotid Artery,Common/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Dialysis</style></keyword><keyword><style face="normal" font="default"> Endothelium,Vascular/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Endothelium,Vascular/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Peritoneal Dialysis</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tunica Intima/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Ultrasonography</style></keyword></keywords><dates><year Day="0" Month="2" Year="2009">2009/2</year></dates><isbn><style face="normal" font="default">0896-8608</style></isbn><abstract><style face="normal" font="default">OBJECTIVES: We compared carotid intima media thickness (CIMT) and flow-mediated dilatation (FMD) between cases [end-stage renal disease patients (diabetic and nondiabetic) on peritoneal dialysis (PD)] and controls (diabetic and hypertensive patients with normal renal function) with the objective of identifying risk factors predicting atherosclerosis. METHODS: This cross-sectional study involved 124 subjects (62 cases, 62 controls). In both the case and control populations, we used B-mode ultrasonography to study CIMT and endothelium-dependent FMD, according to American College of Cardiology guidelines on brachial artery measurement. Pearson correlation was used to evaluate the correlation between CIMT and other variables. RESULTS: Compared with controls, cases had significantly higher systolic blood pressure, total cholesterol, low-density lipoprotein cholesterol, triglycerides, serum uric acid, inorganic phosphate, C-reactive protein, and parathyroid hormone, and significantly lower hemoglobin, calcium, and high-density lipoprotein. Compared with controls, cases showed significantly greater CIMT (0.60 +/- 0.08 mm vs 0.54 +/- 0.03 mm, p &lt; 0.001) and significantly lower FMD (0.15 +/- 0.08 cm vs 0.21 +/- 0.04 cm, p = 0.02). Among cases, patients with diabetes had significantly greater CIMT (0.62 +/- 0.08 mm vs 0.58 +/- 0.07 mm, p = 0.05) than did patients without diabetes; FMD was similar in diabetic and nondiabetic patients on continuous ambulatory PD (0.16 +/- 0.03 cm vs 0.18 +/- 0.03 cm, p = 0.20). CONCLUSIONS: Compared with controls, cases had significantly higher CIMT and lower FMD. Cases with diabetes had significantly higher CIMT than did cases without diabetes, but FMD was similar in diabetic and nondiabetic cases. Serum inorganic phosphate is an independent risk factor for atherosclerosis and was significantly correlated with CIMT. The noninvasive CIMT and FMD tests can be used to monitor atherosclerosis and endothelial dysfunction</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Nephrology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. narayan@sgpgi.ac.inJC - a2i, 8904033CP - CanadaPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19270241</style></custom1><custom3><style face="normal" font="default">AS - Perit Dial Int. 29 Suppl 2:S96-S101, 2009 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>323</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Pratte,K.A.</style></author><author><style face="normal" font="default"> Bar&amp;#x00F3</style></author><author><style face="normal" font="default">n AE</style></author><author><style face="normal" font="default"> Ogden,L.G.</style></author><author><style face="normal" font="default"> Hassell,K.L.</style></author><author><style face="normal" font="default"> Rewers,M.</style></author><author><style face="normal" font="default"> Hokanson,J.E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Plasminogen activator inhibitor-1 is associated with coronary artery calcium in Type 1 diabetes</style></title><secondary-title><style face="normal" font="default">Journal of Diabetes &amp; its Complications</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Diabetes &amp; its Complications</style></full-title></periodical><pages end="393" start="387">387-393</pages><volume><style face="normal" font="default">23</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Artery Disease/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 1/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 1/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Plasminogen Activator Inhibitor 1/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Plasminogen Activator Inhibitor 1)</style></keyword><keyword><style face="normal" font="default"> 0 (SERPINE1 protein,human)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Calcinosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Diabetic Angiopathies/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Diabetic Angiopathies/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Insulin Resistance</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="11" Year="2009">2009/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Elevated levels of plasminogen activator inhibitor-1 (PAI-1), the major inhibitor of fibrinolysis, is associated with coronary artery disease (CAD). This association may not be independent of factors related to insulin resistance (IR). Patients with Type 1 diabetes mellitus have increased CAD and an increase in sub-clinical CAD which develops earlier in life. It is not known if PAI-1 is associated with sub-clinical CAD in Type 1 diabetes or if this association is independent of IR. METHODS AND RESULTS: Type 1 diabetes patients (n=560) and participants without diabetes (n=693) were assessed for coronary artery calcium (CAC), a surrogate for subclinical CAD, by electron-beam computed tomography. PAI-1 was associated with CAC in both Type 1 diabetes (OR=1.32, 95% CI=1.12-1.58) and non-diabetes (OR=1.34, 95% CI=1.13-1.58), after controlling for traditional risk factors not associated with IR. In Type 1 diabetes, the relationship between PAI-1 and CAC was strongest for younger participants (P=.02 for PAI-1-by-age interaction) after controlling for factors related to IR. PAI-1 was positively associated with CAC for Type 1 diabetes participants younger than 45 years of age. CONCLUSION: PAI-1 levels are independently related to CAC in younger Type 1 diabetes participants. PAI-1 levels were not independently related to CAC in non-diabetes participants</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Epidemiology, Colorado School of Public Health, University of Colorado Denver, Denver, CO 80262, USAJC - a9v, 9204583CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - HL61753 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18768333</style></custom1><custom3><style face="normal" font="default">AS - J Diabetes Complications. 23(6):387-93, 2009 Nov-Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>277</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Pressman,G.S.</style></author><author><style face="normal" font="default"> Agarwal,A.</style></author><author><style face="normal" font="default"> Braitman,L.E.</style></author><author><style face="normal" font="default"> Muddassir,S.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Mitral annular calcium causing mitral stenosis</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="391" start="389">389-391</pages><volume><style face="normal" font="default">105</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Echocardiography</style></keyword><keyword><style face="normal" font="default"> *Mitral Valve Stenosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mitral Valve Stenosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Mitral Valve Stenosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Mitral Valve/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Mitral Valve/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Outpatients</style></keyword><keyword><style face="normal" font="default"> Rest</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="1" Month="2" Year="2010">2010/2/1</year></dates><abstract><style face="normal" font="default">Mitral annular calcium (MAC) is a common finding at echocardiography, although it is an unusual cause of severe mitral stenosis. Although MAC is known to be associated with atherosclerosis and chronic kidney disease, little is known about its natural history as affects mitral valve function. This report describes a cohort of 37 outpatients with severe MAC (>5 mm) of whom 32 were followed longitudinally with echocardiography (mean follow-up 2.6 + or - 1.6 years). Progression of the mitral valve gradient occurred in 16 of 32 (50%). There was wide variation in rate of progression with a few subjects demonstrating a rapid increase in gradient, up to 9 mm Hg/year. Progression of mitral valve gradient correlated with baseline gradient at rest and with severity of overall cardiac calcification as measured by a semiquantitative echocardiographic score. Age at index echocardiogram was inversely related to mitral valve gradient after baseline, suggesting that calcification may proceed at a greater rate in younger patients. In conclusion, although severe mitral stenosis is uncommon in patients with MAC, those with a pre-existing gradient at rest and severe overall cardiac calcification appear to be at greater risk for development of this disease state. Copyright 2010 Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiology, Albert Einstein Medical Center, Philadelphia, Pennsylvania, USA. PressmanG@einstein.eduJC - 3dq, 0207277CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20102954</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 105(3):389-91, 2010 Feb 1.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>522</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Preston,R.J.</style></author><author><style face="normal" font="default"> Morse,C.</style></author><author><style face="normal" font="default"> Murden,S.L.</style></author><author><style face="normal" font="default"> Brady,S.K.</style></author><author><style face="normal" font="default"> O'Donnell,J.S.</style></author><author><style face="normal" font="default"> Mumford,A.D.</style></author></authors></contributors><titles><title><style face="normal" font="default">The protein C omega-loop substitution Asn2Ile is associated with reduced protein C anticoagulant activity</style></title><secondary-title><style face="normal" font="default">British Journal of Haematology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">British Journal of Haematology</style></full-title></periodical><pages end="953" start="946">946-953</pages><volume><style face="normal" font="default">144</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Amino Acid Substitution</style></keyword><keyword><style face="normal" font="default"> *Blood Coagulation/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Protein C Deficiency/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Protein C/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> 0 (Autoantigens)</style></keyword><keyword><style face="normal" font="default"> 0 (Protein C)</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Autoantigens/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Blood Coagulation Tests</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> EC 3-4-21-5 (Thrombin)</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Pedigree</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Protein C Deficiency/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Protein C Deficiency/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Protein C/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> Protein C/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Purpura Fulminans/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Thrombin/bi [Biosynthesis]</style></keyword><keyword><style face="normal" font="default"> Thrombosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Thrombosis/ge [Genetics]</style></keyword></keywords><dates><year Day="0" Month="3" Year="2009">2009/3</year></dates><abstract><style face="normal" font="default">We report a kindred with heritable protein C (PC) deficiency in which two siblings with severe thrombosis showed a composite type I and IIb PC deficiency phenotype, identified using commercial PC assays (proband: PC antigen 42 u/dl, amidolytic activity 40 u/dl, anticoagulant activity 9 u/dl). The independent PROC nucleotide variations c.669C>A (predictive of Ser181Arg) and c.131C>T (predictive of Asn2Ile) segregated with the type I and type IIb PC deficiency phenotypes respectively, but co-segregated in the siblings with severe thrombosis. Soluble thrombomodulin (sTM)-mediated inhibition of plasma thrombin generation from an individual with PC-Asn2Ile was lower (endogenous thrombin potential (ETP) 56 +/- 1% that of ETP determined without sTM) than control plasma (ETP 15 +/- 2%) indicating reduced PC anticoagulant activity. Recombinant APC-Asn2Ile exhibited normal amidolytic activity but impaired anticoagulant activity. Protein S (PS)-dependent anticoagulant activity of recombinant APC-Asn2Ile and binding of recombinant APC-Asn2Ile to endothelial protein C receptor (EPCR) were reduced compared to recombinant wild-type APC. Asn2 lies within the omega-loop of the PC/APC Gla domain and this region is critical for calcium-induced folding and subsequent interactions with anionic phospholipids, EPCR and PS. The disruption of these interactions in this naturally-occurring PC variant highlights their collective importance in mediating APC anticoagulant activity in vivo</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Haemostasis Research Group, Institute of Molecular Medicine, Trinity College Dublin, St James Hospital, Dublin, IrelandJC - axc, 0372544CP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19133979</style></custom1><custom3><style face="normal" font="default">AS - Br J Haematol. 144(6):946-53, 2009 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>562</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Pulvirenti,D.</style></author><author><style face="normal" font="default"> Aikaterini,T.</style></author><author><style face="normal" font="default"> Campagna,A.</style></author><author><style face="normal" font="default"> Ignaccolo,L.</style></author><author><style face="normal" font="default"> Giustolisi,N.</style></author><author><style face="normal" font="default"> Costa,E.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Medical-surgical integrated approach in the treatment of non-paraneoplasic hyperparathyroidism: our experience]. [Italian]</style></title><secondary-title><style face="normal" font="default">Clinica Terapeutica</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinica Terapeutica</style></full-title></periodical><pages end="310" start="307">307-310</pages><volume><style face="normal" font="default">159</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Hyperparathyroidism/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Hyperparathyroidism/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Parathyroidectomy</style></keyword><keyword><style face="normal" font="default"> 0 (Bone Density Conservation Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Diphosphates)</style></keyword><keyword><style face="normal" font="default"> 0 (Diuretics)</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 1406-16-2 (Vitamin D)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Bone Density Conservation Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcium/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Diphosphates/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Diuretics/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Drug Therapy,Combination</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Primary/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Secondary/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Secondary/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Primary/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Parathyroid Neoplasms/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Parathyroid Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Parathyroidectomy</style></keyword><keyword><style face="normal" font="default"> Parathyroidectomy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Postoperative Care/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Preoperative Care/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Vitamin D/tu [Therapeutic Use]</style></keyword></keywords><dates><year Day="0" Month="9" Year="2008">2008/9</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Hyperparathyroidism is a generalized alteration of calcium, phosphorus and bone metabolism due to an increased secretion of parathyroid hormone (PTH). In addition to the paraneoplastic ectopic type, we can distinguish three eutopic types of hyperparathyroidism, i.e., the primary form, mostly due to a benign or malignant tumor of parathyroid gland, the secondary form, typical of kidney disease and tertiary form, due to the progression of secondary forms. There is not agreement, in medical literature, on the treatment of these patients. To establish the correct therapeutic approach in patients with hyperparathyroidism, we have followed a group of symptomatic subjects suffering from primary, secondary and tertiary hyperparathyroidism, taking into account the therapeutic needs. METHODS: We followed for 12 months 155 patients suffering from primary, secondary and tertiary hyperparathyroidism; 82 were in end stage kidney disease, 93 were hypertensive. Subjects with primary forms has been treated, before parathyroidectomy, with hydration (physiological solution of NaCl), bisphosphonates i.v. (pamidronate 60-90 mg in 4-6h) and, if serum calcium was higher than 12 mg/dl, loop diuretics (furosemide 40 mg/day). Subjects with secondary forms has been treated with hypo-phosphoric diet, phosphate bindings (calcium carbonate 1 g/day) and oral calcitriol (1 microg/d) before subtotal parathyroidectomy. After surgery it was administered support therapy with calcium gluconate (40 ml/day) and vitamin D (2.5mg/d) until serum calcium normalization. RESULTS: There were 55 cases of post surgery hypertensive attack treated with clonidine (300 microg/d); 8 months later there was not relapses but in all patients there was reduction of serum calcium concentration that required a substitutive treatment (calcium 1 g/day and calcitriol 1 microg/day). There was 1 case of heavy hypocalcemic state treated with calcium gluconate i.v. (40 ml/day). CONCLUSIONS: A correct approach to a non-paraneoplastic hyper-parathyroid patient need of an integration of both current medical and surgical options. In primary forms the fi rst option is the surgical approach supported by medical treatment. In secondary forms medical approach is preferable to control renal and vascular complications, while surgical therapy is to prefer in non-responders to medical therapy forms</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Medicina Interna, Policlinico Universitario, Catania, Italia. d.pulvirenti2@virgilio.itOT - Approccio integrato medico-chirurgico nel trattamento dell'iperparatiroidismonon-paraneoplastico: la nostra esperienzaJC - dkn, 0372604CP - ItalyPT - English AbstractPT - Journal ArticleLG - Italian</style></notes><urls/><custom1><style face="normal" font="default">UI - 18998031</style></custom1><custom3><style face="normal" font="default">AS - Clin Ter. 159(5):307-10, 2008 Sep-Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>550</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Pundziute,G.</style></author><author><style face="normal" font="default"> Schuijf,J.D.</style></author><author><style face="normal" font="default"> Jukema,J.W.</style></author><author><style face="normal" font="default"> Decramer,I.</style></author><author><style face="normal" font="default"> Sarno,G.</style></author><author><style face="normal" font="default"> Vanhoenacker,P.K.</style></author><author><style face="normal" font="default"> Reiber,J.H.</style></author><author><style face="normal" font="default"> Schalij,M.J.</style></author><author><style face="normal" font="default"> Wijns,W.</style></author><author><style face="normal" font="default"> Bax,J.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Head-to-head comparison of coronary plaque evaluation between multislice computed tomography and intravascular ultrasound radiofrequency data analysis</style></title><secondary-title><style face="normal" font="default">Jacc: Cardiovascular Interventions</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Jacc: Cardiovascular Interventions</style></full-title></periodical><pages end="182" start="176">176-182</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> *Ultrasonography,Interventional</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Image Interpretation,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> User-Computer Interface</style></keyword></keywords><dates><year Day="0" Month="4" Year="2008">2008/4</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The purpose of this study was to perform a head-to-head comparison of plaque observations with multislice computed tomography (MSCT) to virtual histology intravascular ultrasound (VH IVUS). BACKGROUND: The VH IVUS allows in vivo coronary plaque characterization with high spatial resolution. Noninvasively, plaques may be evaluated with MSCT, but limited data are available. METHODS: A total of 50 patients underwent 64-slice MSCT followed by VH IVUS. The Agatston score was evaluated on MSCT in coronary segments where IVUS was performed. Plaques were classified on MSCT as noncalcified, mixed, and calcified. Four plaque components (fibrotic, fibro-fatty, and necrotic core tissues and dense calcium) were identified on VH IVUS, and the presence of thin-cap fibroatheroma was evaluated. RESULTS: A moderate correlation was observed between the Agatston score and calcium volume on VH IVUS (r = 0.69, p &lt; 0.0001). In total, 168 coronary plaques were evaluated (48 [29%] noncalcified, 71 [42%] mixed, 49 [29%] calcified). As compared with calcified plaques, noncalcified plaques contained more fibrotic (60.90 +/- 9.21% vs. 54.60 +/- 8.33%, p = 0.001) and fibro-fatty tissues (28.11 +/- 13.03% vs. 21.37 +/- 9.75%, p = 0.006) on VH IVUS. Mixed and calcified plaques contained more dense calcium (7.61 +/- 8.94% vs. 2.68 +/- 3.01%, p = 0.001; 10.18 +/- 6.71% vs. 2.68 +/- 3.01%, p &lt; 0.0001, respectively). Thin-cap fibroatheromas were most frequently observed in mixed plaques as compared with noncalcified and calcified plaques (32%, 13%, 8%, p = 0.002, respectively). CONCLUSIONS: A good correlation was observed between calcium quantification on MSCT and VH IVUS. In addition, plaque classification on MSCT paralleled relative plaque composition on VH IVUS, although VH IVUS provided more precise plaque characterization. Mixed plaques on MSCT were associated with high-risk features on VH IVUS</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Leiden University Medical Center, Leiden, the NetherlandsCM - Comment in: JACC Cardiovasc Interv. 2008 Apr;1(2):183-5; PMID: 19463298]JC - 101467004CP - United StatesPT - Comparative StudyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19463297</style></custom1><custom3><style face="normal" font="default">AS - JACC Cardiovasc Interv. 1(2):176-82, 2008 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>249</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Pundziute,G.</style></author><author><style face="normal" font="default"> Schuijf,J.D.</style></author><author><style face="normal" font="default"> van Velzen,J.E.</style></author><author><style face="normal" font="default"> Jukema,J.W.</style></author><author><style face="normal" font="default"> Van Werkhoven,J.M.</style></author><author><style face="normal" font="default"> Nucifora,G.</style></author><author><style face="normal" font="default"> van der,Kley F.</style></author><author><style face="normal" font="default"> Kroft,L.J.</style></author><author><style face="normal" font="default"> de,Roos A.</style></author><author><style face="normal" font="default"> Boersma,E.</style></author><author><style face="normal" font="default"> Reiber,J.H.</style></author><author><style face="normal" font="default"> Schalij,M.J.</style></author><author><style face="normal" font="default"> van der Wall,E.E.</style></author><author><style face="normal" font="default"> Bax,J.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Assessment with multi-slice computed tomography and gray-scale and virtual histology intravascular ultrasound of gender-specific differences in extent and composition of coronary atherosclerotic plaques in relation to age</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="486" start="480">480-486</pages><volume><style face="normal" font="default">105</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> *Ultrasonography,Interventional</style></keyword><keyword><style face="normal" font="default"> Age Distribution</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Sex Distribution</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> User-Computer Interface</style></keyword></keywords><dates><year Day="15" Month="2" Year="2010">2010/2/15</year></dates><abstract><style face="normal" font="default">Data evaluating gender- and age-specific differences in plaque observations on multislice computed tomography (MSCT) are scarce. Accordingly, the aim of this study was to evaluate coronary plaque patterns in men and women in relation to age using MSCT. The findings were compared to observations on grayscale intravascular ultrasound (IVUS) and virtual histology (VH) IVUS. In total, 93 patients (59 men, 34 women) underwent 64-slice MSCT followed by conventional coronary angiography with IVUS. Plaque extent and composition were assessed on MSCT, grayscale IVUS, and VH IVUS. Coronary plaque patterns were compared between men and women in 2 age groups (&lt;65 and >or=65 years old). In patients aged &lt;65 years, more plaques were observed on MSCT in men (6 +/- 4 vs 2 +/- 2 in women, p &lt;0.001). Also, a larger plaque burden was observed on grayscale IVUS in men (45.7 +/- 11.4% vs 36.3 +/- 11.6% in women, p &lt;0.001). Similarly, more mixed plaques were observed in men (3 +/- 3 vs 1 +/- 1 in women, p = 0.003), whereas a larger arc of calcium was detected on grayscale IVUS in men (91.7 +/- 93.5 degrees vs 25.7 +/- 51.0 degrees in women, p &lt;0.001). On VH IVUS, the prevalence of thin-cap fibroatheroma was higher in men (31% vs 0%) compared to women. In patients aged >or=65 years old, no important differences in plaque patterns were observed between men and women. In conclusion, more extensive atherosclerosis and more calcified lesions were observed in men than in women. These differences were predominantly present in patients aged &lt;65 years and were lost in those aged >or=65 years. Copyright 2010 Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Leiden University Medical Center, Leiden, The NetherlandsJC - 3dq, 0207277CP - United StatesPT - Comparative StudyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20152242</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 105(4):480-6, 2010 Feb 15.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>480</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Qian,J.</style></author><author><style face="normal" font="default"> Maehara,A.</style></author><author><style face="normal" font="default"> Mintz,G.S.</style></author><author><style face="normal" font="default"> Margolis,M.P.</style></author><author><style face="normal" font="default"> Lerman,A.</style></author><author><style face="normal" font="default"> Rogers,J.</style></author><author><style face="normal" font="default"> Banai,S.</style></author><author><style face="normal" font="default"> Kazziha,S.</style></author><author><style face="normal" font="default"> Castellanos,C.</style></author><author><style face="normal" font="default"> Dani,L.</style></author><author><style face="normal" font="default"> Fahy,M.</style></author><author><style face="normal" font="default"> Stone,G.W.</style></author><author><style face="normal" font="default"> Leon,M.B.</style></author></authors></contributors><titles><title><style face="normal" font="default">Impact of gender and age on in vivo virtual histology-intravascular ultrasound imaging plaque characterization (from the global Virtual Histology Intravascular Ultrasound [VH-IVUS] registry)</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="1214" start="1210">1210-1214</pages><volume><style face="normal" font="default">103</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Artery Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Registries</style></keyword><keyword><style face="normal" font="default"> *Ultrasonography,Interventional</style></keyword><keyword><style face="normal" font="default"> *User-Computer Interface</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Biopsy,Needle</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="1" Month="5" Year="2009">2009/5/1</year></dates><abstract><style face="normal" font="default">Virtual histology intravascular ultrasound (VH-IVUS) analyses were performed in the first 990 patients enrolled in the 3,000+ patient global VH-IVUS Registry to assess the impact of gender and age on in vivo VH-IVUS plaque characterization. The 990 patients were divided into 3 age group terciles (&lt;58, 58 to 68, and >68 years) and again divided according to gender. In conclusion, (1) both women and men had an increase in plaque with increasing age; (2) at any age, men had more plaque than women; (3) percentages of dense calcium and necrotic core increased with increasing patient age in both men and women; and (4) gender differences were lowest in the oldest tercile (>68 years)</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Cardiovascular Research Foundation and Columbia University Medical Center, New York, New York, USACM - Comment in: Am J Cardiol. 2009 Sep 1;104(5):739; PMID: 19699357]JC - 3dq, 0207277CP - United StatesPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19406261</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 103(9):1210-4, 2009 May 1.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>492</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Raichlin,E.</style></author><author><style face="normal" font="default"> Bae,J.H.</style></author><author><style face="normal" font="default"> Kushwaha,S.S.</style></author><author><style face="normal" font="default"> Lennon,R.J.</style></author><author><style face="normal" font="default"> Prasad,A.</style></author><author><style face="normal" font="default"> Rihal,C.S.</style></author><author><style face="normal" font="default"> Lerman,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Inflammatory burden of cardiac allograft coronary atherosclerotic plaque is associated with early recurrent cellular rejection and predicts a higher risk of vasculopathy progression</style></title><secondary-title><style face="normal" font="default">Journal of the American College of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of the American College of Cardiology</style></full-title></periodical><pages end="1286" start="1279">1279-1286</pages><volume><style face="normal" font="default">53</style></volume><number><style face="normal" font="default">15</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Artery Disease/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Graft Rejection/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> *Heart Transplantation/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Inflammation/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Ultrasonography,Interventional</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="14" Month="4" Year="2009">2009/4/14</year></dates><abstract><style face="normal" font="default">OBJECTIVES: This study was designed to investigate tissue characterization of the coronary allograft atherosclerotic plaque with virtual histology intravascular ultrasound (VH-IVUS) imaging to assess the presence and predictors of vessel wall inflammation and its significance in cardiac allograft vasculopathy (CAV) progression. BACKGROUND: A unique form of accelerated atherosclerosis, CAV remains the leading cause of late morbidity and mortality in heart transplant patients. The pathogenesis of CAV is not fully elucidated. METHODS: A total of 86 patients with coronary allograft vasculopathy underwent VH-IVUS examination of the left anterior descending coronary artery 3.61 +/- 3.04 years following cardiac transplantation. Based on the VH-IVUS plaque characteristics, coronary allograft plaque was divided on virtual histology intravascular ultrasound-derived "inflammatory" (VHD-IP) (necrotic core and dense calcium > or =30%) and "noninflammatory" plaque (VHD-NIP) (necrotic core and dense calcium &lt;30%). Total rejection scores were calculated based on the 2004 International Society of Heart and Lung Transplantation rejection grading system. RESULTS: In the whole study population, the mean percentage of fibrous, fibrofatty, dense calcified, and necrotic core plaques in a mean length of 62.3 +/- 17.4 mm of the left anterior descending coronary artery were 50 +/- 17%, 16 +/- 11%, 15 +/- 11%, and 18 +/- 9%, respectively. Patients with a 6-month total rejection score >0.3 had significantly higher incidence of VHD-IP than those with a 6-month total rejection score &lt; or =0.3 (69% vs. 33%, p = 0.011). The presence of VHD-IP at baseline was associated with a significant increase in plaque volume (2.42 +/- 1.78 mm(3)/mm vs. -0.11 +/- 1.65 mm(3)/mm, p = 0.010), plaque index (7 +/- 9% vs. 0 +/- 8%, p = 0.04), and remodeling index (1.24 +/- 0.44 vs. 1.09 +/- 0.36, p = 0.030) during 12 months of follow-up when compared with the presence of VHD-NIP at baseline and during follow-up. CONCLUSIONS: The presence of VHD-IP as assessed by VH-IVUS is associated with early recurrent rejection and with higher subsequent progression of CAV. A VH-IVUS assessment may add important information in the evaluation of transplant recipients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Mayo Clinic, Rochester, Minnesota 55905, USACM - Comment in: J Am Coll Cardiol. 2009 Apr 14;53(15):1287-8; PMID: 19358942]JC - h50, 8301365CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19358941</style></custom1><custom3><style face="normal" font="default">AS - J Am Coll Cardiol. 53(15):1279-86, 2009 Apr 14.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>231</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Rajpathak,S.N.</style></author><author><style face="normal" font="default"> Xue,X.</style></author><author><style face="normal" font="default"> Wassertheil-Smoller,S.</style></author><author><style face="normal" font="default"> Van,Horn L.</style></author><author><style face="normal" font="default"> Robinson,J.G.</style></author><author><style face="normal" font="default"> Liu,S.</style></author><author><style face="normal" font="default"> Allison,M.</style></author><author><style face="normal" font="default"> Martin,L.W.</style></author><author><style face="normal" font="default"> Ho,G.Y.</style></author><author><style face="normal" font="default"> Rohan,T.E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Effect of 5 y of calcium plus vitamin D supplementation on change in circulating lipids: results from the Women's Health Initiative</style></title><secondary-title><style face="normal" font="default">American Journal of Clinical Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Clinical Nutrition</style></full-title></periodical><pages end="899" start="894">894-899</pages><volume><style face="normal" font="default">91</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Dietary Supplements</style></keyword><keyword><style face="normal" font="default"> *Lipids/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Micronutrients/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> *Vitamin D/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> 0 (Lipids)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipoprotein(a))</style></keyword><keyword><style face="normal" font="default"> 0 (Micronutrients)</style></keyword><keyword><style face="normal" font="default"> 1406-16-2 (Vitamin D)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcium/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Drug Therapy,Combination</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lipoprotein(a)/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Postmenopause</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Vitamin D/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Women's Health</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Dietary calcium and vitamin D intakes may be inversely associated with cardiovascular disease (CVD) risk, possibly because of their potential beneficial effects on circulating lipids. Clinical trials that have evaluated the effect of calcium supplementation on lipids are limited by a short follow-up, and data on vitamin D are scarce. OBJECTIVE: The objective was to evaluate the effect of a longer-term effect (over 5 y) of calcium and vitamin D (CaD) supplementation on changes in the concentrations of several lipids: LDL, HDL, non-HDL, total cholesterol, triglycerides, and lipoprotein(a) [Lp(a)]. DESIGN: The study was conducted in 1259 postmenopausal women in the Calcium plus Vitamin D Trial (1 g elemental Ca as carbonate plus 400 IU vitamin D(3)/d compared with placebo) of the Women's Health Initiative. Analyses were conducted by intention-to-treat. Repeated measurements on lipids during follow-up were analyzed by linear mixed-effects models. RESULTS: Overall, the change in lipids was relatively small [&lt; or =5% except for Lp(a), which was 20-25%], and there was no significant difference in the mean change of any lipid variable between the active and placebo groups. CONCLUSIONS: Our results indicate that CaD supplementation is not associated with lipid changes over 5 y. Existing and future CaD trials should consider evaluating this association for different doses of supplements. This study was registered at clinicaltrials.gov as NCT00000611</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA. swapnil.rajpathak@einstein.yu.eduJC - 3ey, 0376027CP - United StatesPT - Journal ArticlePT - Randomized Controlled TrialPT - Research Support, N.I.H., ExtramuralPT - Research Support, U.S. Gov't, P.H.SSI - ClinicalTrials.govSA - ClinicalTrials.gov/NCT00000611NO - N01WH22110, (United States WHI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20181812</style></custom1><custom3><style face="normal" font="default">AS - Am J Clin Nutr. 91(4):894-9, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>554</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Raman,S.V.</style></author><author><style face="normal" font="default"> Winner,M.W.,III</style></author><author><style face="normal" font="default"> Tran,T.</style></author><author><style face="normal" font="default"> Velayutham,M.</style></author><author><style face="normal" font="default"> Simonetti,O.P.</style></author><author><style face="normal" font="default"> Baker,P.B.</style></author><author><style face="normal" font="default"> Olesik,J.</style></author><author><style face="normal" font="default"> McCarthy,B.</style></author><author><style face="normal" font="default"> Ferketich,A.K.</style></author><author><style face="normal" font="default"> Zweier,J.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">In vivo atherosclerotic plaque characterization using magnetic susceptibility distinguishes symptom-producing plaques</style></title><secondary-title><style face="normal" font="default">Jacc: Cardiovascular Imaging</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Jacc: Cardiovascular Imaging</style></full-title></periodical><pages end="57" start="49">49-57</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Carotid Artery Diseases/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Iron/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> *Magnetic Resonance Angiography</style></keyword><keyword><style face="normal" font="default"> 7439-89-6 (Iron)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Carotid Artery Diseases/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Carotid Artery Diseases/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Endarterectomy,Carotid</style></keyword><keyword><style face="normal" font="default"> Feasibility Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Motion</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="1" Year="2008">2008/1</year></dates><abstract><style face="normal" font="default">OBJECTIVES: We investigated the role of iron deposition in atherosclerotic plaque instability using a novel approach of in vivo plaque characterization by a noninvasive, noncontrast magnetic resonance-based T2* measurement. This approach was validated using ex vivo plaque analyses to establish that T2* accurately reflects intraplaque iron composition. BACKGROUND: Iron catalyzes free radical production, a key step for lipid peroxidation and atherosclerosis development. The parameter T2* measures tissue magnetic susceptibility, which historically has been used to quantify hepatic and myocardial iron. The T2* measurement has not been used for in vivo plaque characterization in patients with atherosclerosis. METHODS: Thirty-nine patients referred for carotid endarterectomy were prospectively enrolled to undergo preoperative carotid magnetic resonance imaging (MRI) and postoperative analysis of the explanted plaque. Clinical history of any symptoms attributable to each carotid lesion was recorded. We could not complete MRI in 4 subjects because of their claustrophobia, and 3 patients scanned before the institution of a neck stabilizer had motion artifact, precluding quantification. RESULTS: Symptomatic patients had significantly lower plaque T2* values (20.0 +/- 1.8 ms) compared with asymptomatic patients (34.4 +/- 2.7 ms, p &lt; 0.001). Analytical methods demonstrated similar total iron (138.6 +/- 36.5 microg/g vs. 165.8 +/- 48.3 microg/g, p = NS) but less low molecular weight Fe(III) (7.3 +/- 3.8 microg/g vs. 17.7 +/- 4.0 microg/g, p &lt; 0.05) in the explanted plaques of symptomatic versus asymptomatic patients, respectively, which is consistent with a shift in iron from Fe(III) to greater amounts of T2*-shortening forms of iron. Mass spectroscopy also showed significantly lower calcium (37.5 +/- 10.8 mg/g vs. 123.6 +/- 19.3 mg/g, p &lt; 0.01) and greater copper (3.2 +/- 0.5 microg/g vs. 1.7 +/- 0.1 microg/g, p &lt; 0.01) in plaques from symptomatic patients. CONCLUSIONS: In vivo measurement of intraplaque T2* using MRI is feasible and distinguishes symptom-producing from non-symptom-producing plaques in patients with carotid artery atherosclerosis. Symptom-producing plaques demonstrated characteristic changes in iron forms by ex vivo analysis, supporting the dynamic presence of iron in the microenvironment of atherosclerotic plaque</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Davis Heart and Lung Research Institute and Heart Center, The Ohio State University, Columbus, Ohio 43210, USA. Raman.1@osu.eduCM - Comment in: JACC Cardiovasc Imaging. 2008 Jan;1(1):58-60; PMID: 19356406]JC - 101467978CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Validation StudiesNO - R21 HL080474-01 (United States NHLBI NIH HHS)NO - R21 HL080474-01 (United States NHLBI NIH HHS)NO - R21 HL080474-02 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19356405</style></custom1><custom3><style face="normal" font="default">AS - JACC Cardiovasc Imaging. 1(1):49-57, 2008 Jan.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>331</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">rcoveanu,E.</style></author><author><style face="normal" font="default"> Niculescu,D.</style></author><author><style face="normal" font="default"> Moldovanu,R.</style></author><author><style face="normal" font="default"> Cotea,E.</style></author><author><style face="normal" font="default"> Vasilescu,A.</style></author><author><style face="normal" font="default"> Danila,N.</style></author><author><style face="normal" font="default"> Lazescu,D.</style></author><author><style face="normal" font="default"> Ferariu,D.</style></author><author><style face="normal" font="default"> Crumpei,F.</style></author><author><style face="normal" font="default"> Ichim,M.</style></author><author><style face="normal" font="default"> Zbranca,E.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Surgical treatment of hyperparathyroidism]. [Romanian]</style></title><secondary-title><style face="normal" font="default">Chirurgia (Bucuresti)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Chirurgia (Bucuresti)</style></full-title></periodical><pages end="544" start="531">531-544</pages><volume><style face="normal" font="default">104</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Hyperparathyroidism,Primary/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Parathyroid Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Parathyroidectomy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 7723-14-0 (Phosphorus)</style></keyword><keyword><style face="normal" font="default"> Adenoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Carcinoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Primary/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Primary/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Hyperplasia</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Parathyroid Glands/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Parathyroid Neoplasms/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Parathyroidectomy</style></keyword><keyword><style face="normal" font="default"> Phosphorus/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Ultrasonography</style></keyword></keywords><dates><year Day="0" Month="9" Year="2009">2009/9</year></dates><isbn><style face="normal" font="default">1221-9118</style></isbn><abstract><style face="normal" font="default">BACKGROUND: Hyperparathyroidism (HPT), the result of excessive secretion of the parathormone, is one of the most common endocrine disorders. In most forms of HPT, surgical parathyroidectomy is the best choice. AIM: This paper aims to examine patients with hyperparathyroidism operated in First Surgical Unit Ia&amp;#x015F;i, in terms of indications, surgical technique and postoperative results. MATERIAL AND METHOD: We performed a retrospective study, in First Surgical Unit Ia&amp;#x015F;i, during 2000-2008. Clinical, laboratory, intraoperative and histopathological data were included in a MS Access Office XP database. Statistical analysis was performed with the SPSS ver. 15.0 for Windows (Statistical Package for the Social Sciences, Chicago, Ilinois). RESULTS: There were examined 34 patients with HPT: 32 cases were primary HPT (94.12%), and two cases with secondary HPT (patients with renal failure). The men/women ratio was 6/28 and mean age was 50.09 +/- 2.23 years old. Clinical presentation was variable: the dominant symptoms were osteoarticular (67.6%) followed by neuropsychological (64.7%), digestive (17.6%) and renal (11.8%). Associated diseases were recorded at 47.06% of patients: arterial hypertension--32.4%, coronary heart disease--23.5%, heart rhythm disorders--17.6%, diabetes--11.8%, biliary lithiasis--5.9%, renal lithiasis--8.8% and thyroid hypertrophy--55.9%. In 8 cases, primary hyperparathyroidism was associated with other diseases of the endocrine glands: 4 cases with Multiple Endocrine Neoplasia (MEN) type 1; a patient with von Recklinghausen disease; a patient with associated hypothyroidism and diabetes; two cases that with papillary thyroid carcinoma. Positive diagnosis was supported by determining serum calcium, phosphorus and serum concentration of the parathormone (PTH). All patients were evaluated by ultrasound exam; the sensitivity of the investigation was 88.23%. 99Tc-sestamibi scintigraphy was performed in 32.35% of patients with a sensitivity of 72.72%. Parathyroidectomy was performed by Kocher's incision in 88.23% and minimally-invasive open approach in 11.76%. The following types of interventions have been performed: tumor resections (73.53%), subtotal parathyroidectomies (17.6%), total parathyroidectomies (8.82%). In patients with associated thyroid disease total thyroidectomies (26.5%) and subtotal thyroidectomies were done (11.8%). The postoperative morbidity rate was 2.9% (transient hypocalcemia). Histopathological examination revealed the presence of parathyroidian adenoma in 67.6% of patients (N=23), parathyroidian hyperplasia in 26.5% (N=9) and parathyroidian carcinoma in the others 5.9% (N=2). CONCLUSIONS: The diagnosis of HPT involves positive determination of calcium and PTH. The most useful imaging techniques, are 99Tc-sestamibi scintigraphy and ultrasonography, which locates in most cases, the parathyroid pathological glands. Surgical treatment is the only curative treatment of HPT, with medical treatment only role in preoperative preparation. The precise site of the parathyroidian lesion facilitates minimally-invasive approach. The postoperative follow-up is mandatory because of the increased potential for recurrence and for diagnosis of other endocrine tumors (in patients with MEN)</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Clinica I Chirurgie, Universitatea de Medicina &amp;#x015F;i Farmacie Gr. T. Popa Ia&amp;#x015F;i. etarco@iasi.mednet.roOT - Tratamentul chirurgical al hiperparatiroidismuluiJC - blb, 9213031CP - RomaniaPT - English AbstractPT - Journal ArticleLG - Romanian</style></notes><urls/><custom1><style face="normal" font="default">UI - 19943551</style></custom1><custom3><style face="normal" font="default">AS - Chirurgia (Bucur). 104(5):531-44, 2009 Sep-Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>255</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">re,L.</style></author><author><style face="normal" font="default"> Templier,I.</style></author><author><style face="normal" font="default"> Carron,P.L.</style></author><author><style face="normal" font="default"> Maurizi,J.</style></author><author><style face="normal" font="default"> Salameire,D.</style></author><author><style face="normal" font="default"> Beani,J.C.</style></author><author><style face="normal" font="default"> Blaise,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Two cases of iatrogenic cutis and subcutis calcinosis after calcium-containing heparin injection]. [French]</style></title><secondary-title><style face="normal" font="default">Journal des Maladies Vasculaires</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal des Maladies Vasculaires</style></full-title></periodical><pages end="371" start="366">366-371</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Anticoagulants/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> *Calcium/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Heparin/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Skin Diseases/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> 0 (Anticoagulants)</style></keyword><keyword><style face="normal" font="default"> 37270-89-6 (calcium heparin)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 9005-49-6 (Heparin)</style></keyword><keyword><style face="normal" font="default"> Abdomen</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Anticoagulants/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Anticoagulants/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Calcinosis</style></keyword><keyword><style face="normal" font="default"> Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Calciphylaxis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Calcium/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus,Type 2/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Diagnosis,Differential</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Heart Failure/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Heart Failure/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Heparin/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Heparin/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Injections</style></keyword><keyword><style face="normal" font="default"> Injections,Subcutaneous</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Panniculitis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Postoperative Complications/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Skin Diseases,Bacterial/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Skin Diseases/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Skin Diseases/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Subcutaneous Tissue</style></keyword><keyword><style face="normal" font="default"> Thigh</style></keyword><keyword><style face="normal" font="default"> Thrombophlebitis/dt [Drug Therapy]</style></keyword></keywords><dates><year Day="0" Month="11" Year="2009">2009/11</year></dates><isbn><style face="normal" font="default">0398-0499</style></isbn><abstract><style face="normal" font="default">BACKGROUND: Subcutis calcinosis, characterized by abnormal calcium deposition in the skin, is a rare side effect of calcium containing heparins. PATIENTS AND METHODS: Two patients with renal failure presented skin lesions after receiving a calcium-containing heparin treatment. The first patient exhibited erythematous nodules on the abdomen and the second a large erythematous induration of the abdomen and nodules on the thighs. Both had normal blood analysis. The diagnosis of subcutis calcinosis was confirmed by the histological exam showing calcium deposit in the dermis and hypodermis. Outcome was unfavourable in one of the patients who developed a superinfection and skin necrosis lesion requiring surgery at 2 months. DISCUSSION: Subcutis calcinosis is a rare and probably underdiagnosed disease. To our knowledge, only 10 cases have been reported. The pathogenesis is not well-known, tissue damage and calcium disorders are considered as risk factors. The differential diagnoses that can be suspected include calciphylaxis, such as calcifying panniculitis and other local side effects of heparins. Outcome is usually favourable without treatment. CONCLUSION: We describe two cases of iatrogenic subcutis calcinosis after injections of calcium-containing heparins, including the second case of poor outcome. Clinicians should be aware of this adverse effect since other heparins such as fondaparinux or low-weight molecular heparins are contraindicated in patients with renal failure, leading to a large prescription of calcium-containing heparins in this population</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Service d'anatomie pathologique et cytologique, p&amp;#x00F4;le pluridisciplinaire de m&amp;#x00E9;decine, clinique universitaire de dermato-v&amp;#x00E9;n&amp;#x00E9;rologie, photobiologie et allergologie, h&amp;#x00F4;pital Albert-Michallon, CHU de Grenoble, BP 217, 38043 Grenoble cedex 09, France. LBonnecarrere@chu-grenoble.frOT - Calcinose cutan&amp;#x00E9;e et sous-cutan&amp;#x00E9;e apr&amp;#x00E8;s injection d'h&amp;#x00E9;parine calcique : &amp;#x00E0; propos de deux casJC - iyn, 7707965CP - FrancePT - Case ReportsPT - English AbstractPT - Journal ArticleLG - French</style></notes><urls/><custom1><style face="normal" font="default">UI - 19782485</style></custom1><custom3><style face="normal" font="default">AS - J Mal Vasc. 34(5):366-71, 2009 Nov.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>346</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Reaven,P.D.</style></author><author><style face="normal" font="default"> Moritz,T.E.</style></author><author><style face="normal" font="default"> Schwenke,D.C.</style></author><author><style face="normal" font="default"> Anderson,R.J.</style></author><author><style face="normal" font="default"> Criqui,M.</style></author><author><style face="normal" font="default"> Detrano,R.</style></author><author><style face="normal" font="default"> Emanuele,N.</style></author><author><style face="normal" font="default"> Kayshap,M.</style></author><author><style face="normal" font="default"> Marks,J.</style></author><author><style face="normal" font="default"> Mudaliar,S.</style></author><author><style face="normal" font="default"> Harsha,Rao R.</style></author><author><style face="normal" font="default"> Shah,J.H.</style></author><author><style face="normal" font="default"> Goldman,S.</style></author><author><style face="normal" font="default"> Reda,D.J.</style></author><author><style face="normal" font="default"> McCarren,M.</style></author><author><style face="normal" font="default"> Abraira,C.</style></author><author><style face="normal" font="default"> Duckworth,W.</style></author><author><style face="normal" font="default"> Veterans Affairs,Diabetes Trial</style></author></authors></contributors><titles><title><style face="normal" font="default">Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis</style></title><secondary-title><style face="normal" font="default">Diabetes</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Diabetes</style></full-title></periodical><pages end="2648" start="2642">2642-2648</pages><volume><style face="normal" font="default">58</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 2/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Diabetic Angiopathies/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Hypoglycemic Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *United States Department of Veterans Affairs</style></keyword><keyword><style face="normal" font="default"> 0 (Hemoglobin A,Glycosylated)</style></keyword><keyword><style face="normal" font="default"> 0 (Hypoglycemic Agents)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Age of Onset</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Blood Pressure/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus,Type 2/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Diabetic Angiopathies/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Diabetic Angiopathies/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Heart Rate/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Hemoglobin A,Glycosylated/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Random Allocation</style></keyword><keyword><style face="normal" font="default"> Research Design</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> United States/ep [Epidemiology]</style></keyword></keywords><dates><year Day="0" Month="11" Year="2009">2009/11</year></dates><abstract><style face="normal" font="default">OBJECTIVE: This study investigated the hypothesis that baseline calcified coronary atherosclerosis may determine cardiovascular disease events in response to intensive glycemic control within the Veterans Affairs Diabetes Trial (VADT). RESEARCH DESIGN AND METHODS: At baseline, 301 type 2 diabetic participants in the VADT, a randomized trial comparing the effects of intensive versus standard glucose lowering on cardiovascular events, had baseline coronary atherosclerosis assessed by coronary artery calcium (CAC) measured by computed tomography. Participants were followed over the 7.5-year study for development of cardiovascular end points. RESULTS: During a median follow-up duration of 5.2 years, 89 cardiovascular events occurred. Although intensive glucose-lowering therapy did not significantly reduce cardiovascular events in the substudy cohort as a whole, there was evidence that the response was modified by baseline CAC, as indicated by significant P values for treatment by log(CAC + 1) interaction terms in unadjusted and multivariable-adjusted models (0.01 and 0.03, respectively). Multivariable-adjusted hazard ratios (HRs) for the effect of treatment indicated a progressive diminution of benefit with increasing CAC. Subgroup analyses were also conducted for clinically relevant CAC categories: those above and below an Agatston score of 100. Among those randomized to intensive treatment, for the subgroup with CAC >100, 11 of 62 individuals had events, while only 1 of 52 individuals with CAC &lt; or = 100 had an event. The multivariable HR for intensive treatment for those with CAC >100 was 0.74 (95% CI 0.46-1.20; P = 0.21), while for the subgroup with CAC &lt; or = 100, the corresponding HR was 0.08 (0.008-0.77; P = 0.03), with event rates of 39 and 4 per 1,000 person-years, respectively. CONCLUSIONS: These data indicate that intensive glucose lowering reduces cardiovascular events in those with less extensive calcified coronary atherosclerosis</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Phoenix Veterans Affairs Health Care System, Phoenix, Arizona, USA. peter.reaven@va.govJC - e8x, 0372763CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, U.S. Gov't, Non-P.H.SNO - R01067690 (United States PHS HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19651816</style></custom1><custom3><style face="normal" font="default">AS - Diabetes. 58(11):2642-8, 2009 Nov.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>65</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Rennenberg,R.J.</style></author><author><style face="normal" font="default"> de Leeuw,P.W.</style></author><author><style face="normal" font="default"> Kessels,A.G.</style></author><author><style face="normal" font="default"> Schurgers,L.J.</style></author><author><style face="normal" font="default"> Vermeer,C.</style></author><author><style face="normal" font="default"> van Engelshoven,J.M.</style></author><author><style face="normal" font="default"> Kemerink,G.J.</style></author><author><style face="normal" font="default"> Kroon,A.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Calcium scores and matrix Gla protein levels: association with vitamin K status</style></title><secondary-title><style face="normal" font="default">European Journal of Clinical Investigation</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">European Journal of Clinical Investigation</style></full-title></periodical><pages end="349" start="344">344-349</pages><volume><style face="normal" font="default">40</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis</style></keyword><keyword><style face="normal" font="default"> *Calcium-Binding Proteins/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Extracellular Matrix Proteins/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Osteocalcin/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Vitamin K/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> 0 (Calcium-Binding Proteins)</style></keyword><keyword><style face="normal" font="default"> 0 (Extracellular Matrix Proteins)</style></keyword><keyword><style face="normal" font="default"> 0 (matrix Gla protein)</style></keyword><keyword><style face="normal" font="default"> 104982-03-8 (Osteocalcin)</style></keyword><keyword><style face="normal" font="default"> 12001-79-5 (Vitamin K)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcium-Binding Proteins/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies</style></keyword><keyword><style face="normal" font="default"> Extracellular Matrix Proteins/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Vitamin K/bl [Blood]</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Vascular calcification in humans is associated with an increased cardiovascular risk. Carboxylated matrix Gla protein (cMGP) inhibits vascular calcification. Vitamin K is an essential cofactor for the activation of uncarboxylated matrix Gla protein (ucMGP). It has been suggested that patients on long-term treatment with vitamin K antagonists develop aortic valve calcifications because of lower levels of circulating MGP. We therefore hypothesized that arterial calcification and a low vitamin K status are associated with ucMGP. To that aim, we measured arterial calcium scores, the osteocalcin ratio (OCR), as a proxy for vitamin K status, and ucMGP. MATERIALS AND METHODS: In 36 hypertensive patients, we determined the Agatston score with computer tomography scans of the abdominal aorta, carotid and coronary arteries. The total calcium score was calculated as the sum of the separate Z-scores. RESULTS: The total calcium Z-score was significantly correlated to age (r = 0.683, P &lt; 0.001), smoking (r = 0.372, P = 0.026), total cholesterol (r = 0.353, P = 0.034), LDL cholesterol (r = 0.490, P = 0.003), triglycerides (r = 0.506, P = 0.002), fasting glucose (r = 0.454, P = 0.005), systolic blood pressure (r = 0.363, P = 0.029) and pulse pressure (r = 0.685, P &lt; 0.001). In multivariate regression analyses, OCR and total calcium score were significantly associated with ucMGP. CONCLUSIONS: We found a positive association of total arterial calcium score and a high OCR (reflecting low vitamin K status) with ucMGP serum levels. This warrants further studies to explore the pathophysiological background of this phenomenon</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Internal Medicine, Maastricht University Medical Centre (MUMC+) and Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands. r.rennenberg@mumc.nlJC - en3, 0245331CP - EnglandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20486996</style></custom1><custom3><style face="normal" font="default">AS - Eur J Clin Invest. 40(4):344-9, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>533</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">rez,J.A.</style></author><author><style face="normal" font="default"> Garcia,F.C.</style></author><author><style face="normal" font="default"> Palacios,S.</style></author><author><style face="normal" font="default"> rez,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Epidemiology of risk factors and symptoms associated with menopause in Spanish women</style></title><secondary-title><style face="normal" font="default">Maturitas</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Maturitas</style></full-title></periodical><pages end="36" start="30">30-36</pages><volume><style face="normal" font="default">62</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Depression/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> *Hot Flashes/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> *Menopause/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Dairy Products</style></keyword><keyword><style face="normal" font="default"> Depression/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Health Surveys</style></keyword><keyword><style face="normal" font="default"> Hot Flashes/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Osteoporosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sleep Disorders,Intrinsic/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Sleep Disorders,Intrinsic/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword></keywords><dates><year Day="20" Month="1" Year="2009">2009/1/20</year></dates><isbn><style face="normal" font="default">0378-5122</style></isbn><abstract><style face="normal" font="default">OBJECTIVES: (1) To assess the prevalence of risk factors for osteoporosis and cardiovascular disease and the prevalence and severity of the appearance of menopausal symptoms among Spanish menopausal women. (2) To identify the main factors responsible for this severity. (3) To detect symptom differences between perimenopausal and postmenopausal women. METHODS: Cross-sectional descriptive study encompassing women aged 45-65 years in the whole Spanish territory. The study population sample was collected through random sampling. A total of 10,514 women were included. The sociodemographic, medical history and lifestyle data were assessed by means of a survey. The Kupperman scale was used to assess the severity of menopausal symptoms. RESULTS: The prevalence of risk factors for osteoporosis and cardiovascular disease were 67.6% and 74.8%, respectively. The most common risk factors were physical inactivity (53.6%), obesity (44.3%), arterial hypertension (36.6%), hypercholesterolemia (31.4%), low calcium intake (30.1%) and smoking (28.7%). The predominant symptoms experienced by menopausal women were hot flushes (51.4%), insomnia (45.7%) and irritability (42.2%). These were severe in 3.3% of the sample, moderate in 27.3%, mild in 24.6% while 44.8% had no symptoms. The prevalence of joint pain (40.1%) and depressive mood (40%) was higher in perimenopausal than in postmenopausal women. Logistic regression analysis showed that there were differences for age, BMI, smoking, social class and poor consumption of dairy products in the severity of menopausal symptoms. CONCLUSIONS: A high prevalence of risk factors for osteoporosis and cardiovascular disease was observed in our study. The main factors contributing to more severe menopausal symptoms were age, BMI, smoking social class and poor consumption of dairy products. In general, postmenopausal women presented significantly higher rates of menopausal symptoms when compared to perimenopausal women</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Primary Health Centre Guadalajara-Sur, Guadalajara, Spain. jmartinezp@semergen.esJC - mwn, 7807333CP - IrelandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19010615</style></custom1><custom3><style face="normal" font="default">AS - Maturitas. 62(1):30-6, 2009 Jan 20.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>138</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Rezaieyazdi,Z.</style></author><author><style face="normal" font="default"> Falsoleiman,H.</style></author><author><style face="normal" font="default"> Khajehdaluee,M.</style></author><author><style face="normal" font="default"> Saghafi,M.</style></author><author><style face="normal" font="default"> Mokhtari-Amirmajdi,E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Reduced bone density in patients on long-term warfarin</style></title><secondary-title><style face="normal" font="default">International Journal of Rheumatic Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">International Journal of Rheumatic Diseases</style></full-title></periodical><pages end="135" start="130">130-135</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Anticoagulants/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Bone Density/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> *Osteoporosis/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> *Rheumatic Heart Disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Warfarin/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> 0 (Anticoagulants)</style></keyword><keyword><style face="normal" font="default"> 12001-79-5 (Vitamin K)</style></keyword><keyword><style face="normal" font="default"> 81-81-2 (Warfarin)</style></keyword><keyword><style face="normal" font="default"> Absorptiometry,Photon</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Bone Density</style></keyword><keyword><style face="normal" font="default"> Bone Density/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Femur/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Health Surveys</style></keyword><keyword><style face="normal" font="default"> Heart Valve Prosthesis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lumbar Vertebrae/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Osteoporosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Rheumatic Heart Disease/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Vitamin K/ai [Antagonists &amp; Inhibitors]</style></keyword><keyword><style face="normal" font="default"> Vitamin K/me [Metabolism]</style></keyword></keywords><dates><year Day="0" Month="7" Year="2009">2009/7</year></dates><abstract><style face="normal" font="default">AIM: Vitamin K is an essential factor for carboxylation of bone matrix protein. Low vitamin K may be associated with reduced bone mineral density (BMD). The issue of whether long-term sodium warfarin therapy as oral anticoagulant that antagonizes vitamin K, results in decreased bone density, is controversial. Our purpose in this study was to assess the effects of warfarin on BMD. METHODS: We performed a case control study survey of bone density in 70 patients with rheumatic valvular heart disease 'mechanical valve replacement' on long-term warfarin compared with 103 randomly selected matched controls. RESULTS: There was a marked reduction in BMD (g/cm(2)) and T-score of lumbar spine between patients and controls (P = 0.048, 0.005). Duration of warfarin use was the only risk factor of significant importance respectively on spinal T-score (P &lt; 0.03). CONCLUSIONS: Screening of patients on long-term warfarin for reduced bone density should be considered. We strongly suggest the prophylactic use of calcium-vitamin D supplements for these patients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Rheumatology, Mashhad University of Medical Sciences, Mashhad, Iran. rezaieyazdi-z@mums.ac.irJC - 101474930CP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20374330</style></custom1><custom3><style face="normal" font="default">AS - Int J Rheum Dis. 12(2):130-5, 2009 Jul.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>471</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Reznik,A.G.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Morphological prerequisites of heart ventricles fibrillation in sudden cardiac death]. [Russian]</style></title><secondary-title><style face="normal" font="default">Kardiologiia</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Kardiologiia</style></full-title></periodical><pages end="25" start="22">22-25</pages><volume><style face="normal" font="default">49</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Death,Sudden,Cardiac/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Heart Ventricles/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Myocardium/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Ventricular Fibrillation/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> 0 (Blood Glucose)</style></keyword><keyword><style face="normal" font="default"> 7440-23-5 (Sodium)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Blood Glucose/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="default"> Microscopy,Polarization</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Myocytes,Cardiac/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Pericardial Effusion/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Russia</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sodium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Ventricular Fibrillation/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Ventricular Fibrillation/me [Metabolism]</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><isbn><style face="normal" font="default">0022-9040</style></isbn><abstract><style face="normal" font="default">We studied morphological changes in the myocardium and content of glucose, magnesium, calcium, sodium in pericardial fluid of victims of out of hospital sudden death due to acute coronary insufficiency and prenecrotic stage of myocardial infarction. We established that both in regions of ischemic injury appearing as III degree contracture lesions of cardiomyocytes, zones of intracellular myocytolysis and primary breakdown of myofibrils, as will as in zones of relaxation myocardium loses its contractile properties. This in turn leads to asynchronous contraction of left and right ventricles. As fibrillation develops in both ventricles simultaneously there are all grounds to believe that morphological prerequisite (source of origin) of fibrillation is the presence of areas of ischemic injury and relaxation in the myocardium</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)JC - 0376351, ku9CP - Russia (Federation)PT - Comparative StudyPT - English AbstractPT - Journal ArticleLG - Russian</style></notes><urls/><custom1><style face="normal" font="default">UI - 19463130</style></custom1><custom3><style face="normal" font="default">AS - Kardiologiia. 49(5):22-5, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>157</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Reznik,A.G.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Morphology of acute myocardial infarction at prenecrotic stage]. [Russian]</style></title><secondary-title><style face="normal" font="default">Kardiologiia</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Kardiologiia</style></full-title></periodical><pages end="8" start="4">4-8</pages><volume><style face="normal" font="default">50</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Myocardial Infarction/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Myocardium/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Pericardial Effusion/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> 50-99-7 (Glucose)</style></keyword><keyword><style face="normal" font="default"> 7440-09-7 (Potassium)</style></keyword><keyword><style face="normal" font="default"> 7440-23-5 (Sodium)</style></keyword><keyword><style face="normal" font="default"> Cadaver</style></keyword><keyword><style face="normal" font="default"> Energy Metabolism</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glucose/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Microscopy,Polarization</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Pericardial Effusion/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Potassium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Sodium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Spectrophotometry,Atomic</style></keyword></keywords><dates><year Day="0" Month="0" Year="2010">2010</year></dates><isbn><style face="normal" font="default">0022-9040</style></isbn><abstract><style face="normal" font="default">We studied morphological changes of myocardium and content of glucose, potassium, calcium, sodium in pericardial fluid in persons who died suddenly of myocardial infarction at its prenecrotic stage at prehospital phase. It was established that acute myocardial infarction at prenecrotic stage can run in 2 morphological forms - either with transmural or with subendo- or epicardial localization of ischemic process in left ventricular wall. Transmural injury is characterized by large volume of ischemic damage of the left ventricle, generalized spasm of arterial system of the heart, changes of cardiomyocytes with derangement of their energy metabolism and contractile capacity. In subendo- or epicardial localization foci of ischemic injury alternated with areas of normal blood supply. Similar character of disturbances of rheological properties of blood with thrombosis of microcirculatory bed and of number of markers of ventricular fibrillation between these two forms create preconditions for increase of the zone of necrosis in myocardium and cause high risk of development of rhythm disorders</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)JC - 0376351, ku9CP - Russia (Federation)PT - Comparative StudyPT - English AbstractPT - Journal ArticleLG - Russian</style></notes><urls/><custom1><style face="normal" font="default">UI - 20144151</style></custom1><custom3><style face="normal" font="default">AS - Kardiologiia. 50(1):4-8, 2010.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>326</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Rho,Y.H.</style></author><author><style face="normal" font="default"> Chung,C.P.</style></author><author><style face="normal" font="default"> Oeser,A.</style></author><author><style face="normal" font="default"> Solus,J.</style></author><author><style face="normal" font="default"> Asanuma,Y.</style></author><author><style face="normal" font="default"> Sokka,T.</style></author><author><style face="normal" font="default"> Pincus,T.</style></author><author><style face="normal" font="default"> Raggi,P.</style></author><author><style face="normal" font="default"> Gebretsadik,T.</style></author><author><style face="normal" font="default"> Shintani,A.</style></author><author><style face="normal" font="default"> Stein,C.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis</style></title><secondary-title><style face="normal" font="default">Arthritis &amp; Rheumatism</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Arthritis &amp; Rheumatism</style></full-title></periodical><pages end="1585" start="1580">1580-1585</pages><volume><style face="normal" font="default">61</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Arthritis,Rheumatoid/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Inflammation Mediators/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (E-Selectin)</style></keyword><keyword><style face="normal" font="default"> 0 (IL6 protein,human)</style></keyword><keyword><style face="normal" font="default"> 0 (Inflammation Mediators)</style></keyword><keyword><style face="normal" font="default"> 0 (Interleukin-1alpha)</style></keyword><keyword><style face="normal" font="default"> 0 (Interleukin-6)</style></keyword><keyword><style face="normal" font="default"> 0 (Serum Amyloid A Protein)</style></keyword><keyword><style face="normal" font="default"> 0 (Tumor Necrosis Factor-alpha)</style></keyword><keyword><style face="normal" font="default"> 0 (Vascular Endothelial Growth Factor A)</style></keyword><keyword><style face="normal" font="default"> 0 (VEGFA protein,human)</style></keyword><keyword><style face="normal" font="default"> 126547-89-5 (Intercellular Adhesion Molecule-1)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age of Onset</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Arthritis,Rheumatoid/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Arthritis,Rheumatoid/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> E-Selectin/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> EC 1-11-1-7 (Peroxidase)</style></keyword><keyword><style face="normal" font="default"> EC 3-4-24-35 (Matrix Metalloproteinase 9)</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Intercellular Adhesion Molecule-1/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Interleukin-1alpha/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Interleukin-6/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Matrix Metalloproteinase 9/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Peroxidase/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Serum Amyloid A Protein/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Tumor Necrosis Factor-alpha/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Vascular Endothelial Growth Factor A/bl [Blood]</style></keyword></keywords><dates><year Day="15" Month="11" Year="2009">2009/11/15</year></dates><isbn><style face="normal" font="default">0004-3591</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: Rheumatoid arthritis (RA) is an inflammatory disease associated with premature atherosclerosis. We hypothesized that mediators of inflammation associated with atherosclerosis in other populations (interleukin-6 [IL-6], tumor necrosis factor alpha [TNFalpha], serum amyloid A [SAA], vascular endothelial growth factor, neutrophil count, IL-1alpha, E-selectin, intercellular adhesion molecule 1 [ICAM-1], myeloperoxidase [MPO], matrix metalloproteinase 9, and vascular cell adhesion molecule 1) would be increased and associated with the severity of coronary atherosclerosis in patients with RA. METHODS: Clinical variables, concentrations of inflammatory mediators, and coronary artery calcification were measured in 169 patients with RA and 92 control subjects. Differences in concentrations of inflammatory mediators were compared using median quantile regression. The relationship of inflammatory mediators with the severity of coronary calcification in RA and control subjects was examined using proportional odds logistic regression, allowing for interaction with disease status. Models were adjusted for traditional cardiovascular risk factors. RESULTS: Median serum concentrations of IL-6, SAA, ICAM-1, E-selectin, TNFalpha, and MPO and peripheral blood neutrophil count were higher in patients with RA than controls (all P &lt; 0.05), independent of Framingham risk score and diabetes mellitus (DM). IL-6 (main effect odds ratio [OR] 1.72; 95% confidence interval [95% CI] 1.12, 2.66) and TNFalpha (main effect OR 1.49; 95% CI 1.16, 1.90) concentrations were significantly associated with higher amounts of coronary calcium, independent of Framingham risk score and DM, and such main effects significantly differed from controls (P = 0.001 and 0.03 for interaction, respectively). CONCLUSION: TNFalpha and IL-6 are significantly associated with the severity of subclinical atherosclerosis, independent of Framingham risk score, in RA</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Vanderbilt University, Nashville, Tennessee 37232-6602, USAJC - 0370605, 90mCP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - GM-07569 (United States NIGMS NIH HHS)NO - HL-65082 (United States NHLBI NIH HHS)NO - HL-67964 (United States NHLBI NIH HHS)NO - P60 AR056116 (United States NIAMS NIH HHS)NO - UL-1 RR-024975 (United States NCRR NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19877084</style></custom1><custom3><style face="normal" font="default">AS - Arthritis Rheum. 61(11):1580-5, 2009 Nov 15.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>21</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Rho,Y.H.</style></author><author><style face="normal" font="default"> Chung,C.P.</style></author><author><style face="normal" font="default"> Oeser,A.</style></author><author><style face="normal" font="default"> Solus,J.F.</style></author><author><style face="normal" font="default"> Gebretsadik,T.</style></author><author><style face="normal" font="default"> Shintani,A.</style></author><author><style face="normal" font="default"> Raggi,P.</style></author><author><style face="normal" font="default"> Milne,G.L.</style></author><author><style face="normal" font="default"> Stein,C.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Interaction between oxidative stress and high-density lipoprotein cholesterol is associated with severity of coronary artery calcification in rheumatoid arthritis</style></title><secondary-title><style face="normal" font="default">Arthritis care &amp; research</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Arthritis care &amp; research</style></full-title></periodical><pages end="1480" start="1473">1473-1480</pages><volume><style face="normal" font="default">62</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Arthritis,Rheumatoid/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Cholesterol,HDL/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Oxidative Stress/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol,HDL)</style></keyword><keyword><style face="normal" font="default"> 0 (F2-Isoprostanes)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Arthritis,Rheumatoid/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Arthritis,Rheumatoid/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Biological Markers/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> F2-Isoprostanes/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="10" Year="2010">2010/10</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To test the hypothesis that oxidative stress is increased in patients with rheumatoid arthritis (RA) due to increased inflammation and contributes to the pathogenesis of atherosclerosis. METHODS: The independent association between urinary F2-isoprostane excretion, a measure of oxidative stress, and RA was tested using multiple linear regression models in 169 patients with RA and 92 control subjects, frequency matched for age, race, and sex. The relationship between F2-isoprostane excretion and coronary calcium, a marker of atherosclerosis, was examined in multivariable proportional odds logistic regression models that also assessed the interactions between oxidative stress and low-density lipoprotein and high-density lipoprotein (HDL) cholesterol. RESULTS: F2-isoprostane excretion was significantly higher in patients with RA (median 2.75 [interquartile range (IQR) 1.60-4.06] ng/mg creatinine) than in control subjects (median 1.86 [IQR 1.25-2.62] ng/mg creatinine; adjusted P = 0.006). In patients with RA, F2-isoprostanes were positively correlated with body mass index (P &lt; 0.001), but not with disease activity or mediators of inflammation such as the Disease Activity Score in 28 joints or serum tumor necrosis factor , interleukin-6, and C-reactive protein concentrations in adjusted multivariable models (P > 0.05 for all). In patients with RA, F2-isoprostanes significantly modified the effect of HDL cholesterol on coronary calcification (P = 0.02 for interaction) after adjustment for age, sex, and race. As F2-isoprostane levels increased, HDL lost its protective effect against coronary calcification. CONCLUSION: Oxidative stress measured as F2-isoprostane excretion was higher in patients with RA than in control subjects. Among patients with RA, higher F2-isoprostane excretion and HDL cholesterol concentrations interacted significantly and were positively associated with the severity of coronary calcification</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Vanderbilt University, Nashville, Tennessee 37232-6602, USAJC - 101518086CP - United StatesPT - Comparative StudyPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - GM07569 (United States NIGMS NIH HHS)NO - HL65082 (United States NHLBI NIH HHS)NO - HL67964 (United States NHLBI NIH HHS)NO - P60 AR056116-03 (United States NIAMS NIH HHS)NO - P60-AR056116 (United States NIAMS NIH HHS)NO - R01 HL065082-09 (United States NHLBI NIH HHS)NO - R01 HL067964-04 (United States NHLBI NIH HHS)NO - UL1-RR024975 (United States NCRR NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20506360</style></custom1><custom3><style face="normal" font="default">AS - Arthritis Care Res (Hoboken). 62(10):1473-80, 2010 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>148</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Rho,Y.H.</style></author><author><style face="normal" font="default"> Chung,C.P.</style></author><author><style face="normal" font="default"> Solus,J.F.</style></author><author><style face="normal" font="default"> Raggi,P.</style></author><author><style face="normal" font="default"> Oeser,A.</style></author><author><style face="normal" font="default"> Gebretsadik,T.</style></author><author><style face="normal" font="default"> Shintani,A.</style></author><author><style face="normal" font="default"> Stein,C.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Adipocytokines, insulin resistance, and coronary atherosclerosis in rheumatoid arthritis</style></title><secondary-title><style face="normal" font="default">Arthritis &amp; Rheumatism</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Arthritis &amp; Rheumatism</style></full-title></periodical><pages end="1264" start="1259">1259-1264</pages><volume><style face="normal" font="default">62</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Adipokines/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Arthritis,Rheumatoid/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Arthritis,Rheumatoid/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Insulin Resistance</style></keyword><keyword><style face="normal" font="default"> 0 (Adipokines)</style></keyword><keyword><style face="normal" font="default"> 0 (Adiponectin)</style></keyword><keyword><style face="normal" font="default"> 0 (adiponectin,human)</style></keyword><keyword><style face="normal" font="default"> 0 (Cytokines)</style></keyword><keyword><style face="normal" font="default"> 0 (Inflammation Mediators)</style></keyword><keyword><style face="normal" font="default"> 0 (Leptin)</style></keyword><keyword><style face="normal" font="default"> 0 (Resistin)</style></keyword><keyword><style face="normal" font="default"> 0 (RETN protein,human)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adiponectin/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcinosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Cytokines/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> EC 2-4-2-12 (Nicotinamide Phosphoribosyltransferase)</style></keyword><keyword><style face="normal" font="default"> EC 2-4-2-12 (nicotinamide phosphoribosyltransferase,human)</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Inflammation Mediators/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Insulin Resistance</style></keyword><keyword><style face="normal" font="default"> Leptin/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Nicotinamide Phosphoribosyltransferase/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Resistin/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="5" Year="2010">2010/5</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The prevalence of subclinical coronary atherosclerosis is increased in patients with rheumatoid arthritis (RA), and the increased risk is associated with insulin resistance. Adipocytokines have been linked to obesity, insulin resistance, inflammation, and coronary heart disease in the general population. This study was undertaken to examine the hypothesis that adipocytokines affect insulin resistance and coronary atherosclerosis among patients with RA. METHODS: The coronary calcium score, homeostatic model assessment for insulin resistance (HOMA-IR) index, and serum adipocytokine (leptin, adiponectin, resistin, and visfatin) concentrations were determined in 169 patients with RA. The independent effect of each adipocytokine on insulin resistance according to the HOMA-IR index and on coronary artery calcification determined by electron beam computed tomography was assessed in models adjusted for age, race, sex, body mass index (BMI), traditional cardiovascular risk factors, and inflammation mediators. In addition, an interaction analysis was performed to evaluate whether the effect of the HOMA-IR index on the coronary calcium score is moderated by adipocytokines. RESULTS: Increased concentrations of leptin were associated with a higher HOMA-IR index, even after adjustment for age, race, sex, BMI, traditional cardiovascular risk factors, and inflammation mediators (P &lt; 0.001), but concentrations of visfatin (P = 0.06), adiponectin (P = 0.55), and resistin (P = 0.98) showed no association with the HOMA-IR index. None of the adipocytokines was independently associated with the coronary calcium score (all P > 0.05). Serum leptin concentrations showed a significant interaction with the HOMA-IR index (P for multivariate interaction = 0.02). Increasing leptin concentrations attenuated the increased risk of coronary calcification related to insulin resistance. Serum concentrations of the other adipocytokines showed no significant interactions with the HOMA-IR index (each P > 0.05). CONCLUSION: Leptin is associated with insulin resistance in patients with RA but, paradoxically, attenuates the effects of insulin resistance on coronary calcification</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Vanderbilt University, Nashville, Tennessee 37232-6602, USAJC - 0370605, 90mCP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - GM-07569 (United States NIGMS NIH HHS)NO - HL-65082 (United States NHLBI NIH HHS)NO - HL-67964 (United States NHLBI NIH HHS)NO - P60-AR-056116 (United States NIAMS NIH HHS)NO - UL1-RR-024975 (United States NCRR NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20213808</style></custom1><custom3><style face="normal" font="default">AS - Arthritis Rheum. 62(5):1259-64, 2010 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>217</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Ripert,T.</style></author><author><style face="normal" font="default"> Menard,J.</style></author><author><style face="normal" font="default"> Schoepen,Y.</style></author><author><style face="normal" font="default"> Nguyen,P.</style></author><author><style face="normal" font="default"> Rieu,P.</style></author><author><style face="normal" font="default"> Staerman,F.</style></author></authors></contributors><titles><title><style face="normal" font="default">Preventing graft thrombosis after renal transplantation: a multicenter survey of clinical practice</style></title><secondary-title><style face="normal" font="default">Transplantation Proceedings</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Transplantation Proceedings</style></full-title></periodical><pages end="4196" start="4193">4193-4196</pages><volume><style face="normal" font="default">41</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Kidney Transplantation/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Venous Thrombosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> 0 (Anticoagulants)</style></keyword><keyword><style face="normal" font="default"> 37270-89-6 (calcium heparin)</style></keyword><keyword><style face="normal" font="default"> 50-78-2 (Aspirin)</style></keyword><keyword><style face="normal" font="default"> 9005-49-6 (Heparin)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Anticoagulants/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> Aspirin/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Consensus</style></keyword><keyword><style face="normal" font="default"> Dialysis</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Health Surveys</style></keyword><keyword><style face="normal" font="default"> Heparin/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Intermittent Pneumatic Compression Devices</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Telephone</style></keyword><keyword><style face="normal" font="default"> Treatment Failure</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Venous Thrombosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Venous Thrombosis/pc [Prevention &amp; Control]</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Renal allograft vascular thrombosis is a complication that often results in graft loss. Since there are no guidelines on immediate postoperative thromboprophylaxis, we performed a telephone survey of clinical practice in all renal transplantation centers in France. METHODS: Each center considered 4 cases relating to renal transplant candidates on dialysis with an increasing risk of thrombosis: Case 1: patient with no identified risk factors; Case 2: patient with an earlier incidence of deep vein thrombosis; Case 3: patient with ischemic heart disease on antiplatelet therapy; Case 4: patient with atrial fibrillation taking a vitamin K antagonist (VKA) with lupus nephritis syndrome. RESULTS: The treatments proposed by the centers (%) were: Case 1: No anticoagulation therapy (57.1%), calcium heparin at prophylactic doses (P-dose) (40%), or unfractionated heparin (UFH); (P-dose; 2.9%). Case 2: No anticoagulation therapy (34.3%), calcium heparin (P-dose; 51.4%), or UFH (P-dose; 5.7%). Case 3: (A) Interruption of aspirin (65.7%), and either no anticoagulation therapy (21.7%) or substitution of aspirin by calcium heparin (P-dose; 56.6%) or by UFH (P-dose; 8.7%). (B) No interruption of aspirin (34.3%), and either no additional prophylaxis (58.3%) or calcium heparin (P-dose; 33.3%). Case 4: Interruption of VKA (100%), and UFH at a curative dose (68.6%), UFH (P-dose; 14.3%), or calcium heparin (P-dose; 11.4%). CONCLUSIONS: Practices varied widely in the absence of studies of sufficiently high power. There is a need for a preoperative classification of thrombotic and hemorrhagic risk among renal transplant candidates and for consensus guidelines</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Urology, CHU Robert Debre, REIMS, Champagne Ardennes, France. thomas_ripert@yahoo.frJC - we9, 0243532CP - United StatesPT - Journal ArticlePT - Multicenter StudyLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20005367</style></custom1><custom3><style face="normal" font="default">AS - Transplant Proc. 41(10):4193-6, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>519</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Ripert,T.</style></author><author><style face="normal" font="default"> Menard,J.</style></author><author><style face="normal" font="default"> Schoepen,Y.</style></author><author><style face="normal" font="default"> N'guyen,P.</style></author><author><style face="normal" font="default"> Rieu,P.</style></author><author><style face="normal" font="default"> Brandt,B.</style></author><author><style face="normal" font="default"> Staerman,F.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Anticoagulation after renal transplantation: a multicenter survey on clinical practice]. [French]</style></title><secondary-title><style face="normal" font="default">Progres en Urologie</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Progres en Urologie</style></full-title></periodical><pages end="191" start="186">186-191</pages><volume><style face="normal" font="default">19</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Anticoagulants/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Kidney Transplantation/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Venous Thrombosis/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> 0 (Anticoagulants)</style></keyword><keyword><style face="normal" font="default"> 0 (Platelet Aggregation Inhibitors)</style></keyword><keyword><style face="normal" font="default"> 37270-89-6 (calcium heparin)</style></keyword><keyword><style face="normal" font="default"> 50-78-2 (Aspirin)</style></keyword><keyword><style face="normal" font="default"> 9005-49-6 (Heparin)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> Aspirin/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Dialysis</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Heparin/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Kidney Transplantation</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Peritoneal Dialysis</style></keyword><keyword><style face="normal" font="default"> Physician's Practice Patterns</style></keyword><keyword><style face="normal" font="default"> Platelet Aggregation Inhibitors/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword></keywords><dates><year Day="0" Month="3" Year="2009">2009/3</year></dates><isbn><style face="normal" font="default">1166-7087</style></isbn><abstract><style face="normal" font="default">OBJECTIVES: Graft thrombosis is a major complication of transplantation. However, there are no recommendation on immediate postoperative thromboprophylaxis after kidney transplantation. We recorded clinical practices in France. MATERIAL AND METHODS: In 29 transplantation centres, four case studies were submitted to the medical kidney transplantation referent (compatible graft from cadaveric donor, without perioperative complication). N(o) 1: Man, 27-years-old, IgA glomerulonephritis, without history of hypercoagulability or cardiovascular risk factor. Hemodialysis since 12months. N(o) 2: Man, 53-years-old, with history of deep venous thrombosis after cholecystectomy 15years before. Membranous nephropathy. Hemodialysis since 10months. N(o) 3: Man, 58-years-old, with history of myocardial infarction. On aspirin therapy. Nephroangiosclerosis and diabetic nephropathy. Peritoneal dialysis since 6months. N(o) 4: Woman, 63-years-old. Atrial fibrillation on vitamin K antagonists therapy. Lupus nephritis without antiphospholipid syndrome. Hemodialysis since 12months. RESULTS: N(o) 1: No anticoagulation therapy (62%), calcium heparin at prophylactic doses (34.5%). N(o) 2: No anticoagulation therapy (38%), calcium heparin at prophylactic doses (44.8%). N(o) 3: 62% interrupted aspirin of whom 22% without any immediate anticoagulation and 55% replaced aspirin with calcium heparin at prophylactic doses. Thirty-eight percent carried on with aspirin of whom 63.6% without other prophylaxis and 27.3% in association with calcium heparin at prophylactic doses. N(o) 4: Unfractionned heparin at curative dose (62%), unfractionned heparin at prophylactic doses (17.2%), calcium heparin at prophylactic doses (13.8%). CONCLUSION: Postoperative anticoagulation after renal transplantation is established as a local dogma rather than evidence-based medicine. Guideline recommendations and standardized protocols for the use of anticoagulation after kidney transplantation should be developed</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - D&amp;#x00E9;partement d'urologie-andrologie, CHU de Reims, rue du G&amp;#x00E9;n&amp;#x00E9;ral-Koenig, 51100 Reims, France. thomas_ripert@yahoo.frOT - Quelle thromboprophylaxie apr&amp;#x00E8;s transplantation r&amp;#x00E9;nale ? Enqu&amp;#x00EA;te sur la pr&amp;#x00E9;vention des thromboses du greffon en FranceJC - brv, 9307844CP - FrancePT - English AbstractPT - Journal ArticlePT - Multicenter StudyLG - French</style></notes><urls/><custom1><style face="normal" font="default">UI - 19268256</style></custom1><custom3><style face="normal" font="default">AS - Prog Urol. 19(3):186-91, 2009 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>377</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Rivera,J.J.</style></author><author><style face="normal" font="default"> Nasir,K.</style></author><author><style face="normal" font="default"> Cox,P.R.</style></author><author><style face="normal" font="default"> Choi,E.K.</style></author><author><style face="normal" font="default"> Yoon,Y.</style></author><author><style face="normal" font="default"> Cho,I.</style></author><author><style face="normal" font="default"> Chun,E.J.</style></author><author><style face="normal" font="default"> Choi,S.I.</style></author><author><style face="normal" font="default"> Blumenthal,R.S.</style></author><author><style face="normal" font="default"> Chang,H.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Association of traditional cardiovascular risk factors with coronary plaque sub-types assessed by 64-slice computed tomography angiography in a large cohort of asymptomatic subjects</style></title><secondary-title><style face="normal" font="default">Atherosclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Atherosclerosis</style></full-title></periodical><pages end="457" start="451">451-457</pages><volume><style face="normal" font="default">206</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiovascular Diseases/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Although prior studies have shown that traditional cardiovascular (CV) risk factors are associated with the burden of coronary atherosclerosis, less is known about the relationship of risk factors with coronary plaque sub-types. Coronary computed tomography angiography (CCTA) allows an assessment of both, total disease burden and plaque characteristics. In this study, we investigate the relationship between traditional CV risk factors and the presence and extent of coronary plaque sub-types in a large group of asymptomatic individuals. METHODS: The study population consisted of 1015 asymptomatic Korean subjects (53+/-10 years; 64% were males) free of known CV disease who underwent 64-slice CCTA as part of a health screening evaluation. We analyzed plaque characteristics on a per-segment basis according to the modified American Heart Association classification. Plaques in which calcified tissue occupied more than 50% of the plaque area were classified as calcified (CAP), &lt;50% calcified area as mixed (MCAP), and plaques without any calcium as non-calcified (NCAP). RESULTS: A total of 215 (21%) subjects had coronary plaque while 800 (79%) had no identifiable disease. Multivariate regression analysis demonstrated that increased age (per decade) and gender are the strongest predictors for the presence of any coronary plaque or the presence of at least one segment of CAP and MCAP (any plaque-age: OR 2.89; 95% CI 2.34, 3.56; male gender: OR 5.21; 95% CI 3.20, 8.49; CAP-age: OR 2.75; 95% CI 2.12, 3.58; male gender: 4.78; 95% CI 2.48, 9.23; MCAP-age: OR 2.62; 95% CI 2.02, 3.39; male gender: OR 4.15; 95% CI 2.17, 7.94). The strongest predictors for the presence of any NCAP were gender (OR 3.56; 95% CI 1.96-6.55) and diabetes mellitus (OR 2.87; 95% CI 1.63-5.08). When looking at the multivariate association between the presence of >/=2 coronary segments with a plaque sub-type and CV risk factors, male gender was the strongest predictor for CAP (OR 7.31; 95% CI 2.12, 25.20) and MCAP (OR 5.54; 95% CI 1.84, 16.68). Alternatively, smoking was the strongest predictor for the presence of >/=2 coronary segments with NCAP (OR 4.86; 95% CI 1.68, 14.07). Low-density lipoprotein cholesterol (LDL-C) was only a predictor for the presence and extent of mixed coronary plaque. CONCLUSION: Age and gender are overall the strongest predictors of atherosclerosis as assessed by CCTA in this large asymptomatic Korean population and these two risk factors are not particularly associated with a specific coronary plaque sub-type. Smoking is a strong predictor of NCAP, which has been suggested by previous reports as a more vulnerable lesion. Whether a specific plaque sub-type is associated with a worse prognosis is yet to be determined by future prospective studies</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Johns Hopkins Ciccarone Preventive Cardiology Center, Baltimore, MD, USACM - Comment in: Atherosclerosis. 2009 Oct;206(2):349-50; PMID: 19541315]JC - 95x, 0242543CP - IrelandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19524922</style></custom1><custom3><style face="normal" font="default">AS - Atherosclerosis. 206(2):451-7, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>472</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Rivera,J.J.</style></author><author><style face="normal" font="default"> Nasir,K.</style></author><author><style face="normal" font="default"> Katz,R.</style></author><author><style face="normal" font="default"> Takasu,J.</style></author><author><style face="normal" font="default"> Allison,M.</style></author><author><style face="normal" font="default"> Wong,N.D.</style></author><author><style face="normal" font="default"> Barr,R.G.</style></author><author><style face="normal" font="default"> Carr,J.J.</style></author><author><style face="normal" font="default"> Blumenthal,R.S.</style></author><author><style face="normal" font="default"> Budoff,M.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Relationship of thoracic aortic calcium to coronary calcium and its progression (from the Multi-Ethnic Study of Atherosclerosis [MESA])</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="1567" start="1562">1562-1567</pages><volume><style face="normal" font="default">103</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aorta,Thoracic/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Aorta,Thoracic/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Aorta,Thoracic/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Ethnic Groups</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="1" Month="6" Year="2009">2009/6/1</year></dates><abstract><style face="normal" font="default">Thoracic aortic calcium (TAC) has been associated with a higher prevalence of coronary arterial calcium (CAC). The purpose of this study was to assess the relations between TAC and incident CAC and CAC progression in a cohort from the Multi-Ethnic Study of Atherosclerosis (MESA). MESA is a prospective cohort study of 6,814 participants free of clinical cardiovascular disease at entry who underwent noncontrast cardiac computed tomographic scanning at baseline examination and at a 2-year follow-up assessment. The independent associations between TAC and incident CAC in those without CAC at baseline and between TAC and CAC progression in those with CAC at baseline were investigated. The final study population consisted of 5,755 subjects (84%; mean age 62 +/- 10 years, 48% men) who had follow-up CAC scores an average of 2.4 years later. Incident CAC was significantly higher in those with TAC compared with those without TAC at baseline (11 per 100 patient-years vs 6 per 100 patient-years). Similarly, TAC was associated with a higher CAC change (p &lt;0.0001) in those with some CAC at baseline. In analysis adjusted for demographics and follow-up duration, TAC was associated with incident CAC (relative risk 1.72, p &lt;0.0001) as well as with a greater CAC change (first quartile: relative risk 2.89, 95% confidence interval -3.16 to 8.95; fourth quartile: relative risk 24.21, 95% confidence interval 18.25 to 30.18). In conclusion, TAC is associated with the incidence and progression of CAC. The detection of TAC may improve risk stratification efforts. Future clinical outcomes studies are needed to support such an approach</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiology, Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins Hospital, Baltimore, Maryland, USA. jriver16@jhmi.eduJC - 3dq, 0207277CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - 1T32 HL076136-02 (United States NHLBI NIH HHS)NO - N01-HC-95159 (United States NHLBI NIH HHS)NO - N01-HC-95160 (United States NHLBI NIH HHS)NO - N01-HC-95161 (United States NHLBI NIH HHS)NO - N01-HC-95162 (United States NHLBI NIH HHS)NO - N01-HC-95163 (United States NHLBI NIH HHS)NO - N01-HC-95164 (United States NHLBI NIH HHS)NO - N01-HC-95165 (United States NHLBI NIH HHS)NO - N01-HC-95169 (United States NHLBI NIH HHS)NO - R01-HL-071739-03 (United States NHLBI NIH HHS)NO - R01-HL-63963-01A1 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19463516</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 103(11):1562-7, 2009 Jun 1.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>483</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Roberts,K.E.</style></author><author><style face="normal" font="default"> Fallon,M.B.</style></author><author><style face="normal" font="default"> Krowka,M.J.</style></author><author><style face="normal" font="default"> Brown,R.S.</style></author><author><style face="normal" font="default"> Trotter,J.F.</style></author><author><style face="normal" font="default"> Peter,I.</style></author><author><style face="normal" font="default"> Tighiouart,H.</style></author><author><style face="normal" font="default"> Knowles,J.A.</style></author><author><style face="normal" font="default"> Rabinowitz,D.</style></author><author><style face="normal" font="default"> Benza,R.L.</style></author><author><style face="normal" font="default"> Badesch,D.B.</style></author><author><style face="normal" font="default"> Taichman,D.B.</style></author><author><style face="normal" font="default"> Horn,E.M.</style></author><author><style face="normal" font="default"> Zacks,S.</style></author><author><style face="normal" font="default"> Kaplowitz,N.</style></author><author><style face="normal" font="default"> Kawut,S.M.</style></author><author><style face="normal" font="default"> Pulmonary Vascular Complications of Liver Disease Study Group</style></author></authors></contributors><titles><title><style face="normal" font="default">Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease</style></title><secondary-title><style face="normal" font="default">American Journal of Respiratory &amp; Critical Care Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Respiratory &amp; Critical Care Medicine</style></full-title></periodical><pages end="842" start="835">835-842</pages><volume><style face="normal" font="default">179</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Hypertension,Portal/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Liver Diseases/co [Complications]</style></keyword><keyword><style face="normal" font="default"> 0 (Angiopoietin-1)</style></keyword><keyword><style face="normal" font="default"> 0 (Calcium-Binding Proteins)</style></keyword><keyword><style face="normal" font="default"> 0 (Estrogen Receptor alpha)</style></keyword><keyword><style face="normal" font="default"> 0 (Receptors,Retinoic Acid)</style></keyword><keyword><style face="normal" font="default"> 0 (retinoic acid receptor beta)</style></keyword><keyword><style face="normal" font="default"> 50-28-2 (Estradiol)</style></keyword><keyword><style face="normal" font="default"> Angiopoietin-1/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Aromatase/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium-Binding Proteins/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Cyclic Nucleotide Phosphodiesterases,Type 5/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> EC 1-14-14-1 (Aromatase)</style></keyword><keyword><style face="normal" font="default"> EC 3-1-4-35 (Cyclic Nucleotide Phosphodiesterases,Type 5)</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Estradiol/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Estrogen Receptor alpha/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Polymorphism,Single Nucleotide</style></keyword><keyword><style face="normal" font="default"> Receptors,Retinoic Acid/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Vascular Resistance</style></keyword></keywords><dates><year Day="1" Month="5" Year="2009">2009/5/1</year></dates><abstract><style face="normal" font="default">RATIONALE: Portopulmonary hypertension (PPHTN) occurs in 6% of liver transplant candidates. The pathogenesis of this complication of portal hypertension is poorly understood. OBJECTIVES: To identify genetic risk factors for PPHTN in patients with advanced liver disease. METHODS: We performed a multicenter case-control study of patients with portal hypertension. Cases had a mean pulmonary artery pressure >25 mm Hg, pulmonary vascular resistance >240 dynes.s(-1).cm(-5), and pulmonary capillary wedge pressure &lt; or =15 mm Hg. Controls had a right ventricular systolic pressure &lt; 40 mm Hg (if estimated) and normal right-sided cardiac morphology by transthoracic echocardiography. We genotyped 1,079 common single nucleotide polymorphisms (SNPs) in 93 candidate genes in each patient. MEASUREMENTS AND MAIN RESULTS: The study sample included 31 cases and 104 controls. Twenty-nine SNPs in 15 candidate genes were associated with the risk of PPHTN (P &lt; 0.05). Multiple SNPs in the genes coding for estrogen receptor 1, aromatase, phosphodiesterase 5, angiopoietin 1, and calcium binding protein A4 were associated with the risk of PPHTN. The biological relevance of one of the aromatase SNPs was supported by an association with plasma estradiol levels. CONCLUSIONS: Genetic variation in estrogen signaling and cell growth regulators is associated with the risk of PPHTN. These biologic pathways may elucidate the mechanism for the development of PPHTN in certain patients with severe liver disease</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, Tufts Medical Center, Boston, MA 02111, USA. kroberts@tuftsmedicalcenter.orgJC - 9421642, bzsCP - United StatesPT - Journal ArticlePT - Multicenter StudyLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19218192</style></custom1><custom3><style face="normal" font="default">AS - Am J Respir Crit Care Med. 179(9):835-42, 2009 May 1.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>31</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Rogulj,D.</style></author><author><style face="normal" font="default"> Hauptfeld,M.</style></author><author><style face="normal" font="default"> Iskra,M.S.</style></author><author><style face="normal" font="default"> Zorko,V.K.</style></author><author><style face="normal" font="default"> Strasek,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Extreme hyperkalaemia caused by concomitant use of a NSAID and an ace inhibitor in an elderly patient</style></title><secondary-title><style face="normal" font="default">Arhiv Za Higijenu Rada i Toksikologiju</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Arhiv Za Higijenu Rada i Toksikologiju</style></full-title></periodical><pages end="245" start="241">241-245</pages><volume><style face="normal" font="default">61</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Angiotensin-Converting Enzyme Inhibitors/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Anti-Inflammatory Agents,Non-Steroidal/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Diclofenac/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Hyperkalemia/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> 0 (Angiotensin-Converting Enzyme Inhibitors)</style></keyword><keyword><style face="normal" font="default"> 0 (Anti-Inflammatory Agents,Non-Steroidal)</style></keyword><keyword><style face="normal" font="default"> 15307-86-5 (Diclofenac)</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Angiotensin-Converting Enzyme Inhibitors/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Anti-Inflammatory Agents,Non-Steroidal/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Drug Interactions</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperkalemia/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="1" Month="6" Year="2010">2010/6/1</year></dates><isbn><style face="normal" font="default">0004-1254</style></isbn><abstract><style face="normal" font="default">Extreme hyperkalaemia is a life-threatening electrolyte disorder. It is relatively common in patients with severe renal insufficiency. This report describes a case of extreme hyperkalaemia caused by drugs in an 82-year-old female patient without severe renal insufficiency, who was successfully treated without haemodialysis. The patient had been treated for arterial hypertension and type 2 diabetes mellitus for 30 years. Over the last years she had been receiving enalapril and metformin. Three weeks before the admission to the hospital, she was receiving a non-steroidal anti-inflammatory drug (NSAID) because of the back pain. She was admitted to hospital due to a collapse and weakness in the limbs. Laboratory tests showed extreme hyperkalaemia, high blood sugar, metabolic acidosis, elevated serum creatinine and blood urea nitrogen (BUN), and a slightly elevated serum sodium. On ECG, we noticed typical signs of hyperkalaemia.The patient was treated with a slow intravenous bolus of calcium gluconate and intravenous infusion of sodium chloride with insulin, glucose with insulin and sodium bicarbonte. After the treatment, all laboratory findings normalised together and the patient felt better. This case shows that physicians should be very careful when prescribing NSAIDs to elderly patients treated with drugs that affect renal function</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Internal Medicine, General Hospital Brezice, Brezice, Slovenia. dinko.rogulj@zg.t-com.hrJC - 8mk, 0373100CP - CroatiaPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20587399</style></custom1><custom3><style face="normal" font="default">AS - Arh Hig Rada Toksikol. 61(2):241-5, 2010 Jun 1.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>409</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Rohatgi,A.</style></author><author><style face="normal" font="default"> Owens,A.W.</style></author><author><style face="normal" font="default"> Khera,A.</style></author><author><style face="normal" font="default"> Ayers,C.R.</style></author><author><style face="normal" font="default"> Banks,K.</style></author><author><style face="normal" font="default"> Das,S.R.</style></author><author><style face="normal" font="default"> Berry,J.D.</style></author><author><style face="normal" font="default"> McGuire,D.K.</style></author><author><style face="normal" font="default"> de Lemos,J.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Differential associations between soluble cellular adhesion molecules and atherosclerosis in the Dallas Heart Study: a distinct role for soluble endothelial cell-selective adhesion molecule</style></title><secondary-title><style face="normal" font="default">Arteriosclerosis, Thrombosis &amp; Vascular Biology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Arteriosclerosis, Thrombosis &amp; Vascular Biology</style></full-title></periodical><pages end="1690" start="1684">1684-1690</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Cell Adhesion Molecules/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> 0 (Cell Adhesion Molecules)</style></keyword><keyword><style face="normal" font="default"> 0 (Vascular Cell Adhesion Molecule-1)</style></keyword><keyword><style face="normal" font="default"> 126547-89-5 (Intercellular Adhesion Molecule-1)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aorta/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cell Adhesion Molecules/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Intercellular Adhesion Molecule-1/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Vascular Cell Adhesion Molecule-1/bl [Blood]</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Endothelial cell-selective adhesion molecule (ESAM) is a junctional-type cellular adhesion molecule (CAM) that is uniquely expressed in vascular endothelium and activated platelets and mediates neutrophil and monocyte diapedesis across the endothelium. Given its role in endothelial pathobiology, we hypothesized that soluble ESAM (sESAM) would be independently associated with atherosclerosis and vascular stiffness. METHODS AND RESULTS: We measured sESAM, soluble intercellular adhesion molecule (sICAM)-1, and soluble vascular cell adhesion molecule (sVCAM)-1 in 3222 subjects participating in the Dallas Heart Study, a probability-based population sample. Coronary artery calcium (CAC) was measured by electron beam computed tomography, and abdominal aortic wall thickness (AWT), aortic plaque burden (APB), and aortic compliance (AC) by MRI. Increasing levels of sESAM were associated with all major cardiovascular risk factors as well as with inflammatory markers such as monocyte chemoattractant protein-1, but only weakly correlated with sICAM-1 and sVCAM-1. In multivariate analyses, sESAM was independently associated with prevalent CAC (OR 1.2 per SD increase, 95% CI 1.1 to 1.3; P=0.005), AWT (P=0.035), and AC (P=0.006), but not APB (P=0.15). In contrast, no independent associations were observed between sICAM-1 or sVCAM-1 and any of the atherosclerosis phenotypes. CONCLUSIONS: In this first reported clinical study of sESAM in humans, sESAM levels were independently associated with CAC, AWT, and AC, whereas sICAM-1 and sVCAM-1 were not. These findings support a unique role of this cellular adhesion molecule in atherosclerosis and suggest the need for further exploration of sESAM as a predictive biomarker and potential mediator of atherosclerosis</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9047, USA. anand.rohatgi@utsouthwestern.eduJC - 9505803, B89CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - M01-RR00633 (United States NCRR NIH HHS)NO - UL1 RR024982 (United States NCRR NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19759376</style></custom1><custom3><style face="normal" font="default">AS - Arterioscler Thromb Vasc Biol. 29(10):1684-90, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>364</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Romashchenko,O.V.</style></author><author><style face="normal" font="default"> Kamenev,V.F.</style></author><author><style face="normal" font="default"> Tret'iakov,A.I.</style></author><author><style face="normal" font="default"> Alferov,P.K.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Erythrone system in aged patients with chronic cardiac insufficiency]. [Russian]</style></title><secondary-title><style face="normal" font="default">Klinicheskaia Meditsina</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Klinicheskaia Meditsina</style></full-title></periodical><pages end="25" start="21">21-25</pages><volume><style face="normal" font="default">87</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> *Erythrocyte Deformability/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Erythrocytes/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> *Erythrocytes/ul [Ultrastructure]</style></keyword><keyword><style face="normal" font="default"> *Heart Failure/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cell Membrane Permeability</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Erythrocyte Membrane/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Microscopy,Electron,Scanning</style></keyword><keyword><style face="normal" font="default"> Nanotechnology</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Russia</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><isbn><style face="normal" font="default">0023-2149</style></isbn><abstract><style face="normal" font="default">Basic mechanisms underlying the development of chronic cardiac insufficiency (CCI) in aged subjects were investigated in a randomized study of 30 patients with I-IV functional class CCI and preserved left ventricular systolic function. CCI affected the left side of the heart in 23 patients due to concurrent hypertensive disease and the right side in 7 patients with concomitant chronic broncho-pulmonary pathology. Mean age of the patients was 65 years. Control group comprised 8 practically healthy middle-age subjects. Erythrone system condition was evaluated from erythrocyte morphological characteristics and chemical composition studied by scanning electron microscopy on a FEI quanta 2003D apparatus in the Nanotechnologies and Nanomaterials Centre, Belgorod State University. Pathological changes in the erythrone system of CCI patients included changes of erythrocyte shape and chemical composition especially well apparent in cases with chronic pulmonary heart. As CCI progressed, erythrocytes in the form of bi-convex disks turned to spheres with the papillose surface. The sphere to disk ratio in the compensation, sub- and decompensation stages was 1:7, 1:4, and 9:1 respectively compared with 1:60 in controls. Spherocytes contained less nitrogen than normal diskocytes. Protein degradation was more apparent in aged CCI patients. Their erythrocytes contained 4.5-5, 2, 3 and 4 times more calcium, magnesium, aluminium, and silicon respectively than the cells of healthy subjects. It suggests development of calcium paradox, abnormal membrane permeability and gradual cell death (hemolysis). Anemia in aged CCI patients appears be of haemolytic nature. It occurred in 6.7-11.5% of the cases of left ventricular CCI and in 33.3% of the aged patients with chronic pulmonary heart, the lethality rate being 0.93 and 28.6% respectively. It is concluded that changes in the erythrone system in the form of erythrocyte spherulation, accumulation of calcium and other chemical elements suggest a poor prognosis of CCI in elderly patients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)JC - kw2, 2985204rCP - Russia (Federation)PT - Comparative StudyPT - English AbstractPT - Journal ArticlePT - Randomized Controlled TrialLG - Russian</style></notes><urls/><custom1><style face="normal" font="default">UI - 19827525</style></custom1><custom3><style face="normal" font="default">AS - Klin Med (Mosk). 87(8):21-5, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>266</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Rominger,A.</style></author><author><style face="normal" font="default"> Saam,T.</style></author><author><style face="normal" font="default"> Vogl,E.</style></author><author><style face="normal" font="default"> Ubleis,C.</style></author><author><style face="normal" font="default"> la,Foug</style></author><author><style face="normal" font="default"> rster,S.</style></author><author><style face="normal" font="default"> Haug,A.</style></author><author><style face="normal" font="default"> Cumming,P.</style></author><author><style face="normal" font="default"> Reiser,M.F.</style></author><author><style face="normal" font="default"> Nikolaou,K.</style></author><author><style face="normal" font="default"> Bartenstein,P.</style></author><author><style face="normal" font="default"> Hacker,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">In vivo imaging of macrophage activity in the coronary arteries using 68Ga-DOTATATE PET/CT: correlation with coronary calcium burden and risk factors</style></title><secondary-title><style face="normal" font="default">Journal of Nuclear Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Nuclear Medicine</style></full-title></periodical><pages end="197" start="193">193-197</pages><volume><style face="normal" font="default">51</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> *Macrophages/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Macrophages/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> *Positron-Emission Tomography</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> 0 (68Ga-DOTATATE)</style></keyword><keyword><style face="normal" font="default"> 0 (Gallium Radioisotopes)</style></keyword><keyword><style face="normal" font="default"> 0 (Organometallic Compounds)</style></keyword><keyword><style face="normal" font="default"> 0 (Radiopharmaceuticals)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Gallium Radioisotopes/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neuroendocrine Tumors/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Neuroendocrine Tumors/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> Organometallic Compounds/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> Radiopharmaceuticals/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="2" Year="2010">2010/2</year></dates><abstract><style face="normal" font="default">We measured the uptake of the somatostatin receptor ligand (68)Ga-[1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid]-D-Phe(1),Tyr(3)-octreotate (DOTATATE) in the left anterior descending coronary artery (LAD) in association with calcified plaques (CPs) and cardiovascular risk factors. METHODS: Seventy consecutive tumor patients were examined by whole-body (68)Ga-DOTATATE contrast-enhanced PET/CT. Blood-pool-corrected standardized uptake value (target-to-background ratio) was measured in the LAD, and CT images were used to detect CP. Cardiovascular risk factors and history of prior cardiovascular events were recorded. RESULTS: (68)Ga-DOTATATE uptake was detectable in the LAD of all patients. Target-to-background ratio in the LAD correlated significantly with the presence of CP (R = 0.34; P &lt; 0.01), prior vascular events (R = 0.26; P &lt; 0.05), and male sex (R = 0.29; P &lt; 0.05), whereas CP correlated with these parameters but also with age (R = 0.34; P &lt; 0.01) and hypertension (R = 0.25; P &lt; 0.05). CONCLUSION: In a series of oncologic patients, those with prior cardiovascular events and calcified atherosclerotic plaques showed significantly increased (68)Ga-DOTATATE uptake in the LAD, suggesting a potential role of this tracer for plaque imaging in the coronary arteries</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Nuclear Medicine, University of Munich, Munich, GermanyJC - jec, 0217410CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20080898</style></custom1><custom3><style face="normal" font="default">AS - J Nucl Med. 51(2):193-7, 2010 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>498</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Roos,M.</style></author><author><style face="normal" font="default"> Richart,T.</style></author><author><style face="normal" font="default"> Kouznetsova,T.</style></author><author><style face="normal" font="default"> von,Eynatten M.</style></author><author><style face="normal" font="default"> Lutz,J.</style></author><author><style face="normal" font="default"> Heemann,U.</style></author><author><style face="normal" font="default"> Baumann,M.</style></author><author><style face="normal" font="default"> Staessen,J.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Fetuin-A and arterial stiffness in patients with normal kidney function</style></title><secondary-title><style face="normal" font="default">Regulatory Peptides</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Regulatory Peptides</style></full-title></periodical><pages end="43" start="39">39-43</pages><volume><style face="normal" font="default">154</style></volume><number><style face="normal" font="default">1-3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*alpha-Fetoproteins/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Aorta/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Carotid Artery,Common/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Kidney/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Vascular Resistance</style></keyword><keyword><style face="normal" font="default"> 0 (alpha-Fetoproteins)</style></keyword><keyword><style face="normal" font="default"> 60-27-5 (Creatinine)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Alleles</style></keyword><keyword><style face="normal" font="default"> alpha-Fetoproteins/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Blood Flow Velocity</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Creatinine/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Creatinine/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Dialysis</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Gene Frequency</style></keyword><keyword><style face="normal" font="default"> Heterozygote</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Polymorphism,Single Nucleotide</style></keyword><keyword><style face="normal" font="default"> Pulsatile Flow</style></keyword><keyword><style face="normal" font="default"> Pulse</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword></keywords><dates><year Day="10" Month="4" Year="2009">2009/4/10</year></dates><isbn><style face="normal" font="default">0167-0115</style></isbn><abstract><style face="normal" font="default">AIM: To evaluate the association between fetuin-A level (AHSG), its encoding gene (Thr256Ser) and arterial function in subjects with normal kidney function. INTRODUCTION: The aortic pulse wave velocity (aPWV) is a predictor for cardiovascular mortality. Fetuin-A is a calcification inhibitor and correlates negatively with increased vascular stiffness in dialysis patients. The fetuin-A polymorphism (Thr256Ser) is associated with reduced fetuin levels and accelerated vascular calcification in dialysis patients. Little is known about the role of fetuin-A as an independent predictor for the development of arterial stiffness in healthy subjects. MATERIALS AND METHODS: We studied 116 subjects with normal kidney function (age 47+/-12 years, 50 females and 66 males) of the FLEMENGHO study. Calcium measurements, plasma fetuin-A, its encoding gene (Thr256Ser) and indexes of arterial stiffness, such as aPWV and arterial distensibility, were determined. RESULTS: Fetuin-A levels were negatively correlated with aPWV (r=-0.21, p=0.029). After an adjustment for multiple covariables, fetuin-A levels were independently associated with aPWV (r=-0.30, p=0.022) in males but not in females. Male fetuin-A SerSer carrier had lower fetuin-A levels and higher aPWV (fetuin-A: 61.9+/-29.0 microg/ml; aPWV: 14.3+/-0.9 m/s) as compared to ThrThr (fetuin-A: 109.9+/-54.9 microg/ml; aPWV: 6.4+/-1.3 m/s) and ThrSer carrier (fetuin-A: 100.8+/-52.5 microg/ml; aPWV: 6.6+/-1.3 m/s). Other calcium variables were not significantly associated with arterial stiffness. CONCLUSION: With respect to common calcium variables, only fetuin-A level showed an inverse relation with aPWV in men with normal renal function. Male fetuin-A SerSer carriers demonstrate particularly high aortic stiffness, possibly implying a status of increased cardiovascular risk</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Nephrology, Klinikum rechts der Isar, Technische Universit&amp;#x00E4;t M&amp;#x00FC;nchen, Munich, Germany. marphiro@hotmail.comJC - rbb, 8100479CP - NetherlandsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19110009</style></custom1><custom3><style face="normal" font="default">AS - Regul Pept. 154(1-3):39-43, 2009 Apr 10.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>28</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Rosario,M.A.</style></author><author><style face="normal" font="default"> Lima,J.J.</style></author><author><style face="normal" font="default"> Parga,J.R.</style></author><author><style face="normal" font="default"> Avila,L.F.</style></author><author><style face="normal" font="default"> Gowdak,L.H.</style></author><author><style face="normal" font="default"> Lemos,P.A.</style></author><author><style face="normal" font="default"> Rochitte,C.E.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Coronary calcium score as predictor of stenosis and events in pretransplant renal chronic failure]</style></title><secondary-title><style face="normal" font="default">Arquivos Brasileiros de Cardiologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Arquivos Brasileiros de Cardiologia</style></full-title></periodical><pages end="243" start="236">236-243</pages><volume><style face="normal" font="default">94</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Stenosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure,Chronic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Epidemiologic Methods</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Kidney Transplantation</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> ROC Curve</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="0" Year="252">252</year></dates><abstract><style face="normal" font="default">BACKGROUND: Coronary artery disease (CAD) is the major cause of death among chronic renal failure (CRF) patients. Traditional, non-invasive exams to detect CAD and to predict events have shown insufficient results in this group. CT Scan evaluation of Coronary Calcium Score (CCS) has proven to be of prognostic value for the population reporting no renal condition. OBJECTIVE: To investigate CCS accuracy in detecting obstructive CAD and in predicting cardiovascular events in candidates to renal transplant as compared to quantitative invasive coronary angiography (ICA). METHODS: Ninety-seven (97) CRF patients aged > or =35 were evaluated. Obstructive CAD was considered as > or =50% or > or =70% stenosis on ICA. Descriptive data, concordance, diagnostic tests, Kaplan-Meier, and multivariate analysis were used. RESULTS: Agatston mean score was 580.6 +/- 1,102.2. Minimum and maximum values were 0 and 7,994, with median at 176. Only 14 patients had zero calcium score. No differences were reported in regard to ethnicity. Highest regional calcium was associated to the highest probability of coronary stenosis in the same segment. Agatston calcium score showed high accuracy for the diagnosis of > or =50% and > or =70% stenosis, with area under ROC curve (AUC) of 0.75 and 0.70, respectively. At the threshold of 400, calcium score identified a subgroup with a higher rate of cardiovascular events at an average follow-up time of 29+/-11.0 months. CONCLUSION: CCS proved to have good diagnostic and prognostic performance for cardiovascular events evaluation in CRF patients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BrasilJC - 8pm, 0421031CP - BrazilPT - Comparative StudyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English, Portuguese, Spanish</style></notes><urls/><custom1><style face="normal" font="default">UI - 20428622</style></custom1><custom3><style face="normal" font="default">AS - Arq Bras Cardiol. 94(2):236-43, 252-60, 239-47, 2010 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>329</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Rosen,B.D.</style></author><author><style face="normal" font="default"> Fernandes,V.</style></author><author><style face="normal" font="default"> McClelland,R.L.</style></author><author><style face="normal" font="default"> Carr,J.J.</style></author><author><style face="normal" font="default"> Detrano,R.</style></author><author><style face="normal" font="default"> Bluemke,D.A.</style></author><author><style face="normal" font="default"> Lima,J.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Relationship between baseline coronary calcium score and demonstration of coronary artery stenoses during follow-up MESA (Multi-Ethnic Study of Atherosclerosis)</style></title><secondary-title><style face="normal" font="default">Jacc: Cardiovascular Imaging</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Jacc: Cardiovascular Imaging</style></full-title></periodical><pages end="1183" start="1175">1175-1183</pages><volume><style face="normal" font="default">2</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Stenosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Stenosis/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Coronary Stenosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Ethnic Groups</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Population Surveillance</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The MESA (Multi-Ethnic Study of Atherosclerosis) is a population-based study of 6,814 men and women. We sought to analyze the relationship between the extent of coronary artery calcium (CAC) at baseline and the severity of coronary stenoses in clinically indicated coronary angiography studies during follow-up. BACKGROUND: CAC is an established predictor of major cardiovascular events. Yet, the relationship between CAC and the distribution and severity of coronary artery stenoses has not been widely explored. METHODS: All MESA participants underwent noncontrast enhanced cardiac computed tomography during enrollment to determine baseline CAC. We analyzed 175 consecutive angiography reports from participants who underwent coronary catheterization for clinical indications during a median follow-up period of 18 months. The relationship between baseline CAC and the severity of coronary stenosis detected in coronary angiographies was determined. RESULTS: Baseline Agatston score was 0 in only 7 of 175 (4%) MESA participants who underwent invasive angiography during follow-up. When coronary arteries were studied separately, 13% to 18% of coronary arteries with >or=75% stenosis had 0 calcium mass scores at baseline. There was close association between baseline calcium mass score and the severity of stenosis in each of the coronary arteries (test for trend, p &lt; 0.001). For example, mean calcium mass scores for &lt;50%, 50% to 74%, and >or=75% stenosis in the left anterior descending coronary artery were 105.1 mg, 157.2 mg, and 302.2 mg, respectively (p &lt; 0.001). Finally, there was a direct relationship between the total Agatston Score at baseline and the number of diseased vessels (test for trend, p &lt; 0.001). CONCLUSIONS: The majority of patients with clinically indicated coronary angiography during follow-up had detectable coronary calcification at baseline. Although there is a significant relationship between the extent of calcification and mean degree of stenosis in individual coronary vessels, 16% of the coronary arteries with significant stenoses had no calcification at baseline</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Cardiology Division, Johns Hopkins Medical Institutions, Baltimore, Maryland, USACM - Comment in: JACC Cardiovasc Imaging. 2009 Oct;2(10):1184-6; PMID: 19833307JC - 101467978CP - United StatesPT - Journal ArticlePT - Multicenter StudyPT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - N01-HC-95159 (United States NHLBI NIH HHS)NO - N01-HC-95166 (United States NHLBI NIH HHS)NO - N01-HC-95168 (United States NHLBI NIH HHS)NO - N01-HC-95169 (United States NHLBI NIH HHS)NO - R01-HL6607-01 (United States NHLBI NIH HHS)NO - R01-HL66075-01 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19833306</style></custom1><custom3><style face="normal" font="default">AS - JACC Cardiovasc Imaging. 2(10):1175-83, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>560</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Rossi,M.</style></author><author><style face="normal" font="default"> Mosca,M.</style></author><author><style face="normal" font="default"> Tani,C.</style></author><author><style face="normal" font="default"> Franzoni,F.</style></author><author><style face="normal" font="default"> Santoro,G.</style></author><author><style face="normal" font="default"> Bombardieri,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Integrated backscatter analysis of carotid intima-media complex in patients with systemic lupus erythematosus</style></title><secondary-title><style face="normal" font="default">Clinical Rheumatology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinical Rheumatology</style></full-title></periodical><pages end="1488" start="1485">1485-1488</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Arteriosclerosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Carotid Arteries/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Hypertension/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Lupus Erythematosus,Systemic/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Ultrasonography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Lupus Erythematosus,Systemic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tunica Intima/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Tunica Media/us [Ultrasonography]</style></keyword></keywords><dates><year Day="0" Month="12" Year="2008">2008/12</year></dates><abstract><style face="normal" font="default">A number of studies based on conventional ultrasound scanning (CUS) gave contrasting results about the occurrence of early atherosclerosis in patients with systemic lupus erythematosus (SLE), while no study on early arterial sclerosis in the same patients are available. Recently, information on early arterial sclerosis can be provided by the integrated backscatter (IBS) analysis which reflects the collagen and calcium content within the vascular wall. In order to evaluate if atherosis and/or sclerosis of carotid arteries are early features of SLE, we performed carotid CUS and IBS analysis in 16 SLE patients (15 females; aged 37 +/- 10 years), free from clinically evident cardiovascular diseases and cardiovascular risk factors, with the only exception of five patients who had arterial hypertension. The same investigations were performed in 16 sex- and age-matched healthy control subjects. No statistically significant difference was observed either in carotid corrected IBS values or in carotid intima-media thickness (IMT) values between SLE patients and control subjects (-17.9 +/- 2.5 dB vs -19.0 +/- 1.7 dB, p = 0.14; 0.66 +/- 0.08 mm vs 0.62 +/- 0.13 mm, p = 0.35, respectively). The little sub-group of hypertensive SLE patients exhibited a significantly higher carotid corrected IBS mean value compared to control subjects (-16.4 +/- 3.1 dB vs -19.0 +/- 1.7 dB, p = 0.026), while it did not significantly differ in carotid IMT value from control group (0.67 +/- 0.09 mm vs 0.62 +/- 0.13 mm, respectively; p = 0.86). These findings show that neither atherosis nor sclerosis of carotid arteries are early features of SLE patients free from cardiovascular risk factors. Further studies are needed to clearly demonstrate that early carotid sclerosis affects hypertensive SLE patients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Internal Medicine, University of Pisa, Pisa, Italy. mrossi@int.med.unipi.itJC - 8211469, di6CP - BelgiumPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18654734</style></custom1><custom3><style face="normal" font="default">AS - Clin Rheumatol. 27(12):1485-8, 2008 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>434</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Rozie,S.</style></author><author><style face="normal" font="default"> de Weert,T.T.</style></author><author><style face="normal" font="default"> de,Mony</style></author><author><style face="normal" font="default"> Homburg,P.J.</style></author><author><style face="normal" font="default"> Tanghe,H.L.</style></author><author><style face="normal" font="default"> Dippel,D.W.</style></author><author><style face="normal" font="default"> van der,Lugt A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Atherosclerotic plaque volume and composition in symptomatic carotid arteries assessed with multidetector CT angiography; relationship with severity of stenosis and cardiovascular risk factors</style></title><secondary-title><style face="normal" font="default">European Radiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">European Radiology</style></full-title></periodical><pages end="2301" start="2294">2294-2301</pages><volume><style face="normal" font="default">19</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Carotid Stenosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Cerebral Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Imaging,Three-Dimensional/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Radiographic Image Interpretation,Computer-Assisted/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Image Enhancement/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword></keywords><dates><year Day="0" Month="9" Year="2009">2009/9</year></dates><abstract><style face="normal" font="default">The purpose of this study was to examine the volume and the composition of atherosclerotic plaque in symptomatic carotid arteries and to investigate the relationship between these plaque features and the severity of stenosis and the presence of cardiovascular risk factors. One hundred patients with cerebrovascular symptoms underwent CT angiography. We measured plaque volume (PV) and the relative contribution of plaque components (calcifications, fibrous tissue, and lipid) in the symptomatic artery. The contribution of different components was measured as the number of voxels within defined ranges of HU values (calcification >130 HU, fibrous tissue 60-130 HU, lipid core &lt;60 HU). Fifty-seven patients had atherosclerotic plaque in the symptomatic carotid artery. The severity of stenosis and PV were moderately correlated. Age and smoking were independently related to PV. Patients with hypercholesterolemia had significantly less lipid and more calcium in their plaques than patients without hypercholesterolemia. Other cardiovascular risk factors were not significantly related to PV or plaque composition. Luminal stenosis of the carotid artery partly reflects the amount of atherosclerotic carotid disease. Plaque volume and plaque composition are associated with cardiovascular risk factors</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Departments of Radiology, Erasmus MC, University Medical Center Rotterdam, s-Gravendijkwal 230, Rotterdam 3015 CE, The NetherlandsJC - cl3, 9114774CP - GermanyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19384548</style></custom1><custom3><style face="normal" font="default">AS - Eur Radiol. 19(9):2294-301, 2009 Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>468</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Roztoczynska,D.</style></author><author><style face="normal" font="default"> Starzyk,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">[The role of a pediatric endocrinologist in diagnostics and therapeutic management of anorexia nervosa--own experiences and review of literature]. [Polish]</style></title><secondary-title><style face="normal" font="default">Przeglad Lekarski</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Przeglad Lekarski</style></full-title></periodical><pages end="57" start="52">52-57</pages><volume><style face="normal" font="default">66</style></volume><number><style face="normal" font="default">1-2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Anorexia Nervosa/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Anorexia Nervosa/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> *Physician's Practice Patterns</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age Distribution</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Amenorrhea/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Amenorrhea/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Amenorrhea/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Anorexia Nervosa/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Anorexia Nervosa/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Bone Density</style></keyword><keyword><style face="normal" font="default"> Bulimia Nervosa/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Bulimia Nervosa/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Bulimia Nervosa/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Celiac Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Diagnosis,Differential</style></keyword><keyword><style face="normal" font="default"> Eating</style></keyword><keyword><style face="normal" font="default"> Endocrinology</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Nutritional Status</style></keyword><keyword><style face="normal" font="default"> Osteoporosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Osteoporosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Osteoporosis/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Poland/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Urine</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><isbn><style face="normal" font="default">0033-2240</style></isbn><abstract><style face="normal" font="default">INTRODUCTION: Anorexia nervosa and bulimia nervosa are counted among psychosomatic diseases, whose incidence has been rapidly increasing in the last decades. To date, the etiology, diagnostic and therapeutic management of eating disorders have not been uniformly determined. The objective of the study is determination of the role of a pediatric endocrinologist in diagnostics and management of eating disorders. MATERIAL: In the years 1992-2007 in Department of Pediatric and Adolescent Endocrinology Chair of Pediatrics, Polish-American Institute of Pediatrics, Collegium Medicum, Jagiellonian University in Krakow, Poland were hospitalized 164 patients with suspected anorexia nervosa, aged 9-20 years, 150 girls, and 14 boys. All girls were included in psychological and dietetic treatment. Additionally, in group of 36 girls, the 3-years observation of bone mineralization changes was performed. METHODS: The indications for hospitalization included the assessment of nutritional status, particularly electrolyte imbalance, cardiovascular complications and nutritional treatment. II. Procedure included on department: 1) Correction of general children's state. 2) Monitoring of cardiovascular system disorders. 3) Nutritional treatment. 4) Differential diagnosis. III. Prevention and treatment of late complications was performed in group of 36 girls. In this group, every 6 months were evaluated: body mass index, duration of secondary amenorrhea, serum sex hormone, IGF-I and cortisol levels and 24-hour urine cortisol. Spine densitometry in the AP projection was performed every 12 months, using a Lunar unit (DEXA). The pharmacological treatment of osteoporosis was introduced in girls with duration of secondary amenorrhea lasted for more than 6 months, with decreased bone mineralization BMD &lt; (-) 1SD and body mass deficit &lt; 20%. 16 girls which did not presented disorders of bone mineralization, or refused treatment have not got the pharmacological treatment, while in 20 girls the pharmacological therapy (calcium and vitamin D3 supplementation and hormonal treatment - Estraderm TTS and Provera 5 mg) was provided. RESULTS: Anorexia nervosa was diagnosed in 150 cases, bulimia in 6 cases, in 2 children was diagnosed celiac disease, in 2 patients adrenal insufficiency, in 1 girl myasthenia, in 1 girl diabetes mellitus type 1, in 1 boy hypothalamo-pituitary tumor and in 1 boy psychosis was diagnosed. The nutritional improvement was evaluated in group of 36 girls, which continued treatment in time 3 years. At the beginning of the observation period the mean value of the body mass index (BMI) was 15.95 kg/m2, and after 36 months of the treatment the mean BMI value was 20 kg/m2. Before the treatment one patient was still menstruated despite her body mass loss, 8 girls were pre-menarche, and the remaining 27 patients had secondary amenorrhea of the mean duration of 11.14 months. In the initial period of the follow-up, all the anorectic patients demonstrated a decreased bone mineral density. Before treatment the median Z score in the entire experimental group was (-)1,2 SD whereas after 3 years of treatment value of Z score decreased by 0,5 SD in group of 16 girls without the pharmacological treatment and increased by 0,5 SD in 20 girls on pharmacological treatment. The significant, negative correlation between secondary amenorrhea and Z score value was observed. CONCLUSIONS: The role of a pediatrician in therapeutic management of eating disorders is intervention in life-threatening conditions, treatment of acute complications, differential diagnosis, nutritional treatment, prevention and management of late complications. Because of etiology and special way of treatment the management of anorexia nervosa should have been taken by psychiatrist. The duty of endocrinologists and gynecologists is the late complications treatment, such as an amenorrhea and osteoporosis</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Klinika Endokrynologii Dzieci i Mlodziezy, Katedry Pediatrii, Polsko-Amerykanski Instytut Pediatrii, Uniwersytet Jagiellonski Collegium Medium w KrakowieOT - Rola endokrynologa dzieciecego w diagnostyce i leczeniu jadlowstretu psychicznego--do&amp;#x015B;wiadczenia wlasne i przeglad pi&amp;#x015B;miennictwaJC - q96, 19840720rCP - PolandPT - English AbstractPT - Journal ArticleLG - Polish</style></notes><urls/><custom1><style face="normal" font="default">UI - 19485257</style></custom1><custom3><style face="normal" font="default">AS - Przegl Lek. 66(1-2):52-7, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>166</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Rubinshtein,R.</style></author><author><style face="normal" font="default"> Halon,D.A.</style></author><author><style face="normal" font="default"> Gaspar,T.</style></author><author><style face="normal" font="default"> Peled,N.</style></author><author><style face="normal" font="default"> Lewis,B.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Cardiac computed tomographic angiography for risk stratification and prediction of late cardiovascular outcome events in patients with a chest pain syndrome</style></title><secondary-title><style face="normal" font="default">International Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">International Journal of Cardiology</style></full-title></periodical><pages end="115" start="108">108-115</pages><volume><style face="normal" font="default">137</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiovascular Diseases/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Chest Pain/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Chest Pain/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="2" Month="10" Year="2009">2009/10/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: Contrast-enhanced multidetector cardiac computed tomographic angiography (CCTA) has high sensitivity and specificity for diagnosing anatomic coronary stenoses, but its role in predicting late clinical outcome events has not been well studied. METHODS: We examined predictive value of CCTA for late major adverse cardiovascular (CV) outcome events (MACE)(CV death, myocardial infarction, myocardial revascularization) (follow-up 18.2+/-6.3, range 9-30 months) in 545 consecutive symptomatic patients (368 (68%) men, 177 (32%) women) with clinical suspicion, but without previously diagnosed, coronary artery disease (CAD) who underwent 40- or 64-channel CCTA. RESULTS: MACE occurred in 53/545 (9.7%) patients (early 30 day CCTA-driven events excluded): CV death/myocardial infarction in 3/327 (0.9%) patients with no coronary luminal narrowing >25% (group 1), in 3/127 (2.4%) with >or=1 luminal narrowing(s) of 26-69% (group 2) and in 9/91 (9.9%) with >or=1 coronary luminal narrowing(s) of >or=70% (group 3) (p&lt;0.0001). CV death/myocardial infarction/revascularization occurred in 5/327 (1.5%) group 1 patients, 19/127 (14.9%) group 2 and 29/91 (31.9%) group 3 (p&lt;0.0001). Multivariate analysis (adjusting for age, gender, coronary risk factors and coronary calcium score) identified CCTA stenosis (>25%) as a powerful independent predictor of MACE (HR 10.9, 95%CI 4.1-29.0, p&lt;0.0001). CONCLUSIONS: CCTA was useful to predict late clinical outcome events in patients undergoing evaluation of a chest pain syndrome</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiovascular Medicine, Lady Davis Carmel Medical Center and the Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, IsraelJC - gqw, 8200291CP - NetherlandsPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18718681</style></custom1><custom3><style face="normal" font="default">AS - Int J Cardiol. 137(2):108-15, 2009 Oct 2.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>400</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Rudd,J.H.</style></author><author><style face="normal" font="default"> Myers,K.S.</style></author><author><style face="normal" font="default"> Bansilal,S.</style></author><author><style face="normal" font="default"> Machac,J.</style></author><author><style face="normal" font="default"> Woodward,M.</style></author><author><style face="normal" font="default"> Fuster,V.</style></author><author><style face="normal" font="default"> Farkouh,M.E.</style></author><author><style face="normal" font="default"> Fayad,Z.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study</style></title><secondary-title><style face="normal" font="default">Circulation</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Circulation</style></full-title></periodical><pages end="115" start="107">107-115</pages><volume><style face="normal" font="default">Cardiovascular</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Fluorodeoxyglucose F18/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> *Positron-Emission Tomography</style></keyword><keyword><style face="normal" font="default"> *Radiopharmaceuticals/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Radiopharmaceuticals)</style></keyword><keyword><style face="normal" font="default"> 63503-12-8 (Fluorodeoxyglucose F18)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Arteries/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Inflammation/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="3" Year="2009">2009/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: Fluorodeoxyglucose positron-emission tomography (FDG PET) imaging of atherosclerosis has been used to quantify plaque inflammation and to measure the effect of plaque-stabilizing drugs. We explored how atherosclerotic plaque inflammation varies across arterial territories and how it relates to arterial calcification. We also tested the hypotheses that the degree of local arterial inflammation measured by PET is correlated with the extent of systemic inflammation and presence of risk factors for vascular disease. METHODS AND RESULTS: Forty-one subjects underwent vascular PET/computed tomography imaging with FDG. All had either vascular disease or multiple risk factors. Forty subjects underwent carotid imaging, 27 subjects underwent aortic, 24 subjects iliac, and 13 subjects femoral imaging. Thirty-three subjects had a panel of biomarkers analyzed. We found strong associations between FDG uptake in neighboring arteries (left versus right carotid, r=0.91, P&lt;0.001; ascending aorta versus aortic arch, r=0.88, P&lt;0.001). Calcification and inflammation rarely overlapped within arteries (carotid artery FDG uptake versus calcium score, r=-0.42, P=0.03). Carotid artery FDG uptake was greater in those with a history of coronary artery disease (target-to- BACKGROUND: &lt;0.01) and in males versus females (target-to- BACKGROUND: &lt;0.05). Similar findings were also noted in the aorta and iliac arteries. Subjects with the highest levels of FDG uptake also had the greatest concentrations of inflammatory biomarkers (descending aorta target-to- BACKGROUND: =0.53, P=0.01; carotid target-to- BACKGROUND: =0.50, P=0.01). Nonsignificant positive trends were seen between FDG uptake and levels of interleukin-18, fibrinogen, and C-reactive protein. Finally, we found that the atheroprotective biomarker adiponectin was negatively correlated with the degree of arterial inflammation in the descending aorta (r=-0.49, P=0.03). CONCLUSIONS: This study shows that FDG PET imaging can increase our knowledge of how atherosclerotic plaque inflammation relates to calcification, serum biomarkers, and vascular risk factors. Plaque inflammation and calcification rarely overlap, supporting the theory that calcification represents a late, burnt-out stage of atherosclerosis. Inflammation in one arterial territory is associated with inflammation elsewhere, and the degree of local arterial inflammation is reflected in the blood levels of several circulating biomarkers. We suggest that FDG PET imaging could be used as a surrogate marker of both atherosclerotic disease activity and drug effectiveness. Prospective, event-driven studies are now underway to determine the role of this technique in clinical risk prediction</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Imaging Science Laboratories, Mount Sinai School of Medicine, New York, NY, USA. jhfr2@cam.ac.ukJC - 101479935CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - R0I HL71021 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19808576</style></custom1><custom3><style face="normal" font="default">AS - Circ Cardiovasc Imaging. 2(2):107-15, 2009 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>128</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Rudman,A.</style></author><author><style face="normal" font="default"> Pearson,E.R.</style></author><author><style face="normal" font="default"> Smith,D.</style></author><author><style face="normal" font="default"> Srivastava,R.</style></author><author><style face="normal" font="default"> Murphy,M.J.</style></author><author><style face="normal" font="default"> Leese,G.P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Insulin resistance before and after parathyroidectomy in patients with primary hyperparathyroidism--a pilot study</style></title><secondary-title><style face="normal" font="default">Endocrine Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Endocrine Research</style></full-title></periodical><pages end="93" start="85">85-93</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Hyperparathyroidism,Primary/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Hyperparathyroidism,Primary/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Insulin Resistance/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Parathyroidectomy</style></keyword><keyword><style face="normal" font="default"> 0 (Blood Glucose)</style></keyword><keyword><style face="normal" font="default"> 0 (Hemoglobin A,Glycosylated)</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 0 (Triglycerides)</style></keyword><keyword><style face="normal" font="default"> 11061-68-0 (Insulin)</style></keyword><keyword><style face="normal" font="default"> 57-88-5 (Cholesterol)</style></keyword><keyword><style face="normal" font="default"> 7439-95-4 (Magnesium)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Alkaline Phosphatase/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Blood Glucose/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Cholesterol/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> EC 3-1-3-1 (Alkaline Phosphatase)</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hemoglobin A,Glycosylated/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Insulin Resistance</style></keyword><keyword><style face="normal" font="default"> Insulin/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Magnesium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Parathyroidectomy</style></keyword><keyword><style face="normal" font="default"> Pilot Projects</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Statistics,Nonparametric</style></keyword><keyword><style face="normal" font="default"> Triglycerides/bl [Blood]</style></keyword></keywords><dates><year Day="0" Month="5" Year="2010">2010/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: Primary hyperparathyroidism (PHPT) is associated with insulin resistance and an increased cardiovascular mortality. We aimed to see if parathyroidectomy improved insulin resistance. METHODS: Twelve PHPT patients undergoing parathyroidectomy and ten control patients undergoing non-neck surgery were recruited to the study. Fasting venous blood samples were collected immediately pre-operatively and again at five to six weeks post-operatively. Samples were assayed for plasma glucose, serum insulin, total cholesterol, triglycerides, calcium, alkaline phosphatase, magnesium, parathyroid hormone (PTH), and haemoglobin A1c (HbA1c). Insulin resistance was calculated from fasting insulin and glucose values using Homeostasis Model Assessment (HOMA). RESULTS: Parathyroidectomy decreased serum calcium (mean pre-op = 2.85 mmol/L, post-op 2.28 mmol/L, P &lt; 0.001) and PTH concentrations (mean pre-op = 23.33 pmol/L, post-op = 10.23 pmol/L, P &lt; 0.001) and increased phosphate concentration. However, there was no improvement in insulin resistance in the PHPT group at between 5 and 6 weeks post-operatively (geometric mean; pre-op = 0.88 (95% CI 0.59 - 1.33) vs. post-op = 0.88 (0.66 - 1.17) P = 0.95). In the control group, an increase in serum calcium was observed post-operatively (mean pre-op = 2.29 mmol/L, post-op = 2.35 mmol/L, P = 0.03). No change in insulin resistance was observed (geometric mean; pre-op = 1.37 (95% CI 0.89 - 2.11) vs. post-op = 1.38 (0.72 - 2.67) P = 0.96). CONCLUSION: In summary, no significant change in insulin resistance post-parathyroidectomy in patients with PHPT was observed. This indicates that surgical treatment of PHPT does not improve insulin resistance for patients currently selected for parathyroidectomy</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - University of Dundee, Dundee, UKJC - eih, 8408548CP - EnglandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20408756</style></custom1><custom3><style face="normal" font="default">AS - Endocr Res. 35(2):85-93, 2010 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>529</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Russo,D.</style></author><author><style face="normal" font="default"> Morrone,L.F.</style></author><author><style face="normal" font="default"> Brancaccio,S.</style></author><author><style face="normal" font="default"> Napolitano,P.</style></author><author><style face="normal" font="default"> Salvatore,E.</style></author><author><style face="normal" font="default"> Spadola,R.</style></author><author><style face="normal" font="default"> Imbriaco,M.</style></author><author><style face="normal" font="default"> Russo,C.V.</style></author><author><style face="normal" font="default"> Andreucci,V.E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Pulse pressure and presence of coronary artery calcification</style></title><secondary-title><style face="normal" font="default">Clinical Journal of The American Society of Nephrology: CJASN</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinical Journal of The American Society of Nephrology: CJASN</style></full-title></periodical><pages end="322" start="316">316-322</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Blood Pressure</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Kidney Diseases/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aorta</style></keyword><keyword><style face="normal" font="default"> Aortic Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Aortic Diseases/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Dialysis</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Kaplan-Meiers Estimate</style></keyword><keyword><style face="normal" font="default"> Kidney Diseases/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Kidney Diseases/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Pulse</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> ROC Curve</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="2" Year="2009">2009/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: Coronary calcification (CAC) is found in early stages of CKD. Pulse pressure (PP) predicts CAC in dialysis patients. This study evaluates the accuracy of PP in predicting CAC in patients not yet on dialysis (CKD patients). METHODS: CKD patients (n = 388) underwent coronary calcium score (CAC score) and abdominal x-ray (n = 128) for estimating aorta calcification (AAC). Biochemistry and PP were measured every 3 and 6 months in patients with stage 4 to 5 and 2 to 3 CKD, respectively. The accuracy of PP and AAC was assessed by receiver operating characteristics analysis. RESULTS: PP correlated with CAC score in the whole cohort and in patients with stages 2 to 3 and stages 4 to 5 CKD. PP >60 mmHg predicted CAC score >0 (OR: 2.14; P &lt; 0.001), > or =100 (OR: 2.92; P &lt; 0.001), > or =400 (OR: 6.17; P &lt; 0.001) after multivariable adjustment. Area under the curve (AUC) was 0.626 for CAC score >0, 0.676 for score >100, and 0.746 for score >400. PP >60 mmHg reduced the rate of event-free survival. AAC was found in 58% of patients and correlated with CAC score. AUC was 0.628 for CAC score >0, 0.652 for score >100, 0.831 for score >400. CONCLUSION: PP may identify CKD patients with subclinical CAC who need further evaluation. Accuracy of PP and AAC is nearly similar in predicting CAC. High PP indicates vessel wall alterations leading to adverse outcome</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Nephrology, University Federico II., Via G Marconi, 80, 80024 Cardito, Napoli, Italy. domenicorusso51@hotmail.comJC - 101271570CP - United StatesPT - Evaluation StudiesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19218471</style></custom1><custom3><style face="normal" font="default">AS - Clin J Am Soc Nephrol. 4(2):316-22, 2009 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>99</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Russo,V.</style></author><author><style face="normal" font="default"> Zavalloni,A.</style></author><author><style face="normal" font="default"> Bacchi Reggiani,M.L.</style></author><author><style face="normal" font="default"> Buttazzi,K.</style></author><author><style face="normal" font="default"> Gostoli,V.</style></author><author><style face="normal" font="default"> Bartolini,S.</style></author><author><style face="normal" font="default"> Fattori,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Incremental prognostic value of coronary CT angiography in patients with suspected coronary artery disease</style></title><secondary-title><style face="normal" font="default">Circulation</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Circulation</style></full-title></periodical><pages end="359" start="351">351-359</pages><volume><style face="normal" font="default">Cardiovascular</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Chi-Square Distribution</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Interviews as Topic</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword></keywords><dates><year Day="1" Month="7" Year="2010">2010/7/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Multidetector CT coronary angiography (MDCTCA) is capable of detecting coronary artery disease (CAD) with a high diagnostic accuracy. In particular, this technique is credited with having a negative predictive value close to 100%. However, data about the prognostic value of MDCTCA are currently lacking. We sought to determine the prognostic value of MDCTCA in patients with suspected but undocumented CAD and, in particular, the incremental prognostic value as compared with clinical risk and calcium scoring. METHODS AND RESULTS: A total of 441 patients (age, 59.7+/-11.6 years) with suspected CAD underwent MDCTCA to evaluate the presence and severity of the disease. Patients were followed up as to the occurrence of hard cardiac events (cardiac death, nonfatal myocardial infarction, and unstable angina requiring hospitalization). Coronary lesions were detected in 297 (67.3%) patients. During a mean follow-up of 31.9+/-14.8 months, 44 hard cardiac events occurred in 40 patients. CT calcium scoring showed a statistically significant incremental prognostic value as compared to a baseline clinical risk model (P=0.018), whereas MDCTCA provided an additional incremental prognostic value as compared with a baseline clinical risk model plus calcium scoring if considering both nonobstructive versus obstructive CAD (P=0.016) or, better, plaque composition (calcified versus noncalcified and/or mixed plaques, P=0.0001). During follow-up, an excellent prognosis was noted in patients with normal coronary arteries, with an annualized incidence rate of 0.88% if compared with those with mild CAD (3.89%) and with patients with significant coronary disease (8.09%). The presence of noncalcified or mixed plaques, regardless of lesion severity, was found to be the strongest predictor of events (P&lt;0.0001) as a potential marker of plaque vulnerability. CONCLUSIONS: MDCTCA provides independent and incremental prognostic information as compared to baseline clinical risk factors and calcium scoring in patients with suspected CAD</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Cardio-Thoracic-Vascular Department, Cardiovascular Radiology Unit, and Cardiology Institute, University Hospital S. Orsola, Via Massarenti 9, Bologna, Italy. virusso@fastwebnet.itJC - 101479935CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20460497</style></custom1><custom3><style face="normal" font="default">AS - Circ Cardiovasc Imaging. 3(4):351-9, 2010 Jul 1.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>359</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Sam,S.</style></author><author><style face="normal" font="default"> Haffner,S.</style></author><author><style face="normal" font="default"> Davidson,M.H.</style></author><author><style face="normal" font="default"> D'Agostino,R.B.,Sr.</style></author><author><style face="normal" font="default"> Feinstein,S.</style></author><author><style face="normal" font="default"> Kondos,G.</style></author><author><style face="normal" font="default"> Perez,A.</style></author><author><style face="normal" font="default"> Mazzone,T.</style></author></authors></contributors><titles><title><style face="normal" font="default">Hypertriglyceridemic waist phenotype predicts increased visceral fat in subjects with type 2 diabetes</style></title><secondary-title><style face="normal" font="default">Diabetes Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Diabetes Care</style></full-title></periodical><pages end="1920" start="1916">1916-1920</pages><volume><style face="normal" font="default">32</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Diabetes Mellitus,Type 2/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 2/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Hypertriglyceridemia/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Intra-Abdominal Fat/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Intra-Abdominal Fat/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Waist Circumference/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Research Design</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Waist Circumference</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Greater accumulation of visceral fat is strongly linked to risk of cardiovascular disease. However, elevated waist circumference by itself does not always identify individuals with increased visceral fat. RESEARCH DESIGN AND METHODS: We examined 375 subjects with type 2 diabetes from the CHICAGO cohort for presence of hypertriglyceridemic waist phenotype (waist circumference >90 cm in men or >85 cm in women, in conjunction with a plasma triglyceride concentration of > or =177 mg/dl) to determine its usefulness for identifying subjects with increased amounts of visceral fat. We divided subjects into three groups: group 1 (low waist circumference and low triglycerides; waist circumference &lt; or =90 cm in men or &lt; or =85 cm in women and triglyceride &lt;177 mg/dl, n = 18), group 2 (high waist circumference and low triglycerides; waist circumference >90 cm in men or >85 cm in women and triglycerides &lt;177 mg/dl, n = 230), and group 3 (high waist circumference and high triglycerides; waist circumference >90 cm in men or >85 cm in women and triglycerides > or =177 mg/dl, n = 127). RESULTS: Subjects in group 3 had significantly higher visceral fat (P &lt; 0.0001), A1C (P &lt; 0.01), and coronary artery calcium (P &lt; 0.05) compared with group 2, despite similar age, BMI, and waist circumference. The relationship of the phenotype to atherosclerosis, however, was attenuated by adjustment for HDL cholesterol, triglyceride-rich lipoprotein cholesterol, apolipoprotein B, or LDL particle number. CONCLUSIONS: The presence of hypertriglyceridemic waist phenotype in subjects with type 2 diabetes identifies a subset with greater degree of visceral adiposity. This subset also has greater degree of subclinical atherosclerosis that may be related to the proatherogenic lipoprotein changes</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, University of Illinois, Chicago, Illinois. susansam@uic.eduJC - eag, 7805975CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - DK 71711 (United States NIDDK NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19592623</style></custom1><custom3><style face="normal" font="default">AS - Diabetes Care. 32(10):1916-20, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>421</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Santos,D.G.</style></author><author><style face="normal" font="default"> Medeiros,A.</style></author><author><style face="normal" font="default"> Brum,P.C.</style></author><author><style face="normal" font="default"> Mill,J.G.</style></author><author><style face="normal" font="default"> Mansur,A.J.</style></author><author><style face="normal" font="default"> Krieger,J.E.</style></author><author><style face="normal" font="default"> Pereira,A.C.</style></author></authors></contributors><titles><title><style face="normal" font="default">No evidence for an association between the -36A>C phospholamban gene polymorphism and a worse prognosis in heart failure</style></title><secondary-title><style face="normal" font="default">BMC Cardiovascular Disorders</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">BMC Cardiovascular Disorders</style></full-title></periodical><pages end="" start="33">33-</pages><volume><style face="normal" font="default">9</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium-Binding Proteins/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Heart Failure/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Polymorphism,Genetic</style></keyword><keyword><style face="normal" font="default"> 0 (Calcium-Binding Proteins)</style></keyword><keyword><style face="normal" font="default"> 0 (phospholamban)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Gene Frequency</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Heart Failure/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Heart Failure/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Heart Failure/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Kaplan-Meiers Estimate</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Ventricular Function,Left</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><abstract><style face="normal" font="default">BACKGROUND: In Brazil, heart failure leads to approximately 25,000 deaths per year. Abnormal calcium handling is a hallmark of heart failure and changes in genes encoding for proteins involved in the re-uptake of calcium might harbor mutations leading to inherited cardiomyopathies. Phospholamban (PLN) plays a prime role in cardiac contractility and relaxation and mutations in the gene encoding PLN have been associated with dilated cardiomyopathy. In this study, our objective was to determine the presence of the -36A>C alteration in PLN gene in a Brazilian population of individuals with HF and to test whether this alteration is associated with heart failure or with a worse prognosis of patients with HF. METHODS: We genotyped a cohort of 881 patients with HF and 1259 individuals from a cohort of individuals from the general population for the alteration -36A>C in the PLN gene. Allele and genotype frequencies were compared between groups (patients and control). In addition, frequencies or mean values of different phenotypes associated with cardiovascular disease were compared between genotypic groups. Finally, patients were prospectively followed-up for death incidence and genotypes for the -36A>C were compared regarding mortality incidence in HF patients. RESULTS: No significant association was found between the study polymorphism and HF in our population. In addition, no association between PLN -36A>C polymorphism and demographic, clinical and functional characteristics and mortality incidence in this sample of HF patients was observed. CONCLUSION: Our data do not support a role for the PLN -36A>C alteration in modulating the heart failure phenotype, including its clinical course, in humans</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), Sao Paulo University Medical School, Sao Paulo, Brazil. diogobiagi@gmail.comJC - 100968539CP - EnglandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19638213</style></custom1><custom3><style face="normal" font="default">AS - BMC Cardiovasc Disord. 9:33, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>159</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Santos,R.D.</style></author><author><style face="normal" font="default"> Rumberger,J.A.</style></author><author><style face="normal" font="default"> Budoff,M.J.</style></author><author><style face="normal" font="default"> Shaw,L.J.</style></author><author><style face="normal" font="default"> Orakzai,S.H.</style></author><author><style face="normal" font="default"> Berman,D.</style></author><author><style face="normal" font="default"> Raggi,P.</style></author><author><style face="normal" font="default"> Blumenthal,R.S.</style></author><author><style face="normal" font="default"> Nasir,K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Thoracic aorta calcification detected by electron beam tomography predicts all-cause mortality</style></title><secondary-title><style face="normal" font="default">Atherosclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Atherosclerosis</style></full-title></periodical><pages end="135" start="131">131-135</pages><volume><style face="normal" font="default">209</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aorta,Thoracic/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Aortic Diseases/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword></keywords><dates><year Day="0" Month="3" Year="2010">2010/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: The presence of coronary artery calcium (CAC) is an independent marker of increased risk of cardiovascular disease (CVD) events and mortality. However, the predictive value of thoracic aorta calcification (TAC), which can be additionally identified without further scanning during assessment of CAC, is unknown. METHODS: We followed a cohort of 8401 asymptomatic individuals (mean age: 53+/-10 years, 69% men) undergoing cardiac risk factor evaluation and TAC and CAC testing with electron beam computed tomography. Multivariable Cox proportional hazards models were developed to predict all-cause mortality based on the presence of TAC. RESULTS: During a median follow-up period of 5 years, 124 (1.5%) deaths were observed. Overall survival was 96.9% and 98.9% for those with and without detectable TAC, respectively (p&lt;0.0001). Compared to those with no TAC, the hazard ratio for mortality in the presence of TAC was 3.25 (95% CI: 2.28-4.65, p&lt;0.0001) in unadjusted analysis. After adjusting for age, gender, hypertension, dyslipidemia, diabetes mellitus, smoking and family history of premature coronary artery disease, and presence of CAC the relationship remained robust (HR 1.61, 95% CI: 1.10-2.27, p=0.015). Likelihood ratio chi(2) statistics demonstrated that the addition of TAC contributed significantly in predicting mortality to traditional risk factors alone (chi(2)=13.62, p=0.002) as well as risk factors+CAC (chi(2)=5.84, p=0.02) models. CONCLUSION: In conclusion, the presence of TAC was associated with all-cause mortality in our study; this relationship was independent of conventional CVD risk factors as well as the presence of CAC</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Lipid Clinic Heart Institute - InCor, University of Sao Paulo Medical School Hospital, Sao Paulo, BrazilJC - 95x, 0242543CP - IrelandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19782363</style></custom1><custom3><style face="normal" font="default">AS - Atherosclerosis. 209(1):131-5, 2010 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>110</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Sarno,G.</style></author><author><style face="normal" font="default"> Onuma,Y.</style></author><author><style face="normal" font="default"> Garcia Garcia,H.M.</style></author><author><style face="normal" font="default"> Garg,S.</style></author><author><style face="normal" font="default"> Regar,E.</style></author><author><style face="normal" font="default"> Thuesen,L.</style></author><author><style face="normal" font="default"> Dudek,D.</style></author><author><style face="normal" font="default"> Veldhof,S.</style></author><author><style face="normal" font="default"> Dorange,C.</style></author><author><style face="normal" font="default"> Ormiston,J.A.</style></author><author><style face="normal" font="default"> Serruys,P.W.</style></author></authors></contributors><titles><title><style face="normal" font="default">IVUS radiofrequency analysis in the evaluation of the polymeric struts of the bioabsorbable everolimus-eluting device during the bioabsorption process</style></title><secondary-title><style face="normal" font="default">Catheterization &amp; Cardiovascular Interventions</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Catheterization &amp; Cardiovascular Interventions</style></full-title></periodical><pages end="918" start="914">914-918</pages><volume><style face="normal" font="default">75</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Angioplasty,Transluminal,Percutaneous Coronary</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> *Drug-Eluting Stents</style></keyword><keyword><style face="normal" font="default"> *Immunosuppressive Agents/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Sirolimus/aa [Analogs &amp; Derivatives]</style></keyword><keyword><style face="normal" font="default"> *Ultrasonography,Interventional</style></keyword><keyword><style face="normal" font="default"> 0 (Immunosuppressive Agents)</style></keyword><keyword><style face="normal" font="default"> 159351-69-6 (everolimus)</style></keyword><keyword><style face="normal" font="default"> 53123-88-9 (Sirolimus)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Catheterization</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sirolimus/ad [Administration &amp; Dosage]</style></keyword></keywords><dates><year Day="1" Month="5" Year="2010">2010/5/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: In the ABSORB study cohort A the changes in the amount of dense calcium and necrotic core have not been reported in comparison to the prestenting phase; this evaluation could be useful to better clarify the bioabsorption process. Aim of this study was therefore to evaluate the dynamic changes in plaque size and plaque tissue composition observed between 6 months and 2 years follow-up, and to compare these findings to the prestenting phase. METHODS: Angiography, intravascular ultrasound and derived parameters (virtual histology, palpography, and echogenicity) were serially assessed postprocedure, at 6 months and at 2 years in 20 patients. In a subset of 8 patients the same measurements were also recorded in the prestenting phase. RESULTS: In the total population a reduction of 18% in the plaque area was observed between 6 month and 2 year follow-up (7.56 +/- 2.32 mm2 at 6 months vs. 6.16 +/- 2.10 mm2 at 2 year follow-up; P &lt; 0.01). In the subgroup of eight patients who underwent IVUS during the pre-stenting phase, the plaque area at 2 year follow-up was not significantly different when compared to the prestenting plaque area (7.29 +/- 2.29 mm2 at prestenting vs. 7.48 +/- 1.45 mm2 at 2 year follow-up, P = NS). Necrotic core area was reduced by 24% between the 6 month and 2 year follow-up (0.97 +/- 0.66 mm2 at 6 months vs. 0.74 +/- 0.53 mm2 at 2 year follow-up; P = NS), whilst dense calcium was reduced by 14% from 6 month to 2 year follow-up (0.83 +/- 0.50 mm2 at 6 months vs 0.72 +/- 0.64 mm2 at 2 year follow-up; P = NS). Whilst the necrotic core at 2 years follow-up was not significantly different when compared to the pre-stenting phase (0.62 +/- 0.42 mm2 prestenting vs 1.07 +/- 0.56 mm2 at 2 year follow-up; P = NS), the area of dense calcium was significantly higher at follow-up compared to prestenting (0.35 +/- 0.35 mm2 pre-stenting vs. 0.84 +/- 0.66 mm2 at 2 year follow-up; P &lt; 0.05). CONCLUSIONS: The reduction in the necrotic core component between 6 month and two year follow-up could be related to a synergistic effect of the bio-absorption process and the anti-inflammatory action of everolimus. Copyright 2010 Wiley-Liss, Inc</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Thoraxcenter, Erasmus Medical Center, Rotterdam, The NetherlandsJC - dbf, 100884139CP - United StatesPT - Journal ArticlePT - Multicenter StudyLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20091822</style></custom1><custom3><style face="normal" font="default">AS - Catheter Cardiovasc Interv. 75(6):914-8, 2010 May 1.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>195</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Sashida,Y.</style></author><author><style face="normal" font="default"> Rodriguez,C.J.</style></author><author><style face="normal" font="default"> Boden-Albala,B.</style></author><author><style face="normal" font="default"> Jin,Z.</style></author><author><style face="normal" font="default"> Elkind,M.S.</style></author><author><style face="normal" font="default"> Liu,R.</style></author><author><style face="normal" font="default"> Rundek,T.</style></author><author><style face="normal" font="default"> Sacco,R.L.</style></author><author><style face="normal" font="default"> DiTullio,M.R.</style></author><author><style face="normal" font="default"> Homma,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Ethnic differences in aortic valve thickness and related clinical factors</style></title><secondary-title><style face="normal" font="default">American Heart Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Heart Journal</style></full-title></periodical><pages end="704" start="698">698-704</pages><volume><style face="normal" font="default">159</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aortic Valve/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Heart Valve Diseases/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> *Heart Valve Diseases/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Prior studies suggest that the causes of calcific aortic valve (AV) disease involve chronic inflammation, lipoprotein levels, and calcium metabolism, all of which may differ among race-ethnic groups. We sought to determine whether AV thickness differs by race-ethnicity in a large multiethnic population-based cohort. METHODS: The Northern Manhattan Study includes stroke-free community-based Hispanic (57%), non-Hispanic black (22%), and non-Hispanic white (21%) participants. The relation between AV thickness on transthoracic echocardiography and clinical risk factors for atherosclerosis was evaluated among 2,085 participants using polytomous logistic regression models. Aortic valve thickness was graded in 3 categories (normal, mild, and moderate/severe) based on leaflet thickening and calcification. RESULTS: Mild AV thickness was present in 44.4% and moderate/severe thickness in 5.7% of the cohort, with the lowest frequency of moderate/severe thickness seen particularly among Hispanic women. In multivariate models adjusting for age, sex, race-ethnicity, body mass index, hypertension, coronary artery disease, blood glucose, and high-density lipoprotein cholesterol, Hispanics had significantly less moderate/severe AV thickness (odds ratio 0.43, 95% CI 0.25-0.73) than non-Hispanic whites. Men were almost 2-fold as likely to have moderate/severe AV thickness compared with women (odds ratio 1.96, 95% CI 1.24-3.10). CONCLUSIONS: In this large multiethnic population-based cohort, there were ethnic differences in the degree of AV thickness. Hispanic ethnicity was strongly protective against AV thickness. This effect was not related to traditional risk factors, suggesting that unmeasured factors related to Hispanic ethnicity and AV thickness may be responsible. Copyright 2010 Mosby, Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, Columbia University, New York, NY 10032, USAJC - 0370465CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20362732</style></custom1><custom3><style face="normal" font="default">AS - Am Heart J. 159(4):698-704, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>118</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Sato,Y.</style></author><author><style face="normal" font="default"> Iwamoto,J.</style></author><author><style face="normal" font="default"> Honda,Y.</style></author></authors></contributors><titles><title><style face="normal" font="default">Beneficial effect of etidronate therapy in chronically hospitalized, disabled patients with stroke</style></title><secondary-title><style face="normal" font="default">Journal of Stroke &amp; Cerebrovascular Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Stroke &amp; Cerebrovascular Diseases</style></full-title></periodical><pages end="203" start="198">198-203</pages><volume><style face="normal" font="default">19</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Bone Density Conservation Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Disabled Persons</style></keyword><keyword><style face="normal" font="default"> *Etidronic Acid/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Osteoporosis/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Stroke/co [Complications]</style></keyword><keyword><style face="normal" font="default"> 0 (Bone Density Conservation Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 1406-16-2 (Vitamin D)</style></keyword><keyword><style face="normal" font="default"> 2809-21-4 (Etidronic Acid)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Bone Density Conservation Agents/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Bone Density/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Double-Blind Method</style></keyword><keyword><style face="normal" font="default"> Etidronic Acid/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hip Fractures/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Hip Fractures/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Nursing Homes</style></keyword><keyword><style face="normal" font="default"> Osteoporosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sunlight</style></keyword><keyword><style face="normal" font="default"> Vitamin D/me [Metabolism]</style></keyword></keywords><dates><year Day="0" Month="5" Year="2010">2010/5</year></dates><abstract><style face="normal" font="default">Incidence of hip fractures is high in chronically hospitalized, disabled, elderly patients after stroke. Duration of hospitalization was more than 1 year because of insufficiency of nursing homes. Our study showed that immobilization-induced hypercalcemia and 25-hydroxyvitamin D deficiency contribute to reduced bone mineral density (BMD). This study was designed to address the possibility that treatment with etidronate may reduce the bone resorption and lower the incidence of fractures in elderly patients who are chronically hospitalized and disabled as a result of hemiparesis after stroke. Patients with stroke were randomly assigned to daily treatment with 400 mg of etidronate (n = 40) or a placebo (n = 40), and followed up for 2 years. At baseline, both groups had low BMD with high levels of serum ionized calcium and urinary deoxypyridinoline. In the etidronate group, serum calcium and urinary deoxypyridinoline levels decreased significantly during the study period, whereas the levels in the placebo group were increased. BMD on the hemiplegic side increased by 1.4% in the etidronate group and decreased by 2.2% in the placebo group (P &lt; .001). Two patients sustained hip fractures in the placebo group, and no hip fracture occurred in the etidronate group. Treatment with etidronate increases BMD in chronically hospitalized patients poststroke, and may prevent hip fracture. Copyright (c) 2010 National Stroke Association. Published by Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Neurology, Mitate Hospital, Tagawa, Japan. y-sato@ktarn.or.jpJC - 9111633CP - United StatesPT - Journal ArticlePT - Randomized Controlled TrialLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20434046</style></custom1><custom3><style face="normal" font="default">AS - J STROKE CEREBROVASC DIS. 19(3):198-203, 2010 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>349</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Sawyer,K.</style></author><author><style face="normal" font="default"> Mundandhara,S.</style></author><author><style face="normal" font="default"> Ghio,A.J.</style></author><author><style face="normal" font="default"> Madden,M.C.</style></author></authors></contributors><titles><title><style face="normal" font="default">The effects of ambient particulate matter on human alveolar macrophage oxidative and inflammatory responses</style></title><secondary-title><style face="normal" font="default">Journal of Toxicology &amp; Environmental Health Part A</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Toxicology &amp; Environmental Health Part A</style></full-title></periodical><pages end="57" start="41">41-57</pages><volume><style face="normal" font="default">73</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Air Pollution/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Inflammation/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> *Macrophages,Alveolar/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> *Particulate Matter/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> 0 (Cytokines)</style></keyword><keyword><style face="normal" font="default"> 0 (Interleukin-6)</style></keyword><keyword><style face="normal" font="default"> 0 (Interleukin-8)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipopolysaccharides)</style></keyword><keyword><style face="normal" font="default"> 0 (Particulate Matter)</style></keyword><keyword><style face="normal" font="default"> 0 (Tumor Necrosis Factor-alpha)</style></keyword><keyword><style face="normal" font="default"> 0 (Vehicle Emissions)</style></keyword><keyword><style face="normal" font="default"> 11062-77-4 (Superoxides)</style></keyword><keyword><style face="normal" font="default"> 16561-29-8 (Tetradecanoylphorbol Acetate)</style></keyword><keyword><style face="normal" font="default"> 7782-44-7 (Oxygen)</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cytokines/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Interleukin-6/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Interleukin-8/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Lipopolysaccharides/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> Macrophages,Alveolar/im [Immunology]</style></keyword><keyword><style face="normal" font="default"> Macrophages,Alveolar/mi [Microbiology]</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Oxygen/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Superoxides/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Tetradecanoylphorbol Acetate/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> Tumor Necrosis Factor-alpha/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Vehicle Emissions/to [Toxicity]</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="0" Year="2010">2010</year></dates><isbn><style face="normal" font="default">1528-7394</style></isbn><abstract><style face="normal" font="default">Epidemiologic and occupational studies demonstrated that ambient particulate matter (PM) and diesel exhaust particles (DEP) exert deleterious effects on human cardiopulmonary health, including exacerbation of pre-existing lung disease and development of respiratory infections. The effects of ambient PM on lung cell responsiveness are poorly defined. Human alveolar macrophages (AM) were exposed to SRM 1649 (Washington, DC, urban dust; UD), SRM 2975 (forklift diesel exhaust particles; DEP), and fine or coarse ambient PM collected in Chapel Hill, NC, during the late fall (November) and early summer (June) of 2001-2002. AM were subsequently incubated with lipopolysaccharide (LPS), phorbol myristate acetate (PMA), or calcium ionophore A23817 for 6 or 24 h after PM exposure. UD and DEP markedly suppressed O2- release 24 h post-PM exposure. UD exposure significantly inhibited tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, and IL-8 release after exposure to 10 nanog/ml LPS. DEP significantly suppressed only TNF-alpha and IL-6 release. Suppressed cytokine release may also be produced by reduced cellular cytokine production. Data suggested that decreased cytokine release is not produced by the presence of benzo[a]pyrene (BaP), a polycyclic aromatic hydrocarbon. Comparison of TNF-alpha release after LPS, PMA, or A23817 revealed that suppressive effects of UD are LPS dependent, whereas inhibitory effects of DEP may work across multiple mechanistic pathways. November and June Chapel Hill PM exposure stimulated TNF-alpha and IL-8 release before LPS exposure. Fine and coarse November PM exposure markedly suppressed TNF-alpha release 6 h after LPS stimulation, but appeared to exert a stimulatory effect on IL-8 release 24 h after LPS exposure. June fine and coarse PM suppressed IL-8 release after LPS exposure. Data suggest that seasonal influences on PM composition affect AM inflammatory response before and after bacterial exposure. Overall, delayed or inhibited AM immune responses to LPS after PM exposure suggest human exposure to ambient PM may enhance pulmonary susceptibility to respiratory infections</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Environmental Science and Engineering, School of Public Health, University of North Carolina, Chapel Hill, North Carolina, USAJC - ds5, 100960995CP - EnglandPT - Journal ArticlePT - Research Support, U.S. Gov't, Non-P.H.SLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19953419</style></custom1><custom3><style face="normal" font="default">AS - J Toxicol Environ Health A. 73(1):41-57, 2010.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>251</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Schettino,C.D.</style></author><author><style face="normal" font="default"> Siqueira Filho,A.G.</style></author><author><style face="normal" font="default"> Domingues,R.C.</style></author><author><style face="normal" font="default"> Kuroki,I.</style></author><author><style face="normal" font="default"> Deus,F.C.</style></author><author><style face="normal" font="default"> alves,R.T.</style></author><author><style face="normal" font="default"> Torres,H.M.</style></author><author><style face="normal" font="default"> Gasparetto,E.</style></author><author><style face="normal" font="default"> Pacheco,L.C.</style></author><author><style face="normal" font="default"> Rocha,E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Evaluation of atherosclerosis in renal transplanted patients by non-invasive methods</style></title><secondary-title><style face="normal" font="default">Arquivos Brasileiros de Cardiologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Arquivos Brasileiros de Cardiologia</style></full-title></periodical><pages end="344" start="339">339-344</pages><volume><style face="normal" font="default">92</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Diagnostic Techniques,Cardiovascular</style></keyword><keyword><style face="normal" font="default"> *Kidney Transplantation</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Brachial Artery/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Carotid Arteries/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Diagnostic Techniques,Cardiovascular/st [Standards]</style></keyword><keyword><style face="normal" font="default"> Dialysis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Reference Values</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Ultrasonography</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="0" Year="356">356</year></dates><abstract><style face="normal" font="default">BACKGROUND: Endothelial dysfunction can be considered an early atherogenic event. OBJECTIVE: To assess atherosclerosis in renal transplanted patients through the coronary calcium score, carotid duplex scan and brachial reactivity through ultrasonography. METHODS: We assessed 30 renal transplanted male patients with stable renal function, with a mean age of 41.3 years. RESULTS: The detection of the atherosclerotic load in this population was very significant when the brachial reactivity technique was used (86.7%); it was less frequent when based on the presence of carotid plaque (33.3%) or the coronary calcium score (20%). The carotid plaque was considered when the thickness was > 12 mm. The coronary calcium score was abnormal when > 80 according to the Agatston scale, being observed in a low percentage of patients (21.7%), possibly due to the fact that the tomography is not the ideal method to detect atherosclerosis in renal patients, as it does not differentiates intimal calcifications of the medial layer. The adequate clinical control, the low age range and the factors related to the time of pre-transplant dialysis or the anti-inflammatory effect of the post-transplant drugs can delay the onset of the calcifications. CONCLUSION: The evaluation of the atherosclerotic load through the carotid duplex scan (33,3%) and the coronary calcium score (20%) was not frequent; there was no correlation with the high rate of endothelial dysfunction detection observed with the brachial reactivity assessment (86.7%)</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil. cdomenico@gaveacor.com.brJC - 8pm, 0421031CP - BrazilPT - Journal ArticleLG - English, Multilingual</style></notes><urls/><custom1><style face="normal" font="default">UI - 19629288</style></custom1><custom3><style face="normal" font="default">AS - Arq Bras Cardiol. 92(5):339-44, 356-61, 369-74, 2009 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>183</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Scheuner,M.T.</style></author><author><style face="normal" font="default"> Setodji,C.M.</style></author><author><style face="normal" font="default"> Pankow,J.S.</style></author><author><style face="normal" font="default"> Blumenthal,R.S.</style></author><author><style face="normal" font="default"> Keeler,E.</style></author></authors></contributors><titles><title><style face="normal" font="default">General Cardiovascular Risk Profile identifies advanced coronary artery calcium and is improved by family history: the multiethnic study of atherosclerosis</style></title><secondary-title><style face="normal" font="default">Circulation</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Circulation</style></full-title></periodical><pages end="105" start="97">97-105</pages><volume><style face="normal" font="default">Cardiovascular</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> African Americans/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Asian Americans/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Demography</style></keyword><keyword><style face="normal" font="default"> European Continental Ancestry Group/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hispanic Americans/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Models,Genetic</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="1" Month="2" Year="2010">2010/2/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: The General Cardiovascular Risk Profile is a multivariable model that predicts global cardiovascular disease risk. Our goal was to assess the ability of the General Cardiovascular Risk Profile to identify individuals with advanced coronary artery calcification (CAC) and determine whether identification is improved with family history. METHODS AND RESULTS: Using data from the Multiethnic Study of Atherosclerosis, 3 sex-specific models were developed with ordinal logistic regressions to relate risk factors to CAC scores. Model 1 included covariates in the General Cardiovascular Risk Profile. Then family history was added, defined as having at least 1 first-degree relative with premature coronary heart disease (model 2) or as a weak, moderate, or strong family history based on number of relatives with coronary heart disease, age at onset, and the presence of stroke or diabetes in the family (model 3). For each model, we estimated mathematical CAC risk functions, derived CAC score sheets, evaluated the ability to discriminate persons having positive CAC scores, and assessed reclassification of individuals with low, intermediate, or high probability of CAC >300. Model 1 worked well to identify women and men with positive CAC scores; c-statistics were 0.752 and 0.718 and chi(2) values were 821.2 (P&lt;0.0001) and 730.6 (P&lt;0.0001), respectively. Addition of family history improved discrimination and fit of model 1. However, reclassification of participants with advanced CAC was significantly improved with model 3 only. CONCLUSIONS: The General Cardiovascular Risk Profile identifies advanced CAC, an emerging indication for aggressive risk factor modification. Incorporation of family history, especially comprehensive familial risk stratification, provides incremental prognostic value</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - RAND Corporation, Santa Monica, CA 90407-2138, USA. Scheuner@rand.orgCM - Comment in: Circ Cardiovasc Genet. 2010 Feb 1;3(1):3-5; PMID: 20160189JC - 101489144CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - 1 R21 HL081175-01A1 (United States NHLBI NIH HHS)NO - N01-HC-95159 (United States NHLBI NIH HHS)NO - N01-HC-95165 (United States NHLBI NIH HHS)NO - N01-HC-95169 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20160201</style></custom1><custom3><style face="normal" font="default">AS - Circ Cardiovasc Genet. 3(1):97-105, 2010 Feb 1.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>478</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Schleicher,M.M.</style></author><author><style face="normal" font="default"> Reis,M.C.</style></author><author><style face="normal" font="default"> Costa,S.S.</style></author><author><style face="normal" font="default"> Rodrigues,M.P.</style></author><author><style face="normal" font="default"> Casulari,L.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Patients with nephrolithiasis and blood hypertension have higher calciuria than those with isolated nephrolithiasis or hypertension?</style></title><secondary-title><style face="normal" font="default">Minerva Urologica e Nefrologica</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Minerva Urologica e Nefrologica</style></full-title></periodical><pages end="15" start="9">9-15</pages><volume><style face="normal" font="default">61</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> *Hypertension/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> *Insulin Resistance</style></keyword><keyword><style face="normal" font="default"> *Nephrolithiasis/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> *Sodium/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> *Uric Acid/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> 69-93-2 (Uric Acid)</style></keyword><keyword><style face="normal" font="default"> 7440-23-5 (Sodium)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Algorithms</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Insulin Resistance</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Nephrolithiasis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Urine</style></keyword></keywords><dates><year Day="0" Month="3" Year="2009">2009/3</year></dates><isbn><style face="normal" font="default">0393-2249</style></isbn><abstract><style face="normal" font="default">AIM: The aim of this study was to determine urinary excretion of calcium, uric acid and sodium and to evaluate insulin resistance in patients with nephrolithiasis and blood hypertension, isolated and in association, and in healthy controls, in absence of obesity and diabetes. METHODS: The study included 83 non-obese or diabetic patients: 17 with nephrolithiasis and hypertension (group D); 25 with nephrolithiasis (group C); 17 with hypertension (group B) and 24 healthy controls (group A). Urinary analysis was done in 24-hour urine collection and insulin resistance was evaluated through the HOMA-IR index. RESULTS: Calciuria was higher in group D in relation to groups A (P&lt;0.01), B (P&lt;0.01) and C (P=0.01). There was no significant difference between groups A and B (P=0.32), A and C (P=0.10) and B and C (P=0.68). Correlation analysis between urinary calcium detected strong correlation with uric acid in group A, regular in groups B and C and, strong with sodium in groups B and C. No differences were detected in uric acid and sodium excretion or insulin resistance among groups. CONCLUSIONS: Patients with blood hypertension and nephrolithiasis present higher calciuria than healthy people, with hypertension or with lithiasis and do not have the positive correlation observed in these latter groups with renal excretion of uric acid and sodium. These results suggest that impaired renal calcium reabsorption in non-obese or diabetic individuals is involved in the association between hypertension and urolithiasis</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Nephrology, Medical School (ESCS), Federal District General Hospital, Brasilia, DF, BrazilJC - u9r, 8503649CP - ItalyPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19417722</style></custom1><custom3><style face="normal" font="default">AS - Minerva Urol Nefrol. 61(1):9-15, 2009 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>388</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Schlieper,G.</style></author><author><style face="normal" font="default"> Brandenburg,V.</style></author><author><style face="normal" font="default"> Djuric,Z.</style></author><author><style face="normal" font="default"> Damjanovic,T.</style></author><author><style face="normal" font="default"> Markovic,N.</style></author><author><style face="normal" font="default"> Schurgers,L.</style></author><author><style face="normal" font="default"> Kruger,T.</style></author><author><style face="normal" font="default"> Westenfeld,R.</style></author><author><style face="normal" font="default"> Ackermann,D.</style></author><author><style face="normal" font="default"> Haselhuhn,A.</style></author><author><style face="normal" font="default"> Dimkovic,S.</style></author><author><style face="normal" font="default"> Ketteler,M.</style></author><author><style face="normal" font="default"> Floege,J.</style></author><author><style face="normal" font="default"> Dimkovic,N.</style></author></authors></contributors><titles><title><style face="normal" font="default">Risk factors for cardiovascular calcifications in non-diabetic Caucasian haemodialysis patients</style></title><secondary-title><style face="normal" font="default">Kidney &amp; Blood Pressure Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Kidney &amp; Blood Pressure Research</style></full-title></periodical><pages end="168" start="161">161-168</pages><volume><style face="normal" font="default">32</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Cardiomyopathies/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *European Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure,Chronic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcinosis/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Dialysis</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Pulse</style></keyword><keyword><style face="normal" font="default"> Renal Dialysis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><abstract><style face="normal" font="default">BACKGROUND/AIMS: Dialysis patients display an increased mortality which is associated with cardiovascular calcifications. Diabetes mellitus and ethnicity are known factors that affect the extent of cardiovascular calcifications. However, most studies have investigated mixed cohorts with diabetics and/or mixed ethnicity. METHODS: Cardiovascular calcifications were assessed in non-diabetic Caucasian haemodialysis patients by the semiquantitative Adragao calcification score (X-ray pelvis and hands) and a novel composite calcification score encompassing the Adragao score as well as calcifications detected by X-ray of the fistula arm, echocardiography of heart valves and carotid ultrasound. RESULTS: Using multivariate analysis, age, male gender, dialysis vintage, lower Kt/V, calcium-phosphate product, smoking and high-sensitivity CRP were independent risk factors for cardiovascular calcifications as assessed by the Adragao or the composite score. Pulse wave velocity was independently related to both calcification scores. Body mass index, cholesterol, triglycerides, iPTH and serum levels of fetuin-A and uncarboxylated matrix Gla protein were not associated with cardiovascular calcifications. CONCLUSIONS: In our cohort of non-diabetic Caucasian haemodialysis patients, age, male gender, dialysis vintage, smoking, calcium-phosphate product, high-sensitivity CRP and lower Kt/V were independent risk factors for cardiovascular calcifications. Whether lowering the calcium-phosphate product and increasing dialysis efficiency can reduce cardiovascular calcifications in dialysis patients remains to be determined. Copyright (c) 2009 S. Karger AG, Basel</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Nephrology, University Hospital Aachen, Aachen, Germany. gschlieper@ukaachen.deJC - ckc, 9610505CP - SwitzerlandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19468238</style></custom1><custom3><style face="normal" font="default">AS - Kidney Blood Press Res. 32(3):161-8, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>169</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Schlieper,G.</style></author><author><style face="normal" font="default"> Grotemeyer,D.</style></author><author><style face="normal" font="default"> Aretz,A.</style></author><author><style face="normal" font="default"> Schurgers,L.J.</style></author><author><style face="normal" font="default"> ger,T.</style></author><author><style face="normal" font="default"> Rehbein,H.</style></author><author><style face="normal" font="default"> Weirich,T.E.</style></author><author><style face="normal" font="default"> Westenfeld,R.</style></author><author><style face="normal" font="default"> Brandenburg,V.M.</style></author><author><style face="normal" font="default"> Eitner,F.</style></author><author><style face="normal" font="default"> Mayer,J.</style></author><author><style face="normal" font="default"> Floege,J.</style></author><author><style face="normal" font="default"> Sandmann,W.</style></author><author><style face="normal" font="default"> Ketteler,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Analysis of calcifications in patients with coral reef aorta</style></title><secondary-title><style face="normal" font="default">Annals of Vascular Surgery</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Annals of Vascular Surgery</style></full-title></periodical><pages end="414" start="408">408-414</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aorta/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> *Aorta/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Aortic Diseases/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Blood Proteins/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Calcium-Binding Proteins/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> *Extracellular Matrix Proteins/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> 0 (alpha2HS glycoprotein)</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Blood Proteins)</style></keyword><keyword><style face="normal" font="default"> 0 (Calcium-Binding Proteins)</style></keyword><keyword><style face="normal" font="default"> 0 (Extracellular Matrix Proteins)</style></keyword><keyword><style face="normal" font="default"> 0 (matrix Gla protein)</style></keyword><keyword><style face="normal" font="default"> 0 (Osteoprotegerin)</style></keyword><keyword><style face="normal" font="default"> 0 (TNFRSF11B protein,human)</style></keyword><keyword><style face="normal" font="default"> 1306-06-5 (Durapatite)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aorta/ul [Ultrastructure]</style></keyword><keyword><style face="normal" font="default"> Aortic Diseases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Aortic Diseases/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Aortic Diseases/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Aortography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Biological Markers/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Blood Proteins/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium-Binding Proteins/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Durapatite/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Extracellular Matrix Proteins/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Microscopy,Electron,Scanning</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Osteoprotegerin/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Coral reef aorta is a rare vascular disease with intraluminal calcifications of the dorsal part of the visceral aorta. The pathogenesis of this disease with its topographic and morphologic characteristics is unknown. The aim of our study was to investigate calcification inhibitors and the ultrastructure of calcifications in patients with coral reef aorta. METHODS: Ten patients with coral reef aorta were examined. Calcified specimens were investigated by immunohistochemical techniques for the expression of the calcification inhibitors matrix gla protein (MGP) and fetuin-A. Vessel walls were also assessed by electron microscopic techniques including electron energy-lost spectroscopy, electron dispersive spectroscopy, and electron diffraction. Sera of patients were analyzed for fetuin-A, uncarboxylated MGP (ucMGP), and osteoprotegerin. RESULTS: As assessed by immunohistochemistry, most MGP was detected in the vicinity of calcified regions. Serum levels of the calcification inhibitors ucMGP, fetuin-A, and osteoprotegerin were 370+/-107 nmol/L, 0.57+/-0.03 g/L, and 5.64+/-0.79 pmol/L, respectively. Ultrastructural analysis of calcified specimens showed a core-shell structure with multiple calcification nuclei. Calcifications displayed a fine-crystalline character, and elemental analysis revealed hydroxyl apatite as the chemical compound. CONCLUSION: The coral reef aorta represents an extreme exophytic growth of vascular calcification with multiple nuclei which resemble typical media calcification. Positive vascular immunostaining and low serum levels of both fetuin-A and ucMGP suggest a pathophysiologic role of these calcification inhibitors in the development of coral reef aorta. Copyright (c) 2010 Annals of Vascular Surgery Inc. Published by Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Nephrology and Clinical Immunology, RWTH University Hospital, and Central Facility for Electron Microscopy, RWTH University, Aachen, Germany. gschlieper@ukaachen.deJC - avs, 8703941CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20144533</style></custom1><custom3><style face="normal" font="default">AS - Ann Vasc Surg. 24(3):408-14, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>29</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Schutte,R.</style></author><author><style face="normal" font="default"> Huisman,H.W.</style></author><author><style face="normal" font="default"> Schutte,A.E.</style></author><author><style face="normal" font="default"> Malan,N.T.</style></author><author><style face="normal" font="default"> van Rooyen,J.M.</style></author><author><style face="normal" font="default"> Fourie,C.M.</style></author><author><style face="normal" font="default"> Malan,L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Serum calcium revisited: associations with 24-h ambulatory blood pressure and cardiovascular reactivity in Africans</style></title><secondary-title><style face="normal" font="default">Hypertension Research - Clinical &amp; Experimental</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Hypertension Research - Clinical &amp; Experimental</style></full-title></periodical><pages end="694" start="688">688-694</pages><volume><style face="normal" font="default">33</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Blood Pressure Monitoring,Ambulatory</style></keyword><keyword><style face="normal" font="default"> *Blood Pressure/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Vascular Resistance</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> African Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword><keyword><style face="normal" font="default"> Stroke Volume/ph [Physiology]</style></keyword></keywords><dates><year Day="0" Month="7" Year="2010">2010/7</year></dates><abstract><style face="normal" font="default">Sub-Saharan Africans face an increasing burden of hypertension. Although controversial, recent experimental evidence strongly suggests that serum calcium contributes to elevated blood pressure through increased vascular resistance. We investigated the associations of 24-h blood pressure and cardiovascular reactivity with serum calcium in African men stratified by age. The study consisted of 50 younger (median age: 38 years) and 49 older (median age: 49 years) participants. We measured 24-h ambulatory blood pressure with a mean successful inflation rate of 72.6%. Total peripheral resistance and stroke volume reactivity were obtained using a Finometer device during application of the Stroop color and word conflict test. Total serum calcium was adjusted for serum albumin. Results showed that serum calcium levels were similar between the younger and older groups. However, in the younger group, 24-h systolic blood pressure, 24-h diastolic blood pressure and total peripheral resistance reactivity correlated positively, whereas stroke volume reactivity correlated negatively with serum calcium in single and multiple regression analyses (systolic blood pressure: B=34.99, P=0.017; diastolic blood pressure: B=34.93, P&lt;0.001; total peripheral resistance reactivity: B=65.44, P=0.048; stroke volume reactivity: B=-45.40, P=0.017). No associations were evident in the older African men. In conclusion, 24-h ambulatory systolic and diastolic blood pressures are positively associated with serum calcium in African men younger than 43 years. The blood pressure-serum calcium relationship seems to be mediated through increased vascular resistance during stress</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Hypertension in Africa Research Team (HART), School for Physiology, Nutrition, and Consumer Sciences, North-West University (Potchefstroom Campus), Potchefstroom, South Africa. rudolph.schutte@nwu.ac.zaJC - 9307690CP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20448635</style></custom1><custom3><style face="normal" font="default">AS - Hypertens Res. 33(7):688-94, 2010 Jul.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>387</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Schwarz,C.P.</style></author><author><style face="normal" font="default"> Koppelstaetter,C.</style></author><author><style face="normal" font="default"> Amann,E.</style></author><author><style face="normal" font="default"> Mayer,G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Impact of anemia on aortic pulse wave velocity in hemodialysis patients</style></title><secondary-title><style face="normal" font="default">Kidney &amp; Blood Pressure Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Kidney &amp; Blood Pressure Research</style></full-title></periodical><pages end="216" start="210">210-216</pages><volume><style face="normal" font="default">32</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Anemia/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure,Chronic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Pulsatile Flow</style></keyword><keyword><style face="normal" font="default"> 0 (Hemoglobins)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Aorta/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hemoglobins/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Pulse</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Renal Dialysis</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><abstract><style face="normal" font="default">BACKGROUND: Recent studies indicate an increased mortality of anemic patients with renal failure when near-normal hemoglobin levels are aimed for by treatment with erythropoiesis stimulating agents. Aortic pulse wave velocity (aPWV) is a strong predictor of all-cause and cardiovascular mortality in patients with end-stage renal disease. The relationships between aPWV, hemoglobin levels and erythropoiesis stimulating agent dosage have not been evaluated to date. METHODS: In 75 patients, aPWV was measured by applanation tonometry. Associations of aPWV and a broad range of clinical, laboratory and therapeutic parameters were determined by stepwise linear regression analysis. RESULTS: aPWV was positively correlated to age (r = 0.55, p &lt; 0.001), whereas the association with hemoglobin was significant, but negative (r = -0.31, p = 0.01). Multivariate analysis determined age (beta = 0.513, p &lt; 0.001), mean blood pressure (beta = 0.255, p = 0.01), the presence of heart failure (beta = 0.188, p = 0.03), hemoglobin (beta = -0.226, p = 0.01), daily calcium load (beta = -0.230, p = 0.01) and the presence of diabetes mellitus (beta = 0.179, p = 0.04) to have a significant and independent influence on aPWV. CONCLUSIONS: This study demonstrates that in hemodialysis patients, aPWV is significantly but negatively associated with the serum hemoglobin concentration, even after multiple adjustments for other covariates. Copyright (c) 2009 S. Karger AG, Basel</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Internal Medicine IV, Informatics and Health Economics, Innsbruck Medical University, Innsbruck, AustriaJC - ckc, 9610505CP - SwitzerlandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19590228</style></custom1><custom3><style face="normal" font="default">AS - Kidney Blood Press Res. 32(3):210-6, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>40</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Seabra-Gomes,R.</style></author><author><style face="normal" font="default"> Investigadores do Registo,P.U.L.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Characterization of an ambulatory population with stable coronary artery disease and importance of heart rate: the PULSAR registry</style></title><secondary-title><style face="normal" font="default">Revista Portuguesa de Cardiologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Revista Portuguesa de Cardiologia</style></full-title></periodical><pages end="508" start="483">483-508</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Artery Disease/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Heart Rate</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Ambulatory Care</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><isbn><style face="normal" font="default">0870-2551</style></isbn><abstract><style face="normal" font="default">AIMS: To characterize a population with stable coronary artery disease (CAD) in an outpatient setting and to evaluate the importance of resting heart rate (HR), a recently recognized prognostic risk factor. TYPE OF STUDY: A prospective and observational registry of patients with stable CAD followed mainly by cardiologists in private outpatient clinics. METHODS: Patients were selected by at least one of the following inclusion criteria: coronary angiography with at least one significant stenosis; positive stress test; previous myocardial infarction; or revascularization by angioplasty or surgery. Demographics, concomitant diseases, HR, blood pressure (BP), presence of angina and medical therapy were all recorded. Data compilation and statistical analysis were performed by a CRO independent of the sponsor and the investigators. RESULTS: Between May and October 2009, 3477 consecutive patients were included by 186 doctors. Mean age was 66.6 +/- 10.1 years and 26.3% were female, 76% had arterial hypertension, 34% diabetes, 47% previous infarction, 42% angioplasty and 25% coronary surgery. Of concomitant diseases, 13% of patients had peripheral vascular disease or erectile dysfunction. Medical therapy included antiplatelet agents (97%), lipid-lowering agents (92%), beta-blockers (72%), ACEIs (54%), nitrates (39%), calcium blockers (36%), ARBs (28%), ivabradine (24%) and trimetazidine (17%). Mean HR was 67 +/- 12 bpm and 67% of patients had HR > 60 bpm. Mean systolic BP was 134 +/- 18 mmHg and mean diastolic BP was 76 +/- 10 mmHg. Angina was present in 31.3% of patients and 53.4% had class II angina. The population with angina was more severe, 74% had HR > 60 bpm and 68% were taking beta-blockers. In patients with angina and HR > 60 bpm, beta-blocker use was only 64%. CONCLUSION: In an outpatient population with stable CAD of whom a third had angina, there was an increased number of patients with HR > 60 bpm and decreased use of beta-blockers with increasing disease severity. These findings support increased use of newly developed drugs for the treatment of stable CAD and angina</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Instituto do Coracao, Carnaxide. seago@esoterica.ptJC - aow, 8710716CP - PortugalPT - Journal ArticlePT - Multicenter StudyLG - English, Portuguese</style></notes><urls/><custom1><style face="normal" font="default">UI - 20734572</style></custom1><custom3><style face="normal" font="default">AS - Rev Port Cardiol. 29(4):483-508, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>98</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Seneviratne,S.K.</style></author><author><style face="normal" font="default"> Truong,Q.A.</style></author><author><style face="normal" font="default"> Bamberg,F.</style></author><author><style face="normal" font="default"> Rogers,I.S.</style></author><author><style face="normal" font="default"> Shapiro,M.D.</style></author><author><style face="normal" font="default"> Schlett,C.L.</style></author><author><style face="normal" font="default"> Chae,C.U.</style></author><author><style face="normal" font="default"> Cury,R.</style></author><author><style face="normal" font="default"> Abbara,S.</style></author><author><style face="normal" font="default"> Brady,T.J.</style></author><author><style face="normal" font="default"> Nagurney,J.T.</style></author><author><style face="normal" font="default"> Hoffmann,U.</style></author></authors></contributors><titles><title><style face="normal" font="default">Incremental diagnostic value of regional left ventricular function over coronary assessment by cardiac computed tomography for the detection of acute coronary syndrome in patients with acute chest pain: from the ROMICAT trial</style></title><secondary-title><style face="normal" font="default">Circulation</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Circulation</style></full-title></periodical><pages end="383" start="375">375-383</pages><volume><style face="normal" font="default">Cardiovascular</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Acute Coronary Syndrome/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Chest Pain/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Ventricular Dysfunction,Left/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> 0 (Contrast Media)</style></keyword><keyword><style face="normal" font="default"> Acute Coronary Syndrome/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Acute Disease</style></keyword><keyword><style face="normal" font="default"> Area Under Curve</style></keyword><keyword><style face="normal" font="default"> Chest Pain/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Contrast Media</style></keyword><keyword><style face="normal" font="default"> Coronary Stenosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Diagnosis,Differential</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Rest</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Triage/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Ventricular Dysfunction,Left/pp [Physiopathology]</style></keyword></keywords><dates><year Day="1" Month="7" Year="2010">2010/7/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: The incremental value of regional left ventricular function (LVF) over coronary assessment to detect acute coronary syndrome (ACS) is uncertain. METHODS AND RESULTS: We analyzed 356 patients (mean age, 53+/-12 years; 62% men) with acute chest pain and inconclusive initial emergency department evaluation. Patients underwent 64-slice contrast-enhanced cardiac computed tomography before hospital admission. Caregivers and patients remained blinded to the results. Regional LVF and presence of coronary atherosclerotic plaque and significant stenosis (>50%) were separately assessed by 2 independent readers. Incremental value of regional LVF to predict ACS was determined in the entire cohort and in subgroups of patients with nonobstructive coronary artery disease, inconclusive assessment for stenosis (defined as inability to exclude significant stenosis due to calcium or motion), and significant stenosis. During their index hospitalization, 31 patients were ultimately diagnosed with ACS (8 myocardial infarction, 22 unstable angina), of which 74% (23 patients) had regional LV dysfunction. Adding regional LVF resulted in a 10% increase in sensitivity to detect ACS by cardiac computed tomography (87%; 95% confidence interval, 70% to 96%) and significantly improved the overall accuracy (c-statistic: 0.88 versus 0.94 and 0.79 versus 0.88, for extent of plaque and presence of stenosis, respectively; both P&lt;0.03). The diagnostic accuracy of regional LVF for detection of ACS has 89% sensitivity and 86% specificity in patients with significant stenosis (n=33) and 60% sensitivity and 86% specificity in patients with inconclusive coronary computed tomographic angiography (n=33). CONCLUSIONS: Regional LVF assessment at rest improves diagnostic accuracy for ACS in patients with acute chest pain, especially in those with coronary artery disease and thus may be helpful to guide further management in patients at intermediate risk for ACS</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Cardiac MR PET CT Program, Department of Radiology and Division of Cardiology, Massachusetts General Hospital and Harvard Medical School, 165 Charles River Plaza, Boston, MA 02114, USAJC - 101479935CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tSI - ClinicalTrials.govSA - ClinicalTrials.gov/NCT00990262NO - R01 HL080053 (United States NHLBI NIH HHS)NO - T32HL076136 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20484542</style></custom1><custom3><style face="normal" font="default">AS - Circ Cardiovasc Imaging. 3(4):375-83, 2010 Jul 1.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>515</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Serafin,Z.</style></author><author><style face="normal" font="default"> Laskowska,K.</style></author><author><style face="normal" font="default"> Marzec,M.</style></author><author><style face="normal" font="default"> Sinjab,T.A.</style></author><author><style face="normal" font="default"> Lasek,W.</style></author><author><style face="normal" font="default"> Wlodarczyk,Z.</style></author></authors></contributors><titles><title><style face="normal" font="default">Coronary artery calcium distribution and interscan measurement variability in end-stage renal and coronary heart disease patients</style></title><secondary-title><style face="normal" font="default">Acta Radiologica</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Acta Radiologica</style></full-title></periodical><pages end="295" start="288">288-295</pages><volume><style face="normal" font="default">50</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Angiography/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Image Processing,Computer-Assisted/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure,Chronic/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,Spiral Computed/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Software</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword></keywords><dates><year Day="0" Month="4" Year="2009">2009/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Coronary heart disease patients and end-stage renal disease patients have been documented to have an increased amount of coronary artery calcifications (CAC). Purpose: To evaluate the distribution of CAC and its influence on interscan variability of measurement in end-stage renal disease and coronary heart disease patients, proven to have calcifications. MATERIAL AND METHODS: 69 patients having CAC, including 34 with coronary heart disease and 35 with end-stage renal disease, were scanned twice with multidetector-row computed tomography (MDCT). Amount of CAC was determined as the number of calcified lesions (CN), total calcium score (CS), calcium volume (CV), and calcium mass (CM). Distribution of CAC was evaluated on a per-patient basis as the median CS and CM of a single lesion. Density of the calcifications was calculated as the patient's CM divided by CV. RESULTS: The overall median CS was 457.2, and the median CM was 75.6 mg. There were no significant differences in the number of calcified lesions, CS, or CM between the two groups. Both CS and CM of a single lesion, as well as the mean calcium density were lower in renal disease patients (P&lt;0.05) than in coronary heart disease subjects. The relative interscan variability of coronary calcium measurement was higher in the renal disease group (P&lt;0.05). There was a negative correlation between the calcium concentration and the relative interscan variability. CONCLUSION: The results indicate that the coronary calcium distribution influences the measurement interscan reproducibility, and the distribution may differ between end-stage renal disease patients and coronary heart disease patients, reflecting the dissimilar nature of coronary calcifications in those groups</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Radiology and Diagnostic Imaging, Nicolaus Copernicus University, Collegium Medicum, Bydgoszcz, Poland. serafin@mp.plJC - 8706123, ataCP - SwedenPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19241190</style></custom1><custom3><style face="normal" font="default">AS - Acta Radiol. 50(3):288-95, 2009 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>284</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Serebruany,V.</style></author><author><style face="normal" font="default"> Malinin,A.</style></author><author><style face="normal" font="default"> Qiu,F.H.</style></author><author><style face="normal" font="default"> Xu,X.C.</style></author><author><style face="normal" font="default"> Kunsch,C.</style></author><author><style face="normal" font="default"> Scott,R.</style></author><author><style face="normal" font="default"> ALPS Study Group</style></author></authors></contributors><titles><title><style face="normal" font="default">Selective thromboxane inhibition after vascular protectant AGI-1067: results of assessment of lipoprotein profiles (ALPS) biomarkers in vitro and in vivo substudy</style></title><secondary-title><style face="normal" font="default">Journal of Thrombosis &amp; Thrombolysis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Thrombosis &amp; Thrombolysis</style></full-title></periodical><pages end="446" start="438">438-446</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Artery Disease/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Lipoproteins/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Probucol/aa [Analogs &amp; Derivatives]</style></keyword><keyword><style face="normal" font="default"> *Thromboxanes/ai [Antagonists &amp; Inhibitors]</style></keyword><keyword><style face="normal" font="default"> *Thromboxanes/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipoproteins)</style></keyword><keyword><style face="normal" font="default"> 0 (Thromboxanes)</style></keyword><keyword><style face="normal" font="default"> 216167-82-7 (succinobucol)</style></keyword><keyword><style face="normal" font="default"> 23288-49-5 (Probucol)</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cells,Cultured</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Drug</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Probucol/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Vascular Diseases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Vascular Diseases/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="5" Year="2009">2009/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: Oxidative stress play an important role triggering platelet/endothelial activation. AGI-1067 is a novel, phenolic antioxidant, and vascular protectant which dose-dependently inhibits PEA biomarkers in vitro. Whether treatment with AGI-1067 alters platelets in vivo is not known. We serially assessed release of established PEA biomarkers in subjects treated with AGI-1067 versus placebo in the frame of Assessment of Lipoprotein Profiles Randomized Trial (ALPS). METHODS: Healthy subjects (18-65 years) with multiple risk factors for coronary artery disease were randomized 1:1 to receive 300 mg AGI-1067 (n = 112) or matching placebo (n = 117) daily for 12 weeks. Anticoagulants, aspirin, NSAIDS, and COX inhibitors were not permitted in this study. Plasma samples were collected at baseline, and at week 12 after randomization. Platelet factor 4 (PF4), beta-thromboglobulin (betaTG), P-selectin, thromboxane (TxB2), and prostacyclin (6-keto-PGF1a) were measured by ELISA. RESULTS: Treatment with AGI-1067 was associated with a highly significant reduction of TxB2 release (P &lt; 0.0001) when compared to the placebo. There were no differences in PF4, betaTG, P-selectin, and 6-keto-PGF1a between and within groups. AGI-1067 also inhibits TxB2 release from calcium ionophore (A23187)-stimulated human platelets with the IC50 equals 1 microM; but does not interfere with 6-keto-PGF1alpha release in either A23187-, or TXA2-stimulated human aortic endothelial cells. CONCLUSION: AGI-1067 selectively reduces TxB(2 )production from stimulated platelets, and diminishes plasma TxB2 levels in ALPS participants. These data support earlier in vitro, and pilot ex vivo experiments suggesting antiplatelet properties of AGI-1067. Lack of 6-keto-PGF1a down regulation may represent an attractive advantage of AGI-1067 over currently available antiplatelet regimens</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - HeartDrug Research Laboratories, Johns Hopkins University, Baltimore, MD, USA. Heartdrug@aol.comJC - ddy, 9502018CP - NetherlandsPT - Comparative StudyPT - Journal ArticlePT - Multicenter StudyPT - Randomized Controlled TrialPT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18521540</style></custom1><custom3><style face="normal" font="default">AS - J Thromb Thrombolysis. 27(4):438-46, 2009 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>542</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Serefoglu,E.C.</style></author><author><style face="normal" font="default"> Erdamar,H.</style></author><author><style face="normal" font="default"> Ozdemir,A.T.</style></author><author><style face="normal" font="default"> Atmaca,A.F.</style></author><author><style face="normal" font="default"> Berktas,M.</style></author><author><style face="normal" font="default"> Balbay,M.D.</style></author></authors></contributors><titles><title><style face="normal" font="default">Penile blood cyclic guanosin monophosphate level is associated with penile Doppler ultrasound findings</style></title><secondary-title><style face="normal" font="default">International Journal of Impotence Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">International Journal of Impotence Research</style></full-title></periodical><pages end="56" start="51">51-56</pages><volume><style face="normal" font="default">21</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cyclic GMP/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Penis/bs [Blood Supply]</style></keyword><keyword><style face="normal" font="default"> *Penis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> 7665-99-8 (Cyclic GMP)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age Distribution</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases</style></keyword><keyword><style face="normal" font="default"> Erectile Dysfunction/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Erectile Dysfunction/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="1" Year="2009">2009/1</year></dates><abstract><style face="normal" font="default">The aim of this study was to look into a molecule in penile blood sample that shows correlation with the tumescence grade and/or penile Doppler ultrasound findings. Patients admitted to urology outpatient clinic with the complaint of erectile dysfunction between November 2006 and April 2007 were evaluated. Patients with the history of phosphodiesterase inhibitor usage or genital trauma, genital abnormalities, Peyronie's disease, endocrinopathies, cardiovascular diseases and major psychiatric or neurological disorders were excluded. Those patients were later evaluated with a penile Doppler ultrasound, 10-20 min after intracavernosal injection of 60 mg of papaverine hydrochloride. Tumescence grade, peak-systolic velocity (PSV), end-diastolic velocity (EDV) and resistive index (RI) were recorded. Blood samples were drawn from penis and the levels of calcium, myeloperoxidase, malondialdehyde, nitrite, nitrate, vasoactive intestinal peptide and cyclic guanosin monophosphate (cGMP) and the activity of superoxide dismutase were measured. A total of 46 patients with erectile dysfunction were included. The median age of the patients was 49.3+/-10.2 (range 24-67). We could not find any significant correlation between penile Doppler ultrasound parameters and any of penile blood measurements except cGMP that demonstrated a significant negative correlation with PSV (rho=-0.533, P=0.001) and RI (rho=-0.468, P=0.005). However, a positive correlation between cGMP and EDV was detected (rho=0.322, P=0.059). Mean cGMP levels were 3.347+/-0.694 pmol ml(-1) (2.295-4.685), 3.193+/-0.669 pmol ml(-1) (2.165-4.094) and 2.742+/-0.690 pmol ml(-1) (1.290-4.011) in grades 2, 3 and 4 tumescence groups, respectively, and the difference among mean cGMP levels of these groups were statistically significant (P=0.027). As a conclusion, penile blood cGMP level showed a significant negative correlation with mean PSV, RI values and tumescence grade, whereas there was a positive but insignificant correlation between cGMP and mean EDV value</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of 1st Urology, Ataturk Training and Research Hospital, Ankara, Turkey. egecanserefoglu@hotmail.comJC - bux, 9007383CP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18987642</style></custom1><custom3><style face="normal" font="default">AS - Int J Impot Res. 21(1):51-6, 2009 Jan-Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>85</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Severi,S.</style></author><author><style face="normal" font="default"> Pogliani,D.</style></author><author><style face="normal" font="default"> Fantini,G.</style></author><author><style face="normal" font="default"> Fabbrini,P.</style></author><author><style face="normal" font="default"> Vigan&amp;#x00F2</style></author><author><style face="normal" font="default"> MR</style></author><author><style face="normal" font="default"> Galbiati,E.</style></author><author><style face="normal" font="default"> Bonforte,G.</style></author><author><style face="normal" font="default"> Vincenti,A.</style></author><author><style face="normal" font="default"> Stella,A.</style></author><author><style face="normal" font="default"> Genovesi,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Alterations of atrial electrophysiology induced by electrolyte variations: combined computational and P-wave analysis</style></title><secondary-title><style face="normal" font="default">Europace</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Europace</style></full-title></periodical><pages end="849" start="842">842-849</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atrial Fibrillation/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Atrial Fibrillation/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Electrocardiogram Pattern</style></keyword><keyword><style face="normal" font="default"> *Heart Conduction System/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Water-Electrolyte Imbalance/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> 7439-95-4 (Magnesium)</style></keyword><keyword><style face="normal" font="default"> 7440-09-7 (Potassium)</style></keyword><keyword><style face="normal" font="default"> 7440-23-5 (Sodium)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Action Potentials/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atrial Fibrillation/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Blood Pressure/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cardiomegaly/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Cardiomegaly/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Atria</style></keyword><keyword><style face="normal" font="default"> Heart Rate/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Magnesium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Models,Biological</style></keyword><keyword><style face="normal" font="default"> Potassium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Renal Dialysis</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sodium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Water-Electrolyte Imbalance/co [Complications]</style></keyword></keywords><dates><year Day="0" Month="6" Year="2010">2010/6</year></dates><abstract><style face="normal" font="default">AIMS: Haemodialysis (HD) therapy represents a unique model to test in vivo, in humans, the effects of changes in plasma ionic concentrations. Episodes of paroxysmal atrial fibrillation (AF) often occur during the treatment. We investigated the effects of HD-induced electrolyte variations on atrial electrophysiology by analysing ECG P-wave duration (PWd), which reflects atrial conduction velocity (CV), and simulated atrial action potential (AP). METHODS AND RESULTS: In 20 end-stage renal disease patients PWd (signal-averaged ECG), heart rate (HR), blood pressure, Na(+), K(+), Ca(2+), and Mg(2+) plasma concentrations were measured before and after HD session. The Courtemanche computational model of human atrial myocyte was used to simulate the atrial AP. AP upstroke duration (AP(ud)), AP duration and atrial cell effective refractory period (ERP) were computed. Extracellular electrolyte concentrations and HR were imposed to the average values measured in vivo. HD decreased K(+) (from 4.9 +/- 0.5 to 3.9 +/- 0.4 mmol/L, P &lt; 0.001) and Mg(2+) (0.92 +/- 0.08 to 0.86 +/- 0.05 mmol/L, P &lt; 0.05), and increased Na(+) (139.8 +/- 3.4 to 141.6 +/- 3.1 mmol/L, P &lt; 0.05) and Ca(2+) (1.18 +/- 0.09 to 1.30 +/- 0.07 mmol/L, P &lt; 0.001) plasma concentrations. PWd systematically increased in all the patients after HD (131 +/- 11 to 140 +/- 12 ms, P &lt; 0.001), indicating an intra-atrial conduction slowing. PWd increments were inversely correlated with K(+) variations (R = 0.73, P &lt; 0.01). Model-based analysis indicated an AP(ud) increase (from 2.58 to 2.94 ms) after HD, coherent with experimental observations on PWd, and a reduction of ERP by 12 ms. CONCLUSION: Changes of plasma ionic concentrations may lead to modifications of atrial electrophysiology that can favour AF onset, namely a decrease of atrial CV and a decrease of atrial ERP</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Laboratorio di Ingegneria Biomedica-D.E.I.S, Universit&amp;#x00E0; di Bologna, Cesena, ItalyJC - dxd, 100883649CP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20185484</style></custom1><custom3><style face="normal" font="default">AS - Europace. 12(6):842-9, 2010 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>383</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Shadnia,S.</style></author><author><style face="normal" font="default"> Sasanian,G.</style></author><author><style face="normal" font="default"> Allami,P.</style></author><author><style face="normal" font="default"> Hosseini,A.</style></author><author><style face="normal" font="default"> Ranjbar,A.</style></author><author><style face="normal" font="default"> mini-Shirazi,N.</style></author><author><style face="normal" font="default"> Abdollahi,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">A retrospective 7-years study of aluminum phosphide poisoning in Tehran: opportunities for prevention</style></title><secondary-title><style face="normal" font="default">Human &amp; Experimental Toxicology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Human &amp; Experimental Toxicology</style></full-title></periodical><pages end="213" start="209">209-213</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aluminum Compounds/to [Toxicity]</style></keyword><keyword><style face="normal" font="default"> *Pesticides/to [Toxicity]</style></keyword><keyword><style face="normal" font="default"> *Phosphines/to [Toxicity]</style></keyword><keyword><style face="normal" font="default"> 0 (Aluminum Compounds)</style></keyword><keyword><style face="normal" font="default"> 0 (Pesticides)</style></keyword><keyword><style face="normal" font="default"> 0 (Phosphines)</style></keyword><keyword><style face="normal" font="default"> 20859-73-8 (aluminum phosphide)</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Blood Gas Analysis</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Gastrointestinal Diseases/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Iran/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Poisoning/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Poisoning/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Poisoning/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Seasons</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="4" Year="2009">2009/4</year></dates><abstract><style face="normal" font="default">The objective of this study was to survey aluminum phosphide (AIP) poisoning in a referral poisoning hospital in Tehran servicing an estimation of 10,000,000 populations. Records of all patients admitted and hospitalized during a period of 7 years from January 2000 to January 2007 were collected and analyzed according to gender, age, cause of intoxication, amount of AIP consumed, route of exposure, time between exposure and onset of treatment, signs and symptoms of intoxication at admission, therapeutic intervention, laboratory tests, and outcome. During the studied years, 471 patients were admitted to the hospital with AIP poisoning; 50% of them were men. The overall case fatality ratio was 31%. The mean age was 27.1 years, and most of the patients were between 20 and 40 years old. Self-poisoning was observed in 93% of cases. The average ingested dose was 5.1 g, and most of the patients (73%) consumed 1-3 tablets of AIP. A wide range of symptoms and signs was seen on admission, but the most common one was cardiovascular manifestations (78.12%). The majority (65%) of patients were from Tehran. Poisoning in spring and winter (34% and 24%, respectively) was more common than other seasons. Gastric decontamination with potassium permanganate, and administration of calcium gluconate, magnesium sulfate, sodium bicarbonate, and charcoal were considered for most of the patients. Mean arterial blood pH was 7.23 and bicarbonate concentration was 12.7 mEq/L. One-hundred percent of patients with blood pH &lt;7 died and 100% of patients with blood pH >or= 7.35 survived. Electrocardiogram (EKG) abnormalities were noted in 65.6% of cases. There was a significant difference between survival and non-survival according to pH, HCO(3) concentration, and EKG abnormality. Even without an increase in resources, there appears to be significant opportunities for reducing mortality by better medical management and further restrictions on the AIP tablets usage. Arterial blood pH seems to be a prognostic factor for the outcome of AIP-poisoned patients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Loghman-Hakim Hospital Poison Center, School of Medicine and Toxicological Research Center, Shaheed Beheshti University of Medical Sciences, Tehran, IranJC - aql, 9004560CP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19734272</style></custom1><custom3><style face="normal" font="default">AS - Hum Exp Toxicol. 28(4):209-13, 2009 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>473</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Shah,S.J.</style></author><author><style face="normal" font="default"> Blair,J.E.</style></author><author><style face="normal" font="default"> Filippatos,G.S.</style></author><author><style face="normal" font="default"> Macarie,C.</style></author><author><style face="normal" font="default"> Ruzyllo,W.</style></author><author><style face="normal" font="default"> Korewicki,J.</style></author><author><style face="normal" font="default"> Bubenek-Turconi,S.I.</style></author><author><style face="normal" font="default"> Ceracchi,M.</style></author><author><style face="normal" font="default"> Bianchetti,M.</style></author><author><style face="normal" font="default"> Carminati,P.</style></author><author><style face="normal" font="default"> Kremastinos,D.</style></author><author><style face="normal" font="default"> Grzybowski,J.</style></author><author><style face="normal" font="default"> Valentini,G.</style></author><author><style face="normal" font="default"> Sabbah,H.N.</style></author><author><style face="normal" font="default"> Gheorghiade,M.</style></author><author><style face="normal" font="default"> HORIZON-HF,Investigators</style></author></authors></contributors><titles><title><style face="normal" font="default">Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial</style></title><secondary-title><style face="normal" font="default">American Heart Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Heart Journal</style></full-title></periodical><pages end="1041" start="1035">1035-1041</pages><volume><style face="normal" font="default">157</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiovascular Agents/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> *Etiocholanolone/aa [Analogs &amp; Derivatives]</style></keyword><keyword><style face="normal" font="default"> *Heart Failure/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Heart/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> *Sodium-Potassium-Exchanging ATPase/ai [Antagonists &amp; Inhibitors]</style></keyword><keyword><style face="normal" font="default"> 0 (3-((2-aminoethoxy)imino)androstane-6,17-dione)</style></keyword><keyword><style face="normal" font="default"> 0 (Cardiovascular Agents)</style></keyword><keyword><style face="normal" font="default"> 53-42-9 (Etiocholanolone)</style></keyword><keyword><style face="normal" font="default"> Acute Disease</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Diastole</style></keyword><keyword><style face="normal" font="default"> EC 3-6-3-9 (Sodium-Potassium-Exchanging ATPase)</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Etiocholanolone/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> Etiocholanolone/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Failure/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Stroke Volume</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="6" Year="2009">2009/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: Istaroxime is a novel intravenous agent with inotropic and lusitropic properties related to inhibition of the Na+/K+ adenosine triphosphatase and stimulation of sarcoplasmic reticulum calcium adenosine triphosphatase activity. We analyzed data from HORIZON-HF, a randomized, controlled trial evaluating the short-term effects of istaroxime in patients hospitalized with heart failure and left ventricular ejection fraction &lt; or = 35% to test the hypothesis that istaroxime improves diastolic stiffness in acute heart failure syndrome. METHODS: One hundred twenty patients were randomized 3:1 (istaroxime/placebo) to a continuous 6-hour infusion of 1 of 3 doses of istaroxime or placebo. All patients underwent pulmonary artery catheterization and comprehensive 2-dimensional/Doppler and tissue Doppler echocardiography at baseline and at the end of the 6-hour infusion. We quantified diastolic stiffness using pressure-volume analysis and tissue Doppler imaging of the lateral mitral annulus (E'). RESULTS: Baseline characteristics were similar among all groups, with mean age 55 +/- 11 years, 88% men, left ventricular ejection fraction 27% +/- 7%, systolic blood pressure (SBP) 116 +/- 13 mm Hg, and pulmonary capillary wedge pressure (PCWP) 25 +/- 5 mm Hg. Istaroxime administration resulted in an increase in E' velocities, whereas there was a decrease in E' in the placebo group (P = .048 between groups). On pressure-volume analysis, istaroxime decreased end-diastolic elastance (P = .0001). On multivariate analysis, increasing doses of istaroxime increased E' velocity (P = .043) and E-wave deceleration time (P = .001), and decreased E/E' ratio (P = .047), after controlling for age, sex, baseline ejection fraction, change in PCWP, and change in SBP. CONCLUSIONS: Istaroxime decreases PCWP, increases SBP, and decreases diastolic stiffness in patients with acute heart failure syndrome</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. sanjiv.shah@northwestern.eduJC - 0370465CP - United StatesPT - Journal ArticlePT - Randomized Controlled TrialSI - ClinicalTrials.govSA - ClinicalTrials.gov/NCT00616161LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19464414</style></custom1><custom3><style face="normal" font="default">AS - Am Heart J. 157(6):1035-41, 2009 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>265</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Shah,S.M.</style></author><author><style face="normal" font="default"> Carey,I.M.</style></author><author><style face="normal" font="default"> Harris,T.</style></author><author><style face="normal" font="default"> DeWilde,S.</style></author><author><style face="normal" font="default"> Cook,D.G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Calcium supplementation, cardiovascular disease and mortality in older women</style></title><secondary-title><style face="normal" font="default">Pharmacoepidemiology &amp; Drug Safety</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pharmacoepidemiology &amp; Drug Safety</style></full-title></periodical><pages end="64" start="59">59-64</pages><volume><style face="normal" font="default">19</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Bone Density Conservation Agents/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Calcium,Dietary/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> *Dietary Supplements/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> 0 (Bone Density Conservation Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Calcium,Dietary)</style></keyword><keyword><style face="normal" font="default"> 1406-16-2 (Vitamin D)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Bone Density Conservation Agents/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Calcium,Dietary/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Drug Therapy,Combination</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Stroke/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Stroke/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Vitamin D/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Vitamin D/ae [Adverse Effects]</style></keyword></keywords><dates><year Day="0" Month="1" Year="2010">2010/1</year></dates><abstract><style face="normal" font="default">PURPOSE: To investigate the long-term cumulative effect of calcium and vitamin D supplementation on cardiovascular outcomes and death in older women. METHODS: We undertook an observational cohort study using UK electronic primary care records in the Doctor's Independent Network (DIN-LINK) database; 9910 women aged 60-89 who started calcium and vitamin D supplementation between 2000 and 2005, with no heart disease or stroke history and who survived disease free for 2 years after supplement initiation were studied. The main outcome was first occurrence of myocardial infarction (MI), stroke or death more than 2 years after initiation. RESULTS: In the period from 2 years after supplement initiation, women who had received >600 days supplementation in these first 2 years were no more at risk of MI, stroke or death (hazard ratio 0.82 (0.67-1.01)) compared to women who received &lt; or = 90 days supplementation in the first 2 years. Outcomes in the first 2 years were analysed separately and showed similar baseline risks in our comparison groups. CONCLUSION: Two years after initiation, women who have consistently received supplementation with calcium and vitamin D do not experience more cardiovascular events or deaths than women who received minimal supplementation</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Community Health Sciences, St George's University of London, London SW17 0RE, UK. sushah@sgul.ac.ukJC - d0r, 9208369CP - EnglandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19757413</style></custom1><custom3><style face="normal" font="default">AS - Pharmacoepidemiol Drug Saf. 19(1):59-64, 2010 Jan.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>373</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Shaw,L.J.</style></author><author><style face="normal" font="default"> Polk,D.M.</style></author><author><style face="normal" font="default"> Kahute,T.A.</style></author><author><style face="normal" font="default"> Wong,N.D.</style></author><author><style face="normal" font="default"> Moon,J.</style></author><author><style face="normal" font="default"> Miranda-Peats,R.</style></author><author><style face="normal" font="default"> Rozanski,A.</style></author><author><style face="normal" font="default"> Friedman,J.D.</style></author><author><style face="normal" font="default"> Hayes,S.</style></author><author><style face="normal" font="default"> Thomson,L.</style></author><author><style face="normal" font="default"> Berman,D.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Prognostic accuracy of B-natriuretic peptide measurements and coronary artery calcium in asymptomatic subjects (from the Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research [EISNER] study)</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="1250" start="1245">1245-1250</pages><volume><style face="normal" font="default">104</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Natriuretic Peptide,Brain/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Risk Assessment</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 114471-18-0 (Natriuretic Peptide,Brain)</style></keyword><keyword><style face="normal" font="default"> 9007-41-4 (C-Reactive Protein)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> C-Reactive Protein/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Disease/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Coronary Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperlipidemias/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Ischemic Attack,Transient/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Ischemic Attack,Transient/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Stroke/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Stroke/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="1" Month="11" Year="2009">2009/11/1</year></dates><abstract><style face="normal" font="default">B-type natriuretic peptide (BNP) has prognostic implications in patients with acute and chronic cardiac symptoms. Its prognostic role in asymptomatic patients with evidence of subclinical disease remains unclear. The population of this study included 2,458 asymptomatic adults (47% women) with an average Framingham risk score of 8.8 +/- 7% who underwent computed tomographic evaluation of coronary artery calcium (CAC). BNP levels were measured using the Triage CardioProfilER panel method. Cox proportional-hazards models were used to estimate time to a cardiovascular (CV) event (n = 84; 16 deaths, 12 myocardial infarctions, 8 cerebrovascular accidents or transient ischemic attacks, and 48 diagnoses of incident symptomatic coronary disease). Relative risk was calculated. The median follow-up time was 3.9 years (25th and 75th percentiles 2.9 and 4.0). The relative hazard for a CV event ranged from 2.2 to 7.5 for BNP values of 40 to 99.9 and > or =100 pg/ml (p &lt;0.0001) compared to BNP &lt;40 pg/ml. Similarly, CAC score was also highly predictive of CV events, with elevated hazard ratios of 2.8- to 48.7-fold for scores of 11 to 100 to > or =1,000 (p &lt;0.0001) compared to no CAC. In a stepwise model, BNP was the second greatest estimator of CV outcomes (p = 0.016) after CAC (p &lt;0.0001), even in models that included blood pressure and age. Hypertension, age > or =65 years, and CAC contained 28.4%, 40.7%, and 56.8%, respectively, of BNP risk. The combination of BNP > or =100 pg/ml and CAC score > or =400 identified 52.4% and 35.7% of CV events in patients with hypertension and in elderly patients beyond the Framingham risk score. In conclusion, BNP and CAC are independently predictive of CV events</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. lshaw3@emory.eduJC - 3dq, 0207277CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19840570</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 104(9):1245-50, 2009 Nov 1.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>406</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Shaw,L.J.</style></author><author><style face="normal" font="default"> Min,J.K.</style></author><author><style face="normal" font="default"> Budoff,M.</style></author><author><style face="normal" font="default"> Gransar,H.</style></author><author><style face="normal" font="default"> Rozanski,A.</style></author><author><style face="normal" font="default"> Hayes,S.W.</style></author><author><style face="normal" font="default"> Friedman,J.D.</style></author><author><style face="normal" font="default"> Miranda,R.</style></author><author><style face="normal" font="default"> Wong,N.D.</style></author><author><style face="normal" font="default"> Berman,D.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Induced cardiovascular procedural costs and resource consumption patterns after coronary artery calcium screening: results from the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) study</style></title><secondary-title><style face="normal" font="default">Journal of the American College of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of the American College of Cardiology</style></full-title></periodical><pages end="1267" start="1258">1258-1267</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">14</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Mass Screening/ec [Economics]</style></keyword><keyword><style face="normal" font="default"> 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)</style></keyword><keyword><style face="normal" font="default"> 0 (Platelet Aggregation Inhibitors)</style></keyword><keyword><style face="normal" font="default"> 50-78-2 (Aspirin)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Aspirin/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography/ut [Utilization]</style></keyword><keyword><style face="normal" font="default"> Costs and Cost Analysis</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Drug Utilization</style></keyword><keyword><style face="normal" font="default"> Echocardiography,Stress/ut [Utilization]</style></keyword><keyword><style face="normal" font="default"> Electrocardiography/ut [Utilization]</style></keyword><keyword><style face="normal" font="default"> Exercise Test/ut [Utilization]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Platelet Aggregation Inhibitors/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> United States/ep [Epidemiology]</style></keyword></keywords><dates><year Day="29" Month="9" Year="2009">2009/9/29</year></dates><abstract><style face="normal" font="default">OBJECTIVES: We prospectively evaluated procedural costs and resource consumption patterns in the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) study after coronary calcium (CAC) measurements. BACKGROUND: Controversy surrounds expansion of cardiovascular disease (CVD) screening to include atherosclerosis imaging as the result of concern whether induced costs will outweigh any benefit. METHODS: Detailed risk factor and CAC measurements with 4-year follow-up for CVD death or myocardial infarction and procedures were performed. Costs were estimated with the use of Medicare reimbursement rates (discounted and inflation corrected). Cox survival analysis was used to estimate procedures and events. RESULTS: CAC scores varied widely but were skewed toward low scores with 56.7% of screened subjects having CAC scores&lt;or=10 and only 8.2% having CAC scores>or=400. Noninvasive testing was infrequent and medical costs were low among subjects with low CAC scores, both rising progressively with increasing CAC scores (p&lt;0.001), particularly in the 31 (2.2% of subjects) that had CAC scores>or=1,000. Similarly, invasive coronary angiography rose progressively with increasing scores (p&lt;0.001) but occurred exclusively among subjects first undergoing noninvasive testing and overall, was performed in only 19.4% of subjects with CAC scores>or=1,000. CONCLUSIONS: CAC scanning is associated with a marked differential in downstream frequency of medical tests and costs, ranging from a very low frequency of testing and invasive procedures among a predominantly large percentage of subjects with low CAC scores, to selectively concentrated testing and procedures among a small number of subjects with CAC scores>400. Thus, CAC scanning appears to foster efficient selective testing patterns among asymptomatic individuals at risk for CVD</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Emory University School of Medicine, Atlanta, Georgia, USACM - Comment in: J Am Coll Cardiol. 2009 Sep 29;54(14):1268-70; PMID: 19778668]JC - h50, 8301365CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19778667</style></custom1><custom3><style face="normal" font="default">AS - J Am Coll Cardiol. 54(14):1258-67, 2009 Sep 29.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>475</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Shea,M.K.</style></author><author><style face="normal" font="default"> O'Donnell,C.J.</style></author><author><style face="normal" font="default"> Hoffmann,U.</style></author><author><style face="normal" font="default"> Dallal,G.E.</style></author><author><style face="normal" font="default"> wson-Hughes,B.</style></author><author><style face="normal" font="default"> Ordovas,J.M.</style></author><author><style face="normal" font="default"> Price,P.A.</style></author><author><style face="normal" font="default"> Williamson,M.K.</style></author><author><style face="normal" font="default"> Booth,S.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Vitamin K supplementation and progression of coronary artery calcium in older men and women</style></title><secondary-title><style face="normal" font="default">American Journal of Clinical Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Clinical Nutrition</style></full-title></periodical><pages end="1807" start="1799">1799-1807</pages><volume><style face="normal" font="default">89</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Calcium-Binding Proteins/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> *Dietary Supplements</style></keyword><keyword><style face="normal" font="default"> *Extracellular Matrix Proteins/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Vitamin K/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Vitamins/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> 0 (Calcium-Binding Proteins)</style></keyword><keyword><style face="normal" font="default"> 0 (Extracellular Matrix Proteins)</style></keyword><keyword><style face="normal" font="default"> 0 (Interleukin-6)</style></keyword><keyword><style face="normal" font="default"> 0 (matrix Gla protein)</style></keyword><keyword><style face="normal" font="default"> 0 (Osteoprotegerin)</style></keyword><keyword><style face="normal" font="default"> 0 (Vitamins)</style></keyword><keyword><style face="normal" font="default"> 12001-79-5 (Vitamin K)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 9007-41-4 (C-Reactive Protein)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aging</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> C-Reactive Protein/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> Double-Blind Method</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Interleukin-6/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Osteoprotegerin/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Postmenopause</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Vitamin K/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Vitamin K/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> Vitamins/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Vitamins/pd [Pharmacology]</style></keyword></keywords><dates><year Day="0" Month="6" Year="2009">2009/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: Coronary artery calcification (CAC) is an independent predictor of cardiovascular disease. A preventive role for vitamin K in CAC progression has been proposed on the basis of the properties of matrix Gla protein (MGP) as a vitamin K-dependent calcification inhibitor. OBJECTIVE: The objective was to determine the effect of phylloquinone (vitamin K1) supplementation on CAC progression in older men and women. DESIGN: CAC was measured at baseline and after 3 y of follow-up in 388 healthy men and postmenopausal women; 200 received a multivitamin with 500 microg phylloquinone/d (treatment), and 188 received a multivitamin alone (control). RESULTS: In an intention-to-treat analysis, there was no difference in CAC progression between the phylloquinone group and the control group; the mean (+/-SEM) changes in Agatston scores were 27 +/- 6 and 37 +/- 7, respectively. In a subgroup analysis of participants who were > or =85% adherent to supplementation (n = 367), there was less CAC progression in the phylloquinone group than in the control group (P = 0.03). Of those with preexisting CAC (Agatston score > 10), those who received phylloquinone supplements had 6% less progression than did those who received the multivitamin alone (P = 0.04). Phylloquinone-associated decreases in CAC progression were independent of changes in serum MGP. MGP carboxylation status was not determined. CONCLUSIONS: Phylloquinone supplementation slows the progression of CAC in healthy older adults with preexisting CAC, independent of its effect on total MGP concentrations. Because our data are hypothesis-generating, further studies are warranted to clarify this mechanism. This trial was registered at clinicaltrials.gov as NCT00183001</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - US Department of Agriculture, Human Nutrition Research Center on Aging, Tufts University, Boston, MA 02111, USAJC - 3ey, 0376027CP - United StatesPT - Journal ArticlePT - Randomized Controlled TrialPT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tPT - Research Support, U.S. Gov't, Non-P.H.SSI - ClinicalTrials.govSA - ClinicalTrials.gov/NCT00183001NO - AG14759 (United States NIA NIH HHS)NO - HL69272 (United States NHLBI NIH HHS)NO - T32HL69772 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19386744</style></custom1><custom3><style face="normal" font="default">AS - Am J Clin Nutr. 89(6):1799-807, 2009 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>153</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Shi,X.M.</style></author><author><style face="normal" font="default"> Yin,Z.X.</style></author><author><style face="normal" font="default"> Qian,H.Z.</style></author><author><style face="normal" font="default"> Zhai,Y.</style></author><author><style face="normal" font="default"> Liu,Y.Z.</style></author><author><style face="normal" font="default"> Xu,J.W.</style></author><author><style face="normal" font="default"> Zeng,Y.</style></author></authors></contributors><titles><title><style face="normal" font="default">[A study on chronic diseases and other related health indicators of centenarians in longevity areas in China]. [Chinese]</style></title><secondary-title><style face="normal" font="default">Chung-Hua Yu Fang i Hsueh Tsa Chih [Chinese Journal of Preventive Medicine]</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Chung-Hua Yu Fang i Hsueh Tsa Chih [Chinese Journal of Preventive Medicine]</style></full-title></periodical><pages end="107" start="101">101-107</pages><volume><style face="normal" font="default">44</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Chronic Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Health Status Indicators</style></keyword><keyword><style face="normal" font="default"> *Longevity</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> China/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Dyslipidemias/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Food Habits</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword></keywords><dates><year Day="0" Month="2" Year="2010">2010/2</year></dates><isbn><style face="normal" font="default">0253-9624</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: To describe chronic diseases and other related health indicators of centenarians, compare these health indicators with other age groups in longevity areas in China. METHODS: Residents who participated in the project of Chinese Longitudinal Healthy Longevity Survey (CLHLS) conducted in 2008 - 2009 were selected from 7 Longevity Areas.2029 people aged 40 and over attended the study from March to June, 2009, including 469 aged 40 and over, 436 aged 60 and over, 346 aged 80 and over, 380 aged 90 and over, 398 centenarians. Information, including socio-demographic, were collected by self-designed questionnaire. Calibrated instruments were used by the clinical personnel who had worked over 3 years to manually check subjects' health. Venous blood and urine samples were collected for blood and urine routine test, plasma macro and trace elements test, plasma biological test, using standard methods such as instrument analysis, atomic absorption spectrometry. Data analysis was conducted using descriptive statistical methods. RESULTS: In the groups aged 40 and over, 60 and over, 80 and over, 90 and over, 100 and over, the body mass index (BMI) were (23.2 +/- 4.6), (22.1 +/- 3.7), (20.2 +/- 3.4), (20.2 +/- 3.9) and (19.1 +/- 5.0) kg/m(2) in males (F = 22.78, P &lt; 0.01) and (23.3 +/- 4.0), (21.6 +/- 3.5), (19.7 +/- 3.9), (19.0 +/- 4.8), (18.4 +/- 3.8) kg/m(2) in females (F = 51.84, P &lt; 0.01); the prevalence of hypertension were 38.3% (80/209), 60.8% (166/273), 63.5% (106/167), 61.8% (68/110), 54.8% (34/62) in males (chi(2) = 34.26, P &lt; 0.01) and 32.3% (84/260), 60.1% (98/163), 69.8% (125/179), 61.5% (166/270), 58.9% (198/336) in females (chi(2) = 78.45, P &lt; 0.01); the prevalence of diabetes were 10.5% (22/209), 12.5% (34/273), 9.0% (15/167), 18.2% (20/110), 12.9% (8/62) in males (chi(2) = 5.92, P = 0.20) and 4.2% (11/260), 15.3% (25/163), 10.1% (18/179), 12.2% (33/270), 7.4% (25/336) in females (chi(2) = 19.25, P &lt; 0.01). In groups aged 40 and over, 90 and over, 100 and over, the superoxide dismutase (SOD) activity were (29.03 +/- 5.79), (30.93 +/- 5.39), (31.63 +/- 5.92) U/ml in males (F = 4.40, P &lt; 0.05) and (28.27 +/- 6.25), (30.86 +/- 5.72), (31.55 +/- 5.25) U/ml in females (F = 13.13, P &lt; 0.05); levels of plasma calcium were (3.63 +/- 1.08), (3.09 +/- 0.91), (3.34 +/- 1.07) mmol/L in males (F = 5.71, P &lt; 0.01) and (3.84 +/- 1.02), (3.19 +/- 1.16), (3.38 +/- 1.16) mmol/L in females (F = 11.61, P &lt; 0.01); levels of selenium were (1.44 +/- 0.86), (1.28 +/- 0.60), (1.75 +/- 0.57)micromol/L in males (F = 3.79, P &lt; 0.05) and (1.44 +/- 0.80), (1.48 +/- 0.81), (1.78 +/- 0.80) micromol/L in females (F = 8.69, P &lt; 0.01); levels of iron were (63.25 +/- 49.05), (71.86 +/- 54.16), (138.36 +/- 77.60) micromol/L in males (F = 22.78, P &lt; 0.01) and (64.86 +/- 57.72), (74.56 +/- 56.93), (106.56 +/- 74.08) micromol/L in females (F = 17.88, P &lt; 0.01); levels of copper were (23.49 +/- 12.85), (17.96 +/- 7.57), (22.33 +/- 6.89) micromol/L in males (F = 5.18, P &lt; 0.01) and (21.52 +/- 10.63), (19.60 +/- 9.57), (22.99 +/- 8.71) micromol/L in females (F = 5.68, P &lt; 0.01); positive rates of high-sensitivity c-reactive protein (hsCRP) were 5.5% (8/146), 24.0% (18/75), 31.3% (10/32) in males (chi(2) = 22.62, P &lt; 0.01) and 9.8% (12/122), 19.6% (40/204), 25.1% (49/195) in females (chi(2) = 11.24, P &lt; 0.01). CONCLUSION: The results indicate that the centenarians have lower chronic diseases risks and higher anti-oxidants activity compared with other age groups, and have a high level of nutritional elements compared with those aged 90 and over. However, it is more common for them suffering from inflammation</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Chronic Diseases Control and Community Health, Chinese Center for Disease Control and Prevention, Beijing 102206, China. sxmcdc@163.comJC - d74, 7904962CP - ChinaPT - English AbstractPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - Chinese</style></notes><urls/><custom1><style face="normal" font="default">UI - 20388328</style></custom1><custom3><style face="normal" font="default">AS - Chung Hua Yu Fang I Hsueh Tsa Chih. 44(2):101-7, 2010 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>298</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Shimony,A.</style></author><author><style face="normal" font="default"> Zahger,D.</style></author><author><style face="normal" font="default"> Van,Straten M.</style></author><author><style face="normal" font="default"> Shalev,A.</style></author><author><style face="normal" font="default"> Gilutz,H.</style></author><author><style face="normal" font="default"> Ilia,R.</style></author><author><style face="normal" font="default"> Cafri,C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Incidence, risk factors, management and outcomes of coronary artery perforation during percutaneous coronary intervention</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="1677" start="1674">1674-1677</pages><volume><style face="normal" font="default">104</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Angioplasty,Transluminal,Percutaneous Coronary/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/in [Injuries]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Stents</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="15" Month="12" Year="2009">2009/12/15</year></dates><abstract><style face="normal" font="default">Coronary artery perforation (CP) is a rare, sometimes lethal complication of percutaneous coronary intervention. There are limited controlled contemporary data regarding its predictors, incidence, and outcomes. The aim of this study was to define the incidence, associated factors, and outcomes of CP in the current era of coronary intervention. All patients who had CP during percutaneous coronary intervention at a large tertiary center from January 2001 to December 2008 were identified. Demographic, clinical, and procedural data and outcome variables were obtained. Patients with CP were compared with a randomly assigned control group. Fifty-seven patients with CP were identified among 9,568 interventions performed during the study period (0.59%); these patients were compared with 171 who underwent percutaneous coronary intervention without CP. Vessels were perforated by wires (52.6%), balloons (26.3%), and stents (21.1%). Perforations were classified using the Ellis classification. CP was associated with mortality and tamponade rates of 7% and 16%, respectively, but all these serious complications occurred with grade III perforations. Most grade I and II perforations were managed conservatively. Multivariate analysis identified the treatment of chronic total occlusion as the strongest independent predictor of CP; other independent variables included calcium in the coronary artery that was the site of intervention and non-ST elevation myocardial infarction</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Soroka University Medical Center, Ben Gurion University of the Negev, Be'er Sheva, Israel. ashimony@bgu.ac.ilJC - 3dq, 0207277CP - United StatesPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19962473</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 104(12):1674-7, 2009 Dec 15.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>136</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Shin,E.S.</style></author><author><style face="normal" font="default"> Garcia-Garcia,H.M.</style></author><author><style face="normal" font="default"> Serruys,P.W.</style></author></authors></contributors><titles><title><style face="normal" font="default">A new method to measure necrotic core and calcium content in coronary plaques using intravascular ultrasound radiofrequency-based analysis</style></title><secondary-title><style face="normal" font="default">The International Journal of Cardiovascular Imaging</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">The International Journal of Cardiovascular Imaging</style></full-title></periodical><pages end="396" start="387">387-396</pages><volume><style face="normal" font="default">26</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Image Interpretation,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> *Ultrasonography,Interventional/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Angina,Unstable/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Angina,Unstable/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Angioplasty,Transluminal,Percutaneous Coronary</style></keyword><keyword><style face="normal" font="default"> Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">Although previous intravascular ultrasound (IVUS) radiofrequency-based analysis data showed acceptable reproducibility for plaque composition, measurements are not easily obtained, particularly that of lumen contour, because of the limited IVUS resolution. The purpose of this study was to compare a new measurement method (Shin's method) and the conventional measurement method for necrotic core and calcium content in atherosclerotic lesions using Virtual Histology-intravascular ultrasound (VH-IVUS). Fifty-seven patients with unstable angina who underwent elective percutaneous coronary intervention were included. Shin's method focuses on catheter contour, instead of lumen contour, and vessel contour. Patients ages ranged from 46 to 88 years, and 34 were men. A total of 1,401 frames from 59 culprit lesions were assessed. There were no significant differences in the mean area and volume of necrotic core and dense calcium between the two methods. Correlation coefficients (R) were >or=0.99 for all above mentioned parameters (P &lt; 0.001). Between methods, the absolute differences in mean area and volume of necrotic core were 0.02 +/- 0.02 mm(2) and 0.34 +/- 0.29 mm(3), respectively, while for mean area and volume of dense calcium, the absolute differences were 0.04 +/- 0.07 mm(2) and 0.36 +/- 0.52 mm(3), respectively. The reproducibility of Shin's method was excellent. For area of the necrotic core and dense calcium, the means of the differences between the two measurements were nearly zero, and the reproducibility coefficients were within 1% of the means of the two measurements. Mean analysis time for both measurements was 26.8 +/- 6.7 min/segment in the conventional method and 3.3 +/- 0.6 min/segment in Shin's method. Shin's method for measurement of necrotic core and dense calcium using VH-IVUS demonstrated a good correlation with the conventional method and excellent reproducibility. Also, Shin's method required a significantly shorter analysis time than the conventional method. Therefore, Shin's method could replace the conventional method for necrotic core and calcium measurement in atherosclerotic lesions, and it might be useful in the catheterization laboratory for online clinical decision</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Ulsan University Hospital, Thoraxcenter, Erasmus Medical Center, Ulsan, South Korea. sesim98@yahoo.co.krJC - 100969716CP - United StatesPT - Comparative StudyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20063068</style></custom1><custom3><style face="normal" font="default">AS - Int J Cardiovasc Imaging. 26(4):387-96, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>327</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Silvera,S.S.</style></author><author><style face="normal" font="default"> Aidi,H.E.</style></author><author><style face="normal" font="default"> Rudd,J.H.</style></author><author><style face="normal" font="default"> Mani,V.</style></author><author><style face="normal" font="default"> Yang,L.</style></author><author><style face="normal" font="default"> Farkouh,M.</style></author><author><style face="normal" font="default"> Fuster,V.</style></author><author><style face="normal" font="default"> Fayad,Z.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Multimodality imaging of atherosclerotic plaque activity and composition using FDG-PET/CT and MRI in carotid and femoral arteries</style></title><secondary-title><style face="normal" font="default">Atherosclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Atherosclerosis</style></full-title></periodical><pages end="143" start="139">139-143</pages><volume><style face="normal" font="default">207</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Carotid Artery Diseases/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Femoral Artery</style></keyword><keyword><style face="normal" font="default"> *Fluorodeoxyglucose F18/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> *Inflammation/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Magnetic Resonance Angiography</style></keyword><keyword><style face="normal" font="default"> *Positron-Emission Tomography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Radiopharmaceuticals/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> 0 (Lipids)</style></keyword><keyword><style face="normal" font="default"> 0 (Radiopharmaceuticals)</style></keyword><keyword><style face="normal" font="default"> 63503-12-8 (Fluorodeoxyglucose F18)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 9007-34-5 (Collagen)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Carotid Artery Diseases/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Collagen/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Femoral Artery/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> Femoral Artery/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Femoral Artery/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Femoral Artery/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Inflammation/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Lipids/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="11" Year="2009">2009/11</year></dates><abstract><style face="normal" font="default">PURPOSE: To evaluate the relationship between atherosclerotic plaque inflammation, as assessed by FDG-positron emission tomography/computed tomography (FDG-PET/CT), and plaque morphology and composition, as assessed by magnetic resonance imaging (MRI), in the carotid and femoral arteries. MATERIALS AND METHODS: Sixteen patients underwent FDG-PET/CT and MRI (T2-weighted (T2W) and proton density weighted (PDW)) of the carotid and femoral arteries. For every image slice, two observers determined the corresponding regions of the FDG-PET/CT and MRI image sets by matching CT and T2W axial images. Each plaque was then classified into one of three groups according to the CT appearance and T2W/PDW signal: (1) collagen, (2) lipid-necrotic core and (3) calcium. Arterial FDG uptake was measured for each plaque and normalized to vein FDG activity to produce a blood-normalized artery activity called the target to background ratio (TBR). The vessel wall thickness (VWT), the vessel wall area and the total vessel wall area were measured from the T2W MR images. RESULTS: The TBR value was higher in the lipid-necrotic core group compared to the collagen and calcium groups, (p&lt;0.001). The lipid-necrotic core group demonstrated a significant TBR variation according to the median of the VWT (TBR=1.26+/-0.25 vs. 1.50+/-0.12). There was no correlation with other morphological MR parameters. CONCLUSIONS: This study demonstrates the complementary value of non-invasive FDG-PET/CT and MR imaging for the evaluation of atherosclerotic plaque composition and activity. Lipid-rich plaques are more inflamed than either calcified or collagen-rich plaques</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Sinai Translational and Molecular Imaging Institute and Imaging Science Laboratories, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USAJC - 95x, 0242543CP - IrelandPT - Comparative StudyPT - Evaluation StudiesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - R01 HL71021R01 (United States NHLBI NIH HHS)NO - R01 HL78667 (United States NHLBI NIH HHS)NO - (United Kingdom British Heart Foundation)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19467659</style></custom1><custom3><style face="normal" font="default">AS - Atherosclerosis. 207(1):139-43, 2009 Nov.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>555</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Sin'kov,A.V.</style></author><author><style face="normal" font="default"> Sin'kova,G.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Prevalence of arterial hypertension and drawbacks of antihypertensive therapy in Irkutsk region]. [Russian]</style></title><secondary-title><style face="normal" font="default">Klinicheskaia Meditsina</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Klinicheskaia Meditsina</style></full-title></periodical><pages end="69" start="67">67-69</pages><volume><style face="normal" font="default">86</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Antihypertensive Agents/sd [Supply &amp; Distribution]</style></keyword><keyword><style face="normal" font="default"> *Hypertension/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> 0 (Antihypertensive Agents)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Antihypertensive Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> Delivery of Health Care</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Russia</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Siberia/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="0" Year="2008">2008</year></dates><isbn><style face="normal" font="default">0023-2149</style></isbn><abstract><style face="normal" font="default">The aim of this study was to assess the level of awareness, quality of treatment and control of arterial hypertension (AH) and to analyse results of antihypertensive therapy in rural and distant areas of Irkutsk region. A total of 560 residents of these areas aged 19-95 (mean 60.3 +/- 13.6) years (148 men and 412 women) were examined from October 2004 till December 2005. They were people in whom screening studies revealed arterial pressure (AP) > = 140/90 mm Hg and/or intake of antihypertensive drugs (AHD). On the average, 78.2% of them (95% CI = 74.8-81.8%) were aware of their elevated AP, the mean AHD intake rate was 71.3% (95% CI = 67.6-75.1%). A drop of AP to &lt; 140/90 mm Hg was achieved only in 3.8% of the subjects using AHD. The frequency of intake of AHD of different pharmacological classes (in percentage of subjects using them) was 65.4% for ACE inhibitors, 26.3% for beta-blockers, 24.1% for diuretics. AHD of previous generations (drugs with central myotropic activity, spasmolytics) were used by 19.6% of the subjects, calcium antagonists by 15.8%. Monotherapy was reported by 61.9% and combined therapy by 38.1%. It is concluded that overall quality of AH control in residents of rural and distant areas is rather poor despite a relatively high level of awareness of AH and frequency of its treatment. This situation is related to low efficiency of antihypertensive therapy attributable to poor compliance with recommendations of international societies of cardiologists as regards the choice of optimal starting treatment, to the predominance of monotherapy, and rare use of long-acting AHDs or rational combinations of AHDs</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)JC - kw2, 2985204rCP - Russia (Federation)PT - Comparative StudyPT - English AbstractPT - Journal ArticleLG - Russian</style></notes><urls/><custom1><style face="normal" font="default">UI - 19227314</style></custom1><custom3><style face="normal" font="default">AS - Klin Med (Mosk). 86(12):67-9, 2008.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>450</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Sirohiwal,D.</style></author><author><style face="normal" font="default"> Dahiya,K.</style></author><author><style face="normal" font="default"> Khaneja,N.</style></author></authors></contributors><titles><title><style face="normal" font="default">Use of 24-hour urinary protein and calcium for prediction of preeclampsia</style></title><secondary-title><style face="normal" font="default">Taiwanese Journal of Obstetrics &amp; Gynecology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Taiwanese Journal of Obstetrics &amp; Gynecology</style></full-title></periodical><pages end="115" start="113">113-115</pages><volume><style face="normal" font="default">48</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> *Pre-Eclampsia/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Pre-Eclampsia/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> *Proteinuria/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Proteinuria/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Diagnostic Techniques,Obstetrical and Gynecological</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Pre-Eclampsia/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Proteinuria</style></keyword><keyword><style face="normal" font="default"> Proteinuria/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> ROC Curve</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Urine</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="6" Year="2009">2009/6</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To assess the efficacy of 24-hour urinary protein and calcium for the prediction of preeclampsia. MATERIALS AND METHODS: Two hundred normotensive women at 20-28 weeks' gestation were enrolled in the study. All women were asked to collect a 24-hour urine sample. Urinary protein and calcium were measured and expressed as milligrams per 24 hours. Sensitivity, specificity and predictive values were calculated for each test, and cutoff values were calculated using receiver operating characteristic curves. RESULTS: Twenty-one of the 200 women developed preeclampsia, including eight who developed severe preeclampsia and 13 who developed mild preeclampsia. Compared with the normotensive women (n = 179), the hypertensive patients (n = 21) had significantly lower urinary calcium excretion (167.23 +/- 80.63 mg vs. 277.43 +/- 60.38 mg) and higher proteinuria (351.14 +/- 41.58 mg vs. 296.33 +/- 30.03 mg). CONCLUSION: A decrease in 24-hour urinary calcium and increase in protein between 20-28 weeks' gestation are risk factors for preeclampsia</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Obstetrics and Gynecology, Pandit Bhagwat Dayal Sharma, Post-Graduate Institute of Medical Sciences, Rohtak, IndiaJC - 101213819CP - ChinaPT - Controlled Clinical TrialPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19574169</style></custom1><custom3><style face="normal" font="default">AS - Taiwan. j. obstet. gynecol.. 48(2):113-5, 2009 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>192</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Slojewski,M.</style></author><author><style face="normal" font="default"> Czerny,B.</style></author><author><style face="normal" font="default"> Safranow,K.</style></author><author><style face="normal" font="default"> dzik,M.</style></author><author><style face="normal" font="default"> Pawlik,A.</style></author><author><style face="normal" font="default"> Jakubowska,K.</style></author><author><style face="normal" font="default"> Olszewska,M.</style></author><author><style face="normal" font="default"> Golab,A.</style></author><author><style face="normal" font="default"> Byra,E.</style></author><author><style face="normal" font="default"> Chlubek,D.</style></author><author><style face="normal" font="default"> Sikorski,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Does smoking have any effect on urinary stone composition and the distribution of trace elements in urine and stones?</style></title><secondary-title><style face="normal" font="default">Urological Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Urological Research</style></full-title></periodical><pages end="322" start="317">317-322</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Smoking</style></keyword><keyword><style face="normal" font="default"> *Trace Elements/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Urinary Calculi/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> 0 (Trace Elements)</style></keyword><keyword><style face="normal" font="default"> 7439-97-6 (Mercury)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Mercury/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Smoking/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Urine</style></keyword><keyword><style face="normal" font="default"> Urolithiasis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Urolithiasis/me [Metabolism]</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><abstract><style face="normal" font="default">The role of particular elements in lithogenesis is still unclear and debated. Probably some of them may promote or conversely inhibit crystal nucleation of organic or mineral species. A few epidemiological data link smoking with the risk of calcium stones. The aim of this hospital-based study was to evaluate the distribution of trace elements in urine and urinary stones, and possible correlation with stone constituents in smoking and non-smoking individuals. 209 stones and urine samples collected from idiopathic stone-formers were analyzed to evaluate the mineral composition and the distribution of elements, 29 in stones and 21 in urine. Values were statistically compared considering smoking, arterial hypertension and coronary heart disease as grouping variables. No differences were noted either for comparison of mineral components or the elements concentrations in stones in both groups. The concentration of mercury in urine was higher in smokers than in non-smokers, but the statistical significance was at the moderate level. Our findings do not support the concept of possible association between smoking and urinary lithogenesis, but we believe that further investigations are needed in this area</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Urology, Pomeranian Medical University, ul. Powstancow Wlkp. 72, 70-111, Szczecin, Poland. mslojewski@csv.plJC - wrx, 0364311CP - GermanyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19826801</style></custom1><custom3><style face="normal" font="default">AS - Urol Res. 37(6):317-22, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>240</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Solus,J.</style></author><author><style face="normal" font="default"> Chung,C.P.</style></author><author><style face="normal" font="default"> Oeser,A.</style></author><author><style face="normal" font="default"> Avalos,I.</style></author><author><style face="normal" font="default"> Gebretsadik,T.</style></author><author><style face="normal" font="default"> Shintani,A.</style></author><author><style face="normal" font="default"> Raggi,P.</style></author><author><style face="normal" font="default"> Sokka,T.</style></author><author><style face="normal" font="default"> Pincus,T.</style></author><author><style face="normal" font="default"> Stein,C.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Amino-terminal fragment of the prohormone brain-type natriuretic peptide in rheumatoid arthritis</style></title><secondary-title><style face="normal" font="default">Arthritis &amp; Rheumatism</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Arthritis &amp; Rheumatism</style></full-title></periodical><pages end="2669" start="2662">2662-2669</pages><volume><style face="normal" font="default">58</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Arthritis,Rheumatoid/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Inflammation/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Natriuretic Peptide,Brain/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Peptide Fragments/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Interleukin-1)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipids)</style></keyword><keyword><style face="normal" font="default"> 0 (Peptide Fragments)</style></keyword><keyword><style face="normal" font="default"> 0 (pro-brain natriuretic peptide (1-76))</style></keyword><keyword><style face="normal" font="default"> 0 (Tumor Necrosis Factor-alpha)</style></keyword><keyword><style face="normal" font="default"> 114471-18-0 (Natriuretic Peptide,Brain)</style></keyword><keyword><style face="normal" font="default"> 9007-41-4 (C-Reactive Protein)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Arthritis,Rheumatoid/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> C-Reactive Protein/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Inflammation/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Interleukin-1/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Lipids/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Statistics,Nonparametric</style></keyword><keyword><style face="normal" font="default"> Tumor Necrosis Factor-alpha/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="9" Year="2008">2008/9</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Increased concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP) are associated with cardiovascular morbidity and mortality, but little is known about their relationship to chronic inflammation. Patients with rheumatoid arthritis (RA) have chronic inflammation, increased arterial stiffness, and accelerated coronary atherosclerosis. This study was undertaken to test the hypothesis that NT-proBNP concentrations are elevated in patients with RA and are associated with coronary artery calcification and markers of inflammation. METHODS: In 159 patients with RA (90 with early RA and 69 with longstanding RA) without heart failure and 88 control subjects, serum concentrations of NT-proBNP, interleukin-6 (IL-6), and tumor necrosis factor alpha (TNFalpha) were measured and coronary calcification was assessed. Associations between NT-proBNP levels and the other parameters were investigated. RESULTS: NT-proBNP concentrations were elevated in patients with longstanding RA (median 142.8 pg/ml [interquartile range 54.8-270.5]) and those with early RA (median 58.1 pg/ml [interquartile range 19.4-157.6]) compared with controls (18.1 [3.2-46.0]) (P &lt; 0.001). In patients with RA, NT-proBNP concentrations were associated with age (rho = 0.35, P &lt; 0.001), levels of IL-6 (rho = 0.33, P &lt; 0.001), TNFalpha (rho = 0.23, P = 0.003), and C-reactive protein (CRP) (rho = 0.21, P = 0.01), coronary calcium score (rho = 0.30, P &lt; 0.001), systolic blood pressure (rho = 0.30, P &lt; 0.001), and disease activity (rho = 0.29, P &lt; 0.001). After adjustment for age, race, and sex, the associations between NT-proBNP concentrations and disease activity, TNFalpha, IL-6, and CRP remained significant, but those with systolic blood pressure and coronary calcium score were attenuated. CONCLUSION: NT-proBNP concentrations are increased in patients with RA without clinical heart failure and may indicate subclinical cardiovascular disease and a chronic inflammatory state</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Vanderbilt University Medical Center, Nashville, Tennessee 37232-6602, USAJC - 0370605, 90mCP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - GM5-M01-RR-00095 (United States NIGMS NIH HHS)NO - HL-04012 (United States NHLBI NIH HHS)NO - HL-65082 (United States NHLBI NIH HHS)NO - HL-67964 (United States NHLBI NIH HHS)NO - K24 HL004012-09 (United States NHLBI NIH HHS)NO - R01 HL067964-04 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18759301</style></custom1><custom3><style face="normal" font="default">AS - Arthritis Rheum. 58(9):2662-9, 2008 Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>220</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">ssl,M.</style></author><author><style face="normal" font="default"> Versari,D.</style></author><author><style face="normal" font="default"> Hildebrandt,H.A.</style></author><author><style face="normal" font="default"> Bajanowski,T.</style></author><author><style face="normal" font="default"> Sangiorgi,G.</style></author><author><style face="normal" font="default"> Erbel,R.</style></author><author><style face="normal" font="default"> Ritman,E.L.</style></author><author><style face="normal" font="default"> Lerman,L.O.</style></author><author><style face="normal" font="default"> Lerman,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Segmental heterogeneity of vasa vasorum neovascularization in human coronary atherosclerosis</style></title><secondary-title><style face="normal" font="default">Jacc: Cardiovascular Imaging</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Jacc: Cardiovascular Imaging</style></full-title></periodical><pages end="40" start="32">32-40</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Stenosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Neovascularization,Pathologic/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Vasa Vasorum/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> 0 (Glycophorin)</style></keyword><keyword><style face="normal" font="default"> 0 (GYPA protein,human)</style></keyword><keyword><style face="normal" font="default"> 0 (Tumor Necrosis Factor-alpha)</style></keyword><keyword><style face="normal" font="default"> 0 (Vascular Endothelial Growth Factor A)</style></keyword><keyword><style face="normal" font="default"> 0 (VEGFA protein,human)</style></keyword><keyword><style face="normal" font="default"> 7439-89-6 (Iron)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Autopsy</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Coronary Stenosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Coronary Stenosis/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Coronary Stenosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> EC 1-14-13-39 (Nitric Oxide Synthase Type III)</style></keyword><keyword><style face="normal" font="default"> EC 1-14-13-39 (NOS3 protein,human)</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glycophorin/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Hemorrhage/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="default"> Iron/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Neovascularization,Pathologic/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Neovascularization,Pathologic/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Neovascularization,Pathologic/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide Synthase Type III/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Rupture</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tumor Necrosis Factor-alpha/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Vasa Vasorum/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> Vasa Vasorum/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Vascular Endothelial Growth Factor A/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> X-Ray Microtomography</style></keyword></keywords><dates><year Day="0" Month="1" Year="2010">2010/1</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Our aim was to investigate the role of coronary vasa vasorum (VV) neovascularization in the progression and complications of human coronary atherosclerotic plaques. BACKGROUND: Accumulating evidence supports an important role of VV neovascularization in atherogenesis and lesion location determination in coronary artery disease. VV neovascularization can lead to intraplaque hemorrhage, which has been identified as a promoter of plaque progression and complications like plaque rupture. We hypothesized that distinctive patterns of VV neovascularization and associated plaque complications can be found in different stages of human coronary atherosclerosis. METHODS: Hearts from 15 patients (age 52+/-5 years, mean+/-SEM) were obtained at autopsy, perfused with Microfil (Flow Tech, Inc., Carver, Massachusetts), and subsequently scanned with micro-computed tomography (CT). The 2-cm segments (n=50) were histologically classified as either normal (n=12), nonstenotic plaque (&lt;50% stenosis, n=18), calcified (n=10) or noncalcified (n=10) stenotic plaque. Micro-CT images were analyzed for VV density (number/mm2), VV vascular area fraction (mm2/mm2), and VV endothelial surface fraction (mm2/mm3). Histological sections were stained for Mallory's (iron), von Kossa (calcium), and glycophorin-A (erythrocyte fragments) as well as endothelial nitric oxide synthase, vascular endothelial growth factor, and tumor necrosis factor-alpha. RESULTS: VV density was higher in segments with nonstenotic and noncalcified stenotic plaques as compared with normal segments (3.36+/-0.45, 3.72+/-1.03 vs. 1.16+/-0.21, p&lt;0.01). In calcified stenotic plaques, VV spatial density was lowest (0.95+/-0.21, p&lt;0.05 vs. nonstenotic and noncalcified stenotic plaque). The amount of iron and glycophorin A was significantly higher in nonstenotic and stenotic plaques as compared with normal segments, and correlated with VV density (Kendall-Tau correlation coefficient 0.65 and 0.58, respectively, p&lt;0.01). Moreover, relatively high amounts of iron and glycophorin A were found in calcified plaques. Further immunohistochemical characterization of VV revealed positive staining for endothelial nitric oxide synthase and tumor necrosis factor-alpha but not vascular endothelial growth factor. CONCLUSIONS: Our results support a possible role of VV neovascularization, VV rupture, and intraplaque hemorrhage in the progression and complications of human coronary atherosclerosis. Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiovascular Diseases, Department of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USACM - Comment in: JACC Cardiovasc Imaging. 2010 Jan;3(1):41-4; PMID: 20129529JC - 101467978CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - DK73608 (United States NIDDK NIH HHS)NO - DK77013 (United States NIDDK NIH HHS)NO - HL085307 (United States NHLBI NIH HHS)NO - HL77131 (United States NHLBI NIH HHS)NO - K-24 HL69840-02 (United States NHLBI NIH HHS)NO - R01 EB000305 (United States NIBIB NIH HHS)NO - R01 HL63911 (United States NHLBI NIH HHS)NO - R01 HL65432 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20129528</style></custom1><custom3><style face="normal" font="default">AS - JACC Cardiovasc Imaging. 3(1):32-40, 2010 Jan.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>139</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Steadman,E.</style></author><author><style face="normal" font="default"> Raisch,D.W.</style></author><author><style face="normal" font="default"> Bennett,C.L.</style></author><author><style face="normal" font="default"> Esterly,J.S.</style></author><author><style face="normal" font="default"> Becker,T.</style></author><author><style face="normal" font="default"> Postelnick,M.</style></author><author><style face="normal" font="default"> McKoy,J.M.</style></author><author><style face="normal" font="default"> Trifilio,S.</style></author><author><style face="normal" font="default"> Yarnold,P.R.</style></author><author><style face="normal" font="default"> Scheetz,M.H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Evaluation of a potential clinical interaction between ceftriaxone and calcium</style></title><secondary-title><style face="normal" font="default">Antimicrobial Agents &amp; Chemotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Antimicrobial Agents &amp; Chemotherapy</style></full-title></periodical><pages end="1540" start="1534">1534-1540</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Calcium/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Ceftriaxone/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Ceftriaxone/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> 73384-59-5 (Ceftriaxone)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Adverse Drug Reaction Reporting Systems</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Causality</style></keyword><keyword><style face="normal" font="default"> Ceftriaxone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Chemical Precipitation</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Child,Preschool</style></keyword><keyword><style face="normal" font="default"> Drug Interactions</style></keyword><keyword><style face="normal" font="default"> Drug Toxicity</style></keyword><keyword><style face="normal" font="default"> Embolism/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> Infant,Newborn</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> United States Food and Drug Administration</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">In April 2009, the FDA retracted a warning asserting that ceftriaxone and intravenous calcium products should not be coadministered to any patient to prevent precipitation events leading to end-organ damage. Following that announcement, we sought to evaluate if the retraction was justified. A search of the FDA Adverse Event Reporting System was conducted to identify any ceftriaxone-calcium interactions that resulted in serious adverse drug events. Ceftazidime-calcium was used as a comparator agent. One hundred four events with ceftriaxone-calcium and 99 events with ceftazidime-calcium were identified. Adverse drug events were recorded according to the listed description of drug involvement (primary or secondary suspect) and were interpreted as probable, possible, unlikely, or unrelated. For ceftriaxone-calcium-related adverse events, 7.7% and 20.2% of the events were classified as probable and possible for embolism, respectively. Ceftazidime-calcium resulted in fewer probable embolic events (4%) but more possible embolic events (30.3%). Among cases that considered ceftriaxone or ceftazidime and calcium as the primary or secondary drug, one case was classified as a probable embolic event. That patient received ceftriaxone-calcium and died, although an attribution of causality was not possible. Our analysis suggests a lack of support for the occurrence of ceftriaxone-calcium precipitation events in adults. The results of the current analysis reinforce the revised FDA recommendations suggesting that patients >28 days old may receive ceftriaxone and calcium sequentially and provide a transparent and reproducible methodology for such evaluations</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Midwestern University Chicago College of Pharmacy, Downers Grove, Illinois 60515, USAJC - 6hk, c98, 0315061, 0116415CP - United StatesPT - Evaluation StudiesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - 1K01CA134554-01 (United States NCI NIH HHS)NO - 1R01CA 102713-01 (United States NCI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20086152</style></custom1><custom3><style face="normal" font="default">AS - Antimicrob Agents Chemother. 54(4):1534-40, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>361</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Stolzmann,P.</style></author><author><style face="normal" font="default"> Phan,C.</style></author><author><style face="normal" font="default"> Desbiolles,L.</style></author><author><style face="normal" font="default"> Lachat,M.</style></author><author><style face="normal" font="default"> Pfammatter,T.</style></author><author><style face="normal" font="default"> Marincek,B.</style></author><author><style face="normal" font="default"> Prokop,M.</style></author><author><style face="normal" font="default"> Alkadhi,H.</style></author></authors></contributors><titles><title><style face="normal" font="default">The heart of patients with aortic aneurysms: evidence from cardiac computed tomography</style></title><secondary-title><style face="normal" font="default">Interactive Cardiovascular &amp; Thoracic Surgery</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Interactive Cardiovascular &amp; Thoracic Surgery</style></full-title></periodical><pages end="773" start="769">769-773</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aortic Aneurysm,Abdominal/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Aortography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Stenosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Aortic Aneurysm,Abdominal/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Aortic Aneurysm,Abdominal/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Stenosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Coronary Stenosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Ventricular Function,Left</style></keyword></keywords><dates><year Day="0" Month="11" Year="2009">2009/11</year></dates><abstract><style face="normal" font="default">To determine in patients with abdominal aortic aneurysm (AAA) the coronary calcium burden and prevalence of coronary artery disease (CAD) in relation to cardiovascular risk factors, and to assess the left ventricular (LV) function using cardiac computed tomography (CT). Sixty consecutive patients (six females; 72.2+/-9.0 years) with AAA underwent dual-source CT calcium scoring and coronary angiography prior to AAA repair. In the 60 patients, the Framingham risk score (FRS) ranged from 5-43%. Twenty patients (33%) were at low, 16 (27%) at intermediate, and 24 (40%) at high risk for cardiovascular disease. The median Agatston score (AS) was 393 (0-3538). No significant correlation was found between AS and FRS (P=0.76). 846/851 coronary segments (99%) in 57/60 patients (95%) were depicted with a diagnostic image quality. Significant stenoses were found in 132/846 segments (16%) in 33/60 patients (55%). Five patients (8%) with significant coronary artery stenosis showed reduced LV function [ejection fraction (EF)&lt;50%]. The extent of CAD was significantly correlated with AS (r=0.43, P&lt;0.01), whereas no correlation was found for FRS (P=0.55). Cardiac CT is feasible in patients with AAA and allows for the assessment of coronary calcium, coronary stenoses, and LV function. The calcium burden and coronary stenoses assessment with cardiac CT provides incremental information beyond traditional cardiovascular risk factors alone</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Institute of Diagnostic Radiology, University Hospital Zurich, Zurich, Switzerland. paul.stolzmann@usz.chCM - Comment in: Interact Cardiovasc Thorac Surg. 2009 Nov;9(5):773-4; PMID: 19828652JC - 101158399CP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19706720</style></custom1><custom3><style face="normal" font="default">AS - Interact Cardiovasc Thorac Surg. 9(5):769-73, 2009 Nov.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>196</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Sugiura,S.</style></author><author><style face="normal" font="default"> Inaguma,D.</style></author><author><style face="normal" font="default"> Kitagawa,A.</style></author><author><style face="normal" font="default"> Murata,M.</style></author><author><style face="normal" font="default"> Kamimura,Y.</style></author><author><style face="normal" font="default"> Sendo,S.</style></author><author><style face="normal" font="default"> Hamaguchi,K.</style></author><author><style face="normal" font="default"> Nagaya,H.</style></author><author><style face="normal" font="default"> Tatematsu,M.</style></author><author><style face="normal" font="default"> Kurata,K.</style></author><author><style face="normal" font="default"> Yuzawa,Y.</style></author><author><style face="normal" font="default"> Matsuo,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Administration of alfacalcidol for patients with predialysis chronic kidney disease may reduce cardiovascular disease events</style></title><secondary-title><style face="normal" font="default">Clinical &amp; Experimental Nephrology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinical &amp; Experimental Nephrology</style></full-title></periodical><pages end="50" start="43">43-50</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiovascular Diseases/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Hydroxycholecalciferols/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure,Chronic/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> 0 (Hydroxycholecalciferols)</style></keyword><keyword><style face="normal" font="default"> 41294-56-8 (1-hydroxycholecalciferol)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Dialysis</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Kaplan-Meiers Estimate</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Renal Dialysis</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="2" Year="2010">2010/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: Besides its effect on calcium metabolism, vitamin D may play a part in preventing the onset and progression of cardiovascular disease (CVD) events. Only a few reports on the studies relating to whether vitamin D may reduce CVD events in patients with predialysis chronic kidney disease (CKD) are available, and many ambiguities remain. METHODS: We conducted a retrospective cohort study of 665 patients with predialysis CKD. With log-rank test using the Kaplan-Meyer survival curve, comparison of incidences of CVD events, CVD-related mortality, and all-cause mortality were made between patients in the alfacalcidol treatment group (107 patients) in the predialysis stage to whom alfacalcidol 0.25-0.5 microg/day was orally administered for at least 24 weeks, and patients in the nontreatment group (558 patients) who received no administration of alfacalcidol or other type of activated vitamin D and its analogues. Patients to whom alfacalcidol administration was discontinued within 24 weeks as well as initiation of dialysis of &lt;24 weeks were excluded for this study. Factors relating to CVD events were examined using Cox's proportional hazards analysis. RESULTS: The mean follow-up period was 55.1 +/- 38.9 months in the alfacalcidol treatment group and 41.9 +/- 38.4 months in the nontreatment group. CVD events occurred in 172 patients during the follow-up period, and 74 of those occurred during the predialysis period. In the alfacalcidol treatment group, the incidence of cumulative CVD events was significantly lower. In relation to all-cause deaths and CVD-related deaths, the cumulative mortality rate was significantly lower in the alfacalcidol treatment group during the follow-up period. Throughout the follow-up period, the association between CVD events and alfacalcidol use was detected when adjusted for age, sex, diabetes, hypertension, use of renin-angiotensin system inhibitors, estimated glomerular filtration rate, and albumin and parathyroid hormone. CONCLUSION: These data showed that oral administration of alfacalcidol for predialysis CKD patients was associated with reduced risk for CVD</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Nephrology and Rheumatology, Tosei General Hospital, 160 Nishioiwake-cho, Seto, Aichi, 489-8642, JapanJC - 9709923CP - JapanPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19882205</style></custom1><custom3><style face="normal" font="default">AS - Clin Exp Nephrol. 14(1):43-50, 2010 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>512</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Sukhija,R.</style></author><author><style face="normal" font="default"> Prayaga,S.</style></author><author><style face="normal" font="default"> Marashdeh,M.</style></author><author><style face="normal" font="default"> Bursac,Z.</style></author><author><style face="normal" font="default"> Kakar,P.</style></author><author><style face="normal" font="default"> Bansal,D.</style></author><author><style face="normal" font="default"> Sachdeva,R.</style></author><author><style face="normal" font="default"> Kesan,S.H.</style></author><author><style face="normal" font="default"> Mehta,J.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients</style></title><secondary-title><style face="normal" font="default">Journal of Investigative Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Investigative Medicine</style></full-title></periodical><pages end="499" start="495">495-499</pages><volume><style face="normal" font="default">57</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Blood Glucose/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> 0 (Blood Glucose)</style></keyword><keyword><style face="normal" font="default"> 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angiotensin-Converting Enzyme Inhibitors</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Databases,Factual</style></keyword><keyword><style face="normal" font="default"> Diabetes Complications/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Diabetes Complications/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Dyslipidemias/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Dyslipidemias/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Fasting</style></keyword><keyword><style face="normal" font="default"> Food Deprivation</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Hypertension/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Hypertension/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Veterans</style></keyword></keywords><dates><year Day="0" Month="3" Year="2009">2009/3</year></dates><isbn><style face="normal" font="default">1081-5589</style></isbn><abstract><style face="normal" font="default">BACKGROUND: The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) reduce serum cholesterol level and cardiovascular morbidity and mortality. However, the effect of statins on glucose metabolism is unclear. Some studies have suggested that statins may cause hyperglycemia by increasing calcium concentration in the islet cells leading to decrease in insulin release or by decreasing GLUT 4-mediated peripheral glucose uptake. METHODS: We analyzed the data in 345,417 patients (mean age 61 +/- 15 years, 94% males, 6% diabetic, 20% statin users) from the Veterans Affairs VISN 16 database. We studied change in fasting plasma glucose (FPG) in this population over a mean time of 2 years between the first available measurement and the last measurement form the most recent recorded visit. Data were limited to patients who had 2 FPG measurements. Diagnosis of diabetes had to be present before the first FPG measurement. RESULTS: Among patients without diabetes, FPG increased with statin use from 98 mg/dL to 105 mg/dL, and among nonstatin users, FPG increased from 97 mg/dL to 101 mg/dL (increase in FPG with statin use P &lt; 0.0001). Among patients with diabetes, FPG increased with statin use from 102 mg/dL to 141 mg/dL, and among nonstatin users, FPG increased from 100 mg/dL to 129 mg/dL (increase in FPG with statin use; P &lt; 0.0001). After adjustment for age and use of aspirin, beta-blockers, and angiotensin-converting enzyme inhibitors, the change in FPG in nondiabetic statin users was 7 mg/dL (vs 5 mg/dL in nonstatin users, P &lt; 0.0001) and for diabetic statin users it was 39 mg/dL (vs 32 in nonstatin users, P &lt; 0.0001). CONCLUSIONS: Statin use is associated with a rise of FPG in patients with and without diabetes. This relationship between statin use and rise in FPG is independent of age and use of aspirin, beta-blockers, and angiotensin-converting enzyme inhibitors</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiovascular Medicine, Central Arkansas Veterans Healthcare System and the University of Arkansas for Medical Sciences, Little Rock, AR 72205, USAJC - b9k, 9501229CP - CanadaPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19188844</style></custom1><custom3><style face="normal" font="default">AS - J Investig Med. 57(3):495-9, 2009 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>74</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Sun,L.</style></author><author><style face="normal" font="default"> L&amp;#x00FC</style></author><author><style face="normal" font="default"> SZ</style></author><author><style face="normal" font="default"> Jin,Z.N.</style></author><author><style face="normal" font="default"> Song,X.T.</style></author></authors></contributors><titles><title><style face="normal" font="default">Relationship between coronary artery remodeling and cumulative incidence of coronary angiographic lesions with vulnerable characteristics in patients with stable angina pectoris</style></title><secondary-title><style face="normal" font="default">Chinese Medical Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Chinese Medical Journal</style></full-title></periodical><pages end="876" start="871">871-876</pages><volume><style face="normal" font="default">123</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Angina Pectoris/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Angina Pectoris/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Ventricular Remodeling/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="5" Month="4" Year="2010">2010/4/5</year></dates><isbn><style face="normal" font="default">0366-6999</style></isbn><abstract><style face="normal" font="default">BACKGROUND: Development of vulnerable lesions is not limited to the target lesions, but a pan-coronary process. Such lesions are identified by positive remodeling (intravascular ultrasound (IVUS) and complex lesions (angiography)). The prevalence of lesions with vulnerable characteristics in patients with stable angina was not well known. The purpose of the present study was to evaluate the relationship between coronary artery remodeling and incidence of angiographic complex lesions and its calcification in stable angina patients. METHODS: One hundred and sixty-one stable angina patients (95 males, aged (68 +/- 11) years) with 161 de novo target lesions were studied using pre-interventional IVUS. Remodeling index was defined as the lesion divided by reference vessel area; positive remodeling was defined as remodeling index > 1.05. Besides the 161 target lesions, there were 613 angiographic lesions with > 30% diameter stenoses, classified as complex or smooth. Multiple complexes were defined as more than one complex lesion in one patient. Stenoses of at least 70% were described as tight. Calcium arc area was used as a new method to quantify coronary calcification. RESULTS: Fifty-six patients had positive remodeling target lesion, while 105 did not. The overall number of lesions with a diameter stenoses > 30% was similar in patients with or without positive remodeling, and the frequency of angiographically complex lesions was higher in positive remodeling patients, especially at non-target site. Calcium arc area was smaller in patients with positive remodeling. CONCLUSIONS: Positive remodeling on intravascular ultrasound was associated with more complex lesions angiographic findings, especially at non target site. Positive remodeling was found less calcified in patients with stable angina</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, ChinaJC - 0005256, d3b, 7513795CP - ChinaPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20497680</style></custom1><custom3><style face="normal" font="default">AS - Chin Med J. 123(7):871-6, 2010 Apr 5.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>51</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Sung,M.S.</style></author><author><style face="normal" font="default"> Kim,H.G.</style></author><author><style face="normal" font="default"> Woo,K.I.</style></author><author><style face="normal" font="default"> Kim,Y.D.</style></author></authors></contributors><titles><title><style face="normal" font="default">Ocular ischemia and ischemic oculomotor nerve palsy after vascular embolization of injectable calcium hydroxylapatite filler</style></title><secondary-title><style face="normal" font="default">Ophthalmic Plastic &amp; Reconstructive Surgery</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ophthalmic Plastic &amp; Reconstructive Surgery</style></full-title></periodical><pages end="291" start="289">289-291</pages><volume><style face="normal" font="default">26</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Anterior Eye Segment/bs [Blood Supply]</style></keyword><keyword><style face="normal" font="default"> *Biocompatible Materials/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Durapatite/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Embolism/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> *Ischemia/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> *Oculomotor Nerve Diseases/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> 0 (Biocompatible Materials)</style></keyword><keyword><style face="normal" font="default"> 1306-06-5 (Durapatite)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Blepharoptosis/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> Blepharoptosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Embolism/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Injections</style></keyword><keyword><style face="normal" font="default"> Ischemia/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Oculomotor Nerve Diseases/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Pain/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> Rhinoplasty</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Vision Disorders/ci [Chemically Induced]</style></keyword></keywords><dates><year Day="0" Month="7" Year="2010">2010/7</year></dates><abstract><style face="normal" font="default">A healthy 25-year-old man who received a calcium hydroxylapatite filler injection for nose augmentation by a dermatologist suddenly developed blepharoptosis and orbital pain on the right side, associated with progressive visual disturbance of the right eye. Patchy necrosis at the nose and glabella, limitations of extraocular movements, and anterior segment ischemia, as evidenced by conjunctival injection, chemosis, corneal edema, dilated pupil, hyphema, and hypopyon, were noted. Orbital CT demonstrated linear deposits of a similar density to bone in the right medial orbit and eyelid, suggestive of multiple emboli along the conjunctival vessels. A provisional diagnosis of ocular ischemia and ischemic oculomotor nerve palsy secondary to vascular embolization was made. After 3 months, visual acuity, all intraocular inflammation, oculomotor nerve palsy, and skin necrosis resolved completely except for a dilated pupil</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Ophthalmology, Samsung Medical Center, SungKyunKwan University School of Medicine, Seoul, KoreaJC - ay2, 8508431CP - United StatesPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20523258</style></custom1><custom3><style face="normal" font="default">AS - Ophthal Plast Reconstr Surg. 26(4):289-91, 2010 Jul-Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>424</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Suzuki,S.</style></author><author><style face="normal" font="default"> Kashiwagi,G.</style></author><author><style face="normal" font="default"> Nakasone,Y.</style></author><author><style face="normal" font="default"> Tomioka,A.</style></author><author><style face="normal" font="default"> Saito,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Case of unexpected intraoperative hyperkalemia]. [Japanese]</style></title><secondary-title><style face="normal" font="default">Masui - Japanese Journal of Anesthesiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Masui - Japanese Journal of Anesthesiology</style></full-title></periodical><pages end="1016" start="1014">1014-1016</pages><volume><style face="normal" font="default">58</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Hyperkalemia/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Hyperkalemia/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Intraoperative Complications/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Maxillary Sinus/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Monitoring,Intraoperative</style></keyword><keyword><style face="normal" font="default"> 0 (Angiotensin II Type 1 Receptor Blockers)</style></keyword><keyword><style face="normal" font="default"> 0 (Angiotensin-Converting Enzyme Inhibitors)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angiotensin II Type 1 Receptor Blockers/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Angiotensin-Converting Enzyme Inhibitors/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cysts/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Diabetes Complications</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Electrocardiography</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Hypovolemia/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Otorhinolaryngologic Surgical Procedures</style></keyword><keyword><style face="normal" font="default"> Paranasal Sinus Diseases/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="8" Year="2009">2009/8</year></dates><isbn><style face="normal" font="default">0021-4892</style></isbn><abstract><style face="normal" font="default">We experienced a case of unexpected ECG abnormality with hyperkalemia. A 65-year-old man was suffering from maxillary sinus cyst and Caldwell-Luc procedure was scheduled. He had diabetes mellitus and hypertension for 15 years, and was taking oral hypoglycemic agent and hypotensive drug (angiotensin converting enzyme and angiotensin receptor blockers : ARB). Abnormal findings were HbA1c 7.7% and glycosuria over 1,000 mg x dl(-1). ECG and other laboratory tests were within normal limits. The patient was monitored with 3 leads ECG during the operation. At one hour and 33 minutes after the start of operation, we detected sudden ECG changes consisting of wide QRS wave and peaked T wave. We consider hyperkalemia and checked blood potassium concentration three times. The results were 5.8, 6.3, 6.2 mmol x l(-1), respectively. We treated the patient with calcium gluconate injection, saline infusion, furosemide injection and glucose-insulin therapy. The ECG was normalized one hour and 23 minutes after the abnormal ECG finding and the potassium concentration decreased to 4.8 mmol x min(-1). After the operation, the potassium concentration and creatinine clearance were within normal limits. Hyperkalemia in this case might have been induced by diabetes mellitus, administration of ACEI and ARB, and hypovolemia</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Anesthesiology , Gunma University Graduate School of Medicine, Maebashi 371-8511JC - khr, 0413707CP - JapanPT - Case ReportsPT - English AbstractPT - Journal ArticleLG - Japanese</style></notes><urls/><custom1><style face="normal" font="default">UI - 19702222</style></custom1><custom3><style face="normal" font="default">AS - Masui. 58(8):1014-6, 2009 Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>194</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Svagzdiene,M.</style></author><author><style face="normal" font="default"> Sirvinskas,E.</style></author><author><style face="normal" font="default"> Benetis,R.</style></author><author><style face="normal" font="default"> Raliene,L.</style></author><author><style face="normal" font="default"> Simatoniene,V.</style></author></authors></contributors><titles><title><style face="normal" font="default">Atrial fibrillation and changes in serum and urinary electrolyte levels after coronary artery bypass grafting surgery</style></title><secondary-title><style face="normal" font="default">Medicina (Kaunas, Lithuania)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Medicina (Kaunas, Lithuania)</style></full-title></periodical><pages end="970" start="960">960-970</pages><volume><style face="normal" font="default">45</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atrial Fibrillation/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Bypass</style></keyword><keyword><style face="normal" font="default"> *Electrolytes/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Electrolytes/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> *Postoperative Complications</style></keyword><keyword><style face="normal" font="default"> 0 (Chlorides)</style></keyword><keyword><style face="normal" font="default"> 0 (Electrolytes)</style></keyword><keyword><style face="normal" font="default"> 7439-95-4 (Magnesium)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 7487-88-9 (Magnesium Sulfate)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atrial Fibrillation/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Atrial Fibrillation/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Atrial Fibrillation/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Atrial Fibrillation/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcium/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Chlorides/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Bypass</style></keyword><keyword><style face="normal" font="default"> Data Interpretation,Statistical</style></keyword><keyword><style face="normal" font="default"> Electrocardiography</style></keyword><keyword><style face="normal" font="default"> Heart Rate</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Informed Consent</style></keyword><keyword><style face="normal" font="default"> Intensive Care</style></keyword><keyword><style face="normal" font="default"> Magnesium Sulfate/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Magnesium/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Magnesium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Magnesium/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Preoperative Period</style></keyword><keyword><style face="normal" font="default"> Reference Values</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Statistics,Nonparametric</style></keyword><keyword><style face="normal" font="default"> Stroke Volume</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Our study was designed to assess the incidence of atrial fibrillation, changes in serum electrolyte concentrations and urinary electrolyte excretion following coronary artery bypass grafting surgery. MATERIAL AND METHODS: A total of 165 patients who underwent elective coronary artery bypass grafting surgery at the Department of Cardiac Surgery (Heart Center) during the period of 2004-2005 were enrolled. Serum K(+), Na(+), Mg(2+), Ca(2+), Cl(-), and P(-) concentrations were measured before cardiopulmonary bypass (CPB), on the arrival to an intensive care unit, and 15-18 hours after the surgery. Urinary excretion of K(+), Na(+), Mg(2+), Ca(2+), Cl(-), and P(-) was estimated 24 hours before the surgery, during the surgery, and 24 hours after the surgery. Cardiac rhythm was monitored throughout the study. All patients randomly were divided into the group 1 (n=55), which received magnesium sulphate infusion, and group 2 (n=110), which did not receive magnesium sulphate. RESULTS: The overall incidence of atrial fibrillation was 27.4%. The patients in the group 1 had significantly higher levels of serum magnesium before CPB and serum chloride after the surgery. Urinary magnesium and calcium excretion was significantly higher in the group 1 during and after the surgery. Before the surgery and 24 hours after the surgery, phosphate excretion was significantly higher in the group 1. CONCLUSIONS: The incidence of atrial fibrillation after myocardial revascularization surgery remains high (27.4%). Serum electrolyte concentrations after myocardial revascularization varied within normal ranges. Magnesium sulphate infusion did not decrease the rate of postoperative atrial fibrillation during the early postoperative period in normomagnesemic patients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Institute for Biomedical Research, Heart Center, Kaunas University of Medicine, LithuaniaJC - 9425208CP - LithuaniaPT - Comparative StudyPT - Evaluation StudiesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20173399</style></custom1><custom3><style face="normal" font="default">AS - Medicina (Kaunas). 45(12):960-70, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>422</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Szklo,M.</style></author><author><style face="normal" font="default"> Ding,J.</style></author><author><style face="normal" font="default"> Tsai,M.Y.</style></author><author><style face="normal" font="default"> Cushman,M.</style></author><author><style face="normal" font="default"> Polak,J.F.</style></author><author><style face="normal" font="default"> Lima,J.</style></author><author><style face="normal" font="default"> Barr,R.G.</style></author><author><style face="normal" font="default"> Sharrett,A.R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Individual pathogens, pathogen burden and markers of subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis</style></title><secondary-title><style face="normal" font="default">Journal of Cardiovascular Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Cardiovascular Medicine</style></full-title></periodical><pages end="751" start="747">747-751</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Chlamydophila Infections/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Cytomegalovirus Infections/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Helicobacter Infections/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Herpes Simplex/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> 0 (Antibodies,Bacterial)</style></keyword><keyword><style face="normal" font="default"> 0 (Antibodies,Viral)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Antibodies,Bacterial/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Antibodies,Viral/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/mi [Microbiology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Carotid Arteries/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> Chlamydophila pneumoniae/ip [Isolation &amp; Purification]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Endothelium,Vascular/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Ethnic Groups/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Helicobacter pylori/ip [Isolation &amp; Purification]</style></keyword><keyword><style face="normal" font="default"> Herpesvirus 1,Human/ip [Isolation &amp; Purification]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Seroepidemiologic Studies</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> United States/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Viral Load</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><isbn><style face="normal" font="default">1558-2027</style></isbn><abstract><style face="normal" font="default">METHODS: We examined the cross-sectional relationships of subclinical atherosclerosis - expressed by carotid intimal-medial thickness and coronary calcification - with antibodies to Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, herpes simplex virus, hepatitis A virus, and pathogen burden (number of positive pathogens). A random sample of 1056 individuals chosen from 5030 Multi-Ethnic Study of Atherosclerosis cohort participants were included. RESULTS: After multiple adjustment, no associations were found between atherosclerosis measures and either individual pathogens or pathogen burden. Interactions with inflammatory and endothelial function markers, demographic factors, BMI, high-density lipoprotein, diabetes, and smoking were also explored. The only interaction that was large, qualitative, statistically significant (P &lt; 0.05) and in the expected direction was that between hepatitis A virus and soluble intercellular adhesion molecule-1 with regard to Agatston calcium score: the difference between hepatitis A virus-positive and hepatitis A virus-negative participants was -186 units in participants with soluble intercellular adhesion molecule-1 below the median, and +162 units in those with soluble intercellular adhesion molecule-1 equal or above the median. However, given the number of interactions that were explored, these results must be interpreted cautiously. CONCLUSION: Findings from the present analyses do not provide support for an infectious etiology for subclinical atherosclerosis. However, the study's limitations, which include its cross-sectional design and insufficient statistical power, suggest that inferences from its findings should be made cautiously</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. mszklo@jhsph.eduJC - 101259752CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - N01-HC-95162 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19444130</style></custom1><custom3><style face="normal" font="default">AS - J Cardiovasc Med (Hagerstown). 10(10):747-51, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>354</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Takeda,Y.</style></author><author><style face="normal" font="default"> Hoshiga,M.</style></author><author><style face="normal" font="default"> Tatsugami,F.</style></author><author><style face="normal" font="default"> Morinaga,I.</style></author><author><style face="normal" font="default"> Takehara,K.</style></author><author><style face="normal" font="default"> Hotchi,J.</style></author><author><style face="normal" font="default"> Yuki,T.</style></author><author><style face="normal" font="default"> Ishihara,T.</style></author><author><style face="normal" font="default"> Hanafusa,T.</style></author></authors></contributors><titles><title><style face="normal" font="default">Clinical significance of calcification in ascending aorta as a marker for the requirement of coronary revascularization</style></title><secondary-title><style face="normal" font="default">Journal of Atherosclerosis &amp; Thrombosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Atherosclerosis &amp; Thrombosis</style></full-title></periodical><pages end="354" start="346">346-354</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aorta/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Coronary Stenosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Myocardial Revascularization</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Aorta/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Biological Markers</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Stenosis/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> ROC Curve</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Tomography,Spiral Computed</style></keyword></keywords><dates><year Day="0" Month="8" Year="2009">2009/8</year></dates><abstract><style face="normal" font="default">AIM: Vascular or valvular calcification is a manifestation of atherosclerosis. The aim of this study was to clarify the association between calcification in the vascular or valvular area and significant coronary stenosis; that is, the requirements of coronary revascularization (CR), and to analyze the most associated marker among those valuables. METHODS AND RESULTS: A total of 253 consecutive patients underwent multi-detector spiral computed tomography (MDCT) to diagnose coronary artery stenosis. We quantitatively and qualitatively analyzed calcification in vascular (coronary artery, thoracic ascending and descending aorta) and valvular (mitral and aortic valve) areas. Of 253 patients, 56 with suspected coronary artery stenosis or who had heavy calcification that precluded a diagnosis of lumen stenosis underwent selective coronary angiography. Coronary artery stenosis was significant in 47 patients, of whom 40 underwent CR. The calcification score revealed a significant association between any two sites. Univariate analysis revealed that CR patients showed significantly more calcification at sites other than the aortic valve and a significantly higher calcium score at 3 vascular beds. Multivariate analysis revealed that the presence of calcification in the ascending aorta and a calcium score > 103.8, a cut-off value determined by receiver-operating characteristics (ROC) curve analysis, for the coronary artery were independent factors for CR. CONCLUSIONS: Calcification at sites other than the aortic valve was significantly related to CR (+). The presences of calcification in the ascending aorta and a calcium score > 103.8 for the coronary artery were independently associated with CR</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of First Internal Medicine, Osaka Medical College, Takatsuki, Japan. y.takeda@ksh.biglobe.ne.jpJC - 9506298, cwcCP - JapanPT - Evaluation StudiesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19713677</style></custom1><custom3><style face="normal" font="default">AS - J Atheroscler Thromb. 16(4):346-54, 2009 Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>190</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Tapia,P.</style></author><author><style face="normal" font="default"> lez-Aguirre,D.</style></author><author><style face="normal" font="default"> nchez-Aguilar,M.</style></author><author><style face="normal" font="default"> Torres-Corzo,J.</style></author><author><style face="normal" font="default"> guez-Leyva,I.</style></author><author><style face="normal" font="default"> Gordillo-Moscoso,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Evaluation of changes in the treatment of spontaneous intracerebral haemorrhage in a regional hospital in Mexico]. [Spanish]</style></title><secondary-title><style face="normal" font="default">Revista de Neurologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Revista de Neurologia</style></full-title></periodical><pages end="206" start="201">201-206</pages><volume><style face="normal" font="default">50</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cerebral Hemorrhage/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> 0 (Antihypertensive Agents)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Antihypertensive Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Blood Pressure/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Cerebral Hemorrhage/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Cerebral Hemorrhage/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Craniocerebral Trauma/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glasgow Coma Scale</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Intensive Care</style></keyword><keyword><style face="normal" font="default"> Intensive Care Units</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Mexico</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="16" Month="2" Year="2010">2010/2/16</year></dates><abstract><style face="normal" font="default">INTRODUCTION: The spontaneous intracerebral hemorrhage (ICH) shows a high lethal rate. In 1999 appeared the first therapeutic guidelines, after that new therapies have been assessed without substantial success. AIM: To describe treatment changes for ICH in a regional Mexican hospital and to assess their impact on clinical evolution. PATIENTS AND METHODS: We accomplished a retrospective study of patients admitted between 2000 and 2006. We included those elder than 15 years with tomographyc diagnostic of ICH. Patients with head injury four weeks before or undetermined initial National Institute of Health Stroke Scale (NIHSS) were excluded. Epidemiological, clinical characteristics and kind of therapy were studied. RESULTS: We analyzed 175 patients with mean age of 62 years. Etiology and localization more frequently were arterial hypertension and lobar, respectively. More than 20% were intubated and approximately one half of these admitted in intensive care unit. Angiotensin converter enzyme inhibitors were the medicaments more usually used for controlling blood pressure. An initial NIHSS > 15 or Glasgow &lt; 9 were associated to poor outcome. Additional administration of calcium antagonist, statins and surgical decompression was associated to a better outcome. CONCLUSIONS: Use of intensive care units is a measure highly suggested as standard for ICH-therapy. In our center it was not regularly accomplished because of infrastructural deficiencies. This problem could be generated in other Mexican hospitals; attention to that phenomenon is urgently required. Evaluation of new therapeutic strategies is required</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Universidad Autonoma de San Luis Potosi, San Luis de Potosi, Mexico. lehwand@hotmail.comOT - Evaluacion de cambios en el tratamiento de la hemorragia intracerebral espontanea en un hospital regional mexicanoJC - cg9, 7706841CP - SpainPT - English AbstractPT - Journal ArticleLG - Spanish</style></notes><urls/><custom1><style face="normal" font="default">UI - 20198591</style></custom1><custom3><style face="normal" font="default">AS - Rev Neurol. 50(4):201-6, 2010 Feb 16-28.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>45</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Taylor,A.J.</style></author><author><style face="normal" font="default"> Wu,H.</style></author><author><style face="normal" font="default"> Bindeman,J.</style></author><author><style face="normal" font="default"> Bauer,K.</style></author><author><style face="normal" font="default"> Byrd,C.</style></author><author><style face="normal" font="default"> O'Malley,P.G.</style></author><author><style face="normal" font="default"> Feuerstein,I.</style></author></authors></contributors><titles><title><style face="normal" font="default">The relationship between the cardiometabolic syndrome and coronary artery calcium progression</style></title><secondary-title><style face="normal" font="default">Journal of Clinical Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Clinical Hypertension</style></full-title></periodical><pages end="511" start="505">505-511</pages><volume><style face="normal" font="default">11</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Metabolic Syndrome X/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Metabolic Syndrome X/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword></keywords><dates><year Day="0" Month="9" Year="2009">2009/9</year></dates><abstract><style face="normal" font="default">J Clin Hypertens (Greenwich). 2009;11:505-511. (c)2009 Wiley Periodicals, Inc.Cardiometabolic syndrome has been associated with increased likelihood and extent of coronary artery calcium (CAC). The authors examined the relationship of cardiometabolic syndrome to CAC progression in 200 healthy men who volunteered to undergo repeated electron beam tomography separated by 4.2+/-1.3 years. Prediction of clinically significant CAC progression (>/=15% per year) was evaluated using multivariable logistic regression models and principal component analysis. Clinically significant CAC progression was observed in 52.5% of the cohort, with the mean and median rate of annual progression 41.3% and 18.3%, respectively. The cardiometabolic syndrome in clinically significant CAC progression participants was significantly higher compared with those without CAC progression (24.8% vs 11.6%; P=.016). Cardiometabolic syndrome was a significant independent predictor of clinically significant CAC progression (odds ratio, 2.65; P=.022). Cardiometabolic syndrome is associated with the baseline CAC score, and independently associated with the progression of CAC over 4 years</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine and Cardiology Service, Walter Reed Army Medical Center, Washington, DC, USA. allen.taylor@medstar.netJC - 100888554, d2qCP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19751466</style></custom1><custom3><style face="normal" font="default">AS - J Clin Hypertens (Greenwich). 11(9):505-11, 2009 Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>502</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Taylor,A.J.</style></author><author><style face="normal" font="default"> Wu,H.</style></author><author><style face="normal" font="default"> Bindeman,J.</style></author><author><style face="normal" font="default"> Bauer,K.</style></author><author><style face="normal" font="default"> Byrd,C.</style></author><author><style face="normal" font="default"> O'Malley,P.G.</style></author><author><style face="normal" font="default"> Feuerstein,I.</style></author></authors></contributors><titles><title><style face="normal" font="default">Comparison of coronary artery calcium progression in African American and white men</style></title><secondary-title><style face="normal" font="default">Journal of cardiovascular computed tomography</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of cardiovascular computed tomography</style></full-title></periodical><pages end="77" start="71">71-77</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*African Americans</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> *European Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default"> African Americans</style></keyword><keyword><style face="normal" font="default"> African Americans/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> European Continental Ancestry Group/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Military Personnel</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> United States/ep [Epidemiology]</style></keyword></keywords><dates><year Day="0" Month="3" Year="2009">2009/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: Although African Americans have a lower prevalence and extent of coronary artery calcium (CAC) than whites, the relationship between ethnicity and CAC progression is unknown. In a prospective rescan substudy of the Prospective Army Coronary Calcium (PACC) Project, we evaluated ethnic differences in the rates of CAC progression over 4 years. METHODS: Two hundred healthy male PACC Project participants (age, 47.8 +/- 2.8 years) with CAC on their original scan volunteered to undergo a second electron beam tomography (EBT) scan and cardiovascular risk factor assessment (interscan interval, 4.3 +/- 1.2 y). All results were independently examined and blinded to baseline data. A change in CAC score >or=15%/y was defined as clinically significant progression. The relationship between race and CAC progression was evaluated with multivariable linear and logistic regression models controlling for age and other cardiovascular risk factors. RESULTS: African Americans had significantly lower baseline CAC scores (34.3 vs 101.5; P = 0.004); lower follow-up CAC scores (56.6 vs 180.6; P = 0.001); and worse cardiovascular risk profiles. The annualized CAC progression rate was not significantly related to race in the multivariable linear regression model controlling for age, the Framingham risk score, and other cardiovascular risk factors. Significant CAC progression occurred in 43.5% of all participants. The incidence of significant progression of CAC for African American and white men was similar (53.1% vs 52.4%; P = 0.94), even when controlling for age, the Framingham risk score, and other cardiovascular risk factors. CONCLUSION: Although African American men have less CAC than white men, CAC progression occurs at a comparable rate over 4 years</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine and Cardiology Service, Walter Reed Army Medical Center, Washington, DC, USA. allen.taylor@medstar.netCM - Comment in: J Cardiovasc Comput Tomogr. 2009 Mar-Apr;3(2):78-9; PMID: 19213624]JC - 101308347CP - United StatesPT - Comparative StudyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19217367</style></custom1><custom3><style face="normal" font="default">AS - J Cardiovasc Comput Tomogr. 3(2):71-7, 2009 Mar-Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>71</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Taylor,A.J.</style></author><author><style face="normal" font="default"> Fiorilli,P.N.</style></author><author><style face="normal" font="default"> Wu,H.</style></author><author><style face="normal" font="default"> Bauer,K.</style></author><author><style face="normal" font="default"> Bindeman,J.</style></author><author><style face="normal" font="default"> Byrd,C.</style></author><author><style face="normal" font="default"> Feuerstein,I.M.</style></author><author><style face="normal" font="default"> O'Malley,P.G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Relation between the Framingham Risk Score, coronary calcium, and incident coronary heart disease among low-risk men</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="50" start="47">47-50</pages><volume><style face="normal" font="default">106</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword></keywords><dates><year Day="1" Month="7" Year="2010">2010/7/1</year></dates><abstract><style face="normal" font="default">The Prospective Army Coronary Calcium Project is evaluating the predictive value of coronary artery calcium (CAC) in unselected, healthy, lower-risk, 40- to 50-year-old men. Although this study has found that coronary calcium is predictive of future coronary heart disease (CHD), criteria are needed to narrow the screening population to those in whom CAC measurement is most efficient (vs unselected screening of low-risk men). In 1,634 unselected volunteer men (mean age 42 years, mean 10-year CHD Framingham risk score [FRS] 4.6%, CAC prevalence 22.4%), we evaluated the independent relation between CAC and incident CHD over 5.6 years including hard events (hospitalized unstable angina, myocardial infarction, and CHD death) and coronary revascularization. The cohort was analyzed in tertiles of FRS for the relation between CAC and CHD outcomes. FRS tertile cutpoints were 0% to 3% (n = 547), >3% to 5% (n = 547), and >5% (n = 540) 10-year CHD risk. Over a mean follow-up of 5.6 +/- 1.5 years (range 1.0 to 8.3), there were 22 total CHD events, including 14 hard events and 8 revascularizations. Most events occurred in the highest FRS tertile (n = 14) versus the middle (n = 6) and lowest (n = 2) risk tertiles (p = 0.005). CAC and CHD events increased across FRS tertiles. Only in the highest FRS tertile was there a significant relation between CAC and CHD outcomes (hazard ratio 9.3). In conclusion, CAC screening could be of benefit in refining risk assessment of low-risk men, but only when the FRS exceeds approximately 5%. Published by Elsevier Inc</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, Walter Reed Army Medical Center, Washington, DC, USAJC - 3dq, 0207277CP - United StatesPT - Journal ArticlePT - Research Support, U.S. Gov't, Non-P.H.SLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20609646</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 106(1):47-50, 2010 Jul 1.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>403</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Taylor,E.N.</style></author><author><style face="normal" font="default"> Fung,T.T.</style></author><author><style face="normal" font="default"> Curhan,G.C.</style></author></authors></contributors><titles><title><style face="normal" font="default">DASH-style diet associates with reduced risk for kidney stones</style></title><secondary-title><style face="normal" font="default">Journal of the American Society of Nephrology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of the American Society of Nephrology</style></full-title></periodical><pages end="2259" start="2253">2253-2259</pages><volume><style face="normal" font="default">20</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Diet</style></keyword><keyword><style face="normal" font="default"> *Hypertension/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Kidney Calculi/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> 0 (Oxalates)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Dairy Products</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Fruit</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Meat</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Oxalates/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Vegetables</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><abstract><style face="normal" font="default">The impact of the Dietary Approaches to Stop Hypertension (DASH) diet on kidney stone formation is unknown. We prospectively examined the relation between a DASH-style diet and incident kidney stones in the Health Professionals Follow-up Study (n = 45,821 men; 18 yr of follow-up), Nurses' Health Study I (n = 94,108 older women; 18 yr of follow-up), and Nurses' Health Study II (n = 101,837 younger women; 14 yr of follow-up). We constructed a DASH score based on eight components: high intake of fruits, vegetables, nuts and legumes, low-fat dairy products, and whole grains and low intake of sodium, sweetened beverages, and red and processed meats. We used Cox hazards regression to adjust for factors that included age, BMI, and fluid intake. Over a combined 50 yr of follow-up, we documented 5645 incident kidney stones. Participants with higher DASH scores had higher intakes of calcium, potassium, magnesium, oxalate, and vitamin C and had lower intakes of sodium. For participants in the highest compared with the lowest quintile of DASH score, the multivariate relative risks for kidney stones were 0.55 (95% CI, 0.46 to 0.65) for men, 0.58 (95% CI, 0.49 to 0.68) for older women, and 0.60 (95% CI, 0.52 to 0.70) for younger women. Higher DASH scores were associated with reduced risk even in participants with lower calcium intake. Exclusion of participants with hypertension did not change the results. In conclusion, consumption of a DASH-style diet is associated with a marked decrease in kidney stone risk</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Renal Division and Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. entaylor@partners.orgJC - a6h, 9013836CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - CA50385 (United States NCI NIH HHS)NO - CA55075 (United States NCI NIH HHS)NO - CA87969 (United States NCI NIH HHS)NO - DK70756 (United States NIDDK NIH HHS)NO - DK73381 (United States NIDDK NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19679672</style></custom1><custom3><style face="normal" font="default">AS - J Am Soc Nephrol. 20(10):2253-9, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>551</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Tearney,G.J.</style></author><author><style face="normal" font="default"> Waxman,S.</style></author><author><style face="normal" font="default"> Shishkov,M.</style></author><author><style face="normal" font="default"> Vakoc,B.J.</style></author><author><style face="normal" font="default"> Suter,M.J.</style></author><author><style face="normal" font="default"> Freilich,M.I.</style></author><author><style face="normal" font="default"> Desjardins,A.E.</style></author><author><style face="normal" font="default"> Oh,W.Y.</style></author><author><style face="normal" font="default"> Bartlett,L.A.</style></author><author><style face="normal" font="default"> Rosenberg,M.</style></author><author><style face="normal" font="default"> Bouma,B.E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Three-dimensional coronary artery microscopy by intracoronary optical frequency domain imaging</style></title><secondary-title><style face="normal" font="default">Jacc: Cardiovascular Imaging</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Jacc: Cardiovascular Imaging</style></full-title></periodical><pages end="761" start="752">752-761</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Artery Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Imaging,Three-Dimensional</style></keyword><keyword><style face="normal" font="default"> *Tomography,Optical Coherence</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angioplasty,Transluminal,Percutaneous Coronary/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fiber Optic Technology</style></keyword><keyword><style face="normal" font="default"> Heart Catheterization</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperplasia</style></keyword><keyword><style face="normal" font="default"> Image Interpretation,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Microvessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Pilot Projects</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Stents</style></keyword><keyword><style face="normal" font="default"> Tomography,Optical Coherence/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> User-Computer Interface</style></keyword></keywords><dates><year Day="0" Month="11" Year="2008">2008/11</year></dates><abstract><style face="normal" font="default">OBJECTIVES: We present the first clinical experience with intracoronary optical frequency domain imaging (OFDI) in human patients. BACKGROUND: Intracoronary optical coherence tomography (OCT) is a catheter-based optical imaging modality that is capable of providing microscopic (approximately 7-microm axial resolution, approximately 30-microm transverse resolution), cross-sectional images of the coronary wall. Although the use of OCT has shown substantial promise for imaging coronary microstructure, blood attenuates the OCT signal, necessitating prolonged, proximal occlusion to screen long arterial segments. OFDI is a second-generation form of OCT that is capable of acquiring images at much higher frame rates. The increased speed of OFDI enables rapid, 3-dimensional imaging of long coronary segments after a brief, nonocclusive saline purge. METHODS: Volumetric OFDI images were obtained in 3 patients after intracoronary stent deployment. Imaging was performed in the left anterior descending and right coronary arteries with the use of a nonocclusive saline purge rates ranging from 3 to 4 ml/s and for purge durations of 3 to 4 s. After imaging, the OFDI datasets were segmented using previously documented criteria and volume rendered. RESULTS: Good visualization of the artery wall was obtained in all cases, with clear viewing lengths ranging from 3.0 to 7.0 cm at pullback rates ranging from 5 to 20 mm/s. A diverse range of microscopic features were identified in 2 and 3 dimensions, including thin-capped fibroatheromas, calcium, macrophages, cholesterol crystals, bare stent struts, and stents with neointimal hyperplasia. There were no complications of the OFDI procedure. CONCLUSIONS: Our results demonstrate that OFDI is a viable method for imaging the microstructure of long coronary segments in patients. Given its ability to provide microscopic information in a practical manner, this technology may be useful for studying human coronary pathophysiology in vivo and as a clinical tool for guiding the management of coronary artery disease</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Wellman Center for Photomedicine, Massachusetts General Hospital, Department of Pathology, Harvard Medical School, Boston, Massachusetts 02114, USA. gtearney@partners.orgCM - Comment in: JACC Cardiovasc Imaging. 2008 Nov;1(6):762-4; PMID: 19356513]JC - 101467978CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - 5R01HL076398 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19356512</style></custom1><custom3><style face="normal" font="default">AS - JACC Cardiovasc Imaging. 1(6):752-61, 2008 Nov.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>146</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Thanassoulis,G.</style></author><author><style face="normal" font="default"> Massaro,J.M.</style></author><author><style face="normal" font="default"> Cury,R.</style></author><author><style face="normal" font="default"> Manders,E.</style></author><author><style face="normal" font="default"> Benjamin,E.J.</style></author><author><style face="normal" font="default"> Vasan,R.S.</style></author><author><style face="normal" font="default"> Cupple,L.A.</style></author><author><style face="normal" font="default"> Hoffmann,U.</style></author><author><style face="normal" font="default"> O'Donnell,C.J.</style></author><author><style face="normal" font="default"> Kathiresan,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Associations of long-term and early adult atherosclerosis risk factors with aortic and mitral valve calcium</style></title><secondary-title><style face="normal" font="default">Journal of the American College of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of the American College of Cardiology</style></full-title></periodical><pages end="2498" start="2491">2491-2498</pages><volume><style face="normal" font="default">55</style></volume><number><style face="normal" font="default">22</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aortic Valve/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Atherosclerosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Atherosclerosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Heart Valve Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Mitral Valve/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age Distribution</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Heart Valve Diseases/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Sex Distribution</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="1" Month="6" Year="2010">2010/6/1</year></dates><abstract><style face="normal" font="default">OBJECTIVES: To determine the association of long-term exposure to atherosclerosis risk factors with valvular calcification. BACKGROUND: Traditional atherosclerosis risk factors have been associated with aortic and mitral valve calcium in cross-sectional studies, but long-term prospective data are lacking. METHODS: This was a prospective, community-based cohort study with 27-year follow-up (median follow-up 26.9 years; range 23.1 to 29.6 years). Participants from the Framingham Offspring Study (n = 1,323, enrolled between 1971 and 1975, mean age at enrollment 34 +/- 9 years; 52% women) underwent cardiac multidetector computed tomography assessment between 2002 and 2005. Associations between the long-term average of each cardiovascular risk factor and valve calcium were estimated using logistic regression. RESULTS: Aortic valve calcium was present in 39% of participants and mitral valve calcium in 20%. In multivariable models, the odds ratio for aortic valve calcium associated with every SD increment in long-term mean total cholesterol was 1.74 (p &lt; 0.0001); with every SD increment in high-density lipoprotein cholesterol, it was 0.77 (p = 0.002); and with every 9 cigarettes smoked per day, it was 1.23 (p = 0.002). Associations of similar magnitude were seen for mitral valve calcium. The mean of 3 serum C-reactive protein measurements was associated with mitral valve calcium (odds ratio: 1.29 per SD increment in C-reactive protein levels; p = 0.002). A higher Framingham risk score in early adulthood (40 years age or younger) was associated with increased prevalence and severity of aortic valve calcium measured 3 decades later. CONCLUSIONS: Exposure to multiple atherosclerotic risk factors starting in early to mid-adulthood is associated with aortic and mitral valve calcium. Studies evaluating early risk factor modification to reduce the burden of valve disease are warranted</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, Massachusetts, USAJC - h50, 8301365CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - N01-HC-25195 (United States NHLBI NIH HHS)NO - (Canada Canadian Institutes of Health Research)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20510217</style></custom1><custom3><style face="normal" font="default">AS - J Am Coll Cardiol. 55(22):2491-8, 2010 Jun 1.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>141</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Thilo,C.</style></author><author><style face="normal" font="default"> Gebregziabher,M.</style></author><author><style face="normal" font="default"> Mayer,F.B.</style></author><author><style face="normal" font="default"> Zwerner,P.L.</style></author><author><style face="normal" font="default"> Costello,P.</style></author><author><style face="normal" font="default"> Schoepf,U.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Correlation of regional distribution and morphological pattern of calcification at CT coronary artery calcium scoring with non-calcified plaque formation and stenosis</style></title><secondary-title><style face="normal" font="default">European Radiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">European Radiology</style></full-title></periodical><pages end="861" start="855">855-861</pages><volume><style face="normal" font="default">20</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Algorithms</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Stenosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Radiographic Image Interpretation,Computer-Assisted/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Radiographic Image Enhancement/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Statistics as Topic</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To investigate whether regional calcification patterns at CT coronary artery calcium scoring (CCS) correlate with stenosis and non-calcified plaque formation. METHODS: We studied 106 patients with quantitative catheter angiography (QCA), CCS, and coronary CT angiography (cCTA). CCS was determined globally and for each artery separately. The morphological pattern of each calcification was classified as calcified nodule, shell-like, or diffuse. cCTA studies were evaluated for non-calcified plaque. The global and regional CCS and the calcification pattern were correlated with stenosis >or=50% and non-calcified plaque. RESULTS: A total of 48/106 patients had stenosis >or=50% on QCA. There was weak correlation (r = 0.36) of the global CCS with stenosis. Correlation was stronger per vessel (r = 0.55-r = 0.67). Shell-like and diffuse calcifications were significantly (p = 0.0001) more frequently associated with >or=50% stenosis and non-calcified plaque (p = 0.04) than calcified nodules. CONCLUSION: As shown before, the global CCS does not correlate well with stenosis. However, regional calcium distribution and specific patterns of calcification are correlated with stenosis and non-calcified plaque. Thus, the specificity of CT calcium scoring for identifying individuals with obstructive disease could be improved by vessel-based rather than global quantification of calcium and by differentiating specific morphological patterns of calcification</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Radiology and Radiological Science, Medical University of South Carolina, Charleston, SC 29401, USAJC - cl3, 9114774CP - GermanyPT - Evaluation StudiesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19862532</style></custom1><custom3><style face="normal" font="default">AS - Eur Radiol. 20(4):855-61, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>365</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Toi,T.</style></author><author><style face="normal" font="default"> Taguchi,I.</style></author><author><style face="normal" font="default"> Yoneda,S.</style></author><author><style face="normal" font="default"> Kageyama,M.</style></author><author><style face="normal" font="default"> Kikuchi,A.</style></author><author><style face="normal" font="default"> Tokura,M.</style></author><author><style face="normal" font="default"> Kanaya,T.</style></author><author><style face="normal" font="default"> Abe,S.</style></author><author><style face="normal" font="default"> Matsuda,R.</style></author><author><style face="normal" font="default"> Kaneko,N.</style></author></authors></contributors><titles><title><style face="normal" font="default">Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque. Comparison with atorvastatin</style></title><secondary-title><style face="normal" font="default">Circulation Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Circulation Journal</style></full-title></periodical><pages end="1472" start="1466">1466-1472</pages><volume><style face="normal" font="default">73</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Artery Disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Quinolines/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> 0 (Antilipemic Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol,LDL)</style></keyword><keyword><style face="normal" font="default"> 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipids)</style></keyword><keyword><style face="normal" font="default"> 0 (Quinolines)</style></keyword><keyword><style face="normal" font="default"> 147526-32-7 (NK 104)</style></keyword><keyword><style face="normal" font="default"> 57-88-5 (Cholesterol)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Antilipemic Agents/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> Antilipemic Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cholesterol,LDL/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cholesterol/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hydroxymethylglutaryl-CoA Reductase Inhibitors</style></keyword><keyword><style face="normal" font="default"> Lipids/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Quinolines/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword></keywords><dates><year Day="0" Month="8" Year="2009">2009/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Virtual histology intravascular ultrasound (VH-IVUS) is used to diagnose coronary plaques and evaluate statin therapy. However, in most cases, quantitative changes in plaques have been evaluated in the chronic stage. We evaluated the quantitative and qualitative early effects of 2 statins on coronary lesions using VH-IVUS. METHODS AND RESULTS: Patients with acute coronary syndrome who underwent emergency percutaneous coronary intervention (PCI) were randomly assigned to receive pitavastatin (n=80; 2 mg/day) or atorvastatin (n=80; 10 mg/day) immediately after PCI. All patients underwent a blood lipid test and VH-IVUS evaluation of non-PCI lesions at admission and after 2-3 weeks of statin administration. After treatment, total cholesterol and low-density lipoprotein-cholesterol (LDL-C) showed significant decreases to similar levels in each group (P&lt;0.001). In the pitavastatin group, the plaque volume index and fibrofatty volume index (FFVI) also decreased significantly. In patients from the pitavastatin group with a dense calcium ratio of &lt; or =10% (n=61), the percentage changes in FFVI and LDL-C were correlated positively (r=0.305, P=0.017), whereas no significant changes were found after treatment in the atorvastatin group. CONCLUSIONS: Fibrofatty composition and plaque volume decreased significantly following treatment with pitavastatin, which suggests that pitavastatin might have a higher affinity for fibrofat compared with atorvastatin</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology and Pneumology, Dokkyo Medical University School of Medicine, Tochigi, JapanJC - 101137683CP - JapanPT - Comparative StudyPT - Journal ArticlePT - Randomized Controlled TrialLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19531899</style></custom1><custom3><style face="normal" font="default">AS - Circ J. 73(8):1466-72, 2009 Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>86</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Tolouian,R.</style></author><author><style face="normal" font="default"> Hernandez,G.T.</style></author><author><style face="normal" font="default"> Chiang,W.Y.</style></author><author><style face="normal" font="default"> Gupta,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">A new approach for evaluating bone turnover in chronic kidney disease</style></title><secondary-title><style face="normal" font="default">European Journal of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">European Journal of Internal Medicine</style></full-title></periodical><pages end="232" start="230">230-232</pages><volume><style face="normal" font="default">21</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Alkaline Phosphatase/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Bone Remodeling/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Chemistry,Clinical/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Renal Insufficiency,Chronic/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Renal Osteodystrophy/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Renal Osteodystrophy/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (collagen type I trimeric cross-linked peptide)</style></keyword><keyword><style face="normal" font="default"> 0 (Collagen Type I)</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 0 (Peptides)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Chemistry,Clinical/st [Standards]</style></keyword><keyword><style face="normal" font="default"> Collagen Type I/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> EC 3-1-3-1 (Alkaline Phosphatase)</style></keyword><keyword><style face="normal" font="default"> EC 3-1-3-1 (ALPL protein,human)</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Linear Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Outpatients</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Peptides/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="6" Year="2010">2010/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: The validity of serum parathyroid hormone (PTH) as a surrogate marker of bone turnover in chronic kidney disease (CKD) is limited by several factors such as relative resistance of bone to PTH, hyperphosphatemia, diabetes, gender, age, race and vitamin D analog action on the PTH-bone axis. Urinary collagen N-terminal telopeptide X (NTx), a bone collagen degradation product, expressed as bone collagen equivalents (BCE) per mM of creatinine (NTx/Cr ratio), is routinely used to estimate bone turnover in osteoporosis. The purpose of this study is to evaluate NTx as a marker of bone turnover in CKD. METHODS: We studied the relationship between bone-specific alkaline phosphatase (BSAP), PTH and urine NTx/Cr in 37 CKD out-patients. RESULTS: In a multivariate model, PTH had a positive correlation with BSAP (r=0.44, P&lt;0.19) and U-NTx/Cr (r=0.55, P&lt;0.30), after adjusting for age, gender, estimated glomerular filtration rate (GFR), serum phosphorus, corrected calcium, and race. However, the strongest correlation was found between the two direct markers of bone resorption and formation (U-NTx vs. BSAP; r=0.80; P&lt;0.0001), suggesting a tight coupling of bone resorption and formation in CKD. The effect of gender on U-NTx/Cr was studied in a multivariate model after adjusting for age, race, GFR, serum calcium, phosphorus and PTH. Females had a higher U-NTx/Cr than males. CONCLUSION: Our findings indicate that urinary NTx, a promising marker of bone resorption in CKD patients, exhibits a strong positive correlation with other markers used to assess renal osteodystrophy i.e. PTH and BSAP. Unlike PTH and BSAP, urine NTx also measures bone loss secondary to osteoporosis. Published by Elsevier B.V</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Nephrology and Hypertension, Department of Internal Medicine, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, El Paso, Texas 79905, USAJC - 9003220CP - NetherlandsPT - Clinical TrialPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Validation StudiesNO - 5-R01-DK066361-01 (United States NIDDK NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20493428</style></custom1><custom3><style face="normal" font="default">AS - EUR. J. INTERN. MED.. 21(3):230-2, 2010 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>171</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Tong,D.</style></author><author><style face="normal" font="default"> Murad,A.</style></author><author><style face="normal" font="default"> Manolios,N.</style></author><author><style face="normal" font="default"> Howe,G.</style></author><author><style face="normal" font="default"> Spencer,D.</style></author></authors></contributors><titles><title><style face="normal" font="default">Pseudohypercalcaemia in mixed cryoglobulinaemia (IgMkappa/polyclonal IgG): a rare complication of Sj&amp;#x00F6;gren's syndrome</style></title><secondary-title><style face="normal" font="default">Clinical Rheumatology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinical Rheumatology</style></full-title></periodical><pages end="441" start="439">439-441</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Cryoglobulinemia/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Sjogren's Syndrome/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Cryoglobulins)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Cryoglobulinemia/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Cryoglobulins/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypercalcemia/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sjogren's Syndrome/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">This is the first reported case of pseudohypercalcaemia associated with type 2 cryoglobulinaemia, secondary to primary Sj&amp;#x00F6;gren's syndrome. Pseudohypercalcaemia is an asymptomatic syndrome and does not require specific treatment. However, cryoglobulins have been demonstrated to bind to calcium, affecting the cryoprecipitability, and consequently, altering the pathogenicity of the cryoglobulins. This first report highlights potential for further research into this intriguing phenomenon</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Rheumatology Department, Westmead Hospital, Sydney, NSW, Australia. dwytong@yahoo.com.auJC - 8211469, di6CP - GermanyPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20069326</style></custom1><custom3><style face="normal" font="default">AS - Clin Rheumatol. 29(4):439-41, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>201</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Tordjman,K.M.</style></author><author><style face="normal" font="default"> Yaron,M.</style></author><author><style face="normal" font="default"> Izkhakov,E.</style></author><author><style face="normal" font="default"> Osher,E.</style></author><author><style face="normal" font="default"> Shenkerman,G.</style></author><author><style face="normal" font="default"> Marcus-Perlman,Y.</style></author><author><style face="normal" font="default"> Stern,N.</style></author></authors></contributors><titles><title><style face="normal" font="default">Cardiovascular risk factors and arterial rigidity are similar in asymptomatic normocalcemic and hypercalcemic primary hyperparathyroidism</style></title><secondary-title><style face="normal" font="default">European Journal of Endocrinology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">European Journal of Endocrinology</style></full-title></periodical><pages end="933" start="925">925-933</pages><volume><style face="normal" font="default">162</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Arteries/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Hypercalcemia/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Hyperparathyroidism,Primary/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Blood Flow Velocity</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> Elasticity</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Primary/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Pulsatile Flow</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="5" Year="2010">2010/5</year></dates><abstract><style face="normal" font="default">OBJECTIVE: It is still uncertain whether mild primary hyperparathyroidism (PHPT) carries the same risk for increased cardiovascular (CV) morbidity as the more severe symptomatic form. In recent years, the even more subtle normocalcemic (NC) variant is being increasingly recognized. We sought to compare the prevalence of CV risk factors in patients with NC- and hypercalcemic (HC)-PHPT, and to examine whether they differ on a battery of non-invasive vascular parameters. DESIGN/SUBJECTS/METHODS: A retrospective study of two cohorts of patients with PHPT in a referral center: 32 subjects with NC-PHPT and 81 subjects with HC-PHPT, compared for the presence of clinical and biochemical risk factors, and CV morbidity. Non-invasive parameters of arterial stiffness (augmentation index; pulse wave velocity; and vascular compliance indices, C1 and C2) were extracted from the data of gender- and age-matched subsets of these patients, and were related to those of a group of matched control subjects. RESULTS: Despite a similar prevalence of hypertension (approximately 62%), hyperlipidemia (approximately 30%), and impaired glucose metabolism in both PHPT groups, CV or cerebrovascular disease was more common in the HC-PHPT group (24.7 vs 3.1%, P=0.007). Arterial stiffness parameters did not differ in the three groups, and were unrelated to serum calcium or parathyroid hormone concentration. CONCLUSIONS: NC-PHPT and HC-PHPT subjects exhibit similar high rates of traditional CV risk factors, and have comparable indices of arterial stiffness. The lower clinical CV morbidity observed with NC-PHPT remains unexplained, and requires confirmation. Until then, the CV risk associated with NC-PHPT should not be underestimated</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - The Sackler Faculty of Medicine, Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel. karentor@tasmc.health.gov.ilJC - bxu, 9423848CP - EnglandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20421337</style></custom1><custom3><style face="normal" font="default">AS - EUR. J. ENDOCRINOL.. 162(5):925-33, 2010 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>556</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Travascio,L.</style></author><author><style face="normal" font="default"> Ciancamerla,M.</style></author><author><style face="normal" font="default"> Colandrea,M.</style></author><author><style face="normal" font="default"> Di Nicola,A.D.</style></author><author><style face="normal" font="default"> Giacomobono,S.</style></author><author><style face="normal" font="default"> Ugolini,F.</style></author><author><style face="normal" font="default"> Montesano,T.</style></author><author><style face="normal" font="default"> Ronga,G.</style></author></authors></contributors><titles><title><style face="normal" font="default">A finding of myocardial uptake at a bone scintigraphy with Tc-99m HDP</style></title><secondary-title><style face="normal" font="default">Clinica Terapeutica</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinica Terapeutica</style></full-title></periodical><pages end="420" start="419">419-420</pages><volume><style face="normal" font="default">159</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Artery Disease/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> *Heart/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> *Radiopharmaceuticals/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> *Technetium Tc 99m Medronate/aa [Analogs &amp; Derivatives]</style></keyword><keyword><style face="normal" font="default"> *Whole Body Imaging</style></keyword><keyword><style face="normal" font="default"> 0 (Radiopharmaceuticals)</style></keyword><keyword><style face="normal" font="default"> 1306-06-5 (Durapatite)</style></keyword><keyword><style face="normal" font="default"> 63347-66-0 (Technetium Tc 99m Medronate)</style></keyword><keyword><style face="normal" font="default"> 72945-61-0 (technetium Tc 99m hydroxymethylene diphosphonate)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Durapatite/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> Hip Prosthesis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypothyroidism/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Hypothyroidism/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Incidental Findings</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Prosthesis-Related Infections/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> Radiopharmaceuticals/pk [Pharmacokinetics]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Technetium Tc 99m Medronate/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> Technetium Tc 99m Medronate/pk [Pharmacokinetics]</style></keyword></keywords><dates><year Day="0" Month="11" Year="2008">2008/11</year></dates><abstract><style face="normal" font="default">We present a patient admitted to our Department for a Tc-99m HDP three-phase bone scintigraphy to evaluate a hip prosthesis. Delayed images showed diffuse myocardial uptake at whole body scan. In such cases, several diseases should be considered in the differential diagnosis</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Clinical Sciences, Policlinico Umberto I, La Sapienza University, Rome, Italy. laura.travascio@libero.itJC - dkn, 0372604CP - ItalyPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19169601</style></custom1><custom3><style face="normal" font="default">AS - Clin Ter. 159(6):419-20, 2008 Nov-Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>482</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Tripodi,A.</style></author><author><style face="normal" font="default"> Primignani,M.</style></author><author><style face="normal" font="default"> Chantarangkul,V.</style></author><author><style face="normal" font="default"> Viscardi,Y.</style></author><author><style face="normal" font="default"> Dell'Era,A.</style></author><author><style face="normal" font="default"> Fabris,F.M.</style></author><author><style face="normal" font="default"> Mannucci,P.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters</style></title><secondary-title><style face="normal" font="default">Thrombosis Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Thrombosis Research</style></full-title></periodical><pages end="136" start="132">132-136</pages><volume><style face="normal" font="default">124</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Blood Coagulation Disorders</style></keyword><keyword><style face="normal" font="default"> *Liver Cirrhosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Thrombelastography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Blood Coagulation Tests</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Liver Cirrhosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Thrombelastography/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="5" Year="2009">2009/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: Thromboelastometry allows continuous registration of the blood viscoelastic changes upon activation by cephaline or tissue-factor plus calcium-chloride. The technique is used as a near-patient-testing device to guide transfusion in cardiac surgery or liver transplantation and less to investigate hemostasis in acquired or congenital coagulopathies. AIMS: (i) Review of the coagulopathy associated with cirrhosis and (ii) report on its investigation by thromboelastometry in comparison with conventional coagulation parameters. METHODS: We investigated citrated blood samples from 51 adult cirrhotics for the following thromboelastometry parameters: coagulation-time (CT), clot-formation-time (CFT), maximum-clot-firmness (MCF). RESULTS: Relatively few patients [14/51(27%)] were identified as abnormal by CT; in contrast, a greater proportion were identified by the CFT [41/51(80%)] or MCF [39/51(76%)]. CFT and MCF were correlated with the platelet-count, antithrombin and fibrinogen. Prothrombin time (PT) was correlated with CFT and MCF. None of the coagulation parameters were correlated with CT. The correlation of the Child-Pugh-score (taken as index of severity) versus MCF or PT was -0.457(p &lt; 0.001) or 0.484(p &lt; 0.001), suggesting MCF as a suitable prognostic index. CFT and MCF, but not CT obtained ROC curves that were useful to distinguish patients from healthy individuals. CONCLUSIONS: Thromboelastometry, currently used to assist liver transplantation is also suitable for investigating stable cirrhosis. CFT and MCF are the most interesting parameters to be considered for future clinical studies needed to assess their value as measures of bleeding-risk and prognosis in this category of patients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine and Medical Specialties, University and IRCCS Ospedale Maggiore, Mangiagalli and Regina Elena Foundation, Milano, Italy. armando.tripodi@unimi.itJC - vrn, 0326377CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19135704</style></custom1><custom3><style face="normal" font="default">AS - Thromb Res. 124(1):132-6, 2009 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>565</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Tsai,M.Y.</style></author><author><style face="normal" font="default"> Johnson,C.</style></author><author><style face="normal" font="default"> Kao,W.H.</style></author><author><style face="normal" font="default"> Sharrett,A.R.</style></author><author><style face="normal" font="default"> Arends,V.L.</style></author><author><style face="normal" font="default"> Kronmal,R.</style></author><author><style face="normal" font="default"> Jenny,N.S.</style></author><author><style face="normal" font="default"> Jacobs,D.R.,Jr.</style></author><author><style face="normal" font="default"> Arnett,D.</style></author><author><style face="normal" font="default"> O'Leary,D.</style></author><author><style face="normal" font="default"> Post,W.</style></author></authors></contributors><titles><title><style face="normal" font="default">Cholesteryl ester transfer protein genetic polymorphisms, HDL cholesterol, and subclinical cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis</style></title><secondary-title><style face="normal" font="default">Atherosclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Atherosclerosis</style></full-title></periodical><pages end="367" start="359">359-367</pages><volume><style face="normal" font="default">200</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Cholesterol Ester Transfer Proteins/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Cholesterol,HDL/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Polymorphism,Genetic</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol Ester Transfer Proteins)</style></keyword><keyword><style face="normal" font="default"> 0 (Cholesterol,HDL)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Alleles</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Genetic Variation</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Ultrasonography</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="10" Year="2008">2008/10</year></dates><abstract><style face="normal" font="default">The cholesteryl ester transfer protein (CETP) plays a key role in high-density lipoprotein (HDL) metabolism. Genetic variants that alter CETP activity and concentration may cause significant alterations in HDL-cholesterol (HDL-C) concentration; however, controversies remain about whether these genetic variants are associated with atherosclerosis. We genotyped the CETP R451Q, A373P, -629C/A, Taq1B, and -2505C/A polymorphisms in a cohort of Caucasian, Chinese, African-American, and Hispanic individuals within the Multi-Ethnic Study of Atherosclerosis. Genotypes were examined in relationship to HDL-C, CETP activity, CETP concentration, and three measures of subclinical cardiovascular disease (CVD): coronary artery calcium (CAC) measured by fast CT scanning, carotid intimal-medial thickness (IMT), and carotid artery plaque measured by ultrasonography. Carriers of the 451Q and 373P alleles have a significantly higher CETP concentration (22.4% and 19.5%, respectively; p&lt;0.001) and activity (13.1% and 9.4%, respectively; p&lt;0.01) and lower HDL-C (5.6% and 6.0%, respectively; p&lt;0.05). The minor alleles of the R451Q and A373P polymorphisms are associated with the presence of CAC, even after adjusting for CVD risk factors and HDL-C (p=0.006 and p=0.01, respectively). The R451Q polymorphism is also associated with presence of carotid artery plaque (p=0.036). Polymorphism is associated with neither common nor internal carotid IMT. We confirmed that the -629A, Taq1B B2, and -2505A alleles are significantly associated with lower CETP concentration (20.8%, 25.0%, and 23.7%, respectively; p&lt;0.001) and activity (14.8%, 19.8%, and 18.4%, respectively; p&lt;0.001) and higher HDL-C concentration (9.7%, 11.5%, and 10.4%, respectively; p&lt;0.01). However, we did not find any associations between these non-coding polymorphisms and subclinical CVD</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Laboratory Medicine &amp; Pathology, University of Minnesota, Minneapolis, MN 55455, United States. tsaix001@umn.eduJC - 95x, 0242543CP - IrelandPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - N01-HC-95159 (United States NHLBI NIH HHS)NO - N01-HC-95167 (United States NHLBI NIH HHS)NO - N01-HC-95169 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18243217</style></custom1><custom3><style face="normal" font="default">AS - Atherosclerosis. 200(2):359-67, 2008 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>385</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Tsai,N.W.</style></author><author><style face="normal" font="default"> Lu,C.H.</style></author><author><style face="normal" font="default"> Chang,W.N.</style></author><author><style face="normal" font="default"> Shaw,C.F.</style></author><author><style face="normal" font="default"> Huang,C.R.</style></author><author><style face="normal" font="default"> Chen,S.D.</style></author><author><style face="normal" font="default"> Chuang,Y.C.</style></author><author><style face="normal" font="default"> Lee,L.H.</style></author><author><style face="normal" font="default"> Jan,C.R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Dysregulation of Ca2+ movement in platelets from patients with acute ischaemic stroke</style></title><secondary-title><style face="normal" font="default">Clinical &amp; Experimental Pharmacology &amp; Physiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinical &amp; Experimental Pharmacology &amp; Physiology</style></full-title></periodical><pages end="385" start="380">380-385</pages><volume><style face="normal" font="default">36</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Blood Platelets/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Calcium Signaling/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Ischemia/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Stroke/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Blood Platelets/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Ischemia/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Ischemia/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Platelet Activation/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Platelet Aggregation</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Stroke/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Stroke/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Thrombosis/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Thrombosis/pa [Pathology]</style></keyword></keywords><dates><year Day="0" Month="4" Year="2009">2009/4</year></dates><abstract><style face="normal" font="default">1. Platelets play a pivotal role during acute ischaemic stroke. An increase in cytosolic Ca(2+) concentrations ([Ca(2+)](i)) triggers intracellular signal transduction, leading to platelet aggregation and thrombosis. In the present study, we examined the differences between platelets from acute ischaemic stroke patients and at-risk controls in terms of the increase in platelet [Ca(2+)](i). 2. Thirty-one patients with acute ischaemic stroke and 27 at-risk controls were enrolled in the present study. Platelet [Ca(2+)](i) was measured using the fluorescent dye fura-2 after stimulation with 100 micromol/L arachidonic acid (AA), 10 micromol/L ADP, 1 micromol/L platelet-activation factor (PAF) and 0.1 U/mL thrombin. 3. Basal [Ca(2+)](i) was higher in the stroke group compared with at-risk controls, irrespective of the presence or absence of extracellular Ca(2+). In Ca(2+)-containing medium, both PAF and ADP, but not AA and thrombin, significantly increased platelet [Ca(2+)](i) in the stroke group compared with the at-risk controls. However, in Ca(2+)-free medium, only PAF significantly increased platelet [Ca(2+)](i) in the stroke group compared with the at-risk controls. Basal [Ca(2+)](i) and PAF-induced platelet [Ca(2+)](i) increases were still higher in the stroke group at the subacute stage than in the at-risk controls. 4. The results of the present study provide direct evidence that Ca(2+) signalling in platelets from acute ischaemic stroke patients was altered in response to particular stimuli. The dysregulation of Ca(2+) movement in platelets may persist up to the subacute stage of ischaemic stroke</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Neurology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, TaiwanJC - 0425076, dd8CP - AustraliaPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19018807</style></custom1><custom3><style face="normal" font="default">AS - Clin Exp Pharmacol Physiol. 36(4):380-5, 2009 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>25</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Tsiflikas,I.</style></author><author><style face="normal" font="default"> Drosch,T.</style></author><author><style face="normal" font="default"> Brodoefel,H.</style></author><author><style face="normal" font="default"> Thomas,C.</style></author><author><style face="normal" font="default"> Reimann,A.</style></author><author><style face="normal" font="default"> Till,A.</style></author><author><style face="normal" font="default"> Nittka,D.</style></author><author><style face="normal" font="default"> Kopp,A.F.</style></author><author><style face="normal" font="default"> Schroeder,S.</style></author><author><style face="normal" font="default"> Heuschmid,M.</style></author><author><style face="normal" font="default"> Burgstahler,C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Diagnostic accuracy and image quality of cardiac dual-source computed tomography in patients with arrhythmia</style></title><secondary-title><style face="normal" font="default">International Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">International Journal of Cardiology</style></full-title></periodical><pages end="85" start="79">79-85</pages><volume><style face="normal" font="default">143</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Arrhythmias,Cardiac/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Stenosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/st [Standards]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Artifacts</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography/st [Standards]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Image Processing,Computer-Assisted/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Image Processing,Computer-Assisted/st [Standards]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Reference Standards</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword></keywords><dates><year Day="6" Month="8" Year="2010">2010/8/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: Cardiac multi-detector computed tomography (MDCT) permits accurate visualization of high-grade coronary artery stenosis. However, in patients with heart rate irregularities, MDCT was found to have limitations. Thus, the aim of the present study was to evaluate the diagnostic accuracy of a new dual-source computed tomography (DSCT) scanner generation with 83 ms temporal resolution in patients without stable sinus rhythm. METHODS: 44 patients (31 men, mean age 67.5+/-9.2 years) without stable sinus rhythm and scheduled for invasive coronary angiography (ICA) because of suspected (n=17) or known coronary artery disease (CAD, n=27) were included in this study. All patients were examined with DSCT (Somatom Definition, Siemens). Besides assessment of total calcium score, all coronary segments were analyzed with regard to the presence of significant coronary artery lesions (>50%). The findings were compared to ICA in a blinded fashion. RESULTS: During CT examination, heart rhythm was as follows: 25 patients (57%) atrial fibrillation, 7 patients (16%) ventricular extrasystoles (two of them with atrial fibrillation), 4 patients (9%) supraventricular extrasystoles, 10 patients (23%) sinus arrhythmia (heart rate variability>10 bpm). Mean heart rate was 69+/-14 bpm, median 65 bpm. Mean Agatston score equivalent (ASE) was 762, ranging from 0 to 4949.7 ASE. Prevalence of CAD was 68% (30/44). 155 segments (27%) showed "step-ladder" artifacts and 28 segments (5%) could not be visualized by DSCT. Only 70 segments (12%) were completely imaged without any artifacts. Based on a coronary segment model, sensitivity was 73%, specificity 91%, positive predictive value 63%, and negative predictive value 94% for the detection of significant lesions (>or=50% diameter stenosis). Overall accuracy was 88%. CONCLUSIONS: In patients with heart rate irregularities, including patients with atrial fibrillation and a high prevalence of coronary artery disease, the diagnostic yield of dual-source computed tomography is still hampered due to a high number of segments with "step-ladder" artifacts. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Diagnostic Radiology, University Hospital Tuebingen, and Department of Internal Medicine-Sports Medicine, University of Tuebingen, GermanyJC - gqw, 8200291CP - NetherlandsPT - Clinical TrialPT - Journal ArticlePT - Validation StudiesLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19246109</style></custom1><custom3><style face="normal" font="default">AS - Int J Cardiol. 143(1):79-85, 2010 Aug 6.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>332</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Tsukamoto,S.</style></author><author><style face="normal" font="default"> Maruyama,K.</style></author><author><style face="normal" font="default"> Nakagawa,H.</style></author><author><style face="normal" font="default"> Iwase,Y.</style></author><author><style face="normal" font="default"> Kitamura,A.</style></author><author><style face="normal" font="default"> Hayashida,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Fatal hyperkalemia due to rapid red cell transfusion in a critically ill patient</style></title><secondary-title><style face="normal" font="default">Journal of Nippon Medical School = Nihon Ika Daigahu Zasshi</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Nippon Medical School = Nihon Ika Daigahu Zasshi</style></full-title></periodical><pages end="264" start="258">258-264</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Critical Illness</style></keyword><keyword><style face="normal" font="default"> *Erythrocyte Transfusion/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Hyperkalemia/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Shock,Hemorrhagic/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Fatal Outcome</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><isbn><style face="normal" font="default">1345-4676</style></isbn><abstract><style face="normal" font="default">A 60-year-old woman in severe hemorrhagic shock underwent urgent laparotomy to control massive hematemesis. Severe metabolic acidosis due to hemorrhagic shock and hyperkalemia as well as hypocalcemia associated with rapid blood transfusion were aggressively corrected with administration of sodium bicarbonate, insulin, and calcium chloride. Following rapid transfusion of the last 8 units of red cell concentrate (RCC), however, cardiac arrest occurred because of hyperkalemia and did not respond to cardiopulmonary resuscitation. Blood gas analysis revealed that the serum K(+) concentration had increased from 4.05 to 8.24 mEq/L over a 7-minute period, while the Ca(2+) concentration had decreased from 1.43 to 0.53 mmol/L. Rapid transfusion of irradiated RCC containing a high concentration of K(+), an extreme decrease in the circulating blood volume to dilute the exogenously administered K(+) and citrate, and severe metabolic acidosis impeding the intracellular shift of K(+) seemed to have contributed to the extremely rapid development of fetal hyperkalemia accompanied by hypocalcemia. Anesthesiologists must be aware that hyperkalemia due to rapid blood transfusion can develop extremely rapidly in patients in severe hemorrhagic shock</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Anesthesiology, International Medical Center, Saitama Medical University, Haidaka-city, Saitama, JapanJC - 100935589, dlaCP - JapanPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19915310</style></custom1><custom3><style face="normal" font="default">AS - J Nippon Med Sch. 76(5):258-64, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>268</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Uchida,T.</style></author><author><style face="normal" font="default"> Sugiura,J.</style></author><author><style face="normal" font="default"> Futagawa,K.</style></author><author><style face="normal" font="default"> Okamoto,S.</style></author><author><style face="normal" font="default"> Okuda,T.</style></author><author><style face="normal" font="default"> Koga,Y.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Case of myocardial infarction during emergency clipping surgery of a cerebral aneurysm]. [Japanese]</style></title><secondary-title><style face="normal" font="default">Masui - Japanese Journal of Anesthesiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Masui - Japanese Journal of Anesthesiology</style></full-title></periodical><pages end="1540" start="1538">1538-1540</pages><volume><style face="normal" font="default">58</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aneurysm,Ruptured/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Intracranial Aneurysm/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Intraoperative Complications/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> *Myocardial Infarction/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> *Vascular Surgical Procedures</style></keyword><keyword><style face="normal" font="default"> 51-43-4 (Epinephrine)</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Angioplasty,Transluminal,Percutaneous Coronary</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Electric Countershock</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> Epinephrine/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Subarachnoid Hemorrhage/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Subarachnoid Hemorrhage/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><isbn><style face="normal" font="default">0021-4892</style></isbn><abstract><style face="normal" font="default">An 80-year-old woman with subarachnoid hemorrhage underwent emergency neck clipping of a cerebral aneurysm. She had previously undergone surgery for an abdominal aortic aneurysm 10 years before. Anesthesia was induced with propofol and maintained with a combination of fentanyl and sevoflurane (0.5-1.5%) in air and oxygen. Ventricular fibrillation occurred immediately before clipping of the aneurysm, in the absence of preexisting myocardial ischemia, and recurred 4 times thereafter during the surgery. The ventricular fibrillation was successfully treated with cardioversion. We administered catecholamines, nitrates, calcium antagonists, nicorandil and heparin, following which the patient's hemodynamics gradually improved. After the operation, the patient was transferred to the cardiovascular center of a neighboring university where she successfully underwent emergency percutaneous transluminal coronary angioplasty. The patient was discharged from hospital 10 days later without any complications. Patients undergoing vascular surgical procedures or having a preoperative history of prior vascular surgery are at high risk for perioperative myocardial infarction. It is necessary to perform cardiac examination, including coronary angiography, preoperatively in such patients, even in those who are otherwise asymptomatic</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Anesthesiology, Nara Hospital, Kinki University School of Medicine, Ikoma 630-0293JC - khr, 0413707CP - JapanPT - Case ReportsPT - English AbstractPT - Journal ArticleLG - Japanese</style></notes><urls/><custom1><style face="normal" font="default">UI - 20055203</style></custom1><custom3><style face="normal" font="default">AS - Masui. 58(12):1538-40, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>129</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Uchida,Y.</style></author><author><style face="normal" font="default"> Uchida,Y.</style></author><author><style face="normal" font="default"> Kawai,S.</style></author><author><style face="normal" font="default"> Kanamaru,R.</style></author><author><style face="normal" font="default"> Sugiyama,Y.</style></author><author><style face="normal" font="default"> Tomaru,T.</style></author><author><style face="normal" font="default"> Maezawa,Y.</style></author><author><style face="normal" font="default"> Kameda,N.</style></author></authors></contributors><titles><title><style face="normal" font="default">Detection of vulnerable coronary plaques by color fluorescent angioscopy</style></title><secondary-title><style face="normal" font="default">Jacc: Cardiovascular Imaging</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Jacc: Cardiovascular Imaging</style></full-title></periodical><pages end="408" start="398">398-408</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Angioscopy</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 0 (Fluorescent Dyes)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipoproteins,LDL)</style></keyword><keyword><style face="normal" font="default"> 0 (oxidized low density lipoprotein)</style></keyword><keyword><style face="normal" font="default"> 57-88-5 (Cholesterol)</style></keyword><keyword><style face="normal" font="default"> 7235-40-7 (beta Carotene)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> 9007-34-5 (Collagen)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angioscopy</style></keyword><keyword><style face="normal" font="default"> Autopsy</style></keyword><keyword><style face="normal" font="default"> beta Carotene/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Biological Markers/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Cholesterol/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Collagen/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fluorescent Dyes/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lipoproteins,LDL/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Microscopy,Fluorescence</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">OBJECTIVES: This study was carried out to detect vulnerable coronary plaques by color fluorescent angioscopy. BACKGROUND: Collagen fibers (CFs) mainly provide mechanical support to coronary plaques. Oxidized low-density lipoprotein (Ox-LDL) induces macrophage proliferation, which in turn destroy CFs while accumulating lipids. As such, demonstration of the absence of CFs, deposition of lipids, and the Ox-LDL may suggest plaque instability. METHODS: Fluorescence of the major components of the atherosclerotic plaques was examined by fluorescent microscopy using a 345-nm band-pass filter and 420-nm band-absorption filter (A-imaging). Fluorescence of Ox-LDL was examined using a 470-nm band-pass filter and 515-nm band-absorption filter (B-imaging) and Evans blue dye as an indicator. Fluorescence in 57 excised human coronary plaques was examined by A-imaging color fluorescent angioscopy. Oxidized LDL in 31 excised coronary plaques and in 12 plaques of 7 patients was investigated by B-imaging color fluorescent angioscopy. RESULTS: Collagen I, collagen IV, and calcium exhibited blue, light blue, and white autofluorescence, respectively. In the presence of beta-carotene which coexists with lipids in the vascular wall, collagen I and IV exhibited green, collagen III and V white, cholesterol yellow, cholesteryl esters orange fluorescence. Oxidized LDL exhibited reddish brown fluorescence in the presence of Evans blue dye. Therefore, coronary plaques exhibited blue, green, white-to-light blue, or yellow-to-orange fluorescence based on plaque composition. Histological examination revealed abundant CFs without lipids in blue plaques; CFs and lipids in green plaques; meager CFs and abundant lipids in white-to-light blue plaques; and the absence of CFs and deposition of lipids, calcium, and macrophage foam cells in the thin fibrous cap in yellow-to-orange plaques, indicating that the yellow-to-orange plaques were most vulnerable. Reddish brown fluorescence characteristic of Ox-LDL was observed in excised coronary plaques, as also in patients. CONCLUSIONS: Color fluorescent angioscopy provides objective information related to coronary plaque composition and may help identify unstable plaques. Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Japan Foundation for Cardiovascular Research, Funabashi and Tokyo, Japan. uchiy@ta2.so-net.ne.jpJC - 101467978CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20394902</style></custom1><custom3><style face="normal" font="default">AS - JACC Cardiovasc Imaging. 3(4):398-408, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>419</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Uebleis,C.</style></author><author><style face="normal" font="default"> Becker,A.</style></author><author><style face="normal" font="default"> Griesshammer,I.</style></author><author><style face="normal" font="default"> Cumming,P.</style></author><author><style face="normal" font="default"> Becker,C.</style></author><author><style face="normal" font="default"> Schmidt,M.</style></author><author><style face="normal" font="default"> Bartenstein,P.</style></author><author><style face="normal" font="default"> Hacker,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Stable coronary artery disease: prognostic value of myocardial perfusion SPECT in relation to coronary calcium scoring--long-term follow-up</style></title><secondary-title><style face="normal" font="default">Radiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Radiology</style></full-title></periodical><pages end="690" start="682">682-690</pages><volume><style face="normal" font="default">252</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Artery Disease/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> *Tomography,Emission-Computed,Single-Photon/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Chi-Square Distribution</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Informed Consent</style></keyword><keyword><style face="normal" font="default"> Interviews as Topic</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardial Perfusion Imaging</style></keyword><keyword><style face="normal" font="default"> Perfusion</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Rest</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="9" Year="2009">2009/9</year></dates><abstract><style face="normal" font="default">PURPOSE: To evaluate the incremental prognostic value of coronary artery calcification (CAC) scoring over single photon emission computed tomographic (SPECT) myocardial perfusion imaging in long-term prognosis and survival of patients with stable coronary artery disease (CAD). MATERIALS AND METHODS: All patients provided written informed consent to undergo CAC scoring according to a protocol that was approved by the local clinical institutional review board. Over a median follow-up time of 5.4 years, 260 patients with stable CAD were followed up for severe cardiac events (cardiac death or nonfatal myocardial infarction). CAC scanning and SPECT myocardial perfusion imaging were performed at enrollment. Patients were stratified on the basis of well-established cutoff points for CAC score, summed stress score (SSS), and summed rest score (SRS). Kaplan-Meier survival curves and the Cox proportional hazards model were used. RESULTS: CAC score and SRS were identified as the only independent predictors of event-free survival. Patients with perfusion abnormalities at rest (SRS > or = 2), a CAC score greater than 400, or severe perfusion abnormalities under stress (SSS > or = 13) were identified as having significantly increased risk for subsequent severe cardiac events (P = .023, .0095, and .007, respectively). In addition, a CAC score greater than 400 offered incremental prognostic value over the scintigraphic scores alone (P = .028 with an SSS > 8; P = .008 with an SRS > or = 2). CONCLUSION: CAC score and SRS were identified as independent predictors of severe cardiac events during long-term follow-up of patients with known CAD. CAC scores imparted superior risk stratification information as compared with SPECT myocardial perfusion imaging results alone</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Nuclear Medicine, University of Munich, Marchioninistrasse 15, 81377 Munich, GermanyJC - qsh, 0401260CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19703866</style></custom1><custom3><style face="normal" font="default">AS - Radiology. 252(3):682-90, 2009 Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>386</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Urbanov&amp;#x00E1</style></author><author><style face="normal" font="default"> M</style></author><author><style face="normal" font="default"> Kalousov&amp;#x00E1</style></author><author><style face="normal" font="default"> M</style></author><author><style face="normal" font="default"> Zima,T.</style></author><author><style face="normal" font="default"> Skibov&amp;#x00E1</style></author><author><style face="normal" font="default"> J</style></author><author><style face="normal" font="default"> Wohlfahrt,P.</style></author><author><style face="normal" font="default"> Viklick&amp;#x00FD</style></author><author><style face="normal" font="default"> O</style></author></authors></contributors><titles><title><style face="normal" font="default">Fetuin-A early after renal transplantation</style></title><secondary-title><style face="normal" font="default">Kidney &amp; Blood Pressure Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Kidney &amp; Blood Pressure Research</style></full-title></periodical><pages end="222" start="217">217-222</pages><volume><style face="normal" font="default">32</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*alpha-Fetoproteins/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> *Kidney Transplantation</style></keyword><keyword><style face="normal" font="default"> 0 (alpha-Fetoproteins)</style></keyword><keyword><style face="normal" font="default"> 0 (Immunosuppressive Agents)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Calcineurin/ai [Antagonists &amp; Inhibitors]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Czech Republic</style></keyword><keyword><style face="normal" font="default"> EC 3-1-3-16 (Calcineurin)</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immunosuppressive Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Kidney Function Tests</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><abstract><style face="normal" font="default">BACKGROUND: Fetuin-A is a major inhibitor of ectopic calcium phosphate precipitation and an acute phase reactant. Its deficiency, common in end-stage renal disease, has been suggested to be associated with cardiovascular complications. The aim of this study was to monitor fetuin-A levels in the early period after renal transplantation. METHODS: 30 deceased donor kidney recipients treated with calcineurin inhibitor-based immunosuppression were followed prospectively for the first 3 months and the association of fetuin-A levels with clinical and laboratory parameters was evaluated. RESULTS: Despite a correlation of fetuin-A levels with creatinine clearance (r = 0.348, p &lt; 0.01) and estimated GFR (r = 0.331, p &lt; 0.01), no significant increase in fetuin-A levels over the first 3 months was observed. Moreover, a significant decrease in serum fetuin-A levels was noted at 2 weeks (p &lt; 0.001). Subsequently, fetuin-A levels increased (p &lt; 0.001) reaching pretransplant values at month 3. CONCLUSIONS: In this study there was no increase of fetuin-A levels during the first 3 months, but a decrease 2 weeks after transplantation was observed. Copyright (c) 2009 S. Karger AG, Basel</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Nephrology, Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech RepublicJC - ckc, 9610505CP - SwitzerlandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19622896</style></custom1><custom3><style face="normal" font="default">AS - Kidney Blood Press Res. 32(3):217-22, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>214</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Uz,O.</style></author><author><style face="normal" font="default"> lu,E.</style></author><author><style face="normal" font="default"> iner,O.</style></author><author><style face="normal" font="default"> Ba&amp;#x015F</style></author><author><style face="normal" font="default"> S</style></author><author><style face="normal" font="default"> lu,O.M.</style></author><author><style face="normal" font="default"> Ozmen,N.</style></author><author><style face="normal" font="default"> Aparci,M.</style></author><author><style face="normal" font="default"> zbay,B.Y.</style></author><author><style face="normal" font="default"> ilak,Z.</style></author><author><style face="normal" font="default"> Cebeci,B.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">The relationship between coronary calcification and the metabolic markers of osteopontin, fetuin-A, and visfatin</style></title><secondary-title><style face="normal" font="default">Turk Kardiyoloji Dernegi Arsivi</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Turk Kardiyoloji Dernegi Arsivi</style></full-title></periodical><pages end="402" start="397">397-402</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*alpha-Fetoproteins/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Nicotinamide Phosphoribosyltransferase/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Osteopontin/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (alpha-Fetoproteins)</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 106441-73-0 (Osteopontin)</style></keyword><keyword><style face="normal" font="default"> 57-88-5 (Cholesterol)</style></keyword><keyword><style face="normal" font="default"> Biological Markers/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Cholesterol/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> EC 2-4-2-12 (Nicotinamide Phosphoribosyltransferase)</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Pulse</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword></keywords><dates><year Day="0" Month="9" Year="2009">2009/9</year></dates><isbn><style face="normal" font="default">1016-5169</style></isbn><abstract><style face="normal" font="default">OBJECTIVES: We investigated whether coronary calcification detected by multislice computed tomography (MSCT) was correlated with plasma osteopontin, serum fetuin-A, and visfatin levels. STUDY DESIGN: The study included 64 consecutive patients (51 males, 13 females; mean age 49.5+/-10.9 years; range 33 to 78 years) who underwent MSCT for suspected coronary artery disease. Coronary artery calcification (CAC) scores of the patients were calculated using the Agatston scoring method. Plasma osteopontin, serum fetuin-A, and visfatin levels were measured from fasting blood samples and correlations were sought with calcium scores. RESULTS: Coronary calcification was detected in 32 patients (50%). The mean CAC score was 146.5+/-333.7 Agatston units (AU), indicating an intermediate risk for coronary artery disease. In 10 patients (15.6%), the CAC score exceeded 400 AU. The mean fetuin-A, visfatin, and osteopontin levels were 25.6+/-6.4 ng/ml, 19.7+/-47.2 ng/ml, and 20.4+/-16.1 ng/ml, respectively. Serum visfatin (r=0.15, p=0.37) and fetuin-A (r=0.17, p=0.22) were not correlated with the CAC score, whereas plasma osteopontin level showed a moderate correlation with the CAC score (r=0.35; p=0.008). In ROC analysis, the area under the curve for identification of CAC was greatest for osteopontin (0.741; p=0.004), followed by fetuin-A (0.574; p=0.31), and visfatin (0.580; p=0.27). The cut-off value was 18.45 ng/ml for osteopontin, with a sensitivity of 72% and specificity of 73%. CONCLUSION: Our results suggest that there might be an association between CAC and plasma osteopontin levels. Research should continue to find out a metabolic parameter that will strongly indicate coronary calcification</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, GATA Haydarpa&amp;#x015F;a Training Hospital, Istanbul, Turkey. homeruz@yahoo.comJC - 9426239CP - TurkeyPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20019453</style></custom1><custom3><style face="normal" font="default">AS - TURK KARDIYOLOJI DERNEGI ARS.. 37(6):397-402, 2009 Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>412</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">van der Pols,J.C.</style></author><author><style face="normal" font="default"> Gunnell,D.</style></author><author><style face="normal" font="default"> Williams,G.M.</style></author><author><style face="normal" font="default"> Holly,J.M.</style></author><author><style face="normal" font="default"> Bain,C.</style></author><author><style face="normal" font="default"> Martin,R.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Childhood dairy and calcium intake and cardiovascular mortality in adulthood: 65-year follow-up of the Boyd Orr cohort</style></title><secondary-title><style face="normal" font="default">Heart</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Heart</style></full-title></periodical><pages end="1606" start="1600">1600-1606</pages><volume><style face="normal" font="default">95</style></volume><number><style face="normal" font="default">19</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcium,Dietary/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> *Coronary Disease/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> *Dairy Products/ut [Utilization]</style></keyword><keyword><style face="normal" font="default"> *Stroke/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> 0 (Calcium,Dietary)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cause of Death</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Dairy Products</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> England/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Scotland/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Socioeconomic Factors</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Dairy consumption in childhood may have long-term effects on cardiovascular mortality through influencing the development of risk factors or programming effects. OBJECTIVE: To investigate whether dairy and calcium consumption in childhood is associated with adult mortality due to coronary heart disease (CHD), stroke and all causes. METHODS: In 1937-9, 4999 children in England and Scotland participated in a study of family food consumption, assessed from 7-day household food inventories. Cause of death was ascertained between 1948 and 2005 in 4374 traced cohort members with complete data. Per capita household intake estimates for dairy products and calcium were used as proxies for individual intake. RESULTS: No strong evidence that a family diet in childhood high in dairy products was associated with CHD or stroke mortality was found. However, childhood calcium intake was inversely associated with stroke mortality (multivariable adjusted hazard ratio (HR) for highest versus lowest calcium group: 0.41; 95% confidence interval (CI) 0.16 to 1.05; p for trend = 0.04), but not CHD mortality. All-cause mortality was lowest in those with the highest family dairy (HR = 0.77; 95% CI 0.61 to 0.98; p for trend = 0.04) and calcium intake (HR = 0.77, 95% CI 0.60 to 0.98; p for trend = 0.05). CONCLUSIONS: Children whose family diet in the 1930s was high in calcium were at reduced risk of death from stroke. Furthermore, childhood diets rich in dairy or calcium were associated with lower all-cause mortality in adulthood. Replication in other study populations is needed to determine whether residual confounding explains part of these findings</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Cancer and Population Studies Group, Queensland Institute of Medical Research, 300 Herston Road, Brisbane, Australia, QLD 4006, Australia. jolieke.vanderpols@qimr.edu.auJC - 9602087CP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19643770</style></custom1><custom3><style face="normal" font="default">AS - Heart. 95(19):1600-6, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>523</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">van der Worp,H.B.</style></author><author><style face="normal" font="default"> Fonville,S.</style></author><author><style face="normal" font="default"> Ramos,L.M.</style></author><author><style face="normal" font="default"> Rinkel,G.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Recurrent perimesencephalic subarachnoid hemorrhage during antithrombotic therapy</style></title><secondary-title><style face="normal" font="default">Neurocritical Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Neurocritical Care</style></full-title></periodical><pages end="212" start="209">209-212</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Acute Coronary Syndrome/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Anticoagulants/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Aspirin/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Heparin/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Platelet Aggregation Inhibitors/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Subarachnoid Hemorrhage/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> 0 (Anticoagulants)</style></keyword><keyword><style face="normal" font="default"> 0 (Platelet Aggregation Inhibitors)</style></keyword><keyword><style face="normal" font="default"> 50-78-2 (Aspirin)</style></keyword><keyword><style face="normal" font="default"> 9005-49-6 (Heparin)</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Anticoagulants/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Aspirin/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cerebral Angiography</style></keyword><keyword><style face="normal" font="default"> Fatal Outcome</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heparin/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Mesencephalon/bs [Blood Supply]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardial Ischemia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Platelet Aggregation Inhibitors/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Subarachnoid Hemorrhage/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><isbn><style face="normal" font="default">1541-6933</style></isbn><abstract><style face="normal" font="default">INTRODUCTION: In patients with non-aneurysmal perimesencephalic hemorrhage, spontaneous rebleeding does not occur. The lack of reported recurrences may lead to less cautious administration of antithrombotic therapy. METHODS: Case report. RESULTS: A 57-year-old woman with a perimesencephalic pattern of hemorrhage and negative CT angiography was treated with carbasalate calcium and intravenous heparin because of an acute coronary syndrome. Three days after installment of this antithrombotic therapy she experienced a recurrent perimesencephalic hemorrhage leading to hydrocephalus and a decrease in consciousness. She died the same day as a result of ventricular fibrillation. CONCLUSION: In the early phase after perimesencephalic hemorrhage, anticoagulant therapy may lead to rebleeding. The risks and benefits of antithrombotic therapy should be carefully weighed in patients with a perimesencephalic pattern of hemorrhage and negative CT angiography</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Neurology, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Heidelberglaan 100, 3584 Utrecht, The Netherlands. h.b.vanderworp@umcutrecht.nlJC - 101156086CP - United StatesPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18972074</style></custom1><custom3><style face="normal" font="default">AS - Neurocrit Care. 10(2):209-12, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>135</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">van der,Bijl N.</style></author><author><style face="normal" font="default"> de Bruin,P.W.</style></author><author><style face="normal" font="default"> Geleijns,J.</style></author><author><style face="normal" font="default"> Bax,J.J.</style></author><author><style face="normal" font="default"> Schuijf,J.D.</style></author><author><style face="normal" font="default"> de,Roos A.</style></author><author><style face="normal" font="default"> Kroft,L.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Assessment of coronary artery calcium by using volumetric 320-row multi-detector computed tomography: comparison of 0.5 mm with 3.0 mm slice reconstructions</style></title><secondary-title><style face="normal" font="default">The International Journal of Cardiovascular Imaging</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">The International Journal of Cardiovascular Imaging</style></full-title></periodical><pages end="482" start="473">473-482</pages><volume><style face="normal" font="default">26</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Radiographic Image Interpretation,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Statistics,Nonparametric</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">The purpose of this study was to assess the performance of 0.5 versus 3.0 mm slice reconstructions in depicting coronary calcium with special attention to patients having zero calcium scores at 3.0 mm reconstructions by using computed tomography (CT). Imaging was performed by volumetric 320-detector row CT. Scans of 100 patients with a negative and 100 patients with a positive Agatston score at 3.0 mm reconstructions were consecutively selected. Non-overlapping volume sets with 3.0 and 0.5 mm slice thickness were reconstructed from the same raw data and Agatston and volume scores were obtained. The Wilcoxon signed ranks test was used to determine statistical differences between 3.0 and 0.5 mm calcium scores. Agatston and volume scores obtained at 0.5 mm were significantly higher than at 3.0 mm reconstructions (mean Agatston score: 266 +/- 495 vs. 231 +/- 461. Mean volume score: 223 +/- 399 vs. 206 +/- 385, both P &lt; 0.01). In 21% of patients with zero 3.0 mm Agatston scores, a positive Agatston and/or volume score was found at 0.5 mm reconstructions. With volumetric 320-detector row CT, prospective ECG-triggered calcium scoring at 0.5 mm compared to 3.0 mm reconstructions leads to an increase in Agatston and volume scores and small amounts of coronary calcium are earlier depicted. This may be of special interest in patients with zero calcium scores with traditional 3.0 mm measures, where 0.5 mm reconstructions may help in superior depicting or ruling out coronary artery disease</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Radiology, C2-S, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. n.van_der_bijl@lumc.nlJC - 100969716CP - United StatesPT - Comparative StudyPT - Evaluation StudiesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20072817</style></custom1><custom3><style face="normal" font="default">AS - Int J Cardiovasc Imaging. 26(4):473-82, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>509</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">van Dijk,S.J.</style></author><author><style face="normal" font="default"> Dooijes,D.</style></author><author><style face="normal" font="default"> dos,Remedios C.</style></author><author><style face="normal" font="default"> Michels,M.</style></author><author><style face="normal" font="default"> Lamers,J.M.</style></author><author><style face="normal" font="default"> Winegrad,S.</style></author><author><style face="normal" font="default"> Schlossarek,S.</style></author><author><style face="normal" font="default"> Carrier,L.</style></author><author><style face="normal" font="default"> ten Cate,F.J.</style></author><author><style face="normal" font="default"> Stienen,G.J.</style></author><author><style face="normal" font="default"> van,der,V</style></author></authors></contributors><titles><title><style face="normal" font="default">Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction</style></title><secondary-title><style face="normal" font="default">Circulation</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Circulation</style></full-title></periodical><pages end="1483" start="1473">1473-1483</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiomyopathy,Hypertrophic,Familial/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Cardiomyopathy,Hypertrophic,Familial/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Carrier Proteins/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Carrier Proteins/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> 0 (Carrier Proteins)</style></keyword><keyword><style face="normal" font="default"> 0 (myosin-binding protein C)</style></keyword><keyword><style face="normal" font="default"> 0 (RNA,Messenger)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Frameshift Mutation</style></keyword><keyword><style face="normal" font="default"> Haplotypes</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Myocardial Contraction/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Myocardium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Myocardium/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Myocytes,Cardiac/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Myocytes,Cardiac/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Phosphorylation</style></keyword><keyword><style face="normal" font="default"> Phosphorylation/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> RNA,Messenger/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Sarcomeres/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="24" Month="3" Year="2009">2009/3/24</year></dates><abstract><style face="normal" font="default">BACKGROUND: Mutations in the MYBPC3 gene, encoding cardiac myosin-binding protein C (cMyBP-C), are a frequent cause of familial hypertrophic cardiomyopathy. In the present study, we investigated whether protein composition and function of the sarcomere are altered in a homogeneous familial hypertrophic cardiomyopathy patient group with frameshift mutations in MYBPC3 (MYBPC3(mut)). METHODS AND RESULTS: Comparisons were made between cardiac samples from MYBPC3 mutant carriers (c.2373dupG, n=7; c.2864_2865delCT, n=4) and nonfailing donors (n=13). Western blots with the use of antibodies directed against cMyBP-C did not reveal truncated cMyBP-C in MYBPC3(mut). Protein expression of cMyBP-C was significantly reduced in MYBPC3(mut) by 33+/-5%. Cardiac MyBP-C phosphorylation in MYBPC3(mut) samples was similar to the values in donor samples, whereas the phosphorylation status of cardiac troponin I was reduced by 84+/-5%, indicating divergent phosphorylation of the 2 main contractile target proteins of the beta-adrenergic pathway. Force measurements in mechanically isolated Triton-permeabilized cardiomyocytes demonstrated a decrease in maximal force per cross-sectional area of the myocytes in MYBPC3(mut) (20.2+/-2.7 kN/m(2)) compared with donor (34.5+/-1.1 kN/m(2)). Moreover, Ca(2+) sensitivity was higher in MYBPC3(mut) (pCa(50)=5.62+/-0.04) than in donor (pCa(50)=5.54+/-0.02), consistent with reduced cardiac troponin I phosphorylation. Treatment with exogenous protein kinase A, to mimic beta-adrenergic stimulation, did not correct reduced maximal force but abolished the initial difference in Ca(2+) sensitivity between MYBPC3(mut) (pCa(50)=5.46+/-0.03) and donor (pCa(50)=5.48+/-0.02). CONCLUSIONS: Frameshift MYBPC3 mutations cause haploinsufficiency, deranged phosphorylation of contractile proteins, and reduced maximal force-generating capacity of cardiomyocytes. The enhanced Ca(2+) sensitivity in MYBPC3(mut) is due to hypophosphorylation of troponin I secondary to mutation-induced dysfunction</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Laboratory for Physiology, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The NetherlandsJC - daw, 0147763CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19273718</style></custom1><custom3><style face="normal" font="default">AS - Circulation. 119(11):1473-83, 2009 Mar 24.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>363</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">van Velzen,J.E.</style></author><author><style face="normal" font="default"> Schuijf,J.D.</style></author><author><style face="normal" font="default"> de Graaf,F.R.</style></author><author><style face="normal" font="default"> Nucifora,G.</style></author><author><style face="normal" font="default"> Pundziute,G.</style></author><author><style face="normal" font="default"> Jukema,J.W.</style></author><author><style face="normal" font="default"> Schalij,M.J.</style></author><author><style face="normal" font="default"> Kroft,L.J.</style></author><author><style face="normal" font="default"> de,Roos A.</style></author><author><style face="normal" font="default"> Reiber,J.H.</style></author><author><style face="normal" font="default"> van der Wall,E.E.</style></author><author><style face="normal" font="default"> Bax,J.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Plaque type and composition as evaluated non-invasively by MSCT angiography and invasively by VH IVUS in relation to the degree of stenosis</style></title><secondary-title><style face="normal" font="default">Heart</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Heart</style></full-title></periodical><pages end="1996" start="1990">1990-1996</pages><volume><style face="normal" font="default">95</style></volume><number><style face="normal" font="default">24</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Stenosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Echocardiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Tunica Intima/pa [Pathology]</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Imaging of coronary plaques has traditionally focused on evaluating degree of stenosis, as the risk for adverse cardiac events increases with stenosis severity. However, the relation between plaque composition and severity of stenosis remains largely unknown. OBJECTIVE: To assess plaque composition (non-invasively by multislice computed tomography (MSCT) angiography and invasively by virtual histology intravascular ultrasound (VH IVUS)) in relation to degree of stenosis. METHODS: 78 patients underwent MSCT (identifying three plaque types; non-calcified, calcified, mixed) followed by invasive coronary angiography and VH IVUS. VH IVUS evaluated plaque burden, minimal lumen area and plaque composition (fibrotic, fibro-fatty, necrotic core, dense calcium) and plaques were classified as fibrocalcific, fibroatheroma, thin-capped fibroatheroma (TCFA), pathological intimal thickening. For each plaque, percentage stenosis was evaluated by quantitative coronary angiography. Significant stenosis was defined >50% stenosis. RESULTS: Overall, 43 plaques (19%) corresponded to significant stenosis. Of the 227 plaques analysed, 70 were non-calcified plaques (31%), 96 mixed (42%) and 61 calcified (27%) on MSCT. Plaque types on MSCT were equally distributed among significant and non-significant stenoses. VH IVUS identified that plaques with significant stenosis had higher plaque burden (67% (11%) vs 53% (12%), p&lt;0.05) and smaller minimal lumen area (4.6 (3.8-6.8) mm(2) vs 7.3 (5.4-10.5) mm(2), p&lt;0.05). Interestingly, no differences were observed in percentage fibrotic, fibro-fatty, necrotic core and dense calcium. Non-significant stenoses were more frequently classified as pathological intimal thickening (46 (25%) vs 3 (7%), p&lt;0.05), although TCFA (more vulnerable plaque) was distributed equally (p = 0.18). CONCLUSION: No evident association exists between the degree of stenosis and plaque composition or vulnerability, as evaluated non-invasively by MSCT and invasively by VH IVUS</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Leiden University Medical Centre, Leiden, The NetherlandsJC - 9602087CP - EnglandPT - Evaluation StudiesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19846418</style></custom1><custom3><style face="normal" font="default">AS - Heart. 95(24):1990-6, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>508</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">van Vliet,E.I.</style></author><author><style face="normal" font="default"> van Ouwerkerk,B.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Hypocalcaemia as presenting symptom of velocardiofacial syndrome</style></title><secondary-title><style face="normal" font="default">Netherlands Journal of Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Netherlands Journal of Medicine</style></full-title></periodical><pages end="106" start="105">105-106</pages><volume><style face="normal" font="default">67</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*DiGeorge Syndrome/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Hypocalcemia/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword></keywords><dates><year Day="0" Month="3" Year="2009">2009/3</year></dates><isbn><style face="normal" font="default">0300-2977</style></isbn><abstract><style face="normal" font="default">Hypocalcaemia due to hypoparathyroidism is a rare finding in adults. The coexistence of cardiac abnormalities may be suggestive of a hereditary syndrome. We describe a case of velocardiofacial syndrome in a woman without a family history of this disorder. The hypocalcaemia was treated with calcium and vitamin D supplementation</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the NetherlandsJC - nwy, 0356133CP - NetherlandsPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19307682</style></custom1><custom3><style face="normal" font="default">AS - Neth J Med. 67(3):105-6, 2009 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>180</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Van Werkhoven,J.M.</style></author><author><style face="normal" font="default"> Schuijf,J.D.</style></author><author><style face="normal" font="default"> Gaemperli,O.</style></author><author><style face="normal" font="default"> Jukema,J.W.</style></author><author><style face="normal" font="default"> Kroft,L.J.</style></author><author><style face="normal" font="default"> Boersma,E.</style></author><author><style face="normal" font="default"> Pazhenkottil,A.</style></author><author><style face="normal" font="default"> Valenta,I.</style></author><author><style face="normal" font="default"> Pundziute,G.</style></author><author><style face="normal" font="default"> de,Roos A.</style></author><author><style face="normal" font="default"> van der Wall,E.E.</style></author><author><style face="normal" font="default"> Kaufmann,P.A.</style></author><author><style face="normal" font="default"> Bax,J.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Incremental prognostic value of multi-slice computed tomography coronary angiography over coronary artery calcium scoring in patients with suspected coronary artery disease</style></title><secondary-title><style face="normal" font="default">European Heart Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">European Heart Journal</style></full-title></periodical><pages end="2629" start="2622">2622-2629</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">21</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angina Pectoris/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Angina Pectoris/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Angina Pectoris/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Myocardial Revascularization/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Myocardial Revascularization/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed/mo [Mortality]</style></keyword></keywords><dates><year Day="0" Month="11" Year="2009">2009/11</year></dates><abstract><style face="normal" font="default">AIMS: The purpose of this study was to assess the relationship between calcium scoring (CS) and multi-slice computed tomography coronary angiography (MSCTA) and to determine if MSCTA has an incremental prognostic value to CS. METHODS AND RESULTS: In 432 patients (59% male, age 58 +/- 11 years) referred for cardiac evaluation owing to suspected coronary artery disease (CAD), CS and 64-slice MSCTA were performed. The following events were combined in a composite endpoint: all-cause mortality, non-fatal infarction, and unstable angina requiring revascularization. CS was 0 in 147 (34%) patients, CS 1-99 was present in 122 (28%), CS 100-399 in 75 (17%), CS 400-999 in 56 (13%), and CS > or = 1000 in 32 (7%). MSCTA was normal in 133 (31%) patients, MSCTA 30-50% stenosis was observed in 190 (44%), and MSCTA > or =50% stenosis in 109 (25%). During follow-up [median 670 days (25th-75th percentile: 418-895)], an event occurred in 21 patients (4.9%). After multivariate correction for CS, MSCTA > or = 50% stenosis, the number of diseased segments, obstructive segments, and non-calcified plaques were independent predictors with an incremental prognostic value to CS. CONCLUSION: MSCTA provides additional information to CS regarding stenosis severity and plaque composition. This additional information was shown to translate into incremental prognostic value over CS</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The NetherlandsJC - em8, 8006263CP - EnglandPT - Evaluation StudiesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19567382</style></custom1><custom3><style face="normal" font="default">AS - Eur Heart J. 30(21):2622-9, 2009 Nov.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>124</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Van Werkhoven,J.M.</style></author><author><style face="normal" font="default"> Cademartiri,F.</style></author><author><style face="normal" font="default"> Seitun,S.</style></author><author><style face="normal" font="default"> Maffei,E.</style></author><author><style face="normal" font="default"> Palumbo,A.</style></author><author><style face="normal" font="default"> Martini,C.</style></author><author><style face="normal" font="default"> Tarantini,G.</style></author><author><style face="normal" font="default"> Kroft,L.J.</style></author><author><style face="normal" font="default"> de,Roos A.</style></author><author><style face="normal" font="default"> Weustink,A.C.</style></author><author><style face="normal" font="default"> Jukema,J.W.</style></author><author><style face="normal" font="default"> Ardissino,D.</style></author><author><style face="normal" font="default"> Mollet,N.R.</style></author><author><style face="normal" font="default"> Schuijf,J.D.</style></author><author><style face="normal" font="default"> Bax,J.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Diabetes: prognostic value of CT coronary angiography--comparison with a nondiabetic population</style></title><secondary-title><style face="normal" font="default">Radiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Radiology</style></full-title></periodical><pages end="92" start="83">83-92</pages><volume><style face="normal" font="default">256</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 2/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Chi-Square Distribution</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Electrocardiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword></keywords><dates><year Day="0" Month="7" Year="2010">2010/7</year></dates><abstract><style face="normal" font="default">PURPOSE: To evaluate the prognostic value of multidetector computed tomographic (CT) coronary angiography in a diabetic population known to have or suspected of having coronary artery disease (CAD) compared with that in nondiabetic individuals. MATERIALS AND METHODS: Institutional review board approval and patient informed consent were obtained. Three hundred thirteen patients with type 2 diabetes mellitus (DM) and 303 patients without DM underwent unenhanced 64-detector row CT, at which a calcium score was obtained, followed by CT angiography. Multidetector CT coronary angiograms were retrospectively classified as normal, showing nonobstructive CAD (&lt;or=50% luminal narrowing), or showing obstructive CAD (>50% luminal narrowing). During follow-up after CT angiography, major events (cardiac death, nonfatal myocardial infarction, and unstable angina requiring hospitalization) and total events (major events plus coronary revascularizations) were recorded for each patient. Cox proportional hazards analysis and Kaplan-Meier analysis were used to compare survival rates. RESULTS: In the group of 313 patients with DM, there were 213 men, and the mean age was 62 years +/- 11 (standard deviation). In the group of 303 patients without DM, there were 203 men, and the mean age was 63 years +/- 11. The mean number of diseased segments (5.6 vs 4.4, P = .001) and the rate of obstructive CAD (51% vs 37%, P &lt; .001) were higher in patients with DM. Patients were followed up for a mean of 20 months +/- 5.4 (range, 6-44 months). At multivariate analysis, DM (P &lt; .001) and evidence of obstructive CAD (P &lt; .001) were independent predictors of outcome. Obstructive CAD remained a significant multivariate predictor for both patients with DM and patients without DM. In both patients with DM and patients without DM with absence of disease, the event rate was 0%. The event rate increased to 36% in patients without DM but with obstructive CAD and was highest (47%) in patients with DM and obstructive CAD. CONCLUSION: In both patients with DM and patients without DM, multidetector CT coronary angiography provides incremental prognostic information over baseline clinical variables, and the absence of atherosclerosis at CT coronary angiography is associated with an excellent prognosis. Multidetector CT coronary angiography might be a clinically useful tool for improving risk stratification in both patients with DM and patients without DM</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Departments of Cardiology and Radiology, Leiden University Medical Center, Leiden, the NetherlandsJC - qsh, 0401260CP - United StatesPT - Comparative StudyPT - Journal ArticlePT - Multicenter StudyPT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20574086</style></custom1><custom3><style face="normal" font="default">AS - Radiology. 256(1):83-92, 2010 Jul.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>536</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Van,Campenhout A.</style></author><author><style face="normal" font="default"> Moran,C.S.</style></author><author><style face="normal" font="default"> Parr,A.</style></author><author><style face="normal" font="default"> Clancy,P.</style></author><author><style face="normal" font="default"> Rush,C.</style></author><author><style face="normal" font="default"> Jakubowski,H.</style></author><author><style face="normal" font="default"> Golledge,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Role of homocysteine in aortic calcification and osteogenic cell differentiation</style></title><secondary-title><style face="normal" font="default">Atherosclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Atherosclerosis</style></full-title></periodical><pages end="566" start="557">557-566</pages><volume><style face="normal" font="default">202</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aortic Diseases/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Aortic Diseases/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Homocysteine/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> 454-28-4 (Homocysteine)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cell Communication/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Cell Communication/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Cell Differentiation</style></keyword><keyword><style face="normal" font="default"> Cell Differentiation/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Cell Differentiation/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Cell Line</style></keyword><keyword><style face="normal" font="default"> Cells,Cultured</style></keyword><keyword><style face="normal" font="default"> Fasting</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Homocysteine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Monocytes/cy [Cytology]</style></keyword><keyword><style face="normal" font="default"> Monocytes/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Monocytes/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Myocytes,Smooth Muscle/cy [Cytology]</style></keyword><keyword><style face="normal" font="default"> Myocytes,Smooth Muscle/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Myocytes,Smooth Muscle/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Osteogenesis</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="2" Year="2009">2009/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: The role of homocysteine in atherosclerosis is unclear. We examined the relationship between plasma homocysteine and infrarenal aortic calcification, the presence of homocysteine in human atheroma and the influence of homocysteine on osteogenic differentiation in vitro. METHODS AND RESULTS: In 194 patients with symptomatic peripheral artery disease or abdominal aortic aneurysm, fasting plasma total homocysteine was independently associated with the severity of infrarenal aortic calcification measured by Computer Tomography Angiography (odds ratio 1.91, 95% confidence interval 1.17-3.21 for calcification >or=median). Homocysteine was identified in all 60 atheroma biopsies from 16 patients undergoing endarterectomy, and concentrations were significantly greater in the calcified biopsies (p=0.003). In vitro studies demonstrated that 100 micromol/L homocysteine doubled the calcium deposition by mesenchymal stem cells during 16 days incubation in osteogenic medium (74+/-4 compared to 42+/-5 microg calcium/well without homocysteine, p&lt;0.001). Homocysteine also stimulated monocytic THP1 cells to promote aortic smooth muscle cell calcification as evidenced by significant higher calcium deposition and alkaline phosphatase activity compared to incubation without homocysteine (p&lt;or=0.05). CONCLUSIONS: Homocysteine plays an important role in vascular calcification via multiple mechanisms. The presence of homocysteine in atheroma and its ability to enhance osteogenic cell differentiation may partly explain the association of homocysteine with atherosclerotic events</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Vascular Biology Unit, School of Medicine, James Cook University, Townsville, QLD4811, AustraliaJC - 95x, 0242543CP - IrelandPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tNO - R01 HL080010-01 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18602108</style></custom1><custom3><style face="normal" font="default">AS - Atherosclerosis. 202(2):557-66, 2009 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>317</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Venkataraman,R.</style></author><author><style face="normal" font="default"> Belardinelli,L.</style></author><author><style face="normal" font="default"> Blackburn,B.</style></author><author><style face="normal" font="default"> Heo,J.</style></author><author><style face="normal" font="default"> Iskandrian,A.E.</style></author></authors></contributors><titles><title><style face="normal" font="default">A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images</style></title><secondary-title><style face="normal" font="default">Jacc: Cardiovascular Imaging</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Jacc: Cardiovascular Imaging</style></full-title></periodical><pages end="1309" start="1301">1301-1309</pages><volume><style face="normal" font="default">2</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Acetanilides/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Coronary Circulation/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> *Myocardial Ischemia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Myocardial Perfusion Imaging/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Piperazines/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> *Tomography,Emission-Computed,Single-Photon</style></keyword><keyword><style face="normal" font="default"> 0 (Acetanilides)</style></keyword><keyword><style face="normal" font="default"> 0 (Cardiovascular Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Piperazines)</style></keyword><keyword><style face="normal" font="default"> 110445-25-5 (ranolazine)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angina Pectoris/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Angina Pectoris/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Automation,Laboratory</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Exercise Test</style></keyword><keyword><style face="normal" font="default"> Exercise Tolerance</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardial Ischemia/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Myocardial Ischemia/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> Myocardial Perfusion Imaging</style></keyword><keyword><style face="normal" font="default"> Perfusion</style></keyword><keyword><style face="normal" font="default"> Pilot Projects</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="11" Year="2009">2009/11</year></dates><abstract><style face="normal" font="default">OBJECTIVES: This study examined the hypothesis that the improvement in myocardial blood flow (MBF) with ranolazine therapy could be detected by serial automated quantitative myocardial perfusion imaging (MPI) in patients with coronary artery disease (CAD) and myocardial ischemia. BACKGROUND: Myocardial ischemia enhances late sodium current, which then causes cellular calcium overload leading to mechanical left ventricular dysfunction and arrhythmias. Ranolazine inhibits late sodium current and improves diastolic tension and MBF in the animal model. METHODS: In this open-label, nonrandomized pilot study, we recruited 20 patients with known or a high probability of CAD and who had reversible perfusion defects on exercise treadmill gated single-photon emission computed tomography MPI while receiving conventional antianginal therapy. Ranolazine (up to 1,000 mg twice daily) was added to baseline therapy and a repeat treadmill MPI was obtained after 4 weeks. The extent and severity of total and reversible left ventricular perfusion abnormality (based on polar maps and a 17-segment model) were determined quantitatively using automated methods. RESULTS: We screened 100 patients for 27 potential candidates; 5 declined and 2 did not complete the follow-up study. The mean age of the remaining 20 patients was 64 +/- 9 years; 30% were women and 50% had diabetes mellitus. The exercise time increased (425 +/- 105 s vs. 393 +/- 116 s, p = 0.017), and angina improved in 15 (75%) patients after ranolazine treatment. In the entire cohort, summed stress scores (10 +/- 7 vs. 13 +/- 8, p = 0.04) and summed difference scores (4.7 +/- 4 vs. 7.4 +/- 5, p = 0.0037) decreased at follow-up. An improvement in perfusion pattern and severity was noted in 14 (70%) patients. In these patients, the polar maps showed a decrease in total abnormality from 26 +/- 17% to 19 +/- 15% and a decrease in the reversible abnormality from 16 +/- 10% to 8 +/- 6% (all p values &lt;0.05). CONCLUSIONS: In this preliminary hypothesis-driven study, short-term ranolazine therapy was shown to improve myocardial perfusion and decrease the ischemic burden in patients with CAD</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL 35294-0007, USA. rajeshv@uab.eduCM - Comment in: JACC Cardiovasc Imaging. 2009 Nov;2(11):1310-2; PMID: 19909935JC - 101467978CP - United StatesPT - Clinical TrialPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19909934</style></custom1><custom3><style face="normal" font="default">AS - JACC Cardiovasc Imaging. 2(11):1301-9, 2009 Nov.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>534</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Venkatesh,V.</style></author><author><style face="normal" font="default"> Ellins,M.L.</style></author><author><style face="normal" font="default"> Yang,S.</style></author><author><style face="normal" font="default"> Natarajan,M.</style></author><author><style face="normal" font="default"> Amlani,S.</style></author><author><style face="normal" font="default"> Sheth,T.</style></author></authors></contributors><titles><title><style face="normal" font="default">Incremental detection of coronary artery disease by assessment of non-calcified plaque on coronary CT angiography</style></title><secondary-title><style face="normal" font="default">Clinical Radiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinical Radiology</style></full-title></periodical><pages end="255" start="250">250-255</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Cardiomyopathies/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Image Interpretation,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Outpatients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="3" Year="2009">2009/3</year></dates><abstract><style face="normal" font="default">AIM: The purpose of this study was to evaluate the improved assessment of coronary atherosclerotic plaque burden by measurement of non-calcified plaque in addition to calcified plaque using CT coronary angiography (CTA). MATERIALS AND METHODS: Low to intermediate-risk outpatients with suspected coronary artery disease were prospectively recruited. Patients underwent CTA and calcium scoring in addition to invasive angiography. The presence of plaque (calcified, non-calcified, and mixed) was analysed on a per segment basis (percentage of segments with disease) with stratification by calcium score (CS). RESULTS: Seventy-six patients were enrolled of whom 30 had a CS of 0, 26 had a CS of 1-200, and 20 had a CS of >200. One thousand, one hundred and two segments were analysed using CTA and invasive angiography. The prevalence of segments with calcified or mixed plaque was 3.1% (n=13) for a CS of 0, 15.1% (n=57) for a CS of 1-200, and 50% (n=142) for a CS of >200 (all p&lt;0.0001). The proportion of segments with non-calcified plaque alone was low and similar among the three groups: 5.4% (n=23; CS=0), 8.2% (n=32; CS=1-200), and 8.6% (n=25; CS= >200), (CS=0 versus CS= >200; p=0.04, others p=ns). The relative increase in diseased segments by additional assessment of non-calcified plaque was greatest for patients with a CS of 0 (173%) versus a CS of 1-200 (55%), and a CS of >200 (17%). CONCLUSION: CTA offers increased relative incremental detection of non-calcified plaque, particularly in those with negative CS; however, the absolute detection of non-calcified plaque in those with negative CS is low. The prognostic significance of non-calcified plaque for the prediction of cardiac events, particularly in patients with low CS, requires continued study</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Cardiac CT, Hamilton Health Sciences, Hamilton, Ontario, CanadaJC - diu, 1306016CP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19185654</style></custom1><custom3><style face="normal" font="default">AS - Clin Radiol. 64(3):250-5, 2009 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>189</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Vidal,J.S.</style></author><author><style face="normal" font="default"> Sigurdsson,S.</style></author><author><style face="normal" font="default"> Jonsdottir,M.K.</style></author><author><style face="normal" font="default"> Eiriksdottir,G.</style></author><author><style face="normal" font="default"> Thorgeirsson,G.</style></author><author><style face="normal" font="default"> Kjartansson,O.</style></author><author><style face="normal" font="default"> Garcia,M.E.</style></author><author><style face="normal" font="default"> van Buchem,M.A.</style></author><author><style face="normal" font="default"> Harris,T.B.</style></author><author><style face="normal" font="default"> Gudnason,V.</style></author><author><style face="normal" font="default"> Launer,L.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Coronary artery calcium, brain function and structure: the AGES-Reykjavik Study</style></title><secondary-title><style face="normal" font="default">Stroke</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Stroke</style></full-title></periodical><pages end="897" start="891">891-897</pages><volume><style face="normal" font="default">41</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aging/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Brain/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Environment</style></keyword><keyword><style face="normal" font="default"> *Genetic Predisposition to Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Aging/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Aging/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Brain/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Cognition Disorders/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Cognition Disorders/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Cognition Disorders/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Genetic Predisposition to Disease/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Iceland/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="5" Year="2010">2010/5</year></dates><abstract><style face="normal" font="default">BACKGROUND AND PURPOSE: Several cardiovascular risk factors are associated with cognitive disorders in older persons. Little is known about the association of the burden of coronary atherosclerosis with brain structure and function. METHODS: This is a cross-sectional analysis of data from the Age, Gene, Environment Susceptibility (AGES)-Reykjavik Study cohort of men and women born 1907 to 1935. Coronary artery calcification (CAC), a marker of atherosclerotic burden, was measured with CT. Memory, speed of processing, and executive function composites were calculated from a cognitive test battery. Dementia was assessed in a multistep procedure and diagnosed according to international guidelines. Quantitative data on total intracranial and tissue volumes (total, gray matter volume, white matter volume, and white matter lesion volume), cerebral infarcts, and cerebral microbleeds were obtained with brain MRI. The association of CAC with dementia (n=165 cases) and cognitive function in nondemented subjects (n=4085), and separately with MRI outcomes, was examined in multivariate models adjusting for demographic and vascular risk factors. Analyses tested whether brain structure mediated the associations of CAC to cognitive function. RESULTS: Subjects with higher CAC were more likely to have dementia and lower cognitive scores, more likely to have lower white matter volume, gray matter volume, and total brain tissue, and to have more cerebral infarcts, cerebral microbleeds, and white matter lesions. The relations of cognitive performance and dementia to CAC were significantly attenuated when the models were adjusted for brain lesions and volumes. CONCLUSIONS: In a population-based sample, increasing atherosclerotic load assessed by CAC is associated with poorer cognitive performance and dementia, and these relations are mediated by evidence of brain pathology</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - National Institutes of Health, NIA/LEDB, 7201 Wisconsin Ave, Gateway Building, Suite 3C309, Bethesda, MD 20892-9205, USAJC - v2j, 0235266CP - United StatesPT - Comparative StudyPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, N.I.H., IntramuralPT - Research Support, Non-U.S. Gov'tNO - N01-AG-1-2100 (United States NIA NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20360538</style></custom1><custom3><style face="normal" font="default">AS - Stroke. 41(5):891-7, 2010 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>164</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Villines,T.C.</style></author><author><style face="normal" font="default"> O'Malley,P.G.</style></author><author><style face="normal" font="default"> Feuerstein,I.M.</style></author><author><style face="normal" font="default"> Thomas,S.</style></author><author><style face="normal" font="default"> Taylor,A.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Does prolonged warfarin exposure potentiate coronary calcification in humans? Results of the warfarin and coronary calcification study</style></title><secondary-title><style face="normal" font="default">Calcified Tissue International</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Calcified Tissue International</style></full-title></periodical><pages end="500" start="494">494-500</pages><volume><style face="normal" font="default">85</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Anticoagulants/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> *Cardiomyopathies/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> *Warfarin/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> 0 (Anticoagulants)</style></keyword><keyword><style face="normal" font="default"> 81-81-2 (Warfarin)</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Anticoagulants/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ci [Chemically Induced]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Linear Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Warfarin/tu [Therapeutic Use]</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><abstract><style face="normal" font="default">Warfarin has been shown to accelerate vascular calcification in experimental animals, and possibly humans, through inhibition of the vitamin K-dependent protein matrix gla protein, a potent inhibitor of tissue calcification. We performed a cross-sectional analysis of the extent of coronary artery calcification (CAC) in patients without coronary heart disease, currently taking or referred for warfarin therapy. The primary end point was severity of CAC measured by electron beam computed tomography attributed to duration of warfarin use, after adjustment for cardiovascular risk factors. Seventy patients (46 men, mean age 68 +/- 13 years) were enrolled from three groups of warfarin use duration: (1) &lt;6 months (n = 31, mean duration 1 +/- 1 months), (2) 6-24 months (n = 11), and (3) >24 months (n = 28, mean 67 +/- 40 months). Overall, the mean total CAC score (Agatston) was 293 +/- 560: group 1 (175 +/- 285), group 2 (289 +/- 382), and group 3 (426 +/- 789). In univariate analysis, there was a nonsignificant trend to increased CAC with increasing warfarin exposure (P = 0.18). Bivariate analysis revealed no correlation between warfarin duration and CAC score (r = 0.075, P = 0.537). Linear regression for the independent variable coronary calcium score controlling for warfarin treatment duration and intensity (duration of warfarin use months x mean INR), Framingham risk score, and creatinine clearance showed that only the Framingham risk score was associated with CAC (P = 0.001). Among patients without known coronary heart disease, duration of warfarin exposure was not associated with extent of coronary calcification</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Cardiology Service, Department of Medicine, Walter Reed Army Medical Center, 6900 Georgia Avenue, NW, Washington, DC 20307, USA. todd.villines@amedd.army.milJC - cgh, 7905481CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19847375</style></custom1><custom3><style face="normal" font="default">AS - Calcif Tissue Int. 85(6):494-500, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>235</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Vogt,S.</style></author><author><style face="normal" font="default"> Troitzsch,D.</style></author><author><style face="normal" font="default"> Moosdorf,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Epicardial measurement of alterations in extracellular pH and electrolytes during ischemia and reperfusion in cardiac surgery</style></title><secondary-title><style face="normal" font="default">Biomedizinische Technik</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Biomedizinische Technik</style></full-title></periodical><pages end="321" start="315">315-321</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Biosensing Techniques/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Electrolytes/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> *Pericardium/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> *Reperfusion Injury/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Reperfusion Injury/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> 0 (Electrolytes)</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Bypass</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Bypass/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Electrochemistry/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hydrogen-Ion Concentration</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Reperfusion Injury/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Reperfusion Injury/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Transducers</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><isbn><style face="normal" font="default">0013-5585</style></isbn><abstract><style face="normal" font="default">Simultaneous measurements of extracellular pH, potassium (K(+)), and calcium (Ca(2+)) activity might be indicative of myocardium vitality or ischemia. Ten consecutive patients undergoing elective coronary artery bypass grafting were studied. Epicardial extracellular pH, potassium, and calcium were measured by a miniaturized disposable multi-sensor probe. Blood gases and electrolytes were derived with measurements of arterial and mixed venous blood samples at intervals during surgery. The mean epicardial baseline levels for pH in all patients were 8.04+/-0.22 arbitrary units (AU) for the right ventricle (RV) and 8.03+/-0.21 AU for the left ventricle (LV); for Ca(2+) 0.23+/-0.07 mmol/l (RV) and 0.20+/-0.10 mmol/l (LV); and for K(+) 4.54+/-1.51 mmol/l (RV) and 4.38+/-0.57 mmol/l (LV). Before ischemia, epicardial pH was moderately (p&lt;0.05), and K(+), and Ca(2+) were closely correlated (p&lt;0.001) with blood values. During reperfusion, epicardial measurements were weakly correlated (p&lt;0.001) with blood values for pH, venous K(+) and Ca(2+), but moderately correlated with arterial K(+) and Ca(2+) (p&lt;0.01). The measurements indicated intraoperative episodes of ischemia and reperfusion with reproducible trends of extracellular pH, K(+), and Ca(2+), which results in electrolyte patterns applicable for detecting inadequate myocardial protection during cardiac surgery in patients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Clinic for Heart Surgery, Philipps University of Marburg, Marburg/Lahn, Germany. vogts@med.uni-marburg.deJC - a5l, 1262533CP - GermanyPT - Clinical TrialPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19839713</style></custom1><custom3><style face="normal" font="default">AS - Biomed Tech (Berl). 54(6):315-21, 2009.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>1</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Vyssoulis,G.</style></author><author><style face="normal" font="default"> Karpanou,E.</style></author><author><style face="normal" font="default"> Tzamou,V.</style></author><author><style face="normal" font="default"> Kyvelou,S.M.</style></author><author><style face="normal" font="default"> Michaelidis,A.</style></author><author><style face="normal" font="default"> Stefanadis,C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Serum phosphate in white-coat hypertensive patients: focus on dipping status and metabolic syndrome</style></title><secondary-title><style face="normal" font="default">Hypertension Research - Clinical &amp; Experimental</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Hypertension Research - Clinical &amp; Experimental</style></full-title></periodical><pages end="830" start="825">825-830</pages><volume><style face="normal" font="default">33</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Blood Pressure/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Circadian Rhythm/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Hypertension</style></keyword><keyword><style face="normal" font="default"> *Metabolic Syndrome X/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Phosphates/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Blood Glucose)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipids)</style></keyword><keyword><style face="normal" font="default"> 0 (Phosphates)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Blood Glucose/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure Monitoring,Ambulatory</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> EC 2-7-10-1 (Receptor,Epidermal Growth Factor)</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Hypertension/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Hypertension/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Lipids/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Metabolic Syndrome X/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Physicians' Offices</style></keyword><keyword><style face="normal" font="default"> Receptor,Epidermal Growth Factor/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Waist-Hip Ratio</style></keyword></keywords><dates><year Day="0" Month="8" Year="2010">2010/8</year></dates><abstract><style face="normal" font="default">Recent studies indicate an association between serum phosphate levels and blood pressure in hypertensive patients. A growing body of evidence suggests that white-coat hypertension (WCH) is associated with target organ damage. Furthermore, metabolic syndrome (MS) and a non-dipping pattern are associated with increased cardiovascular risk. The purpose of this study was to explore the nocturnal blood pressure fall in patients with WCH according to their serum phosphate levels and number of MS components fulfilled. The study included 2600 patients with WCH who attended our outpatient clinics. All patients underwent repeated office blood pressure measurements, 24-h ambulatory blood pressure monitoring and full clinical and laboratory evaluation. The diagnosis of MS was made according to the Adult Treatment Panel III criteria. Dipping pattern was defined as follows: 'dippers' had a nocturnal systolic blood pressure (NSBP) fall > or =10% but &lt;20%; 'non-dippers' had an NSBP fall &lt;10%; 'extreme dippers' had an NSBP fall > or =20% and 'reverse dippers' had an NSBP increase. There were 314 extreme dippers, 1337 dippers, 734 non-dippers and 116 reverse dippers. Reverse dippers presented with significantly lower levels of serum phosphate, whereas extreme dippers had significantly higher levels (3.39+/-3.29 vs. 3.58+/-3.52 mg per 100 ml, P&lt;0.0001). The patients were classified according to the number of MS components and the main observation was the inverse relationship of serum phosphate with MS components (3.53+/-0.36, 3.50+/-0.38, 3.49+/-0.38, 3.44+/-0.36 and 3.35+/-0.31 mg per 100 ml, respectively, P=0.003). Patients with WCH and low serum phosphate levels appear to have a higher incidence of a non-dipping NSBP profile and an impaired metabolic profile. This observation may be important for the stratification of the cardiovascular risk in WCH patients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - 1st Cardiology Clinic Athens University, Hippokration Hospital, Athens, GreeceJC - 9307690CP - EnglandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20505672</style></custom1><custom3><style face="normal" font="default">AS - Hypertens Res. 33(8):825-30, 2010 Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>399</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Walker,M.D.</style></author><author><style face="normal" font="default"> Fleischer,J.</style></author><author><style face="normal" font="default"> Rundek,T.</style></author><author><style face="normal" font="default"> McMahon,D.J.</style></author><author><style face="normal" font="default"> Homma,S.</style></author><author><style face="normal" font="default"> Sacco,R.</style></author><author><style face="normal" font="default"> Silverberg,S.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Carotid vascular abnormalities in primary hyperparathyroidism</style></title><secondary-title><style face="normal" font="default">Journal of Clinical Endocrinology &amp; Metabolism</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Clinical Endocrinology &amp; Metabolism</style></full-title></periodical><pages end="3856" start="3849">3849-3856</pages><volume><style face="normal" font="default">94</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Carotid Arteries/ab [Abnormalities]</style></keyword><keyword><style face="normal" font="default"> *Hyperparathyroidism,Primary/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Carotid Arteries/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Carotid Arteries/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Carotid Stenosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Carotid Stenosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Primary/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Tunica Intima/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Tunica Media/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><abstract><style face="normal" font="default">CONTEXT: Data on the presence, extent, and reversibility of cardiovascular disease in primary hyperparathyroidism (PHPT) are conflicting. OBJECTIVE: This study evaluated carotid structure and function in PHPT patients compared with population-based controls. DESIGN: This is a case-control study. SETTING: The study was conducted in a university hospital metabolic bone disease unit. PARTICIPANTS: Forty-nine men and women with PHPT and 991 controls without PHPT were studied. OUTCOME MEASURES: We measured carotid intima-media thickness (IMT), carotid plaque presence and thickness, and carotid stiffness, strain, and distensibility. RESULTS: IMT, carotid plaque thickness, carotid stiffness, and distensibility were abnormal in PHPT patients, and IMT was higher in patients than controls (0.959 vs. 0.907 mm, P &lt; 0.0001). In PHPT, PTH levels, but not calcium concentration, predicted carotid stiffness (P = 0.04), strain (P = 0.06), and distensibility (P = 0.07). Patients with increased carotid stiffness had significantly higher PTH levels than did those with normal stiffness (141 +/- 48 vs. 94.9 +/- 44 pg/ml, P = 0.002), and odds of abnormal stiffness increased 1.91 (confidence interval = 1.09-3.35; P = 0.024) for every 10 pg/ml increase in PTH, adjusted for age, creatinine, and albumin-corrected calcium. CONCLUSIONS: Mild PHPT is associated with subclinical carotid vascular manifestations. IMT, a predictor of cardiovascular outcomes, is increased. Measures of carotid stiffness are associated with extent of PTH elevation, suggesting that those with more severe PHPT may have impaired vascular compliance and that PTH, rather than calcium, is the mediator</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USAJC - hrb, 0375362CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - K24 DK074457 (United States NIDDK NIH HHS)NO - R01 DK066329 (United States NIDDK NIH HHS)NO - UL1 RR024156 (United States NCRR NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19755478</style></custom1><custom3><style face="normal" font="default">AS - J Clin Endocrinol Metab. 94(10):3849-56, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>167</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Walker,M.D.</style></author><author><style face="normal" font="default"> Fleischer,J.B.</style></author><author><style face="normal" font="default"> Di Tullio,M.R.</style></author><author><style face="normal" font="default"> Homma,S.</style></author><author><style face="normal" font="default"> Rundek,T.</style></author><author><style face="normal" font="default"> Stein,E.M.</style></author><author><style face="normal" font="default"> Zhang,C.</style></author><author><style face="normal" font="default"> Taggart,T.</style></author><author><style face="normal" font="default"> McMahon,D.J.</style></author><author><style face="normal" font="default"> Silverberg,S.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Cardiac structure and diastolic function in mild primary hyperparathyroidism</style></title><secondary-title><style face="normal" font="default">Journal of Clinical Endocrinology &amp; Metabolism</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Clinical Endocrinology &amp; Metabolism</style></full-title></periodical><pages end="2179" start="2172">2172-2179</pages><volume><style face="normal" font="default">95</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Diastole/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Heart/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> *Hyperparathyroidism,Primary/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Blood Flow Velocity</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Coronary Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Coronary Disease/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Diabetes Complications/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Ventricles/ah [Anatomy &amp; Histology]</style></keyword><keyword><style face="normal" font="default"> Heart/ah [Anatomy &amp; Histology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Primary/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Primary/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Hypertension/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Hypertension/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mitral Valve/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Ultrasonography,Doppler</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Ventricular Dysfunction,Left/pp [Physiopathology]</style></keyword></keywords><dates><year Day="0" Month="5" Year="2010">2010/5</year></dates><abstract><style face="normal" font="default">CONTEXT: Data on the presence, extent, and reversibility of cardiovascular disease in primary hyperparathyroidism (PHPT) are conflicting. OBJECTIVE: To evaluate the heart in PHPT, we assessed cardiac structure and diastolic function in patients with mild PHPT compared with age- and sex-matched controls. DESIGN: This was a case-control study. SETTINGS: The study was conducted in a university hospital Metabolic Bone Diseases Unit. PARTICIPANTS: Fifty-four men and women with PHPT and 76 controls without PHPT participated in the study. OUTCOME MEASURES: We measured left ventricular mass index (LVMI), the presence of mitral annular calcification, the ratio of early to late diastolic mitral inflow velocities (E/A), and early diastolic velocity of the lateral mitral annulus using Doppler tissue imaging (tissue Doppler e'). RESULTS: Patients had mild disease with mean (+/-sd) serum calcium 10.5 +/- 0.5 mg/dl and PTH 96 +/- 45 pg/ml. LVMI and diastolic function were normal in PHPT. There was no difference in LVMI (98 +/- 23 vs. 96 +/- 24 g/m(2), P = 0.69) or the frequency of mitral annular calcification between PHPT cases and controls. Diastolic function variables (E/A and tissue Doppler e') were higher (better) in cases compared with controls, although both were within the reference range. PHPT patients with low E/A had higher serum PTH (121 +/- 36 vs. 89 +/- 46 pg/ml, P = 0.03) and calcium (10.8 +/- 0.4 vs. 10.5 +/- 0.5 mg/dl, P = 0.05) than those with normal values. Finally, we found LVMI to be inversely associated with serum 25-hydroxyvitamin D in PHPT (r = -0.29, P &lt; 0.05). All findings persisted after adjustment for group differences in cardiovascular risk factors. CONCLUSIONS: Patients with biochemically mild PHPT do not have evidence of increased left ventricular mass, diastolic dysfunction, or increased valvular calcifications. However, the data support an association between low vitamin D levels and the development of left ventricular hypertrophy in this disorder. Finally, the increased serum calcium and PTH levels in those with diastolic dysfunction suggest that disease severity may determine the presence of cardiac manifestations in PHPT</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USAJC - hrb, 0375362CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - K24 DK074457 (United States NIDDK NIH HHS)NO - R01 DK066329 (United States NIDDK NIH HHS)NO - UL1 RR024156 (United States NCRR NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20228165</style></custom1><custom3><style face="normal" font="default">AS - J Clin Endocrinol Metab. 95(5):2172-9, 2010 May.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>78</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Walsh,M.</style></author><author><style face="normal" font="default"> Manns,B.J.</style></author><author><style face="normal" font="default"> Klarenbach,S.</style></author><author><style face="normal" font="default"> Tonelli,M.</style></author><author><style face="normal" font="default"> Hemmelgarn,B.</style></author><author><style face="normal" font="default"> Culleton,B.</style></author></authors></contributors><titles><title><style face="normal" font="default">The effects of nocturnal compared with conventional hemodialysis on mineral metabolism: A randomized-controlled trial</style></title><secondary-title><style face="normal" font="default">Hemodialysis International</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Hemodialysis International</style></full-title></periodical><pages end="181" start="174">174-181</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Hemodialysis,Home/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Hyperphosphatemia/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Hyperphosphatemia/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure,Chronic/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure,Chronic/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> 0 (Calcium Phosphates)</style></keyword><keyword><style face="normal" font="default"> 0 (Minerals)</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 0 (Phosphates)</style></keyword><keyword><style face="normal" font="default"> 10103-46-5 (calcium phosphate)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Alberta</style></keyword><keyword><style face="normal" font="default"> Appointments and Schedules</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Calcium Phosphates/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Circadian Rhythm</style></keyword><keyword><style face="normal" font="default"> Combined Modality Therapy</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperphosphatemia/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Hypertrophy,Left Ventricular/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Hypertrophy,Left Ventricular/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Minerals/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Phosphates/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">Hyperphosphatemia is common among patients receiving dialysis and is associated with increased mortality. Nocturnal hemodialysis (NHD) is a long, slow dialytic modality that may improve hyperphosphatemia and disorders of mineral metabolism. We performed a randomized-controlled trial of NHD compared with conventional hemodialysis (CvHD); in this paper, we report detailed results of mineral metabolism outcomes. Prevalent patients were randomized to receive NHD 5 to 6 nights per week for 6to 10 hours per night or to continue CvHD thrice weekly for 6 months. Oral phosphate binders and vitamin D analogs were adjusted to maintain phosphate, calcium and parathyroid hormone (PTH) levels within recommended targets. Compared with CvHD patients, patients in the NHD group had a significant decrease in serum phosphate over the course of the study (0.49 mmol/L, 95% confidence interval 0.24-0.74; P=0.002) despite a significant reduction in the use of phosphate binders. Sixty-one percent of patients in the NHD group compared with 20% in the CvHD group had a decline in intact PTH (P=0.003). Nocturnal hemodialysis lowers serum phosphate, calcium-phosphate product and requirement for phosphate binders. The effects of NHD on PTH are variable. The impact of these changes on long-term cardiovascular and bone-related outcomes requires further investigation</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medicine, University of Calgary, Alberta, CanadaJC - 101093910CP - CanadaPT - Comparative StudyPT - Journal ArticlePT - Randomized Controlled TrialPT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20041960</style></custom1><custom3><style face="normal" font="default">AS - Hemodial. int.. 14(2):174-81, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>61</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Wanahita,N.</style></author><author><style face="normal" font="default"> See,J.L.</style></author><author><style face="normal" font="default"> Giedd,K.N.</style></author><author><style face="normal" font="default"> Friedmann,P.</style></author><author><style face="normal" font="default"> Somekh,N.N.</style></author><author><style face="normal" font="default"> Bergmann,S.R.</style></author></authors></contributors><titles><title><style face="normal" font="default">No evidence of increased prevalence of premature coronary artery disease in New York City police officers as predicted by coronary artery calcium scoring</style></title><secondary-title><style face="normal" font="default">Journal of Occupational &amp; Environmental Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Occupational &amp; Environmental Medicine</style></full-title></periodical><pages end="665" start="661">661-665</pages><volume><style face="normal" font="default">52</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Police/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> New York City/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> September 11 Terrorist Attacks/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword></keywords><dates><year Day="0" Month="6" Year="2010">2010/6</year></dates><abstract><style face="normal" font="default">OBJECTIVES: To investigate the prevalence of coronary artery disease (CAD) in active New York City police officers as detected by coronary artery calcium (CAC) scoring. METHODS: We assessed 2064 New York City police officers who underwent electron beam computed tomography for quantification of CAC. RESULTS: The mean age of study subjects was 42 +/- 6 years. A CAC score of 0 was present in 74% of men and 80% of women. A subset of 75 officers with known early exposure to World Trade Center dust were evaluated separately. CONCLUSION: New York City police officers do not have an increased prevalence of CAD compared with the general population as assessed with CAC scoring. At 5 years, exposure to World Trade Center dust does not appear to increase the risk of premature CAD</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiology, Department of Medicine, Beth Israel Medical Center, Albert Einstein College of Medicine, New York, NY 10003, USA. wanahita@yahoo.comJC - b7h, 9504688CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20523232</style></custom1><custom3><style face="normal" font="default">AS - J Occup Environ Med. 52(6):661-5, 2010 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>461</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Wang,C.P.</style></author><author><style face="normal" font="default"> Hsu,H.L.</style></author><author><style face="normal" font="default"> Hung,W.C.</style></author><author><style face="normal" font="default"> Yu,T.H.</style></author><author><style face="normal" font="default"> Chen,Y.H.</style></author><author><style face="normal" font="default"> Chiu,C.A.</style></author><author><style face="normal" font="default"> Lu,L.F.</style></author><author><style face="normal" font="default"> Chung,F.M.</style></author><author><style face="normal" font="default"> Shin,S.J.</style></author><author><style face="normal" font="default"> Lee,Y.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Increased epicardial adipose tissue (EAT) volume in type 2 diabetes mellitus and association with metabolic syndrome and severity of coronary atherosclerosis</style></title><secondary-title><style face="normal" font="default">Clinical Endocrinology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinical Endocrinology</style></full-title></periodical><pages end="882" start="876">876-882</pages><volume><style face="normal" font="default">70</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Adipose Tissue/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Diabetes Mellitus,Type 2/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Metabolic Syndrome X/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Pericardium/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> Adipose Tissue</style></keyword><keyword><style face="normal" font="default"> Adipose Tissue/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Metabolic Syndrome X/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Metabolic Syndrome X/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Pericardium/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Waist Circumference</style></keyword></keywords><dates><year Day="0" Month="6" Year="2009">2009/6</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Epicardial adipose tissue (EAT) is a part of visceral fat deposited around the heart between the pericardium and myocardium along the distribution of coronary arteries. EAT thickness is reported to be associated with coronary atherosclerosis; however, no study has measured EAT volume in patients with type 2 diabetes or investigate its association with coronary artery disease. DESIGN: A hospital-based case control study. PATIENTS: A total of 49 patients with type 2 diabetes mellitus (T2DM) and 78 nondiabetic controls were studied. MEASUREMENTS: Cardiac multislice computed tomography was used to measure EAT volume, Gensini score, coronary artery calcium score and, coronary lesions. The relationships between EAT volume, markers of coronary atherosclerosis and anthropometric and biochemical parameters of metabolic syndrome (MetS) were investigated. RESULTS: EAT volume was significantly higher in patients with T2DM than in nondiabetic subjects (166.1 +/- 60.6 cm(3) vs. 123.4 +/- 41.8 cm(3), P &lt; 0.0001). Logistic regression analysis revealed independent and significant associations between EAT and diabetic status. EAT volume was significantly associated with components of MetS (BMI, waist circumference, fasting serum glucose, total cholesterol, HDL-cholesterol, and triglycerides levels), Gensini score, coronary lesions, coronary disease and coronary calcium scores. Univariate, multivariate and trend analyses confirmed that EAT volume was associated with MetS component clustering and the coronary atherosclerosis index. CONCLUSIONS: The analytical results indicate that EAT volume is increased in T2DM patients and is associated with unfavourable components of MetS and coronary atherosclerosis. The close anatomical relationship between EAT and the coronary arteries, combined with other evidence indicating that EAT is a biologically active adipokine-secreting tissue, suggest that EAT participates in the pathogenesis of diabetic coronary atherosclerosis</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Internal Medicine, Division of Cardiology, E-Da Hospital, I-Shou University, Kaohsiung 82445, TaiwanJC - dci, 0346653CP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18778397</style></custom1><custom3><style face="normal" font="default">AS - Clin Endocrinol (Oxf). 70(6):876-82, 2009 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>375</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Wang,S.</style></author><author><style face="normal" font="default"> Yiu,K.H.</style></author><author><style face="normal" font="default"> Mok,M.Y.</style></author><author><style face="normal" font="default"> Ooi,G.C.</style></author><author><style face="normal" font="default"> Khong,P.L.</style></author><author><style face="normal" font="default"> Mak,K.F.</style></author><author><style face="normal" font="default"> Lau,C.P.</style></author><author><style face="normal" font="default"> Lam,K.F.</style></author><author><style face="normal" font="default"> Lau,C.S.</style></author><author><style face="normal" font="default"> Tse,H.F.</style></author></authors></contributors><titles><title><style face="normal" font="default">Prevalence and extent of calcification over aorta, coronary and carotid arteries in patients with rheumatoid arthritis</style></title><secondary-title><style face="normal" font="default">Journal of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Internal Medicine</style></full-title></periodical><pages end="452" start="445">445-452</pages><volume><style face="normal" font="default">266</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aortic Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Arthritis,Rheumatoid/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Atherosclerosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Carotid Artery Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aortic Diseases/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Carotid Arteries/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Carotid Artery Diseases/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hong Kong</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed/mt [Methods]</style></keyword></keywords><dates><year Day="0" Month="11" Year="2009">2009/11</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To evaluate the prevalence and pattern of arterial calcification in patients with rheumatoid arthritis (RA). BACKGROUND: Patients with RA are prone to premature atherosclerosis; nonetheless the prevalence and extent of atherosclerosis in different vascular beds and their relationship to each other remain unknown. METHODS: We studied the distribution and extent of arterial calcification in 85 RA patients and 85 age-and sex-matched controls. Arterial calcification as determined by calcium score (CS) were measured using multi-detector computed tomography in thoracic aorta, coronary and carotid arteries. RESULTS: Compared with controls, RA patients had a significantly higher average CS and prevalence of CS > 0 in aorta, coronary and carotid arteries and overall arteries (all P &lt; 0.05). After adjusting for age and sex, RA patients had a significantly higher relative risk of developing calcification in the aorta [Odds Ratio (OR) = 19.5, 95% Confidence Interval (CI): 8.0-47.6], followed by the carotid arteries (OR = 5.7, 95% CI:1.7-18.7) and coronary arteries (OR = 5.0, 95% CI:2.2-11.1) compared with controls (all P &lt; 0.01). Amongst RA patients aged >60, 90% had diffuse arterial calcification, especially over the thoracic aorta, compared with 55% of controls who had arterial calcification clustered in the coronary arteries (P &lt; 0.05). RA patients with total CS > 0 were older with a higher urea level and C-reactive protein than those without arterial calcification, no factor was found to be independently predictive for arterial calcification (all P > 0.05). CONCLUSIONS: Our results demonstrated that RA patients had earlier onset, more diffuse arterial calcification over multiple vascular beds and more preferential involvement of thoracic aorta, rather than coronary artery when compared with control</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Diagnostic Radiology, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong KongCM - Comment in: J Intern Med. 2009 Nov;266(5):453-6; PMID: 19817967]JC - i2g, 8904841CP - EnglandPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19549093</style></custom1><custom3><style face="normal" font="default">AS - J Intern Med. 266(5):445-52, 2009 Nov.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>175</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Washida,N.</style></author><author><style face="normal" font="default"> Wakino,S.</style></author><author><style face="normal" font="default"> Hayashi,K.</style></author><author><style face="normal" font="default"> Kuwahara,T.</style></author><author><style face="normal" font="default"> Itoh,H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Brachial-ankle pulse wave velocity predicts silent cerebrovascular diseases in patients with end-stage renal diseases</style></title><secondary-title><style face="normal" font="default">Journal of Atherosclerosis &amp; Thrombosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Atherosclerosis &amp; Thrombosis</style></full-title></periodical><pages end="172" start="165">165-172</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Brachial Artery/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Cerebrovascular Disorders/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Cerebrovascular Disorders/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure,Chronic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> *Pulse</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Constriction,Pathologic/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Dialysis</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Kidney Failure,Chronic/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword></keywords><dates><year Day="26" Month="2" Year="2010">2010/2/26</year></dates><abstract><style face="normal" font="default">AIM: Cerebrovascular disease (CVD) is a major determinant of the prognosis in end-stage renal diseases (ESRD). The purpose of this study was to examine whether factors associated with arterial stiffness contributed to the development of CVD in patients with ESRD. METHODS: CVD (lacunes and carotid/intracranial artery stenosis) was evaluated with brain magnetic resonance imaging (MRI), and carotid/intracranial artery magnetic resonance angiography (MRA) in 44 pre-dialytic patients. The severity of CVD was evaluated by the number of lacunes and the degree of stenosis, respectively. The association between CVD and atherosclerotic parameters was evaluated. RESULTS: Patients with severe lacunes (n=18) manifested older age, lower diastolic blood pressure, serum creatinine and albumin, and higher CRP and serum calcium than those with absent-moderate lacunes (n=26). When assessed by multivariate analysis, only baPWV was adopted as an independent risk factor for severe lacunes. Furthermore, baPWV and i-PTH were associated with the severity of carotid/intracranial artery stenosis, both of which were independent of other risk factors, including age and diabetes. CONCLUSIONS: Arterial stiffness may constitute a novel determinant predicting the severity of CVD in pre-dialytic patients besides classical risk factors</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan. washida@sc.itc.keio.ac.jpJC - 9506298, cwcCP - JapanPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20124736</style></custom1><custom3><style face="normal" font="default">AS - J Atheroscler Thromb. 17(2):165-72, 2010 Feb 26.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>280</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Wassel,C.L.</style></author><author><style face="normal" font="default"> Pankow,J.S.</style></author><author><style face="normal" font="default"> Peralta,C.A.</style></author><author><style face="normal" font="default"> Choudhry,S.</style></author><author><style face="normal" font="default"> Seldin,M.F.</style></author><author><style face="normal" font="default"> Arnett,D.K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Genetic ancestry is associated with subclinical cardiovascular disease in African-Americans and Hispanics from the multi-ethnic study of atherosclerosis</style></title><secondary-title><style face="normal" font="default">Circulation</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Circulation</style></full-title></periodical><pages end="636" start="629">629-636</pages><volume><style face="normal" font="default">Cardiovascular</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*African Americans/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Atherosclerosis/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> *Atherosclerosis/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Hispanic Americans/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> African Americans</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> United States/ep [Epidemiology]</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Differences in cardiovascular disease (CVD) burden exist among racial/ethnic groups in the United States, with African-Americans having the highest prevalence. Subclinical CVD measures have also been shown to differ by race or ethnicity. In the United States, there has been a significant intermixing among racial/ethnic groups creating admixed populations. Very little research exists on the relationship of genetic ancestry and subclinical CVD measures. METHODS AND RESULTS: These associations were investigated in 712 black and 705 Hispanic participants from the Multi-Ethnic Study of Atherosclerosis candidate gene substudy. Individual ancestry was estimated from 199 genetic markers using STRUCTURE. Associations of ancestry and coronary artery calcium (CAC) and common and internal carotid intima media thickness were evaluated using log-binomial and linear regression models. Splines indicated linear associations of ancestry with subclinical CVD measures in African-Americans but presence of threshold effects in Hispanics. Among African-Americans, each SD increase in European ancestry was associated with an 8% (95% CI, 1.02 to 1.15; P=0.01) higher CAC prevalence. Each SD increase in European ancestry was also associated with a 2% (95% CI -3.4% to -0.5%, P=0.008) lower common carotid intima media thickness in African-Americans. Among Hispanics, the highest tertile of European ancestry was associated with a 34% higher CAC prevalence (P=0.02) when compared with the lowest tertile. CONCLUSIONS: The linear association of ancestry and subclinical CVD suggests that genetic effects may be important in determining CAC and carotid intima media thickness among African-Americans. Our results also suggest that CAC and common carotid intima media thickness may be important phenotypes for further study with admixture mapping</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Family and Prevention Medicine, University of California, San Diego, CA 92093-0965, USA. cwassel@ucsd.eduCM - Comment in: Circ Cardiovasc Genet. 2009 Dec;2(6):540-3; PMID: 20031632JC - 101489144CP - United StatesPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - N01 HC095159 (United States NHLBI NIH HHS)NO - N01 HC095160 (United States NHLBI NIH HHS)NO - N01 HC095161 (United States NHLBI NIH HHS)NO - N01 HC095162 (United States NHLBI NIH HHS)NO - N01 HC095163 (United States NHLBI NIH HHS)NO - N01 HC095164 (United States NHLBI NIH HHS)NO - N01 HC095165 (United States NHLBI NIH HHS)NO - N01 HC095167 (United States NHLBI NIH HHS)NO - N01 HC095169 (United States NHLBI NIH HHS)NO - N01-HC-95159 (United States NHLBI NIH HHS)NO - N01-HC-95169 (United States NHLBI NIH HHS)NO - R01 HL071051-01A1 (United States NHLBI NIH HHS)NO - R01 HL071205-05 (United States NHLBI NIH HHS)NO - R01 HL071250-01A1 (United States NHLBI NIH HHS)NO - R01 HL071251-01A1 (United States NHLBI NIH HHS)NO - R01 HL071252-01A1 (United States NHLBI NIH HHS)NO - R01 HL071259-05 (United States NHLBI NIH HHS)NO - R01HL071051 (United States NHLBI NIH HHS)NO - R01HL071205 (United States NHLBI NIH HHS)NO - R01HL071250 (United States NHLBI NIH HHS)NO - R01HL071251 (United States NHLBI NIH HHS)NO - R01HL071252 (United States NHLBI NIH HHS)NO - R01HL071258 (United States NHLBI NIH HHS)NO - R01HL071259 (United States NHLBI NIH HHS)NO - T32 HL007779-11 (United States NHLBI NIH HHS)NO - T32 HL097972 (United States NHLBI NIH HHS)NO - T32HL07779 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20031644</style></custom1><custom3><style face="normal" font="default">AS - Circ Cardiovasc Genet. 2(6):629-36, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>341</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Weustink,A.C.</style></author><author><style face="normal" font="default"> Neefjes,L.A.</style></author><author><style face="normal" font="default"> Kyrzopoulos,S.</style></author><author><style face="normal" font="default"> Van,Straten M.</style></author><author><style face="normal" font="default"> Neoh,Eu R.</style></author><author><style face="normal" font="default"> Meijboom,W.B.</style></author><author><style face="normal" font="default"> van Mieghem,C.A.</style></author><author><style face="normal" font="default"> Capuano,E.</style></author><author><style face="normal" font="default"> Dijkshoorn,M.L.</style></author><author><style face="normal" font="default"> Cademartiri,F.</style></author><author><style face="normal" font="default"> Boersma,E.</style></author><author><style face="normal" font="default"> de Feyter,P.J.</style></author><author><style face="normal" font="default"> Krestin,G.P.</style></author><author><style face="normal" font="default"> Mollet,N.R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Impact of heart rate frequency and variability on radiation exposure, image quality, and diagnostic performance in dual-source spiral CT coronary angiography</style></title><secondary-title><style face="normal" font="default">Radiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Radiology</style></full-title></periodical><pages end="680" start="672">672-680</pages><volume><style face="normal" font="default">253</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Coronary Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Heart Rate/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Radiation Dosage</style></keyword><keyword><style face="normal" font="default"> *Tomography,Spiral Computed</style></keyword><keyword><style face="normal" font="default"> 0 (Contrast Media)</style></keyword><keyword><style face="normal" font="default"> 66108-95-0 (Iohexol)</style></keyword><keyword><style face="normal" font="default"> 73334-07-3 (iopromide)</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Contrast Media</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Electrocardiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Rate</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Informed Consent</style></keyword><keyword><style face="normal" font="default"> Iohexol/aa [Analogs &amp; Derivatives]</style></keyword><keyword><style face="normal" font="default"> Iohexol/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Radiographic Image Interpretation,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><abstract><style face="normal" font="default">PURPOSE: To investigate the effect of heart rate frequency (HRF) and heart rate variability (HRV) on radiation exposure, image quality, and diagnostic performance to help detect significant stenosis (> or =50% lumen diameter reduction) by using adaptive electrocardiographic (ECG) pulsing at dual-source (DS) spiral computed tomographic (CT) coronary angiography. MATERIALS AND METHODS: Institutional review committee approval and informed consent were obtained. No prescan beta-blockers were applied. Unenhanced CT and CT coronary angiography with adaptive ECG pulsing were performed in 927 consecutive patients (600 men, 327 women; mean age, 60.3 years +/- 11.0 [standard deviation]) divided in three HRF groups: low, intermediate, and high (&lt; or =65, 66-79, and > or =80 beats/min, respectively), and four HRV groups given mean interbeat difference (IBD) during CT coronary angiography: normal, minor, moderate, and severe (IBDs of 0-1, 2-3, 4-10, and >10, respectively). Radiation exposure and image quality were also evaluated. In 444 of these, diagnostic performance was presented as sensitivity, specificity, positive predictive values (PPVs), and negative predictive values and likelihood ratios with corresponding 95% confidence intervals by using quantitative coronary angiography as the reference standard. RESULTS: CT coronary angiography yielded good image quality in 98% of patients and no significant differences in image quality were found among HRF and HRV groups. Radiation exposure was significantly higher in patients with low versus high HRF and in patients with severe versus normal HRV. No significant differences among HRF and HRV groups in image quality and diagnostic performance were found. A nonsignificant trend was found toward a lower specificity and PPV in patients with a high HRF or severe HRV when compared with low HRF or normal HRV in patients with a low calcium score (Agatston score &lt;100). CONCLUSION: DS spiral CT coronary angiography performed with adaptive ECG pulsing results in preserved diagnostic image quality and performance independent of HRF or HRV at the cost of limited dose reduction in arrhythmic patients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Radiology, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. a.weustink@erasmusmc.nlJC - qsh, 0401260CP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19864512</style></custom1><custom3><style face="normal" font="default">AS - Radiology. 253(3):672-80, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>553</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Williams,M.</style></author><author><style face="normal" font="default"> Shaw,L.J.</style></author><author><style face="normal" font="default"> Raggi,P.</style></author><author><style face="normal" font="default"> Morris,D.</style></author><author><style face="normal" font="default"> Vaccarino,V.</style></author><author><style face="normal" font="default"> Liu,S.T.</style></author><author><style face="normal" font="default"> Weinstein,S.R.</style></author><author><style face="normal" font="default"> Mosler,T.P.</style></author><author><style face="normal" font="default"> Tseng,P.H.</style></author><author><style face="normal" font="default"> Flores,F.R.</style></author><author><style face="normal" font="default"> Nasir,K.</style></author><author><style face="normal" font="default"> Budoff,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Prognostic value of number and site of calcified coronary lesions compared with the total score</style></title><secondary-title><style face="normal" font="default">Jacc: Cardiovascular Imaging</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Jacc: Cardiovascular Imaging</style></full-title></periodical><pages end="69" start="61">61-69</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Georgia</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="1" Year="2008">2008/1</year></dates><abstract><style face="normal" font="default">OBJECTIVES: This study sought to evaluate the long-term prognostic value of the number and sites of calcified coronary lesions and to compare the accuracy of number of calcified lesions with the extent of total calcium score. BACKGROUND: There is a strong relationship between mortality and total coronary artery calcium (CAC) score. It is not known whether the number of calcified lesions or their location influences outcome. METHODS: A total of 14,759 asymptomatic patients were referred for evaluation of CAC scanning using electron beam tomography. Univariable and multivariable Cox proportional hazards models were developed to estimate time to all-cause mortality at, on average, 6.8 years (n = 281). RESULTS: Risk-adjusted annual mortality was 0.19% (95% confidence interval 0.18% to 0.21%) for patients without any calcified lesions. For patients with >20 lesions, annual risk-adjusted mortality exceeded 2% per year. Mortality rates were significantly higher for left main lesions as compared to other coronary arteries with annual mortality rates of 1.3%, 2.1%, 9.2%, and 13.6% for 1 to 2, 3 to 5, and > or =6 lesions, respectively (p &lt; 0.0001). For left main CAC scores of 0 to 10, 11 to 100, 101 to 399, and 400 to 999, annual risk-adjusted mortality was 0.33%, 0.81%, 1.73%, and 7.71%, respectively (p &lt; 0.0001). All 4 patients with a CAC score of > or =1,000 in the left main died during follow-up. However, patients with more frequent calcified lesions also had higher CAC scores. Specifically, > or =81% of patients with >10 calcified lesions also had a CAC score > or =100. With exception, for patients with CAC scores > or =1,000, annual mortality was dramatically higher at 3.0% to 4.5% for those with 1 to 5 calcified lesions as compared with 1.1% to 2.0% for those with 6 or more lesions (p &lt; 0.0001). CONCLUSIONS: We report that mortality rates increased proportionally with the number of calcified lesions. Although predictive information is contained in the number of calcified lesions, its added statistical value is minimal. With exception, patients with frequent lesions in the left main or those with a few large calcified lesions have a particularly high mortality risk</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Emory University School of Medicine, Atlanta, Georgia 30306, USACM - Comment in: JACC Cardiovasc Imaging. 2008 Jan;1(1):70-2; PMID: 19356408]JC - 101467978CP - United StatesPT - Comparative StudyPT - Evaluation StudiesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19356407</style></custom1><custom3><style face="normal" font="default">AS - JACC Cardiovasc Imaging. 1(1):61-9, 2008 Jan.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>53</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Wizemann,V.</style></author><author><style face="normal" font="default"> Tong,L.</style></author><author><style face="normal" font="default"> Satayathum,S.</style></author><author><style face="normal" font="default"> Disney,A.</style></author><author><style face="normal" font="default"> Akiba,T.</style></author><author><style face="normal" font="default"> Fissell,R.B.</style></author><author><style face="normal" font="default"> Kerr,P.G.</style></author><author><style face="normal" font="default"> Young,E.W.</style></author><author><style face="normal" font="default"> Robinson,B.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy</style></title><secondary-title><style face="normal" font="default">Kidney International</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Kidney International</style></full-title></periodical><pages end="1106" start="1098">1098-1106</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atrial Fibrillation/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Kidney Failure/co [Complications]</style></keyword><keyword><style face="normal" font="default"> 0 (Anticoagulants)</style></keyword><keyword><style face="normal" font="default"> 81-81-2 (Warfarin)</style></keyword><keyword><style face="normal" font="default"> Age Distribution</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Anticoagulants/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Anticoagulants/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Atrial Fibrillation/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Data Collection</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Kidney Failure/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Renal Dialysis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Stroke/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Warfarin/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Warfarin/tu [Therapeutic Use]</style></keyword></keywords><dates><year Day="0" Month="6" Year="2010">2010/6</year></dates><abstract><style face="normal" font="default">Using data from the international Dialysis Outcomes and Practice Patterns Study (DOPPS), we determined incidence, prevalence, and outcomes among hemodialysis patients with atrial fibrillation. Cox proportional hazards models, to identify associations with newly diagnosed atrial fibrillation and clinical outcomes, were stratified by country and study phase and adjusted for descriptive characteristics and comorbidities. Of 17,513 randomly sampled patients, 2188 had preexisting atrial fibrillation, with wide variation in prevalence across countries. Advanced age, non-black race, higher facility mean dialysate calcium, prosthetic heart valves, and valvular heart disease were associated with higher risk of new atrial fibrillation. Atrial fibrillation at study enrollment was positively associated with all-cause mortality and stroke. The CHADS2 score identified approximately equal-size groups of hemodialysis patients with atrial fibrillation with low (less than 2) and higher risk (more than 4) for subsequent strokes on a per 100 patient-year basis. Among patients with atrial fibrillation, warfarin use was associated with a significantly higher stroke risk, particularly in those over 75 years of age. Our study shows that atrial fibrillation is common and associated with elevated risk of adverse clinical outcomes, and this risk is even higher among elderly patients prescribed warfarin. The effectiveness and safety of warfarin in hemodialysis patients require additional investigation</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Georg Haas Dialysezentrum, Giessen, GermanyJC - kvb, 0323470CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20054291</style></custom1><custom3><style face="normal" font="default">AS - Kidney Int. 77(12):1098-106, 2010 Jun.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>552</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Wolak,A.</style></author><author><style face="normal" font="default"> Gransar,H.</style></author><author><style face="normal" font="default"> Thomson,L.E.</style></author><author><style face="normal" font="default"> Friedman,J.D.</style></author><author><style face="normal" font="default"> Hachamovitch,R.</style></author><author><style face="normal" font="default"> Gutstein,A.</style></author><author><style face="normal" font="default"> Shaw,L.J.</style></author><author><style face="normal" font="default"> Polk,D.</style></author><author><style face="normal" font="default"> Wong,N.D.</style></author><author><style face="normal" font="default"> Saouaf,R.</style></author><author><style face="normal" font="default"> Hayes,S.W.</style></author><author><style face="normal" font="default"> Rozanski,A.</style></author><author><style face="normal" font="default"> Slomka,P.J.</style></author><author><style face="normal" font="default"> Germano,G.</style></author><author><style face="normal" font="default"> Berman,D.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Aortic size assessment by noncontrast cardiac computed tomography: normal limits by age, gender, and body surface area</style></title><secondary-title><style face="normal" font="default">Jacc: Cardiovascular Imaging</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Jacc: Cardiovascular Imaging</style></full-title></periodical><pages end="209" start="200">200-209</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aorta,Thoracic/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Aorta/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Aortic Diseases/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Aortography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Body Surface Area</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Aorta</style></keyword><keyword><style face="normal" font="default"> Aortic Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Linear Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Reference Values</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Smoking/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="3" Year="2008">2008/3</year></dates><abstract><style face="normal" font="default">OBJECTIVES: To determine normal limits for ascending and descending thoracic aorta diameters in a large population of asymptomatic, low-risk adult subjects. BACKGROUND: Assessment of aortic size is possible from gated noncontrast computed tomography (CT) scans obtained for coronary calcium measurements. However, normal limits for aortic size by these studies have yet to be defined. METHODS: In 4,039 adult patients undergoing coronary artery calcium (CAC) scanning, systematic measurements of the ascending and descending thoracic aorta diameters were made at the level of the pulmonary artery bifurcation. Multiple linear regression analysis was used to detect risk factors independently associated with ascending and descending thoracic aorta diameter and exclude subjects with these parameters from the final analysis. The final analysis groups for ascending and descending thoracic aorta included 2,952 and 1,931 subjects, respectively. Subjects were then regrouped by gender, age, and body surface area (BSA) for ascending and descending aorta, separately, and for each group, the mean, standard deviation, and upper normal limit were calculated for aortic diameter as well as for the calculated cross-sectional aortic area. Also, linear regression models were used to create BSA versus aortic diameter nomograms by age groups, and a formula for calculating predicted aortic size by age, gender, and BSA was created. RESULTS: Age, BSA, gender, and hypertension were directly associated with thoracic aorta dimensions. Additionally, diabetes was associated with ascending aorta diameter, and smoking was associated with descending aorta diameter. The mean diameters for the final analysis group were 33 +/- 4 mm for the ascending and 24 +/- 3 mm for the descending thoracic aorta, respectively. The corresponding upper limits of normal diameters were 41 and 30 mm, respectively. CONCLUSIONS: Normal limits of ascending and descending aortic dimensions by noncontrast gated cardiac CT have been defined by age, gender, and BSA in a large, low-risk population of subjects undergoing CAC scanning</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Departments of Imaging, CSMC Burns &amp; Allen Research Institute, Cedars-Sinai Medical Center, University of California at Los Angeles, USAJC - 101467978CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19356429</style></custom1><custom3><style face="normal" font="default">AS - JACC Cardiovasc Imaging. 1(2):200-9, 2008 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>381</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Wong,N.D.</style></author><author><style face="normal" font="default"> Gransar,H.</style></author><author><style face="normal" font="default"> Narula,J.</style></author><author><style face="normal" font="default"> Shaw,L.</style></author><author><style face="normal" font="default"> Moon,J.H.</style></author><author><style face="normal" font="default"> Miranda-Peats,R.</style></author><author><style face="normal" font="default"> Rozanski,A.</style></author><author><style face="normal" font="default"> Hayes,S.W.</style></author><author><style face="normal" font="default"> Thomson,L.E.</style></author><author><style face="normal" font="default"> Friedman,J.D.</style></author><author><style face="normal" font="default"> Berman,D.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Myeloperoxidase, subclinical atherosclerosis, and cardiovascular disease events</style></title><secondary-title><style face="normal" font="default">Jacc: Cardiovascular Imaging</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Jacc: Cardiovascular Imaging</style></full-title></periodical><pages end="1099" start="1093">1093-1099</pages><volume><style face="normal" font="default">2</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/en [Enzymology]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/en [Enzymology]</style></keyword><keyword><style face="normal" font="default"> *Peroxidase/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Biological Markers/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Calcinosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/en [Enzymology]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> EC 1-11-1-7 (Peroxidase)</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immunoassay</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Up-Regulation</style></keyword></keywords><dates><year Day="0" Month="9" Year="2009">2009/9</year></dates><abstract><style face="normal" font="default">OBJECTIVES: We evaluated whether myeloperoxidase (MPO) predicts future cardiovascular disease (CVD) events in asymptomatic adults and whether subclinical atherosclerosis may affect this relation. BACKGROUND: Myeloperoxidase is a leukocyte-derived enzyme-generating reactive oxidant species that has been shown to predict risk of CVD in selected populations. METHODS: We studied 1,302 asymptomatic adults (mean age 59 years, 47% women) without known CVD who were followed for 3.8 years. We measured MPO by the use of immunoassay. Coronary artery calcium (CAC), a measure of subclinical atherosclerosis, was measured by computed tomography with the Agatston score categorized as none/minimal (0 to 9), mild (10 to 99), and moderate/significant (> or = 100). Cox regression, adjusted for age, sex, and other risk factors, examined the relation of CAC and/or MPO with incident CVD events. RESULTS: Persons with MPO levels at or above compared with below the median (257 pM) were more likely (p &lt; 0.05 to p &lt; 0.001) to be women, have a higher body mass index, greater low-density lipoprotein cholesterol, greater systolic and diastolic blood pressure, and lower high-density lipoprotein cholesterol. Mean MPO levels increased according to CAC categories (p trend = 0.02). Incident CVD events were more likely in those at or above versus below the median MPO level (4.6% vs. 2.3%, p = 0.02), even after adjustment for age, sex, CAC, and risk factors (hazard ratio [HR]: 1.9, 95% confidence interval: 1.0 to 3.6, p = 0.04). Combining CAC and MPO categories, CVD incidence ranged from 0.6% in those with a CAC score of 0 to 9 to 7.1% (adjusted HR: 9.2, p &lt; 0.001) in those with CAC scores of > or = 100 and MPO below the median and 14.0% (adjusted HR: 19.5, p &lt; 0.0001) in those with CAC scores of > or = 100 and MPO at or above the median. CONCLUSIONS: Our study suggests persons with both increased levels of both MPO and CAC are at an increased risk of CVD events. Imaging of subclinical atherosclerosis combined with assessment of biomarkers of plaque vulnerability may help improve CVD risk stratification</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiology, University of California, Irvine, California, USACM - Comment in: JACC Cardiovasc Imaging. 2009 Sep;2(9):1100-2; PMID: 19761989]JC - 101467978CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19761988</style></custom1><custom3><style face="normal" font="default">AS - JACC Cardiovasc Imaging. 2(9):1093-9, 2009 Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>479</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Wood,D.A.</style></author><author><style face="normal" font="default"> Tops,L.F.</style></author><author><style face="normal" font="default"> Mayo,J.R.</style></author><author><style face="normal" font="default"> Pasupati,S.</style></author><author><style face="normal" font="default"> Schalij,M.J.</style></author><author><style face="normal" font="default"> Humphries,K.</style></author><author><style face="normal" font="default"> Lee,M.</style></author><author><style face="normal" font="default"> Al,Ali A.</style></author><author><style face="normal" font="default"> Munt,B.</style></author><author><style face="normal" font="default"> Moss,R.</style></author><author><style face="normal" font="default"> Thompson,C.R.</style></author><author><style face="normal" font="default"> Bax,J.J.</style></author><author><style face="normal" font="default"> Webb,J.G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Role of multislice computed tomography in transcatheter aortic valve replacement</style></title><secondary-title><style face="normal" font="default">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Cardiology</style></full-title></periodical><pages end="1301" start="1295">1295-1301</pages><volume><style face="normal" font="default">103</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Aortic Valve/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Aortic Valve/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Heart Valve Prosthesis Implantation/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Imaging,Three-Dimensional/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Aortic Valve/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Echocardiography,Transesophageal/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Echocardiography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Heart Catheterization/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Heart Valve Diseases/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Heart Valve Diseases/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Surgical Procedures,Minimally Invasive/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="1" Month="5" Year="2009">2009/5/1</year></dates><abstract><style face="normal" font="default">Transcatheter aortic valve replacement (TAVR) required precise knowledge of the anatomic dimensions and physical characteristics of the aortic valve, annulus, and aortic root. Most groups currently use angiography, transthoracic echocardiography (TTE), or transesophageal echocardiography (TEE) to assess aortic annulus dimensions and anatomy. However, multislice computed tomography (MSCT) may allow more detailed 3-dimensional assessment of the aortic root. Twenty-six patients referred for TAVR underwent MSCT. Scans were also obtained for 18 patients after TAVR. All patients underwent pre- and postprocedural aortic root angiography, TTE, and TEE. Mean differences in measured aortic annular diameters were 1.1 mm (95% confidence interval 0.5, 1.8) for calibrated angiography and TTE, -0.9 mm (95% confidence interval -1.7, -0.1 mm) for TTE and TEE, -0.3 mm (95% confidence interval -1.1, 0.6 mm) for MSCT (sagittal) and TTE, and -1.2 mm (95% confidence interval -2.2, -0.2 mm) for MSCT (sagittal) and TEE. Coronal systolic measurements using MSCT, which corresponded to angiographic orientation, were 3.2 mm (1st and 3rd quartiles 2.6, 3.9) larger than sagittal systolic measurements, which were in the same anatomic plane as standard TTE and TEE views. There was no significant association between either shape of the aortic annulus or amount of aortic valve calcium and development of perivalvular aortic regurgitation. After TAVR, the prosthesis extended to or beyond the inferior border of the left main ostium in 9 of 18 patients (50%), and in 11 patients (61%), valvular calcium was &lt;5 mm from the left main ostium. In conclusion, MSCT identified that the aortic annulus was commonly eccentric and often oval. This may in part explain the small, but clinically insignificant, differences in measured aortic annular diameters with other imaging modalities. MSCT after TAVR showed close proximity of both the prosthesis and displaced valvular calcium to the left main ostium in most patients. Neither eccentricity nor calcific deposits appeared to contribute significantly to severity of paravalvular regurgitation after TAVR</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Cardiology, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, CanadaJC - 3dq, 0207277CP - United StatesPT - Comparative StudyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19406275</style></custom1><custom3><style face="normal" font="default">AS - Am J Cardiol. 103(9):1295-301, 2009 May 1.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>82</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Wu,S.H.</style></author><author><style face="normal" font="default"> Ho,S.C.</style></author><author><style face="normal" font="default"> Zhong,L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Effects of vitamin D supplementation on blood pressure</style></title><secondary-title><style face="normal" font="default">Southern Medical Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Southern Medical Journal</style></full-title></periodical><pages end="737" start="729">729-737</pages><volume><style face="normal" font="default">103</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Hypertension/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> *Vitamin D/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> 1406-16-2 (Vitamin D)</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Blood Pressure/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Diastole/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default"> SB - AIM,IM</style></keyword><keyword><style face="normal" font="default"> Systole/de [Drug Effects]</style></keyword></keywords><dates><year Day="0" Month="8" Year="2010">2010/8</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Inconsistent findings from epidemiological studies have continued the controversy over the role of oral vitamin D supplementation in reducing blood pressure in normotensive or hypertensive populations. METHODS: We performed a literature search up to December 2009, with no restrictions. Only double-blind randomized controlled trials (RCTs) of oral vitamin D supplementation in normotensive or hypertensive individuals with blood pressure measurements were included. RESULTS: From 244 retrieved papers, four RCTs involving 429 participants met our inclusion criteria for this meta-analysis. Vitamin D supplementation reduced systolic blood pressure (SBP) by 2.44 mm Hg (weighted mean difference [WMD]: -2.44, 95% confidence interval [CI]: -4.86, -0.02), but not diastolic blood pressure (DBP) (WMD: -0.02, 95% CI: -4.04, 4.01) compared with calcium or placebo. Subgroup analysis suggested that the change of blood pressure did not vary markedly across the dose of vitamin D supplementation, study length, or intervention. CONCLUSIONS: Oral vitamin D supplementation may lead to a reduction in systolic blood pressure but not diastolic blood pressure. Given the small number of trials and small but statistically significant reduction in systolic blood pressure from this meta-analysis, further studies are required to confirm the magnitude of the effect of vitamin D on blood pressure reduction and define the optimum dose, dosing interval, and type of vitamin D to administer</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, People's Republic of ChinaCM - Comment in: South Med J. 2010 Aug;103(8):723-4; PMID: 20622734JC - uvh, 0404522CP - United StatesPT - Journal ArticlePT - Meta-AnalysisLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20622727</style></custom1><custom3><style face="normal" font="default">AS - South Med J. 103(8):729-37, 2010 Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>219</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Xu,Z.S.</style></author><author><style face="normal" font="default"> Lee,B.K.</style></author><author><style face="normal" font="default"> Park,D.W.</style></author><author><style face="normal" font="default"> Lee,S.W.</style></author><author><style face="normal" font="default"> Kim,Y.H.</style></author><author><style face="normal" font="default"> Lee,C.W.</style></author><author><style face="normal" font="default"> Hong,M.K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Relation of plaque size to compositions as determined by an in vivo volumetric intravascular ultrasound radiofrequency analysis</style></title><secondary-title><style face="normal" font="default">The International Journal of Cardiovascular Imaging</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">The International Journal of Cardiovascular Imaging</style></full-title></periodical><pages end="171" start="165">165-171</pages><volume><style face="normal" font="default">26</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Acute Coronary Syndrome/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Angina Pectoris/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Artery Disease/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Vessels/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Myocardial Infarction/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Ultrasonography,Interventional</style></keyword><keyword><style face="normal" font="default"> 0 (Lipids)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Acute Coronary Syndrome/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Acute Coronary Syndrome/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angina Pectoris/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Angina Pectoris/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Angina,Unstable/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Calcium/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Linear Models</style></keyword><keyword><style face="normal" font="default"> Lipids/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="2" Year="2010">2010/2</year></dates><abstract><style face="normal" font="default">As the plaques have enlarged, the changes in specific plaque compositions have not been sufficiently investigated. We evaluated the relation of plaque size to each plaque component (fibrotic, fibrofatty, dense calcium, and necrotic core) in 244 patients with volumetric virtual histology intravascular ultrasound analysis. Plaque volume was significantly correlated with fibrotic volume (r = 0.886, P &lt; 0.001), necrotic core volume (r = 0.716, P &lt; 0.001), fibrofatty volume (r = 0.572, P &lt; 0.001), and dense calcium volume (r = 0.382, P &lt; 0.001). There was a weak correlation between plaque volume and percentage of fibrofatty plaque and dense calcium (r = 0.140, P = 0.030 and r = -0.146, P = 0.023, respectively). Plaque volume was not significantly correlated with percentage of fibrotic plaque and necrotic core. As the plaque volume increased, there was an increase in absolute amounts of each plaque component (fibrotic > necrotic core > fibrofatty > dense calcium). However, there were no significantly relevant correlations between plaque volume and percentage of each plaque component</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, Cangzhou Central Hospital, Cangzhou, People's Republic of ChinaCM - Comment in: Int J Cardiovasc Imaging. 2010 Feb;26(2):173-6; PMID: 20043242JC - 100969716CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19851884</style></custom1><custom3><style face="normal" font="default">AS - Int J Cardiovasc Imaging. 26(2):165-71, 2010 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>67</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Yang,D.</style></author><author><style face="normal" font="default"> Ma,S.</style></author><author><style face="normal" font="default"> Tan,Y.</style></author><author><style face="normal" font="default"> Li,D.</style></author><author><style face="normal" font="default"> Tang,B.</style></author><author><style face="normal" font="default"> Zhang,X.</style></author><author><style face="normal" font="default"> Sun,M.</style></author><author><style face="normal" font="default"> Yang,Y.</style></author></authors></contributors><titles><title><style face="normal" font="default">Increased expression of calpain and elevated activity of calcineurin in the myocardium of patients with congestive heart failure</style></title><secondary-title><style face="normal" font="default">International Journal of Molecular Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">International Journal of Molecular Medicine</style></full-title></periodical><pages end="164" start="159">159-164</pages><volume><style face="normal" font="default">26</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcineurin/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Calpain/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Heart Failure/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Myocardium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> 0 (Receptor,Angiotensin,Type 1)</style></keyword><keyword><style face="normal" font="default"> 0 (Receptor,Angiotensin,Type 2)</style></keyword><keyword><style face="normal" font="default"> 11128-99-7 (Angiotensin II)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Angiotensin II/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Angiotensin II/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Blotting,Western</style></keyword><keyword><style face="normal" font="default"> Calpain/bi [Biosynthesis]</style></keyword><keyword><style face="normal" font="default"> EC 3-1-3-16 (Calcineurin)</style></keyword><keyword><style face="normal" font="default"> EC 3-4-22 (Calpain)</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default"> Heart Failure/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Heart Failure/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardium/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Radioimmunoassay</style></keyword><keyword><style face="normal" font="default"> Receptor,Angiotensin,Type 1/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Receptor,Angiotensin,Type 2/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> Reverse Transcriptase Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="7" Year="2010">2010/7</year></dates><abstract><style face="normal" font="default">The angiotensin (Ang) II/Ang II receptor (ATR)-associated calcium signaling pathway is the major cause of ventricular remodelling in patients with congestive heart failure (CHF). However, the calcium-regulated proteinases responsible for Ang II-induced remodelling are not well understood. We investigated the profiles of the Ang II/ATR/calpain/calcineurin (CaN) pathway in human failing heart. We measured both the plasma and cardiac levels of Ang II and cardiac mRNA expression of ATR in 39 patients with CHF and 38 healthy controls. Importantly, protein expression of calpains, cleavage of cain/cabin1 and activity of CaN were tested. Both plasma and cardiac levels of Ang II were significantly increased in patients with CHF (both p&lt;0.01), and the plasma Ang II concentration was closely correlated with the parameters of ventricular remodelling (r=+/-0.29-0.65, p&lt;0.05 or &lt;0.01). In addition, the cardiac level of AT1R but not AT2R was significantly upregulated in mild failing hearts (p&lt;0.05) but dramatically downregulated in severe failing ones (p&lt;0.01). CHF was associated with a marked upregulation of calpains, an increased cleavage of cain/cabin1, and the activation of CaN in the failing ventricular tissue. In patients with CHF, calpain upregulation was associated with an increase in cleavage of cain/cabin1 and the activation of CaN, indicating that these changes in calcium-regulated proteinases contribute to Ang II-induced cardiac remodelling</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, General Hospital of PLA Chengdu Military Area Command, Chengdu 610083, PR ChinaJC - c8h, 9810955CP - GreecePT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20514436</style></custom1><custom3><style face="normal" font="default">AS - Int J Mol Med. 26(1):159-64, 2010 Jul.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>366</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Yang,Y.J.</style></author><author><style face="normal" font="default"> Zhu,W.L.</style></author><author><style face="normal" font="default"> Zhou,X.W.</style></author><author><style face="normal" font="default"> Zhang,X.</style></author><author><style face="normal" font="default"> Zhu,Z.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Calpain involved in signal transduction of myocardial remodeling in patients with congestive heart failure]. [Chinese]</style></title><secondary-title><style face="normal" font="default">Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology]</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology]</style></full-title></periodical><pages end="250" start="247">247-250</pages><volume><style face="normal" font="default">33</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calpain/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Heart Failure/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> *Myocardium/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Signal Transduction</style></keyword><keyword><style face="normal" font="default"> *Ventricular Remodeling</style></keyword><keyword><style face="normal" font="default"> 0 (CABIN1 protein,human)</style></keyword><keyword><style face="normal" font="default"> 11128-99-7 (Angiotensin II)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Angiotensin II/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcineurin/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> EC 3-1-3-16 (Calcineurin)</style></keyword><keyword><style face="normal" font="default"> EC 3-4-22 (Calpain)</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Failure/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperplasia</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Myocardium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Phosphorylation</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="3" Year="2005">2005/3</year></dates><isbn><style face="normal" font="default">0253-3758</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: To investigate the regulation of calcium sensitive signal substance calpain in signal transduction of myocardial remodeling in patients with congestive heart failure. METHODS: All 39 congestive heart failure (CHF) patients with rheumatic mitral valve stenosis disease were selected and 38 cases of healthy persons were included as controls. Cardiac function parameters were measured by echocardiography. The concentration of angiotension II (AngII) in plasma and myocardial tissues was determined by radio immunoassay (RIA). Western blot was used to assay the protein expression of calpain, cain/cabin 1, cain/cabin 1Delta, and calcineurin (CaN) phosphorylation. RESULTS: The AngII concentrations in the plasma and myocardial tissues in patients with CHF were higher than those in the control group. Meanwhile the AngII concentrations positively correlated to the parameters of the cardiac dilation respectively but negatively correlated to the parameters of cardiac function. Pathological changes of myocardial tissues in CHF with valvular heart disease showed typical myocardial remodeling. The hypertrophy was dominant at early stage of CHF, while at the end stage the characteristics include disordered alignment of the myocytes, the discontinuity and dissolving of cardiomyofibrills, destroyed subcellular organs, and the hyperplasia of interstitial tissue. Compared to the control group, u-calpain, m-calpain, and cain/cabin 1Delta protein expression, CaN phosphorylation in myocardial tissues in CHF groups were highly expressed and their expressions were positively correlated to the severity of CHF. The expression of cain/cabin1 deceased and its expression was negatively correlated to the severity of CHF. CONCLUSION: The degradation of cain/cabin 1 by calpain may play an important role by causing the activation of CaN signal pathway in myocardial remodeling mediated by renin angiotension system in CHF</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Cardiology, General Hospital of Chengdu Army, Chengdu 610083, ChinaJC - ebn, 7910682CP - ChinaPT - English AbstractPT - Journal ArticleLG - Chinese</style></notes><urls/><custom1><style face="normal" font="default">UI - 15929823</style></custom1><custom3><style face="normal" font="default">AS - Chung Hua Hsin Hsueh Kuan Ping Tsa Chih. 33(3):247-50, 2005 Mar.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>269</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Yazbeck,C.</style></author><author><style face="normal" font="default"> Thiebaugeorges,O.</style></author><author><style face="normal" font="default"> Moreau,T.</style></author><author><style face="normal" font="default"> Goua,V.</style></author><author><style face="normal" font="default"> Debotte,G.</style></author><author><style face="normal" font="default"> Sahuquillo,J.</style></author><author><style face="normal" font="default"> Forhan,A.</style></author><author><style face="normal" font="default"> Foliguet,B.</style></author><author><style face="normal" font="default"> Magnin,G.</style></author><author><style face="normal" font="default"> Slama,R.</style></author><author><style face="normal" font="default"> Charles,M.A.</style></author><author><style face="normal" font="default"> Huel,G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Maternal blood lead levels and the risk of pregnancy-induced hypertension: the EDEN cohort study</style></title><secondary-title><style face="normal" font="default">Environmental Health Perspectives</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Environmental Health Perspectives</style></full-title></periodical><pages end="1530" start="1526">1526-1530</pages><volume><style face="normal" font="default">117</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Hypertension,Pregnancy-Induced/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Lead/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 7439-92-1 (Lead)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Gestational Age</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Hypertension,Pregnancy-Induced/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Lead/to [Toxicity]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Spectrophotometry,Atomic</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Prior studies revealed associations of environmental lead exposure with risks of hypertension and elevated blood pressure. OBJECTIVE: We examined the effect of blood lead levels on blood pressure and the incidence of pregnancy-induced hypertension (PIH) in the second and third trimesters of pregnancy. METHODS: One thousand seventeen pregnant women were enrolled in two French municipalities between 2003 and 2005 for the EDEN (Etude des D&amp;#x00E9;terminants pr&amp;#x00E9; et post natals du d&amp;#x00E9;veloppement et de la sant&amp;#x00E9; de l' Enfant) cohort study. Blood lead concentrations were measured by atomic absorption spectrometry in mothers between 24 and 28 weeks of gestation. RESULTS: PIH was diagnosed in 106 subjects (10.9%). Age, parity, weight gain, alcohol, smoking habits, and calcium supplementation were comparable between hypertensive and nonhypertensive women. Lead levels were significantly higher in PIH cases (mean +/- SD, 2.2 +/- 1.4 microg/dL) than in normotensive patients (1.9 +/- 1.2 microg/dL; p = 0.02). Adjustment for potential confounder effects slightly attenuated but did not eliminate the significant association between blood lead levels and the risk of PIH (adjusted odds ratio of PIH = 3.3; 95% confidence interval, 1.1-9.7). We also observed geographic differences in lead exposure and in the incidence of PIH and found significant correlations between blood lead levels and unadjusted as well as adjusted systolic and diastolic blood pressures after 24 weeks of gestation. CONCLUSIONS: These findings confirm the relationship between blood lead levels at mid-pregnancy and blood pressure and suggest that environmental lead exposure may play an etiologic role in PIH</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - INSERM, U780, IFR69, Villejuif, France. chadi.yazbeck@inserm.frJC - ei0, 0330411CP - United StatesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20019901</style></custom1><custom3><style face="normal" font="default">AS - Environ Health Perspect. 117(10):1526-30, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>152</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Yeap,S.S.</style></author><author><style face="normal" font="default"> Goh,E.M.</style></author><author><style face="normal" font="default"> Das,Gupta E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Knowledge about osteoporosis in a Malaysian population</style></title><secondary-title><style face="normal" font="default">Asia-Pacific Journal of Public Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Asia-Pacific Journal of Public Health</style></full-title></periodical><pages end="241" start="233">233-241</pages><volume><style face="normal" font="default">22</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Health Knowledge,Attitudes,Practice</style></keyword><keyword><style face="normal" font="default"> *Osteoporosis</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Malaysia</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> Socioeconomic Factors</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="default">To determine the depth and sources of knowledge about osteoporosis (OP) among the public in Malaysia. A self-administered questionnaire was distributed to attendees of health-related public forums. A total of 87.1% of the attendees had heard of OP. Of these, 89.5% were concerned about getting OP. Significantly more women than men (P = .015), those with more than 10 years of schooling (P &lt; .001), and those earning more than $US285 per month (P = .022) had heard of OP. Knowledge of OP risk factors was good: 97.1% identified low calcium intake, 87.8% lack of exercise, 80.0% family history of OP, and 75.8% postmenopausal status. A total of 38.7% of the attendees thought that OP was more serious than cancer and 35.1% more serious than heart disease; 55.7% obtained information about OP from newspapers and 46.4% from magazines. In this self-selected population, women, the better educated, and those earning higher incomes were more aware of OP. Knowledge of OP was obtained mainly from printed materials</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Sime Darby Medical Centre Subang Jaya, Selangor, Malaysia. yeapss@myjaring.netJC - asj, 8708538CP - ChinaPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20457652</style></custom1><custom3><style face="normal" font="default">AS - Asia Pac J Public Health. 22(2):233-41, 2010 Apr.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>390</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Yee,M.S.</style></author><author><style face="normal" font="default"> Pavitt,D.V.</style></author><author><style face="normal" font="default"> Richmond,W.</style></author><author><style face="normal" font="default"> Cook,H.T.</style></author><author><style face="normal" font="default"> McLean,A.G.</style></author><author><style face="normal" font="default"> Valabhji,J.</style></author><author><style face="normal" font="default"> Elkeles,R.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Changes in lipoprotein profile and urinary albumin excretion in familial LCAT deficiency with lipid lowering therapy</style></title><secondary-title><style face="normal" font="default">Atherosclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Atherosclerosis</style></full-title></periodical><pages end="532" start="528">528-532</pages><volume><style face="normal" font="default">205</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Albumins/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> *Lecithin Acyltransferase Deficiency/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> *Lecithin Acyltransferase Deficiency/ge [Genetics]</style></keyword><keyword><style face="normal" font="default"> *Lecithin Acyltransferase Deficiency/ur [Urine]</style></keyword><keyword><style face="normal" font="default"> *Lipoproteins/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> 0 (Albumins)</style></keyword><keyword><style face="normal" font="default"> 0 (Antilipemic Agents)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipoprotein-X)</style></keyword><keyword><style face="normal" font="default"> 0 (Lipoproteins)</style></keyword><keyword><style face="normal" font="default"> 0 (Triglycerides)</style></keyword><keyword><style face="normal" font="default"> 49562-28-9 (Procetofen)</style></keyword><keyword><style face="normal" font="default"> 57-88-5 (Cholesterol)</style></keyword><keyword><style face="normal" font="default"> 59-67-6 (Niacin)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Antilipemic Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Calcium/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Cholesterol/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lipoprotein-X/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Niacin/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> Procetofen/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Triglycerides/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Urine</style></keyword></keywords><dates><year Day="0" Month="8" Year="2009">2009/8</year></dates><abstract><style face="normal" font="default">Familial lecithin:cholesterol acyltransferase deficiency (FLD) is a monogenic autosomal recessive condition, affecting cholesterol esterification and leads to progressive renal impairment and end-stage renal failure, probably due to the abnormal lipoprotein (X) (Lp(X)). We report a case of FLD, whom we treated with a combination of nicotinic acid 1.5g nocte and fenofibrate M/R 160mg od and report changes in lipid profile and Lp(X), after six weeks and serum creatinine and urine albumin/creatinine ratio after 12 months. We assessed the cardiovascular risk using electron beam computed tomography. At baseline total cholesterol was 6.61mmol/L; HDL cholesterol 0.57mmol/L; Lp(X) cholesterol 3.24mmol/L; triglyceride 4.13mmol/L; apolipoprotein A1 46mg/dL; and apolipoprotein B 53mg/dL. After six weeks of treatment his total cholesterol was 4.16; HDL cholesterol 0.52; Lp(X) cholesterol 1.73mmol/L; triglyceride 1.80mmol/L; apolipoprotein A1 36mg/dL; and apolipoprotein B 50mg/dL. Baseline serum creatinine was 106micromol/L and urine albumin/creatinine ratio was 127.3mg/mmol and after 12 months was 101micromol/L and 31.5mg/mmol respectively. His coronary artery calcification score was zero. We have shown, we believe for the first time, that combination lipid modifying therapy in FLD leads to a reduction in Lp(X) concentration and an associated reduction in urine albumin excretion at 12 months</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Imperial College London, St Mary's Hospital, London, UK. m.yee@imperial.ac.ukJC - 95x, 0242543CP - IrelandPT - Case ReportsPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19230892</style></custom1><custom3><style face="normal" font="default">AS - Atherosclerosis. 205(2):528-32, 2009 Aug.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>155</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Yilmaz,M.I.</style></author><author><style face="normal" font="default"> Qureshi,A.R.</style></author><author><style face="normal" font="default"> Carrero,J.J.</style></author><author><style face="normal" font="default"> Saglam,M.</style></author><author><style face="normal" font="default"> Suliman,M.E.</style></author><author><style face="normal" font="default"> Caglar,K.</style></author><author><style face="normal" font="default"> Eyileten,T.</style></author><author><style face="normal" font="default"> Sonmez,A.</style></author><author><style face="normal" font="default"> Oguz,Y.</style></author><author><style face="normal" font="default"> Vural,A.</style></author><author><style face="normal" font="default"> Yenicesu,M.</style></author><author><style face="normal" font="default"> Axelsson,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Predictors of carotid artery intima-media thickness in chronic kidney disease and kidney transplant patients without overt cardiovascular disease</style></title><secondary-title><style face="normal" font="default">American Journal of Nephrology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">American Journal of Nephrology</style></full-title></periodical><pages end="221" start="214">214-221</pages><volume><style face="normal" font="default">31</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Carotid Artery Diseases/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> *Carotid Artery Diseases/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> *Kidney Transplantation</style></keyword><keyword><style face="normal" font="default"> *Renal Insufficiency,Chronic/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> *Renal Insufficiency,Chronic/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> 0 (Biological Markers)</style></keyword><keyword><style face="normal" font="default"> 69-93-2 (Uric Acid)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Biological Markers</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Carotid Artery,Common/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Kidney Transplantation</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tunica Intima/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Tunica Media/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Uric Acid/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="0" Year="2010">2010</year></dates><abstract><style face="normal" font="default">BACKGROUND/AIMS: Carotid intima-media thickness (IMT) assessed using ultrasonography is a widely used marker of atherosclerosis. In the largest study to date of IMT and chronic kidney disease (CKD), we assessed correlates of IMT in CKD patients with a wide range of renal dysfunction, and also investigated what happens to IMT following renal transplantation. METHODS: We studied 406 patients with different stages of nondiabetic CKD (50% males, 46 +/- 12 years), and 58 kidney transplant recipients (27 +/- 6 years), testing relationships between IMT, assessed by ultrasonography, and selected biomarkers. RESULTS: Despite a lack of overt CVD, patients had significantly higher IMT as compared to controls (0.9 [0.7-1.0] vs. 0.6 [0.4-0.7] mm; p > 0.001). Furthermore, in multivariate analysis IMT was independently associated with CKD stage, mean arterial pressure (MAP) and calcium-phosphate product, but not with Framingham risk factors. Following kidney transplantation, IMT decreased rapidly, reaching levels comparable to those in the controls within 90 days. In a time-dependent multivariate analysis, this decrease was predicted by changes in GFR, MAP, and uric acid levels. CONCLUSION: Our data does not exclude IMT as a predictor of mortality in CKD, but suggests that other etiologies than atherosclerosis may be more important in determining IMT levels in the population with CKD. 2009 S. Karger AG, Basel</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Nephrology, Gulhane School of Medicine, Ankara, Turkey. mahmutiyilmaz@yahoo.comJC - 3mb, 8109361CP - SwitzerlandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20068285</style></custom1><custom3><style face="normal" font="default">AS - Am J Nephrol. 31(3):214-21, 2010.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>300</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Yiu,K.H.</style></author><author><style face="normal" font="default"> Wang,S.</style></author><author><style face="normal" font="default"> Mok,M.Y.</style></author><author><style face="normal" font="default"> Ooi,G.C.</style></author><author><style face="normal" font="default"> Khong,P.L.</style></author><author><style face="normal" font="default"> Mak,K.F.</style></author><author><style face="normal" font="default"> Lam,K.F.</style></author><author><style face="normal" font="default"> Lau,C.S.</style></author><author><style face="normal" font="default"> Tse,H.F.</style></author></authors></contributors><titles><title><style face="normal" font="default">Pattern of arterial calcification in patients with systemic lupus erythematosus</style></title><secondary-title><style face="normal" font="default">Journal of Rheumatology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Rheumatology</style></full-title></periodical><pages end="2217" start="2212">2212-2217</pages><volume><style face="normal" font="default">36</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Atherosclerosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular System/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> *Cardiovascular System/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Lupus Erythematosus,Systemic/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aorta,Thoracic/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Aorta,Thoracic/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular System/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Carotid Arteries/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Carotid Arteries/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Coronary Vessels/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hong Kong</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lupus Erythematosus,Systemic/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Tomography,Spiral Computed</style></keyword></keywords><dates><year Day="0" Month="10" Year="2009">2009/10</year></dates><isbn><style face="normal" font="default">0315-162X</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: To evaluate the prevalence and pattern of arterial calcification in patients with asymptomatic systemic lupus erythematosus (SLE) compared with control subjects. SLE patients are prone to adverse cardiovascular events; however, the underlying atherosclerotic process is unknown. Multidetector computed tomography (MDCT) measured arterial calcium score (CS) reflecting underlying atherosclerosis and is closely associated with cardiovascular events. METHODS: Fifty age and sex matched SLE patients and controls were enrolled. All subjects underwent 64 slice MDCT scan to evaluate CS in coronary, carotid arteries and the aorta. RESULTS: As compared with controls, SLE patients had higher mean CS and prevalence of CS > 0 across all vascular beds. After adjustment for age and sex, SLE patient odds of having CS > 0 in any vascular bed was 33.6 (95% CI: 9.5-165.2) were higher versus patients in the control group, mainly due to more prevalent coronary calcification (OR 30.0, 95% CI: 6.7-203.8). In SLE patients, the most frequent vessel with CS > 0 was coronary (42%) followed by carotid artery (24%). Further, arterial calcification occurred early involving 40% of SLE patients at age &lt; 40 years, with increasing prevalence as age advanced. CONCLUSION: Our study confirms that patients with SLE have significantly higher prevalence and extent of systemic arterial calcification compared with age and sex matched controls</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Cardiology Division, Department of Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong KongCM - Comment in: J Rheumatol. 2009 Oct;36(10):2141-3; PMID: 19820217JC - 7501984, jwxCP - CanadaPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19755615</style></custom1><custom3><style face="normal" font="default">AS - J Rheumatol. 36(10):2212-7, 2009 Oct.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>297</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Young,V.N.</style></author><author><style face="normal" font="default"> Osborne,K.M.</style></author><author><style face="normal" font="default"> Fleming,M.M.</style></author><author><style face="normal" font="default"> Flynn,M.B.</style></author><author><style face="normal" font="default"> Goldstein,R.E.</style></author><author><style face="normal" font="default"> Bumpous,J.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Parathyroidectomy in the elderly population: does age really matter?</style></title><secondary-title><style face="normal" font="default">Laryngoscope</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Laryngoscope</style></full-title></periodical><pages end="252" start="247">247-252</pages><volume><style face="normal" font="default">120</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Hyperparathyroidism,Primary/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> *Parathyroidectomy</style></keyword><keyword><style face="normal" font="default"> 0 (Parathyroid Hormone)</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Primary/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Length of Stay</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Parathyroid Hormone/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Parathyroidectomy</style></keyword><keyword><style face="normal" font="default"> Parathyroidectomy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="2" Year="2010">2010/2</year></dates><abstract><style face="normal" font="default">OBJECTIVES/HYPOTHESIS: Compare parathyroidectomy patients based on age, including demographics, outcomes, and complications. STUDY DESIGN: Retrospective review. METHODS: Prospective parathyroidectomy database covering 1998 to 2007 was reviewed retrospectively. RESULTS: A total of 687 patients underwent parathyroidectomy, including 247 (36%) >65 years old. Discharge was more often on day of surgery in younger patients (42.5% vs. 29.2%, P = .007) and >23 hours for older patients (24.7% vs. 12.3%, P &lt; .0001). Older patients stayed longer in the recovery room (134 vs. 107 minutes, P = .005). Despite postoperative normocalcemia, older patients tended to have persistently elevated parathyroid hormone (PTH) (10.5% vs. 6.4%, P = .07), whereas younger patients had normal PTH (81.6% vs. 70%, P = .0007). PTH levels were low-abnormal (56-110) in younger patients (47% vs. 29%, P = .046), but high-abnormal (>220) in older patients (16.6% vs. 9.55%, P = .009). Overall complication rates were low (6%-8%), with >93% in either group having no major complications. There was no difference in timing or types of complications, except elderly patients were more likely to have cardiac complications (2.83% vs. 0.45%, P = .022). CONCLUSIONS: Nearly 700 parathyroidectomies were performed at our institution over 10 years. Elderly patients comprised one third of this population. They were likely to have longer hospital and recovery room stays, and postoperative normocalcemia with elevated PTH, which may actually be a normal finding for these patients, but it warrants further study. The rate, timing, and types of complications were similar between age groups, although elderly patients had more cardiac complications. When properly indicated, parathyroidectomy remains a safe and effective option for management of hyperparathyroidism in elderly patients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Division of Otolaryngology, University of Louisville, Louisville, Kentucky, USAJC - 8607378, l1wCP - United StatesPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19950385</style></custom1><custom3><style face="normal" font="default">AS - Laryngoscope. 120(2):247-52, 2010 Feb.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>9</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Yu,N.</style></author><author><style face="normal" font="default"> Donnan,P.T.</style></author><author><style face="normal" font="default"> Flynn,R.W.</style></author><author><style face="normal" font="default"> Murphy,M.J.</style></author><author><style face="normal" font="default"> Smith,D.</style></author><author><style face="normal" font="default"> Rudman,A.</style></author><author><style face="normal" font="default"> Leese,G.P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Increased mortality and morbidity in mild primary hyperparathyroid patients. The Parathyroid Epidemiology and Audit Research Study (PEARS)</style></title><secondary-title><style face="normal" font="default">Clinical Endocrinology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clinical Endocrinology</style></full-title></periodical><pages end="34" start="30">30-34</pages><volume><style face="normal" font="default">73</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Hyperparathyroidism,Primary/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> 7440-70-2 (Calcium)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Calcium/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Cerebrovascular Disorders/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fractures,Bone/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperparathyroidism,Primary/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Scotland/ep [Epidemiology]</style></keyword></keywords><dates><year Day="0" Month="7" Year="2010">2010/7</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To describe mortality and disease-specific morbidities in patients with mild primary hyperparathyroidism (PHPT). DESIGN: Retrospective population-based observational study. SETTING: Tayside, Scotland, from 1997 to 2006. PARTICIPANTS: Patients with mild PHPT were selected from a predefined PHPT cohort between 1997 and 2006. MAIN OUTCOME MEASURES: Standardised mortality ratios (SMRs) were examined for all-cause mortality, as well as cardiovascular and cancer mortality. Standardised morbidity ratios and standardised incidence ratios were also calculated for eleven observed co-morbidities. RESULTS: In total, there were 1683 (69.1% female) patients identified with mild PHPT in Tayside. Patients were found to have an increased risk of all-cause mortality and cardiovascular mortality (SMR-all cause 2.62, 95% CI 2.39-2.86; SMR-cardiovascular 2.68, 95% CI 2.34-3.05). Patients with mild PHPT had a significantly increased risk of developing cardiovascular and cerebrovascular disease, renal dysfunction and fractures compared to the age- and sex-adjusted general population. CONCLUSIONS: Mortality and morbidity were increased for patients with mild untreated PHPT, which is similar to more severe PHPT</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Dundee Epidemiology and Biostatistics Unit, Division of Clinical &amp; Population Sciences &amp; Education, University of Dundee, Scotland, UKJC - dci, 0346653CP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20039887</style></custom1><custom3><style face="normal" font="default">AS - Clin Endocrinol (Oxf). 73(1):30-4, 2010 Jul.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>295</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Zeller,T.</style></author><author><style face="normal" font="default"> Krankenberg,H.</style></author><author><style face="normal" font="default"> Steinkamp,H.</style></author><author><style face="normal" font="default"> Rastan,A.</style></author><author><style face="normal" font="default"> Sixt,S.</style></author><author><style face="normal" font="default"> Schmidt,A.</style></author><author><style face="normal" font="default"> Sievert,H.</style></author><author><style face="normal" font="default"> Minar,E.</style></author><author><style face="normal" font="default"> Bosiers,M.</style></author><author><style face="normal" font="default"> Peeters,P.</style></author><author><style face="normal" font="default"> Balzer,J.O.</style></author><author><style face="normal" font="default"> Gray,W.</style></author><author><style face="normal" font="default"> bler,T.</style></author><author><style face="normal" font="default"> Wissgott,C.</style></author><author><style face="normal" font="default"> lder,U.</style></author><author><style face="normal" font="default"> Scheinert,D.</style></author></authors></contributors><titles><title><style face="normal" font="default">One-year outcome of percutaneous rotational atherectomy with aspiration in infrainguinal peripheral arterial occlusive disease: the multicenter pathway PVD trial</style></title><secondary-title><style face="normal" font="default">Journal of Endovascular Therapy: Official Journal of the International Society of Endovascular Specialists</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Journal of Endovascular Therapy: Official Journal of the International Society of Endovascular Specialists</style></full-title></periodical><pages end="662" start="653">653-662</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Arterial Occlusive Diseases/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> *Atherectomy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> *Lower Extremity/bs [Blood Supply]</style></keyword><keyword><style face="normal" font="default"> *Peripheral Vascular Diseases/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> *Suction</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Amputation</style></keyword><keyword><style face="normal" font="default"> Angioplasty,Balloon</style></keyword><keyword><style face="normal" font="default"> Ankle Brachial Index</style></keyword><keyword><style face="normal" font="default"> Ankle/bs [Blood Supply]</style></keyword><keyword><style face="normal" font="default"> Arterial Occlusive Diseases/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Arterial Occlusive Diseases/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Atherectomy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Atherectomy/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Brachial Artery/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Constriction,Pathologic</style></keyword><keyword><style face="normal" font="default"> Equipment Design</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Limb Salvage</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Peripheral Vascular Diseases/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Peripheral Vascular Diseases/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Suction/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Suction/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Ultrasonography,Doppler,Duplex</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="12" Year="2009">2009/12</year></dates><abstract><style face="normal" font="default">PURPOSE: To report a safety and efficacy study of a novel rotational atherectomy system with aspiration capabilities for the treatment of infrainguinal arterial lesions. METHODS: From February 2006 to January 2007, 172 patients (88 women; mean age 72 years, range 51-93; 47% diabetics) with Rutherford class 1-5 lower limb ischemia were enrolled at 9 study sites. Inclusion criteria were atherosclerotic stenoses >70% and up to 10 cm long in the femoropopliteal segment or up to 3 cm long in the infrapopliteal vessels (reference vessel diameter 3.0-5.0 mm). In the study, 210 lesions (mean length 2.7 cm) were treated with the Pathway PV System, including total occlusions (31%), lesions with a moderate to high calcium score (51%), and post-angioplasty (non-stent) restenotic lesions (15%). The primary study endpoint was the 30-day major adverse event (MAE) rate. RESULTS: Device success was 99% (208/210 lesions). MAE at 30 days was 1% (2 preplanned amputations). Clinically driven target lesion revascularization rates at 6 and 12 months were 15% (25/172) and 26% (42/162), respectively. The 1-year restenosis rate was 38.2% based on duplex imaging. The ankle-brachial index increased significantly from 0.59+/-0.21 at baseline to 0.82+/-0.27 (p&lt;0.05) at 12 months. Mean Rutherford class improved from 3.0+/-0.9 at baseline to 1.5+/-1.3 at 1 year (p&lt;0.05). CONCLUSION: The use of the Pathway PV System in atherosclerotic lesions appears to be safe and effective in improving stenosis severity, even in the presence of challenging lesion conditions. Vessel patency following intervention appears to be good up to 12 months, and these results translate into clinical benefit</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Angiology, Heart-Centre Bad Krozingen, Germany. thomas.zeller@herzzentrum.deCM - Comment in: J Endovasc Ther. 2009 Dec;16(6):663-4; PMID: 19995119JC - dmk, 100896915CP - United StatesPT - Clinical TrialPT - Comparative StudyPT - Journal ArticlePT - Multicenter StudyPT - Research Support, Non-U.S. Gov'tSI - ClinicalTrials.govSA - ClinicalTrials.gov/NCT00676494LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 19995118</style></custom1><custom3><style face="normal" font="default">AS - J Endovasc Ther. 16(6):653-62, 2009 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>69</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Zhang,L.J.</style></author><author><style face="normal" font="default"> Wu,S.Y.</style></author><author><style face="normal" font="default"> Wang,J.</style></author><author><style face="normal" font="default"> Lu,Y.</style></author><author><style face="normal" font="default"> Zhang,Z.L.</style></author><author><style face="normal" font="default"> Jiang,S.S.</style></author><author><style face="normal" font="default"> Zhou,C.S.</style></author><author><style face="normal" font="default"> Lu,G.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Diagnostic accuracy of dual-source CT coronary angiography: The effect of average heart rate, heart rate variability, and calcium score in a clinical perspective</style></title><secondary-title><style face="normal" font="default">Acta Radiologica</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Acta Radiologica</style></full-title></periodical><pages end="740" start="727">727-740</pages><volume><style face="normal" font="default">51</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> *Coronary Stenosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Heart Rate/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> 0 (Contrast Media)</style></keyword><keyword><style face="normal" font="default"> 66108-95-0 (Iohexol)</style></keyword><keyword><style face="normal" font="default"> 73334-07-3 (iopromide)</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Chi-Square Distribution</style></keyword><keyword><style face="normal" font="default"> Contrast Media/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Electrocardiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Iohexol/aa [Analogs &amp; Derivatives]</style></keyword><keyword><style face="normal" font="default"> Iohexol/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Radiographic Image Interpretation,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword></keywords><dates><year Day="0" Month="9" Year="2010">2010/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Dual-source CT coronary angiography (CTCA) has been used to detect coronary artery disease; however, the factors with potential to affect its diagnostic accuracy remain to be defined. PURPOSE: To prospectively evaluate the accuracy of dual-source CTCA in diagnosing coronary artery stenosis according to conventional coronary angiography (CAG), and the effect of average heart rate, heart rate variability, and calcium score on the accuracy of CTCA. MATERIAL AND METHODS: A total of 113 patients underwent both dual-source CTCA and CAG. The results were used to evaluate the findings in dual-source CTCA to assess the accuracy in the diagnosis of > or =50% (significant stenosis) and >75% (severe stenosis) of coronary artery according to those by CAG. Patients were divided into subgroups according to their heart rate (HR), HR variability (HRV), and calcium score, and the accuracy of CTCA was further evaluated. The chi-square test was used to analyze the difference in sensitivity and specificity for the detection of > or =50% and >75% coronary stenosis among subgroups. The generalized estimation equation method was used in per-vessel analysis to adjust for within-patient correlation. RESULTS: In all, 113 patients had 338 vessels and 1661 segments evaluated by CAG. Dual-source CTCA displayed 1527 segments (91.9%). Among them, 1468 segments (calcium score by CAG score 1, n=1018; score 2, n=270; score 3, n=180) were assessable in CTCA. On a per-patient analysis, the sensitivity and specificity of CTCA were 93.9% and 93.5% for significant stenosis and 86.9% and 98.1% for severe stenosis. On a per-vessel basis, the sensitivity and specificity were 90.2% and 97.1% for significant and 83.3% and 98.1% for severe stenosis. On a per-segment analysis, the sensitivity and specificity were 90.2% and 97.1% for significant and 83.3% and 98.1% for severe stenosis. Average HR had no effect on the sensitivity and specificity of CTCA (P>0.05); whereas HRV and calcium score had some effect on the sensitivity and specificity of CTCA (P&lt;0.05). CONCLUSION: On a per-patient, per-vessel, and per-segment basis, dual-source CTCA has a high sensitivity and specificity for the diagnosis of coronary artery stenosis. Average HR has no effect on the diagnostic accuracy of CTCA, while HRV and calcium score have a statistically significant effect on the sensitivity and specificity of CTCA</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Medical Imaging, Jinling Hospital, Clinical School of Medical College, Nanjing University, ChinaJC - 8706123, ataCP - EnglandPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20707657</style></custom1><custom3><style face="normal" font="default">AS - Acta Radiol. 51(7):727-40, 2010 Sep.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>570</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Zhang,Z.H.</style></author><author><style face="normal" font="default"> Jin,Z.Y.</style></author><author><style face="normal" font="default"> Zhang,S.Y.</style></author><author><style face="normal" font="default"> Lin,S.B.</style></author><author><style face="normal" font="default"> Li,D.J.</style></author><author><style face="normal" font="default"> Kong,L.Y.</style></author><author><style face="normal" font="default"> Wang,Y.N.</style></author><author><style face="normal" font="default"> Song,L.</style></author><author><style face="normal" font="default"> Wang,Y.</style></author><author><style face="normal" font="default"> Zhao,W.M.</style></author><author><style face="normal" font="default"> Mou,W.B.</style></author><author><style face="normal" font="default"> Zhang,L.R.</style></author><author><style face="normal" font="default"> Zhu,W.L.</style></author><author><style face="normal" font="default"> Miao,Q.</style></author><author><style face="normal" font="default"> Fang,Q.</style></author></authors></contributors><titles><title><style face="normal" font="default">Coronary angiography with dual source computed tomography: initial experience</style></title><secondary-title><style face="normal" font="default">Chinese Medical Sciences Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Chinese Medical Sciences Journal</style></full-title></periodical><pages end="210" start="205">205-210</pages><volume><style face="normal" font="default">22</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> *Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart Rate</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword></keywords><dates><year Day="0" Month="12" Year="2007">2007/12</year></dates><isbn><style face="normal" font="default">1001-9294</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: To explore the scan technique and image quality of coronary angiography with dual source computed tomography (CT) without oral metoprolol preparation. METHODS: Plain and enhanced dual source CT coronary angiography without oral metoprolol preparation was prospectively performed in 600 patients. Calcium scoring with plain scan images as well as multi-planar reconstruction (MPR), maximum intensity projection (MIP), and volume rendering technique (VRT) reconstruction with enhanced scan images were performed in all cases. The scan technique and post-reconstruction experience was summarized. The image quality was classified as 1 to 4 points, and coronary segments classified according to the American Heart Association standards were evaluated. RESULTS: The average calcium score of the 600 cases was 213.6 +/- 298.7 (0-3,216.5). The average heart rate of the enhanced scan was 82.1 +/- 16.2 (47-139) bpm. The post-reconstruction methods with which coronary segments could be shown as best as possible consisted of single phase reconstruction method, two or more phases supplemented method, and electrocardiogram editing method. Altogether 8,457 coronary segments were evaluated, among which 97.2% were evaluated as point 1, 1.7% point 2, 0.5% point 3, and 0.6% point 4. The coronary segments in 261 cases were completely normal, while 360 segments were diagnosed with &lt; 50% stenosis and 625 segments with > or = 50% stenosis. CONCLUSIONS: Excellent coronary artery image can be obtained with dual source CT in patients with any heart rate without oral metoprolol preparation. Heart rate is not a major source of the artifact, coronary segments can be well shown with single or multiple-phase reconstruction method</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, BeijingJC - a8e, 9112559CP - ChinaPT - Journal ArticleLG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 18246666</style></custom1><custom3><style face="normal" font="default">AS - Chin Med Sci J. 22(4):205-10, 2007 Dec.</style></custom3></record><record><database name="Ca CVD update" path="G:\META\Vit D &amp; Ca DRI\Databases (RM)\Ca CVD update">Ca CVD update</database><source-app name="Reference Manager 11.0" version="11.0.0.359">Reference Manager 11.0</source-app><rec-number>151</rec-number><ref-type name="Journal">1</ref-type><contributors><authors><author><style face="normal" font="default">Zhao,X.</style></author><author><style face="normal" font="default"> Zhao,Q.</style></author><author><style face="normal" font="default"> Chu,B.</style></author><author><style face="normal" font="default"> Yang,Y.</style></author><author><style face="normal" font="default"> Li,F.</style></author><author><style face="normal" font="default"> Zhou,X.H.</style></author><author><style face="normal" font="default"> Cai,J.</style></author><author><style face="normal" font="default"> Cai,Z.</style></author><author><style face="normal" font="default"> Yuan,C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Prevalence of compositional features in subclinical carotid atherosclerosis determined by high-resolution magnetic resonance imaging in chinese patients with coronary artery disease</style></title><secondary-title><style face="normal" font="default">Stroke</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Stroke</style></full-title></periodical><pages end="1162" start="1157">1157-1162</pages><volume><style face="normal" font="default">41</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">*Atherosclerosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Calcinosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Carotid Stenosis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> *Magnetic Resonance Angiography</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Asian Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default"> Atherosclerosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Calcinosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Carotid Stenosis/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> SB - IM</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="6" Year="2010">2010/6</year></dates><abstract><style face="normal" font="default">BACKGROUND AND PURPOSE: Previous studies have reported that carotid atherosclerosis frequently can be seen in coronary artery disease (CAD) patients. This study sought to determine the prevalence of compositional features in subclinical carotid atherosclerosis by MRI in CAD patients. METHODS: Ninety-six subjects with suspected CAD but free of neurological symptoms underwent coronary CT angiography and carotid MRI including 3-dimensional time-of-flight, T1-weighted, T2-weighted, and proton density-weighted sequences at 3 T within a 2-week interval. The coronary artery calcium score (CACS) and degree of stenosis were measured. Areas for carotid lumen, wall, total vessel, and percent wall volume (wall volume/total vessel volume) were measured. The prevalence of carotid calcification, lipid-rich necrotic core, intraplaque hemorrhage, and surface disruption in coronary stenosis and CACS categories were determined. RESULTS: Carotid percent wall volume was correlated with CACS (P=0.001). Both coronary stenosis and CACS were significantly associated with presence of carotid calcification (OR=5.79 for 1%-49% vs 0% stenosis; OR=10.23 for >50% vs 0% stenosis; OR=10.65 for CACS 1-399 vs CACS 0; and OR=20.28 for CACS >400 vs CACS 0; all P&lt;0.05) and lipid-rich necrotic core (OR=10.29 for 1%-49% vs 0% stenosis; OR=4.66 for >50% vs 0% stenosis; OR=8.23 for CACS 1-399 vs CACS 0; and OR=11.87 for CACS >400 vs CACS 0; all P&lt;0.05) High prevalence of lipid-rich necrotic core was found in low-grade coronary stenosis (75.6% in 1%-49% stenosis) and CACS (73.5% in CACS 1-399). CONCLUSIONS: Carotid plaque burden and compositional features are significantly associated with CAD severity. The finding of high prevalence of lipid-rich necrotic core in patients with low-grade coronary stenosis and CACS suggests the need for early monitoring of carotid atherosclerosis in CAD patients</style></abstract><notes><style face="normal" font="default">DB - Ovid MEDLINE(R)IN - Department of Radiology, University of Washington, 815 Mercer Street, Box 358050, Seattle, WA 98109, USAJC - v2j, 0235266CP - United StatesPT - Clinical TrialPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralNO - R01 HL 56874 (United States NHLBI NIH HHS)LG - English</style></notes><urls/><custom1><style face="normal" font="default">UI - 20395607</style></custom1><custom3><style face="normal" font="default">AS - Stroke. 41(6):1157-62, 2010 Jun.</style></custom3></record></records></xml>
